<SEC-DOCUMENT>0000950170-24-037242.txt : 20240327
<SEC-HEADER>0000950170-24-037242.hdr.sgml : 20240327
<ACCEPTANCE-DATETIME>20240327163109
ACCESSION NUMBER:		0000950170-24-037242
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		124
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240327
DATE AS OF CHANGE:		20240327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GYRE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562020050
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		24791282

	BUSINESS ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(619) 949-3681

	MAIL ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20150820

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gyre-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-27T16:15:46.6594+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:gyre="http://www.gyretx.com/20231231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_842bb781-f233-4730-ba3c-37b98094cf6b" name="dei:AmendmentFlag" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6">false</ix:nonNumeric><ix:nonNumeric id="F_b532d4fa-0079-4065-a312-e2bb54ce23c3" name="dei:EntityCentralIndexKey" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6">0001124105</ix:nonNumeric><ix:nonNumeric id="F_4f4ea0e9-b2d6-4b36-8e2b-a9e49cc8beee" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6">FY</ix:nonNumeric><ix:nonFraction id="F_10f26d2c-8039-4a92-bb7e-38b5c289f68f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_f851a953-0acb-4a2d-aab6-9fc679e13665" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_510f7079-5465-4c06-acd3-f8ee356eab2a" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a" unitRef="U_shares" xsi:nil="true"/><ix:nonFraction id="F_a1f5be30-a9c8-475c-a877-7a594cbb125d" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a" unitRef="U_shares" xsi:nil="true"/><ix:nonNumeric id="F_b8d10737-f18e-4a8d-80f3-5bcbf043af92" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_c49e00a9-fef7-400c-9f36-c136ff2e6361">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric id="F_ba9e4760-e1ab-447a-a061-08082fe718fe" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_d0b28c28-b43d-409f-912a-9b624322953e">P2Y</ix:nonNumeric><ix:nonFraction id="F_1b8bd787-8774-422a-80fe-04f24efefd08" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_ba6672c5-2601-4669-825e-401398257206" unitRef="U_shares" xsi:nil="true"/><ix:nonFraction id="F_0cb88365-0ef8-49b2-9d9e-5b85398d57d4" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_ba6672c5-2601-4669-825e-401398257206" unitRef="U_shares" xsi:nil="true"/><ix:nonFraction id="F_ce5ebc89-65a5-46e2-8a69-3fd79de6688a" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_ba6672c5-2601-4669-825e-401398257206" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_8616dc92-4123-4729-b301-42d5b83f2786" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_1e540b7e-b631-4275-b3d7-b90e2d47d44e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" unitRef="U_USD" xsi:nil="true"/></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="gyre-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_d40b8acc-faac-42d6-9c51-0c30220f6323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06e4c2d4-f7ea-4792-a208-6e5d5ddb822f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34639a27-12df-4fc6-8cf2-6020aa830e91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:BCTwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e13ef3b0-0f59-4737-ba8d-a801a95ed820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202110Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79108d3a-0a88-4ff0-8ed1-61cd65b0cc7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_115f1247-30e4-4dba-bef9-b573f9c28f0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d486857-5008-4c2c-a4dd-5f5a83f5ac38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8c45cef-ab89-4573-972d-ebd63351515c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebddae99-35cb-4ad8-9ae5-e50276c1c921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5d59667-252a-4ddf-a814-4b5b16c0658d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0be0b3d5-00f8-476d-87f6-73aa39f3c356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b92166d-718c-4785-aa66-2913afa80931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70b83c65-e6f6-4e44-8d27-f4d22fcc2178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a6b4fb6-8b55-4823-9d73-78c42fa47442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b93ebd7b-c921-4c3e-b8e6-a2fb861ebf08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gyre:PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0718b26-6e80-4be3-a6f2-f995da1fdae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1eecc05-fb63-484b-87b6-6c579da56492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">gyre:MainlandChinaContributionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_290b25a7-e794-4501-9b27-3ec91a3fd8f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8689a54-e515-453a-a125-a50eaed49c5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7bd02c2-5511-4949-ab7c-0b820fc02c62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29dd3e9d-3aeb-4cda-b357-0760b9f78c7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:FCContributionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5723249a-64b4-471a-be67-452050b084d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72d98f33-ac25-40da-993c-2ae56eedc53b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_170270bc-ade9-476a-ad13-a1783878c851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:PatentsAndTechnologicalKnowHowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_101acaab-645c-4f44-bbd8-62788657a2a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ca1cf69-934c-4ff2-a707-c448b5a6f581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0b36028-19c9-4a53-a9a7-ee2e782d8999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_255a8a23-07fb-48ff-8e4a-470e48cef83d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be894792-6c69-49f3-93fd-d2f0be6d34a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ChinaResourcesPharmaceuticalGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_812372f4-948a-4dd8-9e62-5d74629f12d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d3825d9-b987-4009-9844-dcb7a6a0f783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:ContinentPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-26</xbrli:startDate><xbrli:endDate>2022-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66c1df00-e0da-4f0b-9563-bfed0377c5ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6077b963-9934-4f32-afc7-404ff0ca15ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28499de6-ca37-4fe6-8aca-3f877d7ec297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14bcbd0d-16c5-428b-aeae-b50976bc4336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db3199b0-d343-4eaa-a0d5-e0379c40bbc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityNonCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed00f272-5d55-43d0-8d10-9b8734e290e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2522893b-b6a7-4707-8268-f07f26458548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a895bc1-6430-4cd0-8079-aca770c79f44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_600857f6-7a26-4dcb-b37f-7638845d2593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0008245-ac04-475a-a3d9-4fa1983c4b11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1815289d-1b7a-4870-a6b4-e40af7ccba71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbd33fe5-ce5f-469c-838c-790bd81dab76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c78a0ae7-fcae-4fbc-826e-d3417a171185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_902ec01f-0e7c-4614-8110-77c86fffbaba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202108Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3822144-76cb-4af5-a440-f0966d1d926a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6948abd4-d444-43bb-a3ca-742236671306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_964a9a24-1974-4f5d-9116-9d0ee44c4aaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39bb62ec-75ae-4ae3-a8f4-d62d0b77c6d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c368eb8c-00d1-4f05-bcc7-415246aeae15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9586f61-cf2b-4213-abab-d860b5741c19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73e506f1-e7cf-4f6e-aabc-dc8fffc52d12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69b8f9e1-11d9-471e-9f88-5c562846ff4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cb6c663-f4e1-4031-ab93-fd048348ccfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d096fdf-4e68-4c03-86ed-d1473a0c1c55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f7731e9-8054-4146-a8d0-8ebfec2ebe77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3a35db5-876f-4dde-b12c-44d79d949c6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb79166d-261c-4aa0-b6cc-fd954e4458bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60d99e53-9b0a-4867-83bb-4f2ef85acc84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_553f64ab-cbff-456e-afae-63d4c635d124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_667dbe67-6d4f-4415-b9bd-2d650d6ff17a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e03b0455-2388-408c-baed-fbbcb9bb45ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_157e8487-e10a-4a43-a91d-f10752747e13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e26cd6a1-f060-48c2-901b-b831f0705204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e49c5cbb-f4c4-4958-97ed-acfefaf3d6d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aaad5e91-28da-4383-82fc-a19aee9f956d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9308c880-d262-4f12-b2e3-dd30805711c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e40eb2f-6361-4ec3-826e-a6b22c03f7bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-26</xbrli:startDate><xbrli:endDate>2022-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbc1263a-94eb-48f4-bda3-2ce54672d636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:PatentsAndTechnologicalKnowHowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63213500-d1dd-4530-b4dc-40f0ab583252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc1f552a-2533-4ff9-b66b-78200f9c38bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cfa6500-f12c-4cdd-861c-f10bc7dc5d69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd01b7d2-757f-4f84-a6ce-a11ccc44dbab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba6672c5-2601-4669-825e-401398257206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37aab4d6-0074-4bef-bcfc-1004484dd02e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:VertexAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7dfcafca-61d1-46f1-a43e-d003319b30c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10152a3b-ae2a-4e24-a1b1-6548fd6edc50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f750731b-6020-454a-871c-e743ff63ef9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3272f59d-b079-4e41-97d2-9aa1f584ff2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d0d85f9-9db6-4218-b101-c8578a8373cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38b72769-64e0-4e0a-befe-f69436730816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42dbc2ab-badc-458b-bb6d-bcbe8dbf6681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_839664df-b2cb-4095-8420-a0a8cd565de5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">gyre:OtherDirectorOrOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4415040d-7158-489d-9d55-5d063148a4eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-26</xbrli:startDate><xbrli:endDate>2022-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_348a8cf8-e659-4115-a553-09b0ef1cf4b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09b4f5a5-c379-45c0-b3a1-76e64d96074d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0eac393-f1de-40db-a17e-e4afc62662a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b9e0cff-7266-4030-8595-3ac948bb97b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1d44dd0-f099-499c-bf24-bbc98c230ca4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b0cf3b8-5d3c-4147-8ceb-467e7bd5ba58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1e216e8-da62-4adc-be21-79756314d405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_456a2f3b-ce96-4cc3-bb0f-c4609478945a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89b8c4e5-1d62-4004-b838-6c1f712ee7f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">gyre:MainlandChinaContributionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0edb0ebb-f503-4b95-827d-83260811c5cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88893ed2-bf18-49f6-9367-143999cca36b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_045ba781-db06-4c6d-8298-49ca507c4865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4819d424-8697-4686-8411-d198d08bf27a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84d9b48e-9b34-4794-916b-eecce30677e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56fd673d-dfd1-4bf2-843c-a213f1c28815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f63f1a6-45b5-4355-b17a-f27ea1669ee5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73a0ea9a-142b-4c0d-8823-cc0148cb7f2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a1e9dcd-1585-4d10-a8bc-e074b80d03a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dd9552a-d96b-49ea-b446-4919e583d048"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6b773b3-ff91-417f-965a-e0e1b202042c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gyre:PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_197f4783-1608-451f-92af-879882f8d860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d846aa23-1a35-4add-bb37-786c605b621a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d497df2-33f4-4686-9867-5db4e7e60cf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f2eb8e2-864a-4564-afac-5ac5ae5e31a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11e895d4-da38-44af-a160-56e416efc9d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4a379ab-79bf-4033-b99c-f6b95eddf94e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2687f77f-ab25-40af-b6b8-1e653689478f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1d8d078-42db-45d4-8278-c6b26dcb880f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:CPIContributionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_532b1d95-8146-458c-919e-7460a7d52b23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b15a99e2-1606-4164-acb1-5d6360dd4a3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3dac587-c2f1-4635-9403-fcc4c1dc69d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ba38967-8a4f-4c72-a845-ec882f409155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea3f5866-c7a2-4019-97c6-761b0043d03a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6d92b17-1eca-4702-9b3c-788a030b8de5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0abe225e-8a79-41e7-a475-5fdcdaca6b2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4e28133-5b1e-4106-ab67-c16e08fd9d3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59d1977f-7c62-42fa-a426-ebf6da7d7d38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c991f1d-66f5-47f8-8e04-683dff126fbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1a6816f-f707-4fb2-a96b-db95ed45787d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c0870ec-cd18-4ecc-826e-33d440e66dab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dee33cb1-134d-4bc4-846b-88a1d3ece761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_445a60cd-e16e-489f-bcf9-7e083b147488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed6adc05-0edc-4467-9e37-a86f39ca0666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7e70b74-1137-44bb-bd33-d9231ea42d4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe01067f-086e-4848-ab35-be3389a6f430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a67805ae-0e8b-4cdd-8b41-5d0c3ff00337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0b28c28-b43d-409f-912a-9b624322953e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77204f22-ab15-4c2a-a5cf-eebb0427fdfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_393225c6-0b98-4833-af11-e65edf2bb418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13201822-62fe-49b2-a82f-aea2f25149ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b323a5d-4464-43f4-83e3-c63e93ede93a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0183b145-8159-4365-809a-9af68dddf568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3881b1d8-2620-4894-97cf-4c70975b00b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-15</xbrli:startDate><xbrli:endDate>2021-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b14d0f10-ff15-45a8-ac65-d7d00fe4ea56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_909bcf41-2baf-4ab5-92c1-98ec48a3f1a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c49e00a9-fef7-400c-9f36-c136ff2e6361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_201559bc-4989-46aa-9233-4a691252ef1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8323d313-5e0d-40e1-8969-c2bf69e0e63f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6707664a-816c-4885-a01e-386eaafa6e47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bf7ff5f-4cf5-4036-a987-5cbcce3b4d9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54337f80-089d-408e-99d9-524dadb15757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d2fc6f7-e605-4510-8d2b-4151172e8647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84bf33ef-ee75-44b7-9ee4-7d137c6aab5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7aad8f7d-ee0c-42f0-82cd-92463b4ee3ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91242d31-4c05-4dae-a9cf-c1b9d11a95ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efb1e330-1a01-4f0a-b587-773cd7fdf361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b3596e0-0ee0-47ca-98ce-acc247c5374c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83452b0c-e779-4d10-8c25-9d61d6a3d570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b46d8f77-6441-4e49-9e95-f82435a4d5d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1aa9e6e5-97ba-4f1a-9591-6fe7ce14496b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d022cce0-2b7e-4ac2-a0b1-f765616cb924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f243cd37-4ca7-40de-bfca-d9278aaf4176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c61ab08-e1b5-45d8-af46-68e14fd32dfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d44f86a-e7e9-43dc-98b7-f45dd3ddd498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8bdbd82-72b3-41d8-88a4-121a036217e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_606d870c-cbd5-409e-9eb7-2056b6dd9718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7863a107-8f27-4048-916f-de1fd40aebc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96f625f2-102b-4612-9ae5-c9bf247174b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:CPIContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1ac7913-1b9e-4353-967b-ae81b61fc740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8dd3a581-c90a-4509-af97-5acd79c8a8e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ec943e7-b2ed-4fe5-9f06-a3c06eb3c01a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4649e540-01e6-41d7-b63f-f6d16f10ba35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f06db74-891e-4ce0-a20f-35ad5be24529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_774dcb44-6e8f-40e2-92fb-74eb3d10f679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4011e20c-cbaf-4cba-ba16-cfe9ea152f93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0222eacd-1eff-471f-9812-cbf6e10d75b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0697f749-db8f-4fa7-9af3-6e4ada46d83a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a775378-ab64-439b-aa16-34b026d36a54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_146bbfb7-b649-4239-b32d-22b491e71629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65d76f22-ab8c-450d-82d6-0c032d5502d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ca366b2-7931-469b-9226-43eecac0ccd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-26</xbrli:startDate><xbrli:endDate>2022-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef376339-fca7-4476-8816-40e8e7832483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67f01725-b921-4008-975b-be0783c4cd88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:GCBiopharmaCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_022304e8-e2d8-4bf5-929c-5ef87abda6aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:SubmissionOfTheNewDrugApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aae4d106-8ca8-4cfc-ac19-e79420fdc9ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b262631e-b3d6-4f19-a20e-4918b4b3ac1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a998271-ce77-46b7-81d2-6b2303da832d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3878656-9f94-4813-a7e0-a59203be9936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8c28c99-2d83-45ea-8686-ca83957381c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0557a3d-1a6e-4667-8a75-0565cef63396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d5d2670-fd6a-4e3f-894d-c0347308d6f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39406448-b6a7-468f-94e5-4643bb470fb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">gyre:NassimUsmanPhdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_182327bb-26af-4f7a-895e-5e3aa7510752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_520d9cfd-45b8-47c9-a6c9-7d44c08a8e84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0063bfe3-5d9c-41a6-8562-8f267b5afe98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ChinaResourcesPharmaceuticalGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c46426ec-a619-48aa-b225-7389e165b89a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cc0a247-7505-4d3e-a327-e08700672f1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc38fe45-e720-4e3e-901d-1a99ab32da43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f319e2ec-8474-4f02-8b68-38c9e4ad3e70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:NDAPassesTheNMPAsReviewAndInspectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1121837-d055-4a18-8650-a77886d17e34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:BCTwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e92cc5b3-03a9-49de-86c5-40c3077730e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d564b606-4a21-47bf-80f7-c37ac338b08b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae49cec5-9016-4f5f-8d21-5329e230331a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1a2d74b-7d0b-4b38-8998-7a1161571cf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_876ccdba-ce87-44d7-a2b1-3ab0b94f2343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5c9b177-fba0-46dd-bf60-5e7f99b3ce8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ea7ec22-706f-4637-98fe-08b2490d6c90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25dbe4a0-c5aa-49dd-826b-9a456c343407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ba0c404-2823-46e7-9d85-bca97b5c230d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8324e115-6f67-4a65-b0da-48617f324eac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e5a19f3-a118-4af6-bfc3-2289de865726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffe88006-6a83-4a40-9c82-c045fa6b0bdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f111bc94-d333-4038-926d-d8d72cc3bed3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ea22d62-a406-408f-8236-ff3e0f11ad07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:NMPAsApprovalOfTheNDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_231bdf89-19b3-4b6a-80d0-3b9f3bf5f8dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">gyre:NassimUsmanPhdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2c5e195-1c21-41fa-be14-653b6ec43f7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_336f98ce-84bd-4119-8b08-938644de6dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b337b32c-b922-4667-afd1-a840403dbad9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a21fb1ae-dd92-411d-bef0-916436903fc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ae8d6c6-9b6a-426c-ba9b-df1d72c1c57c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01c81b79-25d4-4be2-a4ef-98326dc842a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86929c87-30bc-44d5-9aa7-59c41f5a2bc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_666ada80-f898-47d3-8486-3309e25ceb24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04950170-0636-4a37-9b11-630a8bead37c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af914aeb-56e2-4a0a-bc92-2b10d6ce2fdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_969ae12f-04dd-45bd-837a-de4b4c55f1de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7c2a125-5bff-41a6-a0df-4926d0dda919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Individual"><xbrli:measure>gyre:Individual</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqm"><xbrli:measure>utr:sqm</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>gyre:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_CNY"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_4c145f6b-eadd-41ce-9c2e-dc03d3a8bcb1" fromRefs="F_9a272737-bc08-4cc6-aecc-0ad4b9df9699 F_0547b5d9-8cf0-4c86-a882-fafaeb82c402"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878" fromRefs="F_5ee0712a-9495-465c-a62c-57257a6ca510"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9" fromRefs="F_fbaeeda2-4b02-470d-9341-dbf9ecc4a8bb"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9" fromRefs="F_c261cfe5-3da9-46f4-9be9-e6fa353cc3f9"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_f44b5c23-aed9-4b04-8c26-9440275a700b" fromRefs="F_a9daf5d4-b859-4b26-8105-a443654f1988"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_228a2060-914b-44e0-8e10-3c03acdbcf57" fromRefs="F_54bd4cb4-14cc-4d9b-8785-f18793fb39d5"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_9b153e3f-50c6-44f6-b9dc-b8230ec35c82" fromRefs="F_c1c6a69d-fc4c-4151-addc-713c9b9935c2"/></ix:resources></ix:header></div>
  <div style="min-height:0.75in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">Form </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc252744-baa0-4194-8482-57f9bf75547b" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"/>
    <td style="width:95%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_c595a3f8-c547-45ee-8451-525afa92158b" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db99d380-237b-40bd-bf45-d6034777c93c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a3b8dda-b4fd-4d8d-88bf-37ca45258276" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6daa3f4d-381f-469c-bdfc-41a1d4cb465f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"/>
    <td style="width:95%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7bce3dd4-bb31-40a8-8f5c-3c3faa5ea442" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">                     </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">                    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Commission file number: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c07099f1-6e01-40c3-bcec-2a5fcf035341" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">000-51173</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33d3ccae-51bd-41cd-b72d-796d590a0dc8" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_73b71430-6ca3-478f-8847-f1216b493692" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_1d691bbc-05d7-4800-8a6e-22ba7cd6fd68" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">56-2020050</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporation or Organization)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_5c1820b4-6232-4c7d-8c4d-b3562d3ee107" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12770 High Bluff Drive</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_b32fa25c-e960-42ee-b6f6-f5defa5f9382" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 150</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_ec4b4fab-57bc-4666-ba94-97d524ffd96a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_9e374d0b-63a0-4bb8-89df-33e032fd6215" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_e0031cfb-556f-4fcb-9767-3c65ec0a6f90" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92130</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab88693b-f865-4651-abb2-ddaa0830869f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">619</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea6e6893-2956-47ef-bc94-6c6c7726b8fc" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">949-3681</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:33.24%;"/>
    <td style="width:33.38%;"/>
    <td style="width:33.38%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_5e830af1-459b-4468-980b-04b0e30a625f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_ec3305ca-b352-4e2a-8de8-a2ca44ac538d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">GYRE</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;min-width:fit-content;">The </span><span style="font-size:7pt;"><ix:nonNumeric id="F_b592173c-75a0-41e8-a145-22c51ad5ba9e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44b24172-3d66-4c9b-9b3b-e043f6aee3d9" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act.    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_004378da-7879-494d-aa9a-57580147b6ad" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3818740c-3b0f-46d8-934d-fed35346de0d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17bdebde-d654-4fd0-aeeb-a96e75a6c731" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.04%;"/>
    <td style="width:44.8%;"/>
    <td style="width:25.04%;"/>
    <td style="width:5.12%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_392a744c-3b8f-4fd0-bd8f-bfd8c672c4c7" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_31f2600e-4116-46ee-81e5-49a4ab98e886" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7e108f31-ba26-40d7-a6e3-e3bad82019e5" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_d90a2311-3749-46e5-8f90-65b8e030a42d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_8511a8fd-4ee0-4449-b10a-6105cc4b4b0d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4c80c2fd-a074-4015-9a34-a634db6b22ba" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the voting common stock held by non-affiliates of the registrant (based on the closing price of such stock on The Nasdaq Capital Market on June 30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32ca8a36-f3e1-4012-8887-be74ba4ba1d0" contextRef="C_3272f59d-b079-4e41-97d2-9aa1f584ff2f" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded because such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of March 19, 2024, the number of outstanding shares of the registrant&#8217;s common stock, par value $0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> per share, was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_855052e2-5f7a-4958-907e-124fb9852f61" contextRef="C_532b1d95-8146-458c-919e-7460a7d52b23" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,423,246</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87c6f69d-8510-4bdd-9580-47aacdf67235" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2024 (the &#8220;Proxy Statement&#8221;), which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annual Report on Form 10-K</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.02%;"/>
    <td style="width:83.56%;"/>
    <td style="width:6.42%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Page</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 1.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 2.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 3.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 4.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 5.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 6.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 7.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 8.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 9.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_foreign_jurisdiction"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 10.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 11.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 12.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 13.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 14.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 15.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibit and Financial Statement Schedules</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 16.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#list_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">LIST OF EXHIBITS</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> I</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forward-Looking Statements and Market Data</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) and the documents incorporated by reference herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements, other than statements of historical facts, included or incorporated by reference in this Annual Report regarding our strategy, future results of operations, future financial condition, future revenues, projected costs, prospects, plans, intentions and objectives of management, as well as the assumptions that underlie these statements, are forward-looking statements. These forward-looking statements should not be relied upon as predictions of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. Forward-looking statements are identified by words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro forma,&#8221; &#8220;estimates,&#8221; or &#8220;anticipates&#8221; or the negative of these words and phrases or other variations of these words and phrases or comparable terminology, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on our management&#8217;s assumptions and assessments in light of information currently available to our management, its experience and its perception of historical trends, current conditions, expected future developments and other factors our management believes to be appropriate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. For example, forward-looking statements include any statements regarding:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to develop a pipeline of product candidates to address unmet needs in the treatment of organ fibrosis and other inflammatory diseases;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, progress and results of clinical trials for F351 (Hydronidone) from the Phase 2a trial, F573 from the Phase 2 clinical trial, ETUARY from the Phase 2/3 clinical trial, and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available and research and development programs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, scope and likelihood of regulatory filings and approvals, including timing of investigational new drugs (an &#8220;IND&#8221; or &#8220;INDs&#8221;) and final FDA approval of F351 for the treatment of liver fibrosis associated with nonalcoholic associated steatohepatitis (&#8220;NASH&#8221;) and chronic hepatitis B (&#8220;CHB&#8221;), ETUARY for the treatment of dermatomyositis-related interstitial lung disease (&#8220;DM-ILD&#8221;) and sclerosis-related interstitial lung disease (&#8220;SSc-ILD&#8221;), F528 for the treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;), F230 for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;), and any other future product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, scope or likelihood of foreign regulatory filings and approvals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the future pursuit of product development efforts, including whether we will pursue such efforts, estimates regarding the expenses, future revenue, timing of any future revenue, capital requirements and need for additional financing related to such efforts, the timing of and our ability to pursue such efforts and our plans to develop and, if approved, subsequently commercialize any product candidates resulting from such efforts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash and investments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to develop and advance current product candidates and programs into, and successfully complete, clinical studies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our manufacturing, commercialization and marketing capabilities and strategy;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the need to hire additional personnel and our ability to attract and retain such personnel;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of the market opportunity for our product candidates, including estimates of the number of patients who suffer from the diseases we are targeting;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expectations regarding the approval and use of our product candidates in combination with other drugs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expectations regarding the potential for accelerated approval or other expedited regulatory designation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitive position and the success of competing therapies that are or may become available;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates of the number of patients that we will enroll in our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the beneficial characteristics and the potential safety, efficacy and therapeutic effects of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates and our expectations regarding particular lines of therapy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">plans relating to the further development of our product candidates, including additional indications we may pursue;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">existing regulations and regulatory developments in the People&#8217;s Republic of China (the &#8220;PRC&#8221;), the United States, Europe, and other jurisdictions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ETUARY, F351, F573, F528, and F230, and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our continued reliance on third parties to conduct additional clinical trials of our product candidates and for the manufacture of our product candidates for clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our relationships with patient advocacy groups, key opinion leaders, regulators, the research community and payors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pricing and reimbursement of ETUARY, F351, F573, F528, and F230, and other product candidates we may develop, if approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of F351, and other product candidates the Company may develop;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the period over which we estimate our existing cash will be sufficient to fund our planned operating expenses and capital expenditure requirements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expectations about the continued listing of our common stock on The Nasdaq Capital Market;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of laws and regulations; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.983857620229827%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expectations regarding the period during which we will qualify as a smaller reporting company under the Exchange Act.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any such forward-looking statements are not guarantees of future performance and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in or contemplated by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, the risks and uncertainties described in this Annual Report, including those risks described in Part I, Item 1A, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#8221; and Part II, Item 7, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,"&#8221; as well as others that we may consider immaterial or do not anticipate at this time. The risks and uncertainties described in this Annual Report, including in Part I, Item 1A, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#8221; and Part II, Item 7, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#8221; are not exclusive and further information concerning our company and our businesses, including factors that potentially could materially affect our operating results or financial condition, may emerge from time to time. All forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this Annual Report, speak only as of their date, and we undertake no obligation to update or revise these statements considering future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties, and you should carefully consider the factors set forth in other reports or documents that we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in such information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. BU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SINESS.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In this section, unless otherwise specified, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;our company&#8221; refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (&#8220;Gyre Pharmaceuticals&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a financially-sustainable pharmaceutical company with a record of financial success that develops and commercializes small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs. Fibrosis involves a complex, multi-stage process with multiple pathways. While there are numerous potential targets for anti-fibrotic therapy, both established and emerging, addressing a single molecular pathway may not be sufficient to prevent, halt, or reverse fibrosis. Our strategy is to use our experience in the successful development and commercialization of ETUARY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Pirfenidone) to expand into new indications and develop similar drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img98921446_0.jpg" alt="img98921446_0.jpg" style="width:624px;height:338px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pirfenidone, the first anti-fibrotic drug approved for idiopathic pulmonary fibrosis (&#8220;IPF&#8221;) in Japan, the European Union (&#8220;EU&#8221;), the United States (&#8220;U.S.&#8221;), and the PRC, is a small molecule drug that inhibits the synthesis of Tumor Growth Transforming (&#8220;TGF&#8221;)-&#223;1, TNF-&#945;, and other fibrosis and inflammation modulators. We have obtained approval for ETUARY (pirfenidone) in the PRC for IPF.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals successfully advanced Pirfenidone from research and development (&#8220;R&amp;D&#8221;) to commercialization in the PRC for the treatment of IPF. ETUARY&#8217;s annual sales have consistently grown each year, reaching $112.1 million in 2023. In addition to IPF, Pirfenidone is undergoing three additional Phase 3 studies for connective tissue disease associated with interstitial lung disease (&#8220;CTD-ILD&#8221;) to broaden its indications and market: SSc-ILD, DM-ILD and pneumoconiosis (&#8220;PD&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F351, our lead development candidate, is a structural derivative of ETUARY (Pirfenidone). It is a new oral chemical entity with an anti-fibrotic, TGF-&#223;1-targeting mechanism of action, for which we hold patents in major markets. Studies suggest that F351 and its major metabolites have minimal drug-drug interaction risks. Despite potential efficacy in IPF, we are prioritizing F351 for the treatment of liver fibrosis due to the large potential addressable market and significant unmet need.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals has completed a Phase 2 trial of F351 in the PRC for CHB-associated liver fibrosis. The Phase 2 trial showed that F351 was well-tolerated without notable toxicity and patients treated showed statistically-significant improvement of liver fibrosis, with the best efficacy results achieved at 270 mg/day dosing. Based on these results, a confirmatory Phase 3 trial is ongoing in the PRC. The enrollment of 248 patients for the confirmatory Phase 3 trial has been completed, with last patient out expected in 2024 and clinical results expected by early 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., we have completed a Phase 1 clinical trial of F351 in healthy volunteers. We are preparing an IND application and expect to submit it in late 2024. Following results from the PRC Phase 3 trial in CHB-associated liver fibrosis and pending approval of our IND, we expect to initiate a Phase 2a trial to evaluate F351 for the treatment of liver fibrosis associated with NASH in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img98921446_1.jpg" alt="img98921446_1.jpg" style="width:624px;height:306px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combination</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 26, 2022, Catalyst Biosciences, Inc., a Delaware corporation (&#8220;Catalyst&#8221;), acquired (the &#8220;F351 Acquisition&#8221;) the F351 Assets (as defined below) from GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;GNI Japan&#8221;), and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;GNI Hong Kong&#8221; and, together with GNI Japan, the &#8220;Sellers&#8221;), pursuant to that certain Asset Purchase Agreement, dated December 26 2022 (the &#8220;F351 Agreement&#8221;), by and among Catalyst and the Sellers. Pursuant to the F351 Agreement, Catalyst acquired all of the assets and intellectual property rights primarily related to the Sellers&#8217; proprietary F351 compound (collectively, the &#8220;F351 Assets&#8221;), other than such assets and intellectual property rights located in the PRC. Under the terms of the F351 Agreement and upon the effective time of the transactions contemplated by the F351 Agreement, Catalyst paid the Sellers $35,000,000 in the form of: 6,266,521 shares of Catalyst common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;); and 12,340 shares of Catalyst Series X Convertible Preferred Stock, par value $0.001 per share (the &#8220;Convertible Preferred Stock&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also on December 26, 2022, Catalyst, GNI USA, Inc., a Delaware corporation (&#8220;GNI USA&#8221;), GNI Japan, GNI Hong Kong, Shanghai Genomics, Inc., a company organized under the laws of the PRC, the individuals (each, a &#8220;Minority Holder&#8221; and collectively, the &#8220;Minority Holders&#8221;) listed on Annex A to that certain Business Combination Agreement (as amended, the &#8220;Business Combination Agreement&#8221;), and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (&#8220;CPI&#8221;), entered into the Business Combination Agreement, pursuant to which, among other matters, Catalyst would acquire an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the PRC (now doing business as Gyre Pharmaceuticals Co., Ltd.) (&#8220;BC&#8221; or &#8220;Gyre Pharmaceuticals&#8221;), pursuant to the following transactions: (a) GNI USA would contribute all of its ordinary shares in the capital of CPI, par value $0.0001 per share to Catalyst (the &#8220;CPI Contribution&#8221;), (b) GNI USA would contribute its interest in Further Challenger International Limited, a company incorporated and existing under the laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the British Virgin Islands with company number 1982271 (&#8220;FC&#8221;), to Catalyst (the &#8220;FC Contribution&#8221;) and (c) each Minority Holder would contribute 100% of the interest he or she holds in his or her respective Entity (as defined in the Business Combination Agreement) to Catalyst (together with the CPI Contribution and the FC Contribution, the &#8220;Contributions&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2023, Catalyst entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) for a private placement with GNI USA (the &#8220;Private Placement&#8221;). Pursuant to the Securities Purchase Agreement, GNI USA agreed to purchase an aggregate of 8,110,000 units (the &#8220;Units&#8221;) representing (i) 811 shares of Convertible Preferred Stock and (ii) warrants to purchase up to 811 shares of the Convertible Preferred Stock (the &#8220;Warrants&#8221;). The purchase price for each Unit was $0.6165, for an aggregate purchase price of approximately $5.0 million. The Private Placement closed on October 30, 2023. The Warrants were immediately exercisable at an exercise price of $4,915.00 per share of Convertible Preferred Stock, subject to adjustments as provided under the terms of the Warrants, and expire October 30, 2033. The references to share and per share amounts in this paragraph do not reflect the Reverse Stock Split (as defined below).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective at 12:01 a.m. Eastern Time on October 30, 2023 (the &#8220;Closing Date&#8221;), Catalyst (i) increased the number of authorized shares of Common Stock from 100,000,000 shares to 400,000,000 shares, (ii) effected a reverse 1-for-15 reverse stock split (the &#8220;Reverse Stock Split&#8221;) and (iii) changed its name to &#8220;Gyre Therapeutics, Inc.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also on the Closing Date, Gyre consummated the previously announced business combination pursuant to the certain Business Combination Agreement and, after giving effect to the Reverse Stock Split, (i) GNI USA contributed all of its ordinary shares in the capital of CPI to Gyre in exchange for 45,923,340 shares of Common Stock, (ii) GNI USA contributed its interest in FC, to Gyre in exchange for 17,664,779 shares of Common Stock and (iii) each Minority Holder contributed 100% of the interest he or she holds in his or her respective Entity to Gyre in exchange for an aggregate of 10,463,627 shares of Common Stock. Immediately after the Contributions, Catalyst&#8217;s stockholders as of immediately prior to the Contributions owned approximately 2.5% of the outstanding shares of Gyre, GNI USA owned approximately 85.3% of the outstanding shares of Gyre and the Minority Holders owned approximately 12.3% of the outstanding shares of Gyre, in each case, assuming conversion of the Convertible Preferred Stock issued in connection with the F351 Agreement and the Convertible Preferred Stock issued in connection with the Private Placement and subject to certain assumptions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the completion of the Contributions, the business conducted by the registrant became primarily the business conducted by Gyre, which is a biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are committed to bringing </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">better treatments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">through innovation to patients with organ fibrosis. We seek to implement the following strategies to achieve our mission and goals:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leverage our resources and expertise in the PRC to attain rapid proof-of-concept through cost-effective and efficient pre-clinical studies and early-stage clinical development and apply them elsewhere in the world</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Founded in 2002, Gyre Pharmaceuticals became a part of our company in 2023 through a business combination transaction. In the PRC, it has established a strong presence by successfully developing and commercializing ETUARY (pirfenidone capsule) for the treatment of IPF, capturing a significant market share. The success of ETUARY enabled Gyre Pharmaceuticals to develop comprehensive pharmaceutical capabilities, including robust and cost-efficient R&amp;D resources for conducting various clinical trials, manufacturing capabilities, and an extensive nationwide sales and marketing network in the PRC. Additionally, the availability of government support for biotechnology projects in the PRC enhances Gyre Pharmaceuticals&#8217; ability to undertake pre-clinical and clinical development processes effectively and economically. We expect to leverage the knowledge and know-hows from Gyre Pharmaceuticals&#8217; studies in the PRC as a basis for conducting clinical studies to address unmet medical needs in organ fibrosis elsewhere in the world.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Build our position in the treatment of fibrosis diseases, develop our product portfolio and explore indication expansion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have successfully commercialized ETUARY for the treatment of IPF in the PRC and we expect to continue to research and develop the use of ETUARY </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> other indications to build our market position, including ongoing Phase 3 clinical trials for the treatment of SSc-ILD, DM-ILD and PD in the PRC. We have also successfully completed a Phase 1 clinical trial in ETUARY for our diabetic kidney disease (&#8220;DKD&#8221;) program.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to expanding indications for ETUARY, our clinical-stage pipeline includes F351, our lead product candidate, for the treatment of CHB-associated liver fibrosis, the prevalence of which reached 63.6 million patients in 2022 in the PRC according to Frost &amp; Sullivan, and for the treatment of NASH-associated liver fibrosis in the U.S. We commenced patient enrollment for our Phase 3 clinical trial of F351 in the PRC in January 2022 and fully enrolled the 248-patient study in October 2023. We have completed our Phase 1 clinical trial of F351 in the U.S. and expect to submit an IND in late 2024. Our clinical-stage pipeline also includes F573 for the treatment of acute/acute-on-chronic liver failure (&#8220;ALF/ACLF&#8221;). We initiated our Phase 2 clinical trial of F573 in the PRC in March 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our preclinical-stage product pipeline includes F528 for the treatment of COPD, and F230 for the treatment of PAH. We believe that F528 could provide a first-line therapy for COPD and reduce long-term lung function degradation. On March 13, 2024, we submitted an IND application for F230 to the PRC Center for National Medical Products Administration (&#8220;NMPA&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Further enhance our academic promotion and expand our sales network</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enhancing academic promotion is one of our key sales approaches. We work to maintain close and long-term collaboration with academic organizations, promote expert consensus, attend international and domestic academic conferences, closely communicate with Key Opinion Leaders (&#8220;KOLs&#8221;) and improve our brand recognition. We actively participate in online and offline academic activities and host academic conferences to promote market education, raise our brand recognition and increase the clinical use of our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established a comprehensive sales network in the PRC which positions us to quickly realize sales once a product candidate is approved. We provide on-the-job training to our sales team to educate them on the latest research and clinical practice and gain an in-depth understanding of the clinical benefits of our product portfolio. To expand the geographic coverage of product sales, precisely target the clinical needs and improve our market penetration, we deploy our sales teams and resources to hospitals and expand our reach to additional small and medium-sized cities across the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prudently build our product portfolio through value accretive business development and strategic collaborations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Complementary to our in-house R&amp;D efforts, we continue to stay abreast of cutting-edge technology and product developments in the industry by bringing in products and technology that are in line with our development strategies and R&amp;D principle through acquisition, in-licensing or collaboration. We intend to build a dedicated and seasoned business development team to seek value accretive opportunities to support our growing business development needs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We proactively yet prudently source, identify, and execute promising in-licensing or acquisition opportunities. We have acquired or in-licensed the intellectual property rights of certain drug candidates from GNI Japan, particularly the intellectual property rights to F351 outside the PRC. Leveraging our medical and pharmaceutical network, we will continue to collaborate with domestic and multinational industry leaders to optimize our pipeline structure and maximize the clinical and commercial value of our product portfolio.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to focus on high-quality products that are synergistic with our existing product pipeline. For instance, to enrich our hepatic product pipeline, we have acquired promising products for the treatment of thrombocytopenia in patients with chronic liver disease. Meanwhile, leveraging our R&amp;D and commercial experience, we are also exploring other disease areas, such as multiple sclerosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expand and upgrade our facilities to increase production capacity and control production costs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To facilitate R&amp;D of our product pipelines, meet growing market demands, and realize our plan of sales expansion, we commenced the construction of an innovative drug research, development and production center in Shunyi, Beijing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in June 2022. We plan to add additional production capacity of 500 million capsules by 2024 and continue to scale up our production capacity in accordance with our sales and the market demand for our products and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we expect to ramp up our production capacity in line with the development and commercialization progress of our products. To secure stable and sufficient supply of active pharmaceutical ingredients (&#8220;APIs&#8221;) of high quality at reasonable costs, we have built our API production center in Cangzhou, PRC and expanded our production capacity through technology upgrades. We have completed this upgrade, and our annual production capacity is 50 tons of APIs at our Cangzhou facility. Our API production capability reduces our reliance on the upper-stream suppliers of raw materials, improves our cost management and provides us pricing advantages.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Continually attract, develop and retain high-quality talent</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a profitable and innovative pharmaceutical company, maintaining a streamlined, talented team tailored to the features of our product pipeline and our development needs is crucial for our success. To attract and retain talent, we are committed to the consistent development of a cohesive and vibrant corporate culture and attach great importance to the training and development of each of our employees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our experienced sales and marketing team is crucial to our continuous growth. To expand our national network and penetrate into small and medium-sized cities across the PRC, we intend to further strengthen our sales and marketing capabilities by gradually increasing our headcount in this area. As an innovative company, we recruit experienced and skilled production technicians and R&amp;D talent in related fields in the PRC and the U.S. We also plan to build our business development team to coordinate and implement our strategic collaboration plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe the following strengths position us to execute on our strategies:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-term commitment to the treatment of organ fibrosis, with ETUARY being one of the first three drugs approved for the treatment of IPF globally</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our pipeline and our revenue of $112.1 million and $99.2 million for ETUARY in 2023 and 2022, respectively, has laid a solid foundation for us in organ fibrosis treatment. ETUARY is the first drug in the PRC and among the first three drugs in the world approved to treat IPF.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have a pipeline of drug candidates focusing on the treatment of fibrosis of various organs, including lung, liver and kidney. Among them, F351 is being developed for the treatment of CHB- and NASH-associated liver fibrosis. We are also expanding the indication of our ETUARY to various other diseases.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Development of F351 as potentially the first approved drug for CHB-associated liver fibrosis in the PRC and development candidate for the treatment of NASH-associated liver fibrosis in the U.S.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With nearly 20 years of dedicated research in pulmonary fibrosis diseases and deep know-how accumulated in organ fibrosis treatment, coupled with the fact that fibrosis occurs in different organs with a similar pathogenic mechanism, we have expanded from pulmonary fibrosis to the treatment of liver fibrosis to address unmet clinical needs and a growing market. Our innovative small molecule drug, F351, has demonstrated a favorable profile for the treatment of CHB-associated liver fibrosis in clinical trials. It is designed to reverse liver fibrosis by inhibiting hepatic stellate cell proliferation while simultaneously blocking the TGF-&#223;1 signaling pathway, both of which play important roles in CHB-associated liver fibrosis. Due to the severity of the disease and the clinical trial progress of F351 compared with the currently available treatments, in March 2021, the Center for Drug Evaluation (&#8220;CDE&#8221;) of the NMPA in the PRC granted F351 a Breakthrough Therapy designation, which helps to accelerate the review of drugs that have early evidence to suggest that the drug may demonstrate a substantial improvement over currently available therapies. We commenced patient enrollment for our Phase 3 clinical trial in January 2022. As of October 2023, we have completed the full enrollment of 248 subjects and we expect to have the last patient out in 2024 and to submit an NMPA application for F351 in the PRC in early 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., we are actively preparing to file an IND application in late 2024 for a Phase 2 clinical trial to evaluate F351 for the treatment of NASH-associated liver fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Professional sales and marketing team and nationwide sales network</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is an extremely high barrier for commercializing orphan drugs due to the scarcity of patients. We have established a professional sales and marketing team and a broad sales network during the commercialization of ETUARY, which are evidenced by its strong sales track record and dominant market position. Currently, our sales network covers 30 provinces, autonomous regions and municipalities in the PRC. Our sales network has grown significantly, covering 2,901 and 35,512 hospitals and pharmacies in 2022 and 2023, respectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our sales and marketing team had 391 employees with an average of nine years of experience. Among them, our vice president in charge of sales has more than 25 years of experience in multinational pharmaceutical companies and the PRC&#8217;s innovative pharmaceutical companies, and our core regional managers have an average of 17 years of industry experience and 11 years of management experience. One-third of the other members of our sales team worked for international pharmaceutical companies and one-fourth have a bachelor&#8217;s degree or above in biology, medicine or pharmacy. We believe that our integrated sales network and accumulated management and sales experience will allow us to continue to be a dominant player in the IPF market in the PRC and to achieve rapid sales of new products once if and when they are launched.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Large in-house manufacturing facilities and strict quality control</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to produce both APIs and drug products internally provides us with stringent control over the supply chain, which enables us to maintain cost-effective production and lower our exposure to unforeseen supply chain disruptions. For more details about our two manufacturing centers, manufacturing capabilities and processes, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Properties&#8212;Gyre Pharmaceuticals' Properties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; and &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Production and Quality Control&#8212;In-House Manufacturing Facilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Experienced senior management team with strong execution capability</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have an experienced management team with strong execution capability and an average of more than 20 years of industry experience both in the U.S. and the PRC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in part upon our ability to protect our core technology and intellectual property. Our intellectual property is critical to our business and we strive to protect it through a variety of approaches, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, new targets, indications and applications and other inventions important to our business. For our product candidates, we generally pursue patent protection covering compositions of matter, methods of manufacture and methods of use. As we further develop our product candidates, we plan to identify additional novel candidates for patent protection that may potentially enhance commercial success, including pursuit of claims directed to new therapeutic indications. We enter into collaboration agreements and other relationships with pharmaceutical companies and other industry participants to leverage our intellectual property or gain access to the intellectual property of others.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of this Annual Report, Gyre owns 15 granted patents globally, 11 pending patent applications in the PRC and eight Patent Cooperation Treaty (&#8220;PCT&#8221;) patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of this Annual Report, we are the owner of all the patents and patent applications which are material to our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of individual patents depends on the legal term for patents in the jurisdictions in which they are granted. In most jurisdictions, the patent term for inventions is 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable jurisdiction. The actual protection afforded by a patent varies on a claim-by-claim and country-by-country basis and depends upon many factors, including the type of patent, the scope of its coverage, the availability of any patent term extensions or adjustments, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although ETUARY&#8217;s (Pirfenidone) substance patent expired in August 1993, Gyre currently holds one process patent that expires in 2038 and one dosage and administration patent that expires in 2024 regarding Pirfenidone. In addition,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre holds a family of patents for methods using Pirfenidone compositions to treat certain cytotoxic- or radiation-induced injuries, such as pneumonitis, consisting of granted patents in Europe, Japan, the PRC, Canada, and the U.S.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our F351 patent portfolio currently consists of six patent families, including patents and/or patent applications in various countries and under the PCT. The first patent family is for pharmaceutical compositions thereof, as well as methods for preparing or using F351 to treat fibrosis, of which one U.S. patent expires on September 22, 2024. The second patent family is for a method of preparing F351 and consists of one granted patent in the PRC that expires in 2028, two granted pants in Japan, both of which expire in 2037, and 2 PCT patent applications and 6 pending patent applications in the PRC. The third patent family is for a method of preparing a crystal form of F351 and consists of one granted patent in the PRC that expires in 2041. The fourth patent family relates to methods for using F351 to treat and/or prevent chronic hepatitis B with hepatic fibrosis and consists of one PCT patent application and one pending patent application in each of the PRC, Canada, and Australia. The fifth patent family pertains to the use of pharmaceutical compositions or drug kits in the preparation of drugs to treat or relieve pulmonary fibrosis or to improve the symptoms of pulmonary fibrosis and consists of one pending patent application in the PRC and one PCT patent application. The sixth patent family is for F351 compositions and methods of using F351 for treating liver fibrosis, liver cirrhosis, advanced hepatitis B and NASH and consists of one PCT patent application and one pending patent application in each of the PRC, Australia, Canada, Europe, Israel, Japan, South Korea, Mexico, New Zealand, Singapore, and the U.S.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For F573, Gyre owns two granted patents in the PRC, which both expire in 2031, one patent application in the PRC and one PCT patent application. For F528, Gyre owns one PCT patent application and one patent application in each of the PRC, Japan, Europe, and the U.S.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to file patent applications to cover methods of treating additional indications, as well as new forms, formulations, and methods of manufacturing F351 and other drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trade Secrets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may rely, in some circumstances, on trade secret and/or confidential information to protect aspects of our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with consultants, scientific advisers and contractors. We have entered into confidentiality agreements and non-competition agreements with our senior management and key members of our R&amp;D team and other employees who have access to trade secrets or confidential information about our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. For details of risks related thereto, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;Risk Factors&#8212;Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trademarks and Domain Names</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conduct our business under the brand name of &#8220;Continent&#8221; or &#8220;</span><img src="img98921446_2.jpg" alt="img98921446_2.jpg" style="width:46px;height:18px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;. As of December 31, 2023, we own four registered artwork copyrights, 23 registered software copyrights and 35 registered trademarks in the PRC. We also own seven registered trademarks in Hong Kong, one international trademark of &#8220;ETUARY&#8221; and the trademark application of &#8220;ETUARY&#8221; in seven countries and regions including the United States, EU and Japan. As of the same date, we also hold 28 active domain names.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Operations in the United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In this section, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;our company&#8221; refer to Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our U.S. operations are headquartered in San Diego, CA, and primarily focus on the development and commercialization of F351 (Hydronidone) for the treatment NASH-associated liver fibrosis. The development strategy for F351 in NASH-associated liver fibrosis is based on results obtained in mechanistic studies in NASH rodent models and results of Gyre Therapeutics&#8217; Phase 2 clinical trial evaluating F351 for the treatment of CHB-induced liver fibrosis in the PRC, which met the primary endpoints of safety and efficacy and led to Breakthrough</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Therapy designation by the NMPA. We have completed a Phase 1 clinical trial of F351 in the U.S. and intend to submit an IND for our Phase 2 clinical trial in the fourth quarter of 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disease Overview - NASH</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NASH (also known as metabolic dysfunction-associated steatohepatitis, or &#8220;MASH&#8221;), a severe form of non-alcoholic fatty liver disease (&#8220;NAFLD&#8221;), also known as metabolic dysfunction-associated steatotic liver disease (&#8220;MASLD&#8221;), an umbrella of conditions caused by the build-up of extra fat in the liver that is not caused by alcohol intake, is characterized histologically by the additional presence of inflammation and hepatocellular injury, such as visible ballooning, and has a significantly worse prognosis, with the potential to progress to liver fibrosis, cirrhosis or hepatocellular carcinoma (&#8220;HCC&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NASH represents a large and rapidly growing problem in the U.S. and worldwide. Diagnoses have been on the rise and are expected to increase dramatically in the next decade. The prevalence of NAFLD, which affects approximately 25% of the global population, and NASH, which develops in approximately 20% to 30% of NAFLD patients, is driven primarily by the worldwide obesity epidemic. As a result, the prevalence of NASH has increased significantly in recent decades, paralleling similar trends in the prevalence of obesity, insulin resistance and Type 2 diabetes. The prevalence of these conditions is expected to increase further due to unhealthy nutrition habits, such as consumption of a diet high in fructose, sucrose and saturated fats, and sedentary behavior.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical pathophysiologic mechanisms underlying the development and progression of NASH include reduced ability to metabolize clear lipids, increased insulin resistance, injury to hepatocytes and liver fibrosis in response to hepatocyte injury. NASH patients have an excessive accumulation of fat in the liver resulting primarily from a caloric intake above and beyond energy needs. A healthy liver contains less than 5% fat, but a liver in someone with NASH can contain more than 20% fat. This abnormal liver fat contributes to the progression to NASH, a liver necro-inflammatory state, that can lead to scarring, also known as fibrosis, and, for some, can progress to cirrhosis and liver failure&#8212;cirrhosis develops in approximately 20% to 45% of patients. In some cases, cirrhosis progresses to decompensated cirrhosis, which results in permanent liver damage that can lead to liver failure. In addition, it is estimated that 8% of patients with advanced fibrosis will develop HCC. NASH is a complex, multifaceted disease that does not just affect the liver. Patients with NASH frequently have other significant metabolic co-morbidities such as obesity, hyperglycemia, dyslipidemia and systemic hypertension (a constellation of which is commonly referred to as metabolic syndrome) and these further contribute to the risk of cardiovascular disease.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Etiology of NASH</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Understanding of the pathophysiologic mechanisms that lead to NASH has evolved in recent years but still remain insufficiently elucidated. Excessive caloric overload, metabolic dysregulation, cardio-metabolic co-morbidities and genetic risk factors increase the likelihood of developing NASH, with a multitude of potential mechanistic contributors to pathophysiology. In NASH, the liver&#8217;s capacity to handle the primary metabolic energy substrates, carbohydrates and fatty acids, is overwhelmed. This occurs when there is an excess of free fatty acids deposited in the liver or their disposal from the liver is impaired. The accumulation of surplus free fatty acids leads to the formation of toxic lipid species. These toxic lipids then induce endoplasmic reticulum stress, oxidative stress and an inflammatory response, which can result in hepatocellular injury and death. This may lead to fibrosis and genomic instability, which may worsen over time to cirrhosis and HCC, respectively. The critical pathophysiologic mechanisms underlying development and progression of NASH include (1) reduced ability to handle lipids, (2) increased insulin resistance, (3) injury to hepatocytes and (4) development and progression of liver fibrosis in response to hepatocyte injury.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Most people with NASH are asymptomatic and their disease is often discovered incidentally following a liver imaging procedure, such as an ultrasound, prescribed for other reasons or as part of an investigation for elevated liver enzymes. Once suspected clinically, a liver biopsy is required to definitively diagnose NASH, which necessitates the joint presence of steatosis, ballooning, and lobular inflammation. Once pathologically confirmed, the severity of NAFLD and NASH is determined using the histologically validated NAS, which grades disease activity on a scale of 0 to 8. The NAS is the sum of the individual scores for steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) but does not include a score for fibrosis. Fibrosis staging (F0-F4) relies on the Kleiner classification</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(F0 = no fibrosis; F1 = perisinusoidal or periportal fibrosis (not both); F2 = both perisinusoidal and periportal fibrosis; F3 = bridging fibrosis; F4 = cirrhosis).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Histological diagnosis remains the gold standard for assessment of NASH and fibrosis. However, given that liver biopsy is associated with risks of pain, bleeding and other morbidity, as well as significant cost, the procedure is not practical for general patient screening. Additionally, histology diagnosis is confounded by evaluation of a small sliver of a large heterogenous organ that may not represent the full organ, and significant variability in reading of slides including inter- and intra-reader variability. Several non-invasive tools such as clinical risk scores, serum markers and imaging techniques are increasingly used to assess NASH patients. Non-invasive tests (&#8220;NITs&#8221;) such as the Fibroscan-AST score, Fibrosis-4 index, the Enhanced Liver Fibrosis score and vibration-controlled transient elastography, have been validated and are increasingly used. These NITs have an excellent negative predictive value and an acceptable positive predictive value for detection of advanced (&#8805; F3) fibrosis and are increasingly used in clinical settings. Additionally, evidence is emerging that shows a correlation between reduction in steatosis as measured by MRI-proton density fat fraction (MRI-PDFF) and reduction in ALT &#8805;17 U/L and histologic improvement on liver biopsy. In their draft guidance, the FDA encouraged sponsors to identify biochemical or noninvasive imaging biomarkers that, once characterized and agreed by the FDA, could replace liver biopsies for patient selection and efficacy assessment in clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that the validation and subsequent adoption of these NITs will result in an increase in the diagnosis and treatment rates for NASH in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Clinical-Stage Product Candidate: F351</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview of F351</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F351, our Phase 1 clinical-stage drug candidate, has the potential to treat NASH-associated liver fibrosis. We anticipate filing an IND application and initiating a Phase 2a clinical trial for the treatment of NASH-associated liver fibrosis in the United States in 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F351 is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug ETUARY, but with medicinal chemistry that has been modified to potentially reduce the safety liabilities associated with Phase 1 metabolism. F351 is designed to treat liver fibrosis by inhibiting the activation of hepatic stellate cells (&#8220;HSCs&#8221;) through Smad7-mediated TGF-&#223; degradation, as well as decreasing the expression of fibrosis-related genes. The TGF-&#223; is a</span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">central mediator of fibrogenesis in tissues. Activation of the HSCs is recognized as a central event in the progression of liver fibrogenesis, with the TGF-&#223; as one of the key mediators.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F351 has been shown to inhibit </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> both p38&#947; kinase activity and TGF-&#223;1-induced excessive collagen synthesis in HSCs. This is further supported by its anti-proliferative effects on the HSCs in the liver. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> anti-fibrotic effects of F351 were also confirmed in several established </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rodent models of liver fibrosis, such as carbon tetrachloride (&#8220;CCl</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;)-induced liver fibrosis mouse model, DMN-induced liver fibrosis rat model, and HSA-induced liver fibrosis rat model, as well as mouse model of NASH fibrosis (CCl</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> +Western [High Fat] Diet). In the NASH mouse model, F351 significantly reduced the severity of fibrosis, as well as demonstrated improvements in the functional, biochemical and histopathological attributes of the affected liver tissue, including a significant reduction of hydroxyproline content and liver enzymes (ALT), aspartate (AST), a decrease in liver fat degeneration, and decreases in the levels of several of inflammatory cytokines at doses of 3-10 mg/kg/day, as well as a decrease in the NAS score in the CCl</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and WD-induced fibrosis and cell ballooning NASH models at doses of 15-50 mg/kg bid (HEDs of 144 &#8211; 480 mg) which are relevant to human exposure. Thus, the key attributes of F351&#8217;s molecular mechanisms of action in animal models of liver fibrosis support its efficacy potential in liver fibrosis of various etiologies including those associated with NASH.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical development of F351 in the United States includes a completed  Phase 1 clinical trial that evaluated the safety, tolerability, and PK of single and multiple doses of F351 in U.S. healthy volunteers, and collected bridging data to the data obtained in healthy volunteers in the PRC. This Phase 1 clinical trial of F351 was conducted on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">basis of an IND that was filed in 2016 for F351 as an anti-fibrotic agent with a focus on liver fibrosis associated with a spectrum of chronic liver diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following single oral doses of F351 30 mg or 120 mg in Part I of the trial, F351 was rapidly absorbed, showing a linear PK pattern of exposure with mean elimination half-life of five to six hours, and five to seven hours for M3 and M4 metabolites. Following repeated oral doses of F351 30 mg or 120 mg TID for seven days in Part II of the trial, F351 capsules were rapidly absorbed with a similar PK pattern of exposure and similar half-life as seen following single doses of F351. Modest accumulation (less than a 1.5-fold increase) was observed for F351, M3 and M4 with repeated 30 mg or 120 mg TID. Dose-normalized F351 C</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">max</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and AUC values were similar in males and females.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overall, F351 was well tolerated when administered as a single oral dose of 30 mg or 120 mg and when administered as repeated oral doses of 30 mg or 120 mg TID for seven consecutive days. There were no premature discontinuations due to adverse events (&#8220;AEs&#8221;), no serious adverse events (&#8220;SAEs&#8221;), and no deaths reported in this trial. Treatment-emergent AEs reported following single dose administration in Part I of the trial included a single AE of rhinorrhoea and scattered, isolated, reversible laboratory abnormalities. Treatment-emergent AEs reported following repeated dose administration in Part II of the trial included headache (25.0%), constipation (16.7%) and somnolence (12.5%). Abdominal discomfort and flatulence were also reported as gastrointestinal AEs in one subject each. There were no clinically significant overall changes in safety laboratory tests that were attributable to trial drug product, including no evidence of any significant drug-induced liver injury or clinically significant overall changes in vital signs, ECG parameters or physical examinations that were attributable to trial drug product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to initiate Phase 2a clinical development of F351 in NASH-associated liver fibrosis. The goal of the proposed Phase 2a clinical trial is to obtain early Proof-of-Concept (&#8220;PoC&#8221;) for F351 in subjects with NASH-associated liver fibrosis as a basis of expansion into a more comprehensive Phase 2/3 clinical program. This trial will be conducted under a new IND, reflecting the distinct risk-benefit profile that the drug may have in a NASH patient population. To support the IND filing and initiation of the proposed Phase 2a clinical trial, we plan to cross-reference all nonclinical and clinical data obtained in trials completed under the currently-active IND in the United States, as well as those previously completed in the PRC. We believe that the results obtained in these nonclinical and clinical studies provide adequate information on the current clinical risk/benefit profile of the drug and allow for safe initiation of the proposed Phase 2a clinical trial of F351 in NASH-associated liver fibrosis. In connection with the F351 Acquisition, GNI initiated the transfer of ownership of the IND to us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agreements Relating to the F351 Program</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F351 Asset Purchase Agreement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 26, 2022, we acquired the F351 Assets from the GNI Japan and GNI Hong Kong. Pursuant to the F351 Agreement, we acquired all of the assets and intellectual property rights primarily related to GNI Japan&#8217;s and GNI Hong Kong&#8217;s proprietary F351 compound, other than such assets and intellectual property rights located in the PRC. The F351 Assets include 15 issued or pending patents and patent applications outside of the PRC, with the last acquired issued patent expected to expire in August 2037. Under the terms of the F351 Agreement and upon the effective time of the transactions contemplated by the F351 Agreement, we paid GNI Japan and GNI Hong Kong $35,000,000 in the form of: 6,266,521 shares of Common Stock; and 12,340 shares of Convertible Preferred Stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biopharmaceutical industry is intensely competitive and subject to rapid innovation and significant technological advancements. We believe the key competitive factors that will affect the development and commercial success of F351 and any future product candidates are efficacy, safety and tolerability profile, reliability, convenience of dosing, price, the level of generic competition and reimbursement. Our competitors include multinational pharmaceutical companies, specialized biotechnology companies, universities and other research institutions. A number of biotechnology and pharmaceutical companies are pursuing the development or marketing of pharmaceuticals that target the same diseases that we are targeting. Smaller or earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Given the high</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incidence of NASH, it is likely that the number of companies seeking to develop products and therapies for the treatment of liver and cardio-metabolic diseases, such as NASH, will increase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If F351 is approved for the treatment of NASH-associated liver fibrosis, future competition could also arise from five main classes of drugs aiming to reach the market in the current NASH landscape: Farnesoid X receptor agonists, fibroblast grow factor 21, thyroid hormone receptor-&#946; agonists, glucagon-like peptide 1 (&#8220;GLP-1&#8221;) agonists, and PPAR agonists, but there are others as well. Resmetirom, a beta-thyroid hormone receptor agonist from Madrigal Pharmaceuticals, Inc. became the first drug to be approved by FDA for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, to be used along with diet and exercise; other candidates include VK2809 a beta-thyroid hormone receptor agonist from Viking Therapeutics, Inc.; Aldafermin, an FGF19 analog from NGM Biopharmaceuticals, Inc.; denifanstat, novel fatty acid synthase (FASN) inhibitor from Sagimet Biosciences; MK-3655, an FGFR1c/KLB agonist antibody from Merck &amp; Co., Inc.; Efruxifermin, a FGF21 fusion protein from Akero Therapeutics, Inc.; Pegozafermin, a FGF21 fusion protein from 89bio, Inc.; Belapectin, a Galectin-3 inhibitor from Galectin Therapeutics Inc.; Aramchol, a synthetic conjugate of cholic acid and arachidic acid from Galmed Pharmaceuticals Ltd.; Semaglutide, a GLP-1 receptor agonist from Novo Nordisk A/S; Pemvidutide/ALT-801, a dual GLP-1/glucagon agonist from Altimmune; Tirzepatide, a dual GIP/GLP-1 receptor agonist from Eli Lilly and Company; Lanifibranor, a PPAR alpha/delta/gamma agonist from Inventiva; NNC0194-0499, an FGF21 analog from Novo Nordisk; BOS-580, an FGF21 analog from Boston Pharmaceuticals; and BFKB8488A, an FGFR1/KLB agonist antibody from Genentech; and pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 from 89bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing and Supply</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacturing of F351 active pharmaceutical ingredients (&#8220;API&#8221;) and drug product supplies required for supporting the Phase 2a clinical trial in NASH-associated liver fibrosis was completed at WuXi STA, based in the PRC. The API and drug product are of current Good Manufacturing Practice (&#8220;cGMP&#8221;) grade quality, and batch release and stability studies comply with applicable regulatory requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In light of the recently introduced BIOSECURE Act, which would prohibit federal agencies from entering into procurement contracts with an entity that uses biotechnology equipment or services from a biotechnology company of concern, we have taken several measures to strengthen our supply chain in the event that Wuxi Biologics, Inc. (&#8220;Wuxi Biologics&#8221;) or one of our other manufacturers is impacted. We are carefully monitoring and assessing the situation surrounding Wuxi Biologics and deliberating various options, including switching to a different CDMO for F351 clinical trials in the U.S. We will also continue to closely monitor geopolitical risk and implement additional mitigations and supply chain redundancies, as needed. See the risk factor entitled &#8220;Manufacturing pharmaceutical products on a large commercial scale is highly exacting and complex, and we and our third-party manufacturers may encounter problems during the process.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation in the United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States, at the federal, state and local levels, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs. Our current product candidates are expected to be regulated as pharmaceutical drugs. The processes for obtaining regulatory approval in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of our products and our research and development activities and require the expenditure of substantial time, human capital and financial resources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Review and Approval of Drugs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the FDA and other government entities regulate drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) and the regulations promulgated thereunder, as well as other federal and state statutes and regulations. Failure to comply with applicable legal and regulatory requirements in the United States at any time during the product development process, approval process, or after approval, may subject us to a variety of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">administrative or judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, withdrawal of approvals, delay or suspension of clinical trials, issuance of warning letters and other types of regulatory letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil monetary penalties, refusals of or debarment from government contracts, exclusion from the federal healthcare programs, restitution, disgorgement of profits, civil or criminal investigations by the FDA, U.S. Department of Justice, State Attorneys General, and/or other agencies, False Claims Act suits and/or other litigation, and/or criminal prosecutions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An applicant seeking approval to market and distribute a new drug in the United States must typically undertake the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of pre-clinical laboratory tests, animal studies, chemical synthesis and manufacturing and formulation studies in compliance with the FDA&#8217;s GLP, regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND for human clinical testing, which must become effective without FDA objection before human clinical trials may begin;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s good clinical practice (&#8220;GCP&#8221;), regulations, to establish the safety and effectiveness of the proposed drug product for each indication for which approval is sought;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation and submission to the FDA of a New Drug Application (&#8220;NDA&#8221;);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review of the NDA by an FDA advisory committee, where applicable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active pharmaceutical ingredient or ingredients thereof, are produced to assess compliance with cGMP, regulations and to assure that the facilities, methods, and controls are adequate to ensure the product&#8217;s identity, strength, quality, and purity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment of user fees, as applicable, and securing FDA approval of the NDA; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with any post-approval requirements, such as any risk evaluation and mitigation strategy (&#8220;REMS&#8221;), or post-approval studies required by the FDA.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical Studies and an IND</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To file an IND, an organization must produce batches of the actual material of drug substance and drug product to be used in the clinical trial. The batches of drug substance and drug product need to be characterized analytically before release and placed on stability. At least one month of stability data must be included in the IND upon submission.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical studies can include </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and animal studies to assess the potential for adverse events and, in some cases, to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Other studies include laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or API and the physical properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND to justify that the proposed clinical study may safely proceed. Some preclinical testing, such as longer-term toxicity testing, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following commencement of a clinical trial under an IND, the FDA may place a clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Clinical Studies in Support of an NDA</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites in late-stage clinical trials to assure compliance with GCP and the integrity of the clinical data submitted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. In the United States, when a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived, and some of the requirements may be waived upon the FDA&#8217;s decision. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with applicable FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Submission of an NDA to the FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently approximately $4.0 million for fiscal year 2024, for applications requiring clinical data, and the sponsor of an approved NDA is also subject to an annual program fee, currently approximately $0.4 million for fiscal year 2024. These fees are adjusted annually.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under certain circumstances, the FDA will waive the application fee for the first human drug application that a small business, defined as a company with less than 500 employees, including employees of affiliates, submits for review. An affiliate is defined as a business entity that has a relationship with a second business entity if one business entity controls, or has the power to control, the other business entity, or a third-party controls, or has the power to control, both entities. In addition, an application to market a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a disease or condition that affects fewer than 200,000 individuals in the United States, or for which there is no reasonable expectation that U.S. sales will be sufficient to recoup the development and production costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also may require submission of a REMS plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA&#8217;s Decision on an NDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information for the FDA to reconsider the application. If those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. After approval, the FDA may seek to prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast Track Designation, Accelerated Approval, Priority Review, Orphan Drug Designation and Breakthrough Therapy Programs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fast Track</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are several FDA programs intended to help facilitate the development of new drugs that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and data demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug may request the FDA to designate the drug as a Fast Track product at any time during the clinical development of the product. Under a Fast Track designation, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Priority Review</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product is eligible for priority review if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review to facilitate the review.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accelerated Approval</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product that is being studied for safety and effectiveness in treating serious or life-threatening illnesses and provides meaningful advantage over existing treatments may receive accelerated approval, which means that it may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint that can be measured earlier than, and is reasonably likely to predict an effect on, irreversible morbidity or mortality. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. The FDA also has increased authority for expedited procedures to withdraw approval of a product or indication approved under accelerated approval if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, for seven years. These circumstances are an inability to supply the drug in sufficient quantities or a situation in which a new formulation of the drug has shown superior safety or efficacy or a major contribution to patient care. This exclusivity, however, could also block the approval of its product for seven years if a competitor obtains earlier approval of the same drug for the same indication.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA&#8217;s interpretation of the scope of orphan drug exclusivity may change. The FDA&#8217;s longstanding interpretation of the Orphan Drug Act is that exclusivity is specific to the orphan indication for which the drug was actually approved. As a result, the scope of exclusivity has been narrow and protected only against competition from the same &#8220;use or indication&#8221; rather than the broader &#8220;disease or condition.&#8221; In the September 2021 case </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Catalyst Pharmaceuticals, Inc. v. FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a federal circuit court set aside the FDA&#8217;s narrow interpretation and ruled that orphan drug exclusivity covers the full scope of the orphan-designated disease or condition regardless of whether the drug obtains approval only for a narrower use. The decision concerned amifampridine, a drug used to treat Lambert-Eaton myasthenic syndrome (LEMS). Depending on how the FDA applies the decision beyond this case, it may limit the drugs that can receive exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Breakthrough Therapy Designation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product may also be eligible for receipt of a Breakthrough Therapy designation. The Breakthrough Therapy designation is intended to expedite the FDA&#8217;s review of a potential new drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease where &#8220;preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.&#8221; The designation of a drug as a Breakthrough Therapy provides the same benefits as are available under the Fast Track program, as well as intensive FDA guidance on the product&#8217;s development program. Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for approval, but they may expedite the development or approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant criminal and civil liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hatch-Waxman Patent Certification and the 30 Month Stay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the &#8220;Hatch-Waxman Amendments&#8221;) amending the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (&#8220;ANDA&#8221;) to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug (&#8220;RLD&#8221;). To reference that information, however, the ANDA applicant must demonstrate, and the FDA must conclude, that the generic drug does, in fact, perform in the same way as the RLD it purports to copy. Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. However, an applicant may submit an ANDA suitability petition to request the FDA&#8217;s prior permission to submit an abbreviated application for a drug that differs from the RLD in route of administration, dosage form, or strength, or for a drug that has one different active ingredient in a fixed combination drug product (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a drug product with multiple active ingredients).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the generic drug do not show a significant difference from the rate and extent of absorption of the RLD.&#8221; Upon approval of an ANDA, the FDA indicates that the generic product is &#8220;therapeutically equivalent&#8221; to the RLD and it assigns a therapeutic equivalence rating to the approved generic drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider the therapeutic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of a therapeutic equivalence rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, the applicant must certify with respect to each patent that:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the required patent information has not been filed;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the listed patent has expired;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA pursuant to an NDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant, and for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous findings of safety and effectiveness is scientifically and legally appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional bridging studies or measurements, including clinical trials, to support the change from the previously approved reference drug. The FDA may then approve the new drug candidate for all, or some, of the label indications for which the reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that a Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term Restoration and Extension</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments. Those Amendments permit a patent restoration of up to five years for patent term lost during product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of an NDA and ultimate approval. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure of Clinical Trial Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sponsors of clinical trials of FDA-regulated products, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other U.S. Healthcare Laws and Compliance Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), other divisions of the U.S. Department of Health and Human Services (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Office of Inspector General), the U.S. Department of Justice (&#8220;DOJ&#8221;) and individual U.S. Attorney offices within the DOJ and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy provisions of the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) and similar state laws, each as amended.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. There are statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Our practices may not in all cases meet all the criteria for protection under a statutory exception or regulatory safe harbor.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act (&#8220;ACA&#8221;) to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;any request or demand&#8221; for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved and thus non-reimbursable, uses. HIPAA created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for healthcare benefits, items or services.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are also a number of U.S. state privacy laws, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), that govern the privacy and security of personal information in certain circumstances. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked with a particular consumer or household&#8212;unless it is subject to HIPAA&#8212;and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Some of these laws and regulations impose different, and in certain instances, more stringent requirements than HIPAA. Failing to comply with these laws and regulations can result in significant civil and/or criminal penalties, as well as exposure to private litigation, all of which can result in financial and reputational risks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the federal Physician Payments Sunshine Act within the ACA and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing and to prohibit certain other sales and marketing practices. All our activities are potentially subject to federal and state consumer protection and unfair competition laws.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage, Pricing and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, privately managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. This is also true of Medicare reimbursement, where different vendors process payments, so that coverage by one vendor does not assure that all other vendors will provide coverage. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, the United States federal government position on matters related to drug pricing is evolving and uncertain and any changes could have a material impact on drug pricing generally in the United States, including for our product candidates if approved. Recently, the U.S. government passed the Inflation Reduction Act, which authorizes the U.S. Department of Health and Human service to negotiate prices of certain drugs with participating manufacturers in federal healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The National Institute for Health and Care Excellence (NICE) in the United Kingdom also requires consideration of cost-benefit analysis. The downward pressure on healthcare costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Foreign Corrupt Practices Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries and to devise and maintain an adequate system of internal accounting controls for international operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biological, chemical and radioactive substances used in and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government Regulation Outside of the United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain regulatory approval of an investigational drug under EU regulatory systems, we must submit a marketing authorization application.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the United States</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider our ability to recruit, retain and motivate our employees to be critical to our success. We are an equal opportunity employer and are fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. We strive to administer all human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination in accordance with the principal of equal employment opportunity, meaning on the basis of individual skills, knowledge, abilities, job performance and other legitimate criteria and without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 4 full-time employees in the U.S. We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages. We consider our relations with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We aim to provide our employees with competitive salary and benefits that enable them to achieve a good quality of life and plan for the future. Our benefits are based on local norms and market preferences, but include all salary and social benefits required by local law (including paid time off for vacation and sick leave) and many additional benefits that go beyond legal requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Business Organization</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We commenced operations in 2002 and are a Delaware corporation. On August 20, 2015, we merged with Targacept, Inc. and on October 30, 2023, we completed the Contributions and became Gyre Therapeutics, Inc. Our corporate headquarters are in San Diego, California. We conduct our R&amp;D activities and general and administrative functions primarily from our San Diego, California location.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, are available for free at www.gyretx.com as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. They are also available for free on the SEC&#8217;s website at www.sec.gov. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Operations in the PRC: Gyre Pharmaceuticals</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In this section, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;our company&#8221; refer to Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (&#8220;Gyre Pharmaceuticals&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals was founded in 2002 and is an innovative drug development enterprise in the PRC committed to the treatment of organ fibrosis diseases, integrated R&amp;D, production and commercialization. Gyre Pharmaceuticals is an indirect, majority-owned subsidiary of Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview of our PRC Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. We initially focused on the treatment of IPF and have gradually broadened our therapeutic field and R&amp;D efforts to other areas of organ fibrosis. Our flagship product, ETUARY, was approved in the PRC in 2011 and is among the first three approved drugs for IPF worldwide. Thereafter, we have developed a pipeline of additional innovative drug candidates F351, F528, F230 and F573 and have had ten years of successful commercialization of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the PRC&#8217;s first approved treatment for IPF, ETUARY has been included in the National Reimbursement Drug List (the &#8220;NRDL&#8221;) of the PRC since 2017. Filling a vacuum in the PRC as the first approved IPF treatment, ETUARY has developed rapidly and maintained a dominant market share in the PRC. The total estimated market size for IPF treatments in the PRC was $127.4 million in 2022 and is expected to grow to $698.6 million by 2031, according to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Frost &amp; Sullivan. Moreover, as different organ fibrosis diseases share a similar pathogenic mechanism and fibrosis process, we are seeking to expand the use of ETUARY to include other pulmonary fibrosis diseases, such as ILD and pneumoconiosis, as well as diseases causing renal fibrosis, such as DKD. The success of ETUARY in the IPF drug market lays the foundation for our R&amp;D and registration strategy to further expand the use of such drugs to indications with large patient populations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through in-house R&amp;D efforts and collaborative arrangements with GNI Japan, we have developed, in addition to ETUARY, a pipeline of pharmaceutical product candidates at various phases of clinical development, including F351, F528, F230 and F573. Specifically, liver fibrosis is an area of our focus and our key product candidate in this area is F351. F351 is currently in its Phase 3 clinical trial and has the potential to be the world&#8217;s first approved drug to treat liver fibrosis associated with CHB. According to Frost &amp; Sullivan, the number of patients with liver fibrosis in the PRC reached 140.3 million in 2022, of which approximately 45.3%, or 63.6 million, have liver fibrosis caused by CHB. Our Phase 2 clinical trials of F351 demonstrated positive results in reversing the fibrosis process and F351 was granted a Breakthrough Therapy designation by the CDE in March 2021. We commenced patient enrollment for the Phase 3 clinical trial in January 2022 and completed enrollment in the fourth quarter of 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our years of research into organ fibrosis, we have also expanded our R&amp;D to include potential treatments for COPD, PAH and ALF/ACLF:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F528</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are evaluating F528 in preclinical studies for the treatment of COPD. F528 is a novel anti-inflammation agent that targets inhibition of multiple inflammatory cytokines and has the potential to modify the progression of COPD with low toxicity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. According to Frost &amp; Sullivan, the number of COPD patients in the PRC reached 106.4 million in 2022 and is expected to reach 110.1 million by 2031. The current standard of care is primarily used to relieve symptoms, reduce the frequency and severity of disease deterioration and improve cardio endurance. We expect that F528 could provide a first-line therapy for COPD and reduce long-term lung function degradation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F230</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are evaluating F230, a selective endothelin receptor antagonist, in preclinical studies for the treatment of PAH. PAH is a progressive, life-threatening cardiovascular disease. According to Frost &amp; Sullivan, the number of PAH patients in the PRC reached 57,882 in 2022 and is expected to reach 70,279 by 2031. On March 13, 2024, we submitted an IND application for F230 in the PRC.</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F573</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are evaluating F573 in Phase 2 clinical trials for the treatment of ALF/ACLF. According to Frost &amp; Sullivan, the number of patients in the PRC with ALF/ACLF reached 39,247 in 2022. The main treatment options for ALF/ACLF include comprehensive medical therapy, non-biological artificial liver support therapy and liver transplantation. However, there are currently no approved small molecule or biologic drugs for the treatment of ALF/ACLF. We enrolled the first subject for the Phase 1 clinical trial in January 2022 and initiated our Phase 2 clinical trial in March 2023.</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While advancing the R&amp;D of our pipeline products, we are one of only a few biopharmaceutical companies focusing on organ fibrosis drugs in the PRC with manufacturing and commercialization capabilities and an established track record. For further details about our two manufacturing centers, manufacturing capabilities and processes, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Properties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gyre Pharmaceuticals&#8217; Properties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; and &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Production and Quality Control&#8212;In-House Manufacturing Facilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; For further details about our professional sales team and a comprehensive sales network, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales, Marketing and Distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also one of a limited number of biopharmaceutical companies in the PRC that has grown from a development-stage company to achieving sustained profitability. This growth was primarily attributable to the increased market demand for ETUARY, which is the first IPF drug marketed in the PRC. We face limited competition in the IPF drug market and we direct our marketing resources to encourage physician adoption of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Products and Product Pipeline</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ETUARY: National Category 1.1 New Drug for IPF Approved in 2011</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ETUARY (pirfenidone capsule) was approved as a National Category 1.1 New Drug in 2011 for the treatment of IPF, a rare disease. Given the absence of an approved IPF treatment in the PRC, ETUARY was included in the NRDL in 2017 and has since held a dominant market share. Clinical studies have shown that ETUARY can effectively slow down the decline in lung function and IPF disease progression. Moreover, given that different organ fibroses have similar pathogenic mechanisms and fibrosis processes, we are currently working to expand the therapeutic indications of ETUARY to other pulmonary fibrosis diseases, such as SSc-ILD, DM-ILD and pneumoconiosis, as well as diseases causing renal fibrosis, such as DKD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mechanism of Action</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pulmonary fibrosis is caused by activation of alveolar cells after epithelial damage, which secretes a series of pro-inflammatory cytokines, activating fibroblast proliferation and myofibroblast differentiation and reducing the rate of apoptosis. ETUARY reduces Type I Collagen expression by inhibiting the expression of pro-fibrogenic mediators, including TGF-&#223;1, platelet-derived growth factor (&#8220;PDGF&#8221;) and fibroblast growth factor, which ultimately reduces fibroblast proliferation and collagen fiber synthesis and decreases extracellular matrix accumulation. It also inhibits TNF-&#945;, IL-1 and other inflammatory mediators, thus reducing the inflammatory response.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The diagram below illustrates the mechanism of action of pirfenidone.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img98921446_3.jpg" alt="img98921446_3.jpg" style="width:624px;height:305px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunities and Competition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IPF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IPF is a rare disease, defined as a chronic, progressive fibrotic interstitial pneumonia of unknown cause to the lungs, occurring primarily in the elderly. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis. The average five-year survival rate for patients with IPF is 32%, with the average 10-year survival rate dropping to 16%. According to Frost &amp; Sullivan, the prevalence of IPF in the PRC increased from 83,002 patients in 2017 to 131,654 patients in 2022 at a CAGR of 9.7%, and it is expected to increase to 214,664 patients by 2027 at a CAGR of 10.3% from 2022 to 2027 and to 320,677 patients by 2031 at a CAGR of 10.6% from 2027 to 2031. The total market size of IPF in the PRC increased from $13.6 million in 2017 to $127.4 in 2022 at a CAGR of 56.3%, and is expected to reach $344.9 million by 2027 at a CAGR of 22.0% from 2022 to 2027 and $698.6 million by 2031 at a CAGR of 19.3% from 2027 to 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scarring of lung tissues is irreversible. However, proper treatment may slow the rate of fibrosis, increase the patient&#8217;s survival rate, alleviate the patient&#8217;s symptoms and improve the patient&#8217;s quality of life. There are currently two types of IPF drugs approved in the PRC: pirfenidone and nintedanib. They are both clinically shown to slow down the formation of scar tissue in the lungs of IPF patients and are the only drugs that are considered effective for the treatment of organ fibrosis in the PRC. According to the latest guideline for the treatment of IPF issued by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Latin American Thoracic Association, pirfenidone and nintedanib are the only two types of IPF drug conditionally recommended with moderate-quality evidence.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its commercialization in the PRC, ETUARY has remained a dominant player in the IPF drug market. Sales of ETUARY have continued to grow, increasing from $99.2 million in 2022 to $112.1 million in 2023, and we expect our sales growth to continue. Although still a dominant player, the market share of ETUARY declined recently primarily due to the rising market share of new drugs, including &#23433;&#21338;&#21496;, which had $13.5 million of sales in 2022, and OFEV (Nintednib), which had $67.0 million of sales in 2022. In 2022, the annual expenditures per patient in the PRC before NRDL reimbursement for ETUARY, &#23433;&#21338;&#21496;, and OFEV were $13,106 to $13,378, $10,553, and $15,132, respectively. Despite the recent decrease of market share of ETUARY in the IPF market, we continue to expect a strong sales performance due to sustained increases in the prevalence of IPF and future indication expansion of ETUARY for the potential treatment of ILD, pneumoconiosis and other diseases. In addition, there are various barriers to entry for the potential market entrants. For instance, it is difficult for new entrants to build an experienced and specialized sales and marketing team in the short term given that sales and marketing strategies of organ fibrosis drugs significantly differ from that of etiological treatment drugs and long-term and stable collaboration with KOLs and hospitals is critical to developing and optimizing product portfolio, effectively educating and penetrating the market and recruiting patients for clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SSc-ILD and DM-ILD</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CTD-ILD is non-idiopathic interstitial pneumonia. Connective Tissue Diseases ("CTD") is a type of autoimmune disease that causes damage to various organs throughout the body based on chronic inflammation of blood vessels and connective tissue. Interstitial Lung Diseases  ("ILD")  is one of the most serious pulmonary complications and can result in significant morbidity and mortality when associated with CTD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scleroderma (&#8220;SSc&#8221;) is a CTD characterized by degenerative microvascular phenomena and immune system activation, leading to fibrosis of the skin and internal organs. ILD is very frequent in patients affected by SSc, reaching about 50% prevalence, representing the leading SSc-related cause of death. Dermatomyositis ("DM") is characterized by proximal skeletal muscle weakness and muscle inflammation. Among patients with DM, ILD is a major cause of morbidity and mortality. The frequency of ILD in DM has been reported to range between 5% and 45%, depending on the diagnostic method.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of CTD-ILD in the PRC increased from approximately 2.3 million patients in 2017 to 2.4 million patients in 2022, and is expected to reach 2.5 million patients in 2027 and 2.6 million patients in 2031. Among the CTD-ILD patients, approximately 8.4% are SSc-ILD and DM-ILD patients in 2022. The market size of anti-fibrosis drugs for SSc-ILD/DM-ILD patients was $9.1 million in 2022 and is expected to reach $53.1 million by 2027 and $117.6 million by 2031 at a CAGR of 42.4% from 2022 to 2027 and a CAGR of 22.0% from 2027 to 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SSc-ILD and DM-ILD are induced by known factors, including specific exposure or autoimmune diseases (such as scleroderma and rheumatoid arthritis). Symptoms include chronic cough, expectoration, hemoptysis, progressive dyspnea and intermittent fever. The treatment of CTD-ILD (including SSc-ILD and DM-ILD) is a combination of the immunosuppressive treatment for CTD and the anti-fibrosis treatment for ILD, which can effectively prevent or even reverse the progression of ILD lesion and protect the pulmonary function of patients. Recommended immunological drugs include cyclophosphamide, mycophenolate mofetil and azathioprine. Anti-fibrosis treatment methods vary with different types of CTD-related ILD in terms of the timing, drug selection, dosage and treatment duration. Recommended anti-fibrosis drugs include pirfenidone and nintedanib.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pirfenidone is an antifibrotic agent with anti-inflammatory properties, including inhibition of proinflammatory cytokines and inhibition of inflammatory cell proliferation. Despite the differences in their clinical presentation, IPF,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SSc-ILD and DM-ILD share some overlapping pathogenic mechanisms, including injury to structural cells, fibroblast activation, myofibroblast accumulation, expression of fibrogenic cytokines and growth factors and progressive ILD. Based on the results of pirfenidone&#8217;s preclinical studies, we are evaluating its efficacy on patients with SSc-ILD and DM-ILD in Phase 3 clinical trials. Currently, nintedanib is approved for the treatment of anti-fibrosis in patients with SSc-ILD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pneumoconiosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pneumoconiosis refers to a spectrum of pulmonary diseases caused by inhalation of mineral dust, usually as the result of certain occupations. The main pathological features include chronic pulmonary inflammation and progressive pulmonary fibrosis, which can eventually lead to death caused by respiratory and/or heart failure. Pneumoconiosis is widespread globally and a serious global public health concern. Its high incidence and mortality result from improper occupational protection and the lack of early diagnostic methods and effective treatments.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Frost &amp; Sullivan, in the PRC, the prevalence of pneumoconiosis increased from 850,299 patients in 2017 to 926,769 patients in 2022, and it is expected to increase to 962,562 patients by 2027 and 980,917 patients by 2031. The market size of anti-fibrosis drugs for pneumoconiosis is expected to reach $12.1 million by 2027 and $64.1 million by 2031 a CAGR of 51.7% from 2027 to 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, there are two pirfenidone product candidates for the treatment of pneumoconiosis in various clinical stages in the PRC. We enrolled the first patient in our Phase 3 clinical trial of ETUARY for the treatment of pneumoconiosis in June 2022, making ETUARY the most clinically advanced anti-fibrosis drug for the treatment of pneumoconiosis in the PRC. As of December 31, 2023, no small molecule or biologic anti-fibrosis product for the treatment of pneumoconiosis had been approved in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An experimental study on silica-induced lung fibrosis in rats demonstrated that pirfenidone can slow the transformation from epithelial to mesenchymal cells when administered for 14 days and 28 days. These treatments were associated with a significant down-regulation of vimentine and up-regulation of E-cadherin, suggesting that pirfenidone can exhibit an inhibiting effect on silica-induced epithelial-mesenchymal transition in rats.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DKD</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DKD is a chronic kidney disease (&#8220;CKD&#8221;) caused by diabetes mellitus.  DKD is clinically manifested as specific pathological structural and functional changes in the kidney of diabetes patients. In addition, DKD has become the primary cause of progression from CKD to the end-stage renal disease and one of the main diseases causing renal fibrosis. As one of the serious complications of diabetes, DKD in the PRC is characterized by high prevalence, low awareness rate, low treatment rate and low control rate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of DKD in the PRC increased from 45.4 million patients in 2017 to 53.2 million patients in 2022, and it is expected to increase to 61.5 million patients by 2031. The DKD market in the PRC increased from $24.2 billion in 2017 to $37.2 billion in 2022 and it is predicted to expand to $51.5 billion by 2027 and $60.3 billion by 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The standard of care for DKD has been blood glucose control, blood pressure control and blood liquid control. However, current therapeutic strategies are far from being completely effective because no available therapy successfully prevents DKD and many patients still progress to end-stage renal disease. The current available drugs for the treatment of DKD include hypoglycemic drugs, antihypertensive drugs and lipid-lowering drugs. As of December 31, 2023, there was one approved treatment for DKD in many parts of the world, finerenone (marketed under the name KERENDIA).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pirfenidone has demonstrated positive therapeutic effects on DKD due to its unique mechanism of action. Several growth factors or cytokines that are locally produced in the kidney appear to contribute to the extracellular matrix accumulation, inflammation and scarring in progressive DKD. The TGF-&#223;1 system is activated and plays a pathogenetic role in DKD in animal models of type 1 and type 2 diabetes. In addition, several studies in patients with type 1 and type 2 diabetes indicate increased renal production of TGF-&#223;1. The TNF-&#945;&#8217; system has also recently been linked with human DKD on the basis of circulating blood levels and gene expression in kidneys from patients with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DKD. Pirfenidone has been found to inhibit TGF-&#223;1 production and consequent matrix deposition in experimental animal models of kidney disease. In animal models and cell culture studies, pirfenidone also reduces TNF-&#945;&#8217; production. Previous studies also showed that oral pirfenidone administered to db/db mice after the onset of established DKD was effective in reducing glomerulosclerosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Clinical Results</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, Gyre Pharmaceuticals and Shanghai Genomics, Inc. (&#8220;SG&#8221;) have conducted over 10 clinical trials to explore the clinical benefits of pirfenidone in the PRC. As the first drug approved for IPF in the PRC, ETUARY was approved upon completion of Phase 2a clinical trials. Summarized below are current key clinical trials of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registered Phase 2a Clinical Trial of Pirfenidone for IPF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This trial was a randomized, double-blind, multi-dose, parallel-controlled, multicenter Phase 2a clinical trial to investigate the effectiveness of pirfenidone combined with basic treatment for IPF. The objective was to evaluate the safety and efficacy of pirfenidone capsules, as well as to determine the most appropriate clinical treatment dose by observing the therapeutic effects of pirfenidone capsules on pulmonary function (including arterial blood gas analysis), the six-minute walk test (&#8220;6MWT&#8221;), survival, quality of life and high-resolution computed tomography imaging in IPF patients. The treatment group was divided into two dose treatment groups, a 400 mg/tid treatment group and a 600 mg/tid treatment group. 24 patients were enrolled in each treatment group. The placebo group was also divided into two groups, a four capsules/tid group and a six capsules/tid group, with 12 patients in each group. The treatment and placebo groups were assigned in a 2:2:1:1 ratio and patients were stratified and randomized to be assigned to receive pirfenidone or placebo. The primary endpoints were pulmonary function parameters, 6MWT results and survival rate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This trial has been completed with a total of 72 patients enrolled.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The efficacy results of the trial were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.704%;"/>
    <td style="width:1.04%;"/>
    <td style="width:1.04%;"/>
    <td style="width:17.704%;"/>
    <td style="width:1.04%;"/>
    <td style="width:1.04%;"/>
    <td style="width:60.432%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:1pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Therapeutic Effect</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Criteria</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Results (FAS, after 12 months treatment)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pulmonary function</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diffusing capacity of carbon monoxide % (&#8220;DLco%&#8221;)</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">There was a statistically significant difference among the three groups of the change in DLco% (P=0.0306), with a mean change of -2.79&#177;9.34% in the 600 mg treatment group and a mean change of -14.92&#177;16.40% in the placebo group (P=0.0014 for the two groups).</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diffusing capacity of carbon monoxide (&#8220;DLco&#8221;)</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">There was a statistically significant difference among the three groups of the change in DLco (P=0.0049), with a mean change of -0.42&#177;3.45% in the 600 mg treatment group and a mean change of -3.14&#177;4.44% in the placebo group (P=0.0016 for the two groups).</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Arterial oxygen saturation (&#8220;SaO2&#8221;)</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">There was a statistically significant difference among the three groups of the change in arterial oxygen saturation (SaO2) (P=0.0145), with a mean change of -3.83&#177;4.02% in the placebo group and -0.30&#177;3.05% in the 400 mg group (P=0.0055 for the two groups).</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6MWT</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pulse oxygen saturation (&#8220;SpO2&#8221;)</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">There was a statistically significant difference among the three groups of the change in SpO2 after 6MWT (P=0.0168), with a mean change of -9.08&#177;10.66% in the placebo group and 0.22&#177;7.30% in the 400 mg treatment group (P=0.0062 for the two groups).</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.704%;"/>
    <td style="width:1.04%;"/>
    <td style="width:1.04%;"/>
    <td style="width:17.704%;"/>
    <td style="width:1.04%;"/>
    <td style="width:1.04%;"/>
    <td style="width:60.432%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Survival rate</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The mortality of placebo group, 400 mg treatment group and 600 mg treatment group was 20.83%, 21.74% and 16.67%, respectively, with no statistical significance.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17 patients experienced SAEs, but none were drug-related. The incidence of adverse drug reactions (&#8220;ADRs&#8221;) in the placebo group, 400 mg and 600 mg treatment groups was 41.67%, 29.17% and 45.83%, respectively, with no statistical difference between the three groups. The incidence of rash in the treatment groups was statistically different from that in the placebo group and was present in all of the 600 mg treatment groups with an incidence of 20.83%. The common ADRs included nausea (12.5% in each of the 400 mg treatment group and 600 mg treatment group), photosensitivity (4.17% in the 400 mg treatment group and 12.5% in the 600 mg treatment group) and drowsiness (8.33% in the 600 mg treatment group), but these were not statistically significant from the placebo group. The incidence of AEs in the placebo group, 400 mg and 600 mg treatment groups was 70.83%, 66.67% and 66.67%, respectively, with no statistical difference between the three groups. The average incidence of SAEs in each of the placebo group and the 400 mg and 600 mg treatment groups was 54.17%, with no statistical difference between the three groups. The incidence of SAEs (including mortality and hospitalization) in each of the placebo group and the 400 mg and 600 mg treatment groups was 29.17%, 20.83% and 20.83%, with no statistical difference between the three groups.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After 12 months of treatment, pirfenidone was effective in slowing down the decline in DLco%, DLco, SaO2 and SpO2 immediately after 6MWT. No drug-related SAEs were observed and rash and nausea were the most common ADRs. The results show that pirfenidone has potential for the treatment of IPF.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 Clinical Trial of Pirfenidone for the Treatment of SSc-ILD</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are conducting a randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial to evaluate the efficacy and safety of pirfenidone in the treatment of SSc-ILD. The primary endpoint is the change in FVC% at 52 weeks of treatment compared to baseline. 144 patients are planned to be enrolled in the trial, with 108 in the treatment group and 36 in the control group.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This trial enrolled the first patient in June 2018. Due to the outbreak of COVID-19 and the scarcity of eligible patients, this trial is still in the process of recruiting patients and therefore no clinical results are currently available for analysis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 Clinical Trial of Pirfenidone for the Treatment of DM-ILD</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are conducting a randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial to evaluate the efficacy and safety of pirfenidone for the treatment of DM-ILD. The primary endpoint is the change in FVC% at 52 weeks of treatment compared to baseline. 152 patients will be enrolled in the trial, with 114 in the treatment group and 38 in the control group.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This trial enrolled the first patient in June 2018. Due to the outbreak of COVID-19 and the scarcity of eligible patients, this trial is still in the process of recruiting patients and no clinical results are currently available for analysis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 Clinical Trial of Pirfenidone for the Treatment of Pneumoconiosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are conducting a randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical trial to evaluate the efficacy and safety of pirfenidone in the treatment of pneumoconiosis. The primary endpoint is the change in force vital capacity at 52 weeks of treatment compared to baseline. 272 patients will be enrolled in the trial, with 136 in the treatment group and 136 in the control group.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We obtained ethics committee approval as of January 2022 and enrolled the first patient in June 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1 Clinical Trial of Pirfenidone for Our DKD Program</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted an open-label, parallel-controlled, single-center clinical trial is to evaluate the safety and PK of a single dose of pirfenidone capsules in patients with CKD stages G2 and G3a. 24 subjects were enrolled, consisting of 12 patients with renal insufficiency and 12 healthy volunteers.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Phase 1 clinical trial was completed in March 2022. In this trial, pirfenidone was tolerated when used in patients with chronic kidney disease G2 and G3a, there were no significant changes in the main pharmacokinetic parameters compared with healthy controls, and no dose adjustment was required.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Clinical-Stage Product - F351: Category 1 New Drug to Reverse CHB-Associated Liver Fibrosis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F351, our Phase 3 clinical-stage product candidate, has the potential to become the first approved drug to treat CHB-associated liver fibrosis. According to Frost &amp; Sullivan, CHB is the number one cause of liver fibrosis in the PRC and the number of patients with liver fibrosis in the PRC reached approximately 140.3 million in 2022, of which approximately 45.3% were caused by CHB. To date, there is no effective clinical therapy for liver fibrosis and no specific therapeutic drugs have been approved worldwide. F351 demonstrated positive results the reversal of the fibrosis process in its Phase 2 clinical trial. F351 may reverse liver fibrosis by inhibiting hepatic stellate cell proliferation and the TGF-&#223;1 signaling pathway, both of which play major roles in the CHB-associated liver fibrosis. Due to the results of the Phase 2 clinical trial in CHB-induced liver fibrosis, and as one of the first drugs announced to treat liver fibrosis, F351 was granted a Breakthrough Therapy designation by the CDE in March 2021 and we commenced patient enrollment for the Phase 3 clinical trial in January 2022. We completed enrollment in the fourth quarter of 2023 and expect to have the last patient out in 2024 and to submit an NMPA application for F351 in the PRC in early 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mechanism of Action</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When injuries occur and epithelial and/or endothelial cells are damaged, pro-inflammatory cytokines are released by the coagulation cascade for immune cell recruitment, mainly neutrophils and macrophages. These recruited immune cells function as the scavenger to remove tissue debris and dead cells, resulting in acute inflammation. Meanwhile, immune cells themselves release factors like chemokines and cytokines to amplify inflammatory reactions. Next, the released factors, such as TGF-&#223;1, PDGF, interleukin-13 and interleukin-4, induce the limited activation and proliferation of myofibroblasts. F351 is expected to treat and reverse liver fibrosis in chronic viral hepatitis B by inhibiting the proliferation of HSCs and the TGF-&#223;1 signaling pathway.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The diagram below illustrates the mechanism of action of F351:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img98921446_4.jpg" alt="img98921446_4.jpg" style="width:550px;height:383px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunities and Competition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CHB is a major cause of liver morbidity and mortality in Asia. Patients chronically infected with the hepatitis B virus tend to experience liver fibrosis and may develop end-stage liver disease, such as decompensated cirrhosis and HCC, without intervention. In the PRC, about 70% of cirrhoses were developed from HBV infection, which reflects the significant demand for the treatment of CHB-associated liver fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of CHB-associated liver fibrosis globally increased from 221.1 million patients in 2017 to 257.8 million patients in 2022. The prevalence of CHB-associated liver fibrosis in the PRC from 2017 to 2022 ranges from 63.6 million to 66.4 million patients and is expected to remain stable in the next 10 years. The anti-liver fibrosis drug market in the PRC has increased from $138.0 million in 2017 to $162.7 million in 2022 and we expect the market to grow to $338.0 million in 2027 and $801.2 million in 2031, at a CAGR of 15.8% and 24.1%, respectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Etiological treatment is currently the most common treatment of liver fibrosis. For CHB-associated liver fibrosis, antiviral therapy is only able to suppress the viral infection, but is unable to prevent, slow or reverse the progress of fibrosis, suggesting a significant unmet need for effective antifibrotic therapy. Anti-fibrotic treatment is recommended for the treatment of intermediate and advanced liver fibrosis, as well as early-stage cirrhosis. As of December 31, 2023, no chemical or biological drugs treating liver fibrosis that have been approved globally or in the PRC. Globally, there are currently a series of drugs that are in late-stage (Phase 2 or later) clinical trials for the treatment of liver fibrosis. Of these clinical-stage drugs, F351 is the most clinically advanced product candidate in the PRC that has the potential to effectively reverse the fibrosis process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our clinical trials, F351 showed promising results in the reversal of liver fibrosis. Our Phase 2 clinical results in CHB patients with liver fibrosis show that, using the pathological score of Ishak stage as the primary outcome measure, the treatment group showed better results in reversing liver fibrosis than the placebo group after 52 weeks of treatment. In particular, around 56.1% of the patients achieved a fibrosis regression of &gt; 1 in the 270 mg group. We commenced the patient enrollment for the Phase 3 clinical trial in January 2022 and completed enrollment in October 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Clinical Results</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, more than five clinical trials sponsored by us or SG were carried out to explore the clinical risk/benefit of F351. Summarized below are the results of selected key clinical trials of F351.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2 Clinical Trial of F351 for CHB-Associated Liver Fibrosis in the PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted a Phase 2 randomized, double-blind, placebo-controlled, Entecavir-based (the first-line drug for the treatment of CHB virus infection), multi-center, dose-escalation trial assessing the safety and efficacy of F351 for treatment of patients in the PRC with CHB-associated liver fibrosis. The Phase 2 trial was randomized in 240 patients divided into four dose-escalating groups (placebo; 180 mg/day; 270 mg/day; and 360 mg/day) with a primary endpoint of the reduction of the liver fibrosis score (Ishak Scoring System) by greater than or equal to one grade after taking F351 in combination with Entecavir.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trial met its primary endpoint of a statistically-significant improvement in the liver fibrosis score over the 52-week treatment versus placebo (p=0.0245). The percentages of patients who achieved a fibrosis regression of &gt; 1 were 25.58% (placebo), 40.48% (180 mg/day), 56.10% (270 mg/day) and 43.90% (360 mg/day). Accordingly, the 270 mg/day treatment group showed the highest percentage of patients who were able to reach the primary endpoint.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F351 showed better safety results when compared to the placebo in this trial. In the placebo group, 180 mg treatment group, 270 mg treatment group and 360 mg treatment group, rates of SAEs were 4.65%, 2.38%, 2.38% and 7.32%, respectively, with no statistical significance. A total of seven (4.17%) subjects experienced seven SAEs throughout the trial: two (4.6%) in the placebo group, one (2.38%) in the 180 mg group, one (2.38%) in the 270 mg group and three (7.32%) in 360 mg group, with no statistical significance. The SAEs were laboratory abnormalities, elevation of transaminases, embolic infarction, comminuted fracture, osteoporosis, unplanned pregnancy and hypertension. No deaths occurred.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 Clinical Trial of F351 for CHB-Associated Liver Fibrosis in the PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are conducting a Phase 3 randomized, double-blind, placebo-controlled, Entecavir-based, multi-center trial assessing the safety and efficacy of F351 for treatment of patients in the PRC with CHB-associated liver fibrosis. The Phase 3 clinical trial was designed to be randomized in 248 patients with a primary endpoint of the reduction of the liver fibrosis score (Ishak Scoring System) by at least one grade after taking F351 in combination with Entecavir.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We commenced patient enrollment for the Phase 3 clinical trials of F351 in January 2022 and completed enrollment in October 2023. No clinical results are currently available for analysis. We expect to have top line results by early 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F573: Potential Category 1 New Drug for ALF/ACLF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F573 is a caspase inhibitor and a potential Category 1 new drug for the treatment of ALF/ACLF. According to Frost &amp; Sullivan, the number of patients with ALF/ACLF in 2022 reached 39,247 in the PRC. The main treatment options for ALF/ACLF include comprehensive medical therapy, non-biological artificial liver support therapy and liver transplantation. Currently, there are no drugs specifically for the treatment of ALF/ACLF. We enrolled the first subject for the Phase 1 clinical trial in January 2022 and initiated a Phase 2 clinical trial in March 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mechanism of Action</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inflammatory response and immune dysfunction can lead to massive liver cell death, which causes ALF/ACLF. Therefore, inhibiting the apoptosis process of normal hepatocytes helps to delay the progression of ALF/ACLF. The main mediating pathways of hepatocyte apoptosis include the mitochondrial pathway and the death receptors pathway, where the caspase family plays an important role as the main executive molecules. The main mechanism of F573 is to inhibit the activity of the caspase family, including caspases 1, 3, 6, 7, 8 and 9 and to reduce the cleavage effects on poly-ADP-ribose polymerase, thus blocking the cell apoptosis process mediated by endogenous or exogenous signals. As a result, hepatic failure is expected to be alleviated by F573.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The diagram below illustrates the mechanism of action of F573:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img98921446_5.jpg" alt="img98921446_5.jpg" style="width:624px;height:281px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunities and Competition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALF/ACLF is severe liver damage caused by a variety of factors, resulting in severe impairment or loss of synthesis of detoxification, metabolism and biotransformation functions. ALF/ACLF can follow with syndromes of jaundice, coagulation dysfunction, hepatorenal syndrome, hepatic encephalopathy and ascites. The causes of ALF/ACLF are complex and include the hepatitis viruses (especially HBV) and other viruses, drugs, hepatotoxic substances (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, alcohol and chemical agents), bacteria and parasites. In the PRC, HBV, drugs and hepatotoxic substances are the most common causes of ALF/ACLF.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of ALF/ACLF in the PRC was 43,123 patients in 2017 and 39,247 patients in 2022 and is expected to be 34,969 patients in 2027 and 31,485 patients in 2031. The market size of ALF/ACLF in the PRC was $278.6 million in 2017 and $253.5 million in 2022 and it is expected to be $225.9 million in 2027 and $203.3 million in 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The main treatment options for liver failure include comprehensive medical therapy, non-biological artificial liver support treatment and liver transplantation. Medical treatment mainly includes general supportive therapy, symptomatic treatment, etiological treatment and treatment for complications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The efficacy profile of F573 has been demonstrated in four preclinical studies. In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> studies, F573 had a significant inhibitory effect on apoptosis in a variety of cells. Specifically, F573 had a protective effect on HeLa cells, human normal hepatocytes L02 and Jurkat cells, while inhibiting Caspase-3 enzyme activity and reducing its ability to cleave the substrate AC-DEVD-AMC. F573 improved liver function and alleviated the liver injury caused by D-GalN/LPS-induced fulminant liver failure in rats, which significantly inhibited hepatocyte necrosis and apoptosis and showed a preventive and therapeutic effect on acute and severe liver injury. In a pharmacodynamic acute liver injury experiment on D-Gal/LPS mortality in mice, F573 had a protective effect against acute liver injury caused by D-Gal and LPS in km mice and prolonged the survival time of km mice. F573 has been shown to improve liver function and reduce liver injury in ConA-induced acute liver failure in BALB/c mice. F573 significantly inhibits hepatocyte necrosis and apoptosis and has a preventive and therapeutic effect on acute and severe liver injury.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development Plan</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1 Clinical Trial of F573 for ALF/ACLF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enrolled the first subject for our Phase 1 clinical trial to assess the tolerance and PK of single and multiple doses of F573 in January 2022. We recruited 100 healthy subjects for this trial and completed the Phase 1 clinical observations of tolerability and PK in July 2022. The Cmax of F573 was not dose-dependent at the dose range from 0.5 mg/kg to 2.0 mg/kg, and AUC0-t and AUC0-&#8734; of F573 showed linear pharmacokinetics. The rate of absorption of F573 showed sex differences. F573 was administered once a day for seven days without accumulation in the human body.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2 Clinical Trial of F573 for ALF/ACLF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We initiated our Phase 2 clinical trial in March 2023. The Phase 2 clinical trial is designed to be a randomized, double-blind, placebo-controlled clinical trial. The main objective of this trial is to assess the efficacy and safety of F573 for injection in the treatment of liver injury/failure. The Phase 2 trial is divided into three stages:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">First Stage</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: 16 patients with 1/2 grade DILI or other liver injury patients and 9 patients with CHB are expected to enroll. First, DILI or other liver injury patients will be treated with the trial drug at either 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or placebo in a 1:1:1:1 ratio. CHB patients will receive the trial drug.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Second Stage</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: 12 cases in each of the 2/3 grade DILI or other liver injury patients and the CHB patient groups are expected to enroll and are expected to be assigned to the experimental group and the control group in a ratio of 3:1.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After obtaining subject consent, pharmacokinetic blood samples will be collected for CHB patients in stages 1 and 2 in this trial.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third Stage</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: This stage is expected to use a randomized, double-blind, placebo-controlled design. The stage is designed to be divided into screening period (14 days), treatment period (28 days) and follow-up period (90 days).</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48 screen-eligible subjects are expected to receive trial drug or placebo in a ratio of 3:1, once a day for 28 days. Subjects are also expected to receive concurrent drug acetylcysteine injection. After withdrawal, the subjects will be followed up for 90 days for safety.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Preclinical-Stage Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F230: Selective Antagonist of EPA for PAH</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F230 is a selective endothelin-receptor A antagonist to treat PAH. PAH is a rare disease and a progressive, life-threatening disorder characterized by increased pressure in the pulmonary arteries that carry blood from the heart to the lungs. A common pathological hallmark of PAH is vascular remodeling, including increased stiffening and thickening of pulmonary arteries. This restricts blood flow through the lungs, causing pulmonary hypertension and making the heart work harder to pump blood to the lungs. The exact cause of PAH is unknown and there is no known cure for PAH. PAH is a serious disease that has a short life expectancy if left untreated. The prognosis for the treatment of PAH is poor, with a high mortality rate and survival of less than three years in the absence of standard therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of PAH in the PRC increased from 49,004 patients in 2017 to 57,882 patients in 2022 and it is expected to increase to 67,682 patients by 2027 and 70,279 patients by 2031. The market size of PAH in the PRC increased from $0.29 billion in 2017 to $0.37 billion in 2022 and it is expected to increase to $0.47 billion by 2027 and $0.52 billion by 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the study of Hypoxia-induced PAH in rats, F230 resulted in significant decreases of, or exhibited a decrease trend based on different dose groups in, mean pulmonary arterial pressure, right ventricular systolic pressure, right ventricular/left ventricular plus septum and pulmonary artery wall thickness. Even at minimum effective dosage, the differences of those indexes between treatment group and PAH group are statistically significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F528: A Potential First-line Therapy for COPD</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F528 is an anti-inflammatory small molecule drug candidate developed for the treatment of COPD. F528 is a novel anti-inflammation agent that targets inhibition of multiple inflammatory cytokines and could modify the progression of COPD with extreme low toxicity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. COPD is a chronic inflammatory lung disease which causes obstructed air flow from the lungs. It consists of three separate illnesses: emphysema, chronic bronchitis and chronic obstructive asthma. COPD causes the destruction of barriers between alveoli inside the lungs, causing airways to get swollen and clogged with mucus. In most cases, COPD develops very slowly and symptoms may emerge for years before being diagnosed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Frost &amp; Sullivan, prevalence of COPD in the PRC increased from 102.7 million patients in 2017 to 106.4 million patients in 2022 and is expected to increase to 108.6 million patients in 2027 and 110.1 million patients in 2031. The COPD market in the PRC was $0.9 billion in 2017 to $1.1 billion in 2022. The market is predicted to expand to $1.3 billion by 2027 and $1.5 billion by 2031.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The drug treatment of COPD is mainly used to relieve symptoms, reduce the frequency and severity of disease deterioration and improve cardio endurance and health. Currently, there is no conclusive clinical trial evidence showing that existing drugs can slow down the long-term decline in lung function. For late-stage COPD patients, currently-available treatment options achieve limited therapeutic effects. As clinical research results from external parties indicated, 2% of patients were reported to gain improvement in exercise capability after 24 months of standard medical treatment and none were reported to gain improved health-related quality of life. Thus, there are significant unmet clinical needs for COPD patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe F528 could become first-line therapy for COPD. In a preclinical study of the effect of F528 in rats with COPD induced by smoke exposure and LPS tracheal injection, the lung index, the alveolar space and the lung injury score were significantly decreased after the treatment of F528.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Drug Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To supplement and enrich our product candidate pipeline, we acquire the marketing rights to certain generic drugs, including avatrombopag maleate for the treatment of CLD-associated thrombocytopenia, fingolimod hydrocholoride  for the treatment of multiple sclerosis, minocycline hydrochloride foam for the treatment of moderate to severe acne and acetylcysteine injection for the treatment of respiratory diseases with excessive thick mucus discharge.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Occupational, Health, Safety and Environmental Matters</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to various health, safety, social and environmental laws and regulations and our operations are regularly inspected by local government authorities. We are committed to social responsibility and consider environmental, social and governance essential to our continuous development and we believe we have adequate policies to promote compliance with applicable health, safety, social and environmental protection regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the oversight of the senior management, we actively identify and monitor the actual and potential impact of environmental, social and climate-related risks on our business, strategy and financial performance and incorporate considerations for these issues into our business, strategic and financial planning with a particular focus on areas such as employee responsibility, environment responsibility and public responsibility. Corporate social responsibility is viewed as part of our core growth philosophy and pivotal to our ability to create sustainable value for our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we monitor and enforce the compliance of our operations with environment, health and safety laws and regulations. This responsibility is executed through training, formulation and implementation of strategies, policies, standards and metrics, communication of environmental, health and safety policies and procedures through a team of coordinators, environmental, health and safety audits and incident response planning and implementation. With the oversight of our management, our quality control team assesses the likelihood of such risks occurring and the estimated magnitude of any potential impact.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Permits and Other Approvals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have received all material permissions and approvals required for our business operations. As of December 31, 2023, our wholly-owned subsidiary (Beijing Continent Biomedical Technology Co., Ltd., a company organized under the laws of the PRC) has obtained a business license but has no business operations. The following table sets forth the details of material licenses, permits and approvals:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.947%;"/>
    <td style="width:1.04%;"/>
    <td style="width:1.04%;"/>
    <td style="width:31.947%;"/>
    <td style="width:1.04%;"/>
    <td style="width:1.04%;"/>
    <td style="width:31.947%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:1pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">License/Permit</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Validity Period</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:0.75pt solid #ffffff;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.08in;vertical-align:top;padding-bottom:0.06in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Authority</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Drug Production License</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2022 &#8211; September 2025</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Information Service Qualification Certificate</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2021 &#8211; January 2026</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Zhongguancun High- tech Enterprise</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 2022 &#8211; December 2024</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.06in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Administrative Commission of Zhongguancun Science Park</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">High-tech Enterprise Certificate</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 2022 &#8211; November 2025</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Municipal Science &amp; Technology Commission,</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Municipal Finance Bureau, Beijing Municipal Administration of Taxation</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Drug Registration Approval (pirfenidone)</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valid until August 2028</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Drug Registration Approval (pirfenidone capsule)</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valid until August 2028</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GMP Certificate for Pharmaceutical Products (Pirfenidone APIs)</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 2019 &#8211; July 2024</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Medical Products Administration</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign Trade Operators Registration Form</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">From February 2022</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8203;</span></p></td>
    <td style="padding-top:0.04in;vertical-align:top;padding-bottom:0.04in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Municipal Commission of Commerce</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Research and Development</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consistently devote resources to R&amp;D to achieve long-term growth. We believe the diversification and expansion of our product pipeline through both in-house R&amp;D and external collaboration are critical to our long-term competitiveness and success.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a dedicated in-house R&amp;D team of 85 employees in the PRC as of December 31, 2023. Our R&amp;D department is comprised of the following departments: drug discovery, chemistry, manufacturing and control (&#8220;CMC&#8221;), clinical development, medical affairs and regulatory affairs. Our R&amp;D employees possess significant expertise in molecular biology, chemistry regulatory affairs and clinical development. Through cross-functional collaboration, our R&amp;D organization has enabled us to develop new drug products to address unmet clinical needs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We employ a clinical-demand-oriented and market-driven approach to our R&amp;D efforts. We first identify suitable drug development targets and carry out project evaluation and overall project design based on our development strategies and then explore and establish experimental methodology by coordinating across different experimental platforms. We carefully select drug development programs by balancing the commercial potential of each drug candidate and its likelihood of successful development, its potential competition, and the ultimate market size.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug Discovery</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our molecule screening and design capabilities increase the possibility of success of advancing molecules from preclinical studies to market, enable innovative therapeutic approaches and support rich pipeline assets built around key pathways and targets. We have built an efficient system to conduct target identification and validation, compound design and screen and lead compound optimization. During the discovery stage, drug candidates are tested for their</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">absorption, distribution, metabolism, excretion and toxicological properties, and promising compounds are optimized through structure modification to achieve maximum efficacy and minimum toxicity. Our R&amp;D centers support a targeted drug discovery and screening platform, which can efficiently complete target identification and validation, compound design and lead optimization.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the drug discovery stage, we explore new R&amp;D opportunities, conduct feasibility research and provide evaluation for the opportunities. We also design and prepare new chemical compounds, conduct systematic research related to the manufacturing process and quality management of the new drugs and develop technology platforms to support, manage and supervise the related technologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chemistry, Manufacturing &amp; Controls</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CMC Group</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CMC group is a critical link between discovery and clinical study. It is responsible for developing chemical and pharmaceutical processes, so that drug substances can be made with the desired physical and chemical properties and formulated to achieve maximum bio availability and stability. During the CMC stage, the synthesis of each API molecule is investigated thoroughly to ensure that the drug substance can reach pre-determined quality standards, the manufacturing processes are safe, robust, economical and environmentally friendly and the drug products have good stability and suitable storage conditions and shelf life.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development Group</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical development team oversees clinical trials for drug development, sets up the procedural standard of clinical affairs and handles clinical medicine matters. Our clinical development team also focuses on clinical development strategy, clinical trial protocol design, clinical trial operation coordination, pharmacovigilance and clinical trial quality control. Our clinical development team members specialize in management of all stages of our clinical trials, including clinical trial design, implementation, drug supply and the collection and analysis of trial data. We collaborate with top clinical experts in various areas as our principal investigators, leverage the operational capabilities of industry leading clinical research organizations and rely on well-known academic medical institutions and clinical trial centers in the PRC and abroad to promote the high quality and efficient implementation of our clinical trials in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Trial Design and Implementation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical development group manages all stages of clinical trials, including protocol design, operation and the collection and analysis of clinical data. Our rapid trial advancements are driven by (i) our strategic decision to initiate clinical phase trials with our outstanding preclinical results, (ii) rigorous trial design, (iii) long-term partnership with numerous hospitals and principal investigators from different regions and (iv) high-quality execution. Leveraging our extensive knowledge and experience in clinical trials, our clinical development experts identify unique therapeutic opportunities for our drug candidates based on the differentiating properties observed in clinical trials and improve clinical plans accordingly.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The organ fibrosis market is subject to rapid change. While we believe that our robust pipeline of innovative products and drug candidates, strong sales and marketing capability and experienced leadership team provide us with competitive advantages, we face potential competition from many different sources working to develop therapies targeting the same indications which our marketed drug or our drug candidates target. These include major pharmaceutical companies, specialty pharmaceutical and biotechnology companies of various sizes, academic institutions, government agencies and research institutions. Any drug candidates that we successfully develop and commercialize will compete both with existing drugs and with any new drugs that may become available in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our products primarily compete with products that are indicated for similar conditions on the basis of efficacy, price and general market acceptance by medical professionals and hospitals. The identities of our key competitors vary by product or drug candidate, and in certain cases, our competitors may have greater financial resources and expertise in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our continued success will primarily depend on our ability to develop innovative products and advanced technologies, apply technologies to all production lines, continuously develop an extensive product portfolio and pipeline, effectively commercialize and market our existing and future products, expand our distribution network and maintain customer relationships, attract and retain seasoned and talented technology development personnel, maintain high quality standards, maintain a highly efficient operational model and obtain and maintain regulatory approvals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Production and Quality Control</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-House Manufacturing Facilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our manufacturing facilities are situated in Beijing and Cangzhou, Hebei province, in the PRC. During the years ended December 31, 2022 and 2023, 100% of pirfenidone we sold was manufactured at our Beijing and Cangzhou facilities. Our manufacturing facilities are designed and operated in compliance with cGMP regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Quality Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the product quality is fundamental to ensure the safety of patients and achieve our long-term development. Our quality management team monitors every stage of our operations in accordance with NMPA&#8217;s regulations. We implement quality management measures throughout our production process, including supplier examination, raw material inspection and testing and process control, and all products are thoroughly inspected and tested before release.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Procurement Quality Control</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established internal procedures governing the selection for raw material suppliers and quality control to meet the requirements of relevant cGMP and pharmaceutical registration regulations. We select our raw material suppliers based on a variety of factors, including their economic status, capital, reputation, quality control management, production scale and technological strengths and evaluate them based on their qualification, feedback to our questionnaire and our on-site examination.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Logistics and Delivery Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into logistics service agreements with third parties. Pursuant to the arrangement, logistics service providers provide delivery services in a safe and timely manner pursuant to our requirements, while we are responsible for the quality of goods. Our logistics service providers are responsible for any loss caused by their negligence during their provision of the logistics service, including transfer, loading, unloading, transportation and delivery. Our logistics service providers also liaise and handle the insurance aspects, while we arrange the payment of insurance premiums together with the freight charges.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inventory principally consists of raw materials, work-in-progress, semi-finished goods (representing APIs) and finished products. We endeavor to maintain our inventory at a reasonable level that is sufficient to sustain our production without interruption. We enter into supply agreements with reference to our annual sales plan, manufacturing plan and procurement plan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales, Marketing and Distribution</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our In-House Sales and Marketing Team</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our in-house sales and marketing team had market coverage of 30 provinces, autonomous regions and municipalities in the PRC. Our sales and marketing team is primarily responsible for establishing and maintaining relationships with outlets in their covered regions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe the relatively high level of medical knowledge and skill of our sales and marketing team are important to the implementation of our academic marketing approach and maintenance of our reputation as a leading pharmaceuticals company. As of December 31, 2023, our in-house sales and marketing team included 391 employees, with an average of more than nine years of experience in pharmaceutical sales. Our more experienced staff also share their academic promotion networking experience on a regular basis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For more details regarding the qualifications of our employees, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employees and Human Capital</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Academic Promotion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We emphasize academic promotion and patient service in our sales and marketing efforts. We strive to promote and strengthen our academic recognition and brand awareness among medical experts by educating doctors and other medical professionals on ETUARY, our other product candidates and their respective indications. We believe that our working relationships with medical experts help to raise our profile, enhance awareness of ETUARY in the medical community and among patients, increase the clinical capabilities of healthcare providers and provide us with valuable clinical data to improve ETUARY, all of which help us more effectively market and sell ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distribution</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Distributors are our direct customers and they resell our products to the outlets, including hospitals, other medical institutions and pharmacies. Distributors are primarily responsible for the delivery of products and their payments, while our in-house sales and marketing team is responsible for conducting academic marketing activities and other promotional efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we have terminated or opted to not renew our collaboration relationships with certain distributors due to consolidation of distribution channels and unstable business management of the distributors. At the same time, we add new distributors primarily as a result of the continued expansion and optimization of our sales network. In general, our relationships with our major distributors have remained stable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product Pricing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We take into account a number of factors in determining our prices, which primarily includes our R&amp;D, production and marketing costs and expenses, the perceived value of products, our market share and the competitive landscape. In addition, our pricing strategies are also affected by the regulations and policies imposed on the pharmaceutical industry, including medical insurance reimbursement standards and regulation of medical and pricing practices. Our commercialization team closely monitors new policies affecting the pricing of pharmaceutical products in the PRC and keeps updating our pricing strategies to navigate in the evolving regulatory environment and cope with local policies and competition in different provinces, with the goal of maintaining the price levels of our products and maximizing our overall sales in the PRC. For details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Operations in the PRC: Gyre Pharmaceuticals&#8212;Regulatory Requirements in the PRC&#8212;Other PRC Regulations in Relation to the Pharmaceutical Industry&#8212;Price Controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">National Reimbursement Drug List</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participants in the national public medical insurance program are eligible for full or partial reimbursement of the purchase price of drugs included in the NRDL, which sets forth the payment standard for drugs under the basic medical insurance, work-related injury insurance and maternity insurance funds. The government started to regularly adjust the NRDL since 2017 and ETUARY successfully entered into the NRDL within the same year. The latest version of the NRDL has been implemented from March 1, 2023. For further details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Operations in the PRC: Gyre Pharmaceuticals&#8212;Regulatory Requirements in the PRC&#8212;Other PRC Regulations in Relation to the Pharmaceutical Industry&#8212;Coverage of the National Medical Insurance Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Two-Invoice System</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 26, 2016, the State Counsel Healthcare Reform Committee, National Health and Family Planning Commission, the National Development and Reform Commission and other relevant government authorities jointly issued the Circular on Issuing the Implementing Opinions on Carrying out the Two-Invoice System for Drug Procurement among Public Medical Institutions (for trial implementation), which provides detailed rules regarding the implementation of the Two-Invoice System at a national level. For details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Operations in the PRC: Gyre Pharmaceuticals&#8212;Regulatory Requirements in the PRC&#8212;Other PRC Regulations in Relation to the Pharmaceutical Industry&#8212;Drug Distribution and Two-Invoice System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;. To comply with relevant regulations, we primarily adopt the single-layer distribution model with distributors who directly on-sell our products to hospitals and public medical institutions. Certain distributors may engage sub-distributors for the sales to pharmacies, which were not subject to the regime of the Two-Invoice System.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Centralized Tender Process and Centralized Volume-Based Procurement System</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prices of most pharmaceutical products in the PRC sold to public hospitals and public medical institutions are determined through a competitive centralized tender process at the provincial or municipal level with varying terms and procedures. In the centralized tender process, the winning pharmaceutical production companies will be allowed to sell their products to public hospitals and other public medical institutions at the bid prices. The centralized tender process can create pricing pressure among substitute products or products that are perceived by the market to be substitute products and resulted in significant change in how drugs are priced and procured in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Raw Materials and Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the suppliers in our &#8220;Qualified Supplier Directory,&#8221; each of our significant raw material suppliers have backup suppliers. In addition, each material has more than one manufacturer, and each manufacturer has multiple distributors. These distributors have reasonable inventory reserves. If we need to find a new supplier, we conduct comparative research and, after confirming, the supplier is added to our Qualified Supplier Directory to ensure product supply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory Requirements in the PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the PRC extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products. Our current product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the PRC, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of our products and our research and development activities and require the expenditure of substantial time and financial resources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug Regulatory Regime</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The drug regulatory regime in the PRC consists of the Standing Committee of the National People&#8217;s Congress, the State Council and several ministries and agencies under the State Council&#8217;s authority including, among others, the NMPA, the predecessor of which is the China Food and Drug Administration (&#8220;CFDA&#8221;), the National Health Commission (the &#8220;NHC&#8221;), the predecessors of which are the National Health and Family Planning Commission of the PRC and the National Healthcare Security Administration (the &#8220;NHSA&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NMPA, is a regulatory authority responsible for registration and supervision of pharmaceutical products, cosmetics and medical equipment under the supervision of State Administration for Market Regulation (&#8220;SAMR&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NHC is the chief healthcare regulator of the PRC, and is primarily responsible for drafting national healthcare policy, regulating public health, medical services and the health contingency system of the PRC, coordinating healthcare reform in the PRC and overseeing the operation of medical institutions and practicing of medical personnel in the PRC.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NHSA is responsible for drafting and implementing policies, plans and standards of medical insurance, maternity insurance and medical assistance, administering the PRC&#8217;s healthcare fund, formulating a uniform medical insurance catalogue and payment standards for drugs, regulating medical disposables and healthcare services, and formulating and administering the bidding and tendering policies for drugs and medical disposables.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Laws and regulations in relation to Drugs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pharmaceutical Product Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the PRC, the NMPA monitors and supervises the administration of pharmaceutical products, as well as medical devices and equipment. The local provincial medical products administrative authorities in the PRC are responsible for the supervision and administration of drugs within their respective administrative regions. According to the Drug Administration Law of the PRC (the &#8220;Drug Administration Law&#8221;), drugs refer to articles which are used in the prevention, treatment and diagnosis of human diseases and intended for the regulation of the physiological functions of human beings, for which indications or functions, usage and dosage are specified, including traditional PRC drugs, chemical drugs and biological products. The Drug Administration Law and the Implementing Regulations of the Drug Administration Law of the PRC, have established the legal framework for the administration of pharmaceutical products and applies to entities and individuals engaged in the research, production, trade, application, supervision and administration of pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Clinical Research and Animal Testing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The State Administration for Market Regulation requires preclinical data to support registration applications for imported and domestic drugs. Pursuant to the Circular on Administrative Measures for Certification of Good Laboratory Practice for Non-clinical Laboratory Studies</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the NMPA is responsible for the certification of non-clinical research institutions across the PRC and the local provincial medical products administrative authorities are in charge of the daily supervision of non-clinical research institutions in the PRC. The NMPA decides whether an institution is qualified for undertaking pharmaceutical non-clinical research by evaluating such institution&#8217;s organizational administration, research personnel, equipment and facilities and operation and management of non-clinical pharmaceutical projects</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> A GLP Certification will be issued by the NMPA if all the relevant requirements are satisfied, which will also be published on the NMPA&#8217;s website. When the GLP requirements are met, the State Drug Administration will approve and issue the drug GLP certification which is valid for five years.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Administrative Regulations on Experimental Animals, the Administrative Measures on Good Practice of Experimental Animals and the Administrative Measures on the Certificate for Experimental Animals (for Trial Implementation) regulates the use and breeding of experimental animals and performing experimentation on animals requires a Certificate for Use of Laboratory Animals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Approval and Reform for Clinical Trials of New Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Administrative Measures for Drug Registration, the PRC Drug Administration Law and Implementing Regulations of the PRC Drug Administration Law, new drug applications are subject to clinical trials. The NMPA has taken a number of steps to increase efficiency for approving clinical trial applications and has also significantly increased monitoring and enforcement of the Good Clinical Practice for Drug Trials (the &#8220;PRC&#8217;s GCP&#8221;), to ensure data integrity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Administrative Measures for Drug Registration confirms a number of reform actions, including but not limited to: (i) the full implementation of marketing authorization holder system and implied approval of the commencement of clinical trials; (ii) implementing associated review of drugs, excipients and packaging materials; and (iii) introducing procedures for expedited registration of drugs. Upon completion of nonclinical research, clinical trials must be conducted for the application of a new drug registration and applicants must apply for approval of IND from the NMPA, or the CDE before conducting clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Opinions of the State Council on the Reform of Evaluation and Approval System for Drugs and Medical Devices, established a framework for reforming the evaluation and approval system for drugs and medical devices.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Announcement of the CFDA on Several Policies on the Appraisal and Approval of Drug Registration, further simplifies the approval process of drugs and provides that the IND of new drugs is subject to one-off umbrella approval and the declaration review or approval by stages will no longer be adopted. According to the Announcement of the State Drug Administration on Adjusting Evaluation and Approval Procedures for Clinical Trials for Drugs, within 60 days after the acceptance of and the fees paid for the IND, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any negative or questioning opinion from the CDE.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Priority Review and Approval Procedures for Drug Marketing Authorizations (for Trial Implementation) further clarified that a fast track IND or drug registration pathway will be available to the innovative drugs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regarding International Multi-Center Clinical Trials</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the International Multi-Center Clinical Trial Guidelines (for Trial Implementation), promulgated by the NMPA, international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicants plan to implement the International Multi-center clinical trials in the PRC, the applicants must comply with the Drug Administration Law, the Regulations for the Implementation of the PRC Drug Administration Law and the Measures for the Administration of Drug Registration. Additionally, applicants must execute the GCP, make reference to universal international principles such as the ICH-GCP and comply with the laws and regulations of the countries involved in the International Multi-Center clinical trials. Where the applicants plan to use the data derived from the International Multi-Center clinical trials for approval of a drug registration in the PRC, the application must involve at least two countries, including the PRC, and must satisfy the requirements for clinical trials set forth in the Notice on Issuing the International Multi-Center Clinical Trial Guidelines (for Trial Implementation) and the Administrative Measures for Drug Registration and other related laws and regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug Clinical Trial Registration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Administrative Measures for Drug Registration, upon obtaining the approval of its IND, the applicant must, prior to conducting the clinical trial of drugs, register on the registration and information announcement platform for clinical trials of drugs, information regarding the scheme of the clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Announcement on Drug Clinical Trial Information Platform, all clinical trials approved by the NMPA and conducted in the PRC must complete a clinical trial registration and publish trial information through the Drug Clinical Trial Information Platform. The applicant must complete the trial pre-registration within one month after obtaining the approval of the IND in order to obtain the trial&#8217;s unique registration number and complete registration of certain follow-up information before the first subject&#8217;s enrolment in the trial. If the registration is not completed within one year after the approval of the IND, the applicant must submit an explanation and if applicant&#8217;s first submission is not completed within three years, the approval of the IND will automatically expire.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phases of Clinical Trials and the Communication with the CDE</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Administrative Measures for Drug Registration, a clinical trial consists of Phases 1, 2, 3, 4 and bioequivalence trial. In addition to the characteristics of a drug and the research purpose, the research contents must also include clinical pharmacological research, exploratory clinical trial, confirmatory clinical trial and post-marketing research under the Administrative Measures for Drug Registration.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Administrative Measures for Communication on Drug Research, Development and Technical Reviews, during the research and development periods and in the registration applications of the innovative new drugs (among others), the applicants may propose to conduct communication meetings with the CDE. The communication meetings can be classified into three types. Type I meetings are convened to address key safety issues in clinical trials of drugs and key technical issues in the research and development of breakthrough therapeutic drugs. Type II meetings are held during the key research and development periods of drugs, and mainly include meetings before the IND application, meetings upon the completion of Phase 2 trials and before the commencement of Phase 3 trials, meetings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">before submitting a marketing application for a new drug and meetings for risk evaluation and control. Type III meetings refer to meetings not classified as Type I or Type II.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sampling and Collecting Human Genetic Resources Filing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Administrative Regulations of the PRC on the Administration of Human Genetic Resources, further stipulates that in order to obtain marketing authorization for relevant drugs and medical devices in the PRC, no approval is required in international clinical trial cooperation using the PRC&#8217;s human genetic resources at clinical institutions without export of human genetic resource materials. However, the two parties must file the type, quantity and usage of the human genetic resource to be used with the administrative department of science and technology under the State Council before clinical trials may commence. According to the Service Guide for Administrative Licensing Items Concerning Examination and Approval of Sampling, Collecting, Trading or Exporting Human Genetic Resources, or Taking Such Resources out of the PRC (the &#8220;Service Guide&#8221;), the sampling, collection or research activities of human genetic resources by a foreign-invested sponsor falls within the scope of international cooperation and the cooperating organization of the PRC must apply for approval of the China Human Genetic Resources Management Office.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Administrative Regulations of the PRC on Human Genetic Resources, no approval is required in international clinical trial cooperation using the PRC&#8217;s human genetic resources at clinical institutions without export of human genetic resource materials in order to obtain marketing authorization for relevant drugs and medical devices in the PRC. However, the two parties must file the type, quantity and usage of the human genetic resource to be used with the administrative department of science and technology under the State Council before clinical trials commence.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 1, 2023, The Ministry of Science and Technology promulgated the Implementation Rules for the Administrative Regulation on Human Genetic Resources (the &#8220;HGR Implementation Rules&#8221;), which became into effect on July 1, 2023. The HGR Implementation Rules have refined the Regulations of the PRC on the Administration of Human Genetic Resources, including, but not limited to, refining the definition of &#8220;human genetic resources information&#8221;, clarifying the identification standard of &#8220;foreign entities&#8221;, adjusting the scope of collection licensing, and adjusting and improving the approval procedures for international cooperative scientific research and administrative supervision rules.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registration of Drug Marketing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Administrative Measures for Drug Registration, an applicant must complete studies in pharmacy, pharmacology and toxicology, as well as clinical trials of pharmaceuticals. The applicant must submit an application for drug marketing authorization and the relevant research materials in accordance with the submission requirements after determining quality standards, verifying commercial scale manufacturing process and preparing to undergo examination and inspection for drug registration. Once an application is submitted, the CDE will assemble pharmacists, medical professionals and other technical specialists to analyze the drug&#8217;s safety, effectiveness and quality control. After the comprehensive review, the drug will be approved for marketing and a drug registration certificate shall be issued.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketing Authorization Holder System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Drug Administration Law, the state implements the drug marketing authorization holder system for drug management. The drug marketing authorization holder is an enterprise or a drug development institution that has obtained the drug registration certificate and is responsible for non-clinical research, clinical trials, production and operation, post-marketing research, adverse reaction monitoring, reporting and processing of drugs in accordance with the provisions of the Drug Administration Law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Circular of the CFDA on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System (the &#8220;Circular on Drug Marketing Authorization Holder System&#8221;), the drug marketing authorization holder must establish a drug quality assurance system and be equipped with special personnel to take charge of quality management on drugs independently. Additionally, the drug marketing authorization holder must regularly review the quality management system of the drug manufacturer and the drug distributor and supervise its continuous quality assurance and control capabilities. A drug marketing authorization holder who manufactures drugs on its own shall obtain a drug production license in accordance with the Circular on Drug Marketing Authorization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holder System and entrust a qualified drug manufacturer. The drug regulatory authority of the State Council has formulated guidelines for the quality of pharmaceuticals entrusted manufacturing, to guide and supervise the drug marketing authorization holder and the entrusted manufacturer to fulfill their drug quality assurance obligations. The Announcement of the State Drug Administration on Strengthening the Supervision and Administration on Entrusted Manufacturing by the Drug Marketing Authorization Holder, which came into effect on October 17, 2023, reiterates the importance of supervision over entrusted manufacturing and stipulates more stringent and detailed requirements on aspects of license, quality and supervision of the entrusted manufacturing of the drug marketing authorization holder.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drugs&#8217; Registration Classification</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Measures for the Administration of Drug Registration, drugs are classified into PRC medicine, chemical medicine, biological products and others. According to the Notice of the NMPA about the Issuing of the Reform Plan for the Registration Classification of the Chemical Drugs, the registration classification of the chemical drugs are adjusted to five categories. Category 1 drugs refer to innovative chemical drugs that have not been marketed anywhere in the world. Improved new chemical drugs that are not marketed anywhere in the world fall into Category 2 drugs. Generic chemical drugs that have equivalent quality and efficacy to the originator&#8217;s drugs that have been marketed abroad but not yet in the PRC are classified as Category 3 drugs. Generic drugs that have equivalent quality and efficacy to the originator&#8217;s drugs and have been marketed in the PRC fall into Category 4 drugs. Category 5 drugs are drugs which have already been marketed abroad, but are not yet approved in the PRC. Category 1 and 2 drugs must follow the registration application procedure for new drugs according to the Measures for the Administration of Drug Registration; Category 3 and 4 drugs must follow the procedure for generic drugs; and Category 5 drugs must follow the application and regulation requirements for importing drugs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Chemical Drug Registration Classification and Application Data Requirements, innovative chemical drugs and improved new chemical drugs are categorized as Category 5.1 drugs, while generic chemical drugs, all of which shall have been already marketed abroad but not yet approved in the PRC are categorized as Category 5.2 drugs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Special Examination and Fast Track Approval for Drugs Targeting Rare Diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Notice on Publishing the Procedures of Developing the Rare Disease List, the following four criteria must be met at the same time for rare disease designation: (i) the disease has a low incidence or prevalence in PRC and abroad; (ii) the disease significantly impacts the patient and his or her family; (iii) there is a clear diagnosis method; and (iv) the disease can be treated or intervened in an economically feasible way, or it has been included in a national scientific research project if there is no effective treatment or intervention for such disease. With certain drugs targeting rare diseases being listed in National Rare Disease List, a company may be eligible for the priority review and approval of new drugs for these diseases from the NMPA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Administrative Provisions on Special Examination and Approval of the Registration of New Drugs, special examination and approval for new drugs registration applications applies when (1) the effective constituent of a drug extracted from plants, animals and minerals, as well as the preparations thereof, have never been marketed in the PRC and the material medicines and the preparations thereof are newly discovered; (2) the chemical raw materials for medicines as well as the preparations thereof and the biological product have not been approved for marketing, either in the PRC or aboard; (3) new drugs with distinctive clinical treatment advantages for diseases such as AIDS, malignant tumor or other rare diseases; or (4) new drugs for diseases that currently lacking effective treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Opinions of the State Council on the Reform of Evaluation and Approval System of Drugs and Medical Devices, a special evaluation and approval system shall be adopted for innovative drugs to accelerate the evaluation and approval process for innovative drugs for prevention and treatment of AIDS, cancer, major infectious diseases, rare diseases and other diseases.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Announcement of the State Drug Administration and the NHC on Optimizing the Evaluation and Approval of Drug Registration, the CDE will prioritize the allocation of resources for review, inspection, examination and approval of registration applications that have been included in the scope of priority evaluation and approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Good Manufacturing Practices</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Drug Administration Law, one engaged in drug manufacturing activities shall comply with the GMP and establish a sound GMP management system, to ensure that the entire process of drug manufacturing is maintained to meet the statutory requirements and the GMP requirements enacted by the drug regulatory authority under the State Council in accordance with the Drug Administration Law. The legal representative of and principal person in charge of a drug manufacturer are fully responsible for the drug manufacturing activities of the enterprise.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Good Manufacturing Practice for Drugs provided guidance for the quality management, organization and staffing, production premises and facilities, equipment, material and products, recognition and inspection, documentation maintenance, manufacture management, quality control and quality assurance, contractual manufacture and contractual inspection for the products, product delivery and recalls of a manufacturer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug Production License</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Measures for the Supervision and Administration of Drug Production promulgated by SAMR, persons engaging in pharmaceutical manufacturing activities shall be subject to approval by the pharmaceuticals administrative authorities of the province, autonomous region or centrally- administered municipality where the persons engaging in pharmaceutical manufacturing activities are located, obtain a Drug Production License pursuant to the Measures for the Supervision and Administration of Drug Production promulgated by SAMR, comply strictly with the pharmaceutical manufacturing quality control norms and ensure that the manufacturing process complies with statutory requirements at all times. The period of validity of Drug Production License is five years. In the event the license holder needs to continue to manufacture pharmaceuticals upon the expiration of the Drug Production License, it shall apply to the original issuing authorities for reissuance of a Drug Production License six months before the expiration date of the Drug Production License.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug Business License and Good Supply Practice Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Drug Administration Law and the Regulations for the Implementation of the PRC Drug Administration Law, in order to be engaged in the drug wholesale distribution and retailing of drugs, a company must obtain a Drug Business License with an appropriate &#8220;scope of distribution&#8221; from the local drug regulatory authority and comply with the Good Supply Practice for Pharmaceutical Products promulgated by the CFDA under the State Council. Under the Measures for the Supervision and Administration of Drug Quality in Trading and Usage, which became effective on January 1, 2024, a Pharmaceutical Trading License is valid for five years. Each holder of the Pharmaceutical Trading License must apply for an extension of its permit during the period from two months to six months prior to expiration. Otherwise, the holder shall cease its trading activities upon expiration until a new Pharmaceutical Trading License is granted by the drug regulatory authority.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other PRC Regulations in relation to the Pharmaceutical Industry</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug Recall</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Measures on the Administration of Drug Recalls, the term &#8220;drug recalls&#8221; refers to the activities of a drug marketing authorization holder to recall drugs that have been marketed, but have quality problems or other potential safety hazards under the prescribed procedures and take corresponding measures to timely control risks and eliminate potential hazards. The term &#8220;quality problems or other potential safety hazards&#8221; refers to non-compliance of drugs with statutory requirements, or other unreasonable risks that may endanger human health and life safety caused by drugs due to research and development, production, storage and transportation, labeling and other reasons.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrative Protection and Monitoring Periods for New Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Implementing Regulations for the Drug Administration Law of the PRC, based on the needs for protection of public health, the NMPA may set an observation period of not more than five years for new drugs produced by drug manufacturers; and no approval shall be given to any other manufacturers to produce or import the said drugs during the observation period.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Packaging of Pharmaceutical Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Drug Administration Law, drug packaging must be printed or affixed with a label and include the literature pursuant to the provisions. According to the Measures for The Administration of Pharmaceutical Packaging, pharmaceutical packaging must comply with national and professional standards. Drugs that have not been developed and approved for packaging standards cannot be sold or marketed in the PRC (except for drugs for the military). According to the PRC&#8217;s GCP, the packaging labels of the investigational product must indicate the information on the use only for clinical trial, clinical trial information and information on the drug for clinical trial, but the blinded state may be kept in blind trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Insert Sheet and Labels of Pharmaceutical Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Administrative Provisions on Pharmaceutical Directions and Label, the insert sheets and labels of drugs should be reviewed and approved by the NMPA. A drug insert sheet should include the important scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and rational use of drugs. The inner label of a drug should bear such information as the drug&#8217;s name, indication or function, strength, dose and usage, production date, batch number, expiry date and drug manufacturer, and the outer label of a drug should indicate such information as the drug&#8217;s name, ingredients, description, indication or function, strength, dose and usage, adverse reaction, contraindications, precautions, storage, production date, batch number, expiry date, approval number and drug manufacturer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advertising of Pharmaceutical Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Interim Administrative Measures for Censorship of Advertisements for Drugs, Medical Devices, Dietary Supplements and Foods for Special Medical Purpose, the contents of a drug advertisement must be based on the drug instructions approved by the drug administrations under the State Council. Where a drug advertisement involves drug name, indications or major functions and pharmacological effects, the drug advertisement shall not go beyond the scope of instructions and must state contraindications and adverse reactions in a prominent position. Prescription drug advertisements must also state that &#8220;the advertisement is meant to be read only by medical and pharmaceutical professionals&#8221; in a prominent position and OTC drug advertisements must also add the non-prescription drug label (OTC) in a prominent place and state that &#8220;please purchase and use the drugs in accordance with the drug instructions or under the guidance of a pharmacist&#8221; in a prominent position.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug Technology Transfer</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug technology transfer refers to the transfer of drug production technology by the owner to a drug manufacturer as the transferee and the application for drug registration by the drug manufacturer as the transferee pursuant to the provisions under Administrative Provisions for Registration of Drug Technology Transfer. The NMPA promulgated the Administrative Provisions for Registration of Drug Technology Transfer, to standardize the registration process of drug technology transfer, which includes application for, evaluation, review, approval and supervision of drug technology transfer registration. An application for drug technology transfer must be submitted to the provincial drug regulatory authority and the SFDA will ultimately make an approval decision based on the comprehensive opinions of the drug review center. Eligible applications will receive a letter of approval and a drug approval number for the supplementary application.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Online Drug Information Services</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Administrative Measures for Internet-based Drug Information Service, the operational internet drug information service refers to the activities of providing medical information (including medical devices) and other services through the internet. Where any website intends to provide internet drug information services, the website must file an application with the local provincial counterparts of NMPA and will be subject to the examination and approval thereof for obtaining the qualifications for providing internet drug information services. The validity term for a Qualification Certificate for Internet Drug Information Services is five years and may be renewed at least six months prior to its expiration date upon a re-examination by the relevant authority.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Centralized Drug Procurement and Use</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Circular of the General Office of the State Council on Issuing the Pilot Program for Conducting Centralized Drug Procurement and Use by the State and the Opinions of the National Healthcare Security Administration on Supporting Measures Concerning Medical Insurance for the Pilot Program for Conducting Centralized Procurement and Use of Drugs by the State, eleven pilot cities are selected as the pilot cities for the centralized procurement and use of drugs under the organization of the country. The scope of drugs to be procured in a centralized manner includes selected varieties from the generic names corresponding to generic drugs passing consistency evaluation of quality and efficacy. After completing the purchases by the public medical institutions in the pilot regions, the public medical institutions will use the selected drugs as the priority drugs and the quantity of the selected drugs used during the pilot procurement period will be no less than that of the non-selected drugs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Implementation Opinions on Expanding the Regional Scope in the Pilot Program for Conducting Centralized Procurement and Use of Drugs by the State to Wider Areas issued by several authorities including the National Healthcare Security Administration and NMPA, among others, the mode of centralized procurement of drugs with quantity for centralized procurement and use of drugs organized by the country is being promoted throughout the country. Such mode is applicable to 25 designated generic drugs in the pilot program of centralized drug procurement and use of drugs organized by the country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage of the National Medical Insurance Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Decision of the State Council on Establishing the Urban Employees&#8217; Basic Medical Insurance System, all employers in urban cities are required to enroll their employees in the basic medical insurance program and employers and employees must jointly contribute to the insurance premiums. Under the Guiding Opinions of the State Council about the Pilot Urban Resident Basic Medical Insurance, urban residents of the pilot district, rather than urban employees, may voluntarily join Urban Resident Basic Medical Insurance. The Opinions of the State Council on Integrating the Basic Medical Insurance Systems for Urban and Rural Residents requires the integration of the urban resident basic medical insurance and the new rural cooperative medical care system. Additionally, the Guiding Opinions of the State Council about the Pilot Urban Resident Basic Medical Insurance established a unified basic medical insurance system, which covers all urban and rural residents other than rural migrant workers and persons in flexible employment arrangements who participate in the basic medical insurance for urban employees. Program participants are eligible for full or partial reimbursement of the cost of medicines included in the medical insurance catalogue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Notice Regarding the Tentative Measures for the Administration of the Scope of Basic Medical Insurance Coverage for Pharmaceutical Products for Urban Employee, a pharmaceutical product listed in the medical insurance catalogue must be clinically necessary, safe, effective, reasonably priced, easy to use, available in sufficient quantity and must meet one of the following requirements: (1) be set forth in the pharmacopoeia of the PRC, (2) satisfy the standards promulgated by the NMPA and (3) be approved by the NMPA for imported pharmaceutical products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC Ministry of Labor and Social Security, together with other government authorities, has the power to determine the medicines included in the National Medical Insurance Catalog. The Western medicine and Chinese patent medicine included in the National Medical Insurance Catalog are divided into two parts, Part A and Part B. Provincial governments are required to include all Part A and Part B medicines listed on the National Medical Insurance Catalog in their provincial Medical Insurance Catalog in the National Medical Insurance Catalog. Fees incurred for the use of Part A medicines are entitled to reimbursement in accordance with the regulations in respect of basic medical insurance. Fees incurred by the use of Part B are shared by the patient and basic medical insurance. The percentage of reimbursement by basic medical insurance for Part B medicines is stipulated by local authorities and in result may differs from region to region in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">National Essential Drug List</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Opinions of the General Office of the State Council on Improving the National Essential Drugs System, Circular on the Issuance the Administrative Measures for the List of National Essential Drugs, and the National Essential Drug List (2018) (the &#8220;National Essential Drug List&#8221;), basic healthcare institutions funded by government (primarily county-level hospitals, county-level PRC medicine hospitals, rural clinics and community clinics), must store and use drugs listed in the National Essential Drug List. The drugs listed in the National Essential Drug List must be purchased by centralized tender process and shall be subject to the price control by NDRC. Remedial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">drugs in the National Essential Drug List are listed in the National Basic Medical Insurance Catalogue and the entire amount of the purchase price of such drugs is entitled to reimbursement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Medical Insurance Reimbursement Standards</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Decision of the State Council on Establishing the Urban Employees&#8217; Basic Medical Insurance System, Opinions on the Establishment of the New Rural Cooperative Medical System, the Guiding Opinions of the State Council about the Pilot Urban Resident Basic Medical Insurance and the Opinions of the State Council on Integrating the Basic Medical Insurance Systems for Urban and Rural Residents, medical insurance would be available to all employees and residents in both rural and urban areas.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Notice of Opinion on the Diagnosis and Treatment Management, Scope and Payment Standards of Medical Service Facilities Covered by the National Urban Employees Basic Medical Insurance Scheme, the basic medical insurance scheme would cover a portion of the costs of diagnostic and treatment devices, as well as diagnostic testing. The scope and rate of reimbursement are determined by provincial policies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The major aim of the Guidance on Further Deepening the Reform of the Payment Method of Basic Medical Insurance released by the General Office of the State Council is to develop a diverse reimbursement mechanism that includes diagnosis-related groups, per-capita caps and per-bed-day caps. These new reimbursement systems have been implemented across the country, replacing the previous reimbursement method, which is based on service category and product price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Price Controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For drugs with their prices determined by the market, the Drug Administration Law of the PRC requires that these drugs&#8217; prices are determined by the market and marketing authorization holders, manufacturers and distributors of drugs and medical institutions must conduct pricing under the principles of fairness, rationality, good faith and consistency between quality and prices. Marketing authorization holders, manufacturers and distributors of drugs and medical institutions must comply with the price management rules for drugs of the medicinal product price department of the State Council to determine the prices of drugs and are prohibited from making exorbitant profits, price monopoly and price fraud, among others.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Price Law of the PRC, drug prices must be set in compliance with the law of value. Prices of most commodities and services are market-adjusted prices and prices of a very small number of commodities and services are government- guided prices or government-set prices. The prices of pharmaceutical products are mainly determined by market competition. Instead of direct governmental price controls, the government primarily regulates prices by establishing a centralized procurement mechanism, revising medical insurance reimbursement standards and strengthening regulation of medical and pricing practices.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Opinions on Effectively Carrying out Drug Price Administration at Present promulgated by National Healthcare Security Administration seek to further improve the drug pricing formation mechanism and emphasizes the market-oriented drug pricing mechanism. Although narcotic drugs and Category 1 psychotropic drugs are subject to government pricing, other drugs are priced by drug operators according to the market. Meanwhile, the national and provincial medical security departments may implement or delegate third parties to implement price cost investigation on drug suppliers and the results can be used as the basis for determining whether the drugs were sold at unfair prices.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug Distribution and Two-Invoice System</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Implementing Opinions on Promoting the &#8220;Two-Invoice System&#8221; for Drug Procurement By Public Medical Institutions (For Trial Implementation) (&#8220;Two-Invoice System Notice&#8221;) is a system that mandates only two invoices shall be issued during the drug distributions, i.e., pharmaceutical manufacturers to issue one invoice to pharmaceutical distributors and pharmaceutical distributors to provide another one invoice to public medical institutions. The Two-Invoice System excludes the sale of products through a chain of distributors which will, in result, increase the ultimate drug price of the public medial institutions. Pharmaceutical companies must comply with the Two-Invoice System in order to engage in procurement processes with public hospitals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Several Opinions of the General Office of the State Council on Further Reform and Improvement in Policies of Drug Production, Circulation and Use, the Two-Invoice System would be promoted in pilot areas for public hospital reform, and has been implemented nationwide by 2018. Pharmaceutical companies must comply with the Two-Invoice System in order to engage in procurement processes with public hospitals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulation in Relation to Intellectual Property Rights</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Patent Law of the PRC and the Implementation Rules of the Patent Law of the PRC, an invention-creation shall mean an invention, utility model or design. Inventions and utility models for which patent rights are granted and an invention-creation must possess novelty, creativity and practicality. The Patent Office under the State Intellectual Property Office is responsible for receiving, examining and approving patent applications. The protection period is 20 years for an invention patent, 10 years for a utility model patent and 15 years for a design patent, commencing from such patent&#8217;s application date. Any patentee or interested party may file a lawsuit with a people&#8217;s court against any individual or entity that utilizes a patent or conducts any other activity that infringes a patent without the patent holder&#8217;s authorization, and may request regulatory authorities to order the infringer to stop the infringement act forthwith or impose a fine on the infringer. If the patent infringement is found to constitute a crime, the patent infringer shall be held criminally liable in accordance with applicable laws. According to the PRC Patent Law, for public health purposes, the State Intellectual Property Office of the PRC may grant a compulsory license for manufacturing patented drugs and exporting them to countries or regions covered under relevant international treaties to which PRC has acceded. In addition, according to the Patent Law, any organization or individual that applies for a patent in a foreign country for an invention or utility model patent established in the PRC is required to report to the State Intellectual Property Office for confidentiality examination.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trademarks</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Trademark Law of the PRC and the Regulations on the Implementation of the Trademark Law of the PRC, the validity period of registered trademarks is 10 years, calculated from the date of approval of the registration. A trademark registrant intending to continue to use the registered trademark upon expiry of the period of validity must undergo the renewal formalities within 12 months before expiry according to the relevant provisions. If it fails to do so, the trademark registrant may be granted a six-month grace period. The period of validity of each renewal is 10 years, commencing from the day after the expiry date of the last period of validity. If the renewal formalities are not satisfied within the grace period, the registration of the trademark is canceled.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Copyright</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Copyright in the PRC is protected by the Copyright Law of the PRC and Regulations for the Implementation of the Copyright Law of PRC. These laws and regulations provide provisions on the classification of works and the obtaining and protection of copyright and its related rights.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Domain Names</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Domain names are protected under the Measures for the Administration of Internet Domain Names issued by the Ministry of Industry and Information Technology (the &#8220;MIIT&#8221;) and Implementing Rules on Registration of China Country Code Top-level Domain Names issued by China Internet Network Information Center. The MIIT is the regulatory body responsible for the administration of PRC internet domain names. The China Internet Network Information Center is responsible for the administration of registration of China country code top-level domain names.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trade Secrets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Anti-Unfair Competition Law of the PRC and Provisions of the Supreme People&#8217;s Court on Several Issues Concerning the Application of Law in the Trial of Civil Cases Involving Trade Secret Infringement, the term &#8220;trade secrets&#8221; refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for its legal owners or holders and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others&#8217; trade secrets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">by: (1) acquiring a trade secret from the right holder by theft, bribery, fraud, coercion, electronic intrusion or any other illicit means; (2) disclosing, using or allowing another person to use a trade secret acquired from the right holder by any means as specified in the preceding subparagraph; (3) disclosing, using or allowing another person to use a trade secret in its possession, in violation of its confidentiality obligation or the requirements of the right holder for keeping the trade secret confidential; and (4) abetting a person, or tempting or aiding a person into or in acquiring, disclosing, using or allowing another person to use the trade secret of the right holder in violation of his or her non-disclosure obligation or the requirements of the right holder for keeping the trade secret confidential.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulations on Environmental Protection</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Environmental Protection Law of the PRC, the Regulations on the Administration of Construction Project Environmental Protection and the Environmental Impact Assessment Law of the PRC and Law of the PRC on the Prevention and Control of Environment Pollution Caused by Solid Wastes, an enterprise, which causes environmental pollution and discharges other materials that endanger the public, must implement environmental protection methods and procedures into its business operations. Where effects may be exerted on the environment after the completion of construction projects, the construction enterprise must submit an environmental impact report (form) or environmental impact registration form to the relevant environmental protection department. Any project that is required to prepare the environmental impact report (form) in accordance with the law must obtain the approval from the relevant environmental protection department for its environmental impact assessment documents; otherwise, construction on the project may not begin. Pursuant to the Administrative Measures for Pollutant Discharge Licensing (for Trial Implementation) and the Regulations on the Administration of Pollutant Discharge Permits, a pollutant-discharging entity must legally hold a pollutant discharge license and discharge pollutants in compliance with the pollutant discharge license. Any entity must obtain a pollutant discharge license prior to discharging any pollutants. A discharge license issued for the first time shall be valid for three years and a renewed license shall be valid for five years.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Notice of the General Office of the State Council on Issuing the Implementation Plan for the Permit System for Controlling the Discharge of Pollutant Emission and the Classification Administration List of Pollutant Discharge Permitting for Fixed Pollution Sources (2019 Version), the state implements a focused management, a simplification management and a registration management of emission permits based on the pollutant discharging enterprises and other manufacturing businesses&#8217; amount of pollutants, emissions and the extent of environmental damage. The manufacturing of drug substance and manufacturing dose for chemical drugs (except for manufacturing of dose for chemical drugs that are simply mixed or repackaged) fall within the industries that are strictly regulated, and must obtain the discharge permit in accordance with the prescribed time limit.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hazardous Chemicals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulations on Safety Administration of Hazardous Chemicals, provides regulatory requirements on the safe production, storage, use, operation and transportation of hazardous chemicals. The PRC government exerts strict control over implementing overall planning and rational layout for the production and storage of hazardous chemicals and exam safety conditions of construction project concerning manufacturing or storing hazardous chemicals. An enterprise that manufactures and stores hazardous chemicals is required to appoint a qualified institution to conduct safety evaluations of its safety production conditions once every three years and to prepare a safety evaluation report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Administrative Measures for the Registration of Hazardous Chemicals, the state adopts a registration system for hazardous chemicals. The registration of hazardous chemicals are subject to the principles of application by enterprises, two-level review, unified issuance of certificates and hierarchical administration. Where any registering enterprise fails to go through the registration formalities for hazardous chemicals or fails to go through the formalities for altering the registration contents of hazardous chemicals when the type of registration changes or the hazardous chemicals it manufactures or imports have new hazardous characteristics, the registering enterprise must make corrections and may be subject to a fine of not more than 50,000 yuan. If the registering enterprise refuses to make corrections, it shall be given a fine of not less than 50,000 yuan but not more than 100,000 yuan. If the circumstance is serious, the registering enterprise will be ordered to suspend production and business for rectification.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Liability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Product Quality Law of the PRC, manufacturers shall be liable for the quality of products they produce and guarantee that the product quality meets the requirements stipulated by laws and shall not mix impurities or imitations into products, pass fake goods off as genuine ones or shoddy products as good ones or sub-standard products as standard ones. Sellers are required to take measures to ensure the quality of the products sold by them. The manufacturer shall be liable to compensate for any bodily injuries or damage to property other than the defective product itself resulting from the defects in the product, unless the manufacturer is able to prove that: (1) the product has never been circulated; (2) the defects causing injuries or damage did not exist at the time when the product was circulated; or (3) the science and technology at the time when the product was circulated were at a level incapable of detecting the defects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Civil Code of the PRC, where a defect of a product endangers the personal or property safety of another person, the manufacturer or the seller shall assume civil liabilities in accordance with the law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Labor Protection</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Labor Law of the PRC, employers must develop and improve their rules and regulations in accordance with the law to ensure that workers enjoy their labor rights and perform their labor obligations. Employers must develop and improve the system of labor safety and sanitation and strictly implement the national protocols and procedures on labor safety. Employers must guard against labor safety accidents and reduce occupational hazards and labor safety and sanitation facilities must meet the relevant national standards. Employers must provide workers with the necessary labor protection equipment that meets the safety and hygiene conditions stipulated under national regulations by the State and conduct regular health checks for workers who engage in operations with occupational hazards. Laborers engaged in special operations must have received specialized training and obtained the pertinent qualifications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Labor Contract Law of the PRC and the Implementation Regulations of the Labor Contract Law of the PRC, employers and employees must enter into written labor contracts to establish their employment relationships. With respect to a circumstance where a labor relationship has already been established but no formal contract has been made, a written labor contracts must be entered into within one month from the date when the employee begins to work. In addition, wages shall not be lower than the local minimum wage standard.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Interim Provisions on Labor Dispatch, employers may employ dispatched workers only for temporary, auxiliary or substitutable positions and must strictly control the number of dispatched workers which may not exceed 10% of the total number of its workers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Social Insurance and Housing Fund Regulations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the PRC Social Insurance Law (the &#8220;Social Insurance Law&#8221;), the Interim Regulation on Levying Social Insurance Premiums, the Regulation on Work-Related Injury Insurance, the Regulation on Unemployment Insurance and the Trial Measures for Maternity Insurance of Enterprises Employees, the employer must contribute to social insurance plans covering basic pensions insurance, basic medical insurance, maternity insurance, work injury insurance and unemployment insurance. Basic pension, medical and unemployment insurance contributions shall be paid by both employers and employees, while work-related injury insurance and maternity insurance contributions shall only be paid by employers. Employers who fail to promptly contribute social security premiums in full shall be ordered by the social security premium collection agency to make or supplement contributions within a prescribed time limit and shall be subject to a late payment fine computed from the due date at the rate of 0.05% per day; where payment is not made within prescribed time limit, the relevant administrative authorities shall impose a fine ranging from one to three times the outstanding amount.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Regulation on the Administration of Housing Provident Fund, employers must register with the competent managing center for housing provident funds and upon the examination by such center, these employers shall complete procedures for opening an account at the bank for the deposit of employees&#8217; housing provident funds. Employers are also required to pay and deposit housing funds on behalf of their employees in full and in a timely manner. Employers that violate the Regulation on Housing Provident Fund and fail to open housing provident fund accounts for their employees with the housing fund administration center within a designated period or fail to go</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">through the formalities of opening housing provident fund accounts for their employees shall be subject to a fine ranging from approximately $1,412 to $7,062.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Investment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foreign Investment Law of the PRC and the Implementing Regulation for the Foreign Investment Law, applies to any investment activities directly or indirectly conducted by a foreign natural person, enterprise or other organization and a foreign-invested enterprise established prior to the effective date of the Foreign Investment Law shall adjust its legal form or governance structure to comply with the provisions of the Company Law of the PRC or the Partnership Enterprises Law of the PRC, as applicable and complete amendment registration before January 1, 2025. According to the Foreign Investment Law of the PRC, the state applies the administrative system of pre-establishment national treatment plus negative list to foreign investment and accords national treatment to foreign investment outside of the negative list. Furthermore, the Implementing Regulation for the Foreign Investment Law provides implementing measures and detailed rules to ensure the effective implementation of the Foreign Investment Law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 30, 2019, the Ministry of Commerce of the PRC (&#8220;MOFCOM&#8221;) and the State Administration for Market Regulation, or the SAMR, jointly promulgated the Measure for Reporting of Information on Foreign Investment, which came into effect on January 1, 2020 and pursuant to which, the establishment of the foreign-invested enterprises, including establishment through purchasing the equities of a domestic non-foreign-invested enterprise or subscribe to the increased capital of a domestic non-foreign funded enterprise and its subsequent changes are required to submit an initial or change report through the Enterprise Registration System.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Special Administrative Measures for Foreign Investment (2021 Edition) (&#8220;Negative List&#8221;) sets out in a unified manner the special management measures for the access of foreign investments such as requirements for equity and senior management. Any field falling outside the Negative List shall be administered under the principle of equal treatment to domestic and foreign investment. Domestic enterprises engaged in businesses in fields prohibited from investment by the Negative List must be reviewed and approved by the relevant competent authorities of the state before issuing shares abroad and listing for trading. Foreign investors are not allowed to participate in the operation and management of the enterprises and their equity ratio are governed with reference to the relevant regulations on the management of domestic securities investment by overseas investors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulations on Outbound Investment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Administrative Measures on Outbound Investments, the MOFCOM and the commerce departments at provincial levels shall subject the overseas investment of enterprises to recordation or confirmation management, depending on the actual circumstances of investment. Overseas investment involving any sensitive country or region, or any sensitive industry is subject to confirmation management. Overseas investment under other circumstances is subject to recordation management.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Administrative Measures for the Outbound Investment of Enterprises, an enterprise in the territory of the PRC (&#8220;the PRC Investor&#8221;) shall, in overseas investment, undergo the formalities for the confirmation or recordation, among others, of an overseas investment project (the &#8220;Investment Project&#8221;), report the relevant information and cooperate in supervisory inspection. Sensitive Investment Projects conducted by PRC Investors directly or through overseas enterprises controlled by them shall be subject to approval, and non-sensitive Investment Project directly conducted by PRC Investors, namely, non-sensitive Investment Projects involving PRC Investors&#8217; direct contribution of assets or rights and interests or provision of financing or security, shall be subject to filing. The aforementioned sensitive Investment Project means an Investment Project involving a sensitive country or region or a sensitive industry. The NDRC promulgated the Catalogue of Sensitive Sectors for Outbound Investment (2018 Edition) to list the sensitive industries in detail.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Enterprise Income Tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the PRC Enterprise Income Tax Law (the &#8220;EIT Law&#8221;) and its implementation rules, a PRC resident enterprise is subject to EIT at the current uniform rate of 25% commencing from January 1, 2008 unless reduced under</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">certain specific qualifying criteria. The term &#8220;resident enterprise&#8221; refers to any enterprise established in the PRC and any enterprise established outside the PRC with a &#8220;place of effective management&#8221; within the PRC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2018, we obtained a certificate from the Beijing government for a High and New Technology Enterprise (&#8220;HNTE&#8221;) qualification and the certificate was renewed in 2021. This renewed certificate entitled the us to enjoy a preferential income tax rate of 15% for a period of three years from 2021 to 2023 if all the criteria for HNTE status could be satisfied in the relevant year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-resident Enterprises Taxation Arrangement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends (if any) paid by our subsidiaries in the PRC to their direct offshore parent companies are subject to PRC withholding income tax at the rate of 10%, provided that such dividends are not effectively connected with any establishment or place of the offshore parent company in the PRC. The 10% withholding income tax rate may be reduced or exempted pursuant to the provisions of any applicable tax treaties or tax arrangements. Hong Kong has a tax arrangement with mainland PRC that provides for a 5% withholding tax on dividends upon meeting certain conditions and requirements, including, among others, that the Hong Kong resident enterprise directly owns at least 25% equity interests of the PRC enterprise and is a &#8220;beneficial owner&#8221; of the dividends. Under the EIT Law and its implementation rules, gains derived by non-resident enterprises from the sale of equity interests in a PRC resident enterprise are subject to PRC withholding income tax at the rate of 10%. The 10% withholding income tax rate may be reduced or exempted pursuant to applicable tax treaties or tax arrangements. The gains are computed based on the difference between the sales proceeds and the original investment basis. Stamp duty is also payable upon a direct transfer of equity interest in a PRC resident enterprise. The stamp duty is calculated at 0.05% on the transfer value, payable by each of the transferor and transferee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Announcement of the State Taxation Administration on Issues Relating to Withholding at Source of Income Tax of Non-resident Enterprises (&#8220;Circular 37&#8221;) purports to clarify certain issues in the implementation of the above regime, by providing, among others, the definitions of equity transfer income and tax basis, the foreign exchange rate to be used in the calculation of withholding amounts and the date of occurrence of the withholding obligation. Specifically, Circular 37 provides that where the transfer income subject to withholding at its source is derived by a non-PRC resident enterprise by way of installments, the installments may first be treated as recovery of costs of previous investments; upon recovery of all costs, the tax amount to be withheld shall then be computed and withheld.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Value-added Tax (&#8220;VAT&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Provisional Regulations on VAT of the PRC and its implementation rules, unless otherwise specified by relevant laws and regulations, any enterprise or individual engaged in the sale of goods, provision of processing, repair and replacement services, sales of service, intangible assets and real estate and the importation of goods in the PRC are generally required to pay VAT.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Circular of the Ministry of Finance and the State Taxation Administration on Adjustment to Value-Added Tax Rates (&#8220;Circular 32&#8221;) for VAT taxable sales acts or importation of goods originally subject to VAT rates of 17% and 11%, respectively, such tax rate shall be adjusted to 16% and 10%, respectively. For exported goods originally subject to a tax rate of 17% and an export tax refund rate of 17%, the export tax refund rate shall be adjusted to 16%. For exported goods and cross-border taxable acts originally subject to a tax rate of 11% and an export tax refund rate of 11%, the export tax refund rate shall be adjusted to 10%. Circular 32 became effective on May 1, 2018 and supersedes existing provisions which are inconsistent with Circular 32.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Announcement on Policies for Deepening the VAT Reform (&#8220;Circular 39&#8221;) for VAT taxable sales acts or importation of goods originally subject to VAT rates of 16% and 10%, respectively, such tax rate shall be adjusted to 13% and 9%, respectively. For exported goods originally subject to a tax rate of 16% and an export tax refund rate of 16%, the export tax refund rate shall be adjusted to 13%. For exported goods and cross-border taxable acts originally subject to a tax rate of 10% and an export tax refund rate of 10%, the export tax refund rate shall be adjusted to 9%. Circular 39 became effective on April 1, 2019 and supersedes existing provisions which are inconsistent with Circular 39. According to the Circular on the Value-added Tax Policies for Rare Disease Drugs, for the production and sale of drugs for rare diseases, VAT shall be calculated and paid at the rate of 3% under the simplified method.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Exchange</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Regulation of the PRC on Foreign Exchange Administration, the foreign exchange income and expenditure and foreign exchange business operations of PRC institutions and individuals, as well as the foreign exchange income and expenditure and foreign exchange business operations conducted within the territory of the PRC by overseas institutions and individuals, shall be subject to Foreign Exchange Administration. The Renminbi is freely convertible for payments of current account items such as trade and service-related foreign exchange transactions and dividend payments, but is not freely convertible for capital expenditure items such as direct investments, loans or investments in securities outside of the PRC unless approval from the SAFE or its local counterpart is obtained in advance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Administrative Regulation regarding Foreign Exchange Settlement, Sales and Payment, foreign exchange receipts under the current account of foreign-invested enterprises may be retained to the fullest extent specified by the foreign exchange bureau. Any portion in excess of such amount shall be sold to a designated foreign exchange bank or through a foreign exchange swap center.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Circular on Further Simplifying and Improving Policies on Foreign Exchange Administration for Direct Investment, banks shall directly examine and handle foreign exchange registration under overseas direct investment. The State Administration of Foreign Exchange and its branches shall indirectly regulate the foreign exchange registration of direct investment through banks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Decision of the State Council on Matters relating to Canceling and Adjusting a Group of Administrative Examination and Approval Items, the administrative approval by the SAFE and its branches for matters concerning the repatriation and settlement of foreign exchange of overseas-raised funds through overseas listing was canceled. According to the Notice on Issues Concerning the Foreign Exchange Administration of Overseas Listing, a domestic company shall, within 15 business days from the date of the end of its overseas listing issuance, register the overseas listing with the local branch office of SAFE at the place of its establishment. The proceeds from an overseas listing of a domestic company may be remitted to the domestic account or deposited in an overseas account, but the use of the proceeds shall be consistent with the content of the prospectus and other disclosure documents.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Notice on Revolutionizing and Regulating Capital Account Settlement Management Policies, foreign currency earnings in capital accounts that maintain relevant policies of willingness to exchange settlement and have been clearly implemented on (including the recalling of raised capital by overseas listing) may undertake foreign exchange settlement in the banks according to actual business needs of the domestic institutions. The tentative percentage of foreign exchange settlement for foreign currency earnings in capital account of domestic institutions is 100%, subject to adjust of the SAFE in due time in accordance with international revenue and expenditure situations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Circular 37 requires PRC residents to register their legally owned assets or equity interests in domestic enterprises or offshore assets or interests with local branches of SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing. Failure to comply with the various SAFE registration requirements described above could result in liability under the PRC law for evasion of foreign exchange controls. The Circular on Further Simplifying and Improving Policies for Foreign Exchange Administration for Direct Investment allows banks to directly examine and handle the initial foreign exchange registration and amendment registration under the Circular 37 on behalf of the SAFE.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulations relating to stock incentive plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies, or the Stock Option Rules, which prescribed that PRC citizens or non-PRC citizens residing in the PRC for a continuous period of no less than one year (except for foreign diplomatic personnel in the PRC and representatives of international organizations in the PRC) who participate in any stock incentive plan of an overseas publicly-listed company shall, through the domestic company to which the said company is affiliated, collectively entrust a domestic agency (as such agency may be the PRC affiliate of the overseas publicly listed company which participates in stock incentive plan, or other domestic institutions qualified for asset trust business lawfully designated by such company) to handle foreign exchange registration and entrust an overseas institution to handle issues such as the exercise of options, the purchase and sale</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of corresponding stocks or equity and transfer of corresponding funds. In addition, the domestic agency is required to amend the SAFE registration with respect to the stock incentive plan if there is any material change to the stock incentive plan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulations on Dividend Distribution</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal laws, rules and regulations governing dividend distributions by foreign-invested enterprises in the PRC are the PRC Company Law and the Foreign Investment Law and its Implementation Regulations. Under these requirements, foreign-invested enterprises may only pay dividends out of their accumulated profits, if any, as determined in accordance with PRC accounting standards and regulations. A PRC company is required to set aside at least 10% of its after-tax profits each year, after making up previous years&#8217; accumulated losses, if any, to fund certain capital reserve funds until the aggregate amount of these reserve funds have reached 50% of its registered capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EIT Law and its implementation rules provide that since January 1, 2008, a withholding income tax rate of 10% will be applicable to dividends declared to non-PRC resident enterprises, unless otherwise reduced according to treaties or arrangements between the PRC central government and the governments of other countries or regions where the non-PRC resident enterprises are incorporated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hong Kong has a tax arrangement with mainland China that provides for a 5% withholding tax on dividends distributed to a Hong Kong resident enterprise, upon meeting certain conditions and requirements, including, among others, that the Hong Kong resident enterprise directly owns at least 25% equity interests of the Chinese enterprise and is a &#8220;beneficial owner&#8221; of the dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends, Distributions and Other Transfers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, cash is transferred through our organization in the following manner: (i) funds are transferred to us from CPI as needed through BJContinent Pharmaceuticals Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;BJC Limited&#8221;), or from other domestic shareholders, in the form of capital contributions or shareholder loans; and (ii) dividends or other distributions may be paid by us to CPI through BJC Limited, or to other domestic shareholders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, cash proceeds raised from overseas financing activities, may be transferred to us via capital contribution or shareholder loans, as the case may be.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since BC&#8217;s inception to the date of this Annual Report, there were no transfers, dividends, or distributions between BJC Limited, BC, BC Biomedical, or to investors (except as disclosed above and excluding shareholder capital contributions). We intend to retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying any cash dividends on its capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends are at the discretion of Gyre&#8217;s board of directors and will depend upon a number of factors, including Gyre&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors Gyre&#8217;s board of directors deems relevant. For additional information, see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Audited Financial Statements of Gyre Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> included elsewhere in this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Cayman Islands law, CPI is permitted to provide funding to its subsidiaries through loans or capital contributions without restrictions on the amounts of the funds, provided that such funding is in the best interests of CPI and for proper purpose. Subject to compliance with applicable solvency requirements, there is no further Cayman Islands statutory restriction on the amount of funds that may be distributed by BC by dividend provided that no dividend shall be paid other than out of profits or, subject to certain statutory restrictions, the share premium account of CPI. The Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our largest shareholder is BJC Limited. Under Hong Kong law, if BJC Limited were able to declare dividends, such dividends could only be paid by BJC Limited out of its distributable profits (that is, accumulated realized profits, so far as not previously utilized by distribution or capitalization, less accumulated realized losses, so far as not previously written off in a reduction or reorganization of capital), as permitted under Hong Kong law. Dividends cannot be paid out of share capital. There are no restrictions or limitation under the laws of Hong Kong imposed on the conversion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of HKD into foreign currencies and the remittance of currencies out of Hong Kong. Under the current practice of the Inland Revenue Department of Hong Kong. Payments of dividends by BJC Limited are not subject to withholding tax in Hong Kong.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under PRC laws and regulations, we are subject to restrictions on foreign exchange and cross-border cash transfers, including to the parent companies and U.S. shareholders. The ability to distribute earnings to the parent companies and U.S. shareholders is also limited. Current PRC regulations permit us to pay dividends to BJC Limited only out of our accumulated profits as determined in accordance with PRC accounting standards and regulations. We are required to set aside at least 10% of our after-tax profits as the statutory common reserve fund until the cumulative amount of the statutory common reserve fund reaches 50% or more of our registered capital, if any, to fund our statutory common reserves, which are not available for distribution as cash dividends. In addition, our revenue and assets are generally denominated in Chinese Renminbi (&#8220;RMB&#8221;), which is not freely convertible into other currencies. The PRC government imposes controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of currency out of the PRC. As a result, shortages in foreign currencies may limit our ability to remit sufficient foreign currency to offshore entities related to us for such offshore entities to pay dividends or make other payments or otherwise to satisfy its foreign-currency-denominated obligations. Our offshore shareholders are Gyre, which is an indirect shareholder, and Nepenthe Holdings Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;Nepenthe&#8221;), Ratel Holdings Limited, a company incorporated in the British Virgin Islands with limited liability (&#8220;Ratel&#8221;), Aaring Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;Aaring&#8221;), Rosefinch Holdings Limited, a company incorporated in the British Virgin Islands (&#8220;Rosefinch&#8221;), CPI and Further Challenger, each of which are wholly-owned by Gyre.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established stringent controls and procedures for cash flows within our organization. Each transfer of cash between entities, across borders, and to U.S. shareholders, is subject to internal approval. To effect a cash transfer, a number of steps are needed, including but not limited to the issuance of payment receipt, logging into the online banking system and completing its verification process, inspection of the invoice, and payment execution. A single employee is not permitted to complete each and every stage of a cash transfer, but rather only portions of the whole procedure. Only the finance department is authorized to make cash transfers. Within the finance department, the roles of payment approval, payment execution, record keeping, and auditing are segregated to minimize risk.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Foreign Investment Law of the PRC and its implementing rules, which jointly established the legal framework for the administration of foreign-invested companies, a foreign investor may, in accordance with other applicable laws, freely transfer into or out of the PRC its contributions, profits, capital earnings, income from asset disposal, intellectual property, royalties acquired, compensation or indemnity legally obtained, and income from liquidation, made or derived within the territory of the PRC in renminbi, or RMB, or any foreign currency, and any entity or individual shall not illegally restrict such transfer in terms of the currency, amount and frequency. According to the Company Law of the PRC and other PRC laws and regulations, we may pay dividends only out of their respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, we are required to set aside at least 10% of our accumulated after-tax profits, if any, each year to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Where the statutory reserve fund is insufficient to cover any loss we incurred in the previous financial year, our current financial year&#8217;s accumulated after-tax profits shall first be used to cover the loss before any statutory reserve fund is drawn therefrom. At our discretion, we may allocate a portion of our after-tax profits based on PRC accounting standards to a discretionary reserve fund.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RMB is not freely convertible into other currencies. The PRC government imposes controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of currency out of the PRC. Shortages in availability of foreign currency may then restrict our ability to remit sufficient foreign currency to offshore entities related to us for such offshore entities to pay dividends or make other payments or otherwise to satisfy our foreign-currency-denominated obligations. Our offshore shareholders are Gyre, which is an indirect shareholder, and Nepenthe, Ratel, Aaring, Rosefinch, CPI and Further Challenger, each of which is wholly-owned by Gyre. The RMB is currently convertible under the &#8220;current account,&#8221; which includes dividends, trade and service-related foreign exchange transactions, but not under the &#8220;capital account,&#8221; which includes foreign direct investment and foreign currency debt, including loans we may secure for our onshore subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, we may purchase foreign currency for settlement of&#8201; &#8220;current account transactions,&#8221; without the approval of the State Administration of Foreign Exchange of the PRC, or SAFE, by complying with certain procedural requirements. However, the relevant PRC governmental authorities may limit or eliminate our ability to purchase foreign currencies in the future for current account transactions. The PRC government may continue to strengthen its capital controls, and additional restrictions and substantial vetting processes may be instituted by SAFE for cross-border transactions falling under both the current account and the capital account. Any existing and future restrictions on currency exchange may limit our ability to utilize revenue generated in RMB to fund our business activities outside of the PRC or pay dividends in foreign currencies to holders of our securities. Foreign exchange transactions under the capital account remain subject to limitations and require approvals from, or registration with, SAFE and other relevant PRC governmental authorities. This could affect our ability to obtain foreign currency through debt or equity financing for BC and its subsidiaries.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees and Human Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 593 total employees, including 168 employees in Beijing, 40 employees in Cangzhou and 385 employees in other regions, which were primarily our sales and marketing employees located across the nation. We recruit our employees based on a number of factors, including work experience, educational background and the requirements of a relevant vacancy. We provide internal and external training for our management staff and other employees in various areas, such as product knowledge, project development and team building. We provide our employees with regular feedback and assess our employees based on their performance to determine their salary, promotion and career development.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In compliance with the relevant PRC labor laws, we enter into individual employment contracts with our employees covering matters such as terms, wages, bonuses, employee benefits, workplace safety and grounds for termination. The remuneration package of our employees includes salary and bonus, which are generally based on their qualifications, industry experience, position and performance. We consider the remuneration package of our employees to be competitive among our domestic competitors. The social insurance and housing provident funds for our employees have been paid in full during the years ended December 31, 2022 and 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to safety laws and regulations of the PRC. We have implemented various internal occupational health and safety procedures to maintain a safe work environment, including adopting protective measures at our production centers, inspecting our equipment and facilities regularly to identify and address safety hazards and providing regular training to our employees on safety awareness.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have formed a labor union to represent our employees. We believe that we have maintained good working relationships with our employees. During the year ended December 31, 2023, we were not subject to any material claims, lawsuits, penalties or administrative actions relating to non-compliance with occupational health and safety laws or regulations and had not experienced any strikes, labor disputes or industrial actions which have had a material effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PRC Taxation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Article 2 of the PRC Enterprise Income Tax Law, a resident enterprise is an enterprise that is established in the PRC under the PRC laws, or an enterprise that is established under the laws of foreign countries (regions) but whose place of effective management is located in the PRC. We are a PRC resident enterprise for PRC tax purposes because we are a legal entity registered in Beijing, PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we are a PRC resident enterprise for Enterprise Income Tax purposes, dividends (if any) paid by us to direct offshore parent companies are subject to PRC withholding income tax at the rate of 10%, provided that such dividends are not effectively connected with any establishment or place of the offshore parent company in the PRC. In addition, gains derived by non-resident enterprises from the sale of equity interests in a PRC resident enterprise are subject to PRC withholding income tax at the rate of 10%. The 10% withholding income tax rate may be reduced or exempted pursuant to the provisions of any applicable tax treaties or tax arrangements. See the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Business Operations in the PRC&#8212;Since Gyre Pharmaceuticals is a legal entity registered in Beijing, PRC, it is classified as a PRC tax resident for PRC income tax purposes by default, and such classification results in unfavorable tax consequences to Gyre Pharmaceuticals and its non-PRC shareholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to gains realized from the sale or other disposition of the shares, there is a possibility that a PRC tax authority may impose an income tax under the indirect transfer rules set out under the Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise Income Tax on Indirect Property Transfer by Non-Resident Enterprises, or SAT Circular 7, except that such transaction could fall under the safe harbor thereunder. See the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Business Operations in the PRC&#8212;Gyre Pharmaceuticals and its shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company, or other assets attributable to a PRC establishment of a non-PRC company. Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential offshore restructuring transactions or sales of the shares of Gyre Pharmaceuticals&#8217; offshore holding companies or investments where PRC taxable assets are involved</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. RISK </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FACTORS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following section includes the most significant factors that may adversely affect our business and operations. You should carefully consider the risks and uncertainties described below and all information contained in this Annual Report on Form 10-K before deciding to invest in our common stock. If any of the following risks actually occur, our business, financial condition, results of operations and growth prospects may be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose all or part of your investment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing in our securities involves a high degree of risk. Below please find a summary of the principal risks we face. These risks are discussed more fully below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is significantly dependent on the sales of ETUARY&#174;, our marketed product in the PRC, amid a competitive landscape, and there is a possibility that we may not be able to sustain or boost the sales volume, pricing, and profitability of ETUARY.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a risk that our marketed product in the PRC, ETUARY, along with any other products that may receive approval in the future, may not attain sufficient market acceptance among physicians, healthcare facilities, pharmacies, patients, third-party payers, and the broader medical community, which is crucial for their commercial viability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future of our business and financial outcomes is largely contingent on the progress and success of our product candidates in clinical and pre-clinical stages, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC. We face the risk of not being able to finalize their clinical development, secure necessary regulatory approvals, or accomplish their market launch successfully, or we may encounter substantial setbacks in these processes.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To support the growth of our research and development activities and operations, we require further funding, which might not be obtainable on favorable terms or could be entirely unavailable. If we fail to secure the needed capital at the critical time, we might have to postpone, scale down, or halt some of our development projects, market introduction initiatives, or other operational aspects.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The true market potential for our product and product candidates may be less than expected. Our expansion could be constrained by the current and emerging number of IPF patients in the PRC, pending the approval and profitable launch of expanded applications for ETUARY for future indications in the PRC, and our other product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The approval procedures of the NMPA, FDA, and comparable foreign regulatory authorities are extensive, protracted, and inherently uncertain. Failure to secure necessary approvals, or encountering delays in the approval process, will prevent us from marketing our product candidates, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, which may significantly affect our revenue generation.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we or our licensors fail to secure, uphold, defend, or extend adequate patent and other intellectual property rights for our product, ETUARY, which is approved in the PRC, and any product candidates </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">globally, or if the breadth of these intellectual property rights is insufficient, our ability to effectively compete in our markets could be compromised.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established, and may continue to establish, collaborative agreements and strategic partnerships. However, there is no guarantee we will fully achieve the anticipated benefits from these collaborations, alliances, or licensing agreements, and conflicts could emerge with our present or prospective partners.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process and outcomes are uncertain, and we may not successfully complete clinical trials for drugs under development, including ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, or demonstrate the safety and efficacy of our product candidates to the satisfaction of regulatory authorities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing F351 for the treatment of liver fibrosis associated with NASH. The requirements for approval of F351 by the NMPA, FDA and comparable foreign regulatory authorities are unknown, may be difficult to predict, and may change over time, which makes it difficult to predict the timing and costs of clinical development and the likelihood of marketing approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ongoing success is reliant on our capacity to retain key executives and to recruit, maintain, and inspire skilled professionals.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our intangible assets are impaired, our results of operations and financial condition may be adversely affected. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Modifications to laws, regulations, and rules by the PRC government could lead to alterations in our operational processes and business approaches.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock is expected to be volatile.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to integrate successfully and realize the anticipated benefits of the Contributions.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance with regulations related to operating as a public company.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Financial Condition and Capital Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is significantly dependent on the sales of ETUARY, our marketed product in the PRC, amid a competitive landscape, and there is a possibility that we may not be able to sustain or boost the sales volume, pricing, and profitability of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a biotechnology company and have only generated revenues from the commercial sale of ETUARY, which is approved in the PRC, and certain generic drugs. We only have one product and certain generic drugs for commercial sale and are still in the early stages of development of our other product candidates. We are largely dependent on sales of ETUARY, but we may not be able to maintain ETUARY&#8217;s sales volumes, pricing levels or profit margins. Sales of ETUARY accounted for 98.9% and 96.9% of our total revenue in 2023 and 2022, respectively, and we expect that sales of ETUARY will continue to comprise a substantial portion of our total revenue in the near future. As a result, any reduction in sales or profit margins of ETUARY will have a material negative impact on our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the pharmaceutical industries are characterized by rapid changes in technology, constant enhancement of industrial know-how and frequent emergence of new products, which renders our targeted markets highly competitive. Notably, the IPF drug market in the PRC is characterized by increasingly fierce competition, with one pirfenidone product and one nintedanib product approved and commercialized, in addition to our product ETUARY. There are also several drug candidates that have entered into Phase 2 or more advanced clinical trial stage. With the increase in the penetration rate of IPF drugs and the expansion of the overall market, including past new market participants, we expect that more market players will join the IPF market, and, consequently, the sales of our product ETUARY, which accounted for 55.3% of the total market in 2022, has decreased from 78.8% of the total market share in 2021, and may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to decrease. For details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Our Products and Product Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ETUARY: National Category 1.1 New Drug for IPF Approved in 2011</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunities and Competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Annual Report. New entrants to the IPF market in the PRC may exert downward pressure on our average selling price of ETUARY, which may negatively impact sales and/or profit of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors, including foreign pharmaceutical companies, may have substantially greater clinical, research, regulatory, manufacturing, marketing, financial and human resources compared to us. Certain of our competitors may be actively engaged in research and development in areas where we have products or where we are developing product candidates or new indications for our existing products. Other companies may discover, develop, acquire or commercialize products more quickly or more successfully than we do. Moreover, there may also be significant consolidation in the pharmaceutical industry among our competitors or ventures among competitors that may increase their market share. Furthermore, our competitors may apply for and obtain marketing approvals in the PRC, United States or other countries for products with the same intended use as our generic products, ETUARY and product candidates more rapidly than we do. The capacity of the relevant authorities, such as the NMPA, FDA or other comparable foreign regulatory authorities, to concurrently review multiple marketing applications for the same type of innovative drug may be limited. Therefore, such authorities&#8217; review of our product candidates may be delayed when there is concurrent review of our product candidates with our competitors&#8217; products, and the registration process of our products may be prolonged.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to market competition from generic drugs and other products or therapies indicated for the same disease, many of the factors discussed in this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> section could adversely affect sales of ETUARY, including but not limited to, pricing pressures caused by government policies and inclusion or removal from the governmental medical insurance coverage, market acceptance among the medical community, disruptions in manufacturing or distribution, issues with product quality or side effects and disputes over intellectual property. Moreover, despite our efforts, we may be unable to develop or acquire new products that would diversify our business and reduce our dependence on ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The future of our business and financial outcomes is largely contingent on the progress and success of our product candidates in clinical and pre-clinical stages, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC. We face the risk of not being able to finalize their clinical development, secure necessary regulatory approvals, or accomplish their market launch successfully, or we may encounter substantial setbacks in these processes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have devoted most of our financial resources to research and development, including our preclinical and clinical development activities. Our ability to generate revenue and realize profitability depends on the successful completion of the development of our product candidates, obtaining necessary regulatory approvals, and manufacturing and commercializing our product candidates, which is contingent upon various factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical development of ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enhancing our commercial manufacturing capabilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to attract, hire and retain skilled personnel&#894;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the successful enrollment in, and completion of, clinical trials, as well as completion of pre-clinical studies and favorable safety and efficacy data therefrom&#894;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of regulatory approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the performance by contract research organizations (&#8220;CROs&#8221;), or other third parties, of their duties to us in a manner that complies with our trial protocols and applicable laws and protects the integrity of the resulting data;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to acquire or in-license other product candidates and technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining, maintaining, protecting and enforcing patent, trade secret and other intellectual property and proprietary protection and regulatory exclusivity, and ensuring we do not infringe, misappropriate or </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">otherwise violate the patent, trade secret or other intellectual property and proprietary rights of third parties&#894;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully launching commercial sales; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and/or maintaining favorable governmental and private medical reimbursement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">efficiently and cost-effectively enhancing our marketing platform and distribution capabilities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competition with other products and product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continued acceptable safety profile following regulatory approval, including of ETUARY; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">creating additional infrastructure to support operations as a public company and our product development and planned future commercialization efforts&#894; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays or other issues with any of the above.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to achieve one or more of the foregoing factors in a timely manner or at all. As a result, we could experience significant delays in or obtaining or not be able to obtain approval for and/or successful commercialization of our product, ETUARY, and product candidates, which would render us unable to achieve our planned milestones and materially harm our drug development prospects. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to sustain or increase profitability on a quarterly or annual basis. Failure to sustain or increase profitability would depress the value of our common stock and could impair our ability to raise capital, expand our business, maintain research and development efforts, diversify product offerings or even continue operations. A decline in the value of our common stock could also cause you to lose all or part of your investment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">To support the growth of our research and development activities and operations, we require further funding, which might not be obtainable on favorable terms or could be entirely unavailable. If we fail to secure the needed capital at the critical time, we might have to postpone, scale down, or halt some of our development projects, market introduction initiatives, or other operational aspects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development, commercialization, manufacturing, marketing, sales and distribution of biopharmaceutical products and product candidates is capital-intensive. We have only generated revenues from the commercial sale of ETUARY and certain generic drugs in the PRC and will not be able to generate any product revenues in addition to those generated by ETUARY and certain generic drugs until we receive approval to sell our other product candidates from the NMPA, FDA or other regulatory authorities. As we have only generated revenue from commercial sales of ETUARY and certain generic drugs to date and do not expect to generate any revenue from our other product candidates until they obtain regulatory approval, if ever, we will need to raise substantial additional capital in order to fund our future research and development, including any new clinical trials, product development, partnerships with third parties and strategic collaborations. If we continue with preclinical and clinical development activities, we will continue to incur expenses related to the preclinical and clinical development of our product candidates. However, we expect to need to raise substantial additional capital to continue the clinical development of ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, and depending on the availability of capital, may need to delay or cease development of some or all of our product candidates. Even if we raise additional capital, we may elect to focus our efforts on one or more development programs and delay or cease other development programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we expect that the implementation of our strategies and business plans will require us to rely in part on external financing sources, our ability to obtain additional capital on commercially reasonable terms is subject to a variety of factors, many of which are outside of our control, including our future financial condition, results of operations and cash flows, the global economic conditions, industry and competitive conditions, interest rates, prevailing conditions in the credit markets and government policies on lending. Additional funds may not be available when we need them on terms that are acceptable, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate some or all of our research or development programs, and we may not be able to execute our strategies and business plans as currently contemplated, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and commercialize our products under development. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and results of preclinical studies or clinical trials of ETUARY, F351, F573, F528 and F230 or other product candidates, and expenses related to potential clinical development of such candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expenses associated with promoting academic marketing and expanding our sales and distribution network; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and characteristics of product candidates that we pursue;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs we incur related to the sale of our legacy assets or claims;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of any future collaboration, licensing or other arrangements that we may establish;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our need and ability to retain key management and hire scientific, technical, business and medical personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, timing and cost of regulatory approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our efforts to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing associated with manufacturing our products, including ETUARY and generic products and product candidates for which we may receive regulatory approval, and establishing commercial supplies and sales, marketing and distribution capabilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market acceptance of any product candidates for which we may receive regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the capital expenditure required to increase our production capacity and to expand and upgrade our facilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of continuing to operate our business, including costs associated with being a public company; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire, license or invest in businesses, products or technologies.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from public health crises, the conflict between Russia and Ukraine, the Hamas-Israel war or the attacks on marine vessels traversing the Red Sea. For details regarding the risks related to the relations between the PRC and the United States, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Business Operations in the PRC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our strategy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our board of directors elects to seek product candidates for development, we will face the risks related to discovery, development and commercialization of our product candidates set forth in this section, in addition to other risks described in this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional funds by issuing securities or through licensing arrangements may cause dilution to stockholders, restrict our operations or require us to relinquish proprietary rights.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of common stockholders. We currently have in place an Equity Distribution Agreement with Piper Sandler &amp;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Co. that permits us, subject to applicable SEC regulations, to issue up to $50.0 million of shares of our common stock in &#8220;at the market&#8221; transactions at prevailing market prices.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We may also seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. There can be no assurance that we will be able to obtain additional funding if, and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, curtail or eliminate one or more, or all, of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may grow our business in part through acquisitions, which may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and have material adverse effect on our ability to manage our business, and we may fail to successfully complete such acquisitions or enhance post-acquisition performances in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To enhance our growth and benefit our product development, technology advancement and distribution network, we have in the past and may continue to acquire businesses, products, technologies or know-how or enter into strategic partnerships. Any completed, in-process or potential acquisition or strategic partnership may entail numerous risks, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to identify suitable acquisition targets and reach agreement on acceptable terms;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of access to financing for acquisitions on acceptable terms or at all, or otherwise on assumption of additional indebtedness or contingents and issuance of our equity securities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to obtain or secure the governmental approvals and third-party consents necessary to consummate any proposed acquisition;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased operating expenses, including research and development expenses due to an increased number of product candidates, administrative expenses and selling expenses;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products and product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs; and/or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">deficiencies in internal controls, data adequacy and integrity, product quality and regulatory compliance and product liabilities in the acquired business we discover after such acquisition. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our plan to grow our business through such acquisitions may not materialize as expected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our high gross margin during the years ended December 31, 2023 and 2022 may not be sustainable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023 and 2022, we maintained a high level of gross margin. Our profit margins were 95.9% and 95.3% for the years ended December 31, 2023 and 2022, respectively, due to our mature technology and significant cost reduction due to the scale effect. However, there can be no assurance that we will sustain a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">similarly high gross margin in the future. Various factors may affect our gross margin, many of which are beyond our control. For example, changes in the competitive landscape of the relevant markets may decrease the average selling prices of ETUARY, which may have a negative effect on our gross margin. Moreover, our gross margin will be influenced by various components of our costs, such as the cost of raw materials. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;Risks Relating to Manufacture and Supply of Our Product&#8212;Fluctuations in prices of our raw materials and energy supply, as well as other costs associated with our production processes, may have a material adverse effect on us if we are not able to pass the cost increases on to our customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Risk Factors section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our five largest customers accounted for a substantial amount of our revenue during the years ended December 31, 2023 and 2022, which subjects us to concentration risks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our five largest customers accounted for a substantial amount of our revenue for the years ended December 31, 2023 and 2022. As such, we may be exposed to credit risks, and there can be no assurance that we can properly assess and respond in a timely manner to changes in our customers&#8217; credit profile. As of each of December 31, 2023 and 2022, we had certain concentrations of credit risk of 10%. In addition, as of December 31, 2023, 50.5% and 85.5%, and as of December 31, 2022, 45.1% and 78.3%, of our trade receivables were due from our largest customer and our five largest customers, respectively. If such customers&#8217; cash flows, working capital, financial condition or results of operations decrease, they may be unable, or they may otherwise be unwilling, to pay trade receivables owed to us promptly or at all. Any substantial defaults or delays could materially and adversely affect our cash flows, and if we terminate our relationships with our customers as a result of such customers&#8217; default or payment delay, then that may adversely and materially affect our cash flows and operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our major customers stop purchasing ETUARY or substantially reduce order size in the future, whether due to the termination or amendment of our contractual relationship with such customer, or due to any other reason unrelated to us, we may not be able to identify and sell ETUARY to an alternative customer in a timely manner, or at all. As a result, our business and financial performance may be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may face risk regarding the obsolescence of our inventories.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inventories consist of raw materials, works in progress, semi-finished goods and finished goods. As of December 31, 2023 and 2022, our inventories were valued at $4.3 million and $6.1 million, respectively. During the years ended December 31, 2023 and 2022, we did not identify material inventory items requiring impairment provisioning, and we believe that maintaining appropriate levels of inventory helps us meet market demands in a timely manner. We generally purchase supplies based on our estimated demand and manufacturing capacity, and our management system covers each stage of the warehousing process. The storage and distribution of our inventories are closely monitored in order to keep our inventories and logbook consistent. However, as our business expands, our inventory levels may increase and the risk of obsolescence may increase accordingly. Furthermore, any unexpected material fluctuations in the supplies or changes in customers&#8217; preferences may lead to decreased demand and overstocking of supplies and increase the risk of obsolescence.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our intangible assets are impaired, our results of operations and financial condition may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have intangible assets primarily consisting of product development in progress, patents, technological know-how, and computer software, which accounted for a considerable portion of our total assets as of December 31, 2023 and 2022. The value of our intangible assets is based on a number of assumptions made by our management. If any of these assumptions do not materialize, or if the performance of our business is not consistent with such assumptions, we may have to write off a significant portion of our intangible assets and record a significant impairment loss. In addition, our determination on whether intangible assets are impaired requires an estimation of the carrying amount and recoverable amount of an intangible asset. If the carrying amount exceeds its recoverable amount, our intangible assets may be impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to credit risk in collecting trade receivables due from our customers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, our trade receivables amounted to $15.2 million and $15.6 million, respectively, which primarily represented the balances due from our distributors. Our liquidity and cash flow are directly affected</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">by our customers&#8217; ability to pay us in a timely manner, but there can be no assurance that our customers will not default on us in the future, despite our efforts to conduct credit assessments. During the years ended December 31, 2023 and 2022, our trade receivables turnover days were 50 days and 46 days, respectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our customers&#8217; business, cash flow, conditions or results of operations decrease, such customers may be unable or unwilling to pay trade receivables owed to us promptly or at all. Bankruptcy or deterioration of the credit condition of our major customers could also materially and adversely affect our collection of trade receivables. For details of the risk associated with concentrations of credit risk that we are exposed to, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our five largest customers accounted for a substantial amount of our revenue during the years ended December 31, 2023 and 2022, which subjects us to concentration risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Risk Factors section. If significant amounts due to us is not settled in a timely manner, we may incur significant write-offs and our liquidity and cash flow may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have historically received government grants and have been entitled to preferential tax treatment, but we may not continue to receive government financial incentives in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have historically received government grants in connection with certain of our research and development and manufacturing activities, and recognized government grants under other income and gains of $1.0 million and $0.9 million for the years ended December 31, 2023 and 2022, respectively. For details of the amounts of our other recognized income, see Note 4 to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Audited Financial Statements of Gyre Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in this Annual Report. We were also entitled to a preferential corporate income tax rate of 15% for each of the years ended December 31, 2023 and 2022 as a High and New Technology Enterprise. In addition, our product ETUARY, which is approved in the PRC, has been entitled to a preferential VAT treatment at the tax rate of 3%. However, there can be no assurance of the continued availability of such preferential treatment. Our eligibility for government grants and preferential tax rates depends on a variety of factors, including, but not limited to, the assessment of our improvement on existing technologies, relevant government policies and the availability of funding at different granting authorities. In addition, the timing, amount and criteria of government financial incentives are determined within the sole discretion of the PRC government authorities. Government financial incentives are non-recurring in nature, and there can be no guarantee that we will continue to receive government incentives. In addition, some government financial incentives may be subject to the satisfaction of certain conditions, including compliance with the applicable financial incentive agreements and completion of the specific projects therein, which we may not satisfy. Any reduction or elimination of the government financial incentives we currently receive could have an adverse effect on our financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business Operations and Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">There is a risk that our marketed product in the PRC, ETUARY, along with any other products that may receive approval in the future, may not attain sufficient market acceptance among physicians, healthcare facilities, pharmacies, patients, third-party payers, and the broader medical community, which is crucial for their commercial viability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commercial success of our existing and future approved products, if any, depends upon the degree of market acceptance such products can achieve, particularly among physicians, hospitals, pharmacies and other medical institutions, which is contingent upon a number of factors. Such factors affecting the market acceptance of a current or future approved product, if any, may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product is approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the safety and efficacy of the product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages and disadvantages of the product, relative to competing or alternative products or treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the affordability of the product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments and therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of our relationships with patient communities;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the current diagnostic conditions of the disease for which the product is indicated, which may be influenced by the number of physicians from the relevant department and their respective experiences, available diagnostic methods and equipment therefor; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our sales and marketing efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our existing and future approved products, if any, fail to achieve or maintain widespread market acceptance, or if new products introduced by our competitors are perceived more favorably by healthcare practitioners and patients, are more cost-effective or otherwise render our products obsolete, the demand for our products may decline and our business and profitability may be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process and outcomes are uncertain, and we may not successfully complete clinical trials for drugs under development, including ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, or demonstrate the safety and efficacy of our product candidates to the satisfaction of regulatory authorities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining regulatory approval for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate their safety and efficacy, but there can be no assurance that such trials will be completed in a timely or cost-effective manner, due to the inherently unpredictable nature of clinical drug development. We have only obtained regulatory approval for one product, ETUARY for the treatment of IPF in the PRC, that we have developed, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.  Events that may prevent successful or timely completion of clinical development may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators, institutional review boards or ethics committees not authorizing us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to reach agreements on acceptable terms with prospective CROs, SMOs and hospitals as trial centers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing issues, including problems with manufacturing, supply quality, compliance with GMP, or obtaining sufficient quantities of a product candidate for use in a clinical trial in a timely manner; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials producing negative or inconclusive results, resulting in additional clinical trials or abandoning drug development programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes to the clinical trial protocol;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our third-party contractors&#8217; failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our suspending or terminating clinical trials for various reasons, including negative or inconclusive clinical response or a finding that participants are being exposed to unacceptable health risks or experiencing adverse effects; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials being greater than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials being insufficient or inadequate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">participants choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of adverse effects or serious adverse effects associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the occurrence of serious adverse events in clinical trials of competing products or conducted by competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol or other regulatory requirements or committing fraud; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of pre-clinical studies or early clinical trials not being predictive of the results of later-stage clinical trials, and initial or interim results of a trial not being predicative of final results.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are required to conduct additional preclinical studies or clinical trials of our product candidates, including of ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC or other testing, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be delayed in obtaining regulatory approval from the NMPA, FDA, EMA or other regulatory authorities for our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not obtain regulatory approval at all and lose our ability to further develop and commercialize our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be required to conduct additional clinical trials or other testing beyond those that we currently contemplate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to be subject to post-marketing testing requirements from the NMPA, FDA, EMA or other regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be unable to be listed in the NRDL in the PRC; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">experience having the product removed from the market after obtaining regulatory approval.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consequentially, any delays in completing our clinical trials may increase our costs, delay our product candidate development and approval process, and jeopardize our ability to commercialize our approved products and generate revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liver fibrosis is an area of our focus, and our key product candidate in this area is F351. Our future clinical trials for F351 may not be successful.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to invest a substantial amount of our efforts and financial resources into the research and development of F351. F351 is currently in its Phase 3 clinical trial in the PRC and has the potential to be the world&#8217;s first approved drug to treat liver fibrosis associated with CHB. F351 was granted a Breakthrough Therapy designation by the NMPA&#8217;s CDE in March 2021 and the patient enrollment for our Phase 3 clinical trial was commenced in January 2022. As of October 2023, the 248 patient Phase 3 clinical trial in the PRC was fully enrolled. However, F351&#8217;s Breakthrough Therapy designation does not increase the likelihood that F351 will ultimately receive approval from the NMPA or other comparable regulatory authorities. We expect to have the last patient out in 2024 and submit an NMPA application for F351 in the PRC in the first quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are actively preparing an IND application that we expect to file by the end of 2024 for a Phase 2 clinical trial to evaluate F351 for the treatment of advanced liver fibrosis associated with NASH. Following IND clearance, we plan to initiate a Phase 2a, PoC clinical trial in 2025 in the United States to evaluate the safety, tolerability, PK, and PD of F351 for patients with advanced liver fibrosis associated with noncirrhotic NASH. The FDA has provided pre-IND advice on the design of the planned Phase 2a trial of F351 and provided guidance on the contents of the IND filing. If we observe positive trends in the Phase 2a trial of F351, we expect to initiate a Phase 2 trial of F351 in the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F351 will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote F351, or any other product candidates, before we receive marketing approval from the NMPA, FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of F351 will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of F351, even if approved. If we are not successful in commercializing F351, or are significantly delayed in doing so, our business will be materially harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the commencement of clinical trials or patient enrollment in clinical trials, our regulatory approvals could be delayed or prevented.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our collaborators may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate, enroll and maintain enrollment of a sufficient number of eligible patients to participate in these trials as required by the NMPA, FDA or similar regulatory authorities outside the PRC or the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, there are inherent difficulties in enrolling NASH patients, which can currently only be definitively diagnosed through a liver biopsy. Specifically, identifying patients most likely to meet NASH enrollment criteria on biopsy is an on-going challenge, with existing clinical indicators lacking both sensitivity and specificity. As a result, NASH trials often suffer from high levels of screen failure following central review of the baseline liver biopsy, which can lead to lower enrollment. As a result of such difficulties and the significant competition for recruiting NASH patients in clinical trials, we or our future collaborators may be unable to enroll the patients we need to complete clinical trials on a timely basis, or at all. In addition, our competitors, some of whom have significantly greater resources than we do, are conducting clinical trials for the same indications and seek to enroll patients in their studies that may otherwise be eligible for our clinical studies or trials. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which could further reduce the number of patients who are available for our clinical trials in these sites. The availability of other approved products and other products in clinical trials have and may limit the number of patients willing to participate in our clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment is affected by other factors including:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the severity of the disease under investigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the eligibility criteria for the study in question;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perceived risks and benefits of the product candidate under study;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of other product candidates in the same indication;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory testing and turnaround time for samples needed for eligibility assessments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patient referral practices of physicians;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to enroll a sufficient number of patients for our clinical trials will result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in clinical trials conducted by us may also result in increased development costs for our product candidates, which would cause the value of the Company to decline and limit our ability to obtain additional financing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our substantial investment in research and development in order to develop our product, ETUARY, and other product candidates, and to enhance our technologies may ultimately fail to materialize.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global pharmaceutical market is constantly evolving, and we must keep pace with new technologies and methodologies to maintain our competitive position. Our future success partially depends on our ability to launch new products that meet evolving market demands, in particular, new drugs, that are effective in treating new diseases and illnesses. However, there can be no assurance that we will be able to respond to emerging or evolving trends by improving our product portfolio in a timely manner, or at all. For the years ended December 31, 2023 and 2022, we incurred substantial expenditure related to the research and development of our product, ETUARY, and other product candidates, and we expect to continue to invest significant amounts of human and capital resources to develop our product and product candidates while enhancing our technologies that will allow us to advance our pipeline products. We also intend to continue to strengthen our technical capabilities in drug discovery, development, and manufacturing, which are capital and time intensive. However, there can be no assurance that we will be able to develop, improve or adapt to new technologies and methodologies, successfully identify new technological opportunities, or develop and bring new or enhanced products to market.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our commercialized product, ETUARY, which is approved in the PRC, and any other future product, if approved, may be excluded or removed from national, provincial or other government-sponsored medical insurance programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under medical insurance programs in the PRC, patients are entitled to reimbursement of all or a portion of the cost of pharmaceutical products listed in the NRDL, the relevant provincial reimbursement drug lists, or other medical insurance reimbursement lists. However, such inclusion is based on a variety of factors, including clinical needs, use frequency, efficacy, safety and price, which may be outside of our control. Moreover, the relevant PRC government authorities may, from time to time, review and revise, or change the scope of reimbursement for, the products that are included in the medical insurance reimbursement lists.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our product ETUARY, which is approved in the PRC, has been included in the NRDL as a Category B drug for its IPF indication since 2017, there can be no assurance that it will remain so listed, or unimpacted negatively by changes in the scope of reimbursement. To the extent that our future approved product candidates are not included in any medical insurance reimbursement list, or if any such insurance schemes are changed or canceled, which results in the removal of such product candidates from the relevant medical insurance reimbursement lists, patients may choose, and hospitals, pharmacies and other medical institutions may recommend, alternative treatment methods, which may reduce demand for our product, ETUARY, and future products, if approved, and adversely impact our sales.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may face pressure to lower the prices of our commercialized product, ETUARY, which is approved in the PRC, and any other future product, if approved, in order for such products to qualify for medical insurance reimbursement or due to market competition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may face pressure to lower the prices of our commercialized product, ETUARY, which is approved in the PRC, and any other future product, if approved, in order to have such product candidates included in the medical insurance reimbursement lists, while such low price and reimbursement may not necessarily lead to increased sales. It is difficult to estimate the net effect of decreased prices and the potential of increased sales on our profitability, and our profits from the sales of our future products may decrease if we significantly lower prices without a greater increase in sales.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, it is typical that the prices of pharmaceutical products will decline over the life of the product as a result of, among other things, increased competition from substitute products, the tender process by the hospitals or the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">government authorities, pricing policies of the relevant government authorities, or voluntary price adjustments by pharmaceutical companies. Any strategic downward price adjustments of our existing or future approved products due to market competition could have a materially adverse effect on our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, our marketed ETUARY is subject to the risk of being included in the PRC&#8217;s centralized volume-based procurement scheme. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;In the future, the policies of centralized volume-based procurement set by the PRC government may cover our commercialized product, ETUARY, and any other future products, if approved, and the prices of such product may decrease, which in turn may have a material adverse impact on our revenue, financial condition and results of operation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Risk Factors section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may fail to win bids to sell our commercialized product, ETUARY, and any other future products, if approved, to PRC public hospitals through the centralized tender process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because a considerable portion of pharmaceutical products we sell to our distributors are sold to public hospitals and other medical institutions in the PRC, we must submit bids in a centralized tender process to supply our commercialized product, ETUARY, and any other future products, if approved, to these institutions at specified prices. Each public medical institution in the PRC must generally procure drugs through a provincial centralized drug purchase platform and make substantially all of its purchases of pharmaceutical products through a centralized tender process. Our bids submitted in the centralized tender process are generally considered on the basis of price relative to substitute products and the clinical effectiveness of such substitute products, as well as the quality of our product and services, among other things. As a result, our sales volumes and profitability of ETUARY depend on our ability to successfully differentiate our product and price our bids in a manner that enables us to succeed in the centralized tender process at profitable levels.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, we may fail to win bids in a centralized tender process due to various factors, including reduced demand for the relevant product, noncompetitive bidding price, failure to meet certain quality requirements, or the relevant products being perceived to be less clinically effective than competing products. If our commercialized product, ETUARY, and any other future products, if approved, are not selected in the centralized tender process in one or more regions, our sales of the relevant product to the public hospitals in those regions may encounter difficulties, and our market share, revenues and profitability could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In the future, the policies of centralized volume-based procurement set by the PRC government may cover our commercialized product, ETUARY, and any other future products, if approved, and the prices of such product may decrease, which in turn may have a material adverse impact on our revenue, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PRC government authorities have implemented policies that aim to further increase the affordability of pharmaceutical products, including the centralized volume-based drug procurement system. For further details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Product Pricing&#8212;Centralized Tender Process and Centralized Volume-based Procurement System&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> &#8220;Business&#8212;Regulatory Requirements in the PRC&#8212;Other PRC Regulations in Relation to the Pharmaceutical Industry&#8212;Centralized Drug Procurement and Use</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future procurement by the PRC government is expected to include drugs listed in the NRDL that have great market demand and high purchase price, and such future procurement is expected to gradually cover all types of domestically marketed drugs in the PRC necessary for clinical use and of reliable quality to the extent possible. As a result, all appropriate drugs may be procured thereunder in the PRC. Appropriate procurement methods for &#8220;orphan drugs&#8221; and drugs in shortage may be actively explored to ensure stable supply.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our marketed product, ETUARY, is currently not subject to the centralized volume-based procurement process. However, it is uncertain whether the centralized volume-based procurement scope would be expanded in the future and result in the inclusion of our product ETUARY, which is approved in the PRC, or other product candidates if commercialized, which may cause their retail prices to decrease. Moreover, if any products comparable or similar to our product, generic drugs or product candidates if commercialized are included in the centralized volume-based procurement, patients&#8217; willingness to use such products may be materially and adversely affected and we may need to change our pricing strategy. If any or all of the foregoing were to occur, our sales revenue may decrease, which in turn would have a material adverse impact on our financial condition, profitability and results of operation.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The true market potential for our product and product candidates may be less than expected. Our expansion could be constrained by the current and emerging number of IPF patients in the PRC, pending the approval and profitable launch of expanded applications for ETUARY for future indications in the PRC, and our other product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products, since the market opportunities for our product candidates may be smaller than we anticipate. Similarly, the actual market size of our product ETUARY, which is approved in the PRC, may not be as large as we anticipate. The total addressable market opportunity will depend on, among other things, acceptance of the product by the medical community and patient access, product pricing and reimbursement. Moreover, the number of patients in the addressable markets may be lower than expected, patients may not be amenable to treatment with our product, or new patients may become increasingly difficult to identify or access. Further, new studies may change the estimated incidence or prevalence of the diseases that our product candidates target. Any of the above unfavorable developments could have a material adverse effect on our business, financial condition and results of operations. In particular, if the existing and newly identified cases of IPF patients in the PRC are fewer than we expect, our growth and financial position may be negatively impacted until and if the expanded indications of ETUARY and our other product candidates such as F351 are approved and become profitable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Frost &amp; Sullivan, the prevalence of IPF in the PRC has increased from 83,002 patients in 2017 to 131,654 patients in 2022, and is expected to increase to 214,664 patients by 2027 and 320,677 patients by 2031. Notwithstanding the short term increase in the prevalence of IPF, with strengthening of the public health system as well as medical and technological advancement in the PRC, the potential risks that cause IPF may be lowered or eliminated in the future which in turn may lead to corresponding decrease in the prevalence of IPF in the PRC. The shrinking prevalence of IPF in the PRC, as a result, may have a negative impact on the market size of ETUARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to conduct effective academic marketing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective marketing and successful sales are crucial for us to increase the market penetration of ETUARY in the PRC, expand our coverage of hospitals, pharmacies and other medical institutions and promote new products, if any, in the future. In particular, we place a strong emphasis on academic marketing, through which we promote ETUARY to medical professionals, hospitals, pharmacies and other medical institutions. While our sales and marketing force actively works with medical professionals, hospitals, pharmacies and other medical institutions and we endeavor to inform them of the distinctive characteristics, advantages, safety and efficacy of ETUARY as compared to our competitors&#8217; products, we may not be able to successfully enhance our product awareness.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may fail to maintain a qualified sales and marketing force.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to successfully market and sell our commercialized product, ETUARY, which is approved in the PRC, and any other future products, if approved, our sales and marketing teams are expected to possess a relatively high level of technical knowledge, up-to-date understanding of industry trends, necessary expertise in the relevant therapeutic areas and products, as well as sufficient promotion and communication abilities. However, there can be no assurance that there will be a sufficient amount of competent sales professionals with the relevant rare disease knowledge and/or academic KOLs or doctor networks available for hire. As a result, if we are unable to effectively train our in-house sales representatives or monitor and evaluate their academic marketing performances, our sales and marketing may be less successful than desired.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, our ability to attract, motivate and retain a sufficient number of qualified sales professionals is especially important because we primarily rely on our in-house sales force to market our product. As competition for experienced marketing, promotion and sales personnel is intense, we may be unable to attract, motivate and retain a sufficient number of marketing, promotion and sales professionals. If we fail to maintain a qualified sales and marketing force, sales volume of our commercialized product, ETUARY, and any other future products, if approved, may be adversely affected and we may be unable to expand our coverage of hospitals, pharmacies and other medical institutions or increase our market penetration.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may fail to maintain or expand an effective distribution network for our commercialized product, ETUARY, which is approved in the PRC, and any other future products, if approved, or further expand our distribution channel.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we primarily rely on our network of distributors to distribute commercialized product, ETUARY, in the PRC, and intend to continue engaging distributors to sell our commercialized product, ETUARY, and any other future products, if approved, in the foreseeable future, our ability to maintain and grow our business depends on our ability to maintain and manage a sufficient number of distributors with an extensive sales network, which we could fail to achieve for several reasons. Our distributors may be unable to maintain or expand their sales network, or may encounter difficulties in selling our commercialized product, ETUARY, and any other future products, if approved. Our distributors might elect not to renew their agreements with us or otherwise terminate their business relationships with us for various reasons, such as price controls or other factors that substantially reduce the margins they can obtain through the resale of our commercialized product, ETUARY, and any other future products, if approved. Further, we may fail to find an appropriate group of distributors suitable for our commercialized product, ETUARY, and any other future products, if approved, or the costs of doing so may become prohibitively high. Any disruption to our distribution network, including our failure to maintain relationships, form new relationships or renew our existing distribution agreements, could negatively affect our ability to sell our commercialized product, ETUARY, and any other future products, if approved, and may materially and adversely affect our business, results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may fail to sufficiently and promptly respond to clinical demand and market changes in the pharmaceutical industry.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical demand and market conditions for pharmaceutical products may change rapidly and significantly, and our success in part depends on our ability to anticipate product offering lead-times and demand, identify customer preferences and adapt our products to these preferences. We may need to adjust our research and development plan, production scale and schedule, product portfolio and inventory levels based on customer demand, sales trends and other market conditions. However, there can be no assurance that we will be able to sufficiently and promptly respond to changes in clinical demand and purchasing patterns in a timely manner or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Geopolitical events and global economic conditions, such as public health crises, the conflict between Russia and Ukraine and the Israel-Hamas war may impact our third-party supply of the raw materials and components needed for our product, ETUARY, and product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, which increases the risk that we will not have sufficient quantities of such product, generic drugs or product candidates or will not have such quantities at an acceptable cost, which will delay, prevent or impair our commercialization, marketing or development efforts, as applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If supplies of the raw materials for our product, ETUARY, or product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, are significantly delayed, or if the third parties that we engage to supply any materials or to manufacture any products for our preclinical tests and clinical trials should cease to continue to do so for any reason, including due to the effects of global economic conditions, including inflation and rising interest rates, public health crises, the conflict between Russia and Ukraine and the Hamas-Israel war, we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product, generic drugs or product candidates or the substances used to manufacture them, it will be more difficult for us to commercialize, market or develop our product, generic drugs or product candidates, as applicable, and compete effectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated dependence upon third-party suppliers may adversely affect our ability to develop our product, generic drugs, and product candidates and could delay our clinical trials and development programs as well as marketing and commercialization efforts, and otherwise harm our operations and financial condition and increase our costs and expenses. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;Risks Related to Our Reliance on Third Parties&#8212;Because we rely on a limited number of suppliers for certain of our raw materials, we may experience supply interruptions that could harm our ability to manufacture products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For details regarding the risks related to the relations between the PRC and the United States, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;Risks Related to Our Business Operations in the PRC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations, and those of our distributors, suppliers, research institution collaborators and other business partners, could be subject to natural or man-made disasters, health epidemics or business interruptions, for which we are predominantly self-insured. Damage or extended periods of interruption to our and our partners&#8217; administration, development, research, manufacturing or storage facilities due to fire, natural disaster, health epidemic, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development or commercialization of some or all of ETUARY, our generic products or product candidates, seriously harm our and our partners&#8217; operations and financial condition and increase our and our partners&#8217; costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited insurance coverage, and any claims beyond our insurance coverage may result in substantial costs and a diversion of resources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in the pharmaceutical industry, which involves numerous operating risks and occupational hazards. The insurance policies we maintain are required under the applicable laws and regulations as well as based on our assessment of our operational needs and industry practice. However, there can be no assurance that the existing insurance coverage is sufficient to compensate for actual losses suffered or incurred. In addition, there are certain types of losses, such as losses from war, acts of terrorism, health or public security hazards, earthquakes, typhoons, flooding and other natural disasters, for which we cannot obtain insurance at a reasonable cost or at all. If an uninsured loss or a loss in excess of insured limits were to occur, our business, results of operations and financial condition may be materially and adversely affected. For details of the specific risks of inadequate insurance coverage in the event of product liability claims and environmental liabilities, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;We may be subject to product liability claims that could expose us to costs and liabilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; and &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#8221; respectively, in this section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications for these product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to identify, discover, or develop new product candidates, or to identify additional therapeutic opportunities for our product candidates, in order to expand or maintain our product pipeline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to continue to identify and develop new product candidates to enrich our current pipeline. Research programs to pursue the development of our product candidates for additional indications and to identify new product candidates and product targets require substantial technical, financial and human resources. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development. For example, product candidates may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be successfully developed, much less receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will materially and adversely affect our future growth and prospects, which likely would result in significant harm to our financial position and adversely affect our stock price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Results from preclinical or early stage clinical trials, including the results of our preclinical testing and early clinical trials of ETUARY, F351 and F573, may not be confirmed in later trials or be predictive of the success of later clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later-stage clinical trials. Trials of our product candidates in larger numbers of patients may not have similar efficacy results and could result in adverse effects that were not observed in the earlier trials with smaller numbers of patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will be required to demonstrate substantial evidence through well-controlled clinical trials that our product candidates are safe and effective before we can seek marketing approvals for their commercial sale. Demonstrations of efficacy or an acceptable safety profile in our prior preclinical studies does not mean that future clinical trials will yield the same results. For instance, while ETUARY is approved in the PRC for the treatment of IPF, it may not be approved for the treatment of other indications, such as SSc-ILD, DM-ILD, pneumoconiosis or DKD, or in other markets. In addition, we do not know whether F351 will perform in future clinical trials as F351 has performed in preclinical studies and early clinical trials conducted by us in the PRC, and, despite F351&#8217;s Phase 1 trial in the United States showing promising evidence of tolerability and PK and our Phase 2 clinical trial in the PRC demonstrating results in the reversal of CHB-associated fibrosis, to date, there is no effective clinical therapy for liver fibrosis, and no specific therapeutic products have been approved worldwide. We also do not know whether F573 will perform in its Phase 2 clinical trial for ALF/ACLF as it has performed in its Phase 1 clinical observation of tolerability and PK. Product candidates, including ETUARY, F351 and F573, may fail to demonstrate in later-stage clinical trials sufficient safety and efficacy to the satisfaction of the NMPA, FDA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and earlier stage clinical trials. Regulatory authorities may also limit the scope of later-stage trials until we have demonstrated satisfactory safety or efficacy results in earlier-stage trials. In particular, although ETUARY is approved in the PRC for the treatment of IPF, it may not perform in the Phase 3 clinical trials for the treatment of SSc-ILD and DM-ILD, Phase 3 clinical trial for the treatment of pneumoconiosis, or Phase 1 clinical trial of ETUARY for the DKD Program. In addition, we</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are actively preparing an IND application that we expect to file by the end of 2024 for a Phase 2 clinical trial to evaluate F351 for the treatment of advanced liver fibrosis associated with noncirrhotic NASH. Following IND clearance, we plan to initiate a Phase 2a, PoC clinical trial in 2025 in the United States to evaluate the safety, tolerability, PK, and PD of F351 for patients with advanced liver fibrosis associated with noncirrhotic NASH. The FDA has reviewed the planned Phase 2a trial of F351 in the United States and provided comments on the design, trial assessment, and the contents of the IND filing. If we observe positive trends in the Phase 2a trial of F351, we expect to initiate a larger Phase 2 trial in F351. Although data from liver fibrosis associated with CHB patients in our Phase 2 clinical trial in the PRC demonstrated F351 has the potential to improve liver fibrosis, the efficacy of F351 in prior preclinical studies in a NASH model does not mean that future clinical trials will yield the same results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the pre-IND guidance provided, at the time of review of the IND application, the NMPA, FDA or other comparable foreign regulatory authorities may require additional investigations (nonclinical) and analyses (both nonclinical and clinical, including the analysis of the supportive clinical trials conducted in the PRC) before it accepts the IND file to ensure that there is sufficient and adequate information on the risks to human subjects. Such additional requests may delay the timelines for the IND filing and initiation of the planned Phase 2a trial in NASH-associated liver fibrosis. Furthermore, if the NMPA or FDA believes that additional data is necessary to supplement our clinical study data and Phase 2a clinical trial data, then the NMPA or the FDA may require us to conduct additional trials before expanding into a broader Phase 2 clinical trial. There is no guarantee that the NMPA, FDA and other comparable foreign regulatory authorities will consider the data that is expected to be obtained in the planned Phase 2a trial in the United States sufficient to allow us to expand the development of F351 in a larger Phase 2 or confirmatory Phase 3 clinical trial. There is no guarantee that we will be able to complete such trials on the timelines we anticipate or that such trials will produce positive results. Any limitation on our ability to conduct clinical trials could delay or prevent regulatory approval or limit the size of the patient population to which we may market our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage NASH clinical trials after achieving positive results in earlier development, and we may face similar setbacks. Many companies that believed their product candidates performed satisfactorily in preclinical studies and early clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the results of clinical trials for our product candidates warrant marketing approval, the NMPA, FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Any Phase 2, Phase 3 or other clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preliminary, &#8220;top-line&#8221; or interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have publicly disclosed and may in the future publicly disclose preliminary or top-line data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any preliminary or top-line data should be viewed with caution until the final data are available. From time to time, we have also disclosed and may in the future disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the likelihood of approval or commercialization of the particular product candidate and our company in general. In addition, from time to time we may disclose top line or summary information regarding a particular preclinical study or clinical trial. Such summary information is necessarily based on more fulsome and extensive information, and investors or regulators may not agree with what we determine is material or otherwise determine is appropriate information to include in our disclosure. If the preliminary, top-line or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A variety of risks associated with marketing our product candidates internationally may materially adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also seek regulatory approval of our product candidates, including ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, outside of the PRC and United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including differing regulatory requirements in foreign countries. Risks associated with international operations may materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product, ETUARY, which is approved in the PRC, and product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, may cause or be perceived to cause significant adverse events, toxicities or other undesirable side effects that may result in a safety profile that could interrupt, delay or halt clinical trials, delay or prevent regulatory approval, marketing approval or market acceptance, limit their commercial potential and profile of an approved</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">label, adversely affect our reputation and results of operations or result in significant negative consequences following any regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates, including ETUARY, F351, F573, F528 and F230, are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or INDs, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Many times, side effects are only detectable after investigational product candidates are tested in large-scale, Phase 3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our current product candidates and any future product candidates has serious or life-threatening side effects or other side effects that outweigh the potential therapeutic benefit, the development of the product candidate may fail or be delayed, or, if the product candidate has received marketing approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any adverse events or serious adverse events reported in our clinical trials caused by our product candidates could give rise to significant negative consequences. Such consequences may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may seek an injunction against our product candidates manufacture or distribution;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw approvals or revoke licenses of an approved product candidate, or we may determine to do so even if not required; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, of an approved product candidate or impose other limitations on an approved product candidate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may issue safety alerts, require press releases or other communications containing warnings or other safety information about the product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require us to change the way such product is administered;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to develop a REMS for the product candidate, which could include a medication guide outlining the risks of such side effects for distribution to patients, or to incorporate additional requirements under REMS; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to conduct additional clinical trials or post-market studies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be subject to litigation proceedings and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be found in breach of contract with our major customers;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient enrollment may be insufficient or slower than we anticipate or patients may drop out or fail to return for post-treatment follow-up at a higher rate than anticipated;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialized products could be removed from medical insurance reimbursement lists or be rendered unable to participate in the centralized tender process in the PRC;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may impose fines, injunctions or criminal penalties;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may fail to achieve or maintain market acceptance of a particular product candidate, if approved, which may cause serious harm to our business; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Undesirable or unintended side effects may be a result of a number of factors that are outside of our control, including potential side effects not revealed in clinical testing, unusual but severe side effects in isolated cases, defective products not detected by our quality management system, and misuse of our products by end-users.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, our product, generic drugs and future products, if approved, may be perceived to cause severe side effects if other pharmaceutical companies&#8217; products containing the same or similar active pharmaceutical ingredients, raw materials or delivery technologies as our product, generic drugs and future products, if approved, cause or are perceived to have caused severe side effects, or if regulators or international institutions determine that products containing the same or similar pharmaceutical ingredients as our product, generic drugs and future products, if approved, cause severe side effects. Our product, generic drugs and future products, if approved, may also be perceived to cause severe side effects when a conclusive determination as to the cause of the severe side effects is not obtained or is unobtainable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, the anticipated clinical trials of F351 will include patients with advanced liver fibrosis who are at risk of further progression to cirrhosis and deterioration, but are not critically ill. A certain percentage of patients with HBV-induced liver fibrosis treated with F351 have experienced adverse events, including gastrointestinal diseases, ear and labyrinth diseases, systemic diseases, metabolic and nutritional diseases, skin and subcutaneous tissue diseases, heart organ diseases, and hepatobiliary system diseases. However, the risk/benefit of F351 in NASH may differ from that shown in HBV liver fibrosis patients and there is always a risk that the severity and frequency of the adverse events may worsen. See the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;Business&#8212;F351 Overview</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the patient populations treated with our product candidates in our various Phase 3 clinical trials have serious diseases that make them susceptible to significant health risks. Therefore, these patients may experience adverse events, including serious adverse events.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In conducting drug research and development, we face potential liabilities; in particular, product liability claims or lawsuits that could cause us to incur substantial liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability as a result of clinical trials if our product candidates cause, or are perceived to cause, injury, or are found to be otherwise unsuitable during clinical testing. Regardless of the merits or eventual outcome, such liability claims may, among others, result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our product candidates after commercialization; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants and inability to continue clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a diversion of management&#8217;s time and our resources; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To cover such liability claims arising from clinical trials, we have clinical trial insurance for all of our trials, which are necessary for the approval of commercialization of our pipeline products. However, it is possible that our liabilities could exceed our insurance coverage or that our insurance will not cover all situations in which a claim against us could be made. We may also not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse drug reactions and negative results from off-label use of our commercialized product, ETUARY, which is approved in the PRC, and any other future products, if approved, could materially harm our business reputation, product brand name, and financial condition and expose us to liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products distributed or sold in the pharmaceutical market may be subject to off-label drug use, and may be prescribed for an indication, dosage or in a dosage form that is not in accordance with regulatory approved usage and labeling. As such, our product, ETUARY, and future products, if approved, may be subject to off-label drug use and may be prescribed to a patient population, or in a dosage or dosage form that has not been approved by competent authorities, which may render our product, generic drugs and future products, if approved, less effective or entirely ineffective and cause adverse drug reactions. Any of these occurrences can create negative publicity and significantly harm our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business reputation, product brand name, commercial operations and financial condition, including our share price. These occurrences may also expose us to liability and cause, or lead to, a delay in the progress of our clinical trials and may ultimately result in failure to obtain regulatory approval for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Breakthrough Therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F351 was granted a Breakthrough Therapy designation by the PRC&#8217;s NMPA&#8217;s CDE in March 2021 and the patient enrollment for its Phase 3 clinical trial was commenced in January 2022. However, F351&#8217;s Breakthrough Therapy designation does not increase the likelihood that F351 will ultimately receive approval from the NMPA or other comparable regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may, in the future, apply for Breakthrough Therapy designation in the United States, or the equivalent thereof in other foreign jurisdictions (where available), for our product candidates, depending on robustness of the clinical benefit in clinical trials. In the United States, Breakthrough Therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the NDA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Relating to Manufacture and Supply of Our Product and Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Manufacturing pharmaceutical products on a large commercial scale is highly exacting and complex, and we and our third-party manufacturers may encounter problems during the process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacturing of pharmaceutical products is highly complex, and problems may arise during manufacturing for a variety of reasons, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">equipment malfunction;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to follow specific protocols and procedures;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in product specification;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">low quality or insufficient supply of raw materials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in the construction of new facilities or the expansion of our existing manufacturing facilities and limits to manufacturing capacity due to regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the types of products produced;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advances in manufacturing techniques;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">physical limitations that may inhibit continuous supply;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">man-made or natural damages, other disasters and environmental factors; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shortage of qualified personnel or key contractors. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite our quality control and assurance system and procedures, we may not be able to eliminate such risks, which may delay or suspend our manufacturing activities, and we may not be able to secure temporary, alternative manufacturers for our product, generic drugs or product candidates with the terms, quality and costs acceptable to us, or at all. If we encounter any manufacturing problems, including those listed above, our clinical trials and/or the availability of our product, ETUARY, which is approved in the PRC, generic drugs and future products, if approved, for commercial sale may be delayed, and we may spend significant time and costs in order to rectify such problems and maintain production at our manufacturing facilities. Moreover, products with quality issues may have to be discarded, resulting in product shortages or additional expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, manufacturing methods and formulation are sometimes altered through the development of product candidates from clinical trials to approval, and further to commercialization, in an effort to optimize manufacturing processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause the product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay the commercialization of product candidates and require bridging studies or the repetition of one or more clinical trials, which may result in increases in clinical trial costs, delays in product approvals and jeopardize our ability to commence product sales and generate revenue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to use F351 capsules manufactured by Wuxi Biologics, and may continue to use foreign CROs and CMOs in the future. Wuxi Biologics has completed manufacturing one lot of the F351 capsules for our planned Phase 2a clinical trial in the U.S. Foreign CMOs may be subject to U.S. legislation, including the proposed BIOSECURE Act, sanctions, trade restrictions and other foreign regulatory requirements, which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the biopharmaceutical industry in the PRC is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in the PRC which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in the PRC&#8217;s public health, economic, political, and social conditions and the uncertainty around the PRC&#8217;s relationship with other governments, such as the United States and the U.K., could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical development programs. For more details, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Business Operations in the PRC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we plan to enter into various development, manufacturing and clinical supply services agreements with third-party manufacturers for drug substance and drug product manufacturing of our other product candidates. If our third-party manufacturers are not able to provide sufficient quantities or quality of our product candidates on a timely basis, or at all, whether due to production shortages or other supply delays or interruptions resulting from public health crises or otherwise, our preclinical trials, clinical trials or regulatory approvals, as applicable, may be delayed. Significant portions of our research and development resources are focused on manufacturing. If any of our third-party manufacturers experiences difficulties in scaling production or experiences product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error or improper storage conditions, the potential trials of the affected product candidate would be delayed, perhaps substantially, which could materially and adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and our contract manufacturers will be subject to significant regulation with respect to manufacturing our product, ETUARY, which is approved in the PRC, and our product candidates. Delays in completing and receiving regulatory approvals for our and our third-party manufacturing facilities could delay our development plans or commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including us and any contract manufacturers for ETUARY and our other product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product, generic drugs or product candidates that may not be detectable in final product testing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our existing and planned manufacturing facilities, as well as our manufacturing process, and our third-party manufacturing facilities and process, will be subject to ongoing, periodic inspection by the NMPA, the FDA or other comparable regulatory agencies to ensure compliance with GMP, which is usually the prerequisite to obtain marketing approval. Moreover, we and our third-party manufacturers must obtain various permits, certificates and other approvals for our manufacturing facilities and other premises from the relevant administrative authorities at various stages of property development, including, planning permits, construction permits, land use rights certificates, environmental assessments, fire control assessments, construction completion inspections and ownership certificates. Failure to comply with applicable regulations could lead to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased expense and result in sanctions being imposed on us (including fines, injunctions, civil penalties, requirements to suspend or pause one or more of our clinical trials); </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to obtain marketing approval of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays, suspension or withdrawal of approvals; supply disruptions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">license revocation; seizures or recalls of product, generic drugs or product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operating restrictions and criminal prosecutions, </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any of which could materially and adversely harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may experience substantial disruption to our production sites and problems in manufacturing our product, ETUARY, which is approved in the PRC, and future products, if approved.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on our manufacturing facilities in Beijing, PRC and Cangzhou, PRC. The continued operation of our manufacturing facilities and our production safety may be substantially interrupted due to a number of factors, many of which are outside of our control. These factors may include fire, flood, earthquakes, power outages, fuel shortages, mechanical breakdowns, terrorist attacks and wars, or other natural disasters, as well as loss of licenses, certifications and permits, changes in governmental planning for the land underlying these facilities or their vicinity and regulatory changes. Moreover, the production activities on our manufacturing facilities may be suspended on a temporary basis due to governmental policies or regulations, including that on environmental protection or organizing public events. If the operation of any of our manufacturing facilities is substantially disrupted, we may not be able to replace the equipment or inventories at such facilities, or use different sites or a third-party contractor to continue our production in a legal, timely and cost-effective manner or at all. Although we maintain property insurance for certain properties, machinery and equipment and other assets owned, operated or deemed important for us, in line with industry practice in the PRC, we do not have certain types of insurance, such as business interruption insurance. The amount and nature of our insurance coverage may not be sufficient to cover any substantial losses in the event of a significant disruption to any of our manufacturing facilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since September 2021, as a result of the shortage of coal supply combined with high electricity demand from manufacturers, the PRC has experienced widespread power outages. The PRC government has imposed power curbs, including imposing power restrictions on factories in a number of provinces in the PRC to deal with an imbalance in energy supply and demand. As of December 31, 2023, we have not received any notice from relevant government authorities ordering us to temporarily suspend or limit production, and our Beijing and Cangzhou production centers were not subject to any power restrictions. The PRC government imposed power restrictions did not have a material adverse impact on our business operations or financial performance during the years ended December 31, 2023 and 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to meet the increasing demand for our commercialized product, ETUARY, which is approved in the PRC, and any other future products, if approved, maintain adequate manufacturing capacity or successfully manage our anticipated growth.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To produce ETUARY and our increasing number of product candidates, if approved, in the quantities that we believe will be required to meet anticipated market demand, we may need to increase our production capacity over the initial level of production by constructing new manufacturing facilities and production lines. However, our ability to successfully implement our expansion plan for increasing production capacities is subject to a number of risks and uncertainties, including, but not limited to, the risk of construction delays and delays in equipment procurement, and our ability to timely recruit sufficient qualified staff to support the increase in our production capacity. If we are unable to do so, are delayed, face costs that are not economically feasible or cannot find a third-party manufacturer, we may not be able to produce ETUARY and our future approved product candidates, if any, in sufficient quantities to meet future demand. Moreover, our plans to increase our production capacities require significant capital investment and the actual costs of our expansion plan may exceed our original estimates, which could adversely affect the return on our expenditure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, given the size of our existing and planned manufacturing facilities, we may not be able to fully utilize within a reasonable period of time after we commence operation. During the construction and ramp-up period, there may be significant changes in the macroeconomics of the pharmaceutical industry, including, among other things, market demand, product and supply pricing trends and customer preferences. Any adverse trends in this area could result in operational inefficiency and unused capacity in our facilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fluctuations in prices of our raw materials and energy supply, as well as other costs associated with our production processes, may have a material adverse effect on us if we are not able to pass the cost increases on to our customers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to manufacture our commercialized product, ETUARY, which is approved in the PRC, and any other future products, if approved, we must obtain sufficient quantities of high-quality raw materials and stable supply of energy and power at commercially acceptable prices and in a timely manner, which exposes us to risks associated with fluctuations in prices of raw materials. The prices of such materials may be affected by a number of factors, including market supply and demand, the PRC, the United States or international environmental and regulatory requirements, natural disasters and the global and local economic conditions. In addition, we may be subject to fluctuations in other costs associated with our production processes, such as costs of waste disposal, which are beyond our control. We may have limited capability to increase our revenue in a timely manner, and a significant increase in such costs may increase our cost of sales and negatively affect our profit margins.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to maintain optimal inventory levels could increase our operating costs or lead to unfulfilled customer orders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are required to maintain optimal inventory levels in order to satisfy demand coming from our distribution network and successfully meet our customers&#8217; demand. However, we may not be able to maintain proper inventory levels of our commercialized product, ETUARY, which is approved in the PRC, generic drugs and any other future products, if approved, as a result of rapid changes in product life cycles, changing clinical demands and uncertainty of product developments and launches, as well as the volatile economic environment in the PRC. There can be no assurance that we can accurately predict these trends and events and avoid over-stocking or under-stocking our commercialized product, ETUARY, generic drugs and any other future products, if approved. Further, demand for our commercialized product, ETUARY, generic drugs and any other future products, if approved, could change significantly between the time when the products are ordered and the time they are ready for delivery.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory levels in excess of demand may result in inventory write-downs, expiration of our product or an increase in inventory holding costs and a potential negative effect on our liquidity. On the other hand, if we underestimate demand, we may experience inventory shortages which may, in turn, result in unfulfilled customer orders, leading to a negative impact on our customer relationships.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have established, and may continue to establish, collaborative agreements and strategic partnerships. However, there is no guarantee we will fully achieve the anticipated benefits from these collaborations, alliances, or licensing agreements, and conflicts could emerge with our present or prospective partners.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have in the past formed, and may in the future seek and form, strategic alliances, joint ventures or other collaborations, including entering into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our existing commercialized product, ETUARY, which is approved in the PRC, generic drugs and product candidates, including ETUARY, F351, F573, F528, F230, and any future product candidates that we may develop. Our strategic collaboration with partners involves numerous risks. We may not achieve the revenue and cost synergies expected from the transactions, as such synergies are inherently uncertain and subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and are beyond our control. In addition, the synergies from our collaboration with our partners may be offset by other costs incurred during the collaboration, including increases in other expenses, operating losses or problems in the business unrelated to our collaboration.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, disputes may arise between us and our current or future collaboration partners. Such disputes or our partners&#8217; failure to fully perform their obligations may cause delay or termination of the research, development or commercialization of our product, generic drugs or product candidates, or result in costly litigation or arbitration that may divert management attention and resources. In particular, international business relationships subject us to additional risks that may materially and adversely affect our ability to attain or sustain profitable operations, including, difficulty of effective enforcement of contractual provisions in local jurisdictions, and third-party collaborators may not properly obtain, maintain, protect or enforce our patent, trade secret and other intellectual property rights and regulatory exclusivity for our product, generic drugs or product candidates or may use our intellectual property that exposes us to potential litigation or other intellectual property-related proceedings that could jeopardize or invalidate our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we can reach a definitive agreement with a collaborator will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of preclinical trials, the likelihood of approval by the NMPA, FDA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative products, product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us. There can also be no assurance that we will enter into any collaboration agreements, or that any such agreements will be on favorable terms.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations are complex and time consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, and increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize some of our product candidates, are subject, in part, to the terms and conditions of licenses granted to us by others.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of our collaborations with our partners depends on each party&#8217;s performing its respective obligations under the relevant collaboration agreement. Such agreements may impose on us diligence obligations in product development or commercialization, payment obligations when certain development or regulatory milestones and sales are achieved and other obligations. If we fail to comply with our obligations under our current or future agreements,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our counterparties may have the right to terminate these agreements, in which event we may not be able to develop, manufacture or market the product candidate that is covered under the agreements. Termination of the licenses or assignments provided for under these agreements or reduction or elimination of our rights under these agreements may result in us having to negotiate new or amended agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may not have the exclusive right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the product or product candidates that we are licensed or assigned from third parties. In the event that these patents and patent applications are not prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business, our rights to the relevant intellectual property may be reduced or eliminated, and our right to develop and commercialize the product, generic drugs or product candidates covered under the agreement could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the third parties on whom we rely with respect to licenses to certain patent rights and other intellectual property rights that are important or necessary to the development, manufacture or commercialization of our product, generic drugs or product candidates may themselves rely on upstream licenses from other third parties. Such sub-licenses may not provide exclusive rights to use the covered intellectual property in all relevant fields of use or in all territories in which we may wish to develop or commercialize our product candidates, and add further uncertainties and complications as to the scope of our rights under the relevant agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the license or assignment agreements we have entered into, or will enter into in the future, are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our advancement through our collaboration relationship with its partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct certain aspects of our preclinical studies and any clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such tasks or trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties such as CROs, medical institutions and clinical investigators to conduct certain aspects of preclinical development, including assay development and testing, and to enroll qualified patients and conduct, supervise and monitor clinical trials. For more details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;Business&#8212;Our Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Annual Report. Our reliance on these third parties for preclinical and clinical development activities reduces our control over these activities. Our reliance on these third parties, however, will not relieve us of our regulatory responsibilities, including ensuring that our clinical studies are conducted in accordance with good clinical practices, and the investigational plan and protocols contained in the relevant regulatory application, such as an IND. In addition, the CROs with whom we contracts may not complete activities on schedule or may not conduct our preclinical studies or clinical studies in accordance with regulatory requirements or our clinical study design. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, compromise the quality or accuracy of the clinical data obtained by CROs or our investigators due to failure to adhere to our clinical protocols or regulatory requirements, or the quality of the products manufactured fails to comply with GMP, our efforts to complete development and obtain regulatory approvals for, and to commercialize, our product, generic drugs and product candidates may be delayed or prevented.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we, our CROs for clinical programs and our investigators are required to comply with GCP for all of our product candidates in clinical development. If we or any of our CROs or investigators fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the NMPA, FDA or comparable regulatory authorities may require us to perform additional clinical trials before considering whether to approve our marketing applications, which would delay the regulatory approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our distributors act in violation of the relevant agreements, or if sub-distributors with whom we have not entered into distribution agreements do not comply with policies and measures that our distributors agree to comply with, our business, prospects and reputation could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we rely on the distribution agreements and the policies and measures we have in place to manage our distributors, we cannot guarantee that these agreements, policies and measures will be able to effectively manage our distributors, or that our distributors will comply with our agreements and policies. If our distributors take one or more of the following actions, our business, results of operations, prospects and reputation may be adversely affected:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failing to distribute our product, generic drugs and future products, if approved, in the manner we contemplate, impairing the effectiveness of our distribution network;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">breaching the distribution agreements or our policies and measures;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failing to maintain the requisite licenses, permits or approvals or failure to comply with applicable regulatory requirements; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">violating any applicable anti-corruption, anti-bribery, competition or other laws and regulations. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any such actual or alleged violation or non-compliance by our distributors of the distribution agreements, our policies or any applicable laws and regulations could result in the erosion of our goodwill, expose us to liabilities, disrupt our distribution network and create an unfavorable public perception about the quality of our product, ETUARY, generic drugs and future products, if approved.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, some of our distributors engage sub-distributors to distribute our product, and we do not engage these sub-distributors directly or maintain contractual relationships with them. Instead, we mainly rely on our distributors to manage and control their sub-distributors in accordance with regulatory requirements, the terms of the distribution agreements between us and our distributors and our policies for our distributors. Since our control is limited over these sub-distributors, there is no assurance that the sub-distributors will comply with the geographical restrictions agreed to with our distributors or other distribution requirements under our distribution agreements and policies. As a result, there can be no assurance that we will be able to identify or remediate any practices by any sub-distributors&#8217; that may be detrimental to our business in a timely manner or at all, which may adversely affect our results of operations and reputation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we rely on a limited number of suppliers for certain of our raw materials, we may experience supply interruptions that could harm our ability to manufacture products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023 and 2022, we had a small number of suppliers, with whom we believe we have stable relationships. However, the stability of operations and business strategies of our suppliers are beyond our control, and there can be no assurance that we will be able to maintain a stable relationship and high-quality outsourced raw materials or services with our large suppliers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Employee Matters, Managing Growth and Our Business Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ongoing success is reliant on our capacity to retain key executives and to recruit, maintain, and inspire skilled professionals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our executive management and scientific personnel. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. In addition, we will need to add personnel to achieve our business objectives. The loss of the services of any of our executive officers, other key employees, and our inability to find suitable replacements, or our inability to hire new clinical development and manufacturing personnel, could result in delays in product development and harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conduct our U.S. operations at our facility in San Diego, California. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. In the PRC, we compete for qualified personnel with other pharmaceutical and biotechnology companies, universities and research institutions. The pool of suitable candidates is limited, and we may not be able to hire and retain enough skilled and experienced scientists or other technical personnel at the current level of wages, and may need to offer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">higher compensation and other benefits, which could materially and adversely affect our financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To induce valuable employees to remain with us, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of management and scientific and development teams have terminated and may terminate their employment with us on short notice. Our employees are under at-will employment arrangements, which means that any of our employees can leave employment with us at any time, with or without notice. Failure to retain, replace or recruit personnel could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product, generic drugs and product candidates, harming future marketing approvals, sales of our product, generic drugs and product candidates and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the NMPA, FDA, SEC and non-PRC and non-U.S. regulators, to provide accurate information to the NMPA, FDA and non-PRC and non-U.S. regulators, to comply with healthcare fraud and abuse laws and regulations in the PRC, United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained during clinical studies that could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance with regulations related to operating as a public company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we have and will continue to incur significant legal, accounting and other expenses, including costs associated with public company reporting and corporate governance requirements, in order to comply with the rules and regulations imposed by the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection, as well as rules implemented by the SEC and Nasdaq. Stockholder activism, the political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways that are not currently anticipated. Our management and other personnel need to devote a substantial amount of time to compliance with regulations related to operating as a public company. In addition, these rules and regulations make it difficult and expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain our current levels of such coverage. We expect that we will annually incur significant expenses to comply with the requirements imposed on us as a public company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management team has not previously managed and operated a U.S. public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that we comply with all of these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Increased labor costs negatively affect our operations and have an adverse impact on our profitability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our strategies and business growth may require us to hire additional employees, and we may also hire additional employees as a result of acquisitions. The average cost of labor in the PRC has been steadily increasing in recent years as a result of inflation, government-mandated wage increases and other changes in PRC labor laws, as well as competition for talent and qualified employees among pharmaceutical companies. As a result, increased labor costs could have negative effects on our growth and decrease our profitability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we or our licensors fail to secure, uphold, defend, or extend adequate patent and other intellectual property rights for our product, ETUARY, which is approved in the PRC, and any product candidates globally, or if the breadth of these intellectual property rights is insufficient, our ability to effectively compete in our markets could be compromised.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product, ETUARY, and product candidates. In order to protect the technologies, products and product candidates that we consider commercially important, we have filed and continue to file patent applications in the PRC, United States and other countries. However, applying for patent protection is an expensive and time-consuming process, and we may not be able to successfully file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may not be able to prevent competitors from developing and commercializing competitive products in all such fields and territories.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. For example, there can be no assurance that we were the first to make the inventions claimed in our patents or pending patent applications because of the delay between publications of discoveries in scientific or patent literature and actual discoveries and patent applications. Under the &#8220;first-to-file&#8221; system adopted by the PRC, and, recently, the United States, even after reasonable investigation, we may be unable to determine with certainty whether our product, product candidates, processes, technologies, improvement and other related matters are or may become unpatentable because a third party filed or may file a patent application earlier than we have or do for inventions thereunder that are the same or substantially similar to our inventions. Third parties may challenge the validity, enforceability or scope of our patents, which may result in those patents being narrowed or invalidated. The patent applications that we own may fail to result in issued patents with claims that cover our product and product candidates in the PRC, United States or in other foreign countries. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product or product candidates or prevent others from designing around our claims. Certain of our patents also cover processes, for which enforcement can be difficult. Any of these outcomes could impair our ability to prevent competition from third parties that may have an adverse impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the patents or patent applications we hold or have in-licensed for ETUARY, our programs or product candidates are invalidated or fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product or product candidates, it could threaten our ability to commercialize future products. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. In the PRC, the amendment to the PRC Patent Law (the &#8220;Amended PRC Patent Law&#8221;) provides for patent term extension and patent linkage. The Amended PRC Patent Law and relevant implementing regulations provide a cause of action to allow a patent holder to initiate a declarative action during the regulatory review process of a drug to determine whether the drug falls within the patent scope, which may be comparable to the patent linkage system in the United States. The system requires that the NMPA continue to review the potentially infringing follow-on application during any lawsuit by the innovator. However, the NMPA may not approve the follow-on application pending resolution of the patent litigation in favor of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">follow-on application or for a specified period of time, whichever is shorter. The Amended PRC Patent Law and relevant implementing regulations also provide patent term extension, similar to the United States, for the patent term lost during the regulatory review process of a new drug upon the patent holder&#8217;s request. The extended term shall not exceed five years, and the total patent term after market entry of the new drug shall not exceed 14 years. However, the patents we have in-licensed or own in the PRC may not be eligible to be extended for any patent term lost during the regulatory review process. Various extensions may be available; however the life of a patent, and the protection it affords, is limited. Once the patent life has expired for a product, we may be subject to competition from generic medications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent and other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining the physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we expect all of our employees and consultants to assign their applicable inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide guarantee that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. Moreover, some of our employees, including senior management, may have been employed at other pharmaceutical companies, including our competitors or potential competitors. Such employees may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. We may be subject to claims these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. In the event that litigation is necessary to defend against such claims, we may be subject to monetary damages and lose valuable intellectual property rights or personnel.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, filing, prosecuting and defending patents on our product, ETUARY, and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the PRC and United States are less extensive than those in the PRC and United States. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the PRC or United States. As a result, we may encounter significant problems in protecting and defending our intellectual property in the PRC, United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. In addition, we may be involved in claims and disputes of intellectual property infringement in other jurisdictions, and the defense of these claims or disputes, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The China National Intellectual Property Administration (the &#8220;CNIPA&#8221;) and other governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent application process. For example, in several stages over the lifetime of a patent, periodic maintenance fees are due to be paid to the CNIPA and other patent agencies. Although an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, non-compliance could result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Such non-compliance events may include failure to respond to official actions in a timely manner, non-payment of fees, and failure to properly submit formal documents. In addition, under PRC patent law, any applicant that applies for a patent in a foreign country for an invention or utility model accomplished in the PRC must report to the CNIPA for confidentiality examination. If the applicant fails to report to the CNIPA for confidentiality examination, the patent right may not be granted if an application is later filed in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The scope of our patent protection may be uncertain, and third-party claims of intellectual property infringement or challenging the inventorship or ownership of our patents may prevent or delay our development and commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future are to be issued as patents, they may not be issued in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. In addition, the patent position of medical device companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the PRC and United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, third-party submissions of prior art to the CNIPA, USPTO or other related intellectual property offices, oppositions, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reexamination proceedings before the CNIPA, USPTO, and corresponding foreign patent offices and post-grant proceedings such as opposition, derivation, revocation, invalidation, re-examination or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, or interference proceedings or similar proceedings in foreign jurisdictions challenging the priority of our invention or other features of patentability of our patents and patent applications. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product, ETUARY, and product candidates may be subject to claims of infringement of the patent rights of third parties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may assert that the manufacture, use or sale of our product, ETUARY, and our product candidates infringes patents held by such third parties, or that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product, generic drugs and product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or current product may infringe.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief that could effectively block our ability to further develop and commercialize one or more of our product, ETUARY, and our product candidates unless we redesigned infringing products (which may be impossible) or obtained a license under the applicable patents (which may not be available on commercially reasonable terms or at all), or until such patents expire.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our patents. To counter infringement or unauthorized use, we or our collaborators may be required to file infringement claims that can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one of our patents is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse determination or outcome of a third-party submission, proceeding or litigation may result in loss of patent rights or exclusivity, or in patent claims being narrowed, invalidated or held unenforceable,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which could limit our ability to prevent competitors from using or commercializing similar or identical technologies and products, or limit the duration of the patent protection of our technologies, product, ETUARY, and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the PRC or United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims, regardless of their merit, would cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, in addition to paying royalties, redesign infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in patent law could diminish the value of patents generally, which may impair our ability to protect ETUARY and our product candidate pipeline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Decisions made by the National People&#8217;s Congress of the PRC and the CNIPA could change the laws and regulations governing patents in unpredictable ways that may affect our ability to obtain new patents or to enforce our existing patents and/or future patents. The United States has enacted and is currently implementing wide-ranging patent reform legislation. In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. Similar changes in the laws of other jurisdictions may impact the value of our patent rights or our other intellectual property rights. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, there is uncertainty with respect to the value of patents once obtained, if any. As the laws and regulations governing patents evolve in the PRC and other jurisdictions, such changes may have a negative impact on our intellectual property protection.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A third-party may hold intellectual property, including patent rights, that is important to or necessary for the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may fail to protect our trademarks and trade names, which may negatively affect our ability to build brand recognition in our markets of interest.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently own issued trademark registrations and have trademark applications pending in order to build name recognition among potential partners and customers in our markets of interest. However, such trademark registrations and applications subject us to risks of trademark invalidity, dilution and infringement. Our trademark registrations and applications may be subject to a governmental or third-party objection, and may be challenged, infringed, circumvented or declared generic. If an issued trademark registration or trademark application is successfully challenged, then we may not be able to register or maintain such trademark registration or application. Moreover, as our product, ETUARY, continues to be marketed, such product&#8217;s reliance on our trademarks to differentiate us from our competitors may increase. We may not be able to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our trademark rights, or from engaging in conduct that constitutes unfair competition, defamation or other violations of our trademark rights. In addition, owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names may pursue trade name or trademark infringement claims against us. If we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively in our markets of interest, and our business may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights may not address all potential threats to our business or competitive advantage.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. The limitations of currently available intellectual property protection regimes include that:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make products that are similar to ETUARY or our product candidates or utilize similar technologies that are not covered by our owned and licensed patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proprietary technologies on which we rely may not be patentable; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent for certain trade secrets or know-how, yet a third party may subsequently file a patent covering such intellectual property. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Approval of Our Product Candidates and Other Compliance Matters</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">All material aspects of research, development, manufacturing and commercialization of our product, ETUARY, which is approved in the PRC, and product candidates are heavily regulated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining regulatory approvals and maintaining compliance with applicable laws and regulations is a lengthy, expensive and uncertain process which requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the drug development process or approval process, or after approval, may subject us to administrative or judicial sanctions. These sanctions could include, but are not limited to, a regulator&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, warning or untitled letters, voluntary or mandatory product recalls, product seizures, total or partial suspension of production or distribution, import alerts, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The approval procedures of the NMPA, FDA, and comparable foreign regulatory authorities are extensive, protracted, and inherently uncertain. Failure to secure necessary approvals, or encountering delays in the approval process, will prevent us from marketing our product candidates, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, which may significantly affect our revenue generation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of obtaining regulatory approvals, in the PRC, United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than certain generic drugs, we have only one successfully commercialized product, ETUARY, which is approved in the PRC for the treatment of IPF. ETUARY is currently in its Phase 3 clinical trials in the PRC for the treatment of SSc-ILD and DM-ILD, Phase 3 clinical trial for the treatment of pneumoconiosis and Phase 1 clinical trial of ETUARY for the DKD Program. Although ETUARY is approved in the PRC for the treatment of one indication, we may be unable to successfully commercialize ETUARY in the PRC for the treatment of other indications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, F351 is currently in its Phase 3 clinical trial in the PRC for liver fibrosis associated with CHB. In addition, F351 currently has one active IND application with the FDA in the United States for the treatment of liver fibrosis associated with a broad spectrum of chronic liver diseases. In the future, it is expected that an additional IND will be filed for F351 specifically for liver fibrosis associated with NASH, and we may file additional IND applications for future indications or future product candidates. If any such future IND is not timely cleared by the FDA, our clinical development timeline may be negatively impacted and any future clinical programs may be delayed or terminated. As a result, we may be unable to obtain regulatory approvals or successfully commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have an early clinical-stage product pipeline that includes F573 for ALF/ACLF treatment. F573 has entered into Phase 2 clinical trials in the PRC. We completed our Phase 1 clinical observations of tolerability and PK in July 2022 and initiated our Phase 2 clinical study of F573 in March 2023. We have also established a tiered preclinical product pipeline. For instance, we are researching and developing F528 for the treatment of COPD. In addition, our product candidate F230 is currently in its preclinical phase and has demonstrated the potential to significantly alleviate PAH in animal studies, and, on March 13, 2024, we submitted an IND application for F230 in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure at any stage of drug development, including failure to demonstrate efficacy in a clinical trial or across a suitable population of patients, the occurrence of severe or medically or commercially unacceptable adverse events, failure to comply with protocols or applicable regulatory requirements and determination by the NMPA, FDA or any comparable foreign regulatory authority that a drug product is not approvable. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot commercialize product candidates in the PRC or United States without first obtaining regulatory approval from the NMPA or the FDA, respectively. Similarly, we cannot commercialize product candidates outside of the PRC or United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NMPA, FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the NMPA, FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to demonstrate to the satisfaction of the NMPA, FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the NMPA, FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the NMPA, FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the PRC, United States or elsewhere, and we may be required to conduct additional clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the NMPA, FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the NMPA, FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contracts for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the NMPA, FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The approval requirements for our product candidates are likely to vary by jurisdiction such that success in one jurisdiction is not necessarily predicative of success elsewhere.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of financial resources to commence and complete the planned trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining approval at each clinical trial site by an IRB;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recruiting suitable patients to participate in trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">having patients complete a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adding new clinical trial sites&#894; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing sufficient quantities of qualified materials under Current Good Manufacturing Practice (&#8220;cGMPs&#8221;) regulations and applying them on a subject-by-subject basis for use in clinical trials.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We could also experience delays in obtaining approval if physicians encounter unresolved ethical issues, including but not limited to those associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles given the serious nature of the diseases for the core indications for our product candidates. Additionally, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which the trials are being conducted, the Data Monitoring Committee for the trial, or by the NMPA, FDA or other regulatory authorities for a number of reasons, including failure to conduct the clinical trial in accordance with regulatory requirements or its clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues, or adverse side effects, failure to demonstrate a benefit from using a product candidate,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, the FDA review and approval process could be delayed by any future shutdown of the U.S. government, and our development activities could be harmed or delayed as a result. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, our ability to commercialize our product candidates will be harmed and our ability to generate revenue will be materially impaired. Additionally, delays in completing trials will increase costs, delay our product development and approval process, and impair our ability to commence product sales and generate revenue. Many of the factors that could create or lead to a delay in the commencement or completion of clinical trials may lead to the denial of regulatory approval for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the NMPA,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, which would significantly harm our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we were to obtain approval, regulatory authorities may approve any of our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, including ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be materially impaired.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are developing F351 for the treatment of liver fibrosis associated with NASH. The requirements for approval of F351 by the NMPA,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FDA and comparable foreign regulatory authorities are unknown, may be difficult to predict, and may change over time, which makes it difficult to predict the timing and costs of clinical development and the likelihood of marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing F351 for the treatment of liver fibrosis associated with NASH. Although there are guidelines issued by the FDA for the development of drugs for the treatment of NASH, the development of a novel product candidate such as F351 may be more expensive and take longer in the United States than for other, better known or extensively studied product candidates. As other companies are in later stages of clinical trials for their potential NASH therapies, we expect that the path for regulatory approval for NASH therapies may continue to evolve in the near term as these other companies refine their regulatory approval strategies and interact with regulatory authorities. Such evolution may impact our future clinical trial designs, including trial size and endpoints, in ways that we cannot predict today. In particular, regulatory authority expectations about liver biopsy data may evolve especially as more information is published about the inherent variability in liver biopsy data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our competitors have experienced regulatory setbacks for NASH therapies following communications from the FDA. We currently do not know the impact, if any, that these setbacks could have on the path for regulatory approval for NASH therapies generally or for F351.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our anticipated development costs would likely increase if development of F351 or any future product candidate is delayed because we are required by the NMPA, FDA or other comparable regulatory authorities to perform studies or trials in addition to, or different from, those that we currently anticipate, or make changes to ongoing or future clinical trial designs. In addition, if we are unable to leverage our safety database for NASH indications, we may be required to perform additional trials, which would result in increased costs and may affect the timing or outcome of our clinical trials. In addition, F351 may not be developed as a monotherapy, but as a part of a combination therapy, which will add to the complexity of clinical development and may cause further delays in F351&#8217;s development and affect our costs and divert management&#8217;s resources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our failure to obtain or renew certain approvals, licenses, permits and certificates required for our business may materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to relevant laws and regulations, we are required to obtain and maintain various approvals, licenses, permits and certificates from relevant authorities to operate our business. Some of these approvals, permits, licenses and certificates are subject to periodic renewal and/or reassessment by the relevant authorities, and the standards of such renewal and/or reassessment may change from time to time. Any failure to obtain or renew any approvals, licenses, permits and certificates necessary for our operations may result in enforcement actions thereunder, including orders issued by the relevant regulatory authorities ceasing our operations, and may include corrective measures requiring capital expenditure or remedial actions. If the interpretation or implementation of existing laws and regulations changes, or new regulations come into effect requiring us to obtain any additional approvals, permits, licenses or certificates that were previously not required to operate our existing businesses, there can be no assurance that it will successfully obtain such approvals, permits, licenses or certificates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our product, ETUARY, and future products, if approved. As a pharmaceutical company, even though we do not and may not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. These regulations include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Federal Healthcare Anti-Kickback Statute that prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid, and which will constrain our marketing practices and the marketing practices of our licensees, educational programs, pricing policies, and relationships with healthcare providers or other entities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients to providers of &#8220;designated health services&#8221; with whom the physician or a member of the physician&#8217;s immediate family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent, and which may expose entities that provide coding and billing advice to customers to potential criminal and civil penalties, including through civil whistleblower or qui tam actions, and including as a result of claims presented in violation of the Federal Healthcare Anti-Kickback Statute, the Stark Law or other healthcare-related laws, including laws enforced by the FDA;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services that, as amended by HITECH, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal physician sunshine requirements under the ACA, which requires manufacturers of approved drugs, devices, biologics and medical supplies to report annually to the U.S. Department of Health and Human Services, information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Federal Food, Drug, and Cosmetic Act, which, among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and which may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws such as HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations are subject to various fraud and abuse laws, including, but not limited to, the PRC Anti-Unfair Competition Law, the PRC Criminal Law and the physician payment sunshine laws and regulations. There are ambiguities as to what is required to comply with any of these requirements, and violations of such fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension from governmental healthcare programs and debarment from contracting with the relevant jurisdiction. As law enforcement authorities increase their focus on enforcing these laws, efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-corruption and anti-bribery laws of the PRC and other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in certain markets, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations are subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of the PRC and other countries in which we operate. The FCPA and these other laws generally prohibit us, our officers and our employees and intermediaries from, directly or indirectly, offering, authorizing or making improper payments to non-U.S. government officials for the purpose of obtaining or retaining business or other advantage. We may engage third parties for clinical trials outside of the PRC and United States, to sell our commercialized product, ETUARY, and any other future products, if approved, abroad and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. As our business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. If our procedures and controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to monitor anti-bribery compliance fail to protect us from reckless or criminal acts committed by our employees or agents or if we, or our employees, agents, contractors or other collaborators, fail to comply with applicable anti-bribery laws, our reputation could be harmed and we could incur criminal or civil penalties, be required to disgorge profits, and incur other sanctions and/or significant expenses, which could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our commercialized product, ETUARY, and any other future products, if approved, may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our product, ETUARY, and future products, if approved, or our failure to obtain any required import or export authorization for such products, when applicable, could harm our international or domestic sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our product, ETUARY, and future products, if approved, may create delays in the introduction of such products in international markets or, in some cases, prevent the export of such products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons or products targeted by such regulations, could result in decreased use of our product, ETUARY, and future products, if approved, or in our decreased ability to export such products to, existing or potential customers with international operations. Any decreased use of our product, ETUARY, and future products, if approved, or limitation on our ability to export or sell such products would likely adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All jurisdictions in which we conduct our research, development, manufacturing and commercialization activities regulate these activities in great depth and detail. Obtaining regulatory approvals is a lengthy, expensive and uncertain process. We intend to focus our activities in the major markets of the PRC and the United States. These geopolitical areas all have strict regulation on medical devices, and, in doing so, they employ broadly similar regulatory strategies, including regulation of product development, approval, manufacturing, sales and marketing and distribution of medical devices. However, regulatory regimes vary in different regions, which makes regulatory compliance more complex and costly for companies like us that plan to operate in each of these regions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. In the United States, the ACA was enacted in 2010 to expand healthcare coverage. Since then, numerous efforts have been made to repeal, amend or administratively limit the ACA in whole or in part. For example, the Tax Cuts and Jobs Act, signed into law by President Trump in 2017, repealed the individual health insurance mandate, which is considered a key component of the ACA. In December 2018, a Texas federal district court struck down the ACA on the grounds that the individual health insurance mandate is unconstitutional, although this ruling has been stayed pending appeal. The ongoing challenges to the ACA and new legislative proposals have resulted in uncertainty regarding the ACA&#8217;s future viability and destabilization of the health insurance market. The resulting impact on our business is uncertain and could be material.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to control prescription drug prices could also have a material adverse effect on our business. For example, in 2018, President Trump and the Secretary of the U.S. Department of Health and Human Services released the &#8220;American Patients First Blueprint&#8221; and have begun implementing certain portions. The initiative includes proposals to increase generic drug and biosimilar competition, enable the Medicare program to negotiate drug prices more directly and improve transparency regarding drug prices and ways to lower our consumers&#8217; out-of-pocket costs. The Trump administration also proposed to establish an &#8220;international pricing index&#8221; that would be used as a benchmark to determine the costs and potentially limit the reimbursement of drugs under Medicare Part B. Among other pharmaceutical manufacturer industry-related proposals, Congress has proposed bills to alter the benefit structure to increase manufacturer contributions in the catastrophic phase. The volume of drug pricing-related bills dramatically increased under the previous Congress, and the resulting impact on our business is uncertain and could be material. The extent to which the 118th Congress will continue this approach is uncertain.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IRA provides CMS with the ability to directly negotiate prescription drug and biologic prices with manufacturers and to cap out-of-pocket spending for Medicare Part D enrollees. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics covered under Medicare Parts B and D that lack generic or biosimilar competition. Price negotiations for Part D begin in 2023. Taking effect in 2023, the IRA provides a new &#8220;inflation rebate&#8221; that requires drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Parts B or D increases faster than the rate of inflation. The IRA contains a number of other provisions intended to reduce drug spending and the federal deficit, and the IRA&#8217;s impact on competition and commercialization is uncertain but could be material.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, in 2017, California&#8217;s governor signed a prescription drug price transparency state bill into law, requiring prescription drug manufacturers to provide advance notice and explanation for price increases of certain drugs that exceed a specified threshold. Both Congress and state legislatures are considering various bills that would reform drug purchasing and price negotiations, allow greater use of utilization management tools to limit Medicare Part D coverage, facilitate the import of low priced drugs from outside the United States and encourage the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our future products, if approved in the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes to the Medicaid program at the federal or state level could also have a material adverse effect on our business. Proposals that could impact coverage and reimbursement of our future products, if approved in the United States, including giving states more flexibility to manage drugs covered under the Medicaid program and permitting the re-importation of prescription medications from Canada or other countries, could have a material adverse effect by limiting our future products&#8217;, if approved in the United States, use and coverage. Furthermore, state Medicaid programs could request additional supplemental rebates on our products as a result of an increase in the federal base Medicaid rebate. To the extent that private insurers or managed care programs follow Medicaid coverage and payment developments, they could use the enactment of these increased rebates to exert pricing pressure on our future products, if approved in the United States, and the adverse effects may be magnified by their adoption of lower payment schedules.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other proposed regulatory actions affecting manufacturers could have a material adverse effect on our business. It is difficult to predict the impact, if any, of any such proposed legislative and regulatory actions or resulting state actions on the use and reimbursement of our future products, if approved, in the United States, but our results of operations may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The policies of the NMPA may change, or additional government regulations may be enacted, that could prevent, limit or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our profitability. We cannot predict the likelihood, nature or extent of governmental policies or regulations that may arise from future legislation or administrative actions in the PRC, where the regulatory environment is constantly evolving. For example, if changes to regulatory requirements and guidance require us to substantially amend clinical trial protocols, we may experience increased costs or inability to complete clinical trials in a timely manner or at all. Changes in government regulations relating to pharmaceutical product registrations and approvals, such as a relaxation in regulatory requirements, or the introduction of simplified approval procedures, could lower the barriers to entry for potential competitors, or increased regulatory requirements could increase the difficulty to satisfy such requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In recent years in the PRC, there have been, and will likely continue to be, efforts to enact administrative or legislative measures that include more rigorous coverage criteria and may result in downward pressure on prices on our product, ETUARY, and future products, if approved. For details of the risks associated with such downward pricing pressure, see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Business Operations and Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may face pressure to lower the prices of our commercialized product, ETUARY, which is approved in the PRC, and any other future product, if approved, in order for such products to qualify for medical insurance reimbursement or due to market competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Risk Factors section.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, any changes in laws and regulations on collection and transfer of personal data in the PRC, including the Personal Information Protection Law of the PRC and the Administrative Regulations on Human Genetic Resources of the PRC, could affect our ability to use medical data and subject us to liability for the use of such data for previously permitted purposes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC government or other government authorities in countries where we plan to sell our commercialized product, ETUARY, and any other future products, if approved in the PRC, could adopt new or different regulations with respect to sales of pharmaceutical products to address bribery, corruption or other concerns. New or different regulations could result in increased costs incurred by us, our employees or distributors in selling our product, ETUARY, and future products, if approved, or impose restrictions on sales and marketing activities, which could, in turn, increase our costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to evolving privacy and data protection laws, including HIPAA and the EU General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;). If we fail to protect personal information or comply with existing or future data protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of personal information. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA) (&#8220;PHI&#8221;) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. HIPAA requires covered entities and business associates, such as us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the GDPR, which came into force in May 2018, related data protection laws in individual EU Member States as well as implementations of the GDPR in the European Economic Area. The GDPR establishes a number of strict requirements and restrictions applicable to the processing (processing includes collecting, analyzing and transferring) of personal data (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, data which identifies an individual or from which an individual is identifiable) in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities and or data subjects (in particular in case of a data breach), and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation. Furthermore, it affords various rights to individuals (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the right to access or erasure of personal data), and imposes potential penalties for breaches of up to 4% of the annual worldwide turnover or &#8364;20 million, whichever is greater. In case of a breach of the GDPR, individuals (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, study subjects) may also have a right to compensation for financial or non-financial losses (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, distress).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be circumstances under which a failure to comply with the GDPR, or the exercise of individual rights under the GDPR, would limit our ability to utilize clinical trial data collected on study subjects. Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation (EU CTR), EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with these obligations could lead to government enforcement actions and significant penalties, harm to reputation, and adversely impact the business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are subject to various U.S. state laws which may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because our operations involve the use of hazardous chemical materials and may produce hazardous waste, we are subject to numerous environmental, health and safety laws and regulations, including those governing air emissions, discharge of water and the handling, use, storage, treatment and disposal of hazardous materials and wastes. While we have entered into hazardous waste disposal agreements with third parties for the disposal of these materials and wastes, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. Further, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage, use or disposal of hazardous materials and waste.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to extensive ongoing regulatory obligations and continued regulatory review related to our commercialized product, ETUARY, which is approved in the PRC, and we may be subject to such obligations and review related to our future product candidates, if approved, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product, ETUARY, which is approved in the PRC, and any product candidates that are approved in the future remain subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, distribution, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including requirements in the PRC, federal and state requirements in the United States and requirements of comparable foreign regulatory authorities, as described in &#8220;Business&#8212;Government Regulation&#8221; of this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, regulatory approvals may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, our commercialized product, ETUARY, which is approved in the PRC, and our product candidates, if approved, and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the NMPA, FDA and other regulatory agencies in the PRC, United States and by comparable foreign regulatory authorities, respectively. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCPs for any clinical trials that we conduct following approval. Manufacturers of drug products and their facilities are also subject to continual review and periodic, unannounced inspections by the NMPA, FDA and other regulatory authorities for compliance with cGMPs. In addition, following an approval for commercial sale of any product candidates, certain changes to the product, such as changes in manufacturing processes and additional labeling claims, may be subject to additional review and approval by the NMPA, the FDA, and/or comparable regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with applicable regulatory requirements, or there are safety or efficacy problems with a product, a regulatory agency or enforcement authority may, among other things:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue warning or notice of violation letters; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or withdraw regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend any of our ongoing clinical studies; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to approve pending applications or supplements to approved applications submitted by us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seize or detain products, or require a product recall; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require entry into a consent decree.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business Operations in the PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Modifications to laws, regulations, and rules by the PRC government could lead to alterations in our operational processes and business approaches.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC government has some oversight and discretion over the conduct of our business in the PRC and may intervene or influence our operations as the government deems appropriate to further regulatory, political and societal goals. The PRC government has recently published new policies that significantly affected certain industries such as the education and internet industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry that could require us to seek permission from the PRC authorities to continue to operate our business in the PRC that could potentially affect our business, financial condition and results of operations. Furthermore, recent statements made by the PRC government, including the Opinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law, and new rules published for comments by the PRC government, including the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises to become effective on March 31, 2023, establish a new filing-based regime to regulate overseas offerings and listings by domestic companies. If we were to become subject to the direct intervention or influence of the PRC government at any time due to changes in laws or other unforeseeable reasons, it may require a material change in our operations in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the risks that the PRC government may intervene or influence our operations in the PRC at any time could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The pharmaceutical industry in the PRC is highly regulated and such regulations are subject to change, which may affect approval and commercialization of our product, ETUARY, and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical industry in the PRC is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. For details of a discussion of regulatory requirements that are applicable to our current and planned business in the PRC, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;Business&#8212;Regulatory Requirements in the PRC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Annual Report. We believe our strategy and approach are consistent with the PRC government&#8217;s policies, but we cannot ensure that our strategy and approach will continue to be consistent. In recent years, the regulatory framework for the pharmaceutical industry in the PRC has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased compliance costs on our business; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in or prevention of successful development or commercialization of our product candidates; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduction of the current benefits we experience and believe are available to us from developing and manufacturing drugs in the PRC. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC authorities have also become increasingly vigilant in enforcing laws in the pharmaceutical industry, and any failure by us to maintain compliance with applicable laws and regulations may result in the suspension or termination of our business activities in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse changes in political, economic and other policies of the PRC government could have a material adverse effect on the overall economic growth of the PRC, which could reduce the demand for our commercialized product, ETUARY, and any other future products, if approved, or otherwise materially and adversely affect our business, operations or competitive position.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business, results of operations, financial condition and prospects may be influenced to a significant degree by economic, political, legal and social conditions in the PRC. The PRC&#8217;s economy differs from the economies of developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate, control of foreign exchange, allocation of resources and an evolving regulatory system. The PRC government has implemented various measures to encourage economic development and guide the allocation of resources, but some of these measures may have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations that are currently applicable to us. Growth of the PRC economy has been uneven across different regions and among various economic sectors of the PRC, and there can be no assurance that future growth will be sustained at similar rates or at all. If the business environment or economic conditions in the PRC deteriorates from the perspective of domestic or international investment, our business may also be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC legal system is a civil law system based on written codes and statutes. Unlike the common law system, prior court decisions may be cited as persuasive authority, but have limited precedential value. Since the late 1970s, the PRC government has promulgated a comprehensive system of laws, rules and regulations governing economic matters in general. However, as these laws and regulations are relatively recent and the number of published decisions is limited, their interpretation and enforcement involve significant and certainties, and can be inconsistent and unpredictable. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we may experience compared to developed legal systems. These uncertainties may impede our ability to enforce the contracts we have entered into and could materially and adversely affect our business, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, PRC laws and regulations afford significant protection to state-owned assets. Contributions that may lead to losses of state-owned assets are subject to heightened scrutiny by the competent authorities, and the competent authorities have significant discretion in interpreting and implementing the relevant laws and regulations. In the event we or our affiliates conduct transactions with state-owned enterprises or their affiliates, we are exposed to risks and uncertainties involving the potential of loss of state-owned assets, which may subject us to liabilities and could materially and adversely affect our business, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Implementation of the labor laws and regulations in the PRC may adversely affect our business and results of operations, and failure to fully comply with PRC labor-related laws may expose us to potential liabilities and penalties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the PRC Labor Contract Law, employers are subject to stricter requirements in terms of signing labor contracts, minimum wages, paying remuneration, determining the term of employees&#8217; probation and unilaterally terminating labor contracts. Due to lack of detailed interpretative rules and broad discretion of the local competent authorities, it is uncertain as to how the labor contract law and its implementation rules will affect our current employment policies and practices. Our employment policies and practices may violate the labor contract law or its implementation rules, and we may thus be subject to related penalties, fines or legal fees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with the labor contract law and its implementation rules may increase our operating expenses, in particular, our personnel expenses. In the event that we decide to terminate some of our employees or otherwise change our employment or labor practices, the labor contract law and its implementation rules may also limit our ability to effect those changes in a desirable or cost-effective manner, which could adversely affect our business and results of operations. According to the Social Insurance Law, employees must participate in pension insurance, work-related injury insurance, medical insurance, unemployment insurance and maternity insurance, and the employers must, together with their employees or separately, pay the social insurance premiums for such employees. Recently, the PRC government enhanced its measures relating to social insurance collection, which may lead to stricter enforcement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our labor costs to increase due to the implementation of these laws and regulations. Compliance with the Social Insurance Law and its implementation rules may increase our operating expenses, in particular, our personnel expenses. As the interpretation and implementation of these laws and regulations are still evolving, there can be no assurance that our employment practice policy will at all times be deemed to be in full compliance with labor-related laws and regulations in the PRC, which may subject us to labor disputes or government investigations. If we are deemed to have violated relevant labor laws and regulations, we could be required to provide additional compensation to our employees and our business, financial condition and results of operations could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fluctuations in exchange rates may result in foreign currency exchange losses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The change in the value of the Renminbi against other currencies may fluctuate and is affected by, among other things, changes in the PRC&#8217;s political and economic conditions and the PRC&#8217;s foreign exchange policies, as well as supply and demand in the local market. We are exposed to the risks of market forces or government policies and their impact on the exchange rate between Renminbi or other currencies in the future. Substantially all of our revenue and costs are denominated in Renminbi and most of our financial assets are also denominated in Renminbi. Any significant fluctuations in the value of the Renminbi may materially and adversely affect our liquidity and cash flows and the value of our financial assets.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations are subject to and may be affected by changes in PRC tax laws and regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC government from time to time adjusts or changes its tax laws and regulations, and future adjustments or changes to PRC tax laws and regulations, together with any uncertainty resulting therefrom, could have an adverse effect on our results of operations. Our product ETUARY, which is approved in the PRC, has been subject to a preferential VAT treatment at the tax rate of 3%, applicable to a number of drugs for rare diseases, since March 2019. However, there can be no assurance that our applicable VAT rate will stay the same or decrease, and any future changes to the VAT policies may negatively impact the selling price of ETUARY and future approved product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, under the amended Individual Income Tax Law, foreign nationals who have no domicile in the PRC, but have resided in the PRC for a total of 183 days or more in a tax year, are subject to PRC individual income tax on their income gained within or outside the PRC. The amended Individual Income Tax Law may materially affect our ability to attract and retain highly skilled foreign scientists and research technicians to work in the PRC. We are also subject to periodic examinations on fulfillment of our tax obligation under the PRC tax laws and regulations by PRC tax authorities, and there can be no assurance that any such examinations by PRC tax authorities would not result in fines, other penalties or actions that could adversely affect our business, financial condition and results of operations, as well as our reputation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be restricted from transferring our scientific data abroad or using human genetic resources collected in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 17, 2018, the General Office of the State Council promulgated the Measures for the Management of Scientific Data (the &#8220;Scientific Data Measures&#8221;), which provides a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in the PRC must seek governmental approval before any scientific data involving a state secret may be transferred abroad or to foreign parties. Upon approval by the competent authorities, the enterprise shall undergo the required procedures, and enter into the confidentiality agreements with the users of the scientific data. Further, any researcher conducting research</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">funded at least in part by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before such data may be published in any foreign academic journal. Given that the term &#8220;state secret&#8221; is not clearly defined, if and to the extent any data collected or generated in connection with our R&amp;D of medical drug candidates are subject to the Scientific Data Measures and any subsequent laws as required by the relevant government authorities, there can be no assurance that we can always obtain relevant approvals for sending scientific data (such as the results of our pre-clinical studies or clinical trials conducted within the PRC) abroad or to our foreign partners in the PRC. As a result, we may be subject to fines and other administrative penalties imposed by those government authorities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, pursuant to the Service Guide, the sampling, collection or research activities of human genetic resources through clinical trials is required to be filed online with the China Human Genetic Resources Management Office. Furthermore, the Administrative Regulations on Human Genetic Resources of the PRC (the &#8220;Human Genetic Resources Regulation&#8221;) stipulates that collecting human genetic resources of the PRC&#8217;s important genetic families and specific regions, or collecting those human genetic resources in such categories and quantities as prescribed by the administrative department for science and technology under the State Council, preserving the PRC&#8217;s human genetic resources and providing the basic platform for scientific research, utilization of the PRC&#8217;s human genetic resources for international cooperation in scientific research, as well as transporting the PRC&#8217;s materials of human genetic resources abroad shall be subject to the approval of the administrative department for science and technology under the State Council.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain necessary approvals or comply with the regulatory requirements in a timely manner, or at all, our R&amp;D of drug candidates may be hindered. If the relevant government authorities consider the transmission of our scientific data or collection and usage of human genetic resources to be in violation of the requirements under applicable PRC laws and regulations, we may be subject to fines and other administrative penalties imposed by those government authorities. Furthermore, it is possible that the regulation may be interpreted and applied in a manner that is inconsistent with our clinical trial practices, potentially resulting in the confiscation of human genetic resources samples and associated data and administrative fines.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to our operations in the PRC, our business, results of operations and financial condition may be influenced to a certain degree by economic, political, legal and social conditions in the PRC or changes in government relations between the PRC and the United States or other governments. There is significant uncertainty about the future relationship between the United States and the PRC with respect to trade policies, treaties, government regulations and tariffs. the PRC&#8217;s economy differs from the economies of developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. While the PRC&#8217;s economy has experienced significant growth over the past four decades, growth has been uneven across different regions and among various economic sectors. The PRC government has implemented various measures to encourage economic development and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may have a negative effect on us. In addition, in the past, the PRC government implemented certain measures, including interest rate increases, to control the pace of economic growth. These measures may cause a decrease in economic activity in the PRC, which may affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023 and 2022, we directly and indirectly relied on certain overseas suppliers to obtain raw materials, and we have directly and indirectly relied on collaboration with entities in foreign countries and regions in connection with our business operations. We may also pursue partnerships with entities in foreign countries and regions in the future. our business is therefore subject to changing international economic, regulatory, social and political conditions, and local conditions in foreign countries and regions. As a result, the PRC&#8217;s political relationships with those foreign countries and regions may affect development and commercialization of our product, ETUARY, and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the PRC&#8217;s political relationships with those foreign countries and regions may also affect our current and future relationships with third parties. There can be no assurance that our existing or potential collaborators will not alter their perception of us or their preferences as a result of adverse changes to the state of political relationships</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">between the PRC and the relevant foreign countries or regions, and such alteration may cause a decline in the demand for our product, ETUARY, and future products, if approved, and adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, the PRC government provided new guidance on the PRC-based companies raising capital outside of the PRC, including through arrangements called variable interest entities (&#8220;VIEs&#8221;). In light of such developments, the SEC has imposed enhanced disclosure requirements on the PRC-based companies seeking to register securities with the SEC. Although we do not have a VIE structure, due to our operations in the PRC, any future PRC, U.S. or other rules and regulations that place restrictions on capital raising or other activities by companies with operations in the PRC could affect our business and results of operations. If the business environment in the PRC deteriorates from the perspective of domestic or international investment, or if relations between the PRC and the United States or other governments deteriorate, the PRC government may intervene with our operations and our business in the PRC and United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. and PRC regulations may impact our business, our operating results and our ability to raise capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. government, including the SEC, has made statements and taken certain actions that led to changes to United States and international relations, and will impact companies with connections to the United States or the PRC, including imposing several rounds of tariffs affecting certain products manufactured in the PRC, imposing certain sanctions and restrictions in relation to the PRC and issuing statements indicating enhanced review of companies with certain operations based in the PRC. It is unknown whether and to what extent new legislation, executive orders, tariffs, laws or regulations will be adopted, or the effect that any such actions would have on companies with significant connections to the United States or to the PRC, our industry or on us. We conduct research activities and has business operations both in the United States and the PRC. Any unfavorable government policies on cross-border relations and/or international trade, including increased scrutiny on companies with certain operations based in the PRC, capital controls or tariffs, may affect the competitive position of our drug product, generic drugs and product candidates, the hiring of scientists and other research and development personnel, the demand for our drug product, the import or export of raw materials in relation to drug development or our ability to raise capital, or prevent us from selling our drug product in certain countries. Furthermore, the SEC has issued statements primarily focused on companies with certain operations based in the PRC, such as us. For example, on July 30, 2021, Gary Gensler, Chairman of the SEC, issued a Statement on Investor Protection Related to Recent Developments in the PRC, pursuant to which Chairman Gensler stated that he has asked the SEC staff to engage in targeted additional reviews of filings for companies with certain operations based in the PRC. The statement also addressed risks inherent in companies with VIE structures. We do not have a VIE structure and are not in an industry that is subject to foreign ownership limitations by the PRC. However, it is possible that our periodic reports and other filings with the SEC may be subject to enhanced review by the SEC and this additional scrutiny could affect our ability to effectively raise capital in the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In response to the SEC&#8217;s July 30, 2021 statement, the China Securities Regulatory Commission (&#8220;CSRC&#8221;) announced on August 1, 2021 that &#8220;[i]t is our belief that Chinese and U.S. regulators shall continue to enhance communication with the principle of mutual respect and cooperation, and properly address the issues related to the supervision of the PRC-based companies listed in the U.S. so as to form stable policy expectations and create benign rules framework for the market.&#8221; While the CSRC will continue to collaborate &#8220;closely with different stakeholders including investors, companies, and relevant authorities to further promote transparency and certainty of policies and implementing measures,&#8221; it emphasized that it &#8220;has always been open to companies&#8217; choices to list their securities on international or domestic markets in compliance with relevant laws and regulations.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any new legislation, executive orders, tariffs, laws and/or regulations are implemented, if existing trade agreements are renegotiated, if the U.S. or the PRC governments take retaliatory actions due to the recent U.S.-PRC tension or if the PRC government exerts more oversight and control over securities offerings that are conducted in the United States, such changes could have an adverse effect on our business, financial condition and results of operations, and our ability to raise capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with the PRC&#8217;s new Data Security Law, Cyber Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme on cyber security and any other future laws and regulations may entail significant expenses and could affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC has implemented or will implement rules and is considering a number of additional proposals relating to data protection. The Data Security Law provides that the data processing activities must be conducted based on &#8220;data classification and hierarchical protection system&#8221; for the purpose of data protection and prohibits entities in the PRC from transferring data stored in the PRC to foreign law enforcement agencies or judicial authorities without prior approval by the PRC government.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the PRC&#8217;s Cyber Security Law and the Administrative Measures for the Hierarchical Protection of Information Security requires companies to take certain organizational, technical and administrative measures and other necessary measures to ensure the security of their networks and data stored on their networks. Under the multi-level protection scheme (&#8220;MLPS&#8221;), entities operating information systems must have a thorough assessment of the risks and the conditions of their information and network systems to determine the level of the entity&#8217;s information and network systems. These levels range from the lowest Level 1 to the highest Level 5 pursuant to a series of national standards on the grading and implementation of the classified protection of cyber security. The grading result will determine the set of security protection obligations that entities must comply with. Entities classified as Level 2 or above should report the grade to the relevant government authority for examination and approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently, the Cybersecurity Administration of China (&#8220;CAC&#8221;) has taken action against several PRC internet companies in connection with their initial public offerings on U.S. securities exchanges for alleged national security risks and improper collection and use of the personal information of PRC data subjects. According to the official announcement, the action was initiated based on the National Security Law, the Cyber Security Law and the Cybersecurity Review Measures, which are aimed at &#8220;preventing national data security risks, maintaining national security and safeguarding public interests.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Revised CAC Measures, critical information infrastructure operators procuring network products and services, and online platform operators (as opposed to &#8220;data processors&#8221; in the Revised Draft CAC Measures) carrying out data processing activities which affect or may affect national security, shall conduct a cybersecurity review pursuant to the provisions therein. In addition, online platform operators possessing personal information of more than one million users seeking to be listed on foreign stock markets must apply for a cybersecurity review. On November 14, 2021, the CAC further published the Regulations on Network Data Security Management (Draft for Comment), or the Draft Management Regulations, under which data processors refer to individuals and organizations who determine the data processing activities in terms of the purpose and methods at their discretion. The Draft Management Regulations reiterate that data processors shall be subject to cybersecurity review if&#8201; (i) they process personal information of more than one million persons and they are aiming to list on foreign stock markets or (ii) their data processing activities affect or may affect PRC national security. The Draft Management Regulations also request data processors seeking to list on foreign stock markets to annually assess their data security by themselves or through data security service organizations, and submit the assessment reports to relevant competent authorities. As the Draft Management Regulations are released only for public comment, the final version and the effective date thereof is subject to change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of this Annual Report, we have not received any notice from any PRC regulatory authority identifying us as a &#8220;critical information infrastructure operator,&#8221; &#8220;online platform operator&#8221; or &#8220;data processor,&#8221; or requiring us to go through the cybersecurity review procedures pursuant to the Revised CAC Measures and the Draft Management Regulations. Based on our understanding of the Revised CAC Measures, and the Draft Management Regulations if enacted as currently proposed, we do not expect to become subject to cybersecurity review by the CAC for issuing securities to foreign investors because: (i) the clinical and preclinical data we handle in our business operations, either by its nature or in scale, do not normally trigger significant concerns over PRC national security and (ii) we have not processed, and does not anticipate to process in the foreseeable future, personal information for more than one million users or persons. However, there remains uncertainty as to how the Revised CAC Measures, and the Draft Management Regulations, if enacted as currently proposed, will be interpreted or implemented. Furthermore, there remains uncertainty as to whether the PRC regulatory authorities may adopt new laws, regulations, rules, or detailed implementation and interpretation in relation, or in addition, to the Revised CAC Measures and the Draft Management Regulations. While we intend to closely monitor the evolving laws and regulations in this area and take all reasonable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">measures to mitigate compliance risks, we cannot guarantee that our business and operations will not be adversely affected by the potential impact of the Revised CAC Measures, the Draft Management Regulations or other laws and regulations related to privacy, data protection and information security.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the Personal Information Protection Law provides a comprehensive set of data privacy and protection requirements that apply to the processing of personal information and expands data protection compliance obligations to cover the processing of personal information of persons by organizations and individuals in the PRC, and the processing of personal information of persons in the PRC outside of the PRC if such processing is for purposes of providing products and services to, or analyzing and evaluating the behavior of, persons in the PRC. The Personal Information Protection Law also provides that critical information infrastructure operators and personal information processing entities who process personal information meeting a volume threshold to be set by PRC cyberspace regulators are also required to store in the PRC personal information generated or collected in the PRC, and to pass a security assessment administered by PRC cyberspace regulators for any export of such personal information. Lastly, the Personal Information Protection Law contains proposals for significant fines for serious violations of up to approximately $7.2 million or 5% of annual revenues from the prior year and may also be ordered to suspend any related activity by competent authorities. We do not maintain, nor do we intend to maintain in the future, personally identifiable health information of patients in the PRC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interpretation, application and enforcement of these laws, rules and regulations evolve from time to time and their scope may continually change, through new legislation, amendments to existing legislation or changes in enforcement. Compliance with the PRC&#8217;s new Cyber Security Law and Data Security Law could significantly increase the cost to us of providing our service offerings, require significant changes to our operations or even prevent us from providing certain service offerings in jurisdictions in which we currently operate or in which we may operate in the future. Despite our efforts to comply with applicable laws, regulations and other obligations relating to privacy, data protection and information security, it is possible that our practices, offerings or platform could fail to meet all of the requirements imposed on us by the Cyber Security Law, the Data Security Law and/or related implementing regulations. Any failure on our part to comply with such law or regulations or any other obligations relating to privacy, data protection or information security, or any compromise of security that results in unauthorized access, use or release of personally identifiable information or other data, or the perception or allegation that any of the foregoing types of failure or compromise has occurred, could damage our reputation, discourage new and existing counterparties from contracting with us or result in investigations, fines, suspension or other penalties by PRC government authorities and private claims or litigation, any of which could adversely affect our business, financial condition and results of operations. Even if our practices are not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm our reputation and brand and adversely affect our business, financial condition and results of operations. Moreover, the legal uncertainty created by the Data Security Law, the Revised CAC Measures and the recent PRC government actions could adversely affect our ability, on favorable terms, to raise capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restrictions on currency exchange, including the risks of transferring cash outside of the PRC, may limit Gyre Pharmaceuticals&#8217; ability to receive and use effectively financing in foreign currencies or Gyre Therapeutics&#8217; ability to transfer cash from Gyre Pharmaceuticals or other potential investors in the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals&#8217; ability to obtain currency exchange is subject to significant foreign exchange controls and, in the case of transactions under the capital account, requires the approval of and/or registration with PRC government authorities, including the State Administration of Foreign Exchange, or SAFE. In particular, if Gyre Pharmaceuticals finances by means of foreign debt from BJC Limited or other foreign lenders, the amount is not allowed to, among other things, exceed the statutory limits and such loans must be registered with the local branch of SAFE. If Gyre Pharmaceuticals finances by means of additional capital contributions, these capital contributions are subject to registration with the State Administration for Market Regulation or its local branch, reporting of foreign investment information with the MOFCOM, or its local branch or registration with other governmental authorities in the PRC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In light of the various requirements imposed by PRC regulations on loans to, and direct investment in, PRC-based entities by offshore holding companies, there can be no assurance that Gyre Pharmaceuticals will be able to complete the necessary government requirements or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans or capital contributions by Gyre Pharmaceuticals. If Gyre Pharmaceuticals fails to adhere to such requirements or obtain such approval, Gyre Pharmaceuticals&#8217; ability to capitalize or otherwise fund Gyre Pharmaceuticals&#8217; PRC operations, including Gyre Pharmaceuticals&#8217; technology development may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negatively affected, which could materially and adversely affect Gyre Pharmaceuticals&#8217; ability to fund and expand Gyre Pharmaceuticals&#8217; business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics may not be able to transfer funds out of Gyre Pharmaceuticals, or Gyre Therapeutics might face difficulties in transferring funds from investors in the PRC should Gyre Therapeutics decide to solicit investments from investors in the PRC, in a timely manner due to restrictions imposed by the PRC authorities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PRC regulations relating to the establishment of offshore special purpose companies by residents in the PRC may subject our PRC resident beneficial owners in the PRC to liability or penalties, or may otherwise adversely affect us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37 requires residents of the PRC to register with local branches of SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with such residents&#8217; legally owned assets or equity interests in domestic enterprises or offshore assets or interests, referred to in SAFE Circular 37 as a &#8220;special purpose vehicle.&#8221; The term &#8220;control&#8221; under SAFE Circular 37 is broadly defined as the operation rights, beneficiary rights or decision-making rights acquired by residents of the PRC in the offshore special purpose vehicles or PRC companies by such means as acquisition, trust, proxy, voting rights, repurchase, convertible bonds or other arrangements. SAFE Circular 37 further requires amendment to the registration in the event of any changes with respect to the basic information of or any significant changes with respect to the special purpose vehicle, such as an increase or decrease of capital contributed by PRC residents, share transfer or exchange, merger, division or other material events. If the shareholders of the offshore holding company who are residents of the PRC do not complete their registration with the local SAFE branches, the PRC subsidiaries may be prohibited from making distributions of profits and proceeds from any reduction in capital, share transfer or liquidation to the offshore parent company and from carrying out subsequent cross-border foreign exchange activities, and the offshore parent company may be restricted in its ability to contribute additional capital into its PRC subsidiaries. Moreover, failure to comply with the SAFE registration and amendment requirements described above could result in liability under PRC law for evasion of applicable foreign exchange restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain residents of the PRC may hold direct or indirect interests in our company, and we will request residents of the PRC who we know hold direct or indirect interests in our company, if any, to make the necessary applications, filings and amendments as required under SAFE Circular 37 and other related rules. However, we may not at all times be fully aware or informed of the identities of our stockholders or beneficial owners that are required to make such registrations, and we cannot provide any assurance that these residents will comply with our requests to make or obtain any applicable registrations or comply with other requirements under SAFE Circular 37 or other related rules. The failure or inability of our PRC resident stockholders to comply with the registration procedures set forth in these regulations may subject us to fines or legal sanctions, restrictions on our cross-border investment activities. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to make distributions to you could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any failure to comply with PRC regulations regarding the registration requirements for our employee equity incentive plans may subject us to fines and other legal or administrative sanctions, which could adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies, or the Stock Option Rules and other relevant rules and regulations, PRC citizens or non-PRC citizens residing in the PRC for a continuous period of not less than one year who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain procedures. Our employees who are PRC citizens or who reside in the PRC for a continuous period of not less than one year and who participate in our stock incentive plans will be subject to such regulation. We plan to assist our employees to register their equity awards. However, any failure of PRC individual beneficial owners and holders of equity awards under our stock incentive plans to comply with the SAFE registration requirements may subject them to fines and legal sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Since Gyre Pharmaceuticals is a legal entity registered in Beijing, PRC, it is classified as a PRC tax resident for PRC income tax purposes by default, and such classification results in unfavorable tax consequences to Gyre Pharmaceuticals and its non-PRC shareholders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Article 2 of the PRC Enterprise Income Tax Law, a resident enterprise is an enterprise that is established within the territory of the PRC or an enterprise established with a &#8220;de facto management body&#8221; within the PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals is a PRC tax resident for PRC tax purposes by default because it is a legal entity registered in Beijing, PRC. Because Gyre Pharmaceuticals is a PRC tax resident for PRC enterprise income tax purposes, Gyre Pharmaceuticals is subject to PRC tax at a rate of 25% on its world-wide income, which materially reduces Gyre Pharmaceuticals&#8217; net income. In addition, Gyre Pharmaceuticals is also subject to PRC tax resident income tax reporting obligations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because Gyre Pharmaceuticals is a PRC tax resident for enterprise income tax purposes, gains realized on the Contributions may be subject to PRC tax, at a rate of 10% in the case of non-PRC enterprises or 20% in the case of non-PRC individuals (in each case, subject to the provisions of any applicable tax treaty), if such gains are deemed to be from PRC sources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gyre Pharmaceuticals and its shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company, or other assets attributable to a PRC establishment of a non-PRC company. Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential offshore restructuring transactions or sales of the shares of Gyre Pharmaceuticals&#8217; offshore holding companies or investments where PRC taxable assets are involved.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC tax authorities have enhanced their scrutiny over the direct or indirect transfer of certain taxable assets, including, in particular, equity interests in a PRC resident enterprise, by a non-resident enterprise by promulgating and implementing Notice of Ministry of Finance and State Administration of Taxation (&#8220;SAT&#8221;) on Several Issues relating to Treatment of Corporate Income Tax Pertaining to Restructured Business Operations of Enterprises (&#8220;Circular 59&#8221;) and the Notice on Strengthening Administration of Enterprise Income Tax for Share Transfers by Non-PRC Resident Enterprises (&#8220;Circular 698&#8221;). Pursuant to the Bulletin on Issues of Enterprise Income Tax and Indirect Transfers of Assets by Non-PRC Resident Enterprises (&#8220;Bulletin 7&#8221;) an &#8220;indirect transfer&#8221; of assets, including equity interests in a PRC resident enterprise, by non-PRC resident enterprises may be recharacterized and treated as a direct transfer of PRC taxable assets, if such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to Bulletin 7, &#8220;PRC taxable assets&#8221; include assets attributed to an establishment in the PRC, immoveable properties located in the PRC, and equity investments in PRC resident enterprises, in respect of which gains from their transfer by a direct holder, being a non-PRC resident enterprise, would be subject to PRC enterprise income taxes. When determining whether there is a &#8220;reasonable commercial purpose&#8221; of the transaction arrangement, factors to be taken into consideration include: whether the main value of the equity interest of the relevant offshore enterprise derives from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consists of direct or indirect investment in the PRC or if its income mainly derives from the PRC; whether the offshore enterprise and its subsidiaries directly or indirectly holding PRC taxable assets have real commercial nature which is evidenced by their actual function and risk exposure; the duration of existence of the business model and organizational structure; the replicability of the transaction by direct transfer of PRC taxable assets; and the tax situation of such indirect transfer and applicable tax treaties or similar arrangements. In respect of an indirect offshore transfer of assets of a PRC establishment, the resulting gain is to be included with the enterprise income tax filing of the PRC establishment or place of business being transferred, and would consequently be subject to PRC enterprise income tax at a rate of 25%. Where the underlying transfer relates to the immoveable properties located in the PRC or to equity investments in a PRC resident enterprise, which is not related to a PRC establishment or place of business of a non-resident enterprise, a PRC enterprise income tax at 10% would apply, subject to available preferential tax treatment under applicable tax treaties or similar arrangements, and the party who is obligated to make the transfer payments has the withholding obligation. Where the payor fails to withhold any or sufficient tax, the transferor shall declare and pay such tax to the tax authority by itself within the statutory time limit. Late payment of applicable tax will subject the transferor to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">default interest. Bulletin 7 does not apply to transactions of sale of shares by investors through a public stock exchange where such shares were acquired from a transaction through a public stock exchange.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bulletin 7 may be determined by the tax authorities to be applicable to some of Gyre Pharmaceuticals&#8217; offshore restructuring transactions or sales of the shares of Gyre Pharmaceuticals&#8217; offshore holding companies or investments where PRC taxable assets are involved. The transferors and the transferees may be subject to tax filing or withholding and tax payment obligations, while Gyre Pharmaceuticals may be requested to assist in such filings. Furthermore, the transferors or the transferees (as withholding agent) may be required to spend valuable resources to comply with Bulletin 7 or to establish that the transferors should not be taxed under Bulletin 7, for Gyre Pharmaceuticals&#8217; previous and future restructuring or disposal of shares of Gyre Pharmaceuticals&#8217; offshore subsidiaries. The PRC tax authorities have the discretion under Bulletin 7 to adjust the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. If the PRC tax authorities adjust the taxable income of the transactions under Bulletin 7, income tax costs on the transferor side associated with such potential acquisitions or disposals will increase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals faces uncertainties on the reporting and consequences on future private equity financing transactions, share exchange or other transactions involving the transfer of shares in Gyre Pharmaceuticals by investors that are non-PRC resident enterprises. The PRC tax authorities may pursue such non-resident enterprises with respect to a filing or the transferees with respect to withholding obligation, and request Gyre Pharmaceuticals to assist in the filing. As a result, non-resident enterprises in such transactions may become at risk of being subject to filing obligations or being taxed, under Circular 59 or Bulletin 7 and Bulletin 37, and may be required to expend valuable resources to comply with Circular 59, Bulletin 7 and Bulletin 37 or to establish that its non-resident enterprises should not be taxed under these circulars.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRC tax authorities have the discretion under SAT Circular 59, Bulletin 7 and Bulletin 37 to adjust the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. Although Gyre Pharmaceuticals currently has no plans to pursue any acquisitions in the PRC or elsewhere in the world, Gyre Pharmaceuticals may pursue acquisitions in the future that may involve complex corporate structures. Because Gyre Pharmaceuticals is a PRC tax resident by default, and if the PRC tax authorities adjust the taxable income of the transactions under SAT Circular 59 or Bulletin 7 and Bulletin 37, Gyre Pharmaceuticals&#8217; income tax costs associated with such potential acquisitions will be increased, which may have an adverse effect on Gyre Pharmaceuticals&#8217; financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Commercialization of Our Product and Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, to date, no anti-fibrosis product for the treatment of pneumoconiosis has been approved in the PRC, and doctors may not accept or use ETUARY as a treatment for pneumoconiosis even if ETUARY receives marketing approval for such indication. Similarly, to date, no specific therapeutic drugs treating HBV-associated liver fibrosis have been approved worldwide, and doctors may not accept or use F351 as a treatment for liver fibrosis even if F351 receives marketing approval. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues from or receive any return on our investment in any such product candidates. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile of our product candidates, including ETUARY and F351, compared with other competitor anti-fibrosis treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to offer our product, ETUARY, and future products, if approved, for sale at competitive prices&#894;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the convenience of TID dosing compared with alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient understanding of NASH and associated fibrosis and its progressive nature and need for treatment;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">improvement of confirmatory-diagnosis and monitoring of NASH and associated fibrosis;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#894;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support&#894;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement&#894;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects&#894; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any restrictions on the use of our product, ETUARY, which is approved in the PRC, and future products, if approved, together with other medications.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For details related to risks regarding market acceptance of our commercialized product, ETUARY, which is approved in the PRC , see &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">There is a risk that our marketed product in the PRC, ETUARY, along with any other products that may receive approval in the future, may not attain sufficient market acceptance among physicians, healthcare facilities, pharmacies, patients, third-party payers, and the broader medical community, which is crucial for their commercial viability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Many of our product candidates are years away from regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our development candidates are not expected to be commercially available for several years, if at all. Further, the commercial success of product candidates will depend upon its acceptance by physicians, individuals, third-party payors and other key decision-makers as a therapeutic and cost-effective alternative to products available at the time, which may include competing products currently under development by others. See the risk factor titled &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221; If we are unable to successfully develop, obtain regulatory approval in a timely manner (including due to reasons that are beyond our control, such as changes in regulations or a shutdown of the federal government, including the FDA) and commercialize our development candidates, our ability to generate revenue from product sales with respect to any product candidates that ultimately obtain approval may be delayed and our business, growth and financial prospectus may be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For instance, no anti-fibrosis product for the treatment of pneumoconiosis has been approved in the PRC. Although ETUARY is approved in the PRC for the treatment of IPF, we cannot be certain that the NMPA, FDA or other comparable regulatory authority will approve ETUARY for the treatment of other indications, such as pneumoconiosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the regulatory authorities in the PRC, United States and the EU have not approved any products for the treatment of NASH, and while there are guidelines issued by the NMPA and FDA for the development of drugs for the treatment of NASH and an NMPA and FDA surrogate endpoint table for drug approval, respectively, it is unclear whether the requirements for approval will change in the future or whether the NMPA or FDA will rely on regulatory precedent for future regulatory approvals. Any such changes may require us to conduct new trials that could delay our timeframe and increase the costs of our programs related to F351 or any future product candidate for the treatment of NASH. In addition, we cannot be certain which efficacy endpoints or presentation thereof clinical or regulatory agencies may require in a Phase 3 clinical trial of NASH or for approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the NMPA, FDA or other regulatory agency approves our product candidates, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing commitments or requirements for post-approval studies, including additional research and development and clinical trials. The NMPA, FDA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory approval from authorities in foreign countries will be needed to market our product candidates in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. For example, ETUARY is approved for the treatment of pulmonary fibrosis in the PRC but may not be approved in any other jurisdiction, such as the United States, for such indication. If we fail to obtain approvals from foreign jurisdictions, the geographic market for our product candidates would be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition that may result in others discovering, developing, commercializing or marketing products, including our commercialized product, ETUARY, which is approved in the PRC, before or more successfully than we do.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although there are no currently approved therapeutic drug treatments for liver fibrosis, several companies are developing product candidates in clinical studies. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;Business&#8212;Competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face competition with respect to our current product, generic drugs and product candidates and will face competition with respect to any future product candidates from segments of the pharmaceutical, biotechnology and other related industries that pursue targeted therapies for patients with organ fibrosis, such as IPF, NASH, SSc-ILD, DM-ILD, pneumoconiosis, DKD, ALF/ACLF or COPD. If ETUARY, F351, F573, F528, F230, or our future product candidates do not offer sustainable advantages over competing products, we may not be able to successfully compete against current and future competitors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our product, ETUARY, which is approved in the PRC, and future products, if approved, and these competitors may also be more successful than us in manufacturing and marketing their products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity in different indications could be reduced or eliminated if competitors develop and market products or therapies that are more convenient to use, more effective, less expensive, and safer to use than our product, ETUARY, and future products, if approved. Furthermore, if competitors gain NMPA, FDA or other foreign regulatory authority approval earlier than we do, we may be unable to establish a strong market presence or to gain market share. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors. Our product candidates, if any are approved, may compete with these existing drug and other therapies but may not be competitive with them in price. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and individual registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our commercialized product, ETUARY, which is approved in the PRC, and any other future product, if approved, may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives that would harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">United States</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we or our collaborators commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate that receives marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmaco-economic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PRC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the NMPA, FDA or similar regulatory authorities outside the PRC and United States. Moreover, eligibility for reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers its costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover its costs and may not be made permanent.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the PRC or United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that it develops could have a material adverse effect on our operating results, ability to raise capital needed to commercialize products and overall financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, our marketed ETUARY is subject to the risk of being included in the PRC&#8217;s centralized volume-based procurement scheme. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;In the future, the policies of centralized volume-based procurement set by the PRC government may cover our commercialized product, ETUARY, and any other future products, if approved, and the prices of such product may decrease, which in turn may have a material adverse impact on our revenue, financial condition and results of operation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Risk Factors section.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products in the United States and decrease our ability to generate revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments in the United States. Sales of our product candidates will depend substantially, both domestically in the United States and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market price of our common stock is expected to be volatile.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock could be subject to significant fluctuations. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timing and results of INDs, preclinical studies and clinical trials of our product candidates, or those of our competitors or our existing or future collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competitive products or announcements by potential competitors of their product development efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed financial and development projections we may provide to the public; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed the financial and development projections of the investment community; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if we do not achieve the perceived benefits of the Contributions as rapidly or to the extent anticipated by financial or industry analysts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actions taken by regulatory agencies with respect to our product, product candidates, clinical studies, manufacturing process or sales and marketing terms; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lawsuits, including patent or stockholder litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">geo-political developments, general market or macroeconomic conditions including inflation and interest rates; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcement of expectation of additional financing efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of securities by us or our securityholders in the future; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if we fail to raise an adequate amount of capital to fund our operations and continued development of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publicity or announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of any natural disasters or public health emergencies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the introduction of technological innovations or new products or product candidates that compete with our product, ETUARY, and product candidates and our services; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period-to-period fluctuations in our financial results.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, macroeconomic conditions, a recession, depression or other sustained adverse market event or otherwise could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fluctuations in operating results could adversely affect the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating results are likely to fluctuate significantly from quarter to quarter and year to year. These fluctuations could cause our stock price to decline. Some of the factors that may cause operating results to fluctuate on a period-to-period basis include the scope, progress, duration results and costs of preclinical and clinical development programs, as well as non-clinical studies and assessments of product candidates and programs, restructuring costs, implementation or termination of collaboration, licensing, manufacturing or other material agreements with third parties, non-recurring revenue or expenses under any such agreement, the cost, timing and outcomes of regulatory compliance, approvals or other regulatory actions, the likelihood of regulatory approval, failure of regulators to grant regulatory approval and general and industry-specific economic conditions, particularly as it affects the pharmaceutical, biopharmaceutical or biotechnology industries in the PRC or United States. Period-to-period comparisons of our historical and future financial results may not be meaningful, and investors should not rely on them as an indication of future performance. Fluctuating losses may fail to meet the expectations of securities analysts or investors. Failure to meet these expectations may cause the price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current trading volumes are modest, and sales of a substantial number of shares of our common stock in the public market, or the perception that these sales could occur, could cause the market price to decline. Any additional sales in the public market of our common stock or other securities under these shelf registration statements could adversely affect prevailing market prices for our common stock. In addition, we have outstanding options to purchase 18,280,548 shares of common stock at a weighted average exercise price of $1.49 as of December 31, 2023. If such options are exercised and the shares are sold into the open market, such sales also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Conversion or exercise of these securities into shares of our common stock will cause dilution to the other holders of our common stock, and all such stock may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be sold in the public market after conversion or exercise, subject to restrictions under the securities laws, which may lead to a decline in the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions that will be included in our certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the Company that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors will be responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions will:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue the use of a classified board of directors such that not all members of our board of directors are elected at one time; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit the manner in which stockholders can remove directors from our board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide for advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and for nominations to our board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit who may call stockholder meetings; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of the holders of at least two-thirds of the votes that all stockholders would be entitled to cast to amend or repeal certain provisions of our certificate of incorporation or bylaws.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which generally prohibits a person who, together with their affiliates and associates, owns 15% or more of the company&#8217;s outstanding voting stock from, among other things, merging or combining with the company for a period of three years after the date of the transaction in which the person acquired ownership of 15% or more of the company&#8217;s outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our certificate of incorporation and bylaws generally provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our certificate of incorporation and bylaws provide that, unless the company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the sole and exclusive forum for the following types of proceedings: (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to the company or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or our bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. This choice of forum provision will not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which federal courts have exclusive jurisdiction.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This exclusive forum provision may make it more expensive for stockholders to bring a claim than if the stockholders were permitted to select another jurisdiction and may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees or stockholders, which may discourage such lawsuits against us and our directors, officers and other employees and stockholders. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation and bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have been a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and thus have been allowed to provide simplified executive compensation disclosures in our filings. We have also had certain other decreased disclosure obligations in our SEC filings. We cannot predict whether investors find our common stock less attractive because of our reliance on any of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The current expectation is that we will retain our future earnings, if any, to fund the growth of our business as opposed to paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to integrate successfully and realize the anticipated benefits of the Contributions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Contributions involved the combination of two companies which previously operated as independent companies. We may fail to realize some or all of the anticipated benefits of the Contributions if the integration process takes longer than expected or is more costly than expected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential difficulties we may encounter in the integration process include the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to successfully combine the businesses of Catalyst and Gyre Pharmaceuticals in a manner that permits us to achieve the anticipated benefits from the Contributions, which would result in the anticipated benefits of the Contributions not being realized partly or wholly in the time frame currently anticipated or at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">creation of uniform standards, controls, procedures, policies and information systems; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Contributions.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that the integration process also could result in the diversion of our management&#8217;s attention, the disruption or interruption of, or the loss of momentum in, our business or inconsistencies in standards, controls, procedures and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">policies, any of which could adversely affect our ability to maintain our business relationships or the ability to achieve the anticipated benefits of the Contributions, or could otherwise adversely affect our business and financial results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and tax credit carryforwards may be subject to limitations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had approximately $193.5 million of federal and $10.5 million of California state net operating loss carryforwards (&#8220;NOLs&#8221;) available to reduce future taxable income. Under Section 382 and Section 383 of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 &#8220;ownership change&#8221; is generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. We have experienced several ownership changes. Approximately $156.5 million and $75.2 million of the NOLs will expire unutilized for federal and California purposes, respectively. The Contributions resulted in an additional ownership change and we may experience additional ownership changes in the future due to subsequent shifts in our stock ownership (some of which are outside of our control).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our ability to use our NOLs to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our NOLs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we achieve profitability, we may not be able to utilize a material portion of our NOLs and other tax attributes, which could have a material adverse effect on cash flow and results of operations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or in their implementation may adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. Changes in tax law may adversely affect our business or financial condition or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. Prospective investors should consult their tax advisors regarding the potential consequences of changes in tax law on our business and on the ownership and disposition of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards and, as a result, qualify for, and rely on, exemptions from certain corporate governance requirements. Our stockholders do not have the same protections afforded to stockholders of companies that are subject to such requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GNI Parties control a majority of the voting power of our outstanding common stock. As a result, we qualify as a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of Nasdaq. Under these rules, a listed company of which more than 50% of the voting power with respect to the election of directors is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including the requirements that (i) a majority of our board of directors consist of independent directors, (ii) director nominees be selected or recommended to our board of directors entirely by independent directors and (iii) our compensation committee be composed entirely of independent directors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on these exemptions. As a result, we do not have a majority of independent directors, director nominees are not selected or recommended to our board of directors by entirely independent directors and our compensation committee does not consist entirely of independent directors. Accordingly, you may not have the same protections</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. In the event we cease to be a "controlled company" and our shares continue to be listed on Nasdaq, we will be required to comply with these provisions within the applicable transition periods.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our executive officers, directors and principal stockholders, in the aggregate, beneficially owned a majority of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be exposed to increased litigation, including stockholder litigation, which could have an adverse effect on our business and operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may from time to time become subject to various litigation, legal or contractual disputes, investigations or administrative proceedings arising in the ordinary course of our business, including, but not limited to, various disputes with or claims from our suppliers, customers, contractors, licensors, business partners and other third parties that we engage for our business operation. In addition, we may be exposed to increased litigation due to the combination of Catalyst&#8217;s business and Gyre Pharmaceuticals&#8217; business as a result of the consummation of the Contributions. Such litigation may have an adverse impact on our business and results of operations or may cause disruptions to our operations. In addition, in the past, stockholders have initiated class action lawsuits against biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any verdict or award is rendered against us or if we agree to settle with an adverse party, we could be required to pay significant monetary damages, assume other liabilities and/or suspend or terminate the related business projects. Negative publicity arising from litigation, legal disputes, investigations or administrative proceedings may damage our reputation and adversely affect the image of our brands and products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to product liability claims that could expose us to costs and liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to product liability risks as a result of developing, producing, marketing, promoting and selling pharmaceutical products in the PRC, United States and other jurisdictions. Such claims may arise if our product, ETUARY, and future products, if approved, are deemed or proven to be unsafe, ineffective, defective or contaminated, or if we are alleged to have engaged in practices such as insufficient or improper labeling of products or providing inadequate, insufficient or misleading warnings or disclosures regarding side effects. A product liability claim brought against us may, regardless of merit or outcome, result in reputational harm and strain on financial resources and may consume the time and attention of our management. If we are unable to successfully defend itself against such claims, we may, among others, be subject to product recalls, civil liability for physical injury, death or other losses caused by our product, ETUARY, and future products, if approved, criminal liability and the revocation of our business licenses. PRC laws and regulations currently do not require us to, and we do not, maintain liability insurance to cover product liability claims. As a result, we may not be able to recover our losses resulting from future product liability claims.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Breach, failure or disruption in or to our information system could compromise sensitive information related to our business and expose us to liability or reputational harm, and our ability to effectively manage our business operations could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our information systems may fail and are subject to risks of breakdown, breach, interruption or damage from computer viruses, computer hackers, malicious code, employee error or malfeasance, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures or other compromise. Any system damage or failure that interrupts data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">input, retrieval or transmission or increases service time could disrupt our normal operations, including the loss of clinical trial data from completed or future clinical trials. Loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. There can be no assurance that we will be able to effectively handle a failure of our information systems, or that we will be able to restore our operational capacity in a timely manner or at all to avoid disruption to our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate use, disclosure of or access to confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product, ETUARY, and product candidates could be hindered or delayed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may collect and store sensitive personal data in the ordinary course of our business. For details, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8212;Risks Related to Our Business Operations in the PRC&#8212;Compliance with the PRC&#8217;s new Data Security Law, Cyber Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme on cyber security and any other future laws and regulations may entail significant expenses and could affect our business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Risk Factors section. If personal data are compromised due to a material breach of our information, the market perception of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You may have difficulty enforcing judgments obtained against us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of our assets are located outside of the United States. Most of our operations and administrative and corporate functions are conducted in the PRC. In addition, several of our directors and officers are nationals and residents of countries other than the United States. A substantial portion of the assets of these persons are located outside the United States. As a result, due to the lack of reciprocity and treaties between the United States and some of these foreign jurisdictions, together with cost and time constraints, it may be difficult for you to effect service of process within the United States upon these persons. In particular, several of our officers and directors are generally located in the PRC, and it will be more difficult to enforce liabilities and enforce judgments on those individuals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. UNRESOL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VED STAFF COMMENTS.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. CYBERSECURITY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to safeguard our important data, hardware, and internal network from digital attacks, theft and damage. In the ordinary course of our business, we collect, use, store, and digitally transmit confidential, sensitive, proprietary, and personal information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy. To this end, we have implemented processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. At Gyre Therapeutics, these processes are managed and monitored by a third-party information technology (&#8220;IT&#8221;) consulting company (the &#8220;Managed Service Provider&#8221;) and are overseen by our Chief Financial Officer. At Gyre Pharmaceuticals, these processes are managed and monitored by a dedicated IT team, which is led by the General Manager. Gyre Therapeutics&#8217; and Gyre Pharmaceuticals&#8217; processes include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data. For example, Gyre Therapeutics and Gyre Pharmaceuticals maintain software and hardware inventories, perform security monitoring and alerting, and complete ongoing risk assessments. Gyre Therapeutics and Gyre Pharmaceuticals also conduct regular employee trainings on cyber and information security, among other topics. In addition, both companies consult with outside advisors and experts on a regular basis to assist with assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on the Company&#8217;s risk environment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Chief Financial Officer, who reports directly to our Chief Executive Officer, is responsible for assessing and managing Gyre Therapeutics&#8217; cybersecurity risks with support from the Managed Service Provider, which employs IT consultants with over 20 years of experience managing information technology and cybersecurity matters and are certified as Microsoft Certified Systems Engineers. Our Gyre Pharmaceuticals IT department senior supervisor, who reports directly to our General Manager at Gyre Pharmaceuticals and has over 20 years of experience managing information technology and cyber security matters, is responsible for assessing and managing Gyre Pharmaceuticals&#8217; cybersecurity risks. Our General Manager at Gyre Pharmaceuticals reports the Board of Directors. We consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework. In the last fiscal year, we have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the heading &#8220;Breach, failure or disruption in or to our information system could compromise sensitive information related to our business and expose us to liability or reputational harm, and our ability to effectively manage our business operations could be adversely affected.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our management team. The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. PROPERTIES.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics&#8217; Properties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters are in San Diego, California, where we lease approximately 1,643 rentable square feet of office space. The lease commenced on November 11, 2023 and expires on the last day of the 38th full calendar month beginning on or after November 11, 2023. Gyre expects to be able to renew this lease or obtain alternative facilities on commercially reasonable terms.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals&#8217; Properties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Owned Properties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals has land use right certificates for two parcels of land in Shunyi District, Beijing, PRC and Cangzhou, Hebei province, PRC with an aggregate site area of 66,559 square meters and building ownership certificates for six properties with an aggregate gross floor area of 12,206 square meters. Gyre Pharmaceuticals&#8217; two production centers are in Beijing, PRC and Cangzhou, PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leased Properties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals leases 21 properties in the PRC. Among Gyre Pharmaceuticals&#8217; 21 leased properties, eight are used as offices, 12 are used as employee dormitories and one is operated as a laboratory.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. LEGAL PROCEEDINGS.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently not a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. MINE SAFETY DISCLOSURES.</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item  5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PUR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CHASES OF EQUITY SECURITIES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc. is listed on the Nasdaq Capital Market under the symbol &#8220;GYRE.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 19, 2024, there were approximately 46 stockholders of record of our common stock. Since many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 20, 2022, we paid a special, one-time cash dividend of approximately $45.0 million (or $1.43 per share) to our common stockholders of record as of the close of business on September 6, 2022. On January 12, 2023, we paid a special, one-time cash dividend of approximately $7.6 million (or $0.24 per share) to our common stockholders of record as of the close of business on January 5, 2023. In June 2023, we distributed $3.5 million, which reflected, in connection with the Vertex Transaction, the hold-back amount received from Vertex less expenses and a reserve for potential tax liabilities, to the holders of Catalyst Common Stock as of January 5, 2023 (the &#8220;CVR Holders&#8221;). We currently intend to retain all future earnings, if any, for use in our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors our board of directors may deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item  6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED].</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; You should carefully read the &#8220;Cautionary Note About Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; sections of this Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from the results described below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a financially-sustainable pharmaceutical company with a record of financial success that develops and commercializes small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs. Fibrosis involves a complex, multi-stage process with multiple pathways. While there are numerous potential targets for anti-fibrotic therapy, both established and emerging, addressing a single molecular pathway may not be sufficient to prevent, halt, or reverse fibrosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our strategy is to use our experience in the successful development and commercialization of ETUARY&#174; (Pirfenidone) to expand into new indications and develop similar drug candidates. Pirfenidone, the first anti-fibrotic drug approved for IPF in Japan, the EU, the U.S., and the PRC, is a small molecule drug that inhibits the synthesis of TGF-&#223;1, TNF-&#945;, and other fibrosis and inflammation modulators. We have obtained approval for ETUARY (pirfenidone) in the PRC for IPF.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals successfully advanced Pirfenidone from R&amp;D to commercialization in the PRC for the treatment of IPF. ETUARY&#8217;s annual sales have consistently grown each year, reaching $112.1 million in 2023. In addition to IPF, Pirfenidone is undergoing three additional Phase 3 studies for CTD-ILD to broaden its indications and market: SSc-ILD, DM-ILD and PD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F351, our lead development candidate, is a structural derivative of ETUARY (Pirfenidone). It is a new oral chemical entity with an anti-fibrotic, TGF-&#223;1-targeting mechanism of action, for which we hold patents in major markets. Studies suggest that F351 and its major metabolites have minimal drug-drug interaction risks. Despite potential efficacy in IPF, we are prioritizing F351 for the treatment of liver fibrosis due to the large potential addressable market and significant unmet need.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals has completed a Phase 2 trial of F351 in the PRC for CHB-associated liver fibrosis. The Phase 2 trial showed that F351 was well-tolerated without notable toxicity and patients treated showed statistically-significant improvement of liver fibrosis, with the best efficacy results achieved at 270 mg/day dosing. Based on these results, a confirmatory Phase 3 trial is ongoing in the PRC. The enrollment of 248 patients for the confirmatory Phase 3 trial has been completed, with last patient out expected in 2024 and clinical results expected by early 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., we have completed a Phase 1 clinical trial of F351 in healthy volunteers. We are preparing an IND application and expect to submit it in late 2024. Following results from the PRC Phase 3 trial in CHB-associated liver fibrosis and pending approval of our IND, we expect to initiate a Phase 2a trial to evaluate F351 for the treatment of NASH-associated liver fibrosis in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F351 Asset Acquisition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 26, 2022, Catalyst, purchased the F351 Assets from GNI Japan and GNI Hong Kong, other than such assets and intellectual property rights located in the PRC, pursuant to the F351 Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combination Agreement</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 26, 2022, Catalyst entered into a Business Combination Agreement, as amended on March 29, 2023 and August 30, 2023 (the &#8220;Business Combination Agreement&#8221;) with GNI USA, GNI Japan, GNI Hong Kong, SG (collectively with GNI USA, GNI Japan and GNI Hong Kong, the &#8220;Contributors,&#8221; and each a &#8220;Contributor&#8221;), certain individuals and CPI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 30, 2023 (the &#8220;Effective Time&#8221;), the Contributions (as defined below) became effective and Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (doing business as Gyre Pharmaceuticals Co., Ltd.). In connection with the Contributions, and immediately prior to the Effective Time of the Contributions, Catalyst amended its certificate of incorporation, increased the number of authorized shares of its common stock, par value $0.001 per share (the &#8220;Catalyst Common Stock&#8221;) from 100,000,000 shares to 400,000,000 shares, effected the Reverse Stock Split and changed its name to Gyre Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of Catalyst Common Stock were previously listed on The Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221; Catalyst filed a listing application for the combined company with the Nasdaq Stock Market Inc. (&#8220;Nasdaq&#8221;). On October 31, 2023, Gyre&#8217;s common stock commenced trading on the Nasdaq Capital Market under the symbol &#8220;GYRE&#8221;, on a post-reverse stock split adjusted basis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Business Combination Agreement, at the Effective Time of the Contributions, and after giving effect to the 1-for-15 reverse stock split:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GNI USA contributed all of its ordinary shares in the capital of CPI to Catalyst in exchange for 45,923,340 shares of Gyre Common Stock (the &#8220;CPI Contribution&#8221;), </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GNI USA contributed its interest in Further Challenger International Limited (&#8220;Further Challenger&#8221;) for 17,664,779 shares of Gyre Common Stock (the &#8220;FC Contribution&#8221; and together with the CPI Contribution, the &#8220;GNI USA Contributions&#8221;), and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">each Minority Holder contributed 100% of the interest he or she held in his or her respective entity in exchange for an aggregate of 10,463,627 shares of Gyre Common Stock (the &#8220;Minority Holder Contributions&#8221; and together with the GNI USA Contributions, the &#8220;Contributions&#8221;).</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the GNI USA Contributions, Gyre directly and indirectly holds 100% of CPI&#8217;s shares. Through Gyre&#8217;s ownership of CPI, prior to the Minority Holder Contributions, Gyre held a 56.0% indirect interest in Gyre Pharmaceuticals. Upon completion of the Minority Holder Contributions, Gyre obtained additional indirect interests in Gyre Pharmaceuticals and holds, in aggregate, a 65.2% indirect interest in Gyre Pharmaceuticals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately after the closing of the Contributions, excluding potentially dilutive securities, GNI USA owned approximately 83.6% of the outstanding shares of Gyre Common Stock, Catalyst&#8217;s existing stockholders, excluding GNI USA, owned approximately 2.8% of the outstanding Gyre Common Stock, and the Minority Holders owned approximately 13.7% of the outstanding shares of Gyre Common Stock. The Convertible Preferred Stock remained outstanding after the closing of the Contributions and is not included in the above ownership percentages.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the Effective Time, Gyre Pharmaceuticals terminated its 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;) and the options (the &#8220;Gyre Pharmaceuticals Options&#8221;) outstanding under the 2021 Plan were terminated and replaced with options granted under a subplan for Chinese participants under the Gyre 2023 Omnibus Incentive Plan (the &#8220;2023 Omnibus Incentive Plan&#8221;) that are substantially similar in all material respects to the Gyre Pharmaceuticals Options previously outstanding under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remained issued and outstanding, and such shares and options were unaffected by the Contributions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company registered and established in the PRC in 2002. Gyre Pharmaceuticals is committed to the research and development of new drugs as well as manufacturing and commercialization of ETUARY (pirfenidone capsule) for the treatment of idiopathic pulmonary fibrosis and other pharmaceutical products. The registered office of Gyre Pharmaceuticals is located at 60 Shunkang Road, Shunyi District, Beijing, PRC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">127</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The immediate holding company of Gyre Pharmaceuticals is BJContinent Pharmaceuticals Limited (&#8220;BJC&#8221;). The intermediate holding company of Gyre Pharmaceuticals is CPI. Immediately following the GNI USA Contributions, the immediate holding company of CPI is Gyre. The majority stockholder of Gyre is GNI USA and the majority stockholder of GNI USA is GNI Japan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GNI USA Contributions were treated as an asset acquisition under U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), with CPI treated as the accounting acquirer and presented as the predecessor for post-acquisition reporting purposes. Since Catalyst is the legal acquirer, the GNI USA Contributions were accounted for as a reverse asset acquisition. This determination was based upon the terms of the Business Combination Agreement and other factors including that, immediately following the GNI USA Contributions: (i) GNI USA (as the parent company of CPI immediately prior to the GNI USA Contributions) owns a substantial majority of the voting power of the combined company; (ii) GNI USA has the ability to control the board of directors of the combined company; and (iii) senior management of Gyre Pharmaceuticals and GNI USA hold a majority of the key positions in senior management of the combined company. Immediately prior to the closing of the GNI USA Contributions, Catalyst did not meet the definition of a business because Catalyst did not have an organized workforce that significantly contributed to its ability to create output, and substantially all of its fair value was concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the closing date of the GNI USA Contributions, the net assets of Catalyst were recorded at their acquisition-date relative fair values in the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K and the reported operating results prior to the GNI USA Contributions are those of CPI.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where we obtained additional indirect interests in and maintained our control over Gyre Pharmaceuticals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Value Rights Agreement</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with the signing of the Business Combination Agreement on December 26, 2022, Catalyst and the Rights Agent (as defined in the CVR Agreement) executed a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), as amended on March 29, 2023, pursuant to which each CVR Holder, excluding the Sellers, received one contractual contingent value right (a &#8220;CVR&#8221;) issued by the Company for each share of Catalyst common stock held by such holders. Each CVR entitles the CVR Holder thereof to receive certain cash payments in the future. For additional information, see Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We effected a 1-for-15 reverse stock split immediately prior to the Effective Time of the Contributions. The par value of the Catalyst Common Stock following the Reverse Stock Split was not adjusted and remains at $0.001 per share. All of the Catalyst&#8217;s issued and outstanding common stock and options have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding, which resulted in a proportional decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options, warrants, and in the case of stock options and warrants, a proportional decrease in the exercise price of such stock options and warrants.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Stock Split and stockholders who would otherwise be entitled to a fraction of one share received a proportional cash payment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Private Placement and Securities Purchase Agreement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2023, we entered into the Securities Purchase Agreement for a private placement with GNI USA. Pursuant to the Securities Purchase Agreement, GNI USA agreed to purchase (i) 811 shares of Gyre&#8217;s Convertible</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock and (ii) warrants to purchase up to 811 shares of Convertible Preferred Stock (the &#8220;Preferred Stock Warrants&#8221;) for an aggregate purchase price of $5.0 million. The Private Placement closed immediately after the closing of the Contributions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Preferred Stock Warrants are exercisable at an exercise price of $4,915.00 per share of Convertible Preferred Stock and expire on October 30, 2033. Each share of Convertible Preferred Stock is convertible into approximately 666.67 shares of the Gyre Common Stock, as adjusted for the Reverse Stock Split. The Preferred Stock Warrants issued are considered freestanding financial instruments and classified as a liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, we had a net loss of $85.5 million and a net loss attributable to common stockholders of $92.9 million. For the year ended December 31, 2022, our net income was $4.3 million and net income attributable to common stockholders was $2.3 million. As of December 31, 2023, we had accumulated deficit of $85.5 million and cash and cash equivalents of $33.5 million. As of December 31, 2022, we had retained earnings of $7.4 million and cash of $25.2 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenues</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of Pharmaceutical Products</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We generate revenue primarily through sales of ETUARY and certain generic drugs in the PRC. Distributors are our direct customers, and sales to distributors accounted for 100% of the revenue from ETUARY. Such distributors sell ETUARY to certain outlets, including hospitals and other medical institutions, as well as pharmacies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License of Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from licensing intellectual property is recognized when the control of the right to use the license is transferred to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling and Marketing Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling and marketing expenses primarily relate to selling and marketing our product ETUARY in the PRC and consist of expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">129</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs consist primarily of costs related to the pre-clinical and clinical development of our product candidates, which include payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services for pre-clinical research and clinical trials, materials, and consulting costs, as well as allocations of facilities, depreciation and other overhead costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to our functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquired IPR&amp;D</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acquired IPR&amp;D expenses represent costs incurred for acquisitions of IPR&amp;D with no alternative future use, which are expensed immediately upon acquisition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Divestiture Losses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the GNI USA Contributions, we recorded a loss from the divestiture of almost all our assets other than our 56.0% indirect ownership interest in Gyre Pharmaceuticals. This expense was reflected in our consolidated statements of operations and comprehensive (loss) income. The loss is presented net of the direct costs incurred with the transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss on Disposal of Property and Equipment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the GNI USA Contributions, we recorded a loss on disposal of property and equipment. This expense was reflected in our consolidated statements of operations and comprehensive (loss) income. The loss is presented net of loses incurred in connection with the sale of property and equipment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income, Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income consists primarily of interest earned on our long-term certificates of deposit. Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income consists mostly of government grants. Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying amount of the asset and released to profit or loss by way of a reduced depreciation charge.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Fair Value of Warrant Liability</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Private Placement, we issued the Preferred Stock Warrants, which are freestanding financial instruments classified as warrant liability since the underlying securities are contingently redeemable upon the occurrence of events which are outside of our control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period, with any change in fair value recognized in our statements of operations as other (income) expense.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">130</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other expense consists of any non-operating costs, such as loss from equity method investments.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provision for Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provision for income taxes are comprised primarily of current income tax provision, mainly attributable to the profitable Gyre Pharmaceuticals operations in the PRC, and deferred income tax provision, mainly including deferred tax recognized for temporary differences in relation to research and development tax credit and net operating loss carry forwards for U.S. tax purposes, deemed income inclusions from controlled foreign corporations for U.S. tax purposes, and fixed and intangible assets, net of valuation allowances.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize our results of operations for the years ended December 31, 2023 and 2022 (in thousands, except percentage change):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.83%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:9.398%;"/>
    <td style="width:1%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:9.398%;"/>
    <td style="width:1%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:7.798%;"/>
    <td style="width:1%;"/>
    <td style="width:1.28%;"/>
    <td style="width:1%;"/>
    <td style="width:9.078%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change ($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change (%)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,450</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,290</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,160</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,636</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,793</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(157</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3.3</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross Profit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,814</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,497</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,317</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,159</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,238</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,921</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,780</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,686</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,906</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(17.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,662</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,370</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,708</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(15.6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,104</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,104</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">**</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">**</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">628</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">628</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">**</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176,044</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,294</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(67,230</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,203</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(76,433</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">**</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,044</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">726</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">318</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,076</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">857</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,261</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,261</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">**</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,594</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,374</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,220</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88.8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income before income taxes</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(76,965</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,412</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(86,377</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">**</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8,515</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,098</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,417</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67.0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(85,480</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,314</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(89,794</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">**</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,453</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,012</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,441</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">270.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income attributable to common stockholders</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(92,933</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,302</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(95,235</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">**</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">** Not meaningful.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenues</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues for the years ended December 31, 2023 and 2022 were $113.5 million and $102.3 million, respectively. The increase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was primarily due to a $12.6 million increase in pharmaceutical product sales, driven by enhanced marketing and sales initiatives in regions of the PRC where sales were previously lower in 2022, partially offset by a $1.4 million decrease in revenue related to a one-time licensing fee recognized in 2022 from our license agreement with Fu Fang Chuan Gui Tincture entered into in 2021.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">131</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenues</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of revenues for the years ended December 31, 2023 and 2022 was $4.6 million and $4.8 million, respectively. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he decrease of $0.2 million was primarily driven by a $0.3 million reduction attributed to favorable foreign exchange rate fluctuations and a </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$0.2 million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> decrease in stock-based compensation expenses. These reductions were partially offset by a $0.3 million increase in cost of revenues due to increased sales. The change in stock-based compensation is </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to options being fully vested in 2022 and the modification of option terms in 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling and Marketing Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling and marketing expenses increased by $6.9 million, or 12.8%, for the year ended December 31, 2023 compared to the year ended December 31, 2022. The increase was primarily driven by a $3.8 million increase in selling and marketing payroll costs due to an increase in staff headcount, a $3.5 million increase in promotional expenses, and a $0.7 million increase in traveling expenses of our sales staff, partially offset by a $1.3 million decrease in stock-based compensation. The change in stock-based compensation is </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to options being fully vested in 2022 and the modification of option terms in 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below details our costs for research and development for the years ended December 31, 2023 and 2022 (in thousands, except percentage change):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:1%;"/>
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change ($)</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change (%)</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct program expenses:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical trials</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,228</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,132</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Materials and utilities</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,607</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,877</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(270</span></p></td>
    <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9.4</span></p></td>
    <td style="background-color:#cceeff;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-clinical research</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,038</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,236</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,198</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(37.0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Indirect expenses:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related costs including stock-based compensation</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,092</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,716</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,624</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facilities, depreciation and other</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">815</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">725</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,780</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,686</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,906</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(17.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses decreased by $2.9 million, or 17.4%, for the year ended December 31, 2023 compared to the year ended December 31, 2022. The decrease was primarily driven by a $1.8 million decrease in stock-based compensation, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to options being fully vested in 2022 and the modification of option terms in 2023,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as well as by a $1.2 million decrease in pre-clinical research expenses. The latter is a result of several research and development projects advancing to the clinical trials stage or reaching the application phase in 2023. This overall decrease was partially offset by a $0.2 million increase in research and development payroll costs due to increased headcount.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses decreased by $2.7 million, or 15.6%, for the year ended December 31, 2023 compared to the year ended December 31, 2022. The decrease was primarily driven by a $2.8 million decrease in stock-based compensation. The change in stock-based compensation is </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to options being fully vested in 2022, the modification of option terms in 2023 and the new option grants offered after the GNI USA Contributions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquired IPR&amp;D</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acquired IPR&amp;D expenses of $83.1 million for the year ended December 31, 2023 represent costs of incurred for acquisitions of IPR&amp;D with no alternative future use, which were expensed immediately upon the closing of GNI USA Contributions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">132</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Divestiture Losses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, we recorded a loss of $2.7 million from the divestiture of almost all our assets other than our 56.0% indirect ownership interest in Gyre Pharmaceuticals. The loss is presented net of the direct costs incurred with the transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss on Disposal of Property and Equipment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recorded a loss on disposal of property and equipment of $0.6 million during the year ended December 31, 2023. The loss is presented net of loses incurred in connection with the sale of property and equipment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income increased by $0.3 million, or 43.8%, for the year ended December 31, 2023 compared to the year ended December 31, 2022, primarily due to additional investments in long-term certificates of deposit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income increased by $0.2 million, or 25.6%, for the year ended December 31, 2023 compared to the year ended December 31, 2022. The increase in other income was mainly attributed to $1.0 million of PRC government grants income recognized during the year ended December 31, 2023 in comparison to $0.9 million of PRC government grants income recognized during the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change in fair value of warrant liability was a $9.3 million expense for the year ended December 31, 2023 and was related to the remeasurement of the Preferred Stock Warrants liability. There were no warrants outstanding during the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other expenses increased by $1.2 million, or 88.8%, for the year ended December 31, 2023 compared to the year ended December 31, 2022. This increase was primarily driven by a $0.7 million increase in loss from equity method investments and $0.5 million in sponsorships for local charity events.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provision for Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provision for income taxes was $8.5 million and $5.1 million for the years ended December 31, 2023 and 2022, respectively. The increase was primarily attributable to a higher profit from Gyre Pharmaceuticals operations and an increase in deferred tax asset.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash and cash equivalents of $33.5 million and long-term certificates of deposit of $23.4 million, which are available to fund operations, and an accumulated deficit of $85.5 million. Our net loss during the year ended December 31, 2023 was $85.5 million, while cash provided by operating activities was $25.9 million. We believe that our existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund our operating activities and obligations for at least 12 months following the filing date of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Funding Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to use cash flows from operations to meet our current and future financial obligations, including funding our operations, and capital expenditures. Our ability to make these payments depends on our future performance, which will be affected by financial, business, economic, regulatory, and other factors, many of which we cannot control. Factors that may affect financing requirements include, but are not limited to:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, progress, cost and results of our clinical trials, preclinical studies and other discovery and research and development activities;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">133</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and outcome of, and costs involved in, seeking and obtaining marketing approvals for our products, and in maintaining quality systems standards for our products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of, and costs involved in, commercial activities, including product marketing, sales and distribution;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully commercialize and to obtain regulatory approval for, and successfully commercialize our other or future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increases or decreases in revenue from our marketed products, including decreases in revenue resulting from generic entrants or health epidemics or pandemics;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and development requirements of other product candidates that we pursue;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to manufacture sufficient quantities of our products to meet expected demand;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of preparing, filing, prosecuting, maintaining and enforcing any patent claims and other intellectual property rights, litigation costs and the results of litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into collaboration, licensing or distribution arrangements and the terms and timing of these arrangements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential need to expand our business, resulting in additional payroll and other overhead expenses;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential in-licensing of other products or technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the emergence of competing technologies or other adverse market or technological developments; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impacts of inflation and resulting cost increases.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary businesses, products and technologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the periods presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash Flow Data:</span></p></td>
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,892</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,677</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(19,760</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,814</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(298</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,891</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,334</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,028</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2023 was $25.9 million, reflecting our net loss of $85.5 million, offset by non-cash items of $103.9 million primarily related to the acquired IPR&amp;D of $83.1 million in connection with the GNI USA Contributions, $9.3 million related to the change in fair value of warrant liability, stock-based compensation of $7.3 million, divestiture losses of $2.7 million, and equity loss of unconsolidated affiliates of $1.3 million. Additionally, cash provided by operating activities reflected changes in net operating assets and liabilities of $7.5 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2022 was $10.7 million, reflecting our net income of $4.3 million and non-cash items of $14.2 million primarily related to stock-based compensation of $13.4 million, partially offset by net cash outflow of $7.8 million from the changes in net operating assets and liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Investing Activities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in investing activities for the year ended December 31, 2023 was $19.8 million, which consisted of $15.7 million in purchases of certificates of deposit, $8.5 million in purchases of property and equipment and $1.0 million paid for equity method investment, partially offset by $5.6 million of cash acquired in connection with the GNI USA Contributions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">134</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in investing activities for the year ended December 31, 2022 was $13.8 million, which consisted of $7.5 million in purchases of certificates of deposit, $5.0 million in purchases of property and equipment and $1.3 million in cash paid for equity method investments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2023 was $2.5 million due to the portion of proceeds from the issuance of Convertible Preferred Stock and Preferred Stock Warrants in the Private Placement received after the GNI USA Contributions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was no cash provided by or used in financing activities for the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations and Other Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into lease arrangements in (1) San Diego, California for our headquarters, which expires on the last day of the 38th full calendar month beginning on or after November 11, 2023, and (2) the PRC, for office and laboratory spaces through August 2024. As of December 31, 2023, our fixed lease payment obligations were $0.4 million, with $0.2 million payable within 12 months.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Contractual Obligations and Commitments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, we entered into a transfer agreement with Nanjing Healthnice Pharmaceutical Technology Co., Ltd. (&#8220;Nanjing Healthnice&#8221;), an independent third party, pursuant to which Nanjing Healthnice agreed to transfer to us the avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia and all relevant technologies, complete any research or trials and transfer to us all materials necessary for the application of marketing approval by CDE. Upon the completion of the transfer, we expect that we will be approved by NMPA as the marketing authorization holder of the avatrombopag maleate tablets. In exchange, we will pay a total of approximately $2.3 million upon certain milestones (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the completion of bioequivalence study, or the registration application to CDE) being met. We have completed the bioequivalence study and received CDE acceptance on August 1, 2022, and as of December 15, 2023, we have made total payments of approximately $1.8 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, we entered into a transfer agreement with New Jiyuan (Beijing) Pharmaceutical Technology Co., Ltd. (&#8220;New Jiyuan&#8221;), an independent third party, pursuant to which New Jiyuan agreed to transfer to us the minocycline hydrochloride foam for the treatment of moderate to severe acne and all relevant technologies, complete product development and transfer to us all materials necessary for the application of marketing approval of CDE. Upon the completion of the transfer, we expect that we will be approved by NMPA as the marketing authorization holder of the minocycline hydrochloride foam. In exchange, we will pay a total amount of $1.0 million and the payments will be made by installments conditioned upon certain milestones (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the completion of bioequivalence study, or the registration application to CDE) being met. Process verification has been completed. As of December 31, 2023, we have made total payments of approximately $0.7 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, we entered into a transfer agreement with Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. and Zhejiang CDMO Pharmaceutical Co., Ltd., an independent third party, pursuant to which Baicheng agreed to transfer to us the acetylcysteine injection for the treatment of respiratory diseases with excessive thick mucus discharge and all relevant technologies, assist us in completing any research, trial and other required procedures and transfer to us all materials necessary for the application of marketing approval of CDE. Upon the completion of this transfer agreement, we expect that we will be approved by NMPA as the marketing authorization holder of the acetylcysteine injection. We have received CDE acceptance on January 8, 2024. As of December 31, 2023, we have made payments totaling approximately $0.5 million under this agreement. Upon receiving the CDE's final approval, we will make an additional $40,000 in payments.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">135</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Programs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have committed to allocate $12.7 million toward future research and development activities for various programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commitments related to the purchase of property and equipment contracted but not yet reflected in the consolidated financial statements were $2.8 million as of December 31, 2023 and are expected to be incurred within one year.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP and our discussion and analysis of our financial condition and operating results require our management to make judgments, assumptions and estimates that affect the amounts reported in our consolidated financial statements and accompanying notes. Our significant accounting policies and methods used in preparation of the consolidated financial statements are described in Note 2 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management believes our critical accounting policies and estimates discussed below are critical to understanding its historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#8217;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Sale of Pharmaceutical Products</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the asset is transferred to the customer, generally on completion of delivery of the pharmaceutical products and quality inspection by the customer. For the sales of pharmaceutical products, most of our customers are distributors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from product sales is recognized net of estimated sales discounts. These discounts are estimated based on sales volumes from the preceding months and applying the discount percentages specified in each contract.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain contracts for the sale of pharmaceutical products include certain sales rebates which are incurred after the control and rights of products have been passed to customers that give rise to consideration payable to a customer. As the specific amount of the rebates is not finalized at the point of revenue recognition, we make deductions from revenue based on historical experience. In estimating consideration payable to a customer, we are required to use either the expected value method or the most likely amount method depending on which method better predicts the amount of consideration to which the customer will be entitled. We regularly review the information related to these estimates and adjusts the amounts accordingly.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">136</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To estimate the variable consideration for the expected future rebates, the most likely amount method is used for contracts with a single-volume threshold while the expected value method is used for contracts with more than one volume threshold. The selected method that best predicts the amount of variable consideration is primarily driven by the number of volume thresholds contained in the contract. The requirements on constraining estimates of variable consideration are applied and the expected future rebates are deducted from the trade receivables from the customers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) License of intellectual property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from a license agreement is recognized when the control of the right to use the license is transferred to the customer. Milestone payments, which are included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur, represent a form of variable consideration when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered highly probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses and Accruals</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are expensed as incurred when these expenditures relate to our research and development services and have no alternative future uses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-clinical and clinical trial costs are a significant component of our research and development expenses. We have a history of contracting with third parties that perform various pre-clinical and clinical trial activities on our behalf in the ongoing development of our product candidates. Expenses related to pre-clinical and clinical trials are accrued based on our estimates of the actual services performed by the third parties for the respective period.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate the amount of work completed through discussions with internal personnel and external service providers in conjunction with reporting information obtained directly from the external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We record the costs of research and development activities based upon the estimated services provided but not yet invoiced and include these costs in accrued expenses and other current liabilities in our consolidated balance sheets and in research and development expense in our consolidated statements of operations and comprehensive income (loss). We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting expenses that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record income taxes using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for uncertain tax positions in accordance with the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 740,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">137</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits are recorded as a component of income tax expense, if any.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value-based measurement of the award on the date of grant and recognize the related expense over the period during which an employee, non-employee or director is required to provide services in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once we have determined that it is probable that performance conditions will be satisfied.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Determining the fair value of stock-based awards at the grant date requires judgment. We use the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by our assumptions regarding a number of variables including the fair value of our common stock, its expected common stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. We record stock-based compensation as a compensation expense, net of the forfeited awards. We elected to account for forfeitures when they occur. As such, we recognize stock-based compensation expense over their requisite service period based on the vesting provisions of the individual grants. Such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different. We will continue to use judgment in evaluating the assumptions utilized for our stock-based compensation expense calculations on a prospective basis. See Note 12 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Based Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K for more information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liability</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Private Placement, we issued the Preferred Stock Warrants (see Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K) which are freestanding financial instruments classified as warrant liability since the underlying securities are contingently redeemable upon the occurrence of events which are outside of our control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. We use the Black-Scholes option-pricing model to determine the fair value of the Preferred Stock Warrants which is affected by our assumptions regarding a number of variables, including the fair value of our Convertible Preferred Stock, the expected share price volatility over the expected life of the options, expected term of the warrant, risk-free interest rates and expected dividends. Such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our estimated fair value of warrant liability could be materially different. We will continue to use judgment in evaluating the assumptions utilized for our warrant liability fair value calculations on a prospective basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Smaller Reporting Company Status</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 2 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K for a discussion of recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">138</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A.	QUANTITATIVE AND QUALITAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IVE DISCLOSURES ABOUT MARKET RISK.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market risk represents the risk of loss that may impact on our financial position because of adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure resulting from potential changes in exchange rates, interest rates, or inflation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Exchange Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our expenses are generally denominated in the currencies of the jurisdictions in which we conduct our operations, which are primarily in the United States and the PRC. Our results of current and future operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates. A hypothetical 10% increase or decrease in the relative value of the U.S. dollar to other currencies would not have a material effect on our operating results. As the impact of foreign currency exchange rates has not been material to our historical operating results, we have not entered into derivative or hedging transactions, but we may do so in the future if our exposure to foreign currency becomes more significant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inflation Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not believe that inflation has had a material effect on our business, financial condition, or results of operations, other than its impact on the general economy. Nonetheless, if our costs were to become subject to inflationary pressures, we might not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">139</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. FINANCIAL STATEMEN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TS AND SUPPLEMENTARY DATA</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Index to Consolidated Financial Statements and Schedules on page F-1 of this Form 10-K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">140</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. CONTROLS AND PROCEDURES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of disclosure controls and procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our management, with the participation and supervision of our principal executive officer and our principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2023 to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework. Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. OTHER IN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORMATION.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trading Arrangements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e82774e-b5da-4ad3-9bdb-4cdb4206cf36" contextRef="C_a5d59667-252a-4ddf-a814-4b5b16c0658d" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d722f1c-13cc-437f-ba41-a8df05ad37a9" contextRef="C_39406448-b6a7-468f-94e5-4643bb470fb8" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 12, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b317fed-e84f-4347-976d-ccfb42e8c998" contextRef="C_39406448-b6a7-468f-94e5-4643bb470fb8" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nassim Usman, Ph.D</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7b4fa58-d39d-410c-bf73-3e67e40959a9" contextRef="C_39406448-b6a7-468f-94e5-4643bb470fb8" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">director</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company, entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c92562c-801e-4659-a561-e0b9c257b445" contextRef="C_39406448-b6a7-468f-94e5-4643bb470fb8" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (as defined in Item 408 of Regulation S-K). Dr. Usman&#8217;s plan provides for the potential exercise of vested stock options and the associated sale of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9552dbb-6a39-4586-a2a3-178d8c95b8c7" contextRef="C_231bdf89-19b3-4b6a-80d0-3b9f3bf5f8dd" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">240,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of common stock. The trading arrangement terminates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">141</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sale of all shares pursuant to the trading arrangement. During the three months ended December 31, 2023, no other director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47440746-8936-4a0f-bf14-5713b2543ac9" contextRef="C_839664df-b2cb-4095-8420-a0a8cd565de5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_770fd2e7-32f2-4cf6-a19e-c1ce3df25500" contextRef="C_839664df-b2cb-4095-8420-a0a8cd565de5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9109800d-69e5-4828-9c51-b72af4a4b4e4" contextRef="C_839664df-b2cb-4095-8420-a0a8cd565de5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_fd495ba1-6808-4988-bfef-b2a9b24b181c" contextRef="C_839664df-b2cb-4095-8420-a0a8cd565de5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> any &#8220;Rule 10b5-1 trading arrangement&#8221; or any &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_foreign_jurisdiction"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">142</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T III</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. DIRECTORS, EXECUTIVE OFF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ICERS AND CORPORATE GOVERNANCE.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 10 is incorporated herein by reference to the information in our proxy statement for our 2024 Annual Meeting of Stockholders (the &#8220;2024 Proxy Statement&#8221;), which we expect to be filed with the SEC within 120 days of the end of our fiscal year ended December 31, 2023, including under the heading &#8220;Corporate Governance,&#8221; and, as applicable, &#8220;Delinquent Section 16(a) Reports&#8221; per Item 405 of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is available on our website located at www.gyretx.com, under &#8220;Corporate Governance.&#8221; We intend to disclose on our website any amendments to, or waivers from, the code of business conduct and ethics that are required to be disclosed within four business days following the date of the amendment or waiver.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. EXECUTI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VE COMPENSATION.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 11 is incorporated herein by reference to the information in our 2024 Proxy Statement, including under headings </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Executive Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. SECURITY OWNERSHIP OF CERTA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 12 is incorporated herein by reference to information in our 2024 Proxy Statement, including under headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. CERTAIN RELATIONSHIPS, RELATED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRANSACTIONS AND DIRECTOR INDEPENDENCE.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 13 is incorporated herein by reference to information in our 2024 Proxy Statement, including under headings </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain Relationships and Related Party Transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. PRINCIPAL ACCOU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NTANT FEES AND SERVICES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 14 is incorporated herein by reference to information in our 2024 Proxy Statement, including under the heading &#8220;Ratification of Independent Auditor Appointment.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">143</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. EXHIBIT AND FINA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NCIAL STATEMENT SCHEDULES.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following documents are filed as part of this Annual Report on Form 10-K:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Financial Statements</span></div></div>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Index to Consolidated Financial Statements at Part II, Item 8 Financial Statements and Supplementary Data, herein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Financial Statement Schedules</span></div></div>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All schedules are omitted because they are not applicable or the required information is shown under Item 8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</span></p>
  <p style="margin-left:9.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See LIST OF EXHIBITS</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See LIST OF EXHIBITS</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">144</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10-K SUMMARY.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">145</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="list_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LIST OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBITS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.025%;"/>
    <td style="width:1.003%;"/>
    <td style="width:45.086%;"/>
    <td style="width:1.003%;"/>
    <td style="width:6.719%;"/>
    <td style="width:1.003%;"/>
    <td style="width:11.031%;"/>
    <td style="width:1.003%;"/>
    <td style="width:8.063%;"/>
    <td style="width:1.003%;"/>
    <td style="width:14.039%;"/>
    <td style="width:1.023%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by reference</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit title</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1(a)&#134;#</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Asset Purchase Agreement, dated as of December 26, 2022, by and among Catalyst Biosciences, Inc., GNI Group Ltd., and GNI Hong Kong Limited.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dec. 27, 2022</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1(b)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement and Amendment to Asset Purchase Agreement, dated as of March 29, 2023, by and among Catalyst Biosciences, Inc., GNI Group Ltd., and GNI Hong Kong Limited.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mar. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex2-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business Combination Agreement, dated as of December 26, 2022, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the individuals listed on Annex A thereto and Continent Pharmaceuticals Inc.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dec. 27, 2022</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(b)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Business Combination Agreement, dated as of March 29, 2023, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders and Continent Pharmaceuticals Inc.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mar. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(c)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/brhc20058284_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to Business Combination Agreement, dated as of August 30, 2023, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc. and Continent Pharmaceuticals Inc.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aug. 31, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312506103288/dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fourth Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-8</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-133881</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 8, 2006</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312515297752/d24322dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment to Fourth the Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aug. 20, 2015</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312517037156/d326649dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Feb. 10, 2017</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex3-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Company.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6(a)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312517121994/d375894dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed with the Delaware Secretary of State on April 10, 2017.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Apr. 13, 2017</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">146</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.025%;"/>
    <td style="width:1.003%;"/>
    <td style="width:45.086%;"/>
    <td style="width:1.003%;"/>
    <td style="width:6.719%;"/>
    <td style="width:1.003%;"/>
    <td style="width:11.031%;"/>
    <td style="width:1.003%;"/>
    <td style="width:8.063%;"/>
    <td style="width:1.003%;"/>
    <td style="width:14.039%;"/>
    <td style="width:1.023%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by reference</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit title</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6(b)*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex3_6b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Elimination of Series A Preferred Stock, filed with the Delaware Secretary of State on March 25, 2024.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7(a)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Delaware Secretary of State on December 27, 2022.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dec. 27, 2022</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7(b)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex3-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Delaware Secretary of State on October 30, 2023.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8(a)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123030517/brhc20054638_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series Y Preferred Stock, filed with the Delaware Secretary of State on June 20, 2023, with respect to the Series Y Preferred Stock.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 20, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8(b)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/brhc20058284_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Elimination of Series Y Preferred Stock, filed with the Delaware Secretary of State on August 31, 2023.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aug. 31, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312516498295/d117011dex43.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to Silicon Valley Bank on March 3, 2005.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mar. 9, 2016</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312516498295/d117011dex45.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to purchasers of convertible promissory notes.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mar. 9, 2016</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex4-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Warrant to Purchase Series X Convertible Preferred Stock.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1(a)#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123035866/ny20009756x1_ex2-5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Contingent Value Rights Agreement, dated as of December 26, 2022, by and between Catalyst Biosciences, Inc. and American Stock Transfer &amp; Trust Company, LLC.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">  </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-273395</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 24, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2(b)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Contingent Value Rights Agreement, dated as of March 29, 2023, by and between Catalyst Biosciences, Inc. and American Stock Transfer &amp; Trust Company, LLC.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mar. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/brhc10049211_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Asset Purchase Agreement, dated as of February 27, 2023, by and between Catalyst Biosciences, Inc. and GC Biopharma Corp.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mar. 2, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Securities Purchase Agreement, dated as of October 27, 2023, by and between Catalyst Biosciences, Inc. and GNI USA, Inc.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312518265035/d612321dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Employment Agreement, dated as of August 28, 2018, by and between Catalyst Biosciences, Inc. and Dr Nassim Usman</span></a><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aug. 31, 2018</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">147</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.025%;"/>
    <td style="width:1.003%;"/>
    <td style="width:45.086%;"/>
    <td style="width:1.003%;"/>
    <td style="width:6.719%;"/>
    <td style="width:1.003%;"/>
    <td style="width:11.031%;"/>
    <td style="width:1.003%;"/>
    <td style="width:8.063%;"/>
    <td style="width:1.003%;"/>
    <td style="width:14.039%;"/>
    <td style="width:1.023%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by reference</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit title</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001124105/000156459023007276/cbio-ex102_31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Waiver Agreement between Catalyst Biosciences, Inc. and Dr. Nassim Usman, dated January 17, 2023.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 15, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001124105/000156459023007276/cbio-ex103_30.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Waiver Agreement between Catalyst Biosciences, Inc. and Dr. Grant Blouse, dated January 14, 2023.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 15, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001124105/000156459023007276/cbio-ex104_29.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Waiver Agreement between Catalyst Biosciences, Inc. and Ms. Seline Miller, dated January 17, 2023.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 15, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312516554394/d165946ddef14a.htm#toc165946_34"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Catalyst Biosciences, Inc. (formerly Targacept, Inc.) 2015 Stock Incentive Plan (as Amended and Restated Effective June 9, 2016).</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Appendix A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Apr. 25, 2016</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000156459017013442/cbio-ex101_24.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Incentive Stock Option Award Notice.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 14, 2017</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000156459017013442/cbio-ex102_25.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-qualified Stock Option Award Notice.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 14, 2017</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000156459020020531/cbio-def14a_20200611.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Appendix A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 1, 2020</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312518160813/d581034ddef14a.htm#toc581034_35"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Appendix B</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 11, 2018</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000156459022012877/cbio-ex108_9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Award Agreement.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mar. 31, 2022</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated as of October 30, 2023, by and between the Company and Charles Wu.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated as of October 30, 2023, by and between the Company and Ruoyu Chen.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Oct. 30, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/ny20009756x13_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Separation Agreement, dated October 30, 2023, by and between the Company and Dr. Nassim Usman.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nov. 2, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/ny20009756x13_ex10-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Separation Agreement, dated October 30, 2023, by and between the Company and Seline Miller.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nov. 2, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/ef20019132_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated as of January 15, 2024, by and between the Company and Dr. Han Ying.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jan. 19, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/ny20009756x13_ex16-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter to the SEC from EisnerAmper LLC, dated November 2, 2023.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-51173</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nov. 2, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of subsidiaries of the Company.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Grant Thornton Zhitong Certified Public Accountants LLP, Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (included as part of the signature page hereto).</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">148</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.025%;"/>
    <td style="width:1.003%;"/>
    <td style="width:45.086%;"/>
    <td style="width:1.003%;"/>
    <td style="width:6.719%;"/>
    <td style="width:1.003%;"/>
    <td style="width:11.031%;"/>
    <td style="width:1.003%;"/>
    <td style="width:8.063%;"/>
    <td style="width:1.003%;"/>
    <td style="width:14.039%;"/>
    <td style="width:1.023%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by reference</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit title</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1**</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2**</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gyre-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Clawback Policy of the Company</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:70%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">** Furnished.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"># Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) the Company customarily and actually treats that information as private or confidential and (ii) the information was not material.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Denotes management contract, compensatory plan or arrangement.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">149</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">URES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.64%;"/>
    <td style="width:42.3%;"/>
    <td style="width:4.64%;"/>
    <td style="width:48.42%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">GYRE THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 27, 2024</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Han Ying, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Han Ying, Ph.D.</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 27, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ruoyu Chen</span></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ruoyu Chen</span></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATTORNEY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each person whose individual signature appears below hereby authorizes and appoints Han Ying, Ph.D. and Ruoyu Chen, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:38.8%;"/>
    <td style="width:1.7%;"/>
    <td style="width:19.24%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Han Ying, Ph.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Han Ying, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ruoyu Chen</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer (Principal Financial and Accounting Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ruoyu Chen</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ying Luo, Ph.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ying Luo, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Thomas Eastling</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Thomas Eastling</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Gordon Carmichael, Ph.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gordon Carmichael, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Songjiang Ma</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Songjiang Ma</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Rodney L. Nussbaum</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rodney L. Nussbaum</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Renate Parry, Ph.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Renate Parry, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">150</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:38.8%;"/>
    <td style="width:1.7%;"/>
    <td style="width:19.24%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nassim Usman, Ph.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 27, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nassim Usman, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">151</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Index to Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.8%;"/>
    <td style="width:6.2%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID #</span><span><ix:nonNumeric id="F_7aa52c84-518a-4550-9e82-731249cdbd1d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">1487</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consolidated Financial Statements</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36.75pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36.75pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive (Loss) Income</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36.75pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#sose"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Equity</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36.75pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36.75pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36.75pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#schedulei"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Schedule I - Condensed Financial Information of Parent Company</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Board of Directors and Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion on the financial statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Gyre Therapeutics, Inc. (a Delaware corporation) and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements of comprehensive (loss) income, changes in convertible preferred stock and equity, and cash flows for each of the two years in the period ended December 31, 2023, and the related notes and the financial statement schedule included under Item 15(a) (collectively referred to as the &#8220;financial statements&#8221;).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis for opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits.  We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.  Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.  We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical audit matters</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.  The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse asset acquisition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described further in Notes 1 and 7 to the financial statements, the Company completed the GNI USA Contribution on October 30, 2023. The GNI USA Contribution was treated as a reverse asset acquisition for accounting purposes, with Continent Pharmaceuticals Inc. (&#8220;CPI&#8221;) treated as the accounting acquirer. We identified the reverse asset acquisition to be a critical audit matter.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal considerations for our determination that the reverse asset acquisition, including (1) the determination that the transaction was an asset acquisition, (2) the determination that CPI was the accounting acquirer, and (3) the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determination of the fair value of the associated consideration, specifically the expected volatility and expected term assumptions used in the Black-Scholes option pricing model to calculate the fair value of the outstanding stock options assumed in the Merger, is a critical audit matter, is the complexity of the transaction and the significant judgments by management, which in turn led to a high degree of auditor judgment and effort in performing procedures and evaluating audit evidence. The audit effort also involved the use of professionals with specialized skill and knowledge.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our related audit procedures included the following, among others:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reading and evaluating the underlying agreements in consideration of the relevant accounting guidance</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluating management&#8217;s assessment and conclusion on the asset acquisition and accounting acquirer </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluating the disclosures related to the reverse asset acquisition made in the financial statements </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluating, with the assistance of specialists, management&#8217;s assessment of the fair value of stock options assumed by CPI, specifically the reasonableness of the expected volatility and expected term assumptions used by management in determining the fair value of the stock options assumed  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluating the competence, capability and objectivity of the independent valuation firm engaged by the Company</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred stock warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Note 3 and 11 to the financial statements, in October 2023, the Company completed a private placement whereby the Company issued shares of convertible preferred stock and warrants to purchase shares of convertible preferred stock. The warrants were classified as a liability instrument and are subject to fair value remeasurement at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of warrant liabilities was estimated by management using the Black-Scholes option pricing model. As the Company's warrant liabilities are not traded in an active market with readily observable prices, the use of this model includes significant unobservable inputs to measure the fair value of the warrant liabilities. We identified the warrant liabilities to be a critical audit matter.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal considerations for our determination that warrant liabilities is a critical audit matter is the significant judgment by management when assessing the volatility and expected term assumptions, which in turn led to a high degree of auditor judgment and effort in performing procedures and evaluating audit evidence relating to those assumptions. The audit effort also involved the use of professionals with specialized skill and knowledge.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our related audit procedures included the following, among others:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reading and evaluating the </span><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convertible preferred shares and warrants agreement</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluating, with the assistance of specialists, management&#8217;s assessment of the fair value of the warrant liabilities, specifically the reasonableness of the expected volatility and expected term assumptions used by management in determining the fair value  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluating the competence, capability and objectivity of the independent valuation firm engaged by the Company</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212121;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Grant Thornton Zhitong Certified Public Accountants LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33f68d91-8c45-4165-9350-01e010564211" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Grant Thornton Zhitong Certified Public Accountants LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0195143d-c472-4b84-b35d-25ca9355bad0" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beijing, China</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 27, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets">&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_426796ac-5a23-4acf-8de5-5444364bb3f7" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,509</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82c71027-85c8-48be-9726-5f8b7dbd899f" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,175</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts and note receivables, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3edaf278-f51a-49ff-9163-979a60b12575" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,552</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e39bbb0-ae0b-453d-a62e-807964360e45" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,136</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables from GNI</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17ac106c-fa11-45a8-be39-1ef013b45fca" contextRef="C_553f64ab-cbff-456e-afae-63d4c635d124" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,287</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, net</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fcee370-89c2-4373-85f9-d139eb13ab60" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fb9b261-1733-4540-a5d8-e2714f7a1d86" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,122</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid assets</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_683e746a-3c51-4f66-9098-a6935f1ba251" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:PrepaidAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,547</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1acdbdd7-c481-4fc7-ae5c-01ea71366953" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:PrepaidAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">377</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d0cfcb2-591f-4250-acd4-08ff8821a05f" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,045</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e8fe4a0-7178-4602-a936-0177ca54e5b1" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">843</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6af70e79-1103-43d3-9cf0-74185ad75294" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,221</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd77a3b0-4dc7-4b26-aee6-47851bf7d5af" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,653</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e626700-d5b3-4224-b245-fd3b863d5d3f" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff959483-f7a3-4552-ab6d-8d99ba0537a0" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,709</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9954a4f-0ee2-40fa-bdbd-56f1c6055bf2" contextRef="C_67f01725-b921-4008-975b-be0783c4cd88" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51232873-1d03-4465-aef0-bedb809f57d8" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8886742b-069a-448d-b966-833e78ab71ac" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">297</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb302011-b00c-4144-be8f-8ca59acf207f" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69623884-23d1-4575-8c83-6068c23b6437" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">666</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Land use rights, net</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c8c9732-ecd8-4781-941b-5ecf58edffc1" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:LandUseRightsNetNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bfb8039-564f-43e6-994a-12d4361036cc" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:LandUseRightsNetNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,559</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcf1a9cc-9a23-4b22-af66-d452daa7726d" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,695</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d73cc9df-6608-4508-bd74-3b8eb8a3768f" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,081</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term certificates of deposit</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af2d30c0-3ae8-4d5e-b02f-9e4c1d304a55" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f244c0f4-938c-4358-a98f-137229cf1216" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,394</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets, noncurrent</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_267adbd0-4669-45e8-8eb6-27c1c6d60233" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">995</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29734742-d557-4357-a8c0-8293f60b445f" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,394</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d570bf4-b4d6-42e5-8485-b10faf80a8de" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,539</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eca72bd1-dac1-48c2-81a1-e7818b3f9aa5" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,753</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities, convertible preferred stock, and equity</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48e2f8fa-14c5-4bb3-9e27-6f1d758efc18" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29b716c5-ee66-4621-97a5-c1c1711952c0" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ec0c0c4-f039-4d3f-bfd9-c95cf37ac4f1" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c2ae8f0-0397-4fc2-8c6d-dd197f909279" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due to related parties</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_446e62fa-b589-4264-9356-6ef9e896760c" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,369</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31848b1c-f77f-458a-9d56-2785bd905bc2" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR excess closing cash payable</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76a38553-fcac-450c-ba82-85298f86c650" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:CvrExcessClosingCashPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,085</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce60c562-6c2d-4977-89d5-c97ba938ead7" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,935</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35734adc-dfd0-4ee0-b09a-44fea8786329" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c453be44-4a00-458d-8018-e48df6507f1b" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,054</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f353eaa-603b-4048-b017-b365c5ca3d1c" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,101</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bff078e-cc7b-4dd8-aa1d-c0c37326802a" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_101bc6ec-9ecf-4768-9578-a8758432b658" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">492</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9059a97-aa3a-495f-97c3-1e410fc83ee1" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,047</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c5efee6-be67-45c6-a6ff-b5bf2c0633a7" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,242</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8344e090-8186-4548-879f-9366cd4040cd" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d21f36f3-15f3-4b4b-bcfe-d4cb73cbf39e" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred government grants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb848a37-7950-44d0-9f33-cbee4d63d8e8" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c711325c-e888-4dc0-9740-2f5d0914ee28" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR derivative liability, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_534da7fb-dc37-44d8-ad3d-16ee86eb36df" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:CVRDerivativeLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1274d549-11fe-46bf-8f0a-93b52be458f9" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,835</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other noncurrent liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c6148c6-08fd-4fdd-92fd-125140926bbe" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a052ee8-9c1b-4577-b8fe-70ec86993007" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a3a8b39-37a9-4b49-9261-c3d72b1889d5" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,065</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3b0fe8a-691a-41bc-9d73-1d3cf4cd2753" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,536</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_10f26d2c-8039-4a92-bb7e-38b5c289f68f;"><span style="-sec-ix-hidden:F_f851a953-0acb-4a2d-aab6-9fc679e13665;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 13)</span></span></span></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Preferred Stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2889925d-9624-4a63-9d9d-66d220c37e82" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_110e43d5-0200-4f38-99d7-4793346ec4d6" contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08adb3b9-3693-4c27-818a-0c0a4aa2d32a" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_483a7502-92b9-4dca-9c98-3d61e0eba600" contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_862af94d-a9e5-4b5b-953a-04962d8937e7" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fad0c692-46e5-4f29-9564-692e60d26d08" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares and </span><span><span style="-sec-ix-hidden:F_510f7079-5465-4c06-acd3-f8ee356eab2a;"><span style="-sec-ix-hidden:F_a1f5be30-a9c8-475c-a877-7a594cbb125d;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd43f75c-1cba-47fe-ba18-e03b94debd96" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bca1aaff-603b-491d-b05c-adf5c685d0ff" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b9dad4c5-d8f6-4f90-bba4-355e9bb97a79" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b4497b1-13f8-4bf5-bb71-7ddd1c315d63" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6d44751e-f184-4eb9-b5ef-4eaaeff83980" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18416c04-5a35-4bea-bdf0-27e0ade491da" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d5fb55ea-ce94-4f41-8e30-91e04f54b19c" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,595,616</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be0969d1-3529-44e3-9868-61389fc57bd3" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_28c758bd-6bb6-43e4-b6ae-45f4db20fa3b" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,588,119</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022, respectively</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12ed239b-2fa7-40ce-983c-47e166a0992e" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0573541-8af8-46af-b688-56e628e06e6e" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d2f0f88-406a-4473-8473-a519dfa1fda3" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,179</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63041790-5c86-4430-a440-2c26d4c5124d" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,795</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statutory reserve</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5501961b-6559-4534-ab18-3d81eaaf2943" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:StatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69c6c8d9-1650-4f62-8862-d8c7bafc2fd6" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:StatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,660</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Accumulated deficit) retained earnings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f69ea2c1-6702-4952-a322-eb28841594f2" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,538</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c3c3e2a-1e02-444b-a649-d20fb7ceb0bb" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,395</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_061a4cae-6f3f-4cf9-afd7-687796439bb6" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,644</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ea850aa-9486-4dac-8094-c029be91b48a" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Gyre stockholders&#8217; (deficit) equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1f5e18c-d875-4def-9f6c-de9c12ec2180" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,828</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_572823ca-8d87-4b0f-a1cf-234fa7df994e" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b20f590c-3615-4805-a217-3e7763f86287" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,777</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc493640-62ce-4ff7-b3b1-db5de8540cc9" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,695</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_feba733e-51ae-4293-8aa4-00ffd3a7bed5" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eddc3c5d-2f25-492c-b8a1-5c6464ee97fb" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities, convertible preferred stock, and equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a3dcb72-4c06-4123-b50f-c2b9e9845876" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,539</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d9189a1-3073-4a51-8557-142753ae9a53" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,753</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ents of Operations and Comprehensive (Loss) Income</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.347%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:13.305%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:13.305%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_306068e7-3fcb-49a8-9d27-bd8fed1d27c7" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32c94103-4ed5-469a-8653-72c4e02de0d5" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,290</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea68fe28-2007-4066-acc3-db5ed097f690" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,636</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3af64abd-bcd6-4c58-a0e9-47ed4ece9a2c" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99c68f18-2d09-4034-beaf-37400d62f60e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,159</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28b37ab0-b28e-4b79-8e7f-057680211c92" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,238</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_344f1fa0-c8ad-412b-8b55-15666965d645" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,780</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae7cb1df-6313-48d4-ab60-c8b8a40a403e" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,686</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fbbf963-399c-4f34-abf6-3a4a6c2721c7" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,662</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64ba2a23-18dd-4529-8720-9bb9958907d6" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,370</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5de4e92e-63cb-4205-b874-03c3bb9afa28" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b14ced98-e4cd-4154-9632-52ebcd682073" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0998a63e-f57f-415c-903e-cbe1babf3faa" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77502d18-d48f-4fe6-9aba-dd824aabe3d8" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,680</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d33c52f4-d93c-46e5-bde7-45b3b5cb1f9c" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,087</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4798ddad-7c03-4524-bb53-5fb03a1b5455" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aea1e8f8-61cc-459b-9f43-bfda7b7ac9a1" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,203</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf37415a-fd72-4f01-a98d-4054075ba655" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,044</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38898398-8e83-469b-84ee-fb8131967efa" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">726</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3d34c31-a8ad-423c-b30c-af4b3d894f04" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,076</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_973da9f2-2ea4-4bca-adac-e4469060376c" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">857</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c9002b4-0c9b-4492-89fa-5fce56982927" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71e7dceb-4ba8-4503-90ac-ed46f459fa53" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OtherNonoperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,594</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77f9a8aa-901b-42ce-aa2a-f9fdb2bb6184" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OtherNonoperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,374</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income before income taxes</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0633fe83-49cb-42e7-871f-771f11ec7daf" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b56efdea-537e-41a0-980c-75818561ed7f" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,412</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51eef143-a453-4af4-8ce2-88473bde76ac" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,515</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_922de0f0-bbe2-4304-ac29-ee64c9f1853d" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07781598-bdb1-418b-98f0-064caaf068e5" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce0bfe43-96df-487f-b114-5c9bd8a17fb7" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,314</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33e6a6ef-7872-4bfa-94c3-22a27792ab99" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9d8efa4-8913-4a49-92a5-d3b2b1bc0c7f" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,012</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income attributable to common stockholders</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a62a784-4151-46a6-93b8-3c48d2171996" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11b881df-7691-4081-8fee-9b490dc56574" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,302</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income per share attributable to common stockholders:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a646df90-f70b-4d13-a330-cc6368bc0387" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e9c95a8-26d5-4881-9e96-7a1763315e5c" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1292367-28f9-4377-8e3c-b229cb2ecc41" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a84e463-4926-413c-823e-007d44926101" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fec6bfb-fa30-422a-94f6-dabc8dedd7e5" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1b9732d-3872-4492-98c4-6c4d8afcfe51" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">63,588,119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26c56221-7345-4ffc-90fc-91ca2f123aef" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dd1d421-2dd1-4775-81e3-f8c58a7ecf03" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">75,686,406</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive (loss) income:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab7e4138-6974-46d5-9bca-febbf802b2cc" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a066fc80-f08a-45c3-b5d4-1f0333e0140d" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,314</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32cea80f-0d1b-40a3-b2be-b7d8ce488485" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,484</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df92ef61-ec9a-412f-9368-323d80233d61" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,928</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6bb9ee1-0817-42d5-b60a-37ca6ff2ccec" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,964</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8349866-8566-46a0-a4bd-72cb1a4131fc" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">614</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e583c712-05c5-4c7c-8328-6347419f8b8f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1843c363-74e0-43c4-b7a2-0935f9266af5" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,012</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustments attributable to noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dccaab8a-d970-4125-bfda-bb9b649e337c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">647</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_014eab92-838b-4e98-bfd4-931d0b192bb5" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive income (loss) attributable to noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c614127f-c4a5-4126-b12c-3c54175c0fb2" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,806</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af6ab8bc-d185-4031-befe-bb3cfc8eb9a1" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">158</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss attributable to common stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a64e128f-566e-4e38-a364-724986b7ee14" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,770</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e1e43da-39ee-4ef7-82ec-f2aa042d3191" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">456</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="sose"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#1d1c1d;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.035%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.359%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.719%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:4.139%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.699%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.36%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.479%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.179%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.139%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.559%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.919%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.419%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-left:3.75pt solid #000000;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Statutory</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Retained Earnings</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Gyre Stockholders&#8217; Equity</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-controlling</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Equity</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-left:3.75pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Reserve</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Accumulated Deficit)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Deficit)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Interest</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#caf0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af892566-5fd1-45b4-9aef-585ea91c8ae4" contextRef="C_0edb0ebb-f503-4b95-827d-83260811c5cf" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,588,119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84be2f1a-f4bb-401f-970d-8ea2d5312c2e" contextRef="C_0edb0ebb-f503-4b95-827d-83260811c5cf" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fab6efe-2495-4bbe-b43c-d8a08836f0e3" contextRef="C_774dcb44-6e8f-40e2-92fb-74eb3d10f679" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e566e149-24f1-4848-a966-eeecce015ee9" contextRef="C_c368eb8c-00d1-4f05-bcc7-415246aeae15" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,413</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bc16687-9652-4ba5-b3a3-4f88d508c12a" contextRef="C_7dfcafca-61d1-46f1-a43e-d003319b30c3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f7693a0-ba05-4396-9c03-59a7515a8d28" contextRef="C_eb79166d-261c-4aa0-b6cc-fd954e4458bf" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,366</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a73a8a4-ce6f-49be-b950-3663400e1408" contextRef="C_25dbe4a0-c5aa-49dd-826b-9a456c343407" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,498</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ff24a6a-1fc6-4305-8448-07a8cd3dd566" contextRef="C_5f2eb8e2-864a-4564-afac-5ac5ae5e31a4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,967</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d96da30c-9fb9-42bf-ab4d-7a381842a40a" contextRef="C_b7c2a125-5bff-41a6-a0df-4926d0dda919" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,465</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Appropriation of statutory reserve</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ea9463d-a66f-4450-81dc-60e234cf7bf5" contextRef="C_ebddae99-35cb-4ad8-9ae5-e50276c1c921" name="gyre:AppropriationOfStatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e110516d-2fbd-420e-8aab-9a9b639f24d9" contextRef="C_4ae8d6c6-9b6a-426c-ba9b-df1d72c1c57c" name="gyre:AppropriationOfStatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#caf0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb8efb55-cdb3-4a93-868f-f88067a1a8a0" contextRef="C_bc38fe45-e720-4e3e-901d-1a99ab32da43" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,480</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_209d5bdc-6b33-4b01-9bda-84de3e851fef" contextRef="C_06e4c2d4-f7ea-4792-a208-6e5d5ddb822f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,480</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_045a0028-318e-4578-a860-7185b213aa0a" contextRef="C_0b92166d-718c-4785-aa66-2913afa80931" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,886</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3ee813e-31b0-455a-acd4-25f945923ab0" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,366</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdb81173-96d3-4ed7-bcde-ac0e46c2d807" contextRef="C_d1d44dd0-f099-499c-bf24-bbc98c230ca4" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,758</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_639699c4-7e66-4133-9a04-2c71df1d160d" contextRef="C_06e4c2d4-f7ea-4792-a208-6e5d5ddb822f" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,758</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_509c3b87-bb9d-4e55-bbec-d636006176d5" contextRef="C_0b92166d-718c-4785-aa66-2913afa80931" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_713eb98d-5838-4464-90df-bfa4ca3659b8" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,928</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#caf0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d8e9a8a-7f75-48ca-96af-e21925007759" contextRef="C_4ae8d6c6-9b6a-426c-ba9b-df1d72c1c57c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,302</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52c64996-f35f-45e7-b1f0-3436e5a58939" contextRef="C_06e4c2d4-f7ea-4792-a208-6e5d5ddb822f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,302</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c97ccc5-3c34-4cb9-a94d-1d99041bb46e" contextRef="C_0b92166d-718c-4785-aa66-2913afa80931" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,012</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e82e6b16-143a-4068-b47e-29578d245210" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,314</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b518c46-8f59-45e7-beea-be22dc89abc4" contextRef="C_4f7731e9-8054-4146-a8d0-8ebfec2ebe77" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,588,119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f61a662-ba9c-482e-beaa-c195fa890210" contextRef="C_4f7731e9-8054-4146-a8d0-8ebfec2ebe77" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4b0f6dd-50ad-4d30-8c69-b5469774dcda" contextRef="C_969ae12f-04dd-45bd-837a-de4b4c55f1de" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,795</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1cfd4e7-77fa-4580-ae1f-7302143c7efd" contextRef="C_964a9a24-1974-4f5d-9116-9d0ee44c4aaf" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,660</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_373fd3e3-9266-4163-813b-4a28cfc6ad9d" contextRef="C_b15a99e2-1606-4164-acb1-5d6360dd4a3a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,395</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0572f65-ba58-4a3f-b20f-4d2f0deb7a37" contextRef="C_b8689a54-e515-453a-a125-a50eaed49c5b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1a91c49-5b1e-40e9-bae3-c02e2f3a8ab9" contextRef="C_e4e28133-5b1e-4106-ab67-c16e08fd9d3d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e49e198d-e725-4ac1-ba0e-26e6edddbd00" contextRef="C_3ba0c404-2823-46e7-9d85-bca97b5c230d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,695</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_949ba615-a3df-4a10-9dc5-540b0ede23ab" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#caf0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e3e3617-e7fe-4a98-b967-6e0672a7be8b" contextRef="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56" name="gyre:TemporaryEquityIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5d2079c-50ca-47ea-9bdc-d3e7ed314c4d" contextRef="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56" name="gyre:TemporaryEquityIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,099</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cef8a8ac-abad-4a78-b179-dcb7b829a188" contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,531,851</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d9f6df7-0404-41ec-bf27-c53601d17c97" contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8ed74bb-7869-4296-8d76-0f5929ff08be" contextRef="C_f0008245-ac04-475a-a3d9-4fa1983c4b11" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ee38b4c-f127-4dc7-a4ff-cecb823f8834" contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,249</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_107bdcb5-653b-4b48-8aea-0de2c89eb046" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,249</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition of minority interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd28ec2f-0152-4b09-a645-e29f60aaec37" contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b" name="gyre:MinorityInterestDecreaseFromRedemptionsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,463,627</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de1b1e36-a741-4940-b14e-79950d250536" contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a4fddf3-b004-4556-afa3-54cd87872f0d" contextRef="C_f0008245-ac04-475a-a3d9-4fa1983c4b11" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,845</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55d71822-025f-40b0-a8e2-a8179bfa9af8" contextRef="C_c46426ec-a619-48aa-b225-7389e165b89a" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">438</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df35a9e9-8dbf-4371-b4fd-cd82d6a8062d" contextRef="C_8323d313-5e0d-40e1-8969-c2bf69e0e63f" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_943a1845-e65c-42f9-884b-66efa89493bb" contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,878</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2acd930-8a31-4e35-9422-86c0023694cb" contextRef="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be" name="us-gaap:MinorityInterestDecreaseFromRedemptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,878</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#caf0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Preferred Stock upon Private Placement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aae2064c-64db-4ddb-a139-c8308047fca4" contextRef="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56" name="gyre:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffa388d7-d4f1-4e09-8a75-8540a38e73ee" contextRef="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,426</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d26d679-9512-481b-a582-ff5dc28e9cdc" contextRef="C_f0008245-ac04-475a-a3d9-4fa1983c4b11" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0746e621-232a-4cf0-81a0-93dc72643a0c" contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edc5975c-4418-4fbd-a82b-ac2068f364b2" contextRef="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc1bcc80-a66d-4a97-86c2-f291a67439af" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#caf0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercised</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ca4d986-3f95-4e97-8d5b-6e3578a9564a" contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09656bc3-3cc2-4988-9ae8-b350084379c0" contextRef="C_f0008245-ac04-475a-a3d9-4fa1983c4b11" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91b92485-03dc-48a3-9125-ad37ae57a15b" contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43302b4e-919b-4e1d-928c-c78c4ad78ec0" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0426888b-0a70-4e68-a222-944bc6552137" contextRef="C_8323d313-5e0d-40e1-8969-c2bf69e0e63f" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f59bb2c7-d569-4d22-ad24-e639d19ba289" contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66e41301-3bd8-4532-bc22-e5e7daf19ea8" contextRef="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">647</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4df6ca26-387b-4d07-bc85-2610b2dff230" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,484</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#caf0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe6b9def-70cd-4de9-a181-5fe66d70a65c" contextRef="C_3d486857-5008-4c2c-a4dd-5f5a83f5ac38" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51556c1b-d938-4e05-9825-08459d036714" contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc8a0296-8cf1-4b6e-bb04-c7d5354494f7" contextRef="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f654b61-5f79-4c8a-882d-6177633eafd9" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de7650ff-30a6-41a3-bba8-6bafbd98ef0a" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e30a88f3-a436-4431-a7c1-90503ba47f6e" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;border-left:3.75pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90a6adb6-9c1d-4a41-8dd8-02971c016144" contextRef="C_812372f4-948a-4dd8-9e62-5d74629f12d2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,595,616</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f9f9b72-dc62-4e63-a760-dcbfcc6fb2ee" contextRef="C_812372f4-948a-4dd8-9e62-5d74629f12d2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b4c0356-16ff-4261-965f-80ecd87f73df" contextRef="C_3f63f1a6-45b5-4355-b17a-f27ea1669ee5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,179</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdf7d185-eec6-47bc-9c11-273addf4bdb6" contextRef="C_59d1977f-7c62-42fa-a426-ebf6da7d7d38" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c012d0f-2350-4eb7-aaf7-df80acbab0c5" contextRef="C_d564b606-4a21-47bf-80f7-c37ac338b08b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,538</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85a96b1e-ac7b-4ab2-b813-107e21bad7f2" contextRef="C_4011e20c-cbaf-4cba-ba16-cfe9ea152f93" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,644</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6b2c58f-458d-4bfa-aa5b-8b81eaeec983" contextRef="C_84bf33ef-ee75-44b7-9ee4-7d137c6aab5e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,828</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4052d48-b05c-450a-acbb-457b5166da83" contextRef="C_600857f6-7a26-4dcb-b37f-7638845d2593" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,777</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a856c7d-50be-424c-99da-3a3f323bad99" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.263%;"/>
    <td style="width:1%;"/>
    <td style="width:13.151%;"/>
    <td style="width:1%;"/>
    <td style="width:1.01%;"/>
    <td style="width:1%;"/>
    <td style="width:13.575%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Activities</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income from operations</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_211ab679-f8b3-4bdd-968e-ce5e57474110" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daaf52d2-ee3f-43c3-a217-946446917f16" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,314</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11bcf36e-cca5-4a18-b8ab-e38de9e164c2" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38ce9f14-40f7-4249-8e17-3982bef703bb" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00e6c873-1af4-4be9-ac02-561e551d927a" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,366</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be79daff-2f2c-4e62-9c18-373d9c1acaa8" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e57c9079-682f-4cdf-8ca7-fbd12f4d3ab9" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,087</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncash lease expense</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6904f55-86d3-4dea-8870-13e73efcc0f9" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90398fc6-0ac6-45be-9b52-e6e7039bf562" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of land use rights</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c06abf80-2748-4b48-994c-da1ae0de2ead" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AmortizationOfLandUseRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9794bb48-42f9-4fa0-b87a-5d694fa556eb" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:AmortizationOfLandUseRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income taxes, net</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7adc2572-6598-4773-bb06-150c4248f573" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:DeferredIncomeTaxExpenseBenefitNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,160</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46aad5ae-cd68-4805-9c9d-e0e31a1af3bf" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:DeferredIncomeTaxExpenseBenefitNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">838</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bad debt expense and other non-cash items</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30305042-2b1b-425f-b8a8-ba1b8cca210c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:BadDebtExpenseAndOtherNonCashItems" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_963561b9-d38b-4776-ad44-598712735579" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:BadDebtExpenseAndOtherNonCashItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest on long-term certificates of deposit</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b80555bf-eb7d-44d2-8b1a-4c1cb15afaae" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AccruedInterestOnLongTermCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">633</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c26d3f62-ff68-4810-b4d8-a3705f0fbaf2" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:AccruedInterestOnLongTermCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of long-term receivable</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a1f85a2-18f0-46b7-8aa0-15c6d02ca0bc" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ChangeInFairValueOfLongTermReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of derivative liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29264d88-97a7-49db-8211-59a58a59aeeb" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ChangeInFairValueOfDerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb0be00f-a57e-4377-ad18-ad54a683dace" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity loss of unconsolidated affiliates</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_815ee809-1aae-4704-89f9-df10311eff8d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:EquityGainLossOfUnconsolidatedAffiliates" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,314</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4afb205f-29ae-4512-95ca-24836daed04d" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:EquityGainLossOfUnconsolidatedAffiliates" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14b77b3c-3dc7-4abd-9355-d2aeb43225c5" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf8dac94-369b-405d-ab30-6151cf9db692" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d57a239b-6372-402d-8bc1-717e739148a0" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts and note receivables</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43a0126b-eab4-4b35-86d8-fd604407803c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:IncreaseDecreaseInAccountsAndNotesReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,398</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_066a4ef5-03a8-4c4c-8d52-9a6043565aa0" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:IncreaseDecreaseInAccountsAndNotesReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,920</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables from GNI</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75163542-949e-4401-a708-9143c2c4443c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncreaseDecreaseInOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54555040-37d8-4ddf-a87a-8040c89b1bf3" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,747</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa6062fd-22bc-4ab5-907e-84ce61530520" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other assets</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f47ef4b4-5590-4c30-ad3f-d91a33361275" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2df49783-9721-48e4-a0e5-03e3fb5dd481" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">973</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4590241c-945b-4cb6-8f6e-c66b8ba05037" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,003</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aacbcab-c2e3-4599-a370-0e33d65efb47" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,344</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ee3e39e-70fe-4b44-a643-d311d609a750" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0ea9ea5-2a60-4520-b3e3-353d2afcf988" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other noncurrent liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a6a15c9-28f1-40ab-a524-56cd8d659860" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due to related parties</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a84fc8f0-8aba-4cfa-8921-fbf5d837b7fe" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4792910-366b-4212-b5b9-33a203e95d7e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,446</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_defbe7cd-7367-42f4-97a5-8b205f84eef7" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,914</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9531bff-1354-4f24-a533-46149bf7afa4" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">473</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_881b0b00-f1bb-44fb-b159-437196c146d6" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba563666-46e2-465e-af2b-68465657b25a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,892</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c657228-39bc-40d0-9865-3faefd30ef84" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing Activities</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition of intangible assets</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc9e0eff-9af2-47ff-baaa-5921d135ffc2" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45655ecf-c980-481c-934e-1a61fd8a839c" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of certificates of deposit</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a3c7f9a-ca98-47d5-b653-ec1ac0c8cddd" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,735</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_297b8cae-2fc0-47ef-8d0c-8cb86c9e27f5" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,484</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94f9a00e-9024-4027-9a2a-337400204e4e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,517</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_385967bd-c58f-40c1-9f62-9e04c54c76ab" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,985</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sale of equipment</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e790d059-1c9c-4619-8c6e-095f8534cabd" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">664</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of equity method investment</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60cb33ca-8071-45cc-b5b4-6f18e982e75a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a3cfa2d-615c-4e89-b1f2-51b297414d06" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,332</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents acquired in connection with the GNI USA Contributions</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_413c603d-78d6-4a3f-8321-33563e38fd15" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,587</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments made for acquisition costs</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_847ecd5e-cc0f-4234-966d-95588d3d1e7c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:CashPaidForAcquisitionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash balance in a disposed subsidiary</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2395dccd-7321-49f4-b9a0-903c644ee2c1" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:PaymentOfDisposalOfSubsidiary" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e14bcc1-072f-48f6-b20d-b46a9b0abfb3" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19,760</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_618679a3-7141-4fe0-9826-6537007059d2" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,814</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing Activities</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of Convertible Preferred Stock and Preferred Stock Warrants under the Private Placement</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c31a66f3-10fb-4e6e-bfcf-389286e040c1" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80a654ca-0582-4238-b68d-f7191f4eb52c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60362127-4309-4078-ac7d-1ed599978d84" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ebd367f-0905-4412-9810-2cd2aa447b6b" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,891</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63f51b10-5e51-43eb-8790-3f480ad798a1" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,334</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fa16207-d502-4fc3-bb86-7bc61d5d2a56" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,028</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at beginning of the period</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2b12c2d-43bd-4c2f-a49e-38b1cdc9b9d7" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,175</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3c4a61d-13ed-4676-9acd-5be54a69a17a" contextRef="C_b7c2a125-5bff-41a6-a0df-4926d0dda919" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,203</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a237726e-8aad-4f7a-b844-1d1f08d33c39" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,509</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc5300d3-705c-4f0a-ada5-bfb6dbe5d5b2" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,175</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosure of Non-Cash Financing and Investing Activities:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bab83cb-21a5-4f20-bdfb-128a5239ba79" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,348</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Advance payment for Convertible Preferred Stock and Preferred Stock Warrants acquired upon the GNI USA Contributions</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d26d8e42-4bb8-43e1-a36f-4098afb59f95" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Disposal consideration in other receivables from GNI</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d68f438e-ffcc-436a-ae87-d8293b45f516" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:DisposalConsiderationInOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition costs in due to related parties</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5726274-f079-4a58-89f6-6cc6c45b8f87" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AcquisitionCostsInDueToRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">535</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset obtained in exchange for operating lease liabilities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1de81ca-e1e3-4456-b7a4-53163a38fd71" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8c8cdfd-29b0-4588-a19b-eb53f65ff713" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the exercise of stock options included in other receivable</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b28ab6b-2a22-4b16-878f-bac7ef082dec" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment included in accounts payable</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_901e8cff-9f55-4382-9f03-e2aacc9c7d17" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">727</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental Disclosure of Cash Flow Information:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for income taxes</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10dcb768-1b91-4dc6-9fc4-4664dc054d96" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3a959c1-5506-489e-a676-024229ca0b53" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,306</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to the Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3e885c6-238b-4131-b1c0-3f4c2ba833df" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NatureOfOperations" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Organization and Nature of Operations</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Gyre,&#8221; or the &#8220;combined company&#8221;), formerly known as Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;), is a biopharmaceutical company originally incorporated in Delaware on March 7, 1997 under the name Targacept, Inc. Catalyst was a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, Catalyst had several protease assets that were designed to address unmet medical needs in disorders of the complement or coagulation systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After completion of the transactions under the Business Combination Agreement as described below, Gyre became a financially-sustainable pharmaceutical company with a record of financial success that develops and commercializes small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F351 Asset Acquisition</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 26, 2022, Catalyst executed and closed an Asset Purchase Agreement, which was amended on March 29, 2023 (the &#8220;F351 Agreement&#8221;), with GNI Group Ltd. (&#8220;GNI Japan&#8221;) and GNI Hong Kong Limited (&#8220;GNI HK&#8221;) to purchase all of the assets and intellectual property rights primarily related to a clinical-stage proprietary Hydronidone compound for the treatment of nonalcoholic steatohepatitis (&#8220;NASH&#8221;), a severe form of nonalcoholic fatty liver disease (collectively, the &#8220;F351 Assets&#8221;), other than such assets and intellectual property rights located in the People&#8217;s Republic of China (&#8220;PRC&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combination Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 26, 2022, Catalyst entered into a Business Combination Agreement, as amended on March 29, 2023 and August 30, 2023 (the &#8220;Business Combination Agreement&#8221;) with GNI USA, Inc. (&#8220;GNI USA&#8221;), GNI Japan, GNI HK, Shanghai Genomics, Inc. (&#8220;SG&#8221; and collectively with GNI USA, GNI Japan and GNI HK, the &#8220;Contributors,&#8221; and each a &#8220;Contributor&#8221;), certain individuals (each, a &#8220;Minority Holder&#8221; and collectively, the &#8220;Minority Holders&#8221;) and Continent Pharmaceuticals Inc. (&#8220;CPI&#8221;). On October 30, 2023 (the &#8220;Effective Time&#8221;), the Contributions (as defined below) became effective and Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (&#8220;BC&#8221;). In connection with the Contributions, and immediately prior to the Effective Time of the Contributions, Catalyst amended its certificate of incorporation, increased the number of authorized shares of its common stock, par value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_838033a0-d540-4470-b90a-34b4cbf80c0d" contextRef="C_77204f22-ab15-4c2a-a5cf-eebb0427fdfc" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the &#8220;Common Stock&#8221;) from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e733b2bb-2e90-4c4d-9d5d-11fca87ea566" contextRef="C_a0eac393-f1de-40db-a17e-e4afc62662a6" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c939fe3e-3c15-4d57-b42b-87c7d9a76114" contextRef="C_c7e70b74-1137-44bb-bd33-d9231ea42d4e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, effected a</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49b4b748-bfa2-4bc6-bb0c-becb6dbd7134" contextRef="C_3c991f1d-66f5-47f8-8e04-683dff126fbb" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Reverse Stock Split&#8221;) and changed its name to Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of Catalyst Common Stock were previously listed on The Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221; Catalyst had filed a listing application for the combined company with the Nasdaq Stock Market Inc. (&#8220;Nasdaq&#8221;). On October 31, 2023, Gyre&#8217;s Common Stock commenced trading on the Nasdaq Capital Market under the symbol &#8220;GYRE&#8221;, on a post-reverse stock split adjusted basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Business Combination Agreement, at the Effective Time of the Contributions, and after giving effect to the 1-for-15</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a60c8c22-8c69-486e-a87f-ce207eb5c594" contextRef="C_5ca366b2-7931-469b-9226-43eecac0ccd6" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GNI USA contributed all of its ordinary shares in the capital of CPI to Catalyst in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca23a266-2c83-40b6-81d3-fb370fec244b" contextRef="C_d1d8d078-42db-45d4-8278-c6b26dcb880f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">45,923,340</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;CPI Contribution&#8221;), </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GNI USA contributed its interest in Further Challenger International Limited (&#8220;Further Challenger&#8221;) for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df6c4907-c19c-473d-bbd9-506498ab8c26" contextRef="C_29dd3e9d-3aeb-4cda-b357-0760b9f78c7f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,664,779</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;FC Contribution&#8221; and together with the CPI Contribution, the &#8220;GNI USA Contributions&#8221;), and </span></div></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">each Minority Holder contributed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95f8152a-3929-47a8-a4c3-ee8e0ac04830" contextRef="C_11e895d4-da38-44af-a160-56e416efc9d0" name="us-gaap:MinorityInterestOwnershipPercentageByParent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the interest he or she held in his or her respective entity in exchange for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b7c0eb2-4dc7-4628-90d8-1975352bf337" contextRef="C_11e895d4-da38-44af-a160-56e416efc9d0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,463,627</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;Minority Holder Contributions&#8221; and together with the GNI USA Contributions, the &#8220;Contributions&#8221;). </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the GNI USA Contributions, Gyre directly and indirectly holds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6d66542-bbc5-4704-8bcc-7ef4b2619819" contextRef="C_0e40eb2f-6361-4ec3-826e-a6b22c03f7bd" name="gyre:PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of CPI&#8217;s shares. Through Gyre&#8217;s ownership of CPI, prior to the Minority Holder Contributions, Gyre held a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5885b883-6544-4fc3-b499-3ebdfc817ce4" contextRef="C_5d3825d9-b987-4009-9844-dcb7a6a0f783" name="gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">56.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> indirect interest in BC. Upon completion of the Minority Holder Contributions, Gyre obtained additional indirect interests in BC and holds, in aggregate, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f3ba766-d5e0-43d4-8721-0bf1170473dd" contextRef="C_4415040d-7158-489d-9d55-5d063148a4eb" name="gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">65.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> indirect interest in BC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately after the closing of the Contributions, excluding potentially dilutive securities, GNI USA owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f00fc937-1f10-4882-ba5a-e41b021cd5d2" contextRef="C_e8c28c99-2d83-45ea-8686-ca83957381c9" name="gyre:PercentageOfOutstandingSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">83.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the outstanding shares of Gyre Common Stock, Catalyst&#8217;s existing stockholders, excluding GNI USA, owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38e1c572-1c80-42ac-89ab-0440fab68faf" contextRef="C_c8bdbd82-72b3-41d8-88a4-121a036217e7" name="gyre:PercentageOfOutstandingSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the outstanding Gyre Common Stock, and the Minority Holders owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d2354c1-84a6-42b3-837f-367705917291" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the outstanding shares of Gyre Common Stock. The Convertible Preferred Stock remained outstanding after the closing of the Contributions and is not included in the above ownership percentages.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the Effective Time, BC terminated its 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;) and the options (the &#8220;BC Options&#8221;) outstanding under the 2021 Plan were terminated and replaced with options granted under a subplan for Chinese participants under the Gyre 2023 Omnibus Incentive Plan (the &#8220;2023 Omnibus Incentive Plan&#8221;) that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remained issued and outstanding, and such shares and options were unaffected by the Contributions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BC is a commercial-stage biopharmaceutical company registered and established in the PRC in 2002. BC is committed to the research and development of new drugs as well as manufacturing and commercialization of ETUARY (pirfenidone capsule) for the treatment of idiopathic pulmonary fibrosis and other pharmaceutical products. The registered office of BC is located at 60 Shunkang Road, Shunyi District, Beijing, PRC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The immediate holding company of BC is BJContinent Pharmaceuticals Limited (&#8220;BJC&#8221;). The intermediate holding company of BC is CPI. Immediately following the Contributions, the immediate holding company of CPI is Gyre. The immediate holding Company of Gyre is GNI USA and the ultimate holding company of Gyre is GNI Japan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GNI USA Contributions were treated as an asset acquisition under U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), with CPI treated as the accounting acquirer and presented as the predecessor for the post-acquisition SEC reporting purposes. Since Catalyst is the legal acquirer, the GNI USA Contributions were accounted for as a reverse asset acquisition. This determination was based upon the terms of the Business Combination Agreement and other factors including that, immediately following the GNI USA Contributions: (i) GNI USA (as the parent company of CPI immediately prior to the GNI USA Contributions) owns a substantial majority of the voting power of the combined company; (ii) CPI, through GNI USA, has the ability to control the board of directors of the combined company; and (iii) senior management of BC and GNI USA holds a majority of the key positions in senior management of the combined company. Immediately prior to the closing of the Contributions, Catalyst did not meet the definition of a business because Catalyst did not have an organized workforce that significantly contributed to its ability to create output, and substantially all of its fair value was concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the closing date of the GNI USA Contributions, the net assets of Catalyst were recorded at their acquisition-date relative fair values in the accompanying consolidated financial statements of the Company and the reported operating results prior to the GNI USA Contributions are those of CPI.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in BC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Value Rights Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with the signing of the Business Combination Agreement on December 26, 2022, Catalyst and the Rights Agent (as defined in the CVR Agreement) executed a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), as amended on March 29, 2023, pursuant to which each holder of Catalyst Common Stock as of January 5, 2023 (the &#8220;CVR Holder&#8221;), excluding GNI, received one contractual contingent value right (a &#8220;CVR&#8221;) for each share of Catalyst Common Stock held by such holder. Each CVR entitles the holder thereof to receive certain cash payments in the future. For additional information, see Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company effected a 1-for-15 reverse stock split immediately prior to the Effective Time of the Contributions. The par value of the Catalyst Common Stock following the Reverse Stock Split was not adjusted and remains at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a3367bf-a15e-4ba1-9eca-ce349b49c5ca" contextRef="C_812372f4-948a-4dd8-9e62-5d74629f12d2" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. All of the Catalyst&#8217;s issued and outstanding common stock and options have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, warrants, and in the case of stock options and warrants, a proportional decrease in the exercise price of such stock options and warrants.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Stock Split and stockholders who would otherwise be entitled to a fraction of one share received a proportional cash payment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, the Company had a net loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e5806d7-0c36-452c-8dbb-268b2da42f20" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">85.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, while net cash provided by operating activities was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e19997c7-723b-47c2-9dc7-7a769678f85e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8b22f21-33e0-46cc-84be-ae01ac4f0af8" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">85.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4523453-0741-46ea-ab7c-d9e5f51b720a" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Based on the Company&#8217;s current operating plan, management believes that existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund the Company&#8217;s operating activities and obligations for at least 12 months following the issuance of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_470e87d0-0087-4a00-9bb0-1ca8f5663e44" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_470e87d0-0087-4a00-9bb0-1ca8f5663e44_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Summary of Significant Accounting Policies</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_470e87d0-0087-4a00-9bb0-1ca8f5663e44_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0ee2f20-6e67-4af9-ad3f-9ad13c2abd65" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_895eb1f4-4916-4ce5-bf12-693cc4b65f2b" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b786e26b-66d2-4615-9bd0-71b910375ffd" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:NoncontrollingInterestPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Noncontrolling Interest</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reports noncontrolling interest (&#8220;NCI&#8221;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82a6d165-7434-436e-8d74-8adcc5cfce68" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM, as a group, includes Gyre&#8217;s Chief of Executive Officer (&#8220;CEO&#8221;), BC&#8217;s General Manager, and the Chairman of Gyre&#8217;s Board of Directors (&#8220;Gyre&#8217;s Board&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has determined that it operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_002957f1-bec3-4806-8a82-37ae4fec0841" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> distinct operating segments and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5af23b9-b4ba-4953-b6ec-744fa95e7dd4" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43730af2-21f8-4607-a293-5197c01e0e9d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:RisksAndUncertainitiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23cac478-33d5-4985-ae4a-870ab283623d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">f Credit Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts and note receivable, and long-term certificates of deposits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had cash of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74031b36-cbdf-4781-80bf-8d9cc71fdff9" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:Cash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b788baa-4564-49e1-bb30-c0d7814558c9" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:Cash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and long-term certificates of deposit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f29e1880-6b0d-46f2-8638-7a1f0c4394a4" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c27dec9a-85d0-4bfb-ad74-b1397bd78646" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2015, a new Deposit Insurance System (&#8220;DIS&#8221;) managed by the People&#8217;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#8220;RMB&#8221;) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bd8e4d8-1cfe-41c1-9671-817bdca6558f" contextRef="C_14bcbd0d-16c5-428b-aeae-b50976bc4336" name="gyre:DepositsInLicensedBanksProtectedByDepositInsuranceSystem" unitRef="U_CNY" decimals="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ac</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd7f0cd0-8e80-4c4b-8db1-6574369eb2bf" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ConcentrationOfCustomerRiskPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Customer Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, one customer, Sinopharm Group Co., Ltd., accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54f3583e-5cfd-40ac-8fb1-ea59ce8ddb09" contextRef="C_b1ac7913-1b9e-4353-967b-ae81b61fc740" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">50.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0f04600-cb11-403c-8842-74d424c72cad" contextRef="C_c78a0ae7-fcae-4fbc-826e-d3417a171185" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">45.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, of accounts receivable, respectively. For the year ended December 31, 2023, three customers known as Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19092758-8dce-45f8-9aa1-78b32f4052d0" contextRef="C_520d9cfd-45b8-47c9-a6c9-7d44c08a8e84" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">50.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95fa7454-0f95-4548-a609-32e84ca33cee" contextRef="C_0063bfe3-5d9c-41a6-8562-8f267b5afe98" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08a57e64-e649-4e14-86c3-bf78e32738ae" contextRef="C_4a1e9dcd-1585-4d10-a8bc-e074b80d03a8" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total revenue respectively. For the year ended December 31, 2022, three customers known as Sinopharm Group Co., Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, and China Resources Pharmaceutical Group Ltd accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1f36475-e890-4145-9892-fc593b27597b" contextRef="C_e26cd6a1-f060-48c2-901b-b831f0705204" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">47.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8b6b61e-7d27-46de-9be7-aa3481eaa118" contextRef="C_a3878656-9f94-4813-a7e0-a59203be9936" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bb6bdde-abf8-44bb-b010-bb9f5828d976" contextRef="C_be894792-6c69-49f3-93fd-d2f0be6d34a3" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total revenue respectively. All customers are located in the PRC.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41fe0ae3-7531-4ab3-86fc-67f1297ba1f2" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests portion of its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5a87912-c0e5-4602-b181-27afda2f26a0" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Value Measurements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f413a298-59e5-4e20-95aa-7a2005513c0a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments and Contingencies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for additional information regarding the CVR derivative liability.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1592a1f-cb12-4877-b9b4-b202f0580632" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:PreferredStockWarrantsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants to purchase shares of the Convertible Preferred Stock (&#8220;Preferred Stock Warrants&#8221;) are freestanding financial instruments classified as warrant liability on the Company&#8217;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#8217;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ef90a73-c201-4121-bcf2-3a88aedf338a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ConvertiblePreferredStockPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to account for the Convertible Preferred Stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85768063-e5d1-4c91-a043-f520574f8912" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:LongTermCertificatesOfDepositPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-term Certificates of Deposit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The long-term certificates of deposit will mature between February 2025 and July 2026. Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using the effective interest method. The Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0303a52f-2232-44a7-a845-f46e5563e5c4" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:AllowanceForCreditLossesCertificatesOfDeposit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b4d68d3f-974c-42aa-9879-fa32e56c75ee" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:AllowanceForCreditLossesCertificatesOfDeposit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowance for credit losses associated with the certificates of deposit as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b964e84-f8fe-4b5a-81ec-ef15740592ab" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ReceivablesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Term Receivable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#8220;GCBP&#8221;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for additional information regarding the long-term receivable.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6885a679-8cdb-4dfa-b3a0-e8ada2d58965" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts and Note Receivables, Net</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#8217;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#8217;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_806af442-8f2a-4882-bca8-51fcf807c474" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:68.014%;"/>
          <td style="width:1.78%;"/>
          <td style="width:1%;"/>
          <td style="width:12.843%;"/>
          <td style="width:1%;"/>
          <td style="width:1%;"/>
          <td style="width:1%;"/>
          <td style="width:12.362%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33497c87-aa7d-4a7d-a86d-fb5232a0f96b" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,204</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7daa030f-d1ed-4774-817f-6773261ee88b" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,738</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Note receivable</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b88ee15a-6811-4442-8565-e551dab831d4" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:NotesAndLoansReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea97a1ad-fe07-45a9-a092-df1645a6b2ca" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:NotesAndLoansReceivableGrossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,522</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for credit losses</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26d94f00-b9cf-4f0f-9f46-8d339719ebee" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b611fc27-69f9-4bf9-be14-ea34848e2e7c" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts and note receivables, net</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e8fe402-54a5-4859-9846-b1941c853384" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,552</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f01aec73-3c10-4a9a-923e-f4883ed7cc87" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,136</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4beb8835-ff18-4c81-be45-1d2d08c7643e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in the allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:68%;"/>
          <td style="width:1.58%;"/>
          <td style="width:1%;"/>
          <td style="width:13%;"/>
          <td style="width:1%;"/>
          <td style="width:1%;"/>
          <td style="width:1%;"/>
          <td style="width:12.42%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, beginning of year</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1539291-8f7e-4b67-88a1-1844fd25d8b0" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a70cec9-9d4f-4fb6-8d04-5dec5f0f5937" contextRef="C_b7c2a125-5bff-41a6-a0df-4926d0dda919" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for allowance for credit losses</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6116f16c-0cf0-4c30-a100-5e3378faa821" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recoveries collected and write-off</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a17a0cc1-82d5-4f5e-902e-422f3614039a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ec5bcb2-bf8c-440e-89cd-7209ea66170f" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f4ebbb5-2d3e-45bd-9fbf-fe40b390f456" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b7a237f-63b3-4048-a12d-05b21d035eae" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, end of year</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_278e0906-cacc-43e5-a3b4-8e4380b40240" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa18131-69d3-4668-8ce8-31e5facb6957" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
         <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_927231f3-9241-473d-ad4b-56f97902869e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09b4242c-d7d4-40d4-9bc2-18016283dc5c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d45aa1c1-bc38-4457-8a7b-e6c07c764019" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:5.204%;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;"/>
          <td style="width:58.58%;"/>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Buildings</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:nonNumeric id="F_573a983f-4d66-4b86-8e4a-c39d054da5ef" contextRef="C_f243cd37-4ca7-40de-bfca-d9278aaf4176" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_4357fe31-bb24-46b1-ae6b-2cbe887db6bc" contextRef="C_0b0cf3b8-5d3c-4147-8ceb-467e7bd5ba58" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvement</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="-sec-ix-hidden:F_b8d10737-f18e-4a8d-80f3-5bcbf043af92;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of the estimated useful life or the term of the lease</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and electronic devices</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:nonNumeric id="F_1a53947e-c7d8-4d0f-ab49-e056e465027e" contextRef="C_91242d31-4c05-4dae-a9cf-c1b9d11a95ae" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_2dd01598-af4e-47c4-918d-3581ab481ea0" contextRef="C_e49c5cbb-f4c4-4958-97ed-acfefaf3d6d1" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:nonNumeric id="F_68c52526-7eda-4ad8-8b4b-7eb9de243ef0" contextRef="C_3b323a5d-4464-43f4-83e3-c63e93ede93a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_c9d1ce88-4c29-4536-ab4a-2ea0ef9eae53" contextRef="C_182327bb-26af-4f7a-895e-5e3aa7510752" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Motor vehicles</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:nonNumeric id="F_22000c20-bea4-4f15-8735-2e3904dae1fc" contextRef="C_0183b145-8159-4365-809a-9af68dddf568" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_35263630-e887-4966-9569-0336cbbd443b" contextRef="C_b7bd02c2-5511-4949-ab7c-0b820fc02c62" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81016147-05e4-42b5-9b9e-ec7e153b741e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible Assets, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patents and Technological Know-How</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1e9b2b5-26b2-4676-888d-eb29768a0ca3" contextRef="C_dbc1263a-94eb-48f4-bda3-2ce54672d636" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7ef4bef-c6a9-4d55-8427-db4923da51b9" contextRef="C_170270bc-ade9-476a-ad13-a1783878c851" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Computer Software</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ba9e4760-e1ab-447a-a061-08082fe718fe;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e507c4d-1ca6-46c0-9a0a-a9fe7d0f447d" contextRef="C_4649e540-01e6-41d7-b63f-f6d16f10ba35" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0dc9b08e-eac1-4555-ad7f-f5df5e758f95" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#8217;s leases do not contain any residual value guarantees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76e76f5a-6dc6-4632-a763-34b19fa1a9dd" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:LandUseRightsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Land Use Rights, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0482dd50-1ca4-4224-aee8-2b7047f5aa2f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount of an asset group exceeds its fair valu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb48535d-bce1-4c20-9e7d-ad591c7e960a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_85889a43-ae1d-498f-b67e-946f0eb3f430" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any impairment of long-lived assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_254f0e1e-8676-4720-8caf-9e23beefe943" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Expense</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89073922-3ecb-49cf-a279-7189959383fa" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#8217;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Sale of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer, generally upon completion of quality inspection by the distributor after delivery of the pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#8217;s estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) License of Intellectual Property</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from a license agreement is recognized at a point in time when the control of the right to use the license is transferred to the customer. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development or regulatory milestone payments, which are included in the transaction price to the extent that it is probable that a significant reversal of accumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of any milestones, and if necessary, adjusts its estimated transaction price on a cumulative catch-up basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58c4f6da-c8e2-4e71-b269-79315868e47c" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5a3f1aa5-34fa-43d2-95de-a1d614dd1ada" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any contract assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bdd30bc-93e1-44b3-bba0-403660b67905" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue is recognized when a payment is received from a customer before the Company transfers the related goods or services. Deferred revenue is recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of December 31, 2023, the Company&#8217;s deferred revenue balance was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac8633b7-6315-445d-9c5d-faf7c2f5ea4f" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">39,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Deferred revenue was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0cde050-e5e8-4afa-867f-df0758ffdab3" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">145,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2022 which has been recognized as revenue during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90097d20-dba4-4e87-ae02-be20f3cfc5cf" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CostOfSalesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3f6ed57-c569-481c-bd1d-ecb918e39b99" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#8217;s assumptions regarding a number of variables including the fair value of its common stock, its expected common stock price volatility over the expected</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5fd0c28-3cff-4122-9fce-0cf67c22fff4" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:InProcessResearchAndDevelopmentPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquired IPR&amp;D</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition date. Refer to Note 7 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for a more detailed description.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf4bbfca-9698-4ae8-9435-4b59dc58abb9" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0710859-907a-46c4-9a56-f3ed1f77b68b" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:SellingAndMarketingExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling and Marketing Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d95cbf22-f03c-42d5-89ac-8956515c7708" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:GeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_799f2a62-ac95-45ad-9293-292d04abbbdf" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GovernmentAssistancePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government Grants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive (loss) income.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f364d9d-2bd2-4ffe-bc2b-7aa40c24f3d5" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:InterestIncomePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb329b68-a531-4fd3-a4dc-5f3b956610e6" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Income (Loss)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0cb3e3f7-42a3-449e-ada1-c3e6743ab182" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Income (Loss) </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Per Share (&#8220;EPS&#8221;) Attributable to Common Stockholders</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 260&#8221;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#8217;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EPS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91484053-d76d-459d-9f56-ad519e85083c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Translation and Remeasurement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of BC is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company uses the U.S. Dollar as its reporting currency.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and  equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive (loss) income. During the year ended December 31, 2023, the Company had translation loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36c88dde-644f-4f00-b503-047fcaadd43e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. During the year ended December 31, 2022, the Company had translation loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41512493-4af1-4348-a2d6-c40acc69f639" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operations and comprehensive (loss) income. The foreign currency transaction gains or losses for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">were immaterial.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7db4b53f-40bf-4a90-a65d-d398cfe754ed" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ForeignCurrencyRiskPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#8217;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. 99.5% of the Company&#8217;s cash and long-term certificates of deposit as of December 31, 2023 of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5575d880-f55d-4398-b20a-b5eac4c613be" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c40029a0-1d05-480d-ac78-549f89706418" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:LongTermCertificatesOfDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, were denominated in RMB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32105c8c-c4ac-479e-b938-7ff3f753e32d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Pronouncements Recently Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, the FASB issued ASU 2021-04, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_148214c6-f1e3-46b7-a470-c5af2af0664a" contextRef="C_e8c45cef-ab89-4573-972d-ebd63351515c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2021-04 and related updates on</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d71a3ebf-2c31-49be-a365-863b9d184e6f" contextRef="C_e8c45cef-ab89-4573-972d-ebd63351515c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> January 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the adoption </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d02b904e-344f-4acb-8ad2-d4d24465f73a" contextRef="C_e8c45cef-ab89-4573-972d-ebd63351515c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have a material impact</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, FASB issued ASU 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the previous models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2021. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd2e06bc-0fc4-4e58-a32a-bfb9eb32f443" contextRef="C_b262631e-b3d6-4f19-a20e-4918b4b3ac1c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2020-06 on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_473464eb-6d9e-439a-af4b-a0d847ea99ad" contextRef="C_b262631e-b3d6-4f19-a20e-4918b4b3ac1c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the adoption </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a85faeff-d8c2-4ced-9ccc-2423b720e479" contextRef="C_b262631e-b3d6-4f19-a20e-4918b4b3ac1c" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have a material impact</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_965d21a9-3048-483f-bdba-d76a91f30e66" contextRef="C_902ec01f-0e7c-4614-8110-77c86fffbaba" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2021-08 and related updates on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9296bef2-02c2-41f1-b428-f7683b520665" contextRef="C_902ec01f-0e7c-4614-8110-77c86fffbaba" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The adoption of ASU 2021-08 had </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1883b40c-fa94-432d-adbf-691c06f26708" contextRef="C_902ec01f-0e7c-4614-8110-77c86fffbaba" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impact on the consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the FASB issued ASU 2021-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government Assistance (Topic 832) &#8212; Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The amendments in this ASU require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity&#8217;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8d2c6ab-6fcf-402d-89cc-335b3d5b7696" contextRef="C_e13ef3b0-0f59-4737-ba8d-a801a95ed820" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> this standard as of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ccdf1a3-199e-4d5c-ada4-27abc9a27df0" contextRef="C_e13ef3b0-0f59-4737-ba8d-a801a95ed820" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The adoption of this ASU </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7ebf4fe-ef4d-4ddf-a335-bb7d102eee5e" contextRef="C_e13ef3b0-0f59-4737-ba8d-a801a95ed820" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have any material impact</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the Company&#8217;s consolidated financial statements.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbdcb199-8765-406a-b928-8cc5c5c14d89" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company plans to adopt annual requirements and related updates under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently assessing the impact of adoption of this standard on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#8217;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"></span></p></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_352f4c26-2162-49ce-a577-3daabe2dcd49" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:FairValueDisclosuresTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">3.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements and Financial Instruments</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a description of the fair value hierarchy and fair value methodology, see Note 2 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the Company&#8217;s highly liquid money market funds are included within cash equivalents.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28535115-7fb7-4acc-ac2c-4cfe1f9038d7" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a272737-bc08-4cc6-aecc-0ad4b9df9699" contextRef="C_045ba781-db06-4c6d-8298-49ca507c4865" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0547b5d9-8cf0-4c86-a882-fafaeb82c402" contextRef="C_9f06db74-891e-4ce0-a20f-35ad5be24529" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c3b286c-029e-4c52-9923-d87a2be264f1" contextRef="C_115f1247-30e4-4dba-bef9-b573f9c28f0d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1972e2d-35d3-4e05-9ace-a536ccb7d688" contextRef="C_4819d424-8697-4686-8411-d198d08bf27a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1959363-1b20-41bc-b9f9-d68b1bb96fa6" contextRef="C_157e8487-e10a-4a43-a91d-f10752747e13" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_714c49e7-f4fd-4a85-b65d-0df9648f0211" contextRef="C_a0b36028-19c9-4a53-a9a7-ee2e782d8999" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ba05a34-112c-4e1f-a23d-c4ab7a0e4744" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,582</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a4d2fff-9acd-494c-857c-1b9d2af3b0e1" contextRef="C_445a60cd-e16e-489f-bcf9-7e083b147488" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b17963a-c7c8-4e8f-8d81-688db319ac02" contextRef="C_4dd9552a-d96b-49ea-b446-4919e583d048" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4080e83b-0649-4725-84d7-6adcc5297f62" contextRef="C_13201822-62fe-49b2-a82f-aea2f25149ff" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,835</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c4f97d8-e997-46bf-801f-bd90a80dedf6" contextRef="C_d0718b26-6e80-4be3-a6f2-f995da1fdae5" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,835</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f71c091-d812-490f-adb2-b3676a9977ad" contextRef="C_a0b36028-19c9-4a53-a9a7-ee2e782d8999" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,557</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_241df060-5562-4490-8902-6062da4739fc" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,557</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(1)  </span><ix:footnote id="FNT_4c145f6b-eadd-41ce-9c2e-dc03d3a8bcb1" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</span></ix:footnote></p></ix:nonNumeric></div><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash, accounts and note receivables, net, other receivables, accounts payable, due to related parties, CVR excess closing cash payable, and accrued liabilities approximate their fair values due to their short maturities.</span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9b830be-caf6-41dc-957a-69e83b07912f" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers of fair value measurement between Level 1 and Level 2 and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e7f9cdf-b7aa-4082-a904-f42d0180e21d" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:FairValueAssetsAndLiabilitiesLevel3TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers into or out of Level 3 for both financial assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df96abdc-dd48-454b-8c1b-86c5a77c09c6" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e53234c6-4ddb-476a-a44b-6d5ae63e034c" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> financial assets and liabilities measured at fair value as of December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-term Receivables and CVR Derivative Liability</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The long-term receivable and the corresponding CVR derivative liability, noncurrent relate to the asset purchase agreement with GCBP. The fair value of this long-term receivable and derivative liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The estimated fair value of the long-term receivable and CVR derivative liability, noncurrent was determined based on the anticipated amount and timing of projected cash flows to be received from GCBP pursuant to the GCBP asset purchase agreement discounted to their present values using an estimated discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0b2a85d-3d2b-4768-9e61-b88608085f6c" contextRef="C_1815289d-1b7a-4870-a6b4-e40af7ccba71" name="us-gaap:DerivativeAssetMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_70f77a1f-bf2f-4ed3-8bde-1ac025548259" contextRef="C_db3199b0-d343-4eaa-a0d5-e0379c40bbc8" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.05</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the Company expects to receive a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f8b4362-8b75-4015-950b-495621dcf3d1" contextRef="C_4d497df2-33f4-4686-9867-5db4e7e60cf7" name="gyre:AmountToBeReceivedUnderAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> hold-back payment from GCBP in the first quarter of 2025, which will be distributed, net of expenses, to the CVR Holders. The change in fair value of the long-term receivable from GCBP and the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">corresponding CVR derivative liability, noncurrent was recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, Catalyst entered into a Securities Purchase Agreement for a private placement with GNI USA (the &#8220;Private Placement&#8221;). The Private Placement closed immediately following the closing of the Contributions on October 30, 2023. Upon closing of the Private Placement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ed2b277-2a1b-4540-804a-7a03bbefbeca" contextRef="C_3ca1cf69-934c-4ff2-a707-c448b5a6f581" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock and </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_a514c68d-d9aa-4712-9543-03bb9786dd72" contextRef="C_5b9e0cff-7266-4030-8595-3ac948bb97b6" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Preferred Stock Warrants to purchase shares of Convertible Preferred Stock t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">o GNI for an aggregate purchase price of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d13f962-65e2-461d-bc9b-346acfef965f" contextRef="C_60d99e53-9b0a-4867-83bb-4f2ef85acc84" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Preferred Stock Warrants are immediately exercisable at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cec87790-c877-42c1-8e0a-f91a00adb240" contextRef="C_5b9e0cff-7266-4030-8595-3ac948bb97b6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4,915.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of Convertible Preferred Stock and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa2aa12a-81ac-42a7-a87b-cc647cf739c9" contextRef="C_5b9e0cff-7266-4030-8595-3ac948bb97b6" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 30, 2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he number of shares of Common Stock issuable upon exercise and conversion of the Preferred Stock Warrants is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e592ab8-b5f7-4085-8634-b04d9de48563" contextRef="C_5b9e0cff-7266-4030-8595-3ac948bb97b6" name="gyre:NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">540,666</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company accounted for the Private Placement as a non-arm's length transaction. The Preferred Stock Warrants were initially recognized at fair value upon issuance and the remaining proceeds from the Private Placement were allocated to the Convertible Preferred Stock.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Preferred Stock Warrants are freestanding financial instruments classified as a warrant liability on the Company&#8217;s consolidated balance sheet. The Preferred Stock Warrants are revalued each reporting period with the change in fair value recorded as change in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5644c9ef-41c0-4bff-b201-a4776753e504" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the warrant liability is estimated based on th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Black-Scholes option pricing model using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.984%;"/>
        <td style="width:1.7%;"/>
        <td style="width:1%;"/>
        <td style="width:14.317%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b43a9c89-6a08-4312-912a-643615296607" contextRef="C_ea3f5866-c7a2-4019-97c6-761b0043d03a" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="1" format="ixt:num-dot-decimal">25.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c76c8af-956f-4bdd-a81c-36f0978bd8b5" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4,915.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0be109d-1dde-46d2-89d7-e02c3cc12046" contextRef="C_10152a3b-ae2a-4e24-a1b1-6548fd6edc50" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">3.88</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_fe25e57c-b57d-4e40-b79a-762153588e26" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.83</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_706f2b07-5fa9-459a-917d-2f2b0997d983" contextRef="C_09b4f5a5-c379-45c0-b3a1-76e64d96074d" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">84.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8c649c2-e363-4411-b7b1-5edaa08df82c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level 3 financial assets and liabilities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:12.98%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:12.700000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbe159dd-9175-4a1c-89ea-12b11a629477" contextRef="C_69b8f9e1-11d9-471e-9f88-5c562846ff4d" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b9a61de-444b-41e5-ba17-77f903f6c733" contextRef="C_dee33cb1-134d-4bc4-846b-88a1d3ece761" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0795a4d9-cddb-41a0-8232-bd9908d9f809" contextRef="C_39bb62ec-75ae-4ae3-a8f4-d62d0b77c6d4" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,574</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d4ee1a1-b02b-42f6-a374-cef5c77cb63e" contextRef="C_69b8f9e1-11d9-471e-9f88-5c562846ff4d" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c92ea5de-ff49-403a-8834-6cf2f2438676" contextRef="C_dee33cb1-134d-4bc4-846b-88a1d3ece761" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf70672f-8591-4998-91fc-44046887f8dc" contextRef="C_39bb62ec-75ae-4ae3-a8f4-d62d0b77c6d4" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,261</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_489f3c5c-547d-4a96-b32b-50b55e9eeb75" contextRef="C_4819d424-8697-4686-8411-d198d08bf27a" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c873b42-28ff-49db-81b2-aa399097e191" contextRef="C_4dd9552a-d96b-49ea-b446-4919e583d048" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de607102-baa6-4721-9478-34ad0614bab8" contextRef="C_d0718b26-6e80-4be3-a6f2-f995da1fdae5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,835</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Instruments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_febc5039-dc72-4e3c-8143-ff6150578fe3" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.98%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.02%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds  (cash equivalents)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54bd72a8-67fe-422c-8866-cddd66f40d78" contextRef="C_6b3596e0-0ee0-47ca-98ce-acc247c5374c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a035ab67-b1ea-4261-a610-2b32423aa0a8" contextRef="C_6b3596e0-0ee0-47ca-98ce-acc247c5374c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fad9a72d-4c1b-413c-b80c-01f3d4565ce0" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cc24fb9-6e0d-4e1d-8b3d-ef474815ed01" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a62bc42-9ef3-4744-bdd1-5e8b8c9a9152" contextRef="C_a3a35db5-876f-4dde-b12c-44d79d949c6a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_470e012f-bbc3-42f0-bcff-15864dee1d52" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b89f5f7c-a093-4a1d-9647-3dea2e51d311" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance Sheet Components</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94d4e839-9d59-426d-affd-c34043d1765c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, net of reserves of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c20e51d-0960-434c-83f1-737caf43bc0c" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">46,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_872638c6-e903-456f-9cb6-98f65602cce5" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and 2022, respectively, consisted of the following components (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.986%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:12.637%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:12.997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4ffcf89-faab-4538-8c34-3753f6951d88" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:InventoryRawMaterials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">919</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52a0c044-0a7c-4fdc-8ed8-9bd1e7bad5eb" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:InventoryRawMaterials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,056</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90579243-9e94-4728-baeb-4942eb9fae89" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:InventoryWorkInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,997</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ecf6b6e-fb07-441d-8b2f-dc9691a348f4" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:InventoryWorkInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,667</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_655822e4-77e2-4dc0-a923-93439d86a51c" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:InventoryFinishedGoods" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8de1aec-7172-40d0-ad9f-d6b07d01c139" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:InventoryFinishedGoods" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,399</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e64eb06a-77bb-4d25-87af-bdb0383b3cf3" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e67be5a2-44e9-449b-ad22-98e1ae7fa601" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,122</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision for inventory and write-downs for the years ended December 31, 2023 and 2022 were immaterial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8b4685b-4d52-448b-b1eb-adbeb0bcc8b2" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other liabilities consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.44%;"/>
        <td style="width:1%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1%;"/>
        <td style="width:12.280000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll and welfare</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dca7dbe1-c5b4-48db-831e-b11615630f11" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:AccruedPayrollAndWelfare" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,790</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9621dc3a-f24e-449d-9f0e-945352c2a993" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:AccruedPayrollAndWelfare" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,038</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplier reimbursement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ac0bc67-eae9-418b-9609-ba0426d32103" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:SupplierReimbursement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,247</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85b3e466-2971-402d-b9cc-14a9a72048b9" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:SupplierReimbursement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,474</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses - general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0208dae0-d7cf-471b-8629-f6dc78dbba97" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:AccruedExpensesGeneralAndAdministrative" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,190</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued sales discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd44b7a7-e807-4d8d-81d9-25d600120891" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:AccruedSalesDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">903</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_601818db-4b5d-4d04-8145-5ff4aad9eba3" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:AccruedSalesDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_891ffdb2-a590-4bcf-a33d-1c2e531fa19e" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee reimbursement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08ea7271-9085-4c26-afe4-068e1cdfb515" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">648</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f27da5b-ca12-48a4-a555-6b44b159b7ac" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses - research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64d764cf-2801-47de-ba93-bf1afc339d7c" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:AccruedExpensesResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8b3ffbc-cb2a-4374-a3fc-3b3e14a9786a" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:AccruedExpensesResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses - selling expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c10f53fa-f50a-4267-8bbb-06654e3aa60e" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:AccruedExpensesSellingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02eec63a-7dc3-427c-a44d-5287d652fc44" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:AccruedExpensesSellingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d313a462-8967-485e-b0ea-c145d6c3f187" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:DeferredGovernmentGrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21abf0e7-ea89-4f2b-8395-e10710d6e4ba" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:DeferredGovernmentGrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f7f57d8-d245-4725-a680-4f4afe9863de" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea2b2995-91a0-4392-ab34-97e961cfee40" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2be7285e-3099-478f-b1e0-82d77bed516a" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,935</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5512c22e-a2de-4796-87e0-07d0955e1b64" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,264</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred government grants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred government grants represent funds provided by the government for research and development, construction of new facilities, or improvement of existing production facilities. The amount of deferred government grants as of December 31, 2023 and 2022, is net of the amount recognized as government grant income. During the years ended December 31, 2023 and 2022, the Company received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22f0f823-78d9-4441-bc77-5f8ed2c9e46f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ProceedsFromGovernmentGrantsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3243515e-793d-49cd-b0f2-a9262b8788f0" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:ProceedsFromGovernmentGrantsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> government grants, respectively. During the years ended December 31, 2023 and 2022, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3d4d1ab-016f-432a-b82b-0b3735c01b10" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:GovernmentGrantIncomeWithinOtherIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4155002-c146-4a1b-8487-efce685b593c" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:GovernmentGrantIncomeWithinOtherIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of government grant income within other income in the consolidated statements of operations and comprehensive (loss) income, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31ce4c70-96a5-44b4-9665-e43db3e83cb6" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summarized below are deferred government grants as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.44%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:12.22%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government grants for property and equipment, included in accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e930951-7de3-4165-a207-5119243d5eba" contextRef="C_b93ebd7b-c921-4c3e-b8e6-a2fb861ebf08" name="gyre:DeferredGovernmentGrantsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a202c3e-e45b-4ead-bed5-5e33ebe3fda2" contextRef="C_e6b773b3-ff91-417f-965a-e0e1b202042c" name="gyre:DeferredGovernmentGrantsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9b43d30-8343-4a3d-a888-56c015c22a66" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:DeferredGovernmentGrantsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12d24970-d532-41e8-a393-64a5a2a2e1b5" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:DeferredGovernmentGrantsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government grants for property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54a6ddde-e714-4bc6-91bb-5e2629dc9c31" contextRef="C_0abe225e-8a79-41e7-a475-5fdcdaca6b2b" name="gyre:DeferredGovernmentGrantsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3128ead9-cf56-4f75-ba7d-802e443b9243" contextRef="C_42dbc2ab-badc-458b-bb6d-bcbe8dbf6681" name="gyre:DeferredGovernmentGrantsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd3c03f6-d216-41bc-83a7-23c7cb7ef086" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:DeferredGovernmentGrantsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbf974b2-274a-4fa0-8397-2d375e437d5a" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:DeferredGovernmentGrantsNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d9d74a7-e2d6-49e7-bd0a-77439898dc5b" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:DeferredGovernmentGrantsCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_281d5c51-7b3d-4e94-86cc-a1ec33bf9241" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:DeferredGovernmentGrantsCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbc0643e-0121-497d-9948-71b853fa9cae" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.24%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:12.76%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Buildings</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3143cea6-9a7a-44ac-a492-0a4addbc0d83" contextRef="C_6707664a-816c-4885-a01e-386eaafa6e47" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,289</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1afda7a3-30d5-43a5-9d21-f8d2a0cf4b4d" contextRef="C_7aad8f7d-ee0c-42f0-82cd-92463b4ee3ba" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,837</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1600318f-6aea-416e-9a6c-14d3c6a93a4a" contextRef="C_0be0b3d5-00f8-476d-87f6-73aa39f3c356" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,875</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac6b7315-cd4c-42b6-aec6-70e80187d875" contextRef="C_255a8a23-07fb-48ff-8e4a-470e48cef83d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,851</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and electronic devices</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_683cadce-f02d-45b4-b9a6-f188974ab311" contextRef="C_38b72769-64e0-4e0a-befe-f69436730816" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,598</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4c58e58-59b9-449d-ae35-c8fc8a0bcbbf" contextRef="C_ef376339-fca7-4476-8816-40e8e7832483" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,880</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51ffdb6a-42aa-4bda-9343-ae2c4274f980" contextRef="C_88893ed2-bf18-49f6-9367-143999cca36b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d60816d-d44a-4c88-8d7a-60d838116081" contextRef="C_6077b963-9934-4f32-afc7-404ff0ca15ef" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bdf52f6-0179-4c91-89b4-b889f61d5f84" contextRef="C_c49e00a9-fef7-400c-9f36-c136ff2e6361" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11599b66-8675-413a-83d4-53483d497f21" contextRef="C_6a6b4fb6-8b55-4823-9d73-78c42fa47442" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Motor vehicles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_877f5f59-10f3-42ee-ac06-cd9d7a3e01bb" contextRef="C_63213500-d1dd-4530-b4dc-40f0ab583252" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5295851-c8e3-49b3-b132-3d0ece01c857" contextRef="C_201559bc-4989-46aa-9233-4a691252ef1c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f816099a-9c49-46ab-8ae5-10c1f8aa2de9" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,553</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6567d3bc-1b13-4754-a033-079b8b5a6427" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,707</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_234ddcce-0ebe-45ba-ad50-e99e83819944" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,265</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22b0e29b-b229-40b7-b03f-ca585cf07c52" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88493d25-2cdb-4026-baf0-ba38e86d10e8" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,288</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9fdb267-8552-4623-9273-e7164bd64d20" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,709</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_017738b5-02f6-4b47-a3fc-d90afe764b5b" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe98b6ef-abf5-4d3b-8ed9-8763b2ace97a" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each of the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_11684805-c49e-43d9-b075-316867bd5fdd" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible Assets</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d17b15d4-d2b9-4aae-8fb9-b91c20f42413" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The gross carrying amounts and accumulated amortization of the Company&#8217;s intangible assets with determinable lives as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.99%;"/>
        <td style="width:1%;"/>
        <td style="width:13.197000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.077%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:13.157%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_067f7481-9cd1-4f0a-87a1-b6e4d773e6d9" contextRef="C_b14d0f10-ff15-45a8-ac65-d7d00fe4ea56" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">430</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df2132e8-24e3-4e47-975b-48eba070f3d3" contextRef="C_b14d0f10-ff15-45a8-ac65-d7d00fe4ea56" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_839de51a-dc35-440e-86f0-e07de4a24264" contextRef="C_b14d0f10-ff15-45a8-ac65-d7d00fe4ea56" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2befc976-dea5-4dfb-9b07-064eb0ed58ee" contextRef="C_197f4783-1608-451f-92af-879882f8d860" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3e2f16a-018e-4107-b558-959da07318e8" contextRef="C_197f4783-1608-451f-92af-879882f8d860" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0884f6e-1d7d-4840-aede-831221adeff3" contextRef="C_197f4783-1608-451f-92af-879882f8d860" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbf95666-83c7-46ea-a8b5-064403b5d898" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">601</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93b78413-dc7b-4116-b797-3c0ec667bf08" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e952f84-14aa-4355-87c9-72bd1c4ec5c2" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:14%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81d22d80-95cf-464a-a4f9-fb0ce93d6a96" contextRef="C_ed6adc05-0edc-4467-9e37-a86f39ca0666" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,496</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0fed13f-ef47-418c-803e-9fa353faf665" contextRef="C_ed6adc05-0edc-4467-9e37-a86f39ca0666" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,372</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcce691a-368a-47ea-81df-bc8c60239e89" contextRef="C_ed6adc05-0edc-4467-9e37-a86f39ca0666" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b292ce4-a847-40d9-925b-c2b2ef5e1b92" contextRef="C_fbd33fe5-ce5f-469c-838c-790bd81dab76" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">438</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fa50b97-76e9-4e18-897c-1bf4ab1e156c" contextRef="C_fbd33fe5-ce5f-469c-838c-790bd81dab76" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06b2ae3d-288e-426c-9fea-642e3ba14630" contextRef="C_fbd33fe5-ce5f-469c-838c-790bd81dab76" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91b4f625-6729-476e-a609-ff77c57051a0" contextRef="C_348a8cf8-e659-4115-a553-09b0ef1cf4b9" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_785dd672-c336-4eba-a0ce-4dca1b33bf3e" contextRef="C_348a8cf8-e659-4115-a553-09b0ef1cf4b9" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91d0993f-89ce-4cfd-ab75-fca40a8156cb" contextRef="C_348a8cf8-e659-4115-a553-09b0ef1cf4b9" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c24ce3f-6783-40d0-82ea-7b67f800f64c" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,038</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46d100b7-22e7-4841-890d-e0f2e04d1bac" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,741</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c69b944-59a2-4bc6-abcf-b5a2fac38633" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">297</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets are carried at cost less accumulated amortization and impairment, if applicable, and the amortization expense is recorded in operating expenses. The weighted average amortization period for the intangible assets as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0779ce38-3b8d-486c-9d34-9551fc5f3684" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.05</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amortization expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_812cb21d-509c-45c6-902b-083e529e8293" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de9f083a-6939-44a6-9577-a13a8cc7725a" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each of the years ended December 31, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf1af018-f6b9-42bb-86ca-f8c83338fc0e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true" continuedAt="F_bf1af018-f6b9-42bb-86ca-f8c83338fc0e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on finite-lived intangible assets recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the estimated future amortization expense is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_bf1af018-f6b9-42bb-86ca-f8c83338fc0e_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:85.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.28%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Amortization Expense</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac40e4c5-1731-4822-9886-98a68f986a5b" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daf1f1cd-7a2c-446f-9ad1-eae74ca61ed4" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_955eff3f-d68b-4641-9c3f-d45b8945d238" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f556076b-6e44-4c76-879f-9030af92c853" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42baba12-6c53-49a6-8a4f-f2edbe029923" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64f1e13a-815f-4770-9d9b-26a728883825" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c333e20c-cb0a-48e3-98f9-1be0c21ea330" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">205</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cadc753d-9f28-49ad-8eb7-aab47f2e7d3e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s product revenues were mainly generated from the sale of ETUARY. Sales of ETUARY accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0990ab36-908d-4912-9f61-ae15d90d95c2" contextRef="C_fe01067f-086e-4848-ab35-be3389a6f430" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">98.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d55f46af-50e1-45cb-bb9a-fd489fcd6ebd" contextRef="C_876ccdba-ce87-44d7-a2b1-3ab0b94f2343" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">96.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total revenue for the years ended on December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue mostly through sales of ETUARY and certain generic drugs. The distributors were the Company&#8217;s direct customers, and sales to distributors accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bda87a1-a6b7-4cfb-b642-50b21f36348e" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:PercentageOfRevenueAccountedSalesToDistributors" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of revenue from ETUARY. The distributors sell ETUARY to outlets, including hospitals and other medical institutions, as well as pharmacies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product returns to date have not been significant and the Company has not considered it necessary to record a reserve for product returns. The Company&#8217;s product revenues were recognized at a point in time when the underlying product was delivered to the customer, which was when the customer obtained control of the product. Revenue from sales of pharmaceutical products was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55f68626-caed-482e-a541-471055f18d28" contextRef="C_667dbe67-6d4f-4415-b9bd-2d650d6ff17a" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">113.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c48f808b-4306-49bf-98fe-c456db5d783e" contextRef="C_f5c9b177-fba0-46dd-bf60-5e7f99b3ce8b" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively. All sales are generated in the PRC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from licensing intellectual property is recognized when the control of the right to use the license is transferred to the customer. Milestone payments, which are included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur, represent a form of variable consideration, which is recognized as revenue when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered highly probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_980d6ec5-1ce2-4448-a150-64f9d8fe1d24" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s sales by product categories for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.814%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.323%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:12.863000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales of Pharmaceutical Products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6f5b9eb-5b7c-4440-855f-d7571603e8f7" contextRef="C_667dbe67-6d4f-4415-b9bd-2d650d6ff17a" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e50cfe7-63c6-4821-9c05-39be8acaad97" contextRef="C_f5c9b177-fba0-46dd-bf60-5e7f99b3ce8b" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,876</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">License of Intellectual Property</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f116145-da19-433d-b2a4-14820a9d1970" contextRef="C_f750731b-6020-454a-871c-e743ff63ef9d" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,414</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbee0e48-e353-4ded-9fe7-4cd2aa59fe38" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a64648b6-1dd5-4719-b9ba-e3fcf14dcee1" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,290</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div><ix:nonNumeric id="F_aa4dcf38-b316-4e47-8aa8-b93575a6d1ba" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GNI USA Contributions under the Business Combination Agreement (see Note 1) was treated as a reverse asset acquisition, with CPI as the accounting acquirer and Catalyst as the legal acquirer. Under U.S. GAAP, a company must evaluate if an integrated set of assets and activities qualifies as a business acquisition or an asset acquisition by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assessing if the gross assets&#8217; fair value is primarily concentrated in a single asset or a group of similar assets. If this criterion is met, the acquired operations are not considered a business. Catalyst did not meet the business definition as its fair value was concentrated in one IPR&amp;D asset, it lacked an organized workforce contributing significantly to output creation, and no substantive processes were acquired. As such, the GNI USA Contributions was treated as an asset acquisition. In an asset acquisition, goodwill is not recognized, and the cost allocated to the acquired IPR&amp;D with no alternative future use is expensed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59d8a41f-bed6-4971-9e8c-3a3257ed0992" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:1%;"/>
        <td style="width:84%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Catalyst Common Stock outstanding</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e943dcd-fc6f-4dbf-ba7e-a41b4bc06f28" contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,532</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Multiplied by the fair value per share of Catalyst stock (1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ee0712a-9495-465c-a62c-57257a6ca510" contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a" name="us-gaap:BusinessAcquisitionSharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common shares to be owned by Catalyst&#8217;s stockholders</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cdb87c5-f183-4ec9-aff2-dfd12634cb72" contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a" name="gyre:BusinessCombinationFairValueOfCommonShares" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,420</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of preferred shares to be owned by Catalyst&#8217;s stockholders (2)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbaeeda2-4b02-470d-9341-dbf9ecc4a8bb" contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a" name="gyre:BusinessCombinationFairValueOfPreferredShares" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,099</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of Catalyst</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f224a411-c0cf-4fca-8cb6-5c702156ac66" contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a" name="gyre:BusinessCombinationFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,519</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c261cfe5-3da9-46f4-9be9-e6fa353cc3f9" contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a" name="gyre:PreMergerStockOptionsAssumed" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of consideration issued</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e98bdfce-ba24-4063-8144-bfeab03a8fc3" contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a" name="us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,348</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cb605aa-3130-4ec1-97d1-656c5b634f46" contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">659</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase price</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00c91776-adaf-4b4c-a72c-a92a9accd945" contextRef="C_dd01b7d2-757f-4f84-a6ce-a11ccc44dbab" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,007</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</span></ix:footnote></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This amount is calculated based on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_884520f5-d206-4413-aef6-7cdddfdc52b6" contextRef="C_b46d8f77-6441-4e49-9e95-f82435a4d5d3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,340</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_4fdbb7f8-f8cf-4cf3-8745-f364e85793a1" contextRef="C_b46d8f77-6441-4e49-9e95-f82435a4d5d3" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">666.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</span></ix:footnote></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adcc0073-9fef-4201-8397-398d0314ba70" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true" continuedAt="F_adcc0073-9fef-4201-8397-398d0314ba70_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span></ix:nonNumeric></span></ix:footnote></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_adcc0073-9fef-4201-8397-398d0314ba70_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:84%;"/>
          <td style="width:1%;"/>
          <td style="width:14%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7cd6ec69-a601-4ca9-9e6f-9104cf25e061" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span></ix:nonNumeric></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffcadfc5-a8fe-4d82-a0fb-1f4fd0a3427e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.30</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_433dba2f-890e-41fa-bb69-f079f6a82328" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.65</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
          <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b7c5c36-6872-4710-a424-ffd1ba3fbd5f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:84.96%;"/>
        <td style="width:1%;"/>
        <td style="width:13.04%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bac1b0b-a85b-4066-a562-3a5307caadde" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,587</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables from GNI</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e379039-a6c4-4fa4-b8e0-74e81aa9de39" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">423</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bc68f47-661c-4fea-925c-b3040c096e36" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,097</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bc09f2b-b15a-4780-a5ba-46074887a76b" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_198eee49-92d8-459f-8108-232243e9e477" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets, noncurrent</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96b8ee5b-01f2-4d5b-95b1-e28df96125dd" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">IPR&amp;D</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ea11064-c3a8-459b-90ac-4d6a1d1408ff" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a46e4344-b28a-4335-be66-b7ca4f9cfca5" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Advance payment received from GNI</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0500177a-bae5-4fe0-802c-dd3a55d52e6b" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_763b76f9-4cd2-4a49-bd29-cf5ad96423e8" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,784</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR excess closing cash payable</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6520a18-ea5f-4a1a-9607-d496b96ffd2b" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="gyre:BusinessCombinationExcessClosingCashPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,085</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR derivative liability, noncurrent</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29c404e8-861a-48c5-81d8-674c31188f76" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net assets acquired</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35f55db7-a462-4834-baf1-0f074502d638" contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,007</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in BC.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4ec9d2a-65b0-4ce5-8d17-9789ed5a4634" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true" continuedAt="F_f4ec9d2a-65b0-4ce5-8d17-9789ed5a4634_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Restructuring</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f4ec9d2a-65b0-4ce5-8d17-9789ed5a4634_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Contributions, CPI entered into a CP </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Share Purchase Agreement with GNI USA </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and divested almost all of its assets other than its </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8886d9aa-16d7-4402-8449-f55e2052b81e" contextRef="C_a67805ae-0e8b-4cdd-8b41-5d0c3ff00337" name="gyre:PercentageOfIndirectOwnershipInterest" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">56.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> indirect ownership interest in BC. GNI USA is the parent company of Gyre. In connection with the transaction, the Company recorded a receivable in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1cfac9c-76ae-4091-aa3e-a70c853a47dc" contextRef="C_ffe88006-6a83-4a40-9c82-c045fa6b0bdc" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> included in other receivables from GNI on the consolidated balance sheet as of December 31, 2023 and recognized a loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c190128c-579c-4fa2-bc09-dede3178e532" contextRef="C_a67805ae-0e8b-4cdd-8b41-5d0c3ff00337" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8e68219b-ebcf-438a-abe3-c6ac455c6706" contextRef="C_a67805ae-0e8b-4cdd-8b41-5d0c3ff00337" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during the year ended December 31, 2023, included in divestiture losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the consolidated statements of operations and comprehensive (loss) income.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aac4ad75-e7ac-4c56-92d1-6d7c6cd70a17" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">9.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Leases</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> BC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s corporate headquarters, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_670ac4e3-908c-4d90-9a0b-d6e9b843a906" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:SquareMeterAreaForOfficeSpaceUnderLease" unitRef="U_sqm" decimals="0" format="ixt:num-dot-decimal">968</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square meter office space, is situated in Beijing, PRC, with the lease expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_980c4f41-4752-4ab3-912a-756202539dfa" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Additionally, a laboratory center spanning approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7a31fdf-9f02-43a1-a73a-5f7e261543a2" contextRef="C_65d76f22-ab8c-450d-82d6-0c032d5502d0" name="gyre:SquareMeterAreaForLaboratoryCenterUnderLease" unitRef="U_sqm" decimals="0" format="ixt:num-dot-decimal">640</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square meters was leased in Shanghai, China, which expired in November 2023. In 2022, the Company secured a new lease for an office space of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5884bc41-22f2-4147-b443-65cfdd59c315" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:SquareMeterAreaForOfficeSpaceUnderNewLease" unitRef="U_sqm" decimals="0" format="ixt:num-dot-decimal">180</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square meters in Zhengzhou, China, with the lease set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f37cb650-9a54-4594-b426-79b8f4de97fc" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In November 2023, the Company also secured a new lease for its U.S. headquarters in San Diego, United States, with the lease set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d1b9455-d4a7-463a-badd-8bab88ca23b3" contextRef="C_28499de6-ca37-4fe6-8aca-3f877d7ec297" name="gyre:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also has multiple short-term leased properties used as offices and employee dormitories. The Company recorded a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16b57dc3-12ea-4130-80bc-116aa669f1a6" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">89,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a96a00d0-6725-42bc-8b33-1c5db91b6921" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">52,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> short-term rent expenses during the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The short-term rent expense amounts are recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive (loss) income.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>As of December 31, 2023, the Company recorded an aggregate ROU asset of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02bd0f34-0f8d-4015-b90f-49084c92650f" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and an aggregate lease liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19072959-5534-4899-8d5b-fd42f2aaa226" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rent expense related to operating leases was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04ace930-8fdc-40f7-baf2-9f8d9af35c89" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_98e1d16a-17fa-4e52-9000-12067188b9ca" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each of the years ended December 31, 2023 and 2022, respectively. Variable lease payments for the years ended December 31, 2023 and 2022 were immaterial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc89322e-c867-43dd-9c9e-5ec2ce8be1f4" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.04%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_780f05f8-1479-49e3-8dc6-2409667f599f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">573</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c21359e-2e3f-4451-912d-a34e49ab3f6d" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29945eb2-befa-4f8d-b286-467cfe6c5b97" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The present value assumptions used in calculating the present value of the lease payments were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.687%;"/>
        <td style="width:14.141%;"/>
        <td style="width:2.02%;"/>
        <td style="width:14.141%;"/>
        <td style="width:1.01%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
        <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a6d3a1a2-90c7-46d2-888b-31755ab21c27" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1552c57b-5f90-4c25-a514-76065bcd1398" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_664e994d-d703-4fb9-97dc-9cfce7fb2fb2" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6803b8e7-39d8-49f3-9e6c-9624a9aec7f1" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce01d443-1c8c-418c-80cb-f4f56984f32a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, undiscounted future minimum payments under the Company&#8217;s operating leases were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:83%;"/>
        <td style="width:1.84%;"/>
        <td style="width:1%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3326c3a8-77ce-4967-93d2-af9e8c243d45" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f27fa406-f062-42f3-b7b6-d8967cabab14" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a3d57e3-9d88-4118-a030-385d957461d3" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0264d636-f356-488c-a9b2-21ccdd46a26d" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d30c3661-20b7-44d2-8899-94031854c600" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ad0fcc8-bbb0-4ab5-b18c-bc1cb45abe45" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">409</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aabc90fa-1762-4f8f-9ca1-47e38449fb0a" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cd264dd-b6b5-4894-a4fa-1e6862004577" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to maintain security deposits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17939ca9-cce3-4079-ad40-c900fa596414" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in connection with various leases, which amounts are included in other assets, noncurrent on the Company&#8217;s consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Land use rights</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company held land use rights for two land parcels in Beijing&#8217;s Shunyi District, expiring in 2053, and in Cangzhou, Hebei Province, expiring from 2067 to 2071. These parcels, with a combined area of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_417f93cf-bfa7-4a53-9319-6753454768b1" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" unitRef="U_sqm" decimals="0" format="ixt:num-dot-decimal">66,559</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square meters, are utilized as manufacturing facilities. As of December 31, 2023, the aggregate recorded land use rights, net assets for these parcels was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ae54f3f-bc82-423b-8d93-a8e5ace5f937" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:LandUseRightsNetAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd179929-c9d5-4b87-a287-0710180fb5b5" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders&#8217; Equity</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Company&#8217;s amended and restated certificate of incorporation, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27b44c94-23b4-4a3a-9e0d-3f546c33ceb2" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dd61fef5-d21d-4d44-9d1b-9a9bdb30795c" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">400,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock authorized for issuance with a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a21379b7-38b9-4c53-94a5-5718262f7ef3" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_308a0511-fa31-4e5f-a277-7890aa1f42f8" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value per share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. The holders of Common Stock have voting rights equal to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd5d574b-2bc7-4456-be02-bf52a3dec9d8" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one vote</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of Common Stock held. The holders of Common Stock are entitled to receive dividends when and as declared or paid by the Company&#8217;s board of directors.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_739f6b93-ff55-46a7-9b1b-f9547e8bc2fd" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69%;"/>
        <td style="width:1%;"/>
        <td style="width:13.28%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:12.72%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Preferred Stock issued and outstanding</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afcf9e34-e766-4991-bf31-c35f0696458c" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,767,332</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred Stock Warrants issued and outstanding</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e05630a-559e-489d-88d9-724750142e28" contextRef="C_2522893b-b6a7-4707-8268-f07f26458548" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">540,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ef6fe2c-4bfb-4f4f-97de-be343984db53" contextRef="C_70b83c65-e6f6-4e44-8d27-f4d22fcc2178" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,280,548</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12851e18-4681-4062-95fe-83c27705831f" contextRef="C_e3dac587-c2f1-4635-9403-fcc4c1dc69d4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,036,941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_704b5f2f-959f-43d3-b2a0-fa792f8f2de3" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,588,546</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7bfb11d-1cb1-44f3-a000-7c965c6dfa44" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,036,941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 ATM Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 15, 2021, Catalyst entered into an Equity Distribution Agreement (the &#8220;ATM Agreement&#8221;) with Piper Sandler &amp; Co. (&#8220;Piper Sandler&#8221;) as sales agent, pursuant to which the Company may offer and sell, from time to time,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">through Piper Sandler, shares of the Company&#8217;s Common Stock, par value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf4fe37e-eba2-4205-bc42-8414a216ae1f" contextRef="C_a21fb1ae-dd92-411d-bef0-916436903fc6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, with aggregate gross sales proceeds of up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e94bbc6-0870-4f35-8acc-e4955bb24c09" contextRef="C_3881b1d8-2620-4894-97cf-4c70975b00b9" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through an at-the-market offering program (the &#8220;ATM Program&#8221;). The Company will pay Piper Sandler a commission of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_845c131d-a38d-4363-a8f3-da0426bc2a78" contextRef="C_a21fb1ae-dd92-411d-bef0-916436903fc6" name="gyre:PercentageOfCommissionForSharesSold" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the gross proceeds of any shares sold. The Company also agreed to reimburse Piper Sandler for certain expenses incurred in connection with its services under the ATM Agreement, including up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09550b24-5b4e-4470-ba72-d99b12ac7ced" contextRef="C_3881b1d8-2620-4894-97cf-4c70975b00b9" name="gyre:LegalExpensesIncurred" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for legal expenses in connection with the establishment of the ATM Program. The Company does not currently intend to use this or any other ATM Program prior to April 1, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of shares of common stock under the ATM Program may be made pursuant to the registration statement on Form S-3 (File No. 333-253874), which was declared effective by the SEC on May 3, 2021, and a related prospectus supplement filed with the SEC on October 15, 2021. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19e537cf-257d-41a9-8812-0955acbcdbb5" contextRef="C_83452b0c-e779-4d10-8c25-9d61d6a3d570" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_67d341e0-4254-4de0-8d80-bd8767f5ef86" contextRef="C_606d870c-cbd5-409e-9eb7-2056b6dd9718" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were sold under the ATM Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Net Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under PRC laws and regulations, BC is subject to restrictions on foreign exchange and cross-border cash transfers, including to parent companies and U.S. stockholders. The ability to distribute earnings to the parent companies and U.S. stockholders is also limited. Current PRC regulations permit BC to pay dividends to BJC only out of its accumulated profits as determined in accordance with PRC accounting standards and regulations. Amounts restricted include paid-in capital and the statutory reserves of BC. The aggregate amounts of restricted capital and statutory reserves, which represented the amount of net assets of the relevant subsidiaries not available for distribution were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc9a9e80-5096-4446-957c-7479dd79e90e" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">64.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26558095-c597-4c58-97e2-9f21fbb171cc" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">61.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the above restrictions, parent-only financial statements are presented in Schedule I.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Statutory Reserve</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BC is required to set aside at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_906a3d03-3c12-4a48-a008-ad1b3eeb456a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:StatutoryReserveFund" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of its after-tax profits as the statutory reserve fund until the cumulative amount of the statutory reserve fund reaches </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd979268-81fc-4f66-a7f6-0d3d83e70593" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:CumulativeAmountOfStatutoryReserveFund" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of its registered capital, if any, to fund its statutory reserves, which are not available for distribution as cash dividends. At the Company&#8217;s discretion, the Company may allocate a portion of after-tax profits based on PRC accounting standards to a discretionary reserve fund.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Appropriations to these reserves by BC were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_690c9cf1-bec0-4e32-8cc6-de43bb5287c2" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:AppropriationsToStatutoryReserve" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7a2b98e-7553-4538-8372-29ec8a99489b" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AppropriationsToStatutoryReserve" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> appropriations to these reserves during the year ended December 31, 2023.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62414a84-fa06-4e5c-ab6f-2249fc4857da" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:PreferredStockTextBlock" escape="true" continuedAt="F_62414a84-fa06-4e5c-ab6f-2249fc4857da_1">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">11.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_62414a84-fa06-4e5c-ab6f-2249fc4857da_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_da94008c-f55f-4d04-8dd4-d62952df45c9" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock with par value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ffac470-c959-41dc-9dd1-d994d8255254" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share under its restated certificate of incorporation, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_782172dd-5f9c-4433-b37a-af1898ef1ee1" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">125,040</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares are designated as Convertible Preferred Stock as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, Catalyst issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e4cbaad-38c8-4076-89d5-0cde945348e7" contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,340</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock to GNI in connection with the F351 Asset Acquisition (see Note 1 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Nature of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, immediately following the closing of the Contributions, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3603a962-ec4d-45b0-8ef7-dfb8a1bb1633" contextRef="C_101acaab-645c-4f44-bbd8-62788657a2a3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a2d7e82-4e60-40ae-8a14-ca018792155b" contextRef="C_73e506f1-e7cf-4f6e-aabc-dc8fffc52d12" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Preferred Stock Warrants to GNI under the Private Placement. For additional information, see Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, GNI provided notice to the Company to convert its </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e07d7a5-0ca0-430d-a16d-db8d35555bd0" contextRef="C_86929c87-30bc-44d5-9aa7-59c41f5a2bc4" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock. The conversion became effective on January 22, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Convertible Preferred Stock is classified outside of stockholders&#8217; equity because the shares contain certain redemption features that are not solely within the Company&#8217;s control. The Company does not adjust the carrying value of the Convertible Preferred Stock to its redemption value since the Convertible Preferred Stock is not currently redeemable, and it is not probable that it will become redeemable in the future at any of the balance sheet dates. Subsequent adjustments to the carrying value will be made only when it becomes probable that such redemption will occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Convertible Preferred Stock are entitled to receive dividends equal to, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Company&#8217;s common stock. Except as otherwise required by law, the Convertible Preferred Stock does not have voting rights. However, as long as any shares of Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of Convertible Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to Convertible Preferred Stock or alter or amend the Certificate of Designation that authorized the Convertible Preferred Stock, amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Bylaws of the Company, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Convertible Preferred Stock, (ii) issue further shares of Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Convertible Preferred Stock, or (iii) enter into any agreement with respect to any of the foregoing. Convertible Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4757c84-e1cb-427a-9fef-15e8b85036b8" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_11e755a4-d4c5-476f-a767-5f5f81f3f1dd" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock issued and outstanding. Each share of Convertible Preferred Stock is convertible into approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38aa9671-a511-414a-b97d-bcf3e384a6a8" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">666.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock. As of December 31, 2023, the number of shares of common stock issuable upon conversion of the outstanding shares of Convertible Preferred Stock is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fafb7310-0ad2-4039-93dc-0f52029102cf" contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697" name="gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,767,332</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e19dc7c3-00a1-4a4d-b0c7-87ff0056f607" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Based Compensation</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BC 2021 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2021, the board of directors of BC approved the 2021 Plan to grant options to certain employees and consultants of BC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2021 Plan had a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6077116e-515c-4a58-8965-ceffc46108f6" contextRef="C_e1121837-d055-4a18-8650-a77886d17e34" name="gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Options granted under the 2021 Plan were accounted for as equity awards and subject to a service condition. Upon the Contributions, BC terminated the 2021 Plan and the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BC Options under the 2021 Plan were terminated and replaced with options to purchase Gyre Common Stock granted under the 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, prior to the Contributions, the Board of Directors of BC modified the expiration term of the fully vested BC Options to be extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d0edc5c-af7c-436a-88f7-ec9b52aa2692" contextRef="C_34639a27-12df-4fc6-8cf2-6020aa830e91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 3, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Following this modification, the total incremental stock-based compensation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca5c764c-b273-4c70-99a8-3325c1974635" contextRef="C_34639a27-12df-4fc6-8cf2-6020aa830e91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was immediately recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Omnibus Incentive Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2018, stockholders of Catalyst approved a 2018 Omnibus Incentive Plan, as amended in June 2021 (the &#8220;2018 Omnibus Incentive Plan&#8221;). Each option to purchase shares of Catalyst common stock that was issued and outstanding under the 2018 Omnibus Incentive Plan immediately prior to the Effective Time remains outstanding and unaffected after the Contributions in accordance with its terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Omnibus Incentive Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2023 Omnibus Incentive Plan was approved by Catalyst&#8217;s stockholders in August 2023 and ratified by Gyre&#8217;s Board in October 2023. The 2023 Omnibus Incentive Plan became effective on October 30, 2023. The 2023 Omnibus Incentive Plan permits the Company to deliver up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_857a85ef-5a69-45b9-b812-0eb83b52cf3b" contextRef="C_393225c6-0b98-4833-af11-e65edf2bb418" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,845,496</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock and will automatically increase by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2046a8a7-ea3c-4218-8034-fbb051225c28" contextRef="C_1aa9e6e5-97ba-4f1a-9591-6fe7ce14496b" name="gyre:PercentageOfOutstandingSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of outstanding shares of Common Stock on December 31st of the preceding calendar year and (ii) such smaller number of shares of Common Stock as determined by the Board on the first day of each fiscal year beginning on January 1, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the Contributions, the Company modified the expiration term of the fully vested options originally granted as the BC options to be extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1da8601-e3cc-4cf4-912d-7f3177f59673" contextRef="C_666ada80-f898-47d3-8486-3309e25ceb24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 30, 2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As a result of this modification, the total incremental stock-based compensation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2800122-e5e7-47f1-bc62-27b3231c5138" contextRef="C_666ada80-f898-47d3-8486-3309e25ceb24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was immediately recognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 30, 2023, upon closing of the Contributions, the Gyre Board approved grants to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_985fa3f7-6c68-4bb8-b107-ca44da76d5a4" contextRef="C_1ec943e7-b2ed-4fe5-9f06-a3c06eb3c01a" name="gyre:NumberOfIndividualsApprovedGrantsByBoard" unitRef="U_Individual" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> individuals, to be made on October 31, 2023, of an aggregate of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffeee5e3-0b26-4836-b24c-ada31c656123" contextRef="C_666ada80-f898-47d3-8486-3309e25ceb24" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">820,824</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fully vested stock options in consideration for services rendered in connection with the Contributions transactions. Although the awards were granted for the services in connection with the Contributions, which were direct and incremental costs incurred to complete the reverse asset acquisition, they were issued to Gyre&#8217;s employees and consultants who worked on the Contributions instead of third-parties and therefore, do not qualify as transactions costs of the reverse asset acquisition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e77b05c0-b262-4479-a972-95f9f1e7d7f7" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock option activity considering the conversion of BC Options to Gyre options to purchase shares of Gyre Common Stock upon completion of the GNI USA Contributions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.052%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.031%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.031%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.031%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares Underlying Outstanding Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Remaining Contractual Term (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value (Thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a612877-0a6f-4500-bd9f-5557f60427ee" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,036,941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c85720f-1b31-4554-b04c-d5b56b7e2322" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b314a643-3288-4914-9cba-92b17deca3a1" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f30b82a5-43cb-4c30-b25a-24f6e777bfd6" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,667</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03cd509d-6b98-48fe-be4a-0a2018f84068" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,936</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47cbd9d4-87d6-4dad-89ec-74d594b750d4" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b362e46-b7ac-4f38-9e90-2b0afd331af4" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">435,916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c983cd6-62b5-41e2-9f6a-30d3fbb7bc48" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1778428-63ee-4ec7-910b-5f0d70313d3d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">838,686</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22c1368d-e2f5-43a1-8b0b-60dca29e16d4" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2256ac56-ebd0-4a11-a852-973bbd29d125" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a40ada68-5f89-4776-8803-02893eb1ba6a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.86</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ca429dd-e00a-4748-bfb6-f41da3eba4f4" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,280,548</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0282b888-8f13-4d31-9c99-49eb59cc7d06" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a1e19985-a50f-4194-b370-9719f23c98d7" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c956c7f-6025-49a1-a5c2-ec929316c2ea" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,197</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e8c4534-a4c8-4dec-85a4-29545be0307b" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,262,686</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bb435c8-84ce-4a16-9d4d-ae32b83a2697" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7e5b316f-fe5a-483a-9622-30c47ec59f36" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08b89eb5-2e72-476e-a4a1-7b9a75197e38" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,433</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of options granted during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5d3e63a-f41f-4b78-a633-662f12d36197" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b14bc508-884d-4ea8-8c5c-7ad94dd4aa9d" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options were granted during the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of options exercised during the year ended December 31, 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8af02b31-a3d9-41ae-aacd-f9d122c33ce6" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e9b0bb1-6cbc-419d-a9ef-6f03ec77ff70" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options were exercised during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation Assumptions</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited relevant historical data, the Company estimated its volatility considering a number of factors, including the use of the volatility of comparable public companies. The expected term of options granted under the 2023 Omnibus Incentive Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited relevant history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8af29623-3925-4f35-b64b-69314473b960" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of employee stock options granted was estimated using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.64%;"/>
        <td style="width:4.52%;"/>
        <td style="width:1%;"/>
        <td style="width:12.84%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility (%)</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4faba6c3-77a2-4813-98a7-d0d2d4a5cea1" contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_181177b5-940a-4d67-b354-f0713c6f08ee" contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.30</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate (%)</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3561b36-815e-4715-93ab-e5ea17051061" contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa8c7a04-b6df-42f4-a67c-307ba9e6ee9c" contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.77</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected option life (in years)</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2dd224dd-adc3-48c5-9c2f-5f39f31b777c" contextRef="C_1d2fc6f7-e605-4510-8d2b-4151172e8647" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_b2d30602-5df3-494e-93a6-62b5fc2f4705" contextRef="C_4e5a19f3-a118-4af6-bfc3-2289de865726" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.8</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield (%)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average share price of the Company (USD per share)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bd3974e-9bdc-4fb5-b876-726f7c41b1ce" contextRef="C_ed00f272-5d55-43d0-8d10-9b8734e290e5" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50425f33-588c-41cf-a3b7-22cd4e1e8993" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total stock-based compensation recognized was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.634%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1%;"/>
        <td style="width:12.963000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9e1e328-74a1-43c5-ae48-64d0da6aac7e" contextRef="C_8dd3a581-c90a-4509-af97-5acd79c8a8e3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cab8f2f-8e13-4e91-b5b4-cdb256d44252" contextRef="C_5a775378-ab64-439b-aa16-34b026d36a54" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e23912a-7244-4dcc-9c55-e602f5d1eece" contextRef="C_c1a2d74b-7d0b-4b38-8998-7a1161571cf0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad418c8f-6682-4b4b-ad5b-67925cc50e63" contextRef="C_4ba38967-8a4f-4c72-a845-ec882f409155" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,643</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0205935f-ad70-4c3c-9449-5c68a14cf31b" contextRef="C_146bbfb7-b649-4239-b32d-22b491e71629" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61c327d9-8464-4520-b5ab-1e79e4fef45e" contextRef="C_e03b0455-2388-408c-baed-fbbcb9bb45ff" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,301</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53f6d208-03aa-4ffd-bd6c-7031acfe253c" contextRef="C_b9586f61-cf2b-4213-abab-d860b5741c19" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,404</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcd339a4-0754-4fee-ad96-1be576c123c9" contextRef="C_290b25a7-e794-4501-9b27-3ec91a3fd8f8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,173</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d48d710a-9748-4506-8273-be0fd91d4de1" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b666735-e159-4a18-81aa-563bc393a5fd" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,366</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had an unrecognized stock-based compensation expense of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbaae2ed-12cf-4eb1-b173-395b8ae6607b" contextRef="C_ed00f272-5d55-43d0-8d10-9b8734e290e5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9efb40d-3c87-4dcc-801d-026655f7fff8" contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.87</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bb30de8-76d6-4982-8c41-672867add127" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CommitmentsDisclosureTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">13.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Commitments and Contingencies</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Value Rights Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each CVR under the CVR Agreement (see Note 1 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Nature of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) entitles the holder to receive (i) certain cash payments from the net proceeds related to the disposition of Catalyst&#8217;s legacy assets, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa8dc07-573d-4ecd-b0b2-f1439d8eb60a" contextRef="C_909bcf41-2baf-4ab5-92c1-98ec48a3f1a7" name="gyre:PercentageOfExcessCashOnDispositionsNet" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by the Company in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e572c8fa-3adb-4c4f-b3ca-718e7c1b2075" contextRef="C_909bcf41-2baf-4ab5-92c1-98ec48a3f1a7" name="gyre:ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of the closing date of the transactions under the Business Combination Agreement, (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef9e02a9-fa21-4720-97e0-57789946f2c6" contextRef="C_37aab4d6-0074-4bef-bcfc-1004484dd02e" name="gyre:PercentageOfAmountReceivedOnAgreement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the amount actually received by the Company, net of expenses, pursuant to an asset purchase agreement Catalyst entered into with Vertex Pharmaceuticals Inc. (&#8220;Vertex&#8221;) in May 2022 and (iv) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af03c0db-0d4c-42d9-8e9a-97e6b9715cf4" contextRef="C_909bcf41-2baf-4ab5-92c1-98ec48a3f1a7" name="gyre:PercentageOfExcessPreapprovedCosts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the excess amount, by which the preapproved costs to manage, negotiate, settle and finalize certain third party claims exceed the costs actually incurred with respect to such claims. The CVRs are not transferable, except in certain limited circumstances as provided for in the CVR Agreement, will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August, 2023, Catalyst fully settled the CVR payments related to the Vertex asset purchase agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, Catalyst sold its legacy rare bleeding disorder program to GCBP. As a result, the Company distributed the net cash proceeds received from the GCBP asset sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87762217-25b2-4d29-a5b0-943b58e0e4e7" contextRef="C_9308c880-d262-4f12-b2e3-dd30805711c3" name="gyre:DistributionFromAssetSaleProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the CVR Holders as well as recorded a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_206bd283-15bf-4979-9e0f-51bd04e3350f" contextRef="C_9c0870ec-cd18-4ecc-826e-33d440e66dab" name="gyre:ContingentValueRightsDerivativeLiabilityNonCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> long-term CVR derivative liability for the future distribution of the hold-back amount to be received in May 2025. As of December 31, 2023, the carrying value of the CVR derivative liability was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eb92baf-3256-4764-8cac-2a9e19bbdf5e" contextRef="C_af914aeb-56e2-4a0a-bc92-2b10d6ce2fdf" name="gyre:CVRDerivativeLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the consolidated balance sheet. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for additional information regarding the CVR derivative liability and GCBP asset sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 30, 2023, pursuant to the CVR Agreement, the Company recorded a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9389008-cc2c-43bf-b4bd-6ae83095f16d" contextRef="C_bc1f552a-2533-4ff9-b66b-78200f9c38bd" name="gyre:ContributionsClosingPayableAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CVR excess closing cash payable upon closing of the Contributions, which is anticipated to be distributed among the CVR Holders and remained outstanding as of December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Litigation and Legal Matters</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company&#8217;s consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, separate stockholders of Catalyst filed lawsuits in the Delaware Chancery Court, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bushansky v. Catalyst Biosciences, Inc., et al </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Scott v. Catalyst Biosciences, Inc., et al., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">alleging Catalyst violated its fiduciary duties under Delaware Law by failing to disclose purportedly material information regarding the proposed Business Combination Agreement. In February 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4, both lawsuits were dismissed with prejudice and the Company reimbursed the stockholders for their legal and other expenses related to the litigation in the aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69489664-4c04-4c0f-8f61-2bce6d5ebc59" contextRef="C_73a0ea9a-142b-4c0d-8823-cc0148cb7f2d" name="us-gaap:LitigationSettlementExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company recorded a litigation settlement liability in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cac43ac-8b8c-4f8b-b4ac-2168f815af80" contextRef="C_8a895bc1-6430-4cd0-8079-aca770c79f44" name="us-gaap:LitigationReserve" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in October 2023 when it became probable and estimable, which was included in accrued expenses and other current liabilities on the consolidated balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purchasing Commitments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s commitments related to purchase of property and equipment contracted but not yet reflected in the consolidated financial statements were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aabcbbb4-785a-466d-90a0-76b3c2fcc71c" contextRef="C_b1e216e8-da62-4adc-be21-79756314d405" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and were expected to be incurred within one year.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F351</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, BC entered into an intellectual property (&#8220;IP&#8221;) transfer agreement (the &#8220;F351 Transfer Agreement&#8221;) with GNI Japan and certain of its wholly owned subsidiaries (the &#8220;GNI Group&#8221;). According to the F351 Transfer Agreement, BC acquired the exclusive right to use Hydronidone IP rights in mainland China and the right of first offer for the global IP rights (the &#8220;F351 IP Rights&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the F351 Transfer Agreement, in exchange for the F351 IP Rights, BC is obligated to pay GNI Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e66584c-9e89-4a95-8293-6320d72ab3da" contextRef="C_022304e8-e2d8-4bf5-929c-5ef87abda6aa" name="gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon submission of the F351 New Drug Application (the &#8220;NDA&#8221;) to Center for Drug Evaluation of the National Medical Products Administration (the &#8220;NMPA&#8221;) of the PRC, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec1072c5-68b5-46da-94c4-1d3751bd4eae" contextRef="C_f319e2ec-8474-4f02-8b68-38c9e4ad3e70" name="gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the NDA passes the NMPA&#8217;s Center for Food and Drug Review and Inspection&#8217;s on-site registration inspection for the F351 product, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c78d431-ec8c-48e5-9ebc-e22ea1f3b1c3" contextRef="C_5ea22d62-a406-408f-8236-ff3e0f11ad07" name="gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon NMPA&#8217;s approval of the NDA.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Programs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the F351 program, as of December 31, 2023, the Company has committed to allocate </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4415f98-7bbc-424e-b034-b08b9496a555" contextRef="C_0d0d85f9-9db6-4218-b101-c8578a8373cd" name="gyre:CommittedToAllocate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> toward future research and development activities for various programs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnifications</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, the Company may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.</span></p></ix:nonNumeric></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2700150-4b2c-4d3d-9345-92d214577336" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">14.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Income Taxes</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Company completed its acquisition of the controlling interest in BC. As a result of the Contributions, the Company directly or indirectly owned multiple controlled foreign corporations (&#8220;CFCs&#8221;) for US tax purposes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_375afa3e-bf5e-4488-8c92-f9bdb9efafe6" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the Company&#8217;s provision for income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consist of the following (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.094%;"/>
        <td style="width:1%;"/>
        <td style="width:13.123000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.66%;"/>
        <td style="width:1%;"/>
        <td style="width:13.123000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current income tax provision:</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3d958b3-e6a7-4e6b-abad-95af4eab0fc7" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73f5ec4a-9240-4194-b0e2-e499e99a928a" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0973cd5f-7343-4af8-9386-a83119d57b40" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,343</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76db4fc2-3a2f-4577-ad9f-82cf1426e4ea" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,987</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current income tax provision</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_520ef97e-e717-4245-b940-2445f24dba44" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,349</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99afaaf6-754f-4d43-862c-60694c30ddc8" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,988</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred income tax provision:</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f106cdb-6bf8-40ba-ae51-bc5243d50681" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdf9478b-238c-4b74-98cd-e160477def9f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">834</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_746e6a1d-4830-4289-8797-a40695073de9" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">799</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred income tax provision</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7358bbd6-e374-45c2-bbbd-5d88eda11495" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">834</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23289e19-441c-4efe-9364-826e87c33840" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">890</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax provision</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5c78834-ab87-4ae8-8771-65c5615e7168" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,515</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ffbfe76-175c-4a8e-aa63-a13f191ee1c3" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,098</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db248905-b589-4a59-afb3-80853e22d750" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.066%;"/>
        <td style="width:15.137%;"/>
        <td style="width:1.66%;"/>
        <td style="width:15.137%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7936ebd8-d836-497f-9d49-f2a4a80b517d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc480d24-9f77-4875-aada-d2540da4cb7f" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rate difference due to different jurisdiction</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd183a92-d0ac-4cfb-b96b-c0eb1d36091b" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">2.43</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9234406b-6b77-4536-b7b4-344c01dd2a1f" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferential income tax rate for HNTE</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acccba30-c678-4bba-b196-8e500a295f54" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.19</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd5b9deb-ead3-485c-8b2f-df75d93e7d9b" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">10.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible expense &#8211; Operating</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cad76f50-5b5d-47ad-bcca-c89823b1e6f1" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">6.28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_211b8846-2aa6-47f8-a054-996c993137d6" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">33.06</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible expense &#8211; One-time expense related to the Contributions</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e462696-18d9-480a-9db8-a04db0cbf2c2" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">22.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88532a00-fa0f-4e20-a862-59986ee7d8c4" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D Super-deduction</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_972de8f9-7dc4-4970-8137-9fb1d33ccaea" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">1.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63a83eed-c828-408c-90ed-1eaba15e7670" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">12.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance change</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_238ba441-b90d-4d73-9c2d-6bf847ea3bb2" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">4.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e57d876c-c112-460d-aa41-686ed170b568" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESOP</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dc83638-5540-47ae-96d3-98f9cbdab6cc" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32858147-bff2-4d18-a737-6ad01bcf17c7" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.81</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f107759-df54-4751-9355-263c30adde67" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec23ad81-3814-4269-b5b1-9ecf93f34887" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">2.52</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02011ce9-5aa0-4abe-b73a-368590b7ea3c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">10.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_098d8b39-cf93-457a-8115-49c7aeaa71ec" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">54.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_985fb2db-c41e-43d2-9f00-de2aa54fad18" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.566%;"/>
        <td style="width:1%;"/>
        <td style="width:13.536%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:12.889%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34a6e4d8-3b4e-4c5a-9ff4-6a88987ebad0" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,811</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_420a29cd-a126-4e99-93d7-35ecf87c886d" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f3a00a7-d0c6-4fb1-9f41-b1bb85e02b7a" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_062433ca-4fcf-4f94-8678-fd357ad09f7c" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,669</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other equity investments</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b02192e-d0b6-45e5-a2f2-1c8a6ebad7bf" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carry forwards</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3d27a20-42bb-44e9-a102-1e7c01643bea" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,463</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed and intangible assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df6a3523-c172-4d38-b282-50a887b7e02c" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:DeferredTaxAssetsFixedAssetsAndIntangibles" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,332</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4de3dcc-ae12-4bee-abd4-bae1e0fb9c27" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:DeferredTaxAssetsFixedAssetsAndIntangibles" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,428</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impact from foreign corporations</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b39eb8ed-eb2d-4d0d-9635-63206f8a9f27" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:DeferredTaxAssetsImpactFromForeignCorporations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,590</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized transaction costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86b077cb-971a-4f74-b47f-ee0b55fdf461" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:DeferredTaxAssetsCapitalizedTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">658</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_969b261f-69f1-494f-b60f-bd290c7efe83" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="gyre:DeferredTaxAssetsCapitalizedTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">414</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1db75a87-511b-4bcd-bf8b-dbad8bcc3683" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income tax assets before valuation allowance</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43ca4997-a02e-4e18-a139-b27918418608" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,660</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77150058-8062-4c3b-9322-52525e77cf61" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,175</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability &#8211; ROU assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82dc79f9-c176-41e9-b956-1219910b8d95" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="gyre:DeferredTaxLiabilityRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability &#8211; Fixed assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a73e8df2-e364-4415-8501-97022a25e341" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6867e23d-ebc7-4c29-b102-2566982d0f63" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20d390ba-5f15-457e-8739-36343e8381c1" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,773</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fef3479-8326-468a-933c-5d5ed15b94d0" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,695</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d46334af-0d75-4c97-aa21-cbc1b5f72c7a" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,081</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3469c647-6216-42db-8466-775037f8a38a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SummaryOfValuationAllowanceTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The movements of the valuation allowance are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.566%;"/>
        <td style="width:1%;"/>
        <td style="width:13.536%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:12.889%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes of valuation allowances</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df89721b-e3c5-432d-afc4-dee6b01b8534" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ChangesOfValuationAllowances" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">63,773</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_296948ff-df50-4969-a594-7219a87beb23" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,773</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the available objective evidence on December 31, 2023, the Company does not believe it is more likely than not that its net deferred tax assets will be realizable for US tax purposes. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets on December 31, 2023 for US tax purposes.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, after consideration of certain limitations (see below), the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_647b54fd-2664-44ed-b438-0d5ec1cd4917" contextRef="C_6948abd4-d444-43bb-a3ca-742236671306" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">193.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million federal and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_033a7557-9c1c-487c-b61a-868ce7b77445" contextRef="C_c3822144-76cb-4af5-a440-f0966d1d926a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e381ba56-b1b6-4a64-880d-9f8ec2cffe43" contextRef="C_8d096fdf-4e68-4c03-86ed-d1473a0c1c55" name="gyre:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for federal and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0316bee5-afa7-4575-8e44-13ed710888cd" contextRef="C_66c1df00-e0da-4f0b-9563-bfed0377c5ca" name="gyre:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2034</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for state tax purposes. The federal net operating loss carryforward includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6090ee18-2a46-446c-b41f-232e5d65279f" contextRef="C_6948abd4-d444-43bb-a3ca-742236671306" name="gyre:OperatingLossCarryforwardsWithIndefiniteLife" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">191.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that have an indefinite life.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a1cd898-2c51-4132-b5ee-c513fc3e9e60" contextRef="C_6948abd4-d444-43bb-a3ca-742236671306" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">8,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_264ad8bd-0e69-40b3-ba78-201f1b4540f8" contextRef="C_c3822144-76cb-4af5-a440-f0966d1d926a" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for state. If unused, the federal credit will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f5eb594-0eec-4a90-a75d-6a6dbb0ee1f6" contextRef="C_8d096fdf-4e68-4c03-86ed-d1473a0c1c55" name="gyre:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the state tax credit does not expire.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company&#8217;s stock immediately before such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes under Section 382 occurred on December 31, 2007, August 20, 2015, April 13, 2017, February 15, 2018, February 18, 2020, and December 26, 2022. Approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27046091-715e-43a5-b80e-8ec8a8881bb6" contextRef="C_04950170-0636-4a37-9b11-630a8bead37c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">156.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_651e6557-4536-430c-952b-a429a72a331f" contextRef="C_c2c5e195-1c21-41fa-be14-653b6ec43f7a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">75.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the NOLs will expire unutilized for federal and California state income tax purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd5f9218-9e14-4a37-a245-eb9c4b96e765" contextRef="C_6948abd4-d444-43bb-a3ca-742236671306" name="gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards" unitRef="U_USD" scale="6" decimals="-5">32.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_082cfb1b-faf0-4349-be38-02625a42fd7a" contextRef="C_c2c5e195-1c21-41fa-be14-653b6ec43f7a" name="gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards" unitRef="U_USD" scale="6" decimals="-6">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for federal and California state income tax purposes, respectively, through the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the federal R&amp;D credits could expire unutilized, whereas none of the California R&amp;D credits are subject to expiration. Approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f6cc5a5-8429-4134-bb87-a4e054e64499" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" unitRef="U_USD" scale="6" decimals="-5">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of gross federal R&amp;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and credit carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 29, 2020, the California Governor signed Assembly Bill 85 (&#8220;A.B. 85&#8221;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_667a80b2-8abd-4a29-a777-b7220a9f11a3" contextRef="C_5d5d2670-fd6a-4e3f-894d-c0347308d6f6" name="gyre:MaximumAmountOfTaxOffsetPerYear" unitRef="U_USD" scale="6" decimals="-6">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of tax per year. Generally, A.B. 85 suspends the use of California NOLs for taxable years 2021, 2022, and 2023 for taxpayers with taxable income of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5abafe2-0176-4d93-a89a-c59d449b7a87" contextRef="C_4cb6c663-f4e1-4031-ab93-fd048348ccfa" name="gyre:RequiredMinimumTaxableIncome" unitRef="U_USD" scale="6" decimals="-6">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million or more. Since the Company is not expected to generate California source taxable income of more than $1 million, no material impact is anticipated at this time.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Uncertainty in Income Taxes</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08102d12-27c2-458f-93f5-c2c44eb67474" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of unrecognized tax benefits as of December 31, 2023. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28500997-30cf-4776-aa93-f7aecaccbef3" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.82%;"/>
        <td style="width:1%;"/>
        <td style="width:16.18%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning Balance on January 1, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef427ae9-67c0-4ebc-baf0-802fa38a522a" contextRef="C_b7c2a125-5bff-41a6-a0df-4926d0dda919" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b9c13e1-6597-4d8d-ac04-d790286b4dd6" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b73f60a-bad2-489a-96c8-c18ee7ddd4be" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending Balance on December 31, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa2583ab-18e7-4da2-a40b-d7f7445178fd" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase as a result of the GNI USA Contributions on October 30, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3d3391c-8bcc-41e3-8819-77ad99bfe40d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,833</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6148c2e-48d5-4845-941c-e6a61633f777" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cd472fc-b8ad-4ffc-aed5-fefe35c1e433" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending Balance on December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88ba73ba-25ec-4b39-95e3-938b28298c0f" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,833</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#8217;s consolidated statements of operations. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6f5f1e2-31fc-4f3b-87a5-689866f1944b" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8108e0d3-72b4-447b-b073-62305fa99818" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any tax-related penalties or interest in its consolidated financial statements.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files income tax returns in the United States federal, California, and Florida for tax year 2023. The Company filed an initial return in 2022 in Florida and final returns in 2021 in Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd61d591-1f7b-4ded-8bf4-ca785fc4f16d" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bd3673cf-d735-4d97-8e85-e1af5d3d50f3" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> uncertain tax positions which affected its financial position as its results of operations or its cash flow, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">APB 23</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, a taxable outside basis difference associated with a foreign subsidiary may not be recognized if the indefinite reversal criterion of ASC paragraph 740-30-25-17 (APB Opinion No. 23, Accounting for Income Taxes &#8211; Special Areas (&#8220;APB 23&#8221;)) is met. A deferred tax liability is recognized when an entity no longer meets the indefinite reversal criterion. ASC paragraph 740-30-25-17 provides a presumption that all undistributed earnings will be transferred to the parent entity may be overcome, and no income taxes shall be accrued by the parent entity, if sufficient evidence shows that the subsidiary has invested or will invest the undistributed earnings indefinitely or that the earnings will be remitted in a tax-free liquidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not have a plan of repatriation of earnings from non-US subsidiaries to the Company. However, to the extent the Company will not permanently reinvest in its PRC business, a DTL of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1d74609-0723-4724-a861-6d2d9fae3b8e" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 related to PRC withholding taxes on repatriation of BC&#8217;s earnings (i.e., the Company&#8217;s primary operating subsidiary in the PRC) would need to be recorded.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80ec23a7-7346-4f5c-8fec-2b78540690c7" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">15.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Related Party Transactions</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F351 Transfer Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the F351 Transfer Agreement (see Note 13), as part of the consideration, BC paid </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0c7d2ae-10ab-43cf-81ce-78cde357ec2d" contextRef="C_d022cce0-2b7e-4ac2-a0b1-f765616cb924" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_479d0979-707e-4991-8584-5de43e838fed" contextRef="C_efb1e330-1a01-4f0a-b587-773cd7fdf361" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to GNI during the years ended December 31, 2021 and December 31, 2020, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development with GNI</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b15b4f16-be01-4c8a-9756-577a5ef0d0a5" contextRef="C_84d9b48e-9b34-4794-916b-eecce30677e3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research and development fees were paid to GNI during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. During the year ended December 31, 2022, the Company paid </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84f16f07-2ae0-4ce9-9c5f-335470c2113a" contextRef="C_e92cc5b3-03a9-49de-86c5-40c3077730e8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as research and development fees to GNI.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96eec6bf-2085-4fa1-bf65-f7c91f3f5e5c" contextRef="C_aaad5e91-28da-4383-82fc-a19aee9f956d" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_121336e1-44fb-4fca-b640-a1417746d6dd" contextRef="C_b1a6816f-f707-4fb2-a96b-db95ed45787d" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related parties payable due to GNI, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other receivables from GNI</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ca9eb1f-08f1-4270-b9be-1bc1656da44b" contextRef="C_56fd673d-dfd1-4bf2-843c-a213f1c28815" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in other receivables from GNI, of which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bea5ce5e-4cc1-4c34-83c3-b2d26f160ef4" contextRef="C_96f625f2-102b-4612-9ae5-c9bf247174b2" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was from CPI&#8217;s restructuring transaction (see Note 8) and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2cc8a18-04ac-4cc7-997b-18227a852705" contextRef="C_0697f749-db8f-4fa7-9af3-6e4ada46d83a" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was from Gyre&#8217;s cost sharing with GNI. No amounts were due from GNI as of December 31, 2022.</span></p></ix:nonNumeric></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dafb52ce-40e6-4de0-8049-5d99718e572f" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EarningsPerShareTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">16.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EPS</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The dilutive effect of outstanding stock options and warrants is calculated using the treasury stock method. Stock options and warrants are anti-dilutive and excluded from the diluted net income per share attributable to common stock calculation if the exercise price exceeds the average market price of the common shares.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30a0d9c3-7062-4b95-9616-084b11690a44" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.525%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:13.899000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:12.546%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_641537d9-e700-4f64-8302-9056a4dda64c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,480</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e6ffd03-2742-47b8-a8da-f76c30bc3456" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,314</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55726261-551a-4130-a189-a6d9b2d42d3b" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_563bff32-001b-4de4-9bc6-1ed120f8d749" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,012</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income attributable to common stockholders - basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_354f1755-4501-44ba-8d0a-a10d07b3242a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6694b115-2c15-4862-bca3-e11e967fe627" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_583b90ad-762a-4ff8-90c0-d3a7f4a08d11" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0fe52125-cdb0-4a39-adb8-8304354ae79f" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,302</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic common shares outstanding:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8351c008-1471-49d8-9d0d-cd6c632bd93c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91adf2b4-3290-4b29-9395-1f7a6e94aef8" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">63,588,119</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_490cc304-4cce-4b3d-94d7-8cbcea91fd25" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51d72498-32ff-4f2a-a5c6-94724be1ebc8" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">63,588,119</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">            </span></p></td>
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive potential common shares:</span></p></td>
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f23f4c8a-dfc1-4bc8-90a4-f872b7133f05" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,098,287</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f35d63a0-0803-4c92-944a-68bb2b145aa9" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,831,675</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e70ef2b-521e-44b2-9b15-2ba833d49906" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">75,686,406</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income per share attributable to common stockholders:</span></p></td>
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0be9058-c27e-4ce9-8b17-bd78b8c593ce" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_655c85eb-a149-4a9f-939e-0d24e0f5b417" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8699b949-5cb1-4e8f-8989-6e1d59812245" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a22d93fd-077a-424b-ae13-c828ddbd16ca" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d662467-1ae6-45bd-af9f-a604d8765fc5" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:83%;"/>
        <td style="width:1.34%;"/>
        <td style="width:1%;"/>
        <td style="width:12.66%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17e07694-5c94-4ed8-9d6d-e23369807516" contextRef="C_e0557a3d-1a6e-4667-8a75-0565cef63396" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,280,548</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Preferred stock (as converted)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31a25fe9-d50d-4bd0-829b-fa7464874979" contextRef="C_8324e115-6f67-4a65-b0da-48617f324eac" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,767,332</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred Stock Warrants (as converted)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48733fa9-714b-470e-a23d-76f87476fe4b" contextRef="C_aae4d106-8ca8-4cfc-ac19-e79420fdc9ff" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">540,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8c7797a-146b-4de3-acfc-2f51c9c78380" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,588,546</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4103ba35-464d-4ec5-813b-a7313f17677c" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:DefinedBenefitPlanTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">17.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Employee Benefit Plans</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mainland China Contribution Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to relevant PRC regulations, the Company is required to make contributions to various defined contribution plans organized by municipal and provincial PRC governments. The contribution for each employee is based on a percentage of the employee&#8217;s current compensation as required by the local government. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme. The total</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contributions for such employee benefits were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc1105a4-b736-4a83-8905-7588211ed6f3" contextRef="C_a1eecc05-fb63-484b-87b6-6c579da56492" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_124dc36d-1f69-4974-a90b-85a549f993c7" contextRef="C_89b8c4e5-1d62-4004-b838-6c1f712ee7f9" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023, and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Defined-Contribution Savings Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., the Company maintains a defined-contribution savings plan pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended. The plan is available to employees who meet the minimum age and length of service requirements. The contributions made during the year ended December 31, 2023 were immaterial.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ca2beb7-d3a5-496f-bf3c-d111d79796dc" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">18.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Segment Information</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is a consolidated entity comprised of two distinct operating segments: BC and Gyre after the Contributions. The Company&#8217;s reportable segments are based upon internal organizational structure, the manner in which operations are managed, the criteria used by CODM to evaluate segment performance the availability of separate financial information, and overall materiality considerations. All Gyre&#8217;s operations are within the U.S., while all of BC&#8217;s operations are in mainland China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BC</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BC has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. BC&#8217;s product revenues are mainly generated from the sale of ETUARY and certain generic drugs. BC primarily sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. BC also generates revenue from license agreements. However, the license agreements did not generate any revenue for the year ended December 31, 2023 and an immaterial amount for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gyre</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of NASH-associated liver fibrosis in the United States. Other than the IP associated with F351 in the U.S., Gyre has no other product candidates since the Company sold all of its legacy IP assets prior to the closing of the Contributions. Subsequent to the closing of the Contributions, Gyre has not generated any revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_514e34d6-f6c7-428c-8fc4-1e88626eec8e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Segment information for the years ended December 31, 2023 and 2022 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.218%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9582b20-f8cf-4ce1-a708-5d325b761039" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71526b9c-c630-46b8-b984-164dec02fddd" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11fc7b82-5283-493b-a2da-8ef469e806ec" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,636</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32c82a64-862b-41c6-a984-167967cae0dc" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,636</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross profit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36816463-8482-4222-9c0a-47da9473ccb1" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,814</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b91edcc3-6dd6-465e-8434-4ed3f7077737" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,814</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_695dad36-7abf-4192-978f-90d20ea0a584" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,159</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ecca720-648f-4057-94b3-89a93577a827" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,159</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37cd8cd9-2d2f-4a87-96d5-2d3736352a22" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,698</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0d3281e-f2fd-4aa1-be7b-8565c349b25b" contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f080956-bd35-43be-9a4e-5bea069b535e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,780</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bdbb22d-bb08-43d6-871c-af45a27c927e" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,872</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a75f3a99-0460-4980-89c0-d3cf6c7b1106" contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,214</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9daf5d4-b859-4b26-8105-a443654f1988" contextRef="C_5723249a-64b4-471a-be67-452050b084d7" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">576</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2d331b4-90ef-4a8a-aea5-6464a1bf9a7e" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,662</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired in-process research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a38f9a41-1ffe-4df6-bf7c-46c0a66b202f" contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323" name="gyre:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5078aee-c1ac-4e97-8485-218a2a8367d4" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="gyre:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54bd4cb4-14cc-4d9b-8785-f18793fb39d5" contextRef="C_5723249a-64b4-471a-be67-452050b084d7" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(2)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4370fc66-48e8-4b82-a724-73c0e831ce09" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fd353c1-cc5e-48e9-b52b-a1d29b1e08cf" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff61735-b64d-4310-83de-d852fe0c11a2" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">628</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5173f9ec-ff72-468a-b843-c9e0c170f687" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,357</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41af059c-5380-4ff9-9937-6f3c26185981" contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fde64278-7efb-4065-9cea-627b4f77dbcf" contextRef="C_5723249a-64b4-471a-be67-452050b084d7" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,287</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5a8cf5b-3cde-4f20-8a3a-2d9e1fb4817a" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,044</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income (Loss) from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28658f18-4e9c-4e2b-8a55-2379aa2c2002" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,457</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b70fa1c-7ecd-41c6-b9d7-8c5f8049670f" contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88,400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb87f2cc-5a7f-4b83-9447-85e7a166ee45" contextRef="C_5723249a-64b4-471a-be67-452050b084d7" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,287</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4628582-967b-4e06-aaad-47c59124bb0d" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,230</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2fcd47e-bf0b-48d1-bb3b-e5701f793fd9" contextRef="C_6c61ab08-e1b5-45d8-af46-68e14fd32dfc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_376526ea-55dc-4033-a690-f527f5e19de2" contextRef="C_8dd3a581-c90a-4509-af97-5acd79c8a8e3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a40ebce-f8be-420f-a106-e83e650a49cf" contextRef="C_b337b32c-b922-4667-afd1-a840403dbad9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc603724-a071-4f49-b976-7d862c266eaf" contextRef="C_c1a2d74b-7d0b-4b38-8998-7a1161571cf0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a638a986-c693-4d4b-9fc3-228d6f0b1f60" contextRef="C_0cfa6500-f12c-4cdd-861c-f10bc7dc5d69" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfb9e6d9-1260-46e8-9230-e13745021523" contextRef="C_146bbfb7-b649-4239-b32d-22b491e71629" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccb53fcd-5fc3-4dfa-9fb2-3f0e434e159b" contextRef="C_2687f77f-ab25-40af-b6b8-1e653689478f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3be2f845-981e-4248-b7b9-3f1a2a1dccc2" contextRef="C_79108d3a-0a88-4ff0-8ed1-61cd65b0cc7c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,488</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e78196a6-1062-4c60-a7bb-51143dc1d0af" contextRef="C_b9586f61-cf2b-4213-abab-d860b5741c19" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,404</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ff69d6a-03b7-4fee-a19c-fd1b842e1412" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81b8d301-e88b-4394-b460-1f2f448e53f4" contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,488</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1ab6415-76b0-43e7-8c07-d3eca5547ade" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><ix:footnote id="FNT_f44b5c23-aed9-4b04-8c26-9440275a700b" xml:lang="en-US"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(1) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e799c59c-9c11-4b89-b896-34a418a0e864" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:LegalFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents legal expense recorded in CPI during the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:footnote><ix:footnote id="FNT_228a2060-914b-44e0-8e10-3c03acdbcf57" xml:lang="en-US"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(2) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8168a82-d2b2-4f75-a1cc-e1ec6c33cb02" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents divestiture losses. See Note 8 for details.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.67%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:9.038%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:9.038%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:9.038%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:9.218%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31f0443f-913b-49a5-8eb3-160e654e8420" contextRef="C_7863a107-8f27-4048-916f-de1fd40aebc1" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,761</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_687f351c-b83d-4e48-adf3-8e8931f39bed" contextRef="C_f6d92b17-1eca-4702-9b3c-788a030b8de5" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,865</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0cf9580-6dc8-4eff-8f79-a5545b350a7d" contextRef="C_0222eacd-1eff-471f-9812-cbf6e10d75b5" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ff5e574-c7b3-415c-88be-45d4fb1cd664" contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,539</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.67%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:9.038%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:9.038%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:9.038%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:1%;"/>
         <td style="width:9.218%;"/>
         <td style="width:1%;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fc9090a-8ed2-4936-b758-ffcd794d4036" contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,517</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67a992b7-33e3-4dc3-86e3-5bc83049d655" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,517</ix:nonFraction></span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:footnote><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.218%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fda0ed8b-19fe-4ea3-88cc-61097d95cbcd" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,290</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aee77c88-678b-46d3-98c6-70075643ab9a" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,290</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4bbce5a-1f95-4a28-8c6d-7bc7209e9d24" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45cc3bcf-74e8-4bd4-9e6c-8196b58737cd" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross profit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30dbe165-8fa1-45d2-a08e-092cd828b059" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,497</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05ba6c91-7048-4e9b-872e-e1d62f38a73d" contextRef="C_54337f80-089d-408e-99d9-524dadb15757" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d4b5e68-3829-43b6-84e2-8b9cdbca144e" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,497</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1cdaac7-9c0b-4942-8be0-eb2983edbf04" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,238</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5e06a22-81f6-4b8e-bdbd-23f6ebcee170" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,238</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75565a07-a948-4610-956c-6125586d3922" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,686</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fc4f514-7105-4983-8980-855461169a77" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,686</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b203f7f-e2c7-4c13-a90c-e71881d861dd" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,240</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1c6a69d-fc4c-4151-addc-713c9b9935c2" contextRef="C_54337f80-089d-408e-99d9-524dadb15757" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(3)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1092d47-3043-4d79-ae8a-9be86f1c6d54" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,370</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bdfa83b-4570-426d-8c0d-37f91a2f56ea" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,164</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5916ea6-c202-40a2-b314-328e45cf4f4c" contextRef="C_54337f80-089d-408e-99d9-524dadb15757" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e425d1ed-de3d-4e2e-b975-4e9672559a12" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5df3003-44b7-4485-9913-94177e2d8c53" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,333</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a272290-4bb7-4642-acdb-4d9b2f8d6d90" contextRef="C_54337f80-089d-408e-99d9-524dadb15757" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f60d804-0bef-4ed7-83c5-80e1c06c8acd" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36d59262-a9b3-4766-9763-15a1206e0d44" contextRef="C_ae49cec5-9016-4f5f-8d21-5329e230331a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97de532b-faec-4885-84e7-0d44da25cd06" contextRef="C_5a775378-ab64-439b-aa16-34b026d36a54" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccf3e255-3bd2-4caf-b060-1b70ca843e49" contextRef="C_9ea7ec22-706f-4637-98fe-08b2490d6c90" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,643</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d86009d9-4fd7-4acb-b549-720ec56e328f" contextRef="C_4ba38967-8a4f-4c72-a845-ec882f409155" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,643</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_396e31ca-26d5-406d-b409-c6f9b96a2806" contextRef="C_1a998271-ce77-46b7-81d2-6b2303da832d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,301</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08c6a1c8-8e83-4242-8be4-8644348d7e53" contextRef="C_e03b0455-2388-408c-baed-fbbcb9bb45ff" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,301</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf1d3bb2-4624-4011-b0bc-dc6a97cf38ab" contextRef="C_456a2f3b-ce96-4cc3-bb0f-c4609478945a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,173</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b83c014a-0bd5-4f0c-bb8f-550b64d0c691" contextRef="C_290b25a7-e794-4501-9b27-3ec91a3fd8f8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,173</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae6cb154-106f-4ba9-9b80-c8b69cd213e6" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,366</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a784508e-084b-408c-812e-17ff06aa9313" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,366</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><ix:footnote id="FNT_9b153e3f-50c6-44f6-b9dc-b8230ec35c82" xml:lang="en-US"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(3) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f1adf8d-05d1-426f-9c81-5d94fd681d3b" contextRef="C_d4a379ab-79bf-4033-b99c-f6b95eddf94e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents the other subsidiaries, CPI and GNI HK, etc. reported an aggregate $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88781e8a-1ff3-4117-8e09-66da3acd7e32" contextRef="C_d4a379ab-79bf-4033-b99c-f6b95eddf94e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million general and administrative expense during the year ended December 31, 2022.</span></p></ix:footnote><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.218%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d64b031f-3c68-4538-a934-4c29908d8997" contextRef="C_3bf7ff5f-4cf5-4036-a987-5cbcce3b4d9d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,857</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60c7d668-de61-4274-8db5-496a993cfa51" contextRef="C_8d44f86a-e7e9-43dc-98b7-f45dd3ddd498" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,896</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dbd0c7e-4a5a-4423-b5af-91a0223d8fed" contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,753</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.038%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.218%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae4cfc23-38c4-461e-88ec-2c8e06b8c243" contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,985</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4d81860-374c-41b1-b102-dd87d70d21aa" contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,985</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3786fa1-1f8c-4ef7-9a86-314c98378d26" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:SubsequentEventsTextBlock" escape="true">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"/>
      <td style="width:93.82%;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">19.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Subsequent Events</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conversion of Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 22, 2023, GNI provided notice to the Company to convert </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25cc7580-ec7d-4406-9e90-e10966f9bf98" contextRef="C_3cc0a247-7505-4d3e-a327-e08700672f1b" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock into shares of common stock. On January 22, 2024, subject to the terms and conditions of the Convertible Preferred Stock Certificate of Designation, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c803d91b-825a-4de3-aca3-7dfa3903e7ae" contextRef="C_01c81b79-25d4-4be2-a4ef-98326dc842a2" name="gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,767,332</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued to GNI upon such conversion.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional Financial Information of Parent Company</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements Schedule I</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_931872dc-f293-415d-8461-2a01cadaab45" contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="schedulei"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except shares and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;"/>
      <td style="width:1.62%;"/>
      <td style="width:1%;"/>
      <td style="width:12.883000000000001%;"/>
      <td style="width:1%;"/>
      <td style="width:1.62%;"/>
      <td style="width:1%;"/>
      <td style="width:12.883000000000001%;"/>
      <td style="width:1%;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Related party receivables</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3cb9dd2-0fa5-47f1-8752-74f56ce4944f" contextRef="C_f111bc94-d333-4038-926d-d8d72cc3bed3" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_031bf7af-464c-4a96-a9b4-7e7198d3c5ef" contextRef="C_72d98f33-ac25-40da-993c-2ae56eedc53b" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,159</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da4f4321-554e-414b-b8bc-a9b263c48c80" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5964850a-1131-4a17-b486-273a3506df16" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,159</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investment in subsidiaries</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad40da6d-6668-4d91-a92f-6db3c6c24007" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,709</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3934502-2f72-42f4-97b1-c246a914487e" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,632</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total assets</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a587581-be93-42e1-a544-f0ef6e914813" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,477</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ceb4d70d-c41f-4bb8-ab4b-733add50bf7f" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,791</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities, convertible preferred stock, and stockholders&#8217; equity</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due to related parties</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1cac092-db6c-49b7-94fc-e8c9d65f251a" contextRef="C_f111bc94-d333-4038-926d-d8d72cc3bed3" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">538</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54c022fd-9c71-4d75-bcdf-4b194d21a4a3" contextRef="C_72d98f33-ac25-40da-993c-2ae56eedc53b" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cef44af-36bb-4b7d-b1fe-5e0c1400d87a" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,242</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dd1fc64-168e-470b-b7e2-27a9a6554254" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,264</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cceeff;text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities:</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ea01ef7-1849-4077-92fd-3f08063ac238" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,780</ix:nonFraction></span></p></td>
      <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_675021e6-2a60-43f9-b8f7-6573f0f56869" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,269</ix:nonFraction></span></p></td>
      <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Preferred Stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dfe1da9-368c-4251-8252-3d653c80a066" contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5dd916fb-e0be-4006-a03b-3ef38fa6ec73" contextRef="C_ba6672c5-2601-4669-825e-401398257206" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7df6e049-580a-4b7a-97e0-15f536aa48ea" contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7d860c35-238c-45ac-a7cb-85607296eae5" contextRef="C_ba6672c5-2601-4669-825e-401398257206" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_025fc902-67b7-42e6-921c-580ea681e7f4" contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2c0d7ab6-1acf-4c2f-b359-04b7e381f3bf" contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,151</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares and </span><span><span style="-sec-ix-hidden:F_1b8bd787-8774-422a-80fe-04f24efefd08;"><span style="-sec-ix-hidden:F_0cb88365-0ef8-49b2-9d9e-5b85398d57d4;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022, respectively</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_723e5281-fd4e-452e-a313-21628fa84f29" contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,525</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ce5ebc89-65a5-46e2-8a69-3fd79de6688a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; (deficit) equity:</span></p></td>
      <td style="background-color:#cceeff;text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79ba905e-7551-4d91-a909-190691035c43" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c6e83f72-dee3-4f5d-8ac0-fbaa173a0397" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f731b310-d5a4-4a93-98fd-0f13aad9e4c4" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_62562dab-085f-4bc7-8500-9e2bbb4e15db" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11f81b40-ccfb-4463-a86d-290060045235" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9224dc41-6e23-4cde-8e76-7a0189771868" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">76,595,616</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18837713-364c-4e51-9f6e-a3f34d733388" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7aaf6a54-6a8c-475b-9bb6-8137b8b21066" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,588,119</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022, respectively</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9617e5b9-52a3-49a7-b88d-45a8a238ecba" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c65bf2f-c0eb-4620-968b-71cd44d6806d" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bc04be3-7028-48bf-8024-2508a3370fe1" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,179</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78200dbd-6fea-4fa9-9be6-a9791f84b7aa" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,795</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statutory reserve</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1611aabe-eccb-4a09-9883-4151de95f476" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="gyre:StatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,098</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64aca39c-02b1-42d1-ae21-3645c4d4c833" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="gyre:StatutoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,660</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Accumulated deficit) retained earnings</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c99d0ba-97bc-485b-8e22-e48d74dffa46" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,538</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0b9ab93-eb33-4830-9232-9bc7b73b0138" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,395</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bd811da-4b59-4daf-af81-005915099c71" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,644</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa630031-90f8-4b48-b3e7-96fab2c69c4b" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">392</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; (deficit) equity</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f9109b9-d8c1-46d7-bb12-b87257df341b" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,828</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7507bf5-dadc-4071-9a46-5283913a323f" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,522</ix:nonFraction></span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3834dfcf-ba2d-4abe-968e-e0f1e74a624b" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,477</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe4b52f7-76c5-4dc7-9f3a-593e3544d9a2" contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,791</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;"/>
      <td style="width:1.62%;"/>
      <td style="width:1%;"/>
      <td style="width:12.883000000000001%;"/>
      <td style="width:1%;"/>
      <td style="width:1.62%;"/>
      <td style="width:1%;"/>
      <td style="width:12.883000000000001%;"/>
      <td style="width:1%;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97ec6342-275c-4e8c-ab67-7df6d8e605c7" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13734133-eb33-4ac5-be8a-1e9db32a2b44" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3d0c799-2004-4bc5-a508-e673847174ac" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before equity in (loss) income of subsidiaries</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4220bc96-dda5-40a0-9676-89bbd9b92bbf" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,316</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a858e183-e6ff-465a-ad6d-f2f27f0aa0f0" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity in (loss) income of subsidiaries</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a13fbb3-463a-413c-a515-f56d84ae1aa7" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,617</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fee6fdeb-afe7-49cf-99a4-811b816929e7" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,396</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
      <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3d1594f-3f14-4698-8976-510b98682419" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69c29bbd-9e68-4e3d-b9f0-5ba4c823f87e" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,302</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="background-color:#cceeff;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive (loss) income, net of tax of </span><span><span style="-sec-ix-hidden:F_8616dc92-4123-4729-b301-42d5b83f2786;"><span style="-sec-ix-hidden:F_1e540b7e-b631-4275-b3d7-b90e2d47d44e;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">:</span></p></td>
      <td style="background-color:#cff0fc;text-indent:5pt;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
      <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_936d7ffd-c3e9-4ed3-a437-43a8ee2b8121" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_372e76a4-aaa9-4a04-802d-bde04811e9c0" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,758</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
      <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76368896-e15c-4cbf-b598-2cc1cb3f8713" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,770</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_748201cb-4977-4dd9-95f2-340fee9afa31" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">456</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:68.874%;"/>
      <td style="width:1%;"/>
      <td style="width:12.963000000000001%;"/>
      <td style="width:1%;"/>
      <td style="width:1.5%;"/>
      <td style="width:1%;"/>
      <td style="width:12.663%;"/>
      <td style="width:1%;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Activities</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1d36221-8797-4dc9-b105-ab64e4d92b59" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,933</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_014c795a-708f-4e26-9a53-fa162b29ea5e" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,302</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net (loss) income to net cash used for operating activities:</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity loss (income) of subsidiaries</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08faa946-e405-4206-a870-88f5fee7904c" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,617</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49ea499a-3d96-438c-a2ff-71b243ed359b" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,396</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dc734c8-c369-43ea-ab60-79b43c5b59b8" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,711</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due to related parties</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00a70462-de58-43cb-bc2c-fe9d58f961b9" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">533</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0b2cd79-d93b-4789-b135-296d43704423" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d321998-9898-4bde-97d7-68a69ccc1cf6" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b621bed-60b2-424f-a663-6605d0b2bf5c" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2fd4edd-d20c-44f0-b6fc-dc96ae76b070" contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_817fa357-91b2-4095-9a5d-7ee86a526890" contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at beginning of the period</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a pa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb61254d-cf9e-48ea-aaf0-2de04ad602d4" contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3" name="gyre:PercentageOfRestrictedNetAssetsExceedNetAssets" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percent of consolidated net assets as of the end of the most recently completed fiscal year.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries. CPI, the legal acquiree and accounting acquirer of the Contributions considered the &#8220;registrant&#8221; and presented as the parent company, Gyre Therapeutics, Inc. (&#8220;Gyre&#8221;) to supplement its condensed financial statement in Schedule I. The parent company records its investments in subsidiaries under the equity method of accounting as prescribed in ASC 323, Investments-Equity Method, and Joint Ventures. Such investments are presented on the Condensed Balance Sheets as &#8220;Investment in subsidiaries&#8221;. Ordinarily under the equity method, an investor in an equity method investee would cease to recognize its share of the losses of an investee once the carrying value of the investment has been reduced to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to reflect its share, based on its proportionate interest, of the losses of subsidiaries regardless of the carrying value of the investment even though the parent company is not obligated to provide continuing support or fund losses.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or redemption requirements of redeemable stocks or guarantees of the parent company.</span></div></div></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6(B)
<SEQUENCE>2
<FILENAME>gyre-ex3_6b.htm
<DESCRIPTION>EX-3.6(B)
<TEXT>
<html>
 <head>
  <title>EX-3.6(b)</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GYRE THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#050505;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATE OF ELIMINATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#050505;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">OF</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SERIES A PREFERRED STOCK</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 151(g) of the</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General Corporation Law of the State of Delaware</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General Corporation Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), Gyre Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law, hereby certifies as follows:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">That, at a meeting of the Board of Directors of the Company, resolutions were duly adopted setting forth the proposed elimination of the series of stock as set forth herein:</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Now, Therefore Be It</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="font-variant:small-caps;color:#050505;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Resolved</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that, the officers of the Company be, and each of them hereby is, authorized, personally or by attorney, in the name and on behalf of the Company, to execute, deliver and cause to be filed with the Secretary of State of the State of Delaware a Certificate of Elimination, in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, pursuant to the provisions of Section 151(g) of the DGCL for the purpose of eliminating from the Company&#x2019;s Fourth Amended and Restated Certificate of Incorporation all matters set forth in the Certificate of Designation with respect to the Series A Preferred Stock.</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">That the Certificate of Designation with respect to the Series A Preferred Stock was filed with the Secretary of State of the State of Delaware on April 10, 2017 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Certificate of Designation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">That none of the authorized shares of the Series A Preferred Stock are outstanding, and none will be issued.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">That, in accordance with the provisions of Section 151(g) of the General Corporation Law, the Company&#x2019;s Fourth Amended and Restated Certificate of Incorporation, as amended, is hereby further amended to eliminate all matters set forth in the Certificate of Designation with respect to the Series A Preferred Stock.</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Company has caused this Certificate of Elimination to be signed by its Chief Executive Officer this 25</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> day of March, 2024.</font></p>
  <p style="margin-left:50%;text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:49.173%;text-indent:-1.654%;padding-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Han Ying, Ph.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			 </font></p>
  <p style="margin-left:50%;text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Han Ying, Ph.D.</font></p>
  <p style="margin-left:50%;text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>gyre-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.1</font></p>
  <p style="font-size:10pt;margin-top:17pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES<br>REGISTERED PURSUANT TO SECTION 12 OF<br>THE SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gyre Therapeutics, Inc. (&#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; or the &#x201c;Company&#x201d;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (&#x201c;1934 Act&#x201d;): our common stock. The following summary of the terms of our common stock is based upon our Fourth Amended and Restated Certificate of Incorporation, as amended (our &#x201c;restated certificate of incorporation&#x201d;) and our bylaws. This summary does not purport to be complete and is subject to, and is qualified in its entirety by express reference to, the applicable provisions of our restated certificate of incorporation and our bylaws, which are filed as exhibits to our Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our restated certificate of incorporation, our bylaws and the applicable provisions of the Delaware General Corporation Law (&#x201c;DGCL&#x201d;) for more information.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Description of Common Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Under our restated certificate of incorporation, we have authority to issue 400,000,000 shares of our common stock, par value $0.001 per share. As of December 31, 2023, 76,595,616 shares of our common stock were issued and outstanding. All shares of our common stock will, when issued, be duly authorized, fully paid and nonassessable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to preferential dividend rights of any other class or series of stock, the holders of shares of our common stock are entitled to receive dividends, including dividends of our stock, as and when declared by our board of directors, subject to any limitations imposed by law and to the rights of the holders, if any, of our preferred stock. On September 20, 2022, we paid a special, one-time cash dividend of approximately $45.0 million (or $1.43 per share) to our common stockholders of record as of the close of business on September 6, 2022. On January 12, 2023, we paid a special, one-time cash dividend of approximately $7.6 million (or $0.24 per share) to our common stockholders of record as of the close of business on January 5, 2023. In June 2023, we distributed $3.5 million, which reflected, in connection with an asset purchase agreement with Vertex Pharmaceuticals Inc. (&#x201c;Vertex&#x201d;), the hold-back amount received from Vertex less expenses and a reserve for potential tax liabilities, to holders of the contingent value right issued to our stockholders of record on January 5, 2023. We do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as the board of directors deems relevant.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate provision for all of our known debts and liabilities, each holder of our common stock will be entitled to share ratably in all assets that remain, subject to any rights that are granted to the holders of any class or series of preferred stock.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. For all matters submitted to a vote of stockholders, each holder of our common stock is entitled to one vote for each share registered in his or her name. Except as may be required by law and in connection with some significant actions, such as mergers, consolidations, or amendments to our restated certificate of incorporation that affect the rights of stockholders, holders of our common stock vote together as a single class. There is no cumulative voting in the election of our directors, which means that, subject to any rights to elect directors that are granted to the holders of any class or series of preferred stock, a plurality of the votes cast at a meeting of stockholders at which a quorum is present is sufficient to elect a director.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Rights and Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the preferential rights of any other class or series of stock, all shares of our common stock have equal dividend, distribution, liquidation and other rights, and have no preference, appraisal or exchange rights, except for any appraisal rights provided by Delaware law. Furthermore, holders of our common stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities. Our restated certificate of incorporation and our bylaws do not restrict the ability of a holder of our common stock to transfer his or her shares of our common stock.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The rights, powers, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any series of preferred stock which we may designate and issue in the future.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Listing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Our common stock is listed on the Nasdaq Capital Market under the symbol &#x201c;GYRE.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Transfer Agent and Registrar</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The transfer agent for our common stock is Equiniti Trust Company, LLC. Its address is 6201 15th Avenue, Brooklyn, NY 11219.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Description of Preferred Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Under our restated certificate of incorporation, we have authority, subject to any limitations prescribed by law and without further stockholder approval, to issue from time to time up to 5,000,000 shares of preferred stock, par value $0.001 per share, in one or more series. On December 22, 2022, we designated 123,418 shares of our preferred stock as &#x201c;Series X Convertible Preferred Stock&#x201d; (hereinafter referred to as, &#x201c;Convertible Preferred Stock&#x201d;). As of December 31, 2023, we had 13,151 shares of preferred stock issued and outstanding.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to our restated certificate of incorporation, we are authorized to issue &#x201c;blank check&#x201d; preferred stock, which may be issued from time to time in one or more series upon authorization by our board of directors. Our board of directors, without further approval of the stockholders, is authorized to fix the designation, powers, preferences, relative, participating optional or other special rights, and any qualifications, limitations and restrictions applicable to each series of the preferred stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes could, among other things, adversely affect the voting power or rights of the holders of our common stock and, under certain circumstances, make it more difficult for a third party to gain control of us, discourage bids for our common stock at a premium or otherwise adversely affect the market price of the common stock.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Series X Convertible Preferred Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conversion</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Under our restated certificate of incorporation, (i) effective as of 5:00 p.m. (New York City time) on the second business day after the date on which such stockholder approval is received, each share of Convertible Preferred Stock then outstanding automatically converts into approximately 10,000 of common stock, and (ii) at any time thereafter at the option of the holder thereof, into approximately 10,000 shares of common stock, in the case of each of (i) and (ii) subject to certain beneficial ownership limitations, including that a holder of Convertible Preferred Stock is prohibited from converting shares of Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be initially set at 9.9% and thereafter adjusted by the holder between to a number between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as otherwise provided in the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on December 27, 2022, as amended on October 30, 2023 (as amended, &#x201c;Certificate of Designation&#x201d;) or as otherwise required by the DGCL, Convertible Preferred Stock does not have voting</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">rights. However, as long as any shares of Convertible Preferred Stock are outstanding, in addition to any other requirement of the DGCL or our restated certificate of incorporation, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of Convertible Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to Convertible Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of or add any provision to, our restated certificate of incorporation or our bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of Convertible Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to our restated certificate of incorporation or by merger, consolidation or otherwise, (ii) issue further shares of Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Convertible Preferred Stock, (iii) at any time while at least 30% of the originally issued Convertible Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined in the Certificate of Designation) or (B) any merger or consolidation of the combined company with or into another entity or any stock sale to, or other business combination in which the combined company&#x2019;s stockholders immediately before such transaction do not hold at least a majority of the capital stock of the combined company immediately after such transaction, or (iv) enter into any agreement with respect to any of the foregoing.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Holders of Convertible Preferred Stock shall be entitled to receive when, as and if dividends are declared and paid on shares of common stock, an equivalent dividend (with the same dividend declaration date and payment date), calculated on an as-converted basis without regard to the Beneficial Ownership Limitation (as defined in the Certificate of Designation), provided, however, in no event shall holders of Convertible Preferred Stock be entitled to receive (a) the &#x201c;rights&#x201d; distributed pursuant to the Contingent Value Rights Agreement, dated December 26, 2022, as amended on March 29, 2023 (as amended, the &#x201c;CVR Agreement&#x201d;) or any amounts paid under the CVR Agreement, or (b) cash distributions declared by the combined company on or prior to the closing of the transactions contemplated by the Business Combination Agreement, dated as of December 26, 2022, as amended on March 29, 2023 and August 30, 2023, by and among us, GNI USA, Inc., a Delaware corporation, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability, GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People&#x2019;s Republic of China, the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Convertible Preferred Stock ranks (i) senior to any class or series of capital stock of the combined company hereafter created specifically ranking by its terms junior to any Convertible Preferred Stock; (ii) on parity with common stock and any class or series of capital stock of the combined company hereafter created specifically ranking by its terms on parity with Convertible Preferred Stock; and (iii) junior to (A) any class or series of capital stock of the combined company hereafter created specifically ranking by its terms senior to any Convertible Preferred Stock or (B) any &#x201c;rights&#x201d; distributed pursuant to the CVR Agreement or any amounts paid under the CVR Agreement, in each case, as to distributions of assets upon liquidation, dissolution or winding up of the combined company, whether voluntarily or involuntarily.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certain Effects of Authorized but Unissued Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing requirements of The Nasdaq Capital Market. We may issue these additional shares for a variety of corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved preferred stock may enable our board of directors to issue shares of preferred stock with terms that could render more difficult or</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of common stock and the likelihood that holders of common stock will receive dividend payments or payments upon liquidation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anti-Takeover Effects of Provisions of Our Charter Documents</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our restated certificate of incorporation provides for our board of directors to be divided into three classes serving staggered terms. Approximately one-third of our board of directors will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of the outstanding voting stock from obtaining control of the board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company and could increase the likelihood that incumbent directors will retain their positions. Our restated certificate of incorporation provides that directors may be removed with or without cause only by the affirmative vote of the holders of at least 66 2/3% of the voting power of all outstanding stock entitled to vote in the election of directors, voting together as a single class.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our restated certificate of incorporation requires that certain amendments to the restated certificate of incorporation and amendments by the stockholders of our bylaws require the affirmative vote of holders of at least 66 2/3% of the then outstanding stock entitled to vote generally in the election of directors, voting together as a single class. These provisions could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company and could delay changes in management.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual stockholders meeting, including proposed nominations of persons for election to our board of directors. At an annual stockholders meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors. Stockholders may also consider a proposal or nomination by a person who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to the Secretary of the Company timely written notice, in proper form, of his or her intention to bring that business before the annual stockholders meeting. Our bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of the stockholders. However, our bylaws may have the effect of precluding the conduct of business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our bylaws provide that only our board of directors, the chairperson of the board, the President or the Chief Executive Officer may call a special meeting of stockholders. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of our board of directors by calling a special meeting of stockholders prior to such time as a majority of our board of directors, the chairperson of the board, the President or the Chief Executive Officer believed the matter should be considered or until the next annual meeting provided that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace the board also could be delayed until the next annual stockholders meeting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our restated certificate of incorporation does not allow stockholders to act by written consent without a meeting. Without the availability of stockholder&#x2019;s actions by written consent, a holder controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a stockholders&#x2019; meeting.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anti-Takeover Effects of Provisions of Delaware Law</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the provisions of Section 203 of the DGCL, or Section 203. Under Section 203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">prior to this time, our board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers, and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">at or subsequent to such time, the business combination is approved by our board of directors and authorized at a special or annual stockholders meeting, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Under Section 203, a &#x201c;business combination&#x201d; includes:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder, subject to limited exceptions;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In general, Section 203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limitation of Liability and Indemnification</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our restated certificate of incorporation provides that our directors shall not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability for breach of the director&#x2019;s duty of loyalty to us or our stockholders, for acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, for payment of dividends or approval of stock purchases or redemptions that are prohibited by the DGCL, or for any transaction from which the director derived an improper personal benefit. Under the DGCL, our directors have a fiduciary duty to us that is not eliminated by this provision of the restated certificate of incorporation and, in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available. This provision also does not affect our directors&#x2019; responsibilities under any other laws, such as federal securities laws or state or federal environmental laws.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 145 of the DGCL empowers a corporation to indemnify its directors and officers against expenses (including attorneys&#x2019; fees), judgments, fines and amounts paid in settlements actually and reasonably</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">incurred by them in connection with any action, suit or proceeding brought by third parties by reason of the fact that they were or are directors or officers of the corporation, if they acted in good faith, in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that their conduct was unlawful. The DGCL provides further that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation&#x2019;s bylaws, any agreement, a vote of stockholders or otherwise. Our restated certificate of incorporation provides that, to the fullest extent permitted by Section 145 of the DGCL, we shall indemnify any person who is or was a director or officer of us, or is or was serving at our request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against the expenses, liabilities or other matters referred to in or covered by Section 145 of the DGCL. Our bylaws provide that we will indemnify any person who was or is a party or threatened to be made a party to any proceeding by reason of the fact that such person is or was a director or officer of us or is or was serving at our request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise to the fullest extent permitted by the DGCL.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have entered into indemnification agreements with each of our directors and with certain of our executive officers. Pursuant to the indemnification agreements, we has agreed to indemnify and hold harmless these directors and officers to the fullest extent permitted by the DGCL. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated to pay because of any proceeding to which he or she is made or threatened to be made a party or participant by reason of his or her service as a current or former director, officer, employee or agent of the Company. The agreements also provide for the advancement of expenses to the directors and officers subject to specified conditions. There are certain exceptions to our obligation to indemnify the directors and officers, including any intentional malfeasance or act where the director or officer did not in good faith believe he or she was acting in our best interests, with respect to &#x201c;short-swing&#x201d; profit claims under Section 16(b) of the 1934 Act and, with certain exceptions, with respect to proceedings that he or she initiates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 145 of the DGCL also empowers a corporation to purchase insurance for its officers and directors for such liabilities. We maintain liability insurance for our officers and directors.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>gyre-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">SUBSIDIARIES OF GYRE THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Note: Gyre Therapeutics, Inc. or one of its Subsidiaries has 100% ownership of the Subsidiaries listed below, except for Beijing Continent Pharmaceuticals Co., Ltd. (65.2%) and Beijing Continent Biomedical Technology Co., Ltd (65.2%).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:72.1%;"></td>
    <td style="width:27.9%;"></td>
   </tr>
   <tr style="height:13.7pt;background-color:#e4e5e3;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Subsidiaries</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jurisdiction</font></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Further Challenger International Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">British Virgin Islands</font></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nepenthe Holdings Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hong Kong</font></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ratel Holdings Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">British Virgin Islands</font></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aaring Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hong Kong</font></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rosefinch Holdings Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">British Virgin Islands</font></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Continent Pharmaceuticals Inc.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cayman Islands</font></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">BJContinent Pharmaceuticals Limited</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hong Kong</font></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Continent Pharmaceuticals Co., Ltd.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">People&#x2019;s Republic of China</font></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beijing Continent Biomedical Technology Co., Ltd.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">People&#x2019;s Republic of China</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>gyre-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"><br><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have issued our report dated March 27, 2024, with respect to the consolidated financial statements included in the Annual Report of Gyre Therapeutics, Inc. on Form 10-K for the years ended December 31, 2023 and 2022. We consent to the incorporation by reference of said report in the Registration Statements of Gyre Therapeutics Inc. on Forms S-8 (Nos. 333-206523, 333-206526, 333-212345, 333-219301, 333-225902, 333-239712, 333-264027 and 333-275222), and Form S-3 (No. 333-273395).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Grant Thornton Zhitong Certified Public Accountants LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beijing, China</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 27, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>gyre-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 13</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-14(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) AND 15</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-14(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) of the Securities Exchange Act of 1934</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Han Ying, certify that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Gyre Therapeutics, Inc.;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: March 27, 2024</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Han Ying, Ph.D.</font></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Han Ying, Ph.D.</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer and Director</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>gyre-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 13</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-14(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) AND 15</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-14(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) of the Securities Exchange Act of 1934</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Ruoyu Chen, certify that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Gyre Therapeutics, Inc.;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: March 27, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ruoyu Chen</font></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ruoyu Chen</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>gyre-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br>Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Catalyst Biosciences, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Han Ying, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: March 27, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Han Ying, Ph.D.</font></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Han Ying, Ph.D.</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer and Director</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note: A signed original of this written statement required by &#167; 906 has been provided to Gyre Therapeutics, Inc. and will be retained by Gyre Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>gyre-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br>Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Catalyst Biosciences, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Ruoyu Chen, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="text-indent:4.533%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.53%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: March 27, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ruoyu Chen</font></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Ruoyu Chen</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note: A signed original of this written statement required by &#167; 906 has been provided to Gyre Therapeutics, Inc. and will be retained by Gyre Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>10
<FILENAME>gyre-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GYRE THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INCENTIVE COMPENSATION CLAWBACK POLICY</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recoupment of Incentive-Based Compensation</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">It is the policy of Gyre Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that, in the event the Company is required to prepare an accounting restatement of the Company&#x2019;s financial statements due to material non-compliance with any financial reporting requirement under the federal securities laws (including any such correction that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period), the Company will recover on a reasonably prompt basis the amount of any Incentive-Based Compensation Received by a Covered Executive during the Recovery Period that exceeds the amount that otherwise would have been Received had it been determined based on the restated financial statements (each as defined below). This Incentive Compensation Clawback Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has been adopted by the Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) effective October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Committee may amend or change the terms of this Policy at any time for any reason, including as required to comply with any laws, rules, regulations and listing standards that may be applicable to the Company.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy Administration and Definitions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy is administered by the Committee and is intended to comply with, and as applicable to be administered and interpreted consistent with, and subject to the exceptions set forth in, Listing Rule 5608 adopted by the Nasdaq Stock Market (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to implement Rule 10D-1 under the Securities Exchange Act of 1934, as amended (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10D-1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Policy:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any &#x201c;executive officer&#x201d; of the Company as defined under Rule 10D-1. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Reporting Measure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements and any measure derived wholly or in part from such a measure, and (ii) any measure based in whole or in part on the Company&#x2019;s stock price or total shareholder return. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation granted, earned or vested based in whole or in part on the Company&#x2019;s attainment of a Financial Reporting Measure that was Received by a person (i) on or after the Effective Date and after the person began service as a Covered Executive, and (ii) who served as a Covered Executive at any time during the performance period for the Incentive-Based Compensation.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation is deemed to be &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Received</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in the fiscal period during which the relevant Financial Reporting Measure is attained, regardless of when the compensation is actually paid or awarded. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recovery Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the date that the Company is required to prepare the accounting restatement described in this Policy and any transition period of less than nine months that is within or immediately following such three fiscal years, all as determined pursuant to Rule 10D&#x2011;1. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Determination by the Committee</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Committee determines the amount of Incentive-Based Compensation Received by a Covered Executive during a Recovery Period exceeds the amount that would have been Received if determined or calculated based on the Company&#x2019;s restated financial results, such excess amount of Incentive-Based Compensation shall be subject to recoupment by the Company pursuant to this Policy. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the Committee will determine the amount based on a reasonable estimate of the effect of the accounting restatement on the relevant stock price or total shareholder return. In all cases, the calculation of the excess amount of Incentive-Based Compensation to be recovered will be determined on a pre-tax basis (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, without regard to any taxes paid with respect to such compensation). The Company will maintain and will provide to Nasdaq documentation of all determinations and actions taken in complying with this Policy.  Any determinations made by the Committee under this Policy shall be final and binding on all affected individuals.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Methods of Clawback</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company may effect any recovery pursuant to this Policy in any manner consistent with applicable law, including by requiring payment of such amount(s) to the Company, by set-off, by reducing future compensation, or by such other means or combination of means as the Committee determines to be appropriate. The Company need not recover the excess amount of Incentive-Based Compensation if and to the extent that the Committee determines that such recovery is impracticable, subject to and in accordance with any applicable exceptions under the Nasdaq listing rules and not required under Rule 10D-1, including if the Committee determines that the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered after making a reasonable attempt to recover such amounts. The Company is authorized to take appropriate steps to implement this Policy with respect to Incentive-Based Compensation arrangements with Covered Executives.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Not Exclusive Remedy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any right of recoupment or recovery pursuant to this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any other policy, any employment agreement or plan or award terms, and any other legal remedies available to the Company (including, but not limited to, Section 304 of the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sarbanes-Oxley Act of 2002); provided that the Company shall not recoup amounts pursuant to such other policy, terms or remedies to the extent it is recovered pursuant to this Policy. The Company shall not indemnify any Covered Executive against the loss of any Incentive-Based Compensation pursuant to this Policy, nor will the Company pay or agree to pay any insurance premium to cover any such loss.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Certification</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All Covered Executives subject to this Policy will be required to certify their understanding of and intent to comply with this Policy periodically.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ACKNOWLEDGMENT AND CERTIFICATION</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By signing below, the undersigned covered executive (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) acknowledges and confirms that the Covered Executive has received and reviewed a copy of the Gyre Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) Incentive Compensation Clawback Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and in addition, the Covered Executive acknowledges and agrees that, for good and valid consideration, including continuing participation in the Company&#x2019;s incentive compensation programs, the receipt and sufficiency of which the Covered Executive hereby acknowledges, the Covered Executive will be bound by and abide by the Policy as follows:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:11pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Covered Executive is and will continue to be subject to the Policy and the Policy will apply both during and after the Covered Executive&#x2019;s employment with the Company;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:11pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to the extent necessary to comply with the Policy, the Company hereby amends any employment agreement, equity award agreement or similar agreement that the Covered Executive is a party to with the Company;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:11pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Covered Executive shall abide by the terms of the Policy, including, without limitation, by returning any compensation to the Company to the extent required by, and in a manner permitted by, the Policy, and understands and agrees that the Company is not permitted to, and will not, indemnify the Covered Executive for the loss of any compensation that is subject to recovery by the Company;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:11pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">any amounts payable to the Covered Executive shall be subject to the Policy as may be in effect and interpreted or modified from time to time in the sole discretion of the Compensation Committee of the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or as required by applicable law or the requirements of any securities exchange on which the Company&#x2019;s securities are listed, and that such interpretation or modification will be covered by this acknowledgment;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:11pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Company may recover compensation paid to the Covered Executive through any method of recovery the Committee or its delegate deems appropriate, including without limitation by reducing any amount that is or may become payable to the Covered Executive, and the Covered Executive agrees to comply with any request or demand for repayment by the Company in order to comply with the Policy; and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:11pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Company is not responsible for and shall not make the Covered Executive whole for any effect under any tax law or regulation of the recovery of any compensation pursuant to the Policy, or for any taxes paid by the Covered Executive on compensation that is subject to recovery or is recovered pursuant to the Policy.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.88in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[ACKNOWLEDGMENT AND CERTIFICATION]</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Signature</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Print Name</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.88in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img98921446_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img98921446_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +?!4H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML:K_ &98:D)KSYL1B)QG;UY*@?K7054HRB[25A1DI:IA1114C"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/\0^9?\ ']*M/X@\/R##ZA9,/]I@:I-8>'M;D>.PN(1<!=W^CL.!GJ5Z8YH
MZ.*:.>,20R*Z'HRG(I]<$\>I>%[T,#NB8]1]R0>A]#78Z;J4.IV@GA.#T9">
M5/I0!<HIC2(O4T>;'C.\<T6"X^BDW*.I%*"#T- !1110 4444 %%%% !1137
M<)UH =13!*A4MG@5&\_S87&,XIV%=$]%5!(YP0WZT!V9<^8<\9&:+"YBW154
M.ZDC?GT)(I2[C^//7IBBP<Q9HJ!93GD\>E/24,/FPOU-%AIHDHHS12&%%%%
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M_P#J_6N[I#*]_>Q:=83WDQQ'"A8^_M^/2O#KV[FU&_FNI<M+,Y<X_E^%=O\
M$76<F+2(6Z8DGQ_XZ/Z_E6!X7TO[7'J=ZZYCM;.4C/\ ?*$#],G\J .>KLOA
MM_R,%S_UZM_Z&M<;79?#;_D8+G_KU;_T-: /2KJUAO;9X)T#(P_+W'O7#PM+
MX<UUH78^43AC_>0]#_GWKOJYCQE:![6"[ ^9&V-]#_\ 7'ZT ;08$94@C .<
M\49P.0#U[UGZ)<FXTF!F)RJ[#GV./Y8K25';CGO@U9F-+9;D\Y[FG+OWY5>_
M6GE$4\R8.:%F"G"_J: MW)5+#[[#ITI#,@S@YQZ5 \A8[\X..E-)Y/([TK#Y
MBP9U'_ZZ%EWJ2!R.V:@R,_>I S=,^G<<T6#F9;#@C/(X[U"DY_B(QGKFH][
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M9^7UP >*!G(YZCUI%/RCGMZ^] "D]?3'K2YY[=:3.?XN>:4=3SQGU]J $#<
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M1=J</A7XD4(-7G/=DI95ZD"D1PXRM1B#NSDFI%0(, 5R:'3J.HHHI#"BBB@
MHHHH **** "BHVF5?4_04GGKC(!_*G9BNB6BJYG.< ?F*5)0,DG)/;THL',B
M>H))\$A>W6HV?<V=P&<4PMNY#<XQUII$N1)YCANO>ITD5^G:JI.,G/0TH;YB
M,D<BFT),LF5 <;J575\[3G%5,Y7J>U.#L,D'D4K#YBW12*<@$C%+4EE+5;!=
M1TZ6W/#$90^C#I7,>&=3^P74FGW1**[87=_"_3'XUVE<[XA\/F]S=VBC[0!\
MZ?W_ /Z] &?X[O/"\B6^F>(KF>+D7$8B5B3U7J ?>N*^R_"__G_O_P#OE_\
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M&CC_ )=K[_OA/_BJ0S;TWP[8Z<0^WSIA_'(.GT':M21-Z$5QI^)NBC_EVO\
M_OVG_P 533\4=$'_ "ZZA_W[3_XN@#L8X]G+#G/&*DR#D<&N&?XJ:'C'V741
M](T_^+JN?BGH2_\ +MJ7_?M/_BZ>XMCT$*%& ,4,H88-<%_PMS0!_P NFI?]
M^X__ (NC_A;N@?\ /GJ7_?N/_P"+I#.\5%7H.:=7 _\ "W= _P"?/4O^_<?_
M ,71_P +=T#_ )\]2_[]Q_\ Q= '?45P/_"W= _Y\]2_[]Q__%TJ_%OP^S &
MUU%1ZF)/Z/0!WM%8&D>--!UMUBM+]!.W AE&QB?09ZGZ9K?H **** "BBB@
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M_P#BJ .PHKC_ /A8^C_\^U]_WPG_ ,51_P +'T?_ )]K[_OA/_BJ .HD3;C
MXJ')VGC_ #FN?3XAZ+*=K1W<8/=HQ_1C6M8ZK8:GEK.ZCE]5!(8>Y!Y%4F0T
M6SD'\#2C/&#W_I29]3CH>M&1@Y/3OFJ)$_A)Z<8I3DD_4T'[K8.>O>C(W#/.
M3ZT +UQ]13<' ZY^GO2X49P"/PH)Y(QR,]J  YR2#TSVI?XCSU]J3(W ^O7B
M@8..X.* %!/0YXQVI 3@=Z,XSG\,YHZ>N,&@!<]!D#(-(>G.#UIP .>>G(]:
M=_#G'R]Z06$3US@\58&<\CBHD2-^1GZ9J>I9:04444B@HHHH **** "BBB@
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MDX([T$G/XBEZD_AWIO4#Z9ZTQ"]3C'8]J 3W'7V]J"#D_+U.>/I0#T.#U%
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M@L95FME:_LR8W4Y4@ELG&>AK/U*PUO5]2DU&^OM,ENY-I:0:G:+G  ' < <
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MG!5'0"ES%<I62)FP<8['.:F$*BI**5RE%!1112&%%%% !1110 4444 %%%%
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MSWI?([$8/UH_L_\ O?A_P0^H?WOP/(Z*]<\C/51^='D>HXP.]']G_P![\/\
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M4TR6BL>&4Y[^OM2#G&,9R,T[YL*Q!&3CK2 %@O!)Z=:H@G@CQ\V3]#4U(!@
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M6D')Z]@>M .=IQSG%)C."/;D4P%S\N<]LT-@9()Z\BD((!XZ9Q2/TZ=_7VH
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MYJM(^]^"< X[BEEDWD < 'N.M+"%+'(&>,&FE8EN^@Y8!P2<]*<D84DG!/\
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M&')X/7\N*7MWY!XI<9YP<9S^E("+9\QY[#M2;<#C/3TJ7!XQST[4UAT]-HH
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MU.?0FIJI@D'/H34JS/N(*Y'M4M%ID]%(#D TM24%%%% !1110 4444 %%%%
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M9.NZ1K]S\/+"&[2:[U"&Y661 ?,D"?,!G'+'YAZ_I5O41=ZOXQ\-ZG'IE]%
MJGS!-;E3%AB/FZ@=,_0BD.R-0>*KRWUG2M+OM'%O<7JDG%R'\H D=EP<@9Z]
MZMVWB-9_%M_HAM1&MI )3.9.&R$/W<<?>]>U8WBRUO;?Q9HNMP6%S>6UN"DJ
M6T>]QR>WX_3BJVC6=_J'CC6[RZTR[LK:\LMB-+&> 0@'/3=@9(SP<CM3%8L2
M>.Y'ADOK;0;B?28YQ";L2@,<D#(3&3R>.>>.E4?$>L:LOC;28+:RE>$*)8+<
MS"/[02O)8'[I'(PWI[TW1KO7?"^C2:+'X?N[B_6?]S*L1:!E8CDN#]?IWQ@U
M<\20ZA#XKT+6CI=U/%%%^_CM$,K(W.5[9Z]>,XI#-S3?$AOO$][HKV9B:UB6
M0R"7=DD+QC'^UZ]JJVGCWS- U?4?[-Q_9THC\LSY\S) Z[>.OH:R3]OT7QY?
MZF-'O[JWO[=1";>+)5L+PW]WE2#GZUF:=I>J#P1XEAFTVZCN9YU9(3$VYOF!
M.T8Y'TH!:'8:=XRU"\TQ]2?P[<"T,.^ PRB629\@;0@&0,Y^8]AG'-):^,[S
M^W;'3-7T*337O5W0O]H67)]" !CO[YQQ6?>6^M0?#6SATN*>._C@C$B(I651
MCY@!UW?KUKG[;2[E_%6@ZA#HVLQH)%6[N;Y6:1Y!C+-UPH! #<#KZ4AIG0^#
MO^2@^*_^NH_]"-=_7$>%+"\MO''B:XGM)XH)I 8I'C*J_P Q^Z3P?PKMZ104
M444 %4V&)&'^T>M7*KR(6E(V\'OBFB9! N6)*^E6*0#"@>E+0V-*P4444AA1
MUHHH **** "BBN3O3K=QJTVB/,6@N"LGVE$V^7%SN7CU(P,G/YUK2I>T;UM8
MQKUO9):-WTT[F[:W[7]RQM0ILXF*M,>?,;T3V!ZM^ ]1?J.""*V@C@A0)%&H
M55'85)43:;]U:%P4DO>>H5GZWJ0TC1[F]^4M&OR*W0L> /SK0KB?'MU)--8:
M5!#)<.[>>\,8)9@. !CG^]^58U9\L&R*]3V=-R6YJ>%?$,^MI<Q7L445U P.
MU 1E2.."3_DBNA9E12S$*H&22< "O.K;59[?QI;7\^ESZ;#=@02)*"%;H 02
MHZ?+^5=]?_\ (.NO^N+_ ,C4T9WB[]",/5YH.[NT1'6=+"JQU*SVN2%/GK@_
M3FK4LT<$32S2)'&HRSNP 'U)KS.RTZS;X=WUZUO&UR)>)2/F7#*, ]NIJ[J3
MF>R\)P7C?Z#($\[<V Q&T?-^!/YFH5=VNUT,UBI<MVNB?WNQW4%_9W4;R6]W
M!,B??:.0,%^I'2E2^M);9KF.Z@>W7.Z59 5&.N3TKDY((;#XB6,6F1QQ"2 _
M:(HOE7&&Z@<#H#^7K6)>O/IAU+PQ I_TJZ0P8[*W)'Z*/SINLX[KR'+$N*U7
M=?/H>AR7UD+0737< MVX$QD&P_CG%5;FZB&DW-]:213K'$[HRMN4E03U!]17
M*Z_9R0^(-#TN!;9X8X-L278/E,_(.X#J3A?Q(J:QT^XL+?Q%YEUII62VD+VU
MG(3Y3A3_  D?*.M'MI7:M_5@=>3DXVV_RN='X<OY=4T.VO9U19)=V0@('#$=
MR?2KUS?6ED%-U=00!ON^;(%S],UD>"O^11L?^VG_ *,:LHP6]]\2;F'4$26-
M+8?9XY1N4\*3P>#U<U7.U"+ZNQ:JR5*#ZNQKZ%K5QJFJ:O;2I$([.8)$8P<L
M,L.>3_='2M2#4;&YF,,%[;RRKG*1RJS#'7@&O/+0K;:=XO&G-B-718RAR-F]
MP<'TQFGVFE73V>C7<<^AV84J\,H=DEE/&0Q((8YZC\.E91K2LE:__#F,,3-)
M*U]_SL=]-JFGV\KQ37UM')& 75YE!7/3()XZC\ZIPZHQU*Y\Z^TO[#'&'39-
M^]4''+Y. .>ON*P(;&VOOB7J:W4,<R1P*X210RYVQCH?J:-/M8;CQSKMHZ#R
M9+;RRH&, A!Q5^TDW\[%NM-OYM?F=>]]:1VHNGNH%MVQB4R (<].>E-GU"RM
MHXY+B\MXDD&4:255##V)//6O.;8W%^MCX4EW;K>]<3$#CRUYZ_B_Z5O:M+:W
M/B9K&VTFVN;Z* 9FO)2(8EX/W.A !'3GGZT*LVK_ -7!8ERC=+LOGU-_4M;M
M-/T=]2$L<T6/W>R08D;T!_ _D:SEU^:[T2TO+6[TJ*:1@)EN92%7(/RC!SN]
MC7):8BR>!-:614<13ATXR%;@97\*FU>"&'P3HC11(C22JSE5 +':>3ZFLW6D
MU?R_4R>)FUS=+7_&QZ)'=VTTTD,5Q$\L?WT5P67ZCM217MI.)3#=0R"+B0I(
M#L^N.E<AX@N&\-^)QJL8/EWEL\;X&?WBCC]=GZUG7UE/IOPYB8;A)=SK+.>Y
M5@2 ?R7\ZT=9IM6V_I&TL2XN2MM>_P"GWG=V5_9WCR);7<-P5P3Y<@?'Y&I)
M8\9;KQC%<;9:5=0:_IEUY^AVN% 6*T=E::,CK@CYCCO7='IS6M.;ENC2E)SB
M^96*1 R!D]#S1Q\WX_RI[J3R!WX]Z:>#SP#[5L4 ^\,#TIN 1Z'']:7H1P!_
M]:CG(Z'J*8 0,D8/)_I0"">1W'X4=ST^]_2L+7;K5-/FMY[0B>&7,7DJ@R'P
M2K9ZG^7'OFKI4W4ERIZF=6JJ4>=K3R+\UZQNA96BH]QMW2%ONPJ3P6]2>R]_
M8<U>['Y>YJEI>G?V=:>6Y\RX<EYI>I=SWJ[C/3KG/2BIRIVCLOQ"GS-<T]WT
M[ >N0O.:&*J"S !0,DGC%'49"^]<YXZU/^R_"5VZL!)./L\?'=NO_CNX_A69
MH9'ASQU<:MXH6QN;:".QN&D6TE4,&;:<C))P>/8<UZ C!E,;9[XKPZ\GU*TT
M32E'AR]LI-*D\S[8Z, Q)R<Y48R<=_:O9K&]BU'3K:^A^Y-&KC!Z!AG\QTI%
M;'-VGBM_^$LU;3;^2TMK*S4%)G8H<G'WB3COZ"M?4-0_XD<M[IU[I^?E,<]S
M+^X^\ <L#]1]:X[2]-LM2^*&NB]MHKE8T!594#+D[1G![UB:?\OPU\2P@GRT
MNEVKZ?.E%PL>H)?PP:3#=W]W:1AXT+RK)B%F('*,3T/;VI\6J:=<SK#!?VTL
MK(75$F5F*^H /3WKSF^2.YOO ]I?8-@]I$2K_=9]HX/K_"/QJYIMM9V?Q<G@
ML$CCB6W.8XA\JL5&0 .GTIW%8V/#7C%-2L+FXUBXL;-EN6BCR_EA@%!_B;D\
MU/XN\0W.B)ISVD<$@NIU1C("1M]L$5Q&@:78W/@KQ)>3VL4MQ&SB.1UR4VKD
M;3VY-.U)F?P-X2+-D_:".?9B!2N.VIZY:WMI>/+';7,$SP'9*L<@8QMSPP'0
M\'KZ5&M[9W<S+:W4$[1,4D6.0-L/HV.AXK@-9OF\%^-+S447%OJ=F[ 8X\Y1
MQ^N/^^ZWO NEOIWA>%Y3_I%T?M,A/7+=,_AC]:%N#V-N[U"RT]4:\N[>V5L!
M3-*J _3)J6">&ZB$UO+'-$X.V2-@RMSV(KAO%>D7-UXH@O=/DTN^NH;?8=,O
M&5BPYY"$],-GDCIWZ5C"_9/ _B*SM--&GW5M,B7B0S,Z'<VUMH)./NE2 3Q^
MCN*QZ7:ZIIU]*\-I>VMQ(@)*0S*Y4>I -8VE>(;N^\8ZGI$L, M[1 495(<]
M.ISCOZ5R6G:+?+<>';U)_#MCM*-"89'CEN5.T,IR/G;!P?\ >/K3GDN(?$_C
M.2UR)TLR5*CD?=R1[XS2N.QZ)'JFFRW;6D5[:R7*DAH%F4N".ORYSQ4EW>V=
MA"LEY=0VT9.T/,X0$]<9/?@UY+9:+>7/AO3+J&?P[8(LN^&[>1XYRX)^5FQ@
MG/;V%=)>0)J'Q7AM=4@CE@6S)MX95W(QP23@\'^+\O:G<5CIM6\1V&E:&^K+
M-'<Q8(B$<PQ,W3:I[^^,XP>.*SQXEN+W0].O;*_T:&69E$ZW4Q"J2N2@P?O>
MQK"U;3_#T'@?7(M(D6X\F<.X=MQADW@?*#T&,@$=0.IK/UZT@MO WA=X8(XC
M-+$[E% WMLY)QU/O2N-(]1L[ZVN+A[>"ZAEEA_UL<<@8H?\ : Z?C4\&HV-T
MDSV][;RK"2)3'*K",C^]@\?C7GGB:^;P?XRDU>!"(=0LY(R O'G*/E/YA/S-
M9VKZ=<:+\)+15W"6]N4FNSZJP) /Y)^-)E(]3LM3T_4=_P!AOK:Z\O&_R)5?
M;GIG!XZ'\JM5YMIFA7]GXNTF\:X\-61$>T6^GR,C7$1!Y"D?/]?;VKTFD,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0* Q;N:&.U<XIL@8C"FH&,@.&S
MC/K32N2W8D:<8^7K[BH<Y.2/0T@Z] "/K0,[> /UJDB6[B<>AZ'-*>#D9[T9
M]1ZX/-'<?7W]*8@XSTZGU]J08,8XYVTN>#TXP>]'& "1Z4 ! )P1W.*4CD\=
MQ2=<Y(/_ .JD'KCL*0 !@# /04I]P,?2C QT'3THZ9.T8I@<]XG/ABT:UGUV
MQLKB>=UMH/.MEED8D\*,CH,D^@S[U9/A'PWV\/:3U_Y\H_\ "N#^+6G^?K/A
MR;[9=)YUR+?9')A4^8'>HQP_S=?8>E-U>VU-OB9I/AJV\0:O!9M8#S9%NCYC
MX#DL3TWG &[%;J%XII]S)R]YW1WP\(^&R/\ D7])_P# ./\ PI/^$2\-]?\
MA'M*Z'_ERC_PKSC6]3OD\8OX:6[\436.F6RY;26\RZF=@K;Y'ZD?/CTX''-:
MVD:QK?\ PK_4%UZ_N]%EMI/)BU&^M&\UHCC'R\%GZC()/.>3S0X2LG<%.-[6
M.R/A'PT#_P B]I6/^O./_"LVUL/!=YKEWI%MHFE2W5JH><+8Q[4ST7..O\JX
M71M;N++X@:-:Z=J^O7VFWJ%'?52Q2?(/SQ!@#@$#G /&,D&I/!^BLGQ(\1JN
MJ:D6L3NW&XYGZ_ZWCYA^55[-I.[Z"YTVK(])D\'^&E/_ "+^E<@?\N<?^%(?
M"/AHCCP]I?\ X!Q__$UY#8RZ]=_#*]\22>*=7%Q97&R&);EMI&Y =YZM][C)
MP,>]:UY>ZYI$GA#77\07]S+K#QFZMY''D;7"<+&  ,*V/KSQ2]E+;F#G6]CT
MC_A$_#6/^1>TKO\ \N<?_P 33?\ A$_#>XC_ (1[2NW_ "YQ_P#Q->:ZUX@U
M+6?&&M6?F^)4MK$F&WBT),X?H6EP1D$C@?7IWDU_7O$@^%%M=WSWVG:HEZL+
MR8>WD=0&P>QP1CV)%'LYZ:[ASQUT/1_^$2\-CG_A']*[_P#+E'_A6?'I_@N7
MQ#)H<6B:5)?10F>5%L8\1K\N,G'4[@0/3TXSREV=8\-^-/"P_P"$@U"^&JG9
M=17$F8MQV@E$  4?-P.HQUJ#1=#S\;=7A&IZE_HT<=SO^T?-+GRF\MSCYD^;
M&WT ]*%!VNY=+@Y:VL=SJ.A>$M)TVXO[S0=+2WMT\R1A8QG@>V*S?#,/A7Q/
M;27%OX-CM85"E)+S2XD64-GE",[L8Y^HJ7XEVGVOP'?O]HGA\A1+B%]HDQD;
M7]5YSCU KC%O[[PO\,='_LV^NC=:Q)'&))WWBU!!R(QCY1Q^I/6B$7*&^MPD
MTI;:'I7_  B/AK_H7M*SC_GRC_PH_P"$2\-'IX?TGO\ \N4?^%<7>C4_ GB?
MP^B:YJ.J6FJ3?9KB&_D,I#94;D]/O9P/3J<\5=%M=2\2>/O$UG<>(-7M[&SN
M24BM;HISN8  \X7 / QGCT%+D=K\V@^97M;4]0M+.VL;9+:TMX;>!/NQ1($4
M9.3@#@<DFIL<8YX'44@^Z/E!XI2#M/':L#4"!Z=S2\=L]Z0]3\O>CTZ=<]#0
M <<<'MTH&,8(/^31D@]/3UHXQP".>G- !QM((.,&G%AP,'(;BD8%20<9YZYI
M"0#GCUI -R>H&.,_K2L5 8@9X-'&&Z9&>M*0#QP<Y'Z4P&XW-R#C/]*55  &
M/2D!( !4<8IPQ@' H ,#'ITZ4TKD$$\X]*=T&, ?44$<'('>@ (Y.?6E'R_0
MXSC-)CDX YQUI0#C[I'M0 W!_P#KTO 4]0:,$=5]:/P'Y&@"K>+>R%/L=Q;P
MX)W^=;M+GCC&'7'?UJH(M<SQJ%@>!_RX2?\ QZE\0:[!X=TA[^X0N 0D<:\%
MV(.!GMT))]!WZ5P^N:G>ZCXF\*?;])ETZ5;H,JM() ZLT>#D=#D'((R./6D-
M([@6^O9&-0T_)[?89/\ X]36AUT XU#3CG/2QD_^/5F7OC"XBU*]M=*T:341
M8(3=2"<1!#R<#(.3P??BC5/'5C9>';/6;6T>ZAN93%L:3RV3@YSP>>.E%PLS
M5%OKG#'4-.SQ_P N#_\ QZC[/KA./[1T[(_Z<']?^NU<OXDU<O864VO>&2JO
M<A;>-K[#=,[SL''IM-;]MXB$WB:_T2XME@:WB\Z.4R9$B\<XP,=?4]Z L6OL
M^N<_\3#3NI_Y<'_^/4GV;7#_ ,Q'3_\ P ?_ ./5EV'B^2_T2^U6'2)Y(XIC
M%!% 3(\Y]<!?E'3)Y[]>A2R\673:[!H^J:(;"XN(C)!_I"R!L \$@#'W3_A1
M<+&MY&N9 .H:=_X /_\ 'J/(UO SJ.G8XY^P/_\ 'JXOP]K&KW?BG7/MFGM+
M'C9,C7(Q:*N["C'WL]./K4ND^*+72/",-]8Z&(;%[PQ2QBY9_+)Q\V6!)^G%
M%PL=?]GUWC_B8Z=W_P"7"3_X]0+?7.HU'3O_   D_P#CU5;KQ +;Q-I^BVUL
MMQ)<H97D$N!$G/.,'/ /<=O6LN7QS)_I5W9Z)-=:5:2B.:\68+W&2J'EL9SU
M^N* LSH([?7=XQJ.G]NMA)Q_Y&I\UOKOF+G4=.)]M/D_^/5>TV>*^M(+V!@T
M,T8=#Z@\U@:CXLF7Q!)I6C:1)JEU;)NN-LRQ+'TP-QSD\]/Y\X5]2DM#;M8]
M7$ZM<WUC)",[DBLWC8\=F,K <^QK1K@M9\6OJ_@"^O-+MI4G4^1=QM($>UX^
M9O\ :&< 8P3GM@BI_AG8);>'_M(TO[(]PJ$S>?YGVD#.&V_P=3Q4E';4444
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M6ED^F:D;>T8O GV*[^1NO7;D_C5;5O',R>%=+U.S%E+<7,RQ7$>2XB)4G'#
M@\#K74PZC87-U):V]];33QY#QQRAF7'!R <CGBA U8X'Q5+<^)M6L[!M)OH=
M-MYM[7K6DS%U(&0%V9'<>YQVKLEURR5=JV^HA0H ']FW&/\ T"K5QJNGV4R0
MW5_:02N 0DLP1F'3(!-8OB[Q!=Z FG_9(X'^TS^2_FJQP/;!'-,0S5HO#FN.
MCZCIE],\>0K_ -GW*MCTRJ@X]JFL'T#3; V-IIEXEL^=Z'3+AMX(YW$H2W7'
M.>..E7([^Z/B.6U:[TK[(L0<0K(?M*G Y9<X"\G]*E;7=&6)93JM@(W;"O\
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MGQI(F1T88X(]*'*4=WMY(:C&73<Y^W^'-_)KNDZSJ'B>6]N;!L8:U5%:,=%
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M>]!TK5_X1#PQC/\ PCND8_Z\H_\ XFJO_"*>&CR/#VE8X_Y<H_\ "CVE^OX
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M)'3FL'N:+84L0>IQQCD4G&W! /'!H!P ">/:@_=X((P>U !@'<,=_P J ,D
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MLH-1&;:9Y58L#C&Y1]WJ.,Y&>E-OO%EQ'J.H6VEZ+)J46G+_ *7*)EB"$ Y
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M,&EVC)R0@ QM&,\>@JUH_B"YO_A*ESJ?B1M+D$QMVOS$9967/ &"#NQ_$.<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;6C:OXCLM/DBA58_/N;596 )X4?*2>2>!ZDUGO8^!(M=M=$DT725U*ZA\^*
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M7:EH1"D6<Y.U2<GGK_/C&J?"7AH9_P"*?TG@'_ERC_PI3X2\-_\ 0OZ3R?\
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M<_9[B6214EE0!EF7*8R<?,,'OZU/K.CS'Q$]QI::9>O'"J'3I]I,:@ #"$@
M=#U'6MK4/[%U2WC@O+&\DCC.4 L9UV\8X(4<>U5KFP\.7D<*3Z9>,(4$:$6=
MR#M   )"Y.,=\U<J:=]5TZFLJ2=[-=.O9"^"KNVGTR:""R^R-!+B5!(74L0,
MD$DD=.G\ZZ:LW2/[/MXA9Z?;3P1J"V'MI(P?^!.!D_CG\JTJZ*:M%(ZJ*M!)
MN_H%%%%6:A5=HW#;N/SJQ133$U<I#/&,=_YT'H>1C-2R+&'[C'H*0("3L;G/
M(-5<BQ&.>/O=.U '3'3V'O2E2I .>WX4@!S@+GKVIB#!P<CL17'?$[_D4&Z_
M\?$?]:[(J5&=IQD]JR->@TR[M$M-5MKBX@=@P6&"9^1ZF,$CKWZTAK<XW4;*
MWU'X@>&;:ZC66%M/1F1AD-M5V ([C('%6O"L,=G\0_$%K;1K% $4B.,84<KT
M'XG\ZW-VAG4K3438ZB;JUB\J&3[!=?*N",8VX/#'J*+:71+34KC4H+'44O+@
M8ED^PW1W#CL5P.@Z4AW,SXI?\BK'_P!?2_R:LKQ%9:=IM]X6FT*&*.X>5/+,
M(^:6/Y<%L=<YZGKDU?\ 'T[ZUX?6UT^SU&:87"OM^P3KP <\L@'>KVFV7AK3
M;U;Z#2+R*[(Y8:==':3UV@I@?@!0!CZ%IMEJ'Q$\0->VL-R(V^594# $D<X/
M?BL:TL+_ %B^\2&1-&,@E83RZD6#PJ"0"A'W0/7V%=Y:2Z)9:A<:A;V6HI<W
M)'G/]@NCNY]"N!^%5-1T_P +:M=_:[W2;Z2<C#.+"Z3=]=JC)]S0%SF_$$=Q
M;>#/#ME=WD-S9_:MD]Q;REHW4$[1NXX"Y_[Y]JZVUTSP[IOB]C:M';ZE);C%
MK$VQ-G<A0 ">,XYZ9QWJ:XN=$NM/.GS:==M:;2HA_LNX"@8XQA.,=B,8JII5
MMX:T25IM/TN^AE< %SI]TYQZ LIQ^'7\* .!MO\ DDMYT_Y"(_DM;FIV<-_X
MU\*6US$LD36*%D89#8#$ CN.!Q6]'8>&1I+:4NF:@+-Y/-:+[%>'+<<YVY[#
MO6CM\/?VA9WYT_4S=6<?EP2?8+OY%P1C&S!ZGK2&M3G-"MXK'Q_XHM+>-(H%
MLR1'&-J@X4\#MU/YUSJRSQ_!\+$S".34]DVW^YMSS^(6O2(WT"+4[O44T_4A
M=W:>7/)_9]W\Z\<8V8'0=!3+1?#ECI,FE0:7?BQD)+POIMTX)./[R$]A2*(H
M],\(Z;XDT^X@>*UO#:_Z-%$Q1)$_O''WF()')Y]#CCA-6EL]4\*ZIJ&E:%8V
MEDMUAKRZG,ES,Y8'Y,\J<8)!.,,<=Z[G2K#PIHEW]KT_2-0BGP5$C:?=N5!Z
MXW*<?A5=]#\%O/-,VA7N^;.[_B7W>.>N!MPOX8QVH Q=18OJ'PZ9CEC%$23W
MXCKU*N4,/ALMIS'3=3)TW_CT)L;S]WT/]WGH.N:ZN@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHZ4 %%%!.!DT 0W'W1TQFH#T/3I4DK^8,#H.:C_
M  [&K6QF]Q2.1QZTG4$8!Z4'K['-!QS^&:8@(//'I0>_^%&,$^G%!& >3WH
M4C)Z=Z0'YAZ\=J,<CD4#JO/I2 3E1T]>/QI3_%]:0?=QG(YX-+G/H0:8#D=E
M/!';GUJ59SP&7MVJ#C&.#P*#Q@XX]OK2L.[0^1][9"\<@^M,P/0_Y%&.G [T
M=#C'TH$>>?$.5K[Q/X1T1B?LTUX)I5SPVTJ /R+?G2:Q(S?'G0&R,_V:W/\
MW_J7XCQ?8]8\+^(2"(+*_6.X8#HCE>?PVG\ZT[[PQ>W/Q*TSQ&LMN+.TM# Z
M,S>86/F=!C&/G'?UKI32BO1F+3YGZH\NT#4#9ZAKB_\ "#?\)'NO7/F^1O\
M)Y/&?+;&>O:M&/0]1TGX3^)[F_M#8K?312Q6AR#&OF+V/(ZXP>?EKO\ P3X6
MOO#3ZRUY+;R?;+HS1^2S'"\]<@<\^]:7C#1KCQ%X4OM)M'A2XN-@1IB0HPZL
M<D GH#VJI5ES66V@E3?+=^9YOX7OX[B'1+*7X7J\3B")]2>URKJ=H,Q/E<C^
M+[WX]ZZ#Q<YTOXF^$-0C^5[LO:2?[2Y &?7F3/X5V^B:;-I7A[3+&<HTMK;1
M0R%"2I95"DCVXKBO$L)UKXJ>&M/B.X:=$]],1_ -PQG\47\Q4J:E-OIJ-Q<8
M^>AZ%R001GJ.E!'/X_TI,9SSZ]:.F>?\XKG-@YZCT%.0%F7 [&F@X/7^$=JD
MB;$F.!R<BD-#61E/(XSCD4W'&1CMTJXRAA@U3VE>,#(]/K0F#5@Y[#H.AI3C
MGCUIO52<=OZTIXSQP<TQ!QN [^]*.2./3M0>2!CO2 D,.N#B@!0.F1V[4AYS
M^- Y _SWHZY!]\B@!2.<X[4@S^@HP"?PHQTY].U "\GTR1Z48QDX..:3VSVH
MQ@]NIH D 23H=IR#36C=8V) _.F]!U_B%.61EZ,.<]:0QI.6X(SSB@<D'C_(
MJ7B49P XX^M-\IP0=GI1<+#!G X]*/JOKTIRQD\' (QP:/**]<"BXK#3@9/U
MI?3IBGA4;*@G)SVIC(R@9!'- 6$_+M66ERVK7#K;.R64)VO,A(,S#^%2.BCN
M>_;UJKK>BW-Y=Q7%A*8974Q3L6.#&1Z?AV[D?6MBWMX[.VCMX1MCC0*O^?6N
MBT(04D[M_A_70YKU*DW%JT5^/]=?N)B,@\ \T8.[./XOZ4$#./\ :H[\^M8'
M2<E\1;RZL?"XFM+F6WE^T(-\3E&Q@\9%8^DZ5+->V;K\0GN9-RN;43EB^,$I
MCS>>_:M+XGC_ (I$<Y_TB/\ DU:&D>#M LOLM];V 2Z1 ZR>=(<$CT+8[U/4
MKH9/BFVU.(ZEJE[K\EA:1QE;&&TF9"\F,@.,#)..Q/X 5%K>O:I#\,K6\GDD
MM]0NMB>8F8V'S$[AC&,JO;UJ?Q%XETY9]1TKQ!I?E)'&S6DCJ9!.2I *_+\K
M<]<\'/(Q5.SFO=$\"V$NL:&=12&0DQS %[:/)PV"I]_3' XH TO"+:7<W)DL
M_$^IZA/''^]@N)V*<_Q!64$\]^V:R;[Q5J^I>+-"\F*ZL-)DO1%$"Y4W.'4,
M6 ZK@@8Y'7D\XLV$T7B3XE6^J:0&>RM[8I<7'EE%=B&P.0"3\R_EZ"KWCD8\
M6>#!_P!/C?\ H<5)C1WM<A<?$32H+F_MQ9:G-)8R.DXA@#!0I(+YW8"Y'4XZ
M]*Z^O,M '[WXBG_II+_[6I%&U+\1-#(MKCRM0:S=E1KH6Y\J)SR48D_> Y(&
M>.F:U]8\56.CW-O:F&ZO;NX7?';V47F.4Y^;&1QP:\WG 'P3M?>[/_H;5:UN
MU6Q\66&I:G?:A8:=<V,:"]LF961PGW"0"><9P!W'O0!UFI>-8'\'76KZ3'.\
MR$Q%#%EK=\=9!G@#UY'2JV@^,XK?P9#J&K1W_F(1'YDD7-R[$D>7S\W0^@&*
MS+/3K.3P-XCN=(35YEO%+&2_VEIBN273')!R>3U_.J,?BRXL?AYIB:-<%)()
M%AO9Q!O^S@DD<,,'/K^'4T =OI'C"QU;57TPVE_97JIO$-[!Y;,/;D_KBN-\
M*^-SIMGJC:G_ &KJ+1W)8F-3+Y,?0%BQ 49SW[5#H$T,_P 4;.YAO[R_BN+=
MREU=(5\UMK;M@(&%!! &.,$53\->(]/T70_$-M>K('N7D$)$9*RMM(VYZ C(
M//8T >G3^)])M_#ZZX]T#8N,HP!RYZ;0.N<@\=L'/0U3TOQIIVIZBE@]M?6%
MS*@>%+V'R_-'/*\G/3_#-<+/X?U2W^'6C3O:RN;2Z-U-;[?G6,G^[^I],^QK
M5OM2M_&GBWP^^AK+-%I\GGW4YC*K&"00I)'7Y#^?&>: )-,U.X;7O&J7E]?&
MTMHI"HBF.Z)1NR8\G"M@<>^*IZWXMGL/!NE#1Y=49+MF!O+L!Y"NY@5+@XWY
M'&.<#J*CM/\ D*_$3_KVF_D]9^I1N?A)X>F",8X;LM(P&=HWR#)_&@#T*[\9
M65E;63RV6HF[O,F*P6WS<8&<DIG@<>O/X'%C3O%&GZGI%WJ$ F468?[1;R)M
MEC*@D@KGKQZX_(XX3Q-+:W7BC2_$9U"_AT.YMS"M]9;D:)@6&.F0"?;GG'2M
MSP>NDV5KK.M6#ZS/;D%I+B^VG[1LW$LG0GORV.OUP =1H>M6WB#28M1M$E2&
M0L LH ;@X/0GTK1K.T/6K;Q!I,6HVB2I#(6 64 -P<'H3Z5HT %%%% !1110
M 4444 %%%% !1110 53N+F]COX(8;#SK9_\ 63^<J^7_ ,!/)JY7':__ ,CW
MH7T_J:BI+E5S*M/DC?S1V-9?B#6?["TS[9Y'G_.$V;]O7WP:Y#3](MM4UCQ/
M]JWM'%*Q6,.5&[+X8X/)&#C/J:I/-)-\-%$CEO+O BY/1<9Q^M82KOE=E;?\
M#FEB9<KLK:.WR/3+>7S[:*;;M\Q V,YQD9JG+?7D-S=A]/Q:00F2.X\X?O"
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M  XR:)(@_(.#ZU7#=LD9P:G$R].:FQ:=]QH@.?F8>_'6F2H$8 =#[4KRE^G
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M_P"P6FHQ2W!W )M8!L>A(P?P-(9.)]>!_P"0=IQY_P"?]_3_ *XT@N-=&/\
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M72;Q!%=W 5G15=9$..A(/KU%=7>WMOIUE+>7<GEV\*[G?:3@?0<T 4OM&O\
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M))Y8YSMZ>IJ6VMO"MMK=QJUOXC@C>X9FGM?M\?DR$@C++U/4GKU/X5TUI/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+%K_ "_1(**.]%;'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0!5 [ 5=.IS[&E&LJNRTT'4445H;!1110 4444 %%%% !1110 4444 %%%%
M!59XBGN#5F@C/6FG835RF.O3TI"/E[CCVJR\(;!'!%0O&RC.!T-5<AIH?$^T
MD'.T\U,6 &<U3 !/RJ?IBC'3Y#VI6&G8F>7<F%!R?TJ(*6/  .*0KZJ?TJ6%
M?GW%<8[^M/86[+%%&1ZT5!H%-9@HY!_"G44 -7:1E0,?2@MU&#]<4ZB@"MB3
MG#-D5.N[^("G44VQ)6$R,XSS2T44AA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY'4U9B\7^)-*\6Z?HOB6RTV./5$/V6:R9V\M\\*^X_,>@.,=1@T>SG:^GX=
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MD@LWLXO"%S':R9WPHMH$;/7*^;@TZTD6PC>.S\(W5LCG+K"+5 WU EYK>HH
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M;(L3^:C9;$>1@'/&T\X[5OQZ%?A<_P#"3ZL"?^F5I_\ &*?_ &)J'_0TZO\
M]^K3_P",5+J:6NNW4M0UO_D>?Z7\.]6N_"/B72;^);.XO+W[1:.\BLIP<@G:
M3@'IZ\]*O>'-!UK[=ID-YX&\.Z;#:J#<WLB12R2LN,&,)RK$\Y;/KGC!["32
M+R)0TGBS544L%!9+0#)( '^HZDD#\:@^S,-0&G_\)M??;2N_[-_H?F;?7;Y.
M<>]-U9.^WXB]FE;_ (!D>%O#VJ:=\0O$^J7=KY=E>E3;R>8IW\^@.1^(%<C>
M>!?$CZMXD6;0+/59M29_LVKW-TH$"'D8C.2&QA1@#:1U*UZ=_8FH?]#3J_\
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MVI..PYY%/==DF "0!30"00<\$]Z9 ;1D<%3F@ ^_(% !SR._K[4JXXYSQUH
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MU]LO1%YEU!O>'YXQNC.?E;GK["J_PVTC7O#EG<Z-J>EB.W$K31WJW",)"2H
M"#D<#.3^57?&?AW5-7\1^$KRQM?-AL;X371\Q5\M=\9S@D$\*>F>E*3C[5M[
M?\ <4_9V15/C#Q5?>.=8\-Z-8Z4PLU#1SW1D54'RYW[2=V<X  'KVK9^'_BV
MY\6Z)//?6T=O>VMPT$RQ9V$C!!&2<=<=3T]ZI>'O#VJ6/Q/\1:Q<VNRPO(U6
M"7S%.\C;V!R.AZBCX9^'M4\/6.K1ZI:_9WN+UI8AYBON4@<_*3C\:B?)RNWE
M_P $N//S*_F8/Q3DUL>+_"<5J]F(&O4:S20OS.'3F4#C:,KC'."U5-0EUZ+X
MRV@M(+&76'TM5?>SK;H^P[F_O%00<#KTKJ?B'H&KZG?>'-4T>S6]DTJ\\Y[8
MS+$7&4;AFX'W,?B.#4%IH>N7'Q3M?$=SIAMK1M."2YG1_*E*\IP<G!XR!@U<
M)I06VS)E%\S]4+H/Q"NFLO$H\06MO%=Z"3YOV0G9+]X +N)(.5QR?XATYK&M
M/BKJ43Z=?:E_8+Z;?3>6;:RN2UW;!C\ID4G' '. /P/%7+'P/J=UJ7CN*^A^
MS6VL-_HDWF*VX[G() )( )4X.*J:%X7UVWCT[2KGP/X<06[[+G5;E(YO.0$_
M,J##[B,<GJ>N.SM2U_KH%ZFG]=3UBOF#PSJ/@:UT6:+Q'HM_>:@9&,<MO(54
M)M&!_K%YSGL>O>OI^N'^%?A_5/#?A2:RU:U^SW#7;RA/,5\J50 Y4D=0:SHU
M%",K^76Q=6#E)?,\UELM0LO@1*+Z*6))=366VCE!#"(@8/T)W$<<YSWJA>R>
M"M8T4Z?X:\,:NVOLB;'4LXR"-YVB1N,9_A_*O8/B;H>H^(?![V&EV_VBY,\;
MA-ZIP,YY8@5G^-?!5YJ^BZ;J&DJ8?$6F1QB%E<*7 QE-W3@Y(YQU]:VA63LW
MI=OK^9E*D]4NB,'Q=!J-_+X*\%ZC=21K<Q(=0>-OF=E !&>AQAN3D9P>U=!<
M?"304U'3[W1GN-)EM)O,=H)&D,@],N3M.1UZ8)!!XPWQ)X8UWQ1HVC:S"%TO
MQ1IWSB-W5E+9Y&1D<E<C.1@X/4XHQ0_%+Q!JEBFH"UT"SMY/.DEM75C+T&TC
M>^[@G@X7UR0*CF?*N626]_ZZE65W=7['I3P[Y V>!4M%%<ATV"BBB@ HHHH
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M']A:1_T"K'_P'3_"M"BCECV#V<.QG_V%I'_0*L?_  '3_"C^PM(_Z!5C_P"
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M*3G''H#2L5S,NT5'&Y)VGKC-25):"BBB@ HHHH **** "BBB@ HHHH ****
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MQS)@Y"2@ 'T..F1C-:*,K7Z?(B\;V-(:+?X)_P"$HU88_P"F5K_\9I/[%O\
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M34/^AIU?_OU:?_&*VJ*.9ARHQ?[$U#_H:=7_ ._5I_\ &*/[$U#_ *&G5_\
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M!'7Y0<\4 7:*KM?6:WJV37< NV7<L!D&\CU"]<<'\J(;^SN+F6VANX))X?\
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M.<X(/TI>I_6F(MJ<J#C&:6D0@H,>E+69J%%%% !1110 4444 %%%% !1110
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MNM+T2TN/.6W$]S?H=JVT;$@;2.C':WIC'&>S=&7,H]Q*HK7/1)1^\)]^F*3
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M^+1J/PQ@UOP_?W5N);F-=\;M%(OWMR'!['K@D<<9'-=)J7C6PT+^S[&2WO\
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M#&A.<<^M/HI#$48&,YI:** "BBB@!,8''%+110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)_\ (]'VKQ/_ - C2/\ P:2?_(]'M7>]O/</9JUK_@<9XK_Y+3X2_P"N+_\
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MYH !YQVSTH/#8('4\<4B@<8';KQ5&8H&2. #@=:3D#/!'TZ4HQ\O&3@=J3
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M@[&X/8]C4E !1110 4F #G S2T4 %%%% !1110 4444 %%%% !1110 4444
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MD\!0<^WO5P# J&W48+8YSBIZEEQ04444B@HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#P>E)P!^']: %/([=ZGM_P",8[YJ#C(X]>U6XT"+QU/6I94=QU%%%26%%%%
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MM/:XN%=%P6'FX.<;L_*H !Y/&.:ZK0_%.B>)+:>XTG4([B. XE^5D*<9!(8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3*S!2 0Q .<'(Y]Q34WRV2T^8G%<U[ZF0]TTFH1Z@_@F_:]C78ERWV,R*O/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4R7_ %9R<4^HI\E..::$]BONX.30
M3SUH)(SQZTN3S_C5F89.>I'6C/0GGD4=2.>_K4OD'/#'%(:0Y(5"CO4BHJ]
M!2T5%R[!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 36:BDE:-[W+YFV[RM8ZL'(!&>?48I:16#*&&<$9Y&#^5+7*= 4444 %%%%
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MT#_H!Z;_ . D?^%'_",Z!_T ]-_\!(_\*U:* ,K_ (1G0/\ H!Z;_P" D?\
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M=2#FHA#GG<<>AZU/13N)JX@&  .U+112&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  <X..M5G+XPW'-
M6&.%)]!561MQ!+ 9 --$R&X.,$GM0"002"<=:/R'3D8HYR,$$X/XU9!;1@PR
M*=44493)Z9[5+6;-$%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:L/^?C5?_!M=?_'*/^$:L/\ GXU7_P &UU_\<HM'O^'_  0O+M_7W&Q16/\
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MHM'O^'_!"\NW]?<;%%8__"-6'_/QJO\ X-KK_P".4?\ "-6'_/QJO_@VNO\
MXY1:/?\ #_@A>7;^ON-BF2(60[>O6LK_ (1JP_Y^-5_\&UU_\<H_X1JP_P"?
MC5?_  ;77_QRCW>_X?\ !#WNW]?<:+  ,.N1W--A<*YSQGCK5./P]91$E)M1
MR?[^HW#_ *%S4RZ5 ""7N"<8_P"/B3'Y;J/=)M(OYSTHK,DT*SD3:9+]1_L:
MA.A_,.*8WARQ8*#/JG QQJER/S_><TK1[_U]Y5Y=C6HK'_X1JP_Y^-5_\&UU
M_P#'*/\ A&K#_GXU7_P;77_QRG:/?\/^"%Y=OZ^XV**Q_P#A&K#_ )^-5_\
M!M=?_'*/^$:L/^?C5?\ P;77_P <HM'O^'_!"\NW]?<;%%8__"-6'_/QJO\
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MJP_Y^-5_\&UU_P#'*/\ A&K#_GXU7_P;77_QRBT>_P"'_!"\NW]?<;%%8_\
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DON-BBL^ST6UL;@312W[. 1B:_GE7_OEW(_2M"I=N@U?J?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img98921446_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img98921446_1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *X!8L# 2(  A$! Q$!_\0
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MJ>BBBN0Z0HHHH **** "BBB@ HK@OCSXNU+P%\&?&7B'1Y$AU33=,FN+:21
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MSM.V5%)!VGD BM51J2@ZBB^5;NVGWF;J0C-4W)<SZ=3T&BO&?VLOCAJ?[/\
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M[1VE_M(>"I]5MK0Z7J]A(L&HZ<7\SRF(RKJV!E&PV.,Y4CMDX?[6'PS\,_\
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MM-#]2=<UBU\.Z+J&JWS^596-O)=3R?W8T4LQ_(&OF#]G?]NMOV@/BA'X2M_
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MZM#I,<BQE5DC1DBW 87&\#('&.!VKX._X*@?\E]T#_L6;?\ ]*KNOIOX@?\
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M?2+#;ZKI[O\ 9A(QPJR(Y+("<#=N(R><#FO8OV,_A/HGP_\ @'X5NK?3K?\
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MY3=0>HYKS7QOK=QX@_X)<P7=T[23+IUA;;F.25BU*&)?_'4%8'_!*7_FJ/\
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MWXL S%O-V\?ZG.[\:_8:O*O@O^S+X!^ JSR^%]*;^T;A=DNIWTGG7+)_=#8
M5?90,X&<X%>JUS9MCH8ZM&5-.T5;7=F^6X.>#I.,WJW?39'PU_P5/@O6\&>
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MX#:Y\0ZIXA@%K*\EI+"EHCG#*0X!>3L N5R<Y.,'A_\ @EI_R4;QK_V"8_\
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M"^.O@6?X:?\ !.6X\-7:[+VQT[3!<IC&V9KZW>1?P=F&>^,UP'_!*7_FJ/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[\0O NF_$S
MP5K'A?6/.&F:I ;><V[[) "0<J<'!! /((XZ5T5%5&3A)2B[-$RBI)QELSQ;
MX!?LF^#?V=-2U6_\-WFL7UWJ,*P2R:K<1R;45MV%$<:#D^N>E>TT45I6K5,1
M-U*KNR*5*%&/)35D%%%%8FH4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5YW\<_@7X>_:"\'0>&_$LU_;V4%XE]%-ILJQR
MK*J.@.65@1MD88([UZ)16E.I.E-3@[-$3A&I%PFKIGG?P,^!?A[]GWP=/X;\
M-37]Q93WCWTLVI2K)*TK(B$Y55 &V-1@#M7HE%%%2I.K-SF[MA"$:<5""LD%
M%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?^?GX?\ !#^UY?R?B?LK_P )OX=_Z#^E_P#@9'_\51_PF_AW_H/Z7_X&1_\
MQ5?C511_8D?^?GX?\$/[7E_)^)^RO_";^'?^@_I?_@9'_P#%4?\ ";^'?^@_
MI?\ X&1__%5^-5%']B1_Y^?A_P $/[7E_)^)^RO_  F_AW_H/Z7_ .!D?_Q5
M'_";^'?^@_I?_@9'_P#%5^-5%']B1_Y^?A_P0_M>7\GXG[*_\)OX=_Z#^E_^
M!D?_ ,51_P )OX=_Z#^E_P#@9'_\57XU44?V)'_GY^'_  0_M>7\GXG[*_\
M";^'?^@_I?\ X&1__%4?\)OX=_Z#^E_^!D?_ ,57XU44?V)'_GY^'_!#^UY?
MR?B?LK_PF_AW_H/Z7_X&1_\ Q5'_  F_AW_H/Z7_ .!D?_Q5?C511_8D?^?G
MX?\ !#^UY?R?B?LK_P )OX=_Z#^E_P#@9'_\51_PF_AW_H/Z7_X&1_\ Q5?C
M511_8D?^?GX?\$/[7E_)^)^RO_";^'?^@_I?_@9'_P#%4?\ ";^'?^@_I?\
MX&1__%5^-5%']B1_Y^?A_P $/[7E_)^)^RO_  F_AW_H/Z7_ .!D?_Q5'_";
M^'?^@_I?_@9'_P#%5^-5%']B1_Y^?A_P0_M>7\GXG[*_\)OX=_Z#^E_^!D?_
M ,51_P )OX=_Z#^E_P#@9'_\57XU44?V)'_GY^'_  0_M>7\GXG[*_\ ";^'
M?^@_I?\ X&1__%4?\)OX=_Z#^E_^!D?_ ,57XU44?V)'_GY^'_!#^UY?R?B?
MLK_PF_AW_H/Z7_X&1_\ Q5'_  F_AW_H/Z7_ .!D?_Q5?C511_8D?^?GX?\
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M4?V)'_GY^'_!#^UY?R?B?LK_ ,)OX=_Z#^E_^!D?_P 51_PF_AW_ *#^E_\
M@9'_ /%5^-5%']B1_P"?GX?\$/[7E_)^)^RO_";^'?\ H/Z7_P"!D?\ \51_
MPF_AW_H/Z7_X&1__ !5?C511_8D?^?GX?\$/[7E_)^)^RO\ PF_AW_H/Z7_X
M&1__ !531>+-#GAFECUG3Y(H0#+(MTA5 3@%CGC)..:_&2O5/AA_R1_XP_\
M8.T[_P!.$-95,GC!7Y^JZ=W8TAFKF[<G?KV5S]0?^$W\._\ 0?TO_P #(_\
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M_P"@_I?_ (&1_P#Q5?C511_8D?\ GY^'_!#^UY?R?B?LK_PF_AW_ *#^E_\
M@9'_ /%4?\)OX=_Z#^E_^!D?_P 57XU44?V)'_GY^'_!#^UY?R?B?LK_ ,)O
MX=_Z#^E_^!D?_P 51_PF_AW_ *#^E_\ @9'_ /%5^-5%']B1_P"?GX?\$/[7
ME_)^)^RO_";^'?\ H/Z7_P"!D?\ \51_PF_AW_H/Z7_X&1__ !5?C511_8D?
M^?GX?\$/[7E_)^)^RO\ PF_AW_H/Z7_X&1__ !5'_";^'?\ H/Z7_P"!D?\
M\57XU44?V)'_ )^?A_P0_M>7\GXG[*_\)OX=_P"@_I?_ (&1_P#Q5'_";^'?
M^@_I?_@9'_\ %5^-5%']B1_Y^?A_P0_M>7\GXG[*_P#";^'?^@_I?_@9'_\
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M****[3D"BBB@ HHHH **** "BBB@ HHHH **** "O5/VAO\ D/>$?^Q1T?\
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MZU;M<"Q!)6"56PX7/13N4@=B2!@8 FACZ=>:@E:^VW3\OF.M@IT8.;>V^_\
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MXW_8MN-+\!7GBSP9XUTWQYI]FCRSK8Q*A,: ES&R22*[+C)7(/!QDX!QO^%
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MNO\ TNGKRNO5/BQ_R3'X0_\ 8&NO_2Z>O*ZRH?!\W^;-*WQ?)?D@KV/]G?\
M9W/Q\_X23&OC0_['BBDYL_M'G;_,X_UB;<>7UYZUXY7V1_P3M_YJ1_U[6?\
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MHHH **** "BBB@ KU3]H;_D/>$?^Q1T?_P!)4KRNO5/VAO\ D/>$?^Q1T?\
M])4KGE_%C\_T-X_PY?+]3RNOIOQU\9O"&L_L@>&O!%GJIE\3V<D)GL?LTJ[
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M]>_9UN/!7A/7M1U&]BN8A"FIQW$D\RK-YCRM+(N"#DX!((X 4  #?^'?Q7^
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M0QW%A+ Z7$,J[D>,J0ZD=P1D8KRG_A6OP8_Z$W0?_!4O_P 37J>N?\@34/\
MKWD_]!->+URTG))\K:.F<8O=7-7_ (5K\&/^A-T'_P %2_\ Q-'_  K7X,?]
M";H/_@J7_P")K*HK?FG_ #O[S/DA_*ON-7_A6OP8_P"A-T'_ ,%2_P#Q-'_"
MM?@Q_P!";H/_ (*E_P#B:RJ*.:?\[^\.2'\J^XU?^%:_!C_H3=!_\%2__$T?
M\*U^#'_0FZ#_ ."I?_B:RJ*.:?\ ._O#DA_*ON-7_A6OP8_Z$W0?_!4O_P 3
M1_PK7X,?]";H/_@J7_XFLJBCFG_._O#DA_*ON-7_ (5K\&/^A-T'_P %2_\
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M)K9HH]K4_F?WA[.G_*ON,;_A2_PF_P"A(T#_ ,%J?_$T?\*7^$W_ $)&@?\
M@M3_ .)K9HH]K4_F?WA[.G_*ON,;_A2_PF_Z$C0/_!:G_P 31_PI?X3?]"1H
M'_@M3_XFMFBCVM3^9_>'LZ?\J^XQO^%+_";_ *$C0/\ P6I_\31_PI?X3?\
M0D:!_P""U/\ XFMFBCVM3^9_>'LZ?\J^XQO^%+_";_H2- _\%J?_ !-'_"E_
MA-_T)&@?^"U/_B:V:*/:U/YG]X>SI_RK[C&_X4O\)O\ H2- _P#!:G_Q-'_"
ME_A-_P!"1H'_ (+4_P#B:V:*/:U/YG]X>SI_RK[C&_X4O\)O^A(T#_P6I_\
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M[,/Y)%+.\I_Y^P.\_P"%+_";_H2- _\ !:G_ ,31_P *7^$W_0D:!_X+4_\
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M  I?X3?]"1H'_@M3_P")KB?^&BO!O_/X?^_L/_QRC_AHKP;_ ,_A_P"_L/\
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M!%+J7_(NZI_NQ_\ HQ:\MSJ7LY/[SW5"FUS12.:_X5K\&/\ H3=!_P#!4O\
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M%:_!C_H3=!_\%2__ !-'_"M?@Q_T)N@_^"I?_B:RJ*.:?\[^\.2'\J^XU?\
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M'/&#F@9J?#+X@1^(/#?AFWUSQ)X3U+Q=J6F_;WB\,WXEM;I 0KSVH=C(\()
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MP\#>&]*GTJ>R\/Z79S:3;-9Z=);V4:-9P-MW10D+^[0[5RJX!VCCBM_R9/\
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MZUH?C_D>+_ ?X#I9Q1ZSK,8=F&50_P 7L/\ 9]3W^E?0^H*$\-ZDJ@*JI&
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M=!63]BN/^>$O_?!K=;(S9!14_P!BN/\ GA+_ -\&C[%<?\\)?^^#3$045/\
M8KC_ )X2_P#?!H^Q7'_/"7_O@T 045/]BN/^>$O_ 'P:/L5Q_P \)?\ O@T
M045/]BN/^>$O_?!H^Q7'_/"7_O@T 045/]BN/^>$O_?!H^Q7'_/"7_O@T 04
M5/\ 8KC_ )X2_P#?!H^Q7'_/"7_O@T 045/]BN/^>$O_ 'P:/L5Q_P \)?\
MO@T 045/]BN/^>$O_?!H^Q7'_/"7_O@T =GI_P#R =,_ZYM_Z&U246$,@T/3
M08V!$;9&T\?.U/\ )D_YYM^1K![FIS?C'X=>%/B):PVWBOPQHWB:VA;?%#K&
MGQ7:(WJHD4@'Z5HZ7X?TO0](CTK3=-L]/TN-#&EC:P)% JGJH10% ]L5I^3)
M_P \V_(T>3)_SS;\C2 YZ3P#X8F\(KX5D\.:2_A=8E@&B-8Q&R$:D%4\C;LV
M@@$#& 0*O'P[I1\0+KITRS.N+:FR&I?9T^TBW+AS#YN-VS< VW.,@'&:T_)D
M_P">;?D:/)D_YYM^1H YO3?AWX5T7Q1?>)=/\,Z/8^([Y2EWK%M811W=PI()
M$DRJ'<953@D]!Z53L?A%X$TOQ._B2R\%>';3Q%(Q=]7@TJ!+MF/4F8)O)/UK
ML/)D_P">;?D:/)D_YYM^1H YGQ1\-O"/CB\L;SQ'X6T7Q!=V#;K2XU33H;F2
MW.0<QLZDH<@'C'2M+1O#NE>'([M-)TRSTM+NYDO+A;.W2$33R',DKA0-SL>2
MQY/<UJ>3)_SS;\C1Y,G_ #S;\C0!R7BKX4^"?'6H6U_XD\':!XAOK;'D76JZ
M7!<RQ8.1M9U)7!YXK5U[PGHGBK0Y-%UK1M/UC1Y%"/I]_:I/;LHZ QN"I QZ
M5L>3)_SS;\C1Y,G_ #S;\C0!QFJ?!WP#KFBZ7HVI>!_#>H:1I8VV&GW6DV\M
MO9CTBC9"L?\ P$"MBQ\&Z!IFGZA86>AZ;:6.H.TEY;06D:17+%%C+2*!AR41
M%);/"@= *V_)D_YYM^1H\F3_ )YM^1H YC1?AKX0\.>&;CPYI/A71-+\/7!9
MIM)LM.AAM)"V-Q:)5"$G SD<X%1^%_A;X+\#V%Y8^'/".@Z!97BE+FVTO3(;
M:.=2""'5% 88)Z^M=7Y,G_/-OR-'DR?\\V_(T <GX/\ A5X*^'MS<W'A7P?H
M/AJXNAMGET?3(+1Y1G.',:@MSSS74T_R9/\ GFWY&CR9/^>;?D: -OPU_JI_
M]X5M5C^'$9(IMRE?F'45L5F]RD4=<_Y FH?]>\G_ *":\7KVC7/^0)J'_7O)
M_P"@FO%ZWI[$3"N;A^(_AJ;5?%&G_P!KP1W'AB.*766FW10V2R1F52\K )_J
MU+G#':""V,C/25\@>!Y7U[]B?XV^,)PQO/%<?BK5)7?&["K<6\:]>BI J@=L
M5HV0?6,6NZ;/H::S'J%K)H[VXO%U!9U-NT!7>)1)G:4V_-NSC'.:FTW4K36M
M.M=0T^ZAOK"[B2>WNK:02131L RNC*2&4@@@C@@U\>^'OV@-/M_V/=,T$^#/
M'KS1^!(K'[='X5O&LRPT\)Y@G";#%GGS,[=O/2NR^&?Q4U7X>^#_ -F;2+BW
MLSX0\5>&[/2YKUT83V^H"PBDME#;]NV0+(N-I.X#FES!8^F*PO$GCC1/".H:
M#8ZM??9+K7+W^S].C\IW\^?8S[,JI"_*C'+8'&,YQ7AGCC]J;5/"MY\4[VRT
M>SU31/"MS8:!ID89DFU#69R/,B,A;:L<?FQ _+G[W/2N5^)=U\48_BE\#;3X
M@6?AF>VD\5I/!J'AMIXUBE%I.&@DBF+%N"2)%8 [2"HXHY@L?75%>!:%\5/B
MAXY^,OC?POH.G>&+/P[X3U:VM[G4M2$[37,$D$4ABC1'XE&Z0^8WRX,8V$[B
M,W0_C!\7OBQI>M^+/AYHWA.+PC97=S:Z;:ZX;E[[61;NT<DB/&P2 ,R,J!E?
MD<X%.X6/H^DDD6-&=V"(HR68X 'J:^;-2_:D\0>)/!_P:UOP'H.G7L_C^XGM
M6L=6G=%MI$@D)_>KT6.6,ECL8LJ$* Q!'6?#'XF>,KKXK^(?AK\0[+0GU:VT
MF#6[+4/#Z3);75I)(\+J\<K,RLLB$?>(8<X%%T%CUK0]>TSQ1I-MJFC:C::M
MIERNZ"]L9UFAE7)&5=2589!'![50N/'.B6OC:R\(RWVSQ#>64FHP6?E.=]O&
MZH[[]NT89U&"<\\#@U\V^!OVAM8C_9^^#J^%?#'AO3_&'CFYDL=.TJVA:TTB
MQ6-I6FF\I"6V(J [%.27ZU)H>H>-H?VR/#D7C^UT6*ZL_!NHO%J6A/(+:ZB-
MS;DGRI"7B9<$$%F!X(/. N8+'U717S%I?QP^,?CGX=WOQ/\ "OA[PHG@Q$N+
MRPT/5&N?[4U"TA+#S/.5A'$[A"50HPZ9/.:U/%'[1OB?6K[X-P?#K1M*OA\1
M-*OK]/[<DDC%D8HK:16=D/(02RAE"DL54!E&33YD%CZ)HKP/PG^T!KWAN;XI
M:5\3;+2XM3\"Z?%K,E[X>61;:^LY(I'4I'*S,D@,3*5+')(Q7E>E_MS:E"OA
MS7M4USX<WFBZM=VT-SX8T?4)I-:T^*=U4,7+>7*T>X%U")T;!XS2YD%F?6FD
M>-M%U[Q)KWA^RO1+K.AF$:A:-&Z-#YR;XFRP 967.&4D9##.00-RO O$EVOA
M7]M?P:\#%1XL\*7NGW42\*S6DJSQ2'_: EE7/H?I7OM4!H^'?^0]IW_7=/\
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M  #[A_X2+5/^@C=?]_6_QH_X2+5/^@C=?]_6_P :^'O^%C>(O^@C_P"0(_\
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M_P!!'_R!'_\ $T?\+&\1?]!'_P @1_\ Q-'^JL_^?J^[_@A_Q$"G_P! [_\
M O\ @'W#_P )%JG_ $$;K_OZW^-'_"1:I_T$;K_OZW^-?#W_  L;Q%_T$?\
MR!'_ /$T?\+&\1?]!'_R!'_\31_JK/\ Y^K[O^"'_$0*?_0._P#P+_@'W#_P
MD6J?]!&Z_P"_K?XT?\)%JG_01NO^_K?XU\/?\+&\1?\ 01_\@1__ !-'_"QO
M$7_01_\ ($?_ ,31_JK/_GZON_X(?\1 I_\ 0.__  +_ (!]P_\ "1:I_P!!
M&Z_[^M_C6IX7UK4+G7K2.6]N)(V)RK2$@_*?>O@K_A8WB+_H(_\ D"/_ .)H
M_P"%C>(O^@C_ .0(_P#XFE_JK/\ Y^K[O^"'_$0*?_0._P#P+_@'Z*_VA=?\
M_$O_ 'V:/[0NO^?B7_OLU^=7_"QO$7_01_\ ($?_ ,31_P +&\1?]!'_ ,@1
M_P#Q-1_JG/\ Y_+[O^"5_P 1!I?] S_\"_X!^BO]H77_ #\2_P#?9H_M"Z_Y
M^)?^^S7YU?\ "QO$7_01_P#($?\ \31_PL;Q%_T$?_($?_Q-'^J<_P#G\ON_
MX(?\1!I?] S_ / O^ ?HK_:%U_S\2_\ ?9H_M"Z_Y^)?^^S7YU?\+&\1?]!'
M_P @1_\ Q-'_  L;Q%_T$?\ R!'_ /$T?ZIS_P"?R^[_ ((?\1!I?] S_P#
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MU 8B(_[*^M6=2^$_QC^(7CCX<Z]XQU;P?8V/A;5UOYM*T/[2XN/W,B--YLJ
M[\L L6 H#.2[$**^C:*.5!<\U^&/PSU/P7\0OB?KU]<6DMIXHU6WOK..W=C)
M''':QPD2 J &W(3@$C&.>U>;^&?@[\8?A+H^L^#_  %K7A&3PA=7MS<Z;?ZT
M+H:AI*7$C2.BQH#'/L9V*DLG)YR.*^DJ*+!<\%T[]FA_"-O\#]*\/7L#:/X
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M389G0)YC*N4^8E\E5"U[)\$O"_CSX6_%[XD:-=^#_MO@WQ3XGNO$UOXKAU*
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M/A[^S[J.J_"?XX>"_&-@NGVWC/Q9X@O;1O-CFS:W4F;>X&QCM/1PIPP*C(%
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MZ#2?^ TG^%%PL9%%:_\ 9>F?]!I/_ :3_"C^R],_Z#2?^ TG^%%PL9%%:_\
M9>F?]!I/_ :3_"C^R],_Z#2?^ TG^%%PL9%%:_\ 9>F?]!I/_ :3_"C^R],_
MZ#2?^ TG^%%PL9%%:_\ 9>F?]!I/_ :3_"C^R],_Z#2?^ TG^%%PL9%%:_\
M9>F?]!I/_ :3_"C^R],_Z#2?^ TG^%%PL9%%:_\ 9>F?]!I/_ :3_"C^R],_
MZ#2?^ TG^%%PL9%%:_\ 9>F?]!I/_ :3_"C^R],_Z#2?^ TG^%%PL0^'?^0]
MIW_7PG_H0KL)O]=)_O'^=86AZ=IT>L631ZLLKK,A5/L[C<<CC)%=/+;6WFOF
M\4')_P"6;5G+<N)2HJU]EMO^?Q?^_;4?9;;_ )_%_P"_;5!15HJU]EMO^?Q?
M^_;4?9;;_G\7_OVU %6BK7V6V_Y_%_[]M1]EMO\ G\7_ +]M0!5HJU]EMO\
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M>A1)'?K+'YSD2>4PR<+Q@U,N(<>EI+\!K@[*?Y']Y\Q?\,?M_P!!,?\ ?_\
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M7T7_ &7IG_0:3_P&D_PH_LO3/^@TG_@-)_A6O^L&._F_ C_4[*?Y']Y\Z?\
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MMO\ G\7_ +]M1]EMO^?Q?^_;4?ZQ8_\ F7W!_J;E'\C^\^6O^&/V_P"@F/\
MO_\ _::/^&/V_P"@F/\ O_\ _::^I?LMM_S^+_W[:C[+;?\ /XO_ '[:C_6+
M'_S+[@_U-RC^1_>?+7_#'[?]!,?]_P#_ .TT?\,?M_T$Q_W_ /\ [37U+]EM
MO^?Q?^_;4?9;;_G\7_OVU'^L6/\ YE]P?ZFY1_(_O/EK_AC]O^@F/^__ /\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY_\ D5/_ (W6G^K>-[Q^_P#X!'^O&5]I_<O\SZ3HKYL_X:3U?_GS_P#(J?\
MQNC_ (:3U?\ Y\__ "*G_P ;H_U;QO>/W_\  #_7C*^T_N7^9])T5\V?\-)Z
MO_SY_P#D5/\ XW1_PTGJ_P#SY_\ D5/_ (W1_JWC>\?O_P" '^O&5]I_<O\
M,^DZ*^;/^&D]7_Y\_P#R*G_QNC_AI/5_^?/_ ,BI_P#&Z/\ 5O&]X_?_ , /
M]>,K[3^Y?YGTG17S9_PTGJ__ #Y_^14_^-T?\-)ZO_SY_P#D5/\ XW1_JWC>
M\?O_ . '^O&5]I_<O\SZ3HKYL_X:3U?_ )\__(J?_&Z/^&D]7_Y\_P#R*G_Q
MNC_5O&]X_?\ \ /]>,K[3^Y?YGTG17S9_P -)ZO_ ,^?_D5/_C='_#2>K_\
M/G_Y%3_XW1_JWC>\?O\ ^ '^O&5]I_<O\SZ3HKYL_P"&D]7_ .?/_P BI_\
M&Z/^&D]7_P"?/_R*G_QNC_5O&]X_?_P _P!>,K[3^Y?YGTG6QX1_Y&.R_P!Y
MO_037RI_PTGJ_P#SY_\ D5/_ (W4UG^T]KEA<)/!:[)4Y5O,C..,=XJ'PWC>
M\?O_ . -<<95VG]R_P S[+HKX]_X:P\2_P#/+_QZ+_XU1_PUAXE_YY?^/1?_
M !JLO]6,=WC][_R*_P!>LJ[3^Y?YGV%17Q[_ ,-8>)?^>7_CT7_QJC_AK#Q+
M_P \O_'HO_C5'^K&.[Q^]_Y!_KUE7:?W+_,^PJ*^/?\ AK#Q+_SR_P#'HO\
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MRO/VGM<OKF2XGM=\LARS>9&,_E%4/_#2>K_\^?\ Y%3_ .-UJN&\;;>/W_\
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MC*^T_N7^9])T5\V?\-)ZO_SY_P#D5/\ XW2K^TEJVX;K0A<\D2(3_P"BZ/\
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M$\6^(O%/BSQOJ.DV,%SI5KXCU!)+339G@ +Q0111J6"L5#.&*\8.0#2 ]?\
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M1>(_A;X%T1?$?QHNUO+CQ18Q'7+[PY:RO=12R)&-.\JWC58Q*V1Y^-R;R<X
MQQ&H?M!:-\*_VKOB58^,_%=U9Z(-#T9M,TC]_=DS-]I,S6]K$KL3@*79$Z!2
MQZ4W]IKX>:)\,_@QX)T+P[!=0:<OC[0I5CN[ZXO9-S7T9/[R=W<_3=@=JQ=0
M^*W@_P"#W[;7Q+UKQI(=(T^?PYHUI%K\UF[VULY-PWDR3*I\HR!<J#@,8B,Y
M"@@'OT/[0?P\N/A:OQ'A\46LW@II(H3JT22,B/).D"JZ!=Z'S)$4AE&W.6P
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MV[S<;=HQMZG/'H5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNT\/_P#(MP_]?$G\EJ9<48A?80UP'@G_ ,O9?@?$/_#//C+_ )\#_P!^9O\
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M^^9?_B*^LJ*/]9L1_(@_U#P7_/V7X'R;_P *)\4?\\8_^^9?_B*/^%$^*/\
MGC'_ -\R_P#Q%?65%'^LV(_D0?ZAX+_G[+\#Y-_X43XH_P">,?\ WS+_ /$4
M?\*)\4?\\8_^^9?_ (BOK*BC_6;$?R(/]0\%_P _9?@?)O\ PHGQ1_SQC_[Y
ME_\ B*/^%$^*/^>,?_?,O_Q%?65%'^LV(_D0?ZAX+_G[+\#Y-_X43XH_YXQ_
M]\R__$4^'X!^++B18XK999&Z*D<Q)_#RZ^KZV/"/_(QV7^\W_H)I?ZSXC^1#
M_P!0\%_S]E^!\>_\,\^,O^? _P#?F;_XW1_PSSXR_P"? _\ ?F;_ .-U]T45
M'^M.)_D17^H6"_Y^R_ ^%_\ AGGQE_SX'_OS-_\ &Z/^&>?&7_/@?^_,W_QN
MONBBC_6G$_R(/]0L%_S]E^!\+_\ #//C+_GP/_?F;_XW1_PSSXR_Y\#_ -^9
MO_C=?=%%'^M.)_D0?ZA8+_G[+\#X7_X9Y\9?\^!_[\S?_&Z/^&>?&7_/@?\
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M9;;_ )_%_P"_;4?9;;_G\7_OVU5:* +7V6V_Y_%_[]M1]EMO^?Q?^_;55HH
MM?9;;_G\7_OVU'V6V_Y_%_[]M56B@"U]EMO^?Q?^_;4?9;;_ )_%_P"_;55H
MH M?9;;_ )_%_P"_;4?9;;_G\7_OVU5:* +7V6V_Y_%_[]M1]EMO^?Q?^_;5
M5HH M?9;;_G\7_OVU'V6V_Y_%_[]M56B@"U]EMO^?Q?^_;4?9;;_ )_%_P"_
M;55HH M?9;;_ )_%_P"_;4?9;;_G\7_OVU5:* +7V6V_Y_%_[]M1]EMO^?Q?
M^_;55HH M?9;;_G\7_OVU'V6V_Y_%_[]M56B@"U]EMO^?Q?^_;5C>*K&QFU)
M&FU-;=_)C&TP.W&.#D5?KG_&G_(6C_Z]X_\ T&JCN2]B#^R],_Z#2?\ @-)_
MA1_9>F?]!I/_  &D_P *R**UMYD&O_9>F?\ 0:3_ ,!I/\*/[+TS_H-)_P"
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M9%%%O,#7_LO3/^@TG_@-)_A1_9>F?]!I/_ :3_"LBBBWF!K_ -EZ9_T&D_\
M :3_  H_LO3/^@TG_@-)_A6111;S U_[+TS_ *#2?^ TG^%']EZ9_P!!I/\
MP&D_PK(HHMY@:_\ 9>F?]!I/_ :3_"C^R],_Z#2?^ TG^%9%%%O,#7_LO3/^
M@TG_ (#2?X4?V7IG_0:3_P !I/\ "LBBBWF!K_V7IG_0:3_P&D_PH_LO3/\
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M%_[]M56B@#+\2Z?I\NN7CRZJL$A?F,P.V.!W K,_LO3/^@TG_@-)_A2^+O\
MD9+[_?\ Z"L>MEL9,U_[+TS_ *#2?^ TG^%']EZ9_P!!I/\ P&D_PK(HIV\P
M-?\ LO3/^@TG_@-)_A1_9>F?]!I/_ :3_"LBBBWF!K_V7IG_ $&D_P# :3_"
MC^R],_Z#2?\ @-)_A6111;S U_[+TS_H-)_X#2?X4?V7IG_0:3_P&D_PK(HH
MMY@:_P#9>F?]!I/_  &D_P */[+TS_H-)_X#2?X5D446\P-?^R],_P"@TG_@
M-)_A1_9>F?\ 0:3_ ,!I/\*R**+>8&O_ &7IG_0:3_P&D_PH_LO3/^@TG_@-
M)_A6111;S U_[+TS_H-)_P" TG^%']EZ9_T&D_\  :3_  K(HHMY@>@0QQ0Z
M1IR0S"XC$;8D"E<_.>QIM1Z?_P @'3/^N;?^AM4E8]30****0!1110 4444
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M5:!X)^)&EWL.DO8'7?'US>KNC>5'-O%#=RM(>4WEM@48X))J7]EOPAK?AO\
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M^)6O^$_B)JG@OQ'X8M+9/^$,GNXM2TN[C=G\FZM;5UE*%7ZC<%<,".]-\?\
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M:/\ A)M8_P"@M??^!+_XT?ZJP_Y^O[@_XB!5_P"?"^\^U_[:T_\ Y_K;_O\
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MT?VUI_\ S_6W_?Y?\:^*/^$FUC_H+7W_ ($O_C1_PDVL?]!:^_\  E_\:/\
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M_P#C1_PDVL?]!:^_\"7_ ,:/]5X?\_7]P?Z_5?\ GPOO/T-_X2K1?^@O8?\
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MK@]>_:=\8?"IK/4/BM\*G\)^$9YX[:7Q)HVO1ZM;V#NP5&ND\J%XXR2!O 8
MD \D4#/HFD894@''N.U<U)X@\0?\+ L]*@\,B?PI-IKW4GB8:A&!%<B0*EM]
MGQO;<A+^8#M&,=3734".*^#_ ,)='^"G@>W\,:)/>7MNEQ/=S7VI2+)=74\T
MK222RLJJ&8LW91P .U=K110 4444 %%%9_B#7++POH.I:SJ4PM].TZVDN[F9
MNB11H7=OP4$T :%%?-NI?M0>)O!_[+OA;XHZUX3L]3UWQ%=6JVFAVMVUE&D5
MY.1:AY764AA$T1<[<%B<!15^Z_::\4?#W7-&M_BO\,9/!.AZO=QZ?;>(M+UJ
M/5K&"XD.$2Y(CB>$,> Y4KDCD<X!GT'17SI\2OVQ+7X9_M+>'OA9?^%Y9=+U
M."T>X\3+>A4LI+F62*!7A\OE3(BJ7W@#S!QTSZC\;OBI;?!?X::OXKGL7U:>
MU\N&STN*01R7UU+(L4$"M@X+R.HS@X&3@XH [JBO.?V>?B\_QV^$.A^-Y-'_
M + EU%[J)].^U?:?):"ZEMV DV)N!,1/W1UJ'XD?&@?#WXG?#'P>=(-^?&MY
M>6GVS[3Y?V/R(/-W;-A\S=]W&5QUYZ4 >F45YK\*_C,/B;XT^).@#2#IQ\&Z
MNFE?:/M/F_:]T*R>9MV#9][&W+=,Y[5Q_CO]H;QCIOQVNOACX*^'5GXMO[30
MH==N+R^\1#356-YFBV!?L\N2"JG.1]X\<<@'O5%>1?"#]H ?$;Q1KG@OQ!X9
MOO ?Q!T6!+NZT'498[A9+=SM6XMYXSMGBW84L "&."!5W]GGXJ:C\5/!>HR:
M_;V=GXKT'6+W0-:M]/#+ EU;RE=T89F8(Z&.0 D\..3UH$>H4444 %%%% !1
M110 5XQXL_9?TK7?'6L^+=$\9^,O >K:V(O[57POJ4<,%ZT:!$D>*6*10X10
MNY0IX]SGV>B@#C_A7\*= ^#GA-= \.Q7'V9KB6\N;J]G:XN;RYE;=+/-*W+R
M,>2?H!@ "NPHHH **** "OSQ^(W_ ".>H_\ ;/\ ]%K7Z'5^>/Q&_P"1SU'_
M +9_^BUK[[A/XZWHOU/R3Q!_A8;UE^AS5%%%?HI^,!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%*JEV"J"S$X '4T :?AOQ!>^'-4BN[%V$H(!09^?GI
MQ7W9\+?%6H^*O#L<VHV4L$J*!YTF/G..A_VAWQQ_*O!O@/\  >34IH]8UB,Q
MQ(<JI[>P_P!KU/;Z]/J>UM8K.WC@@C6*&,;511@ 5^<\28W#U6J$%>:Z]O(_
M:>"<KQM!/%U).-.6T>_F2T445\$?K(4444 %%%% !1110!S/B[_D9+[_ '_Z
M"L>MCQ=_R,E]_O\ ]!6/6\=D9O<****8@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH [K3_\ D Z9_P!<V_\ 0VJ2H]/_ .0#IG_7-O\ T-JDK![FH444
M4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#>\-?ZJ?_ 'A6U6+X:_U4
M_P#O"MJLWN4BCKG_ "!-0_Z]Y/\ T$UXO7M&N?\ ($U#_KWD_P#037B];T]B
M)A1116IF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!H^'?^0]IW
M_7PG_H0KL)O]=)_O'^=<?X=_Y#VG?]?"?^A"NPF_UTG^\?YUE/<N.PRBBBH*
M"BBB@ HHHH **** "BBB@ HHHH ^8_\ @I9_R9/\1O\ N&_^G*UKI/VY/$&E
MZ'^RS\08-1=#-JFG/IEA:[0\ES=S?)#'&G5GW$' R0%)[5ZE\2/AOX<^+W@K
M4O"7BW31J_A[41&+JS,TD/F;)%D3YXV5AAT4\$=*XKPA^RE\+/ _B2TU_3O"
MYN=9LSNM+W6-1N]3DMF_O1&ZED\L^ZX- SR_PWH]_H'[47P;TG478:E9_"ZZ
MM;EMVX^:DMFKG)ZG<#UKD/@S\/[#]GGXM>#M.^)'@C[9XXU>^N[72OBCINJ2
MW/\ :]P\<K%;R)W#QNT1;Y6$D8(!7&W*_6VH?#GP[JWC2U\67>G";Q!;:=-I
M,5V9I!MM965Y(]@;8<LB_,1D8X(!-<7X"_97^%WPS\26NOZ!X8,&JV:NEG/>
M:C=7HLPX(80)/*ZPY!(_=A>..G% 'QKX5^&_C3]I;_A8_B*]\#^'?%VNCQ)J
M>EVVM:QXMN[.]T(PR%(8;>&*%A (P$888%\Y;.:]1^(TT.KZ3\*OA_XX\#:C
M\<_B<OALZA/I>EZR+?2I44QQ/>SR2/'%(6? 5F5L;FQC(S[OXO\ V4?A7XZ\
M47OB+5O"BMJU]C[;-97UU9I>X&,SQPRHDQQQF16XJ_XY_9O^&_Q&M=!@UOPO
M"5T&#[)I<FG7$UA+:0;0ODQR6[QL(]H V9VX'2D!\L_ OP=XP^)O[._QR^&^
MB&X\"7MCXJ>TTK1[S5VNETR#;;3R:>;J!B?)8>;'F,Y42MR>127_ (QT_P"!
M_P %?CKI/@WX<3?"7XGZ/H5M>WMK87YO+.2%V>..]M90Q7*AIF)*(^57=G;\
MOT]:_LN_"_3_  7K?A*S\)PV/A[6;J*^O;*SNIX0\\:QJDBLD@:-@(D.4*Y(
M+')))U/A_P# /P#\,=-UFR\/^'(8H=:79J;WTTM]->IM*A)I;AW>1 K, K,0
M 2,<T ?)7@']GOQWH^M_#;Q?X7\(^$/!T\.H6-UJ7BBU\97=[<ZW8R8$\4X>
M +.TRON!).&V[<5]%?MK3W%O^R?\5'MBPD.A7"':,G8PVO\ AM+5>\(_LE_"
MCP+KUEK&B^$DMKNQE^T64<U]=3VUI)R=\-O)*T43 DX**",\5Z#XY\(V7C[P
M7KWAG4@3I^LV$^GW&!DB.6-D8CWPU,#YF_; @MK7]EOX?0V7_'G'KOAQ(,#'
M[L31A?TQ6_\ \%$+ZSE_9;\1^''"76M^);BRTK1M.^5I;N\>ZB9%C4]2 I;C
MH%S70_#_ ."1\??LT>%OA[\8]!^U76D10V=Q#%J#J)FM'*6]RDT$BN-Z)')U
M##<0PSD5T/@7]E_X8_#GQ'%X@T;PP&UV %8-2U2^N=2N+<$8(BDN9)&CR"0=
MA'4^M(#YO^*/PE/Q>_:A^)7@FYFSJ-Y\*+-;:[WD&.]COB\$P;J")41L]>M:
M/PJ^*<G[8'CWX2V5S&5@\"Z=_P )+XLM70C9KR,]I;6[*>59)([J< ]A&<U]
M76_PW\.6OQ$NO'46FA?%5UIR:3-J'G2'=:I(9%CV;M@PQ)W!=W;.*K>!?A-X
M1^&FH^);_P ,Z)#I-WXDOVU3598G=C<W+=7.YCMZD[5PN68XR3D ^=?V2[CX
M@V_[(?@8_#ZQ\-7UZ=1UD72^);VXMHUC_M2[P4,,4A+9[$ 8[U8^,TFOR?'S
M]E-O%$&FVVOG5=8^UQ:1-)-:JWV(X\MY$1B,8ZJ.<U]'^ ?A_H'PO\*6GAKP
MQ8?V9HEH\TD-KYLDNUI97FD.Z1F8Y>1VY/&<#C J/Q)\-_#GB[Q/X8\0ZMIH
MN]8\-337&DW/G2)]FDEC\N0[58*^5XPX('48/- 'AW[*O_):/VDO^QOB_P#2
M1*9H/_*1;Q5_V3FS_P#2]J[3Q%^R!\*O%'BK6/$E[H6HQZQK$PN+^>P\0ZE9
MK/(%"[C'#<(F< = *F\6_LF_"_QQKEEK.KZ'?R:K9Z;#I$5Y:Z]J%K)]EB),
M<;M#.N_!).YLL>Y.* .!U&YM_%7_  4)T,:,ZW,GA?P3=)KD\&"L)N+A?L]O
M(P_C.&D"'M\PJ[^S7).G[0G[2MLHVZ>GB'3Y8POW?.>P3S3]3A,U[%\._A3X
M1^#^AS:7X-\/6FAV<LAGFCM5_>7$F/OR2,2TC]MSL3[UQ7[,?PYUOP3X6\2:
MSXKM/L'BWQAX@O?$.HV7G)-]C\UPL%N'0E6$<,<0X)&=V">M,#V.BBB@0444
M4 %%%% !1110 4444 %%%% !7@GBS]G/1AK#27=Q]KN)8TD:78Z9RH &!)C@
M 5[W7/\ C3_D+1_]>\?_ *#7H83&XC!M^PERWWV/*S#*\'F2BL73YN7;5]?1
M^1X7_P ,Z^'?3_T9_P#'*/\ AG7P[Z?^C/\ XY7JU%>G_;68?\_7]R_R/&_U
M7R?_ *!U]\O\SRG_ (9U\.^G_HS_ ..4?\,Z^'?3_P!&?_'*]6HH_MK,/^?K
M^Y?Y!_JOD_\ T#K[Y?YGE/\ PSKX=]/_ $9_\<H_X9U\.^G_ *,_^.5ZM11_
M;68?\_7]R_R#_5?)_P#H'7WR_P SRG_AG7P[Z?\ HS_XY1_PSKX=]/\ T9_\
M<KU:BC^VLP_Y^O[E_D'^J^3_ /0.OOE_F>4_\,Z^'?3_ -&?_'*/^&=?#OI_
MZ,_^.5ZM11_;68?\_7]R_P @_P!5\G_Z!U]\O\SRG_AG7P[Z?^C/_CE'_#.O
MAWT_]&?_ !RO5J*/[:S#_GZ_N7^0?ZKY/_T#K[Y?YGE/_#.OAWT_]&?_ !RC
M_AG7P[Z?^C/_ (Y7JU%']M9A_P _7]R_R#_5?)_^@=??+_,\I_X9U\.^G_HS
M_P".4?\ #.OAWT_]&?\ QRO5J*/[:S#_ )^O[E_D'^J^3_\ 0.OOE_F>4_\
M#.OAWT_]&?\ QRMK3_V4_#M]IJ7?G[-TC)LV2'H!SGS?>N\KM/#_ /R+</\
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MY_\ (<G_ ,=KW6BC^W,Q_P"?K^Y?Y!_JKDW_ $#K[Y?YGA7_  R9X=_Y^?\
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M_7JI10!;\FS_ .?B3_OW_P#7H\FS_P"?B3_OW_\ 7JI10!;\FS_Y^)/^_?\
M]>CR;/\ Y^)/^_?_ ->JE% %OR;/_GXD_P"_?_UZ/)L_^?B3_OW_ /7JI10!
M;\FS_P"?B3_OW_\ 7H\FS_Y^)/\ OW_]>JE% %OR;/\ Y^)/^_?_ ->CR;/_
M )^)/^_?_P!>JE% %OR;/_GXD_[]_P#UZ/)L_P#GXD_[]_\ UZJ44 6_)L_^
M?B3_ +]__7H\FS_Y^)/^_?\ ]>LC6-9T_P .Z5=ZGJM];:9IMI&TUQ>7DRQ0
MPQJ,L[NQ 50.I)P*L6]Q%>6\4\$J302J'CDC8,KJ1D$$=01WH O^39_\_$G_
M '[_ /KT>39_\_$G_?O_ .O52B@"WY-G_P _$G_?O_Z]'DV?_/Q)_P!^_P#Z
M]5** +?DV?\ S\2?]^__ *]'DV?_ #\2?]^__KU4HH M^39_\_$G_?O_ .O1
MY-G_ ,_$G_?O_P"O52B@"WY-G_S\2?\ ?O\ ^O1Y-G_S\2?]^_\ Z]5** +?
MDV?_ #\2?]^__KT>39_\_$G_ '[_ /KU4HH M^39_P#/Q)_W[_\ KT>39_\
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MNZ3X3\(>-]9^#^LV7@'Q,;>WLM1MM2BN+][B>,M"HL@H)BD8;4D+@L"I*+N
MKO\ P#^T#K^K?%F'P!XW^'T_@75=1TR75](E_M6&_CNH8W59(Y#&H\N9=ZDH
M"ZXSASQGCO%7P9\8:E^RU\%?!UMI(E\0^';GPL^J6GVF$"W6S,'VD[R^UMFQ
MOND[L?+FNY\9?#_7]6_:D^&WB^UL/-\.Z1HFK6=[>>=&/*EF-OY2["V]MWEO
MRH(&.2.* //OAM\=O!WPJ_9KM]=T#P5=Z;;7'B:\T'2/"MC?M>3W^HR:A-$J
M)-,1CS7#R'/"#<!G !]@^&/CCQWXDU.^L?&OPY_X0LQ0I/;7=KK46IVUQDD-
M&65(V21>#@J00>&.#7S[9_LY?$*#]G?PY9V=A:VOCKPGX_N/&>GZ5>7<?DWJ
MK?7+K"\J%U3S()V(/4$@':<X^@_ACXT\?>+M1O&\5?#H^ M-B@7R1=:Q;WUS
M/,3\PVVY9%0#N6R2>@Q0!X%^V!96=A\8O"'B#XF^'M5\5? NVT>X@O;?3XY9
M[?3M3,JLMW>01'+Q"(;5)4[6R>N >]MOBO\ #'X%_!'0-0^&5BOB71-=U2/3
M/#NC:#>&47E].QQ"C2N1"HVL6!P$"GY<\'L?B-XR^*'A+Q5_Q3WPZM?'WA6>
MT7 L=7AL;^WN S;PZW!6.2-E*8*L&!#9!R*^=]+_ &5/B%X;\"CQ3I.G:/9^
M-X/B(_CZV\&V]V!8QP/&87T]9]H42&(D^8%"!L#&.: .Z^.?C;QQXF_9C^--
MGXV^'O\ PA,]OX8N9;>XM=9BU.UNE:*0,H=4C974@95DQ\P()K?U+X^R^ =+
M^'G@KPYX='BSQGJ?AV'4UL9M2CTZVMK2-(T,TT[AMH+L%4*C$G/ QFH/B(WQ
M1^-GP-^*/A^]^&A\)76H:!-9Z38W.MVMS<WEU(C@JQC;RHT^Y@M)SDYVXKA/
MBY^S+JFH?$#X?^/9/AQH_P 5H-/\(Q>%]6\)ZG<P120LCB6.YMWF_<LZLTJ$
M,R_*W!.<@ ]!T_\ :S$GPN^*6O:CX4;3?%GP[@:75O#?]IQSQN3;^?"8KN-2
MK1R)T;9D$'*\4-^U5J6A_#6^\?>*_AWJ'A[P[<+:#PY;K?QW.I:S+<MMBA-L
M%7R'8E" SM\K$G:05KFKCX):A>?LX_%S1O#GP=T+X::UXDTJ6SL=$TN[MFN+
MQO)<)]ID0+"IW2,% =@ 22W-=9\;O@SXF\>? ;PAI>@-:V_C/PK>:3K=C;WT
MF+>6ZLRI,+NN< C>,C(SCMS0 :5^TAXIT'QQX4\/_$OX9R>!8/%5Q]BTG4[7
M6XM3@^U["ZV]QMC0Q2, <8WJ3D \$U-X5_:(\5?$+QYJ^G^%/AO_ &IX2T7Q
M!)X>U+7+C7X+>ZAEBD$<\HLRA)C0DM\SJ[*,JIR >:UGPW\3?VB/&_PY/BSP
M GPV\,>#];A\37+76LV^H7-]>0QR+## +<D+&&D8L[E21CY17->/OA=XY\=?
M%RPUGPW\)F^&OB6WUV&6Z^(5GXDMQ#?:?'*/,$UO"WF7!EB&WRY8_E)QOP.0
M#K4^+W@WX3^,OVE/$ \)7-G<^%3IE[K=_:7CW$NL,]@DD16%\+ 45A'\IP<;
MCCFO0_AC\3/&/B2UN;_QMX&L? VC?9([RUU.+Q)!J,,JO_"Y5$V$ @Y&Y#GA
MC7$:;X#\7>%?B7^T3XG'@N#Q58>)Y-'_ +)TJYOK>*/58XK"."X1B^X( =XQ
M*H#8]#FN;^ GP*U:T\?>*YM2^'J_#_X4ZIHZV3_#W5-4@U:UNKXS;VNE@1I(
M8$\L%"BGYB<E>*8'OOB#XA1P^$]2U7PI9#QYJ%J8TBTK1;R R2R.ZHH,C.$0
M#=N9F/"JQYQ@\'X#^/7B/4/BM;_#_P >^ /^$(UK4--FU72Y[76(]2MKN*)T
M65"ZQQE)5\Q3MVD8YW5E?'/X!S6?P3U[0?@KH.E>#=6O[FVFN[;PXL6BR:C;
MQR RP">)!Y;O'N4.1@9(/!->4_ O]F_6_"/[1WA;QM9?"VY^'OAV#2=1L[_^
MTO%AUF\DG?R?+>0&:14#?/M\IFSM8OM^4% >O_"#]H;Q5\9]0M-4T7X;^7\.
M[N\N;2/Q%-K\'VM/)9T+RV6S* NA7;YA<9!*XZ'@/]H?Q5\3_%MZGAGX;B\\
M$V&MS:'=Z]/K\$-W%)#(8YI?L10G8I&<&0.5Y"<C/FF@_"WQQKGQQ\*^+-(^
M$Q^"UQ#J37GBG5;7Q';W%IK5OL<-;FUMSB9W=E;S98T*X)Y)X7Q!\+?'/C#X
MTZ'XB\/_  G;X5:Y!KT-SK/C2S\1VS6^J:?&Y\V.6VA.ZX:5, >;&"I/WO4
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M+Q7^R.?@E;?#+3;>ZTS2;72)-=?Q!;O#J4-L8UC-K'D,KNL:DF?RPH#8W$@
M ^[:***8@HHHH **** "O!/%G[1FC'6&CN[?[)<11I&T6]WQA00<B/'((KWN
MOSQ^(W_(YZC_ -L__1:U];P_@,/CI5%7C>UK:M=S\]XOS?&93"C+"2MS.5]$
M]K=SWK_AHKP[Z_\ HS_XW1_PT5X=]?\ T9_\;KY@HK[/_5_+_P"1_>S\T_UQ
MSC_GXO\ P&/^1]/_ /#17AWU_P#1G_QNC_AHKP[Z_P#HS_XW7S!11_J_E_\
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M ,:KY!HH_P!7<N_D?WO_ ##_ %RSG_GZO_ 8_P"1]??\-9^'?^?;_P B2?\
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M ,:H_P"&L_#O_/M_Y$D_^-5\@T4?ZNY=_(_O?^8?ZY9S_P _5_X#'_(^OO\
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M17B$?[6W@2/X\:U\-KWQ!X>T]M/LH)%U*XUV!?.O7FDB>Q$1QB9-BDKN+?.
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M0O&<Y/-=?^SG\2-2^+WP-\&>,]8@M;74]:T]+JXAL5985<D@A S,P''=C]:
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M(SK'_0)OO_ 9_P#"CFCW#DEV,VBM+_A&=8_Z!-]_X#/_ (4?\(SK'_0)OO\
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M(SK'_0)OO_ 9_P#"CFCW#DEV,VBM+_A&=8_Z!-]_X#/_ (4?\(SK'_0)OO\
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M(SK'_0)OO_ 9_P#"CFCW#DEV,VBM+_A&=8_Z!-]_X#/_ (4?\(SK'_0)OO\
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MM#(NR0Q.1E-R_*=I&1P>*0SY'^ <>CZ%)^TAI>BPZ39_$*#QEK4FAV8CB2\
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M25P2"1TH ^+]6FT/]GWXA76L6<G@+XH^&O%'CE9WM&,+>(]+U&XN5&87&\7
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M?P  J]3$%%%% !7'^+?#NE6VJ(D.F6<2^1&=J6Z 9(Y/ KL*Y_QI_P A:/\
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M +%T_P#Y\+;_ +\K_A1_8NG_ //A;?\ ?E?\*N44>VJ?S/[P^K4/Y%]R*?\
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M +\K_A1_8NG_ //A;?\ ?E?\*N44>VJ?S/[P^K4/Y%]R*?\ 8NG_ //A;?\
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M5'I__(!TS_KFW_H;5)6#W-0HHHI %%%% !1110 4444 %%%% !1110 4444
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M8T'^]J/Y1_XUD446 U\:#_>U'\H_\:,:#_>U'\H_\:R**+ :^-!_O:C^4?\
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M4 9?B7^Q_P"W+S[0;[SM_P WEA-O0=,FLS&@_P![4?RC_P :7Q=_R,E]_O\
M]!6/6R6ADS7QH/\ >U'\H_\ &C&@_P![4?RC_P :R**=@-?&@_WM1_*/_&C&
M@_WM1_*/_&LBBBP&OC0?[VH_E'_C1C0?[VH_E'_C61118#7QH/\ >U'\H_\
M&C&@_P![4?RC_P :R**+ :^-!_O:C^4?^-&-!_O:C^4?^-9%%%@-?&@_WM1_
M*/\ QHQH/][4?RC_ ,:R**+ :^-!_O:C^4?^-&-!_O:C^4?^-9%%%@-?&@_W
MM1_*/_&C&@_WM1_*/_&LBBBP'H$/D?V1IWV;S/)\MMOFXW??/7'O3:CT_P#Y
M .F?]<V_]#:I*QZF@4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M>\-?ZJ?_ 'A6U6+X:_U4_P#O"MJLWN4BCKG_ "!-0_Z]Y/\ T$UXO7M&N?\
M($U#_KWD_P#037B];T]B)A1116IF%%%% !1110 4444 %%%% !1110 4444
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M/#?\^U]P?VEC?^?TOO9Z7_PT-XR_Y_S_ -_IO_CE6M+_ &C/%=OJ$$MS>/)
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M_P ,RV__ #_R?]_A_P#&Z/[:P'_/Q!_JOFW_ #X9\_45] _\,RV__/\ R?\
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M -IH_MO ?\_4'^J^;_\ /AGS/17TQ_PQ^W_03'_?_P#^TT?\,?M_T$Q_W_\
M_M-']MX#_GZ@_P!5\W_Y\,^9Z*^F/^&/V_Z"8_[_ /\ ]IH_X8_;_H)C_O\
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M^'_QNC^VL!_S\0?ZKYM_SX9\_45] _\ #,MO_P _\G_?X?\ QNC_ (9EM_\
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M #RU=2$X Z8Z"@#YT_X)RWTEY\.?B6A?13;V_C_4DMX_#<C/I<2-#:R%;0L
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M/Y1_XT8T'^]J/Y1_XT7"QD45KXT'^]J/Y1_XT8T'^]J/Y1_XT7"QD5L>$?\
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M!_O:C^4?^-%PL9%%:^-!_O:C^4?^-&-!_O:C^4?^-%PL9%%:^-!_O:C^4?\
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MY]K_ -M:?_S_ %M_W^7_ !H_MK3_ /G^MO\ O\O^-?%'_"3:Q_T%K[_P)?\
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M/Q/H\/A^*-]6L4D$[DHUR@.,+SC-?GW_ ,)-K'_06OO_  )?_&C_ (2;6/\
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M_@2G^-'_  E6B_\ 07L/_ E/\:_/+_A)M8_Z"U]_X$O_ (T?\)-K'_06OO\
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M+KO1)7>1 7*_-L3<V.U6M!_:9\%^*/$/P^TS3)+RZ@\=V%W?:+J8B5;:5K8
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M'"HHYY)["BB@ HHHH **** "O!/%G[.>C#6&DN[C[7<2QI(TNQTSE0 ,"3'
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M^9X5_P ,F>'?^?G_ ,AR?_':/^&3/#O_ #\_^0Y/_CM>ZT4?VYF/_/U_<O\
M(/\ 57)O^@=??+_,\*_X9,\._P#/S_Y#D_\ CM'_  R9X=_Y^?\ R')_\=KW
M6BC^W,Q_Y^O[E_D'^JN3?] Z^^7^9X5_PR9X=_Y^?_(<G_QVC_ADSP[_ ,_/
M_D.3_P".U[K11_;F8_\ /U_<O\@_U5R;_H'7WR_S/"O^&3/#O_/S_P"0Y/\
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M .F?]<V_]#:I*P>YJ%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8T'^]J/Y1_XUD446 U\:#_>U'\H_\:,:#_>U'\H_\:R**+ :^-!_O:C^4?\
MC1C0?[VH_E'_ (UD446 U\:#_>U'\H_\:ZK1?[._L*+RC=>3YSXWA=V<+GIV
MZ5Y]7:>'_P#D6X?^OB3^2U$EH5$U?]!];C\EH_T'UN/R6JE%9EEO_0?6X_):
M/]!];C\EJI10!;_T'UN/R6C_ $'UN/R6JE% %O\ T'UN/R6C_0?6X_):J44
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MC_QK(HHL!KXT'^]J/Y1_XT8T'^]J/Y1_XUD446 U\:#_ 'M1_*/_ !HQH/\
M>U'\H_\ &LBBBP&OC0?[VH_E'_C1C0?[VH_E'_C61118#7QH/][4?RC_ ,:T
M_#/]D?VY:_9S?>=D[?,";?NGK@URM;'A'_D8[+_>;_T$TFM!K<['_0?6X_):
M/]!];C\EJI16)H6_]!];C\EH_P!!];C\EJI10!;_ -!];C\EH_T'UN/R6JE%
M %O_ $'UN/R6C_0?6X_):J44 6_]!];C\EH_T'UN/R6JE% %O_0?6X_):/\
M0?6X_):J44 6_P#0?6X_):/]!];C\EJI10!;_P!!];C\EH_T'UN/R6JE% %O
M_0?6X_):/]!];C\EJI10!E^)?['_ +<O/M!OO.W_ #>6$V]!TR:S,:#_ 'M1
M_*/_ !I?%W_(R7W^_P#T%8];):&3-?&@_P![4?RC_P :,:#_ 'M1_*/_ !K(
MHIV U\:#_>U'\H_\:,:#_>U'\H_\:R**+ :^-!_O:C^4?^-&-!_O:C^4?^-9
M%%%@-?&@_P![4?RC_P :,:#_ 'M1_*/_ !K(HHL!KXT'^]J/Y1_XT8T'^]J/
MY1_XUD446 U\:#_>U'\H_P#&C&@_WM1_*/\ QK(HHL!KXT'^]J/Y1_XT8T'^
M]J/Y1_XUD446 U\:#_>U'\H_\:,:#_>U'\H_\:R**+ >@0^1_9&G?9O,\GRV
MV^;C=]\]<>]-J/3_ /D Z9_US;_T-JDK'J:!1112 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** -[PU_JI_\ >%;58OAK_53_ .\*VJS>Y2*.N?\ ($U#
M_KWD_P#037B]>T:Y_P @34/^O>3_ -!->+UO3V(F%%%%:F84444 %%%% !17
MRS\:93XA_:T\->%=6\;Z]X3\,/X1GOWCTC7YM+22Y6Z"*S,CJ&.TD<^E9_[1
MDFE_#'X6_#BWL?B1XFM_#-]XZM8-4\0_\)-<2W7V1[>Y,L9NPY<(#&IVYP"O
M2IYAV/K:BO&O@+;^ ]7TW7)_!/Q*UKQU!<(L%RU]XGGU)[/AL%!(Y:%CD\@#
M.T>E>1_M'_"F3P!X7T;3/"GQ!^)#>-O%&JV^C:,L_C"_E2-W;=+.Z>9RD<2N
MQ/0<9IWTN!]@T5XW\4O -E=+8R^)OBUKWA'P_9:8L"0V.LKI3RS)DR7<MR"'
MD.TI\N0H()(;=Q!^Q_XG\3>+?@O;7WB:^N=89=0NX--U>]B\N?4+!)2MO<.N
M!RR]^X .3G-%]; >UT444Q!1110 4444 :/AW_D/:=_U\)_Z$*[";_72?[Q_
MG7'^'?\ D/:=_P!?"?\ H0KL)O\ 72?[Q_G64]RX[#****@H**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBOD;]L37?B#XP\86WA#X8>(-0T+5?"6@W
M'C;4GT^9H_MCHVRRL)-K+N64I<$HW!"J2.E SZYHKYB_:4^,5QXD_8-U_P"(
MWA#5;S1KG4-$M+^TO=/N&AN+9I)8=RJZ$,K+N9#@]B*]=^(FK7NG_ /Q-JEM
M=30:C!X9NKF*ZC<K(DJVK,'#=0P89SZT >@5GZSXBTKPZMF^K:G9Z8MY=1V5
MLUY<)")[B0[8X4W$;I&/"J.2>@KY6_9.\&Z%XD\ ?#3Q9J7Q9\9:OXMN]/M;
M^YTN\\<74\,UP8PSH]JTI#+G.4([5V7CH_\ "U?VNO!/A5<3:)\/["3Q7J:]
M4-_.&M[!#Z.B_:)1]5H ^AZ*^(OCU\5/&UI\9]:^(?A_7M0M?AU\)M0TO2]=
MTFUE?[-JGVDEM0=XU;#M;Q3VV-P.U@Q'3->M?M)?$3Q'<^+OAE\+O VM?V#J
MWCRZN9+GQ!;(LLECIMM$)9WASE1)(&54<@@9/?! !]!T5Y5X#^ K_#SQ+::K
M9?$7QUJ]NB.EUIGB+6FU*WNMRX#GS5+1LK88>6RCJ",&N/\ V#_%6M>,OV==
M.U/7]6OM;U)M5U2-KS4+AYY2JWLRHI=B3A5  &>  !P*!'T+17Q/X-TVP^)W
MQP^.$7C+XK^+O#T6C>(H[/3-/T_QG<Z7!% ;=&(2)9%7&[/05]D>']/ATG0=
M-L;>[N+^WMK:.&.ZN[AKB:950 .\K$F1B!DL22223UH&:%%%% @HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *^#/&OC76=)\37EI:7GE6\>S:GE(V,HI
M/)7/4FOO.OSQ^(W_ ".>H_\ ;/\ ]%K7WG"L5*=9-=OU/R;C^4HT\,XNVLOT
M#_A8WB+_ *"/_D"/_P")H_X6-XB_Z"/_ ) C_P#B:YJBOT/V</Y4?CGMJO\
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M./W7O1_;> _Y^H/]5\W_ .?#/FFBOH'_ (9EM_\ G_D_[_#_ .-T?\,RV_\
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MMXECC4)&HPJKT%/K\WS#,*N85>>>B6R/W#)LFH9/0]G3UD]WW_X 4445Y1]
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M^2T?Z#ZW'Y+0!4HJW_H/K<?DM'^@^MQ^2T 5*Y_QI_R%H_\ KWC_ /0:ZO\
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M (;PZ&NJ1ZI/JD<UU<3YB7R([;8IV.[NL<K,-^P$JH=:G;]J/Q;X4N/#5_\
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MA="5;!'#*<$8- C9J"^OK;2[&XO;VXBM+.WC:::XG<)'%&H)9V8\*H ))/
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M+=#\:3Z&_AZ+6$DN+6QEN/.?[-YC"&5CM7!DC"R;<' <#)H$=[1110 4444
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M^@Z* ./U#X7Z#'\-=;\%Z!I>G^&M)U&PN+);?2[1+>&+S8V0L(T 7//IVKY
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ML?\ Z,6I*CU+_D7=4_W8_P#T8M/J#V.%HHHK<R"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K8\(_P#(QV7^\W_H)K'K8\(_\C'9?[S?^@FD]AK<Z:BB
MBL#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?%W_ ",E]_O_
M -!6/6QXN_Y&2^_W_P"@K'K>.R,WN%%%%,04444 %%%% !1110 4444 %%%%
M !1110 4444 =UI__(!TS_KFW_H;5)4>G_\ (!TS_KFW_H;5)6#W-0HHHI %
M%%% !1110 4444 %%%% !1110 4444 %%%% &]X:_P!5/_O"MJL7PU_JI_\
M>%;59O<I%'7/^0)J'_7O)_Z":\7KVC7/^0)J'_7O)_Z":\7K>GL1,****U,P
MHHHH **** .-NOA5I%Y\7+'XBO/>#7+/2)-%C@61?LQA>42EBNW=OW# .[&#
MT[U+\0OA\WCZUM(XO$_B+PM/:LS)=>'KT0.VX $.KHZ..!C<IQSC&376T4 >
M=_#GX':+\.;_ %?5HM2UG7_$FK1+!=^(-=O/M-Z\:YV1JP55C1220J*HSVX%
M>?\ @[]CFU^'^F3:?X>^*WQ&TNUFN)+J98;^Q+33.<O([&S+.Y/5F)/ ]*^A
M**5D.YY1XR_9TTCQ7XJM_%-GXF\4>%/%"V2:?<:OX?OTAEO84R56='C>-R"2
M<[ >?88Z'X6_"'0_A+8ZG%I<VH:C?ZK=&]U+5M7NC<WE[-M"AI'('10 %4!0
M.@ZUVU%.R ****!!1110 4444 :/AW_D/:=_U\)_Z$*[";_72?[Q_G7'^'?^
M0]IW_7PG_H0KL)O]=)_O'^=93W+CL,HHHJ"@HHHH **** "BBB@ HHHH ***
M* "O+/VHOBKJGP1^ GC#QQHEM9WFJZ/;)+;PWZNT#,TJ)\X1E8C#D\,.E>IU
M\\?\%!O^3.?B9_UY0_\ I3#0,Q_%?Q@^./P7\)IXZ\9Z/X,\8^";>*.XU2/P
MK%=V.H6,#8W3JL\DJ3*@;+*"IP#SC)'L%KXVO]6^)>A6VFZUX5G\(:GH#ZG%
M:M</_;-Q)YB;)X8\[3:['&YL9#,OK7DG[27QH\(V/[,>O^';+6['6_$_B;0)
M-!TG0],N4N+R[NKF P(J1(2Q +Y)Q@ =>16)X"\(W/P__:0^!GA>]97O-$^%
M,VFSLIR#)#)91L1[94T@/HVW^*G@N[\72>%8/%^@S>*(RP?1(]3@:]7'7, ;
M>,=^*3Q%\5O!/@_6K71]>\8:!HFK76/L]AJ.IP6\\V3@;(W8,WX"ODCX8W&B
M? #QWX \,6$G@+XI>&/$NOW$>B:]I/DMXAL)9A-,9YBI<7$:J61IU9&"D9SD
M ^<?#[PCJ'CFT^,MGXC\:_#+0=5NO$NIP:];>--"%QJ42;R(9/.DN8\0B+:8
MBJ[5"\'(- 'Z%^+?'7AOP#IRZAXG\0:5X<L&;8+K5KV*UB+>FZ1@,U-I_B[0
MM7\.KK]AK6GWNA-$TPU2WNHY+4QC.7\T';M&#DYQQ7QOXF\5)X27X+> =-T[
MP)\0?%:^$/MMAX[\?7'V;3S: 1IF'*R.\DBA&(4[MJY.1G'*? OPOI7Q3_9]
M^/GA37_%'A7PGI5YXV#0ZAH4XDT*"X*VDRK )BHD@>5%4QG ;<P Y%,#[G\'
M?$;PG\1(+F?PIXHT;Q/#:L$GDT?4(;M8F.<!C&QVDX/!]*@TCXK>"?$'B:?P
MYI?C#0-2\0V^[SM)L]3@ENX\#)W1*Q<8[Y%?(UY\1-<G^&?[0'@W1O#_ (4A
M\=:'X6CG/B;X<J!!J$3QS"-"JC?%.B^:5CWOC>2IYR>2\"_#6S\4>"?@_=V?
MQ6^%&CV-CJ.E76CG0] %MJC3[T'V42?:BYDD)*2*5R26W#@X0'W]XDU^R\*>
M'=4UO49/)T_3;66\N9/[L4:%W/X!37SSHG[1>N> ?V4_#_Q)\902^)?%/BF:
M.71M!LTC@>:6^E+6-C&0HX6)D!=@6(1F.X\'OOVM8;F?]E_XKI:AVF/AC4.(
MSR5^SON'_?.>.]>'_M!*MG^SE^S_ /$'3[62]\->"M7\/^(M0AA0RE-.6WV-
M,%7)8QB16XS@9/04P/8O"=S^T#'JVDW/B:T^'D^CW$R"_P!/TIKV*[LHF^\4
MF<ND[+GD;(P<'!Z5S=C\9OB?\9_%/BB#X3Z=X7TSPGX=U"72)/$7BU+F?^T;
MR(XF6W@@>,B-&^7S&?#'[H/./5;+XW_#W4H]'>S\;^'[L:Q+'!IRV^I0R-=R
M.0%6-0V6))Z <=Z\#_8O\<:!\,_"OBOX8>*=9L]!\7>&?$>I&>UU:X2WENK>
M:=IH;M-Y&^-UD'S#/09QD9 .L\)?M'>(_P"R?BKH/C#0=/TGXC^ =,?4Y8+&
M9Y=.U*W:!Y8+B!FP^PE"K*>5.!G)('GEE^T]\8O!_P &_!WQB\::=X*U?X?Z
MLMC-J=MH-O=VFH:=#=,B)*#+-)'(%:105^7.1@\DC/N]1M?BQ\3OVB_B1X>D
M^W>$-/\ A_)X5MM7A8-;7]TL<T\YA<<.L>44D<9/!-3?L[_L\^)/BU^S[\)(
M_&WQ"_M/X>V^GZ=J<7A'3]%CM/.,2I)#%<W)D=I8U8*2%5-V.>V$!Z+XX^+7
MQ5U3]IF_^&'@%_!VGV=CX9@UZ6\\1V%W<R.[W#Q%%\FXC & IY'KSSQM_"?X
MV^)]6^)&M?"OXD:/8>'?'=IIJZM97VA3M-8:K9,_EF>#S5W(R/A3&^X]^17%
M6^OZ9X?_ ."B'B>;5-1M--BD^'=HB27DZQ*S?;F. 6(R<4N@>(-/^-O[;UEX
MA\(W,>L^%_ _ABYTZ_URS<2VCW]S,I%K'(/E=UC7>Q4D#(!P: /2/V7?B-K7
MQ"^'-[;^*;E;WQ?X8UF^\-:U<QPK"L]S;2E1*$4!5\R)HI,*-OS\<8KU^OF_
M]E-99/BC^T7<(P>Q;QN8HRO3S4M(1*/J,KFOI"F 4444""BBB@ HHHH ****
M "BBB@ HHHH *_/'XC?\CGJ/_;/_ -%K7Z'5Y_XF\ Z#I^HI%;V/EH84<CSI
M#R1SU:OILDS.EELJCJ1;YK;>5SXCB?(Z^=PI1HR4>2][WZV[)]CX,HK[=_X0
M_2/^?3_R(_\ C1_PA^D?\^G_ )$?_&OJ_P#6C#?\^Y?A_F? _P"H6._Y^P_'
M_(^(J*^W?^$/TC_GT_\ (C_XT?\ "'Z1_P ^G_D1_P#&C_6C#?\ /N7X?YA_
MJ%CO^?L/Q_R/B*BOMW_A#](_Y]/_ "(_^-'_  A^D?\ /I_Y$?\ QH_UHPW_
M #[E^'^8?ZA8[_G[#\?\CXBK3\/^'[OQ)J*6EHA9B?F?'"#U-?97_"'Z1_SZ
M?^1'_P :FL_#>FV-PLT%L%E7HQ9FQ^9J)<44.5\E-W^7^9I3X"Q?.O:58\O6
MU[_D<S\-_AO:>#-.C)CW71^8LPYSZGW_ )5W%%%?!XG$U,54=6J[MGZ[@<#0
MR^A'#X>-HK\?-A1117*=X4444 %%%% !7:>'_P#D6X?^OB3^2UQ==IX?_P"1
M;A_Z^)/Y+43V*CN6J***R+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(,BBM?[1HG_/G>?^!"__ !-'VC1/^?.\_P# A?\ XFBX&116O]HT3_GSO/\
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M;\RR_P">,W_?P?X4>99?\\9O^_@_PH J45;\RR_YXS?]_!_A1YEE_P \9O\
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M***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH [K3_\ D Z9_P!<V_\
M0VJ2H]/_ .0#IG_7-O\ T-JDK![FH4444@"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#>\-?ZJ?_ 'A6U6+X:_U4_P#O"MJLWN4BCKG_ "!-0_Z]Y/\
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M(?$D%O)JS:C++>?)-_IGVZ5V",FT,#'QDX55QD5]$? >'7_"6@IX1M/A+?\
M@32K2UEEAU+5=8LKT7%T2"6F\B5I'=V)9G(['IP*\^^,WASXN?M"?#\^ =7^
M%NE^'K^XFA,GBZ36H+FSL=DJ.T]K&O\ I&\A2 I5<9(+$=3H/J:NO>&=*_:
M_:G\5>%?%\4FJ^%/!NB6+P:%)*ZVD]W=%W:>5%(\QE155=W Y(&>:T_V7]_@
MSXA?&'X707EQ=:%X2U.RGTF*ZE>9K2VO;43BW5VY*(P;:"21DY[5-XF\&>./
MAG\<KWX@>$/#:^.M,U[1;;2]6TR._AL[U+BW9O*N5>8K&ZE&*E2P.1GGI70_
M #X>>(_#^H^.?&?C*"VL/%'C+4H[R;3;2<SI8V\,*PV\!DZ.ZJIW,HP2>.!1
MU$>OT4459(4444 %%%% &CX=_P"0]IW_ %\)_P"A"NPF_P!=)_O'^=<?X=_Y
M#VG?]?"?^A"NPF_UTG^\?YUE/<N.Q\N_\%$H;:\^ -A:WP1M/N/%&D1722-A
M'B-TNX-_LXKCM$\->"OAK^V'\--$^"-S:VEAJ6GZG+XRT/0[SSK%+2.%?LMQ
M*@9ECD\Y@JD %L@' SGUO]LCX5ZW\8OA/I_A_0M)BUJ<>(--N[FSFDB1&MHY
MU:8MYC!6 3.5ZD< 'I7J?@[X<^$_AW;36_A3POHWABWF8-+%H^GPVB2$="PC
M4 GZUF6>=_#S]HP>/O@IXP^(*^'S8CP_/JT/]G&\\SS_ +$7&?,\L;=^S^Z=
MN?XL5YQXD\:CXD_&+]CGQ<+/^SQK]KJVJBS,GF>1Y^AF7R]^!NV[\9P,XS@5
MSNC_  X^,_PW^'/Q/^%F@> +#6K#6[W5[K2O%<^MPQ6WV>\+MY<EN3YOGJ&*
M@8"$D9< $GL?#OP7\8:?J'[)4D^DA$\!Z-<6GB%OM,)^QRMHRVRKP_[S,P*Y
MCW#OTYH DU#]K?Q9<R?$63PS\([OQ#I_@/5;NPU>^;6XK:-XX%#LUN&B+2S;
M,N8L  %!O)8"B']LN_DTWPKXO?X9:K9_"SQ#?6NGV_B:\U"&.Z1KAPD4[60!
M(@+D#>9 Q!R$((SM_"GX6^)_#/A?X^6FI:;]GN/%'BS6-3TA/M$3?:;>>T@C
MB?*L0FYD88?!&.0*Y/7O@CXUO/V*?AUX"AT;S/%FD_V!]MT_[5"/*^S7,#S_
M +POL;:J,?E8YQQGB@#N_%_[0FOO\3-;\"?#CP"WCS6O#]O#/K5Q=:O'IEG9
M-,I:&'S6CD+RLHW;0N ",MVK%U#]LC3]/^ GBOXB2>%-0@U3PGK$.A:WX7N9
ME6YM;IKN"!U5T5Q( MPLBE1AP .,DBG-X9^)GP3^.7Q#\3^%?!*_$?PMXW:S
MO6M[75K:QN]-O(8!"X87!59(G"J05;*GC:>M<9XI_9M^(.L?LX?%2&ZT^SNO
MB)X^\467B"71K"[3R+**.]LV%N)I"BNT<,#,S\;CD*#QD ]1\._M(>(U^)_A
M?PGXX^&=WX'MO%BW']A:A)JL-XTDD49E:"YCC7$$AC!8 .XSQG.<)\4_V@/'
MWPWM_$>NQ_!V[U+P1X?\V6]U:37K>"ZEMXN9;B"UVL715#,-[QDA<XY%:WQH
M^'^O>+OBU\%=9TJQ^U:;X=UN[O-4G\Z-/L\3V4L2-M9@S9=E&%!/.3QS7RU\
M4OV6?B)X[O/B;;>(?A_?^/O$6K76H2>'_%UQXX:UTVPM9%;[/$MDLBD.@VCR
MVC:-F W.%R: /I7XI?M-3^#->^&>D>%_!UUXXO?B!97EUI26]XML%,*6\B^8
M64A8REP6:3/R",X5R0*U/"/QRU:^^+UK\._%GA%/"NLWGAQ=>M9(]3%Y%,RS
M&*XMU81("T9*-D'+*X.U>E<A8_"+Q7#\0_V9M2?2P+'P;X<U*PUR;[1%_HL\
MMC:11IC=E\O%(,H& VY) (SD?M\+J?@CP7X5^+/A?R1XQ\%ZJJ64<G6[AO1]
MEEME'<L9(G _Z9GB@#V#X/\ Q>'Q>N/&<UGI)L]%T+79]#L]1-QYG]I- %$T
MJIL&Q!(60<MNV$Y'2O*OVNO#@^/'B/P3\#$NI;:RUTW&NZ_-;MAX;"T7$0/!
M_P!9=20X_P"N35ZU\ _A?'\&?@[X4\'JPEN=-LE%Y.#GS[I\O<2Y[[I6=LGG
MFO)+7]EZ'XM_&SXC^./BCI%]'&\UOH_AB&SUVXM6338(]S2DVDZ'$TTCOLDY
M7;T&>6!K_L^_&#4?^&5[K6=?@-[XJ\"6E]I6N6C2[&DO-.5E<%]O!D5$?.W_
M ):9Q7%^,_VC/B9X_P#V8/&GC7P_\,YO#>C77A2YU#3=:N/$BP7D:&V8O<QQ
M)"679DR1'<#($4_N]PJQH_[.>N_"OQ%\:O#/@O1+B;X?>,O"K76GO<:H)VAU
MKRI+>2 M/*TQ,JF.3S'R@QC<, 5Z/H_PIUJ^_8SLOAI>QQZ=XBF\ )X<FCDD
M5T@NCIPMV!9200KYY4D''&:0'*^!_P!H3Q!X _9MTGQA\2?"[6CK8:7;:6MC
MK(U*\UV:>-$C+;XX_+D=V4G<S8W,2W'.UX(_:4UF\^)VA>"?'/@BW\'W_B*&
MXDT6ZT_7X=6AN'@3S)892B(8I F6'#*<$!L]?-_%'P9^(?QO_97T;P1X@\#V
M7AKQ-X0DTJ:SLM6U*&[L=;DLT"R*QA9O+BE4,H#_ #9;!  W5TGP5^$]M8>/
M])U4?LT^&OA<U@LCR:T;ZRN+E7,;(%M1;!B02Q!=RAVY^7)X .B^$/[1WBCX
MR>*+ZVTKX:36OAG2M9OM%U/Q!=:PBK'+;RR(K00F/=."%C+<J$,FT%RK&LO]
MG_QY!IO[*_A;4_AC\+[MK:6]O;*P\*VVL"06^V^N4DEDN[D@B,M&[DD,1O"J
M#Q76?LN?#_7OASX*\2V'B&Q_L^[O/%>L:G!'YT<NZWGNG>)\HQ W*0<$Y&>0
M#Q7A4?P!^*VF_LA> O!MI87D6J:9XBN[[Q#X<TW78]/N=2T^2^O)1!'>(Q12
MPEA?&]00""P(H ]X^%/QSUCQ=\0]<\ ^,O!A\$>+]-T^'5X[>'5$U&VN[*1V
MC$L<RI&<B1&5E*#![FN8_P""?/\ R9S\,_\ KRF_]*9JXC]EW]GG6OAK^T#K
M7BZ/X=-\._"=_P"&%T^&PN/$AUBY%RMV')E=I'*LR_PHS1@*/FW,P'K7['GP
M^U_X5_LU^!O"GBBQ_LS7M-M9([NT\Z.;RV:>1P-\;,IX8=">M 'AWPY^/G@#
MX._M3?M'6_C?Q;I_AR6^U;2GM4OI"IE5;$!BO!Z97\Q3OAO\<K%?&O[6/Q.\
M"P0>/].L1HM]:P6ET84O$ATQ1,J2>6Y!79+QL.2N.^:]A^"/PU\1^#_CM\=O
M$6K:>+71_$VI:;<:3<>?&_VB.*T\N0[58LF&XPX!/;(YJU\,?AOK6A_'OXZZ
M_K&FHOA_Q3/H[:;,\D<BW20Z>L$P*!BR@."N' SVR* +?BG]HC3]-T'X6WV@
M:=_PD=Q\0M0L[73+5;GR=MO+$9IKECM;Y88@69<9)P.,YKC5_:D\:^)=4\=V
M/@CX.WGBEO!^L76E7US)K<-G#.8=I"P%HRTDS*VXQ;0J@IF0E@*\N_9"^&NJ
M0_'GQ+I.I3Q7WA3X./>^'_"\@?S#NOIC<.23_P M(K?RH3SQNQSVF^#'C3XI
M>%?$WQ^B\%?#JV\;:?<_$+5!!<KK,-E)9WODVP)G28@-!M,1!C)<%7&TY! !
MZY>?M@^'[[X9_#SQ-X7TBY\0ZIX^=XM#T-[B*U8R1JS7'GS.2D:0[&#L-W(&
M V:T?AG^T9=^*_%'B3PCXH\*Q^%?&&CZ6NMK96NKQZE:WEFSN@DCN$1<$.FU
ME9 1D8R*\-U[]BG6]#^$OP,M_P"P]%^)>K_#Z74)=5\,ZE,L-KJJZ@6>Y$3N
MNT-'*59-X4';DXP ?5_@K\+8M%N/$FHV?P*T'X1R7&F/8P-;75K-J%TSG+(W
MV<&-(LJAYD))QD#%&H&!X?\ VG/B/\8/@CJ7C3PQ\)6TW1[K0I+FSOM0\2I;
M2M. %E\M! 6\M 9624[2YB'RJ&5JA^ W[0GB/P;^R9IOCOXHZ*\&BZ9H%C/;
M:S'K1U*_UQY $4O&T:&.5W:, -(V3)R1@FO1/V?_ (8:YX7_ &4?#'@/Q!;C
M2M>AT!M.NH3(DH@D977&Y"5;&[^$D5XW:? GXC?$_P#8UN?@OXF\)6WA'6M!
MT^QMM,U.ZU.&\LM5FMI@ZG;"2\<;+$@;> P\TX4[: /2_#/[3VNKX\\+^'_'
M/@"+PA:^*)FM=*U"S\0P:GBY$;2+!<QQHIB9E5L%2Z[AC/>LN?\ :O\ &6K7
M_C^'PC\'KSQ+:^"=6N]-U.];7(K6*18 K?N T9:68H=QBP H*?O"6 K'^$GP
M?CM_&WAZ[E_9>\*?#V>PE\^Z\0?;[*<PNJ':;-8%9V8OC!D\O"Y/)XKO/@;\
M-?$?@VQ^-D>KZ?\ 9'\2>--4U?2U\^-_/M9K>W2*3Y6.W+1N-K8(QR!0!7\0
M_M5V\GA7X77_ (,\-R>*=8^(T;2Z-I]W?QZ=$BI")91-.P8*R@XVJK%B#C.*
MH_%WQ>EQX1^$^H_$GX;"'69_B!I-I::4FO%UTV]>9XX+U9H5 G502PC=5#!L
M, 17'Z3\+?$7A[]EWX6^ /$WP1A^)SV>GF/5=._MBR@ETNX3'EM&\CA6)#N-
M\<@*[>,[N*MC\!_B>_P<^&&CZM%-J6IZ3\2]/\1/87.K+>2Z/H\5TTBP/=2$
M&X:&,@9&2<X4$ 4 >I>+_P!H37W^)FM^!/AQX!;QYK7A^WAGUJXNM7CTRSLF
MF4M##YK1R%Y64;MH7 !&6[5BZA^V1I^G_ 3Q7\1)/"FH0:IX3UB'0M;\+W,R
MK<VMTUW! ZJZ*XD 6X612HPX '&213F\,_$SX)_'+XA^)_"O@E?B/X6\;M9W
MK6]KJUM8W>FWD, A<,+@JLD3A5(*ME3QM/6N,\4_LV_$'6/V</BI#=:?9W7Q
M$\?>*++Q!+HUA=IY%E%'>V;"W$TA17:.&!F9^-QR%!XR >H^'?VD/$:_$_PO
MX3\<?#.[\#VWBQ;C^PM0DU6&\:22*,RM!<QQKB"0Q@L '<9XSG.-/]L;QY>_
M#?\ 9C^(6N::SQZDNG?8K1X@2Z37,B6T;+C^(-,I'N!3OC1\/]>\7?%KX*ZS
MI5C]JTWP[K=W>:I/YT:?9XGLI8D;:S!FR[*,*"><GCFLW]N3PS?>+/V4?B):
M:;N-];64>J1!%W$FTGBNB .^1">*8'D?[67PW\->&?!G[-/@+4[>T?PC9^+M
M-TNZM[EMMO) EK*C>821P<$DGU)J?X6Q^#_A9^UMK.C_  NU2&V^&MKX/DU/
MQ5IUA>&?2]-O%G_<R@Y98YFC$A**1E5W$5VW[0'P_G_:6T?X%:QH^B6GB7PL
MOB2QU[5+>\:%X?[.>W<LSI(<2CYU!4!B<].M;?Q_^#-U<? G4?A[\*O#&FZ!
M%XCN[?3;_P#L>&WL(K.PED NY]@VJY\H.NU06._@'%(#P#X)2:WX'^,'@;XV
M:S+<Q:=\;[R\L-1M9FRED9#YNB*..I@B\OK_ ,M.]=S\8OBAX7^$O[>WA+6?
M&&O6OA[2&\ 75L+J\<K&9&O@0OU(0_E6C\8OV$/!<WPKU>/X>:7JECXSTR!;
MWPZ9?$E_/'%>0$20*L=Q<M",E @+#"ALY&,CJ-+\ ^-=:_:H\$?$?5= _LS3
M4^'[Z;J>;J%S::C)<)*UOM5R6Q\WSKE/E^]TR <=X;^,W@KXQ_MP>$;KP5XE
ML?$EK9>"M3BN)+%RRQ.UU;$ Y'4@5UW[.MXOA;X\?'SX>PD#3[+6+/Q)91]D
M&HV_F3H!V FB=L?]-,]SCIM>^'^O7G[67A/QG#8[_#=CX4U#3+B]\Z,;+B2X
M@>--A;><JC'(! QR1Q7*? .U'B']J']H?QA I;3?MFE>'()AT>:TM,W(]/E>
M95]MI]:8'T=7YX_$;_D<]1_[9_\ HM:_0ZOSQ^(W_(YZC_VS_P#1:U]]PG\=
M;T7ZGY'X@_PL-ZR_0YJBBBOT4_& HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ]I^#_Q@DT^:/2]4D+QL0J2,?O>Q_P!K^?UKZ[\+W$=WX5MIH7$D;SN0
MP^BU\*?#3X:W?C34(Y'1DL5.2W3?CKSV'J?P%?</@71X=#\'06\.3_I#EF)^
M\=JC-?FG$U+"PFI0=JCW7^9^X<$8C'U*,H55>BMF][]EW7]>NS1117PY^I!1
M110 4444 %%%% !1110 4444 %%%% !1110 5'J7_(NZI_NQ_P#HQ:DJ/4O^
M1=U3_=C_ /1BT^H/8X6BBBMS(**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "MCPC_ ,C'9?[S?^@FL>MCPC_R,=E_O-_Z":3V&MSIJ***P- HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .9\7?\ (R7W^_\ T%8];'B[_D9+
M[_?_ *"L>MX[(S>X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110!W
M6G_\@'3/^N;?^AM4E1Z?_P @'3/^N;?^AM4E8/<U"BBBD 4444 %%%% !111
M0 4444 %%%% !1110 4444 ;WAK_ %4_^\*VJQ?#7^JG_P!X5M5F]RD4=<_Y
M FH?]>\G_H)KQ>O:-<_Y FH?]>\G_H)KQ>MZ>Q$PHHHK4S"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH T?#O_(>T[_KX3_T(5V$W^ND_P!X_P Z
MX_P[_P A[3O^OA/_ $(5V$W^ND_WC_.LI[EQV&4445!04444 %%%% !1110
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MXMFUNDP0JEQ%*KX"*,XV>U?:M<_XT_Y"T?\ U[Q_^@U[>69G4RZ4G3BGS6_
M^9SO(Z.=QIJM)QY+[>=O\CXO_P"%$^*/^>,?_?,O_P 11_PHGQ1_SQC_ .^9
M?_B*^LJ*]_\ UFQ'\B/D_P#4/!?\_9?@?)O_  HGQ1_SQC_[YE_^(H_X43XH
M_P">,?\ WS+_ /$5]944?ZS8C^1!_J'@O^?LOP/DW_A1/BC_ )XQ_P#?,O\
M\11_PHGQ1_SQC_[YE_\ B*^LJ*/]9L1_(@_U#P7_ #]E^!\F_P#"B?%'_/&/
M_OF7_P"(H_X43XH_YXQ_]\R__$5]944?ZS8C^1!_J'@O^?LOP/DW_A1/BC_G
MC'_WS+_\11_PHGQ1_P \8_\ OF7_ .(KZRHH_P!9L1_(@_U#P7_/V7X'R;_P
MHGQ1_P \8_\ OF7_ .(H_P"%$^*/^>,?_?,O_P 17UE11_K-B/Y$'^H>"_Y^
MR_ ^3?\ A1/BC_GC'_WS+_\ $4?\*)\4?\\8_P#OF7_XBOK*BC_6;$?R(/\
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M['^%'_"N=*_O7'_?8_PHHHYI=PL@_P"%<Z5_>N/^^Q_A1_PKG2O[UQ_WV/\
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(.:LT44@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img98921446_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img98921446_2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  E %L# 2(  A$! Q$!_\0
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0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img98921446_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img98921446_3.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )B!. # 2(  A$! Q$!_\0
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M'P&_91^*'PKU[Q!?>)_CUXA\=VNHZ)<:9;6FH2716SN)'C*72^9<N-Z!& P
M?G."._U/10!\&?\ # ?QU_Z.R\8?]_K_ /\ DVO3/CS^RC\4/BIKWA^^\,?'
MKQ#X$M=.T2WTRYM-/DN@MY<1O(7NF\NY0;W#J#D$_(,D]OJ>B@#YB^$7[+GQ
M+^'_ ,/_ (DZ%KWQSU_Q;JGB:P2TTK5[R2Y,NB2JDZF:+?<,P),J'Y&0_NAS
MTQP7@K]AWXT^&_&6@ZOJ/[4'BO6M/T^_@N[G39Y;TQW<22*SPMNNR,. 5.01
M@]#7VU10!\D_'3]D+XL?%#XJ:WXG\-?M"^)/ VB7WD?9] L)+L0VNR".-MHC
MND7YF1G.%'+GJ>3?TW]E'XH6?[/FJ^ IOCUXAN?%5WK:ZG#XP:2Z^U6]N(XE
M-J";G?L)1FX<#YSQUS]3T4 ?'/PE_8R^+_@'XD:!XAUW]I'Q/XLTC3[D37.B
MWDMX8KM "-C![IEQSW4]*H>/_P!B/XS>+/'GB37-+_:<\5:!IFI:E<WMKI-O
M+>B.RADE9T@3;=JNU%8*,*!A> .E?:M% 'S/XP_9A^)/B']GWP?X#L/C?KVD
M>*M&O'N+[QA#)<BZU&,F;$;E;@/@>:GWG8?NAQTQ%^S;^RY\2_@S\0+C7?%_
MQSU_XD:7)826BZ1J<ERT22L\;"8>;<2+D!&'W<_.>:^G:* /@S_A@/XZ_P#1
MV7C#_O\ 7_\ \FUZ9\8/V4?BA\0M!\ V.@?'KQ#X0NO#^B0Z9J5W9R70;5[A
M$4-=2;+E"78J2=Q8_-U-?4]% 'RQ\'_V4?BA\/=!\?6.O_'KQ#XONO$&B3:9
MIMW>271;2+AT8+=1[[ER'4L"-I4_+U%><6G[!/QRM[J&63]J[Q?*B.K-&TU]
MA@#DC_C\[U]W44 ?+'[0W[*/Q0^+OQ(F\0^%/CUXA^'ND/;10KHNFR72Q*Z@
MAGQ'<QKEO]VK7AG]ESXEZ+^SSXN\ WGQSU_4O%>L7\5W9>,99+G[5IT:/ S0
MH3<%\,(I!\KJ/WK<=<_3M% 'Q5X _8C^,WA/QYX;US5/VG/%6OZ9INI6U[=:
M3<2WICO88Y5=X'W7;+M=5*G*D8;D'I5_XM?L9?%_Q]\2-?\ $.A?M(^)_">D
M:A<F:VT6SEO!%:(0!L4)=*N..RCK7V-10!\N^(/V5_B=JW[/OACP':_'?Q!I
M_BG2]2EO;OQA')=?:KZ%C,5@<BX#[5\Q.KD?NQQTQ0^ G[(_Q5^%7Q0TOQ+X
MG_:"\1^/-%M4F6;0M0DNS#.7B9%)$ERZ_*S!AE3RHZ=:^L:* /AOQ!^PG\;=
M6U[4KZU_:G\6V%K<W,DT5I'+?;849R508O ,*"!P!TKT?XN_LN?$OX@?#_X;
M:%H/QSU_PEJGAFP>TU75[.2Y$NMRLD"B:79<*Q(,3GYV<_O3SUS].T4 ?+OP
M$_97^)WPJU3Q+<^*/CMX@\>0ZGH\VG6D&H271%E.[*5N4\RX?YE"D#&#\W45
MY=_PP'\=?^CLO&'_ '^O_P#Y-K[SHH ^7?VB/V5_B=\7O&UCK/A/X[^(/A[I
MT&FPV4FEZ;)=+'+,C.6G/EW$8W,&4'C/RCDT?#;]E?XG>#?A;\0O#.L?';Q!
MXDUKQ%##'IFO74ET9M'9-^YHBUPS MN&=K+]T=:^HJ* /B7P5^P[\:?#?C+0
M=7U']J#Q7K6GZ??P7=SIL\MZ8[N))%9X6W79&' *G((P>AKI/CI^R%\6/BA\
M5-;\3^&OVA?$G@;1+[R/L^@6$EV(;79!'&VT1W2+\S(SG"CESU/)^MJ* /E/
M_ADWXI_\,_\ _""?\+^\1?\ "4_V]_:O_"7^9=?:OLWD[/LF?M._9N^?[^,_
MP]ZH?!/]CWXM?#3XH:%XE\1_M$^)?&NBV#R-<:%?2W9AN@T3H P>Z=>&96Y4
M\J/K7UW10!\2^-?V'?C3XD\9:]J^G?M0>*]%T_4+^>[MM-@EO1':1/(S)"NV
M[ P@(48 &!T%=QXT_97^)WB3X(^!_!FG_'?Q!HWB/0IIY-0\40270N-45V<J
MLA6X#D*& &YV^Z.E?45% 'S/^S/^S#\2?@KX\O\ 6_&/QOU[XE:9<:;)91Z3
MJDERT<4S2Q.)QYMQ(NX+&Z\*#B0\]0?)/^& _CK_ -'9>,/^_P!?_P#R;7WG
M10!\I_&;]DWXI_$?_A#_ /A'OC]XB\&_V-H-MI5]]ADNA_:5S'NWW;[+E/G?
M(SNW'CEC5KX2?LK_ !.\ >"?B+HVN_'?Q!XLU'Q)IHLM+U2\DNC)HTP64>?%
MON&(;,B'Y2A_=CGICZBHH ^&_#_["?QMTG7M-OKK]J?Q;?VMM<QS2VDDM]MF
M17!9#F\(PP!'(/6N]_:&_91^*'Q=^)$WB'PI\>O$/P]TA[:*%=%TV2Z6)74$
M,^([F-<M_NU]3T4 ?,6@_LN_$O2OV<_$?P_NOCGK]_XMU+54O[7QG))<_:[*
M$?9\VZ$W!?:?)DZ2 ?OFXZYXWX;_ +%'QD\&_$#P[KNK_M,>*?$>E:;?PW5U
MH]U+>&*\C1PS0MNNV7# $'*D<]#7V?10!\8?$C]BCXR>,OB!XBUW2/VF/%/A
MS2M2OYKJUT>UEO!%9QNY985VW:KA00!A0..@KK?$'[*_Q.U;]GWPQX#M?COX
M@T_Q3I>I2WMWXPCDNOM5]"QF*P.1<!]J^8G5R/W8XZ8^HJ* /EC]GG]E'XH?
M"+XD0^(?%?QZ\0_$+2$MI86T74I+IHF=@ KXDN9%RO\ NUP7B#]A/XVZMKVI
M7UK^U/XML+6YN9)HK2.6^VPHSDJ@Q> 84$#@#I7W)10!\Q?&3]ESXF?$7P;\
M.=(\/_'/7_!VH>&]*6PU34K*2Y$FM3".%3<2[+A"6)C=OF+G,AYZYH?!G]DW
MXI_#C_A,/^$A^/WB+QE_;.@W.E6/VZ2Z/]FW,FW9=ION7^=,'&W:>>&%?5E%
M 'P9_P ,!_'7_H[+QA_W^O\ _P"3:]6_:2_9<^)?QF^(%OKOA#XYZ_\ #?2X
M[".T;2-,DN5B>57D8S'RKB-<D.H^[GY!S7T[10!\N^"_V5_B=X;^"/CCP9J'
MQW\0:SXCUV:"33_%$\ET;C2U1D++&6N"X#!2#M=?O'K7&> /V(_C-X3\>>&]
M<U3]ISQ5K^F:;J5M>W6DW$MZ8[V&.57>!]UVR[752IRI&&Y!Z5]JT4 ?(GQL
M_8]^+7Q+^*&N^)?#G[1/B7P5HM^\;6^A6,MV(;4+$B$*$ND7EE9N%'+'ZU?_
M .&3?BG_ ,,__P#""?\ "_O$7_"4_P!O?VK_ ,)?YEU]J^S>3L^R9^T[]F[Y
M_OXS_#WKZLHH ^2?@7^R%\6/A?\ %31/$_B7]H7Q)XYT2Q\_[1H%_)=F&ZWP
M21KN$ETZ_*SJXRIY0=#R.1\0?L)_&W5M>U*^M?VI_%MA:W-S)-%:1RWVV%&<
ME4&+P#"@@< =*^Y** /EWXD_LK_$[QE\+?A[X9T?X[>(/#>M>'89H]3UZUDN
MA-K#/LVM*5N%8E=IQN9OO'I4O[./[+GQ+^#OC+5=7\7?'/7_ (BZ?=Z5+80Z
M;J<ERT<$S21,MP/,N)!N41LO !Q(>>N?IVB@#X,_X8#^.O\ T=EXP_[_ %__
M /)M>H_'O]E?XG?%75/#5SX7^.WB#P'#IFCPZ==P:?)= 7LZ,Q:Y?R[A/F8,
M <Y/R]37U%10!\L?#3]E'XH>"_AO\1O#VL?'KQ#XEU?Q);6T.EZU=271ET5X
MS*7>(M<LP+[USM9/N#.>,<%X?_83^-NDZ]IM]=?M3^+;^UMKF.:6TDEOMLR*
MX+(<WA&& (Y!ZU]R44 ?)WQ[_9'^*OQ5^*&J>)?#'[0/B/P'HMTD*PZ%I\EV
M(8"D2HQ CN47YF4L<*.6/7K6SH_[,/Q)T_\ 9OUSX>S_ !OUZ\\77VI+>V_C
M5Y+G[7:Q!H28%)N#)M(C<<2 ?O#QUS],44 ?'/PE_8R^+_@'XD:!XAUW]I'Q
M/XLTC3[D37.BWDMX8KM "-C![IEQSW4]*H>/_P!B/XS>+/'GB37-+_:<\5:!
MIFI:E<WMKI-O+>B.RADE9T@3;=JNU%8*,*!A> .E?:M% 'RQXJ_91^*&N_ W
MP3X*LOCUXATKQ+H=S=3:AXJADNOM.J)++(Z)(1<A\(KJHW.W"#&.E'[//[*/
MQ0^$7Q(A\0^*_CUXA^(6D);2PMHNI2731,[ !7Q)<R+E?]VOJ>B@#X1N_P!@
MGXY7%U-+'^U=XOB1W9EC6:^PH)R!_P ?G:O3/C7^RO\ $[XE:7X'MO#OQW\0
M>"YM"T>/3M0GL9+H-JDZJH-S)LN$RS$$_-N//6OJ*B@#Y8^#_P"RC\4/A[H/
MCZQU_P"/7B'Q?=>(-$FTS3;N\DNBVD7#HP6ZCWW+D.I8$;2I^7J*\S_X8#^.
MO_1V7C#_ +_7_P#\FU]YT4 ?+'[0W[*/Q0^+OQ(F\0^%/CUXA^'ND/;10KHN
MFR72Q*Z@AGQ'<QKEO]VK_@_]F'XD^'OV??&'@._^-^O:OXJUF\2XL?&$TER;
MK3HP8<QH6N"^#Y3_ '74?O3QUS],44 ?&'PW_8H^,G@WX@>'==U?]ICQ3XCT
MK3;^&ZNM'NI;PQ7D:.&:%MUVRX8 @Y4CGH:L_%K]C+XO^/OB1K_B'0OVD?$_
MA/2-0N3-;:+9RW@BM$( V*$NE7''91UK[&HH ^6-2_91^*%Y^SYI7@*'X]>(
M;;Q5::VVIS>,%DNOM5Q;F.51:DBYW[ 75N7(^0<=,5?@)^R/\5?A5\4-+\2^
M)_V@O$?CS1;5)EFT+4)+LPSEXF121)<NORLP894\J.G6OK&B@#X;\0?L)_&W
M5M>U*^M?VI_%MA:W-S)-%:1RWVV%&<E4&+P#"@@< =*]'^+O[+GQ+^('P_\
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MX .)#SUS].T4 ?!G_# ?QU_Z.R\8?]_K_P#^3:]1^/?[*_Q.^*NJ>&KGPO\
M';Q!X#ATS1X=.NX-/DN@+V=&8M<OY=PGS,& .<GY>IKZBHH ^7?A)^RO\3O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HKJU@OK6:VN88[BWF0QR0RJ&1U(P58'@@CL:EHH ^8M-_8'\
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M^%?[07[45O\ $;P_X9^)GP.LX].U6Z2"36]$F80V,>?GFE=)+A.%!(4E-QP
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MOV<_^BEVO_@NO?\ XS0!])45\V_\/&OV<_\ HI=K_P""Z]_^,T?\/&OV<_\
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M"_\ HG.O?^!D/^% S]%Z*_.C_A]!X+_Z)SKW_@9#_A1_P^@\%_\ 1.=>_P#
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M6B07%I8ZHC_Z-= >9#)'(T<B''!PZ-@CJ,'O0!WU%%% !1110 4444 %%%%
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M=^-O^"@WA#X7^!O$-QH_A[PWIWV_Q0L,*2)*KA97217!!!0VL:N!N1KAR.]
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MQ#&JK.\4B\I)(WELJR?*#@ '/[(44A'PA_PYO^"__0S^//\ P867_P B4?\
M#F_X+_\ 0S^//_!A9?\ R)7W?13&?"'_  YO^"__ $,_CS_P867_ ,B4?\.;
M_@O_ -#/X\_\&%E_\B5]WT4 ?"'_  YO^"__ $,_CS_P867_ ,B4?\.;_@O_
M -#/X\_\&%E_\B5]WT4 ?"'_  YO^"__ $,_CS_P867_ ,B4?\.;_@O_ -#/
MX\_\&%E_\B5]WT4 ?"'_  YO^"__ $,_CS_P867_ ,B4?\.;_@O_ -#/X\_\
M&%E_\B5]WT4 ?"'_  YO^"__ $,_CS_P867_ ,B4?\.;_@O_ -#/X\_\&%E_
M\B5]WT4 ?"'_  YO^"__ $,_CS_P867_ ,B4?\.;_@O_ -#/X\_\&%E_\B5]
MWT4 ?G5\2O\ @CGX#A\!ZW+X$\2^*)/%T5NTFFPZS=VLEK-*O(CD"01D;P"H
M;<-I8,00"#YI_P $P?VJK[X8^-IO@1X[^T6=I>7LD&CB\!5].U#>1):.K<JL
MCYP/X9,C!\PD?K!7!:3\"? &A_%#5?B+9>%K"'QKJB+'<ZQL+2D*NW* DK&2
MO#,@!; W$TA'RC_P4T_8R_X7+X1?XD>#]/\ ,\<:%;G[;:VZ_/JEDH)("_Q2
MQC)7NR[E^8B,#R[_ ()H?!_X=?'OX3:G%XY^#^GWEWHMR(;?Q1-:,D6I1MN/
ME[@0&EB(PQ4?=://S9)_3RJVFZ;::/8PV5A:PV-G"NV*WMHQ'&@]%4  #Z4
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MM_="C=GTKX*_9H%_^T%\4O%O[17B.&2--3DDT;PE8S+_ ,>6F1.5WCDX9F#
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M^WU^TMK;\_V+IMCJ$*'E6G%BD<>1]93]*^<Q4O:IL]+#ITTD>L?#?PC;Z_\
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M'XD^%[+Q'X8U2#6M#O=_V>^MB3')L=HVQD=G1A]16[0 4444 %%%% !1110
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M@9ET?P)/>.4_A9Y+F'YL]L2KT[D5]PUZ5#^&CCK.\V%%%%=!B%%%% !1110
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M\+Z1XAT:Y%YI.JVD5[:3@$;XI$#*<'D'!'!Y%:U?/GU@4444 %%%% !1110
M4444 %%%% !7S5^Q?H?PGT7_ (63_P *M\1:SK_GZ\\FM?VO'L^SW?S92/\
M<QY7K_>Z=:^E:^.O^"=OP[\4?#__ (7!_P )+X?U+0?[1\3O<V?]H6SP_:(C
MO^=-P&Y>1R* /L6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HJOJ-U)9:?=7$-K+?2PQ-(EK 5$DS $A%+$+
MDG@9(&3R17Y+:7_P4\^.OP1^(>JZ=\5/!2WMI<74MRFAZE;/IMY91.S%(X)M
MGS1KG +HY8*,,.M 'ZWR2+#&SNRHBC<S,<  =237PM^U-_P5/\&?"G[5H'PV
M6U\>>*5^1[]7)TJT;GK(IS.PX^6,A>?OY!6OB[XM?M??%[]NOQQ:> M$NK/P
MCX?U2806_A^/4DM89_\ KYN9"GGG_8& 2!MC+=?M_P#9;_X)<^!?@X;/7O'C
M0>/O%T8#B&:+_B66CX_Y9Q,/WQ!SAY!CH0BD9I"/CCX;_LO_ !^_X*">)[?Q
MKX\UJ\T[PS(?W>NZTA6/RB1E;&T&T%>G*A(R0<L6!%?I[^SO^R/\-_V9=)$/
MA'1EDUB2/9=:_J&)K^XSU!DP B\#Y$"KP"03S7LRJ%4 # '  I: "BBBF,**
M** "BBB@ HHHH Y_QYX^\._#'PM?>)/%>L6NA:'9)OGO+Q]J+Z*!U9B> J@L
MQ( !)Q7\^^K>(?$/C[]HCQ7J'PS_ +6FU3Q-K.I'3H]+5UO)H+F64E %^8;H
MG(8?W2V>,U^I7[>7[#_CG]J3X@^"[_P_XO%GX?B!M=1T_4IF-OIX&6^UP1+]
M]V'R%>"2(_F"EBGL_P"S]^R[\,OV/?!-S<:8MM#>1VQ?5_%FL,B3R(,,Y:0X
M$4(*@[ 0HV@G<06*$<#_ ,$[OV6?&_[,?P[U:W\9:^DT^MRQ7B^'+8B2'3)
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MF0@&9E R6(P,'8BDD']=OVEOV8?!_P"U-X-LO#_BQ+BW-C=I=VFI6&U;JWY
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M,2ZG!#J)=DEAO<R)):0 A/NJ\@#@@/G O_'3]K[XC^&=0\)ZIH=_:6/@:_\
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M$\Q0F64#NH!ZYYVJ1D9QZCX\^.%EKU]+I-I=OXGO;AV0^'_"I:17S@[+B].
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MT28*P#D'YLO@@A&% 'T1J6I6FCZ?<W^H74-C8VL;33W5S((XHHU&6=F) 50
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MBV*[BF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M..Q:0>]>:Z?J)_;,_:0U;Q3K-VR^%89S;Z8K JD&G++L@7K\AEP9G/4EB 0
MNW[=U3X.^&OAOH=I<&=SIMN/*-C;HD>\D' C QC!^8CG@&NV-.%-+GU;/TC#
MY7EN54Z4LSBZE6HKJ"NDD]KM:MOU5CYOTW]MC]H'PBYO?%/@#0]>TE 3)'96
MMSI\PX_YZ^9.J@8[Q_B*^G_V=_VL?!?[1EO/;:4T^B^)[.(2WGAW5-BW*)D
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MY#<X\L7>[/W_ ",PXQC;@]17M5% !1110 4444 %%%% !1110 4444 %%%%
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M,'P]^)$[7,&T'RM/U@8\V/KA1-D,.F2< !8J]$N;674OAS\+H#ME3Q#XEO\
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MHGPS_9V\)>&_#OBZS\=Z-9?:_(\0:>BI#=;[N:1MH620#:SLA^8\H>G0>QT
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MCC&!@5W/@GP-I?P^T=],TAM1>U:9IR=3U6ZU&7<0 <2W,DC@84?*&P.2!R:
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M_P $^=%N?"'CSXC^&-23R+K2EA%NF[[\+RRDX]=K*!G_ &OI7T)K7_(9O_\
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MXV\36/AN/4#(MJUZQ F*;=X& >FY?SH [>BO#/\ AN/X#?\ 14-"_P"_C_\
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M;\/6>O0V?@[3_P"TM16^M(HW:+9*^(@LK;FQ"_!([<UY=_P]Q^"G_0,\8?\
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M:\W_ .'N/P4_Z!GC#_P70?\ R17VA!IMI:N7AM887(P6CC"G'IP*C_L73_\
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M%SC((SVKOJ\V_:4\/:EXM_9]^(^BZ/9R:AJNH:!>VUK:PCYYI7A951?<D@4
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M_!*/Q<;);^4D&2Y+K;A<B(L2P3S"F[GTXH ^W:*\#_9\^+_Q9^)$VC:CXO\
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M7!/LK#O^( KXK^%>EQ_LZ_M?_$[X3RM]DT#Q41XN\,0_*L>'W?:(HU'3!5E
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M-&D<MS ^Y&64)A6E1XR69%12LL7R@YH [&BBB@ HHHH **** "BBB@ HHHH
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MFE&'DB$:[&88&"5P>@H POB=\;? OP9BT^3QMXFL?#<>H&1;5KUB!,4V[P,
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M*"6'S"O#KC_@I);Z79ZS=ZI\)O$^GVGAG6%TCQ3<&XMY(](9W*1D%6_>DLK
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M55U+M&ORC)Z#-?68.X _TI@>$_!7]D'PW\%O%=EXAB\2^)O%>H:;I T'2_\
MA(KN*9-/L@^]8X@D28(R5#'.%)48'%>[T44 %%%% !1110 4444 %%%% 'A?
MQZ_;.^&W[-_B>PT#QG=:E!J%[9B^A6SLFF4Q%W0$D'@Y1N*D^!O[9WPI_:&U
MB?1_"?B _P!M1KO73=1A-M/,H!):)6XD  )(4D@#) '-?)/[=_BO4? _[>OP
M:U[2?#UWXKU*PTB*:#1;$D37;?:;H;$PK'//]T]*W?A_\/?B?^T-^VMX3^,N
ML_"RY^$GAW0K0QW1O)E6[OI%295+ HCNS>8J$E,"-,;ON@H#V;QQ_P %(O@O
M\/?&FM>%]8OM8CU71[R6QNA%IKNBRQL5;# \C(/->Q_!WX]> _CYH=QJW@3Q
M%;Z[;6SB.YC57BGMV.=HDB<!TSM;!(P<'!.#7R!^Q+_R?9^TU_U_W'_I:]<'
MK"7GPC_;B_:'TSX:V2Z.K?#Z]O$L], CCM[D6$$Z2I&!@/YQ! QUE/0&@#ZK
M^+7_  4&^"GP>\1W/A_5/$<VJZU:3""[M-%M6N?L[9PP>3B/*\[E#%@01C/%
M>C^#?VB/ 7Q"^%FJ?$+PWKB:OX;TRVFN;R2"-A-!Y4?F2(\3 ,KA>=I'.01D
M$&OD?]B6ST'X=?L&W/CGP]\/D^(_B[4+F>/5]'LXQ+>7Q^V^0(&.QSL2 I+L
MVD8+-CYB:PO@+\1? FN>#_VF= \*?""Y^%&MQ^&;^YUJWGU66XWRK%<J(O(=
M56#RS)( J   XQP* /7O^'JGP&_Z"&N_^"I_\:^G/AQ\0-(^*G@?1O%N@O-)
MH^K0"XMFGC,;E"2.5['BOS%_8J\8?M'Z+\#;6V^&7PE\,>,?"POKADU35;N&
M.9I2PWH0]U&< XQ\OXFOU.\/-=MH.FMJ%K%8W[6T;7-M#C9%*5!=%P2,!LCJ
M>G6@"?4M/@U;3[JQN4$EM<Q-#*A (96!!'/L:^<OV ?A7I7P?^"-]H6D>/M!
M^(EN^MSW4FI^'9DEMX7:& & LKL"X"JQS@XD7CN?I:OAG_@C]_R;3XE_[&ZY
M_P#2.RI@?<U%%% !1110 4444 %%%% !1110!\E_\%$/A7J>L?#G2/BKX23;
MXV^&MU_;-NR@_O[(8-U$V",J%42$'^%'4??-=%\/?CEH>I?#?2/B5:2L=#N[
M-+ID4AG7<=K0G'&]7RA[;EKZ.G@CNH9(9HUEAD4H\<BAE92,$$'J"*_+'4O#
M>L_L[_%/Q%^SRJROX=U_5(]<\'2.Y*M;2E@]IN8GE'"?C%(Y^^*Z\/-)N$MF
M<]:\8\RZ'UK\2OAVFH?$J"XTU=_AKQ,8M9U">,@Q3B!5$<2XZJ[2"1L_>W C
ME*3XA>&X+ZUFGDMX[FVG0PW<$BADD1AM.X'J"#@BK?[-OB.?QE\'9M(O)?-O
M]!N&C@4YW^0 "%.?3<RCIP%':NIDC6:-HW4,C##*>A%>GAY<GNOH<W*I+F74
M_.GP.US\,_%>K_!;7&>;3K,S:AX9N)N3/IT[%FAW<9*/O/ ^^9^< 5]T_LNZ
MY)?> Y],N'9Y].N"N2,#:XSD?5A(?Q%?./[97P<O]1\-P>*/#RLOBOPG(VIZ
M;*JY-Q ,&> X(W?*-P'.2I4#]X:Q?!_[55OX)_9M\3^-/#X63Q'KBVFEZ-8*
M/,E&HR><NT+CYO+P[\C#;%'\8KY?,,*Z->\=I'KX6M=>]T.Z\4:1_P -H?MF
M6O@K<+SX7?#)DU#7U4AH;W4,L(K9L9#<AE((! 6X7KBOT$KQ+]CW]GN/]G'X
M*Z9H-TPN?$]^QU/7[TMO::^E +C=D[E080'OMW8RQKVZMJ<%3BHHB<G.7,SP
M+]NCX.O\:OV:/%FE65N9]>TV(:SI!C!\Q;JWRX$>/XG3S(Q_UTK\W?V7?&J6
M/B[3=<OB$36 LYFQA2_SQS@?[K,QQZ#-?L]7Y!? 7X065YX;^(7@S5;L6;^%
M_%E_I<5^,@V#1D".1B/F\MG$@9L93AL$;P=/4]#+ZCC4LC]$_$EM_;GP\T76
M%7,]H/LLS#D[0=H)/U _[[KPCXM6@?1[.["AG@GV_,,C:P.<CZJM>G?LM6OB
M6\^$GBOPEXM@":WH]])9+O&#(GDQM%(1TZ]"."%!!((-<3\0H?/\'Z@,9*JK
M#\'!_E7+45CZW*:JE.5/HG^#,O\ X):^*##X(^)7PZ>621?"'B:4V<;G_5V=
MQN,0'L7BF;_@9K[>K\Y/V#K^XT3]M3XEZ-&RBQUKPM!JTB+VD@FA@7/O^]D/
M?[WX5^C==$7=)GQ6+I^QQ$Z:Z-GDO[6W_)K_ ,5_^Q9U#_TG>ODCX$_"CX@?
M$ZZ_9MUAOAY'X*\.>"/#<\\GB*WU"V8ZRMU:*(%1$/F#?D,X<#!FE&0<;OT&
MU;2+#Q!I=WIFJ65OJ6G7<307%G=Q++#-&PPR.C AE(."",&ETO2[+0],M--T
MVT@T_3K.%+>VM+6)8HH(D4*B(B@!550  !@  51R'PQI?['OC.;_ ()Q?\*T
M70;/1OB2\CWEW8M<0#[<T>HO-'%+/&S*Q,(3:2^ 0@+* <%Y\ _B+\4O&GQ&
M\;'X8V_PN6?X8WOA&P\/6VHV;R:M?2PR!2QA(C6-25C5I"O$<1X (3[QHH ^
M#M(_9B^(\.I:3)<>&5\F#X#MX-DW7MLP76-TA%MCS/=3Y@_=_P"U7E4/[''Q
M>\$KHM[!X0U;6FU+P&/#U_8:5JND(UE=AV!@D-U'*A@=51BT7S99OF'0_J-1
M0!\>_!/]EC6/ '[1GA/6=3\/)<^$]"^&L&BV]]?7EO>M;ZFMX)#&IVH[%8VD
M E$2*1QP3BO(/$W[.?QK\3?$ZSOKKP7=B#2/B4GB%/[)NM(L-'ETU)EVSI;H
MRRRW;*,F29BP1 I)9B!^D-% 'Y[^,_V<_BE>?"?]IOX?Z=X!>YN/%WBU_$>A
MZI%J%G';W4#ZA:2K  \JLC+%'(YW!5&P@$DC-_XF? 'XD:)XZ^.?]F_"NT^)
M-E\3-%L[/3=:GU*TC?1YDMO)99%F(8!&(D4Q_P#/&'YMW*??-%(#XR^'_P"R
MAXF\+_&7P8VO:7;>)?"^D?"1/"=UJ5S+#+$^H?:9&:%8G/F%/+<A6*;=A )S
MD5Z-^R7\%=<\&_L=:#\-O'%E-H>KFTU*SOH+>ZBDE@6>ZN65DEC9TW>7*K @
MG!(SR"*^AZJW&JV5G>VEG/>6\-W=[OL]O)*JR3;1EMBDY; Y..@I@>1^+)-0
MU*X\"3^*]-U:VUCPQK/]I>9H>DRW]KJD@LKFV/EF(NUNC?:B_P"^V[2FW+##
MGLO EEK6H:QK/B;7[#^R)[X16MAI;2K)):V<09@9BA9/.>225FV,5VB%<DH2
M>THH **** "BBN/^*WPG\-?&OP;<>%?%MI/?:)<2QS2007<MLS,C!E^>)E;
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M'@GQ]X<^)&B_VMX8UFSUO3Q(87EM) QBD !:*1?O1R+D91@&&>0*FEB*-?\
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M[K?X5\&^%/A1X8^ W[>7@*[\3PR0> ]6U&>ZT:!MHM-/UEU"JKKC 7S!$R$
M8S%R1&U=O#XR^)/P;U V\<MQ=6:,=NF:U'A74$X$;C@#_=//]ZG_ !2\=>"?
MVHOA[J7@_78G\+>*&02VOVU?DCN%R(Y58 \ D@D?P,XW<BNNM!5H<O7H94Z\
M5+70_2^BOF7]@W]H6^^,WPON/#WBN1D^(_@N4:3KL,S9DFVY$-SG)W>8JD%L
M\NCG@,N?IJO"/3W"OS9_9QB^T_%+]HR["A[2X^(6IJC'H^)Y"1CZ.O7UK]%]
M>URR\,:%J.L:E.MKIVGVTEW<SOPL<4:EW8^P4$_A7YQ?L.6-P_P5N/$5W_Q\
M^*-;OM9<>A:3RB/IF$G\:RJ;'M93'FQ*?9'V[\!K*2R\-WL1E\VUCG$-L&7Y
MX8@H(BW=2BEFV@_=#8'  'RO:^(K^'P]J_A[Q*R/J<-JTEI>1N'CU"W.?+F1
MA\K=LD$@X)_O ?7'AB/_ (1GX6R73@)+)!)<<]"6^Y^8VU\'>++J7P'>7_AV
M[WW6B(S7=AG&^V=UX=&/13C;(.C $XW!2'925GN>G@ZCIXFI6C\-[%O]C(K/
M^WOKGV?]V8? ,@N.<^83>V^/IPR?]\U]&_MZ?M)^,/V8?AAH/B+P7I.EZOJ-
M]K"Z?-#JMM-/&L1@ED+ 12(0VZ-1DDC!/%>$_P#!.O2X/$7[3'QL\4Q-N33=
M/TW2(V (!,H+R#K@D-; ?ET[_H=3BK12/"S":J8JI*.S;/Q^_P"'NGQZ_P"A
M(\'?^"F__P#DNC_A[I\>O^A(\'?^"F__ /DNOV!HJCSS\?O^'NGQZ_Z$CP=_
MX*;_ /\ DNC_ (>Z?'K_ *$CP=_X*;__ .2Z_8&B@#\?O^'NGQZ_Z$CP=_X*
M;_\ ^2Z/^'NGQZ_Z$CP=_P""F_\ _DNOV!HH _'[_A[I\>O^A(\'?^"F_P#_
M )+H_P"'NGQZ_P"A(\'?^"F__P#DNOV!HH _'[_A[I\>O^A(\'?^"F__ /DN
MC_A[I\>O^A(\'?\ @IO_ /Y+K]@:* /Q^_X>Z?'K_H2/!W_@IO\ _P"2Z\6_
M:;_;<^)?[26E>';3Q9HVC^'QHMXU[9W.B6MS;2^:5QG=),_3 (VX(/>OWJKP
MW]J#]D_0/VK+?PII_B;5K[3]'T2\DO);?3@JRW19-H3S&!"#U^4DC@%>M 'Y
MT_LC_P#!2#XU:7K^F^#M1T.^^,MK+\D5M&COK$:#JRS*I\P 98F4$\??45^O
M6AZC/JVCV=[<Z;=:/<3QK(]A?-$TT!(^XYB=TW#_ &68>]<K\*/@EX%^!V@_
MV/X&\,V/AVR;'FFV0F:<C.#+*Q+R$9."[$CI7<4QA1110 45Y)\9OVBM*^!G
MC3X?Z9XCTRY@\.^*[R737\3;@+33KH!3!'-QP)<O\Q("B,DY 8KZU0 M8?C?
MP1H7Q(\)ZGX9\3:9!K&A:E"8+JRN%RLBGD<CE6! 8,""I (((!K<HH _(=M%
M^(W_  3V_:AUSPW\/-5N/$/AF2RBUVW\-ZG-A-7L&;RY%.WY4N8V1E5U7)"9
MQ@^6WZ6? #]H3PE^T=X%A\1^%KO+IB._TN?"W6GSXYBF3L<@X;HP&037QS^V
M85\9?MP^"=(TA5N=2T3PI+->+;D,Y\Z9UCA8#D$ B3![.#[URFM? GXE?#'Q
M,OQ'^&WF>&_%T(!NH8'62TU6/.3#=0JWS G^+''7((#*6/IZ&3K%8!8FG)*=
MWHWNO(_3VBOE?X&_\% ?!/C^ZM/#/CQ#\,?B <1R:7K+;+2Y?D;K:Y/R,K$8
M 8JQ)VKOQD_4]!\W.$J<G&:LT+11100%%%% !1110 4444 %%%8WC#QCHGP_
M\,ZAXA\1ZI;:-HFGQ>==7UVX2.-<XY/<DD  <DD  D@4 ;->:?%K]I3X8_ N
M$GQQXTTO0[C:'%BTAFO&4]&6WC#2$>X7'O7P?\2?VZ_BM^UC\1#\,OV;=,NM
M'L),_:/$4R".Z>#[K3EF!%K#\P(;_6D[,%6;8?HS]G/_ ()X>!?@[>?\)-XN
MD;XF?$&>3[1/K>NQ^;'%+G<6AB<M\V<'S'+/D9!7.*0'T;\//'FE_$[P3HWB
MO1!=?V3JUNMS:F\MGMY3&>A*. 0#U!Z$$$$@@UX9^WQ\)_"_QB^#VCZ+XM^(
MNF_#+3H->AO(]6U2))(Y95M[A!  TL0W%9&;.X\1GCN/I6OC'_@JSX-U_P <
M?L\^'K'PYH>I>(+Z/Q3;SO;:7:27,BQBTNU+E4!(4%E&>F6'K3 [K]K37/A/
MI'Q ^"T7Q'\/:SK>LW6O>7X:GTN3;'9W?FVPWSCSH\KN,)Z/PK<>OTI7RQ^V
M5\"_&7Q>^)'P)U;PMID=_8>%O$7]H:K(]S%$8(?.M6W .P+\1/PN3Q[BOJ>@
M K@?C[XD@\'_  1\>:Y=:19Z_;:=HMW=2:5J*![:[5(F8Q2*004;&"".AKOJ
MX'X^^'(/&'P1\>:'=:O9Z!;:CHMW:R:KJ+A+:T5XF4RR,2 $7.22>@H Y/\
M8U\>6?Q._9M\(>)=/\,:3X-L[[[9LT30X5AM+;9>3QGRT4 #<4+GC[SDU[57
MBO[&O@.S^&/[-OA#PUI_B?2?&=G8_;-FMZ',LUI<[[R>0^6ZD@[2Y0\_>0BO
M:J "FNZQHSNP55&2S'  ]:=7G'[2<UU;_LZ_%.6Q9TO4\*ZJT#1G#"06<I4C
MWSBD]%<#R/PSI8_:@UZQ\>:_;RW/A=)O/\*:!=%OL\<"[A'J,T)PKW$H)D3>
M#Y49CVX?>Q]W3PVEGM\T1HN/]8WS<^E<G\,OL-GX;TJ+23Y=A':0"U(_YXA
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M^(GBCXF?L_\ B#5/%OB#4O$FI0^)[BVCNM4N7GD2(6EHP0,Q)"AG8X]6/K3
M^Q:*** "BBB@ HHHH **** "BBB@#QS]KOXV#]G[]GSQ=XOAD5-6BMOLFE*=
MI+7DQ\N$A3PVPMYA'=8VKY&\ _$*R_90_9YT+PCI">?XMG1KW6+N106.H2X:
M51G.\I\L>\\8C7[Q-7?^"AWC)_B)\?OAE\)[60OINB*?%>LJI#*7!*6Z,.Q
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ML>37'[+/PUFT;POI<>C7]A:>&%NTT@Z;KNH6<MJMTZR7 \V&=78.RJ<,QQC
MP*[GP3X&TOX?:.^F:0VHO:M,TY.IZK=:C+N( .);F21P,*/E#8') Y-=!10!
MA1^!]$B\<7'C!;+'B.?3H])DO?-?YK6.5Y4CV;M@P\KG<%W?-@G  KB_^&:/
MA_\ \)8=?_LR^\\ZG_;?V#^V+S^SOM^_?]J^Q^;Y'F;_ )L[/O?-][FO4:*
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ML&DV<5G"TARS*BA=S>YQD^Y-?&OPK\;:'X4UJ^^+?B&QOM8M1=2>&/!^FZ7
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MMZ_EWME.!^\4*P4R(#TD48QC.ULJ/;*S/YVE%Q=I+4*^1/\ @IS\*?%OQ@^
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MW4<0J4>5HXZM!U)<R9YQXF\50Z5;/%;R+)>L, *<[/<_X54^!'/QFT(GD_\
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M9OI.CLIBED6WMG,YVQH-Q$BKTZ1CGT /IJBBB@ HHHH **** "BBB@ KP_\
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M,9(X1!FO"_V0?@QH>K?&CQ=XST:[N=3\!^&-2N],\)RWAR95:1R)>WW8G!Y
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MN[J5IKB9B\DC=237A'AYYO!/A=XK&[6RMYYFN-0\2ZY*(Y+ZX<DM(6<GDG/
M+'ISG).7I]]-XFM+C4]'T+QUXXT^W5FN=5\/Z%-/:Q!<[B96QD#G)( K514?
MB9^]Y/@<#PYA4L?7C"I+5K=^A]!GCD\"N;UCXA:-H[;&G-W+WCM0'(^IR!^N
M:\0CU&QU6T@O-+OSJ&G7"YCE92C @X9'0_=8$'CZ$<$&K3066FZ1-K6N7Z:1
MHT1V^<XS).^"?+B7^-N/PY]#6G)%+F;/T%4L'3PZQE2JG3:O?H>F#XP:=YA!
MLKH)V;Y<_EG^M.F^*6@:E;RVMW:7,EO,ACECFB1T92,%2-QR"#TQ2^!_V5_C
M+\4-)76?#OPXT_1M!FMQ<VEQXRU5HKF^1@&79%"<QDJ1C>H'/WJYKQ?\&/B/
MX!W+XG^#?C2P8+N-UX>6+6[8#^\6AX0'T9LBHYH=CY'_ %IX?JS=+FT\[V?X
M'CVM_#V;0=2F_P"$0U[.EL^^.ROHF*Q@DG;DC(QGMUZYK,E'C2UD(;3+*\7U
MMYPG_H9KK[[Q+X9TTE;[5KS19E(5X=7TBY@=21D A5<9Q[U0;QYX/5<CQ=9,
M?06MY_\ &*ZH8J=-6C)HXZE'AJLN:EB.3TFOR=['--<>+V_YEW:?7[='@?E2
MQZ?XMN@#]CTZT/?SYF?_ -!KH&\?>%>%A\0PWDA^[%!:71=CZ &(<UU^C>']
M;\16L=SHGP_^(?B."0;HY=*\+S/"XXP1)GIR.=O>G+&57]L\RIA^'Z6LL8W_
M -O)_DCS*/P7XAOMWVW78[6-N#'8P]O9S@BN@\,_#VRT^\#V=I-J.I-SY\N9
MI3[CT_ 5[KX7_9?^.?BI(9-)^"[:5!,59+[Q=K440C7/5[="DH]Q@U[YX+_X
M)M^+_$$,9^(_Q-72+%B3+H'@"T%K'TZ?:I!O8'N#&?K7+*M*?Q.YY_\ ;G#V
M6OGPT'4FMF[_ *[?)'Q=K,FF>%V":_K%MI]R2%73X3]HO')'R@0IDC/3YBM>
MR_"_]C_XS?%B*&\TWPI9_#[0IB"FK>-B6O63."\=D@.TXY"RC!XPW>OT1^#O
M[*_PK^ T49\&^#=/T_4%!!U:=#<7SY&&S/)N< ]U4A?0"O6*R<FSYG,^-,RQ
M]XTW[./EO]Y\/>&_^"7MBT0?QA\8_'&L78.0NA2QZ5;*/[HBQ+@?0BN9^*/_
M  3G\8^$=)GO/A?X]OO&$$<>Z7PKXZD28W9 8D17:A/+8\!0549Y+@5^@]%2
M?(T\RQE.HJL:LN;O=GX9V&JO9ZM,@L[S0]:TN?R[[1]279=6$ZD91U(!*YZ,
M0,]" :W_ !=XMD\67%O(T MXX4*K&'W?,3R<X'H/RK[W_;H_9%_X6]H+^/?!
M%K#;_$W1(2XC6/Y=<M5&6LY=N"SX \MNH("Y&0R?F=<>-(K;PC<>(M/W!D@<
MQ*Q!>WN,;0K<?>1R#R!D '&"*Z:<N_0_H'ACBREC\+-XS^+2BWZI+4V-4FT3
MQ-KT6C:OX:O?%_BF-1Y-IH-M-)JZ8QM.Z+&=O!PYR,].17J'@_1_VR=/O(Y?
M %M\5K"UB7,<'C"^AG0 8&!%>!5 YX&#Z]J_0[]CCX)Z'\%O@3X7M["RC77-
M6T^WU+6M2;#SWEW+&))"\G5E5G*J#T ]22?<:YY/F=S\1SG.GFU>57V48)]E
MK\V?G5X-_:*_;8^&]RB^._@NWCO3E&^4V$$<=X03@!7M6>/CT\HGZ=:]H_:U
M^*'PX7]F[P=XH^-/PVUR^T?4]2M73PRSB.\L+Q[:X93)MFC^Z@E4@MGYQE0<
M@?5M?-7[?'[.OBC]IOX/:/X7\)3Z;;ZC::]#J4C:I,\4?E);W$9 *HYW;IEX
MQTSS4GS1'^UU^T!XB^"_Q"^">C:)9:3=VOB[7_[.OGU&V:62./SK9,PD.NUL
M3-R0>@XXKZ9KY=_;$\%^!O%7Q&^!EUXN\>?\(?J&F^(?/T>R_LZ2Z_M6?SK4
M^3N4XBY6,;FX_>>U?45, KS;]I3Q#J7A+]GWXCZUH]Y)I^JZ?H%[<VMU#P\,
MJ0LRNON" :])KS3]IK1[CQ!^SG\3].M$:6ZN/#.HI#'&,L[_ &:0JH'J3@?C
M0!QO[!_CG7OB1^RGX'\1^)]4GUK7+W[=]HOKD@R2;+ZXC7.!V1%'T KWVOEC
M_@F3K%IJG[&O@RVMIEEFTZXU"UN5'_+.0WLTH4_\ EC/_ J^IZ "L_Q!KEGX
M7T'4M9U&40:?IUM)=W,IZ)%&A=V_  FM"N8^*/A:;QS\,_%WANVD6&XUC2+S
M3XY'^ZK2PO&"?8%J /G+]G/1[[Q+I9\9>*1YOBCQ9MUO4V(YB5P#;VBYY$<$
M3)&%SU#MU=B?I*\ATZRC@>W"2E6'[L-D$8[^E?.W[._C"+4?AKX5U%XG@9M-
MCM+JW=2KV]Q$!'-$RGD,DL;H0>ZFO5]2\96NW-NHDDVX&U-J_4U\Y2KP@INI
M\5S(VF())QC->7?'RUT75/!]Y8ZS;_:K&>,0W*QG;(BLZA75OX70G>I'(901
M@X-7Y-8O9G9C=2C=V5R!^0KQ;]H7XA6?A_P^UE+>P1/(X:XDF<8C&05W'MDD
M'UP/<5Y>+QW[MJFM>GJ9U)<D6SZ5_9L\=:CX_P#A'IEUK=RMWXATVXNM%U2=
M0%\ZYM)WMWF*CA3*(Q+@< 2#'%>H5\1_LX?$3XF>'?#7B/\ L#X6I>66J>(K
M_5X[WQ)K,FER3PR2[8=MNEK,Z$Q1QY\P1G<2=ISN/O'P[_:/@\2>+H/!WB[P
MSJ/@#Q=<J6LK6^=+BSU+:K,XM;I/E=E52QC=8WV\A2 2/KJ-:,XI-ZFZ9[)1
M117244+7Q!I=]]D^S:E:7'VL.UOY4ZMYP0X<I@_,%) ..F>:OU\&_LL_Z[]E
M7_L$>-/_ $L@KZS\=?&*T\!>)M.T6?POXOUF6^1'6\T+0+B^M(=SE,2S1J50
MC&2"> 0>AH [G[7!]J^R^=']IV>9Y.X;]F<;L=<9XS0UW MTEL9HQ<.I=82P
MWE1P2!UP,CGWKYH^%_@:7P/^VOXU%UX@U3Q)?:KX*LM1N+S5'0E6;4+J,1Q(
MBJL<2I&@"@>I)))-<OXL^#O@[Q-\4=-\-_#FTM]0\?:;XJB\4>*O'TJ))>:4
MGVAYFMFN54 RR?ZI+7!58P2Z@8+ 'V+4,U[;V\UO#+/'%-<,4AC=P&D8*6(4
M'J0H)X[ FOC;3_C;\8+'0=4^(EUXFT/4_#.E>.Y_"Y\*+I*_:;NU;51:*_VA
M9 5G02#:@3!5 S;BV:\]F_:2\*?$+]J3X3?$/4O%2V^FP:QJ6F:9H2QS,]A9
M-87$*7$Z!?\ 77,[H< ?)&L(."'- 'Z%?;K;[8;3[1%]J"[S!O&_;Z[>N.#S
M4]?!W_"+:</A+_PMB&R6/XO'XGL@U)9B;TN?$'V'^SS-GF#[+^[\K/E[?X:^
M\: "OD3_ ()]?"KQ;\+_ /A;?_"5:#=Z'_:OB5[NR^U*!Y\)WX=<'IR*^N6=
M8U9F(55&2Q. !ZU\9_\ !-#XA>)?BCX9^)^OZWK^L:_IC^)GBTN35[V2X,,0
M0/Y:!V.P!9(_E&!S[4 ?9U%%% !1110 4444 %%%% !1110!PGQYU*[T?X&_
M$2_L+J:ROK7PYJ,]O=6TACEAD6UD971@<JP(!!'((KE[?X>^/9M.AO7^,?B"
M&*2)927L-( 4$9Y/V&N@_:*_Y-]^)W_8KZI_Z22UF^)M:>73M,TZ-BL45K$T
M@'\3% 0#]!C\ZZ*,'4=D859\BN<??6?C"W8K#\7_ !-=$'EET[2%7];'/Z5R
MWQ#UWX@>$O 'B;7+/XI>(I+O3-,NKV%)[#2#&SQQ,ZA@+$$C*C."/J*[:N&^
M.4XA^#WC9#UET/4$'_@+*W_LM>H\/347H>>JT^9:GUC1117AGKA1110 4444
M ?-W[>WQZ\0?LZ_!.R\4>&K/2[[4)=9@L6BU>W:>'RWBF8D*KJ=V8QSGUKW?
MP7JTVO>#=!U.X6-)[VPM[F18AA SQJQ"CL,FOG__ (*"^#?!/CCX&V.G^/?'
M'_"O]$76[>9-5_L^2]W3"*8+%Y:$$9!8[N@V^]>_^![:VL_!7A^WLKK[=9Q:
M?;QP76PIYT8C4*^T],C!QVS0!MT444 %%%% !6;XF\.Z?XO\.ZGH>JVXNM,U
M*VDM+F%CC?&ZE6&>W!//:M*B@#X^^%6I7OA7P]X_^$.OSO/JGAHC[/<28!NK
M88DMYN_+PJI('1HY,\UE5ZO^TK\(_$>OZ[X?\<>!M.CU/Q+812:7?Z>UTEK]
MNL) 6 \Q_E#1R?, >JR2#N!7D'_"#_&S_HDT?_A36=.Y^@91FF&H4G[>=I-_
MI:Y8KK_V2?"W_"9^*-=^)UTF_3H?,T+P[NY5HT?_ $NZ7J/WDBB,,,';"W]Z
MO/\ 4OA+\;_%UC+HJ>!K?PH+\?9WUJ;7K><6<;'#R!(_G9@N<8[X-6_AKK'C
M;XC7UYI'PR\57GA;X>Z'_P 2OP_!8V]HWVBVMU$3W4DDL3EO-D#,.AY.<YS1
MN1FV/CF,5A\++W=V]D?;E%?(-];?$S3]PF^-E\2IP5B73I"/P6U-1>!?C-XP
M^'OQ9\,V'BSQC<^*_"'B"5M):XO;:")K*]?!MG!BA0E7(:,@C + D]*+6/FJ
MF5XBG2=:UXKL?8=%%%(\<**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **YSQYX\TGX<^'I]:UJX\BTBX55&Z29S]V.-1RSL> !7DUG\4?B
MCXD=;ZWTK0/">ER?-'9ZM#->WNWL9/+EC2,GKM!;TKEK8FEAU>H["/>VZ&OE
ME[1?#7Q4\<Z#)N@EGN_[?MED(_>0S_ZQQ[+*K@^F1ZUT>H_%+XIZ)<>>MMX7
M\0VB#+V4%O<6-P_LDCS2H3Z XY[U/JHLOVD/#5IKGA:Z;P]XY\/RLH@U&+$M
MLY'[RUN5'6-P ,@D<!AG%>)BW0S>@Z5*6H:,J+JTFW:3R.*KS73RMGJ<UR;>
M/;;0KJ:P\965WX+U>)L-'?P/):RG^]#<("KJ>>N".XI__"R=!N'2#1'N_%VI
MN0(M.T&UDF=R3QF0@(B_[3, .M? RP&/G-4I19-K#_&]O_:FBP^'H\27WB6Z
MCTFWA!Y96(:9O8+$KL3VX]17UC;Q)!"D:?=4 #\J\C^$7PKU2RUB7Q=XO6!=
M>EA-O8:;;L'BTJW)!*!_XY&P-S_[( P!7KZKMSSG)S7Z1E. >7X=4Y;]2K#J
M***]L84444 %?+G_  3O^#W_  I/X*ZUH?\ PEWAOQG]H\0SWOV_PO>_:[:/
M=;6R>4SX&''E[B/1U/>OJ.OAG_@C]_R;3XE_[&ZY_P#2.RH ^YJ*** "BBB@
M HHHH **** "N9^*'A,^/?AKXM\,@@'6M(N]-RQ '[Z%X^X_VJZ:B@#XU_X)
MS>)%\0?LD^$8&D9[O29;O3KE6)W1LEQ(R(<],1O'Q7UKHC":QEB8Y )&/8C_
M /77Q;^RC<GX<?M,?M$_">X\NWCCUW_A*M+M8UP/(NP&?';"J]HN/<^E?9'A
M^7;</'V9<_E_^NO-C[E:W<[G[U%/L?''[:_BY)K>31H_F_L^#$H_Z:3%0%QZ
MA=I_X%6-_P $WK.]^$WQ@^,'PNUF7;=W$.G^*+&':0&CFC_?L,_W3-;H?=36
MK\1OAZWB[]JF/PK*&GLVU#^VKUF)(%N%$@0^S,P0?2E_: +?!7]LOX)_%H2&
M#0]:=O!>M-N$<:B7>;=W.>1ND+G/ %L*SP[Y:K3(J)SCSGW37R+_ ,%$OB]J
M6A^ ]'^$WA&7_BM_B-,=,C*MS:6' N9GP"0I4[,X^Z96!RE?5^KZM9>'])O=
M4U*ZAL=.LH'N;FZN'"1PQ(I9W9CP%"@DD] *_-[X+ZE>_M&_&7Q;\?M;@DCL
M+EVT;PC9W'6UT^(E6D .<,QW9P?O-/V85Z<G9#PE!XBJH(]M^#'PIT[P/X9T
M'P;HP\G3M/AVR7#\$@9:69^V68LQ[9;'%5/VF=6;6/"\EYIB%;71QY=I"!RT
M3*8G SW8/W]!GI7=-<?V/HQMXSB\OE#3,.J0]53_ (%PQ]MOJ:\\^*3+_P (
M'JRLN\NBJJCJ6+KC'TZ_A6,79H^S]E&2<GM%67^9Y_\ LY^*+6_T?5Q'<*]F
MNRY1NF,@J^?0_*O%>#VW@_5/VN/B)XG\>Q:@UEX>TB;^R_#3.K!9-IS).O0\
M\8)&2' )!CKA)?&6KZ>WBKP+X5D;^VO&=\ND6RXXBC=S]IE) . % 4GLKLW&
MVOOKX)?"W2?!OA73?#=DC'2](MEB7/#2N22SMCNS;V..YKV,'AU.HZL]D?*9
MOC'*G'"Q^9\):IKWCK]EKXS:!\18D>YU/26$5TN[RUU2Q^[)#(0"#\G1B#C
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MP\;79.3G<[.B]/EBYSD5]/U!^(XB$*=:<(.Z3"BBB@Y@HHHH **** "BBB@
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ML7X+?]%%T;_OXW_Q-<EIOP]\+_"KX4Z(M]I'VJ^:-8K6U:XDCV1A1@':1T4
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M>._U4(.(+"-PYW^GF,JH >H+&M33_"GQ0U]3';>%-.\' _\ +_J^H)>.H/\
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M.2^*/#L]M:7#66J0NEWI]ZAPUM=1L'AE4]L.!T[9KZS^ /Q//QD^#_AGQ<\
MMKJ_MRMU$H^1;B-VBFV<G*>8C[3D\8KY%\90:EXDFTGP7H,ABU_Q1<_V?!,H
MR;:'&ZYN2,CB.+<>#G)6ON+P;X1TSP#X3TCPYHT'V?2]+M8[2WCZG8B@ L>[
M'&2>Y)/>I9\)Q+.E*O&,?B2U_0V:***1\<%%%% !1110 4444 %%%% !1110
M!3UB\&FZ3>7;?=MX7F./103_ $KYM^#-C(-!&L7TGGZOX@E;5KV8G.7E^95&
M>BJFU0.V*^B?%<+W'A?6(HQF1[.95'N4.*^<OAOK D\'>')E"B-M/M\$'_IF
M,C\#Q^%?*9Y6]BZ5]KD2V/7Y(XA: <'BN(U]497Y[5??7,PX!_6N?U"Z\YB<
M\=Z^7S#&4ZD$HD6,KPOJ \)_&;PMJ2MY<.O^;HMZHZ.PC::!R!_$&1ESZ-7T
M\GW:^4[VSFU/QM\-K*W&ZX?Q#'=?2*&"1Y&^F !_P(5]6)G;SZU]=P_*4L#'
MF-4.HHHKZ484444 %%%% !1110 4444 <C\6_'&B?#;X9>)_$WB.>:WT73;"
M6:Y:W*B9EVX"1;B!YC$A5!(RS*,UY=^PYX-\ ^$_@#IUW\-)]=G\*:[=SZI#
M_P )%Y?VI')$+J1&J@*#!QUZYR017+?MR?#[QC^T=X&LOAS\.K[1[J)=<M4\
M6!K^/[3I\.%DB+Q'^$!A,1D.1&FU6W''T?X-\)Z=X#\(Z+X:TB(PZ7I%E#86
ML;')$4:!%R>YPHR>YH V:*** "BBB@ HHHH **** "BBB@ JOJ%A;:K8W-E>
MV\=U9W,;0S6\RADD1@0RL#P002"#ZU8HH ^$?V4YY_V=OC5XZ_9RUJXD_L^V
ME?Q!X+GN7.;C3YB6>%2<;F0Y)"CEEN#T6OK[18K72M4FNX[>*&6ZVK<2QH%:
M3'W2Q'WL9.,],GUK\LOVF/B+XR^+'[0/C/XT^"+_ &Z+\)KRWTO1RH)CO!$S
M&[((.UE):0M_>B=!7Z._"?XF:1\8OASH'C+0WW:=J]JMPL;$%H7Z21-CC<CA
MD/NIKS*R]G/GB>G3A+V:4UH]CD/BY^S4-7UR^UO0KY+:2]<S-9SH?+,AY8AQ
MTR><8/)/05\%?M6>$_$7A3^R_$D44D&O^$KG>L,H.?(;_61[@1F-ASP2#N;'
MWS7ZU:?(NH6;VDI^=1\I]NWY5\0?MN2"?4M0A:,_Z/:06S<=7\T/CWXD7\ZR
MG[K56.S,HMPV=FC(_P"";?@63XK?$'Q5\>=5L6@L(8_^$?\ #4%P S1J &N9
MAQP?FVA@3_K)E[5^B%?GA^R[J][^QG\?+/X5Z],R_#KXDQ1ZIX;NI1A+35&1
M!+:YZ#<2L>.?^7?IO:OT/KU8-2BFCFJSG4J.=1ZL*_.3]FGP_9_%+QY^TUKM
M[F\TC7_&,]A#,><I;O*T;*3Z+/&0,8''45]R_&[XB1_"7X/^,O&4ACW:)I-S
M>Q+,V%DF6,F*//JS[5'NPKY:_8G\!GP#^S5X.AF5?MVJ6YUFZD&<R-<GS$+9
M_B$9C4_[M=V%C>I?L<M3X;'H_A?5?$/@WX":_!<V)OK[PU?)!N0'-U8H8W\S
M_@,3L!_=$8S]TUOZ-K%IK^EVNHV,PGM+E!)&Z]P>Q]".A'8@U'\0+C5=-\#:
M?J6CCS+[2]3.I"U896ZC2(QRPGV9)''2N,T&2R\#^*M.L=-=F\'^+K<ZIH>\
MC_1I,;I;;KV!!QVR!R237=3?+)I]3D;Y6D</\/8[?Q1_P4TN9%DRWAOX>;7V
M8XE>[!"M_P  N=WX"ON2OA[]@&S_ .$^^-W[0GQ6D6.XM[O6X_#NF7:G),-L
MIW@>S)]D/X5]PUY51\TVSNCH@HHHK,H\R_:@_P"3:?BU_P!BCJ__ *1RU^?=
MYX?\2>&OAU^SEK/Q<\47_BC]GV6+2KHV6GV-M:KHMV(A]G6[(1GN+?:SJS94
MD$]&V[_U#LM=TW4KZ]LK34+6ZO+)@MU;PSJ\D#$9 =0<J2.>:O4 ?E!^T?XH
M\47?[17Q6MM9\8OH/B6UO-.3P7*FO:G;-;V\I7RVLK6UM95N=X*>8,J=V[;N
M.2+/[26K>9XU^/MK\6/%VM:?XTL= T]?!VG:;=W,5G<Q2VV+ORHEPCHYXE#
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M?QZTWXK_ !,^*$WQ(\0:-8M8:2@T>/3T@4JZ[V".RL=LLO&!\S[BQP*^I**
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW@OQ5^U7<_"KQY=>)?!OA:T\>6_V3_A&;*VFC-O<YD(N/.(N2!M3!&67GUH
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M\4O%$C7&L7LDWGO C.7$ EYW,6.^1APSD#+!%8_4=%% !1110 4444 %%%%
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MU KBE[VC/OZF"5?#^SA\4=5^J^9^CL,S6\JR(<,IR*\._:6^'#?%2U\'Z_H
M$EE=:I;PZD H^5'*;)CWZI$A]F0CC)KG_P!E']I[_A=_P+U#4M498/&_AB![
M77[1@%<3(C%9MHQ@2!"<8 #+(H^[6S\*?B)<V/[1>M^"X)?M/AR*PAM98F/^
MKF@B6)9/;B$@COO!_A%<T=+TY'Q-35J2-G]IS]GW3_VA_A3=^&7D73M7M66\
MT74E)4V5V@.QLCG:02K#GALCD*18_8L_:$O_ (U?#R\T;Q=&;'XF^#Y_[(\2
MV$@"N95RJ7&!QB0*V<<;U?'R[<^MWMJ;.X:,\CJI]17QY^U1X>US]G_XI:+^
MTGX%LI;PV*KI_C72(#@:AIIVJ)B!U9 %&XYQLA;&U&SK0J>SER2)K04H\\3H
M_P#@I'XCNO$FA_#KX*Z:)/M/Q$UV..^DB4,8K"VDCDF;'4$,T3Y](GKUZSLX
M-/LX+6VB6"V@18HHHQA451@*!V  %?-'P_\ &VE?M3_MD>)_BAH\_P#:/@[P
M?H=KHF@7+1/'YDUPIEFE"L!AUWS1D$9PR5].U]1A8VCS=SR*CNRU>3;HK6$'
M(BBP?3));^1 _"OB[]J/XK2?"7P3X4M[(1K=^'=?U"^LD."!;^;E%!]"PE0C
MU'TKZ:^*'Q.T?X7^&[C6-8N41L'R82V&F?T'MDC)]^Y(!_,CQ3_;7[3'QA\)
M>%1)<,OB;6DLU?;GRH3()+F7'0;0QD('85M4M&-^QR3?--01^G?_  3P^&1^
M%_[)?@B">-4U'6H6UZ[9<Y=KD[XB<]Q!Y*GW6OI&H+*S@TVS@M+6%+>VMXUB
MBBC&%1%&%4#L  !4]>(>H%9GBBSU/4O#.K6FBZBNCZS<6DT5EJ,D G6UG9"(
MY3&>'"L0VT\'&.]:=% 'Y3?LM^-?&WP1^!MIJGAB?1+OQ)\3?'-OX7M+[4M,
M")I\BR3"2>XF0A[C<9%V1L?DPY&[)!]2^)W[6GQ?^%O@'XW^%=6U32[SQU\/
MY-'>U\6:7IZK#=07DL7RS02!D279)T Q]['W=S?54W[)GPGN/A:_PYE\(PR^
M#S?-J2V,EW<.\5T229HYC(9$;EAE6'#,.A(-:T_8]^$EI\/]?\%_\(IY^A>(
M+J.]U83ZA=/<WTT;AT>2Y,OG'##(&_&2W'S'* \9\;^-?V@?!WQ/^#OP\?QS
MX=E\2>,QK4M[>+H@-E;+# DD:HFX2.8P)"IW+N8KN! P?,?AS^V%\;KK0OA9
MXW\1ZOX8E\,:YXQ7P5?::M@;=I=S8^VO-N.PCYQM4!1L!PVX@?>&N_"_PSXF
M\>>&/&>I:9]I\2^&5N4TF]^T2I]F%Q'Y<WR*P1]R<?.IQU&#7(:?^RK\+=+\
M,^'_  _;>%@FCZ#K:^(].M6O[IQ#J )(F),I+\D_(Y*?[- 'RA\/OVM/B[XZ
M^+7A#PW%XFTBZTGQY;:O:6&LV'A6YM]-L;B""1H9[*6Z*R7FQQ&9 Z!!DH,Y
MW#SCX6:SXI@_9-^!6M:YK4'B2'6OBY8BVAU*R2:6T!GO!,QE?+22/(&<2'YE
MW8!K[B\#_L8_"/X=:[H6L:%X;NK;4-!E>729)=:OIEL=^_>D2/,5",9)"5QA
MBQ)!-2Z+^QW\)?#^GVUA9>&9H]/M=;@\16EF=5O#!:WT)E,4D4?F[453-*=@
M&P[N0<# !\V>+OVN/C)'X;^)'Q;T:7PS9^ ? GBE_#DOA&_M9/MM]&LL,32O
M/G,<N9D(4  9?(;:-]CXG?M"_&R\\=_'J3P3XCTG1?#_ (!TG1]>ATS6=(62
MX,4MBMQ- '&-I;]X3O#'(55*#)KZ'US]C'X.>)/'5WXMU#P;%/JUY?)J=W&+
MRX6TNKI<E9I;42"%VRS$Y0[B[$Y+'/6:A\!/ FJZGX]U"ZT+S;SQU9Q6'B*3
M[7./MT$<)A1,"3$>(R5S&%)ZDYYH TO@_P",;KXB?"7P3XKOH8;>]UW0['5)
MX;<$1QR36Z2,JY).T%B!DDX[UX!X[\5^#?#_ .S;X(M?''A>V\6>()X3:?8=
M2TJ2]MX]653'>SW0CC?:J3M*SL%+,<E S$5]->%_#6F^#/#.D>']&MOL>D:3
M:0V%E;[V?RH(D"1IN8EFPJ@98DG')-8VK?#73=0UNYUFTO-4T/5+D*+B?2KY
MXDG(4*'D@),+R;%5/,9"X55 8!5PP. \ I91P?!BQT'4[K76T_1I89]7O;:6
M.:XT]+9(G:19,-&TEREH^&Y/EO@':2/:ZQ/#?@[3/"HN&LHYY+JXQY][>W,E
MU<S %BJM+*S.54N^U,[5W': #6W0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7S+_ ,% =>^%OAWX-Z-<_%SPUJWBGPVV
MOPQV]GH\YAE2Z-O<E9"1+'E0@E&,GEAQW'TU7RO_ ,%&?@7XR_:"^".B>'?
M^F1ZKJUKXB@U"6&2ZBMP(5MKF,MND90?FE08SGGVH O_ +7/QTO/A#\0O@GI
M-KX<T/7(_%.O_P!GRW&KVS2RV:^=;+YD!##:_P"])R<\JOI7TS7S-^US\*?#
MOQ&^(7P3U'6_B#I/@JZT'7_MEC8ZBJF35Y/.MF\B',B_-F-5X#?ZP<>OTS0
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M]6\P$2?:;@!MK@\ATC$49]XS7=C7R)0ZG)AJ:3<CZ$HHHKR#T0HHHH ****
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M"NBZ'_PEWAOP9]G\0P7OV_Q1>_9+:3;;7*>4KX.7/F;@/1&/:OJ.OAG_ (+
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M (22\\-Z@F@^,]+N_#7BF*/=-97$#>7, 0K2P2#*21%NC*Q]#S5CPKX9U/\
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MD+'8S 83+7A<--2[*]^MS$_9^^--KX'^&-A8_86O+>2SBGLVA(4<Q+A3GHO
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MKRDI1UV:VOZD8[.L+6QT9<O-32:?G<\*\7>+M0\:ZP^I:DZ&<H(U6,$(BCH
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M#/A.L.L?\(3IUY%'=VCW^LV\MO.H>.2)[. E64\%3DY!X/-<I\%_$=_^Q/\
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M2:UD+O'(L8+JYZ$80CCD$'J"#7H/QILTN1H4C_>M[RUE3ZG4+)/Y,:Q_'?\
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M9/6NNKS/]G6Y%Y\+;2X52JRWM[(%/49N9#7IE !1110 4444 %%%% !1110
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M<UUE%$8J.B0@HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OC7_@J
MCX#\2_$/]GOP]IWA7P[JWB;4(O%%O<26FCV,MW*D0M+M2Y2-20H+*,D8RP'<
M5]E5\F_\%*?C-XS^!OP+T+7O ^MR:#JUQXD@L9;F.&*4M"UK=.4Q(K#EHT.0
M,_+]:0&I^U_^S_XM^,_Q$^!^L>&X;26R\)>(/[1U,W-P(F6'SK9\H"/F.(7X
M^GK7T]7PS_P46_Y+)^R[_P!C=_[<6-?<U, HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#/\16LM[X?U.WA3?--:RQHN<98H0!^=>-W5C=W
MGP+^(C0VEPYU#4M3GMH_*(>2-[AMK;3SC'//89KW2HHKJ&>-I(Y8Y$4LK,K
M@$'!!/J"#F@#F?A393Z;\,O"MK=0O!<1:9;K)%(,,C"-<@CL?:N<\8:?=3?%
MWPI,EO(\/G1-YBKE0$@O]Y)[8\V/K_?%>EPS)<1)+$ZR1N RNAR&!Z$'N*22
MXBA>-))$1Y#M168 L<9P/4X!/X4 >4:;I]V?VH-6OC:3K9+X:6'[2T9$9<SQ
MD*&Z$X!_(^E>B^*,KH[2[698)X+A]HR0B3([D#OA5)P.>*T_.C\[RMZ^;MW;
M,C=C.,X]*<3@9/ H ^;/&OA[5)OV3/#^F1:=<RZ@5M?]&2(EQERPR.HX(_$@
M5]*5"M[;M:BZ6>,VQ7>)@XV%?7/3%34 >8:;9W)_:"U"Y-M,MLNDRIYS(0A+
M&SVX/0YV/_WPWI3/@UIMU9^)?B'-/;R0Q3:LJQM(I ?;$H8CU&3UZ5Z?YT?G
M"+>OF[=WEY&['3./2A94D9U5U9D.& .2IQG!]."/SH Y[XA6<]]X7E6VA>XD
MCNK6X,<2EG*1W,<CX Y)VHW Y/05X[XP\'Z_)^RMH_A^WTF[GU=HK826441,
MB#?YAW+U&,#(Z@\5]!7%Q%:6\D\\B0PQJ7>21@JHH&223T '>J@U_3&TM-2&
MHVG]G2$!+OSU\IB6V@!\X.6X^O% %^O*]/T'4E_:"O\ 5&L9TT[[!*!=M&1$
MQ9+0 !NA.8WXZ_*:]4JJVJ6:ZB-/-W +\Q^:+4R+YI3)&[;G.,@\^QH \T^$
M>B:KI_C[XCWNH6<]O;W=Y;);331E%F6.-E)3(&Y1P,C@U=^/>CWVL>!9$T^S
MGOI8_M&8;:,R2'?9W$*X4<GYY4''0'/05WUKJEG?7%S;V]W!<3VK!)XHI%9H
MF(R X!RI(YYI=0U&TTFSDN[ZYAL[6/!>>XD"(N3@98\#D@?C0!Y+\3O"^K7B
M_"BVM=.N+IM-UBRFO'@3>D"1[ S,1T'7GV-><?#-8;?Q%\;((DV$>.Y)2!TR
M]I&2?J3D_C7T]-K%A;QVDDM[;QQW;K';,TJ@3,PRJH<_,2.0!UKYK\+S0Q_%
M+XW6,47EE/$EE<MM "G?IT.?Q+ D_6NG#_Q$<]?X&=11117N'CA1110 5RGQ
M&8_V3;CMYX_]!:NKKCOB0P^QV0SSYC?RK:C\:,:WP,Z+]AFQFM_@WJ=RZX@O
MO$NJ7%O(#D21_:"FX>VY&'X5VOQH\.ZEKFK>#I+"RFNXX-0B\YHE+",?:;9]
MS8Z*%C<DG@8]Q7,_L.W45U^S+X4:.6.23SK]IEC8'RW>]GD*GT.'!P><$5[=
MJ&JV6DK$U[>06:S2"*,W$JH'<@D*,GDD \#T-?+S=Y-GT<%:*1YAXJ\/ZE??
MM!>!]2@L;B33K&WO)+B[6,^5'O@**"W3<6[=><UZI=1F:UF1?O,A4?B*CEU*
MT@OH+*2ZACO)U9XK=I ))%7&XJN<D#(SCIFK-06>%:#X7UE_@[\0(3I5W%=Z
MMJU]=6MI+&4F:-Y%"G8>1G:3CN.F<BO0O@SI-WH7PL\,V-_ ]K>162>9#("&
M0GG# ]",\@]#726NO:9?6,][;:C:W%G;EUFN(IU:.,I]\,P.!COGI5FUNX+Z
MWCN+::.X@D&Y)8F#*P]01UH \]^+GA/5O$VM>!I--M/M$.GZU!=W4GF*OE1I
M(C$X)&>%/3T]ZBUOP9JVH?'CPWX@BMA_9&GV-P)KEG7&]U*! N=V><],8[YX
MKNM:\3:7X=^R#4[Z&R-U+Y, E;&]\$X'T ))Z"DN/%&E6OB"VT.6]C35KF)I
MXK4YWM&#@M[#/'/6@#4KQS2_ 6O-\+_'.G7%B+;4=7U*ZN[>V,JL=C;,<@XR
M=IQSZ=*]CK%T[QGH>K:1>:K9ZG;W&FV9D\^Z5OW<>P$N2?0 'GIQ0!F?"?P_
M>>%?AOX=TG44$5]:VB+-&K!MC'DKD<$C.....*P?%'A'5]2^-_@W7;>TWZ1I
MUO<"XN?,4;&:*50-I.3RZ]!W/I7>Z+K5CXBTR#4=-N4N[*<$QS1]&P2#^1!'
MX5%?>)M*TS5K+2[J^A@U"]!-O;LWS2 $ D?B0.>I.* .%\/>#-6M?CMXB\1S
MVPBTF73([2"8NI,SF0.< '("@8.0.>F>M=OXJLYK_0YX[=/-F5HY5C! +[)%
M?:,\9.W SQD]J?;^)=,N]>N]%AO(Y-5M(UFGM5R6C5OND]AG(JY?7UOIEE<7
MEW,MO:V\;2RS2'"HB@EF)]  30!X/XX^%'B36OV8]+\&V]@LNM"*%)[?ST7R
M^22-V<$C('!QU.3BOG;X,WHO_A3X3D7.%TZ&$YQU10A_5:^[%\;:&WAN+Q N
MI0G1YBHCNQG:Y9]B@#&22W'2OA;X5V<>E^%KC3(F1TT[5=2LPT;;EPE[,%P3
MR1C')YIH^QX9E;$SCY?J=?1115'Z4-FD$43N>BJ6/X5R_P"S7\,=5\9W^M:]
MI<<<R6GC#3UN=TH4I%!;1NS8/7'G'H23Z5N:])Y6B:@W3]P^/KM(%=M^Q+KF
MF^"_@]KFHZS>)90ZQXOO_L[LK'<4C2/G X %NYSTP.3FI9\KQ-+EP,8]Y?DG
M_F?5U>4Z#\/];AO?BE-<00P#7RT5@#,&WC9* [8^Z#Y@X/(P>.A/JU9>E^)M
M,UK4M2L+*Z6>ZTZ00W4:JP\MR =N2,$X(S@G&>:1^7''? ?P7J?@/P"NF:M$
ML%X;RXF\M75L*SG;DJ2.0 >#W'?(JY\3O#.H^(O[%_L^!9_)O;<S9=5\N-;J
M"5GY/("PL,#)R1@=:Z3PWXITOQ=IWV_2+L7EINV^8J,HSM#?Q 'HRG\:;XD\
M6:3X1M;>XUB]6RAN)UMHF=6.Z1@2%& >2%/Y4 <1XD\%ZQJGQR\(:_#:J=&T
MN"Z,]T95!W20F-4"9W$YP<XQ@]:].K+O/$VF:?K5KI$]TL>H74;2Q0[6.4#*
MNXD#"C<RJ,D9) &36I0!P?AKP7J5G<>-9+PPQ?VO*$MO+8L/+6$1J[<<$]2O
M;!Y/6G_!7P3>?#WX<Z9H>H/&]W TS/Y9R!OE9@,^N",^^?K6[H?C/2O$=[K5
MK83M*^D7'V6[9HV55D R5!(YQWQ2^$?&&F>.-)&I:3*\UJ7V;GC*'H&!P>Q5
ME;Z-S@Y  ,KXB>%[[Q)'I:V(C/EW=N9_,;;LB6Z@G9QZD"#&WONZ\5G>)/ >
MHZQ\9/"/B>-X5TW2+:Y256)WL\B,@ '_  ('\#[5T7C+QQI/@/3[6]UB9X8;
MFZCLXO+B:1FD?) PHST5C^'<X!L:EXIT_2M:T_2KB1EO+Y7>)0A(VJR*23T'
MS2(OU;ZT :=Q'YT$D>=N]2N?3(KS*W^'>KS_  E\5:%="WCU367O9?+CDW1H
M96.%W8&>.^!UKU&N7TGXDZ#K7A._\2VUS)_8UB9_.N'A<<19WLHQEAQQCK]>
M* /F#X 7,UQ^S3\.H[G_ (^K)+[3Y0005,-RR!3GG@#%=C7*_![4(-0\#>)X
M+16CM=-\;ZU;PPE,&..2<RH#V!PW0<5U5?C>=*V.F2PHHHKPQ!7B7B2PD\1?
M';X<VD(W./&5C.0H.=MN'E8]#T$7/;Z5[;7E7P[B?5/VM/ :J0T,$VKW[@GC
MY;9XE/O@SBO1RN+J9C0BN]_N1A4UG%'U?XR\$W_B#QMX8U&W:-;*QNX[FX=C
M\RB))PH [[C,![;2?:GV?@_44^,VH^*93"NFOH\>G0JK$NS>;O)([8Y'XCWQ
MMZ]XVTGPWK>AZ3?SM%>ZS(\5FBQE@S( 6R1T^\H_X%Z D3?\)7IW_"4-H'F.
M-16!+@KY9V;7W[1NZ9/E.<>BFOV\ZA_BC3Y]3T.X@M=IN04EB5SA69'5PI/;
M)7&>V<UYAXX^$6L>)/@/HG@^VEMTU6SBLUD+L?++1J%?#>@R3G'./>O6]2U"
MWTC3KJ^NW\JUM8GGE?!.U%!9C@<G@&L'_A8VB_\ ")Z=XB,DRZ?J#Q1VP,+"
M21Y&VHH7W)Z],<YQS0!T]<)H_@F_L?BUK?B25XC875MY<04_/N*6ZD$>WV<G
M_@8]Z[:VN([RWBGA?S(94#HP[J1D'\JR_P#A+=-'BH^'3,PU06ZW/E[#MV,7
M ^;IG]VW'M0!R_PK\!7W@S5O&=U>-&8]6U5KJW"-D^7CJ?0DD\>U=AK^FOJV
MDS6\959<K)'N.%+HP=03@X!*@'CI5+PYXVTKQ7?ZS9Z=-)+-I-R;2ZW1,JB0
M$@@$CG!5AQZ>A!-_7]:@\-Z#J6K72R-;6%M)=2K$ 7*(I9@ 2,G />@#S;7/
M@O=:I\'-!\%1ZA#'-8M;M-<,I*ML.7V_B3C([<^M>L5QL7Q0TZ;X?Z=XLCM+
MN2TOF@2*V15\XM+*L2CE@OWF]>@KK+.ZBOK2"YA;=#,BR(V",J1D''T- ''V
MOP_FM_BM<>*S<H;:2S> 0<[_ #&$"^F-H$'KG+>W+O!/@6X\,^*O&6M7-S',
MVNWD<L<40.(XXTVKG/\ $<G/;@5??Q]IZ?$&/P?Y<YU-K#^T/,VCRPF\KC.<
MYX/;'(_"?0?&%MXAUC6M/MX)T;2Y_L[S2 !)6V@L%YS\N1G('48SS@ J?$KP
MG/XU\(WVEVLL<-U-%)'&\Q(0%XGB). 3P)">.X%9OCSX=W'BW6/!5U!=Q00:
M#J"WDJR*2T@4# 7'&<COZ^W.YX\\9V7P]\)W_B#4(YI;2S";T@ +DNZHN,D=
MV&?;-0:UX^L-!L=#N[B"Z:+5I!'&$0%H@87F+.,]%5#G&3Z T =-7!>&OAO/
MI.L>.KN[NXY(O$4H\M800T4>UQSG^+]X?;@'O@=[7/>'?'%AXEUS7M*M4F6X
MT>X%O.TB@*[%0Q*G/(&<<XH H_"CP3/\/? ]GH=Q/'<S0RSR-)%G:=\KN ,@
M= P_'-=?7,^ /'UA\1=$?4].AN((%D$96X4!N8TD!X)'W9%_'([5TU !1110
M 4444 %?&?[:G@;XP^%]+\;_ !1\*_&G4/#GAW3+&.YA\+VUD" 41$<"4OQN
M;+?=XS7V97AG[<?_ ":3\4/^P0__ *&M 'A'[&^D?&#Q!X+\*_&OQ9\8]8\2
M>%VL[^\N_!W]GB22X6-;B%560.-S!U60#;R0![U]"^'?VN/AMXH^!VK_ !9L
MM5G_ .$0TEY(KR22V99XI%*CRS'UW,9(\#OO6N8_X)X?\F:_#;_KWNO_ $LG
MKX#^*GP[\4^"_CAXQ_9>\/">T\,>/_%FFZO8F,$PV]BWF/)M0_>5"8]S9_Y<
M*0'W]JG[>_PB\/+X6DUO4]0T.#Q)I$FN6,U_8.BFU4RA6;&2&?R6V* 2VY,<
ML*Z/X&_M>?#/]H+3M<NO#.M&W?10TM]:ZL@M9HH%ZW!!./*_VL\?Q;>*^,_V
MSM2\.?!G]MOX#W=SHGVOPIX:T"U#6$4+3?9[6&:Y42*@R6\E%\S_ +9<UA:I
M9S?M:_M(_&_Q9\'OM7_".+X&NM,DOH+,P)J]U) %%N590Q:4@XW ']T">V0#
MZ[\-_P#!1+X&>*/'!\,6_BM[6=KC[+;ZC>6DD5C<R9QA)B, =/F?:#D8)S7K
M'Q^\0:AX3^!/Q'US2;EK+5=,\-ZE>VER@!:*:.UD=' ((R&4'D8XK\@_#=W8
M>/O@?X'^$FJ?$+Q%=:FFO/;#X<:7X+MI+O3[DRS#SA=RO"6RTF"&E!7S""-J
M9K]8?VB;6:Q_94^)UM<7!N[B'P7J<<EPRA3*PL907P.F2,X]Z /DO3_'7CK4
M/ \?AI/BKXU_X7_+J4>AQ^&?MNF_8VEDC\Y-2P+$R_8?LQ\\M]X8,9(.&KZ]
M_9A\5:KXX_9Z^'NOZY>-J&L:CHUO<W=U(JJTLC("S$* ,GV%?%6B_&'2=,FM
M/VC6^(_AL^++6"'3D^'JZYIYN'\++@-;F/S XORV;L+O)#@0[<_+7V!^QO\
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MKOVZTLM1V>9JK^;;MY,.Z1#NS$HX#?ZP<>OT?0 4444 %%%% !1110 4444
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MYXFC66ZF>)FQ\Z;MH(]LJ1SZ5)^TTPMO"?AV^EW+96.OVL]U-M9A#%LE0NP
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MI!KZ;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OC'_@JSXRU_
MP/\ L\^'K[PYKFI>'[Z3Q3;P/<Z7=R6TC1FTNV*%D()4E5..F5'I7V=7S?\
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M/J<J1V^UOEVN7.W!SC!ZYQ7P+KUK?Z+<+XK\,2'3_&&E1F6RNH<@S!2&-O*
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M =*/ /Q,3]FOQK87ZS26_@+6));?5M+CW-%!<F-GAN8(^B.S)Y;!<!@ZD@D
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MLPY26)ARKJ<$$?RK(C^*&M?M$ZOIESXICWV_@^VCTYK5MIAN=67(N+W:!C.
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M2JVVW!!-S\T94LN%'4,W2NG^ ?[26D,F@^ ?$NF7/A35TA2RTVZNY4>TU+8
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M$"Q*"69F/"[<'.<%2"#@@U\B?&K]H$?&NUL[+PWX7U ^';.Z6[M];OG$#7K
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MPI#2:==22$$=V?YCZGD\U^I-%%, HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^:OV^?V>?$'[2WP>T?PQX<U31M)OK37H=2>;7+B2&%HUM[B,J&
M2-SNS*IQC& >?7Z5KX9_X+ _\FT^&O\ L;K;_P!([VD!VW[:OP:\8_%+XF?
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M_:5[87,-T1W)A1RA/T< ^U?D6?\ "V*Q&<T\VPL(U%IS1D[;?\ ^TR_-Z5/
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MO7TCX8_8Y\2>(KZU?XD>)M-FT6%]T^@>';>5([T#HLUQ(V_9ZHJC(.,UZ_\
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M +.[ [8KY_.^"YXNK0Q6!FE4IVNI+W79W_/H>%@,]C1IU*.(3<9=MUI8Y/\
M:HUG0/C3-X1^'/AN7[?KGB&^CMYI[5/FM;$,KW$K9'W5C#'V.!U->/\ @6&Y
MT/3)/">J1_9M>\,.-(O[<Y!#1 *DBY RDB!75NA#<5]E?"/]GGPG\'9[G4--
MCNM5\17<?DW6O:O-Y]Y+'NW>6&P%C3./DC55.U<@D U7^*O[-OA'XK:HFM7
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M_5*\*F&3Y8WT?GN?,?P9^)-C\/K[4?[3C;['=QJ3-&N61DSC/L0Q_(5Y[<>
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M<G>3M:[LEMZ(\"O655I05HK9?B%%%%>D<P4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKQ8=[$@!5+[0221P.: /8:*@OK^VTRQGO;RXBM+.WC:6:XG<)'&BC+,S'@
M$DG@5Y5H?[6_P:\2>+%\-:9\2?#UYK#E5CBCO%\N5FSA8Y?]6[''W58GIQR*
M /7**XCXG?&WP+\&8M/D\;>)K'PW'J!D6U:]8@3%-N\# /3<OYUS'A7]KGX.
M^./$5AH.@_$'1]4UB_D\FULX'8O*^,[1\O7@T >O4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBWC/!I]N\DKFW:2X+QW"/&JC*3@85F'WN?5 >(?LM_$+1?BQ_P %+OB=XO\
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M^[U379=3A?2)I9(UB:*) &,D:$-E#P 1TYKZ0I@%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %?4-/M=7T^YL;ZVAO;&ZB:"
M>VN(Q)'+&P*LCJ1AE()!!X(-4O#'A/1/!.BPZ1X=T;3]!TF L8K#2[5+:",L
MQ9BL: *,L23@<DDUJT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#%5O>,OCS\./AWJD6F^*/'7A_P_J$L"W,=KJ6HQ02-$Q(5PK,"5)5L'V-
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MP: .^HK@-+_: ^&>N>'M7U[3_'OAV]T31_+_ +1U"#4HG@M/,;;'YKAL)N/
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M\/\ B#4(H&N9+73=1BGD6)2 SE58D*"RY/N* .\HKR7_ (:V^"G_ $5?P?\
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MK?59] \=>']9ATJV:\OY+'48I1:P*"3)(58[5 !Y/'%8/_#6WP4_Z*OX/_\
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MVNW-G:O?7,6GZE%,T-NA4/*P5CA 64%CP,BL/_AK;X*?]%7\'_\ @ZM__BJ
M/6J*X/Q=\>?AQX!N+*#Q)XZ\/Z%-?6RWEK'J&HQ0F:!B0LB!F&5)!P1QQ3O#
MOQV^'7B[1];U71/'&@:MIFB0BXU.[L]1BEBLHR&(>5@V$!$;G)_NGTH [JBO
M*[/]JKX-ZA=P6MM\4?"4]S.ZQ111ZQ S.S' 4#=R22!6CXK_ &B/A?X%U^ZT
M/Q%\0?#>AZS:[?/L-0U.&&:+<@==R,P(RK*P]B#0!Z'17 P_'WX;7/@^X\61
M>//#TGABWNA8S:PNI1&UCN"%81&3=M#X93MSG#"H/"_[1GPM\;:]::)X?^(?
MAK6M7NRRV]C8ZI#+-*0I8A45B3A5)X[ T >BT5Y-XL_:Q^#O@?5KG2]<^(_A
M^QU*UF>WN+,WBO+!(APR.JY*$'C!QT-9OB[]LOX0>!_ GASQEJOBS9X<\1&9
M=*O(-.NIA<F%]D@ 6(E<'^_MS@XS0![717S3\&?V]_A_^T#\1K_P7X)L=8N=
M1M].GOX;K484MK:Y,90!$.]I 3OSDH, 'BO'9?B]^VC\=(9+7PI\-=,^%&DW
M3[%U76QLN[5>^1.=QXSRML3SQ@T ?;GC+QUX=^'FB2:QXHUS3_#^EQG#7>I7
M*01[NR@L1ECC@#D]J\$\9?M3:K\2O@UJ/B/]G#3+?XC:U#K*:*ZW2/ ML60$
MW'ER;"Z@O&,L57YBQ)",*3XE?L-^%/V@/B!X>\;_ !.N;R_U&STB"SO=!TR\
MDCTV6Y7<9'5CB54); "%"=BD\DY]T\ _#CPO\+/#T>A>$=!L/#NDHV_[+I\"
MQJ[[0I=R.7<A5!9B6.!DT ?.O[)?[+OQ"\!>--;^)WQ:\=W7B/QQK]G]CN-+
M@E#V<$+.)-CY4*64\*L85(\N%W!N/JR.-8HU1%"(HPJJ,  = !3J* "BBB@
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M_AQIWB2P\.>#8-,M/$>GR:7JL:W=R_VFU<%6C):0E00QY7!YZU[#10!\Y_\
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M)7PE^,VOV^M^,O!\&MZI;VB6,=Q)=W$16%"Q5,1R*."[<XSS1H/[)7PE\,^
M/$'@G3/!\%KX7U^2.74]/6[N&6X:,JR$L9"PP57[I'2O7J* /!/#?["/P)\'
M^(M*UW1_A_;66K:7=Q7UG<K?W;&*:)P\;@-*0<,H."".*L^-/V(_@E\0_%6I
M>)/$/@2WU+6]2E,]U=M?72&5R ,[5E"CIV KW*B@#R&?]DKX2W/PQM_AY)X/
M@;P;;WQU*/2_M=QM6X(8>9O\S?T9N-V.>E4? /[%WP7^%_B[3O%'A?P/;Z5K
MVGLS6MXE[=2&,LC(QVO*5.59AR.]>V44 > Z]^P9\!_%&N:CK.I_#ZVN]2U&
MYDN[JX:_NU,DLC%W; F &6).  .:W?%G[(OPC\<>%?"_AO7/!L%_HGAB*6#2
M+1KNY46J2%"X!60,V?+3[Q/2O8:* /'OAS^R+\(OA+J6IW_A+P;!H]WJ6GRZ
M7=R)=W,AEM9"K/'AY& !*+R,'CK7*?\ #O#]GG_HFUK_ .#&\_\ CU?1E% '
MD/Q'_9*^$OQ<O-*NO%O@^'69]+L4TVS=[NXC\JW0DK&-DBYP6/)R>>M/\$_L
MG_"CX<^&_%6@>'?"$.F:1XIMEM-8M5N[AQ=Q*LBA26D)7B6094@_-]*];HH
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M(Z@@YS0!+1110 4444 %%%% !116+XJ\9:-X(T^.]UN^2PM9)!$DC*S98@G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPO\ K #QA@.QW G/4?"?P3XB^'S7^EW]SI^IZ5++)=IJ2&1;R>=RNXRJV0>
M>=Q/ Z]@!GQ>\)ZOJU[X9\0Z+:1:K=Z!=/.VES,$^TJP7.UCP'7:",^I(Y !
MD\+?$C1_%>G>)+O3K"31O$=G ?MUK>6ZQW*LB-L+?WU!+ 9Z<Y SSO\ B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img98921446_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img98921446_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %_ B8# 2(  A$! Q$!_\0
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M#6K@4 %%&** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y'Q.<ZFG_7(?S-==
M7(>)O^0FG_7(?S-=.%_B&-?X#&HHHKTSC"BBB@ HHHH -Q0AAU!%=QI3E[52
M?2N%?[OXC^==QH__ !Z+]*\W&?&O0ZZ'PFE1117*;A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%!H AN;F*TA\V9ML8(!;L,G%2$@]ZKW]LE
M[I]Q;2C*2QLA'U%>?>'_ !7XA72UMVTQ;PQ[HTN3)MR%.,L._2KA3<]B)34=
MROJ6JW.@?$B_O[>&22Q(C2\"#(/RCGZBO2K.]M[^UCN;69989!E64Y%>97.O
MV&BK.EPRZAJ-RQDG*_<0GL/Y5@6GB"&WN7GL)[K2W<Y98B'C;ZJ:['A93@FE
MK^9Q+%1A-IL]UHKRFV^(NHVQ'FWEA>*/[T3Q-^8R*WK'XGZ-*0E\DEHY_BQO
M3\Q_A7/+#58[HZ8XFE+9G<&LG7-;AT6S61D,L\K>7! GWI'/0#_&J%UX\\.6
MUJ9O[3AE./E2+YF)],?XUS/A2XN/%GC*YUF\4"&R7;;Q Y"$]/QQWJ%2=G)K
M1%.JKJ*W9W>DP7\=OYNI7 DN9#N9$&$C_P!D?3U[UH4#I169J%%%% !1110
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M8_*3GIR"#E>YQ2<M96?_  -2K;71/X?\0%-'U+5I/$K>(8+=1^YAL5@D1O\
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M>PFGJA:***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N0\3?\A-/^N0_F:Z^N0\3?\A-/^N0_F:Z
M<+_$,:_P&-1117IG&%%%% !1110 U_N_B/YUW&C_ /'HOTKAW^[^(_G7<:/_
M ,>B_2O-QGQKT.NA\)I4445RFX4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2$\4IZ5PFNZIJ?B*\ET3P\2D*';=7P.%'JJG^>*<8W9,I61SGQ)
M\4MJ5[#H6DGSC"^Z=TY&_H%]\5P&HZ;K-B_V2ZW0_*'V.-K$-QD#O7NOAKP1
MIOAU%D5!-=]YG'0^P[5A>(=(36_BAIL#INC@M/,E^FX\?G7;2Q$8>Y'8XZM"
M4_>EN< ?ASK4UK#>):/'"Z _NOF;IP=N<\UD-X2U\28:PN'Q@G]RQ_#I7TRJ
M[0 !@#I2XJ%C)]C3ZI'HSY[TWX;>(-0E&^TDAB)Y,IV #^9KU;PKX!T_P]&L
ML@6XNQ_&1\J?0?UKKL4H&*SJ8B<U9[%PP\(.^[(+NT@O;.6UN(P\,JE&4]P:
M\1\,>#X;?XEW.CWT8DAM]TBAOXTZK_,5[H>E<KJ=@+7QWI&KJO$\;VDI]\;E
M_D14TZC@FEU+J4U)I]C9AT#2()(Y(M-MD>,Y1EC *GV-:5 Z45D:!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7*>)XF%Y%-CY2FW/N#G^M=75/4;-+RW*,,^GM6E*IR34B*D
M>:-C@Z*O7.EW$#D*NX55^RW7_/']:]#ZS2[G+[&?8CHJ3[-=?\\?UH^S77_/
M']:?UFEW#V,^Q'14GV:Z_P">/ZT?9;H](?UH^LTNX>QGV(7/W5[DBNYTA2+1
M<^E<SI^C323B28=.U=C;Q"*(*.U<%>I[2=T=-.'+&Q-1116)H%%%% !1110
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M F@#VZBN9\&>.]$\<:8+K2Y\3H!Y]I(0)83[CN/0C@_7BNFH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN^;[N[MUQ[U3N/ -R;S[99ZT+>X74;>_C+6F]08K7[/L8;QE6ZG!!P2!@_,
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M6%F/..<$<D$8!P* /J:BJFF:E:ZQI5KJ5E)YEM=1+-$WJK#(SZ'VJW0!X_\
M!_CX@?$U.PU4?^C;BO8*\?\ A+Q\2OB6#U.I _\ D6>O8* "BBB@ HKR6[U_
MXV)>3K:^$-$>W$C")VF7+)G@G_2!V]JA_P"$A^.?_0F:'_W^7_Y(H ]@HKQ_
M_A(?CG_T)FA_]_E_^2*/^$A^.?\ T)FA_P#?Y?\ Y(H ]@HKQ_\ X2'XY_\
M0F:'_P!_E_\ DBC_ (2'XY_]"9H?_?Y?_DB@#V"BO'_^$A^.?_0F:'_W^7_Y
M(H_X2'XY_P#0F:'_ -_E_P#DB@#V"BO'_P#A(?CG_P!"9H?_ '^7_P"2*/\
MA(?CG_T)FA_]_E_^2* /8**\?_X2'XY_]"9H?_?Y?_DBC_A(?CG_ -"9H?\
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M]I7QBG3.GH<?A!_C7L% !1110!EZSHW]K>1^_P#*\K=_!NSG'N/2LK_A#?\
MI_\ _(/_ -E74T4U)HT52459,Y;_ (0W_I__ /(/_P!E1_PAO_3_ /\ D'_[
M*NIHI\S'[:?<Y;_A#?\ I_\ _(/_ -E1_P (;_T__P#D'_[*NIHHYF'MI]SE
MO^$-_P"G_P#\@_\ V5'_  AO_3__ .0?_LJZFBCF8>VGW.6_X0W_ *?_ /R#
M_P#94?\ "&_]/_\ Y!_^RKJ:*.9A[:?<Y;_A#?\ I_\ _(/_ -E1_P (;_T_
M_P#D'_[*NIHHYF'MI]S%TC0/[*NWG^T^;N0IM\O;W!SU/I6U114MW,Y2<G=A
M1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HK+U75FL'$<4<;N$,DF]B JYP.@/)/ ^AJ#1=?\ [3N)+>6)(I%7<FUB
M0P[]0.G'YT&BHS<.>VAMT444&84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >?_$OX=_\)9;PZMI$GV/Q)88>TN4.PO@Y",WUZ'L?
M8FJ7@;XKVFH:1>6OBR6/2];TE2+Y)AY8<*<%U'KG *CN>."*]-KPGXO_  K\
M3^*/$,FNZ3'I]Q&L2QBWC_=3L .K$\.>V<C@ 8H ]TCD2:))8V#(ZAE8="#T
M-.KD_AK/J,O@'2X-6M9[;4+1#:SQ3H58;#M4\]<J%.>^:ZF:58())6#%44L0
MBEF( SP!R3["@#R+PY\O[3WBU?72T/\ X[;?XU[!7SQH7Q!\.CX^ZQKZ74KZ
M?J%E':VS);N6DEQ  NW&>J'KZ5]#T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!RGB>WDAD>1$=X[DIDJI8JR@C''8@_F*R]$:*VU1+BY\
MZ-8E9E B8ECC'0#H,_RKOZX_Q"\D=W=+(?GEV",]O*'8?\"Z_A2/0P]652/L
M.YTMCJ5KJ2R&VD+>6<,&4J1^!JW7$^%1-_:[-&<1",B7/3_9_'.?UKM@0>E,
MYL125*HX)W"BBB@P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BB@T %%<UK>OQ:1XETB">4)#="1'R>%/&TG\>*Z,-D9ZCL13L*Z/)=(
M^$<>G?&>Z\0B)!HZ+]KMD'1;A\@KCT4[F'IE1VKURD) &20!7-ZWXXT;1=R2
M7 N+@#B"#YF_$]!^-$8N3LD*4E%7;.EHKPB]U#7-7U9O$L<$B^2P\HJ,K&H[
M>_O7L'A_7(=?TB&^A."PQ(G=&'4&MJM"5-)LSI5E4;2->BBBL#8**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *JWFFV>H!/M=NDNS.W=VS5JB@:;3NCB-7
MMK2U>=(K2-$1Q&B$9YP&9SGU& /H:E\)W3Q:A):*O[J52^%'"L._X]/RK;UC
M0EU25)%G,+J,-A<AAV_+G\ZP )-!FN3;72N5*QM(8A\S==HYX ')]R/2D>C"
M<*E#V25Y,[:BL'P[K4NH&:"Z93.GS*57&Y?IZ@_S%;U,X*E.5.3C+<****"
MHHHH **** "BBB@ HHHH *3(JCJVI#2[,S_9KBY<G:D4";F8_P!/K7'7:>.?
M$#83RM%M#VWYD(]R*J,;DRE;H=W+<P0C,LT<8_VV _G3$OK21MJ74+'T60&O
M/D^%?VD^9J&M3S2'DD+G]6)J23X2Z=MS!J-S&_8[0:OEI_S?@1S5/Y?Q/1 P
M/0TN:\HG\(>,-#)?2=3EN(UZ*DI!_P"^6XJF?&?C72_W=Y!DCC,]J0?S'%6J
M'-\$DR77Y?B31['17CA^*6O+PT-B#WRC#^M4[OXB^);E"HNX+=3WAB&?S-5'
M!U9;?F0\921Z+XV\5'PY96YMF1[N648B;N@^]]/K4"?$KPZ;$3-<2K+C)@\L
ME\^GI7CL]S/=W#7%S.\\S=9)&W$UOGQ)82Q@3Z);NRJ%5@<?G75]02BKZLYO
MKK<G8VGTZZ\=O=:O<!X$QLM$ZA$'<^N:R+F]\1^%Y4LEUQU5E#*H;> /Q'%6
MU\>RIH]Q9QVJPR.NV-HCPHJGX9T"#7[?49;F[8/;0ED0'YL]<_2M%#DB_:+W
M5\S/GYY+V;]YC6NKK51G4_%,K*?^6:%N?P&!5> ^'( 5\FYN)#GF5Q&M4M52
MR:[\O1\O']G5B\A/^L_B&.]59M!N&B65M\KD#$1^F3@"DZU**]W_ ".REEV(
MJRM4T]=3>7QGJ$*K#:I;Q6:C @"AE(]S3O#?BHZ%KLERL16PN6_?0*<[?]H>
MXKC[-HTFGB:5(P%#JK=^Q JP9X@<&10?K6\:=.I#;<XJWM,/6<+WY3Z2L[ZV
MO[9+BUF26)QE64YS5FOG'3=6O=,E\W3;V2!LY(1LJ?J.AKN=+^*MU$%35+)9
MAWE@.T_]\FO-J8*I'X=3LIXVG+XM&>JT5S6G>._#^H@!-02&0_P3C8?UXKH(
MIXIUW0S1R*>Z,#_*N1Q:T9UJ2>Q+12#IS2TAA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)N&[;D9
MZXHW L1D9'44 +12!@<X(..#BDWIL+[EVCJ<\4 .HIGG1>5YOF)Y?]_<,?G2
M-/$B*[2HJMT8L #0!)7)Z_I-XUR3:6[S0RL92%(^1\8/4C@X!_.M;Q(R#0;M
M3(%8IE1NP200>*YWP_K:Z4LUO<B5[=COC*_,5/<?3O\ G2.S#0J).K3U:Z&I
MX9TB:UDEN[N(QRD;(T8C('4GCUX_*NDK@/$VL?VDI,)=8(HR5!X);'4XKM[(
MHMK%"LBL\4:JPW9(('>@G$PJ:5*F\NA8HIB2QR E)$8#@E6!Q0)HFC,BRH8Q
MU8,,#\:9RCZ*C,\0B$IE01GHY88_.E::- I>1%#<+E@,_2@!]%%% !1110 4
M444 %)@>E+10 8%%%% !BD*JPP5!'O2T4 5)M,L+A"DUG;NIZAHP:YS4OAUX
M?OPVRU:U<_Q0-@?ETKKJ*I3E'9DN,9;H\9U7X1WMMN?3KA+E.H0ML?\ P-<+
MJ6B:EI<QCFCGA<?PR@C\CT-?3Y&:KW=C;7\)ANH(YHSU5U!%=,,9-:2U.:>$
M@_AT/F9)9;>UAEN70K(Q4 'YUQZBNS\.:[:2-'!$=EPRG[2ZJ )$/ 7/I5CQ
M]\/%L(VU'3$8VH_UB#DQ>_\ N_RKS9+N\L9XBK$&$$*O;!.377.?MJ7NF6&C
M&C77M-#U*2>W5V\FUB7&0I _7%<OK4DL]]#:0;B^,X4XR?\ ]59J^+Y0GS1?
M-[H:R;J^N=0F:?RVV%AN]_;CI7)"E)L]]XFC1CS-W*DK^;<R2=ONK]!6GI^C
MW&H3(HCEEE?[L:C+&M7PQX;O=6OBEO:H[,"#N7*1 ]_K7N7AOPM9^';4+&!)
M<,/WD[#D^P]!734JQHJV[/ Y9XFHZCZGE=M\*]<D0/\ 9XH21D!IL']*N+\+
M]?5>&M3]9>?Y5[, !1CTKE6-JK8V^ITCQ67X;>(E_P"6%O(/:4?UK$O=)UCP
M_(//ANK,D\.CD*?Q!Q7T+@^M5K^P@U&REM+F-7BD4J0PS^/UJXXV=_?2:)E@
MX6]S1G@T/B?7K?'E:Q>#'0,^[^=7%\=^)D&/[6)_WHE/]*W_  GX&M+R_P!2
M@U7S&>QG\H1 [0PQD,3Z$5Z):>'-'L0!;Z;;)COY8)_,UI4Q%"^D+F=.A7:U
ME8\CB\7^,KI@(+NXD)XQ':@_TKI]"T[QQJT@?4M9NK"U')Q&GF/[ 8X^M>C)
M&D?"*JCT Q3ZYJE=25HQ2.F%%Q=W)LH:;IG]GA\WEW<L_5KB3=CZ>E7Z!17.
M;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\JWN:>DQW$.DVL=T29UC ?)R:NT45Z25E8XV[NX4444Q!1110 4444 %%%%
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M\J^X/;5/YF1V\$=K;I!"NV-!@"I***VV,PHHHH **** "BBB@ HHHH ****
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4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img98921446_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img98921446_5.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (S!.(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***0]* &C_=J.29(P6<A0!DEC@"N-^)WQ7T'X4:(^H:W<K&
M,'RH%.996]%%?"?Q>_:L\5_$N2:ULIFT#16) M[9L2R#_;?KTZ@<5QU\53H+
MWM^Q\QFV?X3*E:;O/LMS['^(7[3W@3X=^;#=ZJM[>QXS9V/[V7G]/UKYO\:?
MMW^(M0E>/PWI,&FPACMFN_WK,ONO&#7RYW)[DYI:\"KF-6II'1'Y%C^,,?BF
MU1?)'RW^\])\2?M&?$/Q1(SW'B2XLP>#%8_ND/X5Q=]XLUK4V5KS5+JY*]/,
M?.*RJ*\^56<_B=SX^MCL3B'>K-R]1\LTD\ADD<N_]YNM6[;7M2LYDE@OIX94
M^ZZM@CZ51HK(Y%*47=,[+2?C-XXT1T-IXHU"-%.?*,F4/U%>H^&_VW/B!I5Q
M&=1CL-4M%&#$L/E.W_ AFOGRBNF&)K4_AD>QA<YQV$_@U&EZGZ!_#_\ ;6\%
M>*%B@UEY/#UZ5&];D9B+'LK#K^5>^Z7K%EK=I'=6%U%=PR#*R0N&4_B*_'^N
MT^''Q@\5_"N^6?0]3D2WS^\LI3OAD&<D;3T)]1S7JT<R>U5'Z!EO'%2+4,;&
MZ[K?[C]6.?K17@WP'_:GT?XL,FF:@BZ1X@Q_Q[,WR3>\9/\ (\U[UD,.M>]3
MJ1J1YH.Z/UG!XRACJ2JT)7BQ]%%)6AW"T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC)H ]RHHHH **** /G#]MSQO-X9^&$6F6LLD,^K3^1O0X^0#+J?8CBOS] P
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MO2[S5-5UJQL-.LG$=S<SSJL<+$@ ,<\')'!]:/JU/M^+_P P_M['_P Z_P#
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M8>+_ /HM_BO_ ,<H_P"&,/%__1;_ !7_ ..5]7Y]Z,^]'U:GV_%_YA_;V/\
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MI/B+2-,TV#3+%+J)[ .&9C(%P=S'C!KAO^"Q'_)/?!/_ &$&_D*\T_X(Z_\
M)4?'Q_ZA$7_HY: /U:HHHH **** ()(8Y61GC5V0Y4LH)4^H]*GHHH ****
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MCQOJW@7X!2>'=,T7PUH-W/)_9&EZ;))' ]\"/,$RECE/NXS[U]@_!?\ 8_\
M%WA'X<_%^?Q-=Z?/X_\ '=O=0"2WF8VT:R*Q12<9&'<],\5QVL?L/_$BW^!?
MPHTK2KW17\:^"+^6Z$<DK?9)1)CG<5SQM'&* /J+X@3_ ! A_9NU>6%=-3XA
M+H;&;#D6JS[/WI4]< ;\>^*_-CPG=>,-4_X)^_$R76'M;OP=++:M9W,LC27K
MW7VE/,\PDG*[<8S7ZIZ7I6N:[\,XM,\4R6J>(;S3#;:A)8@^2)GC*N4S_#DG
M%?$FA_L8_&*Q_9W\?_"*6Z\.'1KQXI=$N#,XD:1;A79I2%X!11@8ZT 7+/\
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MD#!Y[5]&4 ?,?[?W_)$Y?^OB/^=>[?#;_D0_#_\ UXP?^BUKPG]O[_DB<O\
MU\1_SKW;X;?\B'X?_P"O&#_T6M<D/X\O1'T6(_Y%-#_%+]#IZ***ZSYT****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)_A/I/AC5+C[3=V<DYW>>TQ"/*[HI=AEB%8#/M0!\U_';4]<^(7[4EYX4O\
MPQJ_B_POHND1SQ>&[+4?L:SR2$@W!(P6 Z8SQBO&O'GAG6-2^',^D^+K"<Z/
MHWC.PT_1+>^U$W%U8V\I/G6TCJ1NZ#!/(]:^\_B1^S[X?^(OBW3O%3:AK'A[
MQ-8P-:Q:MH-X;:9H6/,;G!W+R?SK U+]D#P)J7PRG\$RRZRUG-J7]L2:BU^3
M?/=YR)6EQDD'VH X'X@>"-/^(W[1?AWX4ZK+J&F^ M%\._VC;:3:WCQ1W\HD
M" .V=[*JY&,UZC\#?"OASX9WOBSPKH'BLZQ;6EX)SI=S<F:72MZC$)8DD+W
M//-2>-/V</#WCJ/PQ=7>J:Y9^(?#L/D6/B*QOC%?[2,,'DQ\P/4@CK5-/V5?
M!8^'>L>#GGUE[;6+U=0U#4O[087]S."#N:8#/\(X]* /::*JV=JEG:PV\9)C
MA18U+')P!@9/K5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MSP_X+$?\D]\$_P#80;^0KS3_ ((Z_P#)4O'W_8(C_P#1RUV?_!7OQ=HMYH/A
M3P[!J5O)KMI=?:)]/5_WL<;#Y7*]@<&O,O\ @DKXRT3PQ\6O%=MJVJ6^GW&I
MZ=';V44[A6N)/-!VH.YQ0!^NE%%% !1110 4444 %%%% !1110 4444 %%%(
MW2@!GI7CW[1GP.@^,7A-T@"PZY: R6=P1_%_<;_9->P]*4J.HJ)PC4BXRV9R
M8K"TL91E1JJZ9^0?B#P_J?A76+C2M7LY++4+=MDD,@P?J/4>XK.K]/OC%\!?
M#GQBTLQW\/V;4XU_T>_A $D9[9]1[&OA'XK?LY^,/A3-++=V;:EI*\KJ%JI9
M /5QU7\:^5Q.!G1=XZQ/P+.^%L3E\W4HKFI]UT]3R^BD!!Z4M>8?#N/+HPHH
MHH("BBB@ HHHH ***Z/P3\/?$/Q&U);'P_I<U](#AI -L<?^\QX%5&,INT4=
M5'#U<1)4Z4;M]CG54LP5069C@*.I/I7V/^R'^SG<V,T7C7Q-9&&?&=/M)E^9
M ?\ EJP/0^G>NJ^!/['^G> [R'6O%$D>L:P@#10A?W,!^A^\P/?I7TRJA<!<
M #^$5]%@\#[-^TJ;]C]BX<X5>'FL5C%[RVCV\V2*NU<"EHHKW#]7"BBB@#Y6
M_;^_Y$7PE_V'+?\ K7TEX7_Y .G_ /7!/_017S;^W]_R(OA+_L.0?UKZ2\+_
M /(!T_\ ZX)_Z"*XJ?\ 'GZ(^FQ?_(HPWK+\S7HHHKM/F0J-W$:EF(55&22<
M "I*\?\ VM-:U'0/V;_B#?:6LAO$TF8+)"^UH@5P7!]AS0!S/C+]O'X)>!O$
MDNB:AXR@EOH9?*F^R1M*D9]W48/X$U[7X7\4:5XTT.SUC1+^#4]+NTWPW-NX
M9&'^/MVKYE_8_P#@S\.=6_9'\.M?Z#I5VFK:>]QJEY/"CR>8V?,8R$94CKUX
MKJ8M/\)?!?\ 9=UD?"+Q%H^D:9:1/):ZO=W7VBUCE9AN8G)!8Y. .Y% 'T91
M7YF?"O\ :J^(&E_&;P7I\/C^Z^)6C>(7^RW"WVE&QA%P>!Y3$#(!].*P[7]J
M+XAIXMN]/\4?%S4/A_XNMM9EMY-*U311-8&U$F(URJ_(<=6)[T ?J?17Q/\
MM7?%[XD:+\5/@MH/@'Q7:6+^)[>83RQH'LYW.P"3G)V@,2!GTK.^&GQF^*GP
MF^/VN?!_X@>*['Q5+=Z5-J6F^(KF$016TBPF0F0#_EF.^?3B@#[IHK\K+C]K
M;XB>$?$&@ZW;?%63QT'U-;;5=-AT<PZ<B%\!(YB,-UZBO4_VMOV@/'/@7XW#
M2[[Q9J_P_P# ]QH\4^F:GIM@MRDEX1D^8,%F4=U'M0!^@%%?$-Y^U9KWP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5;Y=5L8RTD2DX'G1CD'W&1[UC_LW?MM_$/\ 9SFBM-/OCK_A7>/-T._D+1J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'(5S_>BF7@_@>]?8O[,'_!4O6/"JV7A[XL1-K.D*%C3Q!;K_ *3". #*H^^
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MM*4;W\CT*<L5A^:G"IRJ.NCT?H=.O[+/PP7KX2L#_P!LZ#^RS\,,<>$K$_\
M :3X]>+/B+X7L]*;P!H%KKDLSN+O[0Y'E@ ;2,'OS7G'@SXG?'[4?%6FVVM>
M!]/M-)EF"W,Z2-NC3N1S64I4HRY7#\#T:,<PK4?;K$)+71RL]/(])_X99^&
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M@E>*M<\C%5,1*;A7FY<K:WNODR2BBBM3B"BBB@ HHHH **** "BBB@ HHHH
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M7-54SC"4<3#"SE:4MM-'Z,(8&K4IRJ15U'?R/H+3+1?A_P#%C7?"DN8M'\3
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MJ7F[%09^;:1AOI6_\1/B9\4M)O+/3=+L?"^@6Z:9'<WWB3Q-=M#9_:6&3!"
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M#BOJ:O(Q<H.H_9O30Z:,6HKGW'T445QG2%%%% !1110 4444 %%%% !1110
M4444 ?*/Q C7X:_M9:=J<J^3I/B[3S:M*QPOVA>&)^B!3^-=CKEA<6UU'<VR
M!KRT++Y;=)8S]Y/Q%='^T;\)9/BQ\/WM]/*Q>(=-D%]IDQ_YZKSLSV#XP:\U
M^$/Q.C^)FB"ROLV7B[3/]&OK&?Y9&9."<'O_ /6KR<1!QGS+J<KE*C44XFG<
M7%RVGM-I+>;9='B*_O;<]U8=L50\-L]K_:.HG[MI;.^?<C&/K717FD%KHW5K
M,]A?C@RH.&]G7^(57?3[Z_V0WTENEHCB5X[:/89G'0MZ?2H]M[MGN?5QSR#P
MTJ<E[S*E];?9/ LT73%N&_-@?ZUT+3++,X!Y0*#^59OB;+:#>';N"J"4]1D<
M5EZQ?3Z3KKS1$-%.BR*/X6!%/#=61D<?;<ZZG66K;;J(_P"V/YURUQ_Q+]8O
M[H#"V>I[6;TB=1O-0'Q%<ZA<V\*+Y69%'RGD\UKVL*7&I>(HI5$D;W>UU/0_
M(.*O$/1-'5FT9890F][G.Z])=6]T]G+(6CC;=&WJ#R#74-J6WP3<WLV?WL'V
M4$]2S':/YUGS6,L*1V]W8G5K2+B*:*3;<*O96]0/6K9CN=7FM3=6Z6.GV?,%
MFC9+M_>D^GI2=:/*3BLVHU<*E'XAEG;-9ZQX<@<_-#!-&3[B+%:4BAH7!_NG
M^54M666&2TU"&(W$MFY8PCJZ,,/CWQTK/DBDOX6;3=6@DLY,_)<.(Y$SV(/I
M3H32C8RR>K3<.6<K.Y;\+^(C<2&VGBA>[C&(+AD!? [9]:WM/<_;HB3EBW)K
ME-)\-RVM]#/)J%B@C.1B=<_SK<O-<M-';]U-%?:DX(M[: [@6]6(X %='-%(
M]C%5,/3;E!Z,YZ/"V-HC=(]70;AW_>$UUMY\UW,>OS'I6"NBNN@BT$J_:U/G
M+(>@ESNS],FH)M4MI&9[JZN=$NG^_')&7C=O52,\&N2C-1;N?/Y=B**E-3E:
M[+NO:@+.Q=%/[Z0;%7ZTD*[O$1VC*P:?' Y_VR=V/R-8\?\ 937*S)=76N7"
MG(@AB*C/;)..*W=)MIH!<W%T5-W=R>;*$/RKQ@ ?08IUZBE&R-\UQ5!TE3I2
MNR3PSD^&[6#/SVDSPR-Z'.?ZU:FL9+ZXENKVZ/V.(Y7S#B- ._N:H?V;<VUY
M+=:7=FUEF.9HF3S(Y#Z[>Q]ZE;P[?:MB?6[KSXDY$<F((%QW*]S[T1KI0M8X
MZ6:0I44DM45_M!\3:A;W$2,NE6I_T12.9W/!D(]/3\Z\W_:'UJZUMM&^&&@L
M9-<UNY6.Y,?/E XY..R#D_6M/XB?'K2/!0&E^'<Z[XDG/E01VJ;]K'@!%'4^
MYX%=E^S=\"[_ ,*7EQXX\9L)_&6I(0D+'<+"(\E ?[Y_B/X5-.#K2\CP9U)8
MJIS/8]I\&^&[3P;X7TO0[%!':V%ND$:CT _QS6Y117LG4%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMCP?\%?C-\>/'&DWGQHCMM&\$:+*+J'P[#(DINY0,+O*DY7UW5]M?PT<4Z>
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MX@U!\Y,<;1HA_-2?UI1PLWNOQ/-5.H^EC6U3X@^#]%4F]\1P+MZK&C-^O2N
MUS]HOX80W!$=JVMWGH C$_@/FKU30_V,?A9I+*]QH4FK3CGS;VZD;] P'Z5Z
M5HOPN\(>&XDCTSPSI=J(_NLMHA;_ +Z(S^M;1PDNK-(TJB^U8^1O^%Z2:D2-
M"^%4]RO\,G]G3D'\2N*T+'XE?%)(RVE?"V:VC;KLM47/X$5]H1QK$H1%"J.
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M1> ![4 ?8U)D5\':?\:/'7PM^'/QD\(_\)%<>(+[PIK%IH^D>(;B,2301W#
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M7AN_T'6[*/4-*O(C%/;RC@J1V]#Z$=*WZ* /E_4/V)GUKP];>%=3^*7BN_\
M!$+@_P!@RM'MDC!SY+R8W,F.,&L[]L;0-'U[X:Z/\$?#VA74NO:LD,>C&UMF
M,&GQ1NJO*TO1=J;N,Y.:^L:A\F,RB0HID48#8Y ],T >2^+/V<]%\8? .U^%
MTMU-IFGPVMO#]JL% </'@[P#QRP)_&N?NOV6[K^U/#_B'3?B%K6D^,M-TU=*
MN=:A@A;[? OW1+$1LRN>"*^@** /#M!_9-\):3\.?%_A2\GOM7E\72&XUK5K
MF3%S=3YRLN1PI4XQ@=JK>$_V7VTWQ1X7U7Q1XXUCQO%X75ETBRU2&%8X&*;!
M(VT9=P. QKWJB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#QBS_9B\.V^L?%2^N+V^O8_B%M_M"VDVA(0$V8CP,^_.:Y^X_8S\*R?!GP
M]\.(=6U.VTW1]6BUD7BE#/<3H^_YR1C!/7'I7T/10!YBOP-TI?&7Q!\1-?WC
M3^,[&.PNX#MV0(D/E Q\9R1SSWKSC3_V,;72_ /AOP['X[UP7OA:^:\\/ZPB
M1K/IZM]Z+ &'0]]U?2M% 'C/@']FW3?"_C#6/&'B'6[[QGXLU2S_ +/FU/45
M2/9;$8,*1H H4UQUI^Q=:6^CP^%W\=Z]<^ (+Y;Z/PO,D30_*X<1&0C>8P0/
ME)KZ7HH \]\%_"+3O!/Q \7^++2[N)+KQ(;?SK5PHB@$4811& ,XP.]>6:?^
MQ+H.@^%]+L-&\4:UI>M:3K5SK>GZ[%Y9GADG.9(BN-K1G@8([5]*T4 >*>"_
MV:=-\.ZYXF\1ZSK^H^*/%_B"P;3+G6[Q4C>.W*X\N-$ 50.O3M3-8_9=T/6?
MV=8O@_)K&HQZ/'%%$-039]HPD@D!Z;>2,=*]NHH \ UG]E=G\3:GJWAGQWK?
MA)=9LH;+5K6QCB=+L1QB,2#</DD*C!9:C\._L=^'/#GPKT/P);ZWJCZ?I/B%
M/$45S)L,KS*2=C<8VDD^]?0=% ' :Y\)+'6_BUX=\?RWMTNH:+8SV$5JFWRI
M%E8$LW&<C':O,+[]CV-?^$FTW1/'VO:!X1\17#W.H>'[9(GB+.<R+&[ LBOD
MY ]:^CJ* /)O _[.OAOX=^-K'Q!H4MS:PV&A1:!;:;D&&."-V8-G&XMECWJ_
M\+?@GIGPK\4^/M=L-0N[R?QAJG]JW45SMV0/@C;'@?=Y[UZ510 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7SG_P4 L[C4/V4_&=O;6\UW,XM@(;>-I';_2(\
MX502:^C** /BCXQ?L6Z#K/PMT+Q;X$\/PV?C+1K&WOH],;<UKJ!5 [QRPDX9
MCR!GO7%_$CQ?_P +.U;X.?%":;7?!GAZ&*XT?49-.LW$GA^]& <KMR$.,9 Q
M@"OT+J.1%E4JZAE/!5AD&@#\V/$OPW;X@_\ "R/&'A35/$WCEM&MK**74[Z-
MD_M>-)4E>%$91OVA3SCM7TG_ ,-":'\7]:\'>'/!&AG5]1OH)I;J^NK:2V&@
M+Y)RV63_ %F> HZXKZ4C18E"HH51P%48 IL<,<.[8BKN.6VC&3ZF@#\P_#MI
M8^$/A'XI\(^(O%_C'2?$-O>75K/X,M;1RFI-)(=KH0A!5P02<\5ZQXSN](_9
M_P#B9^S3:ZU#<PZ7IVCW=I*\R-</:Y6/YGP"?E/&0.*^Y/)C\T2%%,@& ^!D
M#TS7 >*OA%;^*/BQX1\<R:C-!/X>M[FW2S5 4F$VW)8GD8V]O6@#XJ^-EO-\
M5+OX\?$7PQI]Q)X5;0['2+>ZAMI$?4IDF1W94*@LJ@8SBO3_ !?XTT^QOO@%
M\5E@OM9\$Z?9R:9?M':._P!ADD@5!.\97<,,""<=J^QUC54"!0$QC:!QBFK#
M&D?EK&JQXQL  'Y4 ?GG\?+Y?C3X[^)/C#PEIEU?>%-.\#3:7+K$-I(@O+F2
M5&$(4J&<  ]O6ON/X3V,>F_#/PM;16ZVJ1Z9;H(53;MQ&.,=JZN.-84"(H1!
MP%48 J2@ HHHH ^$O^"OO_)OOAW_ +#\/_H#5X#_ ,$=_P#DNGCO_L78_P#T
MI6O?O^"OO_)OOAW_ +#\/_H#5X#_ ,$=_P#DNGCO_L78_P#TI6@#]:Z*** "
MBBB@ HHHH **** "BBB@ HHHH **** (CC/3FN;U;P#X;USQ)IVOW^DV=UK.
MG_\ 'I>2Q@RP_P"Z>U=+_.OE?XV>(M6TW]JWX8:?:ZG=V^GW#MY]K'*5BEX/
MWEZ&L*LE%)M7U1Z. PL\54E&G*S46_DEJCZK7I2TU/NCZ4ZMSS@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&01WXKQIOB-XO_X2C]I=_&&B1ZOX<TVWC2XLH]6*M;H!^ZBBPO1@221C!XH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!\)?\%??^3??#O_ &'X?_0&KP'_ (([_P#)=/'?_8NQ_P#I2M=Y_P %
M=OB-JRZ?X;\#7.B"+2+B==3M-863/F/&"KQ%>Q&X?G7@_P#P3'\>:MX/_:+D
MTS2-%_MB?Q%8BQF=F*K:1(XE:4GZ*0/>@#]IZ*** "BBB@ HHHH **** "BB
MB@ HHHH **** (V]J\R\8?'32/!?Q.\-^";JRNI;_7"1#<1@>6G^]7IU?*WQ
MJ\-:SJ7[5GPQU"VTN\N;"V=O-NXH6:*+@_>8# _&N>M*48IQ[H]7+:%'$59J
ML[)1;WMJEH?5:G*BEIJ_=%.KH/*"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ^4M-^!6L?%;]IOQQXR\?:5>:=H&F01Z3X>
MC6Y 6YBZO.-IRN3QSBN;^(W[+>KZ#\7;E?!&DW-QX2\:>'[C2/$$SW(;[+,
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M@;_L%0?^@UZ-7G/[.O\ R0SP-_V"H/\ T&O1J "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **8S!023@#DDU7M]0M;UF2WNH9W3AECD#$?7!H
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M]JLS>9+JVL'S)I&_O(O\!^E>9B<?2PJU=V>_E^38C,)+D5D>KZI^W(=1F?\
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M";PQ<&$ZW-JF!GS-,MS,GYY%?F+XJO&N;^ZNO%'BNYO]5G/F.MDQG;?Z2,Q
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M;*C/:O-QV*6&I.74]S)\OECL3&"V,;Q%XFTOP-H=KI>F6B6=G N+/38CPO\
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M0F31?#&I:HO9K:'=UZ=ZRJ5HTU>;L:TXREI%7-OP'\"?%_Q,L9KKPUI;ZK%
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MY)/='RV:PY(2MLSDJ***^N/A0HHHH **** "BBB@ HHHH @U+_D&W?KY+_\
MH)KY!^/4SV/PX\):DAVR6/B$3*S?=!V#K7U_?*9+&Y4=6B<?H:^6OC)I3:W\
M _%5A' 9[RPGANX\#E5# .?RJ<5!U,%-(SPM14LSI2>ST/UX\(W!N_"VC3L0
M6ELH7)'3F-36S7DG[*?Q 7XH_L\^!/$0VJ]SID:2(A^ZR#9@^_R@_C7K=?EQ
M^SA1110!\Y?MR?M$:_\ LS_"&U\4^'+*QO[^74H;,QW^[9L?.3\O?BOA#_A[
MM\6O^A:\,_E+_C7Z4?M"?L[^&OVEO!4/A;Q5/J%OIL5VEXK:;.(I-ZYQR5/'
M-?.W_#HOX+_]!/Q9_P"#-?\ XW0!\P?\/=OBU_T+7AG\I?\ &C_A[M\6O^A:
M\,_E+_C7T_\ \.B_@O\ ]!/Q9_X,U_\ C='_  Z+^"__ $$_%G_@S7_XW0!\
MP?\ #W;XM?\ 0M>&?RE_QH_X>[?%K_H6O#/Y2_XU]/\ _#HOX+_]!/Q9_P"#
M-?\ XW1_PZ+^"_\ T$_%G_@S7_XW0!\P?\/=/BS_ -"UX9_*7_&O+?B9^WG\
M0OB7XNT7Q0]IINAZYH_-G<6*,P0^I5\@U]WC_@D;\%_^@EXL'_<37_XW7E?Q
M2_X),V;>)M)L_A_J5]:Z1-_Q_7VK7:SM;GU5 HW?2LZBBTKJYWX*I4A-NG)1
M=GJ]-+:KYFQ^S_\ \%9M*U4VNC_%/2#H]VQ$:ZUIBM) YZ#?']X$GJ1P*_0W
M2M4M]9T^UO[23S;6YC66)\8W*PR#^5?.W[/_ .P+\+?@/'#?1:4/$7B10"VK
M:L!*RMC#"-.BJ?0Y/O7TE'&EO&J(JHBC"JHP /0"M#@):Q/&L;2>#]<1&V,U
MC. WI^[:MNJFH6HOK&YMV.U9HVC)],@C^M3+8#Y6_8WNHKOX!YC0(5E9<*/1
ML$UL>(UVZU=#W'\JY?\ 9*D/AW5/'G@2X8@:3J,\$ 88,GS%@V*[/QA;^3J@
M?&/,7)^M?RQQYAY>SYNTG]U]#[_)))56NZ7Y&%1117X6?<BXKCO'GPMT?QX\
M-U<^99ZM;8-MJ%N<21$'(_#-=C25Z."QM?+Z\:^'ERR6S1SUJ,*\'"HKHP_#
M/[3/C;X/2+9_$FQ_X2/P\IPGB/3TQ+$N1S*GH!^)KZVT'6+3Q%H]CJMA)YUE
M>PI<028(W(P!4X/3@U\5^*-)N/BC\1O#'PYLRYM9Y5U#6'BZQ6R'(#>S' _&
MOMRQLX+&SAM;>)8;:%!''&@PJJ!@ >V*_M3A',,;F660Q&-24GMYKN?DN9T:
M5#$.%+9%RBBBON#R0KG/B%KUQX5\">(M:M462YT[3[B[B23.UF2-F /MD5T=
M9/B;0;;Q9X<U31KQI%M-0M9+29HFVN$=2K8/8X- 'Y,_\/=OBUS_ ,4UX9Z^
MDO\ C1_P]V^+7_0M>&?RE_QKZ>_X=%_!;G_B9^+/7_D)K_\ &Z7_ (=%_!?_
M *"?BS_P9K_\;H ^8/\ A[M\6O\ H6O#/Y2_XT?\/=OBU_T+7AG\I?\ &OI_
M_AT7\%_^@GXL_P#!FO\ \;H_X=%_!?\ Z"?BS_P9K_\ &Z /F#_A[M\6O^A:
M\,_E+_C1_P /=OBU_P!"UX9_*7_&OI__ (=%_!?_ *"?BS_P9K_\;H_X=%_!
M?_H)^+/_  9K_P#&Z /DKQ5_P54^*_BOPUJ>C/HVAZ:M] T!N[-I5FAW#&Y#
MGAAVK8_9]_X*G>,_A]';:3\1++_A,M&C 0:A"1'>Q@  9_A8#'.>37O/Q!_X
M)(_#Z'P?J;^#+_7I/$PC_P!"74M24VY?/\?R=,9K8_9]_P""67@;P#':ZGX_
MG_X3;7% 8VK QV,;8'&SJQ![Y'TH ^I_@S\;/"WQZ\&1>)_"-U-=:6[F,M/"
MT3*XZJ0P[>M>A5G:3H]AH5G'::;9P65K& %AMXPB#''0"M&@ JGJV?[+O,=?
M)?'_ 'R:N5!=0_:+>:+_ )Z(R_F,4 ?#/P09_P#AGFP)P9/[=O#..-V_><9_
M"O'=88MJ]\3P3._\Z];^#BG3?#7C[PLXV7&A>)"2C'Y]K Y)^AQ7E?BBU:S\
M07\3#!\TM^9S7YWG2_?7/WS@F2]A)&91117SQ^GA3HY#'(KK]Y2",C--HH$U
M=69H:A;OXT\56.HW/V2YGMW$B:+J#M'I]PX PHVD",G')Z5]B_!?]HWPWJFI
M:?X+O_#4G@7Q'<#%OIJVX%O<X7)>)U&"O'!/6OBQ(_.=8^S''T'<_E7TC^RC
MX=@\<>/-0\<7K1MI6A0+H^BF1P1(RC]Y.N3D$]/QK[K)<54JITY+1=3\(XSR
MO#8.<:U-VE+I^I]CTM,CD5URK!AZ@YIU?5GY8+7XS_\ !03XQ^.?"O[5WBS3
M-'\7ZQI>GPP6ICM;6[D2-28\G !QS7[,5PWB3X*^!/%VKS:KK7A72]2U&8 2
M7-Q &=@!@9/M0!^"_P#PT)\3/^A^\0_^!\O^-'_#0GQ,_P"A^\0_^!\O^-?N
MO_PS;\+_ /H1=%_\!5H_X9M^%_\ T(NB_P#@*M 'X4?\-"?$S_H?O$/_ ('R
M_P"-'_#0GQ,_Z'[Q#_X'R_XU^Z__  S;\+_^A%T7_P !5H_X9M^%_P#T(NB_
M^ JT ?A1_P -"?$S_H?O$/\ X'R_XT?\-"?$S_H?O$/_ ('R_P"-?NO_ ,,V
M_"__ *$71?\ P%6C_AFWX7_]"+HO_@*M 'X.:A\;/'>L+$NH>+M6U%87$D:W
M=R\HC<=&7<>"/45:;]H+XE,I0^/?$!4C!7[?+C'YU^TOQ&_8Z\ >-;?28K#1
M+'0&LKU+J1[.V4&=5ZQM_LFNMD_9K^&$L#Q_\(1HJ[D*[A:C(R.M9J_,]#KJ
M2C[&*4FWKIV_X<_#/X2_'[X@?!'6EO\ P9XCO-/DDD+/9Y,L$Y8Y.8CD9)[X
MS7[+_LD_'#XD?&KPF+WQY\.IO"#JOR:@TNR.Z/&-L+?.,CG=T]*9\#_V&?A5
M\"[J34]/T1=:UYY9)?[3U4"9X]Q)*1KC"J,\<$\=:^AE4*  , < "M#D'TA;
M S2T4 ?!VA*FN_M,:I.HW1RZLQ^?\^?RJ?XF3"X\>:PZG*M,2,TW0532?VI-
M5MTCV1QZLX$>>G'_ ->CXD0FW\<:O&3N*S$9K\:XKYE5E?R_X!Y&*V9S=%%%
M?G)Y(4444 %%%% !5&WD6R\?>%;UL[8[Z(G;UX;-7JI6<8O/B-X2M&3S$DOX
M04]<OC%?7<,<W]H0Y3LPG\56/T8CD$D:..C $?C4M,5!&H51A5& *?7[Z?0G
MY9_\%6/BAXN\#_&CPE9^'_$VJ:):S:,\DD-C<O$KMYN,D*>3BOBK_AH3XF?]
M#]XA_P# ^7_&OWR\6_"GP=X^O8;SQ%X<T_6;J%/*CFNX0[*N<X!],UB?\,V_
M"_\ Z$71?_ 5: /PH_X:$^)G_0_>(?\ P/E_QH_X:$^)G_0_>(?_  /E_P :
M_=?_ (9M^%__ $(NB_\ @*M'_#-OPO\ ^A%T7_P%6@#\*/\ AH3XF?\ 0_>(
M?_ ^7_&C_AH3XF?]#]XA_P# ^7_&OW7_ .&;?A?_ -"+HO\ X"K1_P ,V_"_
M_H1=%_\  5: /PH_X:$^)G_0_>(?_ ^7_&C_ (:$^)G_ $/WB'_P/E_QK]U_
M^&;?A?\ ]"+HO_@*M'_#-OPO_P"A%T7_ ,!5H _"?_AH7XF#_F?O$/\ X'R_
MXU3\'_&;QO\ #WQ7)XG\/^*-0T[6YI?/GNEF+?:']95/#_\  LU^\O\ PS?\
M+_\ H1=%_P# 5:\U\"_L!_"/P9\0M7\92:$NL:I>WAN[>&^PUM8>BPQ] /KF
M@#C_ -B']IGXM?'#3(HO&GP[FM].1%V^*D86\4PV\-Y;\N2?[G K[#JO:V\5
MK"D,$20Q(,+'&H55'H .E6* /S>\>0RK^UQ\5/,<%3H=^ZYXPOEQ<5\E_$LL
M?%<F[KY,>/IBON3]H*Q?PO\ M@::S0,+'Q5IATYKAP-JF0$,0?4;!^=?%_Q?
MTW[+KT5P,_O T9]MIP*_2.'9+V?*?"YW%\_,<%1117VI\L%&,@Y&1110,]:^
M&'Q+N!XHT22^OK:WU'3P(]/GU&,2VC'M'(IX0'IN' ZFOTR^!O[1EG\1KY/#
M&M:8_AWQ?#!YIL3S#/&/^6L+#@IZ5^.9 ;@]#7Z'?\$[? -WJ-Y>^,-5661M
M+M%TFSFDD+\GYI "?0;?SK\[XBP5*E:O%V<GL?:Y)BJM2]&6J74^\****^&/
MK0HHHH *_/\ _P""M'C_ ,1^!?"/P]E\/:[?Z')<:A.LS6,[1&0"+(!VGD9K
M] *YKQA\//#7Q AMH?$FB6>M16S%X4O(@X1B,$C/M0!^ ?\ PT)\3/\ H?O$
M/_@?+_C1_P -"?$S_H?O$/\ X'R_XU^Z_P#PS;\+_P#H1=%_\!5H_P"&;?A?
M_P!"+HO_ ("K0!^%'_#0GQ,_Z'[Q#_X'R_XT?\-"?$S_ *'[Q#_X'R_XU^Z_
M_#-OPO\ ^A%T7_P%6C_AFWX7_P#0BZ+_ . JT ?A1_PT)\3/^A^\0_\ @?+_
M (T?\-"?$S_H?O$/_@?+_C7[K_\ #-OPO_Z$71?_  %6C_AFWX7_ /0BZ+_X
M"K0!^!FL?$CQ7XDU:SU;4_$NJ7NJ60VVU[+=.9H!G.$?.5Y]*^Y_V+/VV/CO
MKVL6GA=O"]U\4-(1EA>]QY,UHO0!IS\GXOD\5]>_$+]@#X2_$CQUHNO:CHHM
M+'38/*_L?3\0V]TV_=NE Y88XP,5[SX/\$Z#X#T6#2?#ND6NC:= H2.WM(@B
M@#IGN?QH U;.:2:UADG@-M,Z!GA+!BAQRN1P<5;HHH PO&7B"/PGX1UG6IL>
M5I]I+<MN;:,*I/7MTK\*_"NDZE\5=:TNTFNVN=2^(7BJ2&ZNI,M(R129*ENX
M93@_05^X/Q9\,OXR^&7BG0HP6DU#3;BV55."2R$ 5^'7PI\:1_#'Q5\,O$@7
MS;GPWXFFCNH6^[&ID$:%AV)RW/M6M/KZ&-17MZG[?:#\-[;P9HFFZ7X=<Z?8
MZ?;I;06_5511@#W_ !JMXN\'ZGXX\+:QX;U296TW5+62SN&3 ;RW4JV/?!-=
MK9WD-]:PW$$JS03('CDC.592,@@]QBK6*GVCZZE<BZ'QQ\-?^"7?P=\"K$^I
MV5UXIN8)5E@FOY2ICP<A=JD @>]?4>I>%8?(A.G@6LL"A8PO P!P*Z(]N:XW
MXH?$K3/A9X3NM;U-_DC&V.)?OS2'HBCU-7#GG-1ANS&M*G2IRJ5'9+J2OXXM
M] M9&\021Z<D0^:XE8*AKPWXT?M2>"M6\(Z]X>TFYFU*]N[:2U7R8F" LN =
MW<?2L?PU\-]?_:0UR+7_ !]J?]F:8R^;9^'+>4+(8<\,ZYR ?<<^U=S\9OA9
M<^!O@MXA/PJ\/VK>*8K8FQ@V*S%NY3<#E\=!W->NHX3"S3G>4UNELGZGSCGC
ML?!JE:--[-[M>ATO[+^G_P!G_!7PRI#!I+82$.,$$GI^E:WQV\#3_$+X9:UH
MUHRI>21;H689^92&Q]3C'XUY=^Q]K_Q9L?@_:-\9+.6'6FF80B:(1W"0_P /
MFA>-WL*]_A\2:=<+G[2B^S'!KSI5I^W]O%:WN>O]5@\+]4F[JUC\H[JUFL[J
M:VN(VAN(7,<D;#E6!P1^=9NL:U8Z#8M>:C<K;6ZG&]O7T%?H?\6/@GX"^(U[
M]MN(Y(=4(YN-/(1I/]_CFO,]6_X)X>#_ !SX4NK#7-5U1)93OMY()0OE-_"2
M,<_2OT6/$E'ZMS--3[>9^2_ZFU_KG+=.GWOK8XG]B_X>R^,O%UOXSBD230]-
M)\FYC((FE(QA3Z $YK[TQ\OKBO!_V0_V8U_98^'M[X<;Q%/XCENKQ[EIGC\J
M.,'[JHF3CCJ<\FNIUSXBZQING?%":VLEN)O#5KYUC&J',S?9C+@^OS>E? 8[
M&3Q]9UI*VA^IY7E\,JH1H0;=V]3\^?\ @I9\7H?&OQVT;P?;3I<:1X)MGU"^
MC<84W;+GRR?=-H^M2_L;ZE=^&/@O?:-X7M9;OQ]X\O6DN)USMM+,$B(D_P!X
M!F^E?),=P_C"QM-5UR^:&?QAX@9=9OG.3  =_E\\@J2?PXK];OV&/!6EZ%\+
M6N[>SA25KN2"*<)\S0I@)@]AR3^-:4(0I4G6FKVM9>9CC9U:]:.%IRY>:]WY
M+>WJ>N?!GX8VOPH\#V6C1,LT_P#K;B8#'F2MRQ^F>E=]M[4=O:FYS7F5)RJ3
M<Y.[9[E&C"A3C3@K):$M%(O2EJ#<**** "BBB@ HHHH **** "BBB@ HHHH
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MWI?^AW:J.0O\!^F*_->*\'*5-U8K>WX'!BH.478X:BBBOQX\$**** "BBB@
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M**DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3:*6BB@ HHHH
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MB]&'N*WXU 50.F*QC"U24N]OP/2KXJ-3"4:"6L&[OO=W)*6D7I2UL>:%%%%
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MAN>:9PB*/4D\"IHY%D0.C!E89# Y!'K4<\NYI[*FK6BM/(E7I2T45)L%%%%
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M*Z_IUH 6BBO.?'OQKT?X>_$#P-X1O[6[FO\ Q=<2VUE+ @,<;1J&;><\#!%
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M#*C@G)49P1D5VGQ8\#>(/B1\ O$'A3S;2+Q+JNCM9F5G;R!<%0"V<9VYYZ4
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MW+:I)/F\-SOWB??C[X;V[5@Z7^R-:K\1/"WC7Q%XZ\1^*M;\-OFP:^>)8U0
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M*X@F;&V,QD;B3D= :U/AK^T%X,^*6IW&EZ-?7$>K01>>VGZE:26DYC)X=5D
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M /IN!K1HH SH]#TZWA:*+3[6*)EV,D<"A2OH0!T]J33?#^F:*KC3].M+ /\
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M_;W@O0KJ&YCMK6P\B\N_).8A--N.=O'0<U]1JH10HX &!3J* "BBB@ HHHH
M*XVX^%'A>X^)-MX_DTJ-O%EO9MI\>H;FW" G)7&<?CC-=E10!Y[X7^!W@KP6
MOC!=&T9;(>+9GGUC;(Y^TNZE&/)^7AB,+BLKQ-^S+X \5^ = \'7ND2)H6@N
MLFFQV]U)');,O1E<'=G\:]7HH XSPC\*_#?@>^UV]TBQ:WO-;=9-0F:9W:=E
M0(&.3UV@=*D^&OPO\-_"#PROA[PKI_\ 9FDK/)<"'S&D_>2-N<Y8D\FNOHH
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MYWAC>:,$)(R LH/7![5:HH **** *T-I!:M*\4,<3RMND94 +GU..IJS110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15+5-6L]%LWNKZYCM
M;=>LDAP*SM!\::1XDFF@L+Q9IXAN>(@JP7.-V#VH WJ*** "BBB@ HHHH **
M** "BBN6\0?$70O"]\+*^NRMUM#F*-"[ 'H3B@#J:*RO#_B&R\3:>+VPD:2
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MM+@?1[Z^OA;_ &>\4'&>!N [5;U34->\/OI.AC4UO=3U:X?_ $Z2( 6\8 )
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M+9W.Y89)XF$D"GCH.&/UJG<?"^;3],\-_P!CSPKJ&BR&0-<@^7,6'SYQSR:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"*:&.XC:.1 \;##*W(-$-O';QK%$BQQJ,*BC %%% $M%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>gyre-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-27T16:15:52.2208+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.gyretx.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:gyre="http://www.gyretx.com/20231231" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" id="DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3">
        <link:definition>100060 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity">
        <link:definition>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical">
        <link:definition>100080 - Statement - Consolidated Statements of Convertible Preferred Stock and Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100090 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations" id="DisclosureOrganizationAndNatureOfOperations">
        <link:definition>995455 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidity" id="Role_DisclosureLiquidity">
        <link:definition>995465 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureF351AssetAcquisition" id="Role_DisclosureF351AssetAcquisition">
        <link:definition>995485 - Disclosure - F351 Asset Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments" id="DisclosureFairValueMeasurementsAndFinancialInstruments">
        <link:definition>995495 - Disclosure - Fair Value Measurements and Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>995505 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>995515 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>995525 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement">
        <link:definition>995535 - Disclosure - GNI USA Contributions under the Business Combination Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuring" id="Role_DisclosureRestructuring">
        <link:definition>995545 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>995555 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureOtherAccruedLiabilities" id="Role_DisclosureOtherAccruedLiabilities">
        <link:definition>995565 - Disclosure - Other Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995575 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>995585 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>995595 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995605 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995615 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995625 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1" id="DisclosureRelatedPartyTransactions1">
        <link:definition>995635 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEps" id="DisclosureEps">
        <link:definition>995645 - Disclosure - EPS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlans1" id="DisclosureEmployeeBenefitPlans1">
        <link:definition>995655 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995665 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>995675 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany" id="DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany">
        <link:definition>995685 - Disclosure - Financial Statements Schedule I Financial Information of Parent Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995695 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995705 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsTables">
        <link:definition>995715 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>995725 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
        <link:definition>995735 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>995745 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables">
        <link:definition>995755 - Disclosure - GNI USA Contributions under the Business Combination Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995765 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>995775 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995785 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995795 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsTables" id="DisclosureEpsTables">
        <link:definition>995805 - Disclosure - EPS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995815 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail" id="DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail">
        <link:definition>995825 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail" id="Role_DisclosureLiquidityAdditionalInformationDetail">
        <link:definition>995835 - Disclosure - Liquidity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995845 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail">
        <link:definition>995855 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail">
        <link:definition>995865 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail">
        <link:definition>995875 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail">
        <link:definition>995885 - Disclosure - Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>995895 - Disclosure - Fair Value Measurements and Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo">
        <link:definition>995905 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail">
        <link:definition>995915 - Disclosure - Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail" id="DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail">
        <link:definition>995925 - Disclosure - Fair Value Measurements and Financial Instruments - Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>995935 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails" id="DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails">
        <link:definition>995945 - Disclosure - Balance Sheet Components - Schedule of Inventories, Net of Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995955 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails" id="DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails">
        <link:definition>995965 - Disclosure - Balance Sheet Components - Schedule of Deferred Government Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" id="DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>995975 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails" id="DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails">
        <link:definition>995985 - Disclosure - Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" id="DisclosureIntangibleAssetsAdditionalInformationDetails">
        <link:definition>995995 - Disclosure - Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" id="DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails">
        <link:definition>996005 - Disclosure - Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" id="DisclosureRevenueAdditionalInformationDetails">
        <link:definition>996015 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails" id="DisclosureRevenueSummaryOfSalesByProductCategoriesDetails">
        <link:definition>996025 - Disclosure - Revenue - Summary of Sales by Product Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail">
        <link:definition>996035 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails">
        <link:definition>996045 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails">
        <link:definition>996055 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail">
        <link:definition>996065 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue" id="DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue">
        <link:definition>996075 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail" id="Role_DisclosureRestructuringAdditionalInformationDetail">
        <link:definition>996085 - Disclosure - Restructuring - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>996095 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail" id="Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail">
        <link:definition>996105 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" id="Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail">
        <link:definition>996115 - Disclosure - Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" id="Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
        <link:definition>996125 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>996135 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" id="DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail">
        <link:definition>996145 - Disclosure - Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>996155 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>996165 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" id="DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>996175 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail" id="DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail">
        <link:definition>996185 - Disclosure - Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail">
        <link:definition>996195 - Disclosure - Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>996205 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>996215 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail" id="Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail">
        <link:definition>996225 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail">
        <link:definition>996235 - Disclosure - Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails" id="DisclosureIncomeTaxesMovementOfValuationAllowanceDetails">
        <link:definition>996245 - Disclosure - Income Taxes - Movement of Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>996255 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail">
        <link:definition>996265 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>996275 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails" id="DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails">
        <link:definition>996285 - Disclosure - EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" id="DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
        <link:definition>996295 - Disclosure - EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" id="Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail">
        <link:definition>996305 - Disclosure - Restructuring - Summary of Restructuring Charges Recorded in Component of Operating Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" id="DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
        <link:definition>996315 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" id="DisclosureSegmentInformationAdditionalInformationDetail">
        <link:definition>996325 - Disclosure - Segment Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail" id="DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail">
        <link:definition>996335 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails" id="DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails">
        <link:definition>996345 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>996355 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails">
        <link:definition>996365 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails">
        <link:definition>996375 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails">
        <link:definition>996385 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails">
        <link:definition>996395 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails">
        <link:definition>996405 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails" id="ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails">
        <link:definition>996415 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="gyre-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:href="gyre-20231231.xsd#DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2" xlink:href="gyre-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3" xlink:href="gyre-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="gyre-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail" xlink:href="gyre-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail" xlink:href="gyre-20231231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails" xlink:href="gyre-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gyre-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails" xlink:href="gyre-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="gyre-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="gyre-20231231.xsd#DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue" xlink:href="gyre-20231231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:href="gyre-20231231.xsd#Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails" xlink:href="gyre-20231231.xsd#DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails" xlink:href="gyre-20231231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails" xlink:href="gyre-20231231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:href="gyre-20231231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="gyre-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:href="gyre-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity" xlink:href="gyre-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureLiquidityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail" xlink:href="gyre-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="gyre-20231231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo" xlink:href="gyre-20231231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" xlink:href="gyre-20231231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails" xlink:href="gyre-20231231.xsd#DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:href="gyre-20231231.xsd#DisclosureRevenueAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails" xlink:href="gyre-20231231.xsd#DisclosureRevenueSummaryOfSalesByProductCategoriesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails" xlink:href="gyre-20231231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails" xlink:href="gyre-20231231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureRestructuringAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:href="gyre-20231231.xsd#DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="gyre-20231231.xsd#DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail" xlink:href="gyre-20231231.xsd#DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:href="gyre-20231231.xsd#DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail" xlink:href="gyre-20231231.xsd#DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails" xlink:href="gyre-20231231.xsd#DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails" xlink:href="gyre-20231231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails" xlink:href="gyre-20231231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails" xlink:href="gyre-20231231.xsd#ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="gyre-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical" xlink:href="gyre-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations" xlink:href="gyre-20231231.xsd#DisclosureOrganizationAndNatureOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidity" xlink:href="gyre-20231231.xsd#Role_DisclosureLiquidity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="gyre-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureF351AssetAcquisition" xlink:href="gyre-20231231.xsd#Role_DisclosureF351AssetAcquisition" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments" xlink:href="gyre-20231231.xsd#DisclosureFairValueMeasurementsAndFinancialInstruments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="gyre-20231231.xsd#DisclosureBalanceSheetComponents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssets" xlink:href="gyre-20231231.xsd#DisclosureIntangibleAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenue" xlink:href="gyre-20231231.xsd#DisclosureRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement" xlink:href="gyre-20231231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuring" xlink:href="gyre-20231231.xsd#Role_DisclosureRestructuring" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureFinancialInstruments" xlink:href="gyre-20231231.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureOtherAccruedLiabilities" xlink:href="gyre-20231231.xsd#Role_DisclosureOtherAccruedLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:href="gyre-20231231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="gyre-20231231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="gyre-20231231.xsd#DisclosureConvertiblePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="gyre-20231231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="gyre-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="gyre-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1" xlink:href="gyre-20231231.xsd#DisclosureRelatedPartyTransactions1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEps" xlink:href="gyre-20231231.xsd#DisclosureEps" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:href="gyre-20231231.xsd#DisclosureEmployeeBenefitPlans1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformation" xlink:href="gyre-20231231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="gyre-20231231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany" xlink:href="gyre-20231231.xsd#DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gyre-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="gyre-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" xlink:href="gyre-20231231.xsd#DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="gyre-20231231.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="gyre-20231231.xsd#DisclosureIntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueTables" xlink:href="gyre-20231231.xsd#DisclosureRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables" xlink:href="gyre-20231231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="gyre-20231231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="gyre-20231231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="gyre-20231231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="gyre-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsTables" xlink:href="gyre-20231231.xsd#DisclosureEpsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="gyre-20231231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail" xlink:href="gyre-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="gyre-20231231.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:href="gyre-20231231.xsd#DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail" xlink:href="gyre-20231231.xsd#DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="gyre-20231231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails" xlink:href="gyre-20231231.xsd#DisclosureIncomeTaxesMovementOfValuationAllowanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail" xlink:href="gyre-20231231.xsd#Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" xlink:href="gyre-20231231.xsd#DisclosureSegmentInformationAdditionalInformationDetail" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SquareMeterAreaForOfficeSpaceUnderNewLease" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_InterestIncomePolicyTextBlock" xlink:label="gyre_InterestIncomePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LeaseExpirationMonthAndYear" xlink:label="gyre_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsLeaseLiabilities" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ProceedsFromGovernmentGrantsReceived" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ReimbursementForOutOfPocketFeesAndExpenses" xlink:label="gyre_ReimbursementForOutOfPocketFeesAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RequiredMinimumTaxableIncome" xlink:label="gyre_RequiredMinimumTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NassimUsmanPhdMember" xlink:label="gyre_NassimUsmanPhdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202108Member" xlink:label="us-gaap_AccountingStandardsUpdate202108Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LeaseLabAndOfficeSpaceMember" xlink:label="gyre_LeaseLabAndOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MinorityHolderContributionsMember" xlink:label="gyre_MinorityHolderContributionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TaxCreditCarryforwardExpirationYear" xlink:label="gyre_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfExcessCashOnDispositionsNet" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NonEmployeeMember" xlink:label="gyre_NonEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncomeTaxTable" xlink:label="gyre_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedExpensesGeneralAndAdministrative" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NDAPassesTheNMPAsReviewAndInspectionMember" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SoftwareMember" xlink:label="gyre_SoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation" xlink:label="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MainlandChinaContributionPlanMember" xlink:label="gyre_MainlandChinaContributionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfRevenueAccountedSalesToDistributors" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MinorityInterestDecreaseFromRedemptionsShares" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LandUseRightsNetAssets" xlink:label="gyre_LandUseRightsNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PostClosingIndemnificationObligation" xlink:label="gyre_PostClosingIndemnificationObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsLineItems" xlink:label="gyre_DeferredGovernmentGrantsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="us-gaap_PaymentsOfDividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LiquidityAbstract" xlink:label="gyre_LiquidityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityNonCurrentMember" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalAdditionsMember" xlink:label="us-gaap_CapitalAdditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StockholdersEquityDisclosureLineItems" xlink:label="gyre_StockholdersEquityDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfAmountReceivedOnAgreement" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommonStockFiledLawsuit" xlink:label="gyre_PercentageOfCommonStockFiledLawsuit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SharesForAggregatePurchasePrice" xlink:label="gyre_SharesForAggregatePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SellingAndMarketingExpensesPolicyTextBlock" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NoncontrollingInterestPolicyPolicyTextBlock" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LongTermCertificatesOfDepositPolicyTextBlock" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsTable" xlink:label="gyre_DeferredGovernmentGrantsTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CostOfServicesAsPerAgreement" xlink:label="gyre_CostOfServicesAsPerAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FirmWorkOrderSupportingClinicalTrials" xlink:label="gyre_FirmWorkOrderSupportingClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncreaseDecreaseInAccountsAndNotesReceivables" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RestructuringLiability" xlink:label="gyre_RestructuringLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SquareMeterAreaForLaboratoryCenterUnderLease" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OperatingLossCarryforwardsWithIndefiniteLife" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsPolicyTextBlock" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LandUseRightsNetNoncurrent" xlink:label="gyre_LandUseRightsNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GMPMember" xlink:label="gyre_GMPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquisitionCostsInDueToRelatedParties" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LegalAndOtherExpensesMember" xlink:label="gyre_LegalAndOtherExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsImpactFromForeignCorporations" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommittedToAllocate" xlink:label="gyre_CommittedToAllocate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedSalesDiscount" xlink:label="gyre_AccruedSalesDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="us-gaap_ExcessStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LiquidityTable" xlink:label="gyre_LiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AllowanceForCreditLossesCertificatesOfDeposit" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LesseeOperatingLeaseRenewalTermDescription" xlink:label="gyre_LesseeOperatingLeaseRenewalTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GCBiopharmaCorpMember" xlink:label="gyre_GCBiopharmaCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance" xlink:label="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserveFund" xlink:label="gyre_StatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NoncashLeaseExpense" xlink:label="gyre_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OrganizationAndNatureOfOperationsTable" xlink:label="gyre_OrganizationAndNatureOfOperationsTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BadDebtExpenseAndOtherNonCashItems" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CvrExcessClosingCashPayable" xlink:label="gyre_CvrExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SeveranceAndOtherCosts" xlink:label="gyre_SeveranceAndOtherCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LandUseRightsPolicyTextBlock" xlink:label="gyre_LandUseRightsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DalcinonacogAlfaMember" xlink:label="gyre_DalcinonacogAlfaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsClosingPayable" xlink:label="gyre_ContingentValueRightsClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ForeignCurrencyRiskPolicyTextBlock" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EmployeeMember" xlink:label="gyre_EmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202110Member" xlink:label="us-gaap_AccountingStandardsUpdate202110Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AppropriationOfStatutoryReserve" xlink:label="gyre_AppropriationOfStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DistributionFromAssetSaleProceeds" xlink:label="gyre_DistributionFromAssetSaleProceeds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AffiliatesBeneficialOwnSharesPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsNonCurrent" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationExcessClosingCashPayable" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember" xlink:label="us-gaap_ServiceAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_VertexPharmaceuticalsIncorporatedMember" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DrenBioIncAndCopiaScientificLLCMember" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserve" xlink:label="us-gaap_LitigationReserve"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AppropriationsToStatutoryReserve" xlink:label="gyre_AppropriationsToStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CollaborationRevenueMember" xlink:label="gyre_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CumulativeAmountOfStatutoryReserveFund" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SubleaseArrangementMember" xlink:label="gyre_SubleaseArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AmortizationOfLandUseRights" xlink:label="gyre_AmortizationOfLandUseRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContinentPharmaceuticalsIncMember" xlink:label="gyre_ContinentPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="us-gaap_AllOtherSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StockholdersEquityDisclosureTable" xlink:label="gyre_StockholdersEquityDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_UpfrontPaymentReceived" xlink:label="gyre_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContributionsClosingPayableAmount" xlink:label="gyre_ContributionsClosingPayableAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfBankAccounts" xlink:label="gyre_NumberOfBankAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PatentsAndTechnologicalKnowHowMember" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfExcessPreapprovedCosts" xlink:label="gyre_PercentageOfExcessPreapprovedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedPayrollAndWelfare" xlink:label="gyre_AccruedPayrollAndWelfare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DivestitureLossesMember" xlink:label="gyre_DivestitureLossesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SinopharmGroupCompanyLimitedMember" xlink:label="gyre_SinopharmGroupCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PrepaidAssetsCurrent" xlink:label="gyre_PrepaidAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetMeasurementInput" xlink:label="us-gaap_DerivativeAssetMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneMember" xlink:label="gyre_FThreeFiveOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DisposalConsiderationInOtherReceivables" xlink:label="gyre_DisposalConsiderationInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredIncomeTaxExpenseBenefitNet" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedExpensesSellingExpenses" xlink:label="gyre_AccruedExpensesSellingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LicenseAgreementTerminationMonthAndYear" xlink:label="gyre_LicenseAgreementTerminationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIUSAMember" xlink:label="gyre_GNIUSAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LegalExpensesIncurred" xlink:label="gyre_LegalExpensesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IntegrityBioMember" xlink:label="gyre_IntegrityBioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_WarrantExpirationMonthAndYear" xlink:label="gyre_WarrantExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChangesOfValuationAllowances" xlink:label="gyre_ChangesOfValuationAllowances"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OperatingLossCarryforwardsExpirationYear" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationFairValueOfPreferredShares" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RisksAndUncertainitiesPolicyTextBlock" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRMergerClosingPayable" xlink:label="gyre_CVRMergerClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChangeInFairValueOfLongTermReceivables" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrants" xlink:label="gyre_DeferredGovernmentGrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommitmentsAndContingenciesDisclosureTable" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserveMember" xlink:label="gyre_StatutoryReserveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsCurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ReverseStockSplitDescription" xlink:label="gyre_ReverseStockSplitDescription"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationAgreementMember" xlink:label="gyre_BusinessCombinationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LeaseCommencementMonthAndYear" xlink:label="gyre_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsAgreement" xlink:label="gyre_ContingentValueRightsAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GovernmentGrantIncomeWithinOtherIncome" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsCapitalizedTransactionCosts" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202104Member" xlink:label="us-gaap_AccountingStandardsUpdate202104Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CashPaidForAcquisitionCosts" xlink:label="gyre_CashPaidForAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedExpensesResearchAndDevelopment" xlink:label="gyre_AccruedExpensesResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LitigationAmount" xlink:label="gyre_LitigationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CpUSSharePurchaseAgreementMember" xlink:label="gyre_CpUSSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FCContributionMember" xlink:label="gyre_FCContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationFairValueOfCommonShares" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfIndividualsApprovedGrantsByBoard" xlink:label="gyre_NumberOfIndividualsApprovedGrantsByBoard"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PaymentOfDisposalOfSubsidiary" xlink:label="gyre_PaymentOfDisposalOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NMPAsApprovalOfTheNDAMember" xlink:label="gyre_NMPAsApprovalOfTheNDAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncomeTaxLineItems" xlink:label="gyre_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ConcentrationOfCustomerRiskPolicyTextBlock" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SubmissionOfTheNewDrugApplicationMember" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" xlink:label="gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxLiabilityRightOfUseAssets" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares" xlink:label="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OrganizationAndNatureOfOperationsLineItems" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PaymentOfTerminationFees" xlink:label="gyre_PaymentOfTerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SupplierReimbursement" xlink:label="gyre_SupplierReimbursement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChangeInFairValueOfDerivativeLiabilities" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MaximumAmountOfTaxOffsetPerYear" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination" xlink:label="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreMergerStockOptionsAssumed" xlink:label="gyre_PreMergerStockOptionsAssumed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PurchaseAgreementAmendmentDate" xlink:label="gyre_PurchaseAgreementAmendmentDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PaymentForResearchAndDevelopmentFees" xlink:label="gyre_PaymentForResearchAndDevelopmentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OtherDirectorOrOfficerMember" xlink:label="gyre_OtherDirectorOrOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationFairValue" xlink:label="gyre_BusinessCombinationFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EquityGainLossOfUnconsolidatedAffiliates" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CostOfCollaborationMember" xlink:label="gyre_CostOfCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LiquidityLineItems" xlink:label="gyre_LiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedInterestOnLongTermCertificatesOfDeposit" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement" xlink:label="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable" xlink:label="gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RemainingNumberOfFullTimeEmployees" xlink:label="gyre_RemainingNumberOfFullTimeEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SquareMeterAreaForOfficeSpaceUnderLease" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AmountToBeReceivedUnderAgreement" xlink:label="gyre_AmountToBeReceivedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SeriesXPreferredStockMember" xlink:label="gyre_SeriesXPreferredStockMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Square Meter Area For Office Space Under New Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Square meter area for office space under new lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable, Amount Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends payable per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Cost And Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Payment to be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lessor, Operating Lease, Payments to be Received, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2014-09</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2014-09 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_InterestIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_InterestIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_InterestIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of minority interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedCashFlowStatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Cash Flow Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government grants received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Government Grants Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from government grants received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Issued, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ReimbursementForOutOfPocketFeesAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement for out-of-pocket fees and expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ReimbursementForOutOfPocketFeesAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement For Out Of Pocket Fees And Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ReimbursementForOutOfPocketFeesAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement for out-of-pocket fees and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Preferred Stock upon Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RequiredMinimumTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum taxable income required to support realizing the company's.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RequiredMinimumTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Required Minimum Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RequiredMinimumTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required Minimum Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements and Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Computer Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software, Intangible Asset [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NassimUsmanPhdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nassim Usman, Ph.D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NassimUsmanPhdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nassim Usman PhD [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NassimUsmanPhdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nassim Usman PhD.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Sales by Product Categories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202108Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2021-08</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202108Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2021-08 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseLabAndOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease lab and office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseLabAndOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Lab And Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseLabAndOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Lab And Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Accrued Expenses And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityHolderContributionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority Holder Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityHolderContributionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minority Holder Contributions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityHolderContributionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minority holder contributions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforward, expire year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Termination of Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on lease termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of excess cash on dispositions net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Excess Cash On Dispositions Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of excess cash on dispositions net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NonEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-employee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NonEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-employee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NonEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-employee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable, Date of Record</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, dividend payable, date of record</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Due from related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Due from Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Due from Related Parties, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses - general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses general and administrative.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends paid per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, cash dividend paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Less: Allocation of undistributed earnings to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NDA Passes the NMPA's Review and Inspection</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">N D A Passes the N M P A's Review and Inspection [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">N D A Passes the N M P A's Review and Inspection.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial liabilities at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Liabilities, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock, and equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Other expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement of legal and other expenses related to the litigation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement of legal and other expenses related to the litigation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Outstanding Options, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Outstanding Options, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive (loss) attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MainlandChinaContributionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mainland China Contribution Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MainlandChinaContributionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mainland China Contribution Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MainlandChinaContributionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mainland China Contribution Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Preferred Stock upon Private Placement (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of revenue accounted sales to distributors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue accounted sales to distributors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of minority interest (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Decrease From Redemptions Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minority interest decrease from redemptions shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement and Securities Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement and Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private placement and securities purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Land use rights, net assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Use Rights, Net Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Land use rights, net assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling and marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total common stock reserved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of employees terminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GNI USA Contributions under the Business Combination Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive (loss) income, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation and Remeasurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liability - Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred Tax Liability - Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PostClosingIndemnificationObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post closing indemnification obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PostClosingIndemnificationObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Closing Indemnification Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PostClosingIndemnificationObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post closing indemnification obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Ordinary Dividends, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount of special dividend payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate amount of special dividend payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shanghai Pharmaceuticals Holding Co., Ltd</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shanghai Pharmaceuticals Holding Company Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shanghai Pharmaceuticals Holding Company Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority holders owned outstanding shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minority Holders Owned Outstanding Shares Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minority holders owned outstanding shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">C V R derivative liability non current member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C V R Derivative Liability Non Current [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Derivative Liability non current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statements, Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents acquired in connection with the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority interest ownership directly and indirectly holds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minority Interest Ownership Directly And Indirectly Holds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minority interest ownership directly and indirectly holds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative liabilities estimated fair value increase decrease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities Estimated Fair Value Increase Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less current portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one ATM program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One A T M Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 ATM Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalAdditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalAdditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Addition Purchase Commitments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidation Basis of Accounting [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total restructuring charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of amount received on agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Amount Received On Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of amount received on agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increase (decrease) resulting from tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(Decrease) of unrecognized tax benefits taken in prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable, Date Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends Payable, date declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax computed at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax computed at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR merger payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement transfer between Level 1 and Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets and Liabilities Level1 To Level2 Transfers Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets and liabilities level1 to level2 transfers amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCommonStockFiledLawsuit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock filed a lawsuit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCommonStockFiledLawsuit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Stock Filed Lawsuit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCommonStockFiledLawsuit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock filed a lawsuit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SharesForAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares for aggregate purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SharesForAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares for Aggregate Purchase Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SharesForAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares for aggregate purchase price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligation to pay in exchange for the intellectual property rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligation to pay in exchange for the intellectual property rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial assets at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling and Marketing Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expenses [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Selling and marketing expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign - PRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority interest ownership indirectly holds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minority Interest Ownership Indirectly Holds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minority interest ownership indirectly holds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncontrolling interest, policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets fixed assets and intangibles.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Fixed Assets And Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed and intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before equity in (loss) income of subsidinaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Certificates of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Certificates of Deposit [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term certificates of deposit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts and note receivables, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts and note receivables, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction In Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax-related penalties or interest recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Issuance Of Options To Former Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options issuance of options to former stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CostOfServicesAsPerAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of services as per agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CostOfServicesAsPerAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Services As Per Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CostOfServicesAsPerAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of services as per agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Value Rights Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Value Rights Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FirmWorkOrderSupportingClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Firm work order supporting clinical trials.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FirmWorkOrderSupportingClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Firm Work Order Supporting Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FirmWorkOrderSupportingClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Firm work order supporting clinical trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts and note receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts And Notes Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accounts and notes receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China Resources Pharmaceutical Group Ltd</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">China Resources Pharmaceutical Group Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">China Resources Pharmaceutical Group Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Advance payment received from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Advance Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed advance payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized employee stock based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in number of shares of common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of Convertible Preferred Stock and Preferred Stock Warrants under the Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeeds from issuance of aggregate gross sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RestructuringLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RestructuringLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RestructuringLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Accumulated deficit) retained earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">(Accumulated deficit) retained earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of stock options included in other receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options included in other receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Stock Options Included In Other Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Square meter area for laboratory center under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Square Meter Area For Laboratory Center Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Square meter area for laboratory center under lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series X Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property And Equipment, Included In Accrued Expenses And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment, Included In Accrued Expenses And Other Current Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment, included in accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Divestiture losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Net gain on disposal of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards with indefinite life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards With Indefinite Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards having indefinite life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Supplemental Disclosure of stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of stock-based compensation expense included in General and administrative expenses above:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Land use rights, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Use Rights Net Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Land use rights net noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total Gyre Stockholders' Equity (Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance costs and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, before Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of restricted net assets of consolidated subsidiaries of consolidated net assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Restricted Net Assets Exceed Net Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of restricted net assets exceed net assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GMPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GMP manufacturing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GMPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G M P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GMPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dalcinonacog alfa.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions for employee benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net (loss) income to net cash used for operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">CVR derivative liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR derivative liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, CVR Derivative Liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed, CVR derivative liability, noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance payment for convertible preferred stock and preferred stock warrants acquired upon contributions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payment for Convertible Preferred Stock and Preferred Stock Warrants acquired upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payment For Convertible Preferred Stock And Preferred Stock Warrants Acquired Upon Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Divestiture losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Loss on divestiture of subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Divestiture losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on divestiture of subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income attributable to common stockholders - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amounts of restricted capital and statutory reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Amounts Of Restricted Capital And Statutory Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate amounts of restricted capital and statutory reserves.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign - PRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen omnibus incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Omnibus Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Omnibus Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock available for future grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit carry forwards derecognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Carry Forwards Derecognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross federal R&amp;D credit-related deferred tax assets derecognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MotorVehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Motor Vehicles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MotorVehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Motor Vehicles [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MotorVehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Motor vehicles.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred stock (as converted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 400,000,000 shares authorized; 76,595,616 shares and 63,588,119 shares issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Excess amount retained from net proceeds related to disposition of assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excess Amount Retained From Net Proceeds Related To Disposition Of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excess amount retained from net proceeds related to disposition of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value of Option Awards Based on Black-scholes Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition costs in due to related parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition costs in due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Costs In Due To Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits in licensed banks protected by DIS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits In Licensed Banks Protected By Deposit Insurance System</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deposits in licensed banks protected by deposit insurance system.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Charges related to write off of prepaid manufacturing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Charges Related To Write Off Of Prepaid Manufacturing Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charges related to write off of prepaid manufacturing cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Option, Issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Issuance Of Options To Former Stockholders In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options issuance of options to former stockholders in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LegalAndOtherExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal and other expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LegalAndOtherExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal And Other Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LegalAndOtherExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal and Other Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact from foreign corporations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Impact From Foreign Corporations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets impact from foreign corporations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommittedToAllocate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Committed to allocate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommittedToAllocate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Committed To Allocate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommittedToAllocate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Committed to allocate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedSalesDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued sales discount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedSalesDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued sales discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedSalesDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Sales Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Authorized shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excess Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets acquisition, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR merger payable, amount distributed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Contingent Consideration Liability, Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Concentration risk percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of customer risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Statements, Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Segment Reporting Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allowance for Credit Losses Certificates of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Allowance for credit losses certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease renewal term description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease renewal term description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Warrants (as converted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License of Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term receivable from GCBP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Share ("EPS") Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiopharmaCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GC Biopharma Corp.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiopharmaCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G C Biopharma Corp [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiopharmaCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GC Biopharma Corp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(Decrease) of unrecognized tax benefits related to current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ParentCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Parent Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ParentCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, post-merger of capital shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Post-merger Of Capital Shares Reserved For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, post-merger of capital shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income (loss) attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses excluding cost of revenues:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory reserve fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statutory Reserve Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statutory reserve fund.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee reimbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Information Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statutory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statutory reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Related party receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Nature of Operations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Operations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Nature Of Operations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issuable upon exercise and conversion of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Stock Shares Issuable Upon Exercise and Conversion Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock shares issuable upon exercise and conversion of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders (deficit) equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements - Issued But Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bad debt expense and other non-cash items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bad Debt Expense And Other Non-cash Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bad debt expense and other non-cash items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturity of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Allowance for Credit Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts and financing receivable, allowance for credit loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated acquisition-date fair value of Catalyst</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CvrExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR excess closing cash payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CvrExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CVR Excess Closing Cash Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CvrExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR excess closing cash payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income per share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeveranceAndOtherCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance and other costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeveranceAndOtherCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance And Other Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeveranceAndOtherCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance and other charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Land Use Rights, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Use Rights [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LandUseRightsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Land use rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Note 13)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Statements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DalcinonacogAlfaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dalcinonacog alfa.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DalcinonacogAlfaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dalcinonacog Alfa [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DalcinonacogAlfaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dalcinonacog Alfa</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsClosingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights closing payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsClosingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Closing Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsClosingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights closing payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR derivative liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C V R Derivative Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Risk [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Issuance Of Common Stock And Convertible Preferred Stock To Former Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed issuance of common stock and convertible preferred stock to former stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired In Process Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee [Member][</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202110Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2021-10</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202110Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2021-10 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Outstanding Shares Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationOfStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Appropriation of statutory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationOfStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Appropriation of statutory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash paid for operating leases that were included in operating cash outflows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income per share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionFromAssetSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Distribution from asset sale proceeds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionFromAssetSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Distribution From Asset Sale Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DistributionFromAssetSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distribution to CVR holders from asset sale proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CPIContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CPI Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CPIContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C P I Contribution [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CPIContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CPI contribution.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cost of revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed, accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase as a result of the GNI USA Contributions on October 30, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Affiliates beneficial own shares percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliates Beneficial Own Shares Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliates beneficial own shares percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants Non current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">CVR excess closing cash payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Excess Closing Cash Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination excess closing cash payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance, end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Balance, beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Allowance for credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts and financing receivable, allowance for credit loss, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivable, Allowance for Credit Loss, Foreign Currency Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts and financing receivable, allowance for credit loss, foreign currency translation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants Current And Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants current and noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Exercisable- December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group, Including Discontinued Operation, Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration for sales agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex pharmaceuticals incorporated.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Pharmaceuticals Incorporated [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Pharmaceuticals Incorporated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BC 2021 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B C Two Thousand Twenty One Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">B C two thousand twenty one stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dren Bio, Inc. and Copia Scientific, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dren Bio Inc And Copia Scientific L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dren Bio, Inc. and Copia Scientific, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation settlement liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Litigation Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCommissionForSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of Commission for shares sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCommissionForSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission For Shares Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfCommissionForSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission for shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Equity, Attributable to Noncontrolling Interest, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Equity, Attributable to Noncontrolling Interest, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity, Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Restructuring and Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restructuring And Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Movement of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Valuation Allowance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationsToStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Appropriations to statutory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationsToStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Appropriations To Statutory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AppropriationsToStatutoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Appropriations to statutory reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, convertible preferred stock, and equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative amount of statutory reserve fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Amount Of Statutory Reserve Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative amount of statutory reserve fund.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Option Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon acquisition of F351 Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling and marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling and Marketing Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Product and Service Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubleaseArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubleaseArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubleaseArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmortizationOfLandUseRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of land use rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmortizationOfLandUseRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Land Use Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmortizationOfLandUseRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of&#160;land use rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContinentPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CPI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContinentPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Continent Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContinentPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Continent pharmaceuticals inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability for Uncertainty in Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Option, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Deemed Issuance Of Options To Former Stockholders In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options deemed issuance of options to former stockholders in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StockholdersEquityDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Exercisable - December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Valuation Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recoveries collected and write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CatalystMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Catalyst</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CatalystMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Catalyst [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CatalystMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Catalyst.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expenses [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GC Biophrarma Corp asset purchase agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G C Biophrarma Corp Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GCBP Asset Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContributionsClosingPayableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions closing payable amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContributionsClosingPayableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contributions Closing Payable Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContributionsClosingPayableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contributions closing payable amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets acquisition, paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfBankAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of bank accounts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfBankAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Bank Accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfBankAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of bank accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PatentsAndTechnologicalKnowHowMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents and Technological Know How [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents and Technological Know-how</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized employee stock based compensation expense, period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessPreapprovedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of excess preapproved costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessPreapprovedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Excess Preapproved Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfExcessPreapprovedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of excess preapproved costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedPayrollAndWelfare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and welfare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedPayrollAndWelfare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll And Welfare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedPayrollAndWelfare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued payroll and welfare.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESOP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Deduction, Employee Stock Ownership Plan Dividend, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DivestitureLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Divestiture Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DivestitureLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Divestiture Losses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DivestitureLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Divestiture losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Service [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment, Expenditure, Addition to Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SinopharmGroupCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sinopharm Group Co., Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SinopharmGroupCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sinopharm Group Company Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SinopharmGroupCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sinopharm Group Company Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrepaidAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrepaidAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Assets Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PrepaidAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid assets current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net (decrease) increase in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MachineryAndElectronicDevicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and Electronic Devices</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MachineryAndElectronicDevicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Electronic Devices [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MachineryAndElectronicDevicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Machinery and electronic devices.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Restricted Certificates of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeAssetMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative asset measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeAssetMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Asset, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-Cash Financing and Investing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">F three five one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">F Three Five One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">F351</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive Security not Included in Diluted per Share Calculations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventories, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Inventory, Current [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DisposalConsiderationInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal consideration in other receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DisposalConsiderationInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal consideration in other receivables from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DisposalConsiderationInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Consideration In Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for allowance for credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Notes Receivable, Provision for Allowance for Credit Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts and notes receivable, provision for allowance for credit losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred income tax expense benefit net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions in the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesSellingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses - selling expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesSellingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses, Selling Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesSellingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses, selling expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LicenseAgreementTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement termination month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LicenseAgreementTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Termination Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LicenseAgreementTerminationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement termination month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIUSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GNI USA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIUSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G N I U S A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIUSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GNI USA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of equity method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LegalExpensesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal expenses incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LegalExpensesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Expenses Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LegalExpensesIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal expenses incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commenced description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual terms of award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award, Contractual Terms of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, contractual terms of award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undiscounted future payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IntegrityBioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Integrity bio .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IntegrityBioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Integrity Bio [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IntegrityBioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Catalent Indiana, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity loss (income) of subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity in (loss) income of subsidinaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equity loss (income) of subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock, policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_WarrantExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_WarrantExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_WarrantExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional and consulting services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period value acquisitions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Value Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangesOfValuationAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes of valuation allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangesOfValuationAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes of Valuation Allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangesOfValuationAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes of valuation allowances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of preferred shares to be owned by Catalyst's stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Fair Value of Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination fair value of preferred shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Asset, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainities [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks And Uncertainities [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant Liability Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRMergerClosingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR merger closing payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRMergerClosingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C V R Merger Closing Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRMergerClosingPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR merger closing payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Components of the Company's Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Receivables Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed, other receivables current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock, Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-Free Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable - December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfIndirectOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indirect ownership interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfIndirectOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Indirect Ownership Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PercentageOfIndirectOwnershipInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of indirect ownership interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Due to Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Due to Related Parties, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Buildings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Building [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CVR derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR derivative liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C V R Derivative Liability Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR derivative liability noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">F351 asset purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">F Three Five One Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">F351 Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beijing Continent Pharmaceuticals Co., Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beijing continent pharmaceuticals Co., Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of long-term receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of long-term receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Long Term Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Assistance [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statutory Reserve [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_StatutoryReserveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Statutory Reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Productive Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Productive Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current deferred government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Government Grants Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredGovernmentGrantsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred government grants current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts and Note Receivables, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets state net operating loss carry forwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets State Net Operating Loss Carry Forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward, derecognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Pronouncements Recently Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ReverseStockSplitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ReverseStockSplitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ReverseStockSplitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed in-process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use asset obtained in exchange for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset and lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from option exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued upon conversion of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards available to offset future federal tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Ownership Percentage, Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferential income tax rate for HNTE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Preferential Income Tax Rate For HNTE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation preferential income tax rate for HNTE.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposit Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deposit Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technological know-how</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Technology-Based Intangible Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Future Amortization Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category of Item Purchased [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, All Other Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government grant income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Grant Income Within Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grant income within other income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized transaction costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202104Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2021-04 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202104Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2021-04</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of outstanding preferred stock redeemed for cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Outstanding Preferred Stock Redeemed For Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of outstanding preferred stock redeemed for cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment Estimated Useful Life [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of property plant and equipment estimated useful life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred income tax assets before valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">F351 Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CashPaidForAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments made for acquisition costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CashPaidForAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Acquisition Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CashPaidForAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for acquisition costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses - research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses, Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedExpensesResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses, research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance at the end of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LitigationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation amount .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LitigationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LitigationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses excluding cost of revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected option life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CpUSSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CP U.S. Share Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CpUSSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CP U.S. Share Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CpUSSharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CP U.S. SHARE PURCHASE AGREEMENT [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EPS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FCContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FC Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FCContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">F C Contribution [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FCContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FC contribution.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common shares to be owned by Catalyst's stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Fair Value of Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination fair value of common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Certificates Of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long Term Certificates Of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Share Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfIndividualsApprovedGrantsByBoard_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of individuals approved grants by board</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfIndividualsApprovedGrantsByBoard_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Individuals Approved Grants by Board</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfIndividualsApprovedGrantsByBoard_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of individuals approved grants by board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfDisposalOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash balance in a disposed subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfDisposalOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Disposal of Subsidiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfDisposalOfSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of disposal of subsidiary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NMPAsApprovalOfTheNDAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NMPA's Approval of the NDA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NMPAsApprovalOfTheNDAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">N M P A's Approval of the N D A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NMPAsApprovalOfTheNDAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">N M P A's Approval of the N D A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of issuance of common stock for public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights derivative liability non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Derivative Liability Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR derivative liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term CVR derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex Asset Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_VertexAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Asset Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Customer Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration of Customer Risk [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of customer risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions in the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Submission of the New Drug Application</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Submission of the New Drug Application [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Submission of the New Drug Application.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock and convertible preferred stock to former stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock And Convertible Preferred Stock To Former Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of complement portfolio to Vertex</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments related to purchase of property and equipment contracted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of Pharmaceutical Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ETUARY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average share price of the Company (USD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated gross unrealized gain before tax available for sale securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Gross Unrealized Gain Before Tax Available For Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; 13,151 shares and nil shares issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other receivables from GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Gross Carrying Amounts and Accumulated Amortization of intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Deemed Issuance Of Options To Former Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options deemed issuance of options to former stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GyreMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gyre</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GyreMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gyre [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GyreMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gyre.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible Expense - Operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liability - ROU assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Liability - ROU Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liability Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liability right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of option grants to purchase common stock shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Option Grants To Purchase Common Stock Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of option grants to purchase common stock shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and nature of operations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Operations [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Operations [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term receivable from GCBP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Long-term Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, recognized identifiable assets acquired and liabilities assumed long-term receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends declared, unpaid, per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, cash dividend declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiplied by the fair value per share of Catalyst stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfTerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of termination fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfTerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Termination Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentOfTerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Or Rights Warrants Issued During Period Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants or rights warrants issued during period shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Omnibus Incentive Plan [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three omnibus incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable - December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Catalyst common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SupplierReimbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplier reimbursement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SupplierReimbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplier reimbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SupplierReimbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplier Reimbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts and Note Receivable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of derivative liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of tax offset per year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Of Tax Offset Per Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of tax offset per year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issuable upon conversion of the outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Of Common Stock Issuable Upon Conversion Of The Outstanding Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of common stock issuable upon conversion of the outstanding shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination and Asset Acquisition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-06 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2020-06</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of consideration issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issued in Business Combination, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income attributable to common stockholders - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net cash flows (used in) provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trial services cost incurred on agreement termination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Services Cost Incurred On Agreement Termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trial services cost incurred on agreement termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement transfer Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets and Liabilities Level3 Transfers Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets and liabilities level3 transfers amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreMergerStockOptionsAssumed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-GNI USA Contributions Catalyst stock options assumed by CPI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreMergerStockOptionsAssumed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Merger Stock Options Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PreMergerStockOptionsAssumed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre merger stock options assumed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign currency translation loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency translation adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Government Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Government Grants Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of deferred government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PurchaseAgreementAmendmentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement amendment date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PurchaseAgreementAmendmentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Amendment Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PurchaseAgreementAmendmentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase agreement amendment date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined square meter area for manufacturing facilities under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Square Meter Area For Manufacturing Facilities Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined square meter area for manufacturing facilities under lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentForResearchAndDevelopmentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Research and Development Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PaymentForResearchAndDevelopmentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for research and development fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OtherDirectorOrOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Director or Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OtherDirectorOrOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Director or Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_OtherDirectorOrOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other director or officer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rate difference due to different jurisdiction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible assets, Weighted average amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of Catalyst</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_BusinessCombinationFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of finite lived intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equity loss of unconsolidated affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Gain Loss of Unconsolidated Affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity gain loss of unconsolidated affiliates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Gyre stockholders' (deficit) equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ETUARY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Statements Schedule I Financial Information of Parent Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CostOfCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of collaboration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CostOfCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Collaboration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_CostOfCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">R&amp;D Super-deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D Super-deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GNI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G N I [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_GNIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">G N I</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total average shares used in net (loss) income per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_LiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible expense - One-time expense related to the Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense One-time Expense Related to the Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible expense one-time expense related to the contributions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Present Value Assumptions used in Calculating Present Value of Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of present value assumptions of lease payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued interest on long-term certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest On Long-term Certificates Of Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest on long-term certificates of deposit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination fee required to pay upon termination of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Fee Required To Pay Upon Termination Of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination fee required to pay upon termination of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period shares acquisitions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Shares Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets with finite lives:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of property and equipment included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Property And Equipment Included In Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of property and equipment included in accounts payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted EPS Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Leasehold Improvement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RemainingNumberOfFullTimeEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining number of full time employees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RemainingNumberOfFullTimeEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Number Of Full Time Employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_RemainingNumberOfFullTimeEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining number of full time employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current income tax provision:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Purchase Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Square meter area for office space under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Square Meter Area For Office Space Under Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Square meter area for office space under lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Affiliates beneficial own shares specified percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliates Beneficial Own Shares Specified Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliates beneficial own shares specified percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmountToBeReceivedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount to be received under agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmountToBeReceivedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount To Be Received Under Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_AmountToBeReceivedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount to be received under agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeriesXPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series X Preferred Stock (as converted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeriesXPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series X Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeriesXPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series X Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gyre_SeriesXPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series X Preferred Stock.</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease" xlink:to="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_InterestIncomePolicyTextBlock" xlink:to="gyre_InterestIncomePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LeaseExpirationMonthAndYear" xlink:to="gyre_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="us-gaap_MinorityInterestDecreaseFromRedemptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsLeaseLiabilities" xlink:to="gyre_DeferredTaxAssetsLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ProceedsFromGovernmentGrantsReceived" xlink:to="gyre_ProceedsFromGovernmentGrantsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ReimbursementForOutOfPocketFeesAndExpenses" xlink:to="gyre_ReimbursementForOutOfPocketFeesAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_RequiredMinimumTaxableIncome" xlink:to="gyre_RequiredMinimumTaxableIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NassimUsmanPhdMember" xlink:to="gyre_NassimUsmanPhdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202108Member" xlink:to="us-gaap_AccountingStandardsUpdate202108Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LeaseLabAndOfficeSpaceMember" xlink:to="gyre_LeaseLabAndOfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MinorityHolderContributionsMember" xlink:to="gyre_MinorityHolderContributionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TaxCreditCarryforwardExpirationYear" xlink:to="gyre_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfExcessCashOnDispositionsNet" xlink:to="gyre_PercentageOfExcessCashOnDispositionsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NonEmployeeMember" xlink:to="gyre_NonEmployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IncomeTaxTable" xlink:to="gyre_IncomeTaxTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedExpensesGeneralAndAdministrative" xlink:to="gyre_AccruedExpensesGeneralAndAdministrative_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NDAPassesTheNMPAsReviewAndInspectionMember" xlink:to="gyre_NDAPassesTheNMPAsReviewAndInspectionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SoftwareMember" xlink:to="gyre_SoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation" xlink:to="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MainlandChinaContributionPlanMember" xlink:to="gyre_MainlandChinaContributionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfRevenueAccountedSalesToDistributors" xlink:to="gyre_PercentageOfRevenueAccountedSalesToDistributors_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MinorityInterestDecreaseFromRedemptionsShares" xlink:to="gyre_MinorityInterestDecreaseFromRedemptionsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:to="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LandUseRightsNetAssets" xlink:to="gyre_LandUseRightsNetAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PostClosingIndemnificationObligation" xlink:to="gyre_PostClosingIndemnificationObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OptionsToPurchaseCommonStockMember" xlink:to="gyre_OptionsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsCommonStock" xlink:to="us-gaap_PaymentsOfDividendsCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LiquidityAbstract" xlink:to="gyre_LiquidityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" xlink:to="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" xlink:to="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CVRDerivativeLiabilityNonCurrentMember" xlink:to="gyre_CVRDerivativeLiabilityNonCurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" xlink:to="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" xlink:to="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TwoThousandTwentyOneATMProgramMember" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalAdditionsMember" xlink:to="us-gaap_CapitalAdditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_StockholdersEquityDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfAmountReceivedOnAgreement" xlink:to="gyre_PercentageOfAmountReceivedOnAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:to="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfCommonStockFiledLawsuit" xlink:to="gyre_PercentageOfCommonStockFiledLawsuit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SharesForAggregatePurchasePrice" xlink:to="gyre_SharesForAggregatePurchasePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" xlink:to="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SellingAndMarketingExpensesPolicyTextBlock" xlink:to="gyre_SellingAndMarketingExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" xlink:to="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NoncontrollingInterestPolicyPolicyTextBlock" xlink:to="gyre_NoncontrollingInterestPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:to="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="us-gaap_DeferredTaxAssetsEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LongTermCertificatesOfDepositPolicyTextBlock" xlink:to="gyre_LongTermCertificatesOfDepositPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsTable" xlink:to="gyre_DeferredGovernmentGrantsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceReceivablesMember" xlink:to="us-gaap_FinanceReceivablesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CostOfServicesAsPerAgreement" xlink:to="gyre_CostOfServicesAsPerAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContingentValueRightsAgreementMember" xlink:to="gyre_ContingentValueRightsAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FirmWorkOrderSupportingClinicalTrials" xlink:to="gyre_FirmWorkOrderSupportingClinicalTrials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IncreaseDecreaseInAccountsAndNotesReceivables" xlink:to="gyre_IncreaseDecreaseInAccountsAndNotesReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" xlink:to="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_RestructuringLiability" xlink:to="gyre_RestructuringLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" xlink:to="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SquareMeterAreaForLaboratoryCenterUnderLease" xlink:to="gyre_SquareMeterAreaForLaboratoryCenterUnderLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:to="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OperatingLossCarryforwardsWithIndefiniteLife" xlink:to="gyre_OperatingLossCarryforwardsWithIndefiniteLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PreferredStockWarrantsPolicyTextBlock" xlink:to="gyre_PreferredStockWarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:to="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LandUseRightsNetNoncurrent" xlink:to="gyre_LandUseRightsNetNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" xlink:to="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GMPMember" xlink:to="gyre_GMPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" xlink:to="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" xlink:to="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:to="gyre_TwoThousandEighteenOmnibusIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:to="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MotorVehiclesMember" xlink:to="gyre_MotorVehiclesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" xlink:to="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AcquisitionCostsInDueToRelatedParties" xlink:to="gyre_AcquisitionCostsInDueToRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" xlink:to="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:to="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:to="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LegalAndOtherExpensesMember" xlink:to="gyre_LegalAndOtherExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsImpactFromForeignCorporations" xlink:to="gyre_DeferredTaxAssetsImpactFromForeignCorporations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CommittedToAllocate" xlink:to="gyre_CommittedToAllocate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedSalesDiscount" xlink:to="gyre_AccruedSalesDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LiquidityTable" xlink:to="gyre_LiquidityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AllowanceForCreditLossesCertificatesOfDeposit" xlink:to="gyre_AllowanceForCreditLossesCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LesseeOperatingLeaseRenewalTermDescription" xlink:to="gyre_LesseeOperatingLeaseRenewalTermDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PreferredStockWarrantsMember" xlink:to="gyre_PreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:to="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GCBiopharmaCorpMember" xlink:to="gyre_GCBiopharmaCorpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance" xlink:to="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StatutoryReserveFund" xlink:to="gyre_StatutoryReserveFund_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NoncashLeaseExpense" xlink:to="gyre_NoncashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StatutoryReserve" xlink:to="gyre_StatutoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="gyre_OrganizationAndNatureOfOperationsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" xlink:to="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:to="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BadDebtExpenseAndOtherNonCashItems" xlink:to="gyre_BadDebtExpenseAndOtherNonCashItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CvrExcessClosingCashPayable" xlink:to="gyre_CvrExcessClosingCashPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SeveranceAndOtherCosts" xlink:to="gyre_SeveranceAndOtherCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LandUseRightsPolicyTextBlock" xlink:to="gyre_LandUseRightsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DalcinonacogAlfaMember" xlink:to="gyre_DalcinonacogAlfaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContingentValueRightsClosingPayable" xlink:to="gyre_ContingentValueRightsClosingPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CVRDerivativeLiabilityMember" xlink:to="gyre_CVRDerivativeLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ForeignCurrencyRiskPolicyTextBlock" xlink:to="gyre_ForeignCurrencyRiskPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" xlink:to="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AcquiredInProcessResearchAndDevelopment" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_EmployeeMember" xlink:to="gyre_EmployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202110Member" xlink:to="us-gaap_AccountingStandardsUpdate202110Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AppropriationOfStatutoryReserve" xlink:to="gyre_AppropriationOfStatutoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DistributionFromAssetSaleProceeds" xlink:to="gyre_DistributionFromAssetSaleProceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CPIContributionMember" xlink:to="gyre_CPIContributionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AffiliatesBeneficialOwnSharesPercentage" xlink:to="gyre_AffiliatesBeneficialOwnSharesPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsNonCurrent" xlink:to="gyre_DeferredGovernmentGrantsNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationExcessClosingCashPayable" xlink:to="gyre_BusinessCombinationExcessClosingCashPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:to="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceAgreementsMember" xlink:to="us-gaap_ServiceAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_VertexPharmaceuticalsIncorporatedMember" xlink:to="gyre_VertexPharmaceuticalsIncorporatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" xlink:to="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DrenBioIncAndCopiaScientificLLCMember" xlink:to="gyre_DrenBioIncAndCopiaScientificLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserve" xlink:to="us-gaap_LitigationReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfCommissionForSharesSold" xlink:to="gyre_PercentageOfCommissionForSharesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AppropriationsToStatutoryReserve" xlink:to="gyre_AppropriationsToStatutoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CollaborationRevenueMember" xlink:to="gyre_CollaborationRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CumulativeAmountOfStatutoryReserveFund" xlink:to="gyre_CumulativeAmountOfStatutoryReserveFund_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SubleaseArrangementMember" xlink:to="gyre_SubleaseArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AmortizationOfLandUseRights" xlink:to="gyre_AmortizationOfLandUseRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContinentPharmaceuticalsIncMember" xlink:to="gyre_ContinentPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:to="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="gyre_StockholdersEquityDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_UpfrontPaymentReceived" xlink:to="gyre_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CatalystMember" xlink:to="gyre_CatalystMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" xlink:to="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContributionsClosingPayableAmount" xlink:to="gyre_ContributionsClosingPayableAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NumberOfBankAccounts" xlink:to="gyre_NumberOfBankAccounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PatentsAndTechnologicalKnowHowMember" xlink:to="gyre_PatentsAndTechnologicalKnowHowMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfExcessPreapprovedCosts" xlink:to="gyre_PercentageOfExcessPreapprovedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedPayrollAndWelfare" xlink:to="gyre_AccruedPayrollAndWelfare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DivestitureLossesMember" xlink:to="gyre_DivestitureLossesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SinopharmGroupCompanyLimitedMember" xlink:to="gyre_SinopharmGroupCompanyLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PrepaidAssetsCurrent" xlink:to="gyre_PrepaidAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MachineryAndElectronicDevicesMember" xlink:to="gyre_MachineryAndElectronicDevicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetMeasurementInput" xlink:to="us-gaap_DerivativeAssetMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FThreeFiveOneMember" xlink:to="gyre_FThreeFiveOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DisposalConsiderationInOtherReceivables" xlink:to="gyre_DisposalConsiderationInOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" xlink:to="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredIncomeTaxExpenseBenefitNet" xlink:to="gyre_DeferredIncomeTaxExpenseBenefitNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedExpensesSellingExpenses" xlink:to="gyre_AccruedExpensesSellingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LicenseAgreementTerminationMonthAndYear" xlink:to="gyre_LicenseAgreementTerminationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GNIUSAMember" xlink:to="gyre_GNIUSAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LegalExpensesIncurred" xlink:to="gyre_LegalExpensesIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IntegrityBioMember" xlink:to="gyre_IntegrityBioMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_WarrantExpirationMonthAndYear" xlink:to="gyre_WarrantExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChangesOfValuationAllowances" xlink:to="gyre_ChangesOfValuationAllowances_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OperatingLossCarryforwardsExpirationYear" xlink:to="gyre_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationFairValueOfPreferredShares" xlink:to="gyre_BusinessCombinationFairValueOfPreferredShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_RisksAndUncertainitiesPolicyTextBlock" xlink:to="gyre_RisksAndUncertainitiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CVRMergerClosingPayable" xlink:to="gyre_CVRMergerClosingPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PercentageOfIndirectOwnershipInterest" xlink:to="gyre_PercentageOfIndirectOwnershipInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CVRDerivativeLiabilityNoncurrent" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChangeInFairValueOfLongTermReceivables" xlink:to="gyre_ChangeInFairValueOfLongTermReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrants" xlink:to="gyre_DeferredGovernmentGrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="gyre_CommitmentsAndContingenciesDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_StatutoryReserveMember" xlink:to="gyre_StatutoryReserveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:to="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredGovernmentGrantsCurrent" xlink:to="gyre_DeferredGovernmentGrantsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:to="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ReverseStockSplitDescription" xlink:to="gyre_ReverseStockSplitDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationAgreementMember" xlink:to="gyre_BusinessCombinationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LeaseCommencementMonthAndYear" xlink:to="gyre_LeaseCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContingentValueRightsAgreement" xlink:to="gyre_ContingentValueRightsAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GovernmentGrantIncomeWithinOtherIncome" xlink:to="gyre_GovernmentGrantIncomeWithinOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxAssetsCapitalizedTransactionCosts" xlink:to="gyre_DeferredTaxAssetsCapitalizedTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202104Member" xlink:to="us-gaap_AccountingStandardsUpdate202104Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" xlink:to="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CashPaidForAcquisitionCosts" xlink:to="gyre_CashPaidForAcquisitionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedExpensesResearchAndDevelopment" xlink:to="gyre_AccruedExpensesResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LitigationAmount" xlink:to="gyre_LitigationAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CpUSSharePurchaseAgreementMember" xlink:to="gyre_CpUSSharePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FCContributionMember" xlink:to="gyre_FCContributionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationFairValueOfCommonShares" xlink:to="gyre_BusinessCombinationFairValueOfCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LongTermCertificatesOfDeposit" xlink:to="gyre_LongTermCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NumberOfIndividualsApprovedGrantsByBoard" xlink:to="gyre_NumberOfIndividualsApprovedGrantsByBoard_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PaymentOfDisposalOfSubsidiary" xlink:to="gyre_PaymentOfDisposalOfSubsidiary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NMPAsApprovalOfTheNDAMember" xlink:to="gyre_NMPAsApprovalOfTheNDAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" xlink:to="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_IncomeTaxLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_VertexAssetPurchaseAgreementMember" xlink:to="gyre_VertexAssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ConcentrationOfCustomerRiskPolicyTextBlock" xlink:to="gyre_ConcentrationOfCustomerRiskPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SubmissionOfTheNewDrugApplicationMember" xlink:to="gyre_SubmissionOfTheNewDrugApplicationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" xlink:to="gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:to="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GyreMember" xlink:to="gyre_GyreMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_DeferredTaxLiabilityRightOfUseAssets" xlink:to="gyre_DeferredTaxLiabilityRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares" xlink:to="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeMember" xlink:to="us-gaap_OtherIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_OrganizationAndNatureOfOperationsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PaymentOfTerminationFees" xlink:to="gyre_PaymentOfTerminationFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:to="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:to="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SupplierReimbursement" xlink:to="gyre_SupplierReimbursement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ChangeInFairValueOfDerivativeLiabilities" xlink:to="gyre_ChangeInFairValueOfDerivativeLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_MaximumAmountOfTaxOffsetPerYear" xlink:to="gyre_MaximumAmountOfTaxOffsetPerYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:to="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination" xlink:to="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PreMergerStockOptionsAssumed" xlink:to="gyre_PreMergerStockOptionsAssumed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" xlink:to="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PurchaseAgreementAmendmentDate" xlink:to="gyre_PurchaseAgreementAmendmentDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" xlink:to="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PaymentForResearchAndDevelopmentFees" xlink:to="gyre_PaymentForResearchAndDevelopmentFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_OtherDirectorOrOfficerMember" xlink:to="gyre_OtherDirectorOrOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_BusinessCombinationFairValue" xlink:to="gyre_BusinessCombinationFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_EquityGainLossOfUnconsolidatedAffiliates" xlink:to="gyre_EquityGainLossOfUnconsolidatedAffiliates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_CostOfCollaborationMember" xlink:to="gyre_CostOfCollaborationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_GNIMember" xlink:to="gyre_GNIMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_LiquidityLineItems" xlink:to="gyre_LiquidityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:to="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AccruedInterestOnLongTermCertificatesOfDeposit" xlink:to="gyre_AccruedInterestOnLongTermCertificatesOfDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement" xlink:to="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable" xlink:to="gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_RemainingNumberOfFullTimeEmployees" xlink:to="gyre_RemainingNumberOfFullTimeEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SquareMeterAreaForOfficeSpaceUnderLease" xlink:to="gyre_SquareMeterAreaForOfficeSpaceUnderLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" xlink:to="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_AmountToBeReceivedUnderAgreement" xlink:to="gyre_AmountToBeReceivedUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gyre_SeriesXPreferredStockMember" xlink:to="gyre_SeriesXPreferredStockMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GCBiopharmaCorpMember" xlink:label="gyre_GCBiopharmaCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRMergerClosingPayable" xlink:label="gyre_CVRMergerClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CvrExcessClosingCashPayable" xlink:label="gyre_CvrExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PrepaidAssetsCurrent" xlink:label="gyre_PrepaidAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LandUseRightsNetNoncurrent" xlink:label="gyre_LandUseRightsNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_GCBiopharmaCorpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="gyre_StatutoryReserve" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CVRMergerClosingPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CvrExcessClosingCashPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="gyre_PrepaidAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="gyre_LandUseRightsNetNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="gyre_LongTermCertificatesOfDeposit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CollaborationRevenueMember" xlink:label="gyre_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CostOfCollaborationMember" xlink:label="gyre_CostOfCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_CostOfCollaborationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserveMember" xlink:label="gyre_StatutoryReserveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AppropriationOfStatutoryReserve" xlink:label="gyre_AppropriationOfStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MinorityInterestDecreaseFromRedemptionsShares" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_19"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_20"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_21"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gyre_StatutoryReserveMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_AppropriationOfStatutoryReserve" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestDecreaseFromRedemptions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_MinorityInterestDecreaseFromRedemptionsShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncreaseDecreaseInAccountsAndNotesReceivables" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" xlink:label="gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" xlink:label="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" xlink:label="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NoncashLeaseExpense" xlink:label="gyre_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DisposalConsiderationInOtherReceivables" xlink:label="gyre_DisposalConsiderationInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AmortizationOfLandUseRights" xlink:label="gyre_AmortizationOfLandUseRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquisitionCostsInDueToRelatedParties" xlink:label="gyre_AcquisitionCostsInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredIncomeTaxExpenseBenefitNet" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BadDebtExpenseAndOtherNonCashItems" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" xlink:label="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CashPaidForAcquisitionCosts" xlink:label="gyre_CashPaidForAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedInterestOnLongTermCertificatesOfDeposit" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable" xlink:label="gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PaymentOfDisposalOfSubsidiary" xlink:label="gyre_PaymentOfDisposalOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChangeInFairValueOfLongTermReceivables" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChangeInFairValueOfDerivativeLiabilities" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EquityGainLossOfUnconsolidatedAffiliates" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gyre_IncreaseDecreaseInAccountsAndNotesReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_NoncashLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_DisposalConsiderationInOtherReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_AmortizationOfLandUseRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_AcquisitionCostsInDueToRelatedParties" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_DeferredIncomeTaxExpenseBenefitNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_BadDebtExpenseAndOtherNonCashItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="gyre_CashPaidForAcquisitionCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_AccruedInterestOnLongTermCertificatesOfDeposit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="gyre_PaymentOfDisposalOfSubsidiary" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_ChangeInFairValueOfLongTermReceivables" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_ChangeInFairValueOfDerivativeLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gyre_EquityGainLossOfUnconsolidatedAffiliates" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NassimUsmanPhdMember" xlink:label="gyre_NassimUsmanPhdMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OtherDirectorOrOfficerMember" xlink:label="gyre_OtherDirectorOrOfficerMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="gyre_NassimUsmanPhdMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="gyre_OtherDirectorOrOfficerMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureF351AssetAcquisition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuring" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureOtherAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEps" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NoncontrollingInterestPolicyPolicyTextBlock" xlink:label="gyre_NoncontrollingInterestPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RisksAndUncertainitiesPolicyTextBlock" xlink:label="gyre_RisksAndUncertainitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ConcentrationOfCustomerRiskPolicyTextBlock" xlink:label="gyre_ConcentrationOfCustomerRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsPolicyTextBlock" xlink:label="gyre_PreferredStockWarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LongTermCertificatesOfDepositPolicyTextBlock" xlink:label="gyre_LongTermCertificatesOfDepositPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LandUseRightsPolicyTextBlock" xlink:label="gyre_LandUseRightsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SellingAndMarketingExpensesPolicyTextBlock" xlink:label="gyre_SellingAndMarketingExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_InterestIncomePolicyTextBlock" xlink:label="gyre_InterestIncomePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ForeignCurrencyRiskPolicyTextBlock" xlink:label="gyre_ForeignCurrencyRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:label="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_NoncontrollingInterestPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_RisksAndUncertainitiesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_ConcentrationOfCustomerRiskPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_PreferredStockWarrantsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_LongTermCertificatesOfDepositPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_LandUseRightsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_SellingAndMarketingExpensesPolicyTextBlock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_InterestIncomePolicyTextBlock" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_ForeignCurrencyRiskPolicyTextBlock" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" xlink:label="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:label="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContinentPharmaceuticalsIncMember" xlink:label="gyre_ContinentPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OrganizationAndNatureOfOperationsTable" xlink:label="gyre_OrganizationAndNatureOfOperationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OrganizationAndNatureOfOperationsLineItems" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FCContributionMember" xlink:label="gyre_FCContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SeriesXPreferredStockMember" xlink:label="gyre_SeriesXPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIUSAMember" xlink:label="gyre_GNIUSAMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PurchaseAgreementAmendmentDate" xlink:label="gyre_PurchaseAgreementAmendmentDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationAgreementMember" xlink:label="gyre_BusinessCombinationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MinorityHolderContributionsMember" xlink:label="gyre_MinorityHolderContributionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ReverseStockSplitDescription" xlink:label="gyre_ReverseStockSplitDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="us-gaap_ExcessStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_CPIContributionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_ContinentPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_OrganizationAndNatureOfOperationsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_FCContributionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="gyre_SeriesXPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIUSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PurchaseAgreementAmendmentDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_BusinessCombinationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_MinorityHolderContributionsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_OwnershipAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="gyre_OrganizationAndNatureOfOperationsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_ReverseStockSplitDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfIndirectOwnershipInterest" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LiquidityAbstract" xlink:label="gyre_LiquidityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LiquidityTable" xlink:label="gyre_LiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LiquidityLineItems" xlink:label="gyre_LiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="us-gaap_PaymentsOfDividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityAbstract" xlink:to="gyre_LiquidityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityTable" xlink:to="gyre_LiquidityLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_PaymentsOfDividendsCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PatentsAndTechnologicalKnowHowMember" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SinopharmGroupCompanyLimitedMember" xlink:label="gyre_SinopharmGroupCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202104Member" xlink:label="us-gaap_AccountingStandardsUpdate202104Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202108Member" xlink:label="us-gaap_AccountingStandardsUpdate202108Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202110Member" xlink:label="us-gaap_AccountingStandardsUpdate202110Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AllowanceForCreditLossesCertificatesOfDeposit" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_PatentsAndTechnologicalKnowHowMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_SinopharmGroupCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202104Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202108Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202110Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_AllowanceForCreditLossesCertificatesOfDeposit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Cash" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_LongTermCertificatesOfDeposit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" xlink:label="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MachineryAndElectronicDevicesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MotorVehiclesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityNonCurrentMember" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetMeasurementInput" xlink:label="us-gaap_DerivativeAssetMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AmountToBeReceivedUnderAgreement" xlink:label="gyre_AmountToBeReceivedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_ContingentValueRightsAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityNonCurrentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_VertexAssetPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_StatementScenarioAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeAssetMeasurementInput" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_AmountToBeReceivedUnderAgreement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ProceedsFromGovernmentGrantsReceived" xlink:label="gyre_ProceedsFromGovernmentGrantsReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GovernmentGrantIncomeWithinOtherIncome" xlink:label="gyre_GovernmentGrantIncomeWithinOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="gyre_ProceedsFromGovernmentGrantsReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="gyre_GovernmentGrantIncomeWithinOtherIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_Depreciation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedPayrollAndWelfare" xlink:label="gyre_AccruedPayrollAndWelfare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SupplierReimbursement" xlink:label="gyre_SupplierReimbursement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedExpensesGeneralAndAdministrative" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedSalesDiscount" xlink:label="gyre_AccruedSalesDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedExpensesResearchAndDevelopment" xlink:label="gyre_AccruedExpensesResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedExpensesSellingExpenses" xlink:label="gyre_AccruedExpensesSellingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrants" xlink:label="gyre_DeferredGovernmentGrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_AccruedPayrollAndWelfare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_SupplierReimbursement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_AccruedExpensesGeneralAndAdministrative" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_AccruedSalesDiscount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_AccruedExpensesResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_AccruedExpensesSellingExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="gyre_DeferredGovernmentGrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsLineItems" xlink:label="gyre_DeferredGovernmentGrantsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsCurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsTable" xlink:label="gyre_DeferredGovernmentGrantsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsNonCurrent" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="gyre_DeferredGovernmentGrantsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsNonCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsTable" xlink:to="gyre_DeferredGovernmentGrantsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MachineryAndElectronicDevicesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MotorVehiclesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SoftwareMember" xlink:label="gyre_SoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_SoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfRevenueAccountedSalesToDistributors" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ProductConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="gyre_PercentageOfRevenueAccountedSalesToDistributors" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationFairValueOfCommonShares" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationFairValueOfPreferredShares" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationFairValue" xlink:label="gyre_BusinessCombinationFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreMergerStockOptionsAssumed" xlink:label="gyre_PreMergerStockOptionsAssumed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CatalystMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValueOfCommonShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValueOfPreferredShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_PreMergerStockOptionsAssumed" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CatalystMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationExcessClosingCashPayable" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationExcessClosingCashPayable" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DrenBioIncAndCopiaScientificLLCMember" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SharesForAggregatePurchasePrice" xlink:label="gyre_SharesForAggregatePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_VertexPharmaceuticalsIncorporatedMember" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CpUSSharePurchaseAgreementMember" xlink:label="gyre_CpUSSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DivestitureLossesMember" xlink:label="gyre_DivestitureLossesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RestructuringLiability" xlink:label="gyre_RestructuringLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RemainingNumberOfFullTimeEmployees" xlink:label="gyre_RemainingNumberOfFullTimeEmployees"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SeveranceAndOtherCosts" xlink:label="gyre_SeveranceAndOtherCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_UpfrontPaymentReceived" xlink:label="gyre_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PostClosingIndemnificationObligation" xlink:label="gyre_PostClosingIndemnificationObligation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_PercentageOfIndirectOwnershipInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_DrenBioIncAndCopiaScientificLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_SharesForAggregatePurchasePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_VertexPharmaceuticalsIncorporatedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CpUSSharePurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="gyre_DivestitureLossesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_RestructuringLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_RemainingNumberOfFullTimeEmployees" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_SeveranceAndOtherCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_UpfrontPaymentReceived" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_PostClosingIndemnificationObligation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SubleaseArrangementMember" xlink:label="gyre_SubleaseArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LeaseLabAndOfficeSpaceMember" xlink:label="gyre_LeaseLabAndOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LesseeOperatingLeaseRenewalTermDescription" xlink:label="gyre_LesseeOperatingLeaseRenewalTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LicenseAgreementTerminationMonthAndYear" xlink:label="gyre_LicenseAgreementTerminationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LeaseCommencementMonthAndYear" xlink:label="gyre_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LeaseExpirationMonthAndYear" xlink:label="gyre_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SquareMeterAreaForOfficeSpaceUnderLease" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SquareMeterAreaForLaboratoryCenterUnderLease" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SquareMeterAreaForOfficeSpaceUnderNewLease" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PaymentOfTerminationFees" xlink:label="gyre_PaymentOfTerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LandUseRightsNetAssets" xlink:label="gyre_LandUseRightsNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_SubleaseArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_LeaseLabAndOfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LesseeOperatingLeaseRenewalTermDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LicenseAgreementTerminationMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LeaseCommencementMonthAndYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LeaseExpirationMonthAndYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForOfficeSpaceUnderLease" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForLaboratoryCenterUnderLease" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SubleaseIncome" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_PaymentOfTerminationFees" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeasePayments" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LandUseRightsNetAssets" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StockholdersEquityDisclosureLineItems" xlink:label="gyre_StockholdersEquityDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StockholdersEquityDisclosureTable" xlink:label="gyre_StockholdersEquityDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_WarrantExpirationMonthAndYear" xlink:label="gyre_WarrantExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LegalExpensesIncurred" xlink:label="gyre_LegalExpensesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserveFund" xlink:label="gyre_StatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CumulativeAmountOfStatutoryReserveFund" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AppropriationsToStatutoryReserve" xlink:label="gyre_AppropriationsToStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AffiliatesBeneficialOwnSharesPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="gyre_StockholdersEquityDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_WarrantExpirationMonthAndYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="gyre_StockholdersEquityDisclosureLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_LegalExpensesIncurred" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_StatutoryReserveFund" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_CumulativeAmountOfStatutoryReserveFund" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AppropriationsToStatutoryReserve" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AffiliatesBeneficialOwnSharesPercentage" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gyre_OptionsToPurchaseCommonStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SeriesXPreferredStockMember" xlink:label="gyre_SeriesXPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="gyre_SeriesXPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NonEmployeeMember" xlink:label="gyre_NonEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EmployeeMember" xlink:label="gyre_EmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfIndividualsApprovedGrantsByBoard" xlink:label="gyre_NumberOfIndividualsApprovedGrantsByBoard"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares" xlink:label="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance" xlink:label="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gyre_NonEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandEighteenOmnibusIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gyre_EmployeeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_OwnershipAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_NumberOfIndividualsApprovedGrantsByBoard" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" xlink:label="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SubmissionOfTheNewDrugApplicationMember" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommitmentsAndContingenciesDisclosureTable" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalAdditionsMember" xlink:label="us-gaap_CapitalAdditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationAgreementMember" xlink:label="gyre_BusinessCombinationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LegalAndOtherExpensesMember" xlink:label="gyre_LegalAndOtherExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneMember" xlink:label="gyre_FThreeFiveOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NDAPassesTheNMPAsReviewAndInspectionMember" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement" xlink:label="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember" xlink:label="us-gaap_ServiceAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DalcinonacogAlfaMember" xlink:label="gyre_DalcinonacogAlfaMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NMPAsApprovalOfTheNDAMember" xlink:label="gyre_NMPAsApprovalOfTheNDAMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ReimbursementForOutOfPocketFeesAndExpenses" xlink:label="gyre_ReimbursementForOutOfPocketFeesAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GMPMember" xlink:label="gyre_GMPMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IntegrityBioMember" xlink:label="gyre_IntegrityBioMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfExcessCashOnDispositionsNet" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfAmountReceivedOnAgreement" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfExcessPreapprovedCosts" xlink:label="gyre_PercentageOfExcessPreapprovedCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DistributionFromAssetSaleProceeds" xlink:label="gyre_DistributionFromAssetSaleProceeds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContributionsClosingPayableAmount" xlink:label="gyre_ContributionsClosingPayableAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserve" xlink:label="us-gaap_LitigationReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommittedToAllocate" xlink:label="gyre_CommittedToAllocate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsAgreement" xlink:label="gyre_ContingentValueRightsAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation" xlink:label="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CostOfServicesAsPerAgreement" xlink:label="gyre_CostOfServicesAsPerAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination" xlink:label="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FirmWorkOrderSupportingClinicalTrials" xlink:label="gyre_FirmWorkOrderSupportingClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommonStockFiledLawsuit" xlink:label="gyre_PercentageOfCommonStockFiledLawsuit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsClosingPayable" xlink:label="gyre_ContingentValueRightsClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LitigationAmount" xlink:label="gyre_LitigationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_SubmissionOfTheNewDrugApplicationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="gyre_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_ContingentValueRightsAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_CapitalAdditionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_BusinessCombinationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="gyre_LegalAndOtherExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gyre_FThreeFiveOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_NDAPassesTheNMPAsReviewAndInspectionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_VertexAssetPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ServiceAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gyre_DalcinonacogAlfaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_NMPAsApprovalOfTheNDAMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ReimbursementForOutOfPocketFeesAndExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GMPMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gyre_IntegrityBioMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfExcessCashOnDispositionsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfAmountReceivedOnAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfExcessPreapprovedCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_DistributionFromAssetSaleProceeds" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementScenarioAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContributionsClosingPayableAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="gyre_CommitmentsAndContingenciesDisclosureLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LitigationReserve" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CommittedToAllocate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContingentValueRightsAgreement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CostOfServicesAsPerAgreement" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_FirmWorkOrderSupportingClinicalTrials" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfCommonStockFiledLawsuit" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContingentValueRightsClosingPayable" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_LitigationAmount" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsImpactFromForeignCorporations" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsCapitalizedTransactionCosts" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsLeaseLiabilities" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxLiabilityRightOfUseAssets" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsEquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxAssetsImpactFromForeignCorporations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxAssetsCapitalizedTransactionCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxAssetsLeaseLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="gyre_DeferredTaxLiabilityRightOfUseAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChangesOfValuationAllowances" xlink:label="gyre_ChangesOfValuationAllowances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_ChangesOfValuationAllowances" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncomeTaxTable" xlink:label="gyre_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncomeTaxLineItems" xlink:label="gyre_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OperatingLossCarryforwardsExpirationYear" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OperatingLossCarryforwardsWithIndefiniteLife" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TaxCreditCarryforwardExpirationYear" xlink:label="gyre_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MaximumAmountOfTaxOffsetPerYear" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RequiredMinimumTaxableIncome" xlink:label="gyre_RequiredMinimumTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_IncomeTaxTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxTable" xlink:to="gyre_IncomeTaxLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_OperatingLossCarryforwardsExpirationYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_OperatingLossCarryforwardsWithIndefiniteLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_TaxCreditCarryforwardExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_MaximumAmountOfTaxOffsetPerYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_RequiredMinimumTaxableIncome" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PaymentForResearchAndDevelopmentFees" xlink:label="gyre_PaymentForResearchAndDevelopmentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gyre_PaymentForResearchAndDevelopmentFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="gyre_CPIContributionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="gyre_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="gyre_PreferredStockWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MainlandChinaContributionPlanMember" xlink:label="gyre_MainlandChinaContributionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="gyre_MainlandChinaContributionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="us-gaap_AllOtherSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_GyreMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GCBiopharmaCorpMember" xlink:label="gyre_GCBiopharmaCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="us-gaap_PaymentsOfDividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_UpfrontPaymentReceived" xlink:label="gyre_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PostClosingIndemnificationObligation" xlink:label="gyre_PostClosingIndemnificationObligation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfBankAccounts" xlink:label="gyre_NumberOfBankAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_GCBiopharmaCorpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfDividendsCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gyre_UpfrontPaymentReceived" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gyre_PostClosingIndemnificationObligation" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gyre_NumberOfBankAccounts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DepositAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="gyre_StatutoryReserve" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedCashFlowStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GCBiopharmaCorpMember" xlink:label="gyre_GCBiopharmaCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRMergerClosingPayable" xlink:label="gyre_CVRMergerClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CvrExcessClosingCashPayable" xlink:label="gyre_CvrExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PrepaidAssetsCurrent" xlink:label="gyre_PrepaidAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LandUseRightsNetNoncurrent" xlink:label="gyre_LandUseRightsNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_GCBiopharmaCorpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="gyre_StatutoryReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CVRMergerClosingPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gyre_CvrExcessClosingCashPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="gyre_PrepaidAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="gyre_LandUseRightsNetNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="gyre_LongTermCertificatesOfDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CollaborationRevenueMember" xlink:label="gyre_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CostOfCollaborationMember" xlink:label="gyre_CostOfCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_CollaborationRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_CostOfCollaborationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserveMember" xlink:label="gyre_StatutoryReserveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" xlink:label="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AppropriationOfStatutoryReserve" xlink:label="gyre_AppropriationOfStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:label="us-gaap_MinorityInterestDecreaseFromRedemptions"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MinorityInterestDecreaseFromRedemptionsShares" xlink:label="gyre_MinorityInterestDecreaseFromRedemptionsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gyre_StatutoryReserveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_AppropriationOfStatutoryReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestDecreaseFromRedemptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_MinorityInterestDecreaseFromRedemptionsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NassimUsmanPhdMember" xlink:label="gyre_NassimUsmanPhdMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OtherDirectorOrOfficerMember" xlink:label="gyre_OtherDirectorOrOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="gyre_NassimUsmanPhdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="gyre_OtherDirectorOrOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OrganizationAndNatureOfOperationsLineItems" xlink:label="gyre_OrganizationAndNatureOfOperationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OrganizationAndNatureOfOperationsTable" xlink:label="gyre_OrganizationAndNatureOfOperationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContinentPharmaceuticalsIncMember" xlink:label="gyre_ContinentPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FCContributionMember" xlink:label="gyre_FCContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SeriesXPreferredStockMember" xlink:label="gyre_SeriesXPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIUSAMember" xlink:label="gyre_GNIUSAMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PurchaseAgreementAmendmentDate" xlink:label="gyre_PurchaseAgreementAmendmentDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationAgreementMember" xlink:label="gyre_BusinessCombinationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MinorityHolderContributionsMember" xlink:label="gyre_MinorityHolderContributionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ReverseStockSplitDescription" xlink:label="gyre_ReverseStockSplitDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="us-gaap_ExcessStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" xlink:label="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_OrganizationAndNatureOfOperationsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_CPIContributionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_ContinentPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_FCContributionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="gyre_SeriesXPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIUSAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PurchaseAgreementAmendmentDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_BusinessCombinationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_MinorityHolderContributionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_ReverseStockSplitDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfIndirectOwnershipInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LiquidityLineItems" xlink:label="gyre_LiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LiquidityTable" xlink:label="gyre_LiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="us-gaap_PaymentsOfDividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_LiquidityLineItems" xlink:to="gyre_LiquidityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_LiquidityTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_PaymentsOfDividendsCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_LiquidityLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:label="gyre_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PatentsAndTechnologicalKnowHowMember" xlink:label="gyre_PatentsAndTechnologicalKnowHowMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SinopharmGroupCompanyLimitedMember" xlink:label="gyre_SinopharmGroupCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" xlink:label="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" xlink:label="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202104Member" xlink:label="us-gaap_AccountingStandardsUpdate202104Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202108Member" xlink:label="us-gaap_AccountingStandardsUpdate202108Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" xlink:label="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202110Member" xlink:label="us-gaap_AccountingStandardsUpdate202110Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AllowanceForCreditLossesCertificatesOfDeposit" xlink:label="gyre_AllowanceForCreditLossesCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_PatentsAndTechnologicalKnowHowMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_SinopharmGroupCompanyLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202104Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202108Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202110Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_AllowanceForCreditLossesCertificatesOfDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="gyre_LongTermCertificatesOfDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MachineryAndElectronicDevicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MotorVehiclesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" xlink:label="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityNonCurrentMember" xlink:label="gyre_CVRDerivativeLiabilityNonCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" xlink:label="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetMeasurementInput" xlink:label="us-gaap_DerivativeAssetMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AmountToBeReceivedUnderAgreement" xlink:label="gyre_AmountToBeReceivedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" xlink:label="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" xlink:label="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" xlink:label="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_ContingentValueRightsAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityNonCurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_VertexAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeAssetMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_AmountToBeReceivedUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityMember" xlink:label="gyre_CVRDerivativeLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_FinanceReceivablesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="gyre_CVRDerivativeLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsLineItems" xlink:label="gyre_DeferredGovernmentGrantsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsTable" xlink:label="gyre_DeferredGovernmentGrantsTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsCurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:label="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsNonCurrent" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_DeferredGovernmentGrantsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsNonCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_DeferredGovernmentGrantsLineItems" xlink:to="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MachineryAndElectronicDevicesMember" xlink:label="gyre_MachineryAndElectronicDevicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MotorVehiclesMember" xlink:label="gyre_MotorVehiclesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MachineryAndElectronicDevicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="gyre_MotorVehiclesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SoftwareMember" xlink:label="gyre_SoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_SoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfRevenueAccountedSalesToDistributors" xlink:label="gyre_PercentageOfRevenueAccountedSalesToDistributors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ProductConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="gyre_PercentageOfRevenueAccountedSalesToDistributors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationFairValueOfCommonShares" xlink:label="gyre_BusinessCombinationFairValueOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationFairValueOfPreferredShares" xlink:label="gyre_BusinessCombinationFairValueOfPreferredShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationFairValue" xlink:label="gyre_BusinessCombinationFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreMergerStockOptionsAssumed" xlink:label="gyre_PreMergerStockOptionsAssumed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CatalystMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValueOfCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValueOfPreferredShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_PreMergerStockOptionsAssumed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CatalystMember" xlink:label="gyre_CatalystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CatalystMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationExcessClosingCashPayable" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationExcessClosingCashPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfIndirectOwnershipInterest" xlink:label="gyre_PercentageOfIndirectOwnershipInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DrenBioIncAndCopiaScientificLLCMember" xlink:label="gyre_DrenBioIncAndCopiaScientificLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SharesForAggregatePurchasePrice" xlink:label="gyre_SharesForAggregatePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_VertexPharmaceuticalsIncorporatedMember" xlink:label="gyre_VertexPharmaceuticalsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CpUSSharePurchaseAgreementMember" xlink:label="gyre_CpUSSharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DivestitureLossesMember" xlink:label="gyre_DivestitureLossesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:label="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RestructuringLiability" xlink:label="gyre_RestructuringLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RemainingNumberOfFullTimeEmployees" xlink:label="gyre_RemainingNumberOfFullTimeEmployees"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SeveranceAndOtherCosts" xlink:label="gyre_SeveranceAndOtherCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_UpfrontPaymentReceived" xlink:label="gyre_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PostClosingIndemnificationObligation" xlink:label="gyre_PostClosingIndemnificationObligation"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_PercentageOfIndirectOwnershipInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_DrenBioIncAndCopiaScientificLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_SharesForAggregatePurchasePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_VertexPharmaceuticalsIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_CpUSSharePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="gyre_DivestitureLossesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_RestructuringLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_RemainingNumberOfFullTimeEmployees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_SeveranceAndOtherCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="gyre_PostClosingIndemnificationObligation" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SubleaseArrangementMember" xlink:label="gyre_SubleaseArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LeaseLabAndOfficeSpaceMember" xlink:label="gyre_LeaseLabAndOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LesseeOperatingLeaseRenewalTermDescription" xlink:label="gyre_LesseeOperatingLeaseRenewalTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LicenseAgreementTerminationMonthAndYear" xlink:label="gyre_LicenseAgreementTerminationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LeaseCommencementMonthAndYear" xlink:label="gyre_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LeaseExpirationMonthAndYear" xlink:label="gyre_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SquareMeterAreaForOfficeSpaceUnderLease" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SquareMeterAreaForLaboratoryCenterUnderLease" xlink:label="gyre_SquareMeterAreaForLaboratoryCenterUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SquareMeterAreaForOfficeSpaceUnderNewLease" xlink:label="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PaymentOfTerminationFees" xlink:label="gyre_PaymentOfTerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" xlink:label="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LandUseRightsNetAssets" xlink:label="gyre_LandUseRightsNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_SubleaseArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_LeaseLabAndOfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LesseeOperatingLeaseRenewalTermDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LicenseAgreementTerminationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LeaseCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForOfficeSpaceUnderLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForLaboratoryCenterUnderLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_PaymentOfTerminationFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gyre_LandUseRightsNetAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StockholdersEquityDisclosureLineItems" xlink:label="gyre_StockholdersEquityDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StockholdersEquityDisclosureTable" xlink:label="gyre_StockholdersEquityDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyOneATMProgramMember" xlink:label="gyre_TwoThousandTwentyOneATMProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_WarrantExpirationMonthAndYear" xlink:label="gyre_WarrantExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommissionForSharesSold" xlink:label="gyre_PercentageOfCommissionForSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LegalExpensesIncurred" xlink:label="gyre_LegalExpensesIncurred"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" xlink:label="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserveFund" xlink:label="gyre_StatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CumulativeAmountOfStatutoryReserveFund" xlink:label="gyre_CumulativeAmountOfStatutoryReserveFund"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AppropriationsToStatutoryReserve" xlink:label="gyre_AppropriationsToStatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" xlink:label="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AffiliatesBeneficialOwnSharesPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" xlink:label="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_StockholdersEquityDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gyre_TwoThousandTwentyOneATMProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_WarrantExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_PercentageOfCommissionForSharesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_LegalExpensesIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_StatutoryReserveFund" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_CumulativeAmountOfStatutoryReserveFund" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AppropriationsToStatutoryReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AffiliatesBeneficialOwnSharesPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_StockholdersEquityDisclosureLineItems" xlink:to="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gyre_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SeriesXPreferredStockMember" xlink:label="gyre_SeriesXPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" xlink:label="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="gyre_SeriesXPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gyre_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NonEmployeeMember" xlink:label="gyre_NonEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandEighteenOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EmployeeMember" xlink:label="gyre_EmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward" xlink:label="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" xlink:label="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfOutstandingSharesOfCommonStock" xlink:label="gyre_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfIndividualsApprovedGrantsByBoard" xlink:label="gyre_NumberOfIndividualsApprovedGrantsByBoard"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares" xlink:label="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance" xlink:label="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gyre_NonEmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandEighteenOmnibusIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gyre_EmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_PercentageOfOutstandingSharesOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_NumberOfIndividualsApprovedGrantsByBoard" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="gyre_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommitmentsAndContingenciesDisclosureTable" xlink:label="gyre_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SubmissionOfTheNewDrugApplicationMember" xlink:label="gyre_SubmissionOfTheNewDrugApplicationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsAgreementMember" xlink:label="gyre_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalAdditionsMember" xlink:label="us-gaap_CapitalAdditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationAgreementMember" xlink:label="gyre_BusinessCombinationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LegalAndOtherExpensesMember" xlink:label="gyre_LegalAndOtherExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneMember" xlink:label="gyre_FThreeFiveOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NDAPassesTheNMPAsReviewAndInspectionMember" xlink:label="gyre_NDAPassesTheNMPAsReviewAndInspectionMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement" xlink:label="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_VertexAssetPurchaseAgreementMember" xlink:label="gyre_VertexAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember" xlink:label="us-gaap_ServiceAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DalcinonacogAlfaMember" xlink:label="gyre_DalcinonacogAlfaMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NMPAsApprovalOfTheNDAMember" xlink:label="gyre_NMPAsApprovalOfTheNDAMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ReimbursementForOutOfPocketFeesAndExpenses" xlink:label="gyre_ReimbursementForOutOfPocketFeesAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GMPMember" xlink:label="gyre_GMPMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IntegrityBioMember" xlink:label="gyre_IntegrityBioMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfExcessCashOnDispositionsNet" xlink:label="gyre_PercentageOfExcessCashOnDispositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" xlink:label="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfAmountReceivedOnAgreement" xlink:label="gyre_PercentageOfAmountReceivedOnAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfExcessPreapprovedCosts" xlink:label="gyre_PercentageOfExcessPreapprovedCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DistributionFromAssetSaleProceeds" xlink:label="gyre_DistributionFromAssetSaleProceeds"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" xlink:label="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContributionsClosingPayableAmount" xlink:label="gyre_ContributionsClosingPayableAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserve" xlink:label="us-gaap_LitigationReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CommittedToAllocate" xlink:label="gyre_CommittedToAllocate"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsAgreement" xlink:label="gyre_ContingentValueRightsAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation" xlink:label="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CostOfServicesAsPerAgreement" xlink:label="gyre_CostOfServicesAsPerAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination" xlink:label="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FirmWorkOrderSupportingClinicalTrials" xlink:label="gyre_FirmWorkOrderSupportingClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfCommonStockFiledLawsuit" xlink:label="gyre_PercentageOfCommonStockFiledLawsuit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ContingentValueRightsClosingPayable" xlink:label="gyre_ContingentValueRightsClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LitigationAmount" xlink:label="gyre_LitigationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" xlink:label="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_SubmissionOfTheNewDrugApplicationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="gyre_ContingentValueRightsAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_CapitalAdditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_BusinessCombinationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="gyre_LegalAndOtherExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gyre_FThreeFiveOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_NDAPassesTheNMPAsReviewAndInspectionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_VertexAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ServiceAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gyre_DalcinonacogAlfaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gyre_NMPAsApprovalOfTheNDAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ReimbursementForOutOfPocketFeesAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GMPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gyre_IntegrityBioMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfExcessCashOnDispositionsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfAmountReceivedOnAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfExcessPreapprovedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_DistributionFromAssetSaleProceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContributionsClosingPayableAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LitigationSettlementExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LitigationReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CommittedToAllocate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContingentValueRightsAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_CostOfServicesAsPerAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_FirmWorkOrderSupportingClinicalTrials" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_PercentageOfCommonStockFiledLawsuit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ContingentValueRightsClosingPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_LitigationAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncomeTaxLineItems" xlink:label="gyre_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncomeTaxTable" xlink:label="gyre_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OperatingLossCarryforwardsExpirationYear" xlink:label="gyre_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OperatingLossCarryforwardsWithIndefiniteLife" xlink:label="gyre_OperatingLossCarryforwardsWithIndefiniteLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_TaxCreditCarryforwardExpirationYear" xlink:label="gyre_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:label="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:label="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MaximumAmountOfTaxOffsetPerYear" xlink:label="gyre_MaximumAmountOfTaxOffsetPerYear"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_RequiredMinimumTaxableIncome" xlink:label="gyre_RequiredMinimumTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_IncomeTaxTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gyre_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_OperatingLossCarryforwardsWithIndefiniteLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_MaximumAmountOfTaxOffsetPerYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="gyre_RequiredMinimumTaxableIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gyre_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PaymentForResearchAndDevelopmentFees" xlink:label="gyre_PaymentForResearchAndDevelopmentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GNIMember" xlink:label="gyre_GNIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CPIContributionMember" xlink:label="gyre_CPIContributionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_FThreeFiveOneAssetPurchaseAgreementMember" xlink:label="gyre_FThreeFiveOneAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gyre_PaymentForResearchAndDevelopmentFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gyre_GNIMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="gyre_CPIContributionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="gyre_FThreeFiveOneAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="gyre_GyreMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_OptionsToPurchaseCommonStockMember" xlink:label="gyre_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PreferredStockWarrantsMember" xlink:label="gyre_PreferredStockWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="gyre_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="gyre_PreferredStockWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_MainlandChinaContributionPlanMember" xlink:label="gyre_MainlandChinaContributionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="gyre_MainlandChinaContributionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:label="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BeijingContinentPharmaceuticalsCoLtdMember" xlink:label="gyre_BeijingContinentPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GyreMember" xlink:label="gyre_GyreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="us-gaap_AllOtherSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_BeijingContinentPharmaceuticalsCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="gyre_GyreMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_GCBiopharmaCorpMember" xlink:label="gyre_GCBiopharmaCorpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" xlink:label="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock" xlink:label="us-gaap_PaymentsOfDividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_UpfrontPaymentReceived" xlink:label="gyre_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PostClosingIndemnificationObligation" xlink:label="gyre_PostClosingIndemnificationObligation"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NumberOfBankAccounts" xlink:label="gyre_NumberOfBankAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="gyre_GCBiopharmaCorpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfDividendsCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gyre_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gyre_PostClosingIndemnificationObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gyre_NumberOfBankAccounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DepositAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="gyre_StatutoryReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" xlink:label="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="gyre_StatutoryReserve" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="gyre_CvrExcessClosingCashPayable" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="gyre_CVRDerivativeLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="gyre_CVRMergerClosingPayable" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="gyre_PrepaidAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="gyre_LandUseRightsNetNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="gyre_LongTermCertificatesOfDeposit" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CvrExcessClosingCashPayable" xlink:label="gyre_CvrExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRDerivativeLiabilityNoncurrent" xlink:label="gyre_CVRDerivativeLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CVRMergerClosingPayable" xlink:label="gyre_CVRMergerClosingPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PrepaidAssetsCurrent" xlink:label="gyre_PrepaidAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LandUseRightsNetNoncurrent" xlink:label="gyre_LandUseRightsNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_LongTermCertificatesOfDeposit" xlink:label="gyre_LongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingExpense" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="7" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_AcquiredInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_AccruedInterestOnLongTermCertificatesOfDeposit" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="gyre_CashPaidForAcquisitionCosts" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="gyre_PaymentOfDisposalOfSubsidiary" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_ChangeInFairValueOfLongTermReceivables" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_EquityGainLossOfUnconsolidatedAffiliates" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_BadDebtExpenseAndOtherNonCashItems" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="18" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_DeferredIncomeTaxExpenseBenefitNet" order="19" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_NoncashLeaseExpense" order="21" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="22" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_AmortizationOfLandUseRights" order="23" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_IncreaseDecreaseInAccountsAndNotesReceivables" order="24" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="26" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_ChangeInFairValueOfDerivativeLiabilities" order="27" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="29" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="31" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="32" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" order="33" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="34" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AcquiredInProcessResearchAndDevelopment" xlink:label="gyre_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedInterestOnLongTermCertificatesOfDeposit" xlink:label="gyre_AccruedInterestOnLongTermCertificatesOfDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_CashPaidForAcquisitionCosts" xlink:label="gyre_CashPaidForAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_PaymentOfDisposalOfSubsidiary" xlink:label="gyre_PaymentOfDisposalOfSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChangeInFairValueOfLongTermReceivables" xlink:label="gyre_ChangeInFairValueOfLongTermReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EquityGainLossOfUnconsolidatedAffiliates" xlink:label="gyre_EquityGainLossOfUnconsolidatedAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BadDebtExpenseAndOtherNonCashItems" xlink:label="gyre_BadDebtExpenseAndOtherNonCashItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredIncomeTaxExpenseBenefitNet" xlink:label="gyre_DeferredIncomeTaxExpenseBenefitNet"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_NoncashLeaseExpense" xlink:label="gyre_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AmortizationOfLandUseRights" xlink:label="gyre_AmortizationOfLandUseRights"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncreaseDecreaseInAccountsAndNotesReceivables" xlink:label="gyre_IncreaseDecreaseInAccountsAndNotesReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_ChangeInFairValueOfDerivativeLiabilities" xlink:label="gyre_ChangeInFairValueOfDerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" xlink:label="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:label="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_AccruedPayrollAndWelfare" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_SupplierReimbursement" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_AccruedExpensesGeneralAndAdministrative" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_AccruedSalesDiscount" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_AccruedExpensesResearchAndDevelopment" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_AccruedExpensesSellingExpenses" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="gyre_DeferredGovernmentGrants" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedPayrollAndWelfare" xlink:label="gyre_AccruedPayrollAndWelfare"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_SupplierReimbursement" xlink:label="gyre_SupplierReimbursement"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedExpensesGeneralAndAdministrative" xlink:label="gyre_AccruedExpensesGeneralAndAdministrative"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedSalesDiscount" xlink:label="gyre_AccruedSalesDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedExpensesResearchAndDevelopment" xlink:label="gyre_AccruedExpensesResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_AccruedExpensesSellingExpenses" xlink:label="gyre_AccruedExpensesSellingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrants" xlink:label="gyre_DeferredGovernmentGrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:to="gyre_DeferredGovernmentGrantsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:to="gyre_DeferredGovernmentGrantsNonCurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsCurrent" xlink:label="gyre_DeferredGovernmentGrantsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredGovernmentGrantsNonCurrent" xlink:label="gyre_DeferredGovernmentGrantsNonCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationExcessClosingCashPayable" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" order="14" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationExcessClosingCashPayable" xlink:label="gyre_BusinessCombinationExcessClosingCashPayable"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" xlink:label="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail"/>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" xlink:label="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="gyre_DeferredTaxLiabilityRightOfUseAssets" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsEquityMethodInvestments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gyre_DeferredTaxAssetsImpactFromForeignCorporations" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gyre_DeferredTaxAssetsCapitalizedTransactionCosts" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gyre_DeferredTaxAssetsLeaseLiabilities" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxLiabilityRightOfUseAssets" xlink:label="gyre_DeferredTaxLiabilityRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:label="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsImpactFromForeignCorporations" xlink:label="gyre_DeferredTaxAssetsImpactFromForeignCorporations"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsCapitalizedTransactionCosts" xlink:label="gyre_DeferredTaxAssetsCapitalizedTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_DeferredTaxAssetsLeaseLiabilities" xlink:label="gyre_DeferredTaxAssetsLeaseLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="gyre_StatutoryReserve" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_StatutoryReserve" xlink:label="gyre_StatutoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="gyre-20231231.xsd#gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" name="NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" name="NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" name="NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_RestructuringLiability" name="RestructuringLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_IntegrityBioMember" name="IntegrityBioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CVRDerivativeLiabilityMember" name="CVRDerivativeLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ReimbursementForOutOfPocketFeesAndExpenses" name="ReimbursementForOutOfPocketFeesAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeferredTaxAssetsFixedAssetsAndIntangibles" name="DeferredTaxAssetsFixedAssetsAndIntangibles" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" name="ChargesRelatedToWriteOffOfPrepaidManufacturingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_NumberOfIndividualsApprovedGrantsByBoard" name="NumberOfIndividualsApprovedGrantsByBoard" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsTable" name="DeferredGovernmentGrantsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_InterestIncomePolicyTextBlock" name="InterestIncomePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_CumulativeAmountOfStatutoryReserveFund" name="CumulativeAmountOfStatutoryReserveFund" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares" name="IssuanceOfOptionGrantsToPurchaseCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_VertexPharmaceuticalsIncorporatedMember" name="VertexPharmaceuticalsIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ContributionsClosingPayableAmount" name="ContributionsClosingPayableAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_PercentageOfOutstandingSharesOfCommonStock" name="PercentageOfOutstandingSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" name="DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AccruedExpensesResearchAndDevelopment" name="AccruedExpensesResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation" name="ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_FCContributionMember" name="FCContributionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_GNIMember" name="GNIMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_EmployeeMember" name="EmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CashPaidForAcquisitionCosts" name="CashPaidForAcquisitionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions" name="TemporaryEquityIssuedDuringPeriodSharesAcquisitions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" name="AccountsAndFinancingReceivableAllowanceForCreditLossCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_VertexAssetPurchaseAgreementMember" name="VertexAssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_NumberOfBankAccounts" name="NumberOfBankAccounts" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfRevenueAccountedSalesToDistributors" name="PercentageOfRevenueAccountedSalesToDistributors" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PaymentOfTerminationFees" name="PaymentOfTerminationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_SharesForAggregatePurchasePrice" name="SharesForAggregatePurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem" name="DepositsInLicensedBanksProtectedByDepositInsuranceSystem" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_AmortizationOfLandUseRights" name="AmortizationOfLandUseRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" name="ShanghaiPharmaceuticalsHoldingCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_TwoThousandTwentyOneATMProgramMember" name="TwoThousandTwentyOneATMProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CommittedToAllocate" name="CommittedToAllocate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AppropriationOfStatutoryReserve" name="AppropriationOfStatutoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_LongTermCertificatesOfDeposit" name="LongTermCertificatesOfDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_NonEmployeeMember" name="NonEmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ChangeInFairValueOfDerivativeLiabilities" name="ChangeInFairValueOfDerivativeLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_MotorVehiclesMember" name="MotorVehiclesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards" name="DeferredTaxAssetsStateNetOperatingLossCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ProceedsFromGovernmentGrantsReceived" name="ProceedsFromGovernmentGrantsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_StatutoryReserveMember" name="StatutoryReserveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" name="SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_LandUseRightsNetAssets" name="LandUseRightsNetAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_OperatingLossCarryforwardsWithIndefiniteLife" name="OperatingLossCarryforwardsWithIndefiniteLife" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_PreMergerStockOptionsAssumed" name="PreMergerStockOptionsAssumed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" name="ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_CostOfCollaborationMember" name="CostOfCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_RisksAndUncertainitiesPolicyTextBlock" name="RisksAndUncertainitiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_BusinessCombinationFairValue" name="BusinessCombinationFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeferredTaxAssetsCapitalizedTransactionCosts" name="DeferredTaxAssetsCapitalizedTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_RequiredMinimumTaxableIncome" name="RequiredMinimumTaxableIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ReverseStockSplitDescription" name="ReverseStockSplitDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_GyreMember" name="GyreMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PatentsAndTechnologicalKnowHowMember" name="PatentsAndTechnologicalKnowHowMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CVRDerivativeLiabilityNonCurrentMember" name="CVRDerivativeLiabilityNonCurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DalcinonacogAlfaMember" name="DalcinonacogAlfaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember" name="TwoThousandTwentyThreeOmnibusIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PostClosingIndemnificationObligation" name="PostClosingIndemnificationObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_SoftwareMember" name="SoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" name="AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AppropriationsToStatutoryReserve" name="AppropriationsToStatutoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ChangesOfValuationAllowances" name="ChangesOfValuationAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_NDAPassesTheNMPAsReviewAndInspectionMember" name="NDAPassesTheNMPAsReviewAndInspectionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_EquityGainLossOfUnconsolidatedAffiliates" name="EquityGainLossOfUnconsolidatedAffiliates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" name="AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" name="CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_FirmWorkOrderSupportingClinicalTrials" name="FirmWorkOrderSupportingClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_NMPAsApprovalOfTheNDAMember" name="NMPAsApprovalOfTheNDAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LegalAndOtherExpensesMember" name="LegalAndOtherExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_StatutoryReserve" name="StatutoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_SquareMeterAreaForLaboratoryCenterUnderLease" name="SquareMeterAreaForLaboratoryCenterUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_SquareMeterAreaForOfficeSpaceUnderLease" name="SquareMeterAreaForOfficeSpaceUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ContingentValueRightsDerivativeLiabilityNonCurrent" name="ContingentValueRightsDerivativeLiabilityNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_StatutoryReserveFund" name="StatutoryReserveFund" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfExcessCashOnDispositionsNet" name="PercentageOfExcessCashOnDispositionsNet" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" name="ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_GovernmentGrantIncomeWithinOtherIncome" name="GovernmentGrantIncomeWithinOtherIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_FThreeFiveOneMember" name="FThreeFiveOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccruedInterestOnLongTermCertificatesOfDeposit" name="AccruedInterestOnLongTermCertificatesOfDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_BusinessCombinationFairValueOfPreferredShares" name="BusinessCombinationFairValueOfPreferredShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_DeferredGovernmentGrants" name="DeferredGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AcquiredInProcessResearchAndDevelopment" name="AcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" name="AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_SellingAndMarketingExpensesPolicyTextBlock" name="SellingAndMarketingExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ForeignCurrencyRiskPolicyTextBlock" name="ForeignCurrencyRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" name="AggregateAmountsOfRestrictedCapitalAndStatutoryReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_PercentageOfAmountReceivedOnAgreement" name="PercentageOfAmountReceivedOnAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AffiliatesBeneficialOwnSharesPercentage" name="AffiliatesBeneficialOwnSharesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ContingentValueRightsAgreementMember" name="ContingentValueRightsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_FThreeFiveOneAssetPurchaseAgreementMember" name="FThreeFiveOneAssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ContinentPharmaceuticalsIncMember" name="ContinentPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PercentageOfIndirectOwnershipInterest" name="PercentageOfIndirectOwnershipInterest" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds" name="PercentageOfMinorityInterestOwnershipIndirectlyHolds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_GMPMember" name="GMPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsLineItems" name="DeferredGovernmentGrantsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_BeijingContinentPharmaceuticalsCoLtdMember" name="BeijingContinentPharmaceuticalsCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LesseeOperatingLeaseRenewalTermDescription" name="LesseeOperatingLeaseRenewalTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_WarrantExpirationMonthAndYear" name="WarrantExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AmountToBeReceivedUnderAgreement" name="AmountToBeReceivedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AccruedExpensesGeneralAndAdministrative" name="AccruedExpensesGeneralAndAdministrative" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" name="FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DeferredTaxAssetsImpactFromForeignCorporations" name="DeferredTaxAssetsImpactFromForeignCorporations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_AllowanceForCreditLossesCertificatesOfDeposit" name="AllowanceForCreditLossesCertificatesOfDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PaymentForResearchAndDevelopmentFees" name="PaymentForResearchAndDevelopmentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DeferredIncomeTaxExpenseBenefitNet" name="DeferredIncomeTaxExpenseBenefitNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" name="PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_BCTwoThousandTwentyOneStockIncentivePlanMember" name="BCTwoThousandTwentyOneStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ChangeInFairValueOfLongTermReceivables" name="ChangeInFairValueOfLongTermReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_SeriesXPreferredStockMember" name="SeriesXPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_MinorityInterestDecreaseFromRedemptionsShares" name="MinorityInterestDecreaseFromRedemptionsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AcquisitionCostsInDueToRelatedParties" name="AcquisitionCostsInDueToRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_SupplierReimbursement" name="SupplierReimbursement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_SquareMeterAreaForOfficeSpaceUnderNewLease" name="SquareMeterAreaForOfficeSpaceUnderNewLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_LiquidityTable" name="LiquidityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CPIContributionMember" name="CPIContributionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_SubleaseArrangementMember" name="SubleaseArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" name="AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination" name="ClinicalTrialServicesCostIncurredOnAgreementTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_BusinessCombinationFairValueOfCommonShares" name="BusinessCombinationFairValueOfCommonShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights" name="ObligationToPayInExchangeForTheIntellectualPropertyRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ContingentValueRightsClosingPayable" name="ContingentValueRightsClosingPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_LongTermCertificatesOfDepositPolicyTextBlock" name="LongTermCertificatesOfDepositPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DivestitureLossesMember" name="DivestitureLossesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsCurrentAndNoncurrent" name="DeferredGovernmentGrantsCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_GeneralAndAdministrativeExpensesPolicyTextBlock" name="GeneralAndAdministrativeExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" name="PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PurchaseAgreementAmendmentDate" name="PurchaseAgreementAmendmentDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_StockholdersEquityDisclosureLineItems" name="StockholdersEquityDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PrepaidAssetsCurrent" name="PrepaidAssetsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_OtherDirectorOrOfficerMember" name="OtherDirectorOrOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LegalExpensesIncurred" name="LegalExpensesIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DistributionFromAssetSaleProceeds" name="DistributionFromAssetSaleProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ContingentValueRightsAgreement" name="ContingentValueRightsAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_AccruedExpensesSellingExpenses" name="AccruedExpensesSellingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage" name="AffiliatesBeneficialOwnSharesSpecifiedPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember" name="GCBiophrarmaCorpAssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccruedPayrollAndWelfare" name="AccruedPayrollAndWelfare" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_MinorityHolderContributionsMember" name="MinorityHolderContributionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" name="EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PercentageOfCommonStockFiledLawsuit" name="PercentageOfCommonStockFiledLawsuit" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_LeaseLabAndOfficeSpaceMember" name="LeaseLabAndOfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PercentageOfCommissionForSharesSold" name="PercentageOfCommissionForSharesSold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_CostOfServicesAsPerAgreement" name="CostOfServicesAsPerAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" name="AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_PreferredStockWarrantsPolicyTextBlock" name="PreferredStockWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsCurrent" name="DeferredGovernmentGrantsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance" name="CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_LitigationAmount" name="LitigationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_PercentageOfExcessPreapprovedCosts" name="PercentageOfExcessPreapprovedCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_OrganizationAndNatureOfOperationsLineItems" name="OrganizationAndNatureOfOperationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DrenBioIncAndCopiaScientificLLCMember" name="DrenBioIncAndCopiaScientificLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_DeferredGovernmentGrantsNonCurrent" name="DeferredGovernmentGrantsNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_BusinessCombinationAgreementMember" name="BusinessCombinationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_IncreaseDecreaseInAccountsAndNotesReceivables" name="IncreaseDecreaseInAccountsAndNotesReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PercentageOfRestrictedNetAssetsExceedNetAssets" name="PercentageOfRestrictedNetAssetsExceedNetAssets" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" name="ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DeferredTaxLiabilityRightOfUseAssets" name="DeferredTaxLiabilityRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_MachineryAndElectronicDevicesMember" name="MachineryAndElectronicDevicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LicenseAgreementTerminationMonthAndYear" name="LicenseAgreementTerminationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_LandUseRightsPolicyTextBlock" name="LandUseRightsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_DisposalConsiderationInOtherReceivables" name="DisposalConsiderationInOtherReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock" name="ScheduleOfDeferredGovernmentGrantsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_OrganizationAndNatureOfOperationsTable" name="OrganizationAndNatureOfOperationsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_LandUseRightsNetNoncurrent" name="LandUseRightsNetNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions" name="TemporaryEquityIssuedDuringPeriodValueAcquisitions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_LiquidityAbstract" name="LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ConversionOfOutstandingPreferredStockRedeemedForCash" name="ConversionOfOutstandingPreferredStockRedeemedForCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CVRDerivativeLiabilityNoncurrent" name="CVRDerivativeLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" name="AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_TwoThousandEighteenOmnibusIncentivePlanMember" name="TwoThousandEighteenOmnibusIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ConcentrationOfCustomerRiskPolicyTextBlock" name="ConcentrationOfCustomerRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_BadDebtExpenseAndOtherNonCashItems" name="BadDebtExpenseAndOtherNonCashItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" name="DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_SinopharmGroupCompanyLimitedMember" name="SinopharmGroupCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_BusinessCombinationExcessClosingCashPayable" name="BusinessCombinationExcessClosingCashPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_MaximumAmountOfTaxOffsetPerYear" name="MaximumAmountOfTaxOffsetPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_NoncontrollingInterestPolicyPolicyTextBlock" name="NoncontrollingInterestPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_StockholdersEquityDisclosureTable" name="StockholdersEquityDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember" name="PrivatePlacementAndSecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CvrExcessClosingCashPayable" name="CvrExcessClosingCashPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_GNIUSAMember" name="GNIUSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_MainlandChinaContributionPlanMember" name="MainlandChinaContributionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ChinaResourcesPharmaceuticalGroupLimitedMember" name="ChinaResourcesPharmaceuticalGroupLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_CVRMergerClosingPayable" name="CVRMergerClosingPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_NassimUsmanPhdMember" name="NassimUsmanPhdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" name="PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement" name="TerminationFeeRequiredToPayUponTerminationOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" name="IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_LiquidityLineItems" name="LiquidityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_AccruedSalesDiscount" name="AccruedSalesDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_GCBiopharmaCorpMember" name="GCBiopharmaCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount" name="FairValueAssetsAndLiabilitiesLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_ConvertiblePreferredStockPolicyPolicyTextBlock" name="ConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" name="ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_RemainingNumberOfFullTimeEmployees" name="RemainingNumberOfFullTimeEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_CpUSSharePurchaseAgreementMember" name="CpUSSharePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_SeveranceAndOtherCosts" name="SeveranceAndOtherCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_SubmissionOfTheNewDrugApplicationMember" name="SubmissionOfTheNewDrugApplicationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gyre_PaymentOfDisposalOfSubsidiary" name="PaymentOfDisposalOfSubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable" name="PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gyre_CatalystMember" name="CatalystMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018844869904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 19, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GYRE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gyre Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,423,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12770 High Bluff Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">949-3681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Grant Thornton Zhitong Certified Public Accountants LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Beijing, China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2024 (the &#8220;Proxy Statement&#8221;), which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018750500816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,509<span></span>
</td>
<td class="nump">$ 25,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and note receivables, net</a></td>
<td class="nump">15,552<span></span>
</td>
<td class="nump">17,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">4,281<span></span>
</td>
<td class="nump">6,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PrepaidAssetsCurrent', window );">Prepaid assets</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">57,221<span></span>
</td>
<td class="nump">49,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">23,288<span></span>
</td>
<td class="nump">17,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LandUseRightsNetNoncurrent', window );">Land use rights, net</a></td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">4,695<span></span>
</td>
<td class="nump">4,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LongTermCertificatesOfDeposit', window );">Long-term certificates of deposit</a></td>
<td class="nump">23,431<span></span>
</td>
<td class="nump">7,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">995<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">116,539<span></span>
</td>
<td class="nump">84,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CvrExcessClosingCashPayable', window );">CVR excess closing cash payable</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,935<span></span>
</td>
<td class="nump">9,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">5,054<span></span>
</td>
<td class="nump">2,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">20,047<span></span>
</td>
<td class="nump">12,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred government grants</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CVRDerivativeLiabilityNoncurrent', window );">CVR derivative liability, noncurrent</a></td>
<td class="nump">4,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability, noncurrent</a></td>
<td class="nump">12,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">38,065<span></span>
</td>
<td class="nump">12,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 400,000,000 shares authorized; 76,595,616 shares and 63,588,119 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">68,179<span></span>
</td>
<td class="nump">32,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatutoryReserve', window );">Statutory reserve</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">2,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">(Accumulated deficit) retained earnings</a></td>
<td class="num">(85,538)<span></span>
</td>
<td class="nump">7,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,644)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gyre stockholders' (deficit) equity</a></td>
<td class="num">(15,828)<span></span>
</td>
<td class="nump">42,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">29,777<span></span>
</td>
<td class="nump">29,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">13,949<span></span>
</td>
<td class="nump">72,217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and equity</a></td>
<td class="nump">116,539<span></span>
</td>
<td class="nump">$ 84,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gyre_GCBiopharmaCorpMember', window );">GC Biopharma Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent', window );">Long-term receivable from GCBP</a></td>
<td class="nump">4,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">GNI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables from GNI</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; 13,151 shares and nil shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">$ 64,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CVRDerivativeLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CVR derivative liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CVRDerivativeLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CvrExcessClosingCashPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CVR excess closing cash payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CvrExcessClosingCashPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LandUseRightsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Land use rights net noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LandUseRightsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LongTermCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Certificates Of Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LongTermCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PrepaidAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid assets current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PrepaidAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gyre_GCBiopharmaCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gyre_GCBiopharmaCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018844897584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755862704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 113,450<span></span>
</td>
<td class="nump">$ 102,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">4,636<span></span>
</td>
<td class="nump">4,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">61,159<span></span>
</td>
<td class="nump">54,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">13,780<span></span>
</td>
<td class="nump">16,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,662<span></span>
</td>
<td class="nump">17,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">83,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">180,680<span></span>
</td>
<td class="nump">93,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="num">(67,230)<span></span>
</td>
<td class="nump">9,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other Income</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(9,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expenses</a></td>
<td class="num">(2,594)<span></span>
</td>
<td class="num">(1,374)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(76,965)<span></span>
</td>
<td class="nump">9,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(8,515)<span></span>
</td>
<td class="num">(5,098)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net (loss) income from operations</a></td>
<td class="num">(85,480)<span></span>
</td>
<td class="nump">4,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to common stockholders</a></td>
<td class="num">$ (92,933)<span></span>
</td>
<td class="nump">$ 2,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share attributable to common stockholders, basic</a></td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic</a></td>
<td class="nump">65,831,675<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted</a></td>
<td class="nump">65,831,675<span></span>
</td>
<td class="nump">75,686,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net (loss) income from operations</a></td>
<td class="num">$ (85,480)<span></span>
</td>
<td class="nump">$ 4,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,484)<span></span>
</td>
<td class="num">(4,928)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss from operations</a></td>
<td class="num">(86,964)<span></span>
</td>
<td class="num">(614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation adjustments attributable to noncontrolling interest</a></td>
<td class="num">(647)<span></span>
</td>
<td class="num">(2,170)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interest</a></td>
<td class="nump">6,806<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) attributable to common stockholders</a></td>
<td class="num">$ (93,770)<span></span>
</td>
<td class="num">$ (456)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018748157184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Statutory Reserve</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Total Gyre Stockholders' Equity (Deficit)</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 59,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 25,315<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
<td class="nump">$ 6,340<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
<td class="nump">$ 35,498<span></span>
</td>
<td class="nump">$ 23,967<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AppropriationOfStatutoryReserve', window );">Appropriation of statutory reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
<td class="num">(1,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 13,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,480<span></span>
</td>
<td class="nump">5,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (4,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,758)<span></span>
</td>
<td class="num">(2,758)<span></span>
</td>
<td class="num">(2,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">4,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">72,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">32,795<span></span>
</td>
<td class="nump">2,660<span></span>
</td>
<td class="nump">7,395<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="nump">42,522<span></span>
</td>
<td class="nump">29,695<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</a></td>
<td class="nump">21,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">21,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,531,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Acquisition of minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">7,845<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415)<span></span>
</td>
<td class="nump">7,878<span></span>
</td>
<td class="num">(7,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_MinorityInterestDecreaseFromRedemptionsShares', window );">Acquisition of minority interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,463,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Preferred Stock upon Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Preferred Stock upon Private Placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,127<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">12,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (1,484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(85,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,933)<span></span>
</td>
<td class="nump">7,453<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 13,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 68,179<span></span>
</td>
<td class="nump">$ 3,098<span></span>
</td>
<td class="num">$ (85,538)<span></span>
</td>
<td class="num">$ (1,644)<span></span>
</td>
<td class="num">$ (15,828)<span></span>
</td>
<td class="nump">$ 29,777<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AppropriationOfStatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Appropriation of statutory reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AppropriationOfStatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_MinorityInterestDecreaseFromRedemptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minority interest decrease from redemptions shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_MinorityInterestDecreaseFromRedemptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period shares acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period value acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018754090896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income from operations</a></td>
<td class="num">$ (85,480)<span></span>
</td>
<td class="nump">$ 4,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">83,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,281<span></span>
</td>
<td class="nump">13,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,074<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NoncashLeaseExpense', window );">Noncash Lease Expense</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AmortizationOfLandUseRights', window );">Amortization of land use rights</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredIncomeTaxExpenseBenefitNet', window );">Deferred income taxes, net</a></td>
<td class="num">(1,160)<span></span>
</td>
<td class="num">(838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BadDebtExpenseAndOtherNonCashItems', window );">Bad debt expense and other non-cash items</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedInterestOnLongTermCertificatesOfDeposit', window );">Accrued interest on long-term certificates of deposit</a></td>
<td class="num">(633)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ChangeInFairValueOfLongTermReceivables', window );">Change in fair value of long-term receivable</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ChangeInFairValueOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">9,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_EquityGainLossOfUnconsolidatedAffiliates', window );">Equity loss of unconsolidated affiliates</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncreaseDecreaseInAccountsAndNotesReceivables', window );">Accounts and note receivables</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="num">(7,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables from GNI</a></td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,747<span></span>
</td>
<td class="num">(879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="num">(82)<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Income tax payable</a></td>
<td class="nump">3,003<span></span>
</td>
<td class="num">(1,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">192<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,446<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(473)<span></span>
</td>
<td class="num">(429)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">25,892<span></span>
</td>
<td class="nump">10,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit', window );">Purchase of certificates of deposit</a></td>
<td class="num">(15,735)<span></span>
</td>
<td class="num">(7,484)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(8,517)<span></span>
</td>
<td class="num">(4,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of equipment</a></td>
<td class="nump">664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of equity method investment</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash and cash equivalents acquired in connection with the GNI USA Contributions</a></td>
<td class="nump">5,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CashPaidForAcquisitionCosts', window );">Payments made for acquisition costs</a></td>
<td class="num">(124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PaymentOfDisposalOfSubsidiary', window );">Cash balance in a disposed subsidiary</a></td>
<td class="num">(566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(19,760)<span></span>
</td>
<td class="num">(13,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of Convertible Preferred Stock and Preferred Stock Warrants under the Private Placement</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(1,891)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">8,334<span></span>
</td>
<td class="num">(5,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">25,175<span></span>
</td>
<td class="nump">30,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">33,509<span></span>
</td>
<td class="nump">25,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Financing and Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders', window );">Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions</a></td>
<td class="nump">84,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions', window );">Advance payment for Convertible Preferred Stock and Preferred Stock Warrants acquired upon the GNI USA Contributions</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DisposalConsiderationInOtherReceivables', window );">Disposal consideration in other receivables from GNI</a></td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquisitionCostsInDueToRelatedParties', window );">Acquisition costs in due to related parties</a></td>
<td class="nump">535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liabilities</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable', window );">Proceeds from the exercise of stock options included in other receivable</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable', window );">Purchase of property and equipment included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 6,346<span></span>
</td>
<td class="nump">$ 6,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedInterestOnLongTermCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on long-term certificates of deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedInterestOnLongTermCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AcquisitionCostsInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition costs in due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AcquisitionCostsInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance payment for convertible preferred stock and preferred stock warrants acquired upon contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AmortizationOfLandUseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of&#160;land use rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AmortizationOfLandUseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BadDebtExpenseAndOtherNonCashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debt expense and other non-cash items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BadDebtExpenseAndOtherNonCashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CashPaidForAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CashPaidForAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ChangeInFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ChangeInFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ChangeInFairValueOfLongTermReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of long-term receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ChangeInFairValueOfLongTermReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed issuance of common stock and convertible preferred stock to former stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredIncomeTaxExpenseBenefitNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred income tax expense benefit net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredIncomeTaxExpenseBenefitNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DisposalConsiderationInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal consideration in other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DisposalConsiderationInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_EquityGainLossOfUnconsolidatedAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity gain loss of unconsolidated affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_EquityGainLossOfUnconsolidatedAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_IncreaseDecreaseInAccountsAndNotesReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accounts and notes receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_IncreaseDecreaseInAccountsAndNotesReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PaymentOfDisposalOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of disposal of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PaymentOfDisposalOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of stock options included in other receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of property and equipment included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018850968768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (85,480)<span></span>
</td>
<td class="nump">$ 4,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756184400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 12, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nassim Usman, Ph.D</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">director</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company, entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (as defined in Item 408 of Regulation S-K). Dr. Usman&#8217;s plan provides for the potential exercise of vested stock options and the associated sale of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">240,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of common stock. The trading arrangement terminates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sale of all shares pursuant to the trading arrangement. During the three months ended December 31, 2023, no other director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> any &#8220;Rule 10b5-1 trading arrangement&#8221; or any &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K.</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=gyre_NassimUsmanPhdMember', window );">Nassim Usman, Ph.D</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Nassim Usman, Ph.D<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 12, 2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=gyre_OtherDirectorOrOfficerMember', window );">Other Director or Officer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=gyre_NassimUsmanPhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=gyre_NassimUsmanPhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=gyre_OtherDirectorOrOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=gyre_OtherDirectorOrOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746775072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Organization and Nature of Operations</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Gyre,&#8221; or the &#8220;combined company&#8221;), formerly known as Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;), is a biopharmaceutical company originally incorporated in Delaware on March 7, 1997 under the name Targacept, Inc. Catalyst was a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, Catalyst had several protease assets that were designed to address unmet medical needs in disorders of the complement or coagulation systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After completion of the transactions under the Business Combination Agreement as described below, Gyre became a financially-sustainable pharmaceutical company with a record of financial success that develops and commercializes small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F351 Asset Acquisition</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 26, 2022, Catalyst executed and closed an Asset Purchase Agreement, which was amended on March 29, 2023 (the &#8220;F351 Agreement&#8221;), with GNI Group Ltd. (&#8220;GNI Japan&#8221;) and GNI Hong Kong Limited (&#8220;GNI HK&#8221;) to purchase all of the assets and intellectual property rights primarily related to a clinical-stage proprietary Hydronidone compound for the treatment of nonalcoholic steatohepatitis (&#8220;NASH&#8221;), a severe form of nonalcoholic fatty liver disease (collectively, the &#8220;F351 Assets&#8221;), other than such assets and intellectual property rights located in the People&#8217;s Republic of China (&#8220;PRC&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combination Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 26, 2022, Catalyst entered into a Business Combination Agreement, as amended on March 29, 2023 and August 30, 2023 (the &#8220;Business Combination Agreement&#8221;) with GNI USA, Inc. (&#8220;GNI USA&#8221;), GNI Japan, GNI HK, Shanghai Genomics, Inc. (&#8220;SG&#8221; and collectively with GNI USA, GNI Japan and GNI HK, the &#8220;Contributors,&#8221; and each a &#8220;Contributor&#8221;), certain individuals (each, a &#8220;Minority Holder&#8221; and collectively, the &#8220;Minority Holders&#8221;) and Continent Pharmaceuticals Inc. (&#8220;CPI&#8221;). On October 30, 2023 (the &#8220;Effective Time&#8221;), the Contributions (as defined below) became effective and Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (&#8220;BC&#8221;). In connection with the Contributions, and immediately prior to the Effective Time of the Contributions, Catalyst amended its certificate of incorporation, increased the number of authorized shares of its common stock, par value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the &#8220;Common Stock&#8221;) from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, effected a</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Reverse Stock Split&#8221;) and changed its name to Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of Catalyst Common Stock were previously listed on The Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221; Catalyst had filed a listing application for the combined company with the Nasdaq Stock Market Inc. (&#8220;Nasdaq&#8221;). On October 31, 2023, Gyre&#8217;s Common Stock commenced trading on the Nasdaq Capital Market under the symbol &#8220;GYRE&#8221;, on a post-reverse stock split adjusted basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Business Combination Agreement, at the Effective Time of the Contributions, and after giving effect to the 1-for-15</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GNI USA contributed all of its ordinary shares in the capital of CPI to Catalyst in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45,923,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;CPI Contribution&#8221;), </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GNI USA contributed its interest in Further Challenger International Limited (&#8220;Further Challenger&#8221;) for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,664,779</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;FC Contribution&#8221; and together with the CPI Contribution, the &#8220;GNI USA Contributions&#8221;), and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">each Minority Holder contributed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the interest he or she held in his or her respective entity in exchange for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,463,627</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Gyre Common Stock (the &#8220;Minority Holder Contributions&#8221; and together with the GNI USA Contributions, the &#8220;Contributions&#8221;). </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the GNI USA Contributions, Gyre directly and indirectly holds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of CPI&#8217;s shares. Through Gyre&#8217;s ownership of CPI, prior to the Minority Holder Contributions, Gyre held a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">56.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> indirect interest in BC. Upon completion of the Minority Holder Contributions, Gyre obtained additional indirect interests in BC and holds, in aggregate, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">65.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> indirect interest in BC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately after the closing of the Contributions, excluding potentially dilutive securities, GNI USA owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">83.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the outstanding shares of Gyre Common Stock, Catalyst&#8217;s existing stockholders, excluding GNI USA, owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the outstanding Gyre Common Stock, and the Minority Holders owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the outstanding shares of Gyre Common Stock. The Convertible Preferred Stock remained outstanding after the closing of the Contributions and is not included in the above ownership percentages.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the Effective Time, BC terminated its 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;) and the options (the &#8220;BC Options&#8221;) outstanding under the 2021 Plan were terminated and replaced with options granted under a subplan for Chinese participants under the Gyre 2023 Omnibus Incentive Plan (the &#8220;2023 Omnibus Incentive Plan&#8221;) that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remained issued and outstanding, and such shares and options were unaffected by the Contributions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BC is a commercial-stage biopharmaceutical company registered and established in the PRC in 2002. BC is committed to the research and development of new drugs as well as manufacturing and commercialization of ETUARY (pirfenidone capsule) for the treatment of idiopathic pulmonary fibrosis and other pharmaceutical products. The registered office of BC is located at 60 Shunkang Road, Shunyi District, Beijing, PRC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The immediate holding company of BC is BJContinent Pharmaceuticals Limited (&#8220;BJC&#8221;). The intermediate holding company of BC is CPI. Immediately following the Contributions, the immediate holding company of CPI is Gyre. The immediate holding Company of Gyre is GNI USA and the ultimate holding company of Gyre is GNI Japan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GNI USA Contributions were treated as an asset acquisition under U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), with CPI treated as the accounting acquirer and presented as the predecessor for the post-acquisition SEC reporting purposes. Since Catalyst is the legal acquirer, the GNI USA Contributions were accounted for as a reverse asset acquisition. This determination was based upon the terms of the Business Combination Agreement and other factors including that, immediately following the GNI USA Contributions: (i) GNI USA (as the parent company of CPI immediately prior to the GNI USA Contributions) owns a substantial majority of the voting power of the combined company; (ii) CPI, through GNI USA, has the ability to control the board of directors of the combined company; and (iii) senior management of BC and GNI USA holds a majority of the key positions in senior management of the combined company. Immediately prior to the closing of the Contributions, Catalyst did not meet the definition of a business because Catalyst did not have an organized workforce that significantly contributed to its ability to create output, and substantially all of its fair value was concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the closing date of the GNI USA Contributions, the net assets of Catalyst were recorded at their acquisition-date relative fair values in the accompanying consolidated financial statements of the Company and the reported operating results prior to the GNI USA Contributions are those of CPI.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in BC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Value Rights Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with the signing of the Business Combination Agreement on December 26, 2022, Catalyst and the Rights Agent (as defined in the CVR Agreement) executed a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), as amended on March 29, 2023, pursuant to which each holder of Catalyst Common Stock as of January 5, 2023 (the &#8220;CVR Holder&#8221;), excluding GNI, received one contractual contingent value right (a &#8220;CVR&#8221;) for each share of Catalyst Common Stock held by such holder. Each CVR entitles the holder thereof to receive certain cash payments in the future. For additional information, see Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company effected a 1-for-15 reverse stock split immediately prior to the Effective Time of the Contributions. The par value of the Catalyst Common Stock following the Reverse Stock Split was not adjusted and remains at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. All of the Catalyst&#8217;s issued and outstanding common stock and options have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, warrants, and in the case of stock options and warrants, a proportional decrease in the exercise price of such stock options and warrants.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Stock Split and stockholders who would otherwise be entitled to a fraction of one share received a proportional cash payment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, the Company had a net loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, while net cash provided by operating activities was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Based on the Company&#8217;s current operating plan, management believes that existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund the Company&#8217;s operating activities and obligations for at least 12 months following the issuance of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755651280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Summary of Significant Accounting Policies</span></p></td>
     </tr>
    </table><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Noncontrolling Interest</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reports noncontrolling interest (&#8220;NCI&#8221;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM, as a group, includes Gyre&#8217;s Chief of Executive Officer (&#8220;CEO&#8221;), BC&#8217;s General Manager, and the Chairman of Gyre&#8217;s Board of Directors (&#8220;Gyre&#8217;s Board&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has determined that it operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> distinct operating segments and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">f Credit Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts and note receivable, and long-term certificates of deposits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had cash of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and long-term certificates of deposit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2015, a new Deposit Insurance System (&#8220;DIS&#8221;) managed by the People&#8217;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#8220;RMB&#8221;) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ac</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Customer Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, one customer, Sinopharm Group Co., Ltd., accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, of accounts receivable, respectively. For the year ended December 31, 2023, three customers known as Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total revenue respectively. For the year ended December 31, 2022, three customers known as Sinopharm Group Co., Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, and China Resources Pharmaceutical Group Ltd accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total revenue respectively. All customers are located in the PRC.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests portion of its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Value Measurements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments and Contingencies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for additional information regarding the CVR derivative liability.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants to purchase shares of the Convertible Preferred Stock (&#8220;Preferred Stock Warrants&#8221;) are freestanding financial instruments classified as warrant liability on the Company&#8217;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#8217;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to account for the Convertible Preferred Stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-term Certificates of Deposit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The long-term certificates of deposit will mature between February 2025 and July 2026. Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using the effective interest method. The Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowance for credit losses associated with the certificates of deposit as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Term Receivable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#8220;GCBP&#8221;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for additional information regarding the long-term receivable.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts and Note Receivables, Net</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#8217;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#8217;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:68.014%;"></td>
          <td style="width:1.78%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.843%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.362%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,204</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,738</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Note receivable</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">389</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,522</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for credit losses</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts and note receivables, net</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,552</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,136</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in the allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:68%;"></td>
          <td style="width:1.58%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.42%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, beginning of year</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for allowance for credit losses</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recoveries collected and write-off</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, end of year</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:5.204%;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;"></td>
          <td style="width:58.58%;"></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Buildings</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvement</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="-sec-ix-hidden:F_b8d10737-f18e-4a8d-80f3-5bcbf043af92;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of the estimated useful life or the term of the lease</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and electronic devices</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Motor vehicles</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible Assets, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patents and Technological Know-How</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Computer Software</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ba9e4760-e1ab-447a-a061-08082fe718fe;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#8217;s leases do not contain any residual value guarantees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Land Use Rights, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount of an asset group exceeds its fair valu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any impairment of long-lived assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Expense</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#8217;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Sale of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer, generally upon completion of quality inspection by the distributor after delivery of the pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#8217;s estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) License of Intellectual Property</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from a license agreement is recognized at a point in time when the control of the right to use the license is transferred to the customer. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development or regulatory milestone payments, which are included in the transaction price to the extent that it is probable that a significant reversal of accumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of any milestones, and if necessary, adjusts its estimated transaction price on a cumulative catch-up basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any contract assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue is recognized when a payment is received from a customer before the Company transfers the related goods or services. Deferred revenue is recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of December 31, 2023, the Company&#8217;s deferred revenue balance was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Deferred revenue was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">145,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2022 which has been recognized as revenue during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#8217;s assumptions regarding a number of variables including the fair value of its common stock, its expected common stock price volatility over the expected</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquired IPR&amp;D</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition date. Refer to Note 7 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for a more detailed description.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling and Marketing Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government Grants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive (loss) income.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Income (Loss)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Income (Loss) </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Per Share (&#8220;EPS&#8221;) Attributable to Common Stockholders</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 260&#8221;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#8217;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EPS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Translation and Remeasurement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of BC is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company uses the U.S. Dollar as its reporting currency.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and  equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive (loss) income. During the year ended December 31, 2023, the Company had translation loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. During the year ended December 31, 2022, the Company had translation loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operations and comprehensive (loss) income. The foreign currency transaction gains or losses for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">were immaterial.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#8217;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. 99.5% of the Company&#8217;s cash and long-term certificates of deposit as of December 31, 2023 of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, were denominated in RMB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Pronouncements Recently Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, the FASB issued ASU 2021-04, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2021-04 and related updates on</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> January 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the adoption </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have a material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, FASB issued ASU 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the previous models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2021. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2020-06 on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the adoption </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have a material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2021-08 and related updates on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The adoption of ASU 2021-08 had </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impact on the consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the FASB issued ASU 2021-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government Assistance (Topic 832) &#8212; Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The amendments in this ASU require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity&#8217;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> this standard as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The adoption of this ASU </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have any material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the Company&#8217;s consolidated financial statements.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company plans to adopt annual requirements and related updates under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently assessing the impact of adoption of this standard on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#8217;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746775072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Financial Instruments</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">3.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements and Financial Instruments</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a description of the fair value hierarchy and fair value methodology, see Note 2 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the Company&#8217;s highly liquid money market funds are included within cash equivalents.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(1)  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</span></p></div><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash, accounts and note receivables, net, other receivables, accounts payable, due to related parties, CVR excess closing cash payable, and accrued liabilities approximate their fair values due to their short maturities.</span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers of fair value measurement between Level 1 and Level 2 and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers into or out of Level 3 for both financial assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> financial assets and liabilities measured at fair value as of December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-term Receivables and CVR Derivative Liability</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The long-term receivable and the corresponding CVR derivative liability, noncurrent relate to the asset purchase agreement with GCBP. The fair value of this long-term receivable and derivative liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The estimated fair value of the long-term receivable and CVR derivative liability, noncurrent was determined based on the anticipated amount and timing of projected cash flows to be received from GCBP pursuant to the GCBP asset purchase agreement discounted to their present values using an estimated discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the Company expects to receive a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> hold-back payment from GCBP in the first quarter of 2025, which will be distributed, net of expenses, to the CVR Holders. The change in fair value of the long-term receivable from GCBP and the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">corresponding CVR derivative liability, noncurrent was recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, Catalyst entered into a Securities Purchase Agreement for a private placement with GNI USA (the &#8220;Private Placement&#8221;). The Private Placement closed immediately following the closing of the Contributions on October 30, 2023. Upon closing of the Private Placement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock and </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Preferred Stock Warrants to purchase shares of Convertible Preferred Stock t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">o GNI for an aggregate purchase price of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Preferred Stock Warrants are immediately exercisable at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,915.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of Convertible Preferred Stock and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 30, 2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he number of shares of Common Stock issuable upon exercise and conversion of the Preferred Stock Warrants is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">540,666</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company accounted for the Private Placement as a non-arm's length transaction. The Preferred Stock Warrants were initially recognized at fair value upon issuance and the remaining proceeds from the Private Placement were allocated to the Convertible Preferred Stock.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Preferred Stock Warrants are freestanding financial instruments classified as a warrant liability on the Company&#8217;s consolidated balance sheet. The Preferred Stock Warrants are revalued each reporting period with the change in fair value recorded as change in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the warrant liability is estimated based on th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Black-Scholes option pricing model using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.984%;"></td>
        <td style="width:1.7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.317%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,915.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.88</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.83</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level 3 financial assets and liabilities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.700000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Instruments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.02%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds  (cash equivalents)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749923488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance Sheet Components</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, net of reserves of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and 2022, respectively, consisted of the following components (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.986%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.637%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,056</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision for inventory and write-downs for the years ended December 31, 2023 and 2022 were immaterial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other liabilities consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.280000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll and welfare</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,038</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplier reimbursement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,247</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses - general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued sales discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">748</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">837</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee reimbursement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses - research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses - selling expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred government grants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred government grants represent funds provided by the government for research and development, construction of new facilities, or improvement of existing production facilities. The amount of deferred government grants as of December 31, 2023 and 2022, is net of the amount recognized as government grant income. During the years ended December 31, 2023 and 2022, the Company received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> government grants, respectively. During the years ended December 31, 2023 and 2022, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of government grant income within other income in the consolidated statements of operations and comprehensive (loss) income, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summarized below are deferred government grants as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government grants for property and equipment, included in accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government grants for property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">253</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.76%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Buildings</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,289</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,837</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,875</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,851</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and electronic devices</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,598</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">631</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Motor vehicles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,288</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,709</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each of the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749885232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible Assets</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The gross carrying amounts and accumulated amortization of the Company&#8217;s intangible assets with determinable lives as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.99%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.197000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.077%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.157%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">171</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">601</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,038</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,741</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">297</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets are carried at cost less accumulated amortization and impairment, if applicable, and the amortization expense is recorded in operating expenses. The weighted average amortization period for the intangible assets as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.05</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amortization expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each of the years ended December 31, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on finite-lived intangible assets recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the estimated future amortization expense is as follows (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:85.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.28%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Amortization Expense</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018867000640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s product revenues were mainly generated from the sale of ETUARY. Sales of ETUARY accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">98.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">96.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total revenue for the years ended on December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue mostly through sales of ETUARY and certain generic drugs. The distributors were the Company&#8217;s direct customers, and sales to distributors accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of revenue from ETUARY. The distributors sell ETUARY to outlets, including hospitals and other medical institutions, as well as pharmacies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product returns to date have not been significant and the Company has not considered it necessary to record a reserve for product returns. The Company&#8217;s product revenues were recognized at a point in time when the underlying product was delivered to the customer, which was when the customer obtained control of the product. Revenue from sales of pharmaceutical products was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">113.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively. All sales are generated in the PRC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from licensing intellectual property is recognized when the control of the right to use the license is transferred to the customer. Milestone payments, which are included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur, represent a form of variable consideration, which is recognized as revenue when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered highly probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s sales by product categories for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.814%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.323%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.863000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales of Pharmaceutical Products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,450</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">License of Intellectual Property</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,414</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755501728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">GNI USA Contributions under the Business Combination Agreement</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GNI USA Contributions under the Business Combination Agreement (see Note 1) was treated as a reverse asset acquisition, with CPI as the accounting acquirer and Catalyst as the legal acquirer. Under U.S. GAAP, a company must evaluate if an integrated set of assets and activities qualifies as a business acquisition or an asset acquisition by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assessing if the gross assets&#8217; fair value is primarily concentrated in a single asset or a group of similar assets. If this criterion is met, the acquired operations are not considered a business. Catalyst did not meet the business definition as its fair value was concentrated in one IPR&amp;D asset, it lacked an organized workforce contributing significantly to output creation, and no substantive processes were acquired. As such, the GNI USA Contributions was treated as an asset acquisition. In an asset acquisition, goodwill is not recognized, and the cost allocated to the acquired IPR&amp;D with no alternative future use is expensed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:1%;"></td>
        <td style="width:84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Catalyst Common Stock outstanding</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,532</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Multiplied by the fair value per share of Catalyst stock (1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common shares to be owned by Catalyst&#8217;s stockholders</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,420</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of preferred shares to be owned by Catalyst&#8217;s stockholders (2)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,099</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of Catalyst</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,519</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of consideration issued</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,348</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">659</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase price</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,007</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This amount is calculated based on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">666.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span></span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:84%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.30</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.65</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
          <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:84.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.04%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables from GNI</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,097</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets, noncurrent</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">IPR&amp;D</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Advance payment received from GNI</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR excess closing cash payable</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,085</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR derivative liability, noncurrent</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net assets acquired</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in BC.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755283712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Restructuring</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Contributions, CPI entered into a CP </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Share Purchase Agreement with GNI USA </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and divested almost all of its assets other than its </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">56.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> indirect ownership interest in BC. GNI USA is the parent company of Gyre. In connection with the transaction, the Company recorded a receivable in the amount of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> included in other receivables from GNI on the consolidated balance sheet as of December 31, 2023 and recognized a loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during the year ended December 31, 2023, included in divestiture losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the consolidated statements of operations and comprehensive (loss) income.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018747026304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">9.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Leases</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> BC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s corporate headquarters, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">968</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square meter office space, is situated in Beijing, PRC, with the lease expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Additionally, a laboratory center spanning approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">640</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square meters was leased in Shanghai, China, which expired in November 2023. In 2022, the Company secured a new lease for an office space of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">180</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square meters in Zhengzhou, China, with the lease set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In November 2023, the Company also secured a new lease for its U.S. headquarters in San Diego, United States, with the lease set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also has multiple short-term leased properties used as offices and employee dormitories. The Company recorded a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">89,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> short-term rent expenses during the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The short-term rent expense amounts are recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive (loss) income.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>As of December 31, 2023, the Company recorded an aggregate ROU asset of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and an aggregate lease liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rent expense related to operating leases was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each of the years ended December 31, 2023 and 2022, respectively. Variable lease payments for the years ended December 31, 2023 and 2022 were immaterial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.04%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">573</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The present value assumptions used in calculating the present value of the lease payments were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.687%;"></td>
        <td style="width:14.141%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:14.141%;"></td>
        <td style="width:1.01%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
        <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.78</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.75</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, undiscounted future minimum payments under the Company&#8217;s operating leases were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:83%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.16%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">409</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to maintain security deposits of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in connection with various leases, which amounts are included in other assets, noncurrent on the Company&#8217;s consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Land use rights</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company held land use rights for two land parcels in Beijing&#8217;s Shunyi District, expiring in 2053, and in Cangzhou, Hebei Province, expiring from 2067 to 2071. These parcels, with a combined area of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">66,559</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square meters, are utilized as manufacturing facilities. As of December 31, 2023, the aggregate recorded land use rights, net assets for these parcels was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746994864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders&#8217; Equity</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Company&#8217;s amended and restated certificate of incorporation, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock authorized for issuance with a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value per share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. The holders of Common Stock have voting rights equal to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one vote</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of Common Stock held. The holders of Common Stock are entitled to receive dividends when and as declared or paid by the Company&#8217;s board of directors.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.72%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Preferred Stock issued and outstanding</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,767,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred Stock Warrants issued and outstanding</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,280,548</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,036,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,588,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,036,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 ATM Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 15, 2021, Catalyst entered into an Equity Distribution Agreement (the &#8220;ATM Agreement&#8221;) with Piper Sandler &amp; Co. (&#8220;Piper Sandler&#8221;) as sales agent, pursuant to which the Company may offer and sell, from time to time,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">through Piper Sandler, shares of the Company&#8217;s Common Stock, par value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, with aggregate gross sales proceeds of up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through an at-the-market offering program (the &#8220;ATM Program&#8221;). The Company will pay Piper Sandler a commission of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the gross proceeds of any shares sold. The Company also agreed to reimburse Piper Sandler for certain expenses incurred in connection with its services under the ATM Agreement, including up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for legal expenses in connection with the establishment of the ATM Program. The Company does not currently intend to use this or any other ATM Program prior to April 1, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of shares of common stock under the ATM Program may be made pursuant to the registration statement on Form S-3 (File No. 333-253874), which was declared effective by the SEC on May 3, 2021, and a related prospectus supplement filed with the SEC on October 15, 2021. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were sold under the ATM Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Net Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under PRC laws and regulations, BC is subject to restrictions on foreign exchange and cross-border cash transfers, including to parent companies and U.S. stockholders. The ability to distribute earnings to the parent companies and U.S. stockholders is also limited. Current PRC regulations permit BC to pay dividends to BJC only out of its accumulated profits as determined in accordance with PRC accounting standards and regulations. Amounts restricted include paid-in capital and the statutory reserves of BC. The aggregate amounts of restricted capital and statutory reserves, which represented the amount of net assets of the relevant subsidiaries not available for distribution were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">64.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">61.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the above restrictions, parent-only financial statements are presented in Schedule I.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Statutory Reserve</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BC is required to set aside at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of its after-tax profits as the statutory reserve fund until the cumulative amount of the statutory reserve fund reaches </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of its registered capital, if any, to fund its statutory reserves, which are not available for distribution as cash dividends. At the Company&#8217;s discretion, the Company may allocate a portion of after-tax profits based on PRC accounting standards to a discretionary reserve fund.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Appropriations to these reserves by BC were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> appropriations to these reserves during the year ended December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746823824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">11.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock with par value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share under its restated certificate of incorporation, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125,040</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares are designated as Convertible Preferred Stock as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, Catalyst issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock to GNI in connection with the F351 Asset Acquisition (see Note 1 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Nature of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, immediately following the closing of the Contributions, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Preferred Stock Warrants to GNI under the Private Placement. For additional information, see Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, GNI provided notice to the Company to convert its </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,151</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock. The conversion became effective on January 22, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Convertible Preferred Stock is classified outside of stockholders&#8217; equity because the shares contain certain redemption features that are not solely within the Company&#8217;s control. The Company does not adjust the carrying value of the Convertible Preferred Stock to its redemption value since the Convertible Preferred Stock is not currently redeemable, and it is not probable that it will become redeemable in the future at any of the balance sheet dates. Subsequent adjustments to the carrying value will be made only when it becomes probable that such redemption will occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Convertible Preferred Stock are entitled to receive dividends equal to, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Company&#8217;s common stock. Except as otherwise required by law, the Convertible Preferred Stock does not have voting rights. However, as long as any shares of Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of Convertible Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to Convertible Preferred Stock or alter or amend the Certificate of Designation that authorized the Convertible Preferred Stock, amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Bylaws of the Company, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Convertible Preferred Stock, (ii) issue further shares of Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Convertible Preferred Stock, or (iii) enter into any agreement with respect to any of the foregoing. Convertible Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,151</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock issued and outstanding. Each share of Convertible Preferred Stock is convertible into approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">666.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock. As of December 31, 2023, the number of shares of common stock issuable upon conversion of the outstanding shares of Convertible Preferred Stock is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,767,332</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755341248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Based Compensation</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BC 2021 Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2021, the board of directors of BC approved the 2021 Plan to grant options to certain employees and consultants of BC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2021 Plan had a contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Options granted under the 2021 Plan were accounted for as equity awards and subject to a service condition. Upon the Contributions, BC terminated the 2021 Plan and the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BC Options under the 2021 Plan were terminated and replaced with options to purchase Gyre Common Stock granted under the 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, prior to the Contributions, the Board of Directors of BC modified the expiration term of the fully vested BC Options to be extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 3, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Following this modification, the total incremental stock-based compensation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was immediately recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Omnibus Incentive Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2018, stockholders of Catalyst approved a 2018 Omnibus Incentive Plan, as amended in June 2021 (the &#8220;2018 Omnibus Incentive Plan&#8221;). Each option to purchase shares of Catalyst common stock that was issued and outstanding under the 2018 Omnibus Incentive Plan immediately prior to the Effective Time remains outstanding and unaffected after the Contributions in accordance with its terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Omnibus Incentive Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2023 Omnibus Incentive Plan was approved by Catalyst&#8217;s stockholders in August 2023 and ratified by Gyre&#8217;s Board in October 2023. The 2023 Omnibus Incentive Plan became effective on October 30, 2023. The 2023 Omnibus Incentive Plan permits the Company to deliver up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,845,496</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock and will automatically increase by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of outstanding shares of Common Stock on December 31st of the preceding calendar year and (ii) such smaller number of shares of Common Stock as determined by the Board on the first day of each fiscal year beginning on January 1, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the Contributions, the Company modified the expiration term of the fully vested options originally granted as the BC options to be extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 30, 2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As a result of this modification, the total incremental stock-based compensation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was immediately recognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 30, 2023, upon closing of the Contributions, the Gyre Board approved grants to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">five</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> individuals, to be made on October 31, 2023, of an aggregate of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">820,824</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fully vested stock options in consideration for services rendered in connection with the Contributions transactions. Although the awards were granted for the services in connection with the Contributions, which were direct and incremental costs incurred to complete the reverse asset acquisition, they were issued to Gyre&#8217;s employees and consultants who worked on the Contributions instead of third-parties and therefore, do not qualify as transactions costs of the reverse asset acquisition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock option activity considering the conversion of BC Options to Gyre options to purchase shares of Gyre Common Stock upon completion of the GNI USA Contributions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.052%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.031%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.031%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.031%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares Underlying Outstanding Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Remaining Contractual Term (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value (Thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,036,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">838,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,280,548</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">444,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,262,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of options granted during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options were granted during the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of options exercised during the year ended December 31, 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options were exercised during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation Assumptions</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited relevant historical data, the Company estimated its volatility considering a number of factors, including the use of the volatility of comparable public companies. The expected term of options granted under the 2023 Omnibus Incentive Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited relevant history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of employee stock options granted was estimated using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.64%;"></td>
        <td style="width:4.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility (%)</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.30</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate (%)</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.82</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.77</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected option life (in years)</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.8</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield (%)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average share price of the Company (USD per share)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total stock-based compensation recognized was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.634%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.963000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,301</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had an unrecognized stock-based compensation expense of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.87</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755322480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">13.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Commitments and Contingencies</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Value Rights Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each CVR under the CVR Agreement (see Note 1 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Nature of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) entitles the holder to receive (i) certain cash payments from the net proceeds related to the disposition of Catalyst&#8217;s legacy assets, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by the Company in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of the closing date of the transactions under the Business Combination Agreement, (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the amount actually received by the Company, net of expenses, pursuant to an asset purchase agreement Catalyst entered into with Vertex Pharmaceuticals Inc. (&#8220;Vertex&#8221;) in May 2022 and (iv) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the excess amount, by which the preapproved costs to manage, negotiate, settle and finalize certain third party claims exceed the costs actually incurred with respect to such claims. The CVRs are not transferable, except in certain limited circumstances as provided for in the CVR Agreement, will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August, 2023, Catalyst fully settled the CVR payments related to the Vertex asset purchase agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, Catalyst sold its legacy rare bleeding disorder program to GCBP. As a result, the Company distributed the net cash proceeds received from the GCBP asset sale of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the CVR Holders as well as recorded a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> long-term CVR derivative liability for the future distribution of the hold-back amount to be received in May 2025. As of December 31, 2023, the carrying value of the CVR derivative liability was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the consolidated balance sheet. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for additional information regarding the CVR derivative liability and GCBP asset sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 30, 2023, pursuant to the CVR Agreement, the Company recorded a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> CVR excess closing cash payable upon closing of the Contributions, which is anticipated to be distributed among the CVR Holders and remained outstanding as of December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Litigation and Legal Matters</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company&#8217;s consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, separate stockholders of Catalyst filed lawsuits in the Delaware Chancery Court, captioned </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bushansky v. Catalyst Biosciences, Inc., et al </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Scott v. Catalyst Biosciences, Inc., et al., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">alleging Catalyst violated its fiduciary duties under Delaware Law by failing to disclose purportedly material information regarding the proposed Business Combination Agreement. In February 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4, both lawsuits were dismissed with prejudice and the Company reimbursed the stockholders for their legal and other expenses related to the litigation in the aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company recorded a litigation settlement liability in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in October 2023 when it became probable and estimable, which was included in accrued expenses and other current liabilities on the consolidated balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purchasing Commitments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s commitments related to purchase of property and equipment contracted but not yet reflected in the consolidated financial statements were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and were expected to be incurred within one year.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F351</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, BC entered into an intellectual property (&#8220;IP&#8221;) transfer agreement (the &#8220;F351 Transfer Agreement&#8221;) with GNI Japan and certain of its wholly owned subsidiaries (the &#8220;GNI Group&#8221;). According to the F351 Transfer Agreement, BC acquired the exclusive right to use Hydronidone IP rights in mainland China and the right of first offer for the global IP rights (the &#8220;F351 IP Rights&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the F351 Transfer Agreement, in exchange for the F351 IP Rights, BC is obligated to pay GNI Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon submission of the F351 New Drug Application (the &#8220;NDA&#8221;) to Center for Drug Evaluation of the National Medical Products Administration (the &#8220;NMPA&#8221;) of the PRC, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the NDA passes the NMPA&#8217;s Center for Food and Drug Review and Inspection&#8217;s on-site registration inspection for the F351 product, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon NMPA&#8217;s approval of the NDA.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Programs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the F351 program, as of December 31, 2023, the Company has committed to allocate </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> toward future research and development activities for various programs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnifications</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, the Company may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018747482000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">14.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Income Taxes</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Company completed its acquisition of the controlling interest in BC. As a result of the Contributions, the Company directly or indirectly owned multiple controlled foreign corporations (&#8220;CFCs&#8221;) for US tax purposes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the Company&#8217;s provision for income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consist of the following (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.094%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.123000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.123000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current income tax provision:</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,343</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,987</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current income tax provision</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,349</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,988</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred income tax provision:</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">834</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred income tax provision</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">834</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">890</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax provision</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,515</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.066%;"></td>
        <td style="width:15.137%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:15.137%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rate difference due to different jurisdiction</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.43</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.31</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferential income tax rate for HNTE</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.19</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.37</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible expense &#8211; Operating</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.28</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33.06</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible expense &#8211; One-time expense related to the Contributions</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.16</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D Super-deduction</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.45</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.42</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance change</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.37</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESOP</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.55</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.81</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.76</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.52</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.91</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54.87</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.566%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.536%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.889%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">183</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other equity investments</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carry forwards</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,463</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed and intangible assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impact from foreign corporations</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized transaction costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">414</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income tax assets before valuation allowance</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,660</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,175</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability &#8211; ROU assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability &#8211; Fixed assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,773</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,695</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,081</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The movements of the valuation allowance are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.566%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.536%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.889%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes of valuation allowances</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,773</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,773</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the available objective evidence on December 31, 2023, the Company does not believe it is more likely than not that its net deferred tax assets will be realizable for US tax purposes. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets on December 31, 2023 for US tax purposes.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, after consideration of certain limitations (see below), the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">193.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million federal and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for federal and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2034</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for state tax purposes. The federal net operating loss carryforward includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">191.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that have an indefinite life.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for state. If unused, the federal credit will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2042</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the state tax credit does not expire.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company&#8217;s stock immediately before such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes under Section 382 occurred on December 31, 2007, August 20, 2015, April 13, 2017, February 15, 2018, February 18, 2020, and December 26, 2022. Approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">156.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the NOLs will expire unutilized for federal and California state income tax purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">32.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for federal and California state income tax purposes, respectively, through the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the federal R&amp;D credits could expire unutilized, whereas none of the California R&amp;D credits are subject to expiration. Approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of gross federal R&amp;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and credit carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 29, 2020, the California Governor signed Assembly Bill 85 (&#8220;A.B. 85&#8221;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of tax per year. Generally, A.B. 85 suspends the use of California NOLs for taxable years 2021, 2022, and 2023 for taxpayers with taxable income of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million or more. Since the Company is not expected to generate California source taxable income of more than $1 million, no material impact is anticipated at this time.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Uncertainty in Income Taxes</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of unrecognized tax benefits as of December 31, 2023. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning Balance on January 1, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending Balance on December 31, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase as a result of the GNI USA Contributions on October 30, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,833</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending Balance on December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,833</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#8217;s consolidated statements of operations. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any tax-related penalties or interest in its consolidated financial statements.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files income tax returns in the United States federal, California, and Florida for tax year 2023. The Company filed an initial return in 2022 in Florida and final returns in 2021 in Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> uncertain tax positions which affected its financial position as its results of operations or its cash flow, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">APB 23</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, a taxable outside basis difference associated with a foreign subsidiary may not be recognized if the indefinite reversal criterion of ASC paragraph 740-30-25-17 (APB Opinion No. 23, Accounting for Income Taxes &#8211; Special Areas (&#8220;APB 23&#8221;)) is met. A deferred tax liability is recognized when an entity no longer meets the indefinite reversal criterion. ASC paragraph 740-30-25-17 provides a presumption that all undistributed earnings will be transferred to the parent entity may be overcome, and no income taxes shall be accrued by the parent entity, if sufficient evidence shows that the subsidiary has invested or will invest the undistributed earnings indefinitely or that the earnings will be remitted in a tax-free liquidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not have a plan of repatriation of earnings from non-US subsidiaries to the Company. However, to the extent the Company will not permanently reinvest in its PRC business, a DTL of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 related to PRC withholding taxes on repatriation of BC&#8217;s earnings (i.e., the Company&#8217;s primary operating subsidiary in the PRC) would need to be recorded.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746842944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">15.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Related Party Transactions</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F351 Transfer Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the F351 Transfer Agreement (see Note 13), as part of the consideration, BC paid </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to GNI during the years ended December 31, 2021 and December 31, 2020, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development with GNI</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research and development fees were paid to GNI during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. During the year ended December 31, 2022, the Company paid </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as research and development fees to GNI.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related parties payable due to GNI, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other receivables from GNI</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in other receivables from GNI, of which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was from CPI&#8217;s restructuring transaction (see Note 8) and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was from Gyre&#8217;s cost sharing with GNI. No amounts were due from GNI as of December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755638816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EPS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EPS</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">16.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EPS</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The dilutive effect of outstanding stock options and warrants is calculated using the treasury stock method. Stock options and warrants are anti-dilutive and excluded from the diluted net income per share attributable to common stock calculation if the exercise price exceeds the average market price of the common shares.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.525%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.899000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.546%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,314</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,012</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income attributable to common stockholders - basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,933</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic common shares outstanding:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,831,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,588,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,831,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,588,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">            </span></p></td>
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive potential common shares:</span></p></td>
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,098,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,831,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,686,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income per share attributable to common stockholders:</span></p></td>
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.04</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:83%;"></td>
        <td style="width:1.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,280,548</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Preferred stock (as converted)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,767,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred Stock Warrants (as converted)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,588,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746842944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">17.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Employee Benefit Plans</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mainland China Contribution Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to relevant PRC regulations, the Company is required to make contributions to various defined contribution plans organized by municipal and provincial PRC governments. The contribution for each employee is based on a percentage of the employee&#8217;s current compensation as required by the local government. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme. The total</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contributions for such employee benefits were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023, and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Defined-Contribution Savings Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., the Company maintains a defined-contribution savings plan pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended. The plan is available to employees who meet the minimum age and length of service requirements. The contributions made during the year ended December 31, 2023 were immaterial.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 715<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482236/912-715-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755296128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">18.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Segment Information</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is a consolidated entity comprised of two distinct operating segments: BC and Gyre after the Contributions. The Company&#8217;s reportable segments are based upon internal organizational structure, the manner in which operations are managed, the criteria used by CODM to evaluate segment performance the availability of separate financial information, and overall materiality considerations. All Gyre&#8217;s operations are within the U.S., while all of BC&#8217;s operations are in mainland China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BC</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BC has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. BC&#8217;s product revenues are mainly generated from the sale of ETUARY and certain generic drugs. BC primarily sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. BC also generates revenue from license agreements. However, the license agreements did not generate any revenue for the year ended December 31, 2023 and an immaterial amount for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gyre</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of NASH-associated liver fibrosis in the United States. Other than the IP associated with F351 in the U.S., Gyre has no other product candidates since the Company sold all of its legacy IP assets prior to the closing of the Contributions. Subsequent to the closing of the Contributions, Gyre has not generated any revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Segment information for the years ended December 31, 2023 and 2022 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,636</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,636</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross profit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,159</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,159</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,780</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,214</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">576</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,662</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired in-process research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(2)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income (Loss) from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,488</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,488</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(1) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents legal expense recorded in CPI during the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(2) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents divestiture losses. See Note 8 for details.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.67%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.218%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101,761</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,865</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">913</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,539</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.67%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.218%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,517</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,517</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross profit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,497</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,497</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(3)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,370</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,301</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,301</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(3) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents the other subsidiaries, CPI and GNI HK, etc. reported an aggregate $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million general and administrative expense during the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,753</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018909174304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:6.18%;"></td>
      <td style="width:93.82%;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">19.</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Subsequent Events</span></p></td>
     </tr>
    </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conversion of Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 22, 2023, GNI provided notice to the Company to convert </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,151</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock into shares of common stock. On January 22, 2024, subject to the terms and conditions of the Convertible Preferred Stock Certificate of Designation, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,767,332</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued to GNI upon such conversion.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746129536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">Financial Statements Schedule I Financial Information of Parent Company</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p><p id="schedulei" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except shares and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;"></td>
      <td style="width:1.62%;"></td>
      <td style="width:1%;"></td>
      <td style="width:12.883000000000001%;"></td>
      <td style="width:1%;"></td>
      <td style="width:1.62%;"></td>
      <td style="width:1%;"></td>
      <td style="width:12.883000000000001%;"></td>
      <td style="width:1%;"></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Related party receivables</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,159</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,159</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investment in subsidiaries</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,709</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,632</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total assets</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,477</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,791</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities, convertible preferred stock, and stockholders&#8217; equity</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due to related parties</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">538</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,242</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,264</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cceeff;text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities:</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,780</span></p></td>
      <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,269</span></p></td>
      <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Preferred Stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,151</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares and </span><span><span style="-sec-ix-hidden:F_1b8bd787-8774-422a-80fe-04f24efefd08;"><span style="-sec-ix-hidden:F_0cb88365-0ef8-49b2-9d9e-5b85398d57d4;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022, respectively</span></p></td>
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,525</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ce5ebc89-65a5-46e2-8a69-3fd79de6688a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; (deficit) equity:</span></p></td>
      <td style="background-color:#cceeff;text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000,000</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,595,616</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,588,119</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022, respectively</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,179</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,795</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statutory reserve</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,098</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,660</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Accumulated deficit) retained earnings</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,538</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,395</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,644</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">392</span></p></td>
      <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;">
      <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; (deficit) equity</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,828</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,522</span></p></td>
      <td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities, convertible preferred stock, and stockholders&#8217; (deficit) equity</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,477</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,791</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;"></td>
      <td style="width:1.62%;"></td>
      <td style="width:1%;"></td>
      <td style="width:12.883000000000001%;"></td>
      <td style="width:1%;"></td>
      <td style="width:1.62%;"></td>
      <td style="width:1%;"></td>
      <td style="width:12.883000000000001%;"></td>
      <td style="width:1%;"></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">605</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before equity in (loss) income of subsidiaries</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,316</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity in (loss) income of subsidiaries</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,617</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,396</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
      <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,933</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,302</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="background-color:#cceeff;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive (loss) income, net of tax of </span><span><span style="-sec-ix-hidden:F_8616dc92-4123-4729-b301-42d5b83f2786;"><span style="-sec-ix-hidden:F_1e540b7e-b631-4275-b3d7-b90e2d47d44e;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">:</span></p></td>
      <td style="background-color:#cff0fc;text-indent:5pt;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="background-color:#cceeff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
      <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">837</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,758</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
      <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,770</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gyre Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:68.874%;"></td>
      <td style="width:1%;"></td>
      <td style="width:12.963000000000001%;"></td>
      <td style="width:1%;"></td>
      <td style="width:1.5%;"></td>
      <td style="width:1%;"></td>
      <td style="width:12.663%;"></td>
      <td style="width:1%;"></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Activities</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,933</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,302</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
      <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net (loss) income to net cash used for operating activities:</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity loss (income) of subsidiaries</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,617</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,396</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
      <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due to related parties</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">533</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at beginning of the period</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
      <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these condensed consolidated financial statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a pa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percent of consolidated net assets as of the end of the most recently completed fiscal year.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries. CPI, the legal acquiree and accounting acquirer of the Contributions considered the &#8220;registrant&#8221; and presented as the parent company, Gyre Therapeutics, Inc. (&#8220;Gyre&#8221;) to supplement its condensed financial statement in Schedule I. The parent company records its investments in subsidiaries under the equity method of accounting as prescribed in ASC 323, Investments-Equity Method, and Joint Ventures. Such investments are presented on the Condensed Balance Sheets as &#8220;Investment in subsidiaries&#8221;. Ordinarily under the equity method, an investor in an equity method investee would cease to recognize its share of the losses of an investee once the carrying value of the investment has been reduced to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to reflect its share, based on its proportionate interest, of the losses of subsidiaries regardless of the carrying value of the investment even though the parent company is not obligated to provide continuing support or fund losses.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or redemption requirements of redeemable stocks or guarantees of the parent company.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480922/205-10-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018851072176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NoncontrollingInterestPolicyPolicyTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Noncontrolling Interest</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reports noncontrolling interest (&#8220;NCI&#8221;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM, as a group, includes Gyre&#8217;s Chief of Executive Officer (&#8220;CEO&#8221;), BC&#8217;s General Manager, and the Chairman of Gyre&#8217;s Board of Directors (&#8220;Gyre&#8217;s Board&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has determined that it operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> distinct operating segments and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_RisksAndUncertainitiesPolicyTextBlock', window );">Risks and Uncertainities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">f Credit Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts and note receivable, and long-term certificates of deposits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, the Company had cash of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and long-term certificates of deposit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2015, a new Deposit Insurance System (&#8220;DIS&#8221;) managed by the People&#8217;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#8220;RMB&#8221;) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ac</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ConcentrationOfCustomerRiskPolicyTextBlock', window );">Concentration of Customer Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Customer Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022, one customer, Sinopharm Group Co., Ltd., accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, of accounts receivable, respectively. For the year ended December 31, 2023, three customers known as Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total revenue respectively. For the year ended December 31, 2022, three customers known as Sinopharm Group Co., Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, and China Resources Pharmaceutical Group Ltd accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total revenue respectively. All customers are located in the PRC.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests portion of its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Value Measurements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Note 13 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments and Contingencies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for additional information regarding the CVR derivative liability.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PreferredStockWarrantsPolicyTextBlock', window );">Preferred Stock Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants to purchase shares of the Convertible Preferred Stock (&#8220;Preferred Stock Warrants&#8221;) are freestanding financial instruments classified as warrant liability on the Company&#8217;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#8217;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ConvertiblePreferredStockPolicyPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC Staff Announcement: Classification and Measurement of Redeemable Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to account for the Convertible Preferred Stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LongTermCertificatesOfDepositPolicyTextBlock', window );">Long-term Certificates of Deposit</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-term Certificates of Deposit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The long-term certificates of deposit will mature between February 2025 and July 2026. Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using the effective interest method. The Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowance for credit losses associated with the certificates of deposit as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Long-Term Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Term Receivable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#8220;GCBP&#8221;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for additional information regarding the long-term receivable.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts and Note Receivables, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts and Note Receivables, Net</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#8217;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#8217;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:68.014%;"></td>
          <td style="width:1.78%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.843%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.362%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,204</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,738</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Note receivable</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">389</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,522</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for credit losses</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts and note receivables, net</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,552</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,136</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in the allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:68%;"></td>
          <td style="width:1.58%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.42%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, beginning of year</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for allowance for credit losses</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recoveries collected and write-off</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, end of year</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:5.204%;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;"></td>
          <td style="width:58.58%;"></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Buildings</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvement</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="-sec-ix-hidden:F_b8d10737-f18e-4a8d-80f3-5bcbf043af92;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of the estimated useful life or the term of the lease</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and electronic devices</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Motor vehicles</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible Assets, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patents and Technological Know-How</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Computer Software</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ba9e4760-e1ab-447a-a061-08082fe718fe;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#8217;s leases do not contain any residual value guarantees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LandUseRightsPolicyTextBlock', window );">Land Use Rights, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Land Use Rights, Net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount of an asset group exceeds its fair valu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record any impairment of long-lived assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Expense</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#8217;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Sale of Pharmaceutical Products</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer, generally upon completion of quality inspection by the distributor after delivery of the pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#8217;s estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) License of Intellectual Property</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from a license agreement is recognized at a point in time when the control of the right to use the license is transferred to the customer. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development or regulatory milestone payments, which are included in the transaction price to the extent that it is probable that a significant reversal of accumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of any milestones, and if necessary, adjusts its estimated transaction price on a cumulative catch-up basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any contract assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Deferred Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue is recognized when a payment is received from a customer before the Company transfers the related goods or services. Deferred revenue is recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of December 31, 2023, the Company&#8217;s deferred revenue balance was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Deferred revenue was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">145,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2022 which has been recognized as revenue during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#8217;s assumptions regarding a number of variables including the fair value of its common stock, its expected common stock price volatility over the expected</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired IPR&amp;D</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquired IPR&amp;D</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition date. Refer to Note 7 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GNI USA Contributions under the Business Combination Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for a more detailed description.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SellingAndMarketingExpensesPolicyTextBlock', window );">Selling and Marketing Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling and Marketing Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_GeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government Grants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amount </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive (loss) income.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_InterestIncomePolicyTextBlock', window );">Interest Income</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Income (Loss)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share ("EPS") Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Income (Loss) </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Per Share (&#8220;EPS&#8221;) Attributable to Common Stockholders</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings per Share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 260&#8221;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#8217;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EPS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Remeasurement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Translation and Remeasurement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of BC is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company uses the U.S. Dollar as its reporting currency.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and  equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive (loss) income. During the year ended December 31, 2023, the Company had translation loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. During the year ended December 31, 2022, the Company had translation loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operations and comprehensive (loss) income. The foreign currency transaction gains or losses for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">were immaterial.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ForeignCurrencyRiskPolicyTextBlock', window );">Foreign Currency Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#8217;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. 99.5% of the Company&#8217;s cash and long-term certificates of deposit as of December 31, 2023 of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, were denominated in RMB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Pronouncements Recently Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, the FASB issued ASU 2021-04, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2021-04 and related updates on</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> January 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the adoption </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have a material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, FASB issued ASU 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the previous models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2021. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2020-06 on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the adoption </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have a material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2021-08 and related updates on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The adoption of ASU 2021-08 had </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impact on the consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the FASB issued ASU 2021-10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government Assistance (Topic 832) &#8212; Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The amendments in this ASU require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity&#8217;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> this standard as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The adoption of this ASU </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have any material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the Company&#8217;s consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock', window );">New Accounting Pronouncements - Issued But Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#8217;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#8217;s profit or loss in assessing segment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company plans to adopt annual requirements and related updates under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently assessing the impact of adoption of this standard on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#8217;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ConcentrationOfCustomerRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of customer risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ConcentrationOfCustomerRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ConvertiblePreferredStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock, policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ConvertiblePreferredStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ForeignCurrencyRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ForeignCurrencyRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_GeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_GeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_InterestIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_InterestIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LandUseRightsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Land use rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LandUseRightsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LongTermCertificatesOfDepositPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term certificates of deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LongTermCertificatesOfDepositPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NoncontrollingInterestPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NoncontrollingInterestPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PreferredStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PreferredStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_RisksAndUncertainitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Uncertainities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_RisksAndUncertainitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SellingAndMarketingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SellingAndMarketingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 25<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480270/815-25-40-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EEEE<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4EEEE<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018855187648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts and Note Receivable, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:68.014%;"></td>
          <td style="width:1.78%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.843%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.362%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,204</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,738</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Note receivable</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">389</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,522</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allowance for credit losses</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts and note receivables, net</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,552</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,136</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Changes in Allowance for Credit Losses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in the allowance for credit losses as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:68%;"></td>
          <td style="width:1.58%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.42%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, beginning of year</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for allowance for credit losses</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recoveries collected and write-off</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, end of year</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Estimated Useful Lives of Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:5.204%;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:41.42%;"></td>
          <td style="width:58.58%;"></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Buildings</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvement</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="-sec-ix-hidden:F_b8d10737-f18e-4a8d-80f3-5bcbf043af92;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of the estimated useful life or the term of the lease</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and electronic devices</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Motor vehicles</span></p></td>
          <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and financing receivable, allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018748131088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant liability, noncurrent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(1)  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the warrant liability is estimated based on th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Black-Scholes option pricing model using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.984%;"></td>
        <td style="width:1.7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.317%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,915.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.88</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.83</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level 3 financial assets and liabilities (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.700000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CVR derivative liability</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrant liability</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,835</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.02%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds  (cash equivalents)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755424080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories, Net of Reserves</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories, net of reserves of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and 2022, respectively, consisted of the following components (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.986%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.637%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,056</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other liabilities consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.280000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll and welfare</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,038</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplier reimbursement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,247</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses - general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued sales discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">748</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">837</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee reimbursement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses - research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses - selling expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock', window );">Schedule of Deferred Government Grants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summarized below are deferred government grants as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government grants for property and equipment, included in accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government grants for property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred government grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">253</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.76%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Buildings</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,289</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,837</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,875</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,851</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Machinery and electronic devices</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,598</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">606</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">631</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Motor vehicles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,288</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,709</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of deferred government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746918672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Gross Carrying Amounts and Accumulated Amortization of intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The gross carrying amounts and accumulated amortization of the Company&#8217;s intangible assets with determinable lives as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.99%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.197000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.077%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.157%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">171</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">601</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets, net</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets with finite lives:</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patents</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Technological know-how</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,038</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,741</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">297</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on finite-lived intangible assets recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the estimated future amortization expense is as follows (in thousands):</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:85.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.28%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Amortization Expense</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755703072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Sales by Product Categories</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s sales by product categories for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.814%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.323%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.863000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales of Pharmaceutical Products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,450</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">License of Intellectual Property</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,414</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746751232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Summary of Purchase Price</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:1%;"></td>
        <td style="width:84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#65279;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Catalyst Common Stock outstanding</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,532</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Multiplied by the fair value per share of Catalyst stock (1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common shares to be owned by Catalyst&#8217;s stockholders</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,420</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of preferred shares to be owned by Catalyst&#8217;s stockholders (2)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,099</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of Catalyst</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,519</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of consideration issued</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,348</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">659</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase price</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,007</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This amount is calculated based on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">666.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span></span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:84%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.30</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.65</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
          <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Summary of Estimated Fair Value of Option Awards Based on Black-scholes Model</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:84%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span></span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.30</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.65</span></p></td>
          <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
          <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:84.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.04%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables from GNI</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,097</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term receivable from GCBP</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets, noncurrent</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">IPR&amp;D</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Advance payment received from GNI</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR excess closing cash payable</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,085</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CVR derivative liability, noncurrent</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net assets acquired</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746017312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.04%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">573</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock', window );">Schedule of Present Value Assumptions used in Calculating Present Value of Lease Payments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The present value assumptions used in calculating the present value of the lease payments were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.687%;"></td>
        <td style="width:14.141%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:14.141%;"></td>
        <td style="width:1.01%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
        <td style="background-color:#cff0fc;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.78</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.75</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, undiscounted future minimum payments under the Company&#8217;s operating leases were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:83%;"></td>
        <td style="width:1.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.16%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">409</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of present value assumptions of lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756153424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock, Reserved for Future Issuance</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.72%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Preferred Stock issued and outstanding</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,767,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred Stock Warrants issued and outstanding</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,280,548</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,036,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,588,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,036,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018750488640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock option activity considering the conversion of BC Options to Gyre options to purchase shares of Gyre Common Stock upon completion of the GNI USA Contributions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.052%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.031%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.031%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.031%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares Underlying Outstanding Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Remaining Contractual Term (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value (Thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,036,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">838,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,280,548</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">444,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,262,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options Granted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of employee stock options granted was estimated using the following weighted-average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.64%;"></td>
        <td style="width:4.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility (%)</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84.30</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate (%)</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.82</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.77</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected option life (in years)</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.8</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield (%)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average share price of the Company (USD per share)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Recognized</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total stock-based compensation recognized was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.634%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.963000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,301</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018747012976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Provision for Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the Company&#8217;s provision for income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consist of the following (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.094%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.123000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.123000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current income tax provision:</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,343</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,987</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current income tax provision</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,349</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,988</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred income tax provision:</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign - PRC</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">834</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred income tax provision</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">834</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">890</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax provision</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,515</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.066%;"></td>
        <td style="width:15.137%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:15.137%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rate difference due to different jurisdiction</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.43</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.31</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferential income tax rate for HNTE</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.19</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.37</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible expense &#8211; Operating</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.28</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33.06</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible expense &#8211; One-time expense related to the Contributions</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.16</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">R&amp;D Super-deduction</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.45</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.42</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance change</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.37</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESOP</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.55</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.81</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.76</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.52</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.91</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54.87</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of the Company's Deferred Tax Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.566%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.536%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.889%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">183</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other equity investments</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carry forwards</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,463</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed and intangible assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impact from foreign corporations</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized transaction costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">414</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income tax assets before valuation allowance</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,660</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,175</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability &#8211; ROU assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability &#8211; Fixed assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,773</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,695</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,081</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Movement of Valuation Allowance</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The movements of the valuation allowance are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.566%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.536%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.889%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes of valuation allowances</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,773</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,773</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:81.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning Balance on January 1, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending Balance on December 31, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase as a result of the GNI USA Contributions on October 30, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,833</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits taken in prior years</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(Decrease) of unrecognized tax benefits related to current year</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending Balance on December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,833</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755030912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EPS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted EPS Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.525%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.899000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.546%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,314</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,012</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income attributable to common stockholders - basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,933</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic common shares outstanding:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,831,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,588,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,831,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,588,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">            </span></p></td>
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive potential common shares:</span></p></td>
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,098,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,831,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,686,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income per share attributable to common stockholders:</span></p></td>
        <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.04</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-dilutive Security not Included in Diluted per Share Calculations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:83%;"></td>
        <td style="width:1.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,280,548</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Preferred stock (as converted)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,767,332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred Stock Warrants (as converted)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,588,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746928656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Segment information for the years ended December 31, 2023 and 2022 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,636</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,636</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross profit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,159</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,159</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,780</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,214</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">576</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,662</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired in-process research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Divestiture losses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(2)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,711</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income (Loss) from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,488</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,488</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(1) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents legal expense recorded in CPI during the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(2) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents divestiture losses. See Note 8 for details.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.67%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.218%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101,761</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,865</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">913</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,539</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.67%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.218%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,517</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,517</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross profit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,497</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,497</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses excluding cost of revenues:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(3)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,370</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses excluding cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental Disclosure of stock-based compensation expense</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,301</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,301</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(3) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents the other subsidiaries, CPI and GNI HK, etc. reported an aggregate $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million general and administrative expense during the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,857</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,753</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.67%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.038%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.218%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018751269792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 27, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 15, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (85,480)<span></span>
</td>
<td class="nump">$ 4,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,538<span></span>
</td>
<td class="num">(7,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock', window );">Minority holders owned outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,892<span></span>
</td>
<td class="nump">$ 10,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyOneATMProgramMember', window );">2021 ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfCommissionForSharesSold', window );">Percentage of commission for shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gyre_GyreMember', window );">Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfOutstandingSharesOfCommonStock', window );">Percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds', window );">Minority interest ownership directly and indirectly holds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gyre_GyreMember', window );">Gyre | CPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds', window );">Minority interest ownership indirectly holds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gyre_GyreMember', window );">Gyre | BC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds', window );">Minority interest ownership indirectly holds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember', window );">Business Combination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio</a></td>
<td class="text"> 1-for-15 reverse stock split<span></span>
</td>
<td class="text"> reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember', window );">Business Combination Agreement | Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,463,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember', window );">Business Combination Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember', window );">Business Combination Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, shares issued upon conversion of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gyre_GNIUSAMember', window );">GNI USA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfOutstandingSharesOfCommonStock', window );">Percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gyre_CPIContributionMember', window );">CPI Contribution | Business Combination Agreement | Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,923,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gyre_FCContributionMember', window );">FC Contribution | Business Combination Agreement | Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,664,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Assets acquisition, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,531,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_OrganizationAndNatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and nature of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_OrganizationAndNatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfCommissionForSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Commission for shares sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfCommissionForSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minority holders owned outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minority interest ownership directly and indirectly holds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minority interest ownership indirectly holds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyOneATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyOneATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gyre_GyreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gyre_GyreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_ContinentPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_ContinentPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gyre_BusinessCombinationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gyre_GNIUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gyre_GNIUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gyre_CPIContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gyre_CPIContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gyre_FCContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gyre_FCContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018868476240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
<th class="th"><div>Oct. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 85,538<span></span>
</td>
<td class="num">$ (7,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 85,480<span></span>
</td>
<td class="num">$ (4,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyOneATMProgramMember', window );">2021 ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfCommissionForSharesSold', window );">Percentage of commission for shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfCommissionForSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Commission for shares sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfCommissionForSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyOneATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyOneATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755109792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2015 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AllowanceForCreditLossesCertificatesOfDeposit', window );">Allowance for credit losses certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,500,000<span></span>
</td>
<td class="nump">25,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LongTermCertificatesOfDeposit', window );">Long-term certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,431,000<span></span>
</td>
<td class="nump">7,394,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,484,000<span></span>
</td>
<td class="nump">4,928,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Sinopharm Group Co., Ltd. | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of customer risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.10%<span></span>
</td>
<td class="nump">47.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Sinopharm Group Co., Ltd. | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of customer risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.50%<span></span>
</td>
<td class="nump">45.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | China Resources Pharmaceutical Group Ltd | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of customer risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Shanghai Pharmaceuticals Holding Co., Ltd | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of customer risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem', window );">Deposits in licensed banks protected by DIS | &#165;</a></td>
<td class="nump">&#165; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_PatentsAndTechnologicalKnowHowMember', window );">Patents and Technological Know How [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of finite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_PatentsAndTechnologicalKnowHowMember', window );">Patents and Technological Know How [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of finite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of finite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of finite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202104Member', window );">ASU 2021-04</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202108Member', window );">ASU 2021-08</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202110Member', window );">ASU 2021-10</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AllowanceForCreditLossesCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for credit losses certificates of deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AllowanceForCreditLossesCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits in licensed banks protected by deposit insurance system.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LongTermCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Certificates Of Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LongTermCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gyre_SinopharmGroupCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gyre_SinopharmGroupCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gyre_ChinaResourcesPharmaceuticalGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gyre_ChinaResourcesPharmaceuticalGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_PatentsAndTechnologicalKnowHowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_PatentsAndTechnologicalKnowHowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202108Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202108Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202110Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202110Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018844366624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 15,204<span></span>
</td>
<td class="nump">$ 15,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Note receivable</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent', window );">Allowance for credit losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and note receivables, net</a></td>
<td class="nump">$ 15,552<span></span>
</td>
<td class="nump">$ 17,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and financing receivable, allowance for credit loss, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755313232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent', window );">Balance, beginning of year</a></td>
<td class="num">$ (124)<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses', window );">Provision for allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff', window );">Recoveries collected and write-off</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation', window );">Foreign currency translation adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent', window );">Balance, end of year</a></td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and financing receivable, allowance for credit loss, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and financing receivable, allowance for credit loss, foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and notes receivable, provision for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756051120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember', window );">Machinery and Electronic Devices | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember', window );">Machinery and Electronic Devices | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember', window );">Motor Vehicles | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember', window );">Motor Vehicles | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755055104">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,582,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,557,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Long-term receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember', window );">CVR Derivative Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember', window );">Warrant Liability Non Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,835,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Long-term receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | CVR Derivative Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Warrant Liability Non Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,835,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749661632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 27, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value measurement transfer between Level 1 and Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount', window );">Fair value measurement transfer Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued | shares</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember', window );">Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares | shares</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price of warrants</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share | $ / shares</a></td>
<td class="nump">$ 4,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Oct. 30,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants', window );">Number of shares of common stock issuable upon exercise and conversion of warrants | shares</a></td>
<td class="nump">540,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Long-term receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement | GCBP Asset Purchase Agreement | CVR Derivative Liability non current | Estimated Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement | GCBP Asset Purchase Agreement | Long-term receivable | Estimated Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetMeasurementInput', window );">Derivative asset measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement | GCBP Asset Purchase Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AmountToBeReceivedUnderAgreement', window );">Amount to be received under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AmountToBeReceivedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be received under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AmountToBeReceivedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assets and liabilities level1 to level2 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assets and liabilities level3 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock shares issuable upon exercise and conversion of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756048544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.65%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">9 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="nump">$ 4,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">3.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018905548704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Long-term receivable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Additions in the period</a></td>
<td class="nump">$ 4,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Changes in fair value</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at December 31, 2023</a></td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember', window );">CVR Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions in the period</a></td>
<td class="nump">4,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in fair value</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2023</a></td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember', window );">Warrant Liability Non Current</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions in the period</a></td>
<td class="nump">3,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in fair value</a></td>
<td class="nump">9,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2023</a></td>
<td class="nump">$ 12,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=gyre_CVRDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018757129888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Cash Equivalents (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 5,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 5,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018748085760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ProceedsFromGovernmentGrantsReceived', window );">Government grants received</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_GovernmentGrantIncomeWithinOtherIncome', window );">Government grant income</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_GovernmentGrantIncomeWithinOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government grant income within other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_GovernmentGrantIncomeWithinOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ProceedsFromGovernmentGrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from government grants received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ProceedsFromGovernmentGrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756198000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Inventories, Net of Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 919<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 4,281<span></span>
</td>
<td class="nump">$ 6,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756049840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedPayrollAndWelfare', window );">Accrued payroll and welfare</a></td>
<td class="nump">$ 5,790<span></span>
</td>
<td class="nump">$ 5,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SupplierReimbursement', window );">Supplier reimbursement</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="nump">2,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedExpensesGeneralAndAdministrative', window );">Accrued expenses - general and administrative</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedSalesDiscount', window );">Accrued sales discount</a></td>
<td class="nump">903<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Employee reimbursement</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedExpensesResearchAndDevelopment', window );">Accrued expenses - research and development</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AccruedExpensesSellingExpenses', window );">Accrued expenses - selling expenses</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrants', window );">Deferred government grants</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 11,935<span></span>
</td>
<td class="nump">$ 9,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedExpensesGeneralAndAdministrative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses general and administrative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedExpensesGeneralAndAdministrative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedExpensesResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses, research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedExpensesResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedExpensesSellingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses, selling expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedExpensesSellingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedPayrollAndWelfare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll and welfare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedPayrollAndWelfare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AccruedSalesDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued sales discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AccruedSalesDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SupplierReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplier reimbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SupplierReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756313504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Deferred Government Grants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsLineItems', window );"><strong>Deferred Government Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsCurrent', window );">Current deferred government grants</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsNonCurrent', window );">Non-current deferred government grants</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsCurrentAndNoncurrent', window );">Total deferred government grants</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember', window );">Property And Equipment, Included In Accrued Expenses And Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsLineItems', window );"><strong>Deferred Government Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsCurrent', window );">Current deferred government grants</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property Plant And Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsLineItems', window );"><strong>Deferred Government Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredGovernmentGrantsNonCurrent', window );">Non-current deferred government grants</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrantsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrantsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrantsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrantsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredGovernmentGrantsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grants non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredGovernmentGrantsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756272352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 27,553<span></span>
</td>
<td class="nump">$ 21,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(4,265)<span></span>
</td>
<td class="num">(3,998)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">23,288<span></span>
</td>
<td class="nump">17,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">12,289<span></span>
</td>
<td class="nump">10,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction In Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,875<span></span>
</td>
<td class="nump">4,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember', window );">Machinery and Electronic Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,598<span></span>
</td>
<td class="nump">4,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember', window );">Motor Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MachineryAndElectronicDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gyre_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755928352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 601<span></span>
</td>
<td class="nump">$ 2,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(396)<span></span>
</td>
<td class="num">(1,741)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,372)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technological know-how</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(277)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755982784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, Weighted average amortization period</a></td>
<td class="text">5 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018754521920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets -Schedule of Estimated Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756015344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfRevenueAccountedSalesToDistributors', window );">Percentage of revenue accounted sales to distributors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from sales</a></td>
<td class="nump">$ 113,450<span></span>
</td>
<td class="nump">$ 102,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">ETUARY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from sales</a></td>
<td class="nump">$ 113,450<span></span>
</td>
<td class="nump">$ 100,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">ETUARY | Sales | ETUARY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">98.90%<span></span>
</td>
<td class="nump">96.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfRevenueAccountedSalesToDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue accounted sales to distributors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfRevenueAccountedSalesToDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755317200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of Sales by Product Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 113,450<span></span>
</td>
<td class="nump">$ 102,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Sales of Pharmaceutical Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 113,450<span></span>
</td>
<td class="nump">100,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018754487792">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Catalyst common stock outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember', window );">Catalyst</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Catalyst common stock outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Multiplied by the fair value per share of Catalyst stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 7.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationFairValueOfCommonShares', window );">Fair value of common shares to be owned by Catalyst's stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 19,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationFairValueOfPreferredShares', window );">Fair value of preferred shares to be owned by Catalyst's stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">63,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationFairValue', window );">Fair value of Catalyst</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PreMergerStockOptionsAssumed', window );">Pre-GNI USA Contributions Catalyst stock options assumed by CPI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure', window );">Fair value of consideration issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Acquisition costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total Purchase price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 85,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This amount is calculated based on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">666.67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</span></span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationFairValueOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination fair value of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationFairValueOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationFairValueOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination fair value of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationFairValueOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PreMergerStockOptionsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre merger stock options assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PreMergerStockOptionsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of equity issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018852957696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details) - Convertible Preferred Stock - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 22, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 30, 2023</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, shares issued upon conversion of common stock</a></td>
<td class="nump">666.67<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember', window );">Catalyst</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, shares issued upon conversion of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gyre_CatalystMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746810080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">84.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.65%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755350320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details) - GNI USA Contributions<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent', window );">Other receivables from GNI</a></td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid assets</a></td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable', window );">Long-term receivable from GCBP</a></td>
<td class="nump">4,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets, noncurrent</a></td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="nump">83,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived', window );">Advance payment received from GNI</a></td>
<td class="num">(2,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationExcessClosingCashPayable', window );">CVR excess closing cash payable</a></td>
<td class="num">(1,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent', window );">CVR derivative liability, noncurrent</a></td>
<td class="num">(4,683)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 85,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationExcessClosingCashPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination excess closing cash payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationExcessClosingCashPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed, accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed advance payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed, CVR derivative liability, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed in-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed long-term receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed, other receivables current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018754632656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="nump">$ 2,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gyre_CpUSSharePurchaseAgreementMember', window );">CP U.S. Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfIndirectOwnershipInterest', window );">Indirect ownership interest</a></td>
<td class="nump">56.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables from GNI</a></td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfIndirectOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of indirect ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfIndirectOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gyre_CpUSSharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gyre_CpUSSharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018851073696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277,000<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted future payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">2026-12<span></span>
</td>
<td class="text">2024-06<span></span>
</td>
<td class="text">2024-08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SquareMeterAreaForOfficeSpaceUnderLease', window );">Square meter area for office space under lease | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SquareMeterAreaForLaboratoryCenterUnderLease', window );">Square meter area for laboratory center under lease | m&#178;</a></td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_SquareMeterAreaForOfficeSpaceUnderNewLease', window );">Square Meter Area For Office Space Under New Lease | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,000<span></span>
</td>
<td class="nump">666,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease', window );">Combined square meter area for manufacturing facilities under lease | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LandUseRightsNetAssets', window );">Land use rights, net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined square meter area for manufacturing facilities under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LandUseRightsNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Land use rights, net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LandUseRightsNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SquareMeterAreaForLaboratoryCenterUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square meter area for laboratory center under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SquareMeterAreaForLaboratoryCenterUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SquareMeterAreaForOfficeSpaceUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square meter area for office space under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SquareMeterAreaForOfficeSpaceUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_SquareMeterAreaForOfficeSpaceUnderNewLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square meter area for office space under new lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_SquareMeterAreaForOfficeSpaceUnderNewLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018911178864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Cash Flow Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash Flow, Operating Activities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating lease</a></td>
<td class="nump">$ 573<span></span>
</td>
<td class="nump">$ 517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018867000640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.78%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755813040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liabilities</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">$ (492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749145280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Catalyst common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeeds from issuance of aggregate gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves', window );">Aggregate amounts of restricted capital and statutory reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,300,000<span></span>
</td>
<td class="nump">$ 61,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatutoryReserveFund', window );">Statutory reserve fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CumulativeAmountOfStatutoryReserveFund', window );">Cumulative amount of statutory reserve fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AppropriationsToStatutoryReserve', window );">Appropriations to statutory reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyOneATMProgramMember', window );">2021 ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeeds from issuance of aggregate gross sales</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfCommissionForSharesSold', window );">Percentage of commission for shares sold</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_LegalExpensesIncurred', window );">Legal expenses incurred</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amounts of restricted capital and statutory reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AppropriationsToStatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Appropriations to statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AppropriationsToStatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CumulativeAmountOfStatutoryReserveFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of statutory reserve fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CumulativeAmountOfStatutoryReserveFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_LegalExpensesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal expenses incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_LegalExpensesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfCommissionForSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Commission for shares sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfCommissionForSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StatutoryReserveFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StatutoryReserveFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StockholdersEquityDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StockholdersEquityDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyOneATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gyre_TwoThousandTwentyOneATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756121920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved</a></td>
<td class="nump">27,588,546<span></span>
</td>
<td class="nump">17,036,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved</a></td>
<td class="nump">8,767,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember', window );">Preferred Stock Warrants Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved</a></td>
<td class="nump">540,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gyre_OptionsToPurchaseCommonStockMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved</a></td>
<td class="nump">18,280,548<span></span>
</td>
<td class="nump">17,036,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gyre_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gyre_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749623952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 22, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember', window );">Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">125,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, shares issued upon conversion</a></td>
<td class="nump">666.67<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares', window );">Number Of Shares Of Common Stock Issuable Upon Conversion Of The Outstanding Shares</a></td>
<td class="nump">8,767,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issuable upon conversion of the outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gyre_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018750426512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>Individual</div>
</th>
<th class="th">
<div>Oct. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,588,546<span></span>
</td>
<td class="nump">17,036,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,059<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,686<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized employee stock based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized employee stock based compensation expense, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=gyre_GyreMember', window );">Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfOutstandingSharesOfCommonStock', window );">Percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember', window );">2023 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,845,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfOutstandingSharesOfCommonStock', window );">Percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">820,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental stock-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 30,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember', window );">2023 Incentive Plan | Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NumberOfIndividualsApprovedGrantsByBoard', window );">Number of individuals approved grants by board | Individual</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gyre_BCTwoThousandTwentyOneStockIncentivePlanMember', window );">BC 2021 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward', window );">Contractual terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gyre_BCTwoThousandTwentyOneStockIncentivePlanMember', window );">BC 2021 Stock Incentive Plan | BC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental stock-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  03,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NumberOfIndividualsApprovedGrantsByBoard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of individuals approved grants by board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NumberOfIndividualsApprovedGrantsByBoard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, contractual terms of award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gyre_GyreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gyre_GyreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gyre_BCTwoThousandTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gyre_BCTwoThousandTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018756282160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares Underlying Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Beginning Balance</a></td>
<td class="nump">17,036,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Underlying Outstanding Options, Options Forfeited</a></td>
<td class="num">(18,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders', window );">Number of Shares Underlying Outstanding Options, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</a></td>
<td class="nump">435,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Underlying Outstanding Options, Options granted</a></td>
<td class="nump">838,686<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Underlying Outstanding Options, Options Exercised</a></td>
<td class="num">(12,059)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Ending Balance</a></td>
<td class="nump">18,280,548<span></span>
</td>
<td class="nump">17,036,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Underlying Outstanding Options, Exercisable- December 31, 2022</a></td>
<td class="nump">18,262,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options forfeited</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Option, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options granted</a></td>
<td class="nump">6.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options Exercised</a></td>
<td class="nump">13.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Ending Balance</a></td>
<td class="nump">1.49<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable - December 31, 2022</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable - December 31, 2022</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 444,197<span></span>
</td>
<td class="nump">$ 12,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable - December 31, 2023</a></td>
<td class="nump">$ 19,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options deemed issuance of options to former stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award options deemed issuance of options to former stockholders in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018750474864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">84.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">84.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average share price of the Company (USD per share)</a></td>
<td class="nump">$ 6.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749558320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 7,281<span></span>
</td>
<td class="nump">$ 13,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">1,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">2,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 6,404<span></span>
</td>
<td class="nump">$ 9,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018754696128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 30, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CVRDerivativeLiabilityNoncurrent', window );">CVR derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,517<span></span>
</td>
<td class="nump">$ 4,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommittedToAllocate', window );">Committed to allocate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfExcessCashOnDispositionsNet', window );">Percentage of excess cash on dispositions net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets', window );">Excess amount retained from net proceeds related to disposition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfExcessPreapprovedCosts', window );">Percentage of excess preapproved costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DistributionFromAssetSaleProceeds', window );">Distribution to CVR holders from asset sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ContingentValueRightsDerivativeLiabilityNonCurrent', window );">Long-term CVR derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CVRDerivativeLiabilityNoncurrent', window );">CVR derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ContributionsClosingPayableAmount', window );">Contributions closing payable amount</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Litigation settlement liability</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gyre_VertexAssetPurchaseAgreementMember', window );">Vertex Asset Purchase Agreement | Contingent Value Rights Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfAmountReceivedOnAgreement', window );">Percentage of amount received on agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember', window );">F351 | BC | Submission of the New Drug Application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights', window );">Obligation to pay in exchange for the intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember', window );">F351 | BC | NDA Passes the NMPA's Review and Inspection</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights', window );">Obligation to pay in exchange for the intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember', window );">F351 | BC | NMPA's Approval of the NDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights', window );">Obligation to pay in exchange for the intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CVRDerivativeLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CVR derivative liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CVRDerivativeLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_CommittedToAllocate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Committed to allocate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_CommittedToAllocate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ContingentValueRightsDerivativeLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights derivative liability non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ContingentValueRightsDerivativeLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ContributionsClosingPayableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contributions closing payable amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ContributionsClosingPayableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DistributionFromAssetSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distribution from asset sale proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DistributionFromAssetSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess amount retained from net proceeds related to disposition of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligation to pay in exchange for the intellectual property rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfAmountReceivedOnAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount received on agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfAmountReceivedOnAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfExcessCashOnDispositionsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of excess cash on dispositions net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfExcessCashOnDispositionsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfExcessPreapprovedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of excess preapproved costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfExcessPreapprovedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gyre_VertexAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gyre_VertexAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gyre_SubmissionOfTheNewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gyre_SubmissionOfTheNewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gyre_NDAPassesTheNMPAsReviewAndInspectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gyre_NDAPassesTheNMPAsReviewAndInspectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gyre_NMPAsApprovalOfTheNDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gyre_NMPAsApprovalOfTheNDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755664832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign - PRC</a></td>
<td class="nump">9,343<span></span>
</td>
<td class="nump">5,987<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax provision:</a></td>
<td class="nump">9,349<span></span>
</td>
<td class="nump">5,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign - PRC</a></td>
<td class="num">(834)<span></span>
</td>
<td class="num">(799)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax provision:</a></td>
<td class="num">(834)<span></span>
</td>
<td class="num">(890)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision:</a></td>
<td class="nump">$ 8,515<span></span>
</td>
<td class="nump">$ 5,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018844507296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax computed at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Rate difference due to different jurisdiction</a></td>
<td class="num">(2.43%)<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte', window );">Preferential income tax rate for HNTE</a></td>
<td class="nump">3.19%<span></span>
</td>
<td class="num">(10.37%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible Expense - Operating</a></td>
<td class="num">(6.28%)<span></span>
</td>
<td class="nump">33.06%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions', window );">Non-deductible expense - One-time expense related to the Contributions</a></td>
<td class="num">(22.16%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">R&amp;D Super-deduction</a></td>
<td class="nump">1.45%<span></span>
</td>
<td class="num">(12.42%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance change</a></td>
<td class="num">(4.37%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends', window );">ESOP</a></td>
<td class="num">(0.55%)<span></span>
</td>
<td class="nump">21.81%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(0.76%)<span></span>
</td>
<td class="num">(2.52%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(10.91%)<span></span>
</td>
<td class="nump">54.87%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible expense one-time expense related to the contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation preferential income tax rate for HNTE.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749602944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">$ 2,811<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">40,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Other equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carry forwards</a></td>
<td class="nump">4,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsFixedAssetsAndIntangibles', window );">Fixed and intangible assets</a></td>
<td class="nump">15,332<span></span>
</td>
<td class="nump">3,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsImpactFromForeignCorporations', window );">Impact from foreign corporations</a></td>
<td class="nump">4,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsCapitalizedTransactionCosts', window );">Capitalized transaction costs</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred income tax assets before valuation allowance</a></td>
<td class="nump">68,660<span></span>
</td>
<td class="nump">4,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxLiabilityRightOfUseAssets', window );">Deferred tax liability - ROU assets</a></td>
<td class="num">(108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Deferred tax liability - Fixed assets</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(63,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">$ 4,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsCapitalizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsCapitalizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsFixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets fixed assets and intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsFixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsImpactFromForeignCorporations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets impact from foreign corporations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsImpactFromForeignCorporations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxLiabilityRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liability right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxLiabilityRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746859200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Movement of Valuation Allowance (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ChangesOfValuationAllowances', window );">Changes of valuation allowances</a></td>
<td class="num">$ (63,773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the end of the year</a></td>
<td class="num">$ (63,773)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ChangesOfValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes of valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ChangesOfValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749671312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized', window );">Gross federal R&amp;D credit-related deferred tax assets derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,833,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Tax-related penalties or interest recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards', window );">Net operating loss carryforward, derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_MaximumAmountOfTaxOffsetPerYear', window );">Maximum amount of tax offset per year</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_RequiredMinimumTaxableIncome', window );">Required Minimum Taxable Income</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OperatingLossCarryforwardsWithIndefiniteLife', window );">Net operating loss carryforwards having indefinite life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to offset future federal tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_TaxCreditCarryforwardExpirationYear', window );">Credit carryforward, expire year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards', window );">Net operating loss carryforward, derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to offset future federal tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets state net operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_MaximumAmountOfTaxOffsetPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of tax offset per year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_MaximumAmountOfTaxOffsetPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_OperatingLossCarryforwardsWithIndefiniteLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards with indefinite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_OperatingLossCarryforwardsWithIndefiniteLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_RequiredMinimumTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum taxable income required to support realizing the company's.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_RequiredMinimumTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit carry forwards derecognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018750646352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Increase as a result of the GNI USA Contributions on October 30, 2023</a></td>
<td class="nump">1,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Increase/(Decrease) of unrecognized tax benefits taken in prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase/(Decrease) of unrecognized tax benefits related to current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 1,833<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increase (decrease) resulting from tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018844864912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - Related Party - G N I - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other Receivables</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">CPI Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other Receivables</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Gyre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other Receivables</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">F351 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Due to related parties</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gyre_GNIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gyre_GNIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gyre_CPIContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gyre_CPIContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gyre_GyreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gyre_GyreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gyre_FThreeFiveOneAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gyre_FThreeFiveOneAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018844507168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net (loss) income from operations</a></td>
<td class="num">$ (85,480)<span></span>
</td>
<td class="nump">$ 4,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Allocation of undistributed earnings to noncontrolling interest</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to common stockholders</a></td>
<td class="num">(92,933)<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income attributable to common stockholders - diluted</a></td>
<td class="num">$ (92,933)<span></span>
</td>
<td class="nump">$ 2,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares outstanding</a></td>
<td class="nump">65,831,675<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic</a></td>
<td class="nump">65,831,675<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,098,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted</a></td>
<td class="nump">65,831,675<span></span>
</td>
<td class="nump">75,686,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share attributable to common stockholders, basic</a></td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755184928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">27,588,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">18,280,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred stock (as converted)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">8,767,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_PreferredStockWarrantsMember', window );">Preferred Stock Warrants (as converted)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">540,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gyre_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746721552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=gyre_MainlandChinaContributionPlanMember', window );">Mainland China Contribution Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions for employee benefits</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=gyre_MainlandChinaContributionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=gyre_MainlandChinaContributionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018748166528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018754271952">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 113,450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 102,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,636<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">108,814<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">97,497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses excluding cost of revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,159<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54,238<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,780<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,686<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,662<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,104<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">628<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses excluding cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">176,044<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">88,294<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(67,230)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,203<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,281<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,366<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116,539<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">84,753<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Purchase of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,517)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,985)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">249<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">344<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">481<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,301<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,404<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,173<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember', window );">BC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">113,450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">102,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,636<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">108,814<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">97,497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses excluding cost of revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,159<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54,238<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,686<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,872<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">628<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses excluding cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84,357<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">88,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,457<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,366<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">101,761<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">79,857<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Purchase of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,517)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember', window );">BC | Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">249<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember', window );">BC | Selling and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">344<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember', window );">BC | Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">481<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,301<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember', window );">BC | General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,173<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyreMember', window );">Gyre</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses excluding cost of revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,214<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,104<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses excluding cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">88,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(88,400)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,865<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyreMember', window );">Gyre | General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses excluding cost of revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses excluding cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,287)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(130)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract', window );"><strong>Supplemental Disclosure of stock-based compensation expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 913<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,896<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(1) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents legal expense recorded in CPI during the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(3) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents the other subsidiaries, CPI and GNI HK, etc. reported an aggregate $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million general and administrative expense during the year ended December 31, 2022.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(2) $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents divestiture losses. See Note 8 for details.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.67%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.218%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101,761</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,865</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">913</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,539</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.67%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.038%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:1%;"></td>
         <td style="width:9.218%;"></td>
         <td style="width:1%;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</span></p></td>
         <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,517</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
         <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,517</span></p></td>
         <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentExpenditureAdditionToLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=gyre_BeijingContinentPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=gyre_GyreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=gyre_GyreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018755936336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expense</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 14,662<span></span>
</td>
<td class="nump">$ 17,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018750671168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - Convertible Preferred Stock - shares<br></strong></div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666.67<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares', window );">Number of shares of common stock issuable upon conversion of the outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,767,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares', window );">Number of shares of common stock issuable upon conversion of the outstanding shares</a></td>
<td class="nump">8,767,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issuable upon conversion of the outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018750436224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">$ 57,221<span></span>
</td>
<td class="nump">$ 49,653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">116,539<span></span>
</td>
<td class="nump">84,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,935<span></span>
</td>
<td class="nump">9,264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">38,065<span></span>
</td>
<td class="nump">12,536<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">20,047<span></span>
</td>
<td class="nump">12,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 400,000,000 shares authorized; 76,595,616 shares and 63,588,119 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">68,179<span></span>
</td>
<td class="nump">32,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatutoryReserve', window );">Statutory Reserve</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">2,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">(Accumulated deficit) retained earnings</a></td>
<td class="num">(85,538)<span></span>
</td>
<td class="nump">7,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,644)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gyre stockholders' (deficit) equity</a></td>
<td class="num">(15,828)<span></span>
</td>
<td class="nump">42,522<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and equity</a></td>
<td class="nump">116,539<span></span>
</td>
<td class="nump">84,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">3,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in subsidiaries</a></td>
<td class="nump">49,709<span></span>
</td>
<td class="nump">40,632<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">50,477<span></span>
</td>
<td class="nump">43,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">1,780<span></span>
</td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 400,000,000 shares authorized; 76,595,616 shares and 63,588,119 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">68,179<span></span>
</td>
<td class="nump">32,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_StatutoryReserve', window );">Statutory Reserve</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">2,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">(Accumulated deficit) retained earnings</a></td>
<td class="num">(85,538)<span></span>
</td>
<td class="nump">7,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,644)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gyre stockholders' (deficit) equity</a></td>
<td class="num">(15,828)<span></span>
</td>
<td class="nump">42,522<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and equity</a></td>
<td class="nump">50,477<span></span>
</td>
<td class="nump">43,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Related party receivables</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">3,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; 13,151 shares and nil shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">64,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; 13,151 shares and nil shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">$ 64,525<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749299392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">76,595,616<span></span>
</td>
<td class="nump">63,588,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">13,151<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018749297760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 14,662<span></span>
</td>
<td class="nump">$ 17,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(76,965)<span></span>
</td>
<td class="nump">9,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(85,480)<span></span>
</td>
<td class="nump">4,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,484)<span></span>
</td>
<td class="num">(4,928)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) attributable to common stockholders</a></td>
<td class="num">(93,770)<span></span>
</td>
<td class="num">(456)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">3,316<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in (loss) income of subsidinaries</a></td>
<td class="num">(89,617)<span></span>
</td>
<td class="nump">2,396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(92,933)<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(837)<span></span>
</td>
<td class="num">(2,758)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) attributable to common stockholders</a></td>
<td class="num">$ (93,770)<span></span>
</td>
<td class="num">$ (456)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018754746752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income, net of tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018754574960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (85,480)<span></span>
</td>
<td class="nump">$ 4,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">25,892<span></span>
</td>
<td class="nump">10,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(1,891)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">8,334<span></span>
</td>
<td class="num">(5,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">25,175<span></span>
</td>
<td class="nump">30,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">33,509<span></span>
</td>
<td class="nump">25,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(92,933)<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss (income) of subsidiaries</a></td>
<td class="nump">89,617<span></span>
</td>
<td class="num">(2,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Divestiture losses</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Due to related parties</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140018746908016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gyre_PercentageOfRestrictedNetAssetsExceedNetAssets', window );">Percentage of restricted net assets of consolidated subsidiaries of consolidated net assets</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gyre_PercentageOfRestrictedNetAssetsExceedNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of restricted net assets exceed net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gyre_PercentageOfRestrictedNetAssetsExceedNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gyre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>118
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M)2^CQL"46I57:0R<DXR!=$'@.8F6ZAF.(R*69;5[MGVE7MLU:@U,J55QE=;
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MHQ:K,0Z&5DO7D=#'3L<ME?F936/[JN.FD4:1<:]AL?.#OM1,#BZ[UEPNZSM
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MRE=3]5"0[D8AOI04K/3FH=,BAX\$/JM'&CMD5S+<YSJ,XI$F8]Q[]/%()^A
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MR 8H]#^@P O" P5-_QX>G"@G[!L9.K[P7QIYJ%\M7728S@[OM:II!@DVTZE
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M77"JS+*:/* M"Q2@0F4L!+C+^)1,6U-#(9;<A91"XN4<?&3LU,A5FSNGLV!
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MT #ZOB.41@.6ZUHM54W(U 5OK0KG&'V*3[.<"R#@&D/F)^UT_:!<&)BN"PW
MMI0&PRL*H_.QDIB0Y^'8@FJHKP)  S//)T $N0867^?(4_V<PZOHZ0!YL98J
M#]_[G=RE^%(-,LA ] XQ1+(.>/58(_*UJG)).(3S5SAH50,9X*&C@N:]751$
M@;(K]<'*TIP'ID@U<%/3'ZFQ[;A%^5*44+%]1.1=Z[I!" W$""B#"1+/QY5%
ML<P!JRFR@0S(NVJ:H_GR8".NB7KJ8\Y'5#41'ZAR.8"^$\B2_IS&!M.:\<5N
M!(K^2UO;>N4/?'447T6W'M_E8H\''CYZ.IZLLW=;RM /+#8/G7]""N)9=C=F
M],.AW?-EY%'"[+5G"'E3+H"SU[TYRLTE?9Q/I_-P M'7C9]$T9J=PV8:#ZE[
M/[64) <,C+^%+-NE3)NV9H5MC4;C9<V'W[^>W_Q+/*MTO51AH"4KU%7U?'R@
MI3.(*INU3F'%'#8C;!FFGDZE7..WU(&TEK5P-9>=>DHQ2S22[#A.]#!D@HU/
MI^B/VO(;P(JX,3)+^.M&B_?87.L42-NWT0DIT9&.[2Z7,Q(^7C.$(RY^WMUU
M;^-*K.U0Q^\!>#UZ!##!L# N39Z;>UH[4@V;Q_@F>*G=]<\N*2^[U9Q6:+FO
MG"$U BQQ91D[H;^'ITCNG%%0Y9,C>049RC*(Y!FR[,VB7:KX.KF=B)4JZ:J#
M\$%*=S2T*TU-6W+-!70JD1MSU0U$>=>G\_/KK1$RMRK=N5QU.D)^ %.SP'[4
MWBW$@TS1M0&\.G@V=X!]IF\_7%*:-[7CK*VQ@LK7+5CL92OM2.; 2'D\-MD-
M0YW&/*O*C8JE@["NJWN@/E*_I@%4J$$\YL&>!4]6VLKWP/1SO/1Y[(HF!B=E
M!E-;7\*=5TJ$D][IL:-B_22>Z:Z?>Q84C>1:-@_<=]<8:I3R<\(1UE734,B0
MT_YTF,F+>V><E<R]&S"-C2E>@T7PR!B]"5 ^@+EU\*&%SHDNW>ZY>1T_7ACI
M;IX<\#6#V[6M4TBW. E'P>M(.B1@%(:0-3W"#K*ZOD,^D.B;VI!/:N<T* JC
MQ,8X&&:;@8+W(_'HTYG.&-85](8++>3AIPZ50HI%\"X:@[;]XAVVKB7/1-U5
M& _ZZ$T3.#MBAVMZ[UX+7/:;6_!*Z*]O"8YSJN!5VX3BW4<UO2''4NHP-*08
M 6&"1_$669<O4'_XRG!G(0VIY^KZYD=95*_?#YK-H'6ORLQWRX_TL"7%M+M<
MZ0,C3@;N7M,5.JP%_[WH?\$'\&T4P9M.O#B_H5S"AG=Y/+R40;FENR;MWK^(
MMG<Q&2J"2W54A=V[!^Y:&W7"/B%&&6@V:R1('^.N9.QM3<=*AX+89/+NVIDN
M'GE=C^4G=;,L&*% O]9-EUU$^V[5E?X5F?P/=I@;=[G5I4FL0/?).2P.*MAQ
MNQAZ)-&:_9=80?OQ9/:_WG6#M_'E'S<=T>>]VUN6R0OAO-[?T,G(PF :UZ?3
MFSOMN1Q+J/;%F:>[!N8!E>N-]^!\]K6?@3X)%YZ,W, 0-X,;HN=;C79"L:'@
M]\27<O:3[D9R7&[HKD=\,/=33VA->!(#O,^M@9//]S3$*L_-")N0"%YZJJ&*
M7,$$5N,%62KM&A5PX\+.&W+9TCL^$_&1RG[??=V[@NSQ5BGQFT'4SXY8F-G\
M-;.I&T>JNQ"#^"F]7#(1(S<1OOEW,?/4VXW_SQ61"_KNTB:L&57U$%.,L4_I
MFTI)',&[QIMBVE*J?' GA/3<W?@_&.SL:"#[-TZ#-I KV$(I>H\264.&J];(
M#IM\F?.$G@#:F R,[L 4>-0FLQT4=;PZ=V2,&B^V>J[ J.01%E8\T1U<%/Q'
MC"1 YSGE+X:#]^[%IXPO]#)ZU<DP C8T^O#G.B?D[%W(3(53.PF0G=!<TJRC
MIGXNY+CN^B_</\ B_-I/A+!Q)[B]4VX.1X"#5,7"!.,0S7M9USQ%&73V+D&Y
MTN7RI^2W%[P4.3*KNY,,$?F K6&!C/XS<!3_'I^#[RP'-04LQPX9W+2A+T02
M)?"WL^$ZQE71W0(GCXFT98#1TP<4)\@W8EF[DBOSH FVL8\;/7[+/.9KC,]Z
MTU/8!(7#M'G6<[*%"OG4OV,3CB=V*=D[7XKY?TOD?G*=H%4'<,@(.GST[=P&
MT$ZXBA;K;W?#V$<3=.LI&9\!T;'U?Q O3R8GHM!Y3ORP3^4.PKEC:W.G,S<9
MZM!2[UT_REP_B/G)Y%4D$J#C4YBA]Z[3MFC="TB$!%+=C##&HQQB*'X@_(3<
M&W#>#^+HJ+=^(BZX8_3!]L#!/=+I1*+A9=+O.!8JUS"X?]TNCLIW,I&X)TMD
M>NLNY$U\L]7?=_K7]TR\ABSX[A9*!-?D);:EL1"_&X=5R]9GDVWN1PW!^7R1
MZY5_F9:S( R-8&G$;"X*][[UL!;%<':)P*K'0?5$C+U^?-A[Q;Q0]8I?I*=$
M@L[?O6T>G\9W]<_=*^K=<O>B/R#9BLI>KI;8.IV<G1PXP!.^-*;B%]87IFE,
MP1_7"MFYI@7X?6D */P7.B#^'PSO_@U02P,$%     @ U8-[6,?^CB!A*@
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M=+P*]6%2:D].$Z1\78C!69/=RRF;0GTF8B-/7"0W2J CS@.O94-135)I0-%
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M S+:!0L*V'%N.<T+B$XE.?XE50Z2&]-:P \UN,5 K4RF=QB_4B/;-YP5J$Q
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M\$C1#+;:@V&^Y) B&>E8%@-PLX<UB(K%1A:/$D>1<$*/M/6XW</;2]LEJ?F
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M1T6//.)$KTV(Q-^T>VBD12)ET2U/R-](W3JLL 8)-8L"*'E2UP4XXZO<L>T
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M+H[J!^V"HO2/']#&U442Y(Q&_<]IU+_4_49;:(QNI_K*DZA#F">(CA-1UO
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MEEK+6BPPCF >P[M: >QTN(F,_M?Q--%78O/<-FCLL&FU776LE?]+7R$Z&=8
M\K<Q*J4V 8=FID7&3AOA^7TJU#!;OR6P8T85_&]N++=:JLFQ89]#ID-'_"8E
MEU' &X=JX6"]'+U1E!0ZD3KVWMH1:17BA:395SC]I6[B>L(XZ,B]G0**%M?F
M?C8[3[)%6)(F[LG0)6 ;N@/VZMB$T%=L&WXX@J95Q&[+_DT2CW2B4E"D!F6P
MV:F.$$)Z<!LC25NUGEE%EO_9P4@*<A$!5:53*,A7G8YBD2JEY]&"^+M=X0)D
M&7W$_YJ$WSP(3*Y=Z*AK7"<34$W5^+ZL+#=I_;PZE"V71Q)4]$L>VZHR%F^A
MEI_T#^'V#FN@.6U+!1GJFGN]'E6^15.$:+9(!)*G,D7R$4\\%IG*W=E8_5TA
MLJUD3#PIV3D/$"N)J,R6;I=WHPE4.B&L=L9WC [0%G">HM2N,(<DC<.?E]8%
MWYR2>?0*=_&/$JW;X=%*8U^L# 6*@$WQ9(D ?F[N,*3!@7#Z_3$/+4W4Q^Q6
M=!2//R6D6AJ4,4BBB$PZ_D?LI$@=DP;1$031XEC"K;!L\3P3^(;G.^<I538#
MXJ<5)CPUVA6MG45E4QA>1Z,4J[< D/421UR).?3AZOH?^6K]ZMVX,:II'!U%
MQ\,.\&5?_!%''W!>J<^8SU KTD_.4*1,TL*)M4F6!LEY D<#SW'5L)]W$WGK
M8E?_!#XBF3!1X62H&-N&E<7 R#=1$WU2W9AO8\E/!JU W-0RL59J3%F>1!,N
ME&>T'#?L*./#T^F$S_T,JI\^?<B^W%QPF03F4=C*\.[T6T7M94!M-$5<YEHT
MG-G)+9(:DX6T7ES'OY <AQ[?ZURBZUV_H<Q>FY9MD<6:QR7UGYJ:4WC\XQ'X
M*R]%%*Q"T+9]>W7'=OYR,X<Z=6J ]^6'C>!6?D'=EE&K@!_\1H0E)F[TDD\=
M,0'6R<&V8Q*<FZ"PO"F34U!7@]9@3SA=A^$Q*Z-YJ=#0M)$!I5'_;8RH:>YW
MFMYW)?IKF]2;O,%?8H[;)?0'1H\&_I63854<!Y194<KW^8(CICYZL_-^%.Y)
M/(E,,B/XDZJ^-W\2%TL)LVD%VSPOXL)#ACP=@H6_A,R#J?")CV3PX%^>;N.O
M5_YK/VXK!"L8#QKBH/W??_YR<?V?'FQ!)OZ(O8R*\,OXL E%W)8-*ZV\R$LC
M/[^J!8X30 VZ$U(9ZS8KK!K+7U'NHI%)27[=89A<+#K,A(G8KQ5*G?0C/Y_B
M2S<X)!%'6+8"-#(WSN6OGW1O7C^Q#OY3P/_:Y@[^2UT;[_(N?_-Z94"275+9
M"=GA/QR<'$2?8J[^AX.+DY<7IP=/X,WP^)O7:Z =N)X%%F=59@ZO'D^?/SW@
MI)#^T35K7#*;-5W7K.B?>-6FQ0?@^WD#8E'^P UP^!&!]^9_ %!+ P04
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MVH3&FQAJM"9RTO"C;(*C6TEV87Z#/KBV#*V39C_- D'R15;VYLO.O/B-^:B
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M1&/-F.P=S:BR/P=_EFD2_(11 VLJ53!Z!EVCE)6N:3[:(^73[59,8G3[=7K
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M<5&"Q'3JS(/SQ=#X6X>O'!NU-P93R5J(GV9RG4P=WQ#"'&-M$!C]W>$2\]P
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MSYQ>L"B- 9VO!:6Y6Y@+MF_BQ;]02P,$%     @ UH-[6!E'NQO= P  DP@
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MW33QA,T22=;B+!J<] +.*(5GHWWAX+/.,3\'2(A4SRSMF"W2JXB?,(MA/!I
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MEX*70M,&K,\5CJCV@0QTGW7/_P=02P,$%     @ UH-[6.E:VY^K @  ' 8
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULC551;]HP$/XKITS:$R(D
MH2WM *G0;NND=JAHV\.T!R<YB-?83FT'VG^_LQ-2IA76E\3GN^^[[^S<9;Q5
M^L$4B!:>1"G-)"BLK2["T&0%"F;ZJD))GI72@EDR]3HTE4:6>Y HPW@P. T%
MXS*8COW>0D_'JK8EE[C08&HAF'Z>8:FVDR *=AOW?%U8MQ%.QQ5;XQ+MMVJA
MR0H[EIP+E(8K"1I7D^ RNI@-7;P/^,YQ:_;6X"I)E7IPQDT^"09.$):86<?
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MZ*!_=A* ;F918UA5^?Y/E:5IXI<%C6_4+H#\*Z7LSG )NA_"] ]02P,$%
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M)A#5J9+P+BNC9]O<8:V6OM<*C\A=6Y4(8C@!.KLW:@V6A$&;^2',N^O[#F7
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M[>B-0&D(ZYYUP!6;M.A;A4RP\9$UOH3(U66Z;S>@RL',U7,A4\0_<=.Z%NW
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MU6'XZAT8=S!J,;+(S07V%:Q1YEC8G^$03G4(/W9UR03$>LIG_%L>NI!GWE7
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M9B*ZD _[@"IZ(V +GH7- 6FI6D>#OA3F&L*+[G?PA(4?QDY(0UE%XQ<AE/"
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M3L\UM"Q WS-#MUJ]80?- W#Q'U!+ P04    " #6@WM8D#'H.3 %   ^#@
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M]QM3-T4T#AD+UR+]/CEJ3,,7.S;*V>,48O&6UK=PN?9]/,N8PE;/H;)2C0'
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M1U1^2CA,P6F@\\#08+X&5>7.5EB@WTHKLJ)4DCFXC2ZMR%,+)S#N?$=AJNP
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MU+\8XT:1[<YI'2UJ.^<KH7%K6+/ -0W2!.#]6@B]<TR"?O&G?P!02P,$%
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MV[./&]^*?:[TQF0YK^D>-J!^K]<"5Y,>)2LJ8++@C C8+>R5-[N*M+TQ^*.
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M9Z#ZK,.4ETQGA]!DH=9D8<<.OD--9Z "K<.(UD![""46:246=6P.//ATYNY
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MK@K(WV=E*9XO5 .;T_,F_P=02P,$%     @ UH-[6-D5$-_5 @  ^@@  !D
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M,KCI8[U4.3++A9%+-W46TN ,<X\Y_LL 90/P?2JEV2[L#]3_6Z(_4$L#!!0
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M3%G)S<O?IJ-%4;VVS876(JN:2Z )2#O!?$^%T&\=^X!7O[^._P502P,$%
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M?$7LI^!'7P.D/SBO8K *H[;4ZLG3..H;H>W B40A<@ >G0(1H49$:*8[0QF
M?\%A4PUS$ZW79$[!BU#S(O3/JC:@5>:TI59/7F4MT(AE!TXX]HCLF' 45OLK
MRBQ_; XT.D(S.NZNJ*;5VK%9K77_GX(QH69,V#FOXK&*J+;4ZLG3B K-:YF'
M?5@*D?W3#7-KQT:CF1%:8T;8P(S-Z\?F-H^-23,C/)89 _FQ/'0MVMQ(ZT%[
M"I2$&B7A>:$DM(J2MM3JR=,H"6V@)-Q&R1T5?PJ4##1*!L>BI*J.-NMPYH;:
M=K(MM7I:-% &YP64@56@M*563YX&RL#,@BV^(L$V'S:7B;G)8T.J_.Q[-!_*
M,FF]2F=NK75WGX(? \V/P7GQ8V"5'VVIU9.G^3'8\UMXBUKI;F\K:%ZE,[=Y
M;$R*(NM7-(,%9@:3LT-9-F&4SN08(!2$B"^S[L\.\(]4?F&B;)M.MJ<J3.(5
MHF]J2(0)Y4E$9DA(RRF*$ TQR/8-73;YZE:V%,68+;*M65RJI%3DNSS*J^7V
MK]MLE]2OUX/>]5B&W'2G+^]D.\9<W42^W^P1L06A'$1X+IOS+ONR(UB^A2L_
M$<DJV]0T381(XNQPB=$,,_6 O#]/$O%^HAHH-]*-_@-02P,$%     @ UH-[
M6)QNK)85!P  ACH  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULQ9OO
M;YLX&,?_%2LWG39I:\ )2;MK([4![RJU=U6K;2].]\(E3H(&.&>;I)/VQY_Y
M$8@3X@NW1^I>K 3PQX;OX\?V%[C<</%-+AE3Z"6)4WG56RJU^MCORW#)$BK/
M^(JE^LB<BX0J_5,L^G(E&)T5A9*XCQUGU$]HE/8FE\6^!S&YY)F*HY0]""2S
M)*'B^PV+^>:JY_:V.QZCQ5+E._J3RQ5=L">F/J\>A/[5KRFS*&&IC'B*!)M?
M]:[=CV3@Y 6*,[Y$;"-WME%^*<^<?\M_W,ZN>D[>(A:S4.4(JO^LV93%<4[2
M[?BG@O;J.O."N]M;.BDN7E_,,Y5LRN.OT4PMKWKG/31C<YK%ZI%O?F?5!7DY
M+^2Q+/Y'F^I<IX?"3"J>5(5U"Y(H+?_2E^I&[!08'BN JP)XKP#&1PH,J@*#
M4VL85@6&^S6X1PIX50%OO\#%D0*CJL"HN/?ES2KNM$\5G5P*OD$B/UO3\HU"
MKJ*TOL%1FD?6DQ+Z:*3+J0FAD4!?:)PQ=,^HS 338:,DHND,D2BE:1C1&-VF
M4HFL//(!7<]F41X6Q8$RN/,@>>LS1:/XW65?Z8;E^'Y8->*F; 0^T@@7W?-4
M+24*TAF;F>7[^H+JJ\+;J[K!5N"?H3I# _<]P@X>H,]//GK[YAUZ@_I(+JE@
MLOK3TM*I'7Q/10WVMN 6C&_'^"S\G^T+3KAP/*[ 1RGD].;ANGEM-$.=01US
M@P(_^.^8NZ&Q#C&&GHHL^DGP;!6EBYW(>U)4%2&)IG25AYE$?]UI'KK5N^7?
M;;%65CYLKSS/U!_EBH;LJJ=3L61BS7J37W]Q1\YO;>$ "?,A80$DC #!C' 8
MUN$PM-'+<%@7X9 T*0@I05,Y9WK@8&K#6(KNV)K%R"U24[F-V^2W5M95?DB8
M7\+&!2P?\=<3Y[*_WM44LCH"!#,T]6I-O9_2M-1OT*:?%=Q5/TB87\(\BWZ0
MU1$@F*'?J-9O9->O3L!42I;/!Q2:UYJVR6;E=94-$N:/#F1S'>]<3[WWU8.L
ME8PLG=V09%Q+,CY1DCBBSU&LIV#L!%VLT*ZZ0,+\\<$=<L>>-S[4!;)6<ECK
M$5W.:UW.K;I\I4)G-=U%V L382096HE(3VE6.LT54R;T8V=FUR:1E=]5(DB8
M?WYPLX87KK<G#V2-! AF*'E1*WEA57+*TS43*GJ.&7K0"UPF!)OI&2@/O[7)
M9H5UE0T2YD/" D@8 8(9\KI.L]9U7G/A4=4.%!&@-!^4%H#2"!3-C(H=!\2U
M=ONFJ\N\JV^7X)&4F=[WPY*X*_#NU.+<=<WT.+77WEG'PRK=@>OM51J<TC+2
MQL*#X9'QT,7-#<4GWM B=Z+M"-EZ"ZVHSGT&DN:#T@)0&H&BF1(W#H[[JA:.
M"^KA@-)\4%H 2B-0-#,J&B/'M3LY]518<;3*1+BD>C9<I5-K'AV>DD=!O1A0
M6G#*!1"H*DUQ&D?&M5LRUXN%8 O=%1MIRH4*GZ.-+4-[!XL SRG^[0L$:K:
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M=7@ ?1L+E.:#T@)0&H&BF5'1^(#8[N+M# _%,N+$H0'T%2]0FE_13A@:0"U
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M\W[YF- -"Y7]@.8W4IJG@770W-G"OP!02P,$%     @ UH-[6!VT._^1 P
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M)G(@M\!,K@&WW!K"9$RNN&0RXDR0:VFLSLN9]^0B87('AG!)/AC+<6L %S=
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MA$'8A*OQ$'9W]GZE\2E@G3*L4X:.M[F!=TS%G!0"X?,4CA=DE4VH0]L*8XH
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ME8P[P/%UU2S%!I1I7BB^48&E8#W$Q@.&27A:*Q>W_$'%)UU"DXL)O<]++IX
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MQ4J9$XIO.1!E42#^\S/.6;5VH//:<4=VF=0=;KS:HQV^Q_+[_I:KEMNAI*3
M5!!& <?;M7,-KS:^IQ/JB!\$5V)P#;241\:>=.-;NG8\S0CG.)$: JF_9[S!
M>:Z1%(]_6U"G>Z9.'%Z_HG^IQ2LQCTC@#<O_(:G,UL[" 2G>HC*7=ZSZ"[>"
M9AHO8;FH?T'5QGH.2$HA6=$F*P8%H<T_>FD+,4B X8D$OTWP?S<A:!."6FC#
MK)9U@R2*5YQ5@.MHA:8OZMK4V4H-H?HUWDNN[A*5)^-O5"*Z(X\Y!M="8"G
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MVK@(O5^ E@Q#BS,<>F'@':QTQJ 3C@'VE@':\PS0X ?\Y1%/4U1T8DV&O6N
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MJL[.#)>J^0:N#=3W.6-R-]$!BG8^^@]02P,$%     @ UH-[6,NBT=D" P
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M?* ^*5YT8,5$LLPT,2LF54MDAK'J6H'K /5\S9C<3?0+JC[8_P]02P,$%
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M.\#W)>?J[44/4%]-3OX#4$L#!!0    ( -:#>U@UJK6)@@(  .X%   9
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M.AN>!Z";[M),K*I\@2Z5I7+WPX(:,FH70/NY4G8[<0=T+3[Y"U!+ P04
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MX E8$'% &8L"^0FLS 4= J-D7P2EV/1X]KO$;B?\@5IL(<)68Y@L(Z0UHP$
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M'7'CNFVSZQYBOV*?^EU7^_IJ9>Y,WV092JV-KO'BMMF+K^4N&%)!M@4M]5Y
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M(%9]Q"$WUPP;K!*HFPNE>5":#Z4%*%I7,JV;2U_:S:50-Q=*<Z$T#TKSH;0
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M;"]W;W)K<VAE971S+W-H965T-S@N>&ULS5C;;N,V$/T50ET4N\ FNEJ.4UN
M[?2R0!<(XMWVH>@#+8TM(1+IDK2]Z==W2"FR9"M"L]!#7FR1GCDZYW!$#S4]
M<O$H4P!%OA4YDS,K56IW:]LR3J&@\IKO@.$O&RX*JG HMK;<":")22IRVW.<
MT"YHQJQH:N;N133E>Y5G#.X%D?NBH.)I 3D_SBS7>IYXR+:ITA-V--W1+:Q
M?=W="QS9-4J2%<!DQAD1L)E9<_=VZ88ZP43\D<%1-JZ)EK+F_%$//B4SR]&,
M((=8:0B*7P=80IYK).3Q3P5JU??4B<WK9_1?C'@4LZ82ECS_,TM4.K-N+)+
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M0"UI9_DCCJ='%SYMW>_^Z6'AI=ENUHFZ_?X9FM1W1#$=G2E--#YPC5LW?<#
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MFDD!BE:38#JXGHV<O3=X8;35!S*X3)92OCKE+I\$?4>(.&7&(:#];>B&.'=
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M5+>%X@1]/!9"/6X4"9KO0A;_ 5!+ P04    " #6@WM8'"MG$A\#   0"0
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MYL[403%LR3X3]_3X.]03T@E&-./Z-SK6L9Z#HCT7-*_%,H,\+:I/\JTVXDR
MQR\(_%K@?R\8OB 8U(+!I8)A+1A>*AC5 CUUMYJ[-BX@@BQFC!X14]&2IBZT
M^UHM_4H+M5 >!)-O4ZD3BWO(B( 8K0D3C^A/1@I.= DY>H=NXSA5UR1#JZ):
ME*JX;P(0),W>RHBV_!WZ@#ZCE?S\\A"@-S^_G;E"YJA&<J,ZG[LJ'_^%?+"/
M/M%")!R%10QQ&^#*R34S])]F>.=W$@.(KM  _XI\SQ\8$EI>+O<-\N!R.3;(
MP\OE7H<9@Z;< \T;]"TW^N>C#$4K 3G_UU2VBCLT<U4[N^$EB6#NR'[%@1W
M6?SR$QY[OYDLMPD+;,)"2[!6<89-<89==%D<#H1%"2)%+)O=07;Q4O9D@;8
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M=ER+]/A[QCSH-X4VD)& >6:AD0K3R!ZF&[C9)*&=0U=W=\6MKJ^*] @><RE
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M9YNFV8%D2;KO^,2D9%$ZW ,)@.L =7W+F'P]T%N9Q=;UZAM02P,$%     @
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MB_WGAWM\\$"[!(R72MGCQ#7A\(1F?P!02P,$%     @ UH-[6)Q!%%!I P
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ML%T2AG%L1P"S.PA##('=B".8 _" (6%8W@?W[D?>]C[E-?^ '_\&4$L#!!0
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M[I/:MYYENT_=6%P20_-2VQUFEG7@?)!O[?,JUYE]]TR\D;DL4R6ZX-8$T .
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MN&?D3MT">-)91LA"$?>,W&E,-_8I)K)0]!QW?88QW4P#Q82+DL]UW\=%L]<
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M7Y[I4'?C2WZV_&/P]B=02P$"% ,4    " #5@WM8!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -6#
M>UCM':85[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( -6#>UB97)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ U8-[6+RU3Y,0
M"0  ;#8  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( -6#>UB[%CA';P@  (\I   8              "
M@501  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #5@WM8
MLWH.,]H"   H"@  &               @('Y&0  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ U8-[6%E$*>J2!@  H1T  !@
M     ("!"1T  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M -6#>UB/)6*T,PD  '=1   8              " @=$C  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " #5@WM8C/W/Y$D*  !?,@  &
M            @($Z+0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ U8-[6'-W9!A* @  H@4  !@              ("!N3<  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -6#>UBC^N1W8 0  )L/
M   8              " @3DZ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " #5@WM8V<$.UK,0  #-,   &               @('//@
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ U8-[6,?^CB!A
M*@  ](4  !D              ("!N$\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " #5@WM8 NU"!PL)  "4&0  &0
M@(%0>@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( -6#
M>U@<9F*5Y04  )L/   9              " @9*#  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ U8-[6#40%2(1!   '0H  !D
M         ("!KHD  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " #5@WM8E 5BY)$%  #@#0  &0              @('VC0  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -6#>U@?6#U9  @  ,<3
M   9              " @;Z3  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ U8-[6.FHA$0_ P  #@<  !D              ("!]9L
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #5@WM8XK]>
MH&L&  "X#P  &0              @(%KGP  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( -6#>UBADOSK"P@  (@3   9
M  " @0VF  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MU8-[6"2RA#;^!@  )1(  !D              ("!3ZX  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " #5@WM80/IOJ(\*  "1&P  &0
M            @(&$M0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( -6#>UAAS47UW H  !$;   9              " @4K   !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ U8-[6/_S&=SV#@
M'"H  !D              ("!7<L  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " #5@WM8?"-EWTX#  !F"   &0              @(&*
MV@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -6#>UBE
M4(.KD 0  !\+   9              " @0_>  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ UH-[6!E'NQO= P  DP@  !D
M     ("!UN(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -:#>UA.!)YV( 0   P*   9              "
M@<TT 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ UH-[
M6) QZ#DP!0  /@X  !D              ("!)#D! 'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " #6@WM8,! =8# %  "U#0  &0
M        @(&+/@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( -:#>UB8+K@/LP,  ($)   9              " @?)# 0!X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ UH-[6'@." ZZ @  Y@4
M !D              ("!W$<! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " #6@WM8TL3VU:<&  "P$0  &0              @('-2@$
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( -:#>U@1V^JW
MWP,  ,$)   9              " @:M1 0!X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ UH-[6%"L^=VV @  ! 8  !D
M ("!P54! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #6
M@WM8&13"LR0%  #A"P  &0              @(&N6 $ >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -:#>UAHF;1GB08  %(3   9
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M970T,RYX;6Q02P$"% ,4    " #6@WM8;G4K?_T(  !)3P  &0
M    @($%@@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M -:#>UC9%1#?U0(  /H(   9              " @3F+ 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ UH-[6 X\:=LG P  PP@  !D
M             ("!18X! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " #6@WM8C<)YRP $  "+%0  &0              @(&CD0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( -:#>UB0M'5O8P4
M %0G   9              " @=J5 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ UH-[6)QNK)85!P  ACH  !D              ("!
M=)L! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #6@WM8
M#RGO2K0#  "_#0  &0              @(' H@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( -:#>U@=M#O_D0,  &P-   9
M      " @:NF 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ UH-[6#\E7<&X @  )0D  !D              ("!<ZH! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #6@WM8/0@SX<0"  "[!P
M&0              @(%BK0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( -:#>UAE@BZ:G (  /<&   9              " @5VP 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ UH-[6#D-X$.W
M P  <PP  !D              ("!,+,! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    " #6@WM8#F,?'QP#   Q#   &0
M@($>MP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( -:#
M>UAQ/&DH- 0  )T6   9              " @7&Z 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ UH-[6).T[='! P  NQ(  !D
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M=#8R+GAM;%!+ 0(4 Q0    ( -:#>UB_7=(4+ 8  + 9   9
M  " @57/ 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @
MUH-[6'-^:EJH P  -A8  !D              ("!N-4! 'AL+W=O<FMS:&5E
M=',O<VAE970V-"YX;6Q02P$"% ,4    " #6@WM8D_[)DK("   R!@  &0
M            @(&7V0$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4
M Q0    ( -:#>UAX8ZFJN@,  .(*   9              " @8#< 0!X;"]W
M;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ UH-[6$>&.Q7) @
MO0<  !D              ("!<> ! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX
M;6Q02P$"% ,4    " #6@WM8\N$M+XP$  "F%   &0              @(%Q
MXP$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( -:#>U@U
MJK6)@@(  .X%   9              " @33H 0!X;"]W;W)K<VAE971S+W-H
M965T-CDN>&UL4$L! A0#%     @ UH-[6,B_3$5X @  - 8  !D
M     ("![>H! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -:#>U@>+5M[P <  .]'   9              "
M@6G^ 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ UH-[
M6**??\TK!0  NQD  !D              ("!8 8" 'AL+W=O<FMS:&5E=',O
M<VAE970W-BYX;6Q02P$"% ,4    " #6@WM8\1\CHIH#   &#@  &0
M        @('""P( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0
M   ( -:#>UCSR>4=MP,  *X1   9              " @9,/ @!X;"]W;W)K
M<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ UH-[6/40-/*)!P  M$$
M !D              ("!@1," 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q0
M2P$"% ,4    " #6@WM86BD#YA #  "N"@  &0              @(%!&P(
M>&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( -:#>UB)<(J5
M[ ,  -4,   9              " @8@> @!X;"]W;W)K<VAE971S+W-H965T
M.#$N>&UL4$L! A0#%     @ UH-[6$/KN,(1!   )0\  !D
M ("!JR(" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    " #6
M@WM8FT<[P&$"  !:!0  &0              @('S)@( >&PO=V]R:W-H965T
M<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( -:#>UC-J\YA+@8  ",R   9
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M970X."YX;6Q02P$"% ,4    " #6@WM874GCM9 "  #6!@  &0
M    @('</@( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    (
M -:#>UA#+RN6)@(  +,$   9              " @:-! @!X;"]W;W)K<VAE
M971S+W-H965T.3 N>&UL4$L! A0#%     @ UH-[6".A3[^<"@  O$L  !D
M             ("! $0" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"
M% ,4    " #6@WM8P]]^@,0"   L"   &0              @('33@( >&PO
M=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( -:#>UBM6^7("@,
M )(-   9              " @<Y1 @!X;"]W;W)K<VAE971S+W-H965T.3,N
M>&UL4$L! A0#%     @ UH-[6"@RH7@'!P  F"<  !D              ("!
M#U4" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4    " #6@WM8
MY,E)QRT$  #&%@  &0              @(%-7 ( >&PO=V]R:W-H965T<R]S
M:&5E=#DU+GAM;%!+ 0(4 Q0    ( -:#>U@DE.6Q9P0  (T2   9
M      " @;%@ @!X;"]W;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%
M  @ UH-[6%_'P3.B @  7 <  !D              ("!3V4" 'AL+W=O<FMS
M:&5E=',O<VAE970Y-RYX;6Q02P$"% ,4    " #6@WM8:DA3"MT$   _%0
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M+G)E;'-02P$"% ,4    " #6@WM8-U/W _D&   $00  #P
M@ % = ( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ UH-[6+?ZQO#1 @
M,CH  !H              ( !9GL" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ UH-[6!6+*+]4 @  .3@  !,              ( !
M;WX" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &L :P!D'0  ]( "

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>239</ContextCount>
  <ElementCount>523</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>99</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100090 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Fair Value Measurements and Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995535 - Disclosure - GNI USA Contributions under the Business Combination Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995645 - Disclosure - EPS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureEps</Role>
      <ShortName>EPS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlans1</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Financial Statements Schedule I Financial Information of Parent Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenue</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995755 - Disclosure - GNI USA Contributions under the Business Combination Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995805 - Disclosure - EPS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsTables</Role>
      <ShortName>EPS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/DisclosureEps</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail</Role>
      <ShortName>Organization and Nature of Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Liquidity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail</Role>
      <ShortName>Liquidity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Fair Value Measurements and Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Fair Value Measurements and Financial Instruments - Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Balance Sheet Components - Schedule of Inventories, Net of Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Inventories, Net of Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Balance Sheet Components - Schedule of Deferred Government Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Deferred Government Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Revenue - Summary of Sales by Product Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails</Role>
      <ShortName>Revenue - Summary of Sales by Product Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996045 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996055 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996065 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996075 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue</Role>
      <ShortName>GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Restructuring - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail</Role>
      <ShortName>Restructuring - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996105 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail</Role>
      <ShortName>Leases - Schedule of Supplemental Cash Flow Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996115 - Disclosure - Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail</Role>
      <ShortName>Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996125 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996135 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996145 - Disclosure - Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996155 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996165 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996175 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996185 - Disclosure - Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail</Role>
      <ShortName>Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996195 - Disclosure - Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail</Role>
      <ShortName>Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996205 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996215 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996225 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996235 - Disclosure - Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996245 - Disclosure - Income Taxes - Movement of Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Movement of Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996255 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996265 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996275 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996285 - Disclosure - EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails</Role>
      <ShortName>EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996295 - Disclosure - EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail</Role>
      <ShortName>EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996315 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996325 - Disclosure - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996335 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996345 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996355 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996365 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996375 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>996385 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>996395 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>996405 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="gyre-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>996415 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails</Role>
      <ShortName>Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountingStandardsUpdate202110Member in us-gaap/2023 used in 3 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. gyre-20231231.htm 8994</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:FiniteLivedIntangibleAssetUsefulLife -  gyre-20231231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="gyre-20231231.htm">gyre-20231231.htm</File>
    <File>gyre-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img98921446_0.jpg</File>
    <File>img98921446_1.jpg</File>
    <File>img98921446_2.jpg</File>
    <File>img98921446_3.jpg</File>
    <File>img98921446_4.jpg</File>
    <File>img98921446_5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="882">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>125
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gyre-20231231.htm": {
   "nsprefix": "gyre",
   "nsuri": "http://www.gyretx.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "gyre-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "gyre-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 395,
   "keyCustom": 128,
   "axisStandard": 37,
   "axisCustom": 0,
   "memberStandard": 55,
   "memberCustom": 37,
   "hidden": {
    "total": 14,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://fasb.org/us-gaap/2023": 11
   },
   "contextCount": 239,
   "entityCount": 1,
   "segmentCount": 99,
   "elementCount": 1001,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 882,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 10
   },
   "report": {
    "R1": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "shortName": "Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:CostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity",
     "longName": "100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Equity",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_b7c2a125-5bff-41a6-a0df-4926d0dda919",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b7c2a125-5bff-41a6-a0df-4926d0dda919",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100090 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_a5d59667-252a-4ddf-a814-4b5b16c0658d",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a5d59667-252a-4ddf-a814-4b5b16c0658d",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations",
     "longName": "995455 - Disclosure - Organization and Nature of Operations",
     "shortName": "Organization and Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments",
     "longName": "995495 - Disclosure - Fair Value Measurements and Financial Instruments",
     "shortName": "Fair Value Measurements and Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents",
     "longName": "995505 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssets",
     "longName": "995515 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenue",
     "longName": "995525 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement",
     "longName": "995535 - Disclosure - GNI USA Contributions under the Business Combination Agreement",
     "shortName": "GNI USA Contributions under the Business Combination Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuring",
     "longName": "995545 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995575 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "longName": "995585 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStock",
     "longName": "995595 - Disclosure - Convertible Preferred Stock",
     "shortName": "Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995605 - Disclosure - Stock Based Compensation",
     "shortName": "Stock Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995615 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995625 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1",
     "longName": "995635 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEps",
     "longName": "995645 - Disclosure - EPS",
     "shortName": "EPS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlans1",
     "longName": "995655 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995665 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "longName": "995675 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany",
     "longName": "995685 - Disclosure - Financial Statements Schedule I Financial Information of Parent Company",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995695 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995705 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables",
     "longName": "995715 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)",
     "shortName": "Fair Value Measurements and Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "longName": "995725 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsTables",
     "longName": "995735 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueTables",
     "longName": "995745 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables",
     "longName": "995755 - Disclosure - GNI USA Contributions under the Business Combination Agreement (Tables)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995765 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables",
     "longName": "995775 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995785 - Disclosure - Stock Based Compensation (Tables)",
     "shortName": "Stock Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995795 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsTables",
     "longName": "995805 - Disclosure - EPS (Tables)",
     "shortName": "EPS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995815 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
     "longName": "995825 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)",
     "shortName": "Organization and Nature of Operations - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "gyre:PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
     "longName": "995835 - Disclosure - Liquidity - Additional Information (Detail)",
     "shortName": "Liquidity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995845 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail",
     "longName": "995855 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Accounts and Notes Receivable, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail",
     "longName": "995865 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Credit Losses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_a20c4dd4-fc29-4856-9c78-305b31b62bcd",
      "name": "gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef",
      "name": "gyre:AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
     "longName": "995875 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_f243cd37-4ca7-40de-bfca-d9278aaf4176",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f243cd37-4ca7-40de-bfca-d9278aaf4176",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
     "longName": "995885 - Disclosure - Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Financial Assets and Liabilities Measured at Fair Value (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9f06db74-891e-4ce0-a20f-35ad5be24529",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
     "longName": "995895 - Disclosure - Fair Value Measurements and Financial Instruments - Additional Information (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo",
     "longName": "995905 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
     "longName": "995915 - Disclosure - Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_69b8f9e1-11d9-471e-9f88-5c562846ff4d",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_69b8f9e1-11d9-471e-9f88-5c562846ff4d",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail",
     "longName": "995925 - Disclosure - Fair Value Measurements and Financial Instruments - Cash Equivalents (Detail)",
     "shortName": "Fair Value Measurements and Financial Instruments - Cash Equivalents (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "longName": "995935 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails",
     "longName": "995945 - Disclosure - Balance Sheet Components - Schedule of Inventories, Net of Reserves (Details)",
     "shortName": "Balance Sheet Components - Schedule of Inventories, Net of Reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995955 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "gyre:AccruedPayrollAndWelfare",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "gyre:AccruedPayrollAndWelfare",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails",
     "longName": "995965 - Disclosure - Balance Sheet Components - Schedule of Deferred Government Grants (Details)",
     "shortName": "Balance Sheet Components - Schedule of Deferred Government Grants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "gyre:DeferredGovernmentGrantsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "gyre:DeferredGovernmentGrantsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "995975 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
     "longName": "995985 - Disclosure - Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule of Carrying Amounts and Accumulated Amortization of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails",
     "longName": "995995 - Disclosure - Intangible Assets - Additional Information (Details)",
     "shortName": "Intangible Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails",
     "longName": "996005 - Disclosure - Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)",
     "shortName": "Intangible Assets -Schedule of Estimated Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
     "longName": "996015 - Disclosure - Revenue - Additional Information (Details)",
     "shortName": "Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef",
      "name": "gyre:PercentageOfRevenueAccountedSalesToDistributors",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef",
      "name": "gyre:PercentageOfRevenueAccountedSalesToDistributors",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails",
     "longName": "996025 - Disclosure - Revenue - Summary of Sales by Product Categories (Details)",
     "shortName": "Revenue - Summary of Sales by Product Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f750731b-6020-454a-871c-e743ff63ef9d",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
     "longName": "996045 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement - Summary of Purchase Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d846aa23-1a35-4add-bb37-786c605b621a",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
     "longName": "996055 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement - Summary of Summary of Purchase Price (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b46d8f77-6441-4e49-9e95-f82435a4d5d3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail",
     "longName": "996065 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement - Schedule of Estimated Fair Value of Option Awards Based on Black-scholes Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
     "longName": "996075 - Disclosure - GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)",
     "shortName": "GNI USA Contributions under the Business Combination Agreement - Schedule Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
     "longName": "996085 - Disclosure - Restructuring - Additional Information (Detail)",
     "shortName": "Restructuring - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a67805ae-0e8b-4cdd-8b41-5d0c3ff00337",
      "name": "gyre:PercentageOfIndirectOwnershipInterest",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
     "longName": "996095 - Disclosure - Leases - Additional Information (Detail)",
     "shortName": "Leases - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_28499de6-ca37-4fe6-8aca-3f877d7ec297",
      "name": "gyre:LeaseExpirationMonthAndYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail",
     "longName": "996105 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail)",
     "shortName": "Leases - Schedule of Supplemental Cash Flow Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail",
     "longName": "996115 - Disclosure - Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "shortName": "Leases - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail",
     "longName": "996125 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "shortName": "Leases - Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
     "longName": "996135 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
     "longName": "996145 - Disclosure - Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)",
     "shortName": "Stockholders' Equity - Schedule of Common Stock, Reserved for Future Issuance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "longName": "996155 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "longName": "996165 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
     "longName": "996175 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity (Detail)",
     "shortName": "Stock Based Compensation - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_a20c4dd4-fc29-4856-9c78-305b31b62bcd",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
     "longName": "996185 - Disclosure - Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)",
     "shortName": "Stock Based Compensation - Fair Values of Stock Options Granted Estimated Using Black-Scholes Valuation Model (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_212e7d79-56da-4ebd-9b86-9ca7abe1a962",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail",
     "longName": "996195 - Disclosure - Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)",
     "shortName": "Stock Based Compensation - Summary of Stock-Based Compensation Recognized (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "996205 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "gyre:CVRDerivativeLiabilityNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1e216e8-da62-4adc-be21-79756314d405",
      "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
     "longName": "996215 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Components of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail",
     "longName": "996225 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)",
     "shortName": "Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail",
     "longName": "996235 - Disclosure - Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)",
     "shortName": "Income Taxes - Significant Components of the Company's Deferred Tax Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails",
     "longName": "996245 - Disclosure - Income Taxes - Movement of Valuation Allowance (Details)",
     "shortName": "Income Taxes - Movement of Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "gyre:ChangesOfValuationAllowances",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "gyre:ChangesOfValuationAllowances",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "996255 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail",
     "longName": "996265 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_a20c4dd4-fc29-4856-9c78-305b31b62bcd",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
     "longName": "996275 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_84d9b48e-9b34-4794-916b-eecce30677e3",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_84d9b48e-9b34-4794-916b-eecce30677e3",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
     "longName": "996285 - Disclosure - EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)",
     "shortName": "EPS - Basic and Diluted EPS Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
     "longName": "996295 - Disclosure - EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "shortName": "EPS - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail",
     "longName": "996315 - Disclosure - Employee Benefit Plans - Additional Information (Detail)",
     "shortName": "Employee Benefit Plans - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "C_a1eecc05-fb63-484b-87b6-6c579da56492",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a1eecc05-fb63-484b-87b6-6c579da56492",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
     "longName": "996325 - Disclosure - Segment Information - Additional Information (Detail)",
     "shortName": "Segment Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R91": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
     "longName": "996335 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Detail)",
     "shortName": "Segment Information - Schedule of Segment Reporting Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:GrossProfit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
     "longName": "996345 - Disclosure - Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)",
     "shortName": "Segment Information - Schedule of Segment Reporting Information (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:LegalFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:LegalFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail",
     "longName": "996355 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697",
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01c81b79-25d4-4be2-a4ef-98326dc842a2",
      "name": "gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
     "longName": "996365 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
     "longName": "996375 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Financial Position (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "C_336f98ce-84bd-4119-8b08-938644de6dc9",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
     "longName": "996385 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails",
     "longName": "996395 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Statements of Operations (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R98": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
     "longName": "996405 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Condensed Consolidated Statements of Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
     "longName": "996415 - Schedule - Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)",
     "shortName": "Financial Statements Schedule I Financial Information of Parent Company - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3",
      "name": "gyre:PercentageOfRestrictedNetAssetsExceedNetAssets",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3",
      "name": "gyre:PercentageOfRestrictedNetAssetsExceedNetAssets",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gyre-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201409Member",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2014-09",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606)."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-13",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202104Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate202104Member",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2021-04 [Member]",
        "terseLabel": "ASU 2021-04",
        "documentation": "Accounting Standards Update 2021-04 Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202108Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate202108Member",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2021-08",
        "label": "Accounting Standards Update 2021-08 [Member]",
        "documentation": "Accounting Standards Update 2021-08 Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202110Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate202110Member",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2021-10",
        "label": "Accounting Standards Update 2021-10 [Member]",
        "documentation": "Accounting Standards Update 2021-10 Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686"
     ]
    },
    "gyre_AccountsAndFinancingReceivableAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLossCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail": {
       "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodEndLabel": "Balance, end of year",
        "negatedPeriodStartLabel": "Balance, beginning of year",
        "negatedLabel": "Allowance for credit losses",
        "label": "Accounts and Financing Receivable, Allowance for Credit Loss, Current",
        "documentation": "Accounts and financing receivable, allowance for credit loss, current."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Accounts and Financing Receivable, Allowance for Credit Loss, Foreign Currency Translation",
        "documentation": "Accounts and financing receivable, allowance for credit loss, foreign currency translation."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recoveries collected and write-off",
        "label": "Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off",
        "documentation": "Accounts And Financing Receivable Allowance For Credit Loss Recovery and Write-off"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Allowance for Credit Losses",
        "label": "Accounts and Financing Receivable, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Accounts and financing receivable, allowance for credit loss."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInAllowanceForCreditLossesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for allowance for credit losses",
        "label": "Accounts and Notes Receivable, Provision for Allowance for Credit Losses",
        "documentation": "Accounts and notes receivable, provision for allowance for credit losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts and note receivables, net",
        "totalLabel": "Accounts and note receivables, net",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r990"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureOtherAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Other Accrued Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued expenses and other current liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r1016"
     ]
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail": {
       "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r360",
      "r361",
      "r976"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "gyre_AccruedExpensesGeneralAndAdministrative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccruedExpensesGeneralAndAdministrative",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses - general and administrative",
        "documentation": "Accrued expenses general and administrative.",
        "label": "Accrued Expenses General and Administrative"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccruedExpensesResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccruedExpensesResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses - research and development",
        "label": "Accrued Expenses, Research And Development",
        "documentation": "Accrued expenses, research and development."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccruedExpensesSellingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccruedExpensesSellingExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses - selling expenses",
        "label": "Accrued Expenses, Selling Expenses",
        "documentation": "Accrued expenses, selling expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r187"
     ]
    },
    "gyre_AccruedInterestOnLongTermCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccruedInterestOnLongTermCertificatesOfDeposit",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued interest on long-term certificates of deposit",
        "label": "Accrued Interest On Long-term Certificates Of Deposit",
        "documentation": "Accrued interest on long-term certificates of deposit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AccruedPayrollAndWelfare": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccruedPayrollAndWelfare",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and welfare",
        "label": "Accrued Payroll And Welfare",
        "documentation": "Accrued payroll and welfare."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued professional services",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional and consulting services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee reimbursement",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r977"
     ]
    },
    "gyre_AccruedSalesDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccruedSalesDiscount",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued sales discount.",
        "terseLabel": "Accrued sales discount",
        "label": "Accrued Sales Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r230",
      "r799"
     ]
    },
    "gyre_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated gross unrealized gain before tax available for sale securities.",
        "label": "Accumulated Gross Unrealized Gain Before Tax Available For Sale Securities",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r140",
      "r240",
      "r794",
      "r838",
      "r842"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r20",
      "r46",
      "r640",
      "r643",
      "r712",
      "r833",
      "r834",
      "r1142",
      "r1143",
      "r1144",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "gyre_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development",
        "label": "Acquired In Process Research And Development",
        "documentation": "Acquired in process research and development."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AcquisitionCostsInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AcquisitionCostsInDueToRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition costs in due to related parties.",
        "terseLabel": "Acquisition costs in due to related parties",
        "label": "Acquisition Costs In Due To Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1016",
      "r1314"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r857",
      "r1152",
      "r1153",
      "r1154",
      "r1288",
      "r1315"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r281",
      "r282",
      "r283",
      "r284",
      "r294",
      "r365",
      "r366",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r440",
      "r575",
      "r576",
      "r577",
      "r605",
      "r606",
      "r607",
      "r608",
      "r620",
      "r621",
      "r622",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r666",
      "r667",
      "r670",
      "r671",
      "r672",
      "r673",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r763",
      "r764",
      "r765",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r536"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs of issuance of common stock for public offering",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r169"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash used for operating activities:",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance payment for convertible preferred stock and preferred stock warrants acquired upon contributions.",
        "terseLabel": "Advance payment for Convertible Preferred Stock and Preferred Stock Warrants acquired upon the GNI USA Contributions",
        "label": "Advance Payment For Convertible Preferred Stock And Preferred Stock Warrants Acquired Upon Contributions"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AffiliatesBeneficialOwnSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AffiliatesBeneficialOwnSharesPercentage",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates beneficial own shares percentage.",
        "label": "Affiliates Beneficial Own Shares Percentage",
        "terseLabel": "Affiliates beneficial own shares percentage"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AffiliatesBeneficialOwnSharesSpecifiedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AffiliatesBeneficialOwnSharesSpecifiedPercentage",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates beneficial own shares specified percentage.",
        "label": "Affiliates Beneficial Own Shares Specified Percentage",
        "terseLabel": "Affiliates beneficial own shares specified percentage"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AggregateAmountsOfRestrictedCapitalAndStatutoryReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AggregateAmountsOfRestrictedCapitalAndStatutoryReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amounts of restricted capital and statutory reserves",
        "label": "Aggregate Amounts Of Restricted Capital And Statutory Reserves",
        "documentation": "Aggregate amounts of restricted capital and statutory reserves."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1052",
      "r1062",
      "r1088"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1055",
      "r1065",
      "r1091"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1056",
      "r1066",
      "r1083",
      "r1092",
      "r1096",
      "r1104"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Segments [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r583"
     ]
    },
    "gyre_AllowanceForCreditLossesCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AllowanceForCreditLossesCertificatesOfDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses certificates of deposit",
        "label": "Allowance for Credit Losses Certificates of Deposit",
        "documentation": "Allowance for credit losses certificates of deposit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r71",
      "r74"
     ]
    },
    "gyre_AmortizationOfLandUseRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AmortizationOfLandUseRights",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of land use rights",
        "label": "Amortization Of Land Use Rights",
        "documentation": "Amortization of\u00a0land use rights."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AmountToBeReceivedUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AmountToBeReceivedUnderAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be received under agreement.",
        "label": "Amount To Be Received Under Agreement",
        "terseLabel": "Amount to be received under agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "gyre_AppropriationOfStatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AppropriationOfStatutoryReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Appropriation of statutory reserve",
        "documentation": "Appropriation of statutory reserve"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_AppropriationsToStatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "AppropriationsToStatutoryReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Appropriations to statutory reserve",
        "label": "Appropriations To Statutory Reserve",
        "documentation": "Appropriations to statutory reserve."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1283"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Assets acquisition, paid",
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1284",
      "r1285",
      "r1286"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1283"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureF351AssetAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "F351 Asset Acquisition",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1283"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets",
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r233",
      "r270",
      "r324",
      "r345",
      "r351",
      "r398",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r626",
      "r631",
      "r668",
      "r789",
      "r897",
      "r1016",
      "r1029",
      "r1180",
      "r1181",
      "r1299"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets:",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r244",
      "r270",
      "r398",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r626",
      "r631",
      "r668",
      "r1016",
      "r1180",
      "r1181",
      "r1299"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets at fair value",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035",
      "r1048"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035",
      "r1048"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035",
      "r1048"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r417",
      "r788"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r417",
      "r779",
      "r1164"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "gyre_BCTwoThousandTwentyOneStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BCTwoThousandTwentyOneStockIncentivePlanMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BC 2021 Stock Incentive Plan",
        "label": "B C Two Thousand Twenty One Stock Incentive Plan [Member]",
        "documentation": "B C two thousand twenty one stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BadDebtExpenseAndOtherNonCashItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BadDebtExpenseAndOtherNonCashItems",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense and other non-cash items",
        "label": "Bad Debt Expense And Other Non-cash Items",
        "documentation": "Bad debt expense and other non-cash items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BeijingContinentPharmaceuticalsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BeijingContinentPharmaceuticalsCoLtdMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BC",
        "label": "Beijing Continent Pharmaceuticals Co., Ltd [Member]",
        "documentation": "Beijing continent pharmaceuticals Co., Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r618",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiplied by the fair value per share of Catalyst stock",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination agreement.",
        "label": "Business Combination Agreement [Member]",
        "terseLabel": "Business Combination Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total Purchase price",
        "terseLabel": "Purchase price",
        "totalLabel": "Total Purchase price",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r17"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR merger payable",
        "label": "Business Combination, Contingent Consideration, Liability",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r105",
      "r623"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GNI USA Contributions under the Business Combination Agreement",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r619"
     ]
    },
    "gyre_BusinessCombinationExcessClosingCashPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationExcessClosingCashPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "CVR excess closing cash payable",
        "label": "Business Combination Excess Closing Cash Payable",
        "documentation": "Business combination excess closing cash payable."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Catalyst",
        "label": "Business Combination Fair Value",
        "documentation": "Business combination fair value."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationFairValueOfCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationFairValueOfCommonShares",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common shares to be owned by Catalyst's stockholders",
        "label": "Business Combination Fair Value of Common Shares",
        "documentation": "Business combination fair value of common shares."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationFairValueOfPreferredShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationFairValueOfPreferredShares",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of preferred shares to be owned by Catalyst's stockholders",
        "label": "Business Combination Fair Value of Preferred Shares",
        "documentation": "Business combination fair value of preferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued expenses and other current liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses and Other Current Liabilities",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advance payment received from GNI",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Advance Payment Received",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed advance payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "CVR derivative liability, noncurrent",
        "terseLabel": "CVR derivative liability, noncurrent",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, CVR Derivative Liability, noncurrent",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, CVR derivative liability, noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed In-Process Research and Development",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed in-process research and development."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term receivable from GCBP",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Long-term Receivable",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed long-term receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated acquisition-date fair value of Catalyst",
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, noncurrent",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "gyre_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables from GNI",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Receivables Current",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, other receivables current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CPIContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CPIContributionMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CPI Contribution",
        "label": "C P I Contribution [Member]",
        "documentation": "CPI contribution."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CVRDerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CVRDerivativeLiabilityMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVR derivative liability.",
        "label": "C V R Derivative Liability [Member]",
        "terseLabel": "CVR Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CVRDerivativeLiabilityNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CVRDerivativeLiabilityNonCurrentMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C V R derivative liability non current member.",
        "label": "C V R Derivative Liability Non Current [Member]",
        "terseLabel": "CVR Derivative Liability non current"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CVRDerivativeLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CVRDerivativeLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CVR derivative liability",
        "terseLabel": "CVR derivative liability, noncurrent",
        "label": "C V R Derivative Liability Noncurrent",
        "documentation": "CVR derivative liability noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CVRMergerClosingPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CVRMergerClosingPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR merger closing payable",
        "label": "C V R Merger Closing Payable",
        "documentation": "CVR merger closing payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalAdditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalAdditionsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Capital Addition Purchase Commitments [Member]",
        "documentation": "Contractual obligation to increase property, plant and equipment either through construction or future purchases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r791",
      "r868",
      "r891",
      "r1016",
      "r1029",
      "r1132"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents acquired in connection with the GNI USA Contributions",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r228",
      "r974"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r154",
      "r267"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "negatedTotalLabel": "Net (decrease) increase in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r154"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1309"
     ]
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CashPaidForAcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CashPaidForAcquisitionCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments made for acquisition costs",
        "label": "Cash Paid For Acquisition Costs",
        "documentation": "Cash paid for acquisition costs."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CatalystMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CatalystMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Catalyst",
        "label": "Catalyst [Member]",
        "documentation": "Catalyst."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r217",
      "r218",
      "r280",
      "r365",
      "r366",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r440",
      "r605",
      "r620",
      "r621",
      "r634",
      "r635",
      "r636",
      "r648",
      "r649",
      "r659",
      "r666",
      "r667",
      "r669",
      "r670",
      "r671",
      "r685",
      "r687",
      "r688",
      "r689",
      "r708",
      "r763",
      "r764",
      "r831",
      "r832"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r217",
      "r218",
      "r365",
      "r366",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r410",
      "r440",
      "r605",
      "r620",
      "r621",
      "r622",
      "r634",
      "r635",
      "r636",
      "r637",
      "r648",
      "r649",
      "r650",
      "r653",
      "r659",
      "r666",
      "r667",
      "r669",
      "r670",
      "r671",
      "r685",
      "r687",
      "r688",
      "r689",
      "r708",
      "r763",
      "r764",
      "r831",
      "r832",
      "r1119"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r281",
      "r293",
      "r405",
      "r609"
     ]
    },
    "gyre_ChangeInFairValueOfDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ChangeInFairValueOfDerivativeLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of derivative liabilities.",
        "label": "Change In Fair Value Of Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ChangeInFairValueOfLongTermReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ChangeInFairValueOfLongTermReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of long-term receivable",
        "documentation": "Change in fair value of long-term receivables.",
        "label": "Change In Fair Value Of Long Term Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "gyre_ChangesOfValuationAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ChangesOfValuationAllowances",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes of valuation allowances",
        "label": "Changes of Valuation Allowances",
        "documentation": "Changes of valuation allowances."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ChargesRelatedToWriteOffOfPrepaidManufacturingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ChargesRelatedToWriteOffOfPrepaidManufacturingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges related to write off of prepaid manufacturing costs.",
        "label": "Charges Related To Write Off Of Prepaid Manufacturing Cost",
        "terseLabel": "Charges related to write off of prepaid manufacturing cost"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ChinaResourcesPharmaceuticalGroupLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ChinaResourcesPharmaceuticalGroupLimitedMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China Resources Pharmaceutical Group Ltd",
        "label": "China Resources Pharmaceutical Group Limited [Member]",
        "documentation": "China Resources Pharmaceutical Group Limited."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r234",
      "r235",
      "r236",
      "r270",
      "r299",
      "r303",
      "r310",
      "r312",
      "r318",
      "r319",
      "r398",
      "r457",
      "r459",
      "r460",
      "r461",
      "r464",
      "r465",
      "r471",
      "r472",
      "r476",
      "r479",
      "r487",
      "r668",
      "r846",
      "r847",
      "r848",
      "r849",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r869",
      "r883",
      "r906",
      "r928",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r1111",
      "r1147",
      "r1156"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r318",
      "r471",
      "r472",
      "r474",
      "r476",
      "r479",
      "r485",
      "r487",
      "r846",
      "r847",
      "r848",
      "r849",
      "r996",
      "r1111",
      "r1147"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrants exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "gyre_ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ClassOfWarrantsOrRightsWarrantsIssuedDuringPeriodShares",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issued shares",
        "label": "Class Of Warrants Or Rights Warrants Issued During Period Shares",
        "documentation": "Class of warrants or rights warrants issued during period shares."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ClinicalTrialServicesCostIncurredOnAgreementTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ClinicalTrialServicesCostIncurredOnAgreementTermination",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial services cost incurred on agreement termination.",
        "label": "Clinical Trial Services Cost Incurred On Agreement Termination",
        "terseLabel": "Clinical trial services cost incurred on agreement termination"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "gyre_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue member.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration",
        "verboseLabel": "Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Combined square meter area for manufacturing facilities under lease",
        "label": "Combined Square Meter Area For Manufacturing Facilities Under Lease",
        "documentation": "Combined square meter area for manufacturing facilities under lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 13)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r124",
      "r790",
      "r882"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "gyre_CommittedToAllocate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CommittedToAllocate",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Committed to allocate",
        "label": "Committed To Allocate",
        "documentation": "Committed to allocate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total common stock reserved",
        "verboseLabel": "Common stock, shares reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividends paid per common share",
        "verboseLabel": "Common stock, cash dividend paid",
        "label": "Dividend declared",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared, unpaid, per common share",
        "verboseLabel": "Common stock, cash dividend declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1020",
      "r1021",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1152",
      "r1153",
      "r1288",
      "r1312",
      "r1315"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "gyre_CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CommonStockPostMergerOfCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, post-merger of capital shares reserved for future issuance",
        "label": "Common Stock, Post-merger Of Capital Shares Reserved For Future Issuance",
        "documentation": "Common stock, post-merger of capital shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r883"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares sold",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Catalyst common stock outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r131",
      "r883",
      "r903",
      "r1315",
      "r1316"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, 400,000,000 shares authorized; 76,595,616 shares and 63,588,119 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r792",
      "r1016"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) attributable to common stockholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r248",
      "r250",
      "r258",
      "r783",
      "r810"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss) attributable to noncontrolling interest",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r108",
      "r112",
      "r248",
      "r250",
      "r257",
      "r782",
      "r809"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss from operations",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r182",
      "r248",
      "r250",
      "r256",
      "r781",
      "r808"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computer Software",
        "terseLabel": "Computer software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1171",
      "r1172"
     ]
    },
    "gyre_ConcentrationOfCustomerRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ConcentrationOfCustomerRiskPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Customer Risk",
        "label": "Concentration of Customer Risk [Policy Text Block]",
        "documentation": "Concentration of customer risk."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r119",
      "r120",
      "r359",
      "r956"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r119",
      "r120",
      "r359",
      "r843",
      "r956"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r119",
      "r120",
      "r359",
      "r956",
      "r1118"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r203"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Concentration risk percentage",
        "terseLabel": "Concentration of customer risk",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r119",
      "r120",
      "r359"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r119",
      "r120",
      "r359",
      "r956"
     ]
    },
    "srt_CondensedCashFlowStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedCashFlowStatementTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Cash Flow Statement [Table]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r1113"
     ]
    },
    "srt_CondensedCashFlowStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedCashFlowStatementsCaptionsLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Cash Flow Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r1113"
     ]
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFinancialStatementsScheduleIFinancialInformationOfParentCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Statements Schedule I Financial Information of Parent Company",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r276",
      "r1113"
     ]
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r1113"
     ]
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r1113"
     ]
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r1113"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r626",
      "r627",
      "r631",
      "r632",
      "r721",
      "r966",
      "r1179",
      "r1182",
      "r1183"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r626",
      "r627",
      "r631",
      "r632",
      "r721",
      "r966",
      "r1179",
      "r1182",
      "r1183"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction In Progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ContinentPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ContinentPharmaceuticalsIncMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CPI",
        "label": "Continent Pharmaceuticals Inc [Member]",
        "documentation": "Continent pharmaceuticals inc."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ContingentValueRightsAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ContingentValueRightsAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Value Rights Agreement",
        "documentation": "Contingent value rights agreement."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ContingentValueRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ContingentValueRightsAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights Agreement.",
        "label": "Contingent Value Rights Agreement [Member]",
        "terseLabel": "Contingent Value Rights Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ContingentValueRightsClosingPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ContingentValueRightsClosingPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value rights closing payable",
        "label": "Contingent Value Rights Closing Payable",
        "documentation": "Contingent value rights closing payable."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ContingentValueRightsDerivativeLiabilityNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ContingentValueRightsDerivativeLiabilityNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights derivative liability non current.",
        "label": "Contingent Value Rights Derivative Liability Non Current",
        "terseLabel": "CVR derivative liability, noncurrent",
        "verboseLabel": "Long-term CVR derivative liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r492",
      "r511"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r511"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "terseLabel": "Remaining obligations",
        "totalLabel": "Contractual Obligation, Total",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "gyre_ContributionsClosingPayableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ContributionsClosingPayableAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions closing payable amount",
        "label": "Contributions Closing Payable Amount",
        "documentation": "Contributions closing payable amount."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ConversionOfOutstandingPreferredStockRedeemedForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ConversionOfOutstandingPreferredStockRedeemedForCash",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of outstanding preferred stock redeemed for cash.",
        "label": "Conversion Of Outstanding Preferred Stock Redeemed For Cash",
        "terseLabel": "Conversion of outstanding preferred stock redeemed for cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Issued and Outstanding",
        "verboseLabel": "Convertible Preferred stock (as converted)",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r476",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "gyre_ConvertiblePreferredStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ConvertiblePreferredStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock, Policy [Policy Text Block]",
        "documentation": "Convertible preferred stock, policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued upon conversion",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Preferred stock, shares issued upon conversion of common stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r82",
      "r130",
      "r167",
      "r482"
     ]
    },
    "gyre_CostOfCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CostOfCollaborationMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of collaboration.",
        "label": "Cost Of Collaboration [Member]",
        "terseLabel": "Cost of collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenues",
        "label": "Cost of Goods and Services Sold",
        "totalLabel": "Cost of Goods and Services Sold, Total",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r761"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of revenues",
        "terseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenue",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "gyre_CostOfServicesAsPerAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CostOfServicesAsPerAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of services as per agreement.",
        "label": "Cost Of Services As Per Agreement",
        "terseLabel": "Cost of services as per agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r466",
      "r474",
      "r719",
      "r978",
      "r980"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CpUSSharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CpUSSharePurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CP U.S. Share Purchase Agreement.",
        "terseLabel": "CP U.S. Share Purchase Agreement",
        "label": "CP U.S. SHARE PURCHASE AGREEMENT [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_CumulativeAmountOfStatutoryReserveFund": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CumulativeAmountOfStatutoryReserveFund",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative amount of statutory reserve fund",
        "label": "Cumulative Amount Of Statutory Reserve Fund",
        "documentation": "Cumulative amount of statutory reserve fund."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current tax provision:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1122",
      "r1149",
      "r1281"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign - PRC",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1122",
      "r1149"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax provision:",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r604",
      "r613",
      "r1149"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax provision:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1122",
      "r1149",
      "r1281"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r359"
     ]
    },
    "gyre_CvrExcessClosingCashPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "CvrExcessClosingCashPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR excess closing cash payable",
        "label": "CVR Excess Closing Cash Payable",
        "documentation": "CVR excess closing cash payable."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DalcinonacogAlfaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DalcinonacogAlfaMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dalcinonacog alfa.",
        "label": "Dalcinonacog Alfa [Member]",
        "terseLabel": "Dalcinonacog Alfa"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "gyre_DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Deemed Issuance Of Common Stock And Convertible Preferred Stock To Former Stockholders",
        "documentation": "Deemed issuance of common stock and convertible preferred stock to former stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign - PRC",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r1149",
      "r1280"
     ]
    },
    "gyre_DeferredGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred government grants",
        "label": "Deferred Government Grants",
        "documentation": "Deferred government grants."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredGovernmentGrantsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails": {
       "parentTag": "gyre_DeferredGovernmentGrantsCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current deferred government grants",
        "label": "Deferred Government Grants Current",
        "documentation": "Deferred government grants current."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredGovernmentGrantsCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred government grants",
        "label": "Deferred Government Grants Current And Noncurrent",
        "documentation": "Deferred government grants current and noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredGovernmentGrantsLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Government Grants [Line Items]",
        "documentation": "Deferred government grants."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredGovernmentGrantsNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails": {
       "parentTag": "gyre_DeferredGovernmentGrantsCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current deferred government grants",
        "label": "Deferred Government Grants Non current",
        "documentation": "Deferred government grants non current."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredGovernmentGrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredGovernmentGrantsTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Government Grants [Table]",
        "documentation": "Deferred government grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r591"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax provision:",
        "terseLabel": "Deferred income taxes, net",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r177",
      "r208",
      "r612",
      "r613",
      "r1149"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax provision:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredIncomeTaxExpenseBenefitNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredIncomeTaxExpenseBenefitNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes, net",
        "label": "Deferred Income Tax Expense Benefit Net",
        "documentation": "Deferred income tax expense benefit net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Current, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred government grants",
        "label": "Deferred Revenue, Noncurrent",
        "totalLabel": "Deferred Revenue, Noncurrent, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1280",
      "r1281"
     ]
    },
    "gyre_DeferredTaxAssetsCapitalizedTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized transaction costs",
        "label": "Deferred Tax Assets Capitalized Transaction Costs",
        "documentation": "Deferred tax assets capitalized transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1279"
     ]
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other equity investments",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1279"
     ]
    },
    "gyre_DeferredTaxAssetsFixedAssetsAndIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets fixed assets and intangibles.",
        "label": "Deferred Tax Assets Fixed Assets And Intangibles",
        "terseLabel": "Fixed and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred income tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredTaxAssetsImpactFromForeignCorporations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredTaxAssetsImpactFromForeignCorporations",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact from foreign corporations",
        "label": "Deferred Tax Assets Impact From Foreign Corporations",
        "documentation": "Deferred tax assets impact from foreign corporations"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets Lease Liabilities",
        "documentation": "Deferred tax assets lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry forwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1279"
     ]
    },
    "gyre_DeferredTaxAssetsStateNetOperatingLossCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredTaxAssetsStateNetOperatingLossCarryForwards",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets state net operating loss carry forwards.",
        "label": "Deferred Tax Assets State Net Operating Loss Carry Forwards",
        "terseLabel": "Net operating loss carryforward, derecognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carry forwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r1279"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1279"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIncomeTaxesMovementOfValuationAllowanceDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodEndLabel": "Balance at the end of the year",
        "periodEndLabel": "Balance at the end of the year",
        "periodStartLabel": "Balance at the beginning of the year",
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "totalLabel": "Net deferred tax liability",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r1278"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liability - Fixed assets",
        "verboseLabel": "Deferred Tax Liability - Fixed Assets",
        "terseLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1279"
     ]
    },
    "gyre_DeferredTaxLiabilityRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DeferredTaxLiabilityRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liability - ROU assets",
        "terseLabel": "Deferred Tax Liability - ROU Assets",
        "label": "Deferred Tax Liability Right Of Use Assets",
        "documentation": "Deferred tax liability right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions for employee benefits",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r517",
      "r524",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlans1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Defined Benefit Plan [Text Block]",
        "documentation": "The entire disclosure for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r757",
      "r1006"
     ]
    },
    "us-gaap_DepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit Assets",
        "terseLabel": "Cash deposit",
        "totalLabel": "Deposit Assets, Total",
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "gyre_DepositsInLicensedBanksProtectedByDepositInsuranceSystem": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DepositsInLicensedBanksProtectedByDepositInsuranceSystem",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits in licensed banks protected by DIS",
        "label": "Deposits In Licensed Banks Protected By Deposit Insurance System",
        "documentation": "Deposits in licensed banks protected by deposit insurance system."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r329"
     ]
    },
    "us-gaap_DerivativeAssetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetMeasurementInput",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset measurement input",
        "label": "Derivative Asset, Measurement Input",
        "documentation": "Value of input used to measure derivative asset."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "gyre_DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DerivativeLiabilitiesEstimatedFairValueIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liabilities estimated fair value increase decrease.",
        "label": "Derivative Liabilities Estimated Fair Value Increase Decrease",
        "terseLabel": "Change in the estimated fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability, noncurrent",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability measurement input",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesMethodsOfAccountingHedgingDerivatives",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r1287"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Sales by Product Categories",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r539",
      "r570",
      "r571",
      "r574",
      "r1011"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DisposalConsiderationInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DisposalConsiderationInOtherReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal consideration in other receivables.",
        "terseLabel": "Disposal consideration in other receivables from GNI",
        "label": "Disposal Consideration In Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Total consideration for sales agreements",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DistributionFromAssetSaleProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DistributionFromAssetSaleProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution from asset sale proceeds.",
        "label": "Distribution From Asset Sale Proceeds",
        "terseLabel": "Distribution to CVR holders from asset sale proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DivestitureLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DivestitureLossesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestiture Losses",
        "label": "Divestiture Losses [Member]",
        "documentation": "Divestiture losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableAmountPerShare",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable, Amount Per Share",
        "terseLabel": "Cash dividends payable per common share",
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableDateDeclaredDayMonthAndYear",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable, Date Declared",
        "terseLabel": "Dividends Payable, date declared",
        "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableDateOfRecordDayMonthAndYear",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable, Date of Record",
        "terseLabel": "Common stock, dividend payable, date of record",
        "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035",
      "r1048"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035",
      "r1048",
      "r1084"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal Income Tax",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_DrenBioIncAndCopiaScientificLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "DrenBioIncAndCopiaScientificLLCMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dren Bio, Inc. and Copia Scientific, LLC.",
        "label": "Dren Bio Inc And Copia Scientific L L C [Member]",
        "terseLabel": "Dren Bio, Inc. and Copia Scientific, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (loss) income per share, Basic",
        "terseLabel": "Net (loss) income per share attributable to common stockholders, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r296",
      "r299",
      "r310",
      "r311",
      "r312",
      "r316",
      "r657",
      "r658",
      "r784",
      "r811",
      "r985"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (loss) income per share, Diluted",
        "terseLabel": "Net (loss) income per share attributable to common stockholders, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r299",
      "r310",
      "r311",
      "r312",
      "r316",
      "r657",
      "r658",
      "r784",
      "r811",
      "r985"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) Per Share (\"EPS\") Attributable to Common Stockholders",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEps"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EPS",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax computed at federal statutory rate",
        "negatedLabel": "Tax computed at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r593",
      "r614"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance change",
        "negatedLabel": "Valuation allowance change",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1275",
      "r1282"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESOP",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Employee Stock Ownership Plan Dividend, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r1275",
      "r1282"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate difference due to different jurisdiction",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r1275",
      "r1282"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible Expense - Operating",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1275",
      "r1282"
     ]
    },
    "gyre_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expense - One-time expense related to the Contributions",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense One-time Expense Related to the Contributions",
        "documentation": "Effective income tax rate reconciliation nondeductible expense one-time expense related to the contributions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "negatedLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1275",
      "r1282"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "R&amp;D Super-deduction",
        "terseLabel": "R&amp;D Super-deduction",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1275",
      "r1282"
     ]
    },
    "gyre_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferential income tax rate for HNTE",
        "label": "Effective Income Tax Rate Reconciliation Preferential Income Tax Rate For HNTE",
        "documentation": "Effective income tax rate reconciliation preferential income tax rate for HNTE."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "EmployeeMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee",
        "label": "Employee [Member][",
        "documentation": "Employee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized employee stock based compensation expense, period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized employee stock based compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r219",
      "r252",
      "r253",
      "r254",
      "r277",
      "r278",
      "r279",
      "r282",
      "r290",
      "r292",
      "r317",
      "r404",
      "r411",
      "r489",
      "r575",
      "r576",
      "r577",
      "r607",
      "r608",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r656",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r712",
      "r833",
      "r834",
      "r835",
      "r857",
      "r928"
     ]
    },
    "gyre_EquityGainLossOfUnconsolidatedAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "EquityGainLossOfUnconsolidatedAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity loss of unconsolidated affiliates",
        "label": "Equity Gain Loss of Unconsolidated Affiliates",
        "documentation": "Equity gain loss of unconsolidated affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityIssuedInBusinessCombinationFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of consideration issued",
        "label": "Equity Issued in Business Combination, Fair Value Disclosure",
        "documentation": "Fair value of equity issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1052",
      "r1062",
      "r1088"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1049",
      "r1059",
      "r1085"
     ]
    },
    "gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess amount retained from net proceeds related to disposition of assets.",
        "label": "Excess Amount Retained From Net Proceeds Related To Disposition Of Assets",
        "terseLabel": "Excess amount retained from net proceeds related to disposition of assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExcessStockSharesAuthorized",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized shares",
        "label": "Excess Stock, Shares Authorized",
        "documentation": "Maximum number of excess stock shares permitted to be issued."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "gyre_FCContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "FCContributionMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FC Contribution",
        "label": "F C Contribution [Member]",
        "documentation": "FC contribution."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_FThreeFiveOneAssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "FThreeFiveOneAssetPurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "F351 asset purchase agreement.",
        "label": "F Three Five One Asset Purchase Agreement [Member]",
        "terseLabel": "F351 Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_FThreeFiveOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "FThreeFiveOneMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "F three five one.",
        "label": "F Three Five One [Member]",
        "terseLabel": "F351"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liability",
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "gyre_FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement transfer between Level 1 and Level 2",
        "label": "Fair Value Assets and Liabilities Level1 To Level2 Transfers Amount",
        "documentation": "Fair value assets and liabilities level1 to level2 transfers amount."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_FairValueAssetsAndLiabilitiesLevel3TransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "FairValueAssetsAndLiabilitiesLevel3TransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement transfer Level 3",
        "label": "Fair Value Assets and Liabilities Level3 Transfers Amount",
        "documentation": "Fair value assets and liabilities level3 transfers amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r665"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r665"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assumptions to Fair Value of Warrant Liability Based on Black-Scholes Option Pricing Model",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r185"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Estimated Fair Value of Level 3 Financial Assets and Liabilities",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r116"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r117",
      "r118"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r662",
      "r728",
      "r729",
      "r730",
      "r994",
      "r995",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements and Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r517",
      "r522",
      "r662",
      "r728",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r517",
      "r522",
      "r662",
      "r729",
      "r994",
      "r995",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r662",
      "r730",
      "r994",
      "r995",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions in the period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at December 31, 2023",
        "periodStartLabel": "Balance at December 31, 2022",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions in the period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at December 31, 2023",
        "periodStartLabel": "Balance at December 31, 2022",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r728",
      "r729",
      "r730",
      "r994",
      "r995",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r29"
     ]
    },
    "us-gaap_FinanceReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceReceivablesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term receivable",
        "label": "Financing Receivable [Member]",
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r469",
      "r485",
      "r646",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r807",
      "r992",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life of finite lived intangible assets",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r436"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r762",
      "r766"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r766"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets with finite lives:",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible assets, net",
        "terseLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r762"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible assets, Weighted average amortization period",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "gyre_FirmWorkOrderSupportingClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "FirmWorkOrderSupportingClinicalTrials",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Firm work order supporting clinical trials.",
        "label": "Firm Work Order Supporting Clinical Trials",
        "terseLabel": "Firm work order supporting clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ForeignCurrencyRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ForeignCurrencyRiskPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Risk",
        "label": "Foreign Currency Risk [Policy Text Block]",
        "documentation": "Foreign currency risk."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation and Remeasurement",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1056",
      "r1066",
      "r1092"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1056",
      "r1066",
      "r1092"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1056",
      "r1066",
      "r1092"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1056",
      "r1066",
      "r1092"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1056",
      "r1066",
      "r1092"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GCBiopharmaCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "GCBiopharmaCorpMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GC Biopharma Corp.",
        "label": "G C Biopharma Corp [Member]",
        "terseLabel": "GC Biopharma Corp"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GCBiophrarmaCorpAssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "GCBiophrarmaCorpAssetPurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GC Biophrarma Corp asset purchase agreement member.",
        "label": "G C Biophrarma Corp Asset Purchase Agreement [Member]",
        "terseLabel": "GCBP Asset Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GMPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "GMPMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GMP manufacturing.",
        "label": "G M P [Member]",
        "terseLabel": "Dalcinonacog alfa."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GNIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "GNIMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GNI",
        "label": "G N I [Member]",
        "terseLabel": "G N I"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_GNIUSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "GNIUSAMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GNI USA",
        "label": "G N I U S A [Member]",
        "documentation": "GNI USA."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of property and equipment",
        "negatedLabel": "Divestiture losses",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Net gain on disposal of assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Divestiture losses",
        "negatedTerseLabel": "Loss on divestiture of subsidiary",
        "negatedLabel": "Divestiture losses",
        "terseLabel": "Loss on divestiture of subsidiary",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r1146"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property and equipment",
        "terseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Loss on lease termination",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r908"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "gyre_GeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "GeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "label": "General and Administrative Expenses [Policy Text Block]",
        "documentation": "General and administrative expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grants",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684"
     ]
    },
    "gyre_GovernmentGrantIncomeWithinOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "GovernmentGrantIncomeWithinOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grant income",
        "label": "Government Grant Income Within Other Income",
        "documentation": "Government grant income within other income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r270",
      "r324",
      "r344",
      "r350",
      "r353",
      "r398",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r668",
      "r987",
      "r1180"
     ]
    },
    "gyre_GyreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "GyreMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gyre",
        "label": "Gyre [Member]",
        "documentation": "Gyre."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035",
      "r1048"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r75",
      "r162"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r163"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired IPR&amp;D",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "terseLabel": "Loss before equity in (loss) income of subsidinaries",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r141",
      "r191",
      "r324",
      "r344",
      "r350",
      "r353",
      "r785",
      "r802",
      "r987"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income from operations",
        "totalLabel": "Net (loss) income from operations",
        "verboseLabel": "Net (loss) income from operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r270",
      "r281",
      "r324",
      "r344",
      "r350",
      "r353",
      "r398",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r658",
      "r668",
      "r802",
      "r987",
      "r1180"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity loss (income) of subsidiaries",
        "terseLabel": "Equity in (loss) income of subsidinaries",
        "negatedLabel": "Equity loss (income) of subsidiaries",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r142",
      "r190",
      "r331",
      "r397",
      "r801"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r445",
      "r913"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r913"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r586",
      "r594",
      "r597",
      "r602",
      "r610",
      "r615",
      "r616",
      "r617",
      "r851"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Tax-related penalties or interest recognized",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Total income tax provision:",
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r213",
      "r291",
      "r292",
      "r332",
      "r592",
      "r611",
      "r812"
     ]
    },
    "gyre_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax.",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r588",
      "r589",
      "r597",
      "r598",
      "r601",
      "r603",
      "r845"
     ]
    },
    "gyre_IncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "IncomeTaxTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "totalLabel": "Income Taxes Paid, Net, Total",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "gyre_IncreaseDecreaseInAccountsAndNotesReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "IncreaseDecreaseInAccountsAndNotesReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts and note receivables",
        "label": "Increase Decrease In Accounts And Notes Receivables",
        "documentation": "Increase decrease in accounts and notes receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Related party receivables",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "gyre_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) In Accrued Expenses And Other Current Liabilities",
        "documentation": "Increase (decrease) in accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due from related parties",
        "label": "Increase (Decrease) in Due from Related Parties",
        "totalLabel": "Increase (Decrease) in Due from Related Parties, Total",
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Increase (Decrease) in Due to Related Parties",
        "totalLabel": "Increase (Decrease) in Due to Related Parties, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes."
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1145"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables from GNI",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average of common stock options",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r312",
      "r538"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1056",
      "r1066",
      "r1083",
      "r1092",
      "r1096",
      "r1104"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1108"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1108"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1108"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r758",
      "r759",
      "r760",
      "r762",
      "r981"
     ]
    },
    "gyre_IntegrityBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "IntegrityBioMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integrity bio .",
        "label": "Integrity Bio [Member]",
        "terseLabel": "Catalent Indiana, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest Income (Expense), Net",
        "totalLabel": "Interest Income (Expense), Net, Total",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "gyre_InterestIncomePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "InterestIncomePolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Income",
        "label": "Interest Income [Policy Text Block]",
        "documentation": "Interest income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r265",
      "r266"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventories, net",
        "terseLabel": "Inventories, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r975",
      "r1016"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, Net",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r227",
      "r241",
      "r421",
      "r422",
      "r423",
      "r756",
      "r982"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserves",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r1140"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoriesNetOfReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in subsidiaries",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "totalLabel": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "gyre_IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "IssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock and convertible preferred stock to former stockholders.",
        "terseLabel": "Issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Issuance Of Common Stock And Convertible Preferred Stock To Former Stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_IssuanceOfOptionGrantsToPurchaseCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "IssuanceOfOptionGrantsToPurchaseCommonStockShares",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of option grants to purchase common stock shares.",
        "label": "Issuance Of Option Grants To Purchase Common Stock Shares",
        "terseLabel": "Issuance of option grants to purchase common stock shares"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LandUseRightsNetAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LandUseRightsNetAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land use rights, net assets",
        "label": "Land Use Rights, Net Assets",
        "documentation": "Land use rights, net assets."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LandUseRightsNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LandUseRightsNetNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land use rights, net",
        "label": "Land Use Rights Net Noncurrent",
        "documentation": "Land use rights net noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LandUseRightsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LandUseRightsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land Use Rights, Net",
        "label": "Land Use Rights [Policy Text Block]",
        "documentation": "Land use rights."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LeaseCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LeaseCommencementMonthAndYear",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement month and year.",
        "label": "Lease Commencement Month And Year",
        "terseLabel": "Lease commencement month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration month and year"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LeaseLabAndOfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LeaseLabAndOfficeSpaceMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease lab and office space.",
        "label": "Lease Lab And Office Space [Member]",
        "terseLabel": "Lease Lab And Office Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leasehold Improvement",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "gyre_LegalAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LegalAndOtherExpensesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal and other expenses.",
        "label": "Legal And Other Expenses [Member]",
        "terseLabel": "Legal and Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LegalExpensesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LegalExpensesIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal expenses incurred.",
        "label": "Legal Expenses Incurred",
        "terseLabel": "Legal expenses incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal expense",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating lease commenced description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1294"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Undiscounted future payment",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "gyre_LesseeOperatingLeaseRenewalTermDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LesseeOperatingLeaseRenewalTermDescription",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease renewal term description.",
        "label": "Lessee Operating Lease Renewal Term Description",
        "terseLabel": "Lessee operating lease renewal term description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Payment to be Received",
        "terseLabel": "Lease payments receivable",
        "totalLabel": "Lessor, Operating Lease, Payments to be Received, Total",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r270",
      "r398",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r627",
      "r631",
      "r632",
      "r668",
      "r881",
      "r986",
      "r1029",
      "r1180",
      "r1299",
      "r1300"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock, and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r189",
      "r797",
      "r1016",
      "r1148",
      "r1169",
      "r1291"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, convertible preferred stock, and equity",
        "verboseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities:",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r226",
      "r270",
      "r398",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r627",
      "r631",
      "r632",
      "r668",
      "r1016",
      "r1180",
      "r1299",
      "r1300"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial liabilities at fair value",
        "negatedLabel": "Liabilities, fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities, fair value",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "verboseLabel": "Uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "gyre_LicenseAgreementTerminationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LicenseAgreementTerminationMonthAndYear",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement termination month and year.",
        "label": "License Agreement Termination Month And Year",
        "terseLabel": "License agreement termination month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License of Intellectual Property",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1186"
     ]
    },
    "us-gaap_LiquidationBasisOfAccountingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiquidationBasisOfAccountingTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidation Basis of Accounting [Text Block]",
        "terseLabel": "Liquidity",
        "documentation": "The entire disclosure for the liquidation basis of accounting."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "gyre_LiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LiquidityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LiquidityLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Line Items]",
        "terseLabel": "Liquidity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LiquidityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LiquidityTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Table]",
        "terseLabel": "Liquidity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LitigationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LitigationAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation amount .",
        "label": "Litigation Amount",
        "terseLabel": "Litigation amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement liability",
        "label": "Estimated Litigation Liability",
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r1176"
     ]
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation expenses",
        "label": "Litigation Settlement, Expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermAccountsNotesAndLoansReceivableNetNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term receivable from GCBP",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "totalLabel": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent, Total",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "gyre_LongTermCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LongTermCertificatesOfDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term certificates of deposit",
        "label": "Long Term Certificates Of Deposit",
        "documentation": "Long Term Certificates Of Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_LongTermCertificatesOfDepositPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "LongTermCertificatesOfDepositPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Certificates of Deposit",
        "label": "Long Term Certificates of Deposit [Policy Text Block]",
        "documentation": "Long term certificates of deposit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to purchase of property and equipment contracted",
        "label": "Long-Term Purchase Commitment, Amount",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_MachineryAndElectronicDevicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "MachineryAndElectronicDevicesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and Electronic Devices",
        "label": "Machinery and Electronic Devices [Member]",
        "documentation": "Machinery and electronic devices."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_MainlandChinaContributionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "MainlandChinaContributionPlanMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mainland China Contribution Plan",
        "label": "Mainland China Contribution Plan [Member]",
        "documentation": "Mainland China Contribution Plan."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r999",
      "r1185",
      "r1310",
      "r1311"
     ]
    },
    "gyre_MaximumAmountOfTaxOffsetPerYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "MaximumAmountOfTaxOffsetPerYear",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of tax offset per year.",
        "label": "Maximum Amount Of Tax Offset Per Year",
        "terseLabel": "Maximum amount of tax offset per year"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r456",
      "r528",
      "r755",
      "r830",
      "r873",
      "r874",
      "r936",
      "r938",
      "r940",
      "r941",
      "r943",
      "r967",
      "r968",
      "r991",
      "r996",
      "r1010",
      "r1018",
      "r1184",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Volatility",
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-Free Interest",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Price",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r456",
      "r528",
      "r755",
      "r830",
      "r873",
      "r874",
      "r936",
      "r938",
      "r940",
      "r941",
      "r943",
      "r967",
      "r968",
      "r991",
      "r996",
      "r1010",
      "r1018",
      "r1184",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306"
     ]
    },
    "gyre_MinorityHolderContributionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "MinorityHolderContributionsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority Holder Contributions",
        "label": "Minority Holder Contributions [Member]",
        "documentation": "Minority holder contributions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, Attributable to Noncontrolling Interest, Ending Balance",
        "periodStartLabel": "Equity, Attributable to Noncontrolling Interest, Beginning Balance",
        "totalLabel": "Equity, Attributable to Noncontrolling Interest, Total",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r188",
      "r270",
      "r398",
      "r457",
      "r459",
      "r460",
      "r461",
      "r464",
      "r465",
      "r668",
      "r796",
      "r885"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of minority interest",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r169",
      "r183"
     ]
    },
    "gyre_MinorityInterestDecreaseFromRedemptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "MinorityInterestDecreaseFromRedemptionsShares",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of minority interest (in shares)",
        "label": "Minority Interest Decrease From Redemptions Shares",
        "documentation": "Minority interest decrease from redemptions shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority interest",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1209"
     ]
    },
    "gyre_MotorVehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "MotorVehiclesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor Vehicles",
        "label": "Motor Vehicles [Member]",
        "documentation": "Motor vehicles."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "gyre_NDAPassesTheNMPAsReviewAndInspectionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NDAPassesTheNMPAsReviewAndInspectionMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NDA Passes the NMPA's Review and Inspection",
        "label": "N D A Passes the N M P A's Review and Inspection [Member]",
        "documentation": "N D A Passes the N M P A's Review and Inspection."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_NMPAsApprovalOfTheNDAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NMPAsApprovalOfTheNDAMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NMPA's Approval of the NDA",
        "label": "N M P A's Approval of the N D A [Member]",
        "documentation": "N M P A's Approval of the N D A."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r999",
      "r1185",
      "r1310",
      "r1311"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "gyre_NassimUsmanPhdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NassimUsmanPhdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nassim Usman, Ph.D",
        "label": "Nassim Usman PhD [Member]",
        "documentation": "Nassim Usman PhD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Nature of Operations",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r214"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "negatedTotalLabel": "Net cash flows (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financing Activities",
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investing Activities",
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Activities",
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net (loss) income",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r156",
      "r192",
      "r224",
      "r246",
      "r249",
      "r254",
      "r270",
      "r281",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r308",
      "r324",
      "r344",
      "r350",
      "r353",
      "r398",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r658",
      "r668",
      "r805",
      "r905",
      "r926",
      "r927",
      "r987",
      "r1027",
      "r1180"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income attributable to noncontrolling interest",
        "label": "Less: Allocation of undistributed earnings to noncontrolling interest",
        "verboseLabel": "Net income attributable to noncontrolling interest",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r184",
      "r246",
      "r249",
      "r291",
      "r292",
      "r804",
      "r1144"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income attributable to common stockholders",
        "terseLabel": "Net (loss) income attributable to common stockholders - basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r285",
      "r286",
      "r287",
      "r288",
      "r296",
      "r297",
      "r309",
      "r312",
      "r324",
      "r344",
      "r350",
      "r353",
      "r987"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income attributable to common stockholders - diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r298",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r312"
     ]
    },
    "gyre_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements - Issued But Not Yet Adopted",
        "label": "New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]",
        "documentation": "New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_NonEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NonEmployeeMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-employee",
        "label": "Non-employee [Member]",
        "documentation": "Non-employee."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1056",
      "r1066",
      "r1083",
      "r1092"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of Non-Cash Financing and Investing Activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash lease expense",
        "label": "Noncash Lease Expense",
        "documentation": "Noncash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r489",
      "r1152",
      "r1153",
      "r1154",
      "r1315"
     ]
    },
    "gyre_NoncontrollingInterestPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NoncontrollingInterestPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest, Policy [Policy Text Block]",
        "documentation": "Noncontrolling interest, policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesAndLoansReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesAndLoansReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail": {
       "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndNotesReceivableNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable",
        "label": "Financing Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r976",
      "r990",
      "r1170"
     ]
    },
    "gyre_NumberOfBankAccounts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NumberOfBankAccounts",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of bank accounts.",
        "label": "Number Of Bank Accounts",
        "terseLabel": "Number of bank accounts"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock issuable upon exercise and conversion of warrants",
        "label": "Number of Common Stock Shares Issuable Upon Exercise and Conversion Of Warrants",
        "documentation": "Number of common stock shares issuable upon exercise and conversion of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_NumberOfIndividualsApprovedGrantsByBoard": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NumberOfIndividualsApprovedGrantsByBoard",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of individuals approved grants by board",
        "label": "Number of Individuals Approved Grants by Board",
        "documentation": "Number of individuals approved grants by board."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "gyre_NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock issuable upon conversion of the outstanding shares",
        "label": "Number Of Shares Of Common Stock Issuable Upon Conversion Of The Outstanding Shares",
        "documentation": "Number of shares of common stock issuable upon conversion of the outstanding shares."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ObligationToPayInExchangeForTheIntellectualPropertyRights",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation to pay in exchange for the intellectual property rights",
        "documentation": "Obligation to pay in exchange for the intellectual property rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expense",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses excluding cost of revenues",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses excluding cost of revenues:",
        "verboseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (Loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r344",
      "r350",
      "r353",
      "r987"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1293"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "negatedLabel": "Less current portion of lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, noncurrent",
        "verboseLabel": "Lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating lease",
        "label": "Operating Lease, Payments",
        "totalLabel": "Cash paid for operating leases that were included in operating cash outflows",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r702"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r1015"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r1015"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "gyre_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OperatingLossCarryforwardsWithIndefiniteLife": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "OperatingLossCarryforwardsWithIndefiniteLife",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards with indefinite life.",
        "label": "Operating Loss Carryforwards With Indefinite Life",
        "terseLabel": "Net operating loss carryforwards having indefinite life"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options Issued and Outstanding",
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options To Purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OrganizationAndNatureOfOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "OrganizationAndNatureOfOperationsLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and nature of operations.",
        "label": "Organization And Nature Of Operations [Line Items]",
        "terseLabel": "Organization and Nature of Operations [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OrganizationAndNatureOfOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "OrganizationAndNatureOfOperationsTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and Nature of Operations [Table]",
        "label": "Organization And Nature Of Operations [Table]",
        "terseLabel": "Organization And Nature Of Operations [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other accrued liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "totalLabel": "Total other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r1016"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments attributable to noncontrolling interest",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r19",
      "r182"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome3": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r19",
      "r182"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency translation loss",
        "verboseLabel": "Foreign currency translation adjustments",
        "terseLabel": "Foreign currency translation loss",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive (loss) income, net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r28",
      "r247",
      "r250",
      "r255",
      "r675",
      "r676",
      "r681",
      "r780",
      "r806",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_OtherDirectorOrOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "OtherDirectorOrOfficerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Director or Officer",
        "label": "Other Director or Officer [Member]",
        "documentation": "Other director or officer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Income, net",
        "label": "Other Income [Member]",
        "documentation": "Primary financial statement caption encompassing other revenue."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Other Liabilities",
        "totalLabel": "Other Liabilities, Total",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r787",
      "r877",
      "r878",
      "r1029",
      "r1313"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r1016"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other expense",
        "negatedLabel": "Other expenses",
        "terseLabel": "Other Expense",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Income",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net:",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r892"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables from GNI",
        "label": "Other Receivables, Net, Current",
        "totalLabel": "Other Receivables, Net, Current, Total",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1042",
      "r1054",
      "r1064",
      "r1090"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1045",
      "r1057",
      "r1067",
      "r1093"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1045",
      "r1057",
      "r1067",
      "r1093"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfOperationsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfOperationsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent Company",
        "label": "Parent Company [Member]"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent",
        "verboseLabel": "Total Gyre Stockholders' Equity (Deficit)",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PatentsAndTechnologicalKnowHowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PatentsAndTechnologicalKnowHowMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PatentsAndTechnologicalKnowHowMember",
        "label": "Patents and Technological Know How [Member]",
        "documentation": "Patents and Technological Know-how"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR merger payable, amount distributed",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "gyre_PaymentForResearchAndDevelopmentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PaymentForResearchAndDevelopmentFees",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Research and Development Fees",
        "documentation": "Payment for research and development fees."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PaymentOfDisposalOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PaymentOfDisposalOfSubsidiary",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash balance in a disposed subsidiary",
        "label": "Payment of Disposal of Subsidiary",
        "documentation": "Payment of disposal of subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PaymentOfTerminationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PaymentOfTerminationFees",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of termination fees.",
        "label": "Payment Of Termination Fees",
        "terseLabel": "Termination fees paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Ordinary Dividends, Common Stock",
        "terseLabel": "Aggregate amount of special dividend payment",
        "verboseLabel": "Aggregate amount of special dividend payment",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equity method investment",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireRestrictedCertificatesOfDeposit",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of certificates of deposit",
        "label": "Payments to Acquire Restricted Certificates of Deposit",
        "documentation": "The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "gyre_PercentageOfAmountReceivedOnAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfAmountReceivedOnAgreement",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of amount received on agreement.",
        "label": "Percentage Of Amount Received On Agreement",
        "terseLabel": "Percentage of amount received on agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfCommissionForSharesSold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfCommissionForSharesSold",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Commission for shares sold.",
        "label": "Percentage Of Commission For Shares Sold",
        "terseLabel": "Percentage of commission for shares sold"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfCommonStockFiledLawsuit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfCommonStockFiledLawsuit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock filed a lawsuit.",
        "label": "Percentage Of Common Stock Filed Lawsuit",
        "terseLabel": "Percentage of common stock filed a lawsuit"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfExcessCashOnDispositionsNet": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfExcessCashOnDispositionsNet",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of excess cash on dispositions net.",
        "label": "Percentage Of Excess Cash On Dispositions Net",
        "terseLabel": "Percentage of excess cash on dispositions net"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfExcessPreapprovedCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfExcessPreapprovedCosts",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of excess preapproved costs.",
        "label": "Percentage Of Excess Preapproved Costs",
        "terseLabel": "Percentage of excess preapproved costs"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfIndirectOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfIndirectOwnershipInterest",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indirect ownership interest",
        "label": "Percentage Of Indirect Ownership Interest",
        "documentation": "Percentage of indirect ownership interest."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority holders owned outstanding shares of common stock",
        "label": "Percentage Of Minority Holders Owned Outstanding Shares Of Common Stock",
        "documentation": "Percentage of minority holders owned outstanding shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority interest ownership directly and indirectly holds",
        "label": "Percentage Of Minority Interest Ownership Directly And Indirectly Holds",
        "documentation": "Percentage of minority interest ownership directly and indirectly holds."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfMinorityInterestOwnershipIndirectlyHolds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfMinorityInterestOwnershipIndirectlyHolds",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority interest ownership indirectly holds",
        "label": "Percentage Of Minority Interest Ownership Indirectly Holds",
        "documentation": "Percentage of minority interest ownership indirectly holds."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfOutstandingSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfOutstandingSharesOfCommonStock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding shares of common stock",
        "label": "Percentage Of Outstanding Shares Of Common Stock",
        "documentation": "Percentage of outstanding shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfRestrictedNetAssetsExceedNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfRestrictedNetAssetsExceedNetAssets",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of restricted net assets of consolidated subsidiaries of consolidated net assets",
        "label": "Percentage of Restricted Net Assets Exceed Net Assets",
        "documentation": "Percentage of restricted net assets exceed net assets."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PercentageOfRevenueAccountedSalesToDistributors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PercentageOfRevenueAccountedSalesToDistributors",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of revenue accounted sales to distributors",
        "documentation": "Percentage of revenue accounted sales to distributors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272"
     ]
    },
    "gyre_PostClosingIndemnificationObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PostClosingIndemnificationObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post closing indemnification obligation.",
        "label": "Post Closing Indemnification Obligation",
        "terseLabel": "Post closing indemnification obligation"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PreMergerStockOptionsAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PreMergerStockOptionsAssumed",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-GNI USA Contributions Catalyst stock options assumed by CPI",
        "label": "Pre Merger Stock Options Assumed",
        "documentation": "Pre merger stock options assumed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r471"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r883"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r471"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r883",
      "r903",
      "r1315",
      "r1316"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "gyre_PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PreferredStockWarrantsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Warrants Issued and Outstanding",
        "verboseLabel": "Preferred Stock Warrants (as converted)",
        "terseLabel": "Preferred Stock Warrants",
        "documentation": "Preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PreferredStockWarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PreferredStockWarrantsPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock Warrants",
        "label": "Preferred Stock Warrants [Policy Text Block]",
        "documentation": "Preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PrepaidAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PrepaidAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid assets",
        "label": "Prepaid Assets Current",
        "documentation": "Prepaid assets current."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PrivatePlacementAndSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PrivatePlacementAndSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement and Securities Purchase Agreement",
        "label": "Private Placement and Securities Purchase Agreement [Member]",
        "documentation": "Private placement and securities purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of stock options included in other receivable.",
        "terseLabel": "Proceeds from the exercise of stock options included in other receivable",
        "label": "Proceeds From Exercise Of Stock Options Included In Other Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ProceedsFromGovernmentGrantsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ProceedsFromGovernmentGrantsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grants received",
        "label": "Proceeds From Government Grants Received",
        "documentation": "Proceeds from government grants received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of Convertible Preferred Stock and Preferred Stock Warrants under the Private Placement",
        "terseLabel": "Proceeeds from issuance of aggregate gross sales",
        "label": "Proceeds from Issuance or Sale of Equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r846"
     ]
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Proceeds from the sale of complement portfolio to Vertex",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equipment",
        "label": "Proceeds from Sale of Productive Assets",
        "totalLabel": "Proceeds from Sale of Productive Assets, Total",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ETUARY",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of Pharmaceutical Products",
        "verboseLabel": "ETUARY",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r761",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r970",
      "r997",
      "r1017",
      "r1121",
      "r1177",
      "r1178",
      "r1185",
      "r1310"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r761",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r970",
      "r997",
      "r1017",
      "r1121",
      "r1177",
      "r1178",
      "r1185",
      "r1310"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedStatementsOfCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income from operations",
        "verboseLabel": "Net (loss) income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r246",
      "r249",
      "r263",
      "r270",
      "r281",
      "r291",
      "r292",
      "r324",
      "r344",
      "r350",
      "r353",
      "r398",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r625",
      "r628",
      "r629",
      "r658",
      "r668",
      "r785",
      "r803",
      "r856",
      "r905",
      "r926",
      "r927",
      "r987",
      "r1013",
      "r1014",
      "r1028",
      "r1144",
      "r1180"
     ]
    },
    "gyre_PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property And Equipment, Included In Accrued Expenses And Other Current Liabilities",
        "label": "Property And Equipment, Included In Accrued Expenses And Other Current Liabilities [Member]",
        "documentation": "Property and equipment, included in accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r229",
      "r800"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfDeferredGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment",
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r786",
      "r800",
      "r1016"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r204",
      "r207",
      "r798"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1173"
     ]
    },
    "gyre_PurchaseAgreementAmendmentDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PurchaseAgreementAmendmentDate",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement amendment date.",
        "label": "Purchase Agreement Amendment Date",
        "terseLabel": "Purchase agreement amendment date"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of property and equipment included in accounts payable",
        "label": "Purchase Of Property And Equipment Included In Accounts Payable",
        "documentation": "Purchase of property and equipment included in accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r456",
      "r516",
      "r528",
      "r565",
      "r566",
      "r567",
      "r731",
      "r755",
      "r830",
      "r873",
      "r874",
      "r936",
      "r938",
      "r940",
      "r941",
      "r943",
      "r967",
      "r968",
      "r991",
      "r996",
      "r1010",
      "r1018",
      "r1021",
      "r1174",
      "r1184",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r456",
      "r516",
      "r528",
      "r565",
      "r566",
      "r567",
      "r731",
      "r755",
      "r830",
      "r873",
      "r874",
      "r936",
      "r938",
      "r940",
      "r941",
      "r943",
      "r967",
      "r968",
      "r991",
      "r996",
      "r1010",
      "r1018",
      "r1021",
      "r1174",
      "r1184",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party receivables",
        "label": "Receivables, Net, Current",
        "totalLabel": "Receivables, Net, Current, Total",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1049",
      "r1059",
      "r1085"
     ]
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "verboseLabel": "Redeemable Convertible Preferred Stock",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ReimbursementForOutOfPocketFeesAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ReimbursementForOutOfPocketFeesAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement for out-of-pocket fees and expenses.",
        "label": "Reimbursement For Out Of Pocket Fees And Expenses",
        "terseLabel": "Reimbursement for out-of-pocket fees and expenses"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ReimbursementOfLegalAndOtherExpensesRelatedToTheLitigation",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement of legal and other expenses related to the litigation",
        "documentation": "Reimbursement of legal and other expenses related to the litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r716",
      "r717",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r902",
      "r904",
      "r935"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "GNI",
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r716",
      "r717",
      "r718",
      "r719",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r902",
      "r904",
      "r935"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r910",
      "r913"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r716",
      "r717",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r902",
      "r904",
      "r935",
      "r1298"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714",
      "r715",
      "r717",
      "r720",
      "r852",
      "r853",
      "r854",
      "r911",
      "r912",
      "r913",
      "r932",
      "r934"
     ]
    },
    "gyre_RemainingNumberOfFullTimeEmployees": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "RemainingNumberOfFullTimeEmployees",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining number of full time employees.",
        "label": "Remaining Number Of Full Time Employees",
        "terseLabel": "Remaining number of full time employees"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r466",
      "r474",
      "r719",
      "r979",
      "r980"
     ]
    },
    "gyre_RequiredMinimumTaxableIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "RequiredMinimumTaxableIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum taxable income required to support realizing the company's.",
        "label": "Required Minimum Taxable Income",
        "terseLabel": "Required Minimum Taxable Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Arrangement [Member]",
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development fees",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r585",
      "r1307"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r1274"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "gyre_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit carry forwards derecognized.",
        "label": "Research And Development Tax Credit Carry Forwards Derecognized",
        "terseLabel": "Gross federal R&amp;D credit-related deferred tax assets derecognized"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1038",
      "r1050",
      "r1060",
      "r1086"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1039",
      "r1051",
      "r1061",
      "r1087"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1058",
      "r1068",
      "r1094"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r444",
      "r447",
      "r452"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of employees terminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Total restructuring charges",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r448",
      "r449",
      "r1175"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost And Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451"
     ]
    },
    "gyre_RestructuringLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "RestructuringLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring liability.",
        "label": "Restructuring Liability",
        "terseLabel": "Restructuring liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Accumulated deficit) retained earnings",
        "verboseLabel": "(Accumulated deficit) retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r169",
      "r795",
      "r837",
      "r842",
      "r850",
      "r884",
      "r1016"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r277",
      "r278",
      "r279",
      "r282",
      "r290",
      "r292",
      "r404",
      "r411",
      "r575",
      "r576",
      "r577",
      "r607",
      "r608",
      "r638",
      "r641",
      "r642",
      "r645",
      "r656",
      "r833",
      "r835",
      "r857",
      "r1315"
     ]
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r1010",
      "r1115",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r1010",
      "r1115",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r343",
      "r348",
      "r349",
      "r355",
      "r357",
      "r359",
      "r509",
      "r510",
      "r761"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueSummaryOfSalesByProductCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from sales",
        "terseLabel": "Total",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r343",
      "r348",
      "r349",
      "r355",
      "r357",
      "r359",
      "r509",
      "r510",
      "r761"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r969"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales",
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r512"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r969",
      "r983"
     ]
    },
    "gyre_ReverseStockSplitDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ReverseStockSplitDescription",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split description",
        "label": "Reverse Stock Split Description",
        "documentation": "Reverse stock split description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use asset obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset and lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r1015"
     ]
    },
    "gyre_RisksAndUncertainitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "RisksAndUncertainitiesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainities",
        "label": "Risks And Uncertainities [Policy Text Block]",
        "documentation": "Risks And Uncertainities [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r1116"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r1155"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r533",
      "r1112",
      "r1155"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts and Note Receivable, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsAntidilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Anti-dilutive Security not Included in Diluted per Share Calculations",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfPurchasePriceDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r618"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Purchase Price",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock, Reserved for Future Issuance",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "documentation": "Schedule of common stock reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Provision for Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r1113"
     ]
    },
    "gyre_ScheduleOfDeferredGovernmentGrantsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ScheduleOfDeferredGovernmentGrantsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Government Grants",
        "label": "Schedule Of Deferred Government Grants Table [Text Block]",
        "documentation": "Schedule of deferred government grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of the Company's Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r86",
      "r87",
      "r88",
      "r89"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted EPS Attributable to Common Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Recognized",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r762"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Carrying Amounts and Accumulated Amortization of intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories, Net of Reserves",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r137",
      "r138",
      "r139"
     ]
    },
    "gyre_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives of Assets",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Life [Table Text Block]",
        "documentation": "Schedule of property plant and equipment estimated useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Acquired Assets And Assumed Liabilities Of Based On Estimated Fair Values",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r909",
      "r910",
      "r913"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule Of Restructuring And Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r537",
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r166",
      "r168",
      "r169",
      "r234",
      "r235",
      "r236",
      "r318",
      "r471",
      "r472",
      "r474",
      "r476",
      "r479",
      "r485",
      "r487",
      "r846",
      "r847",
      "r848",
      "r849",
      "r996",
      "r1111",
      "r1147"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1277"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposits",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r359",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r446",
      "r451",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r993",
      "r1121",
      "r1310"
     ]
    },
    "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentExpenditureAdditionToLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Segment, Expenditure, Addition to Long-Lived Assets",
        "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r989"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r870",
      "r871",
      "r872",
      "r937",
      "r939",
      "r942",
      "r944",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r971",
      "r998",
      "r1021",
      "r1185",
      "r1310"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r336",
      "r347",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r357",
      "r988"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome2": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and marketing",
        "label": "Selling and Marketing Expense",
        "totalLabel": "Selling and Marketing Expense, Total",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and marketing",
        "label": "Selling and Marketing Expense [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "gyre_SellingAndMarketingExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SellingAndMarketingExpensesPolicyTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and Marketing Expenses",
        "label": "Selling and Marketing Expenses [Policy Text Block]",
        "documentation": "Selling and marketing expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfAcquiredAssetsAndAssumedLiabilitiesOfBasedOnEstimatedFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GNI USA Contributions",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "gyre_SeriesXPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SeriesXPreferredStockMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series X Preferred Stock (as converted)",
        "terseLabel": "Series X Preferred Stock",
        "label": "Series X Preferred Stock [Member]",
        "documentation": "Series X Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceAgreementsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Agreements [Member]",
        "terseLabel": "Service Agreements",
        "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "gyre_SeveranceAndOtherCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SeveranceAndOtherCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance and other costs.",
        "label": "Severance And Other Costs",
        "terseLabel": "Severance and other charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Severance costs and expenses",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "gyre_ShanghaiPharmaceuticalsHoldingCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ShanghaiPharmaceuticalsHoldingCompanyLimitedMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai Pharmaceuticals Holding Co., Ltd",
        "label": "Shanghai Pharmaceuticals Holding Company Limited [Member]",
        "documentation": "Shanghai Pharmaceuticals Holding Company Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual terms of award",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Contractual Terms of Award",
        "documentation": "Share based compensation arrangement by share based payment award, contractual terms of award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r537",
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of common stock available for future grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares Underlying Outstanding Options, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Deemed Issuance Of Options To Former Stockholders",
        "documentation": "Share based compensation arrangement by share based payment award options deemed issuance of options to former stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Exercisable- December 31, 2022",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable - December 31, 2022",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options Forfeited",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options granted",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of stock options",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "gyre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholders",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares Underlying Outstanding Options, Issuance of options to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Issuance Of Options To Former Stockholders",
        "documentation": "Share based compensation arrangement by share based payment award options issuance of options to former stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending Balance",
        "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "verboseLabel": "Increase in number of shares of common stock reserved for issuance",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares Underlying Outstanding Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted- Average Exercise Price, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental stock-based compensation",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Option, Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Deemed Issuance Of Options To Former Stockholders In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangements by share based payment award options deemed issuance of options to former stockholders in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Options Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Options forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "gyre_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Option, Issuance of options to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Issuance Of Options To Former Stockholders In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangements by share based payment award options issuance of options to former stockholders in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r543",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r578",
      "r579",
      "r580",
      "r581"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementExpensedAndCapitalizedAmountAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplemental Disclosure of stock-based compensation expense",
        "terseLabel": "Supplemental Disclosure of stock-based compensation expense included in General and administrative expenses above:",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average share price of the Company (USD per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementScheduleOfEstimatedFairValueOfOptionAwardsBasedOnBlackscholesModelDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationFairValuesOfStockOptionsGrantedEstimatedUsingBlackscholesValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Expected option life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable - December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable - December 31, 2022",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Outstanding Balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Options vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Estimated Fair Value of Option Awards Based on Black-scholes Model",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r171"
     ]
    },
    "gyre_SharesForAggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SharesForAggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares for aggregate purchase price",
        "label": "Shares for Aggregate Purchase Price",
        "documentation": "Shares for aggregate purchase price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-Term Investments",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946",
      "r947",
      "r973"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease expenses",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r1015"
     ]
    },
    "us-gaap_ShortTermLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease expenses",
        "label": "Short-Term Lease Payments",
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r268"
     ]
    },
    "gyre_SinopharmGroupCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SinopharmGroupCompanyLimitedMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sinopharm Group Co., Ltd.",
        "label": "Sinopharm Group Company Limited [Member]",
        "documentation": "Sinopharm Group Company Limited."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SoftwareMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software [Member]",
        "documentation": "Software."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SquareMeterAreaForLaboratoryCenterUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SquareMeterAreaForLaboratoryCenterUnderLease",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square meter area for laboratory center under lease",
        "label": "Square Meter Area For Laboratory Center Under Lease",
        "documentation": "Square meter area for laboratory center under lease."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SquareMeterAreaForOfficeSpaceUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SquareMeterAreaForOfficeSpaceUnderLease",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square meter area for office space under lease",
        "label": "Square Meter Area For Office Space Under Lease",
        "documentation": "Square meter area for office space under lease."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SquareMeterAreaForOfficeSpaceUnderNewLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SquareMeterAreaForOfficeSpaceUnderNewLease",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Square Meter Area For Office Space Under New Lease",
        "documentation": "Square meter area for office space under new lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State Income Tax",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r359",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r439",
      "r446",
      "r451",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r993",
      "r1121",
      "r1310"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureGniUsaContributionsUnderTheBusinessCombinationAgreementSummaryOfSummaryOfPurchasePriceParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "verboseLabel": "Series X Redeemable Convertible Preferred Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r234",
      "r235",
      "r236",
      "r270",
      "r299",
      "r303",
      "r310",
      "r312",
      "r318",
      "r319",
      "r398",
      "r457",
      "r459",
      "r460",
      "r461",
      "r464",
      "r465",
      "r471",
      "r472",
      "r476",
      "r479",
      "r487",
      "r668",
      "r846",
      "r847",
      "r848",
      "r849",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r869",
      "r883",
      "r906",
      "r928",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r1111",
      "r1147",
      "r1156"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r42",
      "r219",
      "r252",
      "r253",
      "r254",
      "r277",
      "r278",
      "r279",
      "r282",
      "r290",
      "r292",
      "r317",
      "r404",
      "r411",
      "r489",
      "r575",
      "r576",
      "r577",
      "r607",
      "r608",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r656",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r712",
      "r833",
      "r834",
      "r835",
      "r857",
      "r928"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r870",
      "r871",
      "r872",
      "r937",
      "r939",
      "r942",
      "r944",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r971",
      "r998",
      "r1021",
      "r1185",
      "r1310"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r317",
      "r761",
      "r844",
      "r869",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r883",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r893",
      "r894",
      "r895",
      "r896",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r904",
      "r907",
      "r908",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r928",
      "r1022"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r533",
      "r1112",
      "r1114",
      "r1155"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r317",
      "r761",
      "r844",
      "r869",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r883",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r893",
      "r894",
      "r895",
      "r896",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r904",
      "r907",
      "r908",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r928",
      "r1022"
     ]
    },
    "gyre_StatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "StatutoryReserve",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve",
        "label": "Statutory Reserve",
        "documentation": "Statutory reserve."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StatutoryReserveFund": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "StatutoryReserveFund",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve fund",
        "label": "Statutory Reserve Fund",
        "documentation": "Statutory reserve fund."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StatutoryReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "StatutoryReserveMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory Reserve",
        "label": "Statutory Reserve [Member]",
        "documentation": "Statutory Reserve."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1053",
      "r1063",
      "r1089"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Assets acquisition, shares issued",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r169"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of stock shares, issued",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r41",
      "r82",
      "r169",
      "r468"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options exercised (in shares)",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Option exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r130",
      "r131",
      "r169",
      "r549"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "verboseLabel": "Issuance of common stock upon acquisition of F351 Assets",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r42",
      "r169"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options exercised",
        "terseLabel": "Issuance of common stock from option exercises",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r42",
      "r169"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Gyre stockholders' (deficit) equity",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r134",
      "r135",
      "r158",
      "r885",
      "r903",
      "r929",
      "r930",
      "r1016",
      "r1029",
      "r1148",
      "r1169",
      "r1291",
      "r1315"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity:",
        "verboseLabel": "Stockholders (deficit) equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StockholdersEquityDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "StockholdersEquityDisclosureLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity disclosure.",
        "label": "Stockholders Equity Disclosure [Line Items]",
        "terseLabel": "Stockholders Equity Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_StockholdersEquityDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "StockholdersEquityDisclosureTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity disclosure.",
        "label": "Stockholders Equity Disclosure [Table]",
        "terseLabel": "Stockholders Equity Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r110",
      "r219",
      "r220",
      "r253",
      "r277",
      "r278",
      "r279",
      "r282",
      "r290",
      "r404",
      "r411",
      "r489",
      "r575",
      "r576",
      "r577",
      "r607",
      "r608",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r656",
      "r675",
      "r677",
      "r681",
      "r712",
      "r834",
      "r835",
      "r855",
      "r885",
      "r903",
      "r929",
      "r930",
      "r953",
      "r1028",
      "r1148",
      "r1169",
      "r1291",
      "r1315"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r269",
      "r470",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r486",
      "r489",
      "r647",
      "r931",
      "r933",
      "r954"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split ratio",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "gyre_SubleaseArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SubleaseArrangementMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease arrangement.",
        "label": "Sublease Arrangement [Member]",
        "terseLabel": "Sublease Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease Income",
        "terseLabel": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r1015"
     ]
    },
    "gyre_SubmissionOfTheNewDrugApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SubmissionOfTheNewDrugApplicationMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Submission of the New Drug Application",
        "label": "Submission of the New Drug Application [Member]",
        "documentation": "Submission of the New Drug Application."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r723"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r723"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r723"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r723"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r723"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r724"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingInformationParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries",
        "label": "Subsidiaries [Member]"
       }
      }
     },
     "auth_ref": [
      "r1232",
      "r1295",
      "r1296",
      "r1298"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Present Value Assumptions used in Calculating Present Value of Lease Payments",
        "documentation": "Summary of present value assumptions of lease payments.",
        "label": "Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_SupplierReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "SupplierReimbursement",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier reimbursement.",
        "terseLabel": "Supplier reimbursement",
        "label": "Supplier Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards available to offset future federal tax liabilities",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "gyre_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Credit carryforward, expire year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfCarryingAmountsAndAccumulatedAmortizationOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technological know-how",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedConsolidatedBalanceSheetsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; 13,151 shares and nil shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary Equity, Balance",
        "periodStartLabel": "Temporary equity, Balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r459",
      "r460",
      "r461",
      "r464",
      "r465",
      "r582",
      "r793"
     ]
    },
    "gyre_TemporaryEquityIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "TemporaryEquityIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions (in shares)",
        "documentation": "Temporary equity issued during period shares acquisitions.",
        "label": "Temporary Equity Issued During Period Shares Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TemporaryEquityIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "TemporaryEquityIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions",
        "documentation": "Temporary equity issued during period value acquisitions.",
        "label": "Temporary Equity Issued During Period Value Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, par value",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r78"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Temporary equity, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gyretx.com/20231231/taxonomy/role/ScheduleFinancialStatementsScheduleIFinancialInformationOfParentCompanyCondensedStatementsOfFinancialPositionParentheticalsDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary Equity, Balance (in shares)",
        "periodStartLabel": "Temporary equity, Balance (in shares)",
        "terseLabel": "Temporary equity, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "gyre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Preferred Stock upon Private Placement (in shares)",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Preferred Stock upon Private Placement",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TerminationFeeRequiredToPayUponTerminationOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "TerminationFeeRequiredToPayUponTerminationOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination fee required to pay upon termination of agreement.",
        "label": "Termination Fee Required To Pay Upon Termination Of Agreement",
        "terseLabel": "Termination fee required to pay upon termination of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1297"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts and Note Receivables, Net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r362",
      "r363",
      "r364"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r469",
      "r485",
      "r646",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r807",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "gyre_TwoThousandEighteenOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "TwoThousandEighteenOmnibusIncentivePlanMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen omnibus incentive plan.",
        "label": "Two Thousand Eighteen Omnibus Incentive Plan [Member]",
        "terseLabel": "2018 Omnibus Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TwoThousandTwentyOneATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "TwoThousandTwentyOneATMProgramMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLiquidityAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one ATM program.",
        "label": "Two Thousand Twenty One A T M Program [Member]",
        "terseLabel": "2021 ATM Program"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_TwoThousandTwentyThreeOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "TwoThousandTwentyThreeOmnibusIncentivePlanMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Incentive Plan",
        "label": "Two Thousand Twenty Three Omnibus Incentive Plan [member]",
        "documentation": "Two thousand twenty three omnibus incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r281",
      "r282",
      "r283",
      "r284",
      "r294",
      "r365",
      "r366",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r440",
      "r575",
      "r576",
      "r577",
      "r605",
      "r606",
      "r607",
      "r608",
      "r620",
      "r621",
      "r622",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r666",
      "r667",
      "r670",
      "r671",
      "r672",
      "r673",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r763",
      "r764",
      "r765",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1004",
      "r1308"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Unrecognized tax benefit",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r595"
     ]
    },
    "gyre_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increase (decrease) resulting from tax positions.",
        "label": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Increase/(Decrease) of unrecognized tax benefits taken in prior years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase as a result of the GNI USA Contributions on October 30, 2023",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase/(Decrease) of unrecognized tax benefits related to current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "gyre_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r201",
      "r202",
      "r205",
      "r206"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "totalLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "gyre_VertexAssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "VertexAssetPurchaseAgreementMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex Asset Purchase Agreement.",
        "label": "Vertex Asset Purchase Agreement [Member]",
        "terseLabel": "Vertex Asset Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_VertexPharmaceuticalsIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "VertexPharmaceuticalsIncorporatedMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex pharmaceuticals incorporated.",
        "label": "Vertex Pharmaceuticals Incorporated [Member]",
        "terseLabel": "Vertex Pharmaceuticals Incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "gyre_WarrantExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.gyretx.com/20231231",
     "localname": "WarrantExpirationMonthAndYear",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant expiration month and year.",
        "label": "Warrant Expiration Month And Year",
        "terseLabel": "Warrant expiration month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsChangesInEstimatedFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo",
      "http://www.gyretx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability Non Current",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1020",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsAdditionalInformationDetail",
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndFinancialInstrumentsSummaryOfAssumptionsToFairValueOfWarrantLiabilityBasedOnBlackscholesOptionPricingMo"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term (years)",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted",
        "verboseLabel": "Total average shares used in net (loss) income per common share, diluted",
        "terseLabel": "Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r312"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.gyretx.com/20231231/taxonomy/role/DisclosureEpsBasicAndDilutedEpsAttributableToCommonStockholdersDetails",
      "http://www.gyretx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic",
        "terseLabel": "Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r312"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4F"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-30/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480922/205-10-S99-6"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479719/606-10-65-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715-20/tableOfContent"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEEE",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EEEE"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479092/842-20-40-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "715",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482236/912-715-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-48"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "25",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480270/815-25-40-8A"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>126
<FILENAME>0000950170-24-037242-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-037242-xbrl.zip
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MI@L>^AKXK!^]@R<UZ37\UGW=;%__XXI9OFY][#GO;)J,%JX3/,A2 1OJ'2<
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M\3(EHHH"*1/^1#%8)G)#+>%]GG@@$.F5;\=PP%; * 9 $+*-4@'G)SY8$..
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M;7KC+>/"\"*)D];/4C==UIRH9*3FKC">!F>KNZ5E=0W]\2H)RU5R)#C;EP8
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MUO%D ]94"R[J63$J)XPCIH00:<2$B.&G'PXPZV%Y17(42->:D5@XR&X<T\=
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MD1-'62#!"E:HH8K3P<IFZQ:R>KN*3#=B&D_QJB<'&<OH1U .BXR22*<LR$;
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M91^Q_4"VV"."9P/\ ?\4(#8EV5#,X&H;+U>?6T_A6/(4(O>!!(\V<67A4]#
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M%:%B6>E2A>=@,R=62X_M$22V1XA$^:A\5EFPM8]WNZ\.,RO*3&?9.H4]V[T
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M29G!!0H/U46VHO[>4J,T9HB6$NA]E@[$8Z=(L5P*Y652:; MRI92[_SVPO@
M.U(N*\2)9FVY*9+XS$$V]\82AVTIN35""UEB""OW@:Z'6LF\=UEG(&4F>)"3
M&+ ;Y1C1)9N8F91NP/UVAQ6M-P!H)E"D8@2Y@0>3X=Q'3CP-C!2CE68Z!E!.
MAPK-)ZEW$%(ON_G!9<L[N 6X=$R8>1<]^L93)J%$[.W$C?6^2&8&&[2R"F/*
MC<[)>N<OZ*B9#]22S+ WI$J6 )PUT1;83DF"#SA_82T+I&\UW03$/;\2C_\
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M$^TQ*-U+2ERTG$0J5?$:U,DT6!IQ3<.WH]]W>EIPVR9'@S$#%L98B$Z2) 3
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MKC"B,V5]#7T"O#D2[E6)A0HE)+LK)^X#^X]?PUK>]$L9Q"[#NXABS%PK_-_
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MJQFCHM1%>-V_IK-.NWW:ES\Z:IM/-9"W#+<\&+'X'W=++KN#,7[.:%[WJ6$
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M=85]D$!OD!6>5]:V*JK:!%1+0GO9W.(2N1'E^567^^&(\AQ1GI\7S&%:@\C
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M[FG?XG L07V9?0^#+G0IT.6LVIC1]KMY$WW-T7(;.<X&^2)XNP0RKBEQ]4=
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M'P]_??")H2%9! $\_XXU( >KWI#ER$RT*T\A\IFK<GR@(B7(Z'A 0EDIT+I
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MG: ,)U<WE.UA]R>FW"@3R2@C/URMB[3! 5L;)I#K5DBJ,P4SW95)BS[YQ;9
MB*Q :W1;PP@6CQA'6)/!D)YR[9$HZ,JC),ENH8A @"2U6K%9C9ZE[$NX5'>J
M4;Y2VS'1!M\V'LD>ZO743/Z(__-[?)\[!W>'_!^58.OUW#F\^Q'/Y\[1W2N\
MGSO'=S\VJM_K(-T6%7]+31>-.N8W#E9X';[S-YWH2U"YK@UI\C P@ ARJB0M
MS&^COD[N\T@X].;T$/S A?&LBF9<#Z;=$M#J4[A^].0BWU;#W*3@NMKX("32
M3P4=P$W5P;]'M)ST[%3;HEI^??JSTIPVTK&"^5"99I:6<"''&6XPA;D(X%NF
M_/<&4.CD->*I3==HY-0F_5'0:@<YS:MUPX0P\%1S=0$S,\]!LX9C )%:CL%'
M<>W2L,4EW2.84!?@J2AI)2DY#@3T\U!%-=5#SN>U=+A\S/B\&!?=U61Y*',L
MLHM:""<A<T<JPQ$.<,0R.$V8:W!++]'&%*^\6'27G<T"*/?&?6S&E?-;P!?;
MT(T\H7M8FD=R+-+->*-T-EQ9ZS=@)6[0/D1H=MQ")'?X$4=W)X,K$/QY(,?G
MUU"OHV,1-K*+2MA3-95W\ZL]'/"9/=SHT&2QO//LWMZSX[O"9.3PB3\7)@<5
M]XQ,G89C%!C9"'*[+2"WPQ'D-H+</F/.I%62_TWJR&F>'Y)G!_0+^KN12NZ:
MBK1OP6VXZ1?N E1XP_L.]!C8E.[2;8=T&S,K]>YE^WW[9KKC"'?4><;Z+?C]
MF'YWSLX(.KAQ$_TI..*MN<(6S4JH )&J1\D8!ZO26JRL%.F+QF+''2^=/S%_
MJBYA;4R2!>?A)7K5,YH"!!*;DU)ISZD(M#F>%L9DMBV7F'4VPK2)Z)+"C #:
M']ODO5J.%E^T!H"(9XD9:"\LF_:@8[\V!@;"?G+B<$0P]JP)M D6AZ/_Y1P&
MJ""6+,3>YL6;%7IQ-!JFF3LDQQ)&5H5P ZH:ZD4:=*S"&!WX0^(N75'(59HV
M#R8*QE3K]K/+G=I((KTU,V&]()<O[EF(:YWNX6(:5_"(_>0MMY J&'-&1G+:
M2%NUJO#)%(=[Y8">V&@@0JC)AD.5HZ4YL;8[DRODOW5&"C\T#$%_(4N2H5Z<
M+X$@Q3G3_>15- @#ID.'=#M[9RN.[KJ18;'$1J.UV3MY^TY&-W&&V]XQS$MD
MJ'#I4^D'EB4O^/MXZXY-/TSA@GX20F7MQ5U(C6C9L+ 8,O#:B@S?]1(2XM U
MWCZVV)JM2=M8&>81)8?I%?3DTBQ2;=QMN"W%!3=6Z(SK"SJ;F77+O2N$>7+H
MVKE06&C_"LB?3>=A&1_=NP]]?S>.@0U_(E!-V\_>F!99Z::_0PSZF,/]0&IQ
M96KY^!#K9EE=2GZPMAW/:*':2\/%M[;_,_+-SLKG!%J*SN2\L5Z^.4-3CY8N
MRY"4:S><5I[S7H;5CPO.GSQ[=E>K9(*'GKQXE^AT#QXFOWSW0CP#I^\LS:BH
ML3+23QPQ5B^V)F,M673T93E@QL+VY(0\Q5G5H?D&XJ#D;&KHV36OHP?-EL@I
MRI%=POU0D;8[A"ZQ&P?KA6ICM*F+L([\;<#SXW"5]'(P>'<%YDOV^LR$0\^-
MZXTGBHVI4"SVT5?D> T>?F.&M(]4/3=NH@&)(3:FZ]?B4;%(:TB^G;1%Y3!>
MK==6EY)/LC%WCJ9H,D?3$OZ$%$X?6U]6NXZ-&L+6XPVM(Z^!K(U%$E\^#(SR
MSU/5*GMO6R!5SK7KYZDEI?R>ZW"N3WSDEGR:6SIM5YRC]5_?7N_</"G_MAS4
M]%$G0:6>+_S;:U@!Q92X$T90;-5J"$O]QPK$02932@_>UMA>=%HOV.>5YFR
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MOV?T[L->.?Y=$T"GG'1&O]\YO+]_[Q]W)T)&!\@A'Q,'I%K_(74O3;4J*Z&
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MS&OKP(8S:,LRM\'UK&J8BYB.4$N'Q24&^!L7(W _!K?+E)<K7TW)*N!UV4]
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M'6_-*J5MC8W, \4.WB$]KZJ+BOX/'9;-^^3DN[=8FQ4ZN.#F[TY>O-M[=.^
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MN3;*S:2B%[OJ]"^!J*,63?Z=2[)/3DS'D>D(N&TF\V/E @E#17SQ &<XJ[D
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M0_+D!;S5QJ/B*;QZ<O+7D80Q./^E=L5IT0=L7K!3RL'WN!.]ZNI(DW@*+IQ
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M3Y:KI_IK2C,QY64*46T9E,Y_?>-9'[59?-KBM.(#<V&@IVR618X/S^"7&G%
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MG/N"6(S#I(98S"S&'LY_6</$5R1B<Q?'42-Y*9'V9$KSJ QRRIR'%,FIC O
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MIHD,4O.:/!-C&Z3[X%^RAK<S;Z2L(]]H'\1*W3QA)/%%2;2UN2PI;]Y6P<$
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MII0Z(MN)AA:)@ZA!Y^-V!0J26D+&Z/SX25E4U9[D?ADF K@!NWKTZO;X_?A
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MMTTC4S NBG=6#8*!U +Q)C00R2XS0"M)2Z8O(K-WHE3WJ)>SL#074*.5M[U
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M-%V>[)WI:/P@!SFMY'NI>%$#_B]^\]UD4)=*:_<*TX@.M@A)V,.2H^\K& 7
MB;^QX[?+U&8! F<<5F-[5DG% #J'MS__Y:=!=!;8?E&72)?2WKQF7"Q>E<@%
M*RM:"^=-U!)T+_2HX>'^X*!MI<:^^36/_3U;P+0VAT>#@P<,T3X^\*9J++NJ
M]3!F46'P'\\$/KBLZ6B;O6<F[R%HM#CU39%L\VRF!0 =7.K\\*;2D?V#&\$
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MG5'_GF[Y<?T$^U"<NM]=HR"+3SGW&:/^?-[H>^<[3 %'8G7]A#L#P6O^$HM
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MK" ""BDT$D4,=K+8+&W00_%:4QI[6JVYS @;>'A(@F<CIMSHE']F_5>%]IS
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M:*,_DSJ?IA,3-]A& ^]/+>Y"NCO9[WH['/FPU2+)"CA#&Z6BGM!;4"=&'<+
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MATF)&CUFN'5X74*KN$QFM:ZGJ=HNM\D I+%>INNRN#DCT"Y-;)=TVN+!<G"
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M#F9S;EZK_8CBP4-+$6M^@3[4M&+ML.LZS*KL+N3^EMICB\[^15,(T'J^"_U
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M!NLPFHRFRQC6H'R;EE91.:365T[#"OH6$"N(,T$TG;(N>L:Q(,*5K-K'#6(
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M /C.V)]<C/'G9[^>T$B^J6R\6=58B9@/C_:U<+^4-9K9!MST->=]+SMR[:%
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MVU\M&S1 .>DWR09I\IS#OF7;^896_K&N;IN*#T$\*V:5WY-'I81F;2I%O",
M6\>1Y_UM&).8&@I&>8-["TL_$GS+\%T_6[\&HTL\-"4Z&$X1X+.#[T6@YCU=
MU)RK#-!.^^V&S/'/S7ER#,;075KW^067;=/1&&99S \"0R?:'05)8/F&R9B=
MU/;=-6;WE&M,"*S'_O$L>S++OIIE7UO1/X(2)"LEB*3Z8+\]"\K?\@7P:AU3
M@X98BMV:4![6MYNF<RFQ?J;+-&P8T*H2-XG,4:T#\SP$ ; &A6$5"NDB9P8I
M'/LP,+T'5*"?4?_7\,:3N7S?%KIG+E]7#ISH!K.E7_J#.NQE_-HM+JP0'\E,
M-&[H/5_;P=X J.5I"B.J&/$68PBX6CE1SC$ )A[$[-H/]R/E^0Z!>MS7R)-E
M!&Q8Y=KQS>D25:B-\<:_N& ^$^16R7+CY&I9\^;"4-ON-MQ7C_XG>QY^DPON
M\]+5TF&")!"HR+,W;I=U^=)MM:DS1_X/^<"\8?C%UN][^-&U.TXC,#HL\C+H
M>'%)JF]NP3,>3/G"547\2O'P=[[6X+)+96Q95SLO#OWPD3T/"S8A'O%?X@B&
MHI8CW"^+^^R)]]D@Z\-P0X2S?/LK_788_>Z0E$SPR=N%3WX[P2<G^.0'K%F%
MBZ*]A# UJL2(4FJ<DHM*JA@ZK<*,(=AE]V:(O-:^2EX$1S+8DWOYOW",(&B>
MO#-5@P28_'[R^8]KW:]RP%"U^NVLJ2HGX?I?F7GM%S(YH.9?6A^E[.>RFOB1
M)J_C]G'8UU ;!+B) ;#W0"0'CF\$O]Z6&\\MD&_'@M.'RN6D&D;I0PY6N23@
MB;J)&KMYV@%V8%) REZ8(C#%!$Q1PLS-"UWI0GV_,R R_%@)SPX\E:;?1LWO
MQH<(-7BGV:_-%:#OXB,!XK$!7Z33B,6RK#1A0"J$._Z!3'#'FR)TC/K&#CQ(
M>N8QW:1WHP:L0X7#$\TF[[@4V"F7-WDS"(OL#K58\I5SP\H^AG:+M3\"97\E
M!.,"%.%W/CB2O]&G-;^3YUNWY@Y1"]"M \O^E@Y\%,2/2P),X,XB:3O+7H.,
M$MXHDV30B[E&!G-9X&LA.7H%U%*0SGBQ!QA!D_6DG9LZ/Z6%3@F7*.[/%_KQ
M'3PO'9)>.3:*[-GZ!"UZ.V0BF+X*7#1Y5<4\J/06Z6QS*CF] 4U*CB1.F?Z-
M=RA0,<5KO::PDOUR;HEU2*N]" Q,?Z#4_).F/B:E<@="68<5S,%;^$4+]5M5
M>/=48WAM<2QWYFB$PQ]U]G_ZVG$.Z-&3KV8<P7TAYVG'6CLZ0*_# 8I1YR/
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MXNZ_@1G7.U&2&9^I!50B>Z[KMOWSN9.G'K"),]>Z"ZAR-H$ 3)B%"G]?U6Q
M7VQ)=!:@DT?JJ!81MVAWD<?\Q).*/JYU'RC()X>9.=B$IVG2U).F_G21L&O+
M?SL.C/A2Y"[(PINQ"48:TT*LHF]O,@9:NK,WYMI-6W9,?*+R-<8.Q2T!.)D#
M]A2)::G_>KU(UK;:PU8+HQT#]A@"XTY(*;?_[!"^$OXD-[^FOPBS8T1#"B?8
M$@!*_0.%K7S7RO4S;D&PD]F5[VXP-;58FA9Z"^3$H7%,RIO%A?_YEID17CIM
MTTO"Y[QMUDV2QRFK9HL_K]I\[>-FUQ'9I'HSB9;%;6QN/D2:&;N)D!(. F-.
M-/ED-B99N]H*.:)7)>N/VX-L+("M-FW4R!ZR&30&H;F*C;B.NH747B 4;H,^
M>V W'O(EO-="I$"]K79&"H9?CSQ:5V--7U3"JZ.AQ5K^DP+2IYSWVZ9-NS]R
M&2F.4EGW3=^-[%J$<<H6^2:?:QL56N2-%G5UT<03ZW3#X*( _7]5JT&N*1!]
M>Y%(E\">.R1S;WK*[H[$G?"BMXL7_?N$%YWPHA^PYE2C"2G]MF5T0]3M:D_B
M1E:UDHR@Z,?:=>W&^8-A*"-OT@M-R2J0HICR-8F\'S:S:;DB#3$QRSV/-)#U
M-]5#ICK&QI=\];*OEJ4T<BK;0_JV(7V\4JH5WIOW)J=\M6U=O:*O^934JT%3
MT_W?_.0G_2*)NVE%^ T,$<OBC>7P_EAL&Y1"/_Z[)2I;1Z>P]3URI-&?45TF
M7=C(XSCTRN1%!43<F@'+6WQDU3J%(_U8,<%Z%)O$-G!XD#T.596S\#*B]Q^9
M>8=FD1H3UYV1*0-_S\-D3.FJH=R47.E,\>N+B4/G& [E'7%M_PIOG359Y_*]
M0;T?(Q:1\B!E&_4<#W\:Z3D>LB%C#>*-$&T9,8_,@0EC7(IRI.FGVB_@')QR
MMJ!K+EG 4.HTE7!YK_9R,?JS84?UUBD\0JH9N4DAXG"KIF7'[DS^O<L>#[O4
M1W6<@T$U[(<"SP;].IRAV80Z^8HI]12@=M6T57$*Y(OD<%!P,S8<)HK1KA^(
M@:WR4OW$GUA=)! P;;DX/%M?8KY-E";W.\H7.WNYM#,K).6:UJ>WAB,-UCQO
MF[SP&)N=VT;PO.&))"/03_VKX=0_]HRE*]/>A*/9C6SHUS8K_Y=OHM,D_Q*K
MB8?.*W*OBMWHG@CPR-XM-L8G\V( 8W0(,6-]HPI?9(Z9:TN/ [9'0LF^ZC@?
MWMN_(EE^B-\7IO?U@>FELUC%KU0ZZ^SMYW"$>$TI@>$^::,8GUC;)V=V_JQ.
MZ;W6@7N*)M$"UZH-+7WPY^<9.$M?1J=F=HU$#[BY<1'-,DRUQG\'0NR;T\=6
M14[;4CE_\M,QA,2++IB(#@D$!MED4N0ZH3HB.]XQLR=WXW(<@Y%\E];]2B/\
MP]*@G\&:^YHY]7V54.C2]!K!?VG,B%/UK.S0M7#J-CIY/9\0'Q"HEL^%@="7
MK 3\,JP4R<C;A_&!S7XK.^UX+J8%OK1L^C9;M"7#XGR?O36$ZM;*TERVI4E+
M 0I;>CI>X=#/DV]1Z'IH'W+/SPP&#,B]"\;MTP"T14;F1,*:!75M,ET;%\:C
M#!J&KFF;%?VPH>=:6.RB[# V$&JRRS]HL\*M. H=4T^!%+ H\U7==/076N)%
M4UAGP\OTL<H/LR75 Y5CL'#A?D$.JLX<O:IFK4Q]2_H5(Q:N\AT7!I8"?V -
MIKPI\L/,0\O'X.0D>KAWD'2BD:G730#/R8PD=!KFY&&!S)ZN:SC-_D1VS!@9
MU8'PDBQ^D9@G_@8TGTSS=YODR/G)&9Z'3CBHW402E2Z+AVN(O:O]4=K0'R6N
M! QVN/ZBBZ:2]%Z<(HSW;:'O BB?1^B9.CNDKY\.ZDJ'D'O,0\,CEM0?(FKS
M6,^'$WF8Q8K_P\'#I3O]X+$(C' SP64'_).F-32%3;O.M'3:'0"LHEMF5>(F
M]E+ 5];H9]8E>&FY1@ &Z]-9'#3+F8974-9WV'>WW(VAG7U$*W!(C@TN_KB[
M(H%&UW&!7(6#4'[R,(T@M?E5!*1F\&T8_]UK\'/8CZX-@D?C -]9YDI&(T<K
M!J1AWN0MIOO5P^A],D0 R >2PO*> G#,1&E> "3.;=88*&>BR)I1/'W^[!7Z
M6>#VL$;NU_0U_#^>1B)*?\#?'WS]<"#D_)@<PEGT;<L@D:PBDQ.7843"3_"P
M::&W)W8_;D=;#8\=:&B;!R%\?<-:C\K7WH9:D)>V*N-R@\7"59QP%2E\8%@K
MLQ@=9JG6J-I/+)2"=;746[] %K?%[?\W#\+7%" IN]&S@2D5BB7L3Y,1<]\6
M^H$=-TW__?XK%^_^L2'WBO%#_-=#5VT\N944]:CA76HA#EVF)B2!0I6N, E(
M44TH+)H=-I'XUX?LHD'R(_9VDC)=[Q4<N*U3+.ZXUOU+TPSA.>>PE:$S[G)H
M;4)NWBYR\[L)N3DA-R<KY"-6D*$EBJM7=&]8*P] JXSN"]1B8H,/^RW^\D+Z
M,,85%F1.T%_PR5Y% J-/78V4>N:;I</0;MVPM?I@)HC,YF5M56-"F^IKX'J&
MTZ:%V6I,81[)!ZZ6P(MB/@]C<@_Q#QVH-3A4S<7HULJMN$QM@Y NT[E<^G;G
MVN;2%Y@P3[@O+,G'RC< &>@K+@-)J^)&RCT&[S&@/+5L;W)#[MM"<>"NL:*B
M#";7)!:*+>?C/$26ARL\2\G]!)2<+Y<<>8M*<F@EZ](\7GJZE@3-I*A*1O(!
M2*VA9 0=X-*+9J6D0BF[P2PKFD4?F)!8%M!-IBG/XKN1S'? ))"P"W@D^DP^
MQL\1$(V&\L5-^MF :T$1/#IU"U0"H7_IVIW"<1;,J\C7."D'.%+;_EA]&M8-
MY^&."#NIN\ONS+V5CD>ST&OPT>^JE-&0TGDLU9,.[J^>OG@Y4WNE$R.2K;1Z
M4(?T+GMR[JS9'X=O+;"DMMFPIFG J&:F6F36"),;I#I:YM7-&B%9Q*B$,Q<.
M;(O,_(D?"[FLC'O!P 2#:KCR';X_9'VPT3C,!HH=7[]Z0!"@]U1BL]_6&U/[
M'=5#BVULR%^[K*$BK9MVW6GQ6VK+C],9\5,Y1\KEU <,]BT#_@ IT9(PZ3J#
MM=&9* LM=#NTA64G8'7NI\B]P"0% .\#_[)28:UCJYTK.NT=A )GYBV-U?_P
M\/F&-=Q^,<'0'YC2#' /.>="?9RBKZ7%3U1$Q>=&@K#XQ.K$#I^:KGPK73Z3
MGCO1_ KX+==/\@Z8__<&"GSG3(X?P6",&V@G!G>670.2)SB1WB>(@;^363*9
M)9\H278@:.*C-S&UK:G" 2ENQ'A[,-(5TVG/DZ"7#YA<D5YP'2CY/!]&J*I
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M"(TY0L.B(&%F_OD!D4,'U>:6Z* B7].\)?F:/DMY2&$ @#50&V>DWRD:+=,
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MP'O%$6SA+Z8OZK?*_PH[7"#D$0R,*\RF(#L4>Z7I12,T/A91=)PR5^0M(_<
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M+W)%QCS^3@K8 )(EUP)E86^UJBH*XTDA+<0;;/NZ0XF:1>*B1TWB[;XM= _
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MG"?>QN>E0R/=PXFN!MDR5R1"@R, 2A,V#K_;9+2Z,-:9A 6Q"(I3$G]?:U/
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MZ^9@./,@5ZG+4\P1<<OV0DG/I, <]1K%]+8>H4,[6XTV-4QNU@A/CPB,>CT
MM!_I B@M4[+5-B-7ICUR1 C5T$&#BQ#IR[Y<.R7T%K<@I>"(+$#2&_(/8V,,
M![2&[Q58DMZ:KQO*=N"OY?N($;4!]SK98BJ^L+2N)JT-O=ANGS@S%LNT_15M
M2M[X+()I<?CU;IG> :MG;G<.]6Y!(8,";^Q2*0S\NC74>-]RYPVMO8[?.XM+
MM<A&SLS]H!+O%S2]:! KY)DTA-TCZ!/&SN@;F#(6<JBT0-,S[S%?#8=?]B;W
M[4$5?\]3!%'&J-MTKON?M)8,^!=K7]H)ZP_N=KD<=Q80;%Q9#QM5">&+1(A
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M &-H)JQFD"'XMJ$S9J@0):W<Z1!9;Y&8H6<?8SO%E*?%/<HLM%9I>=!+1%L
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MO&!X4:4]D$'&2*!:#G:8:%U1+-]+4KY#N7.8)..J3RXC!:F=%@P]TC^P$_[
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MTP/'#B5-B;)EWAG+_+BG_<$)FKQDA&6U<L+W'K7CCV;I3@Q3";(]PS7\%U-
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M6[N+:#/*ZY=$YZQK+P;Q-.%FC4K03"<BC/ D$B/=@)R)_C9]FAT<3X +777
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M>QP.7SH)5BQ>/7WV!/__\7?R9:\>/WEXD.LS,CY&]N.JAM1E>0)953]- ^K
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M$0?]>JD+I=?]*"CUC;^8:0"5-^$7>K("C-.. W=J&5X0MH:)K1[?&M$&N-K
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MFH44'&LI7%O,.)D1X2F%Z^@85\UUY(LIXN,)_4C7"!\^P)Z"PWK9\G'-(4M
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M7IY.U'UFQONFZ M%V!7M6J64M7MJ^Z2H2[S-BBB]]R)ZMW1K,]ZT7,A:!*A
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MFM.IR^FG%7"V6#Y61^86/N$]D5$!XW>86$ I\76U^+'M0HNF$<M.X,7JVX2
M!]>I@31F2F;"+98=0.&,P*/+^F* &%"L'86U$6K[37S4?FX*?#164H3+=M!
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M''D[3D\7V:6Z3L9D4X5Z#?L#:$BG7R#^^RIQ;5L2G49R6_5;;T-&<Q?.IZD
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M]<F4P70F$"[P\J+W"S[SW-,BC7Y :DE*1,0!;5:R"]IX\G?Q)'"4TAFB3D9
M]&9Q5]S0^8K.M;8A#WB\M:X6WRO\8QT(CD*\:"$LH&^;%L3'>T7WMS6HUSW]
M]CO)*L@_N?^>.QGPH"_2['VZ,Q#3]^6W1B#[K&G((?DY4#C'O6:=(PT0&IQL
M*6[:W$9FZRY;(@EUPOF2WK==&1E\']PW[S6$8K$U4B7R.%DIB-VD(=&7>AK
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M&,<\*3>6,',^3ZMBF("OY$0P-U*X0 IQ3?B3(IX.JP&;)2Y((VW=!"HW'$\
MK1/L2<MC3@.JB=MKYM]/9^C=Z!IT9U'=@_5"*#B:HOL6LBM/,/'IE\N\'3X4
MQ/_Y-K[_Q=]+:;R>[/2,87R\1(4&<%I)'M7T_.\_O'QF(*:T>B^M4NL3/Z%.
M6C0#B4X(J.YDUT0GZMQNT=HN$DE<)4SEQ1G6\KG 6KZ<82TSK.4]GGFBV<.
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MD+0/XU+V'7NJT//V7#FW6$@&Z>A843^WG3A#TSXN-.VK&9KVF4/3?BTGQZE
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MC-3^PJM"&2C=UBO>$+'$5)>>RFIKN8R7"8U+M&#P?2>?*FR-;3,VH 2,K#:
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MC?;#MMH+-=$J#CONC4[H@!Q%ZKX\MEV">SN+[,B%*5GPY'6U>DW)O^BG=.7
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M4R0Y^BX5V>(6/5J:FEK-X\@Z81FL 'ET? 9:=#+TZNAKI;!V[H;Z6LG.?2G
M)?#R7)QX,&PB<C.47)$/YTS<=;IG:\"!9\6CF%RMO3S=*.KE'VC@:R"&O-L]
M[C9JAX?,Q*KJ5L..8-+PH'9";L9SQ?V#;)IY.^ AZ *)4H][^O&(,0AKC-MJ
M3QJ)>WDM?NO8SI$$S6$[B-@3FOZX75G?<]C$@1]FM8G'!M[Z"[]7T%_ XG!2
M+&N:.8.-8GH(I27V1L?YOW=!:H18F.DA^F%).X#3ZM3X>+7XX0!6B+;O*Z!E
M:'"9-?7P>2VB*YO<^$%2K3P!CM*HI0_7M==RN8WQK!EM]HK:9.FL2B?"!=#7
M1#Y]<C( R!^U'Z"JT0[-6HHIXSQ_XD'NY:+2&SVNG8RXOPU>9N<@E8!2CZ_#
M''L;@TQMD6=O1QSBKOAA<&"B2:%3;A?-8]\*;W=X$]\3\H P;.Z4(*IQ*\EZ
M/(4[[B\@*M"B.Q!4JU9^9PKXND&%>MKQ-&/F 29,A\746\O."BLAI1JQ(Z5I
M"=_FMI![C=*?K$3;59+&<(N(_94X@./$*]'Y5SCV*9.[0VPGW\)FO'^+*9_A
MV+\Q4W]_./;+GY]_^H>?7^Z'(M@8'1O.7FCSX?AD&E5SBPDEJ,)X15$[_D>S
M(>[^YT*+0]8;0!W]TG,]&:B0K,8XI3>UBF5ISNES\!>C52MWR^IZ$#)!N"FW
MZ,5R3;ZCB"<[$7T6E0\'.SU3*^+4K*C1W0_4L *+'-UG?^Y1UR);WTE;ZX[!
MC491_X.ZIIYZ%#)"+6KJ#)R$$PH11%B2_H-B)[0V1S>UD,]"M7_%$Z\G6J]X
M#\"S$6'[+D;G/QGM"N<X-^TJKIE6NQXEQ+%E$SZ Z_B.7B/W0IYS&C_]GI]M
MVJ_46O=/<U@9UP-KH$ "6F"I<H(2QO<2N3]ONV[8'TRRL>?4JB"&OW].I$ (
MX>-^KTOF+GJRXA]I,PK^MNRJ)17IV?7>9"3,2B<TQ W*V\MUI7 S:N'%!#!"
M[4XF%+#F&>C9.NN.(+>P(_RQV9V%J*K0EZ8-ZO.1HRG[.%PC+'"5II70,$7S
M/R'0L@^L&:X#%#[I0N;C&&V35\U1AB-0DK'A#6L?JSC&,H>?4.TTZ1=NF]RF
M2(]V:C%\+X*RC[Y$9PZS!V../J:+I7;CU&RHB6A/S0@?I*/D0C?4X5UL"3-=
MVQ@\92DG*HW<SR!/@PA1M42IK-5+],='<]$>@^<M1;VS4_#G^=:.U"$BKL5_
M!"TE<"A* M"(4P87(7'S9"3LQ8/R?+!41@5XD^)WDT!E-7KY1V8D\.C1F)30
MTP'!(A"@S34QG^6."-WB1,=T.$"^<?0JLB96M*V@@4[8(IV,S'0#74K.7&JE
MB]]%.Z&ZC8DG(;%5G) ,% 1X9YSLM:0"VBSM/:54@'F!">9WZ-^G,=9*KNZP
M=6\%K+*V3N(D^3Q_7&PKX<5+?WY2QA_7S*;LRO71Q2:#+TZ^#3:KE#.=L#\&
MXJ$8ORN:JNH[F@!/MAUE)9R<U])[YS9UIG-F^3@(_ZS!LL'LXGP./QQ>S!D!
M]W$1<'^:$7"?.1':>X([6J*?)!;AW JY_"\Q&DF;TH$L[V =3JO7M9QH*?VP
M@JO.@L\H[.6'-MWG.JBH,O%_%NHVVY<*^4IB\&A]>U^<F+J,*Y!."U$N/LFT
MC,A(O&TM1C[ZB0PG*L$J=1XM[N >SS(K+HDRXAV-!NVZ)74](1*Q?HE!'R"+
MCN@(]74,IL0/(_*3MPM$,K:GH9MBBCLC:59P\^NF;F_/R9M]^C-ECE-^H\8F
M(\7]T%[I:2W*LA8?+EOQU^FJI?IU\ELD4_F_-N_&5V%&\91.CN;#[,W)#36R
MX6%MD,GE/E6YR>TV-,X^%F9@1/,0?G6CO=E$$=W&ETL0OZ1Z.TE,:0JXXXR.
M,\;.R\]R._'OKC_CO><.Y"0LM)OK(E?TXND7\LZRN6$.:/_T*DK6@C]OT1-?
M'!78T:I.CWL8C3>_'L5?^(G%QO'(:*\#+>:KQ??,O$Q2$P4OU7QYIA48XE_:
M'=Z +E2+DT%AN*V,A%SS7S8(AOMHWTV;!E.X\$=LO5 N'$@<5DYO#,SNJ^IT
M4V>N+L"TA7SV ,. ?,C)PQ3I,$UG,3< K3.105^L2$+'^L1R?X(Y576X)KV2
M'^/<TC,RAP+1_^FKZM(8&9G* Z&OU!2AZK;N:'(WB9RG7&V#K29?K*!OKN(Y
MFC$29EQFK8G:N%>@4]YV;MFXZ1="2G>9U8BU?!V4M7SHP_O9&V%W2%=T*5:9
MN/$"+]+#MEX3)W6D8FV,C(I#-SQ#:O:#/0+2P_+NFG&:.+U\I$7R9\E8_B\R
M[\Z>T.P)_6K<C%.RP^+IC!<I6PS%BL&@VWZ4C>.KEVKF;C*H/!)PJYPR^D%.
MS[P5'LQ6>+^G?19-L<<"Y!4$"E@'\S#[4';489*IU"=X=A)9'.OMTI*^X32N
M]H0H#77Z)-[WFKS&>/F]](^M*7]/?'R6U)^4U"4Y/E5E+T:J=D/C?+(5B-3^
MR<S&C+D3+ ,=5=E0F$SI7P;]/BF\G.CC*4/;=6B)08DQ]24=K='QK#F'P-Y.
M%KHTUFYGW7AE \\K^O[TR'TK<#_.T!B;H-:2O-B4R<IYSRT/E+3E)WN)25\[
M>YV%BSI<%X1G!)2KCI[A:O&W]C; ]\N"CFNLRALJ4M#SF?P-?>(H9UG3T_W2
MY<,@#B="*[+<H$2]:;T"'WD28%]$)W]=-I[HF=S5U#S"I'HS2_]OT*C=_[R:
M"69_PZ_YW-/^WYU.E/AF9+5<$3)CB]5&QNBY!6M%.L,GU*Y61MD-F=,-Y5$"
M:71!<^KD3"BT-WMQ6Q(=3KD23IZG7WSYA01%=#_G&8([!&7I5Q53S(<FAL9#
M/%()J:G@.APGRQ :IASDMJA %ARD'J?([SA:1N_HB'#.$ZTNQYY4\ 8.*HX)
M39D\]E_*-XOG@Z0H_E^[%$ 4Y<SQ) 2K*F_)]7T99Q5$'8M?NF&WEZ?\II"!
M,<#'<S%:ZY.RZ3.OB"D[5SV(#PE73]'PXG7@@Z!M)-LB3X*I?Q%63+H6[_G'
M. F+7^)C]-;7Q.<5L0''H_ZP .C_=3Q@;QN;#Y%&I,;L9MTG]=A[C)B&&AT-
M8FFL#@/'V42E8F+ !$L=P Y#3&]X;?T!,G1H)N/\1B#J88)JJ)[;:AL=AZ J
M;SI.>A%9IN0&(?F^[<D7PKK@P(57FCE A^,HT1<O9JU^$J'<&-4.NU]QD/3O
M_V1IUHE9(-= !=7IUH+G*"=06CQ5*M^#\UN23EI>F8_A1V*?70^99E6G3"]R
MH[P*P#[T=M6VD<UBJQ,MP-@<J<_^BM)=:&J5Y?PV%!; 3R-71K\4LLAGT313
M]7#Q4EDEOZ^Z_K#XKAY"?#H6Y"/.2%AZMMO70Y/$5+#7-4J),V98]_@T,8[@
M+2YDS[W;ZR#&%60V0%S5BN>4>>I:C1!6"91?T"'$#7,AM4HI/18!KL)U>P!_
MA7\[<+H-V"5)9LK[<6]MG+O0K+Q]\3]&11>ZTO&L8%H[%)^B_: <I5)BM\/A
M2;MYLF]7T9AHFQ]-@KP_=YI12$DKA:>""[^P5201342:\F;RQ*?RVT:#'M[H
M.V$HJIJ@H5=5R&5\H"T9-F878_1JD 2R2B]:AB<[7'/GP>3<&7%L<_Z2!":_
MNUH\<W0-HX9LW_ELW=G&N&?KH%@\CY?HR+C2Z6*30DR%F/2XF 7KK'QHVO06
MLC64W0\[5B(\BXA7Y:&,OVWW\8"FT?8"+J1.<5:7LA=/8!8=*H]D'9=8B2=S
M2JYKA\16C1Y[GM2V]R&.%8P4(O4'[A<A)X,N_N67?XR[W291NT5%_YT.;ZT^
M9+<9GU,SV.JCGB9??O'%C+9ZI&BKV=_Z$$]+]NV'GY]I-W*THS^^2JU?KA1G
M)WDZ[4\=,W$BP NF1SDNEA-RE)Q'797[T0G>:VBS:<?'WHOHA41OL Z4*?P+
MV=5C*+M"QDO%P>AFK0X2ZN@02Z:U/5 P+/3:V[AAG^!&<LCZ0?<<2]L1DXVA
M7WR'+[]@#Z F;ACUH2 B,N4]746ODDA_=4S<,1V_+D\5_3J@&*(+^O2K>-XP
ML%W\5ODSA]79:RH1SYG/LJF5U&09'SMS5(S:;9H990_-'/Z=AHP39"O51BE)
M5BSJ7?+U^+GYA9^9LOB5%W9VQV>/W@ .[U*D>:"C1^R=\A!\Z-+3TC*-AR:>
MUMZ?N#TT$;WX&0>F)$5" Z(/S!-E<;(X!!;8!X*='Y*G$._E>-;55W O\4R-
M(G,@J-UUCDL?JYW,@'!@U &%CR1/S'\&E0-G[#PJ!1NQ#^&U!&"^W\7^V\I<
M(Y?>N\>)LV*I@"RTJE3MA3B ]_D0(YT5;B.HFS9>DZ/:%.4D1B'N$XF^YXH#
MZS?5;MC)_E^%BFF+F_%8#9RA0BF,B6&V(^GCF(R^OXF6/+[F>/^F*FTSL@$2
MO"T2>F>2 7E,R?=;<O\%9QL+SW=U<HW3V1(2=W3\K$!^1'<!MNL-U8826H_O
MG^R; SCQ^8*73ZH*>(!$TW38QG%LVWI]M?BN]<%$(HC2-<3M(LCT<G*3'D,;
M\25F2T%I%^@URNPDMD@&!X_/(LHYQ@B;ZZC1L J@)[Y/,W-Q=DKNNXY3TW)\
MR*'K^(C61#1AO%?D.DC5UE"/&XKF>11Z_ *9KNU1)]EPGO*&4K#<:!5TA#Y[
M05+%M"]2[H-_Z/<@((8E> ;7Z[!.TC4TYYA@B0\O098TJ,VKN)_>",Y&_D,\
M[7.6'E8W*$F_*!7\(?,CR"[)-KT)]?ND(U^F_!QM8VED8$]$]]1$D4F =V^]
M8'VE_YIUM^0T0]*.4@95\OQY^\MNS=WCZ5EB8"KUDVC9(+XCM@ .4N!L,",!
M#HE,Z'F\Y;KT#22&O[Q7=\52<FO63I'/D)PO]YDHY25-);8,!<SO?SP%FII&
MI:\_>"EJ\",'@Z,O,>NR'A(".!?H@!R9Y-MDE+H$B8<TW9ZO%_WG5E#.G+=B
M98*<"I*;:.G%QF?+:$$V+<X#NVBV_I1SQ2%!E%F*'WE@Q@_V@G:IZ-8'E[[3
MYT8Q,S $.+/%[VR*DT^?KPB#X.U*-.X8L61%-<_61$ YUVS,,JMM(.67V<(_
M%@O_DP:/[*Y?K/[G3N&[='4IY2"!EJH5[6:XEK2S#NH6E50:K\ 85R@)G^*<
M>9!WXSZ%E4ZRW>)MZT>-.4WO=( 49_89A;OMVP->9RCVO(EG\KGYY5Y,2*N:
MJ);;__[CRV<<O\%!+QBI9#Y5)NJ6$WLM@^9C"N]:2R]8H>1$'7>=34&%1]TM
M3AJ\L%8DIZ!(@^_C1.JO'4(8?7BI.86;C27##H1QO+20+-L!@>Z6:@L._P9Y
M .X</(CUSDC>TK1UV40D?M:NZ@-[V&+R1ZU3(^+/<I55<N,N0S=B%\2I3YJ1
MS4W5M9(I9@@6T:A%NQ^$TW:<]-G(NQ1V[NDF0YHQ(P57@F_61W=,;72Z +^6
M<ZZ@^[U=H6M4N&@)YAVCB&;EG5$NS0/0-B*HJHFA:DSD0J7BQ2$N9M+IB"^,
M%?=(,["NKQ8:01(P?7I5,A*0!0VGDV<3C"N&6W<4];C2&Z/_/C.'QD-VTDA)
M4!+VA&VQ)FX2C;/8'P8,H.SBU'5"T7?H&#WM^L<D6XX.?\QF\O:GWZZUZQM/
M8'*4A$W_4/4;:ZE+/YW=\4=B[']H(/T=MP@5\W)#<X"A,<RJ:&]23E=:_A+<
M@MBL1QR2E#D963-J-G2N]"ZN.J3]8!X%*L4)D*ZZ;H&<M=AWU57P^*6MX>C;
M.=O;AO3%L^!5:I]Y8'__SDBVEMS*8J=@--ZO*3?0MRNF/4)E%9O#C2$/I$DQ
MST!G2'L\_?;C>^#W=]Q^QC/]G*08J(?N.P7H_.08TN*,O13[^-R.X$\73#S
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M_Y^]-VURV\BV1?\*X\;Q"RD"JK8DV_+P22T/1_=Z4$CNTW'CQ?L DLDJM$B
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M&1PB<8K N1(UV0P@OS5NZ)V+45R4W8+ COBH(SXS92)N \<RET)OY-#6GCK
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M;T-DO"YI]U<K1QD[!K=F6+!*\A",C,5GMT[M%V.>&,Y&?.H;P]Q%_\MUT;V
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MF:8CLF47G?3A"CA8>\Y&^>8><<:Z>+9XT2^[0VDLAMNM9F5*9\U-V$YZY^N
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M#0E6?#JDO,G1"592E]0GB$]?&"^V1VE8 $F29C$9G,:!#2D)OFH7E%([A2A
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MB5S%2E5\-JT5VA?PSO1/ UKO[T.WK_ +</UN-MI'\MIB3CCKI/3D$)X^&O/
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MOP26R5-U]BIDUD_&66A?&/1NN(F;WI*HU"1?R/@T>IF=G3*U,>B0R6UEEZ'
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MQ@<$"AAP8#H47CZ([F#MM+,..,9%VU)'48RBMG;L"89%HOXE\3I2+=Z?!MR
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M,$=G;F&@D(C1#\2[G N]J4WE' #7MEZXN]*MVD!.='@O3/*)]:[KBJLNPCS
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MWZ89$)Y?\&]C*;MD=[9X$1BN2_LN(Z[B60[;^%YN;[SPS\ TSIA /I0\)&%
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M,\(&W%>+4* 5]6L0\/)0-EAA XB&:?^NCR*?J<<KC(BU6#BBE:8_@'^N8_9
M&R7#CKFMF'C51+[3Y?JALY6$=22^!X.N+IIF/3B>'J-8Z$"Y_SM9$XE=C_V&
MKE,#:(;X,4[Z'@;<L%86HW%FTKR&QX78D_C=;@0M4P J,P#0Q-O-\3-RXBI%
M%N/*+,^&*X%"L[;J!!^+Q7@1XYVF-=,6MIF31#%3>0HE]+\V_;:0YX"!>B+:
MOZ"ESN$6QI]K5ML$Q6--Z<#*;%,U#E+*$.-%=1L0R&ZP1.B\VD.CR7\>IK;>
M_K!7:YCUIDT7EI%=ZU&ZP7%R\JAK6:/497W\K6/>&C]0<&4<UF76N:C[W1(<
MI1M.6[I1BU%<'!>>)1U/<JF@%=BG#(;\)<,0>.=L5M&Z"_F')*HW(CB;[?/6
MV.?;AV[*L)^W<SF VS7K@ V5)F6<H;JBSAL;ZJ2=L@N=--0)'CX?\#V&=%;"
M9?&AQJYA]&*=9IMY?XXZY,HNPI8V]\2<#HD$B6HF4J'XUD!TC@?L+[NSR=UK
M2DU702HH_0&/76:;C#5YW[>K"^@8W/^Z>/#UY\677WSMWD5V:Z02R2X-U2>A
M6 Y_H#':N;WIO^Z???'-@LISB^_#*M K?GB_6#SX_,%#(G=G F>Y")B*'F1M
M]2>Y!OR1%.!((T_J>K49@?-*5)S;X>+B7U\&!#0DYVEBR_2PF&6]0R ,#;S#
MT;^G##3%MQN#01%HP[_$6$3Z>AT01.QY1CN^0HAJUWAS$O;:DVE4]CH[%ZYC
MVNB)])^M=1V#!#9P>0)D7UH>&_FQ"#?% _#SD7KK\>,)(2T&/G$>,'G/ R9?
MSP,FMT0$Z,^YMR_-[8[L>V0QR"9'G%WAR7)5]I/\O.V"6;F^O.I4#LX7WDO=
MCZ<:"'-4>6LM[[UG/<_ R]CY%C+4+RCY.4B+3]5U=?!Q>2196BE?Z:_9)+\/
M\6]4<2ROK&7VDOL<B<(JL:I1W\H;+92!B7N-:A-"*>1[6,4P%%$EX'W+73N0
MMNSVC&8;_I@74MP-27HA_N>NN0PBIZGR/;/UWQKK?[N[=:;-8:9H/WDEU-<Q
M>)+=) EH!.OH*,>HBJ% 8GD+@IK%!"FS=<UBN%<H6B2'MMD.EH$4![RYLL1H
M#5W[=K$I+^-5D6)3FDF.B4_=*5>7Z6T//;H=CV+ZU-1&?[PBL=!X#[NJW\FF
ML.&,L&HEK-:JOUOODEXA4V"UF%138VEDJQGR29>!7H"2,97'08J 4T['\ 7#
M2I='Z^.S</2K][(\@UN&U*48Z<RJB8#2#(\=$E<D ;W?@UC/3DIYF%VHD_XZ
MA')72(;B'A;5.-N>.\F9R2!!?B.'I=4"=W(2*W])D^JC"=O4@0>W<_I<8B(?
M'^AY4AFKS[N1N\33F]GU__) -9UDH:72=XI1 <@DNEG0HIXN/$JNR6\0)VM<
MA:\T2BYV;%E:I 1P(E")80:,SZ9H(Z,D!TB"@BRI"&GN5"B%825[8GD:WJ77
M+()(M)<Q>>NO1_3,)C>;G)&U63 4OU6'-@5EV?:[*FO=S9,%$@AC-K'9Q%Z!
M!!<M!8I,UY<$QHW;)B+@%I7X5CH@@YB/&%";#O@*!CV6->FXT@:*5"=+/JB+
MCD"/40.8@&@4>=)I8C[;Z6RGKW*%5Q>-("_01!DQL-ED9I/)34;K&6,)<?SL
MJJT.@+"C,H*?S?8SVX\&_!KF3R6-&$0@IM)XUDUHV["V)G'\99]O@0E,R!&<
MB1CV79"9!AFBB DN/://O]LW0-\M]M5V2Y_<_TZJC_3;JZ9E?!GZT,&-\#17
M,5;$'#1GRTF[ZZ+IH);))<46Q44>%*@N 6J0.A*!+)U$A([U7 :!],758IK,
MLJK&]NYYXG!>3&DQ23#)^;-B9*5F[2 3T=*VH>QBTG/5W",8L<GF7#8V%SO8
M_3M9$$N2D*X.6UY0*SI.LRAWT-EF]N& <1>69/?51BWV7E>]!["6BO?S&.0G
MUMQ)8Y!:TK\*5!%,!L ='NU(%OJ%<_RL9C_(/0MO4B]DP.O!YP_5B+__Z<G/
MN@,(.IP\;W-1+2$150IK/R+=(AKO>: RN:K,5RV@9]6V,M!_V77-JA*MT*MX
MWOM??D84M$UKXQ'#D3X/.8NK"O_'&P=J!@6HAD[J\VA&"?8_'FU9 =)M5Z4G
MX"121BKXY&T(-.K1"3@!WU[+\I(!36TYI>*&X ?Q&&2G6N=[VEO<8['HZZU!
M8JG%EFZ*%WK5I?VMJKF?U:W::AG64H>9V[JW9N6_=U##;Z_1U<U6-$M4"O9U
M\23N+X1,?7*!&DM[5,.E\0N&9 K<H>ID;&&U[3MT5..RZG=<@4D87:!0MT16
MPJ(URW"XHH%KQ_Z001U\V,FIT? [LGA&M&G*U#!>_*M?,Z B799=!'F$Q'YG
MT6#T36@>"J<*NY:PVV^;8PC=O)INS6IZ!\#S&RX5OT RGZQ[B23D#$0 *HV;
M_8Q3VP8C6@$::!NW%CAO72O%ZRZY.TW<_*O-Q,_63>"I<$J"_M6W5;=F]!R?
M:!/608B#"%:'1=8>%/BP^%X_]F=,>'2Z&/I%-WF!=]4I=,V6<<]CWH&NQ>;^
M#\=]T'%!:)]B(_]V<>?^70(*Q"NN+OF1E3:&GKX)QH6>\!V,:UF&BW*[*19W
M'O#/Y3<83&PY8T13MMKA?("O C>"W'-3K?OH+/ 0>["$77&LA$,,>V;)1Q3)
M-RQ&H ;>2I1F,_-T=QZ^XB(QU4;4"'W;]1C,0990'U/XYL,UHC:C$Z?HA#['
M=#\NR1N$#+&]CNW%P]_YXEU<,!X$D)T4K;XJE:&7RDOQ3EQA],9BPA1H()5$
M6 1!1]D3%)K13R+8/5Y!_/^[.,PP "8A XQGQ#"UK%J(P:S FQ" ^HDVO+IH
M!%S#9IMN@. RU+#?[WF\F'2*S!#C!Z&./R(V!S8F:!3I7@4^B$.ZCA<)ROIX
M)6.D/_PAJ*G'JP/SU1T5344/&4N(7[$N:%F5PG^B"\Z_[^'>-0/HWS. _IL9
M0/^) NCG&.Q=W"UYV6%PD+PLG'HVAL4C^/+5DZUVV?I=*,9JM49)>?DM\&SV
M#KV4M4QR8=:@K-G!9END@JRE/^,/9>F[2T'R:Z!D9)"",$;T@#GT=><RE;=/
M38;AAT>7)_@N(\Y46<_XC5PF-G8V^MO@="9>)N<[6SQ.L>WV2#%J*>$E/700
M6E0RFC>]M\(\F)OJ-6'*#&.J:NS)\=MXJ!C6JV4GI@_P1FH)7:@PMB,\[@HB
MIVE<D^DQK%JU-KG?9GM)Q1GB?;!"T*G9##+8UR'/*L:XCNAGRE> Z,DHM.=\
M]-;XPO=>W?DGUW&C$]I%6PJJ4,BT*3)0 D.)9KT"OS%AS[6!(*ZP#3'' ==Z
M= C;I@, /8/.N,4#SSAQ(I; !E@5[OED[I3RX_) Q,?PUM0P5,**C_]"9X-]
M%W?[3YD)YQZK=H$G35-[PC%C6X>-^O=!^I-G/9O%_6\>?D%)GB9V=_ #.97_
MLAS];B&SWWWG+PY5!M[JM9+3@6"(0=GACWA^,E-BL*T[WEC2 G$<HYCBB/N<
MWCH-@5R4:UMDJL2MA']NE37+K7 *VO%>_/ D.Z8LVOB2UL3#=\']E#100KOG
M*U>;C7IHELTT0X1TJS6W)XH83%_0)D+S]."H>MUSX=7(QB23*I:*RW?% PBU
M@[)BCE .Y)5@&6R1@U'T)_2*,S?-[?$@'V++$X5>-!)6%=2?C3N!=B ,5%$)
MMNPN%D3*&A!8ZXQ5 T5?COUXWFJVGEMC/6^;/ :;!?.*6%67&T@;V#7#@?/$
M72C;FCO%%9'I%R9/ Y,Y;YNKPX7-/!BG;0R\]_M&\$_1ZN#.S-YB[N,]H<HY
MH#4;D$-0NJ%GFZ3JB)[N2!X0A?,N_A=G2$C1TJ]3\7PV[5MKVN_=,<8-6[AG
M3++\-33-"U.+B'_OZU2%&/TN"Z#W^)5?$;*'&Y?28.NF0"P7Z%&>KYEB[G99
MZ]L[XIO$=VD,?;/MF9M=&B#.A-=J=NS$)VU<C5=MTZ)'-<^SQ<\0Y2$23/GQ
MJA&Z*>)A'Z,*OM%0->$=:(CYBJ(3[KB,7ZB=L[#]R'JSTCCF@?A+P1MYDD?N
M'=)CYMO;5[53YK8,JK*U2N/JUQ \9@L0.PIF1Q6<=(T_N:K/XPM&(;93V&XK
M<&).>;P/(9VC^H ^*GD1/ASE&#<ZW0JY4Y?>5KP1+H6"+%/XQM2SL:DTA"1A
M8M,6E<=UV.GPSO0SH!Q-"W5XDGU;7\OHBU>2.[29,/,6>K,/D91(7MK76BE#
M+_F<2 ZZ?@7MA4VOY=YH9UL \WEY:Q:S%KJ7!*1X E]0+?NYKGN[[.GM=\?L
MS:+&TFR!UQ1LR-+16A^N&E]B)=>$48>JZ3NP#E/='V/_.,PZ[%$5JP]>F$*,
MT\0YQ?BHN@,<P=:0[#>V1:T=JXWC6@E] Q14^1(,7$U]3AM8?+J<BX4U;Q'L
MZ]%0V1[SO\\6_HE8^#,;V3'6%3)>-L08Z$$,EN?!IZS(,]@;*.S/P:@RAH&8
MIW#>A5VQL;CF>K:SLN-DD]&8GR&$3\H#Q][8?'\Z1O?S+&.=[[@O+RP%E&8P
M'* 39M=R=4'R.I-.DN%E0S>IH23/]W I2(W^YKZ6VW:L/4"NF[4)MA1,7UTT
MN'<Y* '<-FVYLT(811SI3/#W-( T3XK.R\I8B@ ^E'"CKRM(%"QH^J1LUZ12
M2QEI5[!S7J,!%O^[@72N@#ZJFG0-F'<Z+K3XGN<)RMG(,J8.BPGZ^F7=7-6&
M?E4CZFLI8-=.($TU5H1CL.,"@M-,4>V1$W#.-0G4//CX28293P]()_9-Q^R$
M-JPT%D]28WXUL@]'*U"ZX2&%88+S'<AV=6 B+J>VWRL4G3#C]N^-20A TP7'
MW#4X5@_LWVFY'-"UNJNBQR159ES4*SPOELK,N/Y7 8P_^'P&C'^B@/$/M>UR
MF%8HTL>C4$=AIRZ]VI55;:UR<UNDB(L-]:+:6U?"_>J5R=)8EE/P&#,IJQ@G
M[ZLU9:\1>9YK2'_.JOO4[?\D:G3/J^[EXD>63/SX#V-^V1]PD-TYF1ZRRL)M
M5$,TR<0R*>Y:E6U[C.G$%0(I!AZ4?V#*+F8+@S]*X\;I2]!DQPRFOV46]G9W
M^WA<-TJ$K-9,F?%'A;F,N-W\U_UO'IY]N=B!I5T4'&6F$J;T7_<_S__X)-Y@
MM*>Z*F4>^I46>4<0R[_^]G.G2.5%"34N;1\R+%\!:M%Z95H%RJ%GBW^0Q(0R
MM#S\^@%=6/KWP[3)KH,(O+9,Y2Z*\I[IA2]Z6U[9A$X:IR$QB_.&$@_%62<V
M$\9;%PKEIODAMT@[!@C@10HR&S?L9H?<7[! @2-&1!#/=H=':KH$!T@KN+M+
MY Z;31<.?(*F.]PS40$\(EW6M);#^FSQ.'M:$S=B]^'),!2<3LCF<QK4E<;6
MEY^S4%P,DN*)B1=?I0WN+(^LM'X7.1VN4= -Z93Q&XH2S\;1"/E1,OO,/1(<
M9DJ:L\4+&M1*WHEN,J6SX8]]U5HE#\QIK9<8B8]^8(7+@(J+^%+Z84*R)_GY
M]:(+EV3\P\<%D.-@W7SYE5L:M%@>?7GVP"\6N109%Z%K1MM<'#I#-/QJ<XMK
MW[? 6[)$\%Z9WQCBDM?,^:$( T[M)[F&]Z#S,=29LGN^[A=#1;=USY,Q_;*+
M[QC-U_CES<% _4-6NSN=:#]S*$Y#]/T!PA8)H4-Y_]VSVY/HSQO?GW3CRS0_
M!OF=0IIH.2:/FDJUH[N/0%BV0BM&'\5O*+O=U2")6_(*J3#EH^B$?B_$'.QE
M!S+)^>F&$VPV#(,BKSC0>#M7%Z$NN"-&0S()7B?G0(B'9G1%XB3Y'<FS$"B$
M/I(Y^/M$UL /EX'&'4%[)\6)N&O%[\A:L+E?F9#4&$R3C#)IQ;L]U59."F?R
M&"8?^66$IU.=Y^*&<)@"L4@#*QO(-$P/]RY>Q.U_6[:C$1Q.#[4Q0K.BX&UD
M)(DQ2U5(5JM^U_,:3C].UTZ;*K-Y\9$6+?)N6N&RX?DV#&^,HIQ:0L2DH\%\
MNKS:RY_@B15I5MTU?=#QX4I0#^&_JJ/@F9XP/T&)%?2WZEWZ.@N<Q8F)+TG^
MR?>;YI5]:U;V>R\</'%!&Z\/Z;P(4!ISG]3NX6UH% E^3=W1.I"S3=T:FWI[
M?&;;0_QY#;R-,H7^X^S%F28FA?A,F,*V644S2'Y&6"@(XU@3W6&T(Y:$!&PS
MGCXF?LP/ZI"?DE)LH>"]96(S:UW6-A;Q]/D+D[*FZ_D=3K./'OC[ $P0B38N
M3BW^!E:-K&N$9J*Y5A*:IA^@G!=#*N))+= ^/?(VH-E2&KO>E5J,D#^1/&;U
M,O FE=2R&I97SQ.M>+*#HS&0.!#M?HOX* 8D(M:21DYV%!#B[=$G1A=.)*Z=
M^8-"]S(&$F#S[6D(6ZL(H29I$.K#QEWSO#0T:]?C8[_/IWR\3$ &S05'"-^4
MMM)O43(GP9S3@ZQSJ*5S%10$3"=I20X7FN5UW//_P],5\5V>L[T>!W$'Z[&?
M&,S9XEG;:(KM9L"["YZ&B,\)-\D>E"*'=8Q&\(WX),MVK?* *94@0L1_TY3/
MQ#F-K,\[6@D>4O:,#]%4;I)^ZBS:>VL]\8=C0)&*GI1.P*$^H)F &] E%$IB
M@-9J5-FMRW_'Q=<)T;( ,&!K14YH\.\>U2BBBBXT#XZ+-7J=Q)W 8% M[1D%
MMY -$O&")U@Y6_PV%/:0<4URG,16!4!G=#V'(&H@T8%CH3-7558[W+AA 2:;
M;[/>!GGF[/0?WYCFQ?*NPI:??GVZ>!;C@(JFY7B0$"GGOYJ6-A63(J >0'.5
MM/\\X7B^PV=C['&ST25 Z^(M5MWHPDAK#ZDBK4MM=C!%"05F!;A$ )JRTZ5R
M*DV72'7^L]$[5NJNO2P)FMYTE+Q)(24FOQ=A*Y2O&*_!<'^/\.^\;?H]LW *
M!Z=<1W6CIZ(<<DPSA[5^X"F?Z$Q\7>O5WB,30+X84#>1 [A3W1W8P(0>C"#1
MF%$MU>H<^=N=*AY+_\TB:*!]6RJG<1"="I[W%/\T<3:$!>0\E\?QT]%#BF>,
MIY0-/E'QX 0@ZZ/\'W\A%@8[Y-0=S+[N$_%U_PRZ\8XP%PT=EM]-\X4P8>:G
M%HY-%,=X?3-?'I-93IOY-09N[-VZ/%]MY8O'J^@WX!(P^7QL>JMM3D84MZ?1
M-"-*WS.B]/Z,*)T1I6^C*_?&N8>;-'YE7./COR'#!M%!"+EKN?A?IV'6_TK,
M<1=E*[&P5I8(%-*)T"N?(O4*EW85ZV%(QAN-:[NXT-9S9$(2B$L3#-N8HX[;
M8_D?!*68Z".3(D2^W>_;&+17^W(@ V>[LVO1&QU,M.7X (CUF"K*QIE#RVJ'
M$174Y_IE8K$^$0PE@2M1KYNM\M98Y7M"-C9O88N%C2F?GZ.B>PB%X/=7S%J-
M@NQZ)*^\81VA4LK14R)V&/U%T["'+VGG.)?Z/@E[F%BB-GS?VQ*AVM]5B+\%
MU5\V&L:LW2P2<K;XL<&3+M%(+'2?X :/WNEQ\IZNM*#^JGN8+E/0M3A12M0A
M6!N.1LBZ9ENM33FE*[<, -CRV4XDN>1%0L6%Z:,JVC\1M":D3E904?ZD&)6S
M# _OU&7MA5B5M"F:56AW$B"HAI![ <1-'[IJ)B^\11[J Q(HA3^,4C-- 6^Y
M@<6<F5;O\OK$_ANGJ)MZ!&USVFJ:*?1OG^6]=9V(J(_:@?@3&+'1KG?)R679
M@E(I,Z1MW/FV/)A6$\%U7R;)PD+:HL;AC9UCC;9K1XY2._@L768:6+*O4GVF
MI GVODW4W$GSP<P\;KP]UX@%RQZOMK#+S05"&A&#DAX4[6X]<A/:TE?Q5<2[
M;G6RN)1Z5UR8H>[H/VU! $U0YSH?I&=,?[ $[PJM\7. WY58+^$)=#51_I8@
MJ%<W7>D*,QOAQ%(^%QO0SM;Q&,&+-MD]>:]&(RDGK;M^MTO,6R<$ @K MTO$
MG0P]3!53T D/,PKIHP9]>12&P31;WFE\XM%_V:,44]J7W:$8R22B)1Z8#R':
MA!"OQZLZ$7I95B@#7M1Q19X?70J?M/@DD>6-GRC7$?$9'B$Q9.IL9Q?2<?31
M2Q@X>(04()EV_-JISQ09\R+S\+ NBXM95)B%0 'Q^1^N'=_7ET \RJ\-SYPU
M6>8-Y2E'U]$T"(,.EX]1&K3]6M3AV\R$"2+$L.-S2$F3LM3AL WLK9W3@%=E
M&/)*TQM?AP*EO<L+%C&M"D2GNBYW)0%OXP('_2A[Z@&SRM\HS@<@EQH7B+_A
M3(,T#!D$G#Q_VV!/C,[F5R1^M(^!776%-:^[&&TOIUOE&^Z-%//3G8@^13Q(
M$G,:Y>6M=D($2ZNR+>NUIK/-NE_-L(9;M.(^8/+@XCDQ!*^QR9$1!2X&*&]L
M;TD[R0P4OXUF]-:90-EF,>>I@6#"X20R7(?+L 7/]GDA/Z'_Y*A'/]UQ.83T
M[\*6,,/[+  UOZ11T[/G3XK%/VJ*YTE4UT?:F7"<A$QBO03D;3'Y4+'ODP,7
MBQ]^_\?CY_^746DR_* GY;%>JA !K8H'L0XQ1EJ+:C+&8[@STM==N0EPWX:5
M!?.6PF8E%2IY_U@7;H-KJ<H6SOGA\@@II0:$;=Z3/! "1)T0B5MD&L=J"(;?
M(F"*\>DR; 4G9$]-KK-:<PI5KN/F2$7)X6%V5;<-S,A]):(>"]91-.VFA%"E
MF4O!P6)">,)GF(BOV]GC>RCD2*1J!**G&#@>&.%[X,&U! 5.6UJT!5B&:"6V
MQ*Y2YSPF')X:2(CSDI ('FE3M)CVA+:*>-7EE20ZZHPJ$V\4M'V':*T;NZTN
MV9GF:=%88JQQSG:)_'#4Q[8AFCAHJE;59;5UCP]9X?[BV%4,D8]V353L):>J
M$JPT1--)83Y!K=[0JE=M!;/TIU>H?!LNFU7IGY9%.YS[8MXIKD@>#N$H/N'!
M$Y.F($D4F$W[AHTG\A^+1)J3K@-&VE*+D_:9R]!.;D^G\)61N31 3W 0W(D\
M/OZ!A6;YHSH]R\=W^_.V]H&BH[^3GGU!_-\]C\\Y CL:&=!*PRF-I^;@#;SS
M#MM.%ZB]3?6%]&W-(A0(Y:L>690UF' 8>,7"&O>N!6H[T?8H7FZBTM2EY&F8
M,\SDXK?(Y-_N;G\;-=0N<=S3]I@C3SBRB[Z?<$U0+RGH/[$N<O[&5A-1!O%'
MN^]!]W%9M3T13]@G%^7J9>"!)^3&J,6NFO7_S]Z;-[>-9/N"?\^W0-1SW6N_
M@'A%4JL]]T6H)+E*W2Y;5Y*[HF9BPI$$DB+*(,#"(IG]Z><LF8D$"4JT18E;
M=D1'61* W$Z>_?P."'W=#MF#KZ89>_?BOA0Y"@ *#_:UIE+FI%TE(/=WTOY.
M+K,[ZI-4%/!QK*9-1P,L2@CH;K'_<Z>J/+-_L8-^WC0C%YIRZX+L+XM!FA&J
MAB#I[^,[9<:6NL@+6D!!$XURN'V@,N'/,:4VEDD45%8XA1XS$N2*DU@=IRO^
M /(+Z[^8>6B;/C/,AWM=ZQW/L0Y+N-S#K<D][+C<0Y=[^(0U1PDP7[2K@!/)
M.X[-4<(=L)[<X/%R+ E,3<5/R6A220JL^3!L'(J0V%(?)FLI-((OMG,BQE=0
M9 !Y5B4>8JGRP97*77\8FXX]\)7)BE&%<:V*12V !9/>(3'[4OFI)C-%5*DI
M)Y.C,\LV%4C;(G. +4D<7X,\P!=0:4I2<B,K2\7NF&G9'K8V-H!9Q!@U,;IE
M?X8>F2M8Y.9O9E1=*NO1+HRL"* @%6H2=(RL B:\(.YD0"DU=VD4VFKMA!X*
M"U5U/M^H=QIGIX*@JD,YY]QW>JQT Y./9)7T:J+P+54!C4 <C8Z4\X=B)3IY
MW6"6XOF-,@S'>2SUK3[0?7HIX.XYE,_4QQZB%-]BQP>\R?Y^:V>M: &'Q8QJ
M[5?U! 6KZJ9:UBC(J&VC6J LY'Z9J4;5Y.TR*4Y4XI"A8T(!A.DC;C30M;D9
M8 (8EUA7 T8J/(+[AF3N5/*-8<O* 1]@$G90*-<67NC*6.1\.,WWYDN"X,2Z
M$+OUHG,IEZ;1^_.KC//;UQ1F[KR[(A/CJK*#T4[Y1=NHGRH;M7( JS=/48IP
M0W;3N$#_%</7"4SJ#'?M6K.G#XC4>#KN,03DY.\,%[MBN(G?"2("C9=+?0@7
M%H.^-%5 _(U)*(3;$I@1]HW0R,\H'9F;#M'EM!,CS["*B;P\&,@A=9</:(YF
M0F298;$F\1HE,!M];MPG"@^^%O?4W2 4;R(,ZVDLB^49% 8_$L\XRFM8Q;@-
M*A^F/W$=&"Q$FU"ASGRQLA&40)J6KWXM!P/!*'4C I9W6EHGRDE-*4'Z/(:*
M,AK%0D,DEM WM2-1O\)","3D2/-+V_:VM)C D-5_5:E*A K"5:"JOE81'M;8
MYAP]B.X(H;3*O&'@%(8RA3\&8\;BR&U/E%*Q8ITT2TU&J(9#!R.JD L]JS_5
M1)).6*V,L'IVE^F?JF22HEBFA1UR)+AW&/_S_BK#6U6GU$-G?RWMPY'*RI#*
MTU9[_7!R/,,7I>R=LR!<"9W)#NVVO-]3+JROY_.I])9:7HS":E;5<?TRT3R3
M :50OZ[@HD!-F,@)-%"]/-9$F;&J >%Z9F5EF=1$LCE4&5^):8_HX5.9GR)I
M6M5)+15O FY8[9%)"-205TV;UO1M.PQFI8+&IH=W$&$.D8GS41,S0B,H[A%L
M:NJ;K)<J[%V>$V(/ I75 ^Z^J<Y06 RIZARH_ @)AVTI %GHS!/#)2CFB377
MQE8V?@@.:).99]4.UN=(R*BU#:,#IJS; )M93QUQ=:B4!&G.&[:YPK#6&VYG
M'U#CML(8XP2<42T#IT_L3DXUZM*_MY@@?C8EF"LCPU^2"R[5[U9;'$TJHHK\
MMSO'K>/#]L_&44P][HY;NP>'/T].9'&;X$7A?_]4)IA&@,!R7^!Z]OM?5 ?V
M?#5:>5Q@<*#]2\O[_/'J_/K3AZ<H[ N>VK_.S[SKFY/W[[W33[__?O[QYGHF
M'2_]J%>!WC=-Y'],$U=XYM:WGNM;.D<BX8,=6+^T@R^![8Q:)<$#.O/IG[^<
M7UV?GWZ^NKCY<SLUE4WCW']@,7F&)A1F.XJ^O"T)C:FDW%*P3="!B&X>'[U<
MX3THR$H'QH@X^N(2L!S2["O']L+H%KT$53(&)VZ0DDT>+X-+\F@I'\5IR OE
M<_"'G..^4MAI& 3 Y3AF48O_^)4+W;<#02K>HKV(ED.0NZ'0M9.<BR@9786,
MGBBO!>>TG\_^G54+IE-K\"VSA5-5:0Q0K#W=9,C*V[$*N46(]!:J-DMWLD+;
MEJ$VAF1.!=^W"7OMT&ZD DC:@KY:JDK\XD0>.B"[H;"5Z$+ P9F"F>7DM@&E
M[\ZS4(H+UIOJ3,'E)KI8T!P2A=RXZ2S]DZQZAJ17J6X&[4"-H\-NY'4DTUO%
MG,$<A1,\*;B($:.S8D0IY+D!%C";)NB $TJQIBU*P9),,TZB%5RNN4.%1;.6
MK;M07=R8'E0*V5?!-Q"DX6N<J7KR=S7>M3)I+RDI6V95#RN5?)72KH$9KA)Z
M3P>1['OO39KS)[9:J[5.%&Q^]W)#1(,F&_?B!M8HAKJ\#R@PE@9!6W<1Y(7
M^%,;K>L5'RLEK6;&60,(<(F@QE$^K+7N-?M-73A-.-SN@=5T#32*@@W?3.2"
M 6C%C7R31&8RL8QO'U$]E$,G\^[*&)==6?$<%E!Y#IP*4 .QF-J5F=M1Y3OG
M:;^XISJ )#0LE@K!$C@G6CWP#.XN;R(0?(BZ>$+$,N.B"A5\IO0*N'.W*3Y"
M+2B8/RCHW.^8I^H G:B,=73L9U6R'KETN%I AZVF&MNK2==RXN&H1C#LA!<.
MA./ JJ35<-E<HZU\7@8Q6^7(RHRYBS"3ZXD\RA5+1.0_+AJDY=,>:0YI-HRN
M!UW=6AR0F&8MN26U&K.:KCL#]*#EVIF6A(I(39<$5=7,9=$&SI1"E'0P,KF+
MLC2A$H1M43I<!N$+9Q!V70:ARR!\8O;X#%T$%08,5X\HP8YO+C>FJ!28<X.G
M95ZBTF]LK)E'F,Y& %*:1]>Y\DQ5HX%=,[-72=T*P 08[RS]2RL[+,]RU(&4
MT!&H K#@P3S SBXWZD"=U&IW:.8X0U,D<5R;I8;3T@H?(E9'_8C[9/X>!5F*
M^H!W:GY]K73?\^06074S!7S?**MA^J%I:((F4$0E["-<=9X^<E(3*AZF"38K
M!*2FY(O9%V]R8[Z;,&:HF0VTH39NSF7J;4+R^44#%)]58,%_<$P+J:@^&(C_
M.-7=;Y1V:>7B,)GJE,Z^P.(&%=8B^Y""5+%'TF)$%:ND)5@8:OU,#"5:W,:4
MC@6H.?THQS19/([*;L0*.*7O(#%9=N#7)+U/)K9)Z3*VSC-1UHN&#<PJG5AS
MI3;[O#0:7*?A6.5$!%""P#QJ[0:Q7>NJ37<:OTA5BQDV%OJWKL7EQF>BAW$Z
MTPQG:DQ,+/!.JK:D-D6FDQN@>(B:6T0X04&9YQP"Q!8!WH7OL3OLQ-?6G9VN
M9'KZEAI]WQNHPEKUM"LLX\(RM5';JO)N[$)O&AFF:@@# BC6E=@:HDHAME,^
MI&]$2XX*)7%_RM3#9()I-@K7%&]6J;K+*3"MRC. V$?&'T9\"Z[*OZ5OO&5,
MO\H,U/X"CLDKF8'+.0%>6*#UQE.U7"1T$2GY,(>%/8 NSPNC=E[LKF#T&/;R
M\';A767W3[/T:I@)-1&#FY@;X[<<<0+Y%&N;-,LM:6SK))IQL&F*G((R'0TN
MFB6'T%O$L^+YDZ? 3$A/A-Z<0  M&E8R@Q>C95\ ;8B<D3&3!,'DR,3?DC;/
M/V#:'$TLZS^Q&7@OB_[3ST628\%DU%^=\,?JQ'96)Q#86:' 7P=!'CY=GE_=
M7)R[M(XU"PXNF"!FVN*7A$*#7O+E[XT[^T6Y?*J,6C1B_B[! -)YL&"H7,.4
MSB)YF_H>"AC0+9)(4#M1^/N])*DMN0;S6X2&&>A';?]@KXN@?P55,>;X33"W
MI.0\7_(.>;085BWX&YR'%ZCF$Z E$69[6V&V:ZLFRJ0)-)))' K3O*U[!-8X
MHOAX8"1+;):&013X74_"[G.#-3*]R/TY/8:*F:"/(^ 2T5HA)A8;4=26YXN*
M*"6X@U)$47(RT%!;59$DU:N(:P3C<67+2L;Y7H%(@+M%S\=!9SBM'!/=F..?
MOVKF$[6$<$>_>D>_^(M.3H!8%]1EY.)0$8" K67T=]PC<FT6R)C<ZC%;[M[U
MH$S&$0A<3-?"G*A?9/07Q; 1@@T?.A7)[;\':>E[O\F>C!CZC]!S\ F#G:M;
MDWAY5!#<G<!A#@[\_?UC+9"'TG@$>F44D_^R:B8]->4\^N:-# 4W#'6;8?U_
M/TY1PJH1VQV_LWM0'['UH%.?=H:+Y:DJGYSD1AUY8#^PX&?Y=.?NU0NQU \,
MBN]XZNJ=_3/PU)AA:SIMFP79E7XGE'?T$&.!=V.FF>H3OD=DRGB@.0=HV3Z!
M/[4[M=^;?*@PS881IVUQZ"2A,!*'1/A9@5"M:%2EV7AKF=+2O47&T]9=#;.
M/&U@97XX__7D _K;3L_/SRX^_NH<;EO%X!3>=H6=BP%\P7T../]P7*%;</,
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M(4&EVHNLWO+)C$Y <5?^ 2W#>1-0EU8]3&SL*=PMF61I'.NY=O:.J@7K>_[
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MH%]1$N8,X>9B9GLU',V4XIF?A@G<IOR139CUG%D5%1I@V PF@<M3_%,7WRH
M8-,F5=D4N=:*'MHY._#PR.8YY<'QE*>N]APM: X!ST;(QBKLD2XTU9F?,QZF
MJX'E-Q$BY_*%KHFZ1A^_D8K-;['DIF11)7RK.>7,0\I$Z$BS@NZMR4XG!#>$
M8!MY9Z001E2=MD(7Z47I#/06;I\G,XT%8F&#6*5H5-&PVVDU\^N(HZ91P9A;
M&@M*4J:5!<F@RR>PXI3A6U1M&OX75EHB#%6IRDH>Q(:H(1=@1 )L?OFFN5@C
M"F'QHAA$ 5S8>,B07+7"$8725M\@T'_#,BA4D9VU32E6L$FC\S9LAL[.A@M^
ML.M=#\KDJX U7:4B].G'<>2=43N!H/!U$H]/-6K+IUT'<KM)R<>'+OEXW7ON
M+E7&W!!,H/*JD*</N;,6'@_PP%_^,3LI<3+^!L]6&3HW.C[Q X.>7EZT/-L)
M5$&,/A(P>'"-&*"+.%V2YT=(!.@TL;PT9E[XI!I(VXPSGU?/J5<H\W<%1,#6
M&$XO=X<:24^9_*K.'M/4$ZX XRQ@+B-4YBX6\NJN+NC=# )LO13B/[!G$/DO
M07,*$#8N-S>+WOKUY.2RBAB3)X$2-ZIQR6U6?4CE('.OCZK/G'H0?A%*! X"
M98L;#^6PS=:$&4J59E1F\%>,F'!GO2I1A#\5RUL$R%##^;,OJ>KMQU-4>%R"
MHSV<TS2U;1J/M];>!XVQ'B4-ER.5R(=_-JVA'L[*:FB<P[Y'YB\"=+GH^WC/
M6^]U],;\Z;7>8)$1O,L$ YJ58=WXY3?H ,W9-Z3=,A4;4LN]2_F4TGMF1TVY
MEN]@BM8<!YI:J+O4F$&A*#F=(1ZFFPC-_"[N)GP;/@[T%1$4C,9DG\GC=54$
M326E8-GDHK[*,9*DZG4$ADOCUYNF5!<=M3V>\$7/$"2&O,.(L*2]H92J4Q26
M $3:AA%5%CX6 Y2V!T&_2O7Z0J%54CK[?9I]!;H/)#L6+ 0.F*T=Z<<"=RPB
MM8Z(KCJZ$49EH3T(MKO.ROKJBTBGQM\38@GY_3)=;@H\3D-5SC3Q-/>YN%38
M85.A]ZV4-L[KL: @O]7(C]#C5?;)(RI>@@*"ZZMM_QY)%@:O99,=GHTR6Y3L
MT "$$8]>NNJ"5"F1,$@:$Q;7#)1Y.TAU*;+"N[CP/>KN<#0/DK=6)%FTHA."
M\>XM](S'90*YZ1D.G67*"JB:[DXL2L-\,-FC2=.4W.BML-M1WJM&RM^1%L(P
MB%%2Z%AN9C2"%%%1'LSU<,@HFXU$P#Z 6U0*_D4JQ17C5\P"(W!%W*M$'D];
M+9R]:@M;I6R2TEKIT8_86^G#9>!:*!J:(MW3*KA5TAF;UIJ/OO'D-QEPJ0,Q
M*D6>K/$J>!5AIC#9_':J\OOA\O(Z*@M#85*F;M5(UT[NP<&N$?4%<WY,%V *
M<2!+5<TXFF<-*[<F:N+S*HIH H%L4Z+]+)OCG;7Z-]WCGN*-NJ^\=ZY7(+E;
M2FZV6<D>M)$EGG&J5V&JSJFM[DB,M5K$ -RJ+^][-.MM@0/S'*J"WUQ*;J32
M[M(ZVYUW+U A_CVL#B-@54\AP_J"2.9+M'NT!?O,*JH3Z:O!LY]=I#<4KKNC
M7XFC?W+[%P-0(!XL&GT2V ,'4"KX!?U,8P9-W87:!)F +BKJ$J_+ICEK#@V2
M'(WY272'EG?"KBY[4)-].R-1IR82[70;<M(1'FPFP>(1&M3%S(8$8#^F:ESD
MGTU+(%\V3 J[9J1A7CG<G;?,W>HG>\OB6.EXC)"J04XLU:H"-9Y-Q+=4!%8K
M*_\N4O:],HE1T:?PR7V42]U* <C<N\Q2BABE"6&RTKBLDY#;8BA" ZY>K0#4
M^"S #P$'"J0Q!BHD&%VU#'>:4*Y-R,>\";.]DYQNCUYYW"I:C+[>^,U[D664
M0UO+P6--GEUOK#$)PFA4JT  ?H:GT1KNU+04-FV-M>!N9;K=#,T;@V8T[QES
MYCQ >]*^F;$"YM%%V^SUF[U _[$E3&QXX^BU+ZZ >W%KN.7++/1CZO558P41
M:TJF.ZHD9]0,&#4+[,@N<H$[!18RM9ZLF$1/5ATY">M-#T_W!^QBY@7&5)X@
M8=O87 %J="+MA6R42^I^0I4*016ZOS:E7-ZESMQ^U!'IJ&.]6)0%\-0YU$ZX
M>UG'C&0_VP/4P)H,2CJBHY&A(QNNL>5-HOH\^,VJ?I#<BV&M@@#S0([:[8F"
M.F.86&5TJV,4N.3=9T[>/7+)NRYY]RF@8Q,%MRKCZDUEU-@LJ!SACW4F]%#Y
MKAT:F?S;'VJ &HY.#2W$#&NLB5?[K5W=VT]U-IH2XYCR(>MHH_,5##M?BE,M
M%I%E,8O0/<LE0=X&K(I-&FSF5WO^<1LH?==R93QRT50_G0B?G 0F[G95.&ZN
M+U&A5O5GQL^N5?H?'!RT#FST'E.D.P$?D%?^(5UUU6#EZ7L\8].TOS53+4!#
M4M'ZH!T9WVL5JHH2;'!8!=B"6.1YU(]40HL71RKCT=WUC;CK3=K!,UN8,QO\
M&"+\Q'EWZ.KZ!-1^%\E[=^2;P=[/N/(4.1GV'?8XI<,DH%1PP=1-+:3.J84'
M.@?QR5='^ZU]TYJ8(%FKOXN"-1'5;;'F]=7N+_S&<:=U7*E [Q5??6 V'6X-
MBP,A/OJ0<[9?[;6ZM:E8?Y]G*O2-3O6-EL=)MP_L11"40^P]+D/*O@FBHGE3
MR"-G_H$IB'<B)I:.CX,TVW]LT(X9-),JYQ#V![.*^!N'K;WI$?$/G?U6QWQ\
M^43M+NVSL&K,<$H335%7*CD:_EEQ[N7OC3O[%TQ624KICGQECGS1)WPM8C94
MZBGF&%,F^(;E[XP[^06E)W'U*Y7BT*U&HQJF"U\!-8D!.7--#0HFA!0 E7E*
MKT>!0AZQ^T(S%@=W4R)C%'4JW7H'%@UZ4Z;"Z3P Z$UA[9U:8:J-M*NG2JUB
M>%(M[QKCYK4/Y B"HN:,2IF:<EH6L2P(6U.G" _2G.#7;>02=(8%RD*."M,6
MH,)64= FD4/ 6[O[,#\G_! %,N$LCPN[=^BEZAVZ_)UQ)[^(U5[9+"6F0]=]
MP:;[Q48YU3;>JA+B@30%BURAI;@4%1  X\%29"K,5[2$=?I8'Z;<=SJ77/%$
MYVASU/P"2OPG4^MZ_FV$9+D"2MW64/GRRFGR@BUXXG;+WPAWW1?CGN%CU7HQ
M)NHS?$4>Y>RH"=0CK&IG4B414Z4_Z^0V7C\]3L5+I191/>/'51A^^$O\&OD\
M8:A0(<2<UD:JK E[-IB8DXG["L&6QE.H*'DA^GTU X+"X?'0]2B'HS@=2\F/
MPK,A+B2(..6:_,-#S%-4R(:$+J!R@K3LIKC?WV4T,AEL6&6=W%+L3B$9E#EG
M758CXWAW;[Q"?).Y0OK 2'MV2U/!OZ! QQQ)'EFMAW(#[F">PR@/0)$0B4Q+
ME:_-SSC38<WNX'<X423WED4B^)U:&39)VU68Z<9)Q*U?J$U[0T-[4M&>Q969
M11(O;WP%G3::X2M7BH5@RX"RQ->1K9OO&\%!YM0@55U( Q'*813@*V#[8 O0
M'$N0$4DL4VQU/$28*?$.!QVF*N/<?!?X<XK<7F.W\SP]"=-36+:)GB55>S O
MIPY,VL/S3N7(5S)F2D3I,A 1PZ\5O^_)1/8C)9$PRR_%#U?[Q*!N:LK\><?:
MU^PR?4\$Q +I.K- NIPMM:$+O9H%R\8\A!/5Z.PI<4HSP);W,4TRV2^3D!/8
MPCLJ/S-8#<A.;E,LZ\.6<9C[ DS1** SP>"XVC#2?75T)AB'YHG1D6N*=%@Y
M$E%H.;8U?@@KNYQ,9K\$*G2ID^\*]&W9"V/W.ZO5/&]\+)1Q=,<XWM8J\"^@
M=&--)!8KPI\0"C/VHH*[S'AQ2GTD\?NJA;M"[Y_>D?LHCK%PR8RT;=S5U04\
M<UW L:L+<'4!SR<AM)I<:9NI5D M-X6" MX)0!6GZ"/GY*H?)CH^V+IY@)F]
MB$.3ZSIJA3R#HB9+X]CNR2"S'.M)XQT]LE:P?2\60)&B2+%!=3D:Q5K_!;I'
M;"1X0H,FS19.AFFS]\9:3>T5\]L"74#P9>T-4E%AW+$R+A@K(B_JP5>0>VF@
M<D9A*_HBP"QE:B@WY1/B52-NWD"*T/E=UO+:S:^<_\IXWG3T)R$\A3D!C#+J
MU/,-7:A]YJ)^YL9Y8#DJT/]<0;/[WL6-S[#I_L3;OL5 (FYW'FO^9CL1C.LZ
M#;[N,!@ZXE_#P-H3;3G<557)1-\YX/[(T,%4T%  4]YN8/9]F><**$#-HB^1
MZ55B!9FN@H!/:DCVFBUKD/"[-SK3I>:<UOOE..2:W8WY.>0)]P8(/8,EOOR]
M<&>]B-5.GVS%_PP/FHSN41EIA<Q-"E7U/CE:P5@7,;$_1NLF:$ET4VAML^8
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M:W?<4;M;NQ5'N2FW]O71@=\]7.M2,B=V71:(RP)9@RR0S33O+[/T+LJC-/'
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M/O^F'Z?WRK2:VH< ^$:.VQ0H60,$]A73,^YA:!C3R\L^[@WZ*<QFPN"-$R=
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MB4P9?@[+H%#:79104HQ^\6\P*E&ER\<YDHA',7.1A=.OS\%['<UN&<T^0*=
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MD%>#D)^]!N,*J#LI)<B'( 7"0?:]/KOC5.YYZR\R3#I'_9E/&_0%Y&%92!%
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MJNNFY5%V)>X8H?U!,5JN>E&T6#U4*T,1R#5!F5BH=H26>ZR6=/)QGHM".Y]
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M=0<UA/NEV;UW\J\GL<K&F"F9] _NO014MCU3MM-[!;N?WV?Y%^6Z^6SJAMO
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M)UYHR0WZKN6''KBT 6ML9^KZ3!1UT0-&XG<#J8'_N-#$72#R7 N&:1XGUUK
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MP'5T;O=G*7NWDS1<PS2%[NG$I:X-LX?I$M?QP,,U;#L(3=W4Y4RP-BJY\1.
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M\U.%%[)(C^1)0+K-B6DZ!GBF\!>WJ!=&G$8A;X1FO1]KYS#4SI*3<J U-6-
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M+LO=YN=I\.O;-X._O3NI]UO:1M'2!D^"]=@JT55]W56)Q!-75!=JGE-Q5=:
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M!(79"W5 N$"X0+@X!(79"W5 N#AXN,#$@:\GQ2;E;4P9- D11$P6'#449/E
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M1>P,5Y'[(??K@7]$[G</]]-6^(I0@F4+(CL"WF@',BI;_I)2I8W<E>_F?CO
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MO=+P:WB_[3*6;J2S)FB<]ZH,"P:*L?K*(8+@03-HDAU5C&B(DC H\,C!>Z-
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M<T^V7^B]RR?(G601BS!S$R:\3+ P"23+<YFQR(7C3WD.JM26<]G/I Q4)EG
M%7 G(3G+@RAA;A*[>58DJ4B^&G?RDED<A[,DR9XC=_KY8A=S(@5Z55\J(J0^
M+KC!RD9!6$O+(U5\D#0$(^YB>+!E(#P1P/(OIU78/F*_!M+@"6RPQ]1>/=]2
M]W179;;ST&KWJ=3] :7NQ(UV7:U)KWB47B&>@5Y!N3@;63$C)>/4E( L*E(O
M\CD+,C\#)8"GC(<B8$JERN7"#=/ W50"/$^E&1HFD@=@IX2\8!QN HMB%7JQ
M*D0FW4TEP.[)&Z-@O;VI5-->E<MWJL%J=N Y/]R^ ]%9C=&3EFM,0C#P2<P?
M:@C^_8'G$U(,_GQ$G<3XZCKE%GZN,3%"P4]SRMJ]*M'^=G1_*2PR(4<?O(YD
MO&EF8X[:Y66C+DT"T:G1=)HGPE6YCRB%"0MC/V69*U/F94D41'Y>!,$6-/B7
MT/23*;;N+(R#67P'_/<)*[:;W&^76KI'S=VIR>Y.@ASJN&<[]=MOUG]_["K(
MKU0HV%(=7KN>6\"N?>1!Y*@MEOFMJ57H_HEN^O;D.%01RSB.0A\,;H$9%V[(
MTEP(EJ@BS/W8RU(OV\96"9&I%2P.8H^%"H1TZF.((\Y]7[A!D>1RW+R@DZQO
MB[WB]T>S4>>5?-/M&M[<=A+#3R"&3;(SQ74U0SUS/EXU]?KR:ASTK>T!F;=F
MX^3?.YFLN1(DV_G)T7Z4IE&>I@&#"Q"RL  ZSL,L8X'*92%2+Q%J.THG@]2/
M9,;R+ 6)[KH9RU)X&R&)><S=(DF#SZ?]+R3X>]O"QF<3Q6N*[_+H1[GS%V?.
M[\NZVE$%_A"RKDVC7T0V*(TG=NL[K?X020,2 3-J"6:UUMD)WHNT"'*>Q#&3
MD7)9&&#@)_$]YN:%YX&$2 *YE2,>AE[DAJYDB1>E"'%+^<$1BZ0;!UZ8\E#E
M)W,OXNC,G^[%G?=B@M:8\GJ^>*EO!I5".@>'PN?SFI C=N?K:#<E_GU9XS $
ME '*]'Q-#H!6B75#B#2S3OM&S41B5EQ3?X*+39\[-5Y:N"Y8[$'"O,(#7IJF
MH&GSB#.PY7/7]X2,I+_)2U4J_%2 (N)+#-9'BK,T3F,F>!ID41*DGLCV\M*W
MZU6[ F$#.ZE= 6^+@7?@4!PT#<[VXX&_+ YJR+GN]_TN!T5?"-<IV.J3R>]L
M!]E<PPO1568^!X(/4N6)*/&9)U(@>)\+EF8\9VX8N@7/X[3@6V"=(LUE+N%J
M)'X.!._)E*6@,3#/][@;Q+!-*CDRP?MGZ43O^^A]!Y636VU;CVZ?!0TGT@^B
M4'@L#7D,- Q$F09)P8(X2=PH\Q(_\Q[?O'Z' FPV"?5?^77HV@O.3LFW>V*$
M?0<C/Z-4?U!B"*X5@;S>-:I0#=9M:U=THQ;:/!R.^#!U2/L.6VP=,.HD38@Q
M>0WZ4.^5679T-*7$/W_5^7Q7BOL,'0A -PO,B3?Y83YHCX;0WE1( /CPNSG,
M=Q@"H:?PMZ-:)B+SI4$G& )57#AOEZ. QHAV^Q*.;EA="3.8&@[?J.6<8V$(
MA5/LARX;7N$3>A3NM.M\B2-@' ^Q>+ -!C;%*$4)N[X:8N_1Y2,$AK>+"NY(
M>\^2]SW7@S$A<AX68\,D<'G&VFA+."O>D(-F/G=0.C4(N&<"D1T6?+]/PR*@
M>[9J,JDGOO#E2_T)TSDT@,#>JC2\>_JVC=#&=C^L,5IY"V(&0\7ZY:&@VEEK
MT\FTW6]IO8\ NXSH[.?4:EZQKK@M/,YOMR7?),*>/:D"=R2TY!Z,U*#3[4<P
M;M0E5E VAJ)4BSCO97LU ')[?X$_^J[KGSGZ"SA^N3)0>/C,7CACQ*>#:6ML
M4XZ$"-P=_A=6L2Y YUTW1/$; *K<Q@-^^OC[^?O_<;Y;EDVA+*(>7[;KN7JU
M&U&OE+!4OKHJ!5S#.5PZ+":QV*CZ3E"^P<9V@$TDUR!GM&XYV)2Z*$I!-U\O
MW:+<P26-7>?#U;KZ@\,*WM=<SNB?MR5VVX9K)58S"Q$TPTV<[M>SOU](&QT6
M$\64D'H[)')+(S_\]WY(J,UZ 7BV3V'Y:!.T[OW$Q;LW9\[0V5O4\WE]@\_N
M\/"N[ILWYI;#J*CMF5EL/7W1/TU*(3YNO,%6L5W/5^17V/6%X3L$<39=AV_B
M.NS,QS&V"?)E9)4M90L2C"SO\82-IO[[V8<SYU)5"&>/00N!./SXEA#UNB+O
M[!*$!)@F<]5CHM);OYR?O]M D:7JP/Z[*],1T QDX-T:HE@#B=T_"+^0"N&]
M0:Y8V4(5\<-)?_CI JVLNM$S6S?P!"9P?( I#A2^4@\Y5Y<@7.QG9_LSF/2.
MF:DJC1;+=?:3+N?=VCZ\IR7"VUD3D$#DX)V<<-O62X,)@'_N@/WO@U+OQ"/*
MYKIIC0M$LQ4. JW<RW)V+NM[Y[OR5?>G[^Q&4XKO%O_9!W*W<^17Z(=IM3%K
M[4C0*OZI79YFN=>U/J7Z1L/7[8)M> U3A#E2>LW*9N%8M_^5I2'=YXDZ.-2$
M!DB_SFNN$>)U)+<>=5#8^ KN+7P)/@54AZN#FP6JF=5;3)Z"7:M.6>-;*_I#
MW2)-EIIH0"W;.=BN&8S%Q6B#[PX/=C0M2TENL852VD(A:,72ZFK<R2UU(<CB
M>FC_V%>O."$N:LAZ@A&\J9L_@-CA[I!9-,"?AUD.D^9AKNA\&9X$W7,T@I;K
ME;5_ADZ%05UQP4L+28AW! 9&[T37*008'&B !.V_5Y6UK.?-N_?_P1?+US]N
MH19/[H5)B'Y)CJN]L>8:2I-2?T\V=(7R0&-S#_T2)$AT[PIMIL"S0/L#R<'H
M P1FCMZ%_FITY?:C)KKBO@:Y/=_0_-RJ@UI,H@VEVXSIMC>@)+8/X._D(UQ=
M@7 U\F'2%Y\]J7^\+[MOE]ZH"%QEV!L&&P_0<P.:>U!"(%$F>M',LQJX5HOS
M<>[54Q_#%U0HIB^!OIX<>UX;YI<HSPD1UWFOFQ>\//CYJ?3[)99^9U/I]]<M
M_3YA9ONXU0,G%>N&#/FN=H^LM]Z0O,?;4-_=)\*JD1V')B-L@.AOE-6+O[_O
M!WTUZ&)$LMTP>VWZF4XUO)O"""IH.,X .N.._A,S= !U.'JZ'1)5?^M4PCOB
MA:0T_S>OUAB>B'8T.<#9C)HPO-K(2YRADJ] @<=Y*:W'<-V99_>Z8>\&@X]0
M:=0#0IQ4293?ZA"C7M^90[%1G"I5":.##I=@5H^.)(6D4-NI=CTH!&^OG"6_
MU?:#.<ABC7V)SYR?T?<U5.-T&A5I?JU2#C:'=[R %N/YK[\"VN_GZ!<8&=/+
MZOM?P%&(\IB8TZ>LV+X,R^G)-=L=*,K3H3]K"?MQ8-_VD/$=?NHNI,]'=8K1
MD;^^=XM]9J<X&#O_=Q ?^5G1Y]MA!^L$-;2_6_1+3:UA^LQ]'@1QDB/<1*18
MF'./94IP)E2 6/Z9B 3?S'I./3](_")D69AR%DJ9PCNQSR*9A+&?%9Z/Y2U/
MWAK&I#Z[GY/Y?+HM8LZ<\[Y!Y%:YR)Y\K6'OHU'6%44[<J4J(/M54W/;]*N[
M$:09%7,"1\9@WJYK1)% F!3,L:QEVX<MI[##)%P>$78 DM(:/\7"NQY) VV;
MHI_WD.\E002-\+T_BXAGP&[F:")2V/FF;!6Y;2G'ZLQYU]04::\QP]E\5^O6
MY"A><*GL5_L5@ '8"!P(Y)]0G1G9-S&ST,)PFZD->!<J[]Z$V5XK71F&@4W<
M*EJ,O=@XY@UO&DJ6'B5A:AM0ASFTB<JI4:I9Q1RY)'56LT;/UK3&P92.]XR8
M#.Y><VW2!&@=F'Q Z]BS!IT8.ES$K%N!Z3%GD99UQ&7_@F?W+6GC '9^?33B
ML4,[+X-I?IU5_E8[A9'H?&YIFFZKD9[E[JZ'N[@&1?0'E9EPNVKGIE[/Y8!=
MY,HZ'TQC9OMY)#STC&BNT#E+-HAWZ(DX-AU.8NUK&,J_EO]:E[)<W4ZG??S3
M?F0DQ63IW2HP6K6/MO,H]XUTAG%B;.[#*75B7K?M/N#"%VJ&>BI*W5@FS!5!
MS,+(%RR5V'@R3G-?\M O_"T<T,\IOK5FZ&]J]:8"A4;]"F<P-C@__-B9E/'0
MI&31GRBZ #_=AX\0G46G9%O"TW.8PC'[#<+(<YTOI*5=4U^74E<!]:DYI-X3
MS =Y;J9KT3=@];(L2T3"$C_(69@(GV4(*IKP),[B)"W22!WH6ES ^;PSQ_/#
M[>^MDF^JM_:(SKL3>OB=N1M9(3H[*=C\HU^5,T=GXSU$B%28);=>K.>4JX0Q
M25&N)H$RNCD<Y 8(#8\% <*9Q0($2I@KN!2NQT58N+Q(MQJ1!G&1I4+ADY*%
MGI>Q-'?A^@1I'(92Q;*'X+$WY[W2&5T_\0;CS^UY?S(_ZH.9I,Q3SX!J^%"\
M=#]@YMXU;+))$9WN17\O0+<*PBA@;A)BPSG%&<\3P62FHB+R\L1WM_S]7W(O
M4)S@___4G\1Y)3]<@?7[436+-Q5ZB,BA=B")$@33M=B0*#]0.8[Q,&YY]4P&
M3:^&(3##;%C.D:MYJ:XILX*O>L2JO5=MIG]3S.N;5C>T-X/WO1D%%3I@!85I
MJ[:@1J&@^,%VH4.E76/5:ZET7DNQ-B[4S=GO5!XI )*#;:@_J5V_8&XIWJX<
MSW<6L#=7[4;\L/-A:N]GJ^[/.C^5\,=64T635/=-NQ1P?<.DT8=_8E_+\L15
M:2)=YKH([LM=EV5Y[C)/\+2(XCA0X18@\)?HV!_Z^J+SKB[P'1 :YN=\A+%_
MF!/$DP+VMX3W5LW:Z/9EM5;R?/70R?ZO]R>=6OE?*PHR[$ANY>M5_=JD1N*9
M8:8DG#(^SN;\MEZOX!@^*?FZZV]RYO[9OB P"KMLU?>M6G*L8[+D0KE>>NP_
MV>3.59?<>5VVI:Z@^MZ.T#T&S\F.DNB3\9F7_AD3/_<]D 5GJ3]XXK_^<]5L
M?]0FA2)MY%S\<=G QDMF+FM!__?Z!M:ETTZ_U\FG^(O=5WC7A D+"D26N2#Z
MTAPCV_1+_)S[[IT_\DC_YTJ^E(5_6"\6F!D)XF!P8YW^RCKVSN[>H)X.X2>\
M4 _ATQNMF8+@2?+.GSOK-KR0#]39A_+#PXH,X2J%'DD6JQB_6F2,RZ!@&9=>
M('R>RS@ZA,CX 5N>ORTVQ,6M_N\^D7'23O<G#['0EN'E?:?C_$0L.R,2+^/.
MG3(Q/#Y'\3.K10VJXA";86<)Z: Z#V.[6-I=RI(W:&3TF56P&(03T*D6 JM>
MR8Z@N'('$G&FF[9:P('NJY0;TA<68H.  @%2@;91:,P&WP$KK,, K :K1"2&
M4[9$7MQ5.ZB,2;-(Y1[(BS#S8A8*%;&\\'P69X$081Y'A;_5O/M+9,SOK7I;
M_-1J^)QVDB6#$_Y=YR-UFS-%[8]_Z(^7&9IM=SAO#Y$:^! Z'[$:?,S>G481
MP$X[])NM:OC7'PH1[33A:-]7VZX7)@5-0Y&:W$441@LM%3K< IL2=^_DC%>M
MEX)5O4)0H+<5@9U4ES7^,D>M:.3;4YAH3W-#8=?-=#:"W4$(! )KL G#UZI:
M:XB'2XV^,L,4Q?K&.M!DO<Y7Q7K>R;F9,Z^Q4E,U"Y,'I:4;%FY)X';7&@AB
M7AIPE2XU</BK_A/HT1,@<DN=1('S-0F)VMNG/I%_$7ZJ<]@XM<+,0)CTJFY@
MG-YI.*>D0?)7L+I@:XMRI/?3?KK4XW>+Q17NQ6A1GY:J:E4'%TM@Y\N&@,SZ
MDQO@-U$^JH%,,CY:>..R46VGD^S]&#SX3\2FI>.J%Z#1\$\X64I98WI,I F8
MD29T' !6B4<S+Z]UKB?.#RQXK?(@&2\[)";$*:@N$>"ZU01O\':4?MO"8&N=
M!C^W04:XH&O0E^IUNTWW0VVK=S'7Z/W%9,ZZTJFQ'9BN*!NQ7F"BJ\!/G^M*
M0XOG(2@I3Y9PF1KM=-9TV\WE[#,4E6^1F1]4*\F3-%9^G+,XECX+8R\">QO,
M[\3+,\\-DJ@HMKI$?39(_F]U9;5ON"FV/]1D^]ZGKXSWS;$;]V+4E@E7XB7B
M2GCN'F")"5KB,-?J)4%+#/4:K:MA)>F(K7:03A:5[[>+-QVD 57==/ZB6PVD
M:>-DI)+5E4%*-.A2NS3]G,])W6VOE$)@Z/,.DF!^.\X'LW/4@*&-U5(QX=)H
MAM^AHOS*XES#7EV!4H@Z]\;?5T.XPTV'&"RQ6\5\]YS'H&Q]X/^^+T_JV2&=
M1CZ/I1='+ F#D(5!K%@JDY"E7 H1B4* *G:06+:ZQ*-^;ZV923>[3S<S.W9L
M'])4;W:X57;9T< :+XTWIE$=1A!AO1I^3SP1$06Q7.R67!6Z7+,3#;V+8%@&
MBWT#KGDY)XM8EY-R0GANU.5ZSILY2H#K4MT,&FM<E:IP^KG]J$39EH0?] =8
MR%9H7;S]\6]#J85Y=.3UN:IOJ)AMKML-H)U=KQNA371>48WL=2G1!#?+MC6<
MZ$%I6^/;H#6 #!NY"KKT+?RZQC=R,"-C:=U.JAVW(=>+01\L02NA\'A+71$&
M"_GI;0]3],-%]^HO&M<;EHT^KZ9O3G=QQ4N<FX6&[][XP4(J_]A!*MN/;#]G
MOWG,_+Z/H\3P'I!;63JQV7V*G)BGEHKJNGX6)87'<B4"%J9N#'(J]5F0<!46
M2KAI^*B&>UUQ ]4YORVZ.V%Y\2CSU/QRF'/ZYK>?1TFGK%4"$T\Q/:A5U9_^
MLKJI3RGE5%*"IACF=/:<"3N1[RFN.281B(@7?I!G+ ]SSL(L"E@>*P$*3%CP
M+%*)E ?)OK-$H%46Y*??*A4TW0J[TS^RCGU<\_6PR:)!$KA L<SWBI2%L9LP
M[F<!B[PL$:ZG7)4]WO_YOFS_P&SYWRL#6D>AB$F[O@.!#'>,>%RW9ZORZ ';
M2=E^&L<,Z+_M.O^G 7[A R"31M-!V]:B)*\$!:]T=)0J!%;HCC$-'ZD_V3#@
M*=42*[DIEEE1OXM>V<7B!@RHK70DD )-,,BEZ>@R;%[6?0X19BPU4D*IF,-=
M%GWP:C;L*:%QQ!TNU;_6 XL  [$UK'>)7!VUY9O5U6RS,PAZ;T#R&)PS,TX'
M8PGCS<NB5 2VTR("QES'J%$SUD-5N@,G;IG^Q$9:E%:?3:\<1\&YU M@BO"_
M^BO'%C&G<P,/*F[\0' 1@L ( AF!=I1&($1"SM+$Y;F?!K$?/$K<].ALMBD)
MG"4RTPL*LN-/STG./ %D>[\M3GU*:*^%HX_(P3-Z,1&^9T][>P-H _=/"Q=-
M&VUDQ2]K?,;T*K9B;R -=6.HGD[)UV229% >DIL>+$/;RXP&PD=X"X)DE)"*
MN4.C-!W*AND2>%"643W$2B>0@+S$?E!'!]&:Z._12]T#/D $H,'1-U$(J-1S
MJJT>^C*2T V\/(B9R&7!0&Q[+'7S@J4R$R+Q"ED4V:%JJZ>JZ2<$$YAHNJ?I
M/$G3G',61C'FHBN/Y7G@,N%*H.\PBE*Q1=/<=T4H9<@*X6<L3*,8-%!48MTH
MAPL2^[F03TC3?G3F3S0]@F$">W.I#(CJ Z7ZQ-M']Z#P@?33U&5Q[@*?C@N?
MI7&0LH1[!5![D(5\RT_].;R=''^_PJ$@.L;%X$C>%C_J SG4[0C.PNEV3!Q_
M?T3&3X!8,L[22+HLS(N<<<PAR;T@2W+@^G$8/X;C?S5*3R9"OT,,G$KIX&0O
M/D=[<<,=KSYA+W)*'=2-&QS=N6'DA[ 8W=<F 5*J@J_G*YNX,GX1W2#ERO3F
M1!#F#GG(I"?"1FB,HMO:)';H(BI\<]WT^3#C80LER8-ME)RZN=7/4[JEJ)ME
MW9Q48>UT.Y[C[7B#V5:WCN]ZT8PP?V\<(]J<-QVU?;AM5VK1I1C]^.9#EX^E
M(S,=";]3]7(^R#_BU1_4+.VJK#@AII8+^/N"NAH,TL J!+.ZK*]54Q'$N)U#
MU_5L7@HL6<-\X^H/^BUVR)E3\S :&]/9EDV]TOU_8&28Y,Q9+W78#<O25W8B
M^*WWJH(=R<MN3>__]D.WIE-3<^)<IBJ4*?-$H4 Y%Q[+XL1CJ0=*CN Q6+;%
MIIKCA;G()>C_7BPB%OHIJ$:**Y9';I;$.9@!P3B2;W?\3?6KV6L\O/:=W=,?
M;LT3'5EHJAAI0!>__<]0[W'O47LBUYW!'IV0ZC/.5+-=D-L>2$X."-.6<!9#
MGKY)A,.V$9T\02INULN5N+7X^QVD6S%RKUNY,G9J+CB6(\+&4^H,>M7GO%Q0
M76,W/X20PN\6Z_G\S*06[H#*N^NCCFEU>%5>7EGQ2 %:4XAI06[02[^HJY+R
M$"G;GIZ]J9O5E6YM><_J)A$VB;!'! 3$\<A'V&)X&XBB.[.Z76+N!%R+-3!2
M03H>5;]3SG5#'38H+0.8A5R+E=."S=AN\AZ\L6.U=%#@/L*%&7Q^==74:[BN
MMIS>W$O3X&;8D,M4[M@Z<A"0%F?2<+(^-D<*+&&A4[DVM= QW4" .;2DFQ)#
MV+CW9\Y?Z:]Z,S8#,YAT/I]K7MFOP,!Q"J"H>D'M3$H<;<!7'/0%FF+OJM;M
M= WTV:C@'M-E$#GT9'J G4RNR3/-:"QD4KA"NBQ5J<M"$>;8><%C<92$09RI
MW,^W]*#/SF@<)5*\+2X,'6+NPC-.:WSB=!-0K,T^34D>S^K$'](SIMW7-&80
M<J?FVH8$9LZ'LJJ75[Q9.+]@R0SP_+.9\^M*GG5)'*8K&R&/?"+P"Q"6IV9W
M16$11&F@6"0*R4*7"Y86P&\4CS*A4BES=RN@F'M<))D7,"_/P%8+H@!M-32^
M4B^/O4(DH7MO2ML[U> O0/Y[(_-JN1XT$V7^YW03C=R3BI[_^02#*,<D->X6
M;AB[+A.YYP&I!4!J:>BS))2A'XK$%WPK>U(D*7>Y2E@AP+ /BQS>\6/%9!!Z
M"?<2STNC8Y!:&)V=4M_:(Y+:C&HIM[7TC?"&\] .78U2 \7XCZJ^P5+&N]BM
M=HZ][PHCW^%CL,PUH2&;Y^%1'6G_<,6KRRM>;CS6.G\U7FT[\K-BXU[F9GX2
MI: L"K@G40$J(.<>2](\\(O0C7RYU; K\EV9$=>/\A2[&66,Q_"?1(:A<%,.
M&FAX)#8^W2USMTZ-SK*HX$D8A<PML@@()TR!9MR,!3X0B^!!(-1V!RPW#O)"
M!2P"<F.AQV.61K$/>H8/6D/$"Y6EQZ S+SA+)CK3=':*^@*PH"A1<<C@_S,6
M*B]D:2P"EA=)J@(_"5*^16LA]U0FA61>E )]2L]E/ 6E0;E)F*>N= -^'%KS
M3BH)[IBJ*?K)ZQ5575G\RL_4$_POTQ,>+/GU=7BH6O&L] 3A%4$<)A%3:>8"
M+PXCEJ69#^IUE 4Y:!!9L@5CK/Q8R!B4B<*-X9T4NQZZ7L[R-/ *-P'=PCV*
MGA F$_\^53T!F&Z<QYX"9=)/6!A+Q;(<S#C.@S#U%*BFWA;R$0_2)(TQ5ZW(
M0J S+V \4<# H\QW@UQE67!_I=S3\.YXHK/3U1/2'&A- H7Q'$$ PAQ8DPN"
M/\^S(DK]5&;)5H9D#OPO3(#QQ2(&W2(K I8%8 I)OW!S%<L@Y,%1:,T]2R=:
M>XB><#Z?#^0_1ATU0E*7B/#N_<5I5D$_T\A4Z!7*Y6#&)5'@L9#G :CCA6!Q
M4G@^J W<*_R#%#_S]NJ\DAO=*I]Q7.K)X38N;.(._3#8M!<3HYJ@AE\DU+ W
M00U/4,-/D4)/[9#;(80O]5/0N9"4)PE*!B8X=KF(,UO73X"+#6AS3:D+^Q=U
MI6Y-8UUGL:9N"=A(=R,7BEZ7I,N 9H/IB/#ZO 1F+LU\- @!I03530F;2/UZ
M5^M&M]NE_$/TBIB^NG7CS'&ZI@F#<A 8F!I-K!MQA0TW=).'S;;!D])T0*5)
M1CQ-,L]GPE41 I3Y+/=2C_D)+R3W"S_F6W&9+U&:?N9E\W<^7ZNW18==\::'
MKM#:TZ0T#047[-AC1->33]"A\W3^IC@6T)P"6O&4<W10*4/M!3$7%"C1N:;#
MYGU;6_(E@R3HL\EWMT0R2#$5N_=!W>6JZ1I&_1L['34(4RKF5"X&?Q[,Y<$]
MK["?$8ZY;IJNN=6$0?/L2?7G 2FT0QAM7>XG,)J"]4BE4)JT;JCU4VXABVP\
M1"-1KQS]L_I4KG:^M.2E3OK&+IS8/(KW/<<L+7:023C8HFZ!G.4U)P\<MK8R
M.E9A(DC=9T?C(-(T:N^@70T:?L(,5C?8W=.,L>2-AN S!([C+7I.3+K41.//
MGL:1'0]8WE6I&FSP=MOW$=1,LX.*7_!/Y0(^202QU@TIZQQ;WE%E0EDMUZBC
M7V&?6-WQC'AY]PFM\^_\9 >YCD,7-3;9T\4*H-.S.7:;PQ*HMM7U^4BS&K.^
M;,==ZPP%VUEIPC?U6V9^Z]9<SL$<5^-YV8(O+4H&EP@E2:ZH[$+?!_G]= ^>
MRSUXN/;Y*Q&<=T3_/Q78>J^=_V]=H^I!,J/5S9VI\X"F<]UH$@SG2H?E=Q+L
MQ*F_60KU3X!"WVX)@!IX)RHA,*5_?0GY;K4]'8\R?@?^83&4=[/K$MN$C#\[
MHZ:L-$LSY<XZ&(@S;._**W(2U4U3YXC&H(M^!P\9>0,:$:>)8;NM%;<0F216
MUF#'$+C575)ENJ3?["4-3N"2OMD@<P.>3?6K VJFMC1=:6NC"BS>''1J[F ?
M;$-;2G_?[*F[RXK0E@[JC' ?\2)WI:A;=LIT%9[-5;BKN.PS_##&P-W=4WSD
MEMGE;1E7'7=]A\@0T9+(&-6M<\5!"-1"%PUW5B^9%QT026^3Y+?4 ]HVDL+\
MBLNZ*?^M[8_O1G8'V"O8AE%;*B14NO98P_)E4]<]6-'0KJ8>5#=7]5QA#T3M
M:JBH"Y3B8.ML]NN>8A6'+#T.O8#[6<JB#&,5RG=9%G'.$NZ[;A1Y@7#Y(6(5
M/W:-YMN_ 7G6LGU;G'>.S[\J"=M].7AH"EL,:*#?%Z<'*1]$>G8RUU$6PED4
M!$^2A'#TVW#"='&XJ(%"IJDQV58MW49,$Z1V@!WC=TK4L^M6#?ZNNXY0"US9
MWRU0?N!? U+J+R)BM%62-]*VXK,P4C^??^AQI'8^?U'+WDME7SO_<-&]E2(2
MURGU;QBP&Y+7A@L=$Z0)-8C^I#90A48M"5"7V"A":,?F(X7_^['Z$5 Z4T,K
MH^X*](U3) BI:QB90H0G\DU6\!BC7])S&W*9'./..28T4(" E(KA.$;OT9^A
M;LZLZX\WHW]J*'MCFU)K8O14?EHB8)?V6NY4!9P?=RYP%"J#CUL?:J]TC=H[
M4Y]05(XJ4LEI/N:?G;9CM2KZ^PJ[.^LY@[:WTL!OUM#=N^=+L*;)WA@@OU3
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MA5"YFVD\^G'JQ5D:BXIR6*O!H-H,)"2K8;[=2BUL(M-&PE\%XQD W?:VA>=
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MXH([I#V!?TDOK%(>&[]2(F4I]AS>CY*G!G$M)(1P2B.&A6/$2>I\>,5\F&?
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M?*G;QKF:GF8ANNA7\4=.LS:T">"DE,U] 8DFQ&-@$%2'B$CF'A&":RK,2IM
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MQPI8STN,2^SP^C3W;<M$]G'8M^.5/NIB!DY:?X[2#&PM>%!8)NJP0B)9@[@
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M<)NBT9*%3AJW&NU='<K:;8&<$KN<F;Y^=,W):DJ!QP*/9P>/T5)'#3C=AE@
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M.;E,!!L-1UIZCRR)GC&(!BA?.1#MNHAG&\A)2M5CF;/P@CD+L.+XN6G&76;
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MPNLTB 4SA"E4JY"'(83C%L-2@29S (*4(@=FP26QG#,B2A>]+[5CQ0:ACZ$
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MF@"\D%$S%XF-1A)N2@::''2ZD"7C)9="V0TRL-N8 *G=S[MV3K[^8P:S\GL
M+_,$9N?#:/*[&<XBO- ,)_F#<6U\Y$_DSDD>U9JM4/_C?-5"R*\Q$(3HE>5N
MM^D FJE.$Y"=XPR R.#?9U,8\_^BO-1@N*[,1A87T]'/KMPMYO1T$DY!OL *
M=NC&;>R9)M[4*/9F_ZS*;O8#GMV9Q2NGO*'DD<&>< J+#YDERFM&C HEW+:$
M#7.OV$':$ZC0_JS#E[0^?X3I25J</9G&B1[W>,3^X*9Q?RU,L"T*\$]9]NB-
MV_"9>V6-LQX\.DW!G].^)-PJ20R%/T!=Y87*HRWM1GK"75CCODY'[N]GHP&
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MTFA3ZDZ&Z5PE246;6+>OYIZ"]X\IF'<$D6O<@]T>6':M$F6IP/$BKM026^:
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MM%/0AR^:NU*XNGAG9]MVMNV10J.UG)6 BHH#UG%3"*(]]^#N,VH5,U3HC9C
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MW!*A6<&Y9%:+#:/W3IZ:.PM^-@B?XG:';-7N7>C!%37X#1'@&[S#VP%<^!?
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MH(@47A"N%27*\8((2960QON"RGU$'4!8SZLIIK_6[ZO:#4;U;!)V<B/^4V/
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M@1>R.\=! [T?.9CP83Q+=WC_KVFU,J8P>S[W^:3O$;M8<+;?M =9<$7,BQM
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MF*19ZNED#(B7<E&J)M&F;IK3OWF[U)9Y0Y.@Y5[-J;9QT/3! !J;_]8DQUS
M/2IXD_GSVH;R0/%)#TS5TS,=J4OC>?OKVWER2:-3_N-S,3'?VE+K.NS<%GT^
MPNU5'6"R--&P@&PL ^)<*:12[\NHK;<Z1!-#+^K 9W<>_'00/L9$'J-A4D8_
MQKF2,*M'?@/*,"S_2X*IC=K"X7+NEX;_NNVY8;%E%;^9 E%WX;^J%0"3) #F
M\<!F^BZ8:?Y9.FIL6L[Z'-UFBDM*<*_J.8I$ (#1UP0Y/S56!=@^<&G]\ZNU
M3+U4M_S< BH7D.<"\N<I(&<;"LAS"7D_<G2UA'QN,^S<$KV_+;K.&E6G6/-%
M>W3-1>2NS]DIH0S?_.?.+]SU.>##;M]IP>A>9W:KOJWN[UF?P#=[PUT/8)D;
MP[I='&Q2^K0)R*U?Z$7E_2#\,@>53A!=-M-A*E]T.+KFS=?LCNII<USCP]ZF
M9?X_H(,5[QL5;%$1^NYV/G8+6R+%;"\VL4<:RQR[/8ZEF6-O[5XR43)[/I2@
MOKLIVUU@YI==\PO-_-*?.-L0]W&P%=$=BCSKDP!GD[$6?& WSK%7_7#U_2BP
MMQW; \@^OA4?DU9W?*=[:"M^G!#YKE&T7EXL!H=!.*_'ZCN$RJ+S+-UC\9YX
MCWS%&QW P:?LK/M0W^)]AZ-UF[,O&0=WIIW?=YF;J&"VT+5<L<VE-X[4'D]_
M-CSNI9_^TY'U/H=^.,+T!1QI9NC,T'M@?6;%8>,(C-2J[SCI[%C!9<-<1>9U
MJ2Q#01B)>! 6&6L\TJ6)/!@+S"7[2+":^4(:NGL]]+^-8(-7$JLVUM.QI7HZ
M=D<]G=A83)<I/:M(1W6DAPU>DL4R.&Z0IAPC3G0J^0T4!:YUT-IHJE;Z446B
MK='*(R(" )[W%%GM / DD7 ;QTB(NP2OS9-ACXO2LQ_I.?U(L]1VE+IF]4IO
M=X<=7PQ%/A)['Q1X/21TQCKU4"@CDHPS4!,CJ(E,"604(T3[4EJ^,L3D":KE
MC(:WA<OZ!%:Q76R^3\CY8+GE>)7/#)%'"Y%2> N@1A$S-*)4WHR,UZF9FXN$
M4Q' !.]1@=TR1)8G6FUN9),A<F<>S\>HM/NOM'X935(SD.\DV?1#>FL3PN@I
M3;3G1]-4B[%#H'[F4,L#-N- ,;ND.$0M PH N*G96 GXRS&BG)>1<F]-FK/7
MFUJ[H0:U1ZU6;PFR[T,J+P^TLUZ; 3,#YH.&F6H3C8D"R9*#DNLY0TH # HL
M-*BKV'NG>E1RMPN82<?=/!\@ ^;]M=Q<&95S:',.;<X)S_1\\"O.A47]%A:]
M"S&,VQ%SN;(H<UV6(IF>CV#%.2,D5Q;MN;/G4-+MCKH0(7MX]_A(,T,_BJ%_
M>F2CP =F?$6"A?,6"1L5XM@:9$))D'4EY<R76"C2AZ>WLW]F0NK)'M\:MAQ^
MNBM6=GBIN??CII]WGL"0-;)<LG6$J)W5L*R&'?.19CX^@$//;IM<R+-?%)FS
MU'=K)CH?-9?*(LK2Q',K.=(*3+X A\:E]"'JV$<&Y=Q,;)GBF<Q$Q?A1YL _
MT9;,ZEY&XHS$SXS$DHL@#/&(*X81ITHC);5$AF.A2RR9#[I7A]VS(K'4VTIM
M/V@DSF5)/90E^>^EZ.0T^YQFO_^R@97*6B]08*"@\](!SL/OJ/1*!6\(X;KL
M4TM_\>KYOJ?O9P4]%SYE1'[!B$P9*.B!:,0Y 70%W$2:"8X4%4%)QYA:;:CR
M%&W]N1!9XXS(SZ>H/\*S?LB*>M;/LS1XEC+84#JI0/M$QBI 8A,44E(2)$I7
M"E(&2<1*&>QC].GMUK^JDY*41PK7.8\AZ\T9*;>/E"1&&X,4B,@RH9X*R!C!
MD"$,U%D2 G&L#SUWVYT"L,Z= AZ;*0(_I['5VWWUV6SY>^'@K<=_]XGW7WU+
M';]/+\*X<G^9S?Q>&(S^@*?.N6EVMQDS>4LY6%@ELJ4"R]&4&IEH&5)8E2Q0
MZF792Q?.S^X\^.D@?(SO8PQ [%=ASE]_F$GX(\ S7#6H3.*#+^EPO\ 3WPQ&
M[L\?B@ L=IER>,;3L&5ZW7#H]ZW/?1H)?#D/Q7AI)XI1+";PU]CFLL/KF,ET
M,AI?+UHF:1Q[,1DU%[X=7<!K7S<Y9?*7N@C==M]<";C47'H=S!@N:(8\/])#
MT<.:%\=+%VF(;6&&/OU "S,.A:GA?0>#T==ZJ7+YD/F^P[@&XM:EGAF@@ [=
MT_M4P[.T@G0Y&ICKT70"C_@6_"^S.?(8G^(?NR_ J0[,91U>U>'2)'KHMJ*1
MWNV]?UCG-TC&KP6ZG%R_ZNZQR2'0/%:H4RS$73/NRU/"Y%T7G3[F/GG\]O;*
MJ5D>)WQK]_X'P+1XWV#I(J+EV?#/;4]F@@S/- ]^NSN426:O1J+G)CU/BR:
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MLZG]>4H9EV!-<AE1"-B69?21"]*_-K1 EE]NJ/)M(LJ>="%19I,R:T+Y2(\
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M,[CD+-&-:_*.$W",O@[#N#ZO+HO1%7S7P+?'(,I3IE6Z037RQ4^F^-QV:BD
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M]Y4E7UL6L*.!W]P>-;B0ZM\*1DX>00![M"N9XGL*6CPK9,X(Z$7OYX&3R\,
M\D$)M@<!H113]GCH?&#N;8;7O>>7'!-^DF_S8]L4-54*74['[MR R;E8,I0]
M74]U<1ZZ\_) W?M$!BR%YJAT\ \/7B'MA4>!,B:TPK(D*_TQ BY+:9A'Q(B
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M6<49<CK).8FC4"M#H1[CH?S8<?2LX\$#@FG?SP/G)ZR469YE-V1&Q8R*O1D
MQ$1<:H=*IC "<T CK9E$(C)'!5&E5J2/5GU;0T5UPO&66UP?-2IF3TD&R@R4
MO_Z_Z(/@5"HD0[2(8U$"Z 6#!)661RF]71/@?D1RZ;: DIU0E;7'C),9)S-.
M;A,G0VF4BZ5%S/D "B7%2!EF$/4ZD&@Y&-*F#X_RMG"22'&"^9;KK0\**9\M
MH?5I>?_[Z@?^,'2CBU#\E,(C/Q=Q/+KHG,*C8?;XOL2\\&5BV+36?S](S:-W
M>4*5*%4D*C7S2!T]J 5Y4I:(,JF-H8YBW,L<Y;D\:?DQ<6-/$H7R$[YMQ^V+
M$189N/;X2#-P/0JX?NHV9+OQ*RMQ-,0A&9Q'G#B!K/82*5=&A;D6\'&OGMK'
M .']\C*>PVF[M^SSX +/%\$^&2TS6NX36CJK9*2 ?*61,570,J0Y![0L@S0$
M=,/ >^D%\ QH^0R>V[WEG@R6&2Q?_''O/5AZ+J@J%46@1%JPL;% QAA0,J4K
M-:'<VF0O]^BSW1Y8"GE"658M[^FB?6 Z[UI26^^KW0^W[): ]F!]%$ $Z=/_
M^P/]8<-:]PI8G^=XCW?)F:(/^GCSD@]DR9G(\Y(/?LF9R(]HR5O(*7EQQLL3
MS/S/T\O+04@EM690O*MJ-QC5J8?_*,+-1^Y/9$T=$DM=I-RI)M6DJS_,]D_&
MF*-?<J;H@S[>O.3#6G(F\KSD@U]R)O(C6O*S]6)Y0##U99E ;W/OE)PU<*19
M QM2HFATGLN ;,06<>4)LI99%$J)24P34OS*4 'A!#$6*Q2(+1$OO4(F<H&$
M"H1'SZB/[G:4__5@,')F$OSG<S,.;Y*GX>V"HV%6K]53<GU)#R[6GQ/K,XYE
M'&L//T]P>YF'GGD\\WCF\<SCF<</YKC['QDC14E%,*@LO4,<,X:,T!C%DLI8
M!J)]6*GL5=XS4RJ"G,8&[!&LP1[1$I7&>:F=,BJL%+1E>^3HNT+L"V(\+(@?
M!H/4!3@-*8.G_AE2YGPV_XZ&@[*T6"I_-AP'ZP**R@;$*8[($"Q04"R($ANN
M5_NO6<:D9=0AJVEJ^2LD2 M/D%$<@[SQUB2/UPZE!=MVHZ&#)?:,7P=WI(>"
M7]FB?:F'GEG[&$XYL_81'GIF[6,XY=ZM#NL$9I)R9+ DB$>NP9:0 DFO!'54
MB&!6K Y'#/626[@HQ=DM4TAIK9 TA A22N(BSE;'7A![3K-Z*MO\$>I@QNZ\
M\5+Y<!4&HV:46[;SCH:)LL18E!A&,&6T$L@)S1#W( =T= Q1JKR(V)(H\$HO
M%1>-*#%&D:1>*LY[I 1Q\"NV3GI7>K%;/Q57)$N,C%_Y2 \)O[(Q^U(//;/V
M,9QR9NTC//3,VL=PROW7=D2K@_ :$2HPXB(HI"G#_W][7];<1I*D^3Z_ E8V
M959EAF#'?5 S;:92':O9&DE64L]N/XW%2>8TF& C 16YOWXC$@0)$J0(@HG;
MR[HEBDADID>X?WZ&.XJ$*2XP):(T^K[O=1 NG4M.E=GO!G'*#'*,ANRI.&Y(
M5$12\#IV@]FAF.JU8O-;K./(#MHPE0WYJJH9EUZD7Y=J> *>'DQ[@VEOC^D=
M[P1+/B!18EP\)(M,<A2QA"-G/!)AW$.]0Z562:F$K*,"<6Q3UD!.(Q*E8%(;
MKG3:JMXA?4,D#("#F!@@)2!E9Z<=7*1)<X&,)J5^E6ODE#,9*8FEE@3O_<)I
M!V4(UH%9A*W693@[1CH&@B3Q00J'O5?;/7W-^UQK0,KC<%H!/+?-!T< GNN(
M7 *$ (0 A!P-A#PQEUQI8J25B&!)$?<2(ZN<0X(0SH(G 2]6\CDCM$R2()^H
MRS8;8=EGM0X%+;$3BA-/MALAE7V.850YU/MM\%#J4^VCQ\.Q'70,5D<?(: G
MM,A;&$[<(&Y31VVG\<$RBW&@ZDJG)$V0V?5G3F77/T9DB?$H!>(TIY%PTLG8
M\XVJ*]I7AFU273U@F?U36!!:!> $X'P1<&9\# P3%+7.-CLS'#F>C7V2:.)<
M1\$2[V),^F''68\.."%, EAZQ%BZ_K K( H@"B#*\2#*$U%88IWD1" E'<[6
M651(>ZQ08-%;(;BR(78Q:7RCUIGJTW57JAX8EL['8?//-I/1,DP:#L?U<!RG
MW/+ARW]GD]T)3UG>^V 0=YAG?J'9/.<<4R6LPMA]U[NZ&)P.;'WV[]_%&OWM
M\_PRW)!37OU4GDBIOG^S.T'6NS?1^46^^>PGEOD'\F/O%I[FG[[\K=>0:3'9
M>S(^2RDA><^T0?G_$C%N.=$61RT7/+!59/SW>&8'O\;8/"G&\IX8BV?$&)\\
M7?2W\8WMY:L'94U',=^UR;]L>H-"\&Q.8_[ %U (O:KNO?OTOA<FH](M<GP>
M>]?1CGJQ+A_^''V\<''48Z3?HYBRD^V1= \-YJ3]<=&G5%N*L^=N",^./(^E
M^(E@Q#QFU@?GDU!'+?IT]T0_:2*UU10%ZBCB20EDB?<HDNBE9\P[O!"U7D7T
M?[-5_?NP:3[6G[.@?TP_39JJCLT+D*#)>Y=_>BY@?:)V&Q)"]34VXVI<AKL.
M\H+$YJ3W.<;>AR))NA"7Z1[;:M"<S$O?3@2'7[\B"T;&76JWF!2/ 8&=C(<S
M:ZJ\3X;,\OKE<C2PU\/).#_C*H8WT^<1C$_P][,OY&T>V,LFGC;QTHZR>3E;
MA]9XGM[[7C[X-L'\M6HJ5PVJ\?7I[";S5]ZS"=L'"W)2 .N[OWSK(O+J"\P)
M9GK]CX'W>/%[4/+2][A7W/!(=8/N?F;V\Y/Y]CP3]:+1@[.7>81@W1&]=[&
MM5)\.VN2\&>&3;ZHGFQK"[2L?OYS*BEN. A/KM^"1?T*YEFFN&H7UJ_3\"'
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MG"+K@\LNKG$TZ2"#6>A]]JJ0X2IF3)/7-_^T[>CAUMVVI[;VQ76' (<[0#+
M80>E)$GBH#%'V,6$> P*:>8%TC@2CZ77&<PZC>6MP0NC&+RP;P?J#GT.XYK
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M;+C2AHOMGBXT?:+6G"4YJ)%:@)2 E("4:W6_CQHO=LIY PC9-A\ A "$ (0
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MN_Z]'%'[Y?$C:I"'A3K?G1/FXZ,8JD:@]!>JKD!^H/1W1Q@*) @D"$I_081
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M?F1M]$YHD'DM^]3:_3W:4>^7K#[#O;$3J[+*,IG975C"S<SN R "('IN""@
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MZ+?+]!_#*K_4?^6/,V#G??H\R=IV_GU*>.QN+8?U;%MNB/_)#C+QL??Y/-Y
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M;<&O^"_W>S]<1_0W^'=P1/TEC@+TA-?*@1^>'V[:+HQWJ?LU"J/=X1U4>/>
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M,]S<1>/,[H@=G=^J7&[=<(.P-EMWOD%6SU<4_-CXN8X*GS':-]M^[TN\:PY
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MJ&V35(L%E'(_8Y5^\0*MHQ@)]%>?ON+77A3CX]*-#\1JW(G->LP6+?(0;-P
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M!:RAT5YPE"M?2DUU9O J.,@4>"V?2U/5B1.HL?26'(W7,SNF3G732AGGFZ3
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MLUZD_H:9W&3..'6Y$7V;!/&: "<+GA]J!9*$]&M7LX=.\,,((K9;Z*UKQ6;
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M&30FHNPBP32&Q0^C/2 VR7,%+C W/-SZ.[^17D:CU@PN?@7AJ$!GH97K?H!
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M,S#&+<+4]R"_'-Z51: J5N2Q1H\\RANTPY\;P[I64]/I&^F,-31?]AXA$_N
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M(/W08&GK(\%P_QF<&JOC?JQED&RN8#.!#67ON@F!HIQ^4=J>8-W:%E^"<AU
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MQDS/RB7)&NB_9$J,JKK<^)%. G4L8Q+OF?*R5-OR8Z!ZIS27M4JUE\!+*LR
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MY$Z3PJ"B&0-DLD6+$2.YKL!]W#G"_0JM OP?5<(MK:K6315")&FK2Z2YSE@
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M5."D(&QCHRFK.94A34+N@W=!Q%,&# _UH9;Z:>)Z#'4_$'LNBIN&J)X!JDW
MQP0\^!3PH6%]+]Q Q]-G!?A^(D---0,3A O1YT7L7;D' X3SDC13T A_/<2C
M1TF,.,0*3I9POT#H\EF>>HIGGL*_88..)QFT-/"%!E2;CN:A4H]H0%I1//XD
MHZJ[@Z\R1FP<@'7AWHT[N7ZEYIXKCL:/J5"\)^,I>/Y,#TZ+%RT?+&O$N3_J
MP99MK9U&/++QE5Q]%?#"9Q1B/2? I^G"@SC[)*49N8T"6LZ=#6V&V)7<4D/'
M.-B*PE4;KWJTXUJ/1AIN4%[6')/S61CF8I)%S77^4@XU;J@\&"):S37_&J/U
MF<"_>G1C+(<]U9C6B7<.U!T.(MI35MVC&V=074:6 2\7/277+-4Q"3M.H=6R
M;*E@\KQW_4':4"UKJN]-GC)UC#'68O0$37TECID,^1A'6'EL.1Y:!5C<^%09
M!?LQC.?B<!FXR; H+I'EF/! O1P<(G6J-_$7E!:$YE-P_#,*(K=".!Z6"<>G
MRK<R^O #?F<DR5^<11!$J]RQGH4>7/O0(JA ;@SYWY-O>3+J3/[_8KNAFMVA
M3-^O2<(_$="DG$.JFFMJR*FGD5-JJN./4UOQG.Q8X:>ZNN#"9^CTQ4M"PON'
M!3SEED&J^[.'08G.G\/T_\Y;'-DK=K6X!RKYY&F+OMS=+Y('].JC-SP5-V$"
M!**0O7*X>_)JX=!F"+\<-/1OP 0.39&I*!H[TM&R=?[B7#GEH3IWSKVC'.U$
MKL_1AEWUB78<_NA^4^'3DA!:#;O!"EHNX36(+S-G#3BIURER !H:GAPZ)YY*
M1S>DB@(FCD7*0G9<PRH%,7X+ZR2J1NV+-9$.1)YB[+EWZX?H)D6[WN&9Y%F7
M/_3^#O(<(G!T+4<PRQ^>8C=,7'+V)@-5&M$&?W!$P1/H+KD&1_"7ESV-E\*F
M(QLJ-^'1Y#I_F77ON69)9.1ZXX2?/58?R&:F 6L)]58.7X.2:16_@/"EFQ+.
MHGW.%L[L621; 6GUV$9=OY9R<KOQ!U,#_C#'1$]UX:F&7T+3L"D:'H=L"--C
MR+J.00DBFXC2TM0  K'O)1C9R ,I2.07GH?+)"0K\#*^CZ-7/USU'0BCDF<R
MSVBN89)/F<D]EO%(^/&G'U1AE:(W0(Y#8YOC H5H[:>R=)Q]M1QQW'G67F:P
MA.2]>QAR@EL874N8<-!!9;QUBESG>];L'\[DN48G5/YJ$T-UH8'Q#Y(4S<<S
MD(8%Y(KBV"$JG&]RN-5P;&)1 ]T-RCV=B%%S4)>KI)E,V(0IW2"R<T/P->2Z
MY[@8]J!\BIZVZ!8KQ930S4B*-_SN#J!)@?(E!QUQJ& :$8MED+?\C4Q(8ZZ_
M7A,S?K1+WZP4RSVY@Y9%.DJ:OG$8K(G>:\OI<EQ:'S\_UH;GYV ].A.G[XPE
MU?SFIY'F</D4\K=E+9?H<^BA.#@0#:IHK)BT3_3?%V[@3J!=SV2^\*LB3OO.
MV 7:^&%X1)-&<Q+?A#3I6R6[+?DC1''D)O89?,DLCS-DYF:)ZFI)<TD1&OQ2
M&/#_Q5>B,9TRR1E- V<*%PXA,B?N@F@_*G>;R$<?HRV>.O^5)2[#KX7END_F
M!\&N6Q+K?!\0N$L5]+,2H(K,MGI$PPUD(RWA>\C#"U:4I&NI@GWNW2F,]_7(
MC?S%B3@(ALR \.LB%YN!<#]B.*'M?%MC#?)ARN)6BE<X$F(#V7XH_;'HP9CV
MP:?8A5OS\;![B8*^07)4AD.%S+:WI0BX2;I,V2)=/\05O<NM'[HB621D$#+
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M(57SOGRK<U;&7M!VWGU_E6\D_/%ERIV7NK^A$#S4>S)O!^3&XY.^<S:Q>_<
M)F[(2(N[&[A8_[YR#W=1F$(R<4@BV1<0R%MP6!-G)-.NPULYXA&*JRT9)F '
M .,YR3 I0B)/I8(W,9#VXFLD"E?X747SIJ37"#_^W  04!D$/)8*#U+J\$:&
MI%<9P!O=U%G3A@!+05L:E>+7QB1(T0?_>M-0R0W 6Q89 4">4V[]#":'=<#)
M>U"M-!D)MB3_'3BN\=V &\<_);['HK)SA^M0GH\=PF^%&&@5X;#X!@;(=H L
MVQ^)$&2-.:76! #+-S %XM.P]SR,_'R$\+='_$VY6,=X#@G-Y]K'-^$0:SV7
M-[J=WFCGRTS@5.C8FQ"H"_$3#\ ;&_+<&A0X&>"?HI@&6P@RB:%2_#=-8Y9N
MW= I5YJ&$]+(H,OAED-'/GZ>FDL$P*?@_V?O79<;QY%UT5=!['-B376$/*>K
M>LWL=?DERW:-8[LLAR_=9\[\6$&3D,UIBM20E%V:IS_(Q)VB9%NX2%1-[%A[
MJEVN3'P ""3R\B5TSOC^?^BNIRF7180P[ 3RG3!Q!S_^GBX[T4#@(W!KA.&*
MOM#B\WV%__L%F^3,V("YZ\6IG9VN\C+:UO&.ETP#>^NUKY0]\E Q^8S[E?_Y
MRY',QGHD163K(U2C(HQK!5YTKI<HQ<(/=R03TG$\&3LDT1-CU@P6?&+:BO_I
MB]H]C7#<!>^Z(<+@(LEP6M]"VQ;9SOT.@G"<W"4I"IJ=KL3O->(7G8YV*<MJ
M=<!I'(\,M;S%99* 3.FL:H("1T1WNM?:"5=/'E=$397\%_%*CPU*SXN\@-?O
M:[/,_08<3,9.,@,M)"$%5Q0OX. ):6^XP6IU@=*)$#\T>)M##=M6,7B"%?N'
M0,;A]+8!(8*6)%(2DMNPK:608S_$XJYQ5BU:FNVC$DZH/OCZMQVGR%O96\+U
MAR9>9W]]4=6J"XE,GG7FX!+TV,"^F:@6)\JH"$K+%0):L89*-VY1"<=!^;="
MH%JGQ7]KS0(WNU*-)Z&!_.JR//^>XC?$$-\_4R!;8098VBZ30B;:.ME_6A^:
MO G0J1 J=.(\ '5$;JB%\@R>X%N'M_JB34>WXYGSM 1_)9D-?'TTL/MZ?7GX
M0[;X7LU6PX<_]*)GU/'XQ_&MK[P..NW6;<]<Y&528J,NZ4QH(Y++> ,EED9R
M,1K.(RUS,& L=GB!:(!K8@:SMBY,C'S'.W;,\S3P;TG].P5[59"X-S=5D:<K
M/]6W7 MZY)0>26@?]IX-![!X#S;R-ZXE6H5K.+Q=@]+ /5>XJ= 5H8&QR5XI
M6N+H#C4>:2M'JMM-^*ZW@= 576""?U3V.1HLL 4F%K+7?=VN+=Y&C"-R2I_R
MLH3]>IHP)+%9I#W!/B^SCX ^YZV;(B$6I"GL-4/SIW*M-XA3+)#+)"?DYG8R
M,!S2RR9X="24WOXN^R<\C42(>W@<N+&);P^/ZW9?!+?1.&TW-]5P,>AY#5:Z
MAY8:[CC$KNUK<A(^+8:=@)<9TY3/\A0W#0_2NJ7WP+%J2Q6QW\'@Z4GWB0X*
M#XWKJDR!<JI"JU\>%_Q)X?&E:*M11^50H15;48V(>!S&?B0&1-PY^#O(<X5\
M@6I"$W1SJYA],<)[DW^7]+[(X2Z)3UVO-ZD(RXZ$PW &NLQ4I%RK&RILL9T5
M7#B*1!8:ZI#_P>G[E9J!HK7>''PUK66,Q<2-M1M75=-(CL&\7+*/25!65F5S
M2F?L':'*3&AS_KVMDZIF[[VD7B%]0O\7[\1LS4M*/A5L8#^11QP"U'C"#]N0
MS1@/<5Y,^@,V(#D=@LPE+^4TB?EA-G"S?&QR'$@$RM0#FJK"WCU7."V*T9(/
MB^AQR9DTNWR.2&0K09G8]"DI+JC;28)"I)_T8$=<F(,% <%YZ55GV3';!EE>
M+*&<0.=GGG\'7E/>)V^"A8 );SIZGM3@R6MDPR(DE-RYWD;WX36'8>:)RH'(
M3:N& O](#D9W<1(,EQ$[\^YC_NR2'S&)TW=,XD5W$J?[G,1N)?MEJ7BA):^A
M6X<$5=EOE*ZSVT&S3ZOVW1$;)83"O)XN!R00I%)@^_/T@WM*UBQ&3MGUC;;/
M508M:QM.+.G$!H_U4>K^5S*'BFVSY3^2C&=<![F,!U87D)39':U?D(IY.E.Y
M&Y<EL CA4*!4KNG_*Z<L9ITG8DB,EM&\SPFP7T<]LQ#TU0>]=*#C]P1ZI:(?
M#-"=462/\>B/PIX][ ?LDC(TP54O= T69:$!8N_T30"C.Z="@N[X;1 \KF[:
M 9]Q=<&C#RJ?R*!%A/8!#V7UV+ O&LP>SI)H\SS<6HR->!*C&-=(LH@.0[H;
M,P@PA8_\\GE$OOS\Y9<?8R[,9((MLQ&LK/109D-><"HS;611=V+;"7,LDLRS
MRT>BQL.9+T?<;. B@S^*X/& #1S@B<$>W)RA1=>QGZ[TK]PD*ZRA?TWJC'=W
M:"3O>%+HK+S&M4D:*#SA727,45GE]8\K8OZ>&!K!L8U$[PF82C4^(VVPB?AX
M.*@)MLI=*>2JT^QD_,)>&T] DP-&#CZQ1.<42&W'B^\34%0UP=(M5 (IKPAJ
MKBMVQT!==,6,-TY'"-_/-6T]=*&22O!153)-@HP0-#11J,K#P33S9H\79M&#
M4-C7;/-J#2.2S-C*DW%15*]X2T'QQH0]SIC-!F[5:(VK@' 'V5K9AWQ98K\,
MVGAH8&'*9;<+D9*'A*?H@9)K*-'*))1G__Q[,A>L23>4G;O@<>%A,G2ALVU7
M+W<N'C5HQ@P]P#8F-.%N5OE/0MG L7?8^DYJ40>S4*#9=ZDRG31'Y=!AK\<"
M/[CND3K>0N-"2NVN@8WSLQF%CDBG;V 3E\K=*S([2)6$+LR0KL2O%;/02C ,
MOR+KADO\1KDGM5#"I8:.(/B'M"G%Y$E#>T+I@1N$.%KXETVS!.MD.A,_N*\N
MJGI.:[-IAE/&F"9SX4GO#R436:PPCJSSW_6C28X(_DFE^P#.<%2\Y$/V\F"_
M,4G8$;5BA]9R4?%N\U^O+\G#W9B_(_+'97C>Y8-< _,Y2]YXSIZ*YRSI><[*
MA='K,IVIG]U7A(_4:B?^XTUV7S$_><3)3,U)3VP?0F/\WD),>H*3+C=^_NZ/
M(;PK%!\Y5+]P/#PAM/M>OP^'@L..,%EOOS@M%B=5TP)!%\25F,4(&0*^6F"
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MLH'EY=..&)58D40RXN9Y0PS10X/&76/GI>PPMX[Q-"FPBOY37G*6U_!EUV%
MWK5)W:[!I,<#TSQ/U@%R4*2*MU=% 0:6D69X1LM6 _<5^/C0Q<<SD=S:(JKT
M;'8 +<PR%AJYC,4KU-YJ%MX15^@8$:D%*)0-MRG7%):I-2\K;-"""1G@Q$C*
MU54^S]FR>.C'*J6+?(])]<<1N6H#TTKZQU1L@H.BB9 =J2> =W1=3N3M*(-;
M9MK-9P:*V,-+$#$UM^SY?5'5RIWG:O28WE K-@6//:F4@%8BU JW74QC*-ZL
M=!F=]"L7)NB4/N5E*1NQG.,-I&[=;1,8-FA04\A[Y0>F!QYF(8^7A1W^T M[
MU"(M.##3LK?1=P-LUMP3D5$3_-BY2/(:2TLNRP4SKJ[8"Z[XQ>FZ (F\9 92
M($$HN_Q +/DE^%41 )5%:+<96O"T^^SO2]$=Z;[23:^@Y]5E*3I>H0W^V(T/
MW5*>)B]3)'AB@Y'5@(!V]7;?7$Y&_3$R,XODLDQK[% _PWZ:31LS1>30IFZ-
MU?]D<_K'#S<W)I^#A[T5B=I!G3?\1AB7F>Q,F(.O,($6#=F4S1D<Z[Q=W'4%
M)@/_3X8N;UPBV^;!I)2@J6*JB16QWMML])_5TC" 2)PQ$")'0J:E,6GC[J3A
M<&)$K%7$Q(G.2<==8G$XR8Q@8''"F4;R!$=2(Y5FC#1.*'9$."M#/*HBO\AZ
M$]RAHR@W^?XKWF>I#GT_;: FO((F+\D,/CHL)S9:0)%"=FD=!L)>+]V18=QT
M?1 M-4:W*[,Y^,YU8]SRD&; &>7_JZJOS HU'MAV,4J -2J7%L>G3"C["3;&
MWJHG#W3V[._HOC.)UMR)^123^(/.5Y?=U5<=HDC,5W;R)SGHG\P:1;L0D@\]
M>"HVK_0'"Q'SC)+"U6R0$CE%J9 9P6) K]"W)'W.2\X4?@X\\'55YND9A>>1
MA\P-)9[[()4"(C0,#5OQ/EAQX@L!\'4<?#9.JG%F7$GX/J#\]0P/?6!.J*EQ
MQM&ZS6=YRC[]9CH[H]CCWE]8,S7$PW]G7,%@ :^=.3SEN:V(4&0=R!WP9W'
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M0FK@.*@/(#+JB0"D,"*E'?[XK7!F_RJ$_EK GT^IRL6]XL6H35KG2-FS\XJ
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M-:-N\^9WJ!A^8$M9MTE>XL7D,3L)%:#3SE8Q/%2%"6B\!BAZ&E(0D!W+]Q#
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MH3\6?, ?J-8Q3&1F]/L#RQB+E'97-B[Y\79:Y]S4>2KI]1K9[,6)YXT3="U
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M94XFIK"4$\Q06T*.@*"9< _#*(F26F, XR\V##U.H,4/ABZA1Q=+\'2J_KI
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M=0%BB:V>6+/4_=V+8YVECOVJ9ZN[3VI[MA;OV5/!*V;.Z*)B1Y;3^2!D1"+
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M :AZURBL>W:<IO629B)O)4!_+*& 4*&!G&SL)#0\H(6-40H?Z695XXC-JH)
M[&S6[G*.]M<72G:_9N<</!_=.KVK5MI"VBAT@W>_*'I[GB^XR($@,*S_C8L1
MZ16PYG7Z57J^QM+QM>/5?--I[22?!$E+V(N'4/8)53/\8PRN#9\X-_2N.E*
M9JNJ#L1'U9-JH$![C<DK\'0?@@/8?06W>8.5=#*.A1!-2(AHB1O5Y>#$T]%H
MCR-OZ4/'(.U[$,,[GP4>."=18E;V$]]+.[%\=4FNE#B2H#P2F-7*<?ABTHUA
MA^59\S)H*_[1G? (AQ%T-1*]O" 4[<71=#Y?%-6*4B($8SP^ N6"-S#Z1,6N
M5":,J&Y ]!H;$2IWMB]#V*$/OMC7N.5M$_("@_YOQ1)SF, I J95S9Z:Y7(
M^.3"*%"A+S>D%663U58U="%TZ&LOI! IYH!';+V (PW;> &#4\2DW"LSGX'(
M-2<:V$B5Q4<8L0=B$+@=5YK)$ A@HT<S=^[::A9W+>>2.IT7ZT&RQF<G4T%6
M_;78!"HO29P^4(<S&S;EL9H/T>D%<NY^R&D1GX^'G@5&R:0Q.*/@-$IO+DA/
M?JZ*C.U]2/5L5[<4<IIY%YV[1>'62E<($UG0#8@#BK:\&B NN?*&Y#\0+AOB
M$!PH3WM'^>&+QL995D,N)O^?*_8F^.)6\B8DC>0?",@D]Z_!ELLKEIY*N.B
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M)D[<XSN#C8]]P4;KG\'(HLYEETZ$>X0ATN6A:PQW:\>(E?J&(;Z+-1*4$3%
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M!;%_D.<)1P1D)4SV4-#(<Y)\(S>D%PLY(^,X?CJ/L+J'XG9XX0GFEXM%@<^
MI##94<UB$3^-ODUR5#!BJS)&:GE(?-+%8*@@-DZ[$B8>4\*6=I:[$<F;[0%
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MJYC^<VA.>=6<^J$$R\W9LQ<WKX(+%>_B%,ELF=PD\C*XO/ F/\QVR3:(Z+^
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M&)Q-O_\'J2TQ8R'_QXY5L^,97!]3]N\GYAR\IOHQ/T5;I\SA3:%8A.(N\TL
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MZ5IE.W]-95$0HO.)KK83J(<R:L@AWK-7,RC(5W @%*5 +VUT)?V???)NQB
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MD5A4P?F2IOK$#?J2*(C0/QU!A*'9%-A5Q_^>JH%J]4I4Z5P3Q^QQWW(JQQY
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M\E^G&1A7M7/F6!4%F1U94%$]]['C[3+*R*I(LV6V7*^I'I<9/+ILA5%PWB5
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M(./9G-(5^RL5]O^>1DGQ,RV^RTQ9:XYH$,$J8& QC^D%X284$K(U:GXKZZJ
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M;-(A+E@(>7Q-!>WW_R![XQB;Y28:I+BS5OO O+6-12?EYR\DCO\C2:F*3&\
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MSR;W7>%._C[][K6ZKXU+CLZV9\$TLW=NC6-=[K!GP2NS%ZW**YW;ZACL081
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MWX"_C\/_%( MP<S[;5.@I1'!MSAYST"*+Z*'^%CDR+$ ,H4HK-:EA-2$OV*
M%H "=GI!.W#K7_=)FB/_;.3ZF>5G7BFN# P>V(R[683+$J-XA)F9$V+C2!BG
M8I%.B)<3D; X#W4B!EP6916L=[X0<8UR_+47(37Q=0\ KBN2Q$N5V-LKJ0H!
MB\ON@IT-$"6:,)'R>2:7%!@XW0U88&W8>/9.V)(1!_!?T@*T[RC)10\8<C);
MXFW%+L[.&%]P.*B,W5!P#//R+@_.N&R:X"K';,@W$^\D.R&ZJ@!R",=P0C:5
M!W<@LW)"!AU.JB+\T EILQ]WN$0Y\TN2!#_"*,+>]MWE"-=(EQO# *&L%2!*
MW$-Q64Q\).W+3EB3O2]RM$<'E&7LOYA6*U]D*3R4?,(,]CCH7) O= EJ<T)(
M4@:M&HJ>3W;2>%55P7U+O*$X<8F<NTFTM[Z*:F'F[78IV%5)Y-H[Q>.[8GW-
M./62V]C)V24&D<6%@L\'^4L<?LL\C&#X7F 7\&_P>*9O>W!=9&$,LNPF.;R'
M<;FW$#7LS+#$@T]:3URF#;CRH<Z1X=ANGBE4;A#M4MIF6\^X-;WL^M3ZF[AT
M*C&4WOHK^R2"-)PA33(_X0>-.B[XV3N5SQF\1<L.8\!.5QD*_@N%EP#%.6_#
M.BL&WB+(H[IOF?"WX@ "215%S5?,N$2&L02R6"YSSIR0RQ6 *WV6W3!<*J1:
M13S#8J_.%_B?W\X"4YG?:HGR3YF?2]@*1VUNP$V'7!;NH^3':W$\1E@@]:*6
MM7F FYCX:*K?/NM8I>>2>FKOE^* CTVVV6**:W@=_R%TU(":*YMNC@"E+HAW
M>(XUWSE]]?(",16AC1TRDAF,G7="Z3X\$H?!"=E#!$D5Q\\)>4.&+ <=8XNE
MAU90*LK-W1%FERA$5&(X6W3H-9K,6P@*P(<DQL"BK$OI!PCND[2TU*. :/0@
M+>,Y-& \,TXH>5<(+@M#$+/8#MJ3[3$N%^GCEGA,SVO">]ZLI?+,0'D%,ZQ(
MO[<5:<ZQ'CFH 7H#.3\@WO8R22#4>O/P0U325#"P4:!46W;UPTN#]MR;:(:6
M8#08H!$?,0"LN\,Q2DX O$+>&2)W)]*^H_ABOWE<J@TLSP"RS_*4B..F^GMF
MW%=JV!-9'1I^QIW0C.:!?@PG<4*GFG(;E/,HB_6SG@389$9?IHFWF;ZPE9?5
MPX#K]AQTA2("JJE6CE?7( ;;4#;$1WY$ V"XVVX!NK3.]/D"N40OZ%$.AP%#
M&@!$[7(/ITN*SI7$0&XT?<NO;93GV[-.8,-=JTA7 _;U&XJ?KNX@N!O50<P@
M=X[NDQ1)$9);*SV@&6*!  .G/ +(,THGQ-W!@ YAN4Y(KH,1E>3=3D1-R8(I
M=!,X4;U],!G*7S7SE777^#QU=URDQM-/!\Y[F:(U-T &ZL\-93KQ4161,"IR
M:3=-N=$,6/Y5G(<!FAR\<U]1MA=\*]Q]^E$!":ST\S\<B[RR6?37)Y'O0-6'
MS&"$O!- $6_DB,T)67$8DNKHUHG(L5>P0Z;,AWB;I(?%OJ]6JW@!1Q0/&.\X
MUPZUN0%\MS^WULY<GZH?)=[YI$8SX]SS-I/RV"&'F\5>%*VWC'3GQ55X+$J+
MA_R](%25.QAZ>@N"L%QK"ZY;D'MAM"P&<)6F7KQK$OL^P26=_Z5=7^4K.+R#
ME')N9$=1[$EU\_S0COPC3I714!OSNHF\+(,G$#TLWB8'+XPI^!(:ZIMT$G\
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MM6?XE>\7AZ*LH 6VH4^5N04ZZCL7PH5E:<=#? !]WDZ?/L@R&:6"U6-";OL
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MW_A+FA1'].CKQ5#=.T :#NC4(M!KW@NH#11)9J<TTD;056GDH%1_F5R2V-0
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M-2T]0SCS-D$Q\R;P>LU[*Y4EN/W!5U2WOP%Y\81E!:X>TY<3[;2&BPL&Q&2
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M82*@E#M7'F+:0/JJ+0-_'R=1LCM=0Z'U\K9D74QB?4W<3_I3**>3QN?IP[&
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M+6Q"[K$JPN);,#7O<4(2-VPOR QK/N_!)8NKM2=-5>84[R)R[GH,O7=$UB&
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MYR&OJ(/L**H=)0O(_Y 5Z_Q1NN<RO;$VUZXW.#84N\X38@19D-MJF_HCE'A
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MP6V1-M:ZJO#*^=+(ZAKJM'C8 0,MEL;J)30;_);DZ)$QA^O.0G]*PA+Z]/*
MQ=I9$H3;T,==L+48_>I%[9&0G4@UL#*?UB_V04$A] %YL4_(K0+Q<KRN#%-&
M?PE/2?XOD+\ /]G%*'BS?3)Y(N2DWUX>S=Y]'L.T]"F O%PU6?9&MX_R2O8%
M);7JGU"[G^8F0?(DED>+1+'C2YIDRM]$&5]:'FSX/TC^;>05&@4J_83^")R!
MWD5G1[]+YQXGH@4YR7,E'7B<@HP6$D!)GFXW*'3'HH:69!Q^G,!,G7^05 6
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MBH;5X='32@%4-<<)3"7/_RCR=@+0B1@ [^2K?3),<B\R"=1)3K[;D$H>? /
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MZE_ ZT,NUW>V.?\:YOL'**-MPSC,P6.X)=[T4OVU$0WQ4;HNOD6D&E8/Q5M
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M"A!\.R9QV3"#.R$K>S!&4LR:ZCS=Y1<WVQ;TZ/.(]W<GL-F^[<&FR+/<BU&
M5MF1Q,Q4#:UMHRMO(SCUA@I;:Z#L*:>343(!*F:(RM$/EPEH(^C;,^1Z#8(,
M19Z7AI0'J.C&.W3&F!E<!#HJ/GK?CML48E81#,01(.<8TDFBM%0\G^<D@[=?
MDF$WE  <XG ;EL['F_<HW.$_D68GU&\BMG7MQ=^O?!]Y^S%Y4*>=QBJ V K*
MI,-N&T-,<VR#3,<:3C=^./'61+><=$-2.:8*)[#B63A8=.50H6N>.:)3%4E&
M\W<"/6$CP3FPGJRM.X$6UW;-.)-. \5]';ZT0]C^=,ZQ7[11$CBD+E(5D]6+
MV5>L]T00/8<T$=:-3!8\:VB'L @B;.V#\'MKN97<T1M@ 70D7E[T0%)O!S>2
M5PA0FUK[K!/!\P-O@\<+SSVG8&+R.IX1?)*H[R4#)F5HGR(P>='HB=COW8C
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M#X&7DA2Y9Q @9/-NM^QLS0<@^=F"$FC'H;: -:(+YUE[!!_D%]9)#5IJ6@[
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M56+G._Y;5'@LZC"]1X .[-7[9.!@HH\9Y=W--)ELZ4%X1.\D29WD<'7.)&/
M7.5I&(,49SF\A[%7%GC'KSY.A&N6>A>1^I"53-=ZPD*"8(^(W2)QHE-FFXJ
M<6M:Q=8(TT4W38&KU5/<++8S,+R\SJ)5"NZV.;=<+I%R0"Q[*\M2+4S<9GS)
MU;&0"!;OE#AB1S,[@HW2X34Q.FK'FMUH$:0:C> ^77<=)6+<4<PP LHQT)2@
M;JN!Y/((:AAX!64+ 5;#*%'>33*HM%O3AQ*O[3@F!L8@G&IV2$516XVDH<\F
M-:Z:^UCTJ,P1O"@^H*,1X_Q3*A7K>Y+8)0*PK4:$\%%A!V=7KPL'6XZ 3KLD
M(V%W_A[(Q(VVM#&Y^&RKL2'UG$A$:S?Q(@@E=@0?O&=$)T(<N39R)4B'I+$W
M,46_>HX@AD<QDV#&$=(9H.'TL]!;$IDH+MYQ=$CE8K2KT$E$UEN-%"GV,B#2
MOHDE9>W1$8SQ^,Z\*)N6(<U;_W2DJ5X)\39C:T8;+"W'PE'4B(RP[>0,1X$<
M8Z!DYWTXCHP1-DK%E!)'$:5F;E+-5G$4*3IM#XW4%IL+,$_Z#'><0S;C888'
M=GRVD*,(5#1M#\@V<A0Q&OE-,RW)YH+?LXC]7,N@S=BQF0M-531X!MSIO&>-
MY#";2\G/<L^XD5 V8\?2>];/PG,4B7H?MK],>>%TM3*87)"F.85M1LB$=VQD
M<J2C6--ZJ4[YDS;WQ3#UBG7"D6Q&T=373#&IU>4>(SI>?9(:ZW)GD;'T(LC6
M=;GMB [ZX.8 .]UQ1 -VY!*+)\&20XXZR2SE2=#DDKF5G_$\"7H<L@--E44]
M"5Y=TOL%"=:3X,<!G6U4SO8D2'-  M>4\3T)^ER2RKE9XLXT.5/M;_;B;T&0
MXY[K-VD68M-B4,E1!RR4%S+#N(9GXXL9P 3I^-GQ*<(PQ 'FG21PLG>BW8H%
MXHGF&K74F&?NDM8J37GZI3_2I3_2!%=/6,9)9J9]8 E[W,G,M ^L?IB^+%B-
MF><)EOG*Y5=Y2.)6N-4*.X,N%<H'\:IKD/HP)*(;TD4!W-U@D2O%-J2;.-^5
MDO)PCB:YOC$4W0,O!=LD"NZ04I\<BDPF+MWQ9F@NXOC@^5LDE\$CQFT$_ PF
M<>A?@T/H _HFI:>9JX.80R3L(W$<;>XV_,1_XN.;,T$WNA,T\E>P#?V(BU[*
M,.=*8*EK$JT:'=*BNM6)2)=*-%^F$LTP.I<2]JW&C%1VHH+P+X6=,ZM=-AUZ
MSB8-6D$A:=NUVX*^S5@0AM4,M6-)T<S40:*7Q$)'WAM9A>U<\<=G*%QUSF:4
M3,I=SB.E;"!IR&O2CB=J#+PR/(7<\4CZ091",P(XZ.V\]4)(HB<>$$M$?]^5
MY2-+7[<7W<5I!O.BKD_U;X5S$XVJ7.,AQ@&9'RRR>DG#WL]Z'[SMKN)GX.<0
M8J]^'#PF,:S^>N6E8=_UW;4Z:?V&.6N;!C!X3E=]ZYONF)0^)AE([Q,O;MR2
M>',J\G!U//U9X!(;M:3!)L?-O7"]2-2AKF[<O+^KN#PG]EHS<19],<>;9S3-
MYZ;^Q[^%2"^!_O;([["LM(9Y4._B?9ZE][ALV<]\%P9GAGDPKHY]'),M\OI^
MRTTVV6T+I]^<KKO Q\0:;K3E$'HTNH&Q[!/A3##(F)&(&>*\0OKNZ/_*/:E1
M2UX0T:F^:0PA#TD,C@\>_ &RVSP.^* R!IOGG'.]=>;/JR'5RXLI@DGFSZ_Q
M'/-;JO-FZ.YQ_^OS-8#HOF;A =01ZIR.]KSQ5J'X%V44_V(:C.\>A%Z<<3?>
M'N-L(,@D1I66G5&?*<)F-Z%DN7$-1H=V&66:"NP(GKC5QV= U-EXX2>_PQQ#
MQ;F@3D6FH[(WFE7 9N1(>QZUVY*IZ!-8(VS&I 29\4R5G:1^AOW":@3(M?@2
MFC8Z#0)&J,Z.8(O;^&LV=)W-.ZC#W-)$*LM:836:Y/I2*!F!J0Q;[L%T!%7<
MAA3SX,J-3A0V2*,BH]2YX$^G2#II??79@^$F%4EY#Z_-V)OQ@92P6#H>;#C)
M)?S%!>38<0G'V7]LQJ\!.;9CSC[SJ,9%$(0%.'?Q.H&[HA.=):&+5UY$JNMN
M <A(,QA$S340=1'^I4<.1#Y:<>BRYAU%5T?:WJ5B#WE3+V&%E[#"H2$XN-W5
M:OV2)?X/[K8I \UM.HD/N(@LPN$36A% ]/:2C7%]F*)9LQ;7>/%![*&GZ2U.
M]\ /UR$(J.CGCS6R95P#TO=2NL.8,]!<S:WZ26C0,(<%L<=K#H/@"I6%<^4U
M*81I4EMSC<O[[S![I 5)C%C-9 BC:O_3?E2C] KF(L%.@AS1D(2/!&>"-4!@
M@153SS.Z+?S0-O'$>1E9=;\K1L4HQ$8?Y]XS83ZRCD;.G#O-'&X5  ,O\$2G
M(2"D)Y@$N4]>A1< 248HDY#88S6_?]^65V&RWT+<SF^9P#UAVT\Y]+=>"A8;
M" C^V&&!2O-M?.-X'6?EWSGJ*KHC-NOJPD3$> XW6T0@XB.2FF=:^RE-1BM(
MMB>C!E%G:$9Y6TDIO\@IV<4=;X+9K&#)/ACO*W78)9OFDDUC3Q+)/('OCTG9
M48''2.5FVL5*><3''&\7"$-?@]%BWF";P1^UV IZJVB&XU< ,_"I*O%)S+HD
M.%\RH,B^J/[ZME;&@$AFI@5@$0)2!HD^2_/M+GC&:W)5"D@@>(L# .N[2KO;
MPCFZW^(6\TY+[IU6?[]+TQP$USEVWS\A["7!R]:#H/N>C5K*KJ?N,<<,=+5^
MP5$+Y#XOO2C"_5*[@*D\APJKFJPA[@,0I+<PV>'#PI+]Z3@9T HFV76V-Y\
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MV:HH[J%%)Y3;9C4*Q R$&S31A+T3HN HV(QH!@PH):+ :B"YY$V-0:B@;"'
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M:.I%&6X, /1]D&:A3^(9X9';PH0^UMC6L?!:"&E1E'QXL4_BC$O3,+8^A$F
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M8I_YY0PE65:4V-)+M[=1\F$V2*S:Q4!)5F:Z&5FVMS.A-,N8<0ZBR44 =UT
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M@AL/QHAN4_2PYKN<) F@QR;T0Z=@%O)>G&P5XX>E2;3_83]@,BSHU^<' #<
MEBRHRWX<@)+-?MK*[#,&8[5^2PL.Y!*(0@&ORWW00 K_<0!2297]Q&_D"EVZ
M@P F,RI"1B#8>V% ]Z+\I_W023O <.)$6UCL:J@N@=UG4>0T[[TX>"L94TK7
M/AT 3F11[)R;FT#*Z6?T>_DG^\%3NI>-QAD.@LH6%RH[20U?7U-Q #Y)>Q_=
MSM\]SS_;#R^+MY8VOR6 68A4$B0KI*OU-=@C,==Q^"@LA\)4_Z(&VDS5-&EL
MM%L&LS7&:&4GB;@K*@AR<XV!)FN%ZT EG&:R^3$[/(Q^0IP9-IP+_XI0!IJ[
MTHQH-?K=I@\VS(^XC,C<YO0&,'2 T[2X1<B1!M2*"RZ^V6;9:3N@C<E#6\.,
M;7A 1!H5(O5UC(',BD"CPL48;+*6-"?$C H"=XHQ0/J18-3-]X:9ZQ0FCN^B
M0B">9[!"/R-^B_ZH,T8;EY\D0K.X(I5XOMGV=-+"+6NTN5=[4/@0_7D?LI0M
M;XP0.O9XS=GV_4B?UG[H8\R2/R-TAWT#Z!,T(Y(;@=+'*6^X,?2*@DRH*!9,
MTHUF880(!=>B.<80+A/]046ZQ$2#G4.:,1[4[;>&Z*<0>AP&E3"H0RV1*7MA
M%A+R9'>.P1=/$$G!>/?XLTS*EFIQ$BP)4VD5W:5UJ#$/_7M!'6<2]3(Q#"R$
M2\S5C&9>,$(?V9S1UJ@98J66/<$L$#)N,LI T\1."PS@$3AEO'%=A^;\YRH[
ME F6O,1]K[Z*:6<BC4/@EZ=P&NX$&^ZI')_IC>V73>D41IFY;@JNH8DDRAP"
M0@CIJ5K3 ]*DL?ERM:;3"JY%1&I,_F))414&28\(A'$AE1_IY0 PX$%* G%V
M7^> A@7NW+<XP.55\QC7GB+J?^$0<0DYXRG"S13H,43!Q-DP\(T^@6IOGW7;
M-_*"CS><*Q)?UU@N.]U. -EL4QU:YEJV$:I>1Z(5<A&UE-RI7&4M%*%?22A9
MPSB"S2*%?F"+9-3N*%;$O>7H-$XPZ"J24NM%9?^+*Q"#=4@5&O[=UM=3C*TK
ML$X@:"BR-Y\9]!"(8>S!(ZG[JH*RXK=BN1)OS?!S!P2M99*2D,JJZPD-3CQF
MM?Z6) $)) 7P$"*6]I)$@4N0MMJ;+ Y(_2FN2",LJ@P[N_+2T*<AHKV$2N&1
M\[@]>GG-1/?4'6%_9G9%S!IH>%(]Z<6Z+F%LU=YZT0Z1SK#:3*T/HK774(8C
MOP!RVFC4@P=_@(PT^B'#73I-#1QY*I[E#A)G9B*W7@A)]/"IA]AJ_=V#T".M
M;?L5?*R]9Y*\I R.JI"+VTE]#[/M$@&/9N'XFH*\L+T8_5_0S%]WH)"1#+?!
M$5EH39PB=8VP$24DD+><<4* _UL>$@?+$TQ(T%'B5N4UT\]QEX/_T8%+)$,^
MWY F";T(C5H$NS .<4\V''S!@==6<.<F$1J+<J<V!H\XB*^PQS+HG.9<8*XO
M!+/1<+_ @MLWOP-H*RFDS@BA97=+@3U7I.&4:G$O9G&2CQE&'L6JR(&^/]KB
MLQ_-[Y4)8/@7#:*192AEX( QW&"&)9W9]3(L.\.,;IAELF5NG3'!&! #[0,=
MR%17L03<X6^(^CIFH[)H)DFZ+Y(QVKQ3M6]"8+E1&R/-Y>)SK(?4W7,FF$LC
MXANBJ'#PYQA,T!E@8J(".&0E@V"/,"LQP!^^HCT\D'\7F<.- 2"T[U#A$,W2
M',<L;6IH;59IJKD#8-H3Z)AG#;<& ):=0 H<QN2S#%/ZHR5A2I04LVZ26J<#
M&VOXV455C(9UHC 4!_&E*_R$E15YFT"$G+B(P_6/KT@L3)$$A;\4!^1O)2YJ
MZ;':&75#G69Z;N->\1J?N]=]@EL]$U6>->[G"U";D\!GJR(GNOS]@G+,&3:"
M,<*F-G;5BU'1"@K0Z*G3_16S]H?YI"&V46.V/9P[JI7HV.R>+/;L.N75M\*D
M\8S^\P^A70,7(;N-DH_4$ML%KM:&ZZ+!Y! B^*^.;RFV]=4>FP4B^@.S70J:
MM@ZS5F26"XH> KA3[?X9410,?718937\]C\T1CX!&":XC@;$*8'7H/C?FH)O
M/OVM%V_ ,SKRF_4:^"P;AC36W<$K RI<B2R5H*4R1_8U*4W.W5)W3AF^&+BX
M#6,O]F7NE0] 0!CF79KF: Y8P<+"6]4/=YXN)'G,RQ;)+5?HCA$S,'JDR>><
M4MEMY3?4F^D.7C7SF\81<-OPN)!&->S*#0I+=B"WP=H+2'T.W,&KY@O(K)KO
M5&;5N-<.,1L(_)!\!/TY J7.N=AAU>A?[;?/@9P1\U>O^ 7)38W1JWC4ONH=
M7(<I>AN\Z!M,\CWFC[CN"=%O07!2;UTZKY%7NB&WUO$(08[G=(7X\\=%E[T5
M@OL#R+:8IO$:Y'=:?L^9,;=2KBC+:!;VFU4LU_30A6R@<81"N$TI=.&+0_Z<
MABU.[T#3V7'O7I_)=[JOX3>P5VG8I5:GPXBD**)..A>$P6T"&\1!\BUH&#BS
M>U+4RRZX*>(/Y9.[6K_D[VD8A!X\#LZALP@)DO=$,:GPKV>/D#[CJ&*$RQ)M
M-';Q\]E;S819MC^?N1EC281]I&)760^K=25P-)K5G-!Q_JHEXZ90L>%"]841
MQ%&(XO4=6;]A#V/MKUNLUXAA8''TA) S%\ZOO. :O%?)(E4#!\1$\8(DJ_:$
MBB\HBPJ+"[LK?TKB1*[RT<^*?=S=P0.Y);TN"NU,_6;QRY__>M:8P.(5FDJN
M0[>2S2_NNHX&,XCK'+PFSX"T'7KR8-N0[ZXE7\JNT[!,(QFKV6KGA )WK7TR
M*& ;+]!+2KIFTH2L7\Y7IN!:=1C=HDYO+$5A^^5L'UB6LD)MTW;"QY_/%1]<
M'HO-HRPN^Q5-'563QR8B_GB^BCT;$64[O4I Z^@Q7=?35]3U&R632HLZB5AN
M_//IC3IAZFS?;6F_PPD7BO7W9LMP482^G]HBNX Q()MAQE0@&@/,)=X8B73H
MYN7,NPG;R)[C29(C>]H"YLA>'!%-OPW">;:=&R<L6N[<: N89%?"Z&T6&Q--
M-%<VBQ&&306$,=B>FR2,]96[6*)E+F5\AA\1)QI4[G#8"QCLVRL3W4D%3VJJ
M,<!L"+*DHLV"C5GQ#K&B,87O$&.B/7R"&58IQR58T[6S;K7H1QH'5UK!J![$
M#&=D*BVL&293I <%)%(A'+B89AKDAA'V"8XW7//.!-%]_;WQ)WR54GZF;P0O
MTD[R'G"6L.84YZXHR;J^DA%ME)LL-],VRF)#I3!1\R'(1X[UCT%ZKN8]RP1W
M]7<K,<LF@E'JI"X__U+AFT55,L%0?:J2F*5YG]10I?[&:,,LHF]J@)$D;=/F
MZE9O>$% %%V&,USSSA1C<_I[55O (I)1#;61UUQ4EIU>"&)$RDB)0?2Y%ATB
M(^A%_N939EL$7BN 11*HYAR+0)$+09&$46HQBX!7BRZ1/FB%12U"1B^"9)A-
MR+H*=]B^'25I#L$+CLN!Q]7Z)=S$Q/889^7N216_*/31[7SQMR#(L4K,?C'1
MB5Z#S LC2^KA53LEVT3;O4^\N+W=HB8DM=1$-?DT_AM$FEX]PYV278/04)FI
MJZ.NG?*GB8LH2CZP6_LV@4O$V(J@G2Z"7(A@'$4HC$E4:E','IB'Z2E#WV%^
M\O.-@\@Z'BY<C$GZG4K#[QK5PS1X.7,113)7B7I6,C/M?8)K)>8!"0_H[\1K
M>3HY+[J+TPSFY)\[#FR['MRJ)R4B*VP_QS;'%^#GL% M"T,!CB-*,]RADEI7
M)M_E1,$A1_<6(W$JPG.PI;7H%XL+U7>^<_H&O:[H[W_ZR=:79P3&6&N<YK=7
MH[Y"<JB9B4L/1$:7;ZLNHY^3CR5B*C\?N:@UQ\JF3ZGC9$ZWE[]?>1%^;%^V
M ,E"R6Z?Q)AUGU2JAA6$:,4XG@\>0,G<;2DO7NWRV' 'M-,ORM^?O8\'1*@0
M/5Q.U;R6!O![ G_4P9<N5=F5AO 6][%$Y$G::-NMOM!@ZIEG&D/,;[1]/_@[
M;HTUO_4.Y?/WWAYL?O,=HN9OOCW8W;>E=/&45N?:O[/LQ>C8]=C(Q-1QS%9X
M))J*^XR@J=]!M/8@<.DM&@/_2[[?1R$.G0EW[SE,0:N,G //E(;#K^B=U9S9
MI=+<&M"!!>>4Q+3G#5)P("-X(.R-Z805P&2-WB "V2T /;NL8CJPNXA =.#!
ML(\ !^J :60*@BX(#M0GT8B,%T!Z<55_I=5?/4<L5.[X;\D!P!B?_[=V_3,'
MRI^-Y E%_ %[1K_NK#U:WP#0&>X=F16F22"B"*A4PQ]]K.8],83&_H;H Z?!
MD%B*8R),.'6:'7<$+>;VVN-,7B.N?,2Z.;Q)IH'IR3@\(+J#IZ5CE1QOF8G3
M[K8G&0BWV9TQ49AZ_\WN[XPYUFS/7-572C#)7;L4ZWSL,$-Q2:A$/@F JY+=
MI.5+AP+(ID,"SCQBQXEIDS(5V0@/)!G60IT_[]X';'>N'3;/7'Z3C5GN\KHJ
M^[=9N*0.EC7-ZJJ7AEEBA>$K9(XG\0DN\+>AD#=B,60JN8A;(:K&R,Y6<D2(
MEGZQ$?84^P I*54-E&*2225'$_&QU"(]R]O+K;L5]$Y\^B;-PAT&_3;/T, F
MH*5*8Q?+QC[J#-R'!U)*I@44@W5Q9E"@?41X?_T T0$\)'&V=8JI3XV;OR-]
M_/4C<<FM.@M*$)MSRKDZ!U)NDQRZY'2=!2=-)[P#_M>I<;)89P#V$*/HEYVI
MG(44*KKU+/B3; 1&ZD54!59F44>043^!&G!0K>42Z,53IPMXLII#X!>/FB;H
MR6(N =]W/HY<S!'@.\^4!@RT5[17;?P6AV^IMT0<&H;O.?Y>^H861Q<75%7B
MELGN/8P+N62#KC-6A)N1N$59S!(3,?Y#OFNY=59K4FA[%9\TT2HUT!*5DP+J
M,_"338Q3D>X"!'"X#KW3>5<PQZTB,P7@#+E)YR?*^K^-A$F7=-@)D5V4A=.X
M?K=8W\C4]S-#]R2T7;J;R,BRR(R@6=+E#*8\ X)REW1:E_A+O\BI2\'+CI%U
MIY)OAXTX$!_M$F4+.X"X$Y#L&)GWD^!8#>-<:$CI$LTO@@..F"A+OQ<\'>MI
ME3/EIPN^]>);-@OT= 0N--8T< 0WGYA5+Z,$_;(IVBJT6<7/?[P@3B^7/L!^
M:==C,T2OPKQJ$^YY#&P3X;IC=-/]E;- %\W\,SGV*!_5W01@#KM-/T9SCL^>
M!]G)6V:FIT;IO9P?ZDN#S+PX+CYJ\8VG65*FO>R4+YX%L3',))/3&_V[%I/<
M@":G<W[^+(A1PI@Q%R/D[,%B(F79)*:E3<97;<:3O"UA8M1);V1Z;++- E(X
M8$ZWF [$>OFTQR_\OFVQ),_H/_\X!920]E2-[ -26('$C'@1)H';*/FXB]<)
MW)4I&*32\Q_LVO2#E^'ZJ\?5FMYUK2XL9TG\RCTB/@ 8'>*JAL+7.6A:M%3G
MNIPV,0=^'$R=F TM8](GYI%955'1$3>EIUL/H&0L^.#EK$< /_Y;=14WP.7$
M?*NO8[F TFC.=<IJ)]GLAQ"7_;E-8&.(7:F1@MZD-#Y=3;D% :X8Q9SISF.N
M 'RI-)T!T")(F+"_9%X&2 \9M&VG43"&^!.(@(M%=." R#8 ^#. >C#UEP>O
M#?AYWFY)2N^\U*)9QL$1/4%<J 2333;75(#&NNW+W:P.%())IH$1/7D\F 1S
MS=\AP4O&OT/\R:;/C<VL>2?&G.6.'H*-Q;&/-"KR[=6ZY'68%G/<M:,>^HR(
M\S7!:HL7'U]NUFO@8S-Q^8M5)LEZ<ZW-XT3#,,Z1(EEJE$E,[?Y&G]W&TR+C
MXLDET79Z9'6O/J&7$$W$5RA$F'!(&AR&+>*ID4'5$P0U6EK#$ [_%F=.U8&9
MGK >$\P6<S3L/0(E!W8I-6]B8J*A9Q6#UW!7_>T9D+IDK\GK%K3RL%W*N3-#
M9X+4(@<RZ*;'VW+KQ1LTH)(!<3M-XH7&^?<%L%7;9)=2X:9'W'5!;6B%F]T^
M2HX O&2)_V/U$0.8;L,]+@YX'1[" ,F%3O47,7-7VVG$BEE_\Z@AZHCI:"0*
M"U@&I*)DK0"]VLI6HT4L0P_&BW!IS1%3>N3@?B24EG6M)@*ZO#OXX*G+&3CL
M47+J,#H8\TGG2$0J1'RBCUB-+"7Y=#"V5+YB-;H4I=+!"%/[CM4HXTBC6F]?
M+T7*<JOS"Q(XPG7H>W&CO<-J75F7>U?%*O-R;W>,PAJ]<<[U<6!!( $K^D/U
M;XT7 AY(5@'),R"]VAW&!2U+OS&H#E1[QG"MUF\IZ%3]46U28074\A30C@EP
MR<@_X((WHO/%W4E<* 0RXN!/ 9MHQM*#\+A.X(<'&Z8J!]P7@[D\Q[CI0B&3
M$0>/*3T[/H!LFZ!;CUA]MFL5"'7 )3/NQ5NBOX<9G>0=\*2(@>\^<L6PV_"S
M483W5*$X=<D=,A3X.R2R^MDM6JLTI"T3N$]J8ZT[MOFA"%AZ^S#S(IQO^ J]
M./6([K9,4K=:?P\%OYN<9W>7;]ZKQHC<:@VU9^.\5F.,P?9L7E([D@-.;K&)
MFE+R-9V^=59JGCT'U55BY$ZD,\L&<.04%!%X4JO8 *Y8$Y$[2<X*]H I;:ZV
MV@0MKT[(P<::;@^ +(U!FNW39D_'YX7"/I?;BV9/O6^!G"ZQ=_X*4^^?*V9+
M[)XW?^J]]V5DB0WW)MGFWCAY-F[VZ967ACYV?H91GB%!;)\NLL)IC(NOD,#Y
M71(31]8VB9""8%EZ+Q+N"VD%/W2+ ]H9:]\$4II%Y#0?WQ%:Z!$:$>4!^J<G
MW+0(A^0T480+S6!/>Q*AI3>(-P"(F+9+/H+O9'^(P1T0Q!OPF._> 5RM2YIX
MV7H(H%6>I8CK82S0D,A8HC>W/ 5W<*.!P-I+J-"."ZX6#<2#L .K>D<%6LFL
M-JK(OY&N6&4)A06$.$*A;:NU,CEU( UU)"G550SG=^IGJ%2L3/0Q8\@;>)TZ
M6%%=Q39P6>^&"K",-2SA L,I7GT=DYQ@-&-GW?JQ"]LFEE>E]&[#V(O]L(CW
M+O9:_717_]8H![A:/WDX-+@,0EKB,*L8P8S^D"91&.!PT"LOPD:2ERVH@Y)L
M$>!++:]=*;(I'#1JPR/*[W83=$"";!:LC(/F.UV8>FA TQPS;H'*.5$2]4<;
MZ@Z@;4=!$[@./;L#$L7.P:!(!X&3NW4-2;IHM>L0A$.XS"O884,@/!9#B$$6
MR0V+':[4W7Y+BS?&I6@X.5Y4EHYN8Z_+H%P"F\V9&LZ$NWBQ7I/ ;)"^Y.]I
M&(0>+ HJ)S[Y5X2%_TW"./L5#<^A6RB0(_Y%$(3%OI^\,+B+2T/S^0!*S--U
MTF#I6W<IE'$(2Z.-<B>,3P[&9RS QR"X\6",V#5NK9#O<I+W=0W6H=^HU78V
M,#=@+&K[(VT'@BW2=.JL$ZP.(PUAM7[U/H>&+\ZC%E-UGHZ&VQYC;*L,[8NZ
M9?I8<^5\)=E'MWJO:)H- (GW;L4V^?1"&6ALTTR=E+ISUFC#'(7+2LQM3OKJ
MV739^KH@=<N]8<8V/$"9HT*DOHXYJI=3WNB70FJN0<OY*&6-830?LZ:Y4V8I
M:O1S98S6'"O4UZM:NZ&/,2C%B34&AD@GG&CR]JNI!"P^H+3*5W(;G9:JNSJA
M7^WR'U'.JWOB/=\#XXRK\$@BS/G'1K@A8H;D;R5LP3_S@H_VU$T'#,7B@(DK
M@*BD6?;@YC.#'H(0D1$\WJ&54[[#NHGP;R#&Q:MP2D>P"^,PS?!7#KVZES\Y
M$.K4\KP/"R4<@5MW2$SQ3G;0ZH[]=>ZKA)YB_+%5_.+AEGM790]%EU"F>(5$
MJ=E6-D:3(/^^%LF<8=8D,L%3R;:HZ/^8Q3&0HUF#<B#D\"\:0Z-0>J"B0C3+
MCA! F? ^@YAG/C9TE+.&6W(#U9+RY.9^556PZDELF2:(?4ZX83;N2H@0>75\
M2W$J<YT*N\ 5ZICQ36C:.LQ:$J@#DO8XF-5D+1>243 R\/]C6 Z($:']/R-
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MGQ%Q,3V%RGB[(<IKZ*I-"N?4-'G\M>.&,HB;S8&A/17'C"?55SEH:K>J*VY
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M]XD/(! G_.LW'-5\=P#E[>__ %!+ P04    " #9@WM8_#@$D_D#  "L(P
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M.EXQ%:7@3@;@VN[> ';<I.2A"XP,& DF1:#5M,QX.R'A@HF(W@"D@SIR@M'
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MB%HRVYD+3!?=SNOQ&%'B\W3,)]KNM;T#.BUX^D/OP)XS_!-02P,$%     @
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MELS8PA0E<[]%WXOWG_1;Q9?F_P%02P,$%     @ V8-[6'9!<M9#!@  QAT
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MO%83+.;7;O?YE@1[GXC[)S=61(O/]=W]7'4B 1\D#ZQ0$F;"QF!C#@,I<Y;
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ML!)A%UY-71$A57A#Y**W6C8LV;2L7N<W0\F.KSG[Z!7_._3B9B]>%W-!-4?
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M^@D>%=>O\2$:9WP$0^%S.%IX4US^Z^+'\U?/+\7YQ35.-GYR_.CNL+X+MG4
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M[*20F4^8C+^+Y.TB>5\!/+]6\1,EC=HDTWU.,L4N$OF" P.3>B/=M!U&\+&
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M\?3AQ*3K[_[GZ<-YG6??_3]02P,$%     @ V8-[6.ZXVF!B$   -GX   \
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M@%34#\/X8/'-H$06#4JB2>/&'/["07A82J$%<"-A4Q5LB2Q,2G0"J$-5AI,
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MVR"6>6JJ%,RU-@'/EFC-SF2]X3GLA/M]V$SX'&F*8AR84DC-=:Z1R@F3''I
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M[TQ:1^L@K8UD;,814,'D;#XMPJLDJ)_[=)8$;Z]22XMCG0!3,]HB49M%,R6
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MSKGOK_?N63WFH%;57+-Z5GTUYU?4&GT_<[\"/):6@$@ * \   7Y >[G 3$
M"P,#$P,="Q,3\^%#+&Q<XD>X.#BX9(1$^,24Y" J2G(*"FHZ-GIJ&A9:"@H&
M7D86=@YN;FX0/;\P'Z<0&Q<WYQ\C* \?/L3%P25]](B4\SG%<\[_]G7?"A!@
M/5A&ET9%H0$>$*"@$J#<=P(@Y/=$1_GK OY^H3Q 14/'P,1ZB(V#5*AZ##Q
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MWO:0EDOYF.2]PRCV$SKNU1>P/Z[]Y=E_S3'__R//_LVQ?_HU!^"BHB G#Y4
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MW(B#R?@/,D]TO+S3!:M)%KA@QL[4QKQ%M0LL8T"J]R'@RK* ^% (62M]*-U
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M\=]C/+6EH/T/<Y/<M2!">5YIT9VT]*@3JO.YZ2\2Z<<Q7F^MU]D_]R%'RUX
MOP?UM,3K77)HZ&+*U[XJ=*PC5KSLMF8*.;8N6S/9)?FZ;816P8Y(<U4<C$BU
M-M336X"1C,8</OL@Q;:/&O6@K03QDT?AD47R8/^"?N<13<8;M=YUNHN;9,><
MNW0Z3.6 "Y&AM.!(,2(%(;OOO%)M$MZ0KH]N81VQ;AZ:!(=/C#ACL?1J:<E
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M;\H]K#)IYCH1[,B]S=JM",#=B#Y\R+N7S'@H">FE++9]4QPT3I3^?'GY%J2
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M#589@J)L^0T^W-E2P&MMQ>#3#^,1_\+U&U*[>$$#^#A]/)<9.6%(9UCRU;?
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M36E>-']V5?7L(^=!G<I\3<(%(S+UV9K+H[I>/HB$OS;Y/+U[)CKB8">\=>:
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M34X +_ 9F8R27RMJ*(+$C0'*L1Y;:?&=_CBL/Y27=LS/HZ-[R7O6,>V@*-Z
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M/J1_M+U=([%A;O(Z\?+'K),8ZD-"$&JZ=N/H%W1+Q]V;:49?JR!/J)K,M'U
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M21IFN]I>D,(/Z3ZGUC%85?T;0O=(E?T1V,3LHA6:,9)Q/Y<V;P9!6;&=+M5
M6YY/A]*]EWE^+K(SFQ.6K28L6V:->C@A8!FYIT["RR=CE8X4\&2.AENEPB<N
M)KD]GMX^"SPKC;$;4?MR!Z_:L?>(:F(;'3[),19YW>PX8TRF.4X[<3S]4>J0
M:2-CI!#'P51D6HE://GQDW5TM<K<:!'T<&E7[,5T_?,*WA#U!/.310(-'%J9
M@[2C&8;*)4\"J@5LV7KE#XI^LO(?R1J/9,,?2N"R0B2[!,<<VET<G)P[H7\4
M8A(;4[?5)ZI@G'@WRHV'O=L7+469)084:[9;HD.?G:C$Q83]=X\04&-5D14?
M&I>^ZY??.%\?.=1AZXV];9"K2OL<C-X$*IP"'G"-5;HCZ4(V$&=S? L&6JG:
M4^FB!=FYNHEO#P4U<0%GZ*5B=5],%X1N$E;)::(LWL>S%<V'Z@91=M561(+G
MZ$O7CPD90J<R51MR#ERAZ3#"* +8(4*Q=;I-Y9HM?+T7^(LH)6/YU9],+Q6N
M%,#)KI.-I\S=^<F ?F>$2G%UK+ MPV_^O'Z'/,?OCNI>)FU]KLM@P:JD3Y<N
MUOQQ>7I;&:$-+[:(*>RK?&M>L?7QD!D&REO@G@ZP&+WL?DFI$TW5)R!\FCJC
MCDHK)D8]7'06,J1^>Z430U=)?;CA?D*@9V1X<H"[U71(&%U]A_)TEP7ASOV"
MMC@FJ!QW+NU!%:2CM<?O7EJ+,=7-G+VUE ^&VU,'&H0NWI!@;PJMIXRZQ.BX
M?#[<]^,?TT/LP4YNTTO9RL^_UJN;>0 >+;4R \RHL36,/7'WC $-A]7G54NO
M>OV*=Z_&?JDN+!SL:&X/8,YNGFANV+>0PI3-/@5$=1 '<7(PP%IJN4<<J2L8
MG;6E?J+_!H!_6!E5(PPO0UQ660?Y,+=">U]M??!\K&/4.+AETQN3($([,R5=
M5?UM9 ZB&KD[Q9_@YT:=">M70B>>G[-139C%B$)+FP "A[#-TC<AJQ3UK48&
M;XY1N\,L==3KI8,L!*JJ8^38?(+L+Z:72O-C(-77X]OU38[VN^RKDPZ)FV<O
M7RA](Q(Q*Z%#_Q'6RM&$JO9I 9E5E.GD88C<#.O\!DG*(9$#ES/Q05=L@!/+
MLH,DD^OF#Y\,]C VR6W0@!!)EGTWX*@[AQKP9 T9<N%)'T,["3"EZ:6Y![
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M9\.MSO^20#N?IDQ9DJEUYJE_L6!1?&;-]W';"06)2=?]!38F.HQ^!9Z?+WZ
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MY9">W<R]!(FF4NIO0QB:.A&N/96.7\=QNLD'T+A,H'$P+F#Z%RW)L:B7VVI
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M'C2^*N5^X?_%*E'+4 /;,/4M+#.@!]A9":G8/J,G L%3TJWW$+AYR.(Y57L
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MK!6K,2PA>@\/N#WF&'I'2_G!HFM;I.0_F@V5'S]<DL8IT-5G25$""X'5M<-
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MX!LL3_7RV:/@L28S8P$;_R"*?0\_[-K[EL*89<;^H>393F]( &Z=KZLOWL6
M(_3B\T: &DLFR:!)G$O0I787NEJD9OS@P[$ O.B(96[%[;WKJR?B1%VT(L-V
MYJ8J?N)4KB+,^FE.+"UXX> X/JUR"5-OY-EKX>]N7([[.>M."%/R.JRYNSE9
MVRV#]V=6[EWTW@"_X]E'@+B*I;N_RYM;ZZA9P4:2RR'FDSV$\@;_ 5W/ SGG
MG83"X<&ZX=K+^<W@!%2U>%+W6AUZ?CX6W$-]=_%'S[R>+8I6AR0LV,B^#K)T
M=H==2ZQ^]G"Y>@KBBC[K@*B&2Q\_9%3:G2JG[O>;F;_+$7([9(A+>\ARUUZ:
M52@+D%'DDHTAF<=\S4[&Y'A;$/?7;/; T>-.V2>E?G-:O>-!P5_.=0F?WFK*
M<UB4V;E.1NAP+/-@,^H4\[3TSM%35*9X!L$G0[;Q8#(2!73&I$*CT&47OU"@
M6++@17_YSO*9W?(<"-&H^]HSCS80_Y\$8<,B/JP9OC"OQ!&)]BG9*5<?A[YT
M'5%#G]7V:Y:0%FLGU^:-\XV<GCT-'V?%6G.J7=?/$L:"?S#] Z*$SU$G)<E*
M@C_J)P=UBS9^U'O7W5;/')7\B-X6^Q]UTN(XD1XL -7KL?2DN]RU=>3:6X)G
M^9%O?A"QAPX]X5D*VW?M&@4]%;6]V(!9Q)W_JUD0(+9$KO7>V)'5%O<P?$96
M+ L:FO<9"RZBZ:AVQ^+=UN(HZE%EID$KK9.H9UO,..Q?)0\)61H 'M:XYR9Z
M\M^KC>WGLHNMG6 276MO:2,Q13AP,,<<]Y:O3\S( D61O9V6S1,-(&KC9EBP
MM=WWW!R,G^JK;=-8).?G\;_G!#X9-45G.3X$2BB];Q2;O[0/Z&.L%L>8YJ\2
MH\L.CHDW(B66![HX#/'W/0)B>$IJ5YY!'B*30=?^M_18MF[])S-F,E29C- _
MM\W G?N@;R:DZJT0(LH[*'W4 ^)/HN]2\'=DF&L3W5)#?J%:R=*SOH>,"^(X
M68N1-V<4MPL>-_H4=@6&VX\ "LZ/^Y<QEK:&K^V>^P:SNSQC6F<$QUK,V0L9
MV82+*W!FU+L-E%3(RS+QOAUQ\?= K"NO;X*2^ITU-?>M:4J[^GSAH7D.>M13
M2;Y%V\1V4P5L9D(78:IU>8@_^N)$ UT77;3;5S%RG8U3GL;##M)M?SE1"0T=
MFPT]V$TP8C] %P#GMH>&FHNFY/RSQ!5X_Q%@A&J()U^8]8D&$:I-O-1HMVV?
MPEZU!/@3$_C<Z.;@+1LOV7KI"S91\/W6#/'_@5>,I_!'@6JM>2\6J-I\]<O1
MJG$1+_%EBCE/I)6(X^R(W\6.#$YV+E]H L91M-&9&HM2XTG3YP 9KM8/W^;4
M'0]6B<E><!E882QOTLV.2%4\'Y8_O%W].+ZH?!9CJBA#.N)F^&0#[Q(>S*'%
M>E&&Z#PA:XCK++;MHSVL]GZ'P(W&V,B^9H 1!F5:9U./\=]3]UDW?(J)21NO
M8K;Y8&=,-3!PJ"0.K70-8AE#SW=&^YFV7\S_^/6YX_>194>(!2$POE446@CP
MO''^TEDOKEMJFP,]?>C-:S_B$[L))A#>VW7(K>:L&:OPK/Z2?E]YVG]1"W\6
M865-$*1J@T42_0?9D"6C>N58CG!P9TMS_D2D2'GXA8 O?/X14&6+.6M;S3[&
MSVF/T!\_\AA^HB8QC]/T-=B6J=R5"FY0Y;/.@CF/&7VN_'^-)M4!PWK>7#XB
M)N@^)3X/S8%=.6F,T7_9+'W-=/,LCO==,.X[R0UN/TDQHM&BMX'"%P*RT7XN
M& 6H[ 6"R69@ S,.L)22%.">T^5Z->9&UDF-L^T+YYF >5*";C6>/ *(@(4,
M_7 1&@W1D]&@;WA6KG$@5@"J%L7\S6W1'[6G!+LX].FC"1-FT  0D+K/T$\E
M,1#D=[">8VW@!>G0 9M$<@$K1/T(4*O699=XO*9B( A2R,T4]R[H&T9R^96[
MVO2WHA^IQ' ==NDF-\1+@!MO=+?2J!M?%YJ,^,H8(HM;9V^?:X%1;@H G[[Y
MF"V*ICR0%V:D68][>Z8\U=RB#Z5_(,H@" XNR^X\HVA[!*Q_(\2;V0AZ!.C1
M/ +&C/8> 7%Z(WSS6.,PFGB3\6&NU<$VJIW56- Z\("Z\X& ZQ%PM:GY"/C$
MHA#VH%)/L>?.%O'5<_)0IID6PYF/"7>[<N09+:A,";K$MX!K<@IQ:]$V)NLX
M6YA8WQ*#!.\HRC^C-UNJI]=ZYW,@&5XS>FE[DV-FR]AT*Y&-ICF5SJ['^, R
MN/*/Z'EMOS+<A8?OZ?9X#5!UE_8.(=,SR+,NJ1E$KM/\3Z:^LV%9 &4.E$]3
M=[H>&MA^]N<+W]E.&O$V@?HOUE*=U8&4!WJJBO*"T;:A0#/;9K>?G9M76F=)
MB$K#=PB8(YEI/IOK>5%:>DV:6)0(90'5'!A7\Z^;2!=5'_,[GE&Z)70O\!%@
M_8\#,]U'0:4X_4<+'OGA\PS9S;F8F>X'4OWXH_3W?L %X()--$_V4CV +A\(
M%D(7 X6IW$=$D3+>(O]B*0K"5L=^"[!A21G8^\IZ#H+[:XXRG!<>NO!=:6"@
M&>G5OZ'?NU1&:A^H L[I!S]I^9KET[P/S=VY7YJ,$MY)URI4Q/+JSJV2*F)@
MR%R?[L 4BY_4@E9K\65_*["L&R$0TWBJTM09"[VE[:B?O7T(.* #\7SZ>(F^
MLZ_-,>G!++9;OOJ/OAA5J:>:48]L'87HIRT<%:S%VHQL]7<8Z+(4,XZQAI>/
M@!HC>QX5%V] A@$V(H\1>,P?J<XR'?JOA/3*]'T$Y%RB_VU1_K!U4\I'P)>@
M+.1#\/(C (;T-"?>GJ,9H,L/J%%<=RN"?T"4XC[#W-/U#":=F;DR;<BP^]&L
M8)IR-4(MTZ\=IR"3X(JDT<#^QN?0YL:_R)]Y+OH?];GTU /J1\ ])O_R':72
M(P#N0"]UDIWCNBH[Z>R<;_@*PRDM3Z/*MXL2%:\Z!8]?4V,T/P/7<6NYTR^;
M5E2 CKMH_"=_C@7FFS\"<C]D/ +"GX&OANEMI\\> 0S#0H\ ;.+@D_01Y\\2
MY(J7C14ASF_CV=1FZ>;=XX.25>!!@C%RXP<%2.9HXXP__*HZ-40);NNU#.OA
M>V-K"<-']0Z/ #0>,OC8\C\AS/_OUOGV3L8AL,+VR'J-GFUNGS@EYSWG128/
M$,7XMI_QN-PH*O9.I'!IP,:[] >$GJ#\Y2_DMG(8WX$D^</X?YJ(^?[31/PI
MY^Y#_'^U4D%/[1-YIJY&;,I\@J7OC6$XKCLE*[RM*-$AY^G=U'CC^:TIU<W7
MZ[@*%5BP$@CDQU#YK\NRO97O? 1(_K^N_SZ&Q)+TNIIQ;M3V><5-5. 6<+@
M<FD1X0,B*+"4D=>#X/'BT@^.5W\M'<(V2<DL*A0L-AQ%#L)'/XX]K?Y?!T O
M&C#XWUF3^*^^-=CFXOWO)RFW9LZ]?5AT=,3FJ>MOMG/?R_RQWE1I]#\YM]F!
M6E&R22:-[>V3:V&'HR_?VXT'/ECX'AE/Z@P*R8Z(#R)$_H$ SGDL/)_?:+C%
MX6*1U:'DF'#X,O@H?UI U>X7)3751'#CVJU(ZO#B14F3S1X,>ESU*SK^0R/O
M!=L4\O#H3*2M>W5OUF.6:<JQ&SG#;^R4?_UY_K+S*!%)ZGA\=%%YF']?YXPR
M[=GH[[2/MS7!0'0.LA=4&)N_J(2WE-B-.F]6IE/P.8^L(CZZ3GW[D31=4DA9
MU%)9G9I:#7W*3XA;\ 2C.H>IQB;^8#PB(2XCPMZ,.XK[#3*KP<$ GMV=IW@(
MQ8QM!HJL;Y*Y#9D$:BND/P(@/^V^6[VEX620OD*(B!-T%MK-B_^<ES_KV1@<
M?(YH%NS929SZ9DG>L=R?IAVN%UMQEW.=B1Z_\C/]:#]0A7B*&&J7\8G^^12!
M)Q8>@G-14!/>(TC>E-*CVY#^LG&1;=B=ZJXV>F>/ON?F\F)?G_O"F7$@=0A^
M/]]Q@^OT5J5P.5&=2$MI[O!>XJ$(U)BZZL,<L6QL_#GWS8\P_TG;,90X;CLD
M*JY=(/X@)K@>:[;I0',?SH.LWC,E(_W+WUCSE[3Q_^D?1GU\V7/CE>?O3U#[
M<<),< =S 2XIP@(+M'?40O6T]B49+=D+JE&)8)GDLBU^%MD;=M*$)*EXL,_>
MMK<:(Q^>#>U,/= @CX+F/)L/#Z7WE9RJ-0<)I9!3E78NVXD.^OI>?IG:BV8V
M'M(>SL'?"!S\HLG$</F_-L[Y!G?CLOZH%_P?J@E$*\;0A/FA2VUSJ5MH/C*I
M"C'G)HK7#9R_+KJMLT+S[S 2@'8;K>:VR[M M3G*?2><15&!5BGI?Q?(!Q$>
MO.)#)$_$2ED: V^FYO%HZ,"XHU,-_H'/5;X^[(-3Z;")W R20I[R$KBKUQ\W
MQ!6D?_KU1N6V9/JCLW\)4[8!2LS/+SUE;OYWX]PBO-)Y39C1/_)#]O3!R34O
M,<X0M_9D=@=DU52@X!%@7]O4\K9&A7@@KLT- VX/7V@$^=%H6BZLC$;>O9@Z
M,R8D^=:0# N;]12^:YZ/_ZX_B0'+/#'RGLK&G^17H>5U])OD_*SI+&HN_T85
MFHE&T27/L?X.\=>:I*;A^E[L(Z,ZM?X7V;L#6LO3\X^5%SKCY4D!N<>)7I"]
M24X-JT ?2'?M>7F33Y_Z)G%,UWKN=9M LQW\UGOU:GS2D5(X1YZB5$K;)2$\
M>PM?.\!FB/<APFK<:L=>WX.=?9:8568YM:V;VR>AGI\\KB7APG=E8AWTW<B%
M117GM>J:-TNJQX:[K@5N))F;ZGX;)Q-M-ZR8Z?63=SR%LS(VT'*[Q'G90MVG
M<S0V.>9::OJ$JY KI51S"8;Z6X.8P=F+F48HY<XT.-:S ',J(1,*0S97N,QE
MYZS<JVBDWX")$9:@WQ\S9^UYX,ST!P3N]_Z3J2EFS]J.]_VH]_3TIER;$WR%
M:K$Y^ 981$8<_!X!O7I3H@]9^:3>K1T+/31LK,"O_AMA[T WKEG1,CQK)Q11
MJQ&O3=W5V*))/QR*GUQ-<;50?#J?GW>8%5?!+UQL35:J%, 9K_&WR=%&3DY;
MFSP"HL4A_TZBM5DF+S5?=U_N9%)I*4J6N HI!)/&4UKQ*VVU:6<!GW8Y^TLA
M6V*I-_MR/@A&2I'UJ5QDQ1U%\4[JG.O4?I6CL]49L](1=&]?GW+GO*H.DKZ[
M!G_KS"DQX-*#"O]#_!%UVQ-NP@0F;F!O2C/T43X\>.T&.U8>P:!KAJV%<-CY
MF8?7#^TY-)[PFG64'32J=,@+*08O8E(^F,>QMU> G_ND+_=10TU[2*28G'\:
MI*$<H.)TZ\O1 Q._&.9WL]D"*0VO79V_"CNU+WS!O76D[+]$G^<2#$:C[M36
MG*\47D+HH;<*\RRGG5,?9Y'942"[)8X3EKO7-U9"G5:WD R7FOTS02@;0J3[
MX6A/\N7D_X_NEO_E^!1!Q4):/Z##;T5?"=!CJAV"@H*-I$43%[Q)B8[B.DJ$
M-]S\+BKQ(KI'D:!2<,PQ;4F7^%E.(:T_:I/V*0"3<0>=GYWIFCWIHE!R21I,
ML;YS((F++;5SR"//*[7M4X"9MW>EV443KSX)L-CPH*$VH3D+$RG ?;:#%*',
M/0N--YL$-'<+,U:C"P9F" XG@P)HLED1@X!1:58, Q2#A>?Z5%(+%:T<,"E;
MX1%0ECY18!TP0.9-]OPKMM(^J^)+&K[03*)0>5%_?\TX,*&4 EUG(0"+M@":
M8__L$6!U?Z1<6F+?^B&E3(!6>FY,4;W'E0W11NOZE6\RR%./GF1;B 2!1WWX
MG>.GL$XL5_Z']SX @"__A/^,OGP1Q(1^,%5B4<%$<VPE2%;#17AGNN%5M!#[
MQ@O"B4IV9TA0<JIOB<$,SO#!04=3^CSC6<&SC@YL"'.]Q6W4GK**2C)%9?0^
MP3L7'](*PA+^Z_=P XQH&,PF?N(3<PCL#"&-#\A)<SID[1H1H;K(IR$)SR28
M*6+8*,6Z.5,0H6(L+6I/S'\M%C+2IT&, 0US :EC@$.+W1-'@W<D<=O/$%#)
M'61U R;]4(,H_\+,J+HO:4C-IY]/Y$3+8I5[=X$0BD;XN;YO(W%U&L6TDWN<
MW]^R2/NPQ&_O-K2M4X1?VUDG0F.Q#1=6,';5)$+86DMH!'W112LG"2*C N()
M42) NOH!C=<E>Z.%6E;\\L B$<9*!J"SY2@$'@<2A390=NWD_"Y)V"WP -GY
M"6]X\J?M(4I6-.,SQ,]'E0&\@>YPWYN)%RX+-VO?T"*TGTO7/Y.* '/,)C-J
M)EJ(2[U68''!RI U*AJ8;H-&QU,I-J$T"/1 B:?!2A98'. :;28IC$8HJ_^[
MW]AP:!(3$86:3+#G1?*\PHRDGP?JL;5 )XJTR1E 9&[!R*$ZX:JB-UVVX;57
MCK)=; B82V$BO87CG2^JP5B.380I'2)5Z!YR51(1P$[%2+_SKSS*;;#V"3N"
M_&T@Q)7):R=T^_E*+B3,4JH^XJ,'7)0N36 B0 [)W5!)_IQ6=/R0F2^*292M
M!'"^T).4/;OMIQ?QG=PM(RV T9T6637+##,J[Y1V6W*",(I/?+2C&4D5R$XZ
MX381G3PQ'F!C-U9QZ=8IKJ,3M0C"\JJH% 0]/#_)&J[XF&YUEE)O6H"?%R^%
MG@,3VA]5,YG*,OPZCOT[IKI/$J,_G]W\IUUG*%AT/L;S>/@JA+F;TL$QSQ4&
M'8;SS"4J?+<__7)'LFH3=@A^/25GG"+)]$+DMC!U)YO0'-YJ3CAG/+R>TYA#
MAB@W+VPQ)'_.4#8 PVNE;:?Q/W[J_+MF?E[%&1AN$_VL<ZKWBVW9(T#C3?>=
MO8J(?&9%HP1Q:X.^B"6@01*Q3#P&?+KJ\QY,*&[X-E:E3O$YT0#N=_I$I@<!
M@KJD8_\>5$T[E43X9<,V#^5*8\H</7 !@35[]EZN'O=ZY?")"3W\6W]1SS[P
MMY#\Z$/@B</F^>CBF>MT3B7 W8RA)>QL32BBN#%;9-53S.I+#WM KXL"66B9
M3V@#B,5<<6.BWM_S6V2#(G#.:<3US&;Y:Y<5%)F.IIS 2<>.[T[*-T8-L*6$
M()*2FB[;W936IR(-Z'8.,[KK&GK"Z+12(F:(PI.V-C9<T;D$0!V18^^PEM&C
M1\"%I5FWR8Z!$8Z%!'YF#\8BGC6G(-P]L^3,1P1=WCDWW8GFMC>_/)W_1^EC
MP/0KQ[G@"+^M' >V?_S#LR&XV_/GM"O>=7Z:LO_^[4W?0[S_,4(164%'Y?GD
MO>)!/E6R]0C- 0TL\]X-Y- 1.C%WJ-(6C&/2Y\X5,)!OK.L],##TS,W-MZCW
M==A)]:MCSUYO517^[930 9"2)9=O+GXY4[K8<X]F1R2',I/(B#'-0P-(SI%]
MU.FGDC-G6^;66^44,_\#)O]C>Z/_[3L8]B\GM#_-?(Z4&Q,S%3B>FC"2<71*
MZ#/6TM!#31LLEOM^Y+PP7E[<=97QM6^351-E[1[8H N._EG^LJ#]#P_15K29
M[6;]/=W4NOXT_RS>LF7#,I/&,P/6H-#64\GU]'*.4\CQ% ]CW;5W*(7K""EF
MZ,VTL=,OVL9)[FH2PR9>LS F?$\Z[$#P0-F)P949B$"-87?JU+CMNY# I/_?
M#BD:+W15L$UADFGP"DT00C[)6*+3U;R7*=C!1]$FA]_U"J$+;8P^ZJ-CCO18
MIFIB@B4B[6A!7>6U=F94<5L3FPV/ $$'??R7*@&Q70P1CP /:"Y"6[\2$>5X
M;CPL:7\Q_&;N()%Z"]2\GKLW/U6><G@X_Y#"G3BH[[7<F1RGK_ZS"1*5GKR+
MB(F2,)98'XS2PA;5:3KF'+R2!B;F&S+J<D1A657+[!D=[V13A\%W!\2E'F)=
MWKT7JDV&I-&4[/O ';C-'P8<97HN-);Z!#+!;8F]NUY5^BF6R+@[/;=X#C^/
MNS_6! 8>LYQWP\^-#=#T],8S=GU?)W87ZFL..3 P:GQ'+Q6V')[,7:P-_38J
M-VYC5/)C_* =1AH&.46LFSI])XSRF)_E_D=2K:V>\RA3,\8:NI 3U8:ZXX[&
M'._WGL9VN:V!ATRM\0RW1##=9HE8SD< B8)21[KQ^=S6A_B"W12CCMCAE(0+
MO=ZG+8\ 54/9LN#/L =Q?7^3K(C4R KGUZV.KEP%$5XR%QF3KI3_+DC7Z#T>
M8\UXMEID9#R'T2. >YSA1QQ:#Z&H*4<*^%\-6%XD/BZ.QK.!PA\AK[."3+L\
M]DQ8>N<5WQR7-ON<<1!7I\R"N=8PUMK.+B$3+:-$"OF+=O&6%68]SF2(16XV
M^*P6@4[VROK999DQ,=KF:?7VU)C1E>C@N.IS3\$M:_>LT4WK4*:5O_&D,PI%
MN^D*41Z+(@7(+:AXBH,+]%8&E>?%4C1^?<^NZ_$(P(6J$5_ECSR,Y(R$# 63
MT-QUO@4OO@1BTNX^-+%$-,SDW:JWV-%,'=)1K;3+?N5+',R\)1R,P=WD)C#<
M30=>#-F3)]G>D!C7)^:V*0VW0;,^66UL)"(L)\_7SV7KZQLFS@-)U"8KDZN"
M-][X"A.KHYAB<]&($SR;1-/##(>5MI?&,SG&]>W^F_/N HLWXE^YB_9A030/
MTC]'(P.(+^P<6&+H%-=$/DD4$[TX2ZJ!8H*N#K0,L4MS=YK,*2H//C0NXO>U
M9.LN];BOCK@1*$AUK97.;GOYC92O1W6<T3I:?U5,4-25_300U26>V 0[&:C*
MUP__G?ZKV+FTZ<MZ?4<8F$/-KD06-G0T/8E&&,6-79F-.+XW:+C]N-O[O<>T
MUPOEO8B^157Y:]=DU/8J6<0>SRV;^QZ::T=N0L/<Q3XP:4?H4G5A4E&B!.K6
MV-L.W/M$S3+>A._JK0UP2?1R!40DSRIQ&<?E(!>F9I#M-$MDYH0Y1)*<LME.
MCX#&GBT;D3U84+)$J>/*O29'C$_DTM+6\!,93\=@:F52/"@(#-FRP^N)'C*:
M:"=:$P,I#ZHX<&;LK_M'9 QIJ>N[@(!#.TNU OBOER%7OOE[4Z<C A 15Z'T
M6;GKSQI\(=A Y8/*2G$JA[RE'=>]J4)G-R<NNAO!=&F(%H3J#JQESSY/"%SR
ML9^7=7XQ_]S?C<K4^?V2:W9QL?M<*.7#ZW&/O:,OK>+ZY-WYDPQG7#IB^/N8
MT%\*B[0@]O$&JG2$?%OVTZ<K3=YRXJ=EBO2%;D;U06133@=<UB>D7DV"I3_%
M8E2NQD^V(1+W/)/3LME,QX^ ;R6>PR*1"\27KAOWOKDDXKOSLHV=5X&N:^4Q
MY5'3O&<QG:#P//FY\FE:4G_8R5S>"1Z1 _D#X62UY:)W"6^/V^WG,U+>4+C/
MB-(ZK4-NDM2Q6/_N+T;%?:L$Y9L O_3G7D[@*)&#/32"K+B<$&?WU*Z:JPV*
M@RP@?"+E35Q-V<68+:'9U8<IFJ&BR,&Q6M^HEB =RFB2%"**E^W0WTYOO=:6
M=LY\_%!L9P=HM7P]DOMU*9]UL1S9N<H\!MX6*7H$K)@$KQM28UYI]R2:(&S6
MGBM0$%]7H\QZ70)KXU@Q13E%'NBO*'1:TK<A)9 S_FA%.FA OK-[F'MV<78R
M"FJ"=/3@I/KXOD7-Z/?&R,1/+L3  -5(<(0"XU2'=B_WJCGQ7(^C_QJ[3N1;
M\>&:I5ZA3&@F*D[-K/-O.T_)3M+.V9ZH\^P6#-[MM$Y)>3!*>2!)D]/KT'G
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MI3"V7]\O3SQ%%@]>8G +)DFZFB9<)WQF'OS; ?B%P\-8S>T9PRG71RY3BBW
M:K=K?3!AZ<K-AC40J+GL%%FGM6$*-[B3:NXXUJLKY>PHF42GS#+$PA(4_;"U
M")2S_2_V#),")$_4(D,+KZ(O52>FE5L3H3[C!6=Q[BE4PAK2F8092PV$40T.
M.8 ]P<H\.SWJV-U0LJ(<:L1I>)?WR)33K^5L[.#/[2R5RP%LXQX.#K0W$77P
MB;ZMW+DGS>(IW;MB4T.SRT5;D.SEU]5?"DZHK@8*^C[<^&8Y+LQP'+!\>Y%_
MR O-0N!?!I(W=*YRG>CEKZOI2XX?U&<:)@P)+*<!S"0ND -,%YB%D+6LEZ80
M>MLEY@F/OLFO4XMY/D\'I=UD0MP6?P7-WC8X_'Z@^<OQ\,HG1J^]GL=@J>R:
MF.I%"D-<UU=1;S(NS4VU>>=)>]ZMGX=R>3X3.P<!RND;7B>+VTY]?<UL3##,
M,$QB7X;+0S!=>-=<=F'EE=&T[M_W86\/FT29< >?V#S/3!J ^Z%?M^^M?8CA
MR ;7-B"+B9H^OU9Q*#!K-J1 2<SH/@)^X?N_J:S7\TJ8ZVJSC"#G-Y?#! 1)
MUY4/_DC?NP_Z\.WH#W+;5<-![->[A1WZV5:7>2NF6XOP>Z;CSK<!]TM^T)HJ
M!\A5S+\ _*:8NV_,^%%!3B [RI)QVQTA++?XU_VKBGMB* +$04?WEV0=?Z1]
MJAE)UR];=QTS9.DSG[48;]]WC H_GR?\U+H4Y0[=W!7B51SK0;U:P,VE?_>1
M0&K7?KKN9T=K<#<)JG/Y$0 8NHJOLC=:COAW*\SCO*KM^"K$PR?X" !G$PBS
M@D7W/(/)?<)^7RH>+S849;FN.6S_^=EH8M0;TC1\O_:N\MI[18^Y;J7#;V^U
M.HJ#<__O.:>@U5=C;=XG"L.9@EZHQ.7I'2-1>.R:R/GB2W@*M:J,3M.G;L^"
M ;?OK"J$*9"V3!Z1&\\=R((=)W_G'8;_M#/RX5GQ:@[YKKX$4\?QZ&='SMR_
MCNLD3"D1,#X%!*,WPZGH.:J(O2+3ZBW";^V.;_7@/0JN_XMK^N!];;9!T*BS
M-<T/;>J3,SZ"9^M-I3NF[3T\V7QQ#KB994;4\$/19-==,)&\Q/$<*\)\\>9&
M0U[I&@)13L06<?YV_O -NCE:4XC)(:&W<:/[^0=./H/3H1S^C)T)XQ?) 9H<
MHZ_1;/@<I$2)T:RYN$X%-HR)"JM[6I2+!2)F!+X%'C@S<*GREJS/QVY^:+IO
MEB$C0"3I)\ [>7G1M53*=;LC5=E:&F5OPKQR,D47]_KS4?LZT@PX#D.\44IT
MS+;-;FMV3NX\YU*A"T,3+Y;>S/"918(PUH4 E@3W&$M=6UN\)FQ^[D6=HF98
MF'O(,WJ>E?N%:=")PX,<*WCO!(P&EDBP&"LYY]O^)N<QF#<I:\-:8%S'5;[L
MPK]>[U!2,MBK#R;>OKE.L$L=$%,8XIK2PYS&PT!T?'#(%ABO@$YRO/_[6DV=
MU>ITVNZ5%:[BR]HFD7V(&:B<0KHA+)A6P6^)(T:O,VXQO+ C0=?V6'(H;[Z;
ML1H$++2\\KI50;93K!GC&RE")V%?*Q)58D\%%U@Q2U_5(8O-6*FF;>FX(KFQ
M=_Q2.OQO;YM\>K/UERSV ;_Q" "5M['NZ@U_.>L'#@7-3/%ZZ.!B4:"NKFV_
M]%/CLZ;5X$@KAOVX0VD4+=CGO*/47L\HOH^;\#YZESWYBV";[.HD2?,Z8[AD
MW)#N25#X#]/[5(U)K;<G2=3Y(N958ZY7?S,J@Y5_3FCK-/_Z\C'GY1O@J[,Q
M@ A+->;8C3[PA^E.JU/;.J6X[ G3UQ:Q#PQ4[\7B_H[P)>@#_'6YB57L0$V?
MCCPB1;WB?OXLB'=.Q/IN_OW;,2)\1-VKB1\/G45O/G&^;96JVJX2 5OM>FKH
MCF0(\47E0'<,?_&?"!_#8U&R1-7,8A8*6&$^ \)HX*2>4(0CYRBLNEJ[]V1W
M.G*!LRMR]/T+KY4C[9ILH+K?#77;B8C2,6@<D, $R_2ZC@#8VOUBF]@\;C?J
MZ+O!T=1E3OY6?20=VX7GYCY#6&@T?J>6[S#Z^C_9A/,.-"2&G/< %"^K2'J]
MR9&&/KSGFW&!S'.R*HTR'42U]/BP"WS$]%35HHFQ_3*9Q_=ZNQ\Y Z&Q"\>T
M0TWXW9;=N\"U?_F"4-AJ&9DM/C]^_=,B]>FZ)\]7%^P)7E\L%S%=4P6C2)4.
M;.- UXJ\CJ2-B(J8C.[DK@&J^.I_I[*_?J9/926WN*5OF9&!BFNAD0KQ+K;@
M;^6NE8= B?;+JO*^2_)+LU?'XA=5U<YOQFUG1<D6R7DD:=4KUX8)99J- Q4T
M%#]89H52]=.M2B'6=1KNW>9OZ> WR-ZWQ?,+RD],WE3/8>4#-^ 29EG^4++A
M'6\]:N=X<9U6=$T/JKA_&@MP0K^*==X_WX6^J'@$D)G849AACUN-<Z8O#1VL
MX,SB)DAG;IPUWV[<VV+F=9[<=U3'KDVD6T7_9AAR94GY S=Y05$LZ=I_MU>"
M]#S@TZ]+/QS<5L+#T]-C[=<(34KHHDN&[U*\F VP:DC?M5WY/&LA7D&F+H,Q
M<+E6*Z[$.1HI4.FOW"#/X^!:/A^Q_V?&\J;YK@1STJ/2:,CH)T5Z -S!K4]F
MWWJ UL<"W[2,FCDM7?"+33$S3MB[@KB#O_%K2@)!_W,I\&)7=W_:NQ<]EBAC
M\,W W:8Y]\,37P&WYH/@!X6.YSOW:G)*;N7?]7*8G+?BX"5[U 5^$JD"Z,\3
M.%V_N5]^$<8$M1R9Z.44&-NG([X\_.W(C]9CIW3+]S+'<_%E!%*="RC^6+P3
M.D,-#3BX_B3G"))4W@AJB*EF%^-Z!(2.<NBT&*OD-_7O;)Q8+]8+\B[:/FBT
M)W $[[SZI1V?$7&Y8ZKF.U5I[0PM\K%VS)]YDVP=G)99^RQIV&!:7WW24TT.
M6M\Y6?T*%O[]B8QSZ @AK<@*BH4_V5#^<MIY:$RS6G@YP[23'6V>MS1N9NKM
MRO\((*@0'S!,%SOXW+L10E8#QAW[->[XL=W:LGB^X[?Q8L_#5ZSA[PK#"0@1
M%,U??Z\+TT[B7_5+XP?3+=O\^IESU3-1,?PSSY\KKGDI#A&3G@J/-IV22>^I
M1R.[TYUJG_]I&A9<YE<,TCRS(%1UI*]D^>PU R&?Z.0.ZLAJHRN7<ZF&DD>L
M9W&Q"R;+]<JJ&P[P)OW#F,F5![+O%559P03%OC9VP?Z\X"-NFP0VN=%CC,NH
MC]!"(=,"]%\R#I5H;Z-J< ZT:=K3A_\S@Z]NUF8"DVW':,L^NU$[TBS6F9^;
MT&S!Z>N6QFM?JCA#A>K.3J._DQ]7<_JHG:,4?= E*[PX9/W$]&FG[DG(Z[%R
MY2/UJ>LO[]_\01\X?Y_7-.$LRV(WF_)PT$N8"8PM-)AMPLFP%;?9#5:N7*W&
MF]U]H$CWU>B8IU T:>D-< U%5H-CP1_G?QKM79'6$CLG*YCZ75S31<GY_E@>
MJMCV4XCJMG29QGZ+T"(2#:($7QWXJ;H6:#*YENA(DDGN/S45S;REUJPHVZ\?
M\R35-'KY/_V?GIY/M'^XGBTCR*[84L M;0\YD1"?VKP^5]'^JD8!2X?[)>L(
M4$;7C=HV %*?X%Y_IDT.L!%0!4 &BW>B>9 ;H%(#NYGOFPMI&F[!RI_?0KL
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MH4=4D)_5C#F)(H&_.RLS[H-RH2-_3Q%&&[]C_!\K)LZ2 %;N40]113P ]MA
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MW7(K'_"8=?3@W:N-&<1-(]!5O @=X]6BGR$<, 3;Y/C'#0FI&_SV5GP B/N
M'@"/':$G$E;:;&/:V8OR.-/H0HMD$18>:\^TOJY1#9_EJ>3$RL">*]MV32A+
MF%K\5U$-;SQ7PKX:E;W]/,$V\[X$J\2U?CTRS#+NM4-8-VQ^#3,L@\&!;&TJ
M*U2VDA5 7<,GZ1#S#L/>@"0)Q:1)B<IX#ETKUQ+<AV7D6Z,(?9X)Y*1H 9X
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MVX-N*3T[:U]]TT-PXN37:_JZ$7[8Y[875>-V+H4,Y;$^XR0>/^=,9[AIT!X
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M\B/.TS2?5RWME@^6>/(9:?//RL$,W!M)\<,:%UI9#B8V=DP'V%YG1M.D*3<
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MEWV"-5" SO5"+JCM)-3!A(\9]$6*:"#"\QQOXM81,I>\ 630)]\ _&ZCTD"
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MF:ALXCS,E37C&4,&Z-Z%)C&KCPU>S1DN^N2O7S[(U['RN3>T6P0QJ:SBL8D
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MRPT SO8'7AQ_^='[C0V^!@YE,L:W*DO Z 8@05UZ35 "0Z\P_)Z53-;\_@W
MGR+!;FM7D*W(]P\H9/V!5Z7G-</^BX.=*^_.#K+(/X+@^WM6Y)&^;=<X?R+^
M)^)_(OXGXG\B_B?B?R+^)^)_(OXGXO]BQ!.9R*5K2G5Z_@;ND6Y_P1VT>XN[
MQ0\ ]U;TS+"1?8E3I_O6:^3^\9>77Y+5NJ^OL^QO -^<-#CC (P)M:R4-X#(
M8)XSVZS9QT-<:R"VHFY^=N$'EC%7X OJC^N^W$M?YVC+##,0W^UY.@L<)23F
MG!0&]ZZ\5_3UPJW^UF2Y_O\BE(QHV_9\>I\">&ZA4SKB5_8?>&G]??^9]Z?
M_ZW91%0,0FQLL085??HQ*).N/;2OS]R8CXKQ$FP#M#=];R;_!U!+ P04
M" #9@WM8Z=ET$J;' 0 5AP( $0   &EM9SDX.3(Q-#0V7S$N:G!GM+H'5%--
MV"X:!$2Z2)$>%00I@O0J$94F"M*E1D"D1$"D!0@)BO0F(*"@(+T)D8Z A([2
M>^@0>B=!2B"%D^\[Y__/_<\]=ZU[[UIGLF>MG;5G[SWO[/=]WN>9F?/)\T7
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M17^3+T:WI^4T"+ZQG>76[_2IU*S)?>=DW ^U8MUWYQS06(4_'ET)_J,%$R-
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M2:,RDZ]/_(XT<DB%( B2%3Z@>#QAZ#*]'RTM)-N:WWDMSC'A@W *UJ_X6@A
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M'[AS8D."(=\I@Q($$\,:QFE0S[D)7L?ZO46"RVN\+C>,'=9+W;PD]#YL=LN
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MN2\-0RSEQ#(V358'-.H\>1Z^3[R6]>,P<NR:FH1&.I6=(!&YA^)[J3(I6^/
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MD;:U*C*2^" V[\: 5DI///S:-:'*Q<:J4+!"$?-]I2>'^;\<\[3<2)ODJ^O
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M@APQAW(B/'1 *)0JD=I4S@!JACY()&#!!XR8/13H*J2'=UKY^UT'8&=4"65
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MIA#OK4X?I #""<LR0;Y-,IU&,"Z!Q\(Q,<HV3:YS(;/QMXN>??N8>$^+CA?
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M?Z.C\C)T[-RE)KR;)PP@^ZF[;)]QTW>MS':12.,]]'32%DJ56]M?"L064OK
M+*H23OXFV<4P*M *9?-Y^9#)P_;]A/7M6$]MQO;8VP\2G_PT.??,_SZ\_T";
M-(;)E"56),'T3(;E8LYTM=P_,*GQ\_ 02G)_ZJNG%"6:+!7]0,.(.+XGQ[$P
MM=B3*LNWM2#Z\^M0G'CBMC(ZQ%_SF1R*P^HFD<]R0):5U95_NKH_6U+0BO'&
MAQN1>J\*X@\GWWE!K6@@.?W@.MR<8!.!*[9LJ\ZM2XG5+YXI_?3%W*KHD=27
MBC+ZMG=GAQN]#8M?&.<5*I4/#57M,:<(]X8$1_JN(S:9+V75Q%Y%&9$>_/HD
M&@\Z#"E?/U14LS&U*2!@?G4[:04?,#IA]Y^$?5TFBPU!TN2SB7#DS#_>,RSJ
M/4/PU I/(4>6IWW#Y#*,1I;]6^I&S<8"T\Q5YA)[6K,]"XSWONR]1*4M%(GI
MQ\ V=/9+*T0_9TLXA@:*40$6FLD16B"$9U3 &4G24>VM.8"L]!UBJ_R^;LH_
M/GA[N.Y,LSC1WA@W&[<8R)?+@\D2;C:%6+^MW+A6\'', <>2ZI% HS@NW2?\
MLE2@3*?]L%+):^[QR"X'LFZ,WV70X?!]T$GX'P3-%VTO:_6G)1FQCH305*W>
MT6G.Y.#"SS*W0\U5;QBMF0!4@$T+%?JA1/O^Y0[+\C4L%JV6ISB:T/?]H_ N
M&$KVIX5?Y#0VKIZWV\_'IX!DT:I<,3AE)A)IB9 [J<'4E"*ZQ/33#)Y?XK=8
M1 4<)5\@C@<)D,+O$O*CX.IXS?KGV>6]V\9OIBN$S8U/Y40<T5 X$5W:M'L]
MZ$Q6_H$J4LAI4]6XC^*[ D$9S;U:*=DG%P4F$?)W7A'NUA%<M FF,;7:TR"&
MI6NWQ*\ZCS*4-?5I/"N".:H)<(2*+AG%'Y_/IS_0A-\B")1.%8O=(H1'PZWQ
M?(.UI\<GET=#!TK]G*.!C=G1FMVKYXH"Z68<&.?OB&E-%33EET<%3$Y 4&_8
M6[J\]X12AM"&7TGG/7!\>I%I1]MB=ZA D]@)E/!4HDB"MMG;5MZ37/;2# SW
M@V4R9: 6<'M2%($1_VI(T(:$1(V:C8#&%T==W_:.A<_P,E=DL_]4_*["]OI[
M=Y.1L4F31H6Z_O>\&DORZX*'UI>NP0ORL92SBT%"9B3;/XB5^:Y3$QK+)H2!
MQ\%=&\0['><NY58=B>CM %4KTB];#7*8VIF*WME5$J)E*N9MO1%?BDY;* *+
MI&&*6908RN@P%3%3"S,]W*,ABDR+ME-DWGW(MZ%PXH,EM$S[PM\"XR[DY_HT
M-%R5DVQ4,Z2B_X%683OU.1E:BD_>3@HBYD0\&SM3NE#<)=4"L^=,MG NYU=Z
MW'EYP#LOG[^W%ZXYN J_202UG,F-SO2)V?GHX\60?F<]9NZ1X2]P],0/Y7D8
M1Z%A?YQ-#)$-='HI7S?5N*I21XZKKV/N\Y6&!QMBKE3 #!G 'U2Q:<W)Z:A1
M(6E_I9S,DF]A5!A@MDYQZ$.7(ELECY,OTB+O&(6]V/1 YD"#Q;N""FBDN4LE
M=8U#GL;$U==Y#%7K/4,+J JT$;B@X4%7A^7<&?4XUCH*%B_HBQ?V[;W[V!IK
M_'Q/R[[1RM/SQMZ9R/F"X'P3 UIQG+_[V%6/VR MVL#$%.JW VG3B\6>V%X?
M&<(WVIP>KN#7V!%[_>)R09N'T*9HYYQ*L7A4,-M=NG.QP#V 'H'#MB">09A]
M+LMUGR!U- _)K[+0XPPD[,O%&^Q68-^P#1@_9*P8+DT,LK(/S^Q^,[JZ7D?1
M0-H@(1#1^J@^K,SR>@BZ(C],?!O[T@(1D5W?XPT^O>2U9#*<YN23-IAS+^9+
ML^]'SMO*21!Y)_2I^HMDL5*2S[0R/]^T>QS9]2-V3(6KQ_E:[GH2W]6VKJ)2
MP8LR\8V?06K0\[VFV\Q69**K:_Y[B'7!]V]] 12A?7B\6N#C77W>51-UIX>&
MP0O'Q]_M?.L,],"]@=B[<C?O^T:N^G2ZM<YU::V]ZW6(G)V.-+[?KGU*2NBD
MXN:=M[Z<&T<Y>RW"*P]T_668Y>KB1O0&=N)&L_'-8'X5+U>O/$MMU_>+\>D!
M$!4ZH9Q*&PWZM9EG1V8([[:%0-Q9D7W)BKW!^:P)&7<2/RHHN35%7BK^H]OH
M]_^A^>>O:E,!85IP16SOH/<OB[4O(T%D'G_);Z-HHL,2%9!9A 9#>&H%IZC
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M/K)@VIUS=''Q@]-3B]88U^F$/+T/%N;.OC>!VWRW-\XIDT,]WX^SR43/<Q)
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M/@Y.E@Q22BJV2F U&,M4^',*K_G24PI_S_DRR@ /.M/)[NN7:AY!]DXQV5A
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MMRF"O[<FQ''3-Z/EK?*##@TV"[U'$\*]!Q<Y*V[2%M77.KT\787,<PU6L"/
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MW7M?[IVTCDY'L.</OEL;->Z@IN"AA-FL-&I6ASV$N?WZ@W9YTY%:M=<+QNB
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M5YE)_8_A/3VGQ3H. ?(>*"6X*158B!W62#A?_-(1\3$?N4RTZ4ADGSMS=6_
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M[W*/Z!#EP^H$0B--% IZAFPG"$K4@"+&SJ#I/NY:4K97S" 9R4'>S(>8%U
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M@";)6D02#/P*P3=3/7&) @AMDB$D^_*0WW-Q,S8-^=D:AN?6PB=OWJQ#RHY
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MS$GK4=3<$2R<0J/"=O7/+OJU7U/K&GSOQAL*,,2>_T]N:-MV\-.?7>WX!5)
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M<!4/7UJ%/UQTV'X';#L0^CTZVN3<V[!(AHV 1Q0 ]8'$'(W\1UA%?$<*UJ7
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MVG4R((,REB&[1/2,#2>\4?\=O-=BEPPZ8/.SPD&J&1GTJFR+1(,&^D@%3:0
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MZ)*:8JJ;S&]>TA=#7+GF4#<:)/5I\@65A6]_7-+2H/&D\7[%0-+/(!)UR:
M"O,W?!3AZWCQ/8JJ+ ]=D3@PE4"QFV!V^!2:5"NXK]VF422H8G:48A^:,[96
MR2"D]KZ&-U\'2F__K9^^_>V,)5XQ!/SK#-B#IPLO11[^NG6^O")O].N8U7LF
M-4+FHS@-5A&)4]\O%NE2)PQ&@L;_GV.D&&;LG*V;=SR=\""C(]K93(G1-CAM
M**"*#.*%MUN =[80%/N0'SM;&Z[>E@7OO3)#!E%IDT%<VI\W(#N';\&G*:L.
MMN!$Y/"D'2\99-N'_BKJ2@8%9I%!D5G??)7V:(K .$XXWOBW2RK[WMST1VA1
M3'MB&^D @B3YVQV5O?VO$,5?IS;8*\F@>LIBV/*7:RJ_O#,DJ/&1@DR% 'HP
MD/_;Y:?];WXE^+?K3Z0_G<2/6SK[7^7N"L90IB^%(-(*$8U_NZ7SRRM/BU.*
M4IF7BR>NX'VZ+Y6:*=>WMSKU%/SJ'8L6&RK _J&H3.XE_4_0]?_0@+FKF _.
M'-=-J^+O2J9^UGRJ[AK-N-ZE\4NF]=C7RCU_)LV*BA<O_KO%*?0+?O]Z\>J_
M%]0F&:'.'J4CTA8,BW//.,HLIAZ 3ZY65UGL3\&@D#UCF8;XQP:KN?=_@XG\
M\P$[\=)%23MS,P;^JD;)V_'.6U3UJ]4EOX)$#[NZ?506/44**EZV*SU[_T_1
M<.U_H@'Z3R&V][B9;;_\7$7\VW"M<:MD![#R2H)^[L;^?6XIP>S'_SV[)="V
M%8I_*U:!ER(UL,,5<HA<. AB98.)W88#6+V*%PH3[Q>.=F %/"S.,;&O?)IZ
M  L\R_)1;L5JJ]F9V@!O_\23B<&\]SY>,")/RQGRT/F[Z@L+1:%&;UD8=9@1
MU:G#XV6HM@8RZ #L)&[KUONA#235<ISU8H;$&M'2SYOU[EO3]D@?PI7G8*7G
M>27>G6C[<]?>V4K)DQ9(VEG:M"8HY>D9B+(FN*JTFX4 !J2G]7E:,SC+4F49
M%PECPX]GTK2O#<@8LKRP=R(\ ,4H8UQ%LD@T3F& K3]S!AE$4S#X=&=>Q<=4
M:[C0S."8D9A3YZOBEQDH79#LC7@;K5&B0J]'1H22H!H",]$L* F+6NYDLB)6
MO7GPR4GD>K+9VVWF81^VH]3\/&/>[A89WT9PRS<'%:)JM3$\Z3L)5SS/.7LZ
M,++(?[S9Z70X7OC+)5B_<\B J^2MO(GD<H3]%GA-B=2%)/:200UQE)@)7?#2
MH(5OE0G(7\:00<'V *2 :(Z_ K5@,I:7'QSNN591[ER\O7Y4Q.Q%9YYQ^UU%
M?"S)"O)N*9[4"!;X)B-=Y'$/MQ4IX[$'UJM$\R"S+WX8_5C>^$C'E>_*-*N!
M8-DF2TP=*]2RK>N-+E8VM(+'E%?T?7'D@OZP2)!'=+3((SV^UG7- ;>/-UQF
M G>OS8\3^7"Q:=-,?@UL1!E%$M>PC'I?P6**RQL3Y04I]BS+M/:6,XR6:W?'
MNZDQ%6AGP9[O\%FAT3)TBA!P5HB8O.D> DSMJGPE@YCJ&": L'I?CPQ<$F!!
M&FD)6L/ZB%8.YI2>&I#OUI59N[R^0#TOJG4:Q&O#!-.PW=4(Z#--/_<^SAK0
M;O2EK<MX6\/X)CD9_[:E">$1W!X=.]Z^XZ>_%5X&+_XB,LF2LFSW,*&)]HO1
MX5N(N$OH!_$L5,0>69?O2BLJJ&6"-^XDP(>K:VO:@3\N8Z ]V^&?:UFVAQJ0
M_M3V2&?TT8=\IOCBNS47HX]ZL?>,7]P%4S0A#ETB10;)@W%VX&W9I;E4FU&;
M1NZ4-T8,:1H;#^ZMW^T==:[K?B)YS.;<11F+T_':0DD#G)\C4[U 69\7XTH1
MC,Z2IXP2:?OXW ILXY@/:M?1JE<;SM8*!/TQQ/E#1KH9XM]-8/<NI\KU\SU.
MP^O7_WI>!L>88M!D)34#0<BOCME?JM+W,\=SK@$V+=6?DAG>UJ5\5BPGC$@T
M.%LKT+G-Z8@GB7-MAH6HR[;YXVN:IQB^>SS.UG_CP.W;FNA':%(BO'WV(E;W
MP#-:U;R;6@'VW=-NYTT3B?<1,^ 6EC#2:< I%W:BSQ.\DNLBOPOA%*L!#1R/
M63M1#14YB!&-YO+/1ZSG-OD^@I<E!\(NX4PQZ(8)^P:+9][J2GV%PH!7,@_+
M7-U;@96<T?B:)(_T<_/&!-L!Y4MJ)\#C)YPMFWS5,U\!Q\N<>CB [-VF.NY0
M?6L5)^=K?,X-2)%**)Z^./9Z\6-AQ;[HI/IY,LA1-G**IS0CI.YP707.E'BB
MNG DZI0T\G4IWHSF[O?CG%(BK@%K?''F9N^- F'MHRU>D\K #;K@@,. '*8U
M#1?)$I7.-^ L7%I9XK=KJ7L;FG6]@F$AT>A[ZT5S*S-V V7DN81IEA:Y7=F.
M-VHE-D#R-7P(.J)4EM'1HK?Z:7\C0^Z;*'VG!<RH,7^8R.-*F4<2U,.H>[N7
MG=)!?:CC.<O6=&$D;NU(%YD[[W&UZ55\X_D7E73E*Y"\DEJYUQ/F$I+IJ3WS
MZSCW<ET\&<#A)NHG<$\!>*L@2]_XK03=BJ&9NO+:LK59.VA1/)U)1'RP%OW3
M<PI-,!] "8N(2<Y@K#LQ190>*(O1;D+"(7E$E9%-/@>FKG?3DM77WKY:O][Z
M@5;<82*F/G(8!VD8O5$/9Q_0!OA>$27KAE!JKMEFXZ,38QUP_U/Q.O17>@.6
MSFWY^,&AH\KB+A('GDV53]:\ 0P:!96& UB6%:VI\&<J*CX,.I=)%,E.8J&=
M%U^W2XB=/.*LRQ!4GR=1$UCT8Q^QE!E= #,/JQ=4 OS!CSVMM*\FF_:+DH9"
M22JYMI[FPG&M69TOO/,D&(KDPE3M8_&F#1E''&T^C#38T%DZG+!A!;P6&GOR
M+?RS6:6'/S40$E!UPZ/%=8LJQ6OS-1E'8>"13<A8 J8B:N6AZA3S(J]8H;V?
MSX*6:MY]19+1-^G:"A_(QZ"#RL*1H/75T"D!E "N@.!4,>+!0FNU6#XB*(;J
M]4#0?YXJF]W:B4YYTB<I,L"&4&AJ=V]DJK<'"=T&;&<0 D#"C;IB/+(I [CX
MZ?H;PHA7]:!%6EFK+M/1>SJC(M;,]'$:F%@FV*[]KC+L8C#%E,REI844(F-1
MXC.[B*.+.\9S7P+TEPHW.]_)2O+<7#^6%JZF<4P@Y]P."P81H^J/7='"HXQQ
M7P$&_4C:-<WA8HB_NVHSL<FYRNXF==7#I[Z,U^D>!WSF-O$2.H(ZCF6)J!,<
M@AGC9,:U*X,(4P:QYBL;*U<_OJOPCKOLAC\4.B1Z;;AC.=!O'!+YHZXA+9&M
M5X$EU$0*:\5A-20\H*J2]4 IU-#'7X7_8HQ4/'W,.S-^&OJ 6S@_H?#)LT F
M1I8+WJ*&6QIIF^1*[WMTRA/Z$++RG5H1M_S(1%GXWLF@=T=81^E.U'GWDT'W
M#,*M^7 2^&L).0\( 4K!6&%@9[RA?.NV61MUZQU_-?LQ3IV[(MN/+QZL;U5^
MQ;P\DQ&#<L5"1A$S^ADQ=8)D4".'&CI4YEY%9=GPW<$5E\37<6?#;L8D#CY.
MM&O[=$BL8E,6\0&@TP-\II',4 ]H2:MO1MB=P>%6YRMJY\?&^N5C& >N8<J#
MOG%=S&)WKV]U9 F/P6O/V-=/1:H+U0(/8**>N0\XS!<5E<Y/%'9US0V&3Q<<
M&?\8HS[/H-M]S0M;:1"542*3EPN[ ,!G1M7Y'U \N5<#1&&>D$W(X27OTYHB
MIV)%8^<GYO<ZSY=<>2(G^_$+Q\M %HT!,LCIC'CC:J0%(0NC-0 SQWT_F&R"
MFR*\=&^='=_&/2^:,2KDC^@KMV-U0UV?*C-YFTE4J,-O19($E@0%<2N-8RS,
MEH5$[_-))=*=SI$<#[E@87>O!W9/2;%[Q9E4%2""+$(6OLW@W;5P"PT3#)CL
M,JR^I*6* (=>3;E35.O:+?$QNPOO\R:$::D^@W2ENSPS^.H8@=2V#"K4\;=?
MF9P@,V#Z28?S$S&U&\\KDI8^Y9VN*7IT:/+L6;G8+[U4;P/Z!4_VPEPQ!BQ$
M/<!>_/%MO'';Y]*T:R.643>"5_P8"FM;/_>V"(-<8Y:N75#EN $U)83C39ME
M!1UWX"'J?!0+"]73Q-.D"PZ6=<8$,/CEWHO4X%^+.OOD>>_3*;F"#]'Y+P-]
M"NV;X!SP!P@^HK+Z*=P!F"*N+7BS$J;O-F+159?I[N_#Z';J=+UT!\,1AR,E
M549:ZH:W1A!U/-"%-AN>4PH93$0Q2&B=:,7(G:1E+%=&A'2STAC,#7%:'\+@
MDWS0+'1*QHQDY(JFCF,N4Y>%*F' T6@' U:6P[=&OP W%Y.K)_;>SGS1>R?W
M622>*P3WGM.$C9A#QQ>KC+P$V.+E6M5%RJK0^(K'[V!,6?Y/53JMKLFR:^0V
M2:)Q53?UGQQ@UII5QL2X\D("B588FPAXJ4%$6] TWC@LXL<AO0\>!:G+T*PA
MV\C&<S)L4=\/44V>D0S\O*%<!)D6KR^T&&B;E$HU GS1+"3.I93SH^"FB1LW
M@TW*JNOD($YO'_/JW#8XQ2F1,R\N"LVFJP."L9R/  .C(=A).U6?7(OG_=)2
MFJC CE.Q2Y&,T1A6IO$7SW'Y;2]OXP*H@4VLVB5LV8^2L(( -8DUQNGZP/TA
MCZH5S_!-*:?*UQ[FUZO;CNJ:?KI1X7!DP?,>S!V@4\AH4//3 *1>+5HS#2&_
M.V?7E..P+:\[<L?;CIVM%X^@2UH5G&/6.JBCRF%] R=+@ P3A7>UH9:MPS8,
M+@&"@!>3N&$)FM2/OS,,$4DC9DC/'G3@HH;MPK(?KMS=#;A^71"-"R:$XDU;
M_2\.W.P+X-N&,W]?E7$6QG..$86<#$33&#KOE4@P9%K5W7&-NS*3.0T>$VJQ
MX2!:^J8?!5QD53GN%'9E3BP/+.,N>7/&M=NFV!1SBM^-?WF4.G%67%C=X151
M&M]:A6]KK#O5K\XA%#3"NJ3O@TTS&6GVVN).&:IK8W)Q=NX6\_8R6;\70S^=
MKHN!:> JVM1/ P.90!2%58?',295!VN9NDMF],!LXPIU>3FM"UVQE@^N+8<F
MGJ9+/2)I,+D)VM W(,3A#<)5;;&U'!A$DQ)^#AGBTIU6X)AL,6MA!WY(?W2E
M<$MKWISU-%-:(/M!GX-9R82F7J0Z&V#?,B845F9E>0LOEN_!I-(8\X&A9T74
MWOS8B^<K$==;Y]XH4SUR;>?JAIIJ ,6[JD 35C,Y3%U0&\_79"V)YQJ)*%U>
M]G<;:_@V7SUV+P@CUO"9GUU0;0'R$*=,\8OO"X4+T@).TVK>VJ1/>+KF#!9H
M^6K+3NS3DKWT_FTDK*6J+-14Z/C-.%JO>M'#Q^Q 5".PVT!(@:--25O+275I
MXK%=L1=O'?!?U!,A6 V%(B3;72]M3WJ1^+/RMH_.(%"57PXC-?&(9A:^!\5?
M"0&TP .2M/D[HWF]U"Y'Z?/=HP8,/,\[11!B5.?8IAGOA3KUU$E;$(V E5TU
MHA%N;Z0)#FAZ,NQ).WM8*<Y8E%55HYXGG=V.X?,Y(]'LYWY<7#H-13];!X:Q
MXRNBU86_\OB&/?&TB;!AR<01%:4P:>(M&9\+''(+GFYQL)P%*USY1I78P1>P
M^(JQ9TR8\ QO'PVV<[9M$63N1<+DWID[Q3^H7B*#G/V3UB]7!QM61.K$8V\L
M'#ZR;1=Z5>1MN&JAGQ!EU7N@YH?I"2[519E//UA1=44NA>GU$66SG5PG1)MH
M9.?5!MK8FQ\;1['G/* N<K4^_BK@8YU*R5Y,@#A1)>IR<1]*.P](MW+2'CB8
M[;)"?%937A5Y_-&"^X%C9T*3G=(9J%*^J:O"3N(1*TP8! A:803<RRFJP>A;
M.T40J;'2UR:A92JZ)]C:ZV!^6--V$_U1(9EK+)T7!'H"X0Y->=""9D$>_&K8
M,9QZS9L'75C9#:N[:D;=,]>T1D]UGCW!VOZ9,3IP[5 [,AWNV#/&T4(&<:!M
MD=S+<D3Q00_( 6AD*UW_9L^*F8L,C;XKAZ;T4.[U.[H@3.)LZURW7,HF@HI(
M78SG3IBQ4B%Q6@?C',<M<9OSH1!,56GEH-WNQ6]WHFZ];J;[!/>IC$,QWD>-
MM$VQ4!@FRT5J7YA.K&B25IQ<OMKO[!&A,(*GK6G*N_30UJSKG0]CT3+O4_NU
MQL#/7W1 U-_']I_A1'&T9)3>C_8,C?T^]2V932N^U'("'T+#'XYO/U'[':T:
M( QO7\@E@\;!>]QEFRAP8-/,6T/3F!4GQQ'W]4G9+OR+JQ*=AZ7<E6TN$RK<
M)]&8URB5Y9_[OQ-"N#YK@<V?6[LN=;=?U_7LV7220?%[WX@#>Z[=X 4LQ<.T
M)6E3UN-]#1'  R3S#AGTM8>D9'/:4'L'G4P&">]^AA<IMQ&)-@ CO'T'3N*5
M:JI#_]BB_5D,C0LS9?-C[[5U>9Y>@@PR7:/$V7 _ELVV<V101A091(78%C(@
M@YHTH=XC/S>SJ\'[R(0U: HMD6R(B-4[I,H%H74\?/H,9<A%,F@?*=I$>=,P
M?_B/;60^Y'.)K+].!3S"/T,*D"4>!,_Z@_>3\B-+:"1N%?ES@]=SG9837K -
M7P/7ANW,O(3W4( 1V$9$Y)!!_YA?B$VX+$E[ZST9=,L=L0V@<4<H(VZ00?LH
MR=K'B)%/G(8DY!P9U$XB""W'NI)!8!X2M=":>L8OE)3ED(;2!8H'C ;:I\JU
M_'=G!2[,")J6P6(T6<(^;*&$)MM(5?;@OS)A>15P O\XK%!!NISPEXJ$]IBI
M;0)EF*=P?/[VP<B,36\9"IGH=9;-3F4*OPM^X[<-O,D<\";YH]=$,GY6"]S?
MC6F[O"&I:&ZJG;1%NO-SO,W_Z_' 0U]JMH4FR:!/X)%3"Z0 Y$_>^_^A(1CS
M[D>DK3ZUS6Y 4K YUJ>]4Y,,%]Z=V@[;F7M)&6#H-PD@T;\TU"8J9(3!%\;)
MH!.Z%"$6S/+^P)/;*@5.9-!IBB1*,K9W?I/$YM:O;7]4>"S!K1)WX;.Z8& (
M%DQ!U7<K"JK@\T++2>X4<9C^%$?=K^V$<,,!/_;/(<0(<3*(%QGW(&O/JA,=
MO[=*;-ISZX8O+/VF)2-3OS:DB+ZG";V^0J%$A")7XS4F"L*JO"D((X.>PXO,
M>XA[ORG+[J\-;XXCQYJ:*G@]AY"CA&V,UMX:_YW'BW-^INT>?Q#)_XT>Y/^N
M;3S__^+: [Y/N[>#*"@AHBDH:?K?;VB6YA&[^E#O*X.9-:/SVW9I+^+LC\76
MV=3"\O[N:/\1C1;ZUU(5ZSZP QG$LGS^#;<3<\^9XDJ=;:$+?=%[<C9'^PLX
M;W^\\EZ9QI,S@WENQ5QC[ULN/OW1F]3<%#*(GC+MC?+A):E.Z$*09M+1@W.>
MRC0WR]8RZN$(=H<2[:QE]J,GW$-LI[[ RY94]GSW#)P\N>90[@TG.AF#W:I?
M!DFMOVR3*4@VGDTO]I,CO$P^G_FRE_!LX^F$%X4S/^Y0Q/D?^E]PUXUK?JHT
M)TH&Q8"CPQZLNKO"M9D=X^8\:UW<WFXLA+M/ARN\VN4'CDX_A,)90%% AOX'
M'"J9W2*[,._JJ97)R_&O;R,5>[4V;A_"%,?IS)<2Q?'4C23U( ?4&:R^</.C
MQ@M)^F(DJ;?1Z8^C'[KV;FX@D\ .^BQ7 ,BN#)%G0%8UU5]8"T\7EE7M$W@F
M?.;&?,DF#?\9\ V+ #84+J<9,=;3:"T.:$,8'IRWCO&GB_0LE.E[55S#3L-=
MOMN8WRE9=VOF' CN'3$OV3;H*Q[N@>2P4!M&Y(TNE>=)U0^8=2><:(\IZ_WP
ME/HD#=L@6[ QRG9&F@=#@1B$> DKK24@KE6L(=KR97;E@HYA/<U3LQ#0 =UC
M(%UDJBVPEP\($_SQ0E$>+(>_LDZ90<?\C\JGG?\\KN$19L0J%\=_U]Y$I.K<
MI#=;K%3Z7E$J%@_(90FQ64$56<#-PP<L_17'5@CS4(L)!E2&8@?UZCF^UJY,
M9C?W!]SJA3@EA+Q!A* 0PK)7YG[UP!NO:%5"@N6Y>^>.M4E*(5JT?(?W8!5X
M%D(:7B@09ID# P]2 B0RZ"+>[CR$D%2(7(Y1Y;T])77JM.7X=IUMN^&E,PX@
M:]0L?>P(H7%0%FXO%&ZM6!Y\<5!5>[ISJ#A=7]&TLG^U1,0LA:/*QE8D!_0R
M],;+2.6X=_Z&YCN0<(_"^ZO7RP8V5526"]4-:;\I#KQ!.!^_WB!B+))U.SBT
MH>$@2@L<!>:$\>!YZ@F"ZGTP.98PXAUOL0P:"Y&2#N^W7\*MS692M%7$&5GS
M[&Z"@@=ME;VGA![6\8R1>M-/U."^)T#HGGCRW3,9N+VKNO.R?_S2W%[V-6_E
MIYKZ ,:UH4T&8SL!LYQ)8ZDO7I0MLO$/\72^,J53HGZC8W[BZOA=Q-R-"M<C
M7QYE57'5V/##7 ;59;B!\W7J [!38_X+S4P'#67#)CV2&B&E=I<D/YI=.23B
M$VZ:N%MY;"1W28A+71AV 8C'3C'!Y#_@)F)3,;HG2M'#JM>2.:2[QEM%3C=Q
MRH1<E))9N.MSCMZW[U'Q]T'33[[)*^98%<ACWZF(&=Q0=( ";B'R#JZ\X'7I
M)\*J*^'YW82.N$05*U':HY4TZY74Z<F7@3R\>./4$=1Q#$NX!234HJV5>ROL
M6B5N^1:DI*HBJAMZ_^Q+'4:?YLB\I^I?LU[0(KS?J5UJ'9-)Q$X(-REYOYZR
M')I.Q[:.SL!NB:BH3B!C:IZ=3ZN:"'YYFUW=&"^^4@;WR8,6+335'0?<,Q>K
MF59:GITWC82\Y4UZ=_N<MX'TT&W3XT$NIM(-*DY9P 2>NZ?%AIYTF&@U(/RT
M XN728#S/]2(OUW-1-M2)3PD>EOG>U#R:;.=V$B)?+8LRDK XC"UB<O882UJ
MA&SVPU'P-%?2/TX)7OGM;*1$KL1/TX5DWTL- .OA]:83PV)0]]01F.WOGI:%
M\D=F%0ES2?B5:<VS52I3ARHGUN4>*1^HY;L(9$Y/<5H[FJ0H17E(6R]?91SI
M-5NZWDT(]#R;7WPR=K?X@H":>[H$X$/14EXG0?XAA4+PRDB= .I\Z/,N^<CW
MMSCMUA6E:-VX4OD:6MU.^R 5 =%=,ZCXC&DX2C]SU,F7J:X@>[G"XEKJO8,5
MM)]V:E%GM,7'CT??B7[(:U"#HN(0:'OIRPH43B=1;/2)K%9>*KP6Q:3?A3LT
M$+[,G%M3@O1@+@@8<W5!4['VP40NT>: XWCKB%<=SC3>-XIR<IL>W@W5MHO5
M8FYRE,N2L&V0O##+&VP)E$U#F!R3>%V0,V"618O85_D$+^^Q-ZQ=;H5;5Q]T
M,P3'1U._[*4SUX0^@9=5/!8&\(4PQ5J*X2LE#'Q[%>\I%>-%NXZT=CCAQ\;6
M*J8?>>6[]'K@34\EHB[^M4'8::+QL*IQ$:!0:L-TZJQ#N:)O?.@V@Z5/%.W6
M\RMMIY ("8GMQ&?3*2 "O53#-S+(0<H@ EXR#O34JTO@N#.PG@,>N\N=$#:G
MBU9@S:?3K3VTW^(2H9]9%'@>7;0Z>&&6Q10?UFQ 3U0MBUQNL1;K(\HY2SG'
M.M\E25UV_\JK!4HYZ"%O&AXP),2M($1#ZJINBT$Q%8Y'E65<W17,<3Q1'3&3
M>KT\Y.-WQFA>90'WX!%A&FKKCH))Q8PWDQ,G0J''?(PM,R7?!,(E:2Q?HY $
M*R OG^@"T$U3W)WEI&&OE*)BB$@%Z^+7Q0,?/BVNT=V_?3JX@'?5HX?GJ\50
MR!XAK=!AA&#"H0?Q<7?RYH\?U^/9^3Q[3T28LM8$U>(O\&Z8JD^QHDZ5G]=?
MAB9K<UN@G!73'D&P:ZNV9M'O<.7?=%XKV(NZ'0B:..@PR8;?"@TX9M;IAX&S
M+:J+E$00\V3DH[X696F3%A]\#O3/I?:-7)\P)40"-S(=DWE=WN)5&JJ]LEQ(
MMX:]+?;>W- B@R;L'*CH/D?V RTS4N@P^"&4*[;FT)W*NMY2E16C2;ZXJP8B
MW*N2!8$:8U<"'VFTN5[H;HS<!NL +;L7+6#\O762$U_3:?#>844;3OZ^JQI]
M=U'O!Y^.Z7#?7WN39)X5WV=&?,,T?HU9AVNY',Y]#_\*,"V"WC#'?;+FPE_W
M60BS?($==,E2G->9*;[PJ+_@@)U)-Y=EY2OMO+Y;M:LM!K2+=:>"&[<"9'N=
M8?K*QE&:J3<>RXI(;UULM/01+Z>3KY/YH8%AZQ:7L!G<7ZUY4U:CH)O^5_A,
M4E_"@K3XJC9>,:='?APFFKZ&VFLZVYL-R^])Z1@SCX5L]E]RX=P0TSK^**",
M)P3FC)D2< "/I?.-;*!9%U,C_2NNH&+G!9IR)Z--A0?DJ<HTW4C<P-OI'GY'
MTQ3O4*+5*R#X>LG1JM+^S7,N]P*I@ZS8(JRALY[9B,C)PQ >>*.DZIU70ISV
M$((XX:60<[<<0MB+2.*D&C+4MS<;>A%N;/BT>9IJV49J,:-,K 0S-6K?"N?W
MM"-]&?A>YA>&FWSV,:F#-LJJ,/%UQ[%;F.='7WQ)B#A]GNI"3WXN4@PGL-7*
MI(AUUL8RM3U&JIXO9W%K:B1LY7ER!AZDKW.J_DBQ3TQ/XDZC\$TP%HHI3YU)
M#B,JS:RH"X$62;3#,I<S1L_R=7A*/&QNX4]] I?JH7]WT0?:S?E^-I#E36Z1
M_8]O/D0!W(Z3#NH&MHNER6B2WU*L.._2@P'^F5GVTQ. J39CWY>+3YN73QE)
MV'DHF]#8L?I%TJA'XM*H9X9K\F$6>Z]0TM))Z>5"+*=*:]+.WM2E*2GK>I+,
M?K@#QBH XKN(?SF[;@7_MH 7-@)J<4H-Z7+#Q\K*!C<+U62*CA>;F!EW''O"
M^*G>=0(Q'*@F&+FMA(&TK(YQS/"$>J(Y 3>AT(5KQ<.0TJ_R?LMZ@(N]GL\+
MD-(!+\W[U,CD: )U-N'M[B4G,H@=?0_"#6PUF*Q!;5OK.)^ZYC\PU1/HM)PP
MT_E@;58E>8DNPOR2!%,$9[2@Q-&-MUSQ%!7F&(6.-U)\K]*1=?D5ZU:FBZ,]
M>,U33B>$=N="G'I_[(N#_DX%ORU$J=J5]9;D <O%K1N-D]:CPH]?7!,V;* >
MKML*X;U1&-"Y"1;%4RD9,+FL[3$K1O:304_L?R2GT=\B48,!2@1SJ+N8#+J0
MNDH\",<A^Y2SOA"=GEI%CTGID=C2;$F/E:8 1DI$JDT4/M^V=P""QE'BIL;8
M!UO,NEYR#PIE 2U/Q [-%'R:$N:%".&BEX4V#O_(M4$)P>@I?2F+?NYZ78K&
M'!T&?^7PIWC\/21.>*/<.WBOV"XEY,L@2LPC'LTFV_XSPK)2U)K^3=6_J?HW
M5?\SJ;K5#V,K=!Q[HEB0\Z7>[J%/PL6/6>O\>R>56Z3*%:ZY>>D48- LDT#"
MS<C^EB,?=43KP>)J4&2-.C=@:HA#AMF&&=8F^5AIK-FUM;L.DD&E?C.(!3,X
M70#S*$"G'^F#9<D]/;'.^$P]9P\Y9YUA\]R^JMD5LK01P#6"SMQ%TC^:_?!U
MSYWCK5:I57)&1K*!5:3$Z[IS>R+[OQS,P_;?='D(W?<98E)%6*G24).S^<_R
M(GA;["]4]&MA@=M;"O02K^-H]^6*^./#-\E+!AF#=QO+"WA^/Y5X?^LDIV?/
M]@%'H<U5<5*04\ORF,(O/WW]V$X7T<VL!MD#")Q!FR!OJ=%(=5*\*],'!#;U
MSAE$2^.(OZ;C?=BH)V;B$B%C+XW$XN@K.I&&(E0G(0HG]\JUJ?<XL?.BDN^N
M/F[*I:.6ZN#:2#/JVU!3:B(4.KU=)%0[E^B)K#"]E&(_*A!5DWC]X/Q=L_0W
M3_6MWH3"1EQWY8$42%!U6W +Z:F"U!1O17B_[:FZ*^,"NB[E'',+G]9&CK0J
MN=;PC[PB]4W1>]I$J],.;.@+SG</+TU9O!]\L9HVQ/CHJD"]Y#MO5N:#9]+?
M>")OO(ZB[6$$(G#V+8^(-I!P$G5"4T7RUIB%P_GT*&SXK*5#DI(L?U\7N\J;
M8%<C^D3AWG5#H@Z@,I,100:55$03!?(FH'<'FL>694=']$/-3DG;FCYY8G_\
M31QII<,_6+1^#(3T_C&& E"!Z[F!WXI4YW4TX>&.T\!DL#)9X%VL@G59*Y+4
MB@/?<$^<P.D<Z5$K",&+?T.[S\2(SV0CWCDJEA,$P:CRZO<I4QX(QSM!7%J)
MYC?M] X]/*E,G2N.R)1XW> ^#^$@'J?$C^>7ZX5P24X!3"7%.'3XQL1]/W\!
M%_.RXQ )^\3TRWOCSG0/KQPZU?SB-*AP&1D"9R<)$J_B$>$D/AOH?3)(%_^P
MV'IRT5K"+UP_;4Q+^&PCKF#5E)Y!F*K]R!WK+4UNA@PE&U*G;Q\@EP=XJ;FT
M7<>[U& +X%Q.YQ,;5;G7KLE@4HPC+G@9LS6S<6[QQZ>K\6'IFM0,6C*.U'%!
M/_1C^Z55&A.6C"9;Y-XG:;C>[ST637L,$WL-B_+HN;)1+?&!TC\ GT8T0T)X
MD\,]R"!:%NKE .XA3[T8DU&4/B=^TJ%'!0(-C#AJ'ZUX92[^O8YXMLA>EGQ-
M+>0:< :WY..\R>1D@A>-:?F6A#LD[.?'N:OYI4/P6LO'5PP)B-.,Z7(;]PR3
M+P[<'[X]-#NP8C=4B/&#0L9HY=HXXJRXK[K0M]R,8SYLN*@9-+<D\?IYS'^R
M/,:/HJ[SPU%W#N:1031C[S]471(MZXD5#C4VD;Q27D=UE(:M034XA:+JX38L
M1 7<%J%H[V58R(8TN*G#1[#VS9>V;$N1PVJO';I./:K.I4JTN@3RY=\9Z8TG
M*N->J@LB-!"-.Z=\.;T/K,BW#&"X.T\G=+&'EZ^PS,-VB].^;,Z7(E$J;QU]
MBU+SK1V2O'V3GMLY\76L],V7GI7I8+RF=<.-F.-PE%_P)..VT#2_KWJ(^,KQ
MMU_?+RK"65_AD\K$PNX+1\B"_ Y9L(@&$!J-VQE:J?U&@F$J@"M/,\LHI FO
MCS?%>(?<:9;K]%$,J; >V!1YIL)3Z90I/H;J"QJG<O[">!K9SP*8!G!1S'L]
MM(1BO85([/%"3Q5ZWFL25IZ/5_2,HX^<:W6-S)XZA**?E%075Z?'+>)/PD\O
MBU\)7DDM29OTZMKN@?7=5N4SP\F$S<@"$JKVS196V>5CD"85OR@/U!-=]JN>
M4L\_!2E^_#[VG4JYWCVVK)'H&'8!H,:NAH-9OUEBMIJEJ:]7E?(N!)=E".]:
M].OTGZ,Q<8--$S/-+-N#Z51TNEG&&# 3)V$7=KX.G&JM)!38C3VO,"A-?337
M+';+Y?/1%T$+1T5FQ-Z[J+-"F==;HK 11 [,*.IJD0CO8,I5)N@1#\BY;"+B
MU@!UO31/(Z_-R@369*2P-$917[OAO/-*RE*\)H>>[+@]\S+Z76 B3:S[QKN\
MTN=E/>$VY85OREVG> 8VFOC/:HE\"K[XD?70;D,QPG<GK-F&F2@UPZ2G/^BY
MROAU9S(SN_)IZZKA^TBLI2D-:Y]*GH0;U<?X=JY,>TR7N/[@IMJ5 ;T/98.>
M6C'([YB*RTG?7M-<DGK\@OX5O1)'X.ESKUA"B3[^&*<>0-2_C2C<OWAV2CQH
M0W.P-=UV_7(GP4/=:](;8J[=U7W);R23U#O%QAK0RSW)WDL)BKXOM'B1^*VT
M##A@.BA6RY8' ^UUET'"*F[OS(I [3U7=NA[IJ<"/?;$3?L+82R8&F<Y,\\$
MHP]A.A4ZD)<"#=D74NV.K3%0=]W">S?9'")J*(:UJ'/UP:XX\_FC"75I3"-/
M)_/F3XX%/*/:7LZR49LB<B"QJ#L;)0X0/(VVDV#0MYV'K@*.+8UCW*#G9[]=
MCW_ZCBD@!D@E:=9:DFI%*?K(9)2*60UQD;><$+1A_+JVJ#1R8FVIX=N)T[>N
M"=S2$_'S*EF][-S,\>S&R\>6GPI.?/@0:G)$4DM#\!G5.@^1@PQJM:!%?TO%
M=5Y-OC5@.QA36LR@5!.M7UOT=JQ&[N7+:$9OI#H@A!=NG&(B,07T5IM&H#1R
MOE879D2C+G[X;'6->WJ[^9"BYE;&)_'#I?\?>^\=U^2V+ P'$5 1HT@1*5%!
M1*I2I4AL-!$144 0HB)=P (2)! 4Z2 ""HI"*")("QV$D BA*=(1I(:$)CVA
MA$#:&SS[["N>O?=YOWOO=^[9]]U_A-_S\*PU:ZV96;-F9LV:)3I8!#&:A!=%
MU;@"38N[BG&!C.V=R\+J,82^N1XL.=IP<V9U='OWD<O/_?<%/#VA4I4)DR/:
MYQ*,*?I(F'B*#32@Z2C<Y:I3?E5WS1'S9IG*/1*VQWGV:<MVTN3>4#KQ\3-Z
M:2ZE.Z<2+G^$:+>,>>E(6<OK;9MNCY=6S'AT;-\CG0=RY-ATF#H]CW'P=$H_
M$.A4AMN6]@69UCY;$U\>-C=^,-'VG%NT[=7MUQ#UZ)<!']#")<&GPD# 21.=
MY BGPZ+/SE9X-=HR 7IL<,\%7HRD]D6]LXV4<&)W9_T0B'3F/L^.0$*D[1G$
MF:C:TNY&=U>"IZ^_@7\=_T"Y-39&OUH]&>BOO8F'G3 >1>2N[JX 8ID EGYU
M8Z[5'-.-)TF^\O3-3#T#:_(HCHQL>*FIL9HM[?\&A#H5O7)H5H<)D&PFW6/4
M\4"8 /UT)&(.?#,JQ.\(T3A8BQWI!.=&'<?3I7TD8VMMA$O*7:]T])VY??V*
M^.4@ ]7KB,]P%$V$@*[K*NXWLC6NR,>4!*W53TD^(G2/'Y4PU?V0+?YNL^)3
M_7W$D\G EUK\I,4/ZYGB;V V63LG'>A\@XZJUO!$[3TGJ+\2;RY9KV(%)5RT
M>']7$'#G]6N 2RM*B,@$7*) \$S 5RS6<H#');MWRASIZ;X/>UHB3E#Q13\]
M?5$5<=ME"K>=QDUQ'TXT45'80=,FY@5D9@Q6=BI;N3C%?_OF']52$7D:6V&&
MS'0JZ^FS2YR=>R5N9'OOCEN,@8OX85WHBX@T_H,&5WFWBDJQ$^B6KD"R+R70
M,^?*QV$%EKI TGMBYE5LRPV-,NQRD[]D+RA<]R'(Y.D;B1!!9%-TLU.?*I)@
MW"<^4KL7$^8GZIB (5?HRM*\4^@5!&N91N.B8MF570\Y.^YF;1DPL%W<1H48
M4TX.'S]4=Y&2U%"M+5I$DLCK,,BQFCRB!YW!>4=4J\7XO%XTA5;BW1\Q]EWM
M&X"FU6@ 0^7EX"-#UI!S09/X"?#^: ,; ZT+7(V""7$OB>[#:M4*FVN3@)0Z
MWTSGGK@UKA"4CG2_HUF0ZLLO*V6O5G9%'.50/[9J#!!!^L<1*=F$0[-*R90T
M"R(DN+C9%!MWQ+D,O0E]/=U2J<Z3NT7BF=25R\8MMSGUU,?1PSTH;CR&'^KK
M(>>"[3-#IN2U5=C1GYGV\Z1QA[P\2]2X4V?6Z2=$ >L5O2_.)[X-MG6YYUBZ
MN]HUX_1>PUOIGSY\XN.,$)*H$>,DC\2> !VB'26)KF"K_.;Q0?%OH8*U28>"
MJP6+H/!Z;:Y'Q_*TRI_S[Z\,]-KS.6;+"[Z[3QJUK])QNRE>1()""*@0%TQX
M14#6S&_#ACC$+;ARNU5E3!E(W5>XW7/*N,0[C:-T4W_YGNN0-+_M%-OA^>##
MMY-V$Y."\1[O][54R+_B27[V)!!58HV+//''ZUX;!TX8ZZ7@[TFY9A^S6MST
M.#)UU=!@[ B']_#$$-J/ B0 @TO!^0CL,]) 'TR,I\O#T%J>.!6@FBN!J)01
MO[M3B&WUA7^&2$#86A#J-%ZO&K(3)D/<436<J1>\C."!NPZUIGUUYA:O5^Z/
M5US=+3^T]_#->(#;E9V LP(#8<;/;>J?X6<E4SR0.-LZ+>%L"[\6>+%Q( HT
M# )90Y%XFXPTYX2W1?A5)+Q$+VA?R6,#/F)C9;K%J/M@CH.Z9D%Y=(1QJ.$P
MYE%N,DV7G@3S=N=9"5'I/_:&*!;[[N!0/'+K^.5G!]\2KC_EE"BTO7;Q2$;"
M6E0U;KL[>F_#'=#C)2#[MSL%_0><$O3S]P;!QU"I_&)6&: #<\"@U;0A]&57
MX6$JQ:K6%!J@1RSS=RV9L_6]B-.QLLH>IMO'6?1XW$+YS1K*OK(:CWJP:D$U
MIT6MK3(!$$\Z*+,A'>H[3ZM2F\_-E8>(4AX, >+)3^C)7+6D%)8EJ4-NNEP"
MX?/6AI /]>YN6H#-QW_"C;OWU\^XC5?9P4 CHC8X;!EFNY_X-VU1BH?R]-&W
MDP;X0+1NR:X\K @3X'1.7*_,_>.'!LM* N[QBM@Q5'$E22&(QD68SE7V-HN=
M3M#XO+#IWOB<G2W[_NJ%3FF*>\+QZ3$OL;U%/3G&O27JQ=T%I2&GW;J/*!NI
M'@WVH!9<NWY?\F3U+?]3!W738LMD(#W+=,O52]7UKT6^.&IZ&.%(ADWS"\_1
M-D1WVNOX69:R>0T!9 (FDQ[,8JXS 4*.W%1YFESGCO=O(PVIDE+H>K>1Q;(Y
M]WC[>XA;YA56%./3)5TED;JBPL;!%[K-E+OF1DHB[= 6;6]N.+ K<ER\Y'8(
M\/18GK$NRXCCH]PS*_ZBC BRV=&QK&D@X.+3='Q3AU#*4Y%@/8MJ,ZX4+I5W
M$TD\5'[:.6+40S\NEI6V"XK0:^OHKWO0501WA.AMU:&:[M2WYTH:JGH'=["Z
M@M3>0KM/>>CI*I^8!NV_TEU"EW,7/UHY63\@85J8SW'ZL3T@JN+DJ$A/50-5
M&R87;JE1 U,A/G*>5;HJO-SF>F;<3*)H-<EFMC;&H,4[$^X(8IO&[&8 *<'5
M:!%4<:=\R5=SHW)4I?WEH!:]R^^E^:WNO3@7EG5[Z_48#L ]1 %,394)*(RJ
M2:]L3?#@-A=BC$B:,@$B,C;MESQ$!5JQEF*);YS:PGW!QF5/.OKXOT7KIIC
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M)B= B4G;*(<R8)J=,)UA3(CV9@HF;PK3YU4_-%VCUK,PN;<JIZ.ROC?(,TC
MSC>O<&8BYOSYXP[U2;O0%!G2Z6&O2 _$)DJX"='O(3X<P3,X:2DBEP5QLNH0
M!]P\U2H=F<XM/^/:>@>1EYGZ 78';P42A#;5@4K<0]Q17$B*,Y 7ZG*^K-W5
M4_B&0]7"C+MMS>-&1=Z/+[J*#GMR;28@*4T?_/:CZ%$,-L=H*/PBPK)CCB;6
M4_'@2F./0)+QTT.*^X1CF]C*>#D'1 CH\E1_+2#!_+&GJPNY@.*4V3^YDF$0
MC+4<2V]YQU-9+-!A2+ZS%^7O:G;L1O+3\YU/GH\P =MIET= CS%%5S$<2/1.
M2IDI"8VP]4[M,W@[Z6<?#A\O3I4)\*G\I/_UF,/0:>"KL8^;T .I#T%"DY =
M,!/J46CE<$]H'NIX%F5"OYVV;8BGFRMHIF]MO&;D<]AUK=O(%E*<;I2T(M]=
M]4UE: 7G(2E2?3HQ8SV<9KIVT8*B4"L8-(_UBG,1R+YG=_S=X\&Z6ZTQC;7/
M(_,G\CA\K778M6T[7EE25JGG*%P-JDD[2<#'J$/#KIJFD?,PHXS2Q#OOK@[I
MB=R0&H8/[1FY)&OM+_R$\\%K!3:H<*T9/#^X#@P<H,!-@ZVK2DG72CK&BIY:
MG[>/FZGA/5#Y CTF\W#1[:K# ?3[5'_M*YTT0<(6QB&_CV5&*5,RKBD4J\ME
M7^Q5D84UYITST;SWZ\7M;]JQY1N8L:?D>0UC(E F5!6:9K??7F?<-I0MP?H!
MUK0+<A;=[A'KF>%R=.#J1]F+!A["-\'31P@7TR_MR BC'@@#4-X"'VM :A18
M5@$>&,!B!R3(&7VX34[>OH1T"/O*8"[/P^7E553!UFM-@#,/;S>VYX<G!:C)
M%QN'^<E1(%1P\XB<@EE7"1U,<,U=QC;=3%W@.<J[?+V\2O^D_@MQ/121[=K6
M 9>9+"EV0FM$>'8O3;][&12 YJ<\QR/"U"QS=K5*=4J("7:?TD@SOM]BB6LZ
MRA[*EX/:H91 /?\W8?*;TMM\(JK6?55D&41E2=?4;LSI['%W0;]FA3MYAG=\
M_%()-_4.#+D_Y4G>43"1C"S #]AM%\FJ6"B9=:^EX2(6!FSLMNVJP;YZ_HD)
M>+@HQ[\$I"G)85C+WT?6(AG\/=."4!R. 6<)I?6T5)$]_4R ZS7P! $LSP1<
M7G1?);8B,I')</Q+5Y;EP#"FTK[G<_A<RM)&F(!#= :(YA8UF\-%HYUD9(_C
M%O$(L GD!!. 560!:J4A5BC?<R!LJ-UO 5RE!-#-FS$36&V_5/1#)B#(KHRU
M<*^"YXE_2^6PH79I/FB1Q+6&? 5O#8+1=7S961.GR9UEORS <?A?,JULK/]]
M!,!EB"KKG]M7U\+6N#:.LOUG"(R^#_#66M 4FM5/;:'%Y7^*IW9ZB3\+> CX
M"ZR? 5.:F)+Y!J+86\%9FG$L@PD KN=Q^ D U86-U>).>-9J&8WBT-IEW@;>
MB,?B&2;@IJGOC3*#=S=4[_HKTT9M&2]].EA]4UB%!K/0N[ZKB%!IAYR#8T%E
M],T-=": "9A5_NG-=1@\,<4:O-KWP2>%K=DR]M QWR3!\^L%G-(VOE'=UWMU
M@=4K#*M7GY?,.T'$AEF6@G&4U6\F@&KT\VL_%+BZMDX]%D6QV@ZIZ!<L](/=
MU[9&4=<A]CG^],KH9Z&VBX5:]^^H/<Z_U$ [2H6WG8/CF !&I]Z&%_(0.\,O
M>9WSX"S.>_D-^1:,C^IG/+)EK ,C)_ST5DH$+2ZO<P:+6X)@K3J^1]=S)N*6
M=H-6UDL4M__T2B];)UHFBV@X%M'&'\A,1E%LR4Q ,FL,&": _O;GUUD4%XU^
M\N^H5_H'U+-DR4V!LJ*DL9)]MH\W?3#^^)$]:M#GYW82_BES9/S"3I#_60Z,
M^@D N9M%CGW_BP7!ET0ULEG4I:JP;KF3<09; :CA]5M>DFRZ?JK9_<>S*/T7
M@L/_1[C\2ZX"6<_0^M36#+1!BAY'=+KLEC5O6_"Y#N]Q-AGJ&96:WDHG'P'O
MLFKXHQ4_C:X#E94A#1DI/(M/MBQK#P5@.M!-[<J&QL!)TI4K9\1#N0@-7=3V
M5,>X)% GH; P1(\76!?U;B5[>17MDM#UV?G^HUZ_'#IR7Z/4:)?;<N8*/'6!
M5A,FA=R\]N%?;JK RJAZSMW?$[PXS0> >%$GIEV&B\NZ4,?A6>?N<+X\7B-S
M4B(X5:;PF?QM@$BTS9=LV$7B_5R>[M#KA$0Q)L "U3EWZ%%]QYJZ?8Q*1-SM
ML-I9$=B@.O]79TN[I)+KQY^D.'$L/YLNM')YT:T_"M$UV[QK.<^K!KX5!ASF
M?R^VA^@03#LF?REGQ*!CN&3QY'#00IL;R)(3)NA-Q-;X@9B 1V:]4,0Y(CTP
M*O1:9\YR8\F+:R;0^-0YK?.25*K_JMXQ[H4GQY!OW>!C^_=ZT6.FD71-JY[B
MC\.@[49X?F).DD@'I&::]X.R;D%([Y:N1^]&77N+=V[9\V'?Y1'\H!3EH6?G
MVRN)=UR-GG:A6Q!. F/8%[ !M]YRSO[7-]DC.M@7%ZLQV[1 WDS YA82(B2#
M.)2H$"+OJE)URNCR[)>\"')/CXP;P711OBX4 / _ EU]XBM#R*C;*J_E0US$
MFHGQ$B5S1YQ0P@*E0X<IT??W%3_BNA;%)R&N^>ESSFS9GJN[HSNGOL*X\=GN
MVYKP(;#CZ3KX=Q?UW[3'?-IO/RFNI/]V9^46>WO9HQ]O&%MF$Z*"M'>02A(C
M,T)0AU*FR7''J!)[W[[B^60U#- J\=Q_C/VMQC; :B=C:Y/OP0DL(M01HJ-*
M9H"[8H; /(VMZ;61/#F!KMP 6.*"N@T7SX<Z7]LK%8>"EJ*V-]P3BTZ_XF0R
M:$0.[:X?W,_;5&+J$\A^S_7,U:3;61ILEI<^L#AF\[\\+N*WS_9X*GR%-7PL
M;SE_6^![7,1S_@V;B9FR[W0V[C<Z;DK?6"1YV[/+&W<M_:5-S#;N6@+^@O)_
M#>4>0YD)>%H,7YX',0*L(7\0,6$R$%_0:&+Y6UOF+G=E;_[V%T%N(3ZS?]R[
MU:FIU^'_QQW:]ML%T3K_N!.K?/6_#_R&" @+BU\A>5HJD+W(?#8F%0NPB7IB
M95%@Z_E!:8DE:7&I[ VA)_97+H9MB#1IXS@KO2%:Y03_3U4 EU)S-T2K%+/]
M)V!D+BNL"GH:K]@R >WAYK]0-G.>44T/S717TS[?A2N6GT<?C:I_*.;Y&TA4
MJ?H\\V<ADI78+B8@^DD3?7S=7R3Y]QJ6?D*,1L9 "54=O5AX?_6A*KVSAS/V
M 8^;\\^<7MOV[S3M1E _GDSVM#G(:& ,H*@GT8MEM"$+HRJN<PF??PUVN+FD
MZ-B86O+;@0U>_VZ4^FWP'C\J+<^^P:)F(C5GAAQBQTIQ:L+HU>FH!ZZV76W_
M5G%\_Q_.HO[#5<3_U=]5>#A,)_WJ5 AQZOY=9/2>@?@MNB=&;[OD(UOG02X)
MSQ'A"BEE7?+)@;"J@@8EZ8CZ#']@KJ^ <9R>XK/.Y^]=*0C16N^9A6,=SZXW
MM\)K<..^[O22]:#9Y3(Z T)BV3[K@;'3[E0:9@3"!Z\QRH&W6;*8<1.$QN+:
MQZ_6,P:4K# V8R@]G4Q %O'[C9G:(+I?-DNA%QSR1?XGH;4SLM?O)"T']TQA
M%O&^$WU,0+\EG&656<%Q8RQN!I>N)_MCK <6-S%42'HTB;X&.@<20SS(,FBB
M* 8E46O<$/BP(8LS05.H]1N5 _[JT[])GZ8]P+N_$2E^4CBS H/-<V=5/K%'
M*!QK]O-E OX :@=,CHL)4( ,<$=E(5=OHQ>7U!B\N8*,1V00A1<QHD<[:*E
MYY@!$P^"ZS%:&+QD-_B;' OD0P6&\H;>.L._Z*]?+,O/!.S:A*11(-YKPDS
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MD4!3O A,P$ZH::U A<1.YR31CJ&EG&YRQ]@9P\7&C&9I:_;--]D**O>Q=^;
MG5L!$-C^8,(!:TC><[D)LN5D[HV)BXPVW!@]? 8KZX"K;U]N&7(DQL\JO(4B
M++N6N)%<4 Q6^W!)I]V77 ]1+^,P[L3S6XC",SE%RA=5"=G%%4\M'-@E8$5(
MOQ:&!DFP^C[I\D2@"G3>75OF*NQ4)='OE1?9^K+RY+-:V\CV^OYD?P/_X;$7
MFX3#EN?]T>Q$Z_DZ%^#.;V@.2KHM_*W%P &7I.,5:'U76G-6FQ[_0%WBZ[MG
M4TSR8;UU $WR#7JJEA')!YLD5T0R#M:"W+K1M?QBA,1^I;??JK>_3D;V?DI:
M_.WR2+^K,^)W%V:[EM! >HJ6Z+!Q[PJ^OC3>Y@CI+#1H3ZZRYO&3'"SIZWE%
MW[[VE;"+/K]%4=P6P%B0KG=K[Z<12^(M,"]#9%I[!^E@7&H?HS++<JKYK;Y'
M4Z73F--^QSF_$24N]B:0ZLE&D9$6FO@P7 BF27&@RD"GC#E=+#&T?:7FY ?S
MP;FWKI080N==:T_=++MUU/'3]F2.L,83HK?9EA%84-@NVKFB+FN4$@&\=>CK
MN?S6#&C<!RNC1?DQ#^E6D1 ]DGC22:[-YLTX?HQC$R8 7C(?>FO.W5/TAG 4
MAT5=,O24<-SA3.=.B/*=-R8.CO=%E$;V\TTD\R_%8Q5"+\+.E70I"-8D'2#6
M/4=E\_$0#-GM5+K-99NX1:>2A^T^2$P\65XLJYWOQ3$$S6>OCUBY>IWMRM72
M]![6/'9+R\"=/;FHRQ;M)!ZSE0A(T!9V5._3USK:R+D2IFQMCE>8P>51P@F8
M)ZCKVI69SO<U@G(]A^FG/_IJ&[@-/]'4Y(\NU7-+;P?M451XT7#0'WF.DD(]
MXXCAT;+.@)X7Y:ZU4219SZ9-B>L0JV*N#IQVS"T>,$2?.6.$DVJZF010&4;P
M*: /TL[160;=<"L?1<^BG!*:/)5@AM#JMO1 <KX7>? \)]S7\?*= \7Z+7CX
ME^>NU;HR^:0W";AJ>!_6E!( ?JQE0&C=!GV%-5N[4$YL#IC:_76P_]-\H;[I
MN,6@Q4ZZFL.Q*8 ZYB%8V$-4X0(]@R&IO/=U B<BJW]*R?+5:1Y"2/'7QP4O
M[ Z7ZMRTVQ\B9%,^7J6&Q92"'L-.$MRW.S4G4Y &'2@3<*\'F'>JPKQWJ5GW
M1GK,L0$T\2I[?J$4S,Y I"<$B\<)4XKPD-E[OIE0KJM$1@;!OV/24KE[W"7\
MN8;S@2VT_#-/;K/+VI6^O_E1VJ63H0X%7^W6W@MC+RYL=T>Z+6'V0F_,D85]
M'*)G]P<&)\KZ Z,O.-P381ORUP0+^W4^4 N$F6=1O/2)&>$P[W??FH2=I_''
MC[J9GI>O;#_H%<UV%Z-:._!UUJP8U.=0[2=% F)GE<[%+$P!1;]:XQPK7H2:
M]9F5 IK=J"\T/B>_3CFOFB^Q*VSUE1E%#^COIPHS+B>5!:(/NVAXA:H@9A.%
M+2AP;S]RJTATIN.AL([+1QLCWG!&WS8''0$X("D(8E;G!TBA>?!Z0,9V9QN^
M+FV1*3#QI5.?:@'4OE*_PUNB,LQ)#;/V5>)EF)O6TRH=@*]H,LVL0\N !*X3
MX\Q_M.!JB+W?';\W<KR6*NMZ6RCML>ILO5$H*K*<+?[U:_-@O_:X"D0$V!D>
M(+85PD]YA:W@S'X[;3J$Q5?9^ZI/0--"T^3;C\@%=*K7&[_+*R,?:W/K9RE#
M3Y:AEJ(^!+$,<)B;;6Q<F%"CP-.)=KFX74]J$;EW(<5VW1DL/:P/,=P0&5^3
M)$D2>)CN5-$E6 1UUT680,4L"!;8G+-G1Y=:E *^.;*UMQ*B>A$CK?XH=84(
MS]:]-$W20)F&QVUHW*@-Q$F-U#!>WSZP:]R SY]?>G2V_MYT)0OX$YL=%"^6
M9=B@,=J'C"BAR,+NP%.$?6T%>SJ==8=U96=,@$?B]]\X_8CKJIE&'^45.88R
M.PSD;<+SN%1C@"CN@RVI,92XKY8V4ST+M3=";<LD/HJ8/+(H?FBX.Q)U\RY#
MF.B;](H811@+K@4&#\GV>$1:$8**O#F2PM^VK#3M'EA]"JG)-#/R3[:+D4W2
M91-*!OJTH36=RFRVD@3#8(;X^5TPK4X//L6A*/XK$CQCCP?'=6]X"YQ\HFUV
M2,M6RQR,=^_+/D7B"O.0$[Y(C(^ @4 AH$_MGL:\3H:N#IF-%RKJGTC8Z]V\
M^*DP:W<$6Y+,AV66FL/'4&,T8X1I@GQ)A\O;\IJCB2:D44.77.,Q#>,[V^M*
M"W2A7\2]\QONN1T;=88=(P(?P:Q'C#DK:4J4YATE;YTO.-^D5)IT@8N*LT,>
M7C\:0X!+NV9(:R6/!5SSWYH,O$E:F;V>2M-$=8M1J[4U4$1&I-+I=]"XIC,M
MB2[%!+V!N4+]D'OO"7HF :W\920N<D@;"ICEJ*$3%(ZDX*R[9UZ9%G6@%.SC
M=PNK2/,TO113UE_XQF:_.0[ #ME'<^A@R$+7<(3Z2((NI4X2HYSP/.]A"D6W
M?@],[4Y&H4;UQ-5;UQ4+;1\(\KY^?EFVILJXH4(^W&Y8(?"VBQ^0DN(T<ER\
MION=+<$8,!G/>_6K_O4S<=VGA?:)-G+K*=Z:C.VZP%5*R2 'M:% >/#VJ;Z@
M<,+^;&@T+5>AIF RQS,\]%0<E/;HQ,6PK?;V6](VEXFK,OAH'NT,&6?+[FBQ
MZ#RH56W"D=#Y8A"OI5S)Z!V#RJ9G'%YZD:7YVR.P,@%/9,8@(>#M?@<I15@,
M .5#DCE%.A12PL/9?[&8I!/\6'YOCWF@_&VYN5UR@X9'+$86TT*+8DYLWL15
MR/@\Q$%,C(I8%W- BE+#FLBB!?;&6D.4?!YJNGBH=4R/IRM7.FOGCO'+0G<%
MM=HXHOH2B-"T>A"7MJ 2/)5266N_:!)\7XLJIR'N+7$&[OE&GXT\4IZG1]"-
M>@<[1Z]TI?%XCH $';6%@O'YW8'Q0<O3B2J6,\Z1P!=#ICP-MK8(G:4\Q,BB
M=C#5V*^9L?]%EM,C)L"R;2PZV"!OYMD'KN.&5M&4GJ,D<8LNM!!CL)2A7D'T
M"B^9W]Y,_.J8NH)]P-/R)ON^I^ZK)O?#YSL+[K5FK;5QMOHO1_'#@/0WRIC
M!SUARV!AZ.DZ2Z.6M&2;Z;PB9U4U@5JAW-$74DJZ)@$RF,];N%LE*!/5K4_$
MU"F)PY7S@3:\)-'9B5I1XUJ-2F<_"53BG!764F.P<*O7T=8$O8_;KT7XSC\#
MN/3!=J50$"/FLZ+I---NF%PF1:G&1J!#7GEP6X-UY(TN]SRWLZL]P&T%1W5W
MW>>X5Q[[>H<.2[6"L(0ML0PK2(G'NW(N&E"0>#COM!+V+>0$N1DYJ6A=]-%N
MWS5NF0B4T2/V8>10(V )'#&T!U-.3T&STQ0#ZH>4.V'J=U*GF(!;\>=)_%^J
MQJ:KM^NJ'TH4448^/6\%]BZ(Z,ZY1TDC.U 6AQ5V&(Z(WJO'[*!YR;4DBH@=
M?"\8WV=$N[-:4.RUV3M&9Q_'V?>:=UZOX6D6I* W3 !(FPUV$<(&'9HX&:SS
MA3'H9(MOR@X?U#8@A%X\C#\C)^S6.)'7H:NGTI:+#,4X*3P9 I!DT3N[4<)$
MZH?"JU.'%4)= ]/G<N&RNE)QFG?/1=?M.1BNSU=PK+_^!&?/S,I=F# ).^*.
M]=3TZ#<ZVU^W]Y)/(:^<KN+*KDP&O]6+L6O@2:08[I1Y"VC;\-Z>V2)2I469
M;'>?352J8X<!34Y33V(F>44Z5\R7^P8ZZNVZ0?1[V8(WA$.AJ8\9&D/ARV )
M$A?%POV*7["*#I_YMXR1_ZI#DB-7[>+[#@7;BI*G=<H.^YXP&KK,^Q!;8'>R
MH=D?U JF-&"-O'L:RV\<P:"N'O[XL=4$)^KK4N.WA;;S/<ESZ4%0BE#8)\4]
M7#9<M_7G?+D(+M-U';/%$"Y<G^69 X^4(P :B"$%B145HI9!)/:LS/9X92H9
M?'4X!RDLA'*)C53K7,4,>S,!AD]3PV2&H[Z>^B-/[L9#]0VY45N8@,8&.\8B
M_)MD[%>7>V]9,-A/_,$9O/_'CJO_=[JYK\+K6H,TO.J-@Q^T!JCX#)XV[EB^
MJ>^6WC%F,>&(S5:^_M*"XW:E5<2L/2"@^3[?A<T"JA><2F];6M;$D4M).2:G
M]]2D2M5DBOH#MB7]!E&B*.G$,GU*&;[)5=PL;JYS)B$P[YV#[[6I>(&R(V<E
MGNCW/G\F\BA#^FX.MNK^#XE81>!8>.":.9;;U]MC<E[!S;/99L*J2\%]T,8I
M3_*:L736IJRL YDBTE(3,3[;?L#6^F5P14D1*D$Q<R.S7KSU,<J5HDK/ =NW
M'OVPJ6INXW%QY.FMD;77^LF\8VBJF-GUY\.+!_G#,YJ;2I'(M 4M!890#Q:-
M6+\YZ8D)$[!]&H\S7K^NJ$'F2R;2F.IRY+NS$3(*Q4VAC9F $]/S\:M)IC\6
ME&("@CR)\QG?KW=Z/M5E0B]YL>['4E@ +D,.L5C=<Z6)UGKXQU+/X%@-BE?G
M]YN7/BT[2S'Z/J_[#>-7N=:0L2S2:U#'& [/F( ?2H'QB3#-R>_W,XT]*.&#
MN]J#%I?I3;0 NOE')N";J.\"$Z#T"?Y#*1"Q!2VZ]/T.J;M5EF'@TJ)U'^ 8
MXR0C>Y0)6-J!7H6_' /_4"B*X@#9L0;_ULI0M\G5 ?5?67>-WF4"U@.K%N!K
M7! 8YO,"XC\*Z=&4D,&^X/4;H$209JE1LSGK7NCW\*?PK%4PG1V)AHQ[&_]0
M)NT'5)MGF^B1NZ]_]W%B&L%?8 C&PQZ<PJ)6Q@^%S+H1U,.4^U0C0PS8?E)(
M]=;3)?;7J^CE(7,G/!.P*L#Z@PP%QW0U:7[F[<AFH8_G=JG1WVG$0OCVEWC<
MZBIK3MV%D_K ^%@M359[X-4=Q@Q-FVD=!_K[%TS =T(IT"]_Q/R"PQK,AH)Z
M-$6'8/C$!!.PGX7G!I=!QS3JO:._, 5H*N_7]OC_67N@_I=1_X'0N^Y_0R@1
M2;G9NG[-52OC-(OT3]I_ K-B*<48^ S_A3NR8^%_8XY .%82ZL7P@R^((&CW
MHS;"Z*EHUR./V_Z*W*NO?D&N#$-("8M97&0"GK)88*1X Y"J[C!PF1+H%Q[)
M&L7]C47P$.+'I/7[W!"T8!8WBZ9MA%$R5VSR'X@$+IM+_IWCM[$X_AQ+<M&8
M@%%U,&76R($J37G0,G4X;GBW,&=U:*MQSF._:SUE/_95D/OFQ\'KZWV5=GI@
M71INRY_^YI24^!Z I_9$5]=:/"V\(H-:P.+WNG?2QPT9.H.F]*\L7K[1$S(Z
M)N^D6>JK9;OWSH5'A7K<.GQFM8%_D *:XQ94CZ&KJ;#RBB4B5*(V>GT/Y7=/
M&+$@<#[\)W*52^F'!<BV#K>@"(%CZ!RVW:1>H2J6O'^[[X^6L@K6W!YE?POO
M464UVO?FIS/I7.\S62N6_Q^YB8>(/6OOF( A_A(+]*\9K=7>Z[_+GF%\K%KT
M\K8Y/=?;(WS^SKR-^=]W@GLR-[B!N[O(!W1_Z\"^6>F^/\/Q_M]-"S&I#)YQ
MGPU7D,!YH^_>&MKM=O?H:['GG4UDT-$%-Z78UQQY@EC,@E@G9AH/7MIO_1@W
MS=(^H4R 1HM5/._/.6"D_LWSIOQO@O%7#IB_<L#\E0/FKQPP_[MSP)@W@??:
M:>^GYVJIX*VMZM=6'M..,'8ET4<Z5%:+BV/&W![)*(EGVA9'MZ8[,-ICG.#;
M_01HQ\H**-$$%_AV''2JF\>T%DR,O6KH2=8K>Z]8[X:-W[+=^?X$ 'DVZ?K7
MM;XP$M*_E,'^96GP+GPS[6PWRI.C1E90SI?@O7RH")]_07\LQ3:VD5U3+]T;
M- LBOC4&0"&ZG5J'25R$T]#^NKVYZ,@T6<81S'-Q+]>.ELGQN]&U>;5+(O:)
M2^6@:^TV:B3##ZKFAK8*H6@YEZ%=1'K<BWP)58U/D\:R'V,/#I3M"WXZ>WAA
M5&I?C+#73K\&QB&26K@?=S\$FK V86'7)3_<Z>GS%?5^F7OSL]PJ;!Z7;!75
M?\?Y>SK+^6(]/QCQ;/^EB_Y^]X?6I1>HX$*TCY "RQYK[X$&7&@K@6QU5!-3
M[4(8OTRCVJ;=*LR/=9$?>Y9>+36P,TM_\D1KGB/R!<;).,)<3((>X,D$A SM
M_.*N[))X^DPQIKBJ<VZO<+A]C(67=,7.3TWOGPZ3#U1Y$21S?3)H["35=ZZ>
MRGLCQ(0JWH=-J<D<.%N:4XWUW+['0;N8[1L_(H<2?I8XU8O.?=<[&>[M*?J\
MR.:JQ &?T!U?\4:U;M%1V])B'FQ;M2*?)[H%$HP!,&62?3K)H=X2$^ZV1+6B
M)LHO-@B:8E6J(Y32^HK?*$ZHG](TMQMA32QN<W(%T3C0?+<C C@C0;)Y6W4!
MU[)WJ!J8EDI/-5FV!*R)A5'"1WKJC(4M80[=Z/T4N$V7G)\H3+)+N4K!NL/5
M#E[DC' Z6,(%_9(_Z\Y'_CJPHWN[WKF>7+\.R"XMO7N$^2 (-XHG%WYM:DBK
MXGW,1*U 8^%'V[?]9PXFXELN&>RSNW1WB]!QX@FN-@_SYU#@L Q-BR3W-MN.
M)-A@654AGM[]DB#G5"+CD]OD/]%\L;VP=(_WK;1,<<YR)N KN,ZR)P+C8*UI
MVK/L,NM^T=7\4B12A3LXZ6*VCV)J_(WS_"< #OX D6V;?;EU8,;#@ZI8@E<#
M\,DN:!,!$XXZ+A!)D)I9:@8;DQ);XC=?$/:XP7LPVERXJ,V\5PS4B>_P$%6M
M'YHC,(;Z^H[95E26NX2^O7R"'95C$!TB)&L@$6-LR>G(8L$M?\1*,L.M>RD]
M5SI@1MY.3MYC5@U%SM[Z7S\=UGK>>M%E7H-&HD0R >))+%K<8@E3RYZAVSF7
M,JZH]"^#)4=6SRH36^3[FI: %(NA RSU*(IQ@K5<AJ8Q!-1",-_$62S.^A%<
M$E(QI\FW&9?\U&>S6 8JM25^8P'6<A 825!8V\)2%5@_2L)X9EHO=O6"CS/F
M,V,Q_>>O8+PM-)SQ"+RZ"<R0?)\EM0Y:K ^Y"$9-PG_\%+6Q5WG.8<=?@Y]S
ME6;36N<U(/^LRU$.P+&3?_7WK_[^[^NOBT,-7- S4M BS*<IJOAD>VE]ECG.
M7VE)Y4.[B8;RA*"0SI4$TSKS=)6+NYV02K/SVRD)G75[/;S,"F7<+IQ]UTHX
MGFV#UJ1XD3:M5%>\OBXT6GQ_7&7TW?$/\W.:/=T) OD5W4GQW,*Z#Q0+GRK-
M0N+M5\_E[YX(RH<_I,[SD+;?>^#W*>^Y+0:!6$U@J1(P/+GZK]BUC;%K7"V@
MG>C=_2QKGMQ ')L/@8D"0VB'N +D#W@O'S_JEF-;0;60?E/QC-=5XN%*_OEC
MS0_<,#F.D$TT\-L^1S1[UYMVV$?57HK:F2LQ[5&?+:IW['&3'4A-NO?: 7$J
M]7D0;((8?Z(+9D<UA 80$LL>ERAP0)W==TB&CDZK(FPKO[@Q.B35C#B]I,Y<
M>/B&[<G\R8?I*107"THHU<Q%6[:[^%43< =4[(.3F!C5M5(WWLN+W7-PP"KX
M\R:.D"/#HR,IR <L?1B/$U%IW6% D"IN%8$)?M'R2<.ZCCNM53WQ3^A+P_#6
MC04JGL =@'VX7CYZ(XW^E"9.@&RA"-<>SG-:Z=L1[8.TMJ;XG.R:TYI.5#)R
M396Z.E9Z=\^JM^:]'HF>BG:=DG(./I-S?]\Z^$_']/W>#QGMMYO&00+7@79"
MJ02_]R- $$SY"\HXMXF_-#:]I"HV[Z4+-1RLJAGN)*)^.9JR;]>^??=BE[_P
ML1%!(6A^2E,-I-!XEIUHUGJ*)(#9$> KDK2G0I57?RTQLJO]ZN/'J1P)^OTM
M.PZ #H,]H?QS@O ]\01(310?5.\\42&JF&X)X;;!"KN(\:.*'HX*Y*2JQ)P!
M5!YENW37^.R:8A@G;)HJ0]M&-/;WVT+3)''F$A?7;RJ/6*)O&W*9/3]])@AW
ML>Q5(WW:8'^$/O)1=>&]C\TF])<EPAC*9<Q.ANJ@DU="7.Z(87_KSKY)<KZ0
M_%CG[,A1)W)C@.SGMMIMF:,O\P$M,M^,^: NYTF(H&5K=O.'><6)%[NM9,H%
MS$,^;@\SZ7FPL^FYA)V^UO*[8M$=6*R&6&+:Y/V/=F^=R*0^RWZ]Q(+3>Q^?
M$9KA8Z-<X&K$L;1<V^.06AR'D)8M"=20L"-[1-]-!<+KJ+J[M\Z%_&H 12J^
M:UD9$+SMPWMUT\81D8E@&HATJO4#@D/K 4PFRWE(E6+DDPF]9]%^,S*YO%NY
M!F.OIEI_#7UG(>;P[M?J<D$2YH.73*YI97\ B[TB*(3D*C>!@OTTVF<'Q0QS
M#6L?B#N5DLLOGD*H!.C7Y:<UF8G$OMY&A'R=)]CAJED"VA+^D&9(G":HH L3
MZE:=KA,C9^)2[%'1[32\V&#E5=[>#_QD7SZVA>#J^=YI[) 4I8F$,R,Q 5AK
M!7-#S&X]R>>^!*-MAVO;?%\JMFFU)WZL5)>^\]2GYXM9:7ZOE8Z[.^])]VU;
M1L(.;@M)OB;%[@\8V93^75P\_*-K_CC\H#1=ED!L-6$"2N%K<BY+&FA[DM=,
MQ\K>T3+!LBEYR3-WY<97 7V :;$'VZABHO47JC]E(V5LNFG&S916N;KQ"RDB
MLNKOKR(I(,7V?W)*W!?S_12Z^,+\GRV?PY_\-/WT^5:RCEJWC$="G+B#%+MQ
MBRYX,KY*839G$Q,0'_+K47?K_U4)'?[4N32,$.23+C[J<U87.8^=D-U,>_WT
M&+VGZJ=6G/XI9\"_<U+@OXCQSF99/\J4K1UFZ^II^VD&E&K)4,&]CGN+O>Z=
M<]OD,40-T<;MJU[)C/-Z&&%E^CY=F[\Y0T7P;,_4/007&JBD]2 O6ZQ;)!4T
M3 ;-^I#7>M"GMUG5%M2GB)L$7OXF%<17%FH;>4HW;5MVF^GT(@Q[)/O%Y8FD
MT%M1 XJW$H*,3_=V=AM[X1@L78U_#/1KN +_#S[([N,_[FXI)V&M$E7X3"SV
M_J&P7-^.;PW'C-Y$L\B^MJTA-^I')V##3?L5EKQ]\>@/ AAV3!NS5.3US!17
M67@\[1R3MG&#*T=L/.6_S<5F@RRB2JXT#XYY RL=KKJJ-U1YV_S=U6AE^C7T
M-T]'6@Z$_RD.9?XN^)V_I9-96(+(:N2Z^!AW%$Y=U7UKF?J>%N#9R3$J\,6J
MFM#'EDW==P?*GV5N/*1\4N=?<Q3Z_W$8,@A2!BTPC0E LJR1I;U3O_CK<R#\
M\)LL67RHSVC^Y6A#E)3DT2<:*^N[6D].A?V&2]TJVO; ;_S?L=SB=\\?RPLH
M2N7^EOL\/# B3.8?'>6I^/_>)F:UP$S @0'P,NG0@F7-'^]TF1Q*,1'ZZ?RV
MB^*G_\ED"WKOX(V56?!*$"/"$O,W(NO!R< 9H]/>[Q?NOZ6G>/F2(OR4MRQF
M_08N<^<<_G3T^DJ,HD7<A\RK,1XY_5"GD]A*UB./(7N;5Q)CRSYO+9M+*E=^
MU>9R[R?>[Y8,_#>9A%RB/P1E9)$4R&#RV$0?STHB9GRAQO6;QLUN^U\7BD,I
ML;J_)9H[_XT)]=M-_+369IP>A=]TPMDO:B'D2E?+!U=:K_ITNORY[SF0%J[,
MG'&U+W\V&\;G)/+PM920"FE^!D=TP&)*U+#E#'F:12>NKF\BS&TN+T=VF?LE
M#SK\9A'JME6_;@[_D8(@>4Z"5>SKF.UKA,5:2S-$CE.?47>&@VO6E(Q,KT7S
M[=#C';5\GVZ<\CIVXI.5X[$!I8CN0)@WJ? +@YOF0T\HQFV%^IB17'JO4!)Z
MC#L80W:)95B78H-[MT=SG"KC[Y[-&N8\QO6%(>;7;LXX" ]) (>B1 \]1MD-
M9]]$H5@60;' ''>(1.AHD(6;@,I [E@^6/+2$SUG /F3S#B.@]&STM=0XX,)
M0TM1X'>&6;HI\9M+EEZ6<9:>RI?:U5!8R&SIX:]S<P6?/JO-;,X*MDS$.(,%
M*!='L.9,P$[&;FN*4HW8OJH X[)N\>[4JH06IY9]@G'3>U^<YF7;CW ZIM7&
MU>YA_A :2WY*NDYY/P(,3MI&@:B%+\-WG':X)S>:T'5?P.]RK>3)<7U2@9X$
M_YD+U-*"@YL2QK5\29TU$#XFP-[W4'W?Q*,\3^%+)+G(R-9@!86A#A>>4\=U
MY!8Z:K5M^1#'1$4 .Q1OLRT?Y"<D*5-8BYX.2?,241#;RH80G:X0?2U8T=6S
M%_7 +CT$<>>1PM$876]KDQ?R;:K#<U-<[Z!@2S1),$AYT-"TW4U+,W/@E-C(
MV<IHB9CN\Q&!;<]O[<(>KMZCO*4W4P&96UPI'-[?'Y(K.SOB]+8\L4:/SWFK
M@[V6M/]6"2( &05WB'K,LGF0J-V>)"]"Y.LDI=C:!Y'S9.V7F<:'OA:_VN(F
M\4@JV?_(9=NQ(J7H\MC^U]WMEHOXR)Y9<>+]XV<738EQL7C5'BVP*&U6J\)#
M3:!(MA1M&_/Y81??YM?;1V,<A<CG7[[KG;9T?9N2,5@-SQBLC1=8,2N4C382
MSKSIX2FA^/3D9I&=)[-52/ :]SZ?6O@VN ,D<&]#B)\@Y"M,L:R]V%5ZHNZB
M<SX]=6<;=M/@JWUOZ"_?R 0K<DE7E]YE6T;N\FL7DRZGI!&0G%!N/(8F:4JY
M[ HO&:_H&>X4429M-7$E>-@>:L2.V^Z=$/<22@;>3T6?[=8^!+,JHI>K&'&=
M);[1*(T$!0S'B4JZ\ZM499_PW"I(U7-X^NG0L:,OB.>[0*CJ#W/+R#[-VD68
M,TD/"]]"4XFO$V2 GGP:G[\0:V&H>;,L26[5WK%%HO53=,1\WV@A1S+P02JJ
M!P^IOTY2JT?P>K"]$3U&43,WDID%.2WZ]53PQW[NS[]%_=H?-_F:G,=N3,_/
M708^9.PBU6KS5E:2N,(]?2*Y=8DEB7T&!^NZO)1JE#2EI?5*!]\XR#SF$ED!
MK$F&K=J.]-1APDLQ1?&UU'<,D;)'R\V:1O9&NDUU6R6<W(B?;:;ZH 1SI5/M
M>;:'A5:[LK_ A:#3)I6L^7G<EM"*]?')O/Y%^6!Q44#MPKF5\XL?"H:TWO$J
M%E8&'TVL+G@TT,;U9<G\)>70R"4;2<HKDG"U1E(\/2 3>C(W8[?A73'-?B&"
M@NBGF.S\384R\E9.D*I6L3L.5#L>JP\VW-W*3 "GT3T"4'@(IX.OVF%DL$]0
M]7[+AZ%6K9#4+9\X8*[WJ+7L]^^= !FTVYPF.HP,MM:Z"T"#JQD'B!T4P_J]
MLCMM/MJYOVMX]W_:^PZPIKIMP8,(*%64(AT%!*E*58'$1A,Q @I2H])%0*0%
M"(E([P(*BD*4(BH"TCNAA]Z+TA.07A) ""0D@_>;>Z_<]__>^>:]>6_NO.'[
MPI>SL_?9^ZRU]FIGK;7-S$U;30SL<]B-SUG;V-@8L%Z8J4S<[.NN/(_+C8(6
MY$3AB ]7R')>60LHIY)^?IF*H (ZKVG_>BL.FA^-G 2[NBBKJT0PH6^*'\Q\
MBC) U,=2@4.G\OPR3"9X]CA?N@/?TN:*;FA;/8\L]Y-1]K4GZ@&6NYGT820I
M!S /%<#R*3 MZLG/S:&=1[[OYN .>6Z/FW1V@3T]649<UV:%:;\.-9@:POPW
M3GS\ENPJ8_2CL/;1S[)MK8<C3<:^Y.<'-\D?ZM2P-^[BFEA[%J5%:?'(I23G
M2(7W(5UD'DQA6>,)]TE8UK1[^$'-,"5U*.F^>&G1A$18>O!(&XN:K@C=^'7K
M-\_2F9^QY4KDTN.WEL5P;$23\6-X="2"9X)XJKZ)R777_\/HPLW1UK4K["]2
M*_P9=A1>-EU>1<#."?M;+FZ^($##U71P67+!2*;OA,%8K.]L[P\!TRGS$#T=
MYRF@@^63HLNLO-W!/(VQ&O4YVCE>J5D_M\W6WKO$*_A5#$4(7YR%4T4>=\PC
M(M0%E>^X+.>8R'IIZN=G#)I9\1BTHI67:UB]*+QDOR'X)8+!+'8V6HV><I @
MX@ =,87%W-;3'-_LUQ:)/YHJ;,+^ZM)UP;*#T=HBP_:Y*4JYPXY-*4RE/1Z0
MXW#A2OS04R6]:Q/7>0N3EBNWBIU<A:-Y9&78M:]*MU4\_-R6H@G+9A.@]*2(
M]E0K0LGR^)AZ[TJK'+-YKN'F4B<3:2<C'M$7_+HBFN,F](J,]+CO78Q'BFC5
MQ\/7<D.H@$ J02L")$;T@O;&UPW'/)4]Z>@O-I$2_[6-(9ESW%.V^^(S3KZG
MS\%GLV/\D<=R0 IPF6ZR RB8(AAQ1T=6YJ%-Z3IJ:=SJD(U5T2/K2.G7CQ[Q
M,R<=]"K\JT.AB]A'N;PGMX8JD3LL[IS3H-/$,6Q$MN%,J:-=M*AF-!:G=5#N
M_<Y2_3W'^V:;9YTQJ$C,O2\Z?K:I49OHV&Y]<RVR+(1I3SFX#";M<O_E ([]
MUQ94X-O+KNV-+A62ES050!%(G>/A.##V,0Q*><I.!2;FT#_/&-A_67 6M3X?
MLKEB0@7 4UO)59P-R+II/'KWH @50/<@?YXFLO_2U@H\V\>V/%I 06)657VD
M0JE 4 L6N7-(BPH@4ZD ;H$211"_/)1+5Y0QK);2&<GPWC.O\7K^DOFQYQ\K
M3F*3;09$WS$2G+:3-3CT+5V7]SE-/%.$J$"LL] .,7Y;QM5C&(:D:)0B%W&0
MZ:)C7S^LF*:&2YW\;=['OC@YG7T5+U W??EE./3-7OW6;?/_<AQS6@ZR^=C-
M/37"&[QQS%+.LF?_M5G?U[ @#GW35W\-]!8T)(AL!O=1!,@7^RJYN0/)$%S7
M$:A#QR<Q=,CRVT1K)O$$D\@"+;+EJ\7;E7HD;5,BN-;G5%46\5B3LM>%SL(D
MEH3 P03T\%%S->>Y$41/P3WV+PP(M^%*#*Y]7#9D<P)? ),<NEHY",;2E[((
M5KDI5:%?;-:6!H>K.'T;\8_TF*EBPHG7(?G)]_'0 ,WL;/L45D)("/D*5V4)
MKT5E>4;*7)Q[U('6NU:QDO%OK ZZ#;Y?-8@>P0XU9*&%=!")( :"5D#CA\O9
M."E?6""IQ%7HA>(K$9?SF'$!1W^785*=YU:26N(P0X0BFGEA2\?."E>Q*UK_
M7D_DC=8Z]SHGE&B2QJAU'J,X$0QFK_1*)WOT4SAA:ZO:A(-3%P5%^CS&3O5\
M;G_&Y.],Z*")W:S&'9)T?>(M_IYAF0Y,5N2.5$0%I B<7!ALTR\>@$,_:3)I
MO!]IP&DOE[B3KK;3<Y^_?3 V0&.#?1[)7JWJ(,0&U[^'#76W\&VLEJ@L<OS1
M4WG>OJ!+X,/]%'C0&/N1+Y*''\8= @9SZ] 1ID*-NZSK^CUQF[UF?"V*I%U5
MPQ+E+4]C"1J83>0L,RUK8#1,"3O!+4W6RJ7T#<;@HV'2(.'Y"P<PN1..:O,L
M]T3CU"N/IGZ,G9$_T-H2*?L8PF3!O>3GR\&K%54H8S0X,X*31647CLO$S;B_
ML;#LX,WO.O:6\83]P&5AVKOF[&\*N/O]V-[.I8:G7O[WYUK1FAAIV-@P?SYS
M*_*INM1WET *'[& )#VWA6;;@(9D$<1KN4J&N 4%^C=V'P^WXGJ'':X_'5Y0
M33!_;H<<US03(6I=V\D)IX>Q9D^B!6&8*:\:%.\#BF!1G^'E @(P)%+0?Q2V
M9#DC<73X3$=>ANB)@ZEWC_@P']7#ES0L$RJF(*'T>UO]*.H(T:#^>I^L&A'=
M*RNB^W:^Q/-[;>SYNS1CM>?.;2U(T,XX=GT;:;!4W'VZ@0H<BN(*P'TEJV?6
MAJ6;B#S=_);ZBGU,Y314GM.@K?1NG())];ENQ!E$[P65D$I.'"K$:!SH>3<@
M7<2"-'UM5E)E]KSXA<W:9UQ@8GMTQ+INP5WUXT,#[C<9HLA*1-]<(G+S.;$'
M5T$2$KE$X"P.$'SE,:LY[FMVZ5%!E'^$[& L0SN]6Y,CQ@5L1P4$.TCG82%U
M;>\"<L;AFDX^?-#B2QUA@T<G==&('M);,V<OSR98;MZ'MVRO?T"9R5I$,.DB
M;+TIY1@>2I:&L!)G)B"^K\W\C(:;9O4J"P-KV%9;LQH(@:+!TH=(U=6KDZ0.
MQYOXSF0/G(SRA-;@3(3?0% V9EBDY#&D6;1FPO_)#4#\7':2!.UW5' U+S&+
M)&NZ"&+N!@F)-Z!HD0[F$W,J/LX%3O?<;#C6>/0*">;Y3]F_X><PPKL];YC&
M^8A"4V:K;.0'A,2($X7@(W"_]);,X3D?O^:X";WB\&'M[.P$NV&>;V\*T$RE
MA">'<]]+O&4+\P '"_&I^9%485:3@@634BS']'35Y73[R59<)0>+%^\]O&=[
MV%E!;IBQX4CDP['2D-KC\V"'O>6=(2;CG*Z!6>""CG)<ET5"+A,SK'".OCPR
MFC3K8H?J)C\=K6_])NS\M5-KL/\F0Z>@)![9 *6C])8+-;!PU]-BROUF ][A
MB]]W+W!MR@]W"4Q!-E/%[O+*BS[\=*">G[;[!Y(%(;A($=K- "G"<BB8YFZX
MAM-;S'L+[YZ2E,%N<^FIN_?;BM(OK=.\(21M7MN#V;)<'9H3P0*W)69X82$'
MOA$Q5PF-&[S9"=FR!9QO?#QJ_._'RJ:YC,L[\_F'W8G%'"0T$:]LPH@HK-"W
MQ<GEQIQX&Y4&EQ#*R7ZEL$JPTK0#"YF;VQAAK7-..G298Z'USK,+*DJ;R1PT
MDQ3)/&(8876RJV&5>1'!$(,EE^=$R 3'<&YFTTWW=8D:!#M41K7PTJ\]J3\K
MG"=\EW%*S08K%$8%N,"V%E+UO"'U0_C9L,(JR!5#FU.Y#A=&-9Q<G=<[H^.<
M;M'P!UE53JW,\NSM0F ;LEE)%"$P-::<Z25KX<L'3RO)>&F4XZ&A&;[/G]1F
MFLOG6QSHK(B4F7DC:[Z-DLA$=%.!_.Z!G.JC"^,\>*/8J2J1&L^^>0.BG''"
M.8/-5FVK*%YQU^]A]\]* 42CENDC4@N?)&CKJ( =-$29PCWP(]E(Z*D/6QU'
MTJ%E')>7<M_$&+SQC>[F(ROMVL.%#/=OZ- >^(#8T[H.NH#DX!9$<2]P\!)<
M!RO IM]_:NA>_]6C%V-U'G"=[&Y%PIC#S]U^>.0PQG2'-1R8^L$6M,.,9/%
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MQE6$X]R^"/H%7Q *0A]R!P<67WAC:CX<G(;\-,8WIFLTL!+5\7UIY')P;+,
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M;G''+JSP.[KG!Y^>:6WRE%D6SZ!]A,AS#^;TR"RITP*APFL2!W;WGXA)!^_
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M\6V!G.9?ND138%L9^V7PG\.[Z5]/I/@[M]9)<=X3Q!V?7CF?I:BOS4;]]C\
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MFE$??PORVL5Y!EP6]:PU\DO\HZKVE^SBT.W> RP=P\RI)[7P>60U&D ^G4?
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MC2!4N3\-0-F?(8:-QZF;U YJ;FR9%F -.@J9&U%A_2DK]WAJW^V')/R!DAY
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M\S/-C>$7YF/L6M-<WB2R?>^4553%AE03>FO*XKNWTZQ/R'*3PV.'.XJ[#'<
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M?)WJB&GM;RRCZE:#2%:XV>$-=_$3I&BE3B6V()?K1"YT!JS]@]M6H8%_Z.+
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M5P9\99!^=S9+)]?Q65O"UX^.5<M"X)4JO]7H[+,]%@TF)\585T#'PS7?%B0
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MNZ)3Y7WY)G]BGXED\.,RF3YN@ 5:PW^+AQ!+OHB9PU XJ;IT6AV=20,D+&@
MMS=)B0;H0U%0@H,3#?B2OA?&WPT_\X\'7B([<JATJ?EM:'Z(+&R-W)(.FZ6O
M\/]V9R+\X=?HFN BB1O,L/J4Q->)EGW1-6Q;F_U8>W"Z/./CM>:X!3:F1][
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M8!,/\\8;RQ8D_%9F_W?1\5\=UVQD&1>0D5"&GK58XE*/32\QX-G1HV.T<H;
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MT27)W%$E?1$)W.--UJ1Z):K!^=O:5UI40RAC9N0)A.3TR,,_?[$2\U*NM)W
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MK"U'D#AC6J=93\GT&*OPZ=)^E\RKHU(7/K>Q$ *T ,=AQ5MZC.TJYDX\-6<
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MD# N$CQ/2'H1];1WLNTBQ^=@/]>&Y+8WZ447";6+9P 2!WJI=N?!4B@AC/B
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M8KP9]*K4FH'36ZSV+S=*GURMJF=KC=UV<%F<TT$%YOPHTHSS.+([ W3IYP4
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M M:@^!% 29V+\"A71[S[8:/^C[FXK,"'K^,Q.V9-#<L^[3L@C'[;G$^[2O!
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MN[?L&@QCZBCH67;E>$5P4;O?75/JWWXI&C)/1[51!U<![*PCF<X X<L$YC.
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MVUN'-1V&?Z-#2B4FW8P.03I$2D5:))2.B3034&D8C) N 0$%"6DD)MVC2TI
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M+1<LE;B'=6W%;4ZZ9F48-$Y9;)NA85Y:C1EL"*R42AJV9#_\@GSO"E!S>L"
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MQ'T( $8@%;4'O^W"U/(QW6!,S3V,R9NZD/QFGP0[)><;/0#T+T8>RX2I:L>
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M]:=NSUI$#./@O4PVO.U,D[S1ATY<+>KU3#3QE&2+06:S,'6 _SF4_F?&6MI
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M'> 'TG]>4X'$_@YD'?8[??P1SON";!&WU;,"3$6IQM53?%Z;/@Z\W]N8,7"
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M:+5+/)P"\>$_-I;A8*(GD!/&3%B)\"Z;66.?C8_Q=;E=5M*DYZ+AE_ZDYKX
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M:R>E=*YPLJ(#S\5[L3@GBY?IG=KFKPINDL8W<,![G-PWB%BK(,&^"U$+[*V
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MSEN!SYI%;&V6^J'VKN!:"6F1DG)/^\'NMYX_^A84VGL?M#L]X]U/%L5?*^Y
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MQGA=&Z-TC*XK2K AI(+BE/C>UTQ&(R5N9"!$X2*?J;]!YP$XOH(,Q:*CD3?
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M&=:J8=:3RFH%1%>8&H/E(*8^KI)[<VM:T*2Q!_>F\ZZR@Z#_(>W_PV")C#.
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M&E$_JL%6NM?^?S&T]*)TN-&57\I,+OM0"TH&PKEJ!MK-_=D6<+A"$.DLK<S
M#JLW-S=^FNT9;.K!SV.,_R:VL \PW@C1!A76/:5;L82]/ .$?" F0-G9;0"-
M8Y7Y1H,EUQ2G[EJN@/87GW$)%5T\&)YJ6@A<]MV>)'#K%!+>HX2:HHU8]'A
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MUT:;919D8T^"KG-0!2A9U-M.&=8I/84E"T2?4X9 )>T,\Z+$7+N2R-S4EP8
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MID)B>K&! A.I+]WUD$Q!$23EP1P[DN0.N?PD$!&.(N1>_!\5V"#8/8)[QQF
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MJ6ZLQ!84J3B>-;J@,V/^>F.R;OT[(7.SJ,R6\,[*3A)^S'1"B2C*5NAR\!P
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M$+M'Y =8TG3[<2>D:2S3P"1I6&O,@\[D105Z7O'(DM"S '^KP;SJ9$#0CE1
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M9@_$;US?E7!9[OE&]U#HG6+0]<0X/=?!.8-2N# YX'8TE5T^=2GOLJO8L[F
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M30]]L34S^V)38%.@_MX0]-C$WZD2H6T+(DYWB([J5#W@RP@4??'M&YVNZ![
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MVD2M&E_:0Y]U].J,JLA3@2P$.#62E0>&R;:E@FTRB<M41MX%VZD#FS/+JH3
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M[SZLM^H;+^<B=@_3]4$/J8AW 8\?_$T=7/&9J^FR7[, 4\3FQ7Y3+G.M\NU
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M"WL61\>:<9./QL6:DN8E'!JGZ]F[WUH\#AGI#-FPQZO+A;CM#) ^D>/Q,O'
M6M8$J@+YVBG (YZ0M8/1&^X/MVN^+,]?S:!FKNO"! L2OV=;@+I(%7,!\B %
M5H3D?F/\<\JG*]J[.[DBCW0Y[!)[L>^/R^!RU23?Y=C5T7<M6486ZDD/<,L;
M8XHA/L>6O^$ITWJ3\HJ?5Z U5Q=CO$?%/[_8,;AG>R%T/)>#R!T)KJ;H7GEV
M#TY^M!S4(7%GA__$/O@M;V(TB/W24@]&\6B\I+<Q,GOZ4:@?\ 9I\]"T$UCW
M-SQ$[VED 7B%]-Y26=!VB#4Y5-3V5W5>X[C9QF#^K)*_<^]93N9.YC*(P[!!
MC8G+QE7.MZXF4R^? ECN>=$JN +<,J,%@-G.+PR.^C(0H3&FR]$;3>7SU&X8
M\!:5<WU4CJ)*3KT25!*U5<2CIV_XX7Q=PXHR>Q4^[S!@M:5\3Z/%3%&B.,FU
M)N=1DI_0=\G=5)(+X22O2T8H=-1B<\M3(1'6+?_G@>SR#8^=VM>%1[>([V7?
M]AC:^E \R+' =ML(JASQ8Y3ZM%BJ;S#[X!]S,;.^.-!1S:;A5CO2XB260@>E
M/5:$J/*FA<Y]L\QQ7+OWN7=2?/#^%/4J;Z+!,6(N,G'-MFK "%NU0N4>ASY8
MP(1E4;B5Q(Z..TS[Z/[2*YM(V,'DJ;0</X!SEQ-.1BV/E*I<X*O^C8D)[<%Z
M']FUUF>%>GXGO?,7'H.Q22M:*[=.AQ85),L=ZXW]*I0R<_ HT$GP:0_)%/4>
M^3E$IR=#2RY_4C5JG=U&E:Y7+8YN3MYSD6VT]&AY2R]832^::CV&N945\D3K
MT$*;E4!2@UV!M>E+VYO+S?.3 Q$DNUB;#;:*4P"@88[,>)R"%#H)>WT*P&J0
MYX[O0TT^V/VL;YK $[8R_4M$.UZ70(0&\^S!D2$=-L;:0TJ_5E;"XR2^]X,&
M2%]. :DN9,0IX%42_!10Z#.Y/+<<3='%PJ-M:])KB+Y=W%2)DSR'^$>-2A8A
MB8AO*_6OKI+\FJ[R;DF1:LJ5GK\WT)I![5\:L![UDUR?D=2_/[&VTQ<^9]FA
MVOQ>EI=F3*!,)-=U'Q#Z-'28*D'4Q&QR$BUFS(GQ*QK7$<VCJ6T^Q2UE,XHM
MS470NFH$ I'F$1">^Z(_9Z9NZ\XU].;U\L!<1?*Q&]&N:WHB#Z\G2&M@2^\R
M[3XW:!(@J^<>C[IYO5WU#NYI*X"YA-YEYJCX=X]HK(A6A6C@GZY[DKD_U4N=
M/Q2:,][X<(^QTT=^DNX]\#.8-?2Z"XPN5 HJ/4$Q]?,N6<FJ;]57ZC#PYF^<
MLZ'E.+Q\@?Y-H=BY_0$)ZM4\,$$FYLR'(_F/;ZR> MC\-O4TR>IE^CC.28\*
M&:=ZW<KTK;\SVMZB9B^RPS>7O[XGUHOL!^)T&;DU?:)]TGG;]CF-C,<4UGF^
M6C]:FIA7BTUGF%C3-+Q5DJ8Y-YZD0ILK0;N#QP4DY)X"'I#YXG&V7,IMZOJ*
M6E%X'%V#4K;44+O::VYE)<-'.$6UQ_SCG["'%R-LW:CMN^2H=9(;8:@G!K$*
MTMFMW?FSQM'2T4]RU+I=WM)IV+NH=??5SYM7RB0C; X49&>U[-(5TY76*K]$
MD/E";C-*5"I;D!-(087I?#)1BG#. 3K-L6FSNB0F_Q6V 6^%1ULZPM\=^M\K
M;\PV #9*O[,R0=I9.0()NB]#\M?JVO1_991UEX'NU2"J$X9[H^E9^1O_RBW[
M_.#?^Y\[N'9/DC<*2, 96D/RV;]V\<DIH,Z,";@!W*"\[FKVVMZES,/&MWHR
M,+S;UI.;EPD15&Y,&YP=PG1L><QT[*A20/U]K#P-RDG5EH:VK#9IV&@0UO-<
M]US_61]*L/UQQ98;R0L5(KRFJF4_BFCERA_1&PBYK5"_OM@:F2H?BJVZ=.]D
MB2F@1Q7&C+++8W>!"=5BXDX!'!H2^D213C[%>#,7"07(WM[;1XW;+Y+Z>UY7
M$]_N:N!ZSB$+\\- \B3=DT]GCI1.X8>O@ DIL';]DXKROF\G!1M ^YUZ;;[
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M4;^RC["VU:_/U4&]W(NK2YJ?PWM*;'Z65SN\3'M5%!LDQ'#\) Y /@7TH*K
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M4VG)R!9(OQCR2M_$M[07>8W(I-XUL*$#'3KPE?_!=,6MK77&FCX**47F[P[
MO"*< A(HZI7S^("IO3D3IEC9=81 %B$O]D@J'7%L/M<3;.<)+5N(5S+^&6G/
M1,T)3*&A%S &\D"O$N"QM667:_74U,C:F2ZE?SKK#DRJRV:3K_32BM !",&F
MQB"%;SV9\KE%?D^L*H!FAC:TQU)0JXEF<_$8"B^NO*;,#2FTXQCQ_(.Q$+7?
M?=ZRL9+^4T)2PET UN"9&Z8\W=LK-:%>^Z%]">?U&L9=F6GY-JHRL:1=/<"
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MPM+(.Y!WN#7D!GSQ)>Y;K3E8#&/\X=23H"+SNBBX2H=I5?,SI]C?^[N45%\
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M^*',+JWOZ>-X/Y_%AH?#18@E[YL+R ^!+>"RT;ILN'30$6)1_/G7W72U99"
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M%"LN/(3<T^K<:OI4?-8=/:@/UT&$O96_$32;="C*#S_XMG;IV!1A.Y5 9T6
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MNLY2-^J\E4/R43'XA*=73W"C^<@&)Q%[)V?610)_\&#PU(=P(/X9;IHANC_
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M-C:"B1?">G[]![]0NK4(STAX>"9KO@[WF.5JO]_X\Z^%2%,Q=2RPB#T_8,+
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M.-@#V+\7"[< A3(G%M#$R.S!PU6#&2U(V?37;H#C&#,2_Q80TRZWS7T//%<
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M+#G95SHQN$ECWJ:F2;XV%JLKPZ;,1@3-(S]E+>7Q;DNN(BGR7P JVVH,T2V
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M%ZR" .4I)6__&#,.A;;4NG[C>;40EQOUFBA@T;V_).MQBW A)OR:]EKV?M9
M:[VP^32T86;WH=ZEM.^?/QT# W3,MKFHE3"7=EKK%8<)_MZ-_(.VKSG<HW]7
M>O"V!V$,#J'2>KD8Q9EEI&ZK ;<]EX%5RG34#AT5]1<6Y4^7&D24__G Q5
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MH=)QHJC(\V1;7L<E->K8OA,J"MI0!,?JXXZ83"D_O39IC+L38LFT4T?#J)>
M@>Q7?5QIF*HR]:/[</K^H[V#T:UH:4MSU$67.XYUBCW50/5EV@2 ).ZPL&&
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MD/3]K8Y9Y1>A](ME,>1?*N6=U\#/$'6<@ATCKB7[/_S>D<]^Y%I>5:*O9^)
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MA!)):,^))TUO?!%( ZU00<E'5-0N![ZKG_2(X<4.Q0P5$D6* G8:.8, FTD
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MX2(O'+-E"^T-*5%);%Y8N:A77"B\!WI*;4KB?YR'M[ZLG4K4!@<\\]F6UZ_
M_FD=D@=?FLN<B3@_CZ6^#R@S6^T$1H,IVABPKYS [^S%@61MWUU^+9B;VU<K
M5[YY3#_4P&O\:(M39A40/B@[EW8[R50A^R+=UYVK,_K1#^8<4>@4Z\V509Y_
MYC)__Y;/[_='9LV?3=T3]\!9KMK40Q$.$Z%\[O]6KI 05F[[E-)1U]C"H2&F
M&^0=(/'"NNRL]BS6(/6"TM1HA#Y=)C)3W#G42MBB$\\]L8]_4PA.M6';G1 Y
M9VS*RO(=INE?X/#0I98,U+D5U/'C*,SY^6$:5^?#V(Y_YD">6(EE5J:QX.?U
M%X^@VL8-,7K:@KIM*]V.[0Z5RJ/ZTERJ?TJ":#:9PR56C.'=UBXTK2UJ>)2\
MKZ,E'O[."P*PX$,7QH 30P@%1/&_ID2=&?C@Z1E( [<[N4<]MP2D1^>B>T@1
M)D_;0H/654G!,OQ6\";(U%_QHPDKVZYB>U2$>E&B#-(A>(];LR'U.Y N0 R*
MBTC)U&<5FRX;3D_Z&J%B8M/2T&SN:Y);3;,6U^,TAC?7]^*\WA65UV,LWV-"
M)9%R%.=*U$[)1_!/RX?&-FPNCRS6S#VK]$<LJX,0D;DYM!D)DI[-O]:.E'VC
M_%,\(A%/4(RLQF=3A9'FK9R;WVR*U$FH:-@W/Z$5R:&AG;:;TC=0K_S*"K*Q
M(_C%B9S+.1C3NZ;]( HK7V%:'K).9OG.TM;5WPZM)&O]GA-HQU]I*-I^M! A
M()(T<U:[O$E+6VUFILE26\-KE6J?^93]<]*P-@!G5!-&4VQW#M_.<+?U=TA+
M%2T?S$OTYB.<_2,$XH. V#&6/[',,Q6_6D]@"IY./NYBQ^D[JK7A3-\X4A+,
M1EP?/A96[U%QSW(#215^GZB050*IZ<:D^17,QW9'[(05:XD7#.<C=\?4,-?H
MZZY[LH(\K#DFMK]*K2;X#N5YL;_@6)/I9&WWT^O):J95V,))PC<T6 7V!(-&
MR,=Y28K:T4G27L5]?W"A,OWS^<5LZ.D_=KD$&YWWIZ,*-"<>KJ4.1=$T[YWT
MW@41?L"WA#:_;<+(K&M2K1/7Y6C-># 5D?VMHL_>[S*BE5[SG_^;XC:4B;3&
M^]ABFM/S]!O6PV[VIX.;ER98^;QQ-0[18+$K/57LP^7G7;<S+T\O;R=$B&6Z
MELNN?39:4+;29U4[[E%$-K+598M?]XE&E&)XRV!+-I/Q\GH-V)_P$"8P)P&A
MH#9>P;B1!5Q:U<\(/GM9%9)*0CI9S"Z6NI;SQ0K;U;+:>=5['#=[W?^B?Z0,
MFFW3GA)%MO52C1;%=QA%VT%8;#F=OL<]OFHX>8R72N93>'ARY/W*G*VL#QC[
MX7K:$ONZ.&+8-KQ[?#N4)6,?V:S8C1IVL,C3+]-0!WLU UV@(3UP[3 /DE9W
M@VFG4R3[K! (LACUH"_J("= Y" Q&G.\KH(D_@&][L]^C':.0"!]#U11-_TY
M7!-371I%RN7QLJ$VY!WX4BM47 W'YA*_,!EZ:-JR7UB^Z7*;)E1[L+/-M-/'
M[S%1EAZA"SU;588*VUIT/#\4L.RMHO16C=_9HY^G&M$_97]@%+4+8-'TVFGQ
M/V.L*?Y0[/Y/20-\_(RN.!S<G6,8NA.9\RS#V,?9DPKV'G4'Z)6'LT',:=OI
MK@)^KB54O4E@4I%KF86'7T2KSA,HOQ,>X/BB@!>O;6W.@+AY(?0P8-*<)>LP
MH+]H'ZY5:.&]K:RWE/]ND!71/_P@,>G%!R_ZBQ?KO39 ^'AAG.N6FXE7=356
M.W58N%VW1SW:6Z/HG1+-#JMKQKH]GCEPVO .,$8('J:\<:@X%"JP[0'3>7;L
M#WD6&\[C$W+ZT#8G'$AC%?+1P]G@L I5*4[V6^?:DSM ]VHT8\[A'> W-&:=
M-DM,=/]%>,DO,V-5HY^-?*2_!J-W@)QHG ;W.@.&S;G6+Q_M+5RQ9[[E>OMG
M-P_SE#WWAY(/2VYYEN1K")$X"*&'\/T 0I%E3$0//"RY"^Z< L@Y_/CZ"6?#
MQU<]+>&=,I&=#]WXHV_20;)0E:XF\Y0U%B=GF$RYJ?:3NJ;V^I,R"6*6J(?)
MN G"I()S<"V Z:9!+$91\05K;# "OO.^R=*[:.6O6NK^WJV]M9=LDF%V*P&A
MPQ2:,&2NIXVA,4)WRJIAHOQS6#XT(56[VA+G\R;E (?$]EA/=(YYRHOWTL4\
M[2;>\J\22/KW]W6+[=N;;A)J04^P:JC5KAPRC0IHB5Z$VA2'9Z0:F\"DZL(B
ML]V/ZL;.R_=40=HO(9L#_VEY^!@8EX.J7.U:X:@;-YX[1#),?5V.+1^3RS7@
M<;F5K\]J+1G$LFRX4,+,VFI=Z+5O?JP01EP_&,EW6C<)]?KGO.BE]OW+R^;V
M!9=CQE,3&9(L=<2'FOK4?:]!RJZP^2L4?[OLQMZ::PEQ<,$8!#RZ?ZX"PHW@
MB.QNFH^Z7ZF.(__"M?N,LYL-0B%36Q'+ZO>T5H@*1J>/3+%88MWO0+T/4L![
M1%21*6^7  =VL0I/>+;C0'WY5Q_O3_R-<BTR-'&I^I,J3?.=]>-+H2 #RJ/K
M'F;WA.RS!-:#0/Q:34AW&U-SADK".MZKX5(C<.5J3"1'TI[TS5*<B\"/Q&!C
MJ3&]\FJE"4>87,'BWI5GC5>J_D&55!X]P/<Z>3IY4#9];Z3AG%Z6C%29,65'
M_VBL("MGW3H$L:#?\[Y0WROV17D]*/$F.T 6:M +OU_ZKWYE'+TOM'*HR7[M
M__&A\*AD4T['3:KZ^52;\!/01\GK#D ;( )U7YO]S%I0H2F>;-H8WJ]9F3#:
MW/:5]-)5^46F)\]#F40P#?85JOR'![VGX8>F*<^,1YXL5#J&"ZPRD7V;T/F$
M;X^I*0?8;OCJ@93Y&"3Z82"3^5/\FDF/:R8F*P&=^2$(S<P@X Y F>2?T82,
M4H; Y)F*MV@J9XK=9@JMAY9;<WYFO0F>G[= R'29^4N^*)/9V&XLP!JW8:)<
M45?HV?,%)]O)9V?T^=GTRAU6^AUJ0,J0K4W_0^<-GH.Q".#C%GFT25?=+1MJ
MZV1Y_J^Z:NSS(2?>/HRU5C'[3@JH_XN"//MN ,MTBZ;'+-PLL[[ZZ;%UK =K
M_MPW:'./<7\W\!$FY^74=IJZ-M!^?$_2#L<@'.'R;,WGDZ_DPA&7UA)23NG3
MIQVFC_\>+GV[DOUCWS#( ^DUJVC8'3YAE+(#4\@,2GA@S^4.-NJ1?+^P2A-G
M+H102>4F-/EWCL@*6?6J4GT[M'I9W=(CS;$1!IVA,!9%2?6]6YS;26-%[I U
MX.-[FDD],TE=->5<OJ52,UT'^%W,)L]9%GNIA7-(PHB6D]2NGQ2_]F-2U2?1
M@,[RYII'_Q8FW-*%J6+ OU<Q@G[^VEK9?YDP4;5-B>J7;I^;)/'<2ND)&#K7
M6V!"D=_@F+K;\BR\,X<+M3VO<QG(IUG6+.K6PF/&*2>C,^T^EX0FPLX2/Q/(
M-T'/]L=@/@@9H19..0\@R"SJ\F,DU7#\RX/8Q.C+>L0J$L</M=&WPH46;%S+
M4JA9?:1YGH'XM:3B*ICQ3XR4FVX,O,+\M1/'O6:'9BN'&*96@E6O;$'? :*<
M[P U,,4RX;"=/KQ/+V7SHU24&/0MXPNB9.=^V[51SV"5R'J:G+-<_5@:AN,>
M6U&XN!]*E[?,)8A\=9=>.[EZZO#"<=%KU9(92#Z>36G0,[WE<G0":I_$^B-&
M;#M=,4UC)I49W4*.<SGP7.M' NK$-C:R@DO,._BJ;&LA8':8P\T/E;YF$QDA
M,@SX+8BENLFDV=_YLH?,MT/T,TLC4X_5<P3'/?_T;H4&5)3M/V\32$-0+8E"
M%<VF$6C.NJ>J0$YWA@]L9W';X7P/3_]N>DH<O%7@ZIGH)G42J!)^'2_!]3VJ
M T#^JUEL1;8X.)SE0W'ATT0=[[:TO0-WYO:(/+,9:-2"TJ+V\!5X;0S)\!-K
MVI2CDOYWHQOTK#;,IF'\C$[92W%6E5.WSJX3C];TD6NC 7NK3;O<K<#>U4Z7
M_*$+@X;U\ZQ2J/,1B];"XM8_BZ7'Z\^Z?[>\V?\KIPPY96_;"?\7W3A*-MVC
MNUE,9R\D=Y4CE_[AY^>R(773"8>],.IW8$,H0HGZ+>'?.P!*1SO8=ZZO?:$-
M"I.!<-U6(VY>/7/@9X(.C7@RJG"Z*0>YF3@6=##G".$F\?=CW]T!\'6F/!-"
M?05 @ D7"6 L8\@BO"[,NU!-0$3KH4^/XP=K@\N9!X^PP9VN(5>4[YZ5BHS^
M$Q I'16>Q,=)F!XGW+E 'KNLES )+72O>\?!1,YO9+JN@E>@[9I3CS1=[#D3
M;#E4@OO=MADL28???OF1DVG+.+9.&W-M&K"Z2@;31.5.GLL!N[RX_;U[P!;7
M4IZ+W.R.<3W"%D3+@RO7RC-+@2K[4D[K=0E6(OEJF4@E0,!7'$R,/#;ON#?G
M7(_J7F"3^;M?F\#<6E#R2 ;43O>%\:\,5+W2"PIXQKH,U.N9[CL]/EX_*$-B
MN@0GGHSRFO4@OBKA*6UN^BQ3N'(J_9;=Z-NFX/=7">HO T P5I1-!=H2(82,
MR<4X^VN8SIPQE?$85-].)0Q-2\A CYW+8RM81:V29$'4;J,__!%Z\O:!<)G.
M'.H[@"5%F#G)N ?_V9RLZ#EM4]9FNH^&$\@0R1WV@XJU0D21[5UFJ57]<$M
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M'(B$^9V>;/:VVL H5NXIFPD+_ZE=5I;Z%(Y6W-P15PZ7A?WH/+8-B8,[ %,
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MC_"+(0<([:3&I"J$^-?@W\U\)PK %S22<;55>^X5#%G=#%J9A=H77Q96M4V
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MO;#R[1I!=7?Y>5QK2BD0+T)9/OZC_9"Q8+BX_)R$\E_YB[>$L[4HR2"DT!W
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M@ 2R*UER A[K?8,5B&5:V02!/*?;.* YZW.'8]="6-$93\C!?ZZ5]:0QLI;
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M^"Y7NF0BXE:YV/#R2647S?TK!:%FN*AVWO**RAY=D>8%.(R=-)9'&WJ^VK
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M1\VAYZ]<=*DHG@[<0G3S=O%"VW50^W8LR$N4\(]N:8G)!MNCQ@F6E867XX*
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M;IQ#I*=_XGOM18-<$C=<F[6IJ?7&2S+&'7>R6[L942 ^,:0+H?/8C>@7H^]
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ML-,W$]:K G-MC\^U4N6Q;D@9>-W=(*4D]"-O?WKO/BO9CUR%OV=<&[<8[<?
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M,=VQ>Q>$FSC>A'Q[;3?_PG5XMMM]-G-L6< $BNP-_GP*8FSH9G-G/WKR\>!
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MI2-H<3IRQNJ77OYO<,/W_^H'[/3[_P502P,$%     @ V8-[6(^IC=\F50
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M<OQE%^VK.&[&%/.$E:"JU5XND>A?POV/<D_G]W%]2)' X5]UX P*!"UY)F_
M>MNV@-9<9G]JQSV0;O:"<";SE[4+"GXSEIO\97/"N7Y;E"A;77,Z\A/!H2N]
M"^?+'Y9= 4[(CWW^-5@/;%" &#3^8E9,H W2 _@@_#$EG]8]F$*!-ZD&#SM0
M8!,?U+EZ%OZ(:^]ZD0H%HE60?JH:B4$!-% OU:5\S>B(X]-KV?^GFC$P#A?E
MAHQP$"[/*>2,%O7Q+.6Y=18<\[8WB.J8- BYQGWS 6$ ?LP&1#T?GDU U[Q@
MH1?T.ZQL8<2+O60]75_7W@(LQ8U'P!X^=DQOM:?HTH9['/V$ZP4,!%DDGNZ!
MTA _I^7'4:/#QMJI2P48#G/BYL'Z7Y'%+8/P@N?*$2OJL/2:'(MXJIUZ;'W#
M5DAME(5^>E*=!"ZV<+44V&,<'FI,?:;YEE-=@?K^<]S563SL4)^6B$CXV+2A
MOLJY>:V=KO#731/[;-6;*0LB1_,QS(?TJ\($_2%'^.M^T1X4QTJI[R2Y'1>T
M)C[D6S[D[CQ]MD0*KGX\O3L+Q^"V0LJ,\+=O.@SCIM8^R=0E;1).;H5"@73[
M93',E;D?*D.U# (4K(Y=HB2M9XH'4J0#E.DEZ!<@9,K@Z>()XW7ML!1I2_UJ
MU6E"!ZP=+O$\K5<?K=(A?%T)D!P=PX,NY8"PM'N^>[JEV:8^4FG2/M)0:8 E
M, !!>_+R4)%EF.VEB9R)4F3.E6A^J8KS=.'.'WMF?OVAJUUG'I_"0YN%1 OM
MM^HM+*3?R#KH!@PLH !6H@_H6Y&VD%%)N\,HL>J1*KW,A%V_W,':07/<8%;\
M1:I^UPN<9^.)5":SJ?.N"W$L.3*]*#,>LHAS4KNWT*+&%1_!OZ+6>B?XL8WX
M+.TQ)K.Z;:JYJ/K,9;P"L[:BC,S&!+41/"(CXT4>C\'_X)PIEXP^R_<*F8WR
MJF<Z^A0/%;VJT VA??-DM[!@$3+;=2/JK']!*NW@T#STB3Z4$F?FC94*O9+L
MK]Q8V<(R)/73\D_NK,7%G]Q:#&X77F19__YAJRI/GS@8[(!#_UHF) !Q.$=$
M4QS^<F$WO+R<O5JMT4"[=N9.>KMTN+GJ$WA!.N2E130X+:8?B?BX!_C0M\F&
M<7Q2X/-MC; P08%B^/N8?,V !BM9IM52E_4"IC)<.K/I66PH-]]$S5+M1@^A
MPN>FFJ3E<7TAI0$"G2 ).&#K5*!,GOO98!89YL<3=:LK'R?9RO(\[%V=2G<X
MOEU[O(^'V0Z'&W;A7(*9J0H/KMFOL3O<<[O?R\+1471(2<]E9ZA/6'&EHP_W
M"6&;8V;BQ!J4!^!*9WQ!!3J>_E! M3KRP.N8DM['YL-NY!M.<E9.3D2T68QH
MW%RXE&9A[?Q.Q^V&-DH#/"G<]I?YNN"M&$-S%I<) 8SO+$$P'21J=ES=\J60
MY,Z%O!^>_G9\W3(K0E%?WU41@ W#<+[AFXK#MS$6 A;;0YEVH-//2YY)(BPR
MYU=RCG057MFX"B25.N1P]9EN9DN$P#$_/_48DM(3[^G#Q]<K(A?9\N[7##&E
M>;BW]PK(T?H>X31*^(7/CG^)*R?W4(MT"7?8G/5GI!1^T4L.?' ]<&SA1**$
M+!S8@5A?<'I=50A)6#1*5>0M9J]!Z%H8>/GAM(.@>ORW2XFVLQ4Y\P=TG\W<
ML<O%(3%<2/K)!EO239W3@,-BX$JQ(^GK=@$J3O"(H J2Q!\KR!D/SQP_0:H,
M"BRV/7V6-40*%-M*][1[ZM!JNV.VRX L0@'Z<$,H4 =Z9(IMQ((%#0B?SCX&
ME8(NU<;^U,)?V0B,8KR03"<OZA9VR3.WJ?^ME!W +Q;>AD76R2>87_3#J"RO
M] #O=<(%O/]O 0!N+''@ <EVTU=3>)50E%YJ'0WEJZ>/'(A//9UW0Y:< !ZT
M2K?JO$MPG"!3V7U6>UR6IS3#XN2'O.4G;>(IU>&M'.2V?W29][GDHGI"GLOA
M(V,F(P6P!HK@AFER=,3(J]::.2M1Z0ZDDR9&S32!,>+:T/?S6)>-9O<U+. 9
M*5AO>:NRD%;5X!$:<=^>" 5\$Y_VC^P6?K"F6G.P6=8V1+P(LF"F=VC05GLE
M0=$#:(W7I&* Y.NFN8="ZY]I5O_A79 0SECP1+EVJ,'"@3&<\#O'HQF[4?@#
MS@U/F)<ST3YQ(*D'<9-SF'*[27=6$6.E8)7)$[KG2\7/%$CZ39\\^U0\,]$T
M_I+)(=A9$8!H$E;Y"DNMIV8<@7"[5\Q&<5@2Z^X]]Y1OP@V^!R].6&=BO3QU
M[-%5*H "R'VQI6'@\IYS% L8VGH11"QQY0^^!15;J%>".\V6:_9$?:16\SSZ
MH%5J,:M&)?J0]+4;"DXLQ%;_-DC4QF_ =K/SN$SJQZ*-]J<5[UTW<+F.;AS_
M+KR+!#$2;(!H?O8/FY0O915Y>@=::EY)LZHOQ_E^_.P?S;HN=H-Y=F)($$C@
M&8\0A@9H;S'R&O79>X<T^[Z%)&&I%\%! ;#5WWGK%M"FF9%2;2OV..627">C
M3?++;VL9EX&+"UG/%X5O9CRBI% ]/AD_R65BF60W@YYPJ6)!ER^L03>WH%O:
M.(B<OP 4&/OV7'EU&PIL10+7J*Q]4&"=!K(+!23?AT,!4/*SYC+]/]'8Z*2;
M"(=<TH&A:">:ET.>31G]F]OMCPP1[P^\&/<7FMO^L8EF*-!)R0S);>6>.G8K
MEFT&U0XZ?J"_/3:);R)4V:X@1OKX:@D*U(A3J6@+;>:CK0TKT E$8TUI+:<N
MRUNAK73A\S%()/#G<K+499HA@F@TFF7S6\O7#Q>)SW842.8S?F/*GF<6-LGS
M>N+J)R+'7S*2W!02FTSW)APJ<^G^*L5S@-7)-7 1U)98IT)4WF -='4KQTP)
M3]JSO#8^R[PT^*PYK_RF>J;YS:B5E?V./CQ*\P.X4U8&Z7Y^Q.=[RN]JY= [
MQ4^Z[KSVDIM%6-TF]YA0(.;C<YDA++*W095"16>A;B<00<(_?*MO_6DMB,Q:
MBYA6+D<U](T!#$3CLZK$IW]CCS',[C]?<OJO$0'=Y)2V>9YC+H5SOL>&%XY<
M_KQ>ILKO7--6<HB+V*Y:7AQ<ZNH?)*D;?NW.1C[!R3 EP:@F7PO"M(9])(C(
M\LQ1G&4[EES6DRU4A!V9H5W7TYF*/F\F]]G(HF3_6==X?L5:*CJ!52GM?)WC
MG4_(/I*E^95)S#5X580)+BN[BH?"94@AU*&L[&BCZMSH?9)"0&[A8E#F:=<.
M^98YZRP/[Y<?\W;>%J1A&<X$/=5#7SR7#7R").BH3V7-F& 5[M$4U3I]T [=
MZFO24!7PHL,0FY48I_P1(,G]J2,MIZ(Y[&KO".UD15LA4* UH'\+Q^A0H\;^
M19_!1)G;\-ME!S9V/ MPG?.!"+)P\%PDD#YQLO(T0=8DGY.^8H%%7E&K.75)
M/36][FWX5'"JT%V<?<BEX+&V>(LU]QMYH,;,-7C_!,FX6:"_W#G,^H0FUMKB
M#WJ0DP-;4A O02&1B33^ESNLI92W[@>G@_&8E[U_8[%UDC)/4NFS%1W\6V]*
M!8&"3O;GF-O6Y.60LZ,-B1F8%;<X,3$Z,3!!25#S@"D3BPJBW=<C%@&X\;4_
M6Y.\W1QKWQ/Q0QN1/VW1@</GYU#Y]Q//T5]&TJ NNFU[Z D)"E3.LFGDN#FB
M"H^WC*IE-]=&^H;Z&?^Z8F$=LLZ)%RW?\?Y"L%VMVD^E?2'R-O)\@6D+J_@V
M/4_:RQ[?!6GZ852M<#V(S-TRB&E#RVR+-A0A8D#8@SY!T842!PK$E[1=/7=E
M3\$P34'K]7<!BJ!(IEP)HXW.D>.NI04)+LPPN2Z<V\@T357)0AA9 *8][[_V
M"(7PLTR.#PD4'D_+4. R6W!/&.79R5YT&5^CUD"!<04CGWL)3^_KF\X*.RWU
M)?@JD^1X^A!Z,"&93IG3VU8A$(Y(,6AM-/RWFS*,WG#ADH&\JS>A*7DE%[)9
M+YTT4L'0"%)Y#>!-\7?9*O+K8GOA=)[3XTXI.BE\;3-Y GD-!G42$40GY\L2
M>R[Y% RX#IV*)*$H_3RO\,]2THTHFE$>P!9<ANJQX30^3*>-GG!2*]6I7GX&
MO?JB(<H+6-Q2PCU+3/WHZ"1@MX% 2O+C6+G;4(R"S-0\8C@ZY0<MW'=F\<(A
M61IJ[?&R#D*;=*)?I &GUS9$0W9YW;6XW:(=10@AZ)_@8TOQWUS",Z-%0P&4
MR[*"+@_8W:X9>BEG-'IFLKR>ILZ#P4R<FG81GTN18JT_T\7AV4L*H>X%MM[$
M'^(O:M*<9"4+JIB/9%7L^GV%2@_$D)K?M.*>"0_SA9WHI/&IT6U',>9XHZ?+
MGJ9[D\_6:XE%/'#E0YHD,^2F:5;A<U@V?[]Y3%,V$[OK"[*&,]0UE&)&D.NG
M/I5F\RP(?E#XX<MU!N^/=!:]6#V R9VF6*_8T*[FPT'M>H-%Y18D4O:/@PI:
M[QLZR]A O?SUPQD*P(IM&G48B9W>;$-6-[>O6$!GOY]:?!#^Y/!=5CBA0#('
MA.IIR*#&7?3O#NPH8@_$8%&/S8B."5-JD^-E@A9X/3,0OII8!$9OU/]HO,OK
M&K)C6HC[$/E)6SCP<!C#P#4*7$[YS;%XU=BPEX'W8(U6DD WCD2,#V[VK-#!
M#3[J6/7-N4BWJ46$/!4G7JQ?G_#EOB:1?II5NG+5(J=R,/W+D"S'WR;I->2"
MU==W@<UA_'1FO+?6J>J47_%+!K:_%5.%VV\UU&O:1= %VQ)$E^VX<#HI 7#<
M?6/V;!8M?&JC6^V%^]N;SNC*2+6>/>_U;>L(?PLPXP\(+-.[LF\S"HR(6-NK
MJ5-,V:$C)]-(L;P8:_(VIS*ZS?XE8+4T7CO!?9_*)2QSXGJ!&_^9C7B@W5(X
M\?)0;=[3AK$J9H</5EZ".G^LXLX!?NN)X)M-B;PE:<G'VNC#&TOK5F=(I,;,
M";RHQMBBP5I"J;!/Y&X94Q42R:4E2K;U^X07O5MF!929D\SR2]W?+2[:>QA4
MB]K6J6Y1AZ"  =932,W\+,D_',ZX+&V6GX7BJZJ9X6MQA+A'Q8 ZO1V*W<#T
M-Z\=W3]A9VY=PB?>37DC17(OFW7YZGWFX^RQI_@UD=<<3Q/3P;)N3,^\L#SR
M2F(G@*^PA,37,EO:WHH_?4>SJ8Y():_E\X6<*7]W]*?0+U[D/_$W-Q[1#W@7
M?/GB7%U=X3U>LY4V)X9%S/T8:, /^ 9/2 _3ZPP6)_NLS;H!PC.T\7X*SYG'
M2#C ;?O&-:?H\B,R=PVYGX21A*%5=8!XIV@)<L)* 5*J3MAA357XQK'AZFC^
M^K,\/+@P1E6!"]Q0AXTLY(&1PPVSJ&IPF<Y_^N"L4]^<I.Y/SSO>8<-=*1 =
M2#WW28?SA$0-AGS+R9D5TB:E**?#LQCA>_;!XEZX5>YK+!V7_7G7.>+$_  <
MR48 'U.)CJ]^]I*MO"G%5)CVM\Q8*7NF,'EM(?![UNTJC-)V,W_U/=O0MMAJ
MN<LF_:@TN66OI&)W^NL4WR>]7M<("G%7U.]\JW0GZ9[<,%/C<K&5M(VO+$WC
MV[=PI &V_[B-7<)+.&DF01$C=]:%J3\(-W!US_ +B)/%6[)#1AZP(A]#XLF#
MM!IJJ]=7Q'7I=2O;"7:XTI?;U1*RE'%%1-#9,=]*'!XJ)_8,_G9Q6\;3G&8K
M3<M)VAFGG6^1Q_Q!*6U%'>T;V24,*T=;[*D1N $BV8IUEPM_>MNEXRU3GK_G
MCU4[QN.(4Q=^I?@*_RL<<HI37JOUS!M3VC8557G&9S(/[/%PX.\G?TRQKZE-
M=2_M*-,?/)-VH(79T#1<?)A]Y[1F<C&%S6JET))^3<2U3Y3BT$E@WF M;WH@
M7$1N?B#M=816<K"0'(294V2L:ZOL6$C"J$,K7_'U.DPV^D="DPMO\&79>O9,
M]2%^9*_.U;>;M/,#;=8/XI>4[^"I[K?\% &MZ0=SF]Q1S[#>IP,*$4*%^R@+
MR:1(F:/6'?0YXZ\AZ.+'_;^>:,X<8M:CB-EK6&M47=;9-B1)=ND#S]'/!9YG
M?[M1'I]#Q&EA5]-B._.W7O2!#T&;@\_!J524FP"U<+ P071.?%?^P5ZS0?[N
M>L 4^^5>*0]2;0VN#+9#L%L%EPR6 >+QL3C%]E^]C&.,^EL_<W%#*Z5[O_S;
M"Z0YTM\[<Z]\:[3$8OE_-"KV5IFX'3,J![$J^,P[[(0Z;GKX6./$9\X14WI@
MXX.K<28=%HX<N"$.[FA"LU:X>HYS,,1"89B>V?:")%<*BA+?NF<J!DB9Z&RP
MZ@0V'P/C>@,$HLIQ#E7W/59HHW788RPN'&L]OX_2JPJQUL>+3HNQ8C=A$<,'
M>8;I?Z,^D\DB?ZW/776(W1WGC!/_9M6LWPF&_"RV!87B4,\1:4&!>^CZ_G*R
MX.LH;TIL$ IY[0[C]@H<K[Q*ASPC7:+6:E=M@JW,PX!8BB/N!4S8\B'19R2E
M5"7_EOMG NWIH=LZ?IGJ.5T*JN;1+3O9:0Y^4]_ +U_KNX]'Z*+@U/.9"7!=
M+:@[HVPHK(UQ=+3#^'X3M#MJMZBK;1TZA:0SEV/:T8\1Q(?I2;UBC*37865)
M\.7Q,:WG6^I 4V@.)\*7F\;X?I4B_H.V3J$+/6SK^"Y7<Y=9/G5%*_**XN$7
M&T^F:CVQ@@\YQ.T4KZ--X-*>.4SKL:\R0F;*S,:@W4PULZ.YDV_5!: X>I<]
MKX)J@I/ Z?P+V]@.VT9ONK? V;20WKO:21I/CS/D\=(NW<(!44+E=1!7HCX.
MA'>:??WS@6"4_N)RZI"/%*V7JISNMXK0I?8D!Y)8KEX6C].6YK!'O;N+HYMD
MG*6:5O-Y\LB#6_4J#P9$"7KW7B8XEL-N[REOPYM/.81H.;K"B\?IC%P#^$J#
M)_18-<J#W>Q=O3#4Z53%APM'C-UX-H<%MX*O+E"5R:H,.!(J\>'YD;T<OX:1
MQ_+3+Z=V7"<,<SZV/G+O[W -Y^=D!LFR-43<>@0,)VB\4I/OWYK>KR;3W9BA
MLWD!IV58M1:7?&,FEAS+3W$Q#*B<.89<ME% [*L?)5Y1^ YY=<:<BO*;/LHZ
M]WC=! H;%GER&!J'/_$FVN43*4R1IR72\&LN^7Q4\_:;'-/^V4,<AA\ASQ*)
M;U5.,.QYV'[G&%M--/E;0]8IH*9TS*":X_ $RWGU  :@D";8 F'Y.A?MDXZ?
M8L6,?OG1$5+1['J^7"!-%J?FP^<?OD-^M_WW.TL"GHSC*(6,ODGS/V@__!'V
M/N#U'2-L.@D28S]'GXU_64/<;K:$ NS&IV*/20VV![Y_=S C1#'E#T\POC\I
M;;?N4Y3#F?MKF^0S\T ?7/K2H_>L@);:G<9D;B5JNGJ]BY-KQCF3[;:2\&"?
MHA-8YFYP>9BKIQ9C!/:WB"<QX*-)?"G$F&8\\EU/WM9*S;G9)#JX5VA:8@.M
M7'1#':.)+"!K.OY+Y[W5RM>%[4FE\P\AB 'M=)HTJLJ9HS6L7#PHI1%)7>_T
M95N_G/14R6]W1M5Y;2;XN _K*,)..[X/TMV*7]<CWK34=G)]/.'O*!D2T;+C
MI\1B0<EZO[S]*S5 -#N=)V)A1W<W:&$]]YA;(NA1A'G^\Z9H=&.M&9JA$8_=
M5W-ECJTOVO065VM;/L'#+[)R%O3GJJ]7;;^BFUDRC6<8A5.[_T@X]%!'BS\D
M9$3-M5^7_!X@)GJ;K6C[OB8!^;C4%)=]UMILX9?(OFY4D@>7=79DCCFH4^R<
M(/FIGNH1Q:ZJC.OOCTJV&WJ,-Y_#NMSNC68"]HH<3P_Y<8YFCJ(^>F3:A#5%
MVW$.QIT-^V[7>==C@[U3F=9TO-/EM&98LJ*71+(S1",&/1]^E9P@\YME&8HC
M/>EE>%]Y,\$%SPCS\;1%[DQE3_(H'))%,=G/B#"JVPE06T>9O+K(UI:D"D[0
M".X3**8D.CV>2=Q0KJ%X_:$$"E1DUFGH5SE7JG*/[+>T?ER?VHIV[74VS,.'
M"2S>K_,P>GFZ??G:H;;*+E'H!.X]I+8<?FOK3IO9,AL2+'-&D)[?2)X<W^=5
M(ER$T4TK0=%]UOPNZSNLG,$:./#[18 ?2R2PQNV(<3 &J5*<<2B9P =?D45L
MZA*T_GK_RLO:R?\]+2]]F8SK /&+YA3$>F$ACW6$B?GL^BGZ+^Z.HF+,IEZ_
MMB-/+H0[$IHDP?&81VZ7SY*.'E_ZO9_MCA_(W5](^D)F5&6$=8R\.[D3^KVI
MLK>[46[U*!O0V0(/]%><MM;D0SSD(D7P-.MF["_WS(@:M0I0S=Z\?./:>T3G
MAM"XH4123_%H% F4%N0M>=O_,!X@KXM"1=F*-M5[A]'M@Y?",OR?$PB:=H=H
M]F_'2\LV<-_,\0_ 8[L@T\5+;.'T%W.K3-^06VR<I'T+A +(1L]OHHSYH%FQ
M52B0G@:: =7=M.P]SY\<XE @ V]2[##C-Q0856H[%%N\7[EJDY:M"K=P\W-]
MYHAB5"N_L""2EUBW9R)<3PU/4.#A\O"IZK&MY;?VY3*>\@1Z6"\<3CP6UTVT
M!_A!EC%)9+'H1-%:55&2>9G6*J*49XBYMD4WPSQG<?\NO0B$-SAQH)9;A43]
MXW.,.9GGFBF2P47*V+.6_JN=97!QD- U- Z*O6PD4\<B_>VCDSZ=Q;%-B!(B
M2'1ZQ)?O[/%LBOY4.[I.'Q+YZRA25_G!KW!_]&.?P!/-J,%LT2S6&=7Z=EN,
MVU9]+:C2KM;<_<M&0BZV"\&G70=ORA]>%!W "5,Y-\3F#'-7ISZULY4Q>L$S
MO8OID!KM.CXGB:+./ $)WK<K>G-B[T^]Z7N@.7\:]^=6GYK/>J:R?R9!Z\;)
MUU_.(MU&TL.I0JB>O_I3M$#B/1+S6+KE#P4&S^M B$>[E)L3E6WK&%"@X/EF
M!D.!>6UU:9X7,03RTKI<2<^#PO>4 07.L:" I>P#3=LE%'AFZJ![E@/K@E]]
MQP5+V_]PK>KS\#H^BD&!+:JGP<84IAW3_YM5>B:XL8Z*ZS*.11VVF.N&%I?(
MKT2_U$@3L"V-J+EXF$KCJU#_EY[QK;PRU"TAE\5W;@KAE&_YA-K0OH=%?RH:
MECGN#@6.A2+8MB-HP=HN]F92F(_B^WV[$MDY?)@^UO;CTO@D__(9WK_N: &=
M<:RO/C DG1XLO,DP/V,(HYS8QNR$"" /7^WY4)G9)@>VLB[8DDIOET<QQ"G,
M7'ZAO7U!J>-4@##EO0L4GGBN15XNG&9$00'4!^6-..R!LOW7^S<X)0K$=7$W
MZC_ABO&ZTN?[UV B@1NY+?EL>7.3_@,2'3?J2^Z#K2?2T<*A-0IV#+T9'WO)
M<8R2,Z50G0]"&A>S+/B[K79%*9I!* PF/:H*V)&ZG^"$809$.P.$H[HR.(Y%
M-J:O)L:@P&;MZK-B&0M;&V/["HJ*'I+>&;Z]\\^RI"BM8FA*2C 0ASWN]<XZ
MW#>6&H/Y^T6+_P$@,6_X>-& M]YXQ&[EORTR*\F,=IX+OHT<&B=EM5=E9_?=
MFV%XKT)KIK-) >QQ/12WE8EU<]![>"C0W&[/T8DT9\V!VAN?\..DL+0TZ8Z$
MTMAB\^R*7H8M2*[H=B&JY?HCEL[BK:OR73=Q6^$@]R>+B,T_N&;,-)E([+_;
MZ5;3^,'/Z/2L)*_^O>Q3YK/XKGHK;83@#4-:E&T4C#$P%6.HL#WCV4;CJWF2
M R$<I<Y&X60YB"QEVEGZ83<M/:D@Q\)QO)M^>#]KG+305V]+6=NK04EQ$GH8
M@Y6ZS1@RZ:4$ [2H /X@K&]M>&/^W#+L2@.H:JK:'_:MRY%;IGB&C;4<<?O@
MH[9^GD=&E]@*^=S/_O0$&80;3]"TAJS][(Y8)G9'K"V6U)CX,/+%4K4ZQILI
M^R?O_\A?E?R!8J_\^0,8T5F'A*.1Y>4JK<),F^J36#KMVNH:KPE6N7&<;NL0
MJ^^(5@)7Q'![ML8HR\)Z(4F1;8U?%-9E4;O:-B?/2UO,)0W5-,!6KQJC>8EH
MPAV',D9^ HD2*5N+AJQ?6,GDS*BXW!<$UF &;N@FP'N=3D52\PQ>7+79/WV%
M2A4*23(;+;D*?N5IDR7O'V!=$+2\6RM2TMC:9/MC63G@/YIZ;O\/P=I<[B8N
ML?DR=H.T(GR4AJ]00+G4>=9F,P.;%V]PW![+_C8^SH4EARR163]K><@5GHYS
MF-S\L1;N=A+W;D)F(5FEXE(7IEQ4.11D(_H^JU29.SQ!<O?*S%9>%'=_T14Q
MQY7L6DBB>+O@8360?%HL^4P$^Y4(!KO=(.-I>#0WI['\U'9]C#?+6PDHT*H?
MF>]KM6G(<>,1;Q'+)5*$=$&N^8-\]7^U<MW/<#CZ=DD078((4:-%2[#(DJ@)
MLD2)L*M'HH55@J@1Y:N$U8)8O41G68)5EA!M%]&B+:M%6:+WMMK-G3?SYLU[
M][U[Y\[[X?,/G/G,.>=S9C[G:J(@GGB<J/GUIR4H0 3VH_WQ:T;_/,8UP\V+
M.\<((DU4O<3(43A?=N^H)A7$+,#FD:V W_V8)D-_>5L7YU3N31.-.RZ_E8Z&
MU_2%.RH8TJ\#S;6J%H08Q9,'B@I\UH^ TU.RG;U;C_K&P+?=9)O]P:_$K?1R
MS1I%PR!4/)F>'U3O(E?[75%UPM8.^VL57-_&*MYR7\7^>+)ZG<IC+:VKX=L.
M3QA16Q#/9?19NMCY%V.'&P2/JRJ,<[/G*FWG1XT3^-O@17.9Y/0!L\\12QLA
MDVHF3#SIBA[[Y2SR=\YSCZ"] ]E9VA,MOC$P9+FA_8N=9V5%%R9?7 +)@HU^
M*7$&L>ZZN C(+T&OEQN,&G2CSK[QW.>9&(WJTB,-S-_:,K(;=.$03*KK6:1[
M$I *(D\LUQ*;O@3P5R$L(I!BAL/X%[[^]L5J2/I2LTZ[/'+ E\]Q'KK;L_#8
M,%2W^U?6R@;7696BAX$$[OGZ4[D8H2RA)'ZRQZ5U 1TTE?81G.PL/.6N'.]6
M'SOWB\X,,YJT'1&5$JJ;:UMJM:-,$HPS;$UT/2"P9:X'D&_#@GOO)B=XG19#
MG4I(L>&-F??GRT=47QA6F7STM7JH=[X+ZROYJX3GXXNJ++F,9@GVU1JH;)'/
M5CLI@DSV:OCC,^:8CP?SF&M%<,]INI]=11A)Y9X&3M.?F8[@=6UUWI4^";Y_
M55O^YZ2';S2PK\$?D'?8V'BR &H,**E O LA<)V5RF8B02%C1X4A-W59G>C;
M_-HW<'9*ZF1(9N>.6$UQZ?2M2L#@U:3N-9+.@GFB@\O>8S'VIP9*FEA& Q"(
M:J_<]88T/>7&LV#C0D.75@$F'Y1W.XFPHBW[K2MI8WPKNJ+7\(A']Q*0R5]-
M3Q.I4', ^U(REWD'9B+8V!B!$[G-K\'/ZRD<9ZDLNB(6M"/W]3P_O\W""BYM
MR$WMY E"S73E$CIINLIV-$K;O9[R>N=D/!-U,"C<_6V<FY* XQ44T+CREU%P
M)_F;-."=GG"IT1 Z1FQJCQ(\>H I0LM6E?TW,5Q9 9(F0V/Y1'_JGC'=^5VR
M_?_Z<I#"_;E&GRSX[\H"5RMMIU#EWJ_1IP#7_* -%9'-;"Q9Y9"$98PT<_D$
MG,G]@* ]SO3EJ(A#F%71ST2NU'M2B-\[F= YKHW:Y6'4#:)"J,372\!W/&W)
MFS1$LE3LF^4PW';/M;.XQR_UXM,JO*V= ZG#5Z\M11] ]=7?M;/+YJ/EBT)#
MCM\IV8%MZ]#A9LEJ55+Z9"=X[MQ&9098;8+,VR=>YM+9-9AB\B>/* 8*C'>.
MVCLK8_[<*;<(<0<1\E+O+P&-9\B^A,U=K _\*R636H43<Z*%1W9MP6;JJSP.
M67S-X(&(<!W456A,$*OV2=D<>K\<+'XT2%"M;P:&@;HO 0<0Q^-F_6R9EP\P
M'-V8YH81(8>SVG%CEZ/#A0)WM<_IBD>1>1J/^J9*Q$[JI,&3FQ6#D*SLO"E'
MYCL11 3T]&OQ#X[1;5SXEB=L'G%8O/X]I,$]_LKLFB5QKH76Y-AK1-P*_+;]
M*+%R\911U4)6% NO7=^6MX\L7E4J2IKT%\,+_''^]O ;&BH.E8%:]2VT!P>6
M'"/GMLLGT&H Q:U]E%%,::T<*9._T_;8>5[P$H"XN<OHH'E0ICTM;+Q]%C(0
MOMJ;V)[WJ6B'BG7_'F,YI*4RY'D58FA)UB??(%]R8.$ &2OG?33T)M5JSM5#
MPT=&21A?OD.$L85P75':6H:RX0*$5.,V7@?.1.KMEU\"J(\YAG8O 08A1GOL
MZ_:[H2H;=%*?.DC7+2,=YOJX.\A<"R>%'IY89?>.)4FQW,^_9Z\;YH5.BN./
MZKR0QECQ-M9_RI+B*E8>PGR@U=W!EO-^T#;!5*(Y,S2RK$_)8I70O[LY--M$
MB_>OL)"62BS IE)/5\+8V+R%>CA<4L^S>!XD>XN?F\[KC)/\C$@4K/W_0DG7
M?_N^[MWP)[3AZ)ZE56E-^">V"(>LUY])/:^>[0Z\!-SX+1"EK][1[B:..XZR
M'['G/N[TNI;O$U\H+677^]#CN_X7S >P#((LN8--U\8.Z#K%J,)4;!Y !^N[
MZ!\[V_JS;"^71]9),PBBF?'"EP0BJC!=K];-D<$E!Z*\>OJ7W[)R+%"O!I9'
MW]EQ<\8%P?.NTB9)T>W@2LN@'29&LINB.1]B)_YB8&IJKO\L?F,W5L3YSILS
M16\89X*SAA22&0$(TE..+."L'3N:2=[ DR9?-=EN;:*R@WO4DMT<W,T5&Q*U
M7[^-9AA]K72AJ/#>+N_-9LY7'L=:N]IT\M$,9F+&7O"D[,2']-[MXVH)WJB!
M7:G$>JS 9/3!:9,A&UB<I)&UN;L90]=T@]J31T3VOF@49/F]&>FBA@,GL]53
MU]#M>/VENA7?B$1JOAN&H'&U,IJ!>7MM[6F1*"/:B]"K)S%=%IQ]9"W*5J@M
MFD$ZRX_#UD=@QT?U]"4#:=:^A!N:ISG/3)YPC7-L%LR/EJG[)8 =!)[3=0M=
M!X 6,QB7H1"QM:@&Y6IG#FI^_;KK.?RB2KO9'CIH/>"+RNA]6$KK&4-@@9>"
M.YBB[Y3R4TUP@6"5QD8O)=4@V;%!19C1E%DB9%WW(=-*M[K8-&=!M'<=L_F4
MPUA*'150)2?,\ZI_UG+%FDY-[(DUXD),DF0E;AM4,H[+8'H8MKR_CVK4#MO8
M;ZQ_3NRR:$U)\):F% C\'BG+BLX3"G.SNXID3](GU_7*; Q2?.L^FXKR(7X%
MO]_2/EP[=_[:MA,S.VTZN2W_))PTJ>M;A)9V&$*-)XUD2PSL!$\^(KL$X(FV
MM2,2ZPFW)S7BA44E3#XC(@+?^MUP#TC91Z',(-FJM;5N]UI%*-S=C;R=V=<F
M OG Q>JRG4FA,<OL=R*TI#[Y#R0GQIYE]_X\3Z8UR]QPR<:?O./!V[[?+=]T
M6)&:>IQ/P+T#9UJ3[;H[;K! \Y.28N4V-_\LN]3_IG;7,6(E$/V>]JO<JA72
M.YIMK9X"R1SR*K>SJ^6QC*<2D[]A(V^010:&T_-/5K".0TKO$N<&(O@_\PW?
MBPULK(D;D!WQ"9PSFE3H+I%$1V$HI_D#52UQZDX[GAQ5@UB0EL.L>VQR@<D*
M),K9EKR3@^2IM'B$''ENWC<+>2=H]<=4_KWYB8S&5)6K-UF$HVPHB L'N5+H
MZ/A/BL#^CZ'[^4'XL-$T\R_).4W.[$3/F]Y#>H$"]ZMI;*Y<R1 #*&=ZU'&L
M.\R+>)+98F9&345LV*< H/LKV&LD0TBS0/CD\Z91RX[RLE.HWV*28O7DTGR#
M4LO';PV8\=^D<C-+W&-829]<NL=#WP ;KWD5P )(F&28>_&BT&**/OQI%$ *
M!^ .5%@2;U))<WJ@HY3!ZFICS3"U87<Q)US)KIPI6-@LL\$TWOVZV2DH92\S
M0418X&BAZ)M6KV3?R_0"4MQJ4B,7N"5Q'7EG0^+P"_5"[7G13N=C.:2XWX?,
MML_GZ\\VGRZ$2N 6S*O7Z!DB,"P(51<+,HA\ZXNS@,8J=?#[,O#[JQR@X><N
M&],/L*K?<=,TBE@/S<-8GI,6JO.774HET+I%3V^_T$^6[;<FB!@1@3BHT85&
MO7;H[M8]ZXOU?N6=!5-OA?TTU!?',=);AS+CU.O5F=_]O[]G8/B@;JOCRWI
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M=O >+/QUK^[>]\=/0V[[#X@GO. 4WEX8_9W#R# Z%TO/;D"OJZ@V\B;M*%Y
M;H#N;CI?VQ.N=*F0S'PI<RL&0(7=T"5@\;KM'XIFO@2HLKK\>S4>EQ-_ U!+
M P04    " #9@WM8([!2!#N= 0!SN0$ $0   &EM9SDX.3(Q-#0V7S4N:G!G
MW+P'5%/?MRZZ$00$Z1V$H""@-*5*2U2DB8@406E14:J(B$" 0"A*AP@(*$B1
M(B!"1*J41'H3D=Y+0N^)M$#:X_<OYYS_N^><]^Y]=XPWQEW)S!@K>^VUUS?7
MFG/-;^Z=T,9H<P#G37TC?8".C@[X<?P":). +D!_XL1?[^/"</P^R7SR) /#
M218F)D;FTRRG3[.RL+*RL7-SLK%SL;.R<O)S<O'P\O'QG>80$.3G%>3FY>/]
MJQ,Z^N-S&$Z>.GGR%"\;*QOO_W2A_0"XF$\H,^#HZ<X!)[CHZ+GH:*T " #H
M3M+]K0#_*'0GCL?(R,1\BH7UN$$5)W""CI[^! /]7Z,^/AIT?!Q@X#K)??;R
M-48>LX=,Y[QXE4(3/S)+7"]OXC/OQTLJ/WH1=HJ%7T!02/B\E+3,A8LJJFKJ
M5S0T=6_HZ1L8&MVTL+QK97WOOHWCXR=.SBZN;MXO?7S]8/X!X:]>1T1&1<<D
M);]-24U[]SX]-R^_X%-A4?'G;Q655=4UM=_KFEM:V]H[.KNZ!P:'AD=&Q\8G
ML+CYA<6EY975-<*?G=V]_0/BX=%?N.@ >KI_EO\4%]<QKA,,#/0,3'_AHCOA
M]U<#+H:39R\S<E\S8WKHQ7-.*929]WKBQ_*F4Q+*YGB^1R_Z6?@E5;#G"7]!
M^QNR_W? POZ7D/T;L'_'-0&<IJ<[GCQZ+@ "4"QR8V2 _W71'0@1ADP7+;R7
M./GA-? X]<J)VMGH6;Y=T&MAB37AZ>[V2_ BWJ7[MOUZ<&E"X/X7 K3UNU35
MM_>5;'S1)V;&R^7"*37K@T5GK$7A=S599V;+=X2J$:^Z4SYM@WN\-Q!1T,J#
M4+#HX=?IM9+ 0#%E9T?2N#\%8G.(:<^N0415G7* L*U><OT:H>543UE7(J$$
M5?\LOPA,3K?!7UQ2=7,5Y3KDA\1=)GX:%N@"R5-W!N!&)'VX+N%&W(&89&T%
M4S@?<NL-E:]M%E9A,S1NLV-9]UUV\"<<]ZT(!;[K#(F>(AZ-;=P^._-EJM&@
M1R6Y\W%B#^8@H]2V>K1*5B/IGF)AA"6IK#0,G*(?T[E@_M9^4$M>>EX]0<5
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M']3=/C<2L]'MB\9."".L%V>;6;S;L[6;"V_-].X/\5H^"=N[\LF_GP;TZ=$
M=)'H>[5^_7XS2J[BX0KF8!CD$DL-4*3L73V$/C+)C<_-(]V [O0CMC^#^P7(
MNU#26LAB4+1:C%H,<I,+\?<>_MF"/F5?<D)FXB*D\OAK'0'J4=Z_-6&W'DMV
MR7,IHOZC$^0_F^1H_)]V&9N+$$W(-HJR9WY'_'AY</[O-FQK68(R3@J)S_Y1
MUQ%;=9"J S**[/ONXJB ]3N)-7 P+/O<(+*_1@.2#8@9-.#!\3SG.>:P6,]6
M]X6]]!";M1I6411T#5#]884TK_OM=$_HWA-;OX]GEAKKF]%2 PVN6)*\]PUT
MI/D *H_'=OKJ9)*>3A,%PD(LP5EW9,>(T1'IL+W@ ^Q,INM'MW2=JA""EMOU
MI9$N,3Z]5)\QEC-G#D[4];I?BYV#_N!X'<P5C@LG>M^*A;@U]J?]Q R'BCGU
MW**/2].>_R1#OR&,!<O '^"WFP5?"L%UY0A25<4&!3;^G.^5M=]/L&NR:XZV
M^((J(V/ W.O9G-HZ^6O!LIBO&3?"#JY["E\%#SHJ=U4$]X\HUVOHM'D$]T-/
M-=C/Z4"P.DN-! ES0KZUF-RWP-@@0X7^Y^-GL1);14(B03M70<]<9K0'][;Y
MW-%B-1$$Q9>.@K5)+BPW2$.7_DSAI\2\!NK2B32@#<JE?<U]'HFL=N[P(NKW
MW4Z^%=-GWGBGZ]&W&Q'7N$.3-I,3&M+GR$($ S-\Y"8=?JE/EZ"(K)IEAY7Y
M5Y+F<2O-ME/&7Q\%^OZ03*C]\4-GA7Z]T6+>^77E)$2@1_3G1#+L+B[6,JR9
M1R6QZ^SA'1E2[QK3S<TOBCSFY35U44H=VN[G(NTN,3Q^[*MZ..F<[P9AWZ4!
M$X6MPHHQ/IU5HB#+B!DAR>]6]UF[OR==JUEZKD2WJ[HU(S6B;4_PQ$6$XD>-
M"1[;KUZ6(%A;OJR-CLCP;Q$R4[1KIRC]X<FA5T$6_5!.5PRGMA]^VYBX@S]>
M+FU^PN0L[M_LA7GN US[G>$?)Y) =\4??5.-=\<I-F%>TP!6L*P;B,NG%'%G
MN$J$U<16MS;%)*Y_Z@1P+:YLYON6"1"TJ:=Z>Y%IR#HTN%_L(D%G&:E-CY]O
MKELG6LVW#MCU^)4:<+J>"Q,\X(W*HD^2H9]=025IL]* 4Y[-B E-R*N:&:4A
MN"T6P>52(QQ?U9Z#17V1O,W,#GF5=#O(/0J?C02?<YL5R272(^:=:$#T>9);
MFH-,S IK[_5.-?.^3PSOKCP</1$";L.;(E5H@*C>9W VVX*$:6-2.[3ZZB.Y
ME><WE[<5/V[?GX$0&[';$51Q?$)\J;&V'_H"V@-RF[/5WN;.QZA'X)6F=:BB
M+=F%$!&)]\0QC 3\C+2O(QSO5(.*6X[<\G&>SR780A/XC-H#<>5H!;@L0;TE
M.PY4,39"%7<+5JM.:^U8' X[3.S[*O#R(5D2P>$&D 9BB,GSZM%2PPV!\UIJ
MQ/?SK--6OZRHW;\;Z!F)N]^B#-7O"SIO^<]92\]!HJ%<P5K3<);!CX1/!5AB
M5::$F<F+I6Z]^V7@ODO7SGWPDG!,WG*AWR[5O5/=O_',$R5E[&X,FW#]] 9K
MQONX'!S"TH?WC*W$B!&=6J#]S\##!="S23,>^9YVB1] S]WGU^5-6Y4GJ;^S
MF:MF^=<UIPLC=C\6C:TKW^+?[H:I1PF5=Q/"UTZA["F1\"LJD/'LI@15D?4]
M=!7I=L^X[A>A1]JU$8Q#\X4Z)D!@5G&Q;MZJ7]H!0VS@/0=_EKC,SP4)3+^M
MU%MFHX1-6[<95[.D?\_<5RG5AZ@QIBO%65]9$$MQ[!BC :\$6OU7*1G>V:3=
M83Q'Q";9%5^XKX@?;0N"=-BT:D:\.?OR=]Y;A%//T\'/_OK:SI)GDK,JZ0XJ
M8'^:M(- KTX+9$^8.NX3+H50LGNFK,6<3<9%90M1T1@7Q0GEUN.E2@X^FLF6
M2VI3##W;$&DR(<R\M?3^[:V68M9V_Q79=&)7#MF&J(['-,TH><8>C93XE[B-
M7%JKCNM9R-8)/2$&ODL?YY?#4?$R.SI=JH(@8H^_VY LZJ=?';:V*7Q.XI1,
M]\/Z] WW^5A4Y!&JU732&!><[8'+M&B><'/1=#=6B[T4LV0$;Y"1NW;(9.=W
MKIX&C'7@K*/ XC#IU@E$M&*&%1K_J]X[3Z% AK(YY%73O4T=!H*X]'COT/UG
M F6YUT:X<!Q8;\?1 'S9^=^.WTGLF?N8S6WE9[/ROAMC'!I[J+KU98A <*>$
M [$4!P*YS'*2#; Z%O8)@F4?![51<E_<^*Y.?=],!S:I@JL(/L6S(YO!YZ>(
MB(V*UO+QFDB;NXE&#!J/UBY/"J)2&I1Q2(%9^$L:$(% $Q9;C_AC$5)?)C;4
MGZJRZ?-I)=\^#@^HXIJA4 .BQ#Z<P!2.4MQZ0BS'93XIDUNHCO9\)5>]U7+B
M+IW_D\TLV0L(1]-3MG"M 6TMYV(WJ_21C,\*%:"8Q+=KY@[/Y :4$SN?SJ%N
MW6%*<0EF)4 V3\V!^. &0V!)=ZK8D!Q*,<U@<'<<'NNAX?$^+)H3].$-YK).
M_$-7A" YD'3=%<+0P$D5K\67$--_K1W8C%9.Z1^X/_N)ME0DGZ]>F"]SGRC#
M/+[OL4201T<21!Q^OU3D[AQTF[C;<*?.1"+N9N=/93'RA]=[9;K[D43/N6.\
MP:>)CA]M7,"27_O)D!>XEE8'H;@^<-3UA:YS<VGZTEEL@#?X3"U!\<>Q,XYM
MTV2@*H]JVV(IZDW);ON^ 6^7K.-#L:8'4;)#.^$.]@5D0\)6"7Y+,<IW%,.I
M@#Y7+[(B99]W+>G<U-5'TY526GN] 84;'?@MA."QPY0CON:CUI<2'WD(O6P?
MAANY>2P/.2'0CK> \I#+<>Q5J_R8\L+]X##X!7<"J%6-2D=Z4"\F:AGK KT$
M25YV1*0E#JK0+1_3HMD8*@3^DOC:%07K:'40'/!0F5;#JF1*'7Y4.TBR/>N8
M.$RG,3DU8AJ&UH0MMV97H")>NNR18DTYH<3>!I!T](*99,^)SA\_6W??)-"A
M2L@@?*0)WK35E!]6_6MKR3B;2[[.V%UJ]B+=Z8>\4HS^](W^6QDDD6-O@V4O
MG6,<434J]:QZK[KB(]J=QI]VBS2<=_'RGZSW.1Q:M;\;=$DJU-]0MI?3BNU'
M'=$O386GNIX4KTYL-F62VTQF7>*R7F7E?2WU#*7*C?HHAB%$%#U]8B<SZD5U
M[QL;1Q><GV-.>LH<Z"'N.,@W2X3N/S%&@%;02@1DG*KIF74;7GWY\RA< O.F
MTB4[N0?/'FDFWPN6IB#/CCS3?NB>#SNPQX]&P*TUZH95M 1Q,@/9Z"X)MD[!
M/U?G?C/]#!8A1,9Y@H7(J@2FV&VX%PY*#XD<+DQK%LAW: E<5A/#6FX' TWG
MT#\I[[1M'\YSO%9+$T;$;FL[\S7\L<V8OLDAM<6=#SKG-53G?!)ILU )&3^E
MS>J,Q<ZAQ-R#!= #E?,%73ZG+_U4/#MC)R3Q9+*6I^E$H_+<;+/\\<=KR0&5
M]8SXZ^X9Q8K'QE2^-#5E>,U?Y,SIN>=7<CC8*&6H!I-"V.35^O?:9L5DK;!N
M_6$YN)#/(M0 C%VL_YSY,_N:G6D$54;TD6EX-?4,@5J/NF^$.]Q4P(YPM@1Y
M"(7434PMOV?NU$(6H?*#S\.YTMIG% 8:K'-A*'.\9]0NR:]2( #NU5W1W,J=
MI#]7\B!!1S;M-^*Q/:M!P^^J"U6;IG=&=BF^IIQ3:Q;,K6D'BJ"T:$"012#'
M[@[36QA$CX#<U,%Y1HM)-1)#RV!J'!QKWJN::LB"GD7YXFC$R$],1SU*!YVR
MB#CE@Q0EFT7.E;WVF9]^-JQJW/M"Q^'/Q&:J^[M'*0!+R\==G5#5";)E1DN6
M*+&<P-,+XM0^%5@"JNCSS!T3B37E@G]0D>,]? IC")/]C7@"&@^8;\XZ270N
M@R7@UCKL?UL=X>2OR #G)R,F%?3]BLP&O^<P!W,3DZV)7H3P><46VVP!Z*R+
M#7\\>T7ANO#NDO]QH*"D8%E.ZLS?.FB#J2<T^/C/85A=9G3PJ.C@<T2D5?E0
M*7@<%W@X(2],$;,3?"5WC7F\.41V4V1[''5]&'R6?(W@,4Q9&"#VZ2/U&KYY
MH"TOYWJP?W#V&VE8MZ-$YA,0X96(4^XT@!=N4$1T-[CX5(Z!4Y^S<$JAR5MJ
M9K*(_A4QT0L7N#W!@WLUPUYGK,AK.A?+7_%H+6[@\J]6)W%&\0_"&?L^A/UD
M=X*C8;^"ML'\-@LQ##;#.LL!^ZW:BR[VBO_Y(+'6BH$G<<C+81J'''=NF5$@
MJ$?M91I8#)VN&XEFCR&TW[W!*C#]GET)I'UD&2Q$22_\1DB+U-;%99]9%U--
M:XEI,0JC,C\R]I6M">0%ZAWCTH&#B_\@^^#GE!IM3_6(8$&]3S8]DLIK@X<B
MO^<7Z!4*QQ)D=W9/ TPW21 J"UL]"=0,FB;98;*:H(*C74OF+TJ?=>S,"EEE
MWNJ^$Z@G&]2DQVN="@=RG!H1^T%$#G?"-QVOK;WWE5&[ ^\OM:-J.8VD=2['
M$(Z.,/N"G)GJ'0C7CG&UMF7$]T7T]J#J9/@K-RNSI#IP1B2^TNO>2G.E?^[1
MF5_E)$VXUM>!;852JDQL\</H!4-X+=47>-,8F"7+-(?9V'$D&#<'1$:I0KBR
M.28FID4>_(PNKV4Z_R[.IP3#B<%>5W_E R+>>/3>9SIOHWX$VEB?W=AQ:X0&
MM&#BQ7CQIC]Z(3=&&\XC/K<_@W?1@!<, MR,G1X=X:$).B7]=W+6)HS./TL#
M5PMJU\%FG:^TZ4GM>GPZ@EJPMD*/':L*@I\8:%A#6/!+K2O,7)Y63(E2 PQT
M$[QG!^I-(,<!STRY1"FR%5*MXMXX(H-[\5DS.6+.FH]D#%?#S\3FP0+;LX2J
MJ#_+1RV[Y,//>'CDA)6025:O"V+A/)0,R>&SK!Q1<(<>8;NS(M@:"?'B]3 F
M"<KGFYDROVX^[W>G!+SY6JMY)>9KR;47;0ZKC:4%56O>$ X:X)Q*Z(C2OE9O
M']/1?"3_,W70[2?C8]E!E]45M\)V1$@R^6+%X%X@FXG/-@<47@[59V)#XCH$
M=;Z72;?P0"?R/7SX2R"O1AX'Z<\,CS],4>Y\ZI4\*(6.HGQ, G'!3^+1I=A3
M$E5XU;)A89@5]]:CJWU/+_0MWVO.O/CV_'D154I0QTDY*0Z>M.$/KC9FUK/V
M-$ 2F>*2&_.'HZ\Y1B:'(X\&/)P5ZLDEWZSO?_RA-+7 ,Y'#46D7<O#+?7LV
M@-Q)224?.W\P_Q_J]CL2-4,8<_L*JJ0G?U&_+P^24ZM0N;;X2XDDGP].2HW9
M,_W-\0[SS)/'/5B4B/@H%?O%WN7;K%NYK;&7TR+H(5/<"'\:"02K-QM\6.<9
MC[X8]_,S27]F[HQ/"0VH629'47F$^LBFXM2JW<(((VK38 VBCX$&_-;SG_FE
M*MME;'M^.-MUK[OV3"''1?[;MZU]3>I5/?IWU,F7(V-IP$H-$44#SN11!5O:
M:,"N+=F:!B18#YO?^IJG]=7RSOUWNX#?%^@IXOQ5PG!<6I;8B-Q>QKVIUIW[
MMR3O/ASBUAJ9M2J<)""6_!&3QQ'S,I1X&M%YB/F7WLQHP.F'.!IP)$^5I0$=
MLFMDT@A[QKP)T_W1*GGV#NN*NA&5Z4]_VH5TC3WK/^VM*1L,%^^3H8>1^_N0
MPU$J/>@/^-EQU'.)@*#PTP ^&C#_%M$B",-08Q$Q-(#0?630YJ#RF\Q:V('
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M5=C[-02?/-96^CH7[E!PS^$<X6YDI+9BB7M%Y[>QU>H_4[<>/8#%&STY(L0
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M8K05J#JMHQ[QNLXAS:=T.M;"R[\$/.:1=V\HO,/J6?@J5(_\F))--IW?GI#
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MN?#OG^@AS5=V<SA<<S^/3Q1D?E$C)#F^YE>5>_&<D=&TU.;_\78F1Q\'4<Z
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M;'&[TA(3(>#ROV[]Y1?DYW"\HP'_35[EU5_>Y,;B<36*!F0&UK1X'G*2(33
MX1)BI:K,$"'F$'5TO//$N"!BH!\'^_7X1N K____:/A_6N@.#VC R7N4#S0
MJX W0;7)"P_?+LQ13"G>,$VWO?[\3!:)XQIUV%^=S.TY=P8L14A $2!65=PV
M*WD;-M;O/@A-P?\H%K'<) E3] GJD1OD^UB*L?[0N?M?MDMG9BQ]3K-\E2CP
M1C &<ZV 3E!%5X/9\%.F8N\?B+@;OMC:,%:^O">9#FRM_)5NRN_\TJC;.G$[
M:=*SRE9$BKK9UJR/L+@J[*BRMBR DWZ=_9J@D-!1*$  4=*K-Y_E-L0_B;!,
MEUIT4#M=N**GI629/%:NQVLN\Q_S5R:YJ3$W ?W/!U;E]NW]/<(](J>5:AE
M1:K.,2;H71Z98EGE9JIX<&?P20+FO;8:6Q[TLI/RF'JJ$-+7@084P#=Q?6/.
M[9HF_<+G][)0[G';'PX5=R=_N6^C7=JW&D;Y;HD*U]5F7X['_L2<.2QD!:_K
M_D$Y$$'S?6R'?4%8CVORN"OJI\06P',Q\PN#G@]?)-V;EF#/^7&L;.A7$^&N
MEG.)VW?4DEVE=&W;#>IBYE+O<WSK2R[Y ?/7&B@:_0P!3<SX7'&1LECIOP3I
MSMS7RAL86* !DTPT@(7B7HMWB/2_E.ZA,'+?.F2;);D-&JG_#;EEVPZ9._?Q
MB?V"5T=(U<'GU95@<Q<(F[8M+J3#"+]4 !?8]G^>!=&V+B!Z[FL<\SQF7):M
MK+T2_Y4G=1G<,GN3,10A8Y<\[*.[1Z<MZZ_O\C4H39@1,YQ1$7-P/O6 ;R_(
M'&EH,6HS5>AW?L)\:YHW+ PK KZM72L8H'1 7E^!<A"A!OC@]-3TNZ_1[YVY
MYR1=>$^*%9+=7PHO@\5A)G"?N6GGEEZ$=T%9@?OY\H:*I\:<#\.L=U W,X5?
MIN1\"2KCD&U^X-AS/=TA*'AGZ:]_)&BZ2>5? PFJSIY<2T8CG9V]]FUU GQ[
M2WM0[((T@%%$7,P;>O_^K.T:?[G=A*EH;\-GH?/1X;+TO\,T1W&@S0ND$^3K
ME*R)>?,8)H+SJ[MH>ZMVI8$;^7/^_0G7#H3$]I D]>!)!.<QU=;(K1S<3L!@
M[>=[?V\OR N'^/_)^.*\NFHK5DS"Z,$$-I9)3G^%S+M[)@)F]EK0:R0*-^65
M'TN0=458@&.VV\'$WU;=H?4^E08D@IH1^V?"CT8'@H4=*:&%!.24-#5,=@E)
ME.'M\ISC8#629;@Q@G5RT@;HNE 6^(--.OS1I/ZW!"C?:O<Z=S&C5Q.+;%\<
MEF5GR;<?!+7EL.9Z^[#Q[9G2"T\SU@+:3814ER'X?A [9N7I(&*;F$<5EL".
M4MC2G2DT $HH0WF8'J;-P$#CQ+[#/<7OQ^-9&5?5M>N7:S#*FUD-2*FS'W.X
M\=N4(?SB2@L#J+D6271!1D)WU5RS#RB(]O];[6]]_8>N=BR"FX*U\5N17V &
M31CA*C;6'\*O_ABJ^,NU(ED,7W2"-#3(L@-[F#%,RP'BVR1<:-!'Z*E\]9=P
MB\<SLRY30OD7$M_<AO7QK4+_B0"R?40#XD'_6A6;R-Y1;(!4$+)WUJ#>?SU\
M?.R,'RKRNHM=QJM'P4T(YT3UH:PJ=YI</0J8'P4^7OEPJ25[>^_SC"0E# [%
MB2I:XQ=F>?-J\64%Q=5YDG[I-WM@ZI>D%*]4WYQ/J-J-)*L8M*".1%3Z2%3,
MO,&_UJH+R3W;'!MD*/DH;8H&=!X*[+<1;ZE"$[(K,*$-6C[>V'58:9F\W![K
MO?'>[+2O>8CYO&*4/CYM0[FH"\<A0(S$22?D$SJB5$O/5I:X'\K#/U5TIW"?
M5I<6%$1Y),\OMVA\2G FJ"5+EE.ZA/7D,+H3A30@(HIX3(%UG=[3 ,0HV65_
MB :\#\)2LN-H0+8Y*?L0)&^/:-+\OWA[[Z FOV]O-(H*2E/I-2HB E*EMX@H
M]4OO-2(B)13I 4(BHH"T" H(")$N4H(4Z8ET!>F]DP!2 PDU0 @O_LXY\]ZY
M<\\Y]\Q[Y_ZQYID]DZ=]]EJ?O=9ZUEYIM"R&\K2JL0ZKW6V9-(R\8RWS)7M@
MY,%A18>=Y*SVO$M^"+K=<"*H/4N$_!88VRBQL+*K@_J'V[,C U%8.E/L_"#X
MFA4E[@4S?_(:\'\V 3\;)8X974,,-Y;PAI%**663;[:B[T :9GR5?7BJCBL2
M6&XS?C[7O/@<&0FL0,;#1!<DZ->HPN0/]7_2<%/>E;9N^TIF@;-0&CIGN%\"
MRF!O'?L_N[\3OC/<%A_4BKA&-O8&54Y95B3UVWO,+7EQSM0(R.YLQ8(<:TA"
M/\ 7H)> [/>XT6\DDH[&+$-5?PD("T$>-W#V*F<E$_Z'2M>IQDOMQ @0YSI[
M0'ATM J"OZ%8,"^EQB)Q-8?S$^>^4&KDX7FDE_O6RU. 4S",@RB/MVP=PF.K
MY>.\-LLLC8[YYRH..Y4#O0Z_[;&MS?V7-P?]WRUMP4'M)/H/J:89]6;V K\X
M>_Q\8<USS#'[5O7A/X6;FX=^-<-[9;%MP I8_3+A,A[]MK5M5G<]Y-S I8Q]
MNT.AGU+!&0=^8PKM(<#_0MGUIDRIS@=1^_#[U#"]3<0B[#W)&X=^C76>&Q\]
MQGG'_MUK,[/&DS_XI[I">-E>^"('X-.3EX;5(5L4EBD<W]99K/523EYII%(#
MO;Z=J;G<:W+GT9,+/IC@>9K#L;PU%#>&=5W?:^QH/Q8ZNO7GH1<7L-O;."L2
MC9P4P V^I(W9[5>&G_QO98_]=V7G1_;\7TGN_]UL#1P8I^\@_H.^L <4XU,
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MRZDX4.SUF77J!2B,!_^67IOX%9%M]VU/_8#YN)9W;#!$ZZU*$*B]QU*OL9^
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M@>N=;Q,O*M2-3>R^9Z D_8G/97-KR_5$.0U%[/JK&@C\^V] (O<9=G!.GU,
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MDVT>6QW5;G@-)C'4R"84Y86K3C49*]THB^LO:<!Y;!IG1<TVX6<:?PKXC7P
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MMBA.MXJNIJ=5'_]9(-J-]291>X,F%^<F@=<:O0.^V&7IZOD. @M8OP"3 T.
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M(#?6$_T6Q'DOX"QT[2DS=,/I$4P@M9X"RL^LK!/&K:,$ :JB>Z#]1>(<$B,
M Z;^0##MM@85D2.=:QKKTQH;H&):TK3OR3J'/KNR),0979)OT\8&0)ZE=JA)
M?>N?"N3O,XR>3G$@P\I (@ B<D)H7XRD15 L>ZQH725QP;;VV*%B8.&W47 "
M [%GJ]^20-N"?DWE(DO,3TDP0$W_B=4?$C,2OZ9Y:,O;4&/AM.9*UB#V]LUO
MM69RM+!S^,U-KKXXU/'Q9=6FO'__DC:$\*]ROW/9#Y=I^%8#XR<Z9?XM^7G>
M287_L=C9\5I6KDR5\0/&245.3E6WD!?"KO_])M 8K"M]CP:NAF"=#RV*FB $
MZ$O=(XCG 1MV3)4_H+*WK.&2I)+TY/;9AN)IS6RGZ=^2Q=5: ,LQX'4U7K+W
M&2G\&:#H/TVM#S[Y8T5PC:8*.G8E@F4I(/(UXE1'EDC]H"S]<:G%D%X&=]BG
MH62]#[Q)<[/-A%5PEDOC?4N%MI82]^UFZ]J#&J>5;<I@UI6,V,)@B,L:U+*9
MT<6";+I@%9"6PPTEZ>?.K%;8W;FN3>GXJ;A%<(A8V.*\6#T2T&,3(%U_'R,I
M?UWR/'(5; /[AZPQWP<D6_ IMX5XB!:X=6,N/U4SM7G#9QREGC"" ].I7:(H
MDSH:#]+CVXYZ>M\KLEMP2*/N=40MOD.34."6NDKQZT4);2:?W*OI)FJ/ F5;
MEJ^V#F6NSGJM40NCX#W4>V-PUIZO*T./9.(UJ9Q;3J]6)9W#.\Q_J)Z(6N(#
M:V\29[/_/,6? HSOT'WF;:S0]OFQZ0M9ET@X!="I7%M@9#GV;I-K&3S0C96K
MCV_@7'RHMN9S$/E"$O*:3$MT^3%[HZZ"E(SGTVNW* Q^A3<9F)33MK Z\F^F
M'8USH>OC2"B,#@!7QAK,0LJ)AVUW'9<O,L-M[$B@EW#0&)6?;&A,=.+<G='L
M-4FU,+VQ8^H;T;"FSM9.":QL)#V/*H J:[Y2/@5<A1S\@GBZ:\_TZB \G- %
MD/4SAL4QAWLE+70<E)\A]^V&E;AGWETON["1 %[YX?U"V#FRZ+R]_,:L3$74
ML66;;^?Q5$,10[S'HN^7PM<"B5FU7XM: D2>O^CH+7X148]TU))_+5F1RVGC
M.X!9[@)7HA/V)*(<V$8QW#/VXFFEK@=^MN#)[C<227#7G5\7@K8<XHG,'7+\
M0')^&5E-[.$$;J2T(]_;(^F\R9/ ^CC_>7^TQDD9E8T".N:%*S0-)0%YQ<6J
MCK_H6*0U1-%$MBR_MW-&_@"?APKAA"A"5)HJ;[+.[FH.=EA"*/ ^7YX,B0#R
MOQK"-+*K"-<SI4U7>?IU6A 1=.;^SV<9W.=BT*0?#Y7)JS_B G'(*,J .6;T
MEQ(]0V"+[Q*D0^+&F,:]/N$QX>1V7K4[Y&"W8MMP$93XDEV@)A>HMY'&=9%I
M(88:TPU1&F8[<D7(+%N91[8K>XK] ^+]B27&S(@F=UCRY_UII,?+_LAH_7XN
MP6%VI<3A.)(S=/Z<0^E"0U$ @F55Z8+^-_O8!IJ? +\CRY>0D*KTT>Q045@*
ML>OI]RC0/7?.5V&_.FTVV_1FXF4;AJWM>7I&5I %V"=8\@%I["3@[$7Z;3"O
MR,5]K1*LR*,HPU/ 9^[#@WVF,R5<P!ZM0\[&U6&T)#VJ3F$,8H,'1'T).43)
MG46VW:> ZY2^M>EBZJ-U"BB;F+HQA6<4:$6PJ-P/+OGYS8:F^O:[%R5F</.#
MOL[GW-_?9*]]-ZAA%R$<CQ\"Y<XN($+!5K_6SYLJNE!D)*W0V24)V:795Q\3
M))T"-@Z*W6SB<M;L%=.GM:>S%&G7P;5=XK&%EOT4YFM SRM5J>#^/]91M.'4
ME9+2D"-](9VZ^NCP&T!A4+*[]"',*;L#$DU.A'?SE2;)R<,V1#>$.S-S=Q1#
M2\L*SWUQ3QRWG7$?J^A(M,E^ET;;]0SD[[2>OGH*<#X%L$$CYE%Q O4C3M0V
M?O%*CGK/O=$+0=K*#/M_>0-U+$81)2+:MGA_%4 Q4X2WA25!W[\G+6KXJ!EV
M=>9Z O@*R]:.11= S7U1_&K$RY6DE%AW&<8[$M)<-\&"I:Q,B17S7U9_S)/.
M7.&8X)+"J+CI8']]_["!8RRML748W=@'KZ5BPZ\;L P23Z>1>M[:44%N&%O[
M-*GF9\6EH.>< '%?+=E?9&8=$G!C!Z_'N??+( 'V^&E-8)"QW##78BY_)U_Q
M./9YWROL%8H^_OF(MQC0:*QJ@FX0CWE.O^^L8#%U8'>TUQXF2[)M@5\G242(
M+Y "T[Q#\Z;N$"O$N:2&''F+".UPO7"< DXRV54WUS>C(=465?C4#^EMP6*D
M*[7:3T9USDI&&0YZ+2:M>E7K]<TT,Q&V#06(EVB%%$N0D<5XX,O)I;XW 1-Y
M_=5Z9(&&\.3]DN@%0?F@)Z&!Z-RS  <9E77EO7F8R;&Z.KXV-BQ%[^?;]G*!
M[KL\<>'39XX]N!-)!Y5OXV?*6FX/>2;?,OQ\A/0VQ1!'UYI5B\^E;R:VS']U
M--?JD8=[U8A@ D1&<,;--B*C*S!'$HL=RZIWKK5VS>1F"7YR=H#I\+:+@A#-
M^O 0AHT<:TUD2@V=Y[/8M^<Q&WHFU5<HDT%3Q#4-:OJTC\X_>RY@%)6IVG*4
M*987+C>1\:LL5_G'KRL#D3A-26E,<M&Q-EF^.3WAO7?1VJ1*D(. Q51!S_EK
M4N^GD8VTV46YS>79X2E,;#8?,@]3J%EOAOL$3:]^[;J<5^JTR RTGH%I-Y83
M)2);P.NIVQS"7-/?<HJ$?/CNVS._I 0$8CA. :]UM_<]U=9U0<Z-@P5A#7P*
MB@X+<6,C<P 5^GEOQA6Q,)SG+5%5 W#*R9*)%[L=K$O/]U(HDRCR)+>1>;XA
MWJ)CSU^VEN399RWF='.6 =<=/KP0E^6&82JHV'OU1C/=<R8 L]Z/)'PGB3?.
MIX>I,M,1$Y!"[=[Q68R#55JV'ZM$![ZZRPO_]KGE_["5C'0_3C4C8J/V)*Y:
MN0>-ROE!V OE:EANI9U-GW\60F29R@B5;YYE)WZ@;:[WEY,SC:LS5W.2?[&X
MK:VX[@ D=9LUU9R48MC5V88'IBK5R,8_M>;W^-97MQOKL_1>17)SYQT=>'1)
M%V7@EV4.P:*(VVBG==E5/7W#6JQN0-BUG>S_)GO]'W)>DH%.X!;&_*0 ,8]"
M,%-!8KW%SAR46UGBCG4!HG0_$IZ? @J^[7H0Y0/8]NQ9SU%.8/XG'ZFWX#WU
M!\GX,''74O:'G@'=C#V>XLP,O+Y1A;/M09@KIX!743!G(CS^LYLT-$;?HE47
MHY>2-.]56_?RQ>CFR7!"UB=+ BA>1<)MP9M^+41L+S]_@^.=C(/YQD.K"G5
MLL G?L@.A\79952A?_2*GGTCA^.VD0*2'.R5-*]\:;LD[]+LYN(DVF9X%CA:
M9UC:)]E^!\EQ)]=WJ7SO2R$?]A\7/X.S38QUG +*MS:F2);[=L.R8"9RA.7@
MWMS%M2M>.7*/(VSL$IAH_"(!+Q3PF)^?F2!XVOBJOB@UYA$5K>*N6]_*H[N6
M&_C#M>H4V':$FN?HU\XHV3B,Y-TQ %2;WQCT7U[U9#8S4O9Y91A2?:P)X4!P
M8*2A")Q#5J]_J6KN<'4\JF-NN^?<5H+.I2:-]II$*$(':5AEGJ!P58,;31.H
M*'N(8G>YUF+\22+/?"YC!:-5DXK+U+E=@TC\#6UHN^X^%G_5>SJ[F;X?I;XA
MFI6[_BL'BR2-=WU<VRXVGJG<4U'E["_(9BLW?LRVS/=P3(@$UD!<@\F3+L8%
M7U>ME"[G?8650^@N4^]!'.X,[/4QM.>M&[F&6.3[WMOT]KIQ7;!!_DK/AF%^
MT/JQ$$QW6.Q/A#DYU<MST:2VJNK&.TTF'3XI,)J(IG7RZ4UQTG1[K -2Y=J>
M2''31,I>;I_)G0*YH%ALR'/SG:^KS>)Y N)>5++Q5CDY@M+'\O*$@7=CL.HQ
M.WTO3P&7Y^9K6KL-Z3$%DSE3/S<K/DP"GO<"*)"!G7:$W5!LW/64Y3\FE2'T
MC]D8WM^^5MEP\?'%M(_S *7W-DDF[QV&GHS@!_.&Q9R&"S1N6WA*O\W4LKC\
M*7'+)N"P$+]U50>/O 8=VX^M;'+\"G4!1W9J#=G@-'0*'Z[57-2$KU,ZD2%'
MG7B73L)3$/FA/SCRR!P5W6B*7W^.J98/XO'T+$TVS[*F4U28>4G[PI5F)B_1
M,3YS_-:77\\5 "'I!?6C66/]$V(G=8U9$FJB"-F@7\"#$;\DS$+,H<3"7#Q&
M7/]8$68P!-,J< MA0N>K7U;ZCKJ->7R2F]CT6=7BP0LZE2?I-<2QMLD3-!+#
MN1*2%?]YAOP5 5 =R?KFY<QO$T>7H]QP+7[VL!T0%O 8U@ D^ 4S;XP$+T R
M1=A)I06?)QDF5=0IV47!#6R7X)YYCIAD+(D%[](N=F>[3W]P R;QV;8@C:_G
MX*V*?F#_Q$E^Y#]77_IJ[WG; /:\^6":Q.76!D\E\+6U=ZMOO]B59A9E"/6D
M8=88:'Z5Y?-9:TC<B(NAX,C-)"R8O$K<:0E*FEKY7E\0NW N?Z;T$UJL85;X
MY'<BEO30\GU"F.A*WUMLE1P6)\%%#L)U1*HH,\=LRC0C$,60U.>,<K^9Y!*"
M[E^7ILUF>^VN:& $@<"%BJ-;'J8P)=R2;BR8&8,H W4'QZ+@O=BJ^[ G#21@
M5$"HK;(A.]G]$=*(V_Y'5F\ ;".%HT_$IW];=!KBU_6W70K+JK5+&SL].IZS
M%SMYA[F*SJ<O]9/+3@$THTUNEGW :T^O9\ZYVE#Z8<3MNVL^#NJD]YVM.L2$
M-!)'RZ#MK&")[WV#5JE&6YWQ15_%$XBP60S67R\,Z3\SFYB.O:]VG3HQQZOR
MV']RM/ D"W/=-L?&;?[<=Q<UJZEIIC^886+<(,6I.M:*7^K^R@Z@I\#-_9I:
MI"'6VK3M86Y5T)4>XZ*-3^]3G89 .*'!Q@6._?COE'FD;,A10*G@DRXZ1=K\
M%R%[V$@9!1:=6*V8H[7'79.V+=P:U &OSNFQ^TX+#7-TY%@]XO:J_. IP)U=
M;C_)($GG?'A26\2[K#_UP<^J0WDWT:)5U;NJJ0%*=2A&\F!KVUAZ\FO![.&J
M"97B8LOC@21IYEJUG/K'7]T[==UU5P)8C;4=_Q\(GD:A/5BBLP_)#KJT:W6S
MYK5[UMWA2OZ,_**EJ0:,THU-2!.I,-;_%'".;&LZMJ>H4LRG=BG+=/KE_?!-
MR!+Z-3?C<D)UCP9^+.[I=7>E#Z_= J6W4_J1]0#5E\MSLCTVZ%M#?MSOERQL
M*YAI*1S#,.MBB7BUNV#]KQ .H(K<(YR3QD]S\+SA\%CA+%@5^SYG9:"UX''E
M;X0@0%L V*;E:\CF8,C*4QRA/&4P*B:1?/*Y+=@9D^FS-?AE]KY83?0TS9^P
M @76A(; "&1OXY="Q37_>4GXU#7.$=MD+UE&D5[] 5NYXA>%&1FC8GM3*Z*&
M^@D\?#:LE88B?48U\J)TH'OWF#B9RR!IM8.;I9YM@YT5 C]Z_$,@[)A^'C*\
M\QXB 6?/]KG.7ZU5KAFW@O/6N:H'\]0L*A(Z.DCS?.(W*D,CANRH<!K;XW2^
M3C^A8_J)O1=>/> Z&>)N<T5/LNND_JGE&,.#KUEWO[WB@7)SCMP6J[K(!]'U
M.;@VEGQ\%[? P=?]0KNXS,9.DUWJJPU7?CS4Z-?(RSW%/U]F'33\Z!WFW@J&
MYT-+-\R_YXI\8D<8N5.S/?>53RXJ=Q9,NVRS)<MF@*W((73-8O?^"3N4??TT
M4S,-[T@<=G=:[JUZ./6K$"QWB]A>^85ZNP^H8?GT9:[\OMF.1@#WIE+8@I?.
M@XTH,B0G0LM3;>Y7O!%GASU;^!-5[:^6<O" I;@!TCWIXDO[FZ+Y0W&)JZ.M
MN.)"SO;;YAGV\?X@ F>NBP+@X?35M@6WW<41VY2D40V^_09>/V03P]7S FII
M6^82 &K;Z#[R,$:>&J^;7VS;-!:-OA7GG!Y(LU.F:S;4U"<@W+WR5$C6=",C
ML(;C]X\)]_W)C%- WV73GZ!P/GT/-_BMK/U9]30!U^EVL<;YZR5*$78CG6^R
MZ'UD3-DSZ11XX>8EZ"5RAID3M61*78I_D:]SM] &)5(OW5-QQ/HT_U$A7A1(
M[WZ=WE/K04U]G4]MZ8=0P<XB@?S@WH9C$)FC?9"E8.[,(W40QO,LBE8WH2)0
M^8$[[BQN1QY!U]2Z2Q]:IN5O+46\!B:K]3E0A]-YPBPF>5;&-YBZH_XY,!T?
MC.?)^UG8NOF=S\(VRST=U(%X59OZ>*RLVEY$[6+3ZK%S'?AQW^^(.;;5OWUN
M/?GN;.-5Y3O3G<@6AQE/&DV<*P-W9^**CF*F4I2Q5WZ,'85MU"C9(=8)SQ63
M!/=HR4T[9BKF?S?T\*M6.WZQ%LS;EN (C 8H4K?]949T/]BC$:;+Q<;HB%31
M(+7PH3U1>YM!Y6+1Z++2/)XD*SLER;T+YN5PAV1B>U-4&_-$D#&UG[C1:4W\
M@$SSKWDZNBUQ<A^T_>ND]A*FG&Q) JN3FW#YHS(Z%:R'07)))-FJS(&Q;]2
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M_: 9W''7.2 6R  342OK\,Q5J7=@S8JDB))^KT33YTGV/FR#G3(=LCK@$!U
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M>2T\!:KC%RQ4GH_D+#&'KZV\^>Z+;5@@OP&_AQ\:5P$I5\\!6X:T%<-VTN<
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M$I= G4&G1DA$78 /M NK13ME;N[T7I=L7AZR=NB9LM6^A)[. _V]:J[F< X
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MV^C6H+?Z=2;-8G*'K6E?P.XIPL%ZP($V7HD_&#G[X$]:>+EMW>)S6EJ"?(E
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M0?Z?5,CI: CFRKS5E N<V<_"2L^D_<"S[L76O5PF]+OC*+G;9D<MY?9$R;8
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MU%9.K>7%[1)]]G>9\BI' ]2>K!M^("S-DEDU'L6:)VN6IB Z-%H>XRIVK36
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M6O]OEV[N(SJO3N)0.XX%;CZHI#QRHX%,J0B/.)8]0FC]G<&2;7R]O;>[/^]
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MM5W :MY7P8X/[V3*L]P=XIMEPCQ?J_;JS^W%&T1QJ63<@KVNZ.71R9H75!>
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M=A8+8W-]B/+^H5VL+W_@Z9'G.?0(B PQBR$TMO-Q?^(?59)$8J.H6Z(Y;.>
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M[-KGT<N(O84NKM?)?UG;D7D'NM#'KNU/9(WX^VW"O5@L#'A4BD.@<@T5G.+
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M_/SEVMS,#'_:ZR=G&JIOZ2'K?L9?EO(2\JTOLPA0Y57R3%V\ 0J^,=)8J6Z
M4W6.;HE+R ,\5U;[*3>"/7-O3274=S8&[L89SC[9<AJW4<L\+%3[/?2\B1,U
M3(#M IMS ]NPD]^\R=LODD)1,Z!-Z3;W0?C3?GR*0_+K^]1.(/";KWQF@973
MT)?B1=\3EPQ&4@DU07W/2VF6]$6*@^72 @G]F\J^I(_X\ ZHE^J-@8IU<Z]K
M>D:"G4A#Z3Z<'"$%0WH*>>]SF;.R$2>F?OD)%I9Q;6_9"G;@=UDUG..5E]*O
MX3O33]D]&7I>*5?=]4]5O_?)))]8= R8^W(,8%IO=1982='+XJZK,WF^&0.6
M02&:9> *+WN\YF:Y5LQ92,[D!/>'F>NQV>#"S@*K7S7^!:9^5^4 "=BSEPYZ
M/6J&?Q9?+2_5OY>T\9':)T]"K-N0P_?4<&)P.7)Z"X*3(F%FPJ6L Y1IYG>K
MC2?/L=;B9C"/3IS;'H$.?F ISE.4XJ5R^_"&7,-(O8OF\YE&S9&T)Y1W^'HD
M,Z5KS,E/MVOMBI:,H.#.BX#"YL;SM$>CB!>8N \P@5;S"ASF'%I;2M[GH[3#
MFVQ;; &=OSD\4$6TN?W%*_69N(Z!.0^NERJCNZ#GPC]&JPVLU:[U:Y5KW S7
M9@L1%>$^S39LG$KN>_//*%1,^LBBM=@Q(#3VA$#Q8K$/K,0H2D)4HZE23@!B
M2-HZJ@G\!88EYB;,H2*M>4G&TT53=7$U^@G*#LK9)QNX\%U/1+2>S]1A^%-J
M'H>0?19XJ/" /P/C:3@H^9LAI_#^PW]HQ!T105-;>^]S/^Z:Q0'X<X. EO:M
MDM'65RAF>4>HUM21AN J>(W9NV1#I3N7M%%_46*INE!5J=%%$J)%%+3.IV&)
M]4+]?C\QZ:T$0FNBG!8\]8-4^4B_NXM@77O$=NL[*8O)T&6=H*/'3&_ '0LT
MG9"N3*'[UCJ92_@2.3<6P6HE5XJ+_ID5,]TKC\BW47=VC8=2I6.VW/5SS.+W
MB!0$>P''44J$9R<OW7\YML(_D<5FZFFB-)L%UAEH%PMH,TGD6C LT^ M?*M^
M_3ZJ(X> )AI/1+GMJA8KRW^5^X;,7+=FH1R1C@$=*6P6#HUWAC9<[:Q:^KLN
M&ZP9[:,>FES*_!3&E,ETL_$&CLY" ;5>_[+CL/Y*Z+;_99L/R/U0!9UX @++
MBFRVEOQH4F+P+FLUI%=#C29=.G]E%0)-@L4G$><+1M""U/7]=#V!&ZT&EOW[
M"?MG1)@&&STI_E2;I=2D'1ZA.-G)^-/0-6\V[^R)7T?!VBL!QP#%P\N#&\RK
ML,6J5*4(0=Y$T\]W2W9/OX7N*AH7$*[_,$P:6H-/90HK:9LEYW^/6OX75;(+
MIRPU77EU1'^Z98CUSI]YIIBHK_;@<EPEEO: ,C*'"2436_UVBV*;'RX[8CRW
M;,LRYE-)F A$A7U$H(#31-@[4AE,S#/ZYLMA90OO[!;>3"T5B_[#J*UL$B0,
M+2IXF(YZ>[A7*..;N#+1O'T[ 8..IC$M6[\6 NI<J/2QQZ3,C\6TZ"28\:-^
M!$Z%&YSH,OX2Z6PI@9=C;L:2[0VCG[. 7*\3I!+1%AU;?97_;$E%*$3R3&O.
MO.AR\^JFM7,AW"PIVVNHR!A<,;@+"BI^N=J>.DU,AAX("%5 A%&I!>EZ= )(
MJX6DHL"^JK _MD=%3*:U'2J'>J'"!GMK_Q393U;XK+#XI01AG$'A_'*-X7KI
M&XO8PY@@QJMYYZ-4%BGJ.[<;Y8X![S^:+-)O*US;/5B5,8P3?WF%8XKM*:O2
M'F!\M\=8[""/^BO^2I/;)]>'WH'V*]DRMUJA8GIE[=@;_<&L_<.URMN05!"S
MJBP,.Q>PHY\[HU\,<X0AU>L_E!AO#$A3?X+,J1UXA7;)2_#7),H('.1I67QU
M8="@"FI/7XV'Y 28\'+J</ [R&Q?[!9I>Y5T7[1]&OG8[X1V6H7'_,]1!U]<
MVVRH *&H./+\R*9G_%K/0Z6C41>C[FH*+Y\1+H#GP.G'?<#+$Q.636E P6^5
MDCSKS@=I_X"^-;4,^*Y"['*IV5'=71\=/)\9VT<6EHMYQ7G_5EUE[TH%5)-5
M+YO.;3TK5/ Z2K@H[J__$7H1J>WSP]-OP:U)BRW3LE.K"E$2O!$_\3=R/Q"5
M)5T+4$DT,ZH^[$2!SIIZVNE?6AY\R\/_BK%TQA<85*Q(^7'/8=LX,6K[IJ$!
M^ W57>>SS3' [(X0]?<9MFEUJ:.I_&/ 1HG< 2; F<#B\PW<JI#RU"_E<^55
M[SIZ=&\*@;G[Y7W>5Z(],.3J54A/]SI;^&B!-0ZD#6/GH=BW8"KR6D&G#MQ6
M7L$U\S1QZZ!5UJ.*U4/P\"PS71;F0<A-%QS<:%7H8DJSN<]\!YCGMH."LD9E
M1<7+<8M("L"Z[H*C52Y$"1</MIP@W240833'*PLN2HX]^K0)]85F3?=<)!\M
M3=NX_U1I!N!Z0"7QZVP$5TX81(N$:/4/3VO%F?OLY<;_L 2F&5<(!GO$<#Z\
M%% *T:0YQ>G$A\PH1-V;,8.H-QC%R8G]?LH:!%B!_NECHG&,TIRI5^$BPS15
MH0&Z $RO8_U0J9M;6[FIIY')I!F;W\X"\ &="02IX2$A=$FR?BN?'X' K']U
M=KFJ3WC[]EON1R9D86I'\1D_(2QB0AV+85/6E0S[4S)"$R?(Q?>%ZY!9,BM3
M%R[?%8RX['/1:P<54;'.U#HC=?1I!\,^NZPX^G4"T2KZ3<=DZ$V&F]NU5\$5
M2]EV:\HQEVC@?!BPQ5RHC34^E7T"%$6S(D+6 NXL>!!8#%Z%B5Y-NOA23B++
M SXN4"7,B(.K4SUIBJ2-O)]-UW%RNC*/$S(:1RO657+*HEZX_3GX,K\87P2%
M!.*L.>G=)%K=[4@"\(J3WT+:4:%CCJ/\6;/164'7E*_7YPYW4&FRP B3O[M$
MO09& "_0M/$!!G#C5_R9+FEOK!\-VWZHM2@7YGW+>$K[/J%<]1ILCZI/PF%[
M&*W(\IDGR-TBBN?UCY +8-5+M$C;GZ%^ISX4$8EYV[C#L,/9ZCK1.W,,V',D
MV\>A66Q_L(#U?$H2)U;ZWDQX-=U[_>W\@9%'7P$[7)7R"ZY&@#!8.H%5A4I'
M)92!MS,EPS?$'W;XE\0.I?MZ"_S9/0WN!;+L-.@8''U#.'%6#WGMQQNBXQ::
MO6!VT.[/:1_6$U)>GM43'5.]LFH PQ#SFK_9/JU&I^B%-+&^DMV:Z.3IN'M/
M,S9:N/DTOS#CU#K"8?.<)?P*(DI<O)6?7VLZG=NVK:NN5IWMZ=$1EC=@]0L.
M] 9T;MGGN<7$TLQ-W*W2L/N[B+5O<GD\3VJ8.$\#DX*N)W$3T+RM?W=;04R<
M H9<G7B.:*G'R343S?*VOK8DW&:>W&QGN'MJ$OHM1+.*8D&<C3H$1]%LB)+G
MK73RN_U?UAFC45<K7;JI)3GLP6.\;QT8-U'G*-V:Y,7PM=V&LW0^'9UZ7=+4
MPW$3?J3!E,DN#+D6,@>C,9*$'I;'=6WK651]?$85IR8G@^2J\>7]VU_]<57_
MUD?=8_7QQ**R!W&="=\;(E]*$'_"=[?E1N)6M1BB+JL ](0")82O_R%L JTM
MES 7/2/?%#$K(R;$:I/"0.A TSZW7NCW./[BFY851(\+E04#ED/>JLMDSCA9
MUG-F#;WE/\V6DY?>]KC=+09=V *R!TZ!SJ.EW]HH3DWDGH7WW)WZC4S7"'Q)
M^4$N=MTH1AL0ZM..3#P6%,>EOU4?:OU^T#=8H_MPA;DPZU8%B_/5?N6J#[5]
M'A]7(>!P?%T2Q\J3V<CMD>TNS^E,7F2^SRS) !/V3/^"17.A/J\J7^JLC<'*
M6=]#DX6/5 1<:$0H3L"W8$+F&F=-V9WHW?NH3G@JXU_3^HM66WB8Q71ZWN6^
M/P$O J=A^L1%[.8UW6N*"M&RDX4IW%?I;\V8AGDV;;Y("+#RBF8N=;FS!)Z;
M7$DQZ9#N)9+E#E\= TX3R&WM#:1-\P&49#K!2O6/]8S(M5*M+[[M_BZHU-_N
MJ5_\##_6V=>_^^U(Y(TR<:">8!GJW-Y_>-;U87"$>3E[]AK;'W/U;E8\WY)Y
M9#W+L-PYFS#3_06KF@ETNI,#<5OL%%NB;3.?TO/,RJ@!A#=2>J6CX#"U-)U%
MJ3BX?/IKB'FA_%@V ,4+#!;="M_;I<R>D$\=XJV96/9<"!/EC"E7B+-%VE0L
M5CGL.I&_";=TXH7J\U=C3PPLD@W^@L,\0$8OU90C_JQN-D!E=0N\AZ#8>I$_
M$CC?P2^LRHH70O@0YC4"@10&2>:O>^U&1]"R(Z!ZK$1AP5['&B/I+.(,Q8#F
M7]1>1&3E.)'_E+.C_5L_\DI<T)[7P*.*"T49, 7=NH;138&JP77BK%> S'NM
M(/J=:/W*N':M(GSDB^!I;T$'J?P?4H ]5!C&\9N.Z5$>QM%99LXD-D N/DSV
MN\3N@<"OF::SUQ.&G04<5+8M*G/#SF^KZ"(X J?X09180O0L:V OG2<%7%)M
MR]$7@<HX:F**Q0J>9J1.X:*MX:^.OHO3U-SRM,F+FKI^Y^&Y@UG#-Z4W^!YO
M2G+WO*:/SO+=) 4,T=@H!J['@'.;H3L^5R?>U\$F53.]FNS$[M]QEUE%.LW)
ML8XA"+>1^*21VU?MG\$N+U+%M ('.<*\OQX#@%5. KHC'Y\H.)Q(Z[W</UU(
MCU5@.(;T#!$Y>\X+:@4BAH<V3N+'Y;' ",_/M8:*]2\2;FOFBNX F^C*?V<.
M8%C,H73N$>?*;S?7?32\G/"?J,"'*BR!NO0N16#,;A\KU(\S3FQBLWD E<"2
M7LAO=SGDEZ'O!-.J=0A5BA)U J>Z1P5%RF<E%E/PL[%(YT]WK^4T3 8TG5^.
M\_%_68$*>9O]H\WA57B'R(BGW0C.>/A(%I=I5A']Z25@?'@O'RXIC=0(JI[A
MAOP: 7%!DU-=D@0]IK#L'^$%"UJ<!ZF(,"]G>5U57G_HJG\DA_LC#U%D8%C-
MP:TUE$N>?57>NO/O8D^OM.*EJD#! 5?9AH=G:LO0H1FI(NP<KVR"I:"/@'YW
M13^O@I@:I6 *SRA HCX73,1@<+'9KVXU5;RM&[Z @PEG'>UA@3F!PW .\AJ"
MO9&=8M$F79-0*7HN]U-^T[;WN^O\DR'@!12-O;JY@'5=-WOFO$!'A.?M*W>J
M[[T[Q] @NJI/N:T9D6)YE  7=]&IF/#\.*G5-[L?@P6&V)**;OW0_=SLWID=
M8*/!;O*Z^9\FP_J3MUMY?,("F6&3!B-/CL+$;\XK*CEOR_ "ONP*OJ/@,KR<
M* CZA0)B=QKH?2,_Z>S7[KU9+J?2R7LLV]D.ZF<[,E^<N5=8?]/NP+A7E'X>
MF0L9@U\9=I&P<1"K9-ZO+WL^(= ?R(6J%G>%Z ]\7KO^M(;%VHP$:9:",>%1
MX3NB,.5W9RILLOC2&$'%T $OBV6)JZ*6]!6V)O[*=;UK4R56K%?OEGD$Z%FT
M!=Z$L"X;6BGT*/&52A8B=@M;)20$T36)OE\[Q6)K/^_+#<(?XC!5<NU1\L<
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MSJE VTKTW>QSELKZSF9($K9R0O' >Z] ><70]!&,$^J<8SH?J3$[V6\FTY<
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M*Z'G)-_DQ:T,XD\GZ%XYJVEX]YQ ?N&G?^0P\TK%ZD@W,0JFCY WV_HB4I!
MM&,^3/,!IG8HD'_I/L\>ZLV3M$Z_@'29*6\0\LG.[ 21$(I[U\A7')GY2S,*
MKG-GN>H\+WP9C<_NR.@]OX^Z@1Y:.[&XM[NQ)GE7)YY:OR*ZG)ZRENI.=J&\
MR>]SVG8;RPG+_C.\?Q?>:+KV]$65-%J#X"S9-,%7G))K?NO;5^9H%7F!EF-
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M]#:+R= "F+IP/^FIAL9#9DCW<)Y03.7FE?NZ3/K2:ND2N1LJCV&HTT=%LL>
MOQRK5%E&)"MEH=2 1\QR0<X)9E'!:OSI([L5;C^=!")/7<<;/P;01!<EKYIW
M4#4#1_B9*(C<O$E/).L4[[2)0R^G0[,7TS"\)O]WJ50LT[DVT91/+U;T+__0
M<YX,[!A3Y3M*V 5Q.NY5S\B2TW/RGRPEBKEIF4D9 0GS)E,GW,HE)>_W$,6_
M]; Q7 HH-/X'P/IFMRV S]4E>8^LP=7R.-/(G^'=<V=4E&^8P"M1B6E5XD:R
M?NAT^V;#=-^G6V1$&W)\@R!)T<HZ!KSO;G&CY>Y-ZZ==WNU4\8A;;PM@)AT#
M"/SQ9%%LO].AW*#NQ2AFS81&@:-1OEA/!7G2M 5:@2W[@^*'U>MGM#;.J11N
M,^_]H"QGP<]08N6_D/XOXMXSK(EV:QL.HB(H1"G2B0I*+])[5*2#B A(C8+4
M2),.(5&4WI2JM$@7*9'>>XF @!1!.DGH-:$&$L++O;]G']^]][/W\?Y\?\R?
MR3%KKIE9ZUSGNK**IJ5%2>"3F/E1D>*TG]45]NN#O+[6X# 6USRNIR#)Q=2U
M:GC3YW1'K(0,*U_Z:M-( $KZ..?'*< -&&'2K'Q2H.Q4[.3[0%^J?8RV@ ^=
M8RDP(21NXS_XRW0EA<PTWF8*ISE)(#,Y(-P.H%/AN0W>PL$/8\UH]WLWP3%P
M6WA_2P6E@*1.UAYNO&VW;.UXW=?V"4&C_/Y=Y<^#*;4GN.B"9D](3;U)BDO6
MJD^ 2Z+-926M)[.74K(U(EF>!@%8E@UT-<NVC Z;MA:/!06A4O^IW(JJ5MET
MF8;,;#.-)IG KM:/#JO_NF+]."D@J&#S_%=R&23G:!7"C6A[!+^^9BU-O/D"
MF\'"H6_45K/^K=@C[G-.][C"GN$NG"5/X76_U)G??V<UZ%Z.SKC(H'$1+-1'
MD/WJU<1#V2VZQ05\XE<J?.!-S+(E6&# 83 U._'40=<H"9O+--0TJNECJ"YH
M''_'*J/<<4_K<>2QXK6E;RF>RW=9% 3Z?NR8V&R81=C;QAL$Z B@BE29SW#,
MYN]I>?19H6QV!N<#37\&%(2+-[*2'L/X"-YQ6YH'-0<B([YV\9828#QUY+'-
M(KG!'TGZVG]$=R2'[1]-]H0I_WZ!Q8+9<L,M/K8' Y<M_4-DE+ERCY]M]$$5
M_4/D2VO #@+? E[U>Q=,_CP%P+62IGARSSDOPMWAI2R#Q*FNJWZ@MN.!%D_F
M"HO5ZG@K9?="!_?(1P"N> ^K"_QC;U1OGZ11SA&16/[V&,^N@+F(+:\H5+@<
MT]SLQ$FBO19$F/$')\W-0%/._ GBM_4#"/$=OAY+;V X!N=<-WRA''H*B"A%
M<O7="G_+9D<'!!R@?DWJYYS%GAK$")*:'Q1;$+)1":3V"Z0P9NAL:S2F^O.]
MW3PSJL<6LJ]U$,7\BY<4L8U849^ISKGOVQV<^A*6T[,K%-X147$72O^->%H3
M3,257(<W]P<?0;<_E635B-A$\(J\GF*^@C32I6\T.;KV\&.H4K@Q]5]/PGB2
MU<B*%:7&#N3, QE6-[Q T2FR<;[NW_JYB]KZ>VPN,OFAQQI0<;/"*:T(9F7N
M^97]< H74=U+3HNL[U90U=6[<5.]7(=J)Y0&![%ZRGJ=8"DV86-FJM#QE7?_
M"W!@.SAZ<@!%TIM9K8 >=V<$92&^K"F.&ARDS9?5LTL^=>WA\DBWJ?N#J1A3
M%L53=_47K7.(A>0^:XXJ7)L,RLVTCPL($Q@^5T>]I/PV\D2&KJC]C9*[\"(R
MAH?WMQ=B,@&3'V?[U=+<<;QXSGD$$_3=T@$<I"CSPL0C^)'.<<Y('WZW<S31
MJ2_I:\V.SB;L9]R$9T>]?1/IGE]+MZ)#N/<<:UYFVO5DRJW1#UTL$S8@FT+#
M!E?5_:"0QQT<:G2YSE_?/!>*IC(R6?[$;/C4.ZKB1>[L-&HVE.:#PX0V)9%J
MYU$+D"P6-[GFG40^H6Z7$+GFD;C[8T;H.YD^ -$I:CM@5Q.W8#(O0&'F%NY'
MO+Q[DH5!,OK5JU_<-FNN3;7?M[U#12XJ)#SMMK)15^&ETMQ%+94J_LQ?'1B8
M[D<U&'228&D,&<;PR%. ?]P9\]ZM.[YDJ/YZ5I*8](7('L^ML9A*,9ZACZ:S
M=@HZ]W;=ZH_>[5?>QAKO+7./>3FJ7F@H[W-_'""_'IKPRI#J\AD;FK$F^F!<
MHU_?P>,7_"-BCUCV6SHR^-O@=_#-G[&BK/=';KTSK-9N\75]7WKOM@'W?1P>
ME;3G=H7\C#ASN2O'\:.?5(=GJ,FH3.X=,Z,LB/A7U3 V5"'E$EFPABB./^AH
M'SO<=79Z-7BS-AV@JS!]C_I+/^(Y7LPBID]RVS;.9(Q@]6JP3RI:G4O=-0 L
M55=15OT]JK>Z)G)2>?FEP%6'%:%^499CC_D+L,^DE_2FV+!852XRY_"57YHE
M5J< Y[44C8M^)L/4&<5_6I5"W0WD4<6KLK&U2V]4A4^RF[F(:?.E)?-Q4=6S
M-T9A^N*A;MB*NO+(<<FFZ +;+U,)E=[2L#O$(0SR[3I!5YV0;JII4O^[U#N-
M5S2A;JQDBUD:RGE!*0X_OX>J4JVBGE(3"=]F5"J8L7^L<W(6*F.1U_PZ2/RX
ME(UMK'[@_82V,3E%JU&-]@O^V>5.H;=B/ILN\KN??VY32N8E/CH%L+38S85G
MLJ7.:HF[*M\O-'@^(JSQ!,/O$-*M <=SC4\86:B[,^LR_F!><'OL'N3L&OQ&
M5?HD*9\ [.PW0H-8]S<O]_W>*$9@.(:+2Z]]#*\V6DJ76.7%9>[OG@*Z0.%/
MB+L'7J,AA]'>$8W&<.5/%-"*HL7DQ$12BL>NT8OI;ZP*@WR1)[HK0A>J0Q4X
MU$-E?$@_F<_!\\_>%)&_6+. ,F)^D!#HX9D_MSY+.W)CQ"&>]BY?U+GD#EO.
ME%)@GM]@Z(LRO&\[@M7/H#-3AF 2@K*8M9JR),K.]H>/IFHS\$A>#>:ZZIDI
MO+=9@O4W,8G0BY0H??HRB)[7O-V>25K+SO#M3<-:8 G  T(-NZ%\ 1_6;@VB
M];CZ?00;U5<?M,///HD>=6"9'?HK2\9X:^FJ^2#_X;6T'6:J'?%PF7"R-\D4
MFEH</<ZA^<:K@[O!5BBE9*<>"?<DFB;#S,?RXW4#>6_:"DK]G%B,#3P%**["
MZ:?[@N91/-!NC5V9;<;D!-_9YUFA]/YA,:B8,Z1%012,7=X$V$82]78J$D>O
MD< 7GH\WF5A\\C)4AQ62;OS5_X_HXS]T5+=30T^D;&D@=+;(4A@5@V[D51D(
MD*C6<6R_;F%77Q-EV7![N<:M00+WP<#U]P^S%5_3ZDUW8]'B)%V9WWWAN$G%
M#P:SZ"\]I3B,RE+!-Y@)7F7NC8LK[+Y''OO-W][A.,>-4M%/^+0!VC]2Z)(@
M5</0@P3X&&N<Y\ZLQ$\K#H_C*FNSDN$@H"71% _$^L01HMKA @0N./M(90;/
M /;7U$I>TN>7--N";+:U^_U!4/*SG%7UH&F;[#K;,J*^3GDAOT)#M6K=*8#;
M#T:L: LX"*<+'7W%7VD"?]/XZ@LRZU8]G= /524B+TG3$0&@L';,@R(>KYG+
M1<+XV2L=3;JUU8\OWI%[FWAUXHG\CU*UL^!)&4&PQ1B$*!MC2X"D.[TDM*RD
MXZ2>R4_7FQ57?'KN+BR&G:$RJ53WF2O=9QMMNO1";QJ:T:<DS3P C)/ JJ]Z
M\:2XT?:K7P):<?O-1E63XJ2+DG59C4.HEWJ'13*=^],][O4D_%BA-WZ\3=&U
M(L<2XL3!'PTSDZY1%1F7/JA+'7HB&;PD7[UT:P&4QG(LK-)H2G=^B.\;PSWO
M\]3K_8I:MJE2G-VE8=^^GX<_I<++M4Y-N7@>S%?4CRBK88$<J[28GDV^\?VO
MR+[:1-C/CXQ?7G'6\QP5K,[1[[\G'A7 Z()$:MY(E_@8<-+FFCIF3J=WN36P
M]=:!18.VN;3I0M2?_J,A1V90X"^:UEGE$1P>N&E(N+C;9:TT!KO@5CQE,;-:
M_[OQ1H<O1RE]K4O!DEHKS^]-T/?M]R65X##%I2I[&4B%7YAI*D5!QK(XX<K&
M[H.KLJ%3Z39E"#>V/L<Y^E@Y<?)MV8R*=<CCJ>^AO^4(Y1(&W!+"EWI(VNBJ
M%J;?G2]P!C0:]0$#AU;%&Y;9Y5[@:T[P.Q4DZX\(M\))5\%E<[UR@1>_M6F"
M583-:_Y1RDB]")E20AM)!QB\$UF8.DAFE?.;WP2Y!P'!21X'LCFM+738:X6Z
MFZ\29Z)90A@NG0+>\D OXV1SQ*-;'&-,6"V#(E^6Z2&\M=A/ >BB/&*/I!I6
MV$J(]G);_B3Z%8U+ZVOH+H-0EX[X1W (7+QPV:8@9T>>0R"[A5=9XI_%(0H8
MBW!K?G93-IEU9%E!S)V1_0Q(F^EK^UOTO[_8)M0&+?*\HY99V+?%P"O$WU.4
M_)P/;M;.#%1W(BKX?T#WX/1=]=Z+]YOX4+LJRE<V^9GV;D4*H": CD<IF,&P
MR=V#,N*B>_4FU%LUHV"J[:LT_^)):_<8+PW]('<7K SSZ169%8_JMF8AB,<T
M&G]9'SNL\3GD =94V'.D:=^<7'EP52V8P;,+_N6W3U5(/I.TX_#7U@]?I\$<
M9Q#@1HO:6"=PS@]&[3<I/6G&NZ2$@;_G.>7(\6M\PB2; ABEXB4O/,$;A(LT
MWX6/@$!Y^/[H7^A"/P%S<Y'O;.:K!RYFYSXP<'T,#A@?.06PJ3(14[J/!R)0
M1 .T:3/#6&7(QR>W0QPJ&^9B[\34OYW,(=[%R[J%!8R'*QMBN;T;37&0JVR4
MF2*5\M;KTFS/;-4QCP,>TW0AF)K%'%-3-G0Q<:$'[LZFJI*A@1:Z,Z(B=I)F
MTDQV/UO$ $I^O K] 9IO]UT<VIKI3W*J8I0><F3LL4KT7<C8+U(VHCK_/.,]
M',_PB,;2=/HRE$YK1T2K'#SKGL._Y@QC\/L"_&D0:2T4U=6'KYT@DB"$V:J3
MIA=!_B_<;/DX?)+8[,[[!ZIJ7/BNL$(?L-V>X3JKPG20AQ_-QJIX;'GKKFPL
MO.W0O7QOC9M!HC53?JEY/'2,$W9DR!<8^ZCKC&(FN6"9I+/Y&+^WN>=X\+S_
M1=-V"J FZ]OBQ;MGKXTWNK#\SH_ @B^:6Y@YCTPJ==E)Z_W\=9=.A_&2BC#H
M\<@6V0*_?5!(R$=F6UGX03H1#G$Z+UQ[3KZ4?4 )Q''6#18$G%Q*O53*N[,8
M<=M@JSX8S&MV# ZOS'B-W9DS&!5UNU.>T%,73&N<20-J7U,PVG"D7C"8]-2)
M'\<@-O8OA$1_%6W4S$.EN%#;,U^[ZODVB:<.55DH&Z=C#CCBI-#1$^BP'6WU
M_&_WZH 'H2U>V<81S2\X/K[1S&%$;*<> 7%6FRT=IP#@%%%7_X._HGE0PL_H
M!7WW/U)Z*I]PJY$'R+CC%#(?I/K!S N'N/8Q$-3/0.BAD/9YT/$JA(_\_#</
MJ?-:>R=25.]]PKA_?] V$#-R@E-54BP>6="D.6-\*S3=(7]5,P7YD^X0@>VG
M  Z8V9T4;+^:B5Q-LK"OXZ35NH60I,<M6<5T%YE=V;!Y%8-G<9M,0JOF[I/6
MQT3F>[2M0HJU@X?W466G #MDL*I +8'F714]4*]^6%DN:^TUQ!(:D&^3>F)V
MSR]9? M_2>62\G@G@>%68J&0L_6.P^^%2J'NG*^XK8IU9"BX0CR8PDB,UT<\
MT+^_KW!#ME]F'V>PPTC+=2(\MI+=(J\Z_Q^WIXJ54&R.U=8WJW^5>BM9!%DO
MB:M>5LB[S%?8X/H8U#28Y_H_208&,3*ZPIP_ED:W;,M'1'!RK*Q,LJ,/J?D2
MB*8ND,\@O*%X;!B6M7.!:)"S+NG4S#ZT.;G=53/6Y(-2-01O$#[.^>V5")(U
MC%69> ^B3P'!'XE%Z!KST@A\];/&NQAA?XY)-U8K+EU9Q4\M=2/OWJ4?H#+@
M3&0FPAS:Q=X">=Y/PXV5G6_*'QO'G"/3\FEZBS.N;]]R_!>R#+P!<2'T8M%8
M8/3>*:"<>/''IST#AG3LMA,Z3?Q;0@]E'Y[Q;/48'"Q]H;JBIF)(&LH6<:VS
MZ,I5C8O:K:V/A=(3I2.$Q,Q_D%?P"#*3$K8YZV4?%ACYG1CHCIZH3'NA^%7E
M'I\@E^DXLMQ@H\N%)$)6;<!/FV]0;F9N$;86&Y.O75)8R:*21RLOI^*\441!
M_M9-8+>A7Q!9;_Q>WT+?UZG6?I?+RVRBH]&'@/&A>DC$1A4TYH/J?"^/W.8-
MWAMQ[3FS\>(S43(#BO:-O@?I)VDP)=(CF$):QV0/Z3:9;S!_K:ST944:E\2^
MT:]8;%-8GQ6),' 7Z=Q-\&D"A<+D"IU?1Z.AKKL2Q^><U!6T^?2U!>[W6O 2
M.IX2:N*:+Q-;_:2P/)_!D7LHX'00DJ2I$[$XFY/%!TR+]NX6'F8]F"0Z'7@D
M_<9]?#177O6%D4 9@&[,_5GN$/3'T",Z4P@GV3C+Y@2_##6:&.U)_PTU>!*2
M] PF0@S$($-3D_-<YF,N<MOLJ$<JK>RM='[M7*B>EY2_V)PM_XU0^OU#TK#/
M*+$FI$-9I(+N^Z*+U52-&B;#Z""&,-X=8TNYYO8^\WHC2;T]8_+]$%;]@8*K
MGQXB4&85= [&BST%3/ H]:OO!>J;8Y>\@XR>VC%)Q7LN'KW)R.&CR" Q<YR6
M?@;MBOEAN5-HF^.$KYD4ZFJ( *+O9FRD@7E/^5@5M^S VL#8,79V>.-"[5N^
MF[>I*QCV]Q-?!\2[C%6F(,G4\W>YU,_G7)'T6"^ IZ@.XI&;^_@I:\)R&)G)
M_3@D):+*IJQ8W^W3K=>T5+F#:K'RJ'QA F=[)OOHOL$4:VO^0#?TK>A^G<9#
M)?AC[>4OK2PDG[N0=%O\.C \0[HXX==)E%"7LCUCAIE2=96RTL$(08IH=/""
M<++P1-I(NT"E\C5?&KL9Y?']_:46@>;S9,X68C]V[C)9 =^_61TB5I)%#WDV
MEFL@N9J2L4*[$+V)FRN!!R/:GC8:,L21)/KRV,_-.$]F5!J*^SQU'WR[AT*"
MYU-Y@!9QDYQHZQN1)H$@^E5H@8;V8)^ ">B8MEBPAK/2QT2W=!*I#V^%,U<0
M'3 (9N*=V6&!4ND8W9>']^ 'B^$*#BJ$7P'VS66#&(@4O/><B@,:Q"2S4K$P
MO9;[<.;SHT<(G6/;=ZE3W&S=%=H6;C\PO6N/\MEU'ATWP4IUSR"1=B/D/]5[
M.D#-59#AE6F;PH8AKJ_$7P3Z8USC. 5-C/;/C\4P4QV](\EK!Y)$*"/-8D3A
MXH8[45]UQNM%!F1SNM$WH@_:)E5&_W+:K+G")VD\?L_1H!A_()D%U,Y$M :%
M(5GWOMKJSC&L.4%]Q37BY7A[(5]<3@$9 ?P152N-#O-S='[!,YT?9LTCY,3U
MOK/LU;T\6DB8 8FF=L0S5O]<^)H=>8S#//CW/F$RXD<79XZ/Q$\!7U*/:'"C
M@[9X7+MY/'?Y,^)[O>(Y+^YW)4$(6+XN9Q*W.3\H"Y7<+.FD7T*F)AB_=V??
M%N$/W5)F,%8#+.\4=MT?;=/G5195UY7*XZ_X=>*'CVEKP%?'*%TUMQ"P_#CR
M:72LWY]_HX! !1>@#*J>)UR=1'GF:\3? M7_D'U.(G^AR*Q['WF0Y/\QG3)E
MLX?T$'H*J "W<T*8B:][NRD4*QU.*6[*9AI( 2P.%\8 B8$U7:CCZXU21[H4
MF6-#TH._LBQ/\AI9@"&-QJI9;OE=/BF1DZ^P@G*E'CU&:)G=&K*B^'S+R7FR
MV2G@G<PI .=%M4M#5IG"CI]<MF8GYYUY-C!F:^YZRXHY?G!1G/C7Q\"OM 2?
M O:8" Z4*^.G@)BA4P!#%/'L?=T'7T?,]R.(,P#8&9D ^A"K3@$/QD,1@HCN
MN']9V1E:_Z_[(CJR*9=/ ;\,NI!$*0A%[AY( M$QHRIR=JH*@^R%$%"BQ,\D
M?_(#8@IVD[4+Z)2_$K 4UY_1%2EU7C4/<F-\!D>AY<1#*,'6(J!#IC,)UJ8$
M70JME/WLG>%7%-":Z5C]PSG"25"15?&F:Y#QN9@YG8'L*)VU93A=GI9^_6M#
MGX FZ>JBI5?PP;-G-'$1-I:M!W>IW%@Y?/406N(4.7QO^<L<:/9\9JZ[\)Z<
MSF_1_0S5,<JP@>S8DDPR?[><\)5W1Z8#<Q6G@(W+^)IY9?<Y]3S@-;^/]T2+
MG%MU>O]T7!K)+MQ34-W?2_3(:W0._Q:>0_=- K!WKE*>%LK475:9"1R_QFDK
M$STO5[ U6;V6G^4L7NSJ\F?3+,>Q9^\'[_%HWW-5DY.8K>P&(LVG7S?-S-QS
MAK[KO_*+\5DW59M&""V> EX6 L.\#7C\&#'A'(]RE*]>9).$=;VS:0"S61PI
M?H'9_K1$EB!$/)9XK ?3*I$S0<"6'KXDDX:\([:GANKPZT$_:DN5T,C+7@@>
M93E35;O,$I=W+E\MTK6OT?#B^WVDDU;FRZIVC@FHL!21Y'ZN_:_MC5Q"PCG
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MD/2<$[[.<-57@)"[9Q2%<D=/3-F_6#&]2$^K7^[^TV&$L[[)#.\$5T#%6YX
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M;_I]TW(MS>W3ZF'^+&11:R</O@^I!5^'25(DB7;8##H)<WTU_=IJ8Z-@W9L
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M@[TZU<4?7N7"@]\H'^T<,[(EH3X UZUGK&\3Z'BA.,YAI+A0!Y=/*5G$^%'
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M4W&-4.>2#/--;L7FT-&OO47ETHWB&,ZYJ$SY"OP LL[EZ79CK>%'+MM"\(_
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M9!=FF4^J.\:Q:[*"U)ACG,N&EJ]>I4PV-[^1OA8^<3?WP.[B^WI\:LP2.KY
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MA-Z4DNHBQ(U]2 W[A^H@_T6V(F.@++78Y.0__]T?"3Q]"KN!T9#\!555!_X
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M@_?^MH:>I!VXU"VAFU\XM_;[SZ:7?+<EQL*7"BG"DV2#4V5W,X^F-V!#]]!
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M1PHH#? 9JWDMRK^\/)\ZTPO-B0AW3AIA6#\'L))EJD@9ZHZ=%)E<W(J4V<1
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MN <"UKGD[3?"W=JR3=WV(OBO2QWK4Z=F;368T EX$Q#=2H6LNZ!PSGRNWL
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M7_=QKQ921G8 Q7_*-PJ0_6@>N_,NKN5; 3#ZU#(_1(!KO%-N_)G3M@*[=8#
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M4GX()C)%M32-?C5Y>C[JZKA4W1^J'SYK9@MW%51',N*62&BS&70X(59^>#U
M8XQZ"B(XJL]NI9G+E$V<RVZ3;?8CUZP;CJ008MD.#[<D)3V%&?TK<R1U,BE,
M3,FWLY2T2MCKD7LJ-ANV4<!GMO=ZUSUZ1B7%UM.=U7R#23@?FN)$.MT3(--W
M^Y;4M>><C[47/*H]+'?T=@^I)<E-[_F*O9H/XW5U&?*TQ^8.3BYMTDP!D'3#
M:1O.&QOO_ML-"ZSJ@-OC$\Y$0(A(M@A[5L5CT\#NX@+!K/E?2@< [[@_%3/C
MIB%@O*#<RG8^.IK>+I6R9<@+$_(KI((=/<X@CXS@FH6S?UK0%P:;$5WJ<"*
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MAG@<GD2'1;2.B(?):27LRG@5$<NMW_6"!0DM'W=^YMN[2Y)&GR_86F7>614
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M6W]V@V/TMI07'I_2DC@1G0DT;-,_]G/LTY;6HK*&V*87#\DG);<XE4CB!QP
M4G16"JLF330FT]@]=B?O#O@V'+>OTO1#:B\X;V+5*,6,\+25Y<F8WOI*<H_T
M]8^=)XR4'@[%@POK&1[-Y1&8&^2PE^J?QZQYUYP([1;=PK_2EI<MIP\ QQ;W
M!4@;MJ433G74N>*M^)N9]CU!4]IT@W6V0L;FPJJ2WTN8:=->D<"E)\(6TD$T
MWLFUJB\?\X^R#+9,R&%PX-[28(S)G1W]! &X)IU2/M<<^#_FV_G_-=+]01_A
M1=GLA X>]&=UDR")%C"_^0="$5>Z*@>_S=%_=8'\OQAQ!R/_!E!+ 0(4 Q0
M   ( -F#>UB/[<_X:-P% +3)0@ 1              "  0    !G>7)E+3(P
M,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( -F#>U@&//,5MW0" )]@)0 1
M      "  9?<!0!G>7)E+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( -F#>UC\
M. 23^0,  *PC   /              "  7U1" !G>7)E+65X,C%?,2YH=&U0
M2P$"% ,4    " #9@WM8%8I6S"8#  ""#P  #P              @ &C50@
M9WER92UE>#(S7S$N:'1M4$L! A0#%     @ V8-[6.T[ _;C"   03D   \
M             ( !]E@( &=Y<F4M97@S,5\Q+FAT;5!+ 0(4 Q0    ( -F#
M>U@P27&%UP@  &XX   /              "  09B" !G>7)E+65X,S%?,BYH
M=&U02P$"% ,4    " #9@WM8* [,!D4&  !P'@  #P              @ $*
M:P@ 9WER92UE>#,R7S$N:'1M4$L! A0#%     @ V8-[6'9!<M9#!@  QAT
M  \              ( !?'$( &=Y<F4M97@S,E\R+FAT;5!+ 0(4 Q0    (
M -F#>UAT2MT?K@8  ",P   /              "  >QW" !G>7)E+65X,U\V
M8BYH=&U02P$"% ,4    " #9@WM8EQK?<6<@  "9K   #@
M@ ''?@@ 9WER92UE>#1?,2YH=&U02P$"% ,4    " #9@WM8[KC:8&(0   V
M?@  #P              @ %:GP@ 9WER92UE>#DW7S$N:'1M4$L! A0#%
M  @ V8-[6% TPGQB> $ \Z<! !$              ( !Z:\( &EM9SDX.3(Q
M-#0V7S N:G!G4$L! A0#%     @ V8-[6.G9=!*FQP$ %8<" !$
M     ( !>B@* &EM9SDX.3(Q-#0V7S$N:G!G4$L! A0#%     @ V8-[6&+#
M1%5>"   !PD  !$              ( !3_ + &EM9SDX.3(Q-#0V7S(N:G!G
M4$L! A0#%     @ V8-[6,129%J<.P( WE\" !$              ( !W/@+
M &EM9SDX.3(Q-#0V7S,N:G!G4$L! A0#%     @ V8-[6(^IC=\F50  IEX
M !$              ( !IS0. &EM9SDX.3(Q-#0V7S0N:G!G4$L! A0#%
M  @ V8-[6".P4@0[G0$ <[D! !$              ( !_(D. &EM9SDX.3(Q
?-#0V7S4N:G!G4$L%!@     1 !$ ' 0  &8G$     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>gyre-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:gyre="http://www.gyretx.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gyre-20231231.xsd" xlink:type="simple"/>
    <context id="C_d40b8acc-faac-42d6-9c51-0c30220f6323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_06e4c2d4-f7ea-4792-a208-6e5d5ddb822f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_34639a27-12df-4fc6-8cf2-6020aa830e91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:BCTwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_e13ef3b0-0f59-4737-ba8d-a801a95ed820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202110Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_79108d3a-0a88-4ff0-8ed1-61cd65b0cc7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_115f1247-30e4-4dba-bef9-b573f9c28f0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3d486857-5008-4c2c-a4dd-5f5a83f5ac38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e8c45cef-ab89-4573-972d-ebd63351515c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ebddae99-35cb-4ad8-9ae5-e50276c1c921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a5d59667-252a-4ddf-a814-4b5b16c0658d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0be0b3d5-00f8-476d-87f6-73aa39f3c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0b92166d-718c-4785-aa66-2913afa80931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_70b83c65-e6f6-4e44-8d27-f4d22fcc2178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6a6b4fb6-8b55-4823-9d73-78c42fa47442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b93ebd7b-c921-4c3e-b8e6-a2fb861ebf08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gyre:PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d0718b26-6e80-4be3-a6f2-f995da1fdae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a1eecc05-fb63-484b-87b6-6c579da56492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">gyre:MainlandChinaContributionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_290b25a7-e794-4501-9b27-3ec91a3fd8f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b8689a54-e515-453a-a125-a50eaed49c5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b7bd02c2-5511-4949-ab7c-0b820fc02c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_29dd3e9d-3aeb-4cda-b357-0760b9f78c7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:FCContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-26</instant>
        </period>
    </context>
    <context id="C_5723249a-64b4-471a-be67-452050b084d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_72d98f33-ac25-40da-993c-2ae56eedc53b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_170270bc-ade9-476a-ad13-a1783878c851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:PatentsAndTechnologicalKnowHowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_101acaab-645c-4f44-bbd8-62788657a2a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="C_3ca1cf69-934c-4ff2-a707-c448b5a6f581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_a0b36028-19c9-4a53-a9a7-ee2e782d8999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_255a8a23-07fb-48ff-8e4a-470e48cef83d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_be894792-6c69-49f3-93fd-d2f0be6d34a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ChinaResourcesPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_812372f4-948a-4dd8-9e62-5d74629f12d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5d3825d9-b987-4009-9844-dcb7a6a0f783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:ContinentPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-26</startDate>
            <endDate>2022-12-26</endDate>
        </period>
    </context>
    <context id="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_66c1df00-e0da-4f0b-9563-bfed0377c5ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6077b963-9934-4f32-afc7-404ff0ca15ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_28499de6-ca37-4fe6-8aca-3f877d7ec297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_14bcbd0d-16c5-428b-aeae-b50976bc4336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="C_db3199b0-d343-4eaa-a0d5-e0379c40bbc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityNonCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ed00f272-5d55-43d0-8d10-9b8734e290e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2522893b-b6a7-4707-8268-f07f26458548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8a895bc1-6430-4cd0-8079-aca770c79f44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_600857f6-7a26-4dcb-b37f-7638845d2593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0008245-ac04-475a-a3d9-4fa1983c4b11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1815289d-1b7a-4870-a6b4-e40af7ccba71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fbd33fe5-ce5f-469c-838c-790bd81dab76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c78a0ae7-fcae-4fbc-826e-d3417a171185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_902ec01f-0e7c-4614-8110-77c86fffbaba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202108Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c3822144-76cb-4af5-a440-f0966d1d926a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6948abd4-d444-43bb-a3ca-742236671306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_964a9a24-1974-4f5d-9116-9d0ee44c4aaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_39bb62ec-75ae-4ae3-a8f4-d62d0b77c6d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c368eb8c-00d1-4f05-bcc7-415246aeae15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b9586f61-cf2b-4213-abab-d860b5741c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_73e506f1-e7cf-4f6e-aabc-dc8fffc52d12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_69b8f9e1-11d9-471e-9f88-5c562846ff4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4cb6c663-f4e1-4031-ab93-fd048348ccfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="C_8d096fdf-4e68-4c03-86ed-d1473a0c1c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4f7731e9-8054-4146-a8d0-8ebfec2ebe77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a3a35db5-876f-4dde-b12c-44d79d949c6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eb79166d-261c-4aa0-b6cc-fd954e4458bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_60d99e53-9b0a-4867-83bb-4f2ef85acc84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_553f64ab-cbff-456e-afae-63d4c635d124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_667dbe67-6d4f-4415-b9bd-2d650d6ff17a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e03b0455-2388-408c-baed-fbbcb9bb45ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_157e8487-e10a-4a43-a91d-f10752747e13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e26cd6a1-f060-48c2-901b-b831f0705204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e49c5cbb-f4c4-4958-97ed-acfefaf3d6d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aaad5e91-28da-4383-82fc-a19aee9f956d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9308c880-d262-4f12-b2e3-dd30805711c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="C_0e40eb2f-6361-4ec3-826e-a6b22c03f7bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-26</startDate>
            <endDate>2022-12-26</endDate>
        </period>
    </context>
    <context id="C_dbc1263a-94eb-48f4-bda3-2ce54672d636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:PatentsAndTechnologicalKnowHowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_63213500-d1dd-4530-b4dc-40f0ab583252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bc1f552a-2533-4ff9-b66b-78200f9c38bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <context id="C_0cfa6500-f12c-4cdd-861c-f10bc7dc5d69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dd01b7d2-757f-4f84-a6ce-a11ccc44dbab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <context id="C_ba6672c5-2601-4669-825e-401398257206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_37aab4d6-0074-4bef-bcfc-1004484dd02e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:VertexAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7dfcafca-61d1-46f1-a43e-d003319b30c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_10152a3b-ae2a-4e24-a1b1-6548fd6edc50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f750731b-6020-454a-871c-e743ff63ef9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3272f59d-b079-4e41-97d2-9aa1f584ff2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_0d0d85f9-9db6-4218-b101-c8578a8373cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_38b72769-64e0-4e0a-befe-f69436730816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_42dbc2ab-badc-458b-bb6d-bcbe8dbf6681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_839664df-b2cb-4095-8420-a0a8cd565de5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">gyre:OtherDirectorOrOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4415040d-7158-489d-9d55-5d063148a4eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-26</startDate>
            <endDate>2022-12-26</endDate>
        </period>
    </context>
    <context id="C_348a8cf8-e659-4115-a553-09b0ef1cf4b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_09b4f5a5-c379-45c0-b3a1-76e64d96074d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a0eac393-f1de-40db-a17e-e4afc62662a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_5b9e0cff-7266-4030-8595-3ac948bb97b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_d1d44dd0-f099-499c-bf24-bbc98c230ca4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0b0cf3b8-5d3c-4147-8ceb-467e7bd5ba58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b1e216e8-da62-4adc-be21-79756314d405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_456a2f3b-ce96-4cc3-bb0f-c4609478945a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_89b8c4e5-1d62-4004-b838-6c1f712ee7f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">gyre:MainlandChinaContributionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0edb0ebb-f503-4b95-827d-83260811c5cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_88893ed2-bf18-49f6-9367-143999cca36b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_045ba781-db06-4c6d-8298-49ca507c4865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4819d424-8697-4686-8411-d198d08bf27a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_84d9b48e-9b34-4794-916b-eecce30677e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_56fd673d-dfd1-4bf2-843c-a213f1c28815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3f63f1a6-45b5-4355-b17a-f27ea1669ee5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_73a0ea9a-142b-4c0d-8823-cc0148cb7f2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="C_4a1e9dcd-1585-4d10-a8bc-e074b80d03a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4dd9552a-d96b-49ea-b446-4919e583d048">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e6b773b3-ff91-417f-965a-e0e1b202042c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gyre:PropertyAndEquipmentIncludedInAccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_197f4783-1608-451f-92af-879882f8d860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d846aa23-1a35-4add-bb37-786c605b621a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_4d497df2-33f4-4686-9867-5db4e7e60cf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GCBiophrarmaCorpAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_5f2eb8e2-864a-4564-afac-5ac5ae5e31a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_11e895d4-da38-44af-a160-56e416efc9d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-26</instant>
        </period>
    </context>
    <context id="C_d4a379ab-79bf-4033-b99c-f6b95eddf94e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2687f77f-ab25-40af-b6b8-1e653689478f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d1d8d078-42db-45d4-8278-c6b26dcb880f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gyre:CPIContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-26</instant>
        </period>
    </context>
    <context id="C_532b1d95-8146-458c-919e-7460a7d52b23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2024-03-19</instant>
        </period>
    </context>
    <context id="C_b15a99e2-1606-4164-acb1-5d6360dd4a3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e3dac587-c2f1-4635-9403-fcc4c1dc69d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4ba38967-8a4f-4c72-a845-ec882f409155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ea3f5866-c7a2-4019-97c6-761b0043d03a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f6d92b17-1eca-4702-9b3c-788a030b8de5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0abe225e-8a79-41e7-a475-5fdcdaca6b2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4e28133-5b1e-4106-ab67-c16e08fd9d3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_59d1977f-7c62-42fa-a426-ebf6da7d7d38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_56e7366e-1817-430a-b15c-fe11b44bcf0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3c991f1d-66f5-47f8-8e04-683dff126fbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <context id="C_b1a6816f-f707-4fb2-a96b-db95ed45787d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9c0870ec-cd18-4ecc-826e-33d440e66dab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="C_dee33cb1-134d-4bc4-846b-88a1d3ece761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_445a60cd-e16e-489f-bcf9-7e083b147488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">gyre:CVRDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ed6adc05-0edc-4467-9e37-a86f39ca0666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c7e70b74-1137-44bb-bd33-d9231ea42d4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_fe01067f-086e-4848-ab35-be3389a6f430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a67805ae-0e8b-4cdd-8b41-5d0c3ff00337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d0b28c28-b43d-409f-912a-9b624322953e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_77204f22-ab15-4c2a-a5cf-eebb0427fdfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_393225c6-0b98-4833-af11-e65edf2bb418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_13201822-62fe-49b2-a82f-aea2f25149ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3b323a5d-4464-43f4-83e3-c63e93ede93a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0183b145-8159-4365-809a-9af68dddf568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3881b1d8-2620-4894-97cf-4c70975b00b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-15</startDate>
            <endDate>2021-10-15</endDate>
        </period>
    </context>
    <context id="C_b14d0f10-ff15-45a8-ac65-d7d00fe4ea56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_909bcf41-2baf-4ab5-92c1-98ec48a3f1a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c49e00a9-fef7-400c-9f36-c136ff2e6361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_201559bc-4989-46aa-9233-4a691252ef1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8323d313-5e0d-40e1-8969-c2bf69e0e63f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6707664a-816c-4885-a01e-386eaafa6e47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3bf7ff5f-4cf5-4036-a987-5cbcce3b4d9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_54337f80-089d-408e-99d9-524dadb15757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1d2fc6f7-e605-4510-8d2b-4151172e8647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_84bf33ef-ee75-44b7-9ee4-7d137c6aab5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7aad8f7d-ee0c-42f0-82cd-92463b4ee3ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_91242d31-4c05-4dae-a9cf-c1b9d11a95ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_efb1e330-1a01-4f0a-b587-773cd7fdf361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6b3596e0-0ee0-47ca-98ce-acc247c5374c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_83452b0c-e779-4d10-8c25-9d61d6a3d570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b46d8f77-6441-4e49-9e95-f82435a4d5d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CatalystMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-30</instant>
        </period>
    </context>
    <context id="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1aa9e6e5-97ba-4f1a-9591-6fe7ce14496b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d022cce0-2b7e-4ac2-a0b1-f765616cb924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:FThreeFiveOneAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f243cd37-4ca7-40de-bfca-d9278aaf4176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6c61ab08-e1b5-45d8-af46-68e14fd32dfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8d44f86a-e7e9-43dc-98b7-f45dd3ddd498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c8bdbd82-72b3-41d8-88a4-121a036217e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_606d870c-cbd5-409e-9eb7-2056b6dd9718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7863a107-8f27-4048-916f-de1fd40aebc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_96f625f2-102b-4612-9ae5-c9bf247174b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:CPIContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b1ac7913-1b9e-4353-967b-ae81b61fc740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8dd3a581-c90a-4509-af97-5acd79c8a8e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1ec943e7-b2ed-4fe5-9f06-a3c06eb3c01a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_4649e540-01e6-41d7-b63f-f6d16f10ba35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9f06db74-891e-4ce0-a20f-35ad5be24529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_774dcb44-6e8f-40e2-92fb-74eb3d10f679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4011e20c-cbaf-4cba-ba16-cfe9ea152f93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0222eacd-1eff-471f-9812-cbf6e10d75b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0697f749-db8f-4fa7-9af3-6e4ada46d83a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gyre:GyreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5a775378-ab64-439b-aa16-34b026d36a54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_146bbfb7-b649-4239-b32d-22b491e71629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_65d76f22-ab8c-450d-82d6-0c032d5502d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="C_5ca366b2-7931-469b-9226-43eecac0ccd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gyre:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-26</startDate>
            <endDate>2022-12-26</endDate>
        </period>
    </context>
    <context id="C_ef376339-fca7-4476-8816-40e8e7832483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gyre:MachineryAndElectronicDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_67f01725-b921-4008-975b-be0783c4cd88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:GCBiopharmaCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_022304e8-e2d8-4bf5-929c-5ef87abda6aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:SubmissionOfTheNewDrugApplicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aae4d106-8ca8-4cfc-ac19-e79420fdc9ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b262631e-b3d6-4f19-a20e-4918b4b3ac1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1a998271-ce77-46b7-81d2-6b2303da832d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a3878656-9f94-4813-a7e0-a59203be9936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ShanghaiPharmaceuticalsHoldingCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e8c28c99-2d83-45ea-8686-ca83957381c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e0557a3d-1a6e-4667-8a75-0565cef63396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gyre:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5d5d2670-fd6a-4e3f-894d-c0347308d6f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="C_39406448-b6a7-468f-94e5-4643bb470fb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">gyre:NassimUsmanPhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_182327bb-26af-4f7a-895e-5e3aa7510752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_520d9cfd-45b8-47c9-a6c9-7d44c08a8e84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:SinopharmGroupCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0063bfe3-5d9c-41a6-8562-8f267b5afe98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gyre:ChinaResourcesPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c46426ec-a619-48aa-b225-7389e165b89a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gyre:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3cc0a247-7505-4d3e-a327-e08700672f1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-22</instant>
        </period>
    </context>
    <context id="C_bc38fe45-e720-4e3e-901d-1a99ab32da43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f319e2ec-8474-4f02-8b68-38c9e4ad3e70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:NDAPassesTheNMPAsReviewAndInspectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e1121837-d055-4a18-8650-a77886d17e34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:BCTwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_e92cc5b3-03a9-49de-86c5-40c3077730e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gyre:GNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d564b606-4a21-47bf-80f7-c37ac338b08b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae49cec5-9016-4f5f-8d21-5329e230331a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c1a2d74b-7d0b-4b38-8998-7a1161571cf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_876ccdba-ce87-44d7-a2b1-3ab0b94f2343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f5c9b177-fba0-46dd-bf60-5e7f99b3ce8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9ea7ec22-706f-4637-98fe-08b2490d6c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_25dbe4a0-c5aa-49dd-826b-9a456c343407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3ba0c404-2823-46e7-9d85-bca97b5c230d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8324e115-6f67-4a65-b0da-48617f324eac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4e5a19f3-a118-4af6-bfc3-2289de865726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ffe88006-6a83-4a40-9c82-c045fa6b0bdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gyre:CpUSSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f111bc94-d333-4038-926d-d8d72cc3bed3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ea22d62-a406-408f-8236-ff3e0f11ad07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gyre:FThreeFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gyre:NMPAsApprovalOfTheNDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_231bdf89-19b3-4b6a-80d0-3b9f3bf5f8dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">gyre:NassimUsmanPhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c2c5e195-1c21-41fa-be14-653b6ec43f7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_336f98ce-84bd-4119-8b08-938644de6dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b337b32c-b922-4667-afd1-a840403dbad9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gyre:BeijingContinentPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a21fb1ae-dd92-411d-bef0-916436903fc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gyre:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-15</instant>
        </period>
    </context>
    <context id="C_4ae8d6c6-9b6a-426c-ba9b-df1d72c1c57c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_01c81b79-25d4-4be2-a4ef-98326dc842a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="C_86929c87-30bc-44d5-9aa7-59c41f5a2bc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="C_666ada80-f898-47d3-8486-3309e25ceb24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gyre:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <context id="C_04950170-0636-4a37-9b11-630a8bead37c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-12-31</instant>
        </period>
    </context>
    <context id="C_af914aeb-56e2-4a0a-bc92-2b10d6ce2fdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gyre:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_969ae12f-04dd-45bd-837a-de4b4c55f1de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b7c2a125-5bff-41a6-a0df-4926d0dda919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_Individual">
        <measure>gyre:Individual</measure>
    </unit>
    <unit id="U_sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>gyre:Segment</measure>
    </unit>
    <unit id="U_CNY">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_842bb781-f233-4730-ba3c-37b98094cf6b">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_b532d4fa-0079-4065-a312-e2bb54ce23c3">0001124105</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_4f4ea0e9-b2d6-4b36-8e2b-a9e49cc8beee">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      id="F_10f26d2c-8039-4a92-bb7e-38b5c289f68f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      id="F_f851a953-0acb-4a2d-aab6-9fc679e13665"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a"
      id="F_510f7079-5465-4c06-acd3-f8ee356eab2a"
      unitRef="U_shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a"
      id="F_a1f5be30-a9c8-475c-a877-7a594cbb125d"
      unitRef="U_shares"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_c49e00a9-fef7-400c-9f36-c136ff2e6361"
      id="F_b8d10737-f18e-4a8d-80f3-5bcbf043af92">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_d0b28c28-b43d-409f-912a-9b624322953e"
      id="F_ba9e4760-e1ab-447a-a061-08082fe718fe">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_ba6672c5-2601-4669-825e-401398257206"
      id="F_1b8bd787-8774-422a-80fe-04f24efefd08"
      unitRef="U_shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_ba6672c5-2601-4669-825e-401398257206"
      id="F_0cb88365-0ef8-49b2-9d9e-5b85398d57d4"
      unitRef="U_shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_ba6672c5-2601-4669-825e-401398257206"
      id="F_ce5ebc89-65a5-46e2-8a69-3fd79de6688a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      id="F_8616dc92-4123-4729-b301-42d5b83f2786"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      id="F_1e540b7e-b631-4275-b3d7-b90e2d47d44e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_bc252744-baa0-4194-8482-57f9bf75547b">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_c595a3f8-c547-45ee-8451-525afa92158b">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_db99d380-237b-40bd-bf45-d6034777c93c">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_5a3b8dda-b4fd-4d8d-88bf-37ca45258276">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_6daa3f4d-381f-469c-bdfc-41a1d4cb465f">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_7bce3dd4-bb31-40a8-8f5c-3c3faa5ea442">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_c07099f1-6e01-40c3-bcec-2a5fcf035341">000-51173</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_33d3ccae-51bd-41cd-b72d-796d590a0dc8">Gyre Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_73b71430-6ca3-478f-8847-f1216b493692">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_1d691bbc-05d7-4800-8a6e-22ba7cd6fd68">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_5c1820b4-6232-4c7d-8c4d-b3562d3ee107">12770 High Bluff Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_b32fa25c-e960-42ee-b6f6-f5defa5f9382">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_ec4b4fab-57bc-4666-ba94-97d524ffd96a">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_9e374d0b-63a0-4bb8-89df-33e032fd6215">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_e0031cfb-556f-4fcb-9767-3c65ec0a6f90">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_ab88693b-f865-4651-abb2-ddaa0830869f">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_ea6e6893-2956-47ef-bc94-6c6c7726b8fc">949-3681</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_5e830af1-459b-4468-980b-04b0e30a625f">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_ec3305ca-b352-4e2a-8de8-a2ca44ac538d">GYRE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_b592173c-75a0-41e8-a145-22c51ad5ba9e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_44b24172-3d66-4c9b-9b3b-e043f6aee3d9">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_004378da-7879-494d-aa9a-57580147b6ad">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_3818740c-3b0f-46d8-934d-fed35346de0d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_17bdebde-d654-4fd0-aeeb-a96e75a6c731">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_392a744c-3b8f-4fd0-bd8f-bfd8c672c4c7">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_31f2600e-4116-46ee-81e5-49a4ab98e886">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_7e108f31-ba26-40d7-a6e3-e3bad82019e5">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_d90a2311-3749-46e5-8f90-65b8e030a42d">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_8511a8fd-4ee0-4449-b10a-6105cc4b4b0d">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_4c80c2fd-a074-4015-9a34-a634db6b22ba">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_3272f59d-b079-4e41-97d2-9aa1f584ff2f"
      decimals="-5"
      id="F_32ca8a36-f3e1-4012-8887-be74ba4ba1d0"
      unitRef="U_USD">11100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_532b1d95-8146-458c-919e-7460a7d52b23"
      decimals="INF"
      id="F_855052e2-5f7a-4958-907e-124fb9852f61"
      unitRef="U_shares">85423246</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_87c6f69d-8510-4bdd-9580-47aacdf67235">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#x2019;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2024 (the &#x201c;Proxy Statement&#x201d;), which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_a5d59667-252a-4ddf-a814-4b5b16c0658d"
      id="F_8e82774e-b5da-4ad3-9bdb-4cdb4206cf36">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 12, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nassim Usman, Ph.D&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;., a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;director&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the Company, entered into a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (as defined in Item 408 of Regulation S-K). Dr. Usman&#x2019;s plan provides for the potential exercise of vested stock options and the associated sale of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of common stock. The trading arrangement terminates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;upon &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the sale of all shares pursuant to the trading arrangement. During the three months ended December 31, 2023, no other director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; any &#x201c;Rule 10b5-1 trading arrangement&#x201d; or any &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as each term is defined in Item 408 of Regulation S-K.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="C_39406448-b6a7-468f-94e5-4643bb470fb8"
      id="F_7d722f1c-13cc-437f-ba41-a8df05ad37a9">December 12, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="C_39406448-b6a7-468f-94e5-4643bb470fb8"
      id="F_5b317fed-e84f-4347-976d-ccfb42e8c998">Nassim Usman, Ph.D</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_39406448-b6a7-468f-94e5-4643bb470fb8"
      id="F_a7b4fa58-d39d-410c-bf73-3e67e40959a9">director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_39406448-b6a7-468f-94e5-4643bb470fb8"
      id="F_2c92562c-801e-4659-a561-e0b9c257b445">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_231bdf89-19b3-4b6a-80d0-3b9f3bf5f8dd"
      decimals="INF"
      id="F_c9552dbb-6a39-4586-a2a3-178d8c95b8c7"
      unitRef="U_shares">240000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_839664df-b2cb-4095-8420-a0a8cd565de5"
      id="F_47440746-8936-4a0f-bf14-5713b2543ac9">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_839664df-b2cb-4095-8420-a0a8cd565de5"
      id="F_770fd2e7-32f2-4cf6-a19e-c1ce3df25500">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_839664df-b2cb-4095-8420-a0a8cd565de5"
      id="F_9109800d-69e5-4828-9c51-b72af4a4b4e4">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_839664df-b2cb-4095-8420-a0a8cd565de5"
      id="F_fd495ba1-6808-4988-bfef-b2a9b24b181c">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_7aa52c84-518a-4550-9e82-731249cdbd1d">1487</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_33f68d91-8c45-4165-9350-01e010564211">Grant Thornton Zhitong Certified Public Accountants LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_0195143d-c472-4b84-b35d-25ca9355bad0">Beijing, China</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_426796ac-5a23-4acf-8de5-5444364bb3f7"
      unitRef="U_USD">33509000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_82c71027-85c8-48be-9726-5f8b7dbd899f"
      unitRef="U_USD">25175000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3edaf278-f51a-49ff-9163-979a60b12575"
      unitRef="U_USD">15552000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_3e39bbb0-ae0b-453d-a62e-807964360e45"
      unitRef="U_USD">17136000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_553f64ab-cbff-456e-afae-63d4c635d124"
      decimals="-3"
      id="F_17ac106c-fa11-45a8-be39-1ef013b45fca"
      unitRef="U_USD">1287000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_5fcee370-89c2-4373-85f9-d139eb13ab60"
      unitRef="U_USD">4281000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_8fb9b261-1733-4540-a5d8-e2714f7a1d86"
      unitRef="U_USD">6122000</us-gaap:InventoryNet>
    <gyre:PrepaidAssetsCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_683e746a-3c51-4f66-9098-a6935f1ba251"
      unitRef="U_USD">1547000</gyre:PrepaidAssetsCurrent>
    <gyre:PrepaidAssetsCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_1acdbdd7-c481-4fc7-ae5c-01ea71366953"
      unitRef="U_USD">377000</gyre:PrepaidAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_6d0cfcb2-591f-4250-acd4-08ff8821a05f"
      unitRef="U_USD">1045000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_3e8fe4a0-7178-4602-a936-0177ca54e5b1"
      unitRef="U_USD">843000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_6af70e79-1103-43d3-9cf0-74185ad75294"
      unitRef="U_USD">57221000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_cd77a3b0-4dc7-4b26-aee6-47851bf7d5af"
      unitRef="U_USD">49653000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_0e626700-d5b3-4224-b245-fd3b863d5d3f"
      unitRef="U_USD">23288000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_ff959483-f7a3-4552-ab6d-8d99ba0537a0"
      unitRef="U_USD">17709000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="C_67f01725-b921-4008-975b-be0783c4cd88"
      decimals="-3"
      id="F_e9954a4f-0ee2-40fa-bdbd-56f1c6055bf2"
      unitRef="U_USD">4722000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_51232873-1d03-4465-aef0-bedb809f57d8"
      unitRef="U_USD">205000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_8886742b-069a-448d-b966-833e78ab71ac"
      unitRef="U_USD">297000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_cb302011-b00c-4144-be8f-8ca59acf207f"
      unitRef="U_USD">489000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_69623884-23d1-4575-8c83-6068c23b6437"
      unitRef="U_USD">666000</us-gaap:OperatingLeaseRightOfUseAsset>
    <gyre:LandUseRightsNetNoncurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3c8c9732-ecd8-4781-941b-5ecf58edffc1"
      unitRef="U_USD">1493000</gyre:LandUseRightsNetNoncurrent>
    <gyre:LandUseRightsNetNoncurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_5bfb8039-564f-43e6-994a-12d4361036cc"
      unitRef="U_USD">1559000</gyre:LandUseRightsNetNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_fcf1a9cc-9a23-4b22-af66-d452daa7726d"
      unitRef="U_USD">4695000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_d73cc9df-6608-4508-bd74-3b8eb8a3768f"
      unitRef="U_USD">4081000</us-gaap:DeferredIncomeTaxAssetsNet>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_af2d30c0-3ae8-4d5e-b02f-9e4c1d304a55"
      unitRef="U_USD">23431000</gyre:LongTermCertificatesOfDeposit>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_f244c0f4-938c-4358-a98f-137229cf1216"
      unitRef="U_USD">7394000</gyre:LongTermCertificatesOfDeposit>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_267adbd0-4669-45e8-8eb6-27c1c6d60233"
      unitRef="U_USD">995000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_29734742-d557-4357-a8c0-8293f60b445f"
      unitRef="U_USD">3394000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3d570bf4-b4d6-42e5-8485-b10faf80a8de"
      unitRef="U_USD">116539000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_eca72bd1-dac1-48c2-81a1-e7818b3f9aa5"
      unitRef="U_USD">84753000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_48e2f8fa-14c5-4bb3-9e27-6f1d758efc18"
      unitRef="U_USD">355000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_29b716c5-ee66-4621-97a5-c1c1711952c0"
      unitRef="U_USD">122000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3ec0c0c4-f039-4d3f-bfd9-c95cf37ac4f1"
      unitRef="U_USD">39000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_3c2ae8f0-0397-4fc2-8c6d-dd197f909279"
      unitRef="U_USD">145000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_446e62fa-b589-4264-9356-6ef9e896760c"
      unitRef="U_USD">1369000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_31848b1c-f77f-458a-9d56-2785bd905bc2"
      unitRef="U_USD">118000</us-gaap:OtherLiabilitiesCurrent>
    <gyre:CvrExcessClosingCashPayable
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_76a38553-fcac-450c-ba82-85298f86c650"
      unitRef="U_USD">1085000</gyre:CvrExcessClosingCashPayable>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_ce60c562-6c2d-4977-89d5-c97ba938ead7"
      unitRef="U_USD">11935000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_35734adc-dfd0-4ee0-b09a-44fea8786329"
      unitRef="U_USD">9264000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_c453be44-4a00-458d-8018-e48df6507f1b"
      unitRef="U_USD">5054000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_7f353eaa-603b-4048-b017-b365c5ca3d1c"
      unitRef="U_USD">2101000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_6bff078e-cc7b-4dd8-aa1d-c0c37326802a"
      unitRef="U_USD">210000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_101bc6ec-9ecf-4768-9578-a8758432b658"
      unitRef="U_USD">492000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_a9059a97-aa3a-495f-97c3-1e410fc83ee1"
      unitRef="U_USD">20047000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_6c5efee6-be67-45c6-a6ff-b5bf2c0633a7"
      unitRef="U_USD">12242000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_8344e090-8186-4548-879f-9366cd4040cd"
      unitRef="U_USD">199000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_d21f36f3-15f3-4b4b-bcfe-d4cb73cbf39e"
      unitRef="U_USD">121000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_cb848a37-7950-44d0-9f33-cbee4d63d8e8"
      unitRef="U_USD">213000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_c711325c-e888-4dc0-9740-2f5d0914ee28"
      unitRef="U_USD">118000</us-gaap:DeferredRevenueNoncurrent>
    <gyre:CVRDerivativeLiabilityNoncurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_534da7fb-dc37-44d8-ad3d-16ee86eb36df"
      unitRef="U_USD">4722000</gyre:CVRDerivativeLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_1274d549-11fe-46bf-8f0a-93b52be458f9"
      unitRef="U_USD">12835000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_0c6148c6-08fd-4fdd-92fd-125140926bbe"
      unitRef="U_USD">49000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_3a052ee8-9c1b-4577-b8fe-70ec86993007"
      unitRef="U_USD">55000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_0a3a8b39-37a9-4b49-9261-c3d72b1889d5"
      unitRef="U_USD">38065000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_e3b0fe8a-691a-41bc-9d73-1d3cf4cd2753"
      unitRef="U_USD">12536000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_2889925d-9624-4a63-9d9d-66d220c37e82"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a"
      decimals="INF"
      id="F_110e43d5-0200-4f38-99d7-4793346ec4d6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_08adb3b9-3693-4c27-818a-0c0a4aa2d32a"
      unitRef="U_shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a"
      decimals="INF"
      id="F_483a7502-92b9-4dca-9c98-3d61e0eba600"
      unitRef="U_shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_862af94d-a9e5-4b5b-953a-04962d8937e7"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_fad0c692-46e5-4f29-9564-692e60d26d08"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="-3"
      id="F_dd43f75c-1cba-47fe-ba18-e03b94debd96"
      unitRef="U_USD">64525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_bca1aaff-603b-491d-b05c-adf5c685d0ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_b9dad4c5-d8f6-4f90-bba4-355e9bb97a79"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_0b4497b1-13f8-4bf5-bb71-7ddd1c315d63"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_6d44751e-f184-4eb9-b5ef-4eaaeff83980"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_18416c04-5a35-4bea-bdf0-27e0ade491da"
      unitRef="U_shares">76595616</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_d5fb55ea-ce94-4f41-8e30-91e04f54b19c"
      unitRef="U_shares">76595616</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_be0969d1-3529-44e3-9868-61389fc57bd3"
      unitRef="U_shares">63588119</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_28c758bd-6bb6-43e4-b6ae-45f4db20fa3b"
      unitRef="U_shares">63588119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_12ed239b-2fa7-40ce-983c-47e166a0992e"
      unitRef="U_USD">77000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_b0573541-8af8-46af-b688-56e628e06e6e"
      unitRef="U_USD">64000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_9d2f0f88-406a-4473-8473-a519dfa1fda3"
      unitRef="U_USD">68179000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_63041790-5c86-4430-a440-2c26d4c5124d"
      unitRef="U_USD">32795000</us-gaap:AdditionalPaidInCapital>
    <gyre:StatutoryReserve
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_5501961b-6559-4534-ab18-3d81eaaf2943"
      unitRef="U_USD">3098000</gyre:StatutoryReserve>
    <gyre:StatutoryReserve
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_69c6c8d9-1650-4f62-8862-d8c7bafc2fd6"
      unitRef="U_USD">2660000</gyre:StatutoryReserve>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_f69ea2c1-6702-4952-a322-eb28841594f2"
      unitRef="U_USD">-85538000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_9c3c3e2a-1e02-444b-a649-d20fb7ceb0bb"
      unitRef="U_USD">7395000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_061a4cae-6f3f-4cf9-afd7-687796439bb6"
      unitRef="U_USD">-1644000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_0ea850aa-9486-4dac-8094-c029be91b48a"
      unitRef="U_USD">-392000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_c1f5e18c-d875-4def-9f6c-de9c12ec2180"
      unitRef="U_USD">-15828000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_572823ca-8d87-4b0f-a1cf-234fa7df994e"
      unitRef="U_USD">42522000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_b20f590c-3615-4805-a217-3e7763f86287"
      unitRef="U_USD">29777000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_cc493640-62ce-4ff7-b3b1-db5de8540cc9"
      unitRef="U_USD">29695000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_feba733e-51ae-4293-8aa4-00ffd3a7bed5"
      unitRef="U_USD">13949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_eddc3c5d-2f25-492c-b8a1-5c6464ee97fb"
      unitRef="U_USD">72217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_2a3dcb72-4c06-4123-b50f-c2b9e9845876"
      unitRef="U_USD">116539000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_2d9189a1-3073-4a51-8557-142753ae9a53"
      unitRef="U_USD">84753000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_306068e7-3fcb-49a8-9d27-bd8fed1d27c7"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_32c94103-4ed5-469a-8653-72c4e02de0d5"
      unitRef="U_USD">102290000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_ea68fe28-2007-4066-acc3-db5ed097f690"
      unitRef="U_USD">4636000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_3af64abd-bcd6-4c58-a0e9-47ed4ece9a2c"
      unitRef="U_USD">4793000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_99c68f18-2d09-4034-beaf-37400d62f60e"
      unitRef="U_USD">61159000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_28b37ab0-b28e-4b79-8e7f-057680211c92"
      unitRef="U_USD">54238000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_344f1fa0-c8ad-412b-8b55-15666965d645"
      unitRef="U_USD">13780000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_ae7cb1df-6313-48d4-ab60-c8b8a40a403e"
      unitRef="U_USD">16686000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_7fbbf963-399c-4f34-abf6-3a4a6c2721c7"
      unitRef="U_USD">14662000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_64ba2a23-18dd-4529-8720-9bb9958907d6"
      unitRef="U_USD">17370000</us-gaap:GeneralAndAdministrativeExpense>
    <gyre:AcquiredInProcessResearchAndDevelopment
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_5de4e92e-63cb-4205-b874-03c3bb9afa28"
      unitRef="U_USD">83104000</gyre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_b14ced98-e4cd-4154-9632-52ebcd682073"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_0998a63e-f57f-415c-903e-cbe1babf3faa"
      unitRef="U_USD">-628000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:CostsAndExpenses
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_77502d18-d48f-4fe6-9aba-dd824aabe3d8"
      unitRef="U_USD">180680000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_d33c52f4-d93c-46e5-bde7-45b3b5cb1f9c"
      unitRef="U_USD">93087000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_4798ddad-7c03-4524-bb53-5fb03a1b5455"
      unitRef="U_USD">-67230000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_aea1e8f8-61cc-459b-9f43-bfda7b7ac9a1"
      unitRef="U_USD">9203000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_cf37415a-fd72-4f01-a98d-4054075ba655"
      unitRef="U_USD">1044000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_38898398-8e83-469b-84ee-fb8131967efa"
      unitRef="U_USD">726000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_a3d34c31-a8ad-423c-b30c-af4b3d894f04"
      unitRef="U_USD">1076000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_973da9f2-2ea4-4bca-adac-e4469060376c"
      unitRef="U_USD">857000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_1c9002b4-0c9b-4492-89fa-5fce56982927"
      unitRef="U_USD">9261000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_71e7dceb-4ba8-4503-90ac-ed46f459fa53"
      unitRef="U_USD">2594000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_77f9a8aa-901b-42ce-aa2a-f9fdb2bb6184"
      unitRef="U_USD">1374000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_0633fe83-49cb-42e7-871f-771f11ec7daf"
      unitRef="U_USD">-76965000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_b56efdea-537e-41a0-980c-75818561ed7f"
      unitRef="U_USD">9412000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_51eef143-a453-4af4-8ce2-88473bde76ac"
      unitRef="U_USD">8515000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_922de0f0-bbe2-4304-ac29-ee64c9f1853d"
      unitRef="U_USD">5098000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_07781598-bdb1-418b-98f0-064caaf068e5"
      unitRef="U_USD">-85480000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_ce0bfe43-96df-487f-b114-5c9bd8a17fb7"
      unitRef="U_USD">4314000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_33e6a6ef-7872-4bfa-94c3-22a27792ab99"
      unitRef="U_USD">7453000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_d9d8efa4-8913-4a49-92a5-d3b2b1bc0c7f"
      unitRef="U_USD">2012000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_8a62a784-4151-46a6-93b8-3c48d2171996"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_11b881df-7691-4081-8fee-9b490dc56574"
      unitRef="U_USD">2302000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_a646df90-f70b-4d13-a330-cc6368bc0387"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="2"
      id="F_7e9c95a8-26d5-4881-9e96-7a1763315e5c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_d1292367-28f9-4377-8e3c-b229cb2ecc41"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="2"
      id="F_3a84e463-4926-413c-823e-007d44926101"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="0"
      id="F_3fec6bfb-fa30-422a-94f6-dabc8dedd7e5"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="0"
      id="F_c1b9732d-3872-4492-98c4-6c4d8afcfe51"
      unitRef="U_shares">63588119</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="0"
      id="F_26c56221-7345-4ffc-90fc-91ca2f123aef"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="0"
      id="F_4dd1d421-2dd1-4775-81e3-f8c58a7ecf03"
      unitRef="U_shares">75686406</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_ab7e4138-6974-46d5-9bca-febbf802b2cc"
      unitRef="U_USD">-85480000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_a066fc80-f08a-45c3-b5d4-1f0333e0140d"
      unitRef="U_USD">4314000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_32cea80f-0d1b-40a3-b2be-b7d8ce488485"
      unitRef="U_USD">-1484000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_df92ef61-ec9a-412f-9368-323d80233d61"
      unitRef="U_USD">-4928000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_c6bb9ee1-0817-42d5-b60a-37ca6ff2ccec"
      unitRef="U_USD">-86964000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_c8349866-8566-46a0-a4bd-72cb1a4131fc"
      unitRef="U_USD">-614000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_e583c712-05c5-4c7c-8328-6347419f8b8f"
      unitRef="U_USD">7453000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_1843c363-74e0-43c4-b7a2-0935f9266af5"
      unitRef="U_USD">2012000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_dccaab8a-d970-4125-bfda-bb9b649e337c"
      unitRef="U_USD">-647000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_014eab92-838b-4e98-bfd4-931d0b192bb5"
      unitRef="U_USD">-2170000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_c614127f-c4a5-4126-b12c-3c54175c0fb2"
      unitRef="U_USD">6806000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_af6ab8bc-d185-4031-befe-bb3cfc8eb9a1"
      unitRef="U_USD">-158000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_a64e128f-566e-4e38-a364-724986b7ee14"
      unitRef="U_USD">-93770000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_5e1e43da-39ee-4ef7-82ec-f2aa042d3191"
      unitRef="U_USD">-456000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0edb0ebb-f503-4b95-827d-83260811c5cf"
      decimals="INF"
      id="F_af892566-5fd1-45b4-9aef-585ea91c8ae4"
      unitRef="U_shares">63588119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0edb0ebb-f503-4b95-827d-83260811c5cf"
      decimals="-3"
      id="F_84be2f1a-f4bb-401f-970d-8ea2d5312c2e"
      unitRef="U_USD">64000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_774dcb44-6e8f-40e2-92fb-74eb3d10f679"
      decimals="-3"
      id="F_1fab6efe-2495-4bbe-b43c-d8a08836f0e3"
      unitRef="U_USD">25315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c368eb8c-00d1-4f05-bcc7-415246aeae15"
      decimals="-3"
      id="F_e566e149-24f1-4848-a966-eeecce015ee9"
      unitRef="U_USD">1413000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7dfcafca-61d1-46f1-a43e-d003319b30c3"
      decimals="-3"
      id="F_0bc16687-9652-4ba5-b3a3-4f88d508c12a"
      unitRef="U_USD">6340000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_eb79166d-261c-4aa0-b6cc-fd954e4458bf"
      decimals="-3"
      id="F_5f7693a0-ba05-4396-9c03-59a7515a8d28"
      unitRef="U_USD">2366000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_25dbe4a0-c5aa-49dd-826b-9a456c343407"
      decimals="-3"
      id="F_2a73a8a4-ce6f-49be-b950-3663400e1408"
      unitRef="U_USD">35498000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5f2eb8e2-864a-4564-afac-5ac5ae5e31a4"
      decimals="-3"
      id="F_7ff24a6a-1fc6-4305-8448-07a8cd3dd566"
      unitRef="U_USD">23967000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b7c2a125-5bff-41a6-a0df-4926d0dda919"
      decimals="-3"
      id="F_d96da30c-9fb9-42bf-ab4d-7a381842a40a"
      unitRef="U_USD">59465000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <gyre:AppropriationOfStatutoryReserve
      contextRef="C_ebddae99-35cb-4ad8-9ae5-e50276c1c921"
      decimals="-3"
      id="F_9ea9463d-a66f-4450-81dc-60e234cf7bf5"
      unitRef="U_USD">1247000</gyre:AppropriationOfStatutoryReserve>
    <gyre:AppropriationOfStatutoryReserve
      contextRef="C_4ae8d6c6-9b6a-426c-ba9b-df1d72c1c57c"
      decimals="-3"
      id="F_e110516d-2fbd-420e-8aab-9a9b639f24d9"
      unitRef="U_USD">-1247000</gyre:AppropriationOfStatutoryReserve>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_bc38fe45-e720-4e3e-901d-1a99ab32da43"
      decimals="-3"
      id="F_fb8efb55-cdb3-4a93-868f-f88067a1a8a0"
      unitRef="U_USD">7480000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_06e4c2d4-f7ea-4792-a208-6e5d5ddb822f"
      decimals="-3"
      id="F_209d5bdc-6b33-4b01-9bda-84de3e851fef"
      unitRef="U_USD">7480000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0b92166d-718c-4785-aa66-2913afa80931"
      decimals="-3"
      id="F_045a0028-318e-4578-a860-7185b213aa0a"
      unitRef="U_USD">5886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_d3ee813e-31b0-455a-acd4-25f945923ab0"
      unitRef="U_USD">13366000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_d1d44dd0-f099-499c-bf24-bbc98c230ca4"
      decimals="-3"
      id="F_cdb81173-96d3-4ed7-bcde-ac0e46c2d807"
      unitRef="U_USD">-2758000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_06e4c2d4-f7ea-4792-a208-6e5d5ddb822f"
      decimals="-3"
      id="F_639699c4-7e66-4133-9a04-2c71df1d160d"
      unitRef="U_USD">-2758000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0b92166d-718c-4785-aa66-2913afa80931"
      decimals="-3"
      id="F_509c3b87-bb9d-4e55-bbec-d636006176d5"
      unitRef="U_USD">-2170000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_713eb98d-5838-4464-90df-bfa4ca3659b8"
      unitRef="U_USD">-4928000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_4ae8d6c6-9b6a-426c-ba9b-df1d72c1c57c"
      decimals="-3"
      id="F_1d8e9a8a-7f75-48ca-96af-e21925007759"
      unitRef="U_USD">2302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_06e4c2d4-f7ea-4792-a208-6e5d5ddb822f"
      decimals="-3"
      id="F_52c64996-f35f-45e7-b1f0-3436e5a58939"
      unitRef="U_USD">2302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0b92166d-718c-4785-aa66-2913afa80931"
      decimals="-3"
      id="F_5c97ccc5-3c34-4cb9-a94d-1d99041bb46e"
      unitRef="U_USD">2012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_e82e6b16-143a-4068-b47e-29578d245210"
      unitRef="U_USD">4314000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_4f7731e9-8054-4146-a8d0-8ebfec2ebe77"
      decimals="INF"
      id="F_8b518c46-8f59-45e7-beea-be22dc89abc4"
      unitRef="U_shares">63588119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4f7731e9-8054-4146-a8d0-8ebfec2ebe77"
      decimals="-3"
      id="F_9f61a662-ba9c-482e-beaa-c195fa890210"
      unitRef="U_USD">64000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_969ae12f-04dd-45bd-837a-de4b4c55f1de"
      decimals="-3"
      id="F_e4b0f6dd-50ad-4d30-8c69-b5469774dcda"
      unitRef="U_USD">32795000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_964a9a24-1974-4f5d-9116-9d0ee44c4aaf"
      decimals="-3"
      id="F_b1cfd4e7-77fa-4580-ae1f-7302143c7efd"
      unitRef="U_USD">2660000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b15a99e2-1606-4164-acb1-5d6360dd4a3a"
      decimals="-3"
      id="F_373fd3e3-9266-4163-813b-4a28cfc6ad9d"
      unitRef="U_USD">7395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b8689a54-e515-453a-a125-a50eaed49c5b"
      decimals="-3"
      id="F_d0572f65-ba58-4a3f-b20f-4d2f0deb7a37"
      unitRef="U_USD">-392000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e4e28133-5b1e-4106-ab67-c16e08fd9d3d"
      decimals="-3"
      id="F_a1a91c49-5b1e-40e9-bae3-c02e2f3a8ab9"
      unitRef="U_USD">42522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3ba0c404-2823-46e7-9d85-bca97b5c230d"
      decimals="-3"
      id="F_e49e198d-e725-4ac1-ba0e-26e6edddbd00"
      unitRef="U_USD">29695000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_949ba615-a3df-4a10-9dc5-540b0ede23ab"
      unitRef="U_USD">72217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <gyre:TemporaryEquityIssuedDuringPeriodSharesAcquisitions
      contextRef="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56"
      decimals="INF"
      id="F_4e3e3617-e7fe-4a98-b967-6e0672a7be8b"
      unitRef="U_shares">12340</gyre:TemporaryEquityIssuedDuringPeriodSharesAcquisitions>
    <gyre:TemporaryEquityIssuedDuringPeriodValueAcquisitions
      contextRef="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56"
      decimals="-3"
      id="F_b5d2079c-50ca-47ea-9bdc-d3e7ed314c4d"
      unitRef="U_USD">63099000</gyre:TemporaryEquityIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b"
      decimals="INF"
      id="F_cef8a8ac-abad-4a78-b179-dcb7b829a188"
      unitRef="U_shares">2531851</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b"
      decimals="-3"
      id="F_5d9f6df7-0404-41ec-bf27-c53601d17c97"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_f0008245-ac04-475a-a3d9-4fa1983c4b11"
      decimals="-3"
      id="F_d8ed74bb-7869-4296-8d76-0f5929ff08be"
      unitRef="U_USD">21246000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e"
      decimals="-3"
      id="F_1ee38b4c-f127-4dc7-a4ff-cecb823f8834"
      unitRef="U_USD">21249000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_107bdcb5-653b-4b48-8aea-0de2c89eb046"
      unitRef="U_USD">21249000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <gyre:MinorityInterestDecreaseFromRedemptionsShares
      contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b"
      decimals="INF"
      id="F_bd28ec2f-0152-4b09-a645-e29f60aaec37"
      unitRef="U_shares">10463627</gyre:MinorityInterestDecreaseFromRedemptionsShares>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b"
      decimals="-3"
      id="F_de1b1e36-a741-4940-b14e-79950d250536"
      unitRef="U_USD">-10000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_f0008245-ac04-475a-a3d9-4fa1983c4b11"
      decimals="-3"
      id="F_2a4fddf3-b004-4556-afa3-54cd87872f0d"
      unitRef="U_USD">-7845000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_c46426ec-a619-48aa-b225-7389e165b89a"
      decimals="-3"
      id="F_55d71822-025f-40b0-a8e2-a8179bfa9af8"
      unitRef="U_USD">-438000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_8323d313-5e0d-40e1-8969-c2bf69e0e63f"
      decimals="-3"
      id="F_df35a9e9-8dbf-4371-b4fd-cd82d6a8062d"
      unitRef="U_USD">415000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e"
      decimals="-3"
      id="F_943a1845-e65c-42f9-884b-66efa89493bb"
      unitRef="U_USD">-7878000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be"
      decimals="-3"
      id="F_e2acd930-8a31-4e35-9422-86c0023694cb"
      unitRef="U_USD">7878000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <gyre:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56"
      decimals="INF"
      id="F_aae2064c-64db-4ddb-a139-c8308047fca4"
      unitRef="U_shares">811</gyre:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_8c268519-f8e6-48ee-a306-c2e17bcbfc56"
      decimals="-3"
      id="F_ffa388d7-d4f1-4e09-8a75-8540a38e73ee"
      unitRef="U_USD">1426000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f0008245-ac04-475a-a3d9-4fa1983c4b11"
      decimals="-3"
      id="F_2d26d679-9512-481b-a582-ff5dc28e9cdc"
      unitRef="U_USD">6127000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e"
      decimals="-3"
      id="F_0746e621-232a-4cf0-81a0-93dc72643a0c"
      unitRef="U_USD">6127000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be"
      decimals="-3"
      id="F_edc5975c-4418-4fbd-a82b-ac2068f364b2"
      unitRef="U_USD">1154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_dc1bcc80-a66d-4a97-86c2-f291a67439af"
      unitRef="U_USD">7281000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0bd79c6f-bca6-4dae-b6c1-2bd8cc35620b"
      decimals="INF"
      id="F_7ca4d986-3f95-4e97-8d5b-6e3578a9564a"
      unitRef="U_shares">12019</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f0008245-ac04-475a-a3d9-4fa1983c4b11"
      decimals="-3"
      id="F_09656bc3-3cc2-4988-9ae8-b350084379c0"
      unitRef="U_USD">166000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e"
      decimals="-3"
      id="F_91b92485-03dc-48a3-9125-ad37ae57a15b"
      unitRef="U_USD">166000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_43302b4e-919b-4e1d-928c-c78c4ad78ec0"
      unitRef="U_USD">166000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_8323d313-5e0d-40e1-8969-c2bf69e0e63f"
      decimals="-3"
      id="F_0426888b-0a70-4e68-a222-944bc6552137"
      unitRef="U_USD">-837000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e"
      decimals="-3"
      id="F_f59bb2c7-d569-4d22-ad24-e639d19ba289"
      unitRef="U_USD">-837000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be"
      decimals="-3"
      id="F_66e41301-3bd8-4532-bc22-e5e7daf19ea8"
      unitRef="U_USD">-647000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_4df6ca26-387b-4d07-bc85-2610b2dff230"
      unitRef="U_USD">-1484000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_3d486857-5008-4c2c-a4dd-5f5a83f5ac38"
      decimals="-3"
      id="F_fe6b9def-70cd-4de9-a181-5fe66d70a65c"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6d532a01-d3d5-4d7c-a909-21ac39f9b59e"
      decimals="-3"
      id="F_51556c1b-d938-4e05-9825-08459d036714"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_daa2e624-8d9d-4cd2-8c1d-72c00e7ce4be"
      decimals="-3"
      id="F_fc8a0296-8cf1-4b6e-bb04-c7d5354494f7"
      unitRef="U_USD">7453000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_6f654b61-5f79-4c8a-882d-6177633eafd9"
      unitRef="U_USD">-85480000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_de7650ff-30a6-41a3-bba8-6bafbd98ef0a"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="-3"
      id="F_e30a88f3-a436-4431-a7c1-90503ba47f6e"
      unitRef="U_USD">64525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_812372f4-948a-4dd8-9e62-5d74629f12d2"
      decimals="INF"
      id="F_90a6adb6-9c1d-4a41-8dd8-02971c016144"
      unitRef="U_shares">76595616</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_812372f4-948a-4dd8-9e62-5d74629f12d2"
      decimals="-3"
      id="F_2f9f9b72-dc62-4e63-a760-dcbfcc6fb2ee"
      unitRef="U_USD">77000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3f63f1a6-45b5-4355-b17a-f27ea1669ee5"
      decimals="-3"
      id="F_7b4c0356-16ff-4261-965f-80ecd87f73df"
      unitRef="U_USD">68179000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_59d1977f-7c62-42fa-a426-ebf6da7d7d38"
      decimals="-3"
      id="F_bdf7d185-eec6-47bc-9c11-273addf4bdb6"
      unitRef="U_USD">3098000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d564b606-4a21-47bf-80f7-c37ac338b08b"
      decimals="-3"
      id="F_5c012d0f-2350-4eb7-aaf7-df80acbab0c5"
      unitRef="U_USD">-85538000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4011e20c-cbaf-4cba-ba16-cfe9ea152f93"
      decimals="-3"
      id="F_85a96b1e-ac7b-4ab2-b813-107e21bad7f2"
      unitRef="U_USD">-1644000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_84bf33ef-ee75-44b7-9ee4-7d137c6aab5e"
      decimals="-3"
      id="F_c6b2c58f-458d-4bfa-aa5b-8b81eaeec983"
      unitRef="U_USD">-15828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_600857f6-7a26-4dcb-b37f-7638845d2593"
      decimals="-3"
      id="F_d4052d48-b05c-450a-acbb-457b5166da83"
      unitRef="U_USD">29777000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_2a856c7d-50be-424c-99da-3a3f323bad99"
      unitRef="U_USD">13949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_211ab679-f8b3-4bdd-968e-ce5e57474110"
      unitRef="U_USD">-85480000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_daaf52d2-ee3f-43c3-a217-946446917f16"
      unitRef="U_USD">4314000</us-gaap:ProfitLoss>
    <gyre:AcquiredInProcessResearchAndDevelopment
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_11bcf36e-cca5-4a18-b8ab-e38de9e164c2"
      unitRef="U_USD">83104000</gyre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_38ce9f14-40f7-4249-8e17-3982bef703bb"
      unitRef="U_USD">7281000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_00e6c873-1af4-4be9-ac02-561e551d927a"
      unitRef="U_USD">13366000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_be79daff-2f2c-4e62-9c18-373d9c1acaa8"
      unitRef="U_USD">1074000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_e57c9079-682f-4cdf-8ca7-fbd12f4d3ab9"
      unitRef="U_USD">1087000</us-gaap:DepreciationDepletionAndAmortization>
    <gyre:NoncashLeaseExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_f6904f55-86d3-4dea-8870-13e73efcc0f9"
      unitRef="U_USD">355000</gyre:NoncashLeaseExpense>
    <gyre:NoncashLeaseExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_90398fc6-0ac6-45be-9b52-e6e7039bf562"
      unitRef="U_USD">404000</gyre:NoncashLeaseExpense>
    <gyre:AmortizationOfLandUseRights
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_c06abf80-2748-4b48-994c-da1ae0de2ead"
      unitRef="U_USD">40000</gyre:AmortizationOfLandUseRights>
    <gyre:AmortizationOfLandUseRights
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_9794bb48-42f9-4fa0-b87a-5d694fa556eb"
      unitRef="U_USD">42000</gyre:AmortizationOfLandUseRights>
    <gyre:DeferredIncomeTaxExpenseBenefitNet
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_7adc2572-6598-4773-bb06-150c4248f573"
      unitRef="U_USD">-1160000</gyre:DeferredIncomeTaxExpenseBenefitNet>
    <gyre:DeferredIncomeTaxExpenseBenefitNet
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_46aad5ae-cd68-4805-9c9d-e0e31a1af3bf"
      unitRef="U_USD">-838000</gyre:DeferredIncomeTaxExpenseBenefitNet>
    <gyre:BadDebtExpenseAndOtherNonCashItems
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_30305042-2b1b-425f-b8a8-ba1b8cca210c"
      unitRef="U_USD">-61000</gyre:BadDebtExpenseAndOtherNonCashItems>
    <gyre:BadDebtExpenseAndOtherNonCashItems
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_963561b9-d38b-4776-ad44-598712735579"
      unitRef="U_USD">22000</gyre:BadDebtExpenseAndOtherNonCashItems>
    <gyre:AccruedInterestOnLongTermCertificatesOfDeposit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_b80555bf-eb7d-44d2-8b1a-4c1cb15afaae"
      unitRef="U_USD">633000</gyre:AccruedInterestOnLongTermCertificatesOfDeposit>
    <gyre:AccruedInterestOnLongTermCertificatesOfDeposit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_c26d3f62-ff68-4810-b4d8-a3705f0fbaf2"
      unitRef="U_USD">178000</gyre:AccruedInterestOnLongTermCertificatesOfDeposit>
    <gyre:ChangeInFairValueOfLongTermReceivables
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_3a1f85a2-18f0-46b7-8aa0-15c6d02ca0bc"
      unitRef="U_USD">39000</gyre:ChangeInFairValueOfLongTermReceivables>
    <gyre:ChangeInFairValueOfDerivativeLiabilities
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_29264d88-97a7-49db-8211-59a58a59aeeb"
      unitRef="U_USD">39000</gyre:ChangeInFairValueOfDerivativeLiabilities>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_cb0be00f-a57e-4377-ad18-ad54a683dace"
      unitRef="U_USD">9261000</us-gaap:FairValueAdjustmentOfWarrants>
    <gyre:EquityGainLossOfUnconsolidatedAffiliates
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_815ee809-1aae-4704-89f9-df10311eff8d"
      unitRef="U_USD">-1314000</gyre:EquityGainLossOfUnconsolidatedAffiliates>
    <gyre:EquityGainLossOfUnconsolidatedAffiliates
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_4afb205f-29ae-4512-95ca-24836daed04d"
      unitRef="U_USD">-251000</gyre:EquityGainLossOfUnconsolidatedAffiliates>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_14b77b3c-3dc7-4abd-9355-d2aeb43225c5"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_bf8dac94-369b-405d-ab30-6151cf9db692"
      unitRef="U_USD">-628000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_d57a239b-6372-402d-8bc1-717e739148a0"
      unitRef="U_USD">-4000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <gyre:IncreaseDecreaseInAccountsAndNotesReceivables
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_43a0126b-eab4-4b35-86d8-fd604407803c"
      unitRef="U_USD">-1398000</gyre:IncreaseDecreaseInAccountsAndNotesReceivables>
    <gyre:IncreaseDecreaseInAccountsAndNotesReceivables
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_066a4ef5-03a8-4c4c-8d52-9a6043565aa0"
      unitRef="U_USD">7920000</gyre:IncreaseDecreaseInAccountsAndNotesReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_75163542-949e-4401-a708-9143c2c4443c"
      unitRef="U_USD">96000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_54555040-37d8-4ddf-a87a-8040c89b1bf3"
      unitRef="U_USD">-1747000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_fa6062fd-22bc-4ab5-907e-84ce61530520"
      unitRef="U_USD">879000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_f47ef4b4-5590-4c30-ad3f-d91a33361275"
      unitRef="U_USD">82000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_2df49783-9721-48e4-a0e5-03e3fb5dd481"
      unitRef="U_USD">-973000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_4590241c-945b-4cb6-8f6e-c66b8ba05037"
      unitRef="U_USD">3003000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_8aacbcab-c2e3-4599-a370-0e33d65efb47"
      unitRef="U_USD">-1344000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_0ee3e39e-70fe-4b44-a643-d311d609a750"
      unitRef="U_USD">192000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_c0ea9ea5-2a60-4520-b3e3-353d2afcf988"
      unitRef="U_USD">-112000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_2a6a15c9-28f1-40ab-a524-56cd8d659860"
      unitRef="U_USD">-102000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_a84fc8f0-8aba-4cfa-8921-fbf5d837b7fe"
      unitRef="U_USD">425000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_e4792910-366b-4212-b5b9-33a203e95d7e"
      unitRef="U_USD">1446000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_defbe7cd-7367-42f4-97a5-8b205f84eef7"
      unitRef="U_USD">1914000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_e9531bff-1354-4f24-a533-46149bf7afa4"
      unitRef="U_USD">-473000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_881b0b00-f1bb-44fb-b159-437196c146d6"
      unitRef="U_USD">-429000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_ba563666-46e2-465e-af2b-68465657b25a"
      unitRef="U_USD">25892000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_0c657228-39bc-40d0-9865-3faefd30ef84"
      unitRef="U_USD">10677000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_cc9e0eff-9af2-47ff-baaa-5921d135ffc2"
      unitRef="U_USD">69000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_45655ecf-c980-481c-934e-1a61fd8a839c"
      unitRef="U_USD">13000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_2a3c7f9a-ca98-47d5-b653-ec1ac0c8cddd"
      unitRef="U_USD">15735000</us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit>
    <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_297b8cae-2fc0-47ef-8d0c-8cb86c9e27f5"
      unitRef="U_USD">7484000</us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_94f9a00e-9024-4027-9a2a-337400204e4e"
      unitRef="U_USD">8517000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_385967bd-c58f-40c1-9f62-9e04c54c76ab"
      unitRef="U_USD">4985000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_e790d059-1c9c-4619-8c6e-095f8534cabd"
      unitRef="U_USD">664000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_60cb33ca-8071-45cc-b5b4-6f18e982e75a"
      unitRef="U_USD">1000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_6a3cfa2d-615c-4e89-b1f2-51b297414d06"
      unitRef="U_USD">1332000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_413c603d-78d6-4a3f-8321-33563e38fd15"
      unitRef="U_USD">5587000</us-gaap:CashAcquiredFromAcquisition>
    <gyre:CashPaidForAcquisitionCosts
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_847ecd5e-cc0f-4234-966d-95588d3d1e7c"
      unitRef="U_USD">124000</gyre:CashPaidForAcquisitionCosts>
    <gyre:PaymentOfDisposalOfSubsidiary
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_2395dccd-7321-49f4-b9a0-903c644ee2c1"
      unitRef="U_USD">566000</gyre:PaymentOfDisposalOfSubsidiary>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_7e14bcc1-072f-48f6-b20d-b46a9b0abfb3"
      unitRef="U_USD">-19760000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_618679a3-7141-4fe0-9826-6537007059d2"
      unitRef="U_USD">-13814000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_c31a66f3-10fb-4e6e-bfcf-389286e040c1"
      unitRef="U_USD">2500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_80a654ca-0582-4238-b68d-f7191f4eb52c"
      unitRef="U_USD">2500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_60362127-4309-4078-ac7d-1ed599978d84"
      unitRef="U_USD">-298000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_5ebd367f-0905-4412-9810-2cd2aa447b6b"
      unitRef="U_USD">-1891000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_63f51b10-5e51-43eb-8790-3f480ad798a1"
      unitRef="U_USD">8334000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_0fa16207-d502-4fc3-bb86-7bc61d5d2a56"
      unitRef="U_USD">-5028000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_d2b12c2d-43bd-4c2f-a49e-38b1cdc9b9d7"
      unitRef="U_USD">25175000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_b7c2a125-5bff-41a6-a0df-4926d0dda919"
      decimals="-3"
      id="F_e3c4a61d-13ed-4676-9acd-5be54a69a17a"
      unitRef="U_USD">30203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_a237726e-8aad-4f7a-b844-1d1f08d33c39"
      unitRef="U_USD">33509000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_bc5300d3-705c-4f0a-ada5-bfb6dbe5d5b2"
      unitRef="U_USD">25175000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <gyre:DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_1bab83cb-21a5-4f20-bdfb-128a5239ba79"
      unitRef="U_USD">84348000</gyre:DeemedIssuanceOfCommonStockAndConvertiblePreferredStockToFormerStockholders>
    <gyre:AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_d26d8e42-4bb8-43e1-a36f-4098afb59f95"
      unitRef="U_USD">2500000</gyre:AdvancePaymentForConvertiblePreferredStockAndPreferredStockWarrantsAcquiredUponContributions>
    <gyre:DisposalConsiderationInOtherReceivables
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_d68f438e-ffcc-436a-ae87-d8293b45f516"
      unitRef="U_USD">768000</gyre:DisposalConsiderationInOtherReceivables>
    <gyre:AcquisitionCostsInDueToRelatedParties
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_a5726274-f079-4a58-89f6-6cc6c45b8f87"
      unitRef="U_USD">535000</gyre:AcquisitionCostsInDueToRelatedParties>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_c1de81ca-e1e3-4456-b7a4-53163a38fd71"
      unitRef="U_USD">277000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_a8c8cdfd-29b0-4588-a19b-eb53f65ff713"
      unitRef="U_USD">57000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <gyre:ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_6b28ab6b-2a22-4b16-878f-bac7ef082dec"
      unitRef="U_USD">166000</gyre:ProceedsFromExerciseOfStockOptionsIncludedInOtherReceivable>
    <gyre:PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_901e8cff-9f55-4382-9f03-e2aacc9c7d17"
      unitRef="U_USD">727000</gyre:PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_10dcb768-1b91-4dc6-9fc4-4664dc054d96"
      unitRef="U_USD">6346000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_a3a959c1-5506-489e-a676-024229ca0b53"
      unitRef="U_USD">6306000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_b3e885c6-238b-4131-b1c0-3f4c2ba833df">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gyre Therapeutics, Inc. (the &#x201c;Company,&#x201d; &#x201c;Gyre,&#x201d; or the &#x201c;combined company&#x201d;), formerly known as Catalyst Biosciences, Inc. (&#x201c;Catalyst&#x201d;), is a biopharmaceutical company originally incorporated in Delaware on March 7, 1997 under the name Targacept, Inc. Catalyst was a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, Catalyst had several protease assets that were designed to address unmet medical needs in disorders of the complement or coagulation systems.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;After completion of the transactions under the Business Combination Agreement as described below, Gyre became a financially-sustainable pharmaceutical company with a record of financial success that develops and commercializes small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;F351 Asset Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 26, 2022, Catalyst executed and closed an Asset Purchase Agreement, which was amended on March 29, 2023 (the &#x201c;F351 Agreement&#x201d;), with GNI Group Ltd. (&#x201c;GNI Japan&#x201d;) and GNI Hong Kong Limited (&#x201c;GNI HK&#x201d;) to purchase all of the assets and intellectual property rights primarily related to a clinical-stage proprietary Hydronidone compound for the treatment of nonalcoholic steatohepatitis (&#x201c;NASH&#x201d;), a severe form of nonalcoholic fatty liver disease (collectively, the &#x201c;F351 Assets&#x201d;), other than such assets and intellectual property rights located in the People&#x2019;s Republic of China (&#x201c;PRC&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Business Combination Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 26, 2022, Catalyst entered into a Business Combination Agreement, as amended on March 29, 2023 and August 30, 2023 (the &#x201c;Business Combination Agreement&#x201d;) with GNI USA, Inc. (&#x201c;GNI USA&#x201d;), GNI Japan, GNI HK, Shanghai Genomics, Inc. (&#x201c;SG&#x201d; and collectively with GNI USA, GNI Japan and GNI HK, the &#x201c;Contributors,&#x201d; and each a &#x201c;Contributor&#x201d;), certain individuals (each, a &#x201c;Minority Holder&#x201d; and collectively, the &#x201c;Minority Holders&#x201d;) and Continent Pharmaceuticals Inc. (&#x201c;CPI&#x201d;). On October 30, 2023 (the &#x201c;Effective Time&#x201d;), the Contributions (as defined below) became effective and Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (&#x201c;BC&#x201d;). In connection with the Contributions, and immediately prior to the Effective Time of the Contributions, Catalyst amended its certificate of incorporation, increased the number of authorized shares of its common stock, par value &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share (the &#x201c;Common Stock&#x201d;) from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, effected a&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1-for-15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the &#x201c;Reverse Stock Split&#x201d;) and changed its name to Gyre Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Shares of Catalyst Common Stock were previously listed on The Nasdaq Capital Market under the symbol &#x201c;CBIO.&#x201d; Catalyst had filed a listing application for the combined company with the Nasdaq Stock Market Inc. (&#x201c;Nasdaq&#x201d;). On October 31, 2023, Gyre&#x2019;s Common Stock commenced trading on the Nasdaq Capital Market under the symbol &#x201c;GYRE&#x201d;, on a post-reverse stock split adjusted basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the Business Combination Agreement, at the Effective Time of the Contributions, and after giving effect to the 1-for-15&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;GNI USA contributed all of its ordinary shares in the capital of CPI to Catalyst in exchange for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,923,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Gyre Common Stock (the &#x201c;CPI Contribution&#x201d;), &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;GNI USA contributed its interest in Further Challenger International Limited (&#x201c;Further Challenger&#x201d;) for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,664,779&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Gyre Common Stock (the &#x201c;FC Contribution&#x201d; and together with the CPI Contribution, the &#x201c;GNI USA Contributions&#x201d;), and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;c)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;each Minority Holder contributed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the interest he or she held in his or her respective entity in exchange for an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,463,627&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Gyre Common Stock (the &#x201c;Minority Holder Contributions&#x201d; and together with the GNI USA Contributions, the &#x201c;Contributions&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of the GNI USA Contributions, Gyre directly and indirectly holds &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of CPI&#x2019;s shares. Through Gyre&#x2019;s ownership of CPI, prior to the Minority Holder Contributions, Gyre held a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; indirect interest in BC. Upon completion of the Minority Holder Contributions, Gyre obtained additional indirect interests in BC and holds, in aggregate, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; indirect interest in BC.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Immediately after the closing of the Contributions, excluding potentially dilutive securities, GNI USA owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the outstanding shares of Gyre Common Stock, Catalyst&#x2019;s existing stockholders, excluding GNI USA, owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the outstanding Gyre Common Stock, and the Minority Holders owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the outstanding shares of Gyre Common Stock. The Convertible Preferred Stock remained outstanding after the closing of the Contributions and is not included in the above ownership percentages.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the Effective Time, BC terminated its 2021 Stock Incentive Plan (the &#x201c;2021 Plan&#x201d;) and the options (the &#x201c;BC Options&#x201d;) outstanding under the 2021 Plan were terminated and replaced with options granted under a subplan for Chinese participants under the Gyre 2023 Omnibus Incentive Plan (the &#x201c;2023 Omnibus Incentive Plan&#x201d;) that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remained issued and outstanding, and such shares and options were unaffected by the Contributions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;BC is a commercial-stage biopharmaceutical company registered and established in the PRC in 2002. BC is committed to the research and development of new drugs as well as manufacturing and commercialization of ETUARY (pirfenidone capsule) for the treatment of idiopathic pulmonary fibrosis and other pharmaceutical products. The registered office of BC is located at 60 Shunkang Road, Shunyi District, Beijing, PRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The immediate holding company of BC is BJContinent Pharmaceuticals Limited (&#x201c;BJC&#x201d;). The intermediate holding company of BC is CPI. Immediately following the Contributions, the immediate holding company of CPI is Gyre. The immediate holding Company of Gyre is GNI USA and the ultimate holding company of Gyre is GNI Japan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The GNI USA Contributions were treated as an asset acquisition under U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), with CPI treated as the accounting acquirer and presented as the predecessor for the post-acquisition SEC reporting purposes. Since Catalyst is the legal acquirer, the GNI USA Contributions were accounted for as a reverse asset acquisition. This determination was based upon the terms of the Business Combination Agreement and other factors including that, immediately following the GNI USA Contributions: (i) GNI USA (as the parent company of CPI immediately prior to the GNI USA Contributions) owns a substantial majority of the voting power of the combined company; (ii) CPI, through GNI USA, has the ability to control the board of directors of the combined company; and (iii) senior management of BC and GNI USA holds a majority of the key positions in senior management of the combined company. Immediately prior to the closing of the Contributions, Catalyst did not meet the definition of a business because Catalyst did not have an organized workforce that significantly contributed to its ability to create output, and substantially all of its fair value was concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of the closing date of the GNI USA Contributions, the net assets of Catalyst were recorded at their acquisition-date relative fair values in the accompanying consolidated financial statements of the Company and the reported operating results prior to the GNI USA Contributions are those of CPI.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in BC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingent Value Rights Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concurrent with the signing of the Business Combination Agreement on December 26, 2022, Catalyst and the Rights Agent (as defined in the CVR Agreement) executed a contingent value rights agreement (the &#x201c;CVR Agreement&#x201d;), as amended on March 29, 2023, pursuant to which each holder of Catalyst Common Stock as of January 5, 2023 (the &#x201c;CVR Holder&#x201d;), excluding GNI, received one contractual contingent value right (a &#x201c;CVR&#x201d;) for each share of Catalyst Common Stock held by such holder. Each CVR entitles the holder thereof to receive certain cash payments in the future. For additional information, see Note 13 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company effected a 1-for-15 reverse stock split immediately prior to the Effective Time of the Contributions. The par value of the Catalyst Common Stock following the Reverse Stock Split was not adjusted and remains at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. All of the Catalyst&#x2019;s issued and outstanding common stock and options have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All share and per share information has been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented, unless otherwise indicated. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding, which resulted in a proportional decrease in the number of shares of the Company&#x2019;s common stock reserved for issuance upon exercise or vesting of such stock options, warrants, and in the case of stock options and warrants, a proportional decrease in the exercise price of such stock options and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No fractional shares were issued in connection with the Reverse Stock Split and stockholders who would otherwise be entitled to a fraction of one share received a proportional cash payment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the year ended December 31, 2023, the Company had a net loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, while net cash provided by operating activities was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of December 31, 2023, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and cash and cash equivalents of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Based on the Company&#x2019;s current operating plan, management believes that existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund the Company&#x2019;s operating activities and obligations for at least 12 months following the issuance of these consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_77204f22-ab15-4c2a-a5cf-eebb0427fdfc"
      decimals="INF"
      id="F_838033a0-d540-4470-b90a-34b4cbf80c0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a0eac393-f1de-40db-a17e-e4afc62662a6"
      decimals="INF"
      id="F_e733b2bb-2e90-4c4d-9d5d-11fca87ea566"
      unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c7e70b74-1137-44bb-bd33-d9231ea42d4e"
      decimals="INF"
      id="F_c939fe3e-3c15-4d57-b42b-87c7d9a76114"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_3c991f1d-66f5-47f8-8e04-683dff126fbb"
      id="F_49b4b748-bfa2-4bc6-bb0c-becb6dbd7134"> 1-for-15 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_5ca366b2-7931-469b-9226-43eecac0ccd6"
      id="F_a60c8c22-8c69-486e-a87f-ce207eb5c594"> reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d1d8d078-42db-45d4-8278-c6b26dcb880f"
      decimals="INF"
      id="F_ca23a266-2c83-40b6-81d3-fb370fec244b"
      unitRef="U_shares">45923340</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_29dd3e9d-3aeb-4cda-b357-0760b9f78c7f"
      decimals="INF"
      id="F_df6c4907-c19c-473d-bbd9-506498ab8c26"
      unitRef="U_shares">17664779</us-gaap:CommonStockSharesIssued>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_11e895d4-da38-44af-a160-56e416efc9d0"
      decimals="2"
      id="F_95f8152a-3929-47a8-a4c3-ee8e0ac04830"
      unitRef="U_pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_11e895d4-da38-44af-a160-56e416efc9d0"
      decimals="INF"
      id="F_8b7c0eb2-4dc7-4628-90d8-1975352bf337"
      unitRef="U_shares">10463627</us-gaap:CommonStockSharesIssued>
    <gyre:PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds
      contextRef="C_0e40eb2f-6361-4ec3-826e-a6b22c03f7bd"
      decimals="2"
      id="F_f6d66542-bbc5-4704-8bcc-7ef4b2619819"
      unitRef="U_pure">1</gyre:PercentageOfMinorityInterestOwnershipDirectlyAndIndirectlyHolds>
    <gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds
      contextRef="C_5d3825d9-b987-4009-9844-dcb7a6a0f783"
      decimals="3"
      id="F_5885b883-6544-4fc3-b499-3ebdfc817ce4"
      unitRef="U_pure">0.56</gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds>
    <gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds
      contextRef="C_4415040d-7158-489d-9d55-5d063148a4eb"
      decimals="3"
      id="F_8f3ba766-d5e0-43d4-8721-0bf1170473dd"
      unitRef="U_pure">0.652</gyre:PercentageOfMinorityInterestOwnershipIndirectlyHolds>
    <gyre:PercentageOfOutstandingSharesOfCommonStock
      contextRef="C_e8c28c99-2d83-45ea-8686-ca83957381c9"
      decimals="3"
      id="F_f00fc937-1f10-4882-ba5a-e41b021cd5d2"
      unitRef="U_pure">0.836</gyre:PercentageOfOutstandingSharesOfCommonStock>
    <gyre:PercentageOfOutstandingSharesOfCommonStock
      contextRef="C_c8bdbd82-72b3-41d8-88a4-121a036217e7"
      decimals="3"
      id="F_38e1c572-1c80-42ac-89ab-0440fab68faf"
      unitRef="U_pure">0.028</gyre:PercentageOfOutstandingSharesOfCommonStock>
    <gyre:PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="3"
      id="F_7d2354c1-84a6-42b3-837f-367705917291"
      unitRef="U_pure">0.137</gyre:PercentageOfMinorityHoldersOwnedOutstandingSharesOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_812372f4-948a-4dd8-9e62-5d74629f12d2"
      decimals="3"
      id="F_3a3367bf-a15e-4ba1-9eca-ce349b49c5ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:NetIncomeLoss
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_1e5806d7-0c36-452c-8dbb-268b2da42f20"
      unitRef="U_USD">-85500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_e19997c7-723b-47c2-9dc7-7a769678f85e"
      unitRef="U_USD">25900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_a8b22f21-33e0-46cc-84be-ae01ac4f0af8"
      unitRef="U_USD">-85500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_a4523453-0741-46ea-ab7c-d9e5f51b720a"
      unitRef="U_USD">33500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_470e87d0-0087-4a00-9bb0-1ca8f5663e44">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Noncontrolling Interest&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reports noncontrolling interest (&#x201c;NCI&#x201d;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM, as a group, includes Gyre&#x2019;s Chief of Executive Officer (&#x201c;CEO&#x201d;), BC&#x2019;s General Manager, and the Chairman of Gyre&#x2019;s Board of Directors (&#x201c;Gyre&#x2019;s Board&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company has determined that it operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; distinct operating segments and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;f Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts and note receivable, and long-term certificates of deposits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the Company had cash of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, and long-term certificates of deposit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2015, a new Deposit Insurance System (&#x201c;DIS&#x201d;) managed by the People&#x2019;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#x201c;RMB&#x201d;) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Ac&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Customer Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023 and 2022, one customer, Sinopharm Group Co., Ltd., accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, of accounts receivable, respectively. For the year ended December 31, 2023, three customers known as Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of total revenue respectively. For the year ended December 31, 2022, three customers known as Sinopharm Group Co., Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, and China Resources Pharmaceutical Group Ltd accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of total revenue respectively. All customers are located in the PRC.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company invests portion of its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and Note 13 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for additional information regarding the CVR derivative liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants to purchase shares of the Convertible Preferred Stock (&#x201c;Preferred Stock Warrants&#x201d;) are freestanding financial instruments classified as warrant liability on the Company&#x2019;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#x2019;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to account for the Convertible Preferred Stock. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-term Certificates of Deposit&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The long-term certificates of deposit will mature between February 2025 and July 2026. Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using the effective interest method. The Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; allowance for credit losses associated with the certificates of deposit as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-Term Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#x201c;GCBP&#x201d;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for additional information regarding the long-term receivable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts and Note Receivables, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#x2019;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#x2019;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:68.014%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.362%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Note receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts and note receivables, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes in the allowance for credit losses as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:68%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.42%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Recoveries collected and write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventories, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:5.204%;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.42%;"&gt;&lt;/td&gt;
          &lt;td style="width:58.58%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b8d10737-f18e-4a8d-80f3-5bcbf043af92;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of the estimated useful life or the term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patents and Technological Know-How&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Computer Software&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ba9e4760-e1ab-447a-a061-08082fe718fe;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#x2019;s leases do not contain any residual value guarantees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Land Use Rights, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;amount of an asset group exceeds its fair valu&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record any impairment of long-lived assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Tax Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records revenue in accordance with ASC Topic 606 (&#x201c;ASC 606&#x201d;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#x2019;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(a) Sale of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer, generally upon completion of quality inspection by the distributor after delivery of the pharmaceutical products.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(b) License of Intellectual Property&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue from a license agreement is recognized at a point in time when the control of the right to use the license is transferred to the customer. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Development or regulatory milestone payments, which are included in the transaction price to the extent that it is probable that a significant reversal of accumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of any milestones, and if necessary, adjusts its estimated transaction price on a cumulative catch-up basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize any contract assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred revenue is recognized when a payment is received from a customer before the Company transfers the related goods or services. Deferred revenue is recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of December 31, 2023, the Company&#x2019;s deferred revenue balance was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Deferred revenue was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as of December 31, 2022 which has been recognized as revenue during the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cost of Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#x2019;s assumptions regarding a number of variables including the fair value of its common stock, its expected common stock price volatility over the expected&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;amp;D with no alternative future use is charged to expense at the acquisition date. Refer to Note 7 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;GNI USA Contributions under the Business Combination Agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for a more detailed description.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Selling and Marketing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Government Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;amount &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Interest Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Income (Loss) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Per Share (&#x201c;EPS&#x201d;) Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASC 260&#x201d;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#x2019;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#x2019;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;EPS &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for more information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Translation and Remeasurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of BC is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Matters&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company uses the U.S. Dollar as its reporting currency.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and  equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive (loss) income. During the year ended December 31, 2023, the Company had translation loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. During the year ended December 31, 2022, the Company had translation loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;operations and comprehensive (loss) income. The foreign currency transaction gains or losses for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;were immaterial.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#x2019;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. 99.5% of the Company&#x2019;s cash and long-term certificates of deposit as of December 31, 2023 of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, were denominated in RMB.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2021-04 and related updates on&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and the adoption &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;did not have a material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2020, FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the previous models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2021. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2020-06 on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and the adoption &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;did not have a material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Business Combinations &#x2013; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2021-08 and related updates on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The adoption of ASU 2021-08 had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impact on the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2021, the FASB issued ASU 2021-10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Government Assistance (Topic 832) &#x2014; Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The amendments in this ASU require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity&#x2019;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; this standard as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The adoption of this ASU &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;did not have any material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures (Topic 280)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company plans to adopt annual requirements and related updates under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently assessing the impact of adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#x2019;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_c0ee2f20-6e67-4af9-ad3f-9ad13c2abd65">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its controlled subsidiaries have been prepared in accordance with U.S. GAAP. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_895eb1f4-4916-4ce5-bf12-693cc4b65f2b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, CVR derivative liability, warrant liability, allowance for credit losses, reserves for excess or obsolete inventory, operating lease right-of-use assets and liabilities, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, income taxes, stock-based compensation and useful lives of property and equipment and intangibles with definite lives. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <gyre:NoncontrollingInterestPolicyPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_b786e26b-66d2-4615-9bd0-71b910375ffd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Noncontrolling Interest&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reports noncontrolling interest (&#x201c;NCI&#x201d;) in a subsidiary as a separate component of equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;</gyre:NoncontrollingInterestPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_82a6d165-7434-436e-8d74-8adcc5cfce68">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM, as a group, includes Gyre&#x2019;s Chief of Executive Officer (&#x201c;CEO&#x201d;), BC&#x2019;s General Manager, and the Chairman of Gyre&#x2019;s Board of Directors (&#x201c;Gyre&#x2019;s Board&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company has determined that it operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; distinct operating segments and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segments.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="INF"
      id="F_002957f1-bec3-4806-8a82-37ae4fec0841"
      unitRef="U_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="INF"
      id="F_c5af23b9-b4ba-4953-b6ec-744fa95e7dd4"
      unitRef="U_Segment">2</us-gaap:NumberOfReportableSegments>
    <gyre:RisksAndUncertainitiesPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_43730af2-21f8-4607-a293-5197c01e0e9d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from larger and established companies, uncertainty of clinical results, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions.&lt;/span&gt;&lt;/p&gt;</gyre:RisksAndUncertainitiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_23cac478-33d5-4985-ae4a-870ab283623d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;f Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts and note receivable, and long-term certificates of deposits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the Company had cash of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, and long-term certificates of deposit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is exposed to United States credit risk in the event of default by the United States institutions holding cash to the extent beyond the amount insured by the United States federal depository insurance corporation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2015, a new Deposit Insurance System (&#x201c;DIS&#x201d;) managed by the People&#x2019;s Bank of China was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of Chinese Renminbi (&#x201c;RMB&#x201d;) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company maintains cash and deposits in excess of the amount protected by DIS and in the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the creditworthiness of these financial institutions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Ac&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;counts receivable are typically unsecured and are derived from product sales. The Company manages credit risk related to the accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and creditworthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:Cash
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_74031b36-cbdf-4781-80bf-8d9cc71fdff9"
      unitRef="U_USD">33500000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-5"
      id="F_7b788baa-4564-49e1-bb30-c0d7814558c9"
      unitRef="U_USD">25200000</us-gaap:Cash>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_f29e1880-6b0d-46f2-8638-7a1f0c4394a4"
      unitRef="U_USD">23400000</gyre:LongTermCertificatesOfDeposit>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-5"
      id="F_c27dec9a-85d0-4bfb-ad74-b1397bd78646"
      unitRef="U_USD">7400000</gyre:LongTermCertificatesOfDeposit>
    <gyre:DepositsInLicensedBanksProtectedByDepositInsuranceSystem
      contextRef="C_14bcbd0d-16c5-428b-aeae-b50976bc4336"
      decimals="0"
      id="F_6bd8e4d8-1cfe-41c1-9671-817bdca6558f"
      unitRef="U_CNY">500000</gyre:DepositsInLicensedBanksProtectedByDepositInsuranceSystem>
    <gyre:ConcentrationOfCustomerRiskPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_fd7f0cd0-8e80-4c4b-8db1-6574369eb2bf">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Customer Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023 and 2022, one customer, Sinopharm Group Co., Ltd., accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, of accounts receivable, respectively. For the year ended December 31, 2023, three customers known as Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of total revenue respectively. For the year ended December 31, 2022, three customers known as Sinopharm Group Co., Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, and China Resources Pharmaceutical Group Ltd accounted for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of total revenue respectively. All customers are located in the PRC.&lt;/span&gt;&lt;/p&gt;</gyre:ConcentrationOfCustomerRiskPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_b1ac7913-1b9e-4353-967b-ae81b61fc740"
      decimals="3"
      id="F_54f3583e-5cfd-40ac-8fb1-ea59ce8ddb09"
      unitRef="U_pure">0.505</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_c78a0ae7-fcae-4fbc-826e-d3417a171185"
      decimals="3"
      id="F_a0f04600-cb11-403c-8842-74d424c72cad"
      unitRef="U_pure">0.451</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_520d9cfd-45b8-47c9-a6c9-7d44c08a8e84"
      decimals="3"
      id="F_19092758-8dce-45f8-9aa1-78b32f4052d0"
      unitRef="U_pure">0.501</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0063bfe3-5d9c-41a6-8562-8f267b5afe98"
      decimals="3"
      id="F_95fa7454-0f95-4548-a609-32e84ca33cee"
      unitRef="U_pure">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_4a1e9dcd-1585-4d10-a8bc-e074b80d03a8"
      decimals="3"
      id="F_08a57e64-e649-4e14-86c3-bf78e32738ae"
      unitRef="U_pure">0.112</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_e26cd6a1-f060-48c2-901b-b831f0705204"
      decimals="3"
      id="F_c1f36475-e890-4145-9892-fc593b27597b"
      unitRef="U_pure">0.477</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_a3878656-9f94-4813-a7e0-a59203be9936"
      decimals="3"
      id="F_a8b6b61e-7d27-46de-9be7-aa3481eaa118"
      unitRef="U_pure">0.116</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_be894792-6c69-49f3-93fd-d2f0be6d34a3"
      decimals="3"
      id="F_8bb6bdde-abf8-44bb-b010-bb9f5828d976"
      unitRef="U_pure">0.108</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_41fe0ae3-7531-4ab3-86fc-67f1297ba1f2">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company invests portion of its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_d5a87912-c0e5-4602-b181-27afda2f26a0">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_f413a298-59e5-4e20-95aa-7a2005513c0a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates its contracts to determine if those contracts qualify as derivatives under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability. Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and Note 13 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for additional information regarding the CVR derivative liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives>
    <gyre:PreferredStockWarrantsPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_e1592a1f-cb12-4877-b9b4-b202f0580632">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants to purchase shares of the Convertible Preferred Stock (&#x201c;Preferred Stock Warrants&#x201d;) are freestanding financial instruments classified as warrant liability on the Company&#x2019;s consolidated balance sheets since the underlying securities are contingently redeemable upon the occurrence of events which are outside of the Company&#x2019;s control. The Preferred Stock Warrants are recorded at fair value upon issuance and are subject to remeasurement at the end of each reporting period. Any change in the fair value of the Preferred Stock Warrants is recorded as changes in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss). The Company adjusts the liability for changes in fair value of the Preferred Stock Warrants until the warrants are exercised or expired&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</gyre:PreferredStockWarrantsPolicyTextBlock>
    <gyre:ConvertiblePreferredStockPolicyPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_3ef90a73-c201-4121-bcf2-3a88aedf338a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records shares of non-voting Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;SEC Staff Announcement: Classification and Measurement of Redeemable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to account for the Convertible Preferred Stock. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Convertible Preferred Stock could become redeemable upon the occurrence of an event that is not solely within the control of the issuer and therefore, is classified within mezzanine equity in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</gyre:ConvertiblePreferredStockPolicyPolicyTextBlock>
    <gyre:LongTermCertificatesOfDepositPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_85768063-e5d1-4c91-a043-f520574f8912">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-term Certificates of Deposit&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The long-term certificates of deposit will mature between February 2025 and July 2026. Certificates of deposit are accounted for at amortized cost with no adjustments for changes in fair value. Premiums and discounts, if any, are amortized or accreted over the lives of the related fixed maturities as an adjustment to the yield using the effective interest method. The Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; allowance for credit losses associated with the certificates of deposit as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022.&lt;/span&gt;&lt;/p&gt;</gyre:LongTermCertificatesOfDepositPolicyTextBlock>
    <gyre:AllowanceForCreditLossesCertificatesOfDeposit
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_0303a52f-2232-44a7-a845-f46e5563e5c4"
      unitRef="U_USD">0</gyre:AllowanceForCreditLossesCertificatesOfDeposit>
    <gyre:AllowanceForCreditLossesCertificatesOfDeposit
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_b4d68d3f-974c-42aa-9879-fa32e56c75ee"
      unitRef="U_USD">0</gyre:AllowanceForCreditLossesCertificatesOfDeposit>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_4b964e84-f8fe-4b5a-81ec-ef15740592ab">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-Term Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (&#x201c;GCBP&#x201d;) in February 2023. The Company determined that the hold-back from the GCBP asset sale qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. The Company has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss). Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for additional information regarding the long-term receivable.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_6885a679-8cdb-4dfa-b3a0-e8ada2d58965">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts and Note Receivables, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. The Company&#x2019;s trading terms with its customers are mainly on credit, and the credit period is usually within three months. Accounts and note receivables are recorded at net realizable value. The allowance for credit losses is determined by management&#x2019;s best estimate of expected credit losses of the receivables based on historical data, current information, and future economic forecasts. Receivables are grouped into asset pools based on delinquency status and customer type, with fixed reserve percentages set for each pool. The reserve percentages are determined by considering factors such as historical experience with customers, regulatory and legal environments, and other relevant current and future macroeconomic factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:68.014%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.362%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Note receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts and note receivables, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes in the allowance for credit losses as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:68%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.42%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Recoveries collected and write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_806af442-8f2a-4882-bca8-51fcf807c474">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts and note receivables, net, consisted of the following at the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:68.014%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.362%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Note receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts and note receivables, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_33497c87-aa7d-4a7d-a86d-fb5232a0f96b"
      unitRef="U_USD">15204000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_7daa030f-d1ed-4774-817f-6773261ee88b"
      unitRef="U_USD">15738000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_b88ee15a-6811-4442-8565-e551dab831d4"
      unitRef="U_USD">389000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_ea97a1ad-fe07-45a9-a092-df1645a6b2ca"
      unitRef="U_USD">1522000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_26d94f00-b9cf-4f0f-9f46-8d339719ebee"
      unitRef="U_USD">41000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_b611fc27-69f9-4bf9-be14-ea34848e2e7c"
      unitRef="U_USD">124000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3e8fe402-54a5-4859-9846-b1941c853384"
      unitRef="U_USD">15552000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_f01aec73-3c10-4a9a-923e-f4883ed7cc87"
      unitRef="U_USD">17136000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_4beb8835-ff18-4c81-be45-1d2d08c7643e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes in the allowance for credit losses as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:68%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.42%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for allowance for credit losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Recoveries collected and write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossTableTextBlock>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_c1539291-8f7e-4b67-88a1-1844fd25d8b0"
      unitRef="U_USD">124000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_b7c2a125-5bff-41a6-a0df-4926d0dda919"
      decimals="-3"
      id="F_4a70cec9-9d4f-4fb6-8d04-5dec5f0f5937"
      unitRef="U_USD">70000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <gyre:AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_6116f16c-0cf0-4c30-a100-5e3378faa821"
      unitRef="U_USD">88000</gyre:AccountsAndNotesReceivableProvisionForAllowanceForCreditLosses>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_a17a0cc1-82d5-4f5e-902e-422f3614039a"
      unitRef="U_USD">82000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_8ec5bcb2-bf8c-440e-89cd-7209ea66170f"
      unitRef="U_USD">26000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossRecoveryAndWriteOff>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_7f4ebbb5-2d3e-45bd-9fbf-fe40b390f456"
      unitRef="U_USD">1000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_3b7a237f-63b3-4048-a12d-05b21d035eae"
      unitRef="U_USD">8000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_278e0906-cacc-43e5-a3b4-8e4380b40240"
      unitRef="U_USD">41000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_2fa18131-69d3-4668-8ce8-31e5facb6957"
      unitRef="U_USD">124000</gyre:AccountsAndFinancingReceivableAllowanceForCreditLossCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_927231f3-9241-473d-ad4b-56f97902869e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventories, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories, consisting of raw materials, work in progress, and finished goods, are valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. The Company will record a write-down to its net realizable value in cost of sales in the periods that the decline in value is first identified. The average cost of work in progress and finished goods consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third-party suppliers. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal. The Company also regularly monitors inventory quantities on hand and in transit, and reserves for excess and obsolete inventories using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, and expiration and age of on-hand inventory. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory. If actual conditions or product demands are less favorable than assumptions, additional inventory reserves may be required.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_09b4242c-d7d4-40d4-9bc2-18016283dc5c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, except for construction-in-progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expenditure incurred after items of property and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:5.204%;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.42%;"&gt;&lt;/td&gt;
          &lt;td style="width:58.58%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b8d10737-f18e-4a8d-80f3-5bcbf043af92;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of the estimated useful life or the term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Where parts of an item of property and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;An item of property and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the reporting period the relevant asset is derecognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, if applicable, and is not depreciated. Cost comprises the direct costs of construction and machinery, and capitalized borrowing costs on related funds borrowed during the period of construction. Construction in progress is reclassified to the appropriate category of property and equipment when completed and ready for use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment is reviewed for impairment when events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_d45aa1c1-bc38-4457-8a7b-e6c07c764019">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:5.204%;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:41.42%;"&gt;&lt;/td&gt;
          &lt;td style="width:58.58%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b8d10737-f18e-4a8d-80f3-5bcbf043af92;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of the estimated useful life or the term of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;"&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</gyre:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f243cd37-4ca7-40de-bfca-d9278aaf4176"
      id="F_573a983f-4d66-4b86-8e4a-c39d054da5ef">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0b0cf3b8-5d3c-4147-8ceb-467e7bd5ba58"
      id="F_4357fe31-bb24-46b1-ae6b-2cbe887db6bc">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_91242d31-4c05-4dae-a9cf-c1b9d11a95ae"
      id="F_1a53947e-c7d8-4d0f-ab49-e056e465027e">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e49c5cbb-f4c4-4958-97ed-acfefaf3d6d1"
      id="F_2dd01598-af4e-47c4-918d-3581ab481ea0">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_3b323a5d-4464-43f4-83e3-c63e93ede93a"
      id="F_68c52526-7eda-4ad8-8b4b-7eb9de243ef0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_182327bb-26af-4f7a-895e-5e3aa7510752"
      id="F_c9d1ce88-4c29-4536-ab4a-2ea0ef9eae53">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0183b145-8159-4365-809a-9af68dddf568"
      id="F_22000c20-bea4-4f15-8735-2e3904dae1fc">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_b7bd02c2-5511-4949-ab7c-0b820fc02c62"
      id="F_35263630-e887-4966-9569-0336cbbd443b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_81016147-05e4-42b5-9b9e-ec7e153b741e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets acquired separately are measured upon initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives, consisting primarily of patents,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;technological know-how and computer software, are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patents and Technological Know-How&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on a basis that best reflects how their economic benefits are utilized or on the straight-line basis, if not materially different from actual utilization, over their estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Computer Software&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ba9e4760-e1ab-447a-a061-08082fe718fe;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_dbc1263a-94eb-48f4-bda3-2ce54672d636"
      id="F_f1e9b2b5-26b2-4676-888d-eb29768a0ca3">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_170270bc-ade9-476a-ad13-a1783878c851"
      id="F_d7ef4bef-c6a9-4d55-8427-db4923da51b9">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_4649e540-01e6-41d7-b63f-f6d16f10ba35"
      id="F_0e507c4d-1ca6-46c0-9a0a-a9fe7d0f447d">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_0dc9b08e-eac1-4555-ad7f-f5df5e758f95">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assesses at contract inception whether a contract is, or contains, a lease based on the unique facts and circumstances present. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on the accompanying consolidated balance sheets. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the expected lease term at commencement date or the lease modification date, if applicable. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU assets may be required for items such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines the expected lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company&#x2019;s leases do not contain any residual value guarantees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has elected to combine lease and non-lease components as a single component. The lease expense for minimum lease payments is recognized over the expected term on a straight-line basis. Variable lease payments, which are primarily comprised of property maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <gyre:LandUseRightsPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_76e76f5a-6dc6-4632-a763-34b19fa1a9dd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Land Use Rights, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All land in mainland China is subject to government or collective ownership, and land use rights can be purchased for a specified period of time. The purchase price of land use rights represents the operating lease prepayments under ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and is recorded as land use rights, net asset on the consolidated balance sheets, which is amortized over the remaining lease term.&lt;/span&gt;&lt;/p&gt;</gyre:LandUseRightsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_0482dd50-1ca4-4224-aee8-2b7047f5aa2f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets, including property and equipment, finite-lived intangible assets, ROU assets and land use rights, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;amount of an asset group exceeds its fair valu&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value. Calculating the fair value of the assets involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record any impairment of long-lived assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="INF"
      id="F_eb48535d-bce1-4c20-9e7d-ad591c7e960a"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="INF"
      id="F_85889a43-ae1d-498f-b67e-946f0eb3f430"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_254f0e1e-8676-4720-8caf-9e23beefe943">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Tax Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are recorded using the liability method, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are recorded against deferred tax assets, including net operating losses and tax credits, when it is determined it is more-likely-than-not that some or all of the tax benefits will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest and penalties related to unrecognized tax benefits, if any, are recorded as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_89073922-3ecb-49cf-a279-7189959383fa">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records revenue in accordance with ASC Topic 606 (&#x201c;ASC 606&#x201d;), Revenue from Contracts with Customers, whereby revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration expected to be received in exchange for those goods or services. A five-step model is used to achieve the core principle: (1) identify the customer contract, (2) identify the contract&#x2019;s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(a) Sale of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company mainly sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the product is transferred to the customer, generally upon completion of quality inspection by the distributor after delivery of the pharmaceutical products.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records revenue for product sales, net of estimated product returns. Customers have limited return rights related only to the product damage or defect identified upon delivery of the product. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period the related product revenue is recognized. To date, actual returns have not differed materially from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amounts of unpaid or unbilled rebates are recorded as a reduction of revenue, if any. Estimated rebates are determined based on contracted rates and sales volumes and, to a lesser extent, distributor inventories. The Company regularly reviews the information related to these estimates and adjusts the amounts accordingly. The Company uses the expected value method to estimate the amount of consideration to which it will be entitled.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The requirements on constraining estimates of variable consideration, i.e., when it is probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved, are applied and the expected future rebates are deducted from the trade receivables from the customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has applied the practical expedients under ASC 606 with regard to assessment of financing component and concluded that there is no significant financing component given that the period between delivery of goods and payment is generally one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(b) License of Intellectual Property&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue from a license agreement is recognized at a point in time when the control of the right to use the license is transferred to the customer. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Development or regulatory milestone payments, which are included in the transaction price to the extent that it is probable that a significant reversal of accumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of any milestones, and if necessary, adjusts its estimated transaction price on a cumulative catch-up basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize any contract assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_58c4f6da-c8e2-4e71-b269-79315868e47c"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_5a3f1aa5-34fa-43d2-95de-a1d614dd1ada"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_5bdd30bc-93e1-44b3-bba0-403660b67905">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred revenue is recognized when a payment is received from a customer before the Company transfers the related goods or services. Deferred revenue is recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer). As of December 31, 2023, the Company&#x2019;s deferred revenue balance was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Deferred revenue was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as of December 31, 2022 which has been recognized as revenue during the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="0"
      id="F_ac8633b7-6315-445d-9c5d-faf7c2f5ea4f"
      unitRef="U_USD">39000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="0"
      id="F_a0cde050-e5e8-4afa-867f-df0758ffdab3"
      unitRef="U_USD">145000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_90097d20-dba4-4e87-ae02-be20f3cfc5cf">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cost of Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cost of revenue mainly consists of cost of sales representing direct and indirect costs incurred to bring the product to saleable condition. Cost of sales primarily consists of (i) raw material costs; (ii) staff costs for production employees; (iii) depreciation and amortization related to property and equipment and intangible assets used in production; (iv) taxes and surcharges; (v) transportation costs; and (vi) miscellaneous other costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_f3f6ed57-c569-481c-bd1d-ecb918e39b99">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. For equity awards that only contain service conditions, the Company recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. The cost is recognized with a corresponding increase in equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Determining the fair value of stock-based awards at the grant date requires judgment. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by the Company&#x2019;s assumptions regarding a number of variables including the fair value of its common stock, its expected common stock price volatility over the expected&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;life of the options, expected term of the stock option, risk-free interest rates and expected dividends. The Company elected to account for forfeitures when they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For awards that do not ultimately vest because non-market performance or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and service conditions are satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Where the terms of an equity award are modified, a minimum expense is recognized as if the terms had not been modified if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the stock-based payments or is otherwise beneficial to the employee as measured at the date of modification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_d5fd0c28-3cff-4122-9fce-0cf67c22fff4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired IPR&amp;amp;D with no alternative future use is charged to expense at the acquisition date. Refer to Note 7 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;GNI USA Contributions under the Business Combination Agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for a more detailed description.&lt;/span&gt;&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_bf4bbfca-9698-4ae8-9435-4b59dc58abb9">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <gyre:SellingAndMarketingExpensesPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_d0710859-907a-46c4-9a56-f3ed1f77b68b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Selling and Marketing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Selling and marketing expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for in-house marketing and promotion staff.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</gyre:SellingAndMarketingExpensesPolicyTextBlock>
    <gyre:GeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_d95cbf22-f03c-42d5-89ac-8956515c7708">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative expenses consist of (i) accounting, IT, legal, administrative, and other internal service staff costs; (ii) stock-based compensation representing share options granted to its functional employees; (iii) professional service fees, primarily for legal and accounting services; and (iv) other miscellaneous expenses.&lt;/span&gt;&lt;/p&gt;</gyre:GeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:GovernmentAssistancePolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_799f2a62-ac95-45ad-9293-292d04abbbdf">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Government Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;grants are recognized at their fair value where there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual installments or deducted from the carrying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;amount &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the asset and released to profit or loss by way of a reduced depreciation charge. Grant income is included within other income in the consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <gyre:InterestIncomePolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_7f364d9d-2bd2-4ffe-bc2b-7aa40c24f3d5">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Interest Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.&lt;/span&gt;&lt;/p&gt;</gyre:InterestIncomePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_fb329b68-a531-4fd3-a4dc-5f3b956610e6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including net income, unrealized gains and losses on investments and foreign currency translation adjustments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_0cb3e3f7-42a3-449e-ada1-c3e6743ab182">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Income (Loss) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Per Share (&#x201c;EPS&#x201d;) Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company calculates basic and diluted EPS attributable to common stockholders in accordance with ASC Topic 260, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASC 260&#x201d;), which requires EPS for each class of stock (common stock and participating securities) to be calculated using the two-class method. The two-class method determines EPS for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings attributable to stockholders. The two-class method requires earnings available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. The Company&#x2019;s Convertible Preferred Stock is classified as a participating security in accordance with ASC 260. The Convertible Preferred Stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#x2019;s losses. As such, net losses attributable to stockholders for the periods presented were not allocated to these securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic EPS is calculated by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted EPS is computed by giving effect to all potentially dilutive securities outstanding for each period presented. For periods in which the Company reports net loss attributable to common stockholders, diluted EPS attributable to common stockholders is the same as basic EPS attributable to common stockholders since the effects of potentially dilutive securities are antidilutive. See Note 16 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;EPS &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for more information.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_91484053-d76d-459d-9f56-ad519e85083c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Translation and Remeasurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The functional currency of the Company is the US Dollar. The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. The functional currency of BC is RMB. The determination of the respective functional currency is based on the criteria stated in ASC Topic 830, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Matters&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company uses the U.S. Dollar as its reporting currency.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities are translated at foreign exchange rates on the balance sheet date. Equity amounts are translated at historical exchange rates. Revenue and expenses are translated at the average foreign exchange rates. The effects of these translation adjustments are reported within accumulated other comprehensive income in the consolidated balance sheets and consolidated statements of convertible preferred stock and  equity, with the translation gain (loss) shown as a separate component of other comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive (loss) income. During the year ended December 31, 2023, the Company had translation loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. During the year ended December 31, 2022, the Company had translation loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within other income (expense), net in the consolidated statements of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;operations and comprehensive (loss) income. The foreign currency transaction gains or losses for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;were immaterial.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_36c88dde-644f-4f00-b503-047fcaadd43e"
      unitRef="U_USD">-1500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-5"
      id="F_41512493-4af1-4348-a2d6-c40acc69f639"
      unitRef="U_USD">-4900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <gyre:ForeignCurrencyRiskPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_7db4b53f-40bf-4a90-a65d-d398cfe754ed">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The RMB is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People&#x2019;s Bank of China, controls the conversion of RMB into other currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. 99.5% of the Company&#x2019;s cash and long-term certificates of deposit as of December 31, 2023 of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, were denominated in RMB.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</gyre:ForeignCurrencyRiskPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_5575d880-f55d-4398-b20a-b5eac4c613be"
      unitRef="U_USD">26500000</us-gaap:CashEquivalentsAtCarryingValue>
    <gyre:LongTermCertificatesOfDeposit
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_c40029a0-1d05-480d-ac78-549f89706418"
      unitRef="U_USD">23400000</gyre:LongTermCertificatesOfDeposit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_32105c8c-c4ac-479e-b938-7ff3f753e32d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2021-04 and related updates on&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and the adoption &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;did not have a material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2020, FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the previous models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2021. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2020-06 on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and the adoption &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;did not have a material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Business Combinations &#x2013; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2021-08 and related updates on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The adoption of ASU 2021-08 had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impact on the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2021, the FASB issued ASU 2021-10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Government Assistance (Topic 832) &#x2014; Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The amendments in this ASU require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity&#x2019;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; this standard as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The adoption of this ASU &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;did not have any material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_e8c45cef-ab89-4573-972d-ebd63351515c"
      id="F_148214c6-f1e3-46b7-a470-c5af2af0664a">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_e8c45cef-ab89-4573-972d-ebd63351515c"
      id="F_d71a3ebf-2c31-49be-a365-863b9d184e6f">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_e8c45cef-ab89-4573-972d-ebd63351515c"
      id="F_d02b904e-344f-4acb-8ad2-d4d24465f73a">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_b262631e-b3d6-4f19-a20e-4918b4b3ac1c"
      id="F_bd2e06bc-0fc4-4e58-a32a-bfb9eb32f443">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_b262631e-b3d6-4f19-a20e-4918b4b3ac1c"
      id="F_473464eb-6d9e-439a-af4b-a0d847ea99ad">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_b262631e-b3d6-4f19-a20e-4918b4b3ac1c"
      id="F_a85faeff-d8c2-4ced-9ccc-2423b720e479">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_902ec01f-0e7c-4614-8110-77c86fffbaba"
      id="F_965d21a9-3048-483f-bdba-d76a91f30e66">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_902ec01f-0e7c-4614-8110-77c86fffbaba"
      id="F_9296bef2-02c2-41f1-b428-f7683b520665">2023-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_902ec01f-0e7c-4614-8110-77c86fffbaba"
      id="F_1883b40c-fa94-432d-adbf-691c06f26708">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_e13ef3b0-0f59-4737-ba8d-a801a95ed820"
      id="F_b8d2c6ab-6fcf-402d-89cc-335b3d5b7696">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_e13ef3b0-0f59-4737-ba8d-a801a95ed820"
      id="F_6ccdf1a3-199e-4d5c-ada4-27abc9a27df0">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_e13ef3b0-0f59-4737-ba8d-a801a95ed820"
      id="F_c7ebf4fe-ef4d-4ddf-a335-bb7d102eee5e">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <gyre:NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_fbdcb199-8765-406a-b928-8cc5c5c14d89">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures (Topic 280)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment&#x2019;s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment&#x2019;s profit or loss in assessing segment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company plans to adopt annual requirements and related updates under ASU 2023-07 on January 1, 2024 and interim requirements under ASU 2023-07 on January 1, 2025. The Company is currently assessing the impact of adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in the Company&#x2019;s consolidated financial statements, once adopted. The Company plans to adopt ASU 2023-09 and related updates as of January 1, 2025. The Company will assess the impact of adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;</gyre:NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_352f4c26-2162-49ce-a577-3daabe2dcd49">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For a description of the fair value hierarchy and fair value methodology, see Note 2 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of December 31, 2023, the Company&#x2019;s highly liquid money market funds are included within cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrant liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of cash, accounts and note receivables, net, other receivables, accounts payable, due to related parties, CVR excess closing cash payable, and accrued liabilities approximate their fair values due to their short maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; transfers of fair value measurement between Level 1 and Level 2 and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; transfers into or out of Level 3 for both financial assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; financial assets and liabilities measured at fair value as of December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.402%;padding-left:0.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-term Receivables and CVR Derivative Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The long-term receivable and the corresponding CVR derivative liability, noncurrent relate to the asset purchase agreement with GCBP. The fair value of this long-term receivable and derivative liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The estimated fair value of the long-term receivable and CVR derivative liability, noncurrent was determined based on the anticipated amount and timing of projected cash flows to be received from GCBP pursuant to the GCBP asset purchase agreement discounted to their present values using an estimated discount rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of December 31, 2023, the Company expects to receive a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; hold-back payment from GCBP in the first quarter of 2025, which will be distributed, net of expenses, to the CVR Holders. The change in fair value of the long-term receivable from GCBP and the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;corresponding CVR derivative liability, noncurrent was recorded in interest and other income, net on the consolidated statement of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, Catalyst entered into a Securities Purchase Agreement for a private placement with GNI USA (the &#x201c;Private Placement&#x201d;). The Private Placement closed immediately following the closing of the Contributions on October 30, 2023. Upon closing of the Private Placement, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Convertible Preferred Stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Preferred Stock Warrants to purchase shares of Convertible Preferred Stock t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;o GNI for an aggregate purchase price of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Preferred Stock Warrants are immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,915.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of Convertible Preferred Stock and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 30, 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;he number of shares of Common Stock issuable upon exercise and conversion of the Preferred Stock Warrants is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company accounted for the Private Placement as a non-arm's length transaction. The Preferred Stock Warrants were initially recognized at fair value upon issuance and the remaining proceeds from the Private Placement were allocated to the Convertible Preferred Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Preferred Stock Warrants are freestanding financial instruments classified as a warrant liability on the Company&#x2019;s consolidated balance sheet. The Preferred Stock Warrants are revalued each reporting period with the change in fair value recorded as change in fair value of warrant liability in other income (expense), net on the consolidated statement of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of the warrant liability is estimated based on th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81.984%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.317%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,915.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level 3 financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds  (cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_28535115-7fb7-4acc-ac2c-4cfe1f9038d7">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrant liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_045ba781-db06-4c6d-8298-49ca507c4865"
      decimals="-3"
      id="F_9a272737-bc08-4cc6-aecc-0ad4b9df9699"
      unitRef="U_USD">5860000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9f06db74-891e-4ce0-a20f-35ad5be24529"
      decimals="-3"
      id="F_0547b5d9-8cf0-4c86-a882-fafaeb82c402"
      unitRef="U_USD">5860000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_115f1247-30e4-4dba-bef9-b573f9c28f0d"
      decimals="-3"
      id="F_9c3b286c-029e-4c52-9923-d87a2be264f1"
      unitRef="U_USD">4722000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4819d424-8697-4686-8411-d198d08bf27a"
      decimals="-3"
      id="F_f1972e2d-35d3-4e05-9ace-a536ccb7d688"
      unitRef="U_USD">4722000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_157e8487-e10a-4a43-a91d-f10752747e13"
      decimals="-3"
      id="F_f1959363-1b20-41bc-b9f9-d68b1bb96fa6"
      unitRef="U_USD">5860000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a0b36028-19c9-4a53-a9a7-ee2e782d8999"
      decimals="-3"
      id="F_714c49e7-f4fd-4a85-b65d-0df9648f0211"
      unitRef="U_USD">4722000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_8ba05a34-112c-4e1f-a23d-c4ab7a0e4744"
      unitRef="U_USD">10582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_445a60cd-e16e-489f-bcf9-7e083b147488"
      decimals="-3"
      id="F_6a4d2fff-9acd-494c-857c-1b9d2af3b0e1"
      unitRef="U_USD">4722000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_4dd9552a-d96b-49ea-b446-4919e583d048"
      decimals="-3"
      id="F_7b17963a-c7c8-4e8f-8d81-688db319ac02"
      unitRef="U_USD">4722000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_13201822-62fe-49b2-a82f-aea2f25149ff"
      decimals="-3"
      id="F_4080e83b-0649-4725-84d7-6adcc5297f62"
      unitRef="U_USD">12835000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_d0718b26-6e80-4be3-a6f2-f995da1fdae5"
      decimals="-3"
      id="F_7c4f97d8-e997-46bf-801f-bd90a80dedf6"
      unitRef="U_USD">12835000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a0b36028-19c9-4a53-a9a7-ee2e782d8999"
      decimals="-3"
      id="F_8f71c091-d812-490f-adb2-b3676a9977ad"
      unitRef="U_USD">17557000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_241df060-5562-4490-8902-6062da4739fc"
      unitRef="U_USD">17557000</us-gaap:LiabilitiesFairValueDisclosure>
    <gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_e9b830be-caf6-41dc-957a-69e83b07912f"
      unitRef="U_USD">0</gyre:FairValueAssetsAndLiabilitiesLevel1ToLevel2TransfersAmount>
    <gyre:FairValueAssetsAndLiabilitiesLevel3TransfersAmount
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_2e7f9cdf-b7aa-4082-a904-f42d0180e21d"
      unitRef="U_USD">0</gyre:FairValueAssetsAndLiabilitiesLevel3TransfersAmount>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_df96abdc-dd48-454b-8c1b-86c5a77c09c6"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_e53234c6-4ddb-476a-a44b-6d5ae63e034c"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeAssetMeasurementInput
      contextRef="C_1815289d-1b7a-4870-a6b4-e40af7ccba71"
      decimals="4"
      id="F_e0b2a85d-3d2b-4768-9e61-b88608085f6c"
      unitRef="U_pure">0.0505</us-gaap:DerivativeAssetMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_db3199b0-d343-4eaa-a0d5-e0379c40bbc8"
      decimals="4"
      id="F_70f77a1f-bf2f-4ed3-8bde-1ac025548259"
      unitRef="U_pure">0.0505</us-gaap:DerivativeLiabilityMeasurementInput>
    <gyre:AmountToBeReceivedUnderAgreement
      contextRef="C_4d497df2-33f4-4686-9867-5db4e7e60cf7"
      decimals="-5"
      id="F_4f8b4362-8b75-4015-950b-495621dcf3d1"
      unitRef="U_USD">5000000</gyre:AmountToBeReceivedUnderAgreement>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_3ca1cf69-934c-4ff2-a707-c448b5a6f581"
      decimals="INF"
      id="F_1ed2b277-2a1b-4540-804a-7a03bbefbeca"
      unitRef="U_shares">811</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5b9e0cff-7266-4030-8595-3ac948bb97b6"
      decimals="0"
      id="F_a514c68d-d9aa-4712-9543-03bb9786dd72"
      unitRef="U_shares">811</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_60d99e53-9b0a-4867-83bb-4f2ef85acc84"
      decimals="-5"
      id="F_3d13f962-65e2-461d-bc9b-346acfef965f"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5b9e0cff-7266-4030-8595-3ac948bb97b6"
      decimals="2"
      id="F_cec87790-c877-42c1-8e0a-f91a00adb240"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4915</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_5b9e0cff-7266-4030-8595-3ac948bb97b6"
      id="F_fa2aa12a-81ac-42a7-a87b-cc647cf739c9">2033-10-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <gyre:NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants
      contextRef="C_5b9e0cff-7266-4030-8595-3ac948bb97b6"
      decimals="INF"
      id="F_2e592ab8-b5f7-4085-8634-b04d9de48563"
      unitRef="U_shares">540666</gyre:NumberOfCommonStockSharesIssuableUponExerciseAndConversionOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_5644c9ef-41c0-4bff-b201-a4776753e504">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of the warrant liability is estimated based on th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81.984%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.317%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,915.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_ea3f5866-c7a2-4019-97c6-761b0043d03a"
      decimals="1"
      id="F_b43a9c89-6a08-4312-912a-643615296607"
      unitRef="U_pure">25.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="2"
      id="F_3c76c8af-956f-4bdd-a81c-36f0978bd8b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4915</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_10152a3b-ae2a-4e24-a1b1-6548fd6edc50"
      decimals="2"
      id="F_c0be109d-1dde-46d2-89d7-e02c3cc12046"
      unitRef="U_pure">3.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      id="F_fe25e57c-b57d-4e40-b79a-762153588e26">P9Y9M29D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_09b4f5a5-c379-45c0-b3a1-76e64d96074d"
      decimals="2"
      id="F_706f2b07-5fa9-459a-917d-2f2b0997d983"
      unitRef="U_pure">84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_b8c649c2-e363-4411-b7b1-5edaa08df82c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level 3 financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;CVR derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="C_69b8f9e1-11d9-471e-9f88-5c562846ff4d"
      decimals="-3"
      id="F_dbe159dd-9175-4a1c-89ea-12b11a629477"
      unitRef="U_USD">4683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="C_dee33cb1-134d-4bc4-846b-88a1d3ece761"
      decimals="-3"
      id="F_3b9a61de-444b-41e5-ba17-77f903f6c733"
      unitRef="U_USD">4683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="C_39bb62ec-75ae-4ae3-a8f4-d62d0b77c6d4"
      decimals="-3"
      id="F_0795a4d9-cddb-41a0-8232-bd9908d9f809"
      unitRef="U_USD">3574000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="C_69b8f9e1-11d9-471e-9f88-5c562846ff4d"
      decimals="-3"
      id="F_2d4ee1a1-b02b-42f6-a374-cef5c77cb63e"
      unitRef="U_USD">39000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_dee33cb1-134d-4bc4-846b-88a1d3ece761"
      decimals="-3"
      id="F_c92ea5de-ff49-403a-8834-6cf2f2438676"
      unitRef="U_USD">39000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_39bb62ec-75ae-4ae3-a8f4-d62d0b77c6d4"
      decimals="-3"
      id="F_bf70672f-8591-4998-91fc-44046887f8dc"
      unitRef="U_USD">9261000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_4819d424-8697-4686-8411-d198d08bf27a"
      decimals="-3"
      id="F_489f3c5c-547d-4a96-b32b-50b55e9eeb75"
      unitRef="U_USD">4722000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_4dd9552a-d96b-49ea-b446-4919e583d048"
      decimals="-3"
      id="F_2c873b42-28ff-49db-81b2-aa399097e191"
      unitRef="U_USD">4722000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_d0718b26-6e80-4be3-a6f2-f995da1fdae5"
      decimals="-3"
      id="F_de607102-baa6-4721-9478-34ad0614bab8"
      unitRef="U_USD">12835000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_febc5039-dc72-4e3c-8143-ff6150578fe3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds  (cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6b3596e0-0ee0-47ca-98ce-acc247c5374c"
      decimals="-3"
      id="F_54bd72a8-67fe-422c-8866-cddd66f40d78"
      unitRef="U_USD">5860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6b3596e0-0ee0-47ca-98ce-acc247c5374c"
      decimals="-3"
      id="F_a035ab67-b1ea-4261-a610-2b32423aa0a8"
      unitRef="U_USD">5860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_fad9a72d-4c1b-413c-b80c-01f3d4565ce0"
      unitRef="U_USD">5860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_5cc24fb9-6e0d-4e1d-8b3d-ef474815ed01"
      unitRef="U_USD">5860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a3a35db5-876f-4dde-b12c-44d79d949c6a"
      decimals="-3"
      id="F_4a62bc42-9ef3-4744-bdd1-5e8b8c9a9152"
      unitRef="U_USD">5860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_470e012f-bbc3-42f0-bcff-15864dee1d52"
      unitRef="U_USD">5860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_b89f5f7c-a093-4a1d-9647-3dea2e51d311">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories, net of reserves of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as of December 31, 2023 and 2022, respectively, consisted of the following components (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.986%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.637%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The provision for inventory and write-downs for the years ended December 31, 2023 and 2022 were immaterial.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.280000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll and welfare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Supplier reimbursement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses - general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued sales discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee reimbursement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses - research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses - selling expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred government grants represent funds provided by the government for research and development, construction of new facilities, or improvement of existing production facilities. The amount of deferred government grants as of December 31, 2023 and 2022, is net of the amount recognized as government grant income. During the years ended December 31, 2023 and 2022, the Company received &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; government grants, respectively. During the years ended December 31, 2023 and 2022, the Company recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of government grant income within other income in the consolidated statements of operations and comprehensive (loss) income, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Summarized below are deferred government grants as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government grants for property and equipment, included in accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government grants for property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for each of the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_94d4e839-9d59-426d-affd-c34043d1765c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories, net of reserves of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as of December 31, 2023 and 2022, respectively, consisted of the following components (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.986%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.637%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventories, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="0"
      id="F_2c20e51d-0960-434c-83f1-737caf43bc0c"
      unitRef="U_USD">46000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="0"
      id="F_872638c6-e903-456f-9cb6-98f65602cce5"
      unitRef="U_USD">9000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryRawMaterials
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_d4ffcf89-faab-4538-8c34-3753f6951d88"
      unitRef="U_USD">919000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_52a0c044-0a7c-4fdc-8ed8-9bd1e7bad5eb"
      unitRef="U_USD">1056000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_90579243-9e94-4728-baeb-4942eb9fae89"
      unitRef="U_USD">1997000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_0ecf6b6e-fb07-441d-8b2f-dc9691a348f4"
      unitRef="U_USD">3667000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_655822e4-77e2-4dc0-a923-93439d86a51c"
      unitRef="U_USD">1365000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_d8de1aec-7172-40d0-ad9f-d6b07d01c139"
      unitRef="U_USD">1399000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_e64eb06a-77bb-4d25-87af-bdb0383b3cf3"
      unitRef="U_USD">4281000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_e67be5a2-44e9-449b-ad22-98e1ae7fa601"
      unitRef="U_USD">6122000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_e8b4685b-4d52-448b-b1eb-adbeb0bcc8b2">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.280000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll and welfare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Supplier reimbursement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses - general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued sales discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee reimbursement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses - research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses - selling expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <gyre:AccruedPayrollAndWelfare
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_dca7dbe1-c5b4-48db-831e-b11615630f11"
      unitRef="U_USD">5790000</gyre:AccruedPayrollAndWelfare>
    <gyre:AccruedPayrollAndWelfare
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_9621dc3a-f24e-449d-9f0e-945352c2a993"
      unitRef="U_USD">5038000</gyre:AccruedPayrollAndWelfare>
    <gyre:SupplierReimbursement
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_0ac0bc67-eae9-418b-9609-ba0426d32103"
      unitRef="U_USD">2247000</gyre:SupplierReimbursement>
    <gyre:SupplierReimbursement
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_85b3e466-2971-402d-b9cc-14a9a72048b9"
      unitRef="U_USD">2474000</gyre:SupplierReimbursement>
    <gyre:AccruedExpensesGeneralAndAdministrative
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_0208dae0-d7cf-471b-8629-f6dc78dbba97"
      unitRef="U_USD">1190000</gyre:AccruedExpensesGeneralAndAdministrative>
    <gyre:AccruedSalesDiscount
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_fd44b7a7-e807-4d8d-81d9-25d600120891"
      unitRef="U_USD">903000</gyre:AccruedSalesDiscount>
    <gyre:AccruedSalesDiscount
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_601818db-4b5d-4d04-8145-5ff4aad9eba3"
      unitRef="U_USD">748000</gyre:AccruedSalesDiscount>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_891ffdb2-a590-4bcf-a33d-1c2e531fa19e"
      unitRef="U_USD">837000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_08ea7271-9085-4c26-afe4-068e1cdfb515"
      unitRef="U_USD">648000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_4f27da5b-ca12-48a4-a555-6b44b159b7ac"
      unitRef="U_USD">646000</us-gaap:AccruedSalariesCurrent>
    <gyre:AccruedExpensesResearchAndDevelopment
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_64d764cf-2801-47de-ba93-bf1afc339d7c"
      unitRef="U_USD">161000</gyre:AccruedExpensesResearchAndDevelopment>
    <gyre:AccruedExpensesResearchAndDevelopment
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_c8b3ffbc-cb2a-4374-a3fc-3b3e14a9786a"
      unitRef="U_USD">158000</gyre:AccruedExpensesResearchAndDevelopment>
    <gyre:AccruedExpensesSellingExpenses
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_c10f53fa-f50a-4267-8bbb-06654e3aa60e"
      unitRef="U_USD">44000</gyre:AccruedExpensesSellingExpenses>
    <gyre:AccruedExpensesSellingExpenses
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_02eec63a-7dc3-427c-a44d-5287d652fc44"
      unitRef="U_USD">13000</gyre:AccruedExpensesSellingExpenses>
    <gyre:DeferredGovernmentGrants
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_d313a462-8967-485e-b0ea-c145d6c3f187"
      unitRef="U_USD">40000</gyre:DeferredGovernmentGrants>
    <gyre:DeferredGovernmentGrants
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_21abf0e7-ea89-4f2b-8395-e10710d6e4ba"
      unitRef="U_USD">22000</gyre:DeferredGovernmentGrants>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_9f7f57d8-d245-4725-a680-4f4afe9863de"
      unitRef="U_USD">75000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_ea2b2995-91a0-4392-ab34-97e961cfee40"
      unitRef="U_USD">165000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_2be7285e-3099-478f-b1e0-82d77bed516a"
      unitRef="U_USD">11935000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_5512c22e-a2de-4796-87e0-07d0955e1b64"
      unitRef="U_USD">9264000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <gyre:ProceedsFromGovernmentGrantsReceived
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_22f0f823-78d9-4441-bc77-5f8ed2c9e46f"
      unitRef="U_USD">1100000</gyre:ProceedsFromGovernmentGrantsReceived>
    <gyre:ProceedsFromGovernmentGrantsReceived
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-5"
      id="F_3243515e-793d-49cd-b0f2-a9262b8788f0"
      unitRef="U_USD">800000</gyre:ProceedsFromGovernmentGrantsReceived>
    <gyre:GovernmentGrantIncomeWithinOtherIncome
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_c3d4d1ab-016f-432a-b82b-0b3735c01b10"
      unitRef="U_USD">1000000</gyre:GovernmentGrantIncomeWithinOtherIncome>
    <gyre:GovernmentGrantIncomeWithinOtherIncome
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-5"
      id="F_d4155002-c146-4a1b-8487-efce685b593c"
      unitRef="U_USD">900000</gyre:GovernmentGrantIncomeWithinOtherIncome>
    <gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_31ce4c70-96a5-44b4-9665-e43db3e83cb6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Summarized below are deferred government grants as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government grants for property and equipment, included in accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government grants for property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred government grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</gyre:ScheduleOfDeferredGovernmentGrantsTableTextBlock>
    <gyre:DeferredGovernmentGrantsCurrent
      contextRef="C_b93ebd7b-c921-4c3e-b8e6-a2fb861ebf08"
      decimals="-3"
      id="F_1e930951-7de3-4165-a207-5119243d5eba"
      unitRef="U_USD">40000</gyre:DeferredGovernmentGrantsCurrent>
    <gyre:DeferredGovernmentGrantsCurrent
      contextRef="C_e6b773b3-ff91-417f-965a-e0e1b202042c"
      decimals="-3"
      id="F_5a202c3e-e45b-4ead-bed5-5e33ebe3fda2"
      unitRef="U_USD">22000</gyre:DeferredGovernmentGrantsCurrent>
    <gyre:DeferredGovernmentGrantsCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_a9b43d30-8343-4a3d-a888-56c015c22a66"
      unitRef="U_USD">40000</gyre:DeferredGovernmentGrantsCurrent>
    <gyre:DeferredGovernmentGrantsCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_12d24970-d532-41e8-a393-64a5a2a2e1b5"
      unitRef="U_USD">22000</gyre:DeferredGovernmentGrantsCurrent>
    <gyre:DeferredGovernmentGrantsNonCurrent
      contextRef="C_0abe225e-8a79-41e7-a475-5fdcdaca6b2b"
      decimals="-3"
      id="F_54a6ddde-e714-4bc6-91bb-5e2629dc9c31"
      unitRef="U_USD">213000</gyre:DeferredGovernmentGrantsNonCurrent>
    <gyre:DeferredGovernmentGrantsNonCurrent
      contextRef="C_42dbc2ab-badc-458b-bb6d-bcbe8dbf6681"
      decimals="-3"
      id="F_3128ead9-cf56-4f75-ba7d-802e443b9243"
      unitRef="U_USD">118000</gyre:DeferredGovernmentGrantsNonCurrent>
    <gyre:DeferredGovernmentGrantsNonCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_fd3c03f6-d216-41bc-83a7-23c7cb7ef086"
      unitRef="U_USD">213000</gyre:DeferredGovernmentGrantsNonCurrent>
    <gyre:DeferredGovernmentGrantsNonCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_cbf974b2-274a-4fa0-8397-2d375e437d5a"
      unitRef="U_USD">118000</gyre:DeferredGovernmentGrantsNonCurrent>
    <gyre:DeferredGovernmentGrantsCurrentAndNoncurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_2d9d74a7-e2d6-49e7-bd0a-77439898dc5b"
      unitRef="U_USD">253000</gyre:DeferredGovernmentGrantsCurrentAndNoncurrent>
    <gyre:DeferredGovernmentGrantsCurrentAndNoncurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_281d5c51-7b3d-4e94-86cc-a1ec33bf9241"
      unitRef="U_USD">140000</gyre:DeferredGovernmentGrantsCurrentAndNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_dbc0643e-0121-497d-9948-71b853fa9cae">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Machinery and electronic devices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6707664a-816c-4885-a01e-386eaafa6e47"
      decimals="-3"
      id="F_3143cea6-9a7a-44ac-a492-0a4addbc0d83"
      unitRef="U_USD">12289000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7aad8f7d-ee0c-42f0-82cd-92463b4ee3ba"
      decimals="-3"
      id="F_1afda7a3-30d5-43a5-9d21-f8d2a0cf4b4d"
      unitRef="U_USD">10837000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0be0b3d5-00f8-476d-87f6-73aa39f3c356"
      decimals="-3"
      id="F_1600318f-6aea-416e-9a6c-14d3c6a93a4a"
      unitRef="U_USD">7875000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_255a8a23-07fb-48ff-8e4a-470e48cef83d"
      decimals="-3"
      id="F_ac6b7315-cd4c-42b6-aec6-70e80187d875"
      unitRef="U_USD">4851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_38b72769-64e0-4e0a-befe-f69436730816"
      decimals="-3"
      id="F_683cadce-f02d-45b4-b9a6-f188974ab311"
      unitRef="U_USD">6598000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ef376339-fca7-4476-8816-40e8e7832483"
      decimals="-3"
      id="F_d4c58e58-59b9-449d-ae35-c8fc8a0bcbbf"
      unitRef="U_USD">4880000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_88893ed2-bf18-49f6-9367-143999cca36b"
      decimals="-3"
      id="F_51ffdb6a-42aa-4bda-9343-ae2c4274f980"
      unitRef="U_USD">606000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6077b963-9934-4f32-afc7-404ff0ca15ef"
      decimals="-3"
      id="F_7d60816d-d44a-4c88-8d7a-60d838116081"
      unitRef="U_USD">631000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c49e00a9-fef7-400c-9f36-c136ff2e6361"
      decimals="-3"
      id="F_1bdf52f6-0179-4c91-89b4-b889f61d5f84"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6a6b4fb6-8b55-4823-9d73-78c42fa47442"
      decimals="-3"
      id="F_11599b66-8675-413a-83d4-53483d497f21"
      unitRef="U_USD">334000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_63213500-d1dd-4530-b4dc-40f0ab583252"
      decimals="-3"
      id="F_877f5f59-10f3-42ee-ac06-cd9d7a3e01bb"
      unitRef="U_USD">185000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_201559bc-4989-46aa-9233-4a691252ef1c"
      decimals="-3"
      id="F_f5295851-c8e3-49b3-b132-3d0ece01c857"
      unitRef="U_USD">174000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_f816099a-9c49-46ab-8ae5-10c1f8aa2de9"
      unitRef="U_USD">27553000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_6567d3bc-1b13-4754-a033-079b8b5a6427"
      unitRef="U_USD">21707000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_234ddcce-0ebe-45ba-ad50-e99e83819944"
      unitRef="U_USD">4265000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_22b0e29b-b229-40b7-b03f-ca585cf07c52"
      unitRef="U_USD">3998000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_88493d25-2cdb-4026-baf0-ba38e86d10e8"
      unitRef="U_USD">23288000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_b9fdb267-8552-4623-9273-e7164bd64d20"
      unitRef="U_USD">17709000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_017738b5-02f6-4b47-a3fc-d90afe764b5b"
      unitRef="U_USD">1000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-5"
      id="F_fe98b6ef-abf5-4d3b-8ed9-8763b2ace97a"
      unitRef="U_USD">900000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_11684805-c49e-43d9-b075-316867bd5fdd">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The gross carrying amounts and accumulated amortization of the Company&#x2019;s intangible assets with determinable lives as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.99%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.197000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.077%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.157%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Technological know-how&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Technological know-how&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets are carried at cost less accumulated amortization and impairment, if applicable, and the amortization expense is recorded in operating expenses. The weighted average amortization period for the intangible assets as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.05&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amortization expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for each of the years ended December 31, 2023, and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on finite-lived intangible assets recorded as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the estimated future amortization expense is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:85.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Amortization Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_d17b15d4-d2b9-4aae-8fb9-b91c20f42413">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The gross carrying amounts and accumulated amortization of the Company&#x2019;s intangible assets with determinable lives as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.99%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.197000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.077%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.157%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Technological know-how&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Technological know-how&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_b14d0f10-ff15-45a8-ac65-d7d00fe4ea56"
      decimals="-3"
      id="F_067f7481-9cd1-4f0a-87a1-b6e4d773e6d9"
      unitRef="U_USD">430000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_b14d0f10-ff15-45a8-ac65-d7d00fe4ea56"
      decimals="-3"
      id="F_df2132e8-24e3-4e47-975b-48eba070f3d3"
      unitRef="U_USD">290000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_b14d0f10-ff15-45a8-ac65-d7d00fe4ea56"
      decimals="-3"
      id="F_839de51a-dc35-440e-86f0-e07de4a24264"
      unitRef="U_USD">140000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_197f4783-1608-451f-92af-879882f8d860"
      decimals="-3"
      id="F_2befc976-dea5-4dfb-9b07-064eb0ed58ee"
      unitRef="U_USD">171000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_197f4783-1608-451f-92af-879882f8d860"
      decimals="-3"
      id="F_e3e2f16a-018e-4107-b558-959da07318e8"
      unitRef="U_USD">106000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_197f4783-1608-451f-92af-879882f8d860"
      decimals="-3"
      id="F_a0884f6e-1d7d-4840-aede-831221adeff3"
      unitRef="U_USD">65000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_dbf95666-83c7-46ea-a8b5-064403b5d898"
      unitRef="U_USD">601000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_93b78413-dc7b-4116-b797-3c0ec667bf08"
      unitRef="U_USD">396000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_6e952f84-14aa-4355-87c9-72bd1c4ec5c2"
      unitRef="U_USD">205000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_ed6adc05-0edc-4467-9e37-a86f39ca0666"
      decimals="-3"
      id="F_81d22d80-95cf-464a-a4f9-fb0ce93d6a96"
      unitRef="U_USD">1496000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_ed6adc05-0edc-4467-9e37-a86f39ca0666"
      decimals="-3"
      id="F_e0fed13f-ef47-418c-803e-9fa353faf665"
      unitRef="U_USD">1372000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_ed6adc05-0edc-4467-9e37-a86f39ca0666"
      decimals="-3"
      id="F_fcce691a-368a-47ea-81df-bc8c60239e89"
      unitRef="U_USD">124000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_fbd33fe5-ce5f-469c-838c-790bd81dab76"
      decimals="-3"
      id="F_2b292ce4-a847-40d9-925b-c2b2ef5e1b92"
      unitRef="U_USD">438000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_fbd33fe5-ce5f-469c-838c-790bd81dab76"
      decimals="-3"
      id="F_4fa50b97-76e9-4e18-897c-1bf4ab1e156c"
      unitRef="U_USD">277000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_fbd33fe5-ce5f-469c-838c-790bd81dab76"
      decimals="-3"
      id="F_06b2ae3d-288e-426c-9fea-642e3ba14630"
      unitRef="U_USD">161000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_348a8cf8-e659-4115-a553-09b0ef1cf4b9"
      decimals="-3"
      id="F_91b4f625-6729-476e-a609-ff77c57051a0"
      unitRef="U_USD">104000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_348a8cf8-e659-4115-a553-09b0ef1cf4b9"
      decimals="-3"
      id="F_785dd672-c336-4eba-a0ce-4dca1b33bf3e"
      unitRef="U_USD">92000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_348a8cf8-e659-4115-a553-09b0ef1cf4b9"
      decimals="-3"
      id="F_91d0993f-89ce-4cfd-ab75-fca40a8156cb"
      unitRef="U_USD">12000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_9c24ce3f-6783-40d0-82ea-7b67f800f64c"
      unitRef="U_USD">2038000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_46d100b7-22e7-4841-890d-e0f2e04d1bac"
      unitRef="U_USD">1741000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_3c69b944-59a2-4bc6-abcf-b5a2fac38633"
      unitRef="U_USD">297000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      id="F_0779ce38-3b8d-486c-9d34-9551fc5f3684">P5Y18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_812cb21d-509c-45c6-902b-083e529e8293"
      unitRef="U_USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-5"
      id="F_de9f083a-6939-44a6-9577-a13a8cc7725a"
      unitRef="U_USD">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_bf1af018-f6b9-42bb-86ca-f8c83338fc0e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on finite-lived intangible assets recorded as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the estimated future amortization expense is as follows (in thousands):&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:85.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Amortization Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_ac40e4c5-1731-4822-9886-98a68f986a5b"
      unitRef="U_USD">34000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_daf1f1cd-7a2c-446f-9ad1-eae74ca61ed4"
      unitRef="U_USD">34000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_955eff3f-d68b-4641-9c3f-d45b8945d238"
      unitRef="U_USD">34000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_f556076b-6e44-4c76-879f-9030af92c853"
      unitRef="U_USD">33000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_42baba12-6c53-49a6-8a4f-f2edbe029923"
      unitRef="U_USD">18000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_64f1e13a-815f-4770-9d9b-26a728883825"
      unitRef="U_USD">52000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_c333e20c-cb0a-48e3-98f9-1be0c21ea330"
      unitRef="U_USD">205000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_cadc753d-9f28-49ad-8eb7-aab47f2e7d3e">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s product revenues were mainly generated from the sale of ETUARY. Sales of ETUARY accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of total revenue for the years ended on December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sales of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company generates revenue mostly through sales of ETUARY and certain generic drugs. The distributors were the Company&#x2019;s direct customers, and sales to distributors accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of revenue from ETUARY. The distributors sell ETUARY to outlets, including hospitals and other medical institutions, as well as pharmacies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Product returns to date have not been significant and the Company has not considered it necessary to record a reserve for product returns. The Company&#x2019;s product revenues were recognized at a point in time when the underlying product was delivered to the customer, which was when the customer obtained control of the product. Revenue from sales of pharmaceutical products was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the years ended December 31, 2023 and 2022, respectively. All sales are generated in the PRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License of Intellectual Property&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue from licensing intellectual property is recognized when the control of the right to use the license is transferred to the customer. Milestone payments, which are included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur, represent a form of variable consideration, which is recognized as revenue when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered highly probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s sales by product categories for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.814%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.863000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;License of Intellectual Property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_fe01067f-086e-4848-ab35-be3389a6f430"
      decimals="3"
      id="F_0990ab36-908d-4912-9f61-ae15d90d95c2"
      unitRef="U_pure">0.989</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_876ccdba-ce87-44d7-a2b1-3ab0b94f2343"
      decimals="3"
      id="F_d55f46af-50e1-45cb-bb9a-fd489fcd6ebd"
      unitRef="U_pure">0.969</us-gaap:ConcentrationRiskPercentage1>
    <gyre:PercentageOfRevenueAccountedSalesToDistributors
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="2"
      id="F_0bda87a1-a6b7-4cfb-b642-50b21f36348e"
      unitRef="U_pure">1</gyre:PercentageOfRevenueAccountedSalesToDistributors>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_667dbe67-6d4f-4415-b9bd-2d650d6ff17a"
      decimals="-5"
      id="F_55f68626-caed-482e-a541-471055f18d28"
      unitRef="U_USD">113500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_f5c9b177-fba0-46dd-bf60-5e7f99b3ce8b"
      decimals="-5"
      id="F_c48f808b-4306-49bf-98fe-c456db5d783e"
      unitRef="U_USD">100900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_980d6ec5-1ce2-4448-a150-64f9d8fe1d24">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s sales by product categories for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.814%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.323%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.863000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales of Pharmaceutical Products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;License of Intellectual Property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_667dbe67-6d4f-4415-b9bd-2d650d6ff17a"
      decimals="-3"
      id="F_f6f5b9eb-5b7c-4440-855f-d7571603e8f7"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_f5c9b177-fba0-46dd-bf60-5e7f99b3ce8b"
      decimals="-3"
      id="F_9e50cfe7-63c6-4821-9c05-39be8acaad97"
      unitRef="U_USD">100876000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_f750731b-6020-454a-871c-e743ff63ef9d"
      decimals="-3"
      id="F_3f116145-da19-433d-b2a4-14820a9d1970"
      unitRef="U_USD">1414000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_fbee0e48-e353-4ded-9fe7-4cd2aa59fe38"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_a64648b6-1dd5-4719-b9ba-e3fcf14dcee1"
      unitRef="U_USD">102290000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_aa4dcf38-b316-4e47-8aa8-b93575a6d1ba">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;GNI USA Contributions under the Business Combination Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The GNI USA Contributions under the Business Combination Agreement (see Note 1) was treated as a reverse asset acquisition, with CPI as the accounting acquirer and Catalyst as the legal acquirer. Under U.S. GAAP, a company must evaluate if an integrated set of assets and activities qualifies as a business acquisition or an asset acquisition by&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;assessing if the gross assets&#x2019; fair value is primarily concentrated in a single asset or a group of similar assets. If this criterion is met, the acquired operations are not considered a business. Catalyst did not meet the business definition as its fair value was concentrated in one IPR&amp;amp;D asset, it lacked an organized workforce contributing significantly to output creation, and no substantive processes were acquired. As such, the GNI USA Contributions was treated as an asset acquisition. In an asset acquisition, goodwill is not recognized, and the cost allocated to the acquired IPR&amp;amp;D with no alternative future use is expensed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Catalyst Common Stock outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Multiplied by the fair value per share of Catalyst stock (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of common shares to be owned by Catalyst&#x2019;s stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of preferred shares to be owned by Catalyst&#x2019;s stockholders (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of Catalyst&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of consideration issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;This amount is calculated based on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;666.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:84%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:84.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other receivables from GNI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Advance payment received from GNI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CVR excess closing cash payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CVR derivative liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Minority Holder Contributions were treated as an equity transaction, where the Company obtained additional indirect interest and maintained its control in BC.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_59d8a41f-bed6-4971-9e8c-3a3257ed0992">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following summarizes the purchase price paid in the GNI USA Contributions (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Catalyst Common Stock outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Multiplied by the fair value per share of Catalyst stock (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of common shares to be owned by Catalyst&#x2019;s stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of preferred shares to be owned by Catalyst&#x2019;s stockholders (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of Catalyst&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Pre-GNI USA Contributions Catalyst stock options assumed by CPI (3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of consideration issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;This amount is calculated based on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;666.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:84%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a"
      decimals="INF"
      id="F_9e943dcd-fc6f-4dbf-ba7e-a41b4bc06f28"
      unitRef="U_shares">2532</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a"
      decimals="2"
      id="F_5ee0712a-9495-465c-a62c-57257a6ca510"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.67</us-gaap:BusinessAcquisitionSharePrice>
    <gyre:BusinessCombinationFairValueOfCommonShares
      contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a"
      decimals="-3"
      id="F_4cdb87c5-f183-4ec9-aff2-dfd12634cb72"
      unitRef="U_USD">19420000</gyre:BusinessCombinationFairValueOfCommonShares>
    <gyre:BusinessCombinationFairValueOfPreferredShares
      contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a"
      decimals="-3"
      id="F_fbaeeda2-4b02-470d-9341-dbf9ecc4a8bb"
      unitRef="U_USD">63099000</gyre:BusinessCombinationFairValueOfPreferredShares>
    <gyre:BusinessCombinationFairValue
      contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a"
      decimals="-3"
      id="F_f224a411-c0cf-4fca-8cb6-5c702156ac66"
      unitRef="U_USD">82519000</gyre:BusinessCombinationFairValue>
    <gyre:PreMergerStockOptionsAssumed
      contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a"
      decimals="-3"
      id="F_c261cfe5-3da9-46f4-9be9-e6fa353cc3f9"
      unitRef="U_USD">1829000</gyre:PreMergerStockOptionsAssumed>
    <us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure
      contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a"
      decimals="-3"
      id="F_e98bdfce-ba24-4063-8144-bfeab03a8fc3"
      unitRef="U_USD">84348000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="C_d846aa23-1a35-4add-bb37-786c605b621a"
      decimals="-3"
      id="F_1cb605aa-3130-4ec1-97d1-656c5b634f46"
      unitRef="U_USD">659000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_dd01b7d2-757f-4f84-a6ce-a11ccc44dbab"
      decimals="-3"
      id="F_00c91776-adaf-4b4c-a72c-a92a9accd945"
      unitRef="U_USD">85007000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b46d8f77-6441-4e49-9e95-f82435a4d5d3"
      decimals="INF"
      id="F_884520f5-d206-4413-aef6-7cdddfdc52b6"
      unitRef="U_shares">12340</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_b46d8f77-6441-4e49-9e95-f82435a4d5d3"
      decimals="INF"
      id="F_4fdbb7f8-f8cf-4cf3-8745-f364e85793a1"
      unitRef="U_shares">666.67</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_adcc0073-9fef-4201-8397-398d0314ba70">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:84%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_7cd6ec69-a601-4ca9-9e6f-9104cf25e061">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_ffcadfc5-a8fe-4d82-a0fb-1f4fd0a3427e"
      unitRef="U_pure">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_433dba2f-890e-41fa-bb69-f079f6a82328"
      unitRef="U_pure">0.0365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_6b7c5c36-6872-4710-a424-ffd1ba3fbd5f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total purchase price paid in the GNI USA Contributions has been allocated to the net assets acquired and liabilities assumed based on their fair values at the Effective Time. The allocation of the purchase price, as shown above, is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:84.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other receivables from GNI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term receivable from GCBP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Advance payment received from GNI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CVR excess closing cash payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CVR derivative liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_2bac1b0b-a85b-4066-a562-3a5307caadde"
      unitRef="U_USD">5587000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_7e379039-a6c4-4fa4-b8e0-74e81aa9de39"
      unitRef="U_USD">423000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivablesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_7bc68f47-661c-4fea-925c-b3040c096e36"
      unitRef="U_USD">1097000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_5bc09f2b-b15a-4780-a5ba-46074887a76b"
      unitRef="U_USD">41000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_198eee49-92d8-459f-8108-232243e9e477"
      unitRef="U_USD">4683000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermReceivable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_96b8ee5b-01f2-4d5b-95b1-e28df96125dd"
      unitRef="U_USD">168000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_4ea11064-c3a8-459b-90ac-4d6a1d1408ff"
      unitRef="U_USD">83104000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_a46e4344-b28a-4335-be66-b7ca4f9cfca5"
      unitRef="U_USD">44000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_0500177a-bae5-4fe0-802c-dd3a55d52e6b"
      unitRef="U_USD">2500000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdvancePaymentReceived>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_763b76f9-4cd2-4a49-bd29-cf5ad96423e8"
      unitRef="U_USD">1784000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities>
    <gyre:BusinessCombinationExcessClosingCashPayable
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_f6520a18-ea5f-4a1a-9607-d496b96ffd2b"
      unitRef="U_USD">1085000</gyre:BusinessCombinationExcessClosingCashPayable>
    <gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_29c404e8-861a-48c5-81d8-674c31188f76"
      unitRef="U_USD">4683000</gyre:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCvrDerivativeLiabilityNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="C_5c2acdd7-2eeb-456d-a2f6-cef94e75ece8"
      decimals="-3"
      id="F_35f55db7-a462-4834-baf1-0f074502d638"
      unitRef="U_USD">85007000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_f4ec9d2a-65b0-4ce5-8d17-9789ed5a4634">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;8.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Restructuring&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the Contributions, CPI entered into a CP &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;U.S. Share Purchase Agreement with GNI USA &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and divested almost all of its assets other than its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; indirect ownership interest in BC. GNI USA is the parent company of Gyre. In connection with the transaction, the Company recorded a receivable in the amount of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; included in other receivables from GNI on the consolidated balance sheet as of December 31, 2023 and recognized a loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; during the year ended December 31, 2023, included in divestiture losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <gyre:PercentageOfIndirectOwnershipInterest
      contextRef="C_a67805ae-0e8b-4cdd-8b41-5d0c3ff00337"
      decimals="3"
      id="F_8886d9aa-16d7-4402-8449-f55e2052b81e"
      unitRef="U_pure">0.56</gyre:PercentageOfIndirectOwnershipInterest>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_ffe88006-6a83-4a40-9c82-c045fa6b0bdc"
      decimals="-5"
      id="F_c1cfac9c-76ae-4091-aa3e-a70c853a47dc"
      unitRef="U_USD">800000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_a67805ae-0e8b-4cdd-8b41-5d0c3ff00337"
      decimals="-5"
      id="F_c190128c-579c-4fa2-bc09-dede3178e532"
      unitRef="U_USD">-2700000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_a67805ae-0e8b-4cdd-8b41-5d0c3ff00337"
      decimals="-5"
      id="F_8e68219b-ebcf-438a-abe3-c6ac455c6706"
      unitRef="U_USD">-2700000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_aac4ad75-e7ac-4c56-92d1-6d7c6cd70a17">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;9.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; BC&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019;s corporate headquarters, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;968&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square meter office space, is situated in Beijing, PRC, with the lease expiring in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Additionally, a laboratory center spanning approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;640&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square meters was leased in Shanghai, China, which expired in November 2023. In 2022, the Company secured a new lease for an office space of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square meters in Zhengzhou, China, with the lease set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In November 2023, the Company also secured a new lease for its U.S. headquarters in San Diego, United States, with the lease set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also has multiple short-term leased properties used as offices and employee dormitories. The Company recorded a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; short-term rent expenses during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The short-term rent expense amounts are recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;As of December 31, 2023, the Company recorded an aggregate ROU asset of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and an aggregate lease liability of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rent expense related to operating leases was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for each of the years ended December 31, 2023 and 2022, respectively. Variable lease payments for the years ended December 31, 2023 and 2022 were immaterial.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental cash flow information related to operating leases was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The present value assumptions used in calculating the present value of the lease payments were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.687%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.141%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.141%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, undiscounted future minimum payments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:83%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to maintain security deposits of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in connection with various leases, which amounts are included in other assets, noncurrent on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Land use rights&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company held land use rights for two land parcels in Beijing&#x2019;s Shunyi District, expiring in 2053, and in Cangzhou, Hebei Province, expiring from 2067 to 2071. These parcels, with a combined area of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,559&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square meters, are utilized as manufacturing facilities. As of December 31, 2023, the aggregate recorded land use rights, net assets for these parcels was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <gyre:SquareMeterAreaForOfficeSpaceUnderLease
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="0"
      id="F_670ac4e3-908c-4d90-9a0b-d6e9b843a906"
      unitRef="U_sqm">968</gyre:SquareMeterAreaForOfficeSpaceUnderLease>
    <gyre:LeaseExpirationMonthAndYear
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_980c4f41-4752-4ab3-912a-756202539dfa">2024-06</gyre:LeaseExpirationMonthAndYear>
    <gyre:SquareMeterAreaForLaboratoryCenterUnderLease
      contextRef="C_65d76f22-ab8c-450d-82d6-0c032d5502d0"
      decimals="0"
      id="F_a7a31fdf-9f02-43a1-a73a-5f7e261543a2"
      unitRef="U_sqm">640</gyre:SquareMeterAreaForLaboratoryCenterUnderLease>
    <gyre:SquareMeterAreaForOfficeSpaceUnderNewLease
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="0"
      id="F_5884bc41-22f2-4147-b443-65cfdd59c315"
      unitRef="U_sqm">180</gyre:SquareMeterAreaForOfficeSpaceUnderNewLease>
    <gyre:LeaseExpirationMonthAndYear
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      id="F_f37cb650-9a54-4594-b426-79b8f4de97fc">2024-08</gyre:LeaseExpirationMonthAndYear>
    <gyre:LeaseExpirationMonthAndYear
      contextRef="C_28499de6-ca37-4fe6-8aca-3f877d7ec297"
      id="F_8d1b9455-d4a7-463a-badd-8bab88ca23b3">2026-12</gyre:LeaseExpirationMonthAndYear>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="0"
      id="F_16b57dc3-12ea-4130-80bc-116aa669f1a6"
      unitRef="U_USD">89000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="0"
      id="F_a96a00d0-6725-42bc-8b33-1c5db91b6921"
      unitRef="U_USD">52000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_02bd0f34-0f8d-4015-b90f-49084c92650f"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_19072959-5534-4899-8d5b-fd42f2aaa226"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_04ace930-8fdc-40f7-baf2-9f8d9af35c89"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-5"
      id="F_98e1d16a-17fa-4e52-9000-12067188b9ca"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_bc89322e-c867-43dd-9c9e-5ec2ce8be1f4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental cash flow information related to operating leases was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_780f05f8-1479-49e3-8dc6-2409667f599f"
      unitRef="U_USD">573000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_6c21359e-2e3f-4451-912d-a34e49ab3f6d"
      unitRef="U_USD">517000</us-gaap:OperatingLeasePayments>
    <gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_29945eb2-befa-4f8d-b286-467cfe6c5b97">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The present value assumptions used in calculating the present value of the lease payments were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.687%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.141%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.141%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</gyre:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      id="F_a6d3a1a2-90c7-46d2-888b-31755ab21c27">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      id="F_1552c57b-5f90-4c25-a514-76065bcd1398">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="4"
      id="F_664e994d-d703-4fb9-97dc-9cfce7fb2fb2"
      unitRef="U_pure">0.0478</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="4"
      id="F_6803b8e7-39d8-49f3-9e6c-9624a9aec7f1"
      unitRef="U_pure">0.0475</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_ce01d443-1c8c-418c-80cb-f4f56984f32a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, undiscounted future minimum payments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:83%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3326c3a8-77ce-4967-93d2-af9e8c243d45"
      unitRef="U_USD">226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_f27fa406-f062-42f3-b7b6-d8967cabab14"
      unitRef="U_USD">103000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3a3d57e3-9d88-4118-a030-385d957461d3"
      unitRef="U_USD">106000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_0264d636-f356-488c-a9b2-21ccdd46a26d"
      unitRef="U_USD">435000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_d30c3661-20b7-44d2-8899-94031854c600"
      unitRef="U_USD">26000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3ad0fcc8-bbb0-4ab5-b18c-bc1cb45abe45"
      unitRef="U_USD">409000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_aabc90fa-1762-4f8f-9ca1-47e38449fb0a"
      unitRef="U_USD">210000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_8cd264dd-b6b5-4894-a4fa-1e6862004577"
      unitRef="U_USD">199000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SecurityDeposit
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_17939ca9-cce3-4079-ad40-c900fa596414"
      unitRef="U_USD">100000</us-gaap:SecurityDeposit>
    <gyre:CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="0"
      id="F_417f93cf-bfa7-4a53-9319-6753454768b1"
      unitRef="U_sqm">66559</gyre:CombinedSquareMeterAreaForManufacturingFacilitiesUnderLease>
    <gyre:LandUseRightsNetAssets
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_3ae54f3f-bc82-423b-8d93-a8e5ace5f937"
      unitRef="U_USD">1500000</gyre:LandUseRightsNetAssets>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_bd179929-c9d5-4b87-a287-0710180fb5b5">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;10.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Company&#x2019;s amended and restated certificate of incorporation, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Common Stock authorized for issuance with a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; par value per share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#x2019;s stock who are entitled to vote. The holders of Common Stock have voting rights equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one vote&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of Common Stock held. The holders of Common Stock are entitled to receive dividends when and as declared or paid by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Preferred Stock issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preferred Stock Warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,036,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,588,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,036,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 ATM Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 15, 2021, Catalyst entered into an Equity Distribution Agreement (the &#x201c;ATM Agreement&#x201d;) with Piper Sandler &amp;amp; Co. (&#x201c;Piper Sandler&#x201d;) as sales agent, pursuant to which the Company may offer and sell, from time to time,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;through Piper Sandler, shares of the Company&#x2019;s Common Stock, par value of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, with aggregate gross sales proceeds of up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through an at-the-market offering program (the &#x201c;ATM Program&#x201d;). The Company will pay Piper Sandler a commission of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the gross proceeds of any shares sold. The Company also agreed to reimburse Piper Sandler for certain expenses incurred in connection with its services under the ATM Agreement, including up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for legal expenses in connection with the establishment of the ATM Program. The Company does not currently intend to use this or any other ATM Program prior to April 1, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sales of shares of common stock under the ATM Program may be made pursuant to the registration statement on Form S-3 (File No. 333-253874), which was declared effective by the SEC on May 3, 2021, and a related prospectus supplement filed with the SEC on October 15, 2021. For the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were sold under the ATM Program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Net Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under PRC laws and regulations, BC is subject to restrictions on foreign exchange and cross-border cash transfers, including to parent companies and U.S. stockholders. The ability to distribute earnings to the parent companies and U.S. stockholders is also limited. Current PRC regulations permit BC to pay dividends to BJC only out of its accumulated profits as determined in accordance with PRC accounting standards and regulations. Amounts restricted include paid-in capital and the statutory reserves of BC. The aggregate amounts of restricted capital and statutory reserves, which represented the amount of net assets of the relevant subsidiaries not available for distribution were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of the above restrictions, parent-only financial statements are presented in Schedule I.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Statutory Reserve&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;BC is required to set aside at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of its after-tax profits as the statutory reserve fund until the cumulative amount of the statutory reserve fund reaches &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or more of its registered capital, if any, to fund its statutory reserves, which are not available for distribution as cash dividends. At the Company&#x2019;s discretion, the Company may allocate a portion of after-tax profits based on PRC accounting standards to a discretionary reserve fund.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Appropriations to these reserves by BC were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the year ended December 31, 2022. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; appropriations to these reserves during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="0"
      id="F_27b44c94-23b4-4a3a-9e0d-3f546c33ceb2"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="0"
      id="F_dd61fef5-d21d-4d44-9d1b-9a9bdb30795c"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="3"
      id="F_a21379b7-38b9-4c53-94a5-5718262f7ef3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="3"
      id="F_308a0511-fa31-4e5f-a277-7890aa1f42f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_cd5d574b-2bc7-4456-be02-bf52a3dec9d8">one vote</us-gaap:CommonStockVotingRights>
    <gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_739f6b93-ff55-46a7-9b1b-f9547e8bc2fd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Preferred Stock issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preferred Stock Warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,036,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,588,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,036,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</gyre:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_afcf9e34-e766-4991-bf31-c35f0696458c"
      unitRef="U_shares">8767332</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2522893b-b6a7-4707-8268-f07f26458548"
      decimals="INF"
      id="F_9e05630a-559e-489d-88d9-724750142e28"
      unitRef="U_shares">540666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_70b83c65-e6f6-4e44-8d27-f4d22fcc2178"
      decimals="INF"
      id="F_1ef6fe2c-4bfb-4f4f-97de-be343984db53"
      unitRef="U_shares">18280548</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e3dac587-c2f1-4635-9403-fcc4c1dc69d4"
      decimals="INF"
      id="F_12851e18-4681-4062-95fe-83c27705831f"
      unitRef="U_shares">17036941</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_704b5f2f-959f-43d3-b2a0-fa792f8f2de3"
      unitRef="U_shares">27588546</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_c7bfb11d-1cb1-44f3-a000-7c965c6dfa44"
      unitRef="U_shares">17036941</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a21fb1ae-dd92-411d-bef0-916436903fc6"
      decimals="3"
      id="F_cf4fe37e-eba2-4205-bc42-8414a216ae1f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_3881b1d8-2620-4894-97cf-4c70975b00b9"
      decimals="-5"
      id="F_9e94bbc6-0870-4f35-8acc-e4955bb24c09"
      unitRef="U_USD">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <gyre:PercentageOfCommissionForSharesSold
      contextRef="C_a21fb1ae-dd92-411d-bef0-916436903fc6"
      decimals="2"
      id="F_845c131d-a38d-4363-a8f3-da0426bc2a78"
      unitRef="U_pure">0.03</gyre:PercentageOfCommissionForSharesSold>
    <gyre:LegalExpensesIncurred
      contextRef="C_3881b1d8-2620-4894-97cf-4c70975b00b9"
      decimals="0"
      id="F_09550b24-5b4e-4470-ba72-d99b12ac7ced"
      unitRef="U_USD">50000</gyre:LegalExpensesIncurred>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_83452b0c-e779-4d10-8c25-9d61d6a3d570"
      decimals="INF"
      id="F_19e537cf-257d-41a9-8812-0955acbcdbb5"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_606d870c-cbd5-409e-9eb7-2056b6dd9718"
      decimals="INF"
      id="F_67d341e0-4254-4de0-8d80-bd8767f5ef86"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_dc9a9e80-5096-4446-957c-7479dd79e90e"
      unitRef="U_USD">64300000</gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves>
    <gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-5"
      id="F_26558095-c597-4c58-97e2-9f21fbb171cc"
      unitRef="U_USD">61500000</gyre:AggregateAmountsOfRestrictedCapitalAndStatutoryReserves>
    <gyre:StatutoryReserveFund
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_906a3d03-3c12-4a48-a008-ad1b3eeb456a"
      unitRef="U_pure">0.10</gyre:StatutoryReserveFund>
    <gyre:CumulativeAmountOfStatutoryReserveFund
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_dd979268-81fc-4f66-a7f6-0d3d83e70593"
      unitRef="U_pure">0.50</gyre:CumulativeAmountOfStatutoryReserveFund>
    <gyre:AppropriationsToStatutoryReserve
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-5"
      id="F_690c9cf1-bec0-4e32-8cc6-de43bb5287c2"
      unitRef="U_USD">2200000</gyre:AppropriationsToStatutoryReserve>
    <gyre:AppropriationsToStatutoryReserve
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-6"
      id="F_b7a2b98e-7553-4538-8372-29ec8a99489b"
      unitRef="U_USD">0</gyre:AppropriationsToStatutoryReserve>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_62414a84-fa06-4e5c-ab6f-2249fc4857da">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;11.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is authorized to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock with par value &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share under its restated certificate of incorporation, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,040&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares are designated as Convertible Preferred Stock as of December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2022, Catalyst issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Convertible Preferred Stock to GNI in connection with the F351 Asset Acquisition (see Note 1 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, immediately following the closing of the Contributions, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Convertible Preferred Stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Preferred Stock Warrants to GNI under the Private Placement. For additional information, see Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, GNI provided notice to the Company to convert its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,151&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Convertible Preferred Stock. The conversion became effective on January 22, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Convertible Preferred Stock is classified outside of stockholders&#x2019; equity because the shares contain certain redemption features that are not solely within the Company&#x2019;s control. The Company does not adjust the carrying value of the Convertible Preferred Stock to its redemption value since the Convertible Preferred Stock is not currently redeemable, and it is not probable that it will become redeemable in the future at any of the balance sheet dates. Subsequent adjustments to the carrying value will be made only when it becomes probable that such redemption will occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Holders of Convertible Preferred Stock are entitled to receive dividends equal to, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Company&#x2019;s common stock. Except as otherwise required by law, the Convertible Preferred Stock does not have voting rights. However, as long as any shares of Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of Convertible Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to Convertible Preferred Stock or alter or amend the Certificate of Designation that authorized the Convertible Preferred Stock, amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Bylaws of the Company, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Convertible Preferred Stock, (ii) issue further shares of Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Convertible Preferred Stock, or (iii) enter into any agreement with respect to any of the foregoing. Convertible Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,151&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Convertible Preferred Stock issued and outstanding. Each share of Convertible Preferred Stock is convertible into approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;666.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Common Stock. As of December 31, 2023, the number of shares of common stock issuable upon conversion of the outstanding shares of Convertible Preferred Stock is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_da94008c-f55f-4d04-8dd4-d62952df45c9"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_4ffac470-c959-41dc-9dd1-d994d8255254"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_782172dd-5f9c-4433-b37a-af1898ef1ee1"
      unitRef="U_shares">125040</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_97f8f74d-9c50-43ce-8914-9b9e5c020d2a"
      decimals="INF"
      id="F_4e4cbaad-38c8-4076-89d5-0cde945348e7"
      unitRef="U_shares">12340</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_101acaab-645c-4f44-bbd8-62788657a2a3"
      decimals="INF"
      id="F_3603a962-ec4d-45b0-8ef7-dfb8a1bb1633"
      unitRef="U_shares">811</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_73e506f1-e7cf-4f6e-aabc-dc8fffc52d12"
      decimals="0"
      id="F_5a2d7e82-4e60-40ae-8a14-ca018792155b"
      unitRef="U_shares">811</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_86929c87-30bc-44d5-9aa7-59c41f5a2bc4"
      decimals="INF"
      id="F_9e07d7a5-0ca0-430d-a16d-db8d35555bd0"
      unitRef="U_shares">13151</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_f4757c84-e1cb-427a-9fef-15e8b85036b8"
      unitRef="U_shares">13151</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_11e755a4-d4c5-476f-a767-5f5f81f3f1dd"
      unitRef="U_shares">13151</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_38aa9671-a511-414a-b97d-bcf3e384a6a8"
      unitRef="U_shares">666.67</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares
      contextRef="C_92d8bddf-b9c6-4785-9379-7fbbc0ccf697"
      decimals="INF"
      id="F_fafb7310-0ad2-4039-93dc-0f52029102cf"
      unitRef="U_shares">8767332</gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_e19dc7c3-00a1-4a4d-b0c7-87ff0056f607">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;12.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stock Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;BC 2021 Stock Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2021, the board of directors of BC approved the 2021 Plan to grant options to certain employees and consultants of BC.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2021 Plan had a contractual term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Options granted under the 2021 Plan were accounted for as equity awards and subject to a service condition. Upon the Contributions, BC terminated the 2021 Plan and the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;BC Options under the 2021 Plan were terminated and replaced with options to purchase Gyre Common Stock granted under the 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, prior to the Contributions, the Board of Directors of BC modified the expiration term of the fully vested BC Options to be extended to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 3, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Following this modification, the total incremental stock-based compensation of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was immediately recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2018 Omnibus Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2018, stockholders of Catalyst approved a 2018 Omnibus Incentive Plan, as amended in June 2021 (the &#x201c;2018 Omnibus Incentive Plan&#x201d;). Each option to purchase shares of Catalyst common stock that was issued and outstanding under the 2018 Omnibus Incentive Plan immediately prior to the Effective Time remains outstanding and unaffected after the Contributions in accordance with its terms.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Omnibus Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2023 Omnibus Incentive Plan was approved by Catalyst&#x2019;s stockholders in August 2023 and ratified by Gyre&#x2019;s Board in October 2023. The 2023 Omnibus Incentive Plan became effective on October 30, 2023. The 2023 Omnibus Incentive Plan permits the Company to deliver up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,845,496&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Common Stock and will automatically increase by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total number of outstanding shares of Common Stock on December 31st of the preceding calendar year and (ii) such smaller number of shares of Common Stock as determined by the Board on the first day of each fiscal year beginning on January 1, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;After the Contributions, the Company modified the expiration term of the fully vested options originally granted as the BC options to be extended to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 30, 2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As a result of this modification, the total incremental stock-based compensation of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was immediately recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 30, 2023, upon closing of the Contributions, the Gyre Board approved grants to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; individuals, to be made on October 31, 2023, of an aggregate of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;820,824&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; fully vested stock options in consideration for services rendered in connection with the Contributions transactions. Although the awards were granted for the services in connection with the Contributions, which were direct and incremental costs incurred to complete the reverse asset acquisition, they were issued to Gyre&#x2019;s employees and consultants who worked on the Contributions instead of third-parties and therefore, do not qualify as transactions costs of the reverse asset acquisition.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes stock option activity considering the conversion of BC Options to Gyre options to purchase shares of Gyre Common Stock upon completion of the GNI USA Contributions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.052%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares Underlying Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value (Thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,036,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;838,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;444,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,262,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value of options granted during the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options were granted during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value of options exercised during the year ended December 31, 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options were exercised during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Valuation Assumptions&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited relevant historical data, the Company estimated its volatility considering a number of factors, including the use of the volatility of comparable public companies. The expected term of options granted under the 2023 Omnibus Incentive Plan, all of which qualify as &#x201c;plain vanilla&#x201d; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#x2019;s limited relevant history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of employee stock options granted was estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected option life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average share price of the Company (USD per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total stock-based compensation recognized was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.634%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.963000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had an unrecognized stock-based compensation expense of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.87&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward
      contextRef="C_e1121837-d055-4a18-8650-a77886d17e34"
      id="F_6077116e-515c-4a58-8965-ceffc46108f6">P7Y</gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="C_34639a27-12df-4fc6-8cf2-6020aa830e91"
      id="F_5d0edc5c-af7c-436a-88f7-ec9b52aa2692">2028-02-03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_34639a27-12df-4fc6-8cf2-6020aa830e91"
      decimals="-5"
      id="F_ca5c764c-b273-4c70-99a8-3325c1974635"
      unitRef="U_USD">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_393225c6-0b98-4833-af11-e65edf2bb418"
      decimals="0"
      id="F_857a85ef-5a69-45b9-b812-0eb83b52cf3b"
      unitRef="U_shares">17845496</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <gyre:PercentageOfOutstandingSharesOfCommonStock
      contextRef="C_1aa9e6e5-97ba-4f1a-9591-6fe7ce14496b"
      decimals="2"
      id="F_2046a8a7-ea3c-4218-8034-fbb051225c28"
      unitRef="U_pure">0.05</gyre:PercentageOfOutstandingSharesOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="C_666ada80-f898-47d3-8486-3309e25ceb24"
      id="F_d1da8601-e3cc-4cf4-912d-7f3177f59673">2030-10-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_666ada80-f898-47d3-8486-3309e25ceb24"
      decimals="-5"
      id="F_d2800122-e5e7-47f1-bc62-27b3231c5138"
      unitRef="U_USD">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <gyre:NumberOfIndividualsApprovedGrantsByBoard
      contextRef="C_1ec943e7-b2ed-4fe5-9f06-a3c06eb3c01a"
      decimals="INF"
      id="F_985fa3f7-6c68-4bb8-b107-ca44da76d5a4"
      unitRef="U_Individual">5</gyre:NumberOfIndividualsApprovedGrantsByBoard>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_666ada80-f898-47d3-8486-3309e25ceb24"
      decimals="INF"
      id="F_ffeee5e3-0b26-4836-b24c-ada31c656123"
      unitRef="U_shares">820824</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_e77b05c0-b262-4479-a972-95f9f1e7d7f7">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes stock option activity considering the conversion of BC Options to Gyre options to purchase shares of Gyre Common Stock upon completion of the GNI USA Contributions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.052%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.031%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares Underlying Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value (Thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,036,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deemed issuance of options to former stockholders of Catalyst upon the GNI USA Contributions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;838,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;444,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,262,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_7a612877-0a6f-4500-bd9f-5557f60427ee"
      unitRef="U_shares">17036941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="2"
      id="F_2c85720f-1b31-4554-b04c-d5b56b7e2322"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      id="F_b314a643-3288-4914-9cba-92b17deca3a1">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_f30b82a5-43cb-4c30-b25a-24f6e777bfd6"
      unitRef="U_USD">12667000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="INF"
      id="F_03cd509d-6b98-48fe-be4a-0a2018f84068"
      unitRef="U_shares">18936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_47cbd9d4-87d6-4dad-89ec-74d594b750d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="INF"
      id="F_5b362e46-b7ac-4f38-9e90-2b0afd331af4"
      unitRef="U_shares">435916</gyre:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholders>
    <gyre:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_2c983cd6-62b5-41e2-9f6a-30d3fbb7bc48"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.1</gyre:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsDeemedIssuanceOfOptionsToFormerStockholdersInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="INF"
      id="F_d1778428-63ee-4ec7-910b-5f0d70313d3d"
      unitRef="U_shares">838686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_22c1368d-e2f5-43a1-8b0b-60dca29e16d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="INF"
      id="F_2256ac56-ebd0-4a11-a852-973bbd29d125"
      unitRef="U_shares">12059</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_a40ada68-5f89-4776-8803-02893eb1ba6a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_9ca429dd-e00a-4748-bfb6-f41da3eba4f4"
      unitRef="U_shares">18280548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="2"
      id="F_0282b888-8f13-4d31-9c99-49eb59cc7d06"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_a1e19985-a50f-4194-b370-9719f23c98d7">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_0c956c7f-6025-49a1-a5c2-ec929316c2ea"
      unitRef="U_USD">444197000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_4e8c4534-a4c8-4dec-85a4-29545be0307b"
      unitRef="U_shares">18262686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="2"
      id="F_4bb435c8-84ce-4a16-9d4d-ae32b83a2697"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_7e5b316f-fe5a-483a-9622-30c47ec59f36">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_08b89eb5-2e72-476e-a4a1-7b9a75197e38"
      unitRef="U_USD">19433000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_f5d3e63a-f41f-4b78-a633-662f12d36197"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="INF"
      id="F_b14bc508-884d-4ea8-8c5c-7ad94dd4aa9d"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_8af02b31-a3d9-41ae-aacd-f9d122c33ce6"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="INF"
      id="F_7e9b0bb1-6cbc-419d-a9ef-6f03ec77ff70"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_8af29623-3925-4f35-b64b-69314473b960">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of employee stock options granted was estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected option life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield (%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average share price of the Company (USD per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962"
      decimals="4"
      id="F_4faba6c3-77a2-4813-98a7-d0d2d4a5cea1"
      unitRef="U_pure">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962"
      decimals="4"
      id="F_181177b5-940a-4d67-b354-f0713c6f08ee"
      unitRef="U_pure">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962"
      decimals="4"
      id="F_d3561b36-815e-4715-93ab-e5ea17051061"
      unitRef="U_pure">0.0382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962"
      decimals="4"
      id="F_aa8c7a04-b6df-42f4-a67c-307ba9e6ee9c"
      unitRef="U_pure">0.0477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_1d2fc6f7-e605-4510-8d2b-4151172e8647"
      id="F_2dd224dd-adc3-48c5-9c2f-5f39f31b777c">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4e5a19f3-a118-4af6-bfc3-2289de865726"
      id="F_b2d30602-5df3-494e-93a6-62b5fc2f4705">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="C_ed00f272-5d55-43d0-8d10-9b8734e290e5"
      decimals="2"
      id="F_0bd3974e-9bdc-4fb5-b876-726f7c41b1ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.93</us-gaap:SharePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_50425f33-588c-41cf-a3b7-22cd4e1e8993">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total stock-based compensation recognized was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.634%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.963000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8dd3a581-c90a-4509-af97-5acd79c8a8e3"
      decimals="-3"
      id="F_e9e1e328-74a1-43c5-ae48-64d0da6aac7e"
      unitRef="U_USD">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5a775378-ab64-439b-aa16-34b026d36a54"
      decimals="-3"
      id="F_6cab8f2f-8e13-4e91-b5b4-cdb256d44252"
      unitRef="U_USD">249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c1a2d74b-7d0b-4b38-8998-7a1161571cf0"
      decimals="-3"
      id="F_4e23912a-7244-4dcc-9c55-e602f5d1eece"
      unitRef="U_USD">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4ba38967-8a4f-4c72-a845-ec882f409155"
      decimals="-3"
      id="F_ad418c8f-6682-4b4b-ad5b-67925cc50e63"
      unitRef="U_USD">1643000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_146bbfb7-b649-4239-b32d-22b491e71629"
      decimals="-3"
      id="F_0205935f-ad70-4c3c-9449-5c68a14cf31b"
      unitRef="U_USD">481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e03b0455-2388-408c-baed-fbbcb9bb45ff"
      decimals="-3"
      id="F_61c327d9-8464-4520-b5ab-1e79e4fef45e"
      unitRef="U_USD">2301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b9586f61-cf2b-4213-abab-d860b5741c19"
      decimals="-3"
      id="F_53f6d208-03aa-4ffd-bd6c-7031acfe253c"
      unitRef="U_USD">6404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_290b25a7-e794-4501-9b27-3ec91a3fd8f8"
      decimals="-3"
      id="F_fcd339a4-0754-4fee-ad96-1be576c123c9"
      unitRef="U_USD">9173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_d48d710a-9748-4506-8273-be0fd91d4de1"
      unitRef="U_USD">7281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_8b666735-e159-4a18-81aa-563bc393a5fd"
      unitRef="U_USD">13366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_ed00f272-5d55-43d0-8d10-9b8734e290e5"
      decimals="-5"
      id="F_bbaae2ed-12cf-4eb1-b173-395b8ae6607b"
      unitRef="U_USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_212e7d79-56da-4ebd-9b86-9ca7abe1a962"
      id="F_f9efb40d-3c87-4dcc-801d-026655f7fff8">P1Y10M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_9bb30de8-76d6-4982-8c41-672867add127">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;13.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingent Value Rights Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each CVR under the CVR Agreement (see Note 1 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) entitles the holder to receive (i) certain cash payments from the net proceeds related to the disposition of Catalyst&#x2019;s legacy assets, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by the Company in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of the closing date of the transactions under the Business Combination Agreement, (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the amount actually received by the Company, net of expenses, pursuant to an asset purchase agreement Catalyst entered into with Vertex Pharmaceuticals Inc. (&#x201c;Vertex&#x201d;) in May 2022 and (iv) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the excess amount, by which the preapproved costs to manage, negotiate, settle and finalize certain third party claims exceed the costs actually incurred with respect to such claims. The CVRs are not transferable, except in certain limited circumstances as provided for in the CVR Agreement, will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August, 2023, Catalyst fully settled the CVR payments related to the Vertex asset purchase agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2023, Catalyst sold its legacy rare bleeding disorder program to GCBP. As a result, the Company distributed the net cash proceeds received from the GCBP asset sale of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to the CVR Holders as well as recorded a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; long-term CVR derivative liability for the future distribution of the hold-back amount to be received in May 2025. As of December 31, 2023, the carrying value of the CVR derivative liability was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on the consolidated balance sheet. Refer to Note 3 &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements and Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for additional information regarding the CVR derivative liability and GCBP asset sale.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 30, 2023, pursuant to the CVR Agreement, the Company recorded a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; CVR excess closing cash payable upon closing of the Contributions, which is anticipated to be distributed among the CVR Holders and remained outstanding as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Litigation and Legal Matters&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2023, separate stockholders of Catalyst filed lawsuits in the Delaware Chancery Court, captioned &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Bushansky v. Catalyst Biosciences, Inc., et al &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Scott v. Catalyst Biosciences, Inc., et al., &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;alleging Catalyst violated its fiduciary duties under Delaware Law by failing to disclose purportedly material information regarding the proposed Business Combination Agreement. In February 202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4, both lawsuits were dismissed with prejudice and the Company reimbursed the stockholders for their legal and other expenses related to the litigation in the aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company recorded a litigation settlement liability in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in October 2023 when it became probable and estimable, which was included in accrued expenses and other current liabilities on the consolidated balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Purchasing Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s commitments related to purchase of property and equipment contracted but not yet reflected in the consolidated financial statements were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as of December 31, 2023 and were expected to be incurred within one year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;F351&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2020, BC entered into an intellectual property (&#x201c;IP&#x201d;) transfer agreement (the &#x201c;F351 Transfer Agreement&#x201d;) with GNI Japan and certain of its wholly owned subsidiaries (the &#x201c;GNI Group&#x201d;). According to the F351 Transfer Agreement, BC acquired the exclusive right to use Hydronidone IP rights in mainland China and the right of first offer for the global IP rights (the &#x201c;F351 IP Rights&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the F351 Transfer Agreement, in exchange for the F351 IP Rights, BC is obligated to pay GNI Group &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; upon submission of the F351 New Drug Application (the &#x201c;NDA&#x201d;) to Center for Drug Evaluation of the National Medical Products Administration (the &#x201c;NMPA&#x201d;) of the PRC, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; after the NDA passes the NMPA&#x2019;s Center for Food and Drug Review and Inspection&#x2019;s on-site registration inspection for the F351 product, and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; upon NMPA&#x2019;s approval of the NDA.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Programs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition to the F351 program, as of December 31, 2023, the Company has committed to allocate &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; toward future research and development activities for various programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, the Company may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <gyre:PercentageOfExcessCashOnDispositionsNet
      contextRef="C_909bcf41-2baf-4ab5-92c1-98ec48a3f1a7"
      decimals="2"
      id="F_2fa8dc07-573d-4ecd-b0b2-f1439d8eb60a"
      unitRef="U_pure">1</gyre:PercentageOfExcessCashOnDispositionsNet>
    <gyre:ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets
      contextRef="C_909bcf41-2baf-4ab5-92c1-98ec48a3f1a7"
      decimals="-5"
      id="F_e572c8fa-3adb-4c4f-b3ca-718e7c1b2075"
      unitRef="U_USD">1000000</gyre:ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets>
    <gyre:PercentageOfAmountReceivedOnAgreement
      contextRef="C_37aab4d6-0074-4bef-bcfc-1004484dd02e"
      decimals="2"
      id="F_ef9e02a9-fa21-4720-97e0-57789946f2c6"
      unitRef="U_pure">1</gyre:PercentageOfAmountReceivedOnAgreement>
    <gyre:PercentageOfExcessPreapprovedCosts
      contextRef="C_909bcf41-2baf-4ab5-92c1-98ec48a3f1a7"
      decimals="2"
      id="F_af03c0db-0d4c-42d9-8e9a-97e6b9715cf4"
      unitRef="U_pure">1</gyre:PercentageOfExcessPreapprovedCosts>
    <gyre:DistributionFromAssetSaleProceeds
      contextRef="C_9308c880-d262-4f12-b2e3-dd30805711c3"
      decimals="-5"
      id="F_87762217-25b2-4d29-a5b0-943b58e0e4e7"
      unitRef="U_USD">200000</gyre:DistributionFromAssetSaleProceeds>
    <gyre:ContingentValueRightsDerivativeLiabilityNonCurrent
      contextRef="C_9c0870ec-cd18-4ecc-826e-33d440e66dab"
      decimals="-5"
      id="F_206bd283-15bf-4979-9e0f-51bd04e3350f"
      unitRef="U_USD">4500000</gyre:ContingentValueRightsDerivativeLiabilityNonCurrent>
    <gyre:CVRDerivativeLiabilityNoncurrent
      contextRef="C_af914aeb-56e2-4a0a-bc92-2b10d6ce2fdf"
      decimals="-5"
      id="F_9eb92baf-3256-4764-8cac-2a9e19bbdf5e"
      unitRef="U_USD">4700000</gyre:CVRDerivativeLiabilityNoncurrent>
    <gyre:ContributionsClosingPayableAmount
      contextRef="C_bc1f552a-2533-4ff9-b66b-78200f9c38bd"
      decimals="-5"
      id="F_f9389008-cc2c-43bf-b4bd-6ae83095f16d"
      unitRef="U_USD">1100000</gyre:ContributionsClosingPayableAmount>
    <us-gaap:LitigationSettlementExpense
      contextRef="C_73a0ea9a-142b-4c0d-8823-cc0148cb7f2d"
      decimals="-5"
      id="F_69489664-4c04-4c0f-8f61-2bce6d5ebc59"
      unitRef="U_USD">400000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationReserve
      contextRef="C_8a895bc1-6430-4cd0-8079-aca770c79f44"
      decimals="-5"
      id="F_9cac43ac-8b8c-4f8b-b4ac-2168f815af80"
      unitRef="U_USD">400000</us-gaap:LitigationReserve>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_b1e216e8-da62-4adc-be21-79756314d405"
      decimals="-5"
      id="F_aabcbbb4-785a-466d-90a0-76b3c2fcc71c"
      unitRef="U_USD">2800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights
      contextRef="C_022304e8-e2d8-4bf5-929c-5ef87abda6aa"
      decimals="-5"
      id="F_4e66584c-9e89-4a95-8293-6320d72ab3da"
      unitRef="U_USD">4800000</gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights>
    <gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights
      contextRef="C_f319e2ec-8474-4f02-8b68-38c9e4ad3e70"
      decimals="-5"
      id="F_ec1072c5-68b5-46da-94c4-1d3751bd4eae"
      unitRef="U_USD">1200000</gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights>
    <gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights
      contextRef="C_5ea22d62-a406-408f-8236-ff3e0f11ad07"
      decimals="-5"
      id="F_7c78d431-ec8c-48e5-9ebc-e22ea1f3b1c3"
      unitRef="U_USD">7200000</gyre:ObligationToPayInExchangeForTheIntellectualPropertyRights>
    <gyre:CommittedToAllocate
      contextRef="C_0d0d85f9-9db6-4218-b101-c8578a8373cd"
      decimals="-5"
      id="F_d4415f98-7bbc-424e-b034-b08b9496a555"
      unitRef="U_USD">12700000</gyre:CommittedToAllocate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_d2700150-4b2c-4d3d-9345-92d214577336">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;14.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, the Company completed its acquisition of the controlling interest in BC. As a result of the Contributions, the Company directly or indirectly owned multiple controlled foreign corporations (&#x201c;CFCs&#x201d;) for US tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of the Company&#x2019;s provision for income taxes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.094%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current income tax provision:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign - PRC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred income tax provision:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign - PRC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.066%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.137%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.137%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Rate difference due to different jurisdiction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preferential income tax rate for HNTE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible expense &#x2013; Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible expense &#x2013; One-time expense related to the Contributions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;R&amp;amp;D Super-deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESOP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.52&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:5pt;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.566%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.536%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.889%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other equity investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impact from foreign corporations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred income tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liability &#x2013; ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liability &#x2013; Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The movements of the valuation allowance are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.566%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.536%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.889%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes of valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on the available objective evidence on December 31, 2023, the Company does not believe it is more likely than not that its net deferred tax assets will be realizable for US tax purposes. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets on December 31, 2023 for US tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, after consideration of certain limitations (see below), the Company had approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million federal and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million state net operating loss carryforwards (&#x201c;NOL&#x201d;) available to reduce future taxable income which, if unused, will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for federal and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for state tax purposes. The federal net operating loss carryforward includes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;191.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that have an indefinite life.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for federal and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for state. If unused, the federal credit will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the state tax credit does not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company&#x2019;s stock immediately before such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes under Section 382 occurred on December 31, 2007, August 20, 2015, April 13, 2017, February 15, 2018, February 18, 2020, and December 26, 2022. Approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;156.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the NOLs will expire unutilized for federal and California state income tax purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for federal and California state income tax purposes, respectively, through the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All of the federal R&amp;amp;D credits could expire unutilized, whereas none of the California R&amp;amp;D credits are subject to expiration. Approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of gross federal R&amp;amp;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and credit carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 29, 2020, the California Governor signed Assembly Bill 85 (&#x201c;A.B. 85&#x201d;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of tax per year. Generally, A.B. 85 suspends the use of California NOLs for taxable years 2021, 2022, and 2023 for taxpayers with taxable income of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million or more. Since the Company is not expected to generate California source taxable income of more than $1 million, no material impact is anticipated at this time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company had approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of unrecognized tax benefits as of December 31, 2023. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Beginning Balance on January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending Balance on December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase as a result of the GNI USA Contributions on October 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending Balance on December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#x2019;s consolidated statements of operations. As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized any tax-related penalties or interest in its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company files income tax returns in the United States federal, California, and Florida for tax year 2023. The Company filed an initial return in 2022 in Florida and final returns in 2021 in Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; uncertain tax positions which affected its financial position as its results of operations or its cash flow, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;APB 23&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Generally, a taxable outside basis difference associated with a foreign subsidiary may not be recognized if the indefinite reversal criterion of ASC paragraph 740-30-25-17 (APB Opinion No. 23, Accounting for Income Taxes &#x2013; Special Areas (&#x201c;APB 23&#x201d;)) is met. A deferred tax liability is recognized when an entity no longer meets the indefinite reversal criterion. ASC paragraph 740-30-25-17 provides a presumption that all undistributed earnings will be transferred to the parent entity may be overcome, and no income taxes shall be accrued by the parent entity, if sufficient evidence shows that the subsidiary has invested or will invest the undistributed earnings indefinitely or that the earnings will be remitted in a tax-free liquidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company does not have a plan of repatriation of earnings from non-US subsidiaries to the Company. However, to the extent the Company will not permanently reinvest in its PRC business, a DTL of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 related to PRC withholding taxes on repatriation of BC&#x2019;s earnings (i.e., the Company&#x2019;s primary operating subsidiary in the PRC) would need to be recorded.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_375afa3e-bf5e-4488-8c92-f9bdb9efafe6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of the Company&#x2019;s provision for income taxes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.094%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.123000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current income tax provision:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign - PRC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred income tax provision:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign - PRC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_f3d958b3-e6a7-4e6b-abad-95af4eab0fc7"
      unitRef="U_USD">6000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_73f5ec4a-9240-4194-b0e2-e499e99a928a"
      unitRef="U_USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_0973cd5f-7343-4af8-9386-a83119d57b40"
      unitRef="U_USD">9343000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_76db4fc2-3a2f-4577-ad9f-82cf1426e4ea"
      unitRef="U_USD">5987000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_520ef97e-e717-4245-b940-2445f24dba44"
      unitRef="U_USD">9349000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_99afaaf6-754f-4d43-862c-60694c30ddc8"
      unitRef="U_USD">5988000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_0f106cdb-6bf8-40ba-ae51-bc5243d50681"
      unitRef="U_USD">-91000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_cdf9478b-238c-4b74-98cd-e160477def9f"
      unitRef="U_USD">-834000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_746e6a1d-4830-4289-8797-a40695073de9"
      unitRef="U_USD">-799000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_7358bbd6-e374-45c2-bbbd-5d88eda11495"
      unitRef="U_USD">-834000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_23289e19-441c-4efe-9364-826e87c33840"
      unitRef="U_USD">-890000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_e5c78834-ab87-4ae8-8771-65c5615e7168"
      unitRef="U_USD">8515000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_1ffbfe76-175c-4a8e-aa63-a13f191ee1c3"
      unitRef="U_USD">5098000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_db248905-b589-4a59-afb3-80853e22d750">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.066%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.137%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.137%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Rate difference due to different jurisdiction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preferential income tax rate for HNTE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible expense &#x2013; Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible expense &#x2013; One-time expense related to the Contributions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;R&amp;amp;D Super-deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESOP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.52&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:5pt;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_7936ebd8-d836-497f-9d49-f2a4a80b517d"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_cc480d24-9f77-4875-aada-d2540da4cb7f"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_cd183a92-d0ac-4cfb-b96b-c0eb1d36091b"
      unitRef="U_pure">-0.0243</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_9234406b-6b77-4536-b7b4-344c01dd2a1f"
      unitRef="U_pure">0.0431</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_acccba30-c678-4bba-b196-8e500a295f54"
      unitRef="U_pure">0.0319</gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte>
    <gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_dd5b9deb-ead3-485c-8b2f-df75d93e7d9b"
      unitRef="U_pure">-0.1037</gyre:EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateForHnte>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_cad76f50-5b5d-47ad-bcca-c89823b1e6f1"
      unitRef="U_pure">-0.0628</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_211b8846-2aa6-47f8-a054-996c993137d6"
      unitRef="U_pure">0.3306</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_9e462696-18d9-480a-9db8-a04db0cbf2c2"
      unitRef="U_pure">-0.2216</gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions>
    <gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_88532a00-fa0f-4e20-a862-59986ee7d8c4"
      unitRef="U_pure">0</gyre:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOneTimeExpenseRelatedToTheContributions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_972de8f9-7dc4-4970-8137-9fb1d33ccaea"
      unitRef="U_pure">-0.0145</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_63a83eed-c828-408c-90ed-1eaba15e7670"
      unitRef="U_pure">0.1242</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_238ba441-b90d-4d73-9c2d-6bf847ea3bb2"
      unitRef="U_pure">-0.0437</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_e57d876c-c112-460d-aa41-686ed170b568"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_9dc83638-5540-47ae-96d3-98f9cbdab6cc"
      unitRef="U_pure">-0.0055</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_32858147-bff2-4d18-a737-6ad01bcf17c7"
      unitRef="U_pure">0.2181</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_2f107759-df54-4751-9355-263c30adde67"
      unitRef="U_pure">-0.0076</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_ec23ad81-3814-4269-b5b1-9ecf93f34887"
      unitRef="U_pure">-0.0252</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="4"
      id="F_02011ce9-5aa0-4abe-b73a-368590b7ea3c"
      unitRef="U_pure">-0.1091</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="4"
      id="F_098d8b39-cf93-457a-8115-49c7aeaa71ec"
      unitRef="U_pure">0.5487</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_985fb2db-c41e-43d2-9f00-de2aa54fad18">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.566%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.536%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.889%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other equity investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impact from foreign corporations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred income tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liability &#x2013; ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liability &#x2013; Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_34a6e4d8-3b4e-4c5a-9ff4-6a88987ebad0"
      unitRef="U_USD">2811000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_420a29cd-a126-4e99-93d7-35ecf87c886d"
      unitRef="U_USD">183000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3f3a00a7-d0c6-4fb1-9f41-b1bb85e02b7a"
      unitRef="U_USD">39000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_062433ca-4fcf-4f94-8678-fd357ad09f7c"
      unitRef="U_USD">40669000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_6b02192e-d0b6-45e5-a2f2-1c8a6ebad7bf"
      unitRef="U_USD">150000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_f3d27a20-42bb-44e9-a102-1e7c01643bea"
      unitRef="U_USD">4463000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <gyre:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_df6a3523-c172-4d38-b282-50a887b7e02c"
      unitRef="U_USD">15332000</gyre:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <gyre:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_b4de3dcc-ae12-4bee-abd4-bae1e0fb9c27"
      unitRef="U_USD">3428000</gyre:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <gyre:DeferredTaxAssetsImpactFromForeignCorporations
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_b39eb8ed-eb2d-4d0d-9635-63206f8a9f27"
      unitRef="U_USD">4590000</gyre:DeferredTaxAssetsImpactFromForeignCorporations>
    <gyre:DeferredTaxAssetsCapitalizedTransactionCosts
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_86b077cb-971a-4f74-b47f-ee0b55fdf461"
      unitRef="U_USD">658000</gyre:DeferredTaxAssetsCapitalizedTransactionCosts>
    <gyre:DeferredTaxAssetsCapitalizedTransactionCosts
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_969b261f-69f1-494f-b60f-bd290c7efe83"
      unitRef="U_USD">414000</gyre:DeferredTaxAssetsCapitalizedTransactionCosts>
    <gyre:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_1db75a87-511b-4bcd-bf8b-dbad8bcc3683"
      unitRef="U_USD">98000</gyre:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_43ca4997-a02e-4e18-a139-b27918418608"
      unitRef="U_USD">68660000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_77150058-8062-4c3b-9322-52525e77cf61"
      unitRef="U_USD">4175000</us-gaap:DeferredTaxAssetsGross>
    <gyre:DeferredTaxLiabilityRightOfUseAssets
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_82dc79f9-c176-41e9-b956-1219910b8d95"
      unitRef="U_USD">108000</gyre:DeferredTaxLiabilityRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_a73e8df2-e364-4415-8501-97022a25e341"
      unitRef="U_USD">84000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_6867e23d-ebc7-4c29-b102-2566982d0f63"
      unitRef="U_USD">94000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_20d390ba-5f15-457e-8739-36343e8381c1"
      unitRef="U_USD">63773000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_4fef3479-8326-468a-933c-5d5ed15b94d0"
      unitRef="U_USD">4695000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_d46334af-0d75-4c97-aa21-cbc1b5f72c7a"
      unitRef="U_USD">4081000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_3469c647-6216-42db-8466-775037f8a38a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The movements of the valuation allowance are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.566%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.536%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.889%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes of valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <gyre:ChangesOfValuationAllowances
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_df89721b-e3c5-432d-afc4-dee6b01b8534"
      unitRef="U_USD">-63773000</gyre:ChangesOfValuationAllowances>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_296948ff-df50-4969-a594-7219a87beb23"
      unitRef="U_USD">63773000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6948abd4-d444-43bb-a3ca-742236671306"
      decimals="-5"
      id="F_647b54fd-2664-44ed-b438-0d5ec1cd4917"
      unitRef="U_USD">193500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_c3822144-76cb-4af5-a440-f0966d1d926a"
      decimals="-5"
      id="F_033a7557-9c1c-487c-b61a-868ce7b77445"
      unitRef="U_USD">10500000</us-gaap:OperatingLossCarryforwards>
    <gyre:OperatingLossCarryforwardsExpirationYear
      contextRef="C_8d096fdf-4e68-4c03-86ed-d1473a0c1c55"
      id="F_e381ba56-b1b6-4a64-880d-9f8ec2cffe43">2037</gyre:OperatingLossCarryforwardsExpirationYear>
    <gyre:OperatingLossCarryforwardsExpirationYear
      contextRef="C_66c1df00-e0da-4f0b-9563-bfed0377c5ca"
      id="F_0316bee5-afa7-4575-8e44-13ed710888cd">2034</gyre:OperatingLossCarryforwardsExpirationYear>
    <gyre:OperatingLossCarryforwardsWithIndefiniteLife
      contextRef="C_6948abd4-d444-43bb-a3ca-742236671306"
      decimals="-5"
      id="F_6090ee18-2a46-446c-b41f-232e5d65279f"
      unitRef="U_USD">191900000</gyre:OperatingLossCarryforwardsWithIndefiniteLife>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6948abd4-d444-43bb-a3ca-742236671306"
      decimals="0"
      id="F_3a1cd898-2c51-4132-b5ee-c513fc3e9e60"
      unitRef="U_USD">8000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_c3822144-76cb-4af5-a440-f0966d1d926a"
      decimals="-5"
      id="F_264ad8bd-0e69-40b3-ba78-201f1b4540f8"
      unitRef="U_USD">7500000</us-gaap:TaxCreditCarryforwardAmount>
    <gyre:TaxCreditCarryforwardExpirationYear
      contextRef="C_8d096fdf-4e68-4c03-86ed-d1473a0c1c55"
      id="F_3f5eb594-0eec-4a90-a75d-6a6dbb0ee1f6">2042</gyre:TaxCreditCarryforwardExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_04950170-0636-4a37-9b11-630a8bead37c"
      decimals="-5"
      id="F_27046091-715e-43a5-b80e-8ec8a8881bb6"
      unitRef="U_USD">156500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_c2c5e195-1c21-41fa-be14-653b6ec43f7a"
      decimals="-5"
      id="F_651e6557-4536-430c-952b-a429a72a331f"
      unitRef="U_USD">75200000</us-gaap:OperatingLossCarryforwards>
    <gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards
      contextRef="C_6948abd4-d444-43bb-a3ca-742236671306"
      decimals="-5"
      id="F_dd5f9218-9e14-4a37-a245-eb9c4b96e765"
      unitRef="U_USD">32900000</gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards>
    <gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards
      contextRef="C_c2c5e195-1c21-41fa-be14-653b6ec43f7a"
      decimals="-6"
      id="F_082cfb1b-faf0-4349-be38-02625a42fd7a"
      unitRef="U_USD">0</gyre:DeferredTaxAssetsStateNetOperatingLossCarryForwards>
    <gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_9f6cc5a5-8429-4134-bb87-a4e054e64499"
      unitRef="U_USD">6000000.0</gyre:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized>
    <gyre:MaximumAmountOfTaxOffsetPerYear
      contextRef="C_5d5d2670-fd6a-4e3f-894d-c0347308d6f6"
      decimals="-6"
      id="F_667a80b2-8abd-4a29-a777-b7220a9f11a3"
      unitRef="U_USD">5000000</gyre:MaximumAmountOfTaxOffsetPerYear>
    <gyre:RequiredMinimumTaxableIncome
      contextRef="C_4cb6c663-f4e1-4031-ab93-fd048348ccfa"
      decimals="-6"
      id="F_a5abafe2-0176-4d93-a89a-c59d449b7a87"
      unitRef="U_USD">1000000</gyre:RequiredMinimumTaxableIncome>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_08102d12-27c2-458f-93f5-c2c44eb67474"
      unitRef="U_USD">1800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_28500997-30cf-4776-aa93-f7aecaccbef3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:81.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Beginning Balance on January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending Balance on December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase as a result of the GNI USA Contributions on October 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase/(Decrease) of unrecognized tax benefits related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending Balance on December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b7c2a125-5bff-41a6-a0df-4926d0dda919"
      decimals="-3"
      id="F_ef427ae9-67c0-4ebc-baf0-802fa38a522a"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_2b9c13e1-6597-4d8d-ac04-d790286b4dd6"
      unitRef="U_USD">0</gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_1b73f60a-bad2-489a-96c8-c18ee7ddd4be"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_fa2583ab-18e7-4da2-a40b-d7f7445178fd"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_d3d3391c-8bcc-41e3-8819-77ad99bfe40d"
      unitRef="U_USD">1833000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_f6148c2e-48d5-4845-941c-e6a61633f777"
      unitRef="U_USD">0</gyre:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_1cd472fc-b8ad-4ffc-aed5-fefe35c1e433"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_88ba73ba-25ec-4b39-95e3-938b28298c0f"
      unitRef="U_USD">1833000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_a6f5f1e2-31fc-4f3b-87a5-689866f1944b"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_8108e0d3-72b4-447b-b073-62305fa99818"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="INF"
      id="F_fd61d591-1f7b-4ded-8bf4-ca785fc4f16d"
      unitRef="U_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="INF"
      id="F_bd3673cf-d735-4d97-8e85-e1af5d3d50f3"
      unitRef="U_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-5"
      id="F_e1d74609-0723-4724-a861-6d2d9fae3b8e"
      unitRef="U_USD">2500000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_80ec23a7-7346-4f5c-8fec-2b78540690c7">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;15.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;F351 Transfer Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the F351 Transfer Agreement (see Note 13), as part of the consideration, BC paid &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to GNI during the years ended December 31, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and development with GNI&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; research and development fees were paid to GNI during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. During the year ended December 31, 2022, the Company paid &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as research and development fees to GNI.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, the Company had a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; related parties payable due to GNI, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other receivables from GNI&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had recorded &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in other receivables from GNI, of which &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was from CPI&#x2019;s restructuring transaction (see Note 8) and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was from Gyre&#x2019;s cost sharing with GNI. No amounts were due from GNI as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d022cce0-2b7e-4ac2-a0b1-f765616cb924"
      decimals="-5"
      id="F_e0c7d2ae-10ab-43cf-81ce-78cde357ec2d"
      unitRef="U_USD">2600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_efb1e330-1a01-4f0a-b587-773cd7fdf361"
      decimals="-5"
      id="F_479d0979-707e-4991-8584-5de43e838fed"
      unitRef="U_USD">8900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_84d9b48e-9b34-4794-916b-eecce30677e3"
      decimals="0"
      id="F_b15b4f16-be01-4c8a-9756-577a5ef0d0a5"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e92cc5b3-03a9-49de-86c5-40c3077730e8"
      decimals="-5"
      id="F_84f16f07-2ae0-4ce9-9c5f-335470c2113a"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherLiabilities
      contextRef="C_aaad5e91-28da-4383-82fc-a19aee9f956d"
      decimals="-5"
      id="F_96eec6bf-2085-4fa1-bf65-f7c91f3f5e5c"
      unitRef="U_USD">1400000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="C_b1a6816f-f707-4fb2-a96b-db95ed45787d"
      decimals="-5"
      id="F_121336e1-44fb-4fca-b640-a1417746d6dd"
      unitRef="U_USD">100000</us-gaap:OtherLiabilities>
    <us-gaap:OtherReceivables
      contextRef="C_56fd673d-dfd1-4bf2-843c-a213f1c28815"
      decimals="-5"
      id="F_8ca9eb1f-08f1-4270-b9be-1bc1656da44b"
      unitRef="U_USD">1300000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_96f625f2-102b-4612-9ae5-c9bf247174b2"
      decimals="-5"
      id="F_bea5ce5e-4cc1-4c34-83c3-b2d26f160ef4"
      unitRef="U_USD">800000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_0697f749-db8f-4fa7-9af3-6e4ada46d83a"
      decimals="-5"
      id="F_b2cc8a18-04ac-4cc7-997b-18227a852705"
      unitRef="U_USD">500000</us-gaap:OtherReceivables>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_dafb52ce-40e6-4de0-8049-5d99718e572f">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;16.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;EPS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The dilutive effect of outstanding stock options and warrants is calculated using the treasury stock method. Stock options and warrants are anti-dilutive and excluded from the diluted net income per share attributable to common stock calculation if the exercise price exceeds the average market price of the common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.525%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.899000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.546%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income attributable to common stockholders - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Basic common shares outstanding:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,588,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,588,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,098,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,686,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income per share attributable to common stockholders:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:83%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Preferred stock (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preferred Stock Warrants (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,588,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_30a0d9c3-7062-4b95-9616-084b11690a44">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of EPS attributable to common stockholders, basic and diluted (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.525%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.899000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.546%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Less:   Allocation of undistributed earnings to noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income attributable to common stockholders - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Basic common shares outstanding:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,588,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,588,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted average of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,098,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,831,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,686,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income per share attributable to common stockholders:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_641537d9-e700-4f64-8302-9056a4dda64c"
      unitRef="U_USD">-85480000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_6e6ffd03-2742-47b8-a8da-f76c30bc3456"
      unitRef="U_USD">4314000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_55726261-551a-4130-a189-a6d9b2d42d3b"
      unitRef="U_USD">7453000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_563bff32-001b-4de4-9bc6-1ed120f8d749"
      unitRef="U_USD">2012000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_354f1755-4501-44ba-8d0a-a10d07b3242a"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_6694b115-2c15-4862-bca3-e11e967fe627"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_583b90ad-762a-4ff8-90c0-d3a7f4a08d11"
      unitRef="U_USD">2302000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_0fe52125-cdb0-4a39-adb8-8304354ae79f"
      unitRef="U_USD">2302000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="0"
      id="F_8351c008-1471-49d8-9d0d-cd6c632bd93c"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="0"
      id="F_91adf2b4-3290-4b29-9395-1f7a6e94aef8"
      unitRef="U_shares">63588119</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="0"
      id="F_490cc304-4cce-4b3d-94d7-8cbcea91fd25"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="0"
      id="F_51d72498-32ff-4f2a-a5c6-94724be1ebc8"
      unitRef="U_shares">63588119</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="INF"
      id="F_f23f4c8a-dfc1-4bc8-90a4-f872b7133f05"
      unitRef="U_shares">12098287</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="0"
      id="F_f35d63a0-0803-4c92-944a-68bb2b145aa9"
      unitRef="U_shares">65831675</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="0"
      id="F_7e70ef2b-521e-44b2-9b15-2ba833d49906"
      unitRef="U_shares">75686406</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_e0be9058-c27e-4ce9-8b17-bd78b8c593ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="2"
      id="F_655c85eb-a149-4a9f-939e-0d24e0f5b417"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="2"
      id="F_8699b949-5cb1-4e8f-8989-6e1d59812245"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="2"
      id="F_a22d93fd-077a-424b-ae13-c828ddbd16ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_5d662467-1ae6-45bd-af9f-a604d8765fc5">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:83%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,280,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Preferred stock (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preferred Stock Warrants (as converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,588,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e0557a3d-1a6e-4667-8a75-0565cef63396"
      decimals="INF"
      id="F_17e07694-5c94-4ed8-9d6d-e23369807516"
      unitRef="U_shares">18280548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8324e115-6f67-4a65-b0da-48617f324eac"
      decimals="INF"
      id="F_31a25fe9-d50d-4bd0-829b-fa7464874979"
      unitRef="U_shares">8767332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_aae4d106-8ca8-4cfc-ac19-e79420fdc9ff"
      decimals="INF"
      id="F_48733fa9-714b-470e-a23d-76f87476fe4b"
      unitRef="U_shares">540666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="INF"
      id="F_e8c7797a-146b-4de3-acfc-2f51c9c78380"
      unitRef="U_shares">27588546</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DefinedBenefitPlanTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_4103ba35-464d-4ec5-813b-a7313f17677c">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;17.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Mainland China Contribution Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to relevant PRC regulations, the Company is required to make contributions to various defined contribution plans organized by municipal and provincial PRC governments. The contribution for each employee is based on a percentage of the employee&#x2019;s current compensation as required by the local government. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme. The total&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;contributions for such employee benefits were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the years ended December 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Defined-Contribution Savings Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the U.S., the Company maintains a defined-contribution savings plan pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended. The plan is available to employees who meet the minimum age and length of service requirements. The contributions made during the year ended December 31, 2023 were immaterial.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_a1eecc05-fb63-484b-87b6-6c579da56492"
      decimals="-5"
      id="F_cc1105a4-b736-4a83-8905-7588211ed6f3"
      unitRef="U_USD">4300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_89b8c4e5-1d62-4004-b838-6c1f712ee7f9"
      decimals="-5"
      id="F_124dc36d-1f69-4974-a90b-85a549f993c7"
      unitRef="U_USD">3600000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_5ca2beb7-d3a5-496f-bf3c-d111d79796dc">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;18.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is a consolidated entity comprised of two distinct operating segments: BC and Gyre after the Contributions. The Company&#x2019;s reportable segments are based upon internal organizational structure, the manner in which operations are managed, the criteria used by CODM to evaluate segment performance the availability of separate financial information, and overall materiality considerations. All Gyre&#x2019;s operations are within the U.S., while all of BC&#x2019;s operations are in mainland China.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;BC has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. BC&#x2019;s product revenues are mainly generated from the sale of ETUARY and certain generic drugs. BC primarily sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. BC also generates revenue from license agreements. However, the license agreements did not generate any revenue for the year ended December 31, 2023 and an immaterial amount for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of NASH-associated liver fibrosis in the United States. Other than the IP associated with F351 in the U.S., Gyre has no other product candidates since the Company sold all of its legacy IP assets prior to the closing of the Contributions. Subsequent to the closing of the Contributions, Gyre has not generated any revenue.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Segment information for the years ended December 31, 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross profit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating expenses excluding cost of revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Divestiture losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss on disposal of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating expenses excluding cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income (Loss) from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Supplemental Disclosure of stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1) $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; million represents legal expense recorded in CPI during the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(2) $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; million represents divestiture losses. See Note 8 for details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;101,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchase of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross profit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating expenses excluding cost of revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating expenses excluding cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(Loss) income from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Supplemental Disclosure of stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(3) $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; million represents the other subsidiaries, CPI and GNI HK, etc. reported an aggregate $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; million general and administrative expense during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchase of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_514e34d6-f6c7-428c-8fc4-1e88626eec8e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Segment information for the years ended December 31, 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross profit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating expenses excluding cost of revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Divestiture losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss on disposal of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating expenses excluding cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income (Loss) from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Supplemental Disclosure of stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1) $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; million represents legal expense recorded in CPI during the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(2) $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; million represents divestiture losses. See Note 8 for details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;101,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchase of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross profit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating expenses excluding cost of revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating expenses excluding cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(Loss) income from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Supplemental Disclosure of stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(3) $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; million represents the other subsidiaries, CPI and GNI HK, etc. reported an aggregate $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; million general and administrative expense during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.038%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.218%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;BC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gyre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Consolidated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchase of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_c9582b20-f8cf-4ce1-a708-5d325b761039"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_71526b9c-c630-46b8-b984-164dec02fddd"
      unitRef="U_USD">113450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_11fc7b82-5283-493b-a2da-8ef469e806ec"
      unitRef="U_USD">4636000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_32c82a64-862b-41c6-a984-167967cae0dc"
      unitRef="U_USD">4636000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_36816463-8482-4222-9c0a-47da9473ccb1"
      unitRef="U_USD">108814000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_b91edcc3-6dd6-465e-8434-4ed3f7077737"
      unitRef="U_USD">108814000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_695dad36-7abf-4192-978f-90d20ea0a584"
      unitRef="U_USD">61159000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_9ecca720-648f-4057-94b3-89a93577a827"
      unitRef="U_USD">61159000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_37cd8cd9-2d2f-4a87-96d5-2d3736352a22"
      unitRef="U_USD">13698000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323"
      decimals="-3"
      id="F_e0d3281e-f2fd-4aa1-be7b-8565c349b25b"
      unitRef="U_USD">82000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_6f080956-bd35-43be-9a4e-5bea069b535e"
      unitRef="U_USD">13780000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_8bdbb22d-bb08-43d6-871c-af45a27c927e"
      unitRef="U_USD">8872000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323"
      decimals="-3"
      id="F_a75f3a99-0460-4980-89c0-d3cf6c7b1106"
      unitRef="U_USD">5214000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5723249a-64b4-471a-be67-452050b084d7"
      decimals="-3"
      id="F_a9daf5d4-b859-4b26-8105-a443654f1988"
      unitRef="U_USD">576000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_b2d331b4-90ef-4a8a-aea5-6464a1bf9a7e"
      unitRef="U_USD">14662000</us-gaap:GeneralAndAdministrativeExpense>
    <gyre:AcquiredInProcessResearchAndDevelopment
      contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323"
      decimals="-3"
      id="F_a38f9a41-1ffe-4df6-bf7c-46c0a66b202f"
      unitRef="U_USD">83104000</gyre:AcquiredInProcessResearchAndDevelopment>
    <gyre:AcquiredInProcessResearchAndDevelopment
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_c5078aee-c1ac-4e97-8485-218a2a8367d4"
      unitRef="U_USD">83104000</gyre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_5723249a-64b4-471a-be67-452050b084d7"
      decimals="-3"
      id="F_54bd4cb4-14cc-4d9b-8785-f18793fb39d5"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_4370fc66-48e8-4b82-a724-73c0e831ce09"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_3fd353c1-cc5e-48e9-b52b-a1d29b1e08cf"
      unitRef="U_USD">-628000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_4ff61735-b64d-4310-83de-d852fe0c11a2"
      unitRef="U_USD">-628000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingExpenses
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_5173f9ec-ff72-468a-b843-c9e0c170f687"
      unitRef="U_USD">84357000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323"
      decimals="-3"
      id="F_41af059c-5380-4ff9-9937-6f3c26185981"
      unitRef="U_USD">88400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_5723249a-64b4-471a-be67-452050b084d7"
      decimals="-3"
      id="F_fde64278-7efb-4065-9cea-627b4f77dbcf"
      unitRef="U_USD">3287000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_e5a8cf5b-3cde-4f20-8a3a-2d9e1fb4817a"
      unitRef="U_USD">176044000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_28658f18-4e9c-4e2b-8a55-2379aa2c2002"
      unitRef="U_USD">24457000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323"
      decimals="-3"
      id="F_5b70fa1c-7ecd-41c6-b9d7-8c5f8049670f"
      unitRef="U_USD">-88400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5723249a-64b4-471a-be67-452050b084d7"
      decimals="-3"
      id="F_cb87f2cc-5a7f-4b83-9447-85e7a166ee45"
      unitRef="U_USD">-3287000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_d4628582-967b-4e06-aaad-47c59124bb0d"
      unitRef="U_USD">-67230000</us-gaap:OperatingIncomeLoss>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6c61ab08-e1b5-45d8-af46-68e14fd32dfc"
      decimals="-3"
      id="F_c2fcd47e-bf0b-48d1-bb3b-e5701f793fd9"
      unitRef="U_USD">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8dd3a581-c90a-4509-af97-5acd79c8a8e3"
      decimals="-3"
      id="F_376526ea-55dc-4033-a690-f527f5e19de2"
      unitRef="U_USD">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b337b32c-b922-4667-afd1-a840403dbad9"
      decimals="-3"
      id="F_5a40ebce-f8be-420f-a106-e83e650a49cf"
      unitRef="U_USD">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c1a2d74b-7d0b-4b38-8998-7a1161571cf0"
      decimals="-3"
      id="F_bc603724-a071-4f49-b976-7d862c266eaf"
      unitRef="U_USD">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0cfa6500-f12c-4cdd-861c-f10bc7dc5d69"
      decimals="-3"
      id="F_a638a986-c693-4d4b-9fc3-228d6f0b1f60"
      unitRef="U_USD">481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_146bbfb7-b649-4239-b32d-22b491e71629"
      decimals="-3"
      id="F_cfb9e6d9-1260-46e8-9230-e13745021523"
      unitRef="U_USD">481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2687f77f-ab25-40af-b6b8-1e653689478f"
      decimals="-3"
      id="F_ccb53fcd-5fc3-4dfa-9fb2-3f0e434e159b"
      unitRef="U_USD">1916000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_79108d3a-0a88-4ff0-8ed1-61cd65b0cc7c"
      decimals="-3"
      id="F_3be2f845-981e-4248-b7b9-3f1a2a1dccc2"
      unitRef="U_USD">4488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b9586f61-cf2b-4213-abab-d860b5741c19"
      decimals="-3"
      id="F_e78196a6-1062-4c60-a7bb-51143dc1d0af"
      unitRef="U_USD">6404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_8ff69d6a-03b7-4fee-a19c-fd1b842e1412"
      unitRef="U_USD">2793000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d40b8acc-faac-42d6-9c51-0c30220f6323"
      decimals="-3"
      id="F_81b8d301-e88b-4394-b460-1f2f448e53f4"
      unitRef="U_USD">4488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_e1ab6415-76b0-43e7-8c07-d3eca5547ade"
      unitRef="U_USD">7281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LegalFees
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_e799c59c-9c11-4b89-b896-34a418a0e864"
      unitRef="U_USD">600000</us-gaap:LegalFees>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-5"
      id="F_f8168a82-d2b2-4f75-a1cc-e1ec6c33cb02"
      unitRef="U_USD">-2700000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:Assets
      contextRef="C_7863a107-8f27-4048-916f-de1fd40aebc1"
      decimals="-3"
      id="F_31f0443f-913b-49a5-8eb3-160e654e8420"
      unitRef="U_USD">101761000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_f6d92b17-1eca-4702-9b3c-788a030b8de5"
      decimals="-3"
      id="F_687f351c-b83d-4e48-adf3-8e8931f39bed"
      unitRef="U_USD">13865000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0222eacd-1eff-471f-9812-cbf6e10d75b5"
      decimals="-3"
      id="F_b0cf9580-6dc8-4eff-8f79-a5545b350a7d"
      unitRef="U_USD">913000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_336f98ce-84bd-4119-8b08-938644de6dc9"
      decimals="-3"
      id="F_3ff5e574-c7b3-415c-88be-45d4fb1cd664"
      unitRef="U_USD">116539000</us-gaap:Assets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="C_56e7366e-1817-430a-b15c-fe11b44bcf0d"
      decimals="-3"
      id="F_2fc9090a-8ed2-4936-b758-ffcd794d4036"
      unitRef="U_USD">8517000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      decimals="-3"
      id="F_67a992b7-33e3-4dc3-86e3-5bc83049d655"
      unitRef="U_USD">8517000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_fda0ed8b-19fe-4ea3-88cc-61097d95cbcd"
      unitRef="U_USD">102290000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_aee77c88-678b-46d3-98c6-70075643ab9a"
      unitRef="U_USD">102290000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_a4bbce5a-1f95-4a28-8c6d-7bc7209e9d24"
      unitRef="U_USD">4793000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_45cc3bcf-74e8-4bd4-9e6c-8196b58737cd"
      unitRef="U_USD">4793000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_30dbe165-8fa1-45d2-a08e-092cd828b059"
      unitRef="U_USD">97497000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_54337f80-089d-408e-99d9-524dadb15757"
      decimals="-3"
      id="F_05ba6c91-7048-4e9b-872e-e1d62f38a73d"
      unitRef="U_USD">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_8d4b5e68-3829-43b6-84e2-8b9cdbca144e"
      unitRef="U_USD">97497000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_e1cdaac7-9c0b-4942-8be0-eb2983edbf04"
      unitRef="U_USD">54238000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_a5e06a22-81f6-4b8e-bdbd-23f6ebcee170"
      unitRef="U_USD">54238000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_75565a07-a948-4610-956c-6125586d3922"
      unitRef="U_USD">16686000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_9fc4f514-7105-4983-8980-855461169a77"
      unitRef="U_USD">16686000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_0b203f7f-e2c7-4c13-a90c-e71881d861dd"
      unitRef="U_USD">17240000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_54337f80-089d-408e-99d9-524dadb15757"
      decimals="-3"
      id="F_c1c6a69d-fc4c-4151-addc-713c9b9935c2"
      unitRef="U_USD">130000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_f1092d47-3043-4d79-ae8a-9be86f1c6d54"
      unitRef="U_USD">17370000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_1bdfa83b-4570-426d-8c0d-37f91a2f56ea"
      unitRef="U_USD">88164000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_54337f80-089d-408e-99d9-524dadb15757"
      decimals="-3"
      id="F_f5916ea6-c202-40a2-b314-328e45cf4f4c"
      unitRef="U_USD">130000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_e425d1ed-de3d-4e2e-b975-4e9672559a12"
      unitRef="U_USD">88294000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_b5df3003-44b7-4485-9913-94177e2d8c53"
      unitRef="U_USD">9333000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_54337f80-089d-408e-99d9-524dadb15757"
      decimals="-3"
      id="F_9a272290-4bb7-4642-acdb-4d9b2f8d6d90"
      unitRef="U_USD">-130000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_1f60d804-0bef-4ed7-83c5-80e1c06c8acd"
      unitRef="U_USD">9203000</us-gaap:OperatingIncomeLoss>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ae49cec5-9016-4f5f-8d21-5329e230331a"
      decimals="-3"
      id="F_36d59262-a9b3-4766-9763-15a1206e0d44"
      unitRef="U_USD">249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5a775378-ab64-439b-aa16-34b026d36a54"
      decimals="-3"
      id="F_97de532b-faec-4885-84e7-0d44da25cd06"
      unitRef="U_USD">249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9ea7ec22-706f-4637-98fe-08b2490d6c90"
      decimals="-3"
      id="F_ccf3e255-3bd2-4caf-b060-1b70ca843e49"
      unitRef="U_USD">1643000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4ba38967-8a4f-4c72-a845-ec882f409155"
      decimals="-3"
      id="F_d86009d9-4fd7-4acb-b549-720ec56e328f"
      unitRef="U_USD">1643000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1a998271-ce77-46b7-81d2-6b2303da832d"
      decimals="-3"
      id="F_396e31ca-26d5-406d-b409-c6f9b96a2806"
      unitRef="U_USD">2301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e03b0455-2388-408c-baed-fbbcb9bb45ff"
      decimals="-3"
      id="F_08c6a1c8-8e83-4242-8be4-8644348d7e53"
      unitRef="U_USD">2301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_456a2f3b-ce96-4cc3-bb0f-c4609478945a"
      decimals="-3"
      id="F_cf1d3bb2-4624-4011-b0bc-dc6a97cf38ab"
      unitRef="U_USD">9173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_290b25a7-e794-4501-9b27-3ec91a3fd8f8"
      decimals="-3"
      id="F_b83c014a-0bd5-4f0c-bb8f-550b64d0c691"
      unitRef="U_USD">9173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_ae6cb154-106f-4ba9-9b80-c8b69cd213e6"
      unitRef="U_USD">13366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_a784508e-084b-408c-812e-17ff06aa9313"
      unitRef="U_USD">13366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d4a379ab-79bf-4033-b99c-f6b95eddf94e"
      decimals="-5"
      id="F_4f1adf8d-05d1-426f-9c81-5d94fd681d3b"
      unitRef="U_USD">100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d4a379ab-79bf-4033-b99c-f6b95eddf94e"
      decimals="-5"
      id="F_88781e8a-1ff3-4117-8e09-66da3acd7e32"
      unitRef="U_USD">100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:Assets
      contextRef="C_3bf7ff5f-4cf5-4036-a987-5cbcce3b4d9d"
      decimals="-3"
      id="F_d64b031f-3c68-4538-a934-4c29908d8997"
      unitRef="U_USD">79857000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_8d44f86a-e7e9-43dc-98b7-f45dd3ddd498"
      decimals="-3"
      id="F_60c7d668-de61-4274-8db5-496a993cfa51"
      unitRef="U_USD">4896000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_a20c4dd4-fc29-4856-9c78-305b31b62bcd"
      decimals="-3"
      id="F_1dbd0c7e-4a5a-4423-b5af-91a0223d8fed"
      unitRef="U_USD">84753000</us-gaap:Assets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="C_4adb2660-ebbc-4b40-aa0a-86963b2882bb"
      decimals="-3"
      id="F_ae4cfc23-38c4-461e-88ec-2c8e06b8c243"
      unitRef="U_USD">-4985000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="C_f19ba98d-16e7-4dd2-b9cd-9717924c31ef"
      decimals="-3"
      id="F_a4d81860-374c-41b1-b102-dd87d70d21aa"
      unitRef="U_USD">4985000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_c3786fa1-1f8c-4ef7-9a86-314c98378d26">
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:6.18%;"&gt;&lt;/td&gt;
      &lt;td style="width:93.82%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;19.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Conversion of Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 22, 2023, GNI provided notice to the Company to convert &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,151&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Convertible Preferred Stock into shares of common stock. On January 22, 2024, subject to the terms and conditions of the Convertible Preferred Stock Certificate of Designation, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,767,332&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were issued to GNI upon such conversion.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_3cc0a247-7505-4d3e-a327-e08700672f1b"
      decimals="INF"
      id="F_25cc7580-ec7d-4406-9e90-e10966f9bf98"
      unitRef="U_shares">13151</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares
      contextRef="C_01c81b79-25d4-4be2-a4ef-98326dc842a2"
      decimals="INF"
      id="F_c803d91b-825a-4de3-aca3-7dfa3903e7ae"
      unitRef="U_shares">8767332</gyre:NumberOfSharesOfCommonStockIssuableUponConversionOfTheOutstandingShares>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock
      contextRef="C_0e6827f4-ae2c-4a78-9c6d-2873634fcbb6"
      id="F_931872dc-f293-415d-8461-2a01cadaab45">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p id="schedulei" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gyre Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(In thousands, except shares and per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Related party receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Investment in subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Liabilities, convertible preferred stock, and stockholders&#x2019; equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due to related parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;"&gt;
      &lt;td style="background-color:#cceeff;text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Preferred Stock, $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;par value, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;shares authorized; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,151&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;shares and &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_1b8bd787-8774-422a-80fe-04f24efefd08;"&gt;&lt;span style="-sec-ix-hidden:F_0cb88365-0ef8-49b2-9d9e-5b85398d57d4;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;shares issued and outstanding at December 31, 2023 and 2022, respectively&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_ce5ebc89-65a5-46e2-8a69-3fd79de6688a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="background-color:#cff0fc;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stockholders&#x2019; (deficit) equity:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock, $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;par value, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;shares authorized; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,595,616&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;shares and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,588,119&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;shares issued and outstanding at December 31, 2023 and 2022, respectively&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;"&gt;
      &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additional paid-in capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Statutory reserve&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;"&gt;
      &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(Accumulated deficit) retained earnings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;"&gt;
      &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stockholders&#x2019; (deficit) equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities, convertible preferred stock, and stockholders&#x2019; (deficit) equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The accompanying notes are an integral part of these condensed consolidated financial statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gyre Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Condensed Consolidated Statements of Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Divestiture losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss before equity in (loss) income of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity in (loss) income of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="background-color:#cceeff;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other comprehensive (loss) income, net of tax of &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_8616dc92-4123-4729-b301-42d5b83f2786;"&gt;&lt;span style="-sec-ix-hidden:F_1e540b7e-b631-4275-b3d7-b90e2d47d44e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;text-indent:5pt;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cff0fc;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:#cceeff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:#cceeff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Comprehensive loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The accompanying notes are an integral part of these condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gyre Therapeutics, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:68.874%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:12.963000000000001%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:12.663%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Operating Activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Adjustments to reconcile net (loss) income to net cash used for operating activities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity loss (income) of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Divestiture losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="text-indent:20pt;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in operating assets and liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due to related parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effect of exchange rate changes on cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net change in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents at beginning of the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The accompanying notes are an integral part of these condensed consolidated financial statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Notes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a pa&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;rent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; percent of consolidated net assets as of the end of the most recently completed fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries. CPI, the legal acquiree and accounting acquirer of the Contributions considered the &#x201c;registrant&#x201d; and presented as the parent company, Gyre Therapeutics, Inc. (&#x201c;Gyre&#x201d;) to supplement its condensed financial statement in Schedule I. The parent company records its investments in subsidiaries under the equity method of accounting as prescribed in ASC 323, Investments-Equity Method, and Joint Ventures. Such investments are presented on the Condensed Balance Sheets as &#x201c;Investment in subsidiaries&#x201d;. Ordinarily under the equity method, an investor in an equity method investee would cease to recognize its share of the losses of an investee once the carrying value of the investment has been reduced to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to reflect its share, based on its proportionate interest, of the losses of subsidiaries regardless of the carrying value of the investment even though the parent company is not obligated to provide continuing support or fund losses.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or redemption requirements of redeemable stocks or guarantees of the parent company.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_f111bc94-d333-4038-926d-d8d72cc3bed3"
      decimals="-3"
      id="F_b3cb9dd2-0fa5-47f1-8752-74f56ce4944f"
      unitRef="U_USD">768000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_72d98f33-ac25-40da-993c-2ae56eedc53b"
      decimals="-3"
      id="F_031bf7af-464c-4a96-a9b4-7e7198d3c5ef"
      unitRef="U_USD">3159000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_da4f4321-554e-414b-b8bc-a9b263c48c80"
      unitRef="U_USD">768000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_5964850a-1131-4a17-b486-273a3506df16"
      unitRef="U_USD">3159000</us-gaap:AssetsCurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_ad40da6d-6668-4d91-a92f-6db3c6c24007"
      unitRef="U_USD">49709000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_f3934502-2f72-42f4-97b1-c246a914487e"
      unitRef="U_USD">40632000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_7a587581-be93-42e1-a544-f0ef6e914813"
      unitRef="U_USD">50477000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_ceb4d70d-c41f-4bb8-ab4b-733add50bf7f"
      unitRef="U_USD">43791000</us-gaap:Assets>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_f111bc94-d333-4038-926d-d8d72cc3bed3"
      decimals="-3"
      id="F_c1cac092-db6c-49b7-94fc-e8c9d65f251a"
      unitRef="U_USD">538000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_72d98f33-ac25-40da-993c-2ae56eedc53b"
      decimals="-3"
      id="F_54c022fd-9c71-4d75-bcdf-4b194d21a4a3"
      unitRef="U_USD">5000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_5cef44af-36bb-4b7d-b1fe-5e0c1400d87a"
      unitRef="U_USD">1242000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_8dd1fc64-168e-470b-b7e2-27a9a6554254"
      unitRef="U_USD">1264000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_8ea01ef7-1849-4077-92fd-3f08063ac238"
      unitRef="U_USD">1780000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_675021e6-2a60-43f9-b8f7-6573f0f56869"
      unitRef="U_USD">1269000</us-gaap:LiabilitiesCurrent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff"
      decimals="INF"
      id="F_6dfe1da9-368c-4251-8252-3d653c80a066"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_ba6672c5-2601-4669-825e-401398257206"
      decimals="INF"
      id="F_5dd916fb-e0be-4006-a03b-3ef38fa6ec73"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff"
      decimals="INF"
      id="F_7df6e049-580a-4b7a-97e0-15f536aa48ea"
      unitRef="U_shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_ba6672c5-2601-4669-825e-401398257206"
      decimals="INF"
      id="F_7d860c35-238c-45ac-a7cb-85607296eae5"
      unitRef="U_shares">5000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff"
      decimals="INF"
      id="F_025fc902-67b7-42e6-921c-580ea681e7f4"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff"
      decimals="INF"
      id="F_2c0d7ab6-1acf-4c2f-b359-04b7e381f3bf"
      unitRef="U_shares">13151</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_fe5c0fa6-97a9-40ef-afd6-d493719335ff"
      decimals="-3"
      id="F_723e5281-fd4e-452e-a313-21628fa84f29"
      unitRef="U_USD">64525000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="INF"
      id="F_79ba905e-7551-4d91-a909-190691035c43"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="INF"
      id="F_c6e83f72-dee3-4f5d-8ac0-fbaa173a0397"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="INF"
      id="F_f731b310-d5a4-4a93-98fd-0f13aad9e4c4"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="INF"
      id="F_62562dab-085f-4bc7-8500-9e2bbb4e15db"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="INF"
      id="F_11f81b40-ccfb-4463-a86d-290060045235"
      unitRef="U_shares">76595616</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="INF"
      id="F_9224dc41-6e23-4cde-8e76-7a0189771868"
      unitRef="U_shares">76595616</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="INF"
      id="F_18837713-364c-4e51-9f6e-a3f34d733388"
      unitRef="U_shares">63588119</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="INF"
      id="F_7aaf6a54-6a8c-475b-9bb6-8137b8b21066"
      unitRef="U_shares">63588119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_9617e5b9-52a3-49a7-b88d-45a8a238ecba"
      unitRef="U_USD">77000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_6c65bf2f-c0eb-4620-968b-71cd44d6806d"
      unitRef="U_USD">64000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_1bc04be3-7028-48bf-8024-2508a3370fe1"
      unitRef="U_USD">68179000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_78200dbd-6fea-4fa9-9be6-a9791f84b7aa"
      unitRef="U_USD">32795000</us-gaap:AdditionalPaidInCapital>
    <gyre:StatutoryReserve
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_1611aabe-eccb-4a09-9883-4151de95f476"
      unitRef="U_USD">3098000</gyre:StatutoryReserve>
    <gyre:StatutoryReserve
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_64aca39c-02b1-42d1-ae21-3645c4d4c833"
      unitRef="U_USD">2660000</gyre:StatutoryReserve>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_7c99d0ba-97bc-485b-8e22-e48d74dffa46"
      unitRef="U_USD">-85538000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_a0b9ab93-eb33-4830-9232-9bc7b73b0138"
      unitRef="U_USD">7395000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_1bd811da-4b59-4daf-af81-005915099c71"
      unitRef="U_USD">-1644000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_aa630031-90f8-4b48-b3e7-96fab2c69c4b"
      unitRef="U_USD">-392000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_0f9109b9-d8c1-46d7-bb12-b87257df341b"
      unitRef="U_USD">-15828000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_d7507bf5-dadc-4071-9a46-5283913a323f"
      unitRef="U_USD">42522000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="-3"
      id="F_3834dfcf-ba2d-4abe-968e-e0f1e74a624b"
      unitRef="U_USD">50477000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_6dd438f1-a836-4fe2-a573-aa7f8fd94115"
      decimals="-3"
      id="F_fe4b52f7-76c5-4dc7-9f3a-593e3544d9a2"
      unitRef="U_USD">43791000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_97ec6342-275c-4e8c-ab67-7df6d8e605c7"
      unitRef="U_USD">605000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_13734133-eb33-4ac5-be8a-1e9db32a2b44"
      unitRef="U_USD">94000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_d3d0c799-2004-4bc5-a508-e673847174ac"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_4220bc96-dda5-40a0-9676-89bbd9b92bbf"
      unitRef="U_USD">3316000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_a858e183-e6ff-465a-ad6d-f2f27f0aa0f0"
      unitRef="U_USD">94000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_7a13fbb3-463a-413c-a515-f56d84ae1aa7"
      unitRef="U_USD">-89617000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_fee6fdeb-afe7-49cf-99a4-811b816929e7"
      unitRef="U_USD">2396000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_a3d1594f-3f14-4698-8976-510b98682419"
      unitRef="U_USD">-92933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_69c29bbd-9e68-4e3d-b9f0-5ba4c823f87e"
      unitRef="U_USD">2302000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_936d7ffd-c3e9-4ed3-a437-43a8ee2b8121"
      unitRef="U_USD">-837000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_372e76a4-aaa9-4a04-802d-bde04811e9c0"
      unitRef="U_USD">-2758000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_76368896-e15c-4cbf-b598-2cc1cb3f8713"
      unitRef="U_USD">-93770000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_748201cb-4977-4dd9-95f2-340fee9afa31"
      unitRef="U_USD">-456000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_a1d36221-8797-4dc9-b105-ab64e4d92b59"
      unitRef="U_USD">-92933000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_014c795a-708f-4e26-9a53-fa162b29ea5e"
      unitRef="U_USD">2302000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_08faa946-e405-4206-a870-88f5fee7904c"
      unitRef="U_USD">-89617000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_49ea499a-3d96-438c-a2ff-71b243ed359b"
      unitRef="U_USD">2396000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_2dc734c8-c369-43ea-ab60-79b43c5b59b8"
      unitRef="U_USD">-2711000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_00a70462-de58-43cb-bc2c-fe9d58f961b9"
      unitRef="U_USD">533000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_f0b2cd79-d93b-4789-b135-296d43704423"
      unitRef="U_USD">5000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_5d321998-9898-4bde-97d7-68a69ccc1cf6"
      unitRef="U_USD">-72000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_3b621bed-60b2-424f-a663-6605d0b2bf5c"
      unitRef="U_USD">-89000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_51eacde6-e834-42e7-87e7-8f1f5fd8bf78"
      decimals="-3"
      id="F_f2fd4edd-d20c-44f0-b6fc-dc96ae76b070"
      unitRef="U_USD">72000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_8189fafe-4dd8-48f1-bda5-e5498a7f19cb"
      decimals="-3"
      id="F_817fa357-91b2-4095-9a5d-7ee86a526890"
      unitRef="U_USD">89000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <gyre:PercentageOfRestrictedNetAssetsExceedNetAssets
      contextRef="C_1b6c8bb8-11df-4d4e-844a-aa3091cefef3"
      decimals="2"
      id="F_eb61254d-cf9e-48ea-aaf0-2de04ad602d4"
      unitRef="U_pure">0.25</gyre:PercentageOfRestrictedNetAssetsExceedNetAssets>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_0547b5d9-8cf0-4c86-a882-fafaeb82c402"
          xlink:label="F_0547b5d9-8cf0-4c86-a882-fafaeb82c402"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9a272737-bc08-4cc6-aecc-0ad4b9df9699"
          xlink:label="F_9a272737-bc08-4cc6-aecc-0ad4b9df9699"
          xlink:type="locator"/>
        <link:footnote id="FNT_4c145f6b-eadd-41ce-9c2e-dc03d3a8bcb1" xlink:label="FNT_4c145f6b-eadd-41ce-9c2e-dc03d3a8bcb1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0547b5d9-8cf0-4c86-a882-fafaeb82c402"
          xlink:to="FNT_4c145f6b-eadd-41ce-9c2e-dc03d3a8bcb1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9a272737-bc08-4cc6-aecc-0ad4b9df9699"
          xlink:to="FNT_4c145f6b-eadd-41ce-9c2e-dc03d3a8bcb1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_5ee0712a-9495-465c-a62c-57257a6ca510"
          xlink:label="F_5ee0712a-9495-465c-a62c-57257a6ca510"
          xlink:type="locator"/>
        <link:footnote id="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878" xlink:label="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purchase price was based on the closing price of Catalyst Common Stock on October 30, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5ee0712a-9495-465c-a62c-57257a6ca510"
          xlink:to="FNT_64a2b3b9-0858-4689-9cb3-0db3c4783878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_fbaeeda2-4b02-470d-9341-dbf9ecc4a8bb"
          xlink:label="F_fbaeeda2-4b02-470d-9341-dbf9ecc4a8bb"
          xlink:type="locator"/>
        <link:footnote id="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9" xlink:label="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This amount is calculated based on </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,340</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Convertible Preferred Stock outstanding as of October 30, 2023. Each share of preferred stock converts into approximately </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">666.67</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The fair value was calculated using the closing price of Catalyst Common Stock on October 30, 2023 and the number of underlying common shares.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fbaeeda2-4b02-470d-9341-dbf9ecc4a8bb"
          xlink:to="FNT_e74411ad-760f-4d7f-9c78-2bb598fd36a9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_c261cfe5-3da9-46f4-9be9-e6fa353cc3f9"
          xlink:label="F_c261cfe5-3da9-46f4-9be9-e6fa353cc3f9"
          xlink:type="locator"/>
        <link:footnote id="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9" xlink:label="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any option to purchase Catalyst Common Stock that was issued and outstanding at the Effective Time remains issued and outstanding and unaffected by the GNI USA Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the pre-Contributions service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions:</xhtml:span></xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c261cfe5-3da9-46f4-9be9-e6fa353cc3f9"
          xlink:to="FNT_f8030e0a-282c-4e43-bd68-54e6e8c89ae9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_a9daf5d4-b859-4b26-8105-a443654f1988"
          xlink:label="F_a9daf5d4-b859-4b26-8105-a443654f1988"
          xlink:type="locator"/>
        <link:footnote id="FNT_f44b5c23-aed9-4b04-8c26-9440275a700b" xlink:label="FNT_f44b5c23-aed9-4b04-8c26-9440275a700b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(1) $</xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents legal expense recorded in CPI during the year ended December 31, 2023.</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a9daf5d4-b859-4b26-8105-a443654f1988"
          xlink:to="FNT_f44b5c23-aed9-4b04-8c26-9440275a700b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_54bd4cb4-14cc-4d9b-8785-f18793fb39d5"
          xlink:label="F_54bd4cb4-14cc-4d9b-8785-f18793fb39d5"
          xlink:type="locator"/>
        <link:footnote id="FNT_228a2060-914b-44e0-8e10-3c03acdbcf57" xlink:label="FNT_228a2060-914b-44e0-8e10-3c03acdbcf57" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(2) $</xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents divestiture losses. See Note 8 for details.</xhtml:span></xhtml:p><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</xhtml:span></xhtml:p><xhtml:table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><xhtml:tr style="visibility:collapse;"><xhtml:td style="width:51.67%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9.038%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9.038%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9.038%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9.218%;"/><xhtml:td style="width:1%;"/></xhtml:tr><xhtml:tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><xhtml:td style="vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="14"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td></xhtml:tr><xhtml:tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><xhtml:td style="vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="2"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="2"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="2"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="2"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td></xhtml:tr><xhtml:tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:middle;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">$</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101,761</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:middle;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">$</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,865</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">$</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">913</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">$</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,539</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td></xhtml:tr></xhtml:table><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</xhtml:span></xhtml:p><xhtml:table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><xhtml:tr style="visibility:collapse;"><xhtml:td style="width:51.67%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9.038%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9.038%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9.038%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:1%;"/><xhtml:td style="width:9.218%;"/><xhtml:td style="width:1%;"/></xhtml:tr><xhtml:tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><xhtml:td style="vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="14"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td></xhtml:tr><xhtml:tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><xhtml:td style="vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="2"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BC</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="2"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gyre</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="2"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td
          colspan="2"
          style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><xhtml:p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td></xhtml:tr><xhtml:tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">$</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,517</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">)</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:middle;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">$</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">$</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="white-space:pre-wrap;min-width:fit-content;">&#160;</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">$</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,517</xhtml:span></xhtml:p></xhtml:td><xhtml:td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;min-width:fit-content;">)</xhtml:span></xhtml:p></xhtml:td></xhtml:tr></xhtml:table></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_54bd4cb4-14cc-4d9b-8785-f18793fb39d5"
          xlink:to="FNT_228a2060-914b-44e0-8e10-3c03acdbcf57"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_c1c6a69d-fc4c-4151-addc-713c9b9935c2"
          xlink:label="F_c1c6a69d-fc4c-4151-addc-713c9b9935c2"
          xlink:type="locator"/>
        <link:footnote id="FNT_9b153e3f-50c6-44f6-b9dc-b8230ec35c82" xlink:label="FNT_9b153e3f-50c6-44f6-b9dc-b8230ec35c82" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(3) $</xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million represents the other subsidiaries, CPI and GNI HK, etc. reported an aggregate $</xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million general and administrative expense during the year ended December 31, 2022.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c1c6a69d-fc4c-4151-addc-713c9b9935c2"
          xlink:to="FNT_9b153e3f-50c6-44f6-b9dc-b8230ec35c82"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
